pmid,year,mesh,meshTreeNumber
21204569,2011-01-04T00:00:00,Graphite,D01.268.150.300
21204569,2011-01-04T00:00:00,Graphite,D01.578.300
21204569,2011-01-04T00:00:00,Materials Testing,E05.570
21204569,2011-01-04T00:00:00,Nanostructures,J01.637.512
21204569,2011-01-04T00:00:00,"Spectrum Analysis, Raman",E05.196.822.860
21204569,2011-01-04T00:00:00,"Spectrum Analysis, Raman",E05.196.867.890
21204569,2011-01-04T00:00:00,Surface Properties,G02.842.850
21209394,2011-01-05T00:00:00,Animals,B01.050
21209394,2011-01-05T00:00:00,Cell Proliferation,G04.299.233.750
21209394,2011-01-05T00:00:00,Cell Proliferation,G07.700.320.249.410.750
21209394,2011-01-05T00:00:00,Disease Progression,C23.550.291.656
21209394,2011-01-05T00:00:00,"Gene Expression Regulation, Neoplastic",G05.355.315.370
21209394,2011-01-05T00:00:00,Head and Neck Neoplasms,C04.588.443
21209394,2011-01-05T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21209394,2011-01-05T00:00:00,"Models, Genetic",E05.599.395.397
21209394,2011-01-05T00:00:00,Oligonucleotide Array Sequence Analysis,E05.196.630.570.660
21209394,2011-01-05T00:00:00,Oligonucleotide Array Sequence Analysis,E05.393.525.640
21209394,2011-01-05T00:00:00,Oligonucleotide Array Sequence Analysis,E05.393.661.640
21209394,2011-01-05T00:00:00,Oligonucleotide Array Sequence Analysis,E05.393.760.640
21209394,2011-01-05T00:00:00,Oligonucleotide Array Sequence Analysis,E05.588.570.660
21209394,2011-01-05T00:00:00,Oligonucleotide Array Sequence Analysis,E05.601.640
21209394,2011-01-05T00:00:00,Phosphotransferases (Alcohol Group Acceptor),D08.811.913.696.620
21209394,2011-01-05T00:00:00,Proto-Oncogene Proteins c-akt,D08.811.913.696.620.682.700.755
21209394,2011-01-05T00:00:00,Proto-Oncogene Proteins c-akt,D12.776.476.565
21209394,2011-01-05T00:00:00,Proto-Oncogene Proteins c-akt,D12.776.624.664.700.168
21209625,2011-01-06T00:00:00,Animals,B01.050
21209625,2011-01-06T00:00:00,Gene Transfer Techniques,E05.393.350
21209625,2011-01-06T00:00:00,Genetic Vectors,G05.360.337
21209625,2011-01-06T00:00:00,"Hair Cells, Auditory",A08.663.650.250
21209625,2011-01-06T00:00:00,"Hair Cells, Auditory",A08.663.650.915.750.600.350
21209625,2011-01-06T00:00:00,"Hair Cells, Auditory",A08.800.950.750.600.350
21209625,2011-01-06T00:00:00,"Hair Cells, Auditory",A09.246.631.246.577.325
21209625,2011-01-06T00:00:00,"Hair Cells, Auditory",A11.671.650.250
21209625,2011-01-06T00:00:00,"Hair Cells, Auditory",A11.671.650.915.750.600.350
21209625,2011-01-06T00:00:00,Hearing Loss,C09.218.458.341
21209625,2011-01-06T00:00:00,Hearing Loss,C10.597.751.418.341
21209625,2011-01-06T00:00:00,Hearing Loss,C23.888.592.763.393.341
21209625,2011-01-06T00:00:00,"Mice, Inbred CBA",B01.050.050.157.520.440
21209625,2011-01-06T00:00:00,"Mice, Inbred CBA",B01.050.050.199.520.520.440
21209625,2011-01-06T00:00:00,"Mice, Inbred CBA",B01.050.150.900.649.865.635.505.500.400.440
21209625,2011-01-06T00:00:00,"Transduction, Genetic",E05.393.350.800
21209625,2011-01-06T00:00:00,"Transduction, Genetic",G05.355.760.850
21213206,2011-01-06T00:00:00,Cholesterol,D04.808.247.222.284
21213206,2011-01-06T00:00:00,Cholesterol,D04.808.247.808.197
21213206,2011-01-06T00:00:00,Cholesterol,D10.570.938.208
21213206,2011-01-06T00:00:00,Cholesterol,D10.851.208
21213206,2011-01-06T00:00:00,Chylothorax,C08.528.142
21213206,2011-01-06T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21213206,2011-01-06T00:00:00,Pleural Effusion,C08.528.652
21215736,2011-01-06T00:00:00,Aldehyde Dehydrogenase,D08.811.682.657.163.249
21215736,2011-01-06T00:00:00,Animals,B01.050
21215736,2011-01-06T00:00:00,"Evolution, Molecular",G05.355.265.250
21215736,2011-01-06T00:00:00,"Evolution, Molecular",G16.100.275.250
21215736,2011-01-06T00:00:00,Folic Acid,D03.438.733.631.400
21215736,2011-01-06T00:00:00,Genomics,H01.158.273.180.350
21215736,2011-01-06T00:00:00,Genomics,H01.158.273.343.350
21215736,2011-01-06T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21215736,2011-01-06T00:00:00,Phylogeny,G05.697
21215736,2011-01-06T00:00:00,Phylogeny,G16.100.275.605
21215736,2011-01-06T00:00:00,Phylogeny,L01.100.697
21215736,2011-01-06T00:00:00,"Sequence Homology, Amino Acid",G02.111.810.200
21215736,2011-01-06T00:00:00,"Sequence Homology, Amino Acid",G05.810.200
21377805,2011-01-06T00:00:00,Adolescent,M01.060.057
21377805,2011-01-06T00:00:00,Crime Victims,M01.135
21377805,2011-01-06T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21377805,2011-01-06T00:00:00,Juvenile Delinquency,I01.880.735.479
21377805,2011-01-06T00:00:00,Risk Factors,E05.318.740.600.800.725
21377805,2011-01-06T00:00:00,Risk Factors,N05.715.350.200.700
21377805,2011-01-06T00:00:00,Risk Factors,N05.715.360.750.625.700.700
21377805,2011-01-06T00:00:00,Risk Factors,N06.850.490.625.750
21377805,2011-01-06T00:00:00,Risk Factors,N06.850.520.830.600.800.725
21377805,2011-01-06T00:00:00,Risk-Taking,F01.145.722
21377805,2011-01-06T00:00:00,Substance-Related Disorders,C21.739
21377805,2011-01-06T00:00:00,Substance-Related Disorders,F03.900
21377805,2011-01-06T00:00:00,Time Factors,G01.910.857
21377805,2011-01-06T00:00:00,United States,Z01.107.567.875
21377805,2011-01-06T00:00:00,Violence,I01.198.240.856
21377805,2011-01-06T00:00:00,Violence,I01.880.735.900
21212663,2011-01-07T00:00:00,Adult,M01.060.116
21212663,2011-01-07T00:00:00,Age Factors,N05.715.350.075
21212663,2011-01-07T00:00:00,Age Factors,N06.850.490.250
21212663,2011-01-07T00:00:00,Health Surveys,E05.318.308.250
21212663,2011-01-07T00:00:00,Health Surveys,N05.715.360.300.375
21212663,2011-01-07T00:00:00,Health Surveys,N06.850.520.308.250
21212663,2011-01-07T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21212663,2011-01-07T00:00:00,Middle Aged,M01.060.116.630
21212663,2011-01-07T00:00:00,Risk Assessment,E05.318.740.600.800.715
21212663,2011-01-07T00:00:00,Risk Assessment,N04.452.871.715
21212663,2011-01-07T00:00:00,Risk Assessment,N05.715.360.750.625.700.690
21212663,2011-01-07T00:00:00,Risk Assessment,N06.850.505.715
21212663,2011-01-07T00:00:00,Risk Assessment,N06.850.520.830.600.800.715
21212663,2011-01-07T00:00:00,Risk Factors,E05.318.740.600.800.725
21212663,2011-01-07T00:00:00,Risk Factors,N05.715.350.200.700
21212663,2011-01-07T00:00:00,Risk Factors,N05.715.360.750.625.700.700
21212663,2011-01-07T00:00:00,Risk Factors,N06.850.490.625.750
21212663,2011-01-07T00:00:00,Risk Factors,N06.850.520.830.600.800.725
21212663,2011-01-07T00:00:00,Sex Factors,N05.715.350.675
21212663,2011-01-07T00:00:00,Sex Factors,N06.850.490.875
21212663,2011-01-07T00:00:00,Stroke,C10.228.140.300.775
21212663,2011-01-07T00:00:00,Stroke,C14.907.253.855
21212663,2011-01-07T00:00:00,United States,Z01.107.567.875
21216243,2011-01-07T00:00:00,Animals,B01.050
21216243,2011-01-07T00:00:00,Endothelin-1,D12.644.276.400.225
21216243,2011-01-07T00:00:00,Endothelin-1,D12.776.467.400.225
21216243,2011-01-07T00:00:00,Endothelin-1,D23.529.400.225
21216243,2011-01-07T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21216243,2011-01-07T00:00:00,Liver,A03.620
21216243,2011-01-07T00:00:00,"Promoter Regions, Genetic",G02.111.570.080.689.675
21216243,2011-01-07T00:00:00,"Promoter Regions, Genetic",G05.360.080.689.675
21216243,2011-01-07T00:00:00,"Promoter Regions, Genetic",G05.360.340.024.340.137.750.680
21216243,2011-01-07T00:00:00,Protein Precursors,D12.776.811
21216243,2011-01-07T00:00:00,Rats,B01.050.150.900.649.865.635.505.700
21216243,2011-01-07T00:00:00,"Rats, Sprague-Dawley",B01.050.150.900.649.865.635.505.700.750
21216243,2011-01-07T00:00:00,Signal Transduction,G02.111.087.800
21216243,2011-01-07T00:00:00,Signal Transduction,G02.149.115.800
21216243,2011-01-07T00:00:00,Signal Transduction,G04.299.880
21216243,2011-01-07T00:00:00,Tumor Necrosis Factor-alpha,D12.644.276.374.500.800
21216243,2011-01-07T00:00:00,Tumor Necrosis Factor-alpha,D12.644.276.374.750.626
21216243,2011-01-07T00:00:00,Tumor Necrosis Factor-alpha,D12.644.276.972.626
21216243,2011-01-07T00:00:00,Tumor Necrosis Factor-alpha,D12.776.124.900
21216243,2011-01-07T00:00:00,Tumor Necrosis Factor-alpha,D12.776.395.930
21216243,2011-01-07T00:00:00,Tumor Necrosis Factor-alpha,D12.776.467.374.500.800
21216243,2011-01-07T00:00:00,Tumor Necrosis Factor-alpha,D12.776.467.374.750.626
21216243,2011-01-07T00:00:00,Tumor Necrosis Factor-alpha,D12.776.467.972.626
21216243,2011-01-07T00:00:00,Tumor Necrosis Factor-alpha,D23.529.374.500.800
21216243,2011-01-07T00:00:00,Tumor Necrosis Factor-alpha,D23.529.374.750.626
21216243,2011-01-07T00:00:00,Tumor Necrosis Factor-alpha,D23.529.972.626
21216243,2011-01-07T00:00:00,Wound Healing,G16.100.856.891
21224012,2011-01-09T00:00:00,Animals,B01.050
21224012,2011-01-09T00:00:00,Brain,A08.186.211
21224012,2011-01-09T00:00:00,Cations,D01.248.497.300
21224012,2011-01-09T00:00:00,Cell Membrane,A11.284.149
21224012,2011-01-09T00:00:00,Phospholipids,D10.570.755
21224012,2011-01-09T00:00:00,Phospholipids,D10.695
21224012,2011-01-09T00:00:00,Rats,B01.050.150.900.649.865.635.505.700
21224012,2011-01-09T00:00:00,Sepharose,D09.698.813
21224012,2011-01-09T00:00:00,Sphingolipids,D10.570.877
21224012,2011-01-09T00:00:00,Sphingolipids,D10.808
21214500,2011-01-10T00:00:00,"Child, Preschool",M01.060.406.448
21214500,2011-01-10T00:00:00,"Diagnosis, Differential",E01.171
21214500,2011-01-10T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21214500,2011-01-10T00:00:00,Mutation,G05.365.590
21219105,2011-01-10T00:00:00,Acetylcysteine,D02.886.030.230.259
21219105,2011-01-10T00:00:00,Acetylcysteine,D12.125.166.230.259
21219105,2011-01-10T00:00:00,Animals,B01.050
21219105,2011-01-10T00:00:00,"Animals, Newborn",B01.050.050.282
21219105,2011-01-10T00:00:00,Brain,A08.186.211
21219105,2011-01-10T00:00:00,Brain Injuries,C10.228.140.199
21219105,2011-01-10T00:00:00,Brain Injuries,C10.900.300.087
21219105,2011-01-10T00:00:00,Brain Injuries,C21.866.260.118
21219105,2011-01-10T00:00:00,Brain Injuries,C21.866.915.300.200
21219105,2011-01-10T00:00:00,Fetal Diseases,C13.703.277
21219105,2011-01-10T00:00:00,Fetal Diseases,C16.300
21219105,2011-01-10T00:00:00,Pregnancy,G08.686.785.760.769
21219105,2011-01-10T00:00:00,Premature Birth,C13.703.420.491.500
21324838,2011-01-10T00:00:00,Adult,M01.060.116
21324838,2011-01-10T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21324838,2011-01-10T00:00:00,Self Efficacy,F01.752.747.792.700
21324838,2011-01-10T00:00:00,Smoking Cessation,F01.145.940.700
21324838,2011-01-10T00:00:00,Social Support,I01.880.656.600
21656745,2011-01-10T00:00:00,Carcinoma,C04.557.470.200
21656745,2011-01-10T00:00:00,"Carcinoma, Squamous Cell",C04.557.470.200.400
21656745,2011-01-10T00:00:00,"Carcinoma, Squamous Cell",C04.557.470.700.400
21656745,2011-01-10T00:00:00,Cell Movement,G04.299.283
21656745,2011-01-10T00:00:00,Cell Movement,G07.700.560.500.180
21656745,2011-01-10T00:00:00,Disease Progression,C23.550.291.656
21656745,2011-01-10T00:00:00,Head and Neck Neoplasms,C04.588.443
21656745,2011-01-10T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21656745,2011-01-10T00:00:00,Interleukin-6,D12.644.276.374.465.506
21656745,2011-01-10T00:00:00,Interleukin-6,D12.776.467.374.465.506
21656745,2011-01-10T00:00:00,Interleukin-6,D23.529.374.465.506
21656745,2011-01-10T00:00:00,Neoplasm Invasiveness,C04.697.645
21656745,2011-01-10T00:00:00,Neoplasm Invasiveness,C23.550.727.645
21656745,2011-01-10T00:00:00,RNA Stability,G02.111.780
21656745,2011-01-10T00:00:00,Vascular Endothelial Growth Factor A,D12.644.276.100.800.200
21656745,2011-01-10T00:00:00,Vascular Endothelial Growth Factor A,D12.776.467.100.800.200
21656745,2011-01-10T00:00:00,Vascular Endothelial Growth Factor A,D23.529.100.800.200
21656745,2011-01-10T00:00:00,p38 Mitogen-Activated Protein Kinases,D08.811.913.696.620.682.700.567.878
21656745,2011-01-10T00:00:00,p38 Mitogen-Activated Protein Kinases,D08.811.913.696.620.682.700.646.750.843
21656745,2011-01-10T00:00:00,p38 Mitogen-Activated Protein Kinases,D12.644.360.450.835
21656745,2011-01-10T00:00:00,p38 Mitogen-Activated Protein Kinases,D12.776.476.450.835
21222526,2011-01-11T00:00:00,Animals,B01.050
21222526,2011-01-11T00:00:00,Diffusion,G01.595.200
21222526,2011-01-11T00:00:00,Diffusion,G02.149.767.560
21222526,2011-01-11T00:00:00,Diffusion,G02.842.750.560
21222526,2011-01-11T00:00:00,Homeostasis,G07.700.360
21222526,2011-01-11T00:00:00,"Models, Neurological",E05.599.395.642
21222526,2011-01-11T00:00:00,Rats,B01.050.150.900.649.865.635.505.700
21222526,2011-01-11T00:00:00,Stochastic Processes,E05.318.740.996
21222526,2011-01-11T00:00:00,Stochastic Processes,G17.830
21222526,2011-01-11T00:00:00,Stochastic Processes,N05.715.360.750.770
21222526,2011-01-11T00:00:00,Stochastic Processes,N06.850.520.830.996
21222526,2011-01-11T00:00:00,Synapses,A08.850
21222526,2011-01-11T00:00:00,Synapses,A11.284.149.165.420.780
21222526,2011-01-11T00:00:00,Synaptic Transmission,G02.111.087.800.850
21222526,2011-01-11T00:00:00,Synaptic Transmission,G02.149.115.800.850
21222526,2011-01-11T00:00:00,Synaptic Transmission,G04.299.880.850
21222526,2011-01-11T00:00:00,Synaptic Transmission,G07.265.337.900
21222526,2011-01-11T00:00:00,Synaptic Transmission,G07.700.240.900
21222526,2011-01-11T00:00:00,Synaptic Transmission,G11.561.600.835
21224470,2011-01-11T00:00:00,Animals,B01.050
21224470,2011-01-11T00:00:00,Blood Vessels,A07.231
21224470,2011-01-11T00:00:00,Cell Movement,G04.299.283
21224470,2011-01-11T00:00:00,Cell Movement,G07.700.560.500.180
21224470,2011-01-11T00:00:00,Cell Proliferation,G04.299.233.750
21224470,2011-01-11T00:00:00,Cell Proliferation,G07.700.320.249.410.750
21224470,2011-01-11T00:00:00,Endothelial Cells,A11.436.275
21224470,2011-01-11T00:00:00,Homeodomain Proteins,D12.776.260.400
21224470,2011-01-11T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21224470,2011-01-11T00:00:00,"Neovascularization, Physiologic",G09.330.190.751
21224470,2011-01-11T00:00:00,"RNA, Messenger",D13.444.735.544
21224470,2011-01-11T00:00:00,Repressor Proteins,D12.776.260.703
21224470,2011-01-11T00:00:00,Repressor Proteins,D12.776.930.700
21224470,2011-01-11T00:00:00,Signal Transduction,G02.111.087.800
21224470,2011-01-11T00:00:00,Signal Transduction,G02.149.115.800
21224470,2011-01-11T00:00:00,Signal Transduction,G04.299.880
21224470,2011-01-11T00:00:00,"Spheroids, Cellular",A11.251.800
21224470,2011-01-11T00:00:00,Transcription Factors,D12.776.930
21224470,2011-01-11T00:00:00,"Transcription, Genetic",G02.111.087.847
21224470,2011-01-11T00:00:00,"Transcription, Genetic",G02.149.115.847
21224470,2011-01-11T00:00:00,"Transcription, Genetic",G05.355.310.700
21224470,2011-01-11T00:00:00,Vascular Endothelial Growth Factor A,D12.644.276.100.800.200
21224470,2011-01-11T00:00:00,Vascular Endothelial Growth Factor A,D12.776.467.100.800.200
21224470,2011-01-11T00:00:00,Vascular Endothelial Growth Factor A,D23.529.100.800.200
21226034,2011-01-11T00:00:00,Adult,M01.060.116
21226034,2011-01-11T00:00:00,Aged,M01.060.116.100
21226034,2011-01-11T00:00:00,Breast Neoplasms,C04.588.180
21226034,2011-01-11T00:00:00,Breast Neoplasms,C17.800.090.500
21226034,2011-01-11T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21226034,2011-01-11T00:00:00,Middle Aged,M01.060.116.630
21227910,2011-01-11T00:00:00,Adolescent,M01.060.057
21227910,2011-01-11T00:00:00,Child,M01.060.406
21227910,2011-01-11T00:00:00,"Child, Preschool",M01.060.406.448
21227910,2011-01-11T00:00:00,Health Behavior,F01.145.488
21227910,2011-01-11T00:00:00,Health Surveys,E05.318.308.250
21227910,2011-01-11T00:00:00,Health Surveys,N05.715.360.300.375
21227910,2011-01-11T00:00:00,Health Surveys,N06.850.520.308.250
21227910,2011-01-11T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21227910,2011-01-11T00:00:00,Motor Activity,F01.145.632
21227910,2011-01-11T00:00:00,Motor Activity,G11.427.590.530.698
21227910,2011-01-11T00:00:00,Obesity,C18.654.726.500
21227910,2011-01-11T00:00:00,Obesity,C23.888.144.699.500
21227910,2011-01-11T00:00:00,Obesity,E01.370.600.115.100.160.120.699.500
21227910,2011-01-11T00:00:00,Obesity,G07.100.100.160.120.699.500
21227910,2011-01-11T00:00:00,Rural Population,N01.600.725
21227910,2011-01-11T00:00:00,United States,Z01.107.567.875
21227910,2011-01-11T00:00:00,Urban Population,N01.600.900
21225098,2011-01-12T00:00:00,Aged,M01.060.116.100
21225098,2011-01-12T00:00:00,Anticoagulants,D27.505.954.502.119
21225098,2011-01-12T00:00:00,"Arthroplasty, Replacement, Hip",E04.555.110.110.110
21225098,2011-01-12T00:00:00,"Arthroplasty, Replacement, Hip",E04.650.110.110
21225098,2011-01-12T00:00:00,Double-Blind Method,E05.318.780.300
21225098,2011-01-12T00:00:00,Double-Blind Method,E05.581.500.300
21225098,2011-01-12T00:00:00,Double-Blind Method,N05.715.360.780.320
21225098,2011-01-12T00:00:00,Double-Blind Method,N06.850.520.445.300
21225098,2011-01-12T00:00:00,Enoxaparin,D09.698.373.400.300.200
21225098,2011-01-12T00:00:00,Hemorrhage,C23.550.414
21225098,2011-01-12T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21225098,2011-01-12T00:00:00,Middle Aged,M01.060.116.630
21225098,2011-01-12T00:00:00,Postoperative Complications,C23.550.767
21225098,2011-01-12T00:00:00,Venous Thromboembolism,C14.907.355.590.700
21225098,2011-01-12T00:00:00,Venous Thromboembolism,C14.907.355.830.850.700
21225098,2011-01-12T00:00:00,Venous Thrombosis,C14.907.355.830.925
21225269,2011-01-13T00:00:00,Algorithms,G17.035
21225269,2011-01-13T00:00:00,Algorithms,L01.224.050
21225269,2011-01-13T00:00:00,Angiography,E01.370.350.700.060
21225269,2011-01-13T00:00:00,Angiography,E01.370.370.050
21225269,2011-01-13T00:00:00,Artificial Intelligence,L01.224.065
21225269,2011-01-13T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21225269,2011-01-13T00:00:00,Middle Aged,M01.060.116.630
21225269,2011-01-13T00:00:00,Professional Competence,I02.399.630
21225269,2011-01-13T00:00:00,Pulmonary Artery,A07.231.114.715
21225269,2011-01-13T00:00:00,Pulmonary Embolism,C08.381.746
21225269,2011-01-13T00:00:00,Pulmonary Embolism,C14.907.355.350.700
21225269,2011-01-13T00:00:00,"Radiographic Image Interpretation, Computer-Assisted",E01.158.600.680
21225269,2011-01-13T00:00:00,"Radiographic Image Interpretation, Computer-Assisted",E01.370.350.350.700
21225269,2011-01-13T00:00:00,"Radiographic Image Interpretation, Computer-Assisted",E01.370.350.700.705
21225269,2011-01-13T00:00:00,"Radiographic Image Interpretation, Computer-Assisted",L01.700.508.100.158.600.680
21225269,2011-01-13T00:00:00,South Carolina,Z01.107.567.875.075.662
21225269,2011-01-13T00:00:00,South Carolina,Z01.107.567.875.750.700
21225269,2011-01-13T00:00:00,"Tomography, X-Ray Computed",E01.370.350.350.810
21225269,2011-01-13T00:00:00,"Tomography, X-Ray Computed",E01.370.350.600.350.700.810
21225269,2011-01-13T00:00:00,"Tomography, X-Ray Computed",E01.370.350.700.700.810
21225269,2011-01-13T00:00:00,"Tomography, X-Ray Computed",E01.370.350.700.810.810
21225269,2011-01-13T00:00:00,"Tomography, X-Ray Computed",E01.370.350.825.810.810
21233404,2011-01-13T00:00:00,Aged,M01.060.116.100
21233404,2011-01-13T00:00:00,Antineoplastic Combined Chemotherapy Protocols,E02.183.750.500
21233404,2011-01-13T00:00:00,Antineoplastic Combined Chemotherapy Protocols,E02.319.077.500
21233404,2011-01-13T00:00:00,Antineoplastic Combined Chemotherapy Protocols,E02.319.310.037
21233404,2011-01-13T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21233404,2011-01-13T00:00:00,"Leukemia, Myelogenous, Chronic, BCR-ABL Positive",C04.557.337.539.250
21233404,2011-01-13T00:00:00,"Leukemia, Myelogenous, Chronic, BCR-ABL Positive",C15.378.190.636.370
21233404,2011-01-13T00:00:00,"Leukemia, Myeloid, Acute",C04.557.337.539.550
21233404,2011-01-13T00:00:00,"Leukocytes, Mononuclear",A11.118.637.555
21233404,2011-01-13T00:00:00,"Leukocytes, Mononuclear",A15.145.229.637.555
21233404,2011-01-13T00:00:00,"Leukocytes, Mononuclear",A15.382.490.555
21233404,2011-01-13T00:00:00,Middle Aged,M01.060.116.630
21233404,2011-01-13T00:00:00,NF-kappa B,D12.776.260.600
21233404,2011-01-13T00:00:00,NF-kappa B,D12.776.660.600
21233404,2011-01-13T00:00:00,NF-kappa B,D12.776.930.600
21233404,2011-01-13T00:00:00,Quinolones,D03.438.810.835
21233469,2011-01-13T00:00:00,Academic Medical Centers,N02.278.020
21233469,2011-01-13T00:00:00,Brain Ischemia,C10.228.140.300.150
21233469,2011-01-13T00:00:00,Brain Ischemia,C14.907.253.092
21233469,2011-01-13T00:00:00,Health Personnel,M01.526.485
21233469,2011-01-13T00:00:00,Health Personnel,N02.360
21233469,2011-01-13T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21233469,2011-01-13T00:00:00,Quality of Health Care,N04.761
21233469,2011-01-13T00:00:00,Quality of Health Care,N05.715
21233469,2011-01-13T00:00:00,Stroke,C10.228.140.300.775
21233469,2011-01-13T00:00:00,Stroke,C14.907.253.855
21233469,2011-01-13T00:00:00,United States,Z01.107.567.875
21233472,2011-01-13T00:00:00,Aged,M01.060.116.100
21233472,2011-01-13T00:00:00,Brain Ischemia,C10.228.140.300.150
21233472,2011-01-13T00:00:00,Brain Ischemia,C14.907.253.092
21233472,2011-01-13T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21233472,2011-01-13T00:00:00,Middle Aged,M01.060.116.630
21233472,2011-01-13T00:00:00,Stroke,C10.228.140.300.775
21233472,2011-01-13T00:00:00,Stroke,C14.907.253.855
21233472,2011-01-13T00:00:00,Thrombolytic Therapy,E02.319.913
21234685,2011-01-14T00:00:00,Adult,M01.060.116
21234685,2011-01-14T00:00:00,Child,M01.060.406
21234685,2011-01-14T00:00:00,Child Development,F01.525.200
21234685,2011-01-14T00:00:00,Child Development,G07.700.320.374.750
21234685,2011-01-14T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21234685,2011-01-14T00:00:00,Needs Assessment,I02.594
21234685,2011-01-14T00:00:00,Needs Assessment,N03.349.380.565
21234685,2011-01-14T00:00:00,Needs Assessment,N05.300.537
21234685,2011-01-14T00:00:00,Parenting,F01.829.263.370.310
21234685,2011-01-14T00:00:00,Parents,F01.829.263.500.320
21234685,2011-01-14T00:00:00,Parents,I01.880.225.500.340
21234685,2011-01-14T00:00:00,Parents,M01.620
21234685,2011-01-14T00:00:00,Program Development,N04.452.760
21234685,2011-01-14T00:00:00,Questionnaires,E05.318.308.750
21234685,2011-01-14T00:00:00,Questionnaires,L01.280.800
21234685,2011-01-14T00:00:00,Questionnaires,N05.715.360.300.695
21234685,2011-01-14T00:00:00,Questionnaires,N06.850.520.308.750
21234685,2011-01-14T00:00:00,South Carolina,Z01.107.567.875.075.662
21234685,2011-01-14T00:00:00,South Carolina,Z01.107.567.875.750.700
21234685,2011-01-14T00:00:00,"Stress, Psychological",F01.145.126.990
21234685,2011-01-14T00:00:00,"Stress, Psychological",F02.830.900
21239688,2011-01-14T00:00:00,Adult,M01.060.116
21239688,2011-01-14T00:00:00,Colorectal Neoplasms,C04.588.274.476.411.307
21239688,2011-01-14T00:00:00,Colorectal Neoplasms,C06.301.371.411.307
21239688,2011-01-14T00:00:00,Colorectal Neoplasms,C06.405.249.411.307
21239688,2011-01-14T00:00:00,Colorectal Neoplasms,C06.405.469.158.356
21239688,2011-01-14T00:00:00,Colorectal Neoplasms,C06.405.469.491.307
21239688,2011-01-14T00:00:00,Colorectal Neoplasms,C06.405.469.860.180
21239688,2011-01-14T00:00:00,Early Detection of Cancer,E01.390.500
21239688,2011-01-14T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21239688,2011-01-14T00:00:00,Middle Aged,M01.060.116.630
21239688,2011-01-14T00:00:00,Physician's Practice Patterns,N04.590.748
21239688,2011-01-14T00:00:00,Physician's Practice Patterns,N05.300.625
21239688,2011-01-14T00:00:00,Primary Health Care,N04.590.233.727
21240977,2011-01-14T00:00:00,Animals,B01.050
21240977,2011-01-14T00:00:00,Biological Availability,G03.787.151
21240977,2011-01-14T00:00:00,Biological Availability,G07.690.725.129
21240977,2011-01-14T00:00:00,Brain,A08.186.211
21240977,2011-01-14T00:00:00,Central Nervous System Stimulants,D27.505.696.282
21240977,2011-01-14T00:00:00,Central Nervous System Stimulants,D27.505.954.427.220
21240977,2011-01-14T00:00:00,Drug Interactions,G07.690.812.240
21240977,2011-01-14T00:00:00,Drug Interactions,G07.700.680.240
21240977,2011-01-14T00:00:00,Ethanol,D02.033.375
21240977,2011-01-14T00:00:00,Gas Chromatography-Mass Spectrometry,E05.196.181.349.500
21240977,2011-01-14T00:00:00,Gas Chromatography-Mass Spectrometry,E05.196.566.500
21240977,2011-01-14T00:00:00,Methylphenidate,D02.241.223.601.600
21240977,2011-01-14T00:00:00,Methylphenidate,D03.383.621.460
21242019,2011-01-16T00:00:00,Cardiopulmonary Resuscitation,E02.365.647.110
21242019,2011-01-16T00:00:00,Health Personnel,M01.526.485
21242019,2011-01-16T00:00:00,Health Personnel,N02.360
21242019,2011-01-16T00:00:00,Heart Arrest,C14.280.383
21242019,2011-01-16T00:00:00,Hospitals,N02.278.421
21242019,2011-01-16T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21242019,2011-01-16T00:00:00,Time Factors,G01.910.857
21242019,2011-01-16T00:00:00,Treatment Outcome,E01.789.800
21242019,2011-01-16T00:00:00,Treatment Outcome,N04.761.559.590.800
21242019,2011-01-16T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21242275,2011-01-17T00:00:00,Animals,B01.050
21242275,2011-01-17T00:00:00,Cell Movement,G04.299.283
21242275,2011-01-17T00:00:00,Cell Movement,G07.700.560.500.180
21242275,2011-01-17T00:00:00,"Disease Models, Animal",C22.232
21242275,2011-01-17T00:00:00,"Disease Models, Animal",E05.598.500
21242275,2011-01-17T00:00:00,"Disease Models, Animal",E05.599.395.080
21242275,2011-01-17T00:00:00,Down-Regulation,G02.111.087.225
21242275,2011-01-17T00:00:00,Down-Regulation,G02.149.115.225
21242275,2011-01-17T00:00:00,Down-Regulation,G05.355.315.200
21242275,2011-01-17T00:00:00,Down-Regulation,G07.690.812.230
21242275,2011-01-17T00:00:00,Down-Regulation,G07.700.680.230
21242275,2011-01-17T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21242275,2011-01-17T00:00:00,Interleukin-6,D12.644.276.374.465.506
21242275,2011-01-17T00:00:00,Interleukin-6,D12.776.467.374.465.506
21242275,2011-01-17T00:00:00,Interleukin-6,D23.529.374.465.506
21242275,2011-01-17T00:00:00,Lipopolysaccharides,D09.400.500
21242275,2011-01-17T00:00:00,Lipopolysaccharides,D09.698.718.450
21242275,2011-01-17T00:00:00,Lipopolysaccharides,D10.494
21242275,2011-01-17T00:00:00,Lipopolysaccharides,D23.050.161.616.525
21242275,2011-01-17T00:00:00,Lipopolysaccharides,D23.946.123.329.500
21242275,2011-01-17T00:00:00,NF-kappa B,D12.776.260.600
21242275,2011-01-17T00:00:00,NF-kappa B,D12.776.660.600
21242275,2011-01-17T00:00:00,NF-kappa B,D12.776.930.600
21242275,2011-01-17T00:00:00,Periodontal Diseases,C07.465.714
21242275,2011-01-17T00:00:00,Rats,B01.050.150.900.649.865.635.505.700
21242275,2011-01-17T00:00:00,Tumor Necrosis Factor-alpha,D12.644.276.374.500.800
21242275,2011-01-17T00:00:00,Tumor Necrosis Factor-alpha,D12.644.276.374.750.626
21242275,2011-01-17T00:00:00,Tumor Necrosis Factor-alpha,D12.644.276.972.626
21242275,2011-01-17T00:00:00,Tumor Necrosis Factor-alpha,D12.776.124.900
21242275,2011-01-17T00:00:00,Tumor Necrosis Factor-alpha,D12.776.395.930
21242275,2011-01-17T00:00:00,Tumor Necrosis Factor-alpha,D12.776.467.374.500.800
21242275,2011-01-17T00:00:00,Tumor Necrosis Factor-alpha,D12.776.467.374.750.626
21242275,2011-01-17T00:00:00,Tumor Necrosis Factor-alpha,D12.776.467.972.626
21242275,2011-01-17T00:00:00,Tumor Necrosis Factor-alpha,D23.529.374.500.800
21242275,2011-01-17T00:00:00,Tumor Necrosis Factor-alpha,D23.529.374.750.626
21242275,2011-01-17T00:00:00,Tumor Necrosis Factor-alpha,D23.529.972.626
21242505,2011-01-18T00:00:00,Heart Failure,C14.280.434
21242505,2011-01-18T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21242505,2011-01-18T00:00:00,Quality of Life,I01.800
21242505,2011-01-18T00:00:00,Quality of Life,K01.752.400.750
21242505,2011-01-18T00:00:00,Treatment Outcome,E01.789.800
21242505,2011-01-18T00:00:00,Treatment Outcome,N04.761.559.590.800
21242505,2011-01-18T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21244609,2011-01-18T00:00:00,Adult,M01.060.116
21244609,2011-01-18T00:00:00,Aged,M01.060.116.100
21244609,2011-01-18T00:00:00,Decision Making,F02.463.785.373
21244609,2011-01-18T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21244609,2011-01-18T00:00:00,Middle Aged,M01.060.116.630
21244609,2011-01-18T00:00:00,Prostatic Neoplasms,C04.588.945.440.770
21244609,2011-01-18T00:00:00,Prostatic Neoplasms,C12.294.260.750
21244609,2011-01-18T00:00:00,Prostatic Neoplasms,C12.294.565.625
21244609,2011-01-18T00:00:00,Prostatic Neoplasms,C12.758.409.750
21244609,2011-01-18T00:00:00,Social Support,I01.880.656.600
21244609,2011-01-18T00:00:00,Spouses,F01.829.263.500.660
21244609,2011-01-18T00:00:00,Spouses,I01.880.225.500.670
21244609,2011-01-18T00:00:00,Spouses,M01.816
21246608,2011-01-18T00:00:00,Amino Acids,D12.125
21246608,2011-01-18T00:00:00,Animals,B01.050
21246608,2011-01-18T00:00:00,Carbohydrates,D09
21246608,2011-01-18T00:00:00,Fatty Acids,D10.251
21251980,2011-01-18T00:00:00,Alligators and Crocodiles,B01.050.150.900.833.100
21251980,2011-01-18T00:00:00,Animals,B01.050
21251980,2011-01-18T00:00:00,Environmental Exposure,N06.850.460.350
21251980,2011-01-18T00:00:00,Environmental Pollutants,D27.888.284
21251980,2011-01-18T00:00:00,Signal Transduction,G02.111.087.800
21251980,2011-01-18T00:00:00,Signal Transduction,G02.149.115.800
21251980,2011-01-18T00:00:00,Signal Transduction,G04.299.880
21251980,2011-01-18T00:00:00,Transforming Growth Factor beta,D12.644.276.374.687
21251980,2011-01-18T00:00:00,Transforming Growth Factor beta,D12.644.276.954.800.720
21251980,2011-01-18T00:00:00,Transforming Growth Factor beta,D12.644.276.963.720
21251980,2011-01-18T00:00:00,Transforming Growth Factor beta,D12.776.467.374.687
21251980,2011-01-18T00:00:00,Transforming Growth Factor beta,D12.776.467.942.800.720
21251980,2011-01-18T00:00:00,Transforming Growth Factor beta,D12.776.467.960.720
21251980,2011-01-18T00:00:00,Transforming Growth Factor beta,D23.529.374.687
21251980,2011-01-18T00:00:00,Transforming Growth Factor beta,D23.529.942.800.720
21251980,2011-01-18T00:00:00,Transforming Growth Factor beta,D23.529.960.720
21255677,2011-01-18T00:00:00,"Cardiac Pacing, Artificial",E02.145
21255677,2011-01-18T00:00:00,"Defibrillators, Implantable",E07.305.250.159.175
21255677,2011-01-18T00:00:00,"Defibrillators, Implantable",E07.305.250.319.175
21255677,2011-01-18T00:00:00,"Defibrillators, Implantable",E07.695.175
21255677,2011-01-18T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21143599,2011-01-19T00:00:00,Animals,B01.050
21143599,2011-01-19T00:00:00,"Animals, Newborn",B01.050.050.282
21143599,2011-01-19T00:00:00,Apoptosis,G04.299.139.160
21143599,2011-01-19T00:00:00,Cell Survival,G04.299.316
21143599,2011-01-19T00:00:00,Oligodendroglia,A08.637.600
21143599,2011-01-19T00:00:00,Oligodendroglia,A11.650.600
21143599,2011-01-19T00:00:00,Oxidative Stress,G03.495.710
21143599,2011-01-19T00:00:00,Oxidative Stress,G07.700.830.750
21143599,2011-01-19T00:00:00,Rats,B01.050.150.900.649.865.635.505.700
21143599,2011-01-19T00:00:00,Reactive Oxygen Species,D01.339.431
21143599,2011-01-19T00:00:00,Reactive Oxygen Species,D01.650.775
21143599,2011-01-19T00:00:00,Stem Cells,A11.872
21143599,2011-01-19T00:00:00,Tumor Necrosis Factor-alpha,D12.644.276.374.500.800
21143599,2011-01-19T00:00:00,Tumor Necrosis Factor-alpha,D12.644.276.374.750.626
21143599,2011-01-19T00:00:00,Tumor Necrosis Factor-alpha,D12.644.276.972.626
21143599,2011-01-19T00:00:00,Tumor Necrosis Factor-alpha,D12.776.124.900
21143599,2011-01-19T00:00:00,Tumor Necrosis Factor-alpha,D12.776.395.930
21143599,2011-01-19T00:00:00,Tumor Necrosis Factor-alpha,D12.776.467.374.500.800
21143599,2011-01-19T00:00:00,Tumor Necrosis Factor-alpha,D12.776.467.374.750.626
21143599,2011-01-19T00:00:00,Tumor Necrosis Factor-alpha,D12.776.467.972.626
21143599,2011-01-19T00:00:00,Tumor Necrosis Factor-alpha,D23.529.374.500.800
21143599,2011-01-19T00:00:00,Tumor Necrosis Factor-alpha,D23.529.374.750.626
21143599,2011-01-19T00:00:00,Tumor Necrosis Factor-alpha,D23.529.972.626
21248106,2011-01-19T00:00:00,Animals,B01.050
21248106,2011-01-19T00:00:00,Cocaine,D02.145.074.722.388
21248106,2011-01-19T00:00:00,Cocaine,D03.132.889.354
21248106,2011-01-19T00:00:00,Cocaine,D03.605.869.388
21248106,2011-01-19T00:00:00,Cocaine,D04.075.080.875.099.722.388
21248106,2011-01-19T00:00:00,Cues,F02.463.425.234
21248106,2011-01-19T00:00:00,Mitogen-Activated Protein Kinases,D08.811.913.696.620.682.700.567
21248106,2011-01-19T00:00:00,Mitogen-Activated Protein Kinases,D08.811.913.696.620.682.700.646.750
21248106,2011-01-19T00:00:00,Mitogen-Activated Protein Kinases,D12.644.360.450
21248106,2011-01-19T00:00:00,Mitogen-Activated Protein Kinases,D12.776.476.450
21248106,2011-01-19T00:00:00,Motivation,F01.658
21248106,2011-01-19T00:00:00,Motivation,F01.752.543.500.750
21248106,2011-01-19T00:00:00,Nucleus Accumbens,A08.186.211.730.885.287.249.683
21248106,2011-01-19T00:00:00,Phosphorylation,G02.111.087.677
21248106,2011-01-19T00:00:00,Phosphorylation,G02.149.115.677
21248106,2011-01-19T00:00:00,Phosphorylation,G02.149.465.700
21248106,2011-01-19T00:00:00,Phosphorylation,G02.607.750.700
21248106,2011-01-19T00:00:00,Phosphorylation,G03.495.790
21248106,2011-01-19T00:00:00,Prefrontal Cortex,A08.186.211.730.885.287.500.270.700
21248106,2011-01-19T00:00:00,Rats,B01.050.150.900.649.865.635.505.700
21248106,2011-01-19T00:00:00,"Rats, Sprague-Dawley",B01.050.150.900.649.865.635.505.700.750
21248106,2011-01-19T00:00:00,Self Administration,E02.319.890
21248106,2011-01-19T00:00:00,Self Administration,E02.900.890
21248273,2011-01-19T00:00:00,Adult,M01.060.116
21248273,2011-01-19T00:00:00,Brain Ischemia,C10.228.140.300.150
21248273,2011-01-19T00:00:00,Brain Ischemia,C14.907.253.092
21248273,2011-01-19T00:00:00,HIV Infections,C02.782.815.616.400
21248273,2011-01-19T00:00:00,HIV Infections,C02.800.801.400
21248273,2011-01-19T00:00:00,HIV Infections,C20.673.480
21248273,2011-01-19T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21248273,2011-01-19T00:00:00,Incidence,E05.318.308.985.525.375
21248273,2011-01-19T00:00:00,Incidence,L01.280.975.525.375
21248273,2011-01-19T00:00:00,Incidence,N01.224.935.597.500
21248273,2011-01-19T00:00:00,Incidence,N06.850.505.400.975.525.375
21248273,2011-01-19T00:00:00,Incidence,N06.850.520.308.985.525.375
21248273,2011-01-19T00:00:00,Middle Aged,M01.060.116.630
21248273,2011-01-19T00:00:00,Risk Factors,E05.318.740.600.800.725
21248273,2011-01-19T00:00:00,Risk Factors,N05.715.350.200.700
21248273,2011-01-19T00:00:00,Risk Factors,N05.715.360.750.625.700.700
21248273,2011-01-19T00:00:00,Risk Factors,N06.850.490.625.750
21248273,2011-01-19T00:00:00,Risk Factors,N06.850.520.830.600.800.725
21248273,2011-01-19T00:00:00,Stroke,C10.228.140.300.775
21248273,2011-01-19T00:00:00,Stroke,C14.907.253.855
21248273,2011-01-19T00:00:00,United States,Z01.107.567.875
21255617,2011-01-19T00:00:00,Animals,B01.050
21255617,2011-01-19T00:00:00,Cell Line,A11.251.210
21255617,2011-01-19T00:00:00,Cytokines,D12.644.276.374
21255617,2011-01-19T00:00:00,Cytokines,D12.776.467.374
21255617,2011-01-19T00:00:00,Cytokines,D23.529.374
21255617,2011-01-19T00:00:00,Endotoxemia,C01.539.757.100.275
21255617,2011-01-19T00:00:00,Endotoxemia,C01.539.861.375
21255617,2011-01-19T00:00:00,Endotoxemia,C23.550.470.790.500.100.275
21255617,2011-01-19T00:00:00,"GTP-Binding Protein alpha Subunits, Gi-Go",D08.811.277.040.330.300.200.100.200
21255617,2011-01-19T00:00:00,"GTP-Binding Protein alpha Subunits, Gi-Go",D12.644.360.375.100.200
21255617,2011-01-19T00:00:00,"GTP-Binding Protein alpha Subunits, Gi-Go",D12.776.157.325.332.100.200
21255617,2011-01-19T00:00:00,"GTP-Binding Protein alpha Subunits, Gi-Go",D12.776.476.375.100.200
21255617,2011-01-19T00:00:00,"GTP-Binding Protein alpha Subunits, Gi-Go",D12.776.543.325.100.200
21255617,2011-01-19T00:00:00,Gene Deletion,G05.355.600.800.320
21255617,2011-01-19T00:00:00,Gene Deletion,G05.365.590.762.320
21255617,2011-01-19T00:00:00,Lipopolysaccharides,D09.400.500
21255617,2011-01-19T00:00:00,Lipopolysaccharides,D09.698.718.450
21255617,2011-01-19T00:00:00,Lipopolysaccharides,D10.494
21255617,2011-01-19T00:00:00,Lipopolysaccharides,D23.050.161.616.525
21255617,2011-01-19T00:00:00,Lipopolysaccharides,D23.946.123.329.500
21255617,2011-01-19T00:00:00,Peptides,D12.644
21255617,2011-01-19T00:00:00,Sepsis,C01.539.757
21255617,2011-01-19T00:00:00,Sepsis,C23.550.470.790.500
21255617,2011-01-19T00:00:00,Spleen,A10.549.700
21255617,2011-01-19T00:00:00,Spleen,A15.382.520.604.700
21255617,2011-01-19T00:00:00,"T-Lymphocytes, Helper-Inducer",A11.118.637.555.567.569.200.400
21255617,2011-01-19T00:00:00,"T-Lymphocytes, Helper-Inducer",A15.145.229.637.555.567.569.200.400
21255617,2011-01-19T00:00:00,"T-Lymphocytes, Helper-Inducer",A15.382.490.555.567.569.200.400
21251738,2011-01-20T00:00:00,Gait,E01.370.600.250
21251738,2011-01-20T00:00:00,Gait,G11.427.590.530.389
21251738,2011-01-20T00:00:00,"Gait Disorders, Neurologic",C10.597.404
21251738,2011-01-20T00:00:00,"Gait Disorders, Neurologic",C23.888.592.413
21251738,2011-01-20T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21251738,2011-01-20T00:00:00,Leg,A01.378.610.500
21251738,2011-01-20T00:00:00,Middle Aged,M01.060.116.630
21251738,2011-01-20T00:00:00,Muscle Contraction,G11.427.590.540
21251738,2011-01-20T00:00:00,"Muscle, Skeletal",A02.633.567
21251738,2011-01-20T00:00:00,"Muscle, Skeletal",A10.690.552.500
21251738,2011-01-20T00:00:00,Paresis,C10.597.636
21251738,2011-01-20T00:00:00,Paresis,C23.888.592.643
21251738,2011-01-20T00:00:00,Stroke,C10.228.140.300.775
21251738,2011-01-20T00:00:00,Stroke,C14.907.253.855
21251738,2011-01-20T00:00:00,Walking,G11.427.590.530.568.900
21251738,2011-01-20T00:00:00,Walking,G11.427.590.530.698.940
21251738,2011-01-20T00:00:00,Walking,I03.450.642.845.940
21254296,2011-01-20T00:00:00,Adolescent,M01.060.057
21254296,2011-01-20T00:00:00,Adult,M01.060.116
21254296,2011-01-20T00:00:00,Aged,M01.060.116.100
21254296,2011-01-20T00:00:00,Chronic Disease,C23.550.291.500
21254296,2011-01-20T00:00:00,Diagnostic Imaging,E01.370.350
21254296,2011-01-20T00:00:00,Endoscopy,E01.370.388.250
21254296,2011-01-20T00:00:00,Endoscopy,E04.800.250
21254296,2011-01-20T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21254296,2011-01-20T00:00:00,Middle Aged,M01.060.116.630
21254296,2011-01-20T00:00:00,Sialadenitis,C07.465.815.793
21254296,2011-01-20T00:00:00,Stents,E07.695.750
21254296,2011-01-20T00:00:00,Steroids,D04.808
21254296,2011-01-20T00:00:00,Young Adult,M01.060.116.815
21254394,2011-01-20T00:00:00,Animals,B01.050
21254394,2011-01-20T00:00:00,Apoptosis,G04.299.139.160
21254394,2011-01-20T00:00:00,Blood Glucose,D09.546.359.448.500
21254394,2011-01-20T00:00:00,Caspases,D08.811.277.656.262.500.126
21254394,2011-01-20T00:00:00,Caspases,D08.811.277.656.300.200.126
21254394,2011-01-20T00:00:00,Caspases,D12.644.360.075.405
21254394,2011-01-20T00:00:00,Caspases,D12.776.476.075.405
21254394,2011-01-20T00:00:00,Embryonic Development,G07.700.320.500.325.180
21254394,2011-01-20T00:00:00,Embryonic Development,G08.686.785.760.170.104
21254394,2011-01-20T00:00:00,Fetal Diseases,C13.703.277
21254394,2011-01-20T00:00:00,Fetal Diseases,C16.300
21254394,2011-01-20T00:00:00,Glutathione,D12.644.456.448
21254394,2011-01-20T00:00:00,Lipids,D10
21254394,2011-01-20T00:00:00,Oxidative Stress,G03.495.710
21254394,2011-01-20T00:00:00,Oxidative Stress,G07.700.830.750
21254394,2011-01-20T00:00:00,Pregnancy,G08.686.785.760.769
21254394,2011-01-20T00:00:00,Rats,B01.050.150.900.649.865.635.505.700
21254394,2011-01-20T00:00:00,"Rats, Sprague-Dawley",B01.050.150.900.649.865.635.505.700.750
21254394,2011-01-20T00:00:00,Stilbenes,D02.455.426.559.389.150.700
21318025,2011-01-20T00:00:00,Adult,M01.060.116
21318025,2011-01-20T00:00:00,Age Factors,N05.715.350.075
21318025,2011-01-20T00:00:00,Age Factors,N06.850.490.250
21318025,2011-01-20T00:00:00,Benzazepines,D03.438.079
21318025,2011-01-20T00:00:00,Health Surveys,E05.318.308.250
21318025,2011-01-20T00:00:00,Health Surveys,N05.715.360.300.375
21318025,2011-01-20T00:00:00,Health Surveys,N06.850.520.308.250
21318025,2011-01-20T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21318025,2011-01-20T00:00:00,Nicotinic Agonists,D27.505.519.625.120.140.700
21318025,2011-01-20T00:00:00,Nicotinic Agonists,D27.505.696.577.120.140.700
21318025,2011-01-20T00:00:00,Sex Factors,N05.715.350.675
21318025,2011-01-20T00:00:00,Sex Factors,N06.850.490.875
21318025,2011-01-20T00:00:00,Smoking Cessation,F01.145.940.700
21318025,2011-01-20T00:00:00,United States,Z01.107.567.875
21318026,2011-01-20T00:00:00,Adult,M01.060.116
21318026,2011-01-20T00:00:00,Cost Savings,N03.219.151.160.200
21318026,2011-01-20T00:00:00,Health Surveys,E05.318.308.250
21318026,2011-01-20T00:00:00,Health Surveys,N05.715.360.300.375
21318026,2011-01-20T00:00:00,Health Surveys,N06.850.520.308.250
21318026,2011-01-20T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21318026,2011-01-20T00:00:00,Smoking,F01.145.466.753
21318026,2011-01-20T00:00:00,United States,Z01.107.567.875
21356576,2011-01-20T00:00:00,Adolescent,M01.060.057
21356576,2011-01-20T00:00:00,Depressive Disorder,F03.600.300
21356576,2011-01-20T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21356576,2011-01-20T00:00:00,Prescription Drugs,D26.670
21356576,2011-01-20T00:00:00,Rape,I01.198.240.748.640
21356576,2011-01-20T00:00:00,Risk Factors,E05.318.740.600.800.725
21356576,2011-01-20T00:00:00,Risk Factors,N05.715.350.200.700
21356576,2011-01-20T00:00:00,Risk Factors,N05.715.360.750.625.700.700
21356576,2011-01-20T00:00:00,Risk Factors,N06.850.490.625.750
21356576,2011-01-20T00:00:00,Risk Factors,N06.850.520.830.600.800.725
21356576,2011-01-20T00:00:00,Students,I02.233.748
21356576,2011-01-20T00:00:00,Students,I02.851
21356576,2011-01-20T00:00:00,Students,M01.848
21356576,2011-01-20T00:00:00,Substance-Related Disorders,C21.739
21356576,2011-01-20T00:00:00,Substance-Related Disorders,F03.900
21356576,2011-01-20T00:00:00,United States,Z01.107.567.875
21356576,2011-01-20T00:00:00,Young Adult,M01.060.116.815
21256560,2011-01-21T00:00:00,Aged,M01.060.116.100
21256560,2011-01-21T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21256560,2011-01-21T00:00:00,Middle Aged,M01.060.116.630
21256560,2011-01-21T00:00:00,Prostatectomy,E04.950.774.860.625
21256560,2011-01-21T00:00:00,Urethra,A05.360.444.492.726
21256560,2011-01-21T00:00:00,Urethra,A05.810.876
21256560,2011-01-21T00:00:00,Urinary Incontinence,C12.777.934.852
21256560,2011-01-21T00:00:00,Urinary Incontinence,C13.351.968.934.814
21256560,2011-01-21T00:00:00,Urinary Incontinence,C23.888.942.800
21256560,2011-01-21T00:00:00,Urodynamics,G08.852.898
21257205,2011-01-22T00:00:00,Animals,B01.050
21257205,2011-01-22T00:00:00,Choroidal Neovascularization,C11.941.160.244
21257205,2011-01-22T00:00:00,Choroidal Neovascularization,C23.550.589.500.145
21257205,2011-01-22T00:00:00,"Complement Pathway, Alternative",G12.425.255.695
21257205,2011-01-22T00:00:00,Complement System Proteins,D12.776.124.486.274
21257205,2011-01-22T00:00:00,Gene Expression Regulation,G05.355.315
21257205,2011-01-22T00:00:00,"RNA, Messenger",D13.444.735.544
21257205,2011-01-22T00:00:00,Retina,A09.371.729
21257205,2011-01-22T00:00:00,Vascular Endothelial Growth Factor A,D12.644.276.100.800.200
21257205,2011-01-22T00:00:00,Vascular Endothelial Growth Factor A,D12.776.467.100.800.200
21257205,2011-01-22T00:00:00,Vascular Endothelial Growth Factor A,D23.529.100.800.200
21257244,2011-01-22T00:00:00,Adult,M01.060.116
21257244,2011-01-22T00:00:00,Aged,M01.060.116.100
21257244,2011-01-22T00:00:00,Albuminuria,C12.777.934.734.269
21257244,2011-01-22T00:00:00,Albuminuria,C13.351.968.934.734.269
21257244,2011-01-22T00:00:00,Albuminuria,C23.888.942.750.269
21257244,2011-01-22T00:00:00,Chronic Disease,C23.550.291.500
21257244,2011-01-22T00:00:00,Creatinine,D03.383.129.308.207
21257244,2011-01-22T00:00:00,"Diagnosis, Differential",E01.171
21257244,2011-01-22T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21257244,2011-01-22T00:00:00,Incidence,E05.318.308.985.525.375
21257244,2011-01-22T00:00:00,Incidence,L01.280.975.525.375
21257244,2011-01-22T00:00:00,Incidence,N01.224.935.597.500
21257244,2011-01-22T00:00:00,Incidence,N06.850.505.400.975.525.375
21257244,2011-01-22T00:00:00,Incidence,N06.850.520.308.985.525.375
21257244,2011-01-22T00:00:00,Kidney Diseases,C12.777.419
21257244,2011-01-22T00:00:00,Kidney Diseases,C13.351.968.419
21257244,2011-01-22T00:00:00,Middle Aged,M01.060.116.630
21257244,2011-01-22T00:00:00,Primary Health Care,N04.590.233.727
21257244,2011-01-22T00:00:00,United States,Z01.107.567.875
21258145,2011-01-24T00:00:00,Cobalt,D01.268.556.185
21258145,2011-01-24T00:00:00,Cobalt,D01.268.956.155
21258145,2011-01-24T00:00:00,Cobalt,D01.552.544.185
21258145,2011-01-24T00:00:00,Computer Simulation,L01.224.160
21258145,2011-01-24T00:00:00,Crystallization,E05.196.300
21258145,2011-01-24T00:00:00,Crystallization,G02.149.767.505
21258145,2011-01-24T00:00:00,Crystallization,G02.842.750.505
21258145,2011-01-24T00:00:00,Materials Testing,E05.570
21258145,2011-01-24T00:00:00,"Models, Chemical",E05.599.495
21258145,2011-01-24T00:00:00,Nanostructures,J01.637.512
21258145,2011-01-24T00:00:00,Nanotechnology,H01.603
21258145,2011-01-24T00:00:00,Nanotechnology,J01.897.520.600
21258145,2011-01-24T00:00:00,Nonlinear Dynamics,E05.599.850
21258145,2011-01-24T00:00:00,Nonlinear Dynamics,H01.548.675
21258145,2011-01-24T00:00:00,Refractometry,E05.196.808
21258145,2011-01-24T00:00:00,Refractometry,H01.671.617.755
21258145,2011-01-24T00:00:00,Surface Properties,G02.842.850
21258145,2011-01-24T00:00:00,Zinc Oxide,D01.650.550.975
21258145,2011-01-24T00:00:00,Zinc Oxide,D01.975.975
21261450,2011-01-24T00:00:00,Acoustic Stimulation,E02.037
21261450,2011-01-24T00:00:00,Acoustic Stimulation,E02.190.888.030
21261450,2011-01-24T00:00:00,Acoustic Stimulation,E05.723.136
21261450,2011-01-24T00:00:00,Adolescent,M01.060.057
21261450,2011-01-24T00:00:00,Adult,M01.060.116
21261450,2011-01-24T00:00:00,Brain Mapping,E01.370.350.086
21261450,2011-01-24T00:00:00,Brain Mapping,E01.370.376.149
21261450,2011-01-24T00:00:00,Brain Mapping,E05.132
21261450,2011-01-24T00:00:00,Frontal Lobe,A08.186.211.730.885.287.500.270
21261450,2011-01-24T00:00:00,Functional Laterality,F02.830.297.425
21261450,2011-01-24T00:00:00,Functional Laterality,G11.561.225.425
21261450,2011-01-24T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21261450,2011-01-24T00:00:00,"Image Processing, Computer-Assisted",L01.224.308
21261450,2011-01-24T00:00:00,Magnetic Resonance Imaging,E01.370.350.500
21261450,2011-01-24T00:00:00,Magnetic Resonance Imaging,E01.370.350.825.500
21261450,2011-01-24T00:00:00,Oxygen,D01.268.185.550
21261450,2011-01-24T00:00:00,Oxygen,D01.362.670
21261450,2011-01-24T00:00:00,"Pattern Recognition, Physiological",F02.463.593.524
21261450,2011-01-24T00:00:00,Reaction Time,F02.830.650
21261450,2011-01-24T00:00:00,Reaction Time,F04.669.817
21261450,2011-01-24T00:00:00,Reaction Time,G11.561.677
21261450,2011-01-24T00:00:00,Speech Perception,F02.463.593.071.875
21261450,2011-01-24T00:00:00,Temporal Lobe,A08.186.211.730.885.287.500.863
21261450,2011-01-24T00:00:00,Vocabulary,L01.143.506.598.901
21261450,2011-01-24T00:00:00,Young Adult,M01.060.116.815
21265818,2011-01-25T00:00:00,Aged,M01.060.116.100
21265818,2011-01-25T00:00:00,"Anesthesia, General",E03.155.197
21265818,2011-01-25T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21265818,2011-01-25T00:00:00,Masks,E07.700.500
21265818,2011-01-25T00:00:00,Masks,J01.637.708.500
21265818,2011-01-25T00:00:00,Middle Aged,M01.060.116.630
21265818,2011-01-25T00:00:00,Neuromuscular Blockade,E03.706
21265818,2011-01-25T00:00:00,Neuromuscular Blockade,E05.635
21265818,2011-01-25T00:00:00,"Respiration, Artificial",E02.365.647.729
21265818,2011-01-25T00:00:00,"Respiration, Artificial",E02.880.820
21265818,2011-01-25T00:00:00,Tidal Volume,E01.370.386.700.485.750.900.350.750
21265818,2011-01-25T00:00:00,Tidal Volume,G09.772.850.970.500.700
21366847,2011-01-25T00:00:00,Age Factors,N05.715.350.075
21366847,2011-01-25T00:00:00,Age Factors,N06.850.490.250
21366847,2011-01-25T00:00:00,Aged,M01.060.116.100
21366847,2011-01-25T00:00:00,Amides,D02.065
21366847,2011-01-25T00:00:00,Antihypertensive Agents,D27.505.954.411.162
21366847,2011-01-25T00:00:00,Blood Pressure,E01.370.600.875.249
21366847,2011-01-25T00:00:00,Blood Pressure,G09.330.380.076
21366847,2011-01-25T00:00:00,Body Mass Index,E01.370.600.115.100.125
21366847,2011-01-25T00:00:00,Body Mass Index,E05.041.124.125
21366847,2011-01-25T00:00:00,Body Mass Index,G07.100.100.125
21366847,2011-01-25T00:00:00,Body Mass Index,N06.850.505.200.100.175
21366847,2011-01-25T00:00:00,Disease Progression,C23.550.291.656
21366847,2011-01-25T00:00:00,Double-Blind Method,E05.318.780.300
21366847,2011-01-25T00:00:00,Double-Blind Method,E05.581.500.300
21366847,2011-01-25T00:00:00,Double-Blind Method,N05.715.360.780.320
21366847,2011-01-25T00:00:00,Double-Blind Method,N06.850.520.445.300
21366847,2011-01-25T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21366847,2011-01-25T00:00:00,Hypertension,C14.907.489
21366847,2011-01-25T00:00:00,Middle Aged,M01.060.116.630
21366847,2011-01-25T00:00:00,Treatment Outcome,E01.789.800
21366847,2011-01-25T00:00:00,Treatment Outcome,N04.761.559.590.800
21366847,2011-01-25T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21366847,2011-01-25T00:00:00,United States,Z01.107.567.875
21990827,2011-01-25T00:00:00,Animals,B01.050
21990827,2011-01-25T00:00:00,Blood Vessel Prosthesis,E07.695.110
21990827,2011-01-25T00:00:00,Carotid Arteries,A07.231.114.186
21990827,2011-01-25T00:00:00,"Disease Models, Animal",C22.232
21990827,2011-01-25T00:00:00,"Disease Models, Animal",E05.598.500
21990827,2011-01-25T00:00:00,"Disease Models, Animal",E05.599.395.080
21990827,2011-01-25T00:00:00,Dogs,B01.050.150.900.649.147.153.200
21990827,2011-01-25T00:00:00,"Embolization, Therapeutic",E02.520.360
21990827,2011-01-25T00:00:00,Intracranial Aneurysm,C10.228.140.300.510.600
21990827,2011-01-25T00:00:00,Intracranial Aneurysm,C14.907.055.635
21990827,2011-01-25T00:00:00,Intracranial Aneurysm,C14.907.253.560.300
21270158,2011-01-26T00:00:00,"Antigens, Viral",D23.050.327
21270158,2011-01-26T00:00:00,Cell Movement,G04.299.283
21270158,2011-01-26T00:00:00,Cell Movement,G07.700.560.500.180
21270158,2011-01-26T00:00:00,Cell Survival,G04.299.316
21270158,2011-01-26T00:00:00,Gene Expression Regulation,G05.355.315
21270158,2011-01-26T00:00:00,Host-Pathogen Interactions,G06.590.470
21270158,2011-01-26T00:00:00,Host-Pathogen Interactions,G16.100.380
21270158,2011-01-26T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21270158,2011-01-26T00:00:00,Nuclear Proteins,D12.776.660
21270442,2011-01-26T00:00:00,Adult,M01.060.116
21270442,2011-01-26T00:00:00,Aged,M01.060.116.100
21270442,2011-01-26T00:00:00,Antineoplastic Combined Chemotherapy Protocols,E02.183.750.500
21270442,2011-01-26T00:00:00,Antineoplastic Combined Chemotherapy Protocols,E02.319.077.500
21270442,2011-01-26T00:00:00,Antineoplastic Combined Chemotherapy Protocols,E02.319.310.037
21270442,2011-01-26T00:00:00,"Chemotherapy, Adjuvant",E02.186.170
21270442,2011-01-26T00:00:00,"Chemotherapy, Adjuvant",E02.319.170
21270442,2011-01-26T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21270442,2011-01-26T00:00:00,"Leukemia, Myeloid, Acute",C04.557.337.539.550
21270442,2011-01-26T00:00:00,Middle Aged,M01.060.116.630
21270442,2011-01-26T00:00:00,Protein Kinase Inhibitors,D27.505.519.389.755
21270442,2011-01-26T00:00:00,Remission Induction,E02.860
21270442,2011-01-26T00:00:00,Salvage Therapy,E02.186.800
21270442,2011-01-26T00:00:00,Salvage Therapy,E02.895
21270442,2011-01-26T00:00:00,Young Adult,M01.060.116.815
21556189,2011-01-26T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21556189,2011-01-26T00:00:00,Internationality,I01.615
21556189,2011-01-26T00:00:00,Smoking,F01.145.466.753
21556189,2011-01-26T00:00:00,Tobacco,B01.650.388.100.905.900
21270825,2011-01-27T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21270825,2011-01-27T00:00:00,"Lupus Erythematosus, Systemic",C17.300.480
21270825,2011-01-27T00:00:00,"Lupus Erythematosus, Systemic",C20.111.590
21270825,2011-01-27T00:00:00,Mutation,G05.365.590
21270825,2011-01-27T00:00:00,Phenotype,G05.695
21270825,2011-01-27T00:00:00,Phosphoproteins,D12.776.744
21270825,2011-01-27T00:00:00,"Polymorphism, Single Nucleotide",G05.365.795.598
21273292,2011-01-27T00:00:00,Adult,M01.060.116
21273292,2011-01-27T00:00:00,Aged,M01.060.116.100
21273292,2011-01-27T00:00:00,Echocardiography,E01.370.350.850.220
21273292,2011-01-27T00:00:00,Echocardiography,E01.370.370.380.220
21273292,2011-01-27T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21273292,2011-01-27T00:00:00,Liver Cirrhosis,C06.552.630
21273292,2011-01-27T00:00:00,Middle Aged,M01.060.116.630
21273292,2011-01-27T00:00:00,Neutrophils,A11.118.637.415.583
21273292,2011-01-27T00:00:00,Neutrophils,A11.627.340.583
21273292,2011-01-27T00:00:00,Neutrophils,A11.733.689
21273292,2011-01-27T00:00:00,Neutrophils,A15.145.229.637.415.583
21273292,2011-01-27T00:00:00,Neutrophils,A15.382.490.315.583
21273292,2011-01-27T00:00:00,Neutrophils,A15.382.680.689
21273292,2011-01-27T00:00:00,Paracentesis,E01.450.865.632.600
21273292,2011-01-27T00:00:00,Paracentesis,E02.800.550
21273292,2011-01-27T00:00:00,Paracentesis,E04.581
21273292,2011-01-27T00:00:00,Pleural Effusion,C08.528.652
21273292,2011-01-27T00:00:00,Proteins,D12.776
21273292,2011-01-27T00:00:00,Serum Albumin,D12.776.034.841
21273292,2011-01-27T00:00:00,Serum Albumin,D12.776.124.050.700
21273292,2011-01-27T00:00:00,Serum Albumin,D12.776.124.727
21273292,2011-01-27T00:00:00,"Tomography, X-Ray Computed",E01.370.350.350.810
21273292,2011-01-27T00:00:00,"Tomography, X-Ray Computed",E01.370.350.600.350.700.810
21273292,2011-01-27T00:00:00,"Tomography, X-Ray Computed",E01.370.350.700.700.810
21273292,2011-01-27T00:00:00,"Tomography, X-Ray Computed",E01.370.350.700.810.810
21273292,2011-01-27T00:00:00,"Tomography, X-Ray Computed",E01.370.350.825.810.810
21273292,2011-01-27T00:00:00,"Ultrasonography, Interventional",E01.370.350.850.855
21273292,2011-01-27T00:00:00,Young Adult,M01.060.116.815
21273994,2011-01-27T00:00:00,Adult,M01.060.116
21273994,2011-01-27T00:00:00,Body Mass Index,E01.370.600.115.100.125
21273994,2011-01-27T00:00:00,Body Mass Index,E05.041.124.125
21273994,2011-01-27T00:00:00,Body Mass Index,G07.100.100.125
21273994,2011-01-27T00:00:00,Body Mass Index,N06.850.505.200.100.175
21273994,2011-01-27T00:00:00,Coronary Artery Disease,C14.280.647.250.260
21273994,2011-01-27T00:00:00,Coronary Artery Disease,C14.907.137.126.339
21273994,2011-01-27T00:00:00,Coronary Artery Disease,C14.907.585.250.260
21273994,2011-01-27T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21273994,2011-01-27T00:00:00,Middle Aged,M01.060.116.630
21273994,2011-01-27T00:00:00,Obesity,C18.654.726.500
21273994,2011-01-27T00:00:00,Obesity,C23.888.144.699.500
21273994,2011-01-27T00:00:00,Obesity,E01.370.600.115.100.160.120.699.500
21273994,2011-01-27T00:00:00,Obesity,G07.100.100.160.120.699.500
21273994,2011-01-27T00:00:00,Oxygen,D01.268.185.550
21273994,2011-01-27T00:00:00,Oxygen,D01.362.670
21273994,2011-01-27T00:00:00,Quality of Life,I01.800
21273994,2011-01-27T00:00:00,Quality of Life,K01.752.400.750
21273994,2011-01-27T00:00:00,Questionnaires,E05.318.308.750
21273994,2011-01-27T00:00:00,Questionnaires,L01.280.800
21273994,2011-01-27T00:00:00,Questionnaires,N05.715.360.300.695
21273994,2011-01-27T00:00:00,Questionnaires,N06.850.520.308.750
21273994,2011-01-27T00:00:00,Sexuality,F01.145.802.975
21273994,2011-01-27T00:00:00,Sexuality,G08.686.867
21273994,2011-01-27T00:00:00,Testosterone,D04.808.054.079.429.824
21273994,2011-01-27T00:00:00,Testosterone,D06.472.334.851.968.984
21273994,2011-01-27T00:00:00,Time Factors,G01.910.857
21496512,2011-01-27T00:00:00,Adult,M01.060.116
21496512,2011-01-27T00:00:00,Anxiety,F01.470.132
21496512,2011-01-27T00:00:00,Combat Disorders,F03.080.931.249
21496512,2011-01-27T00:00:00,Depression,F01.145.126.350
21496512,2011-01-27T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21496512,2011-01-27T00:00:00,Implosive Therapy,F04.754.137.506.325
21496512,2011-01-27T00:00:00,Middle Aged,M01.060.116.630
21496512,2011-01-27T00:00:00,Psychiatric Status Rating Scales,F04.586
21496512,2011-01-27T00:00:00,"Stress Disorders, Post-Traumatic",F03.080.931.500
21496512,2011-01-27T00:00:00,Telemedicine,H02.403.840
21496512,2011-01-27T00:00:00,Telemedicine,L01.178.847.652
21496512,2011-01-27T00:00:00,Telemedicine,N04.590.374.800
21496512,2011-01-27T00:00:00,Treatment Outcome,E01.789.800
21496512,2011-01-27T00:00:00,Treatment Outcome,N04.761.559.590.800
21496512,2011-01-27T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21496512,2011-01-27T00:00:00,Veterans,M01.930
21274703,2011-01-28T00:00:00,Adult,M01.060.116
21274703,2011-01-28T00:00:00,Alcohol Drinking,F01.145.317.269
21274703,2011-01-28T00:00:00,Alcoholism,C21.739.100.250
21274703,2011-01-28T00:00:00,Alcoholism,F03.900.100.350
21274703,2011-01-28T00:00:00,Ethanol,D02.033.375
21274703,2011-01-28T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21274703,2011-01-28T00:00:00,Middle Aged,M01.060.116.630
21274703,2011-01-28T00:00:00,"Models, Psychological",E05.599.695
21274703,2011-01-28T00:00:00,Psychological Tests,F04.711
21274703,2011-01-28T00:00:00,"Stress, Psychological",F01.145.126.990
21274703,2011-01-28T00:00:00,"Stress, Psychological",F02.830.900
21274703,2011-01-28T00:00:00,Young Adult,M01.060.116.815
21275975,2011-01-28T00:00:00,Adolescent,M01.060.057
21275975,2011-01-28T00:00:00,Adult,M01.060.116
21275975,2011-01-28T00:00:00,Aged,M01.060.116.100
21275975,2011-01-28T00:00:00,Animals,B01.050
21275975,2011-01-28T00:00:00,Child,M01.060.406
21275975,2011-01-28T00:00:00,"Child, Preschool",M01.060.406.448
21275975,2011-01-28T00:00:00,Data Collection,E05.318.308
21275975,2011-01-28T00:00:00,Data Collection,L01.280
21275975,2011-01-28T00:00:00,Data Collection,N05.715.360.300
21275975,2011-01-28T00:00:00,Data Collection,N06.850.520.308
21275975,2011-01-28T00:00:00,Epilepsy,C10.228.140.490
21275975,2011-01-28T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21275975,2011-01-28T00:00:00,Infant,M01.060.703
21275975,2011-01-28T00:00:00,Middle Aged,M01.060.116.630
21275975,2011-01-28T00:00:00,Population Surveillance,E05.318.308.250.700
21275975,2011-01-28T00:00:00,Population Surveillance,N05.715.360.300.375.625
21275975,2011-01-28T00:00:00,Population Surveillance,N06.850.520.308.250.700
21275975,2011-01-28T00:00:00,Population Surveillance,N06.850.780.675
21275975,2011-01-28T00:00:00,Swine,B01.050.150.900.649.077.880
21275975,2011-01-28T00:00:00,Young Adult,M01.060.116.815
21277132,2011-01-28T00:00:00,Coronary Artery Disease,C14.280.647.250.260
21277132,2011-01-28T00:00:00,Coronary Artery Disease,C14.907.137.126.339
21277132,2011-01-28T00:00:00,Coronary Artery Disease,C14.907.585.250.260
21277132,2011-01-28T00:00:00,Cost-Benefit Analysis,N03.219.151.125
21277132,2011-01-28T00:00:00,Health Care Costs,N03.219.151.400
21277132,2011-01-28T00:00:00,Health Care Costs,N05.300.375
21277132,2011-01-28T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21277132,2011-01-28T00:00:00,Middle Aged,M01.060.116.630
21277132,2011-01-28T00:00:00,Myocardial Perfusion Imaging,E01.370.350.710.600.500
21277132,2011-01-28T00:00:00,Myocardial Perfusion Imaging,E01.370.370.380.500
21277132,2011-01-28T00:00:00,Myocardial Perfusion Imaging,E01.370.384.730.354.500
21277132,2011-01-28T00:00:00,"Radiography, Dual-Energy Scanned Projection",E01.370.350.600.350.700.700
21277132,2011-01-28T00:00:00,"Radiography, Dual-Energy Scanned Projection",E01.370.350.700.700.700
21277132,2011-01-28T00:00:00,"Radiography, Dual-Energy Scanned Projection",E01.370.350.760.700
21277132,2011-01-28T00:00:00,"Radiography, Dual-Energy Scanned Projection",L01.224.308.380.800
21277132,2011-01-28T00:00:00,"Tomography, Emission-Computed, Single-Photon",E01.370.350.350.800.800
21277132,2011-01-28T00:00:00,"Tomography, Emission-Computed, Single-Photon",E01.370.350.600.350.800.800
21277132,2011-01-28T00:00:00,"Tomography, Emission-Computed, Single-Photon",E01.370.350.710.800.800
21277132,2011-01-28T00:00:00,"Tomography, Emission-Computed, Single-Photon",E01.370.350.825.800.800
21277132,2011-01-28T00:00:00,"Tomography, Emission-Computed, Single-Photon",E01.370.384.730.800.800
21277132,2011-01-28T00:00:00,"Tomography, X-Ray Computed",E01.370.350.350.810
21277132,2011-01-28T00:00:00,"Tomography, X-Ray Computed",E01.370.350.600.350.700.810
21277132,2011-01-28T00:00:00,"Tomography, X-Ray Computed",E01.370.350.700.700.810
21277132,2011-01-28T00:00:00,"Tomography, X-Ray Computed",E01.370.350.700.810.810
21277132,2011-01-28T00:00:00,"Tomography, X-Ray Computed",E01.370.350.825.810.810
21277132,2011-01-28T00:00:00,United States,Z01.107.567.875
21278178,2011-01-28T00:00:00,Aged,M01.060.116.100
21278178,2011-01-28T00:00:00,Carotid Stenosis,C10.228.140.300.200.360
21278178,2011-01-28T00:00:00,Carotid Stenosis,C14.907.137.230
21278178,2011-01-28T00:00:00,Carotid Stenosis,C14.907.253.123.360
21278178,2011-01-28T00:00:00,Coronary Artery Disease,C14.280.647.250.260
21278178,2011-01-28T00:00:00,Coronary Artery Disease,C14.907.137.126.339
21278178,2011-01-28T00:00:00,Coronary Artery Disease,C14.907.585.250.260
21278178,2011-01-28T00:00:00,"Endarterectomy, Carotid",E04.100.814.456.250
21278178,2011-01-28T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21278178,2011-01-28T00:00:00,Middle Aged,M01.060.116.630
21278178,2011-01-28T00:00:00,Myocardial Infarction,C14.280.647.500
21278178,2011-01-28T00:00:00,Myocardial Infarction,C14.907.585.500
21278178,2011-01-28T00:00:00,Risk Assessment,E05.318.740.600.800.715
21278178,2011-01-28T00:00:00,Risk Assessment,N04.452.871.715
21278178,2011-01-28T00:00:00,Risk Assessment,N05.715.360.750.625.700.690
21278178,2011-01-28T00:00:00,Risk Assessment,N06.850.505.715
21278178,2011-01-28T00:00:00,Risk Assessment,N06.850.520.830.600.800.715
21278178,2011-01-28T00:00:00,Risk Factors,E05.318.740.600.800.725
21278178,2011-01-28T00:00:00,Risk Factors,N05.715.350.200.700
21278178,2011-01-28T00:00:00,Risk Factors,N05.715.360.750.625.700.700
21278178,2011-01-28T00:00:00,Risk Factors,N06.850.490.625.750
21278178,2011-01-28T00:00:00,Risk Factors,N06.850.520.830.600.800.725
21278178,2011-01-28T00:00:00,South Carolina,Z01.107.567.875.075.662
21278178,2011-01-28T00:00:00,South Carolina,Z01.107.567.875.750.700
21278178,2011-01-28T00:00:00,Stroke,C10.228.140.300.775
21278178,2011-01-28T00:00:00,Stroke,C14.907.253.855
21278178,2011-01-28T00:00:00,Time Factors,G01.910.857
21278178,2011-01-28T00:00:00,Treatment Outcome,E01.789.800
21278178,2011-01-28T00:00:00,Treatment Outcome,N04.761.559.590.800
21278178,2011-01-28T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21278197,2011-01-28T00:00:00,Aged,M01.060.116.100
21278197,2011-01-28T00:00:00,Cognition,F02.463.188
21278197,2011-01-28T00:00:00,Cognition Disorders,F03.087.250
21278197,2011-01-28T00:00:00,Depression,F01.145.126.350
21278197,2011-01-28T00:00:00,Geriatric Assessment,E05.318.308.225
21278197,2011-01-28T00:00:00,Geriatric Assessment,I01.240.425.350
21278197,2011-01-28T00:00:00,Geriatric Assessment,L01.280.360
21278197,2011-01-28T00:00:00,Geriatric Assessment,N01.224.425.350
21278197,2011-01-28T00:00:00,Geriatric Assessment,N05.715.360.300.360
21278197,2011-01-28T00:00:00,Geriatric Assessment,N06.850.505.400.425.350
21278197,2011-01-28T00:00:00,Geriatric Assessment,N06.850.520.308.225
21278197,2011-01-28T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21278197,2011-01-28T00:00:00,Middle Aged,M01.060.116.630
21278197,2011-01-28T00:00:00,Neuropsychological Tests,F04.711.513
21278197,2011-01-28T00:00:00,Psychiatric Status Rating Scales,F04.586
21278197,2011-01-28T00:00:00,Psychometrics,F04.711.780
21278197,2011-01-28T00:00:00,Veterans,M01.930
21511213,2011-01-28T00:00:00,Clinical Trials as Topic,E05.318.760.535
21511213,2011-01-28T00:00:00,Clinical Trials as Topic,E05.337.250
21511213,2011-01-28T00:00:00,Clinical Trials as Topic,N05.715.360.775.235
21511213,2011-01-28T00:00:00,Clinical Trials as Topic,N06.850.520.450.535
21511213,2011-01-28T00:00:00,"Databases, Factual",L01.470.750.750
21511213,2011-01-28T00:00:00,"Databases, Factual",L01.700.508.300.188.400
21511213,2011-01-28T00:00:00,Depression,F01.145.126.350
21511213,2011-01-28T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21511213,2011-01-28T00:00:00,Transcranial Magnetic Stimulation,E01.370.376.850
21511213,2011-01-28T00:00:00,Transcranial Magnetic Stimulation,E02.621.820
21275961,2011-01-31T00:00:00,Adolescent,M01.060.057
21275961,2011-01-31T00:00:00,Adult,M01.060.116
21275961,2011-01-31T00:00:00,Biological Markers,D23.101
21275961,2011-01-31T00:00:00,Cell Adhesion,G04.299.117
21275961,2011-01-31T00:00:00,Child,M01.060.406
21275961,2011-01-31T00:00:00,"Child, Preschool",M01.060.406.448
21275961,2011-01-31T00:00:00,Double-Blind Method,E05.318.780.300
21275961,2011-01-31T00:00:00,Double-Blind Method,E05.581.500.300
21275961,2011-01-31T00:00:00,Double-Blind Method,N05.715.360.780.320
21275961,2011-01-31T00:00:00,Double-Blind Method,N06.850.520.445.300
21275961,2011-01-31T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21275961,2011-01-31T00:00:00,Middle Aged,M01.060.116.630
21277711,2011-01-31T00:00:00,Adult,M01.060.116
21277711,2011-01-31T00:00:00,"Depressive Disorder, Major",F03.600.300.375
21277711,2011-01-31T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21277711,2011-01-31T00:00:00,"Interview, Psychological",F04.669.599
21277711,2011-01-31T00:00:00,Mental Disorders,F03
21277711,2011-01-31T00:00:00,Middle Aged,M01.060.116.630
21277711,2011-01-31T00:00:00,Opioid-Related Disorders,C21.739.675
21277711,2011-01-31T00:00:00,Opioid-Related Disorders,F03.900.675
21277711,2011-01-31T00:00:00,Psychiatric Status Rating Scales,F04.586
21277711,2011-01-31T00:00:00,Psychomotor Agitation,C10.597.350.600
21277711,2011-01-31T00:00:00,Psychomotor Agitation,C10.597.606.881.700
21277711,2011-01-31T00:00:00,Psychomotor Agitation,C23.888.592.350.600
21277711,2011-01-31T00:00:00,Psychomotor Agitation,C23.888.592.604.882.700
21277711,2011-01-31T00:00:00,Psychomotor Agitation,F01.700.875.700
21277711,2011-01-31T00:00:00,Substance-Related Disorders,C21.739
21277711,2011-01-31T00:00:00,Substance-Related Disorders,F03.900
21280643,2011-01-31T00:00:00,Biosensing Techniques,E05.601.123
21280643,2011-01-31T00:00:00,Calmodulin,D12.644.360.381.249
21280643,2011-01-31T00:00:00,Calmodulin,D12.776.157.125.412.249
21280643,2011-01-31T00:00:00,Calmodulin,D12.776.476.387.249
21280643,2011-01-31T00:00:00,Surface Plasmon Resonance,E05.196.890
21280643,2011-01-31T00:00:00,Surface Plasmon Resonance,E05.601.123.700
21556194,2011-01-31T00:00:00,Adolescent,M01.060.057
21556194,2011-01-31T00:00:00,Adult,M01.060.116
21556194,2011-01-31T00:00:00,Child,M01.060.406
21556194,2011-01-31T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21556194,2011-01-31T00:00:00,Internationality,I01.615
21556194,2011-01-31T00:00:00,Middle Aged,M01.060.116.630
21556194,2011-01-31T00:00:00,Smoking,F01.145.466.753
21556194,2011-01-31T00:00:00,Tobacco Smoke Pollution,D20.633.937.680
21556194,2011-01-31T00:00:00,Tobacco Smoke Pollution,N06.850.460.100.555
21556194,2011-01-31T00:00:00,Workplace,N01.824.245.925
21556194,2011-01-31T00:00:00,Workplace,N04.452.677.975
21556194,2011-01-31T00:00:00,Young Adult,M01.060.116.815
20352526,2011-02-01T00:00:00,Animals,B01.050
20352526,2011-02-01T00:00:00,Autoimmunity,G12.450.192
20352526,2011-02-01T00:00:00,B-Lymphocytes,A11.063.438
20352526,2011-02-01T00:00:00,B-Lymphocytes,A11.118.637.555.567.562
20352526,2011-02-01T00:00:00,B-Lymphocytes,A15.145.229.637.555.567.562
20352526,2011-02-01T00:00:00,B-Lymphocytes,A15.382.032.438
20352526,2011-02-01T00:00:00,B-Lymphocytes,A15.382.490.555.567.562
20352526,2011-02-01T00:00:00,Dendritic Cells,A11.066.270
20352526,2011-02-01T00:00:00,Dendritic Cells,A11.436.270
20352526,2011-02-01T00:00:00,Dendritic Cells,A15.382.066.270
20352526,2011-02-01T00:00:00,Dendritic Cells,A15.382.812.260
20352526,2011-02-01T00:00:00,"Disease Models, Animal",C22.232
20352526,2011-02-01T00:00:00,"Disease Models, Animal",E05.598.500
20352526,2011-02-01T00:00:00,"Disease Models, Animal",E05.599.395.080
20352526,2011-02-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
20352526,2011-02-01T00:00:00,Immunity,G12.450
20352526,2011-02-01T00:00:00,Macrophages,A11.329.372
20352526,2011-02-01T00:00:00,Macrophages,A11.627.482
20352526,2011-02-01T00:00:00,Macrophages,A11.733.397
20352526,2011-02-01T00:00:00,Macrophages,A15.382.680.397
20352526,2011-02-01T00:00:00,Macrophages,A15.382.812.522
20352526,2011-02-01T00:00:00,"Receptors, Estrogen",D12.776.260.698.750.350
20352526,2011-02-01T00:00:00,"Receptors, Estrogen",D12.776.826.750.350
20352526,2011-02-01T00:00:00,"Receptors, Estrogen",D12.776.930.669.750.350
20352526,2011-02-01T00:00:00,T-Lymphocytes,A11.118.637.555.567.569
20352526,2011-02-01T00:00:00,T-Lymphocytes,A15.145.229.637.555.567.569
20352526,2011-02-01T00:00:00,T-Lymphocytes,A15.382.490.555.567.569
20498624,2011-02-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
20498624,2011-02-01T00:00:00,Lung Neoplasms,C04.588.894.797.520
20498624,2011-02-01T00:00:00,Lung Neoplasms,C08.381.540
20498624,2011-02-01T00:00:00,Lung Neoplasms,C08.785.520
20498624,2011-02-01T00:00:00,"Radiographic Image Interpretation, Computer-Assisted",E01.158.600.680
20498624,2011-02-01T00:00:00,"Radiographic Image Interpretation, Computer-Assisted",E01.370.350.350.700
20498624,2011-02-01T00:00:00,"Radiographic Image Interpretation, Computer-Assisted",E01.370.350.700.705
20498624,2011-02-01T00:00:00,"Radiographic Image Interpretation, Computer-Assisted",L01.700.508.100.158.600.680
20498624,2011-02-01T00:00:00,Software,L01.224.900
20498624,2011-02-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.350.810
20498624,2011-02-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.600.350.700.810
20498624,2011-02-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.700.700.810
20498624,2011-02-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.700.810.810
20498624,2011-02-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.825.810.810
20543748,2011-02-01T00:00:00,Adolescent,M01.060.057
20543748,2011-02-01T00:00:00,Athletic Injuries,C21.866.115
20543748,2011-02-01T00:00:00,Diet,E05.272
20543748,2011-02-01T00:00:00,Diet,G07.610.240
20543748,2011-02-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
20543748,2011-02-01T00:00:00,Life Style,F01.829.458
20543748,2011-02-01T00:00:00,Parathyroid Hormone,D06.472.699.590
20543748,2011-02-01T00:00:00,Parathyroid Hormone,D12.644.548.587
20543748,2011-02-01T00:00:00,Vitamin D,D04.808.812.768
20543748,2011-02-01T00:00:00,Vitamin D Deficiency,C18.654.521.500.133.770
20543748,2011-02-01T00:00:00,Young Adult,M01.060.116.815
20577145,2011-02-01T00:00:00,Animals,B01.050
20577145,2011-02-01T00:00:00,Bone Density Conservation Agents,D27.505.696.242
20577145,2011-02-01T00:00:00,Complement Activation,G12.425.255
20577145,2011-02-01T00:00:00,Complement System Proteins,D12.776.124.486.274
20577145,2011-02-01T00:00:00,"Immunity, Innate",G12.450.575
20577145,2011-02-01T00:00:00,Interleukin-12,D12.644.276.374.465.512
20577145,2011-02-01T00:00:00,Interleukin-12,D12.776.467.374.465.512
20577145,2011-02-01T00:00:00,Interleukin-12,D23.529.374.465.512
20577145,2011-02-01T00:00:00,Macrophages,A11.329.372
20577145,2011-02-01T00:00:00,Macrophages,A11.627.482
20577145,2011-02-01T00:00:00,Macrophages,A11.733.397
20577145,2011-02-01T00:00:00,Macrophages,A15.382.680.397
20577145,2011-02-01T00:00:00,Macrophages,A15.382.812.522
20577145,2011-02-01T00:00:00,Neutrophils,A11.118.637.415.583
20577145,2011-02-01T00:00:00,Neutrophils,A11.627.340.583
20577145,2011-02-01T00:00:00,Neutrophils,A11.733.689
20577145,2011-02-01T00:00:00,Neutrophils,A15.145.229.637.415.583
20577145,2011-02-01T00:00:00,Neutrophils,A15.382.490.315.583
20577145,2011-02-01T00:00:00,Neutrophils,A15.382.680.689
20577145,2011-02-01T00:00:00,Time Factors,G01.910.857
20577145,2011-02-01T00:00:00,Tumor Necrosis Factor-alpha,D12.644.276.374.500.800
20577145,2011-02-01T00:00:00,Tumor Necrosis Factor-alpha,D12.644.276.374.750.626
20577145,2011-02-01T00:00:00,Tumor Necrosis Factor-alpha,D12.644.276.972.626
20577145,2011-02-01T00:00:00,Tumor Necrosis Factor-alpha,D12.776.124.900
20577145,2011-02-01T00:00:00,Tumor Necrosis Factor-alpha,D12.776.395.930
20577145,2011-02-01T00:00:00,Tumor Necrosis Factor-alpha,D12.776.467.374.500.800
20577145,2011-02-01T00:00:00,Tumor Necrosis Factor-alpha,D12.776.467.374.750.626
20577145,2011-02-01T00:00:00,Tumor Necrosis Factor-alpha,D12.776.467.972.626
20577145,2011-02-01T00:00:00,Tumor Necrosis Factor-alpha,D23.529.374.500.800
20577145,2011-02-01T00:00:00,Tumor Necrosis Factor-alpha,D23.529.374.750.626
20577145,2011-02-01T00:00:00,Tumor Necrosis Factor-alpha,D23.529.972.626
20627609,2011-02-01T00:00:00,"Carcinoma, Hepatocellular",C04.557.470.200.025.255
20627609,2011-02-01T00:00:00,"Carcinoma, Hepatocellular",C04.588.274.623.160
20627609,2011-02-01T00:00:00,"Carcinoma, Hepatocellular",C06.301.623.160
20627609,2011-02-01T00:00:00,"Carcinoma, Hepatocellular",C06.552.697.160
20627609,2011-02-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
20627609,2011-02-01T00:00:00,Liver Neoplasms,C04.588.274.623
20627609,2011-02-01T00:00:00,Liver Neoplasms,C06.301.623
20627609,2011-02-01T00:00:00,Liver Neoplasms,C06.552.697
20627609,2011-02-01T00:00:00,Magnetic Resonance Imaging,E01.370.350.500
20627609,2011-02-01T00:00:00,Magnetic Resonance Imaging,E01.370.350.825.500
20922705,2011-02-01T00:00:00,Adult,M01.060.116
20922705,2011-02-01T00:00:00,Aged,M01.060.116.100
20922705,2011-02-01T00:00:00,Brachytherapy,E02.815.150
20922705,2011-02-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
20922705,2011-02-01T00:00:00,Middle Aged,M01.060.116.630
20922705,2011-02-01T00:00:00,Radiotherapy Dosage,E02.815.639
20922705,2011-02-01T00:00:00,Risk Assessment,E05.318.740.600.800.715
20922705,2011-02-01T00:00:00,Risk Assessment,N04.452.871.715
20922705,2011-02-01T00:00:00,Risk Assessment,N05.715.360.750.625.700.690
20922705,2011-02-01T00:00:00,Risk Assessment,N06.850.505.715
20922705,2011-02-01T00:00:00,Risk Assessment,N06.850.520.830.600.800.715
20922705,2011-02-01T00:00:00,"Ultrasonography, Interventional",E01.370.350.850.855
20922705,2011-02-01T00:00:00,Uterine Cervical Neoplasms,C04.588.945.418.948.850
20922705,2011-02-01T00:00:00,Uterine Cervical Neoplasms,C13.351.500.852.593.131
20922705,2011-02-01T00:00:00,Uterine Cervical Neoplasms,C13.351.500.852.762.850
20922705,2011-02-01T00:00:00,Uterine Cervical Neoplasms,C13.351.937.418.875.850
20922705,2011-02-01T00:00:00,Uterine Perforation,C13.351.500.852.904.500
20922705,2011-02-01T00:00:00,Uterine Perforation,C21.866.761.853.500
20922705,2011-02-01T00:00:00,Uterus,A05.360.319.679
20924284,2011-02-01T00:00:00,Animals,B01.050
20924284,2011-02-01T00:00:00,Kidney,A05.810.453
20924284,2011-02-01T00:00:00,Lupus Nephritis,C12.777.419.570.363.680
20924284,2011-02-01T00:00:00,Lupus Nephritis,C13.351.968.419.570.363.680
20924284,2011-02-01T00:00:00,Lupus Nephritis,C17.300.480.680
20924284,2011-02-01T00:00:00,Lupus Nephritis,C20.111.590.560
20924284,2011-02-01T00:00:00,Nitric Oxide,D01.339.387
20924284,2011-02-01T00:00:00,Nitric Oxide,D01.625.550.500
20924284,2011-02-01T00:00:00,Nitric Oxide,D01.625.700.500
20924284,2011-02-01T00:00:00,Nitric Oxide,D01.650.550.587.600
20924284,2011-02-01T00:00:00,Pyrazoles,D03.383.129.539
20924284,2011-02-01T00:00:00,Thromboxane A2,D10.251.355.255.100.825.800
20924284,2011-02-01T00:00:00,Thromboxane A2,D23.469.050.175.800.800
20924284,2011-02-01T00:00:00,Thromboxane B2,D10.251.355.255.100.825.810
20924284,2011-02-01T00:00:00,Thromboxane B2,D23.469.050.175.800.810
20939007,2011-02-01T00:00:00,Animals,B01.050
20939007,2011-02-01T00:00:00,Antibodies,D12.776.124.486.485.114
20939007,2011-02-01T00:00:00,Antibodies,D12.776.124.790.651.114
20939007,2011-02-01T00:00:00,Antibodies,D12.776.377.715.548.114
20939007,2011-02-01T00:00:00,Drug Carriers,D26.255.260
20939007,2011-02-01T00:00:00,Drug Carriers,D27.720.280.260
20939007,2011-02-01T00:00:00,Drug Carriers,E02.319.300.380
20939007,2011-02-01T00:00:00,Nanoparticles,J01.637.512.600
20939007,2011-02-01T00:00:00,Neurons,A08.663
20939007,2011-02-01T00:00:00,Neurons,A11.671
20939007,2011-02-01T00:00:00,Neuroprotective Agents,D27.505.696.706.548
20939007,2011-02-01T00:00:00,Neuroprotective Agents,D27.505.954.427.575
20939007,2011-02-01T00:00:00,Rats,B01.050.150.900.649.865.635.505.700
20939007,2011-02-01T00:00:00,"Receptors, N-Methyl-D-Aspartate",D12.776.543.750.720.200.450.580
20939007,2011-02-01T00:00:00,Superoxide Dismutase,D08.811.682.881
20945123,2011-02-01T00:00:00,Adult,M01.060.116
20945123,2011-02-01T00:00:00,Aged,M01.060.116.100
20945123,2011-02-01T00:00:00,"Arthroplasty, Replacement, Hip",E04.555.110.110.110
20945123,2011-02-01T00:00:00,"Arthroplasty, Replacement, Hip",E04.650.110.110
20945123,2011-02-01T00:00:00,Fracture Fixation,E04.555.300
20945123,2011-02-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
20945123,2011-02-01T00:00:00,Middle Aged,M01.060.116.630
20945123,2011-02-01T00:00:00,Surgical Wound Infection,C01.539.947.692
20945123,2011-02-01T00:00:00,Surgical Wound Infection,C23.550.767.925
21061101,2011-02-01T00:00:00,Biological Markers,D23.101
21061101,2011-02-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21061101,2011-02-01T00:00:00,Lung Diseases,C08.381
21061101,2011-02-01T00:00:00,"Scleroderma, Systemic",C17.300.799
21061101,2011-02-01T00:00:00,"Scleroderma, Systemic",C17.800.784
21107234,2011-02-01T00:00:00,"Carcinoma, Hepatocellular",C04.557.470.200.025.255
21107234,2011-02-01T00:00:00,"Carcinoma, Hepatocellular",C04.588.274.623.160
21107234,2011-02-01T00:00:00,"Carcinoma, Hepatocellular",C06.301.623.160
21107234,2011-02-01T00:00:00,"Carcinoma, Hepatocellular",C06.552.697.160
21107234,2011-02-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21107234,2011-02-01T00:00:00,Liver Neoplasms,C04.588.274.623
21107234,2011-02-01T00:00:00,Liver Neoplasms,C06.301.623
21107234,2011-02-01T00:00:00,Liver Neoplasms,C06.552.697
21107234,2011-02-01T00:00:00,Magnetic Resonance Imaging,E01.370.350.500
21107234,2011-02-01T00:00:00,Magnetic Resonance Imaging,E01.370.350.825.500
21107234,2011-02-01T00:00:00,Middle Aged,M01.060.116.630
21107234,2011-02-01T00:00:00,Spinal Cord Compression,C10.228.854.761
21107234,2011-02-01T00:00:00,Spinal Cord Compression,C21.866.819.678
21128019,2011-02-01T00:00:00,African Americans,M01.686.508.100.100
21128019,2011-02-01T00:00:00,African Americans,M01.686.754.100
21128019,2011-02-01T00:00:00,Blood Pressure,E01.370.600.875.249
21128019,2011-02-01T00:00:00,Blood Pressure,G09.330.380.076
21128019,2011-02-01T00:00:00,Cardiovascular Diseases,C14
21128019,2011-02-01T00:00:00,European Continental Ancestry Group,M01.686.508.400
21128019,2011-02-01T00:00:00,Genome-Wide Association Study,E05.318.416.249
21128019,2011-02-01T00:00:00,Genome-Wide Association Study,E05.318.780.392
21128019,2011-02-01T00:00:00,Genome-Wide Association Study,E05.393.385.500
21128019,2011-02-01T00:00:00,Genome-Wide Association Study,E05.393.522.500
21128019,2011-02-01T00:00:00,Genome-Wide Association Study,E05.393.760.640.500
21128019,2011-02-01T00:00:00,Genome-Wide Association Study,N06.850.520.445.392
21128019,2011-02-01T00:00:00,Genome-Wide Association Study,N06.850.520.470.500
21128019,2011-02-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21128019,2011-02-01T00:00:00,Hypertension,C14.907.489
21128019,2011-02-01T00:00:00,"Polymorphism, Single Nucleotide",G05.365.795.598
21128019,2011-02-01T00:00:00,Renin-Angiotensin System,G03.495.805
21128019,2011-02-01T00:00:00,Renin-Angiotensin System,G09.330.190.400.750
21128019,2011-02-01T00:00:00,Risk Factors,E05.318.740.600.800.725
21128019,2011-02-01T00:00:00,Risk Factors,N05.715.350.200.700
21128019,2011-02-01T00:00:00,Risk Factors,N05.715.360.750.625.700.700
21128019,2011-02-01T00:00:00,Risk Factors,N06.850.490.625.750
21128019,2011-02-01T00:00:00,Risk Factors,N06.850.520.830.600.800.725
21128019,2011-02-01T00:00:00,United States,Z01.107.567.875
21136303,2011-02-01T00:00:00,Adult,M01.060.116
21136303,2011-02-01T00:00:00,Gastroplasty,E02.065.062.750
21136303,2011-02-01T00:00:00,Gastroplasty,E04.062.750
21136303,2011-02-01T00:00:00,Gastroplasty,E04.210.485
21136303,2011-02-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21136303,2011-02-01T00:00:00,Laparoscopy,E01.370.388.250.520
21136303,2011-02-01T00:00:00,Laparoscopy,E04.800.250.520
21136303,2011-02-01T00:00:00,Obesity,C18.654.726.500
21136303,2011-02-01T00:00:00,Obesity,C23.888.144.699.500
21136303,2011-02-01T00:00:00,Obesity,E01.370.600.115.100.160.120.699.500
21136303,2011-02-01T00:00:00,Obesity,G07.100.100.160.120.699.500
21160424,2011-02-01T00:00:00,Animals,B01.050
21160424,2011-02-01T00:00:00,"Behavior, Animal",F01.145.113
21160424,2011-02-01T00:00:00,Central Nervous System Stimulants,D27.505.696.282
21160424,2011-02-01T00:00:00,Central Nervous System Stimulants,D27.505.954.427.220
21160424,2011-02-01T00:00:00,Cues,F02.463.425.234
21160424,2011-02-01T00:00:00,Discrimination (Psychology),F02.463.593.257
21160424,2011-02-01T00:00:00,Methylphenidate,D02.241.223.601.600
21160424,2011-02-01T00:00:00,Methylphenidate,D03.383.621.460
21160424,2011-02-01T00:00:00,Motor Activity,F01.145.632
21160424,2011-02-01T00:00:00,Motor Activity,G11.427.590.530.698
21237438,2011-02-01T00:00:00,Adult,M01.060.116
21237438,2011-02-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21237438,2011-02-01T00:00:00,Middle Aged,M01.060.116.630
21237438,2011-02-01T00:00:00,Treatment Outcome,E01.789.800
21237438,2011-02-01T00:00:00,Treatment Outcome,N04.761.559.590.800
21237438,2011-02-01T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21238870,2011-02-01T00:00:00,Curriculum,I02.158
21238870,2011-02-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21238870,2011-02-01T00:00:00,Organizational Objectives,N04.452.615
21238870,2011-02-01T00:00:00,Primary Prevention,N02.421.726.758
21238870,2011-02-01T00:00:00,Primary Prevention,N06.850.780.680
21238870,2011-02-01T00:00:00,United States,Z01.107.567.875
21238871,2011-02-01T00:00:00,Adolescent,M01.060.057
21238871,2011-02-01T00:00:00,Child,M01.060.406
21238871,2011-02-01T00:00:00,Diet,E05.272
21238871,2011-02-01T00:00:00,Diet,G07.610.240
21238871,2011-02-01T00:00:00,Exercise,G11.427.590.237
21238871,2011-02-01T00:00:00,Exercise,I03.350
21238871,2011-02-01T00:00:00,Health Promotion,N02.370
21238871,2011-02-01T00:00:00,Health Promotion,N02.421.726.507
21238871,2011-02-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21238871,2011-02-01T00:00:00,Schools,I02.233.659
21238871,2011-02-01T00:00:00,Schools,I02.783
21238871,2011-02-01T00:00:00,Smoking,F01.145.466.753
21238871,2011-02-01T00:00:00,Substance-Related Disorders,C21.739
21238871,2011-02-01T00:00:00,Substance-Related Disorders,F03.900
21238871,2011-02-01T00:00:00,United States,Z01.107.567.875
21238871,2011-02-01T00:00:00,Wounds and Injuries,C21.866
21238875,2011-02-01T00:00:00,Curriculum,I02.158
21238875,2011-02-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21238875,2011-02-01T00:00:00,Interdisciplinary Communication,F01.145.209.381
21238875,2011-02-01T00:00:00,Interdisciplinary Communication,F01.829.401.205.249
21238875,2011-02-01T00:00:00,Interdisciplinary Communication,L01.143.474
21238875,2011-02-01T00:00:00,"Models, Organizational",E05.599.670
21238875,2011-02-01T00:00:00,"Models, Organizational",N04.452.534
21238875,2011-02-01T00:00:00,Primary Prevention,N02.421.726.758
21238875,2011-02-01T00:00:00,Primary Prevention,N06.850.780.680
21238875,2011-02-01T00:00:00,Program Development,N04.452.760
21238876,2011-02-01T00:00:00,Diffusion of Innovation,L01.143.320
21238876,2011-02-01T00:00:00,Health Personnel,M01.526.485
21238876,2011-02-01T00:00:00,Health Personnel,N02.360
21238876,2011-02-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21238876,2011-02-01T00:00:00,Organizational Objectives,N04.452.615
21238876,2011-02-01T00:00:00,Primary Prevention,N02.421.726.758
21238876,2011-02-01T00:00:00,Primary Prevention,N06.850.780.680
21238876,2011-02-01T00:00:00,Professional Role,F01.829.316.616.625
21238876,2011-02-01T00:00:00,United States,Z01.107.567.875
21241901,2011-02-01T00:00:00,Cataract Extraction,E04.540.825.249
21241901,2011-02-01T00:00:00,Child,M01.060.406
21241901,2011-02-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21241901,2011-02-01T00:00:00,"Lens Implantation, Intraocular",E04.540.825.600
21241901,2011-02-01T00:00:00,Surgical Flaps,A10.850.710
21241901,2011-02-01T00:00:00,Surgical Flaps,E07.862.710
21248266,2011-02-01T00:00:00,Animals,B01.050
21248266,2011-02-01T00:00:00,"Clinical Trials, Phase I as Topic",E05.318.760.535.200
21248266,2011-02-01T00:00:00,"Clinical Trials, Phase I as Topic",E05.337.250.200
21248266,2011-02-01T00:00:00,"Clinical Trials, Phase I as Topic",N05.715.360.775.235.200
21248266,2011-02-01T00:00:00,"Clinical Trials, Phase I as Topic",N06.850.520.450.535.200
21248266,2011-02-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21248266,2011-02-01T00:00:00,Immunoglobulin G,D12.776.124.486.485.114.619.393
21248266,2011-02-01T00:00:00,Immunoglobulin G,D12.776.124.790.651.114.619.393
21248266,2011-02-01T00:00:00,Immunoglobulin G,D12.776.377.715.548.114.619.393
21248266,2011-02-01T00:00:00,Immunoglobulin Gm Allotypes,D12.776.124.486.485.114.606.586
21248266,2011-02-01T00:00:00,Immunoglobulin Gm Allotypes,D12.776.124.486.485.114.619.393.522.400
21248266,2011-02-01T00:00:00,Immunoglobulin Gm Allotypes,D12.776.124.486.485.705.500.380.500
21248266,2011-02-01T00:00:00,Immunoglobulin Gm Allotypes,D12.776.124.790.651.114.606.586
21248266,2011-02-01T00:00:00,Immunoglobulin Gm Allotypes,D12.776.124.790.651.114.619.393.522.400
21248266,2011-02-01T00:00:00,Immunoglobulin Gm Allotypes,D12.776.124.790.651.705.500.380.500
21248266,2011-02-01T00:00:00,Immunoglobulin Gm Allotypes,D12.776.377.715.548.114.606.586
21248266,2011-02-01T00:00:00,Immunoglobulin Gm Allotypes,D12.776.377.715.548.114.619.393.522.400
21248266,2011-02-01T00:00:00,Immunoglobulin Gm Allotypes,D12.776.377.715.548.705.500.380.500
21248266,2011-02-01T00:00:00,Immunoglobulin Gm Allotypes,G12.500.400.586
21248326,2011-02-01T00:00:00,Animals,B01.050
21248326,2011-02-01T00:00:00,Chick Embryo,A13.350.150
21248326,2011-02-01T00:00:00,Chick Embryo,A16.331.200
21248326,2011-02-01T00:00:00,Temperature,G01.906.595
21248326,2011-02-01T00:00:00,Temperature,G16.500.275.063.725.710
21248326,2011-02-01T00:00:00,Temperature,G16.500.750.775.710
21248326,2011-02-01T00:00:00,Temperature,N06.230.150.450
21248326,2011-02-01T00:00:00,Temperature,N06.230.300.100.725.710
21252714,2011-02-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21252714,2011-02-01T00:00:00,Lung Neoplasms,C04.588.894.797.520
21252714,2011-02-01T00:00:00,Lung Neoplasms,C08.381.540
21252714,2011-02-01T00:00:00,Lung Neoplasms,C08.785.520
21252714,2011-02-01T00:00:00,Neoplasm Staging,E01.370.550
21252794,2011-02-01T00:00:00,Adult,M01.060.116
21252794,2011-02-01T00:00:00,Calcium,D01.268.552.100
21252794,2011-02-01T00:00:00,Calcium,D01.552.539.288
21252794,2011-02-01T00:00:00,Calcium,D23.119.100
21252794,2011-02-01T00:00:00,Diphosphonates,D02.705.206
21252794,2011-02-01T00:00:00,Gynecologic Surgical Procedures,E04.950.300
21252794,2011-02-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21252794,2011-02-01T00:00:00,Hypercalcemia,C18.452.174.451
21252794,2011-02-01T00:00:00,Hypercalcemia,C18.452.950.340
21252794,2011-02-01T00:00:00,"Infant, Newborn",M01.060.703.520
21252794,2011-02-01T00:00:00,Intensive Care,E02.760.190.400
21252794,2011-02-01T00:00:00,Intensive Care,N02.421.585.190.400
21252794,2011-02-01T00:00:00,Pregnancy,G08.686.785.760.769
21252794,2011-02-01T00:00:00,Treatment Outcome,E01.789.800
21252794,2011-02-01T00:00:00,Treatment Outcome,N04.761.559.590.800
21252794,2011-02-01T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21252794,2011-02-01T00:00:00,Uterine Neoplasms,C04.588.945.418.948
21252794,2011-02-01T00:00:00,Uterine Neoplasms,C13.351.500.852.762
21252794,2011-02-01T00:00:00,Uterine Neoplasms,C13.351.937.418.875
21256290,2011-02-01T00:00:00,"Defibrillators, Implantable",E07.305.250.159.175
21256290,2011-02-01T00:00:00,"Defibrillators, Implantable",E07.305.250.319.175
21256290,2011-02-01T00:00:00,"Defibrillators, Implantable",E07.695.175
21256290,2011-02-01T00:00:00,Dermis,A17.815.180
21256290,2011-02-01T00:00:00,"Electrodes, Implanted",E07.305.250.319
21256290,2011-02-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21256290,2011-02-01T00:00:00,"Pacemaker, Artificial",E07.858.082.748
21256290,2011-02-01T00:00:00,Prosthesis-Related Infections,C01.539.685
21256290,2011-02-01T00:00:00,Prosthesis-Related Infections,C23.550.767.868
21256290,2011-02-01T00:00:00,Salvage Therapy,E02.186.800
21256290,2011-02-01T00:00:00,Salvage Therapy,E02.895
21256292,2011-02-01T00:00:00,"Aneurysm, Dissecting",C14.907.055.050
21256292,2011-02-01T00:00:00,"Aortic Aneurysm, Thoracic",C14.907.055.239.125
21256292,2011-02-01T00:00:00,"Aortic Aneurysm, Thoracic",C14.907.109.139.125
21256292,2011-02-01T00:00:00,Computer Simulation,L01.224.160
21256292,2011-02-01T00:00:00,Finite Element Analysis,E05.355
21256292,2011-02-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21256292,2011-02-01T00:00:00,"Models, Cardiovascular",E05.599.395.161
21256292,2011-02-01T00:00:00,"Stress, Mechanical",G01.374.676.830
21256292,2011-02-01T00:00:00,"Stress, Mechanical",G01.595.540.830
21256312,2011-02-01T00:00:00,Coronary Vessel Anomalies,C14.240.400.210
21256312,2011-02-01T00:00:00,Coronary Vessel Anomalies,C14.280.400.210
21256312,2011-02-01T00:00:00,Coronary Vessel Anomalies,C16.131.240.400.210
21256312,2011-02-01T00:00:00,Coronary Vessels,A07.231.114.269
21256312,2011-02-01T00:00:00,Coronary Vessels,A07.231.908.194
21256312,2011-02-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21256312,2011-02-01T00:00:00,Infant,M01.060.703
21256312,2011-02-01T00:00:00,Mitral Valve,A07.541.510.507
21256312,2011-02-01T00:00:00,Pulmonary Artery,A07.231.114.715
21256312,2011-02-01T00:00:00,Vascular Surgical Procedures,E04.100.814
21257857,2011-02-01T00:00:00,Adult,M01.060.116
21257857,2011-02-01T00:00:00,Aged,M01.060.116.100
21257857,2011-02-01T00:00:00,Body Burden,E05.799.638.231
21257857,2011-02-01T00:00:00,Body Burden,N06.850.460.200
21257857,2011-02-01T00:00:00,Coronary Angiography,E01.370.350.700.060.200
21257857,2011-02-01T00:00:00,Coronary Angiography,E01.370.370.050.200
21257857,2011-02-01T00:00:00,Coronary Angiography,E01.370.370.380.200
21257857,2011-02-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21257857,2011-02-01T00:00:00,Middle Aged,M01.060.116.630
21257857,2011-02-01T00:00:00,"Models, Statistical",E05.318.740.500
21257857,2011-02-01T00:00:00,"Models, Statistical",E05.599.835
21257857,2011-02-01T00:00:00,"Models, Statistical",N05.715.360.750.530
21257857,2011-02-01T00:00:00,"Models, Statistical",N06.850.520.830.500
21257857,2011-02-01T00:00:00,"Neoplasms, Radiation-Induced",C04.682
21257857,2011-02-01T00:00:00,"Neoplasms, Radiation-Induced",C21.866.733.476
21257857,2011-02-01T00:00:00,"Phantoms, Imaging",E07.671
21257857,2011-02-01T00:00:00,Radiation Dosage,E05.799.513
21257857,2011-02-01T00:00:00,Radiation Dosage,G01.201.875.740
21257857,2011-02-01T00:00:00,Radiation Dosage,N06.850.810.250
21257857,2011-02-01T00:00:00,Risk Assessment,E05.318.740.600.800.715
21257857,2011-02-01T00:00:00,Risk Assessment,N04.452.871.715
21257857,2011-02-01T00:00:00,Risk Assessment,N05.715.360.750.625.700.690
21257857,2011-02-01T00:00:00,Risk Assessment,N06.850.505.715
21257857,2011-02-01T00:00:00,Risk Assessment,N06.850.520.830.600.800.715
21257857,2011-02-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.350.810
21257857,2011-02-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.600.350.700.810
21257857,2011-02-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.700.700.810
21257857,2011-02-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.700.810.810
21257857,2011-02-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.825.810.810
21258219,2011-02-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21258219,2011-02-01T00:00:00,Lung Neoplasms,C04.588.894.797.520
21258219,2011-02-01T00:00:00,Lung Neoplasms,C08.381.540
21258219,2011-02-01T00:00:00,Lung Neoplasms,C08.785.520
21258219,2011-02-01T00:00:00,Mass Screening,E01.370.500
21258219,2011-02-01T00:00:00,Mass Screening,E05.318.308.250.580
21258219,2011-02-01T00:00:00,Mass Screening,N02.421.143.827.233.443
21258219,2011-02-01T00:00:00,Mass Screening,N02.421.726.233.443
21258219,2011-02-01T00:00:00,Mass Screening,N05.715.360.300.375.500
21258219,2011-02-01T00:00:00,Mass Screening,N06.850.520.308.250.580
21258219,2011-02-01T00:00:00,Mass Screening,N06.850.780.500
21258219,2011-02-01T00:00:00,Neoplasm Staging,E01.370.550
21258219,2011-02-01T00:00:00,Radiology,H02.403.740
21258219,2011-02-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.350.810
21258219,2011-02-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.600.350.700.810
21258219,2011-02-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.700.700.810
21258219,2011-02-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.700.810.810
21258219,2011-02-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.825.810.810
21258219,2011-02-01T00:00:00,United States,Z01.107.567.875
21262781,2011-02-01T00:00:00,Geographic Information Systems,L01.470.750.750.462
21262781,2011-02-01T00:00:00,Geographic Information Systems,L01.700.508.300.314
21262781,2011-02-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21262781,2011-02-01T00:00:00,"Models, Statistical",E05.318.740.500
21262781,2011-02-01T00:00:00,"Models, Statistical",E05.599.835
21262781,2011-02-01T00:00:00,"Models, Statistical",N05.715.360.750.530
21262781,2011-02-01T00:00:00,"Models, Statistical",N06.850.520.830.500
21273516,2011-02-01T00:00:00,Animals,B01.050
21273516,2011-02-01T00:00:00,Contrast Media,D27.720.259
21273516,2011-02-01T00:00:00,"Disease Models, Animal",C22.232
21273516,2011-02-01T00:00:00,"Disease Models, Animal",E05.598.500
21273516,2011-02-01T00:00:00,"Disease Models, Animal",E05.599.395.080
21273516,2011-02-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21273516,2011-02-01T00:00:00,Magnetic Resonance Imaging,E01.370.350.500
21273516,2011-02-01T00:00:00,Magnetic Resonance Imaging,E01.370.350.825.500
21273516,2011-02-01T00:00:00,Organometallic Compounds,D01.632
21273516,2011-02-01T00:00:00,Organometallic Compounds,D02.691
21273516,2011-02-01T00:00:00,Pregnancy,G08.686.785.760.769
21275440,2011-02-01T00:00:00,Double-Blind Method,E05.318.780.300
21275440,2011-02-01T00:00:00,Double-Blind Method,E05.581.500.300
21275440,2011-02-01T00:00:00,Double-Blind Method,N05.715.360.780.320
21275440,2011-02-01T00:00:00,Double-Blind Method,N06.850.520.445.300
21275440,2011-02-01T00:00:00,Drug Interactions,G07.690.812.240
21275440,2011-02-01T00:00:00,Drug Interactions,G07.700.680.240
21275440,2011-02-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21275440,2011-02-01T00:00:00,Middle Aged,M01.060.116.630
21275440,2011-02-01T00:00:00,Treatment Outcome,E01.789.800
21275440,2011-02-01T00:00:00,Treatment Outcome,N04.761.559.590.800
21275440,2011-02-01T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21275440,2011-02-01T00:00:00,"Urinary Bladder, Overactive",C12.777.829.866
21275440,2011-02-01T00:00:00,"Urinary Bladder, Overactive",C13.351.968.829.813
21275440,2011-02-01T00:00:00,"Urinary Bladder, Overactive",C23.888.942.775
21278358,2011-02-01T00:00:00,Blood Glucose,D09.546.359.448.500
21278358,2011-02-01T00:00:00,"Chromatography, High Pressure Liquid",E05.196.181.400.300
21278358,2011-02-01T00:00:00,Diabetes Mellitus,C18.452.394.750
21278358,2011-02-01T00:00:00,Diabetes Mellitus,C19.246
21278358,2011-02-01T00:00:00,"Diagnosis, Differential",E01.171
21278358,2011-02-01T00:00:00,Electrophoresis,E05.196.401
21278358,2011-02-01T00:00:00,Electrophoresis,E05.301.300
21278358,2011-02-01T00:00:00,Electrophoresis,G02.149.767.570
21278358,2011-02-01T00:00:00,Electrophoresis,G02.842.750.570
21278358,2011-02-01T00:00:00,"Hemoglobin A, Glycosylated",D09.408.375
21278358,2011-02-01T00:00:00,"Hemoglobin A, Glycosylated",D12.776.124.400.405.440
21278358,2011-02-01T00:00:00,"Hemoglobin A, Glycosylated",D12.776.422.316.762.380.440
21278358,2011-02-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21278358,2011-02-01T00:00:00,Middle Aged,M01.060.116.630
21284003,2011-02-01T00:00:00,DNA,D13.444.308
21284003,2011-02-01T00:00:00,Molecular Dynamics Simulation,E05.599.595.500
21284003,2011-02-01T00:00:00,Molecular Dynamics Simulation,G02.575.750
21284003,2011-02-01T00:00:00,Molecular Dynamics Simulation,L01.224.160.500
21284003,2011-02-01T00:00:00,Nucleic Acid Conformation,G02.111.570.790.486
21284003,2011-02-01T00:00:00,Nucleic Acid Conformation,G05.360.580
21284003,2011-02-01T00:00:00,Solvents,D27.720.844
21284003,2011-02-01T00:00:00,Surface Properties,G02.842.850
21285253,2011-02-01T00:00:00,Animals,B01.050
21285253,2011-02-01T00:00:00,Breast Neoplasms,C04.588.180
21285253,2011-02-01T00:00:00,Breast Neoplasms,C17.800.090.500
21285253,2011-02-01T00:00:00,Carcinoma,C04.557.470.200
21285253,2011-02-01T00:00:00,Dogs,B01.050.150.900.649.147.153.200
21285253,2011-02-01T00:00:00,Gene Expression Profiling,E05.393.332
21285253,2011-02-01T00:00:00,"Gene Expression Regulation, Neoplastic",G05.355.315.370
21285253,2011-02-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21287591,2011-02-01T00:00:00,Adult,M01.060.116
21287591,2011-02-01T00:00:00,Aged,M01.060.116.100
21287591,2011-02-01T00:00:00,Breast Neoplasms,C04.588.180
21287591,2011-02-01T00:00:00,Breast Neoplasms,C17.800.090.500
21287591,2011-02-01T00:00:00,Contrast Media,D27.720.259
21287591,2011-02-01T00:00:00,Diffusion Magnetic Resonance Imaging,E01.370.350.500.150
21287591,2011-02-01T00:00:00,Diffusion Magnetic Resonance Imaging,E01.370.350.825.500.150
21287591,2011-02-01T00:00:00,Gadolinium DTPA,D01.632.400
21287591,2011-02-01T00:00:00,Gadolinium DTPA,D02.092.782.590.401
21287591,2011-02-01T00:00:00,Gadolinium DTPA,D02.241.081.038.694.400
21287591,2011-02-01T00:00:00,Gadolinium DTPA,D02.691.400
21287591,2011-02-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21287591,2011-02-01T00:00:00,Middle Aged,M01.060.116.630
21287591,2011-02-01T00:00:00,Movement,G07.700.560
21287591,2011-02-01T00:00:00,Movement,G11.427.590.530
21287591,2011-02-01T00:00:00,"Neovascularization, Pathologic",C23.550.589.500
21287591,2011-02-01T00:00:00,Software,L01.224.900
21288568,2011-02-01T00:00:00,Animals,B01.050
21288568,2011-02-01T00:00:00,Calcium,D01.268.552.100
21288568,2011-02-01T00:00:00,Calcium,D01.552.539.288
21288568,2011-02-01T00:00:00,Calcium,D23.119.100
21288568,2011-02-01T00:00:00,Cell Differentiation,G04.299.151
21288568,2011-02-01T00:00:00,Flow Cytometry,E05.196.712.516.600.240.350
21288568,2011-02-01T00:00:00,Flow Cytometry,E05.200.500.386.350
21288568,2011-02-01T00:00:00,Genetic Vectors,G05.360.337
21288568,2011-02-01T00:00:00,Lentivirus,B04.820.650.589
21288568,2011-02-01T00:00:00,Lentivirus,B04.909.777.731.589
21288568,2011-02-01T00:00:00,"Microscopy, Confocal",E01.370.350.515.395
21288568,2011-02-01T00:00:00,"Microscopy, Confocal",E05.595.395
21288568,2011-02-01T00:00:00,"Microscopy, Electron, Transmission",E01.370.350.515.402.580
21288568,2011-02-01T00:00:00,"Microscopy, Electron, Transmission",E05.595.402.580
21288568,2011-02-01T00:00:00,"Myocytes, Cardiac",A07.541.704.570
21288568,2011-02-01T00:00:00,"Myocytes, Cardiac",A10.690.552.750.570
21288568,2011-02-01T00:00:00,"Myocytes, Cardiac",A11.620.500
21288568,2011-02-01T00:00:00,Rats,B01.050.150.900.649.865.635.505.700
21288568,2011-02-01T00:00:00,"Rats, Sprague-Dawley",B01.050.150.900.649.865.635.505.700.750
21288568,2011-02-01T00:00:00,Stromal Cells,A11.329.830
21297647,2011-02-01T00:00:00,Carotid Artery Diseases,C10.228.140.300.200
21297647,2011-02-01T00:00:00,Carotid Artery Diseases,C14.907.253.123
21297647,2011-02-01T00:00:00,Clinical Trials as Topic,E05.318.760.535
21297647,2011-02-01T00:00:00,Clinical Trials as Topic,E05.337.250
21297647,2011-02-01T00:00:00,Clinical Trials as Topic,N05.715.360.775.235
21297647,2011-02-01T00:00:00,Clinical Trials as Topic,N06.850.520.450.535
21297647,2011-02-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21297647,2011-02-01T00:00:00,Stroke,C10.228.140.300.775
21297647,2011-02-01T00:00:00,Stroke,C14.907.253.855
21297647,2011-02-01T00:00:00,Vascular Surgical Procedures,E04.100.814
21303337,2011-02-01T00:00:00,Cross Infection,C01.539.248
21303337,2011-02-01T00:00:00,Hematopoietic Stem Cell Transplantation,E04.936.225.687.500
21303337,2011-02-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21303337,2011-02-01T00:00:00,Infection Control,N06.850.780.200.450
21303337,2011-02-01T00:00:00,Risk Factors,E05.318.740.600.800.725
21303337,2011-02-01T00:00:00,Risk Factors,N05.715.350.200.700
21303337,2011-02-01T00:00:00,Risk Factors,N05.715.360.750.625.700.700
21303337,2011-02-01T00:00:00,Risk Factors,N06.850.490.625.750
21303337,2011-02-01T00:00:00,Risk Factors,N06.850.520.830.600.800.725
21306211,2011-02-01T00:00:00,Biological Markers,D23.101
21306211,2011-02-01T00:00:00,Cerebrovascular Disorders,C10.228.140.300
21306211,2011-02-01T00:00:00,Cerebrovascular Disorders,C14.907.253
21306211,2011-02-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21306211,2011-02-01T00:00:00,Kidney Diseases,C12.777.419
21306211,2011-02-01T00:00:00,Kidney Diseases,C13.351.968.419
21306211,2011-02-01T00:00:00,"Kidney Failure, Chronic",C12.777.419.780.500.602
21306211,2011-02-01T00:00:00,"Kidney Failure, Chronic",C12.777.419.780.750.500
21306211,2011-02-01T00:00:00,"Kidney Failure, Chronic",C13.351.968.419.780.500.602
21306211,2011-02-01T00:00:00,"Kidney Failure, Chronic",C13.351.968.419.780.750.500
21306211,2011-02-01T00:00:00,Neurons,A08.663
21306211,2011-02-01T00:00:00,Neurons,A11.671
21306211,2011-02-01T00:00:00,"Renal Insufficiency, Chronic",C12.777.419.780.750
21306211,2011-02-01T00:00:00,"Renal Insufficiency, Chronic",C13.351.968.419.780.750
21306211,2011-02-01T00:00:00,Risk Factors,E05.318.740.600.800.725
21306211,2011-02-01T00:00:00,Risk Factors,N05.715.350.200.700
21306211,2011-02-01T00:00:00,Risk Factors,N05.715.360.750.625.700.700
21306211,2011-02-01T00:00:00,Risk Factors,N06.850.490.625.750
21306211,2011-02-01T00:00:00,Risk Factors,N06.850.520.830.600.800.725
21306211,2011-02-01T00:00:00,Stroke,C10.228.140.300.775
21306211,2011-02-01T00:00:00,Stroke,C14.907.253.855
21306211,2011-02-01T00:00:00,Treatment Outcome,E01.789.800
21306211,2011-02-01T00:00:00,Treatment Outcome,N04.761.559.590.800
21306211,2011-02-01T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21315203,2011-02-01T00:00:00,Angiotensin-Converting Enzyme Inhibitors,D27.505.519.389.745.085
21315203,2011-02-01T00:00:00,"Child, Preschool",M01.060.406.448
21315203,2011-02-01T00:00:00,Enalapril,D12.644.456.345.360
21315203,2011-02-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21319882,2011-02-01T00:00:00,Allosteric Regulation,G02.111.087.040
21319882,2011-02-01T00:00:00,Allosteric Regulation,G02.149.115.040
21319882,2011-02-01T00:00:00,Animals,B01.050
21319882,2011-02-01T00:00:00,"Behavior, Addictive",F01.145.527.100.120
21319882,2011-02-01T00:00:00,Cocaine,D02.145.074.722.388
21319882,2011-02-01T00:00:00,Cocaine,D03.132.889.354
21319882,2011-02-01T00:00:00,Cocaine,D03.605.869.388
21319882,2011-02-01T00:00:00,Cocaine,D04.075.080.875.099.722.388
21319882,2011-02-01T00:00:00,Motor Activity,F01.145.632
21319882,2011-02-01T00:00:00,Motor Activity,G11.427.590.530.698
21319882,2011-02-01T00:00:00,Pyrazoles,D03.383.129.539
21319882,2011-02-01T00:00:00,Rats,B01.050.150.900.649.865.635.505.700
21319882,2011-02-01T00:00:00,"Rats, Sprague-Dawley",B01.050.150.900.649.865.635.505.700.750
21319882,2011-02-01T00:00:00,"Receptors, Metabotropic Glutamate",D12.776.543.750.100.450
21319882,2011-02-01T00:00:00,"Receptors, Metabotropic Glutamate",D12.776.543.750.720.200.450.500
21319882,2011-02-01T00:00:00,Self Administration,E02.319.890
21319882,2011-02-01T00:00:00,Self Administration,E02.900.890
21323204,2011-02-01T00:00:00,Cataract,C11.510.245
21323204,2011-02-01T00:00:00,Cataract Extraction,E04.540.825.249
21323204,2011-02-01T00:00:00,Child,M01.060.406
21323204,2011-02-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21323204,2011-02-01T00:00:00,Pediatrics,H02.403.670
21323204,2011-02-01T00:00:00,Referral and Consultation,N04.452.758.849
21323231,2011-02-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21323231,2011-02-01T00:00:00,Orthopedic Procedures,E02.718
21323231,2011-02-01T00:00:00,Orthopedic Procedures,E04.555
21323231,2011-02-01T00:00:00,Physician's Practice Patterns,N04.590.748
21323231,2011-02-01T00:00:00,Physician's Practice Patterns,N05.300.625
21323231,2011-02-01T00:00:00,Practice Guidelines as Topic,N04.761.700.350.650
21323231,2011-02-01T00:00:00,Practice Guidelines as Topic,N05.700.350.650
21323231,2011-02-01T00:00:00,United States,Z01.107.567.875
21323231,2011-02-01T00:00:00,Venous Thromboembolism,C14.907.355.590.700
21323231,2011-02-01T00:00:00,Venous Thromboembolism,C14.907.355.830.850.700
21333043,2011-02-01T00:00:00,Alcohol Drinking,F01.145.317.269
21333043,2011-02-01T00:00:00,Health Services Accessibility,N04.590.374.350
21333043,2011-02-01T00:00:00,Health Services Accessibility,N05.300.430
21333043,2011-02-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21333043,2011-02-01T00:00:00,Middle Aged,M01.060.116.630
21333043,2011-02-01T00:00:00,Penile Neoplasms,C04.588.945.440.715
21333043,2011-02-01T00:00:00,Penile Neoplasms,C12.294.260.500
21333043,2011-02-01T00:00:00,Penile Neoplasms,C12.294.494.591
21333043,2011-02-01T00:00:00,Penile Neoplasms,C12.758.409.500
21333043,2011-02-01T00:00:00,United States,Z01.107.567.875
21337277,2011-02-01T00:00:00,Decision Making,F02.463.785.373
21337277,2011-02-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21337277,2011-02-01T00:00:00,"Infant, Newborn",M01.060.703.520
21337277,2011-02-01T00:00:00,Judgment,F02.463.785.626
21337277,2011-02-01T00:00:00,Parents,F01.829.263.500.320
21337277,2011-02-01T00:00:00,Parents,I01.880.225.500.340
21337277,2011-02-01T00:00:00,Parents,M01.620
21337277,2011-02-01T00:00:00,Physicians,M01.526.485.810
21337277,2011-02-01T00:00:00,Physicians,N02.360.810
21337277,2011-02-01T00:00:00,Quality of Life,I01.800
21337277,2011-02-01T00:00:00,Quality of Life,K01.752.400.750
21337277,2011-02-01T00:00:00,Uncertainty,E05.318.740.600.900
21337277,2011-02-01T00:00:00,Uncertainty,F02.463.785.373.820
21337277,2011-02-01T00:00:00,Uncertainty,G17.680.875
21337277,2011-02-01T00:00:00,Uncertainty,N05.715.360.750.625.850
21337277,2011-02-01T00:00:00,Uncertainty,N06.850.520.830.600.900
21337277,2011-02-01T00:00:00,United States,Z01.107.567.875
21337893,2011-02-01T00:00:00,Adult,M01.060.116
21337893,2011-02-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21337893,2011-02-01T00:00:00,Pregnancy,G08.686.785.760.769
21337899,2011-02-01T00:00:00,Digestive System Surgical Procedures,E04.210
21337899,2011-02-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21337899,2011-02-01T00:00:00,"Infant, Newborn",M01.060.703.520
21337899,2011-02-01T00:00:00,Pregnancy,G08.686.785.760.769
21403837,2011-02-01T00:00:00,Animals,B01.050
21403837,2011-02-01T00:00:00,Antineoplastic Combined Chemotherapy Protocols,E02.183.750.500
21403837,2011-02-01T00:00:00,Antineoplastic Combined Chemotherapy Protocols,E02.319.077.500
21403837,2011-02-01T00:00:00,Antineoplastic Combined Chemotherapy Protocols,E02.319.310.037
21403837,2011-02-01T00:00:00,Antioxidants,D27.505.519.217
21403837,2011-02-01T00:00:00,Antioxidants,D27.505.696.706.125
21403837,2011-02-01T00:00:00,Antioxidants,D27.720.799.047
21403837,2011-02-01T00:00:00,Apoptosis,G04.299.139.160
21403837,2011-02-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21403837,2011-02-01T00:00:00,Prostatic Neoplasms,C04.588.945.440.770
21403837,2011-02-01T00:00:00,Prostatic Neoplasms,C12.294.260.750
21403837,2011-02-01T00:00:00,Prostatic Neoplasms,C12.294.565.625
21403837,2011-02-01T00:00:00,Prostatic Neoplasms,C12.758.409.750
21403837,2011-02-01T00:00:00,"Receptor, IGF Type 1",D08.811.913.696.620.682.725.400.185
21403837,2011-02-01T00:00:00,"Receptor, IGF Type 1",D12.776.543.750.060.468
21403837,2011-02-01T00:00:00,"Receptor, IGF Type 1",D12.776.543.750.750.400.780.400
21492686,2011-02-01T00:00:00,Athletic Injuries,C21.866.115
21492686,2011-02-01T00:00:00,Brain Concussion,C10.228.140.199.250
21492686,2011-02-01T00:00:00,Brain Concussion,C10.900.300.087.125
21492686,2011-02-01T00:00:00,Brain Concussion,C10.900.300.350.300
21492686,2011-02-01T00:00:00,Brain Concussion,C21.866.260.118.150
21492686,2011-02-01T00:00:00,Brain Concussion,C21.866.915.300.200.150
21492686,2011-02-01T00:00:00,Brain Concussion,C21.866.974.150
21492686,2011-02-01T00:00:00,Brain Concussion,C21.866.974.382.200
21492686,2011-02-01T00:00:00,Health Promotion,N02.370
21492686,2011-02-01T00:00:00,Health Promotion,N02.421.726.507
21492686,2011-02-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22057642,2011-02-01T00:00:00,Career Choice,F02.463.785.373.346.400
22057642,2011-02-01T00:00:00,"Education, Medical",I02.358.399
22057642,2011-02-01T00:00:00,Guidelines as Topic,N04.761.700.350
22057642,2011-02-01T00:00:00,Guidelines as Topic,N05.700.350
22057642,2011-02-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22057642,2011-02-01T00:00:00,"Schools, Medical",I02.783.660.552
22057642,2011-02-01T00:00:00,"Schools, Medical",N02.278.020.578
22057642,2011-02-01T00:00:00,"Students, Medical",I02.851.686.602
22057642,2011-02-01T00:00:00,"Students, Medical",M01.848.769.602
22057642,2011-02-01T00:00:00,United States,Z01.107.567.875
22057645,2011-02-01T00:00:00,Brain Injuries,C10.228.140.199
22057645,2011-02-01T00:00:00,Brain Injuries,C10.900.300.087
22057645,2011-02-01T00:00:00,Brain Injuries,C21.866.260.118
22057645,2011-02-01T00:00:00,Brain Injuries,C21.866.915.300.200
22057645,2011-02-01T00:00:00,Child,M01.060.406
22057645,2011-02-01T00:00:00,Head Protective Devices,E07.700.380
22057645,2011-02-01T00:00:00,Head Protective Devices,J01.637.708.380
22057645,2011-02-01T00:00:00,Hospitalization,E02.760.400
22057645,2011-02-01T00:00:00,Hospitalization,N02.421.585.400
22057645,2011-02-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22057645,2011-02-01T00:00:00,Incidence,E05.318.308.985.525.375
22057645,2011-02-01T00:00:00,Incidence,L01.280.975.525.375
22057645,2011-02-01T00:00:00,Incidence,N01.224.935.597.500
22057645,2011-02-01T00:00:00,Incidence,N06.850.505.400.975.525.375
22057645,2011-02-01T00:00:00,Incidence,N06.850.520.308.985.525.375
22057645,2011-02-01T00:00:00,South Carolina,Z01.107.567.875.075.662
22057645,2011-02-01T00:00:00,South Carolina,Z01.107.567.875.750.700
21285430,2011-02-02T00:00:00,Health Policy,I01.880.604.825.608.400
21285430,2011-02-02T00:00:00,Health Policy,N03.706.825.608.428
21285430,2011-02-02T00:00:00,Heart Failure,C14.280.434
21285430,2011-02-02T00:00:00,Hospital Mortality,E05.318.308.985.550.400
21285430,2011-02-02T00:00:00,Hospital Mortality,L01.280.975.550.400
21285430,2011-02-02T00:00:00,Hospital Mortality,N01.224.935.698.400
21285430,2011-02-02T00:00:00,Hospital Mortality,N06.850.505.400.975.550.400
21285430,2011-02-02T00:00:00,Hospital Mortality,N06.850.520.308.985.550.400
21285430,2011-02-02T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21285430,2011-02-02T00:00:00,Medicare,N03.219.521.346.506.564.663
21285430,2011-02-02T00:00:00,Medicare,N03.219.521.576.343.840
21285430,2011-02-02T00:00:00,Medicare,N03.706.615.696
21285430,2011-02-02T00:00:00,Myocardial Infarction,C14.280.647.500
21285430,2011-02-02T00:00:00,Myocardial Infarction,C14.907.585.500
21285430,2011-02-02T00:00:00,"Quality Indicators, Health Care",N04.761.789
21285430,2011-02-02T00:00:00,United States,Z01.107.567.875
21286651,2011-02-02T00:00:00,Antioxidants,D27.505.519.217
21286651,2011-02-02T00:00:00,Antioxidants,D27.505.696.706.125
21286651,2011-02-02T00:00:00,Antioxidants,D27.720.799.047
21286651,2011-02-02T00:00:00,Copper,D01.268.556.195
21286651,2011-02-02T00:00:00,Copper,D01.268.956.170
21286651,2011-02-02T00:00:00,Copper,D01.552.544.195
21286651,2011-02-02T00:00:00,Cystine,D01.248.497.158.874.390.369
21286651,2011-02-02T00:00:00,Cystine,D01.875.350.850.150.369
21286651,2011-02-02T00:00:00,Cystine,D02.886.030.230.369
21286651,2011-02-02T00:00:00,Cystine,D02.886.520.150.087
21286651,2011-02-02T00:00:00,Cystine,D12.125.095.369
21286651,2011-02-02T00:00:00,Cystine,D12.125.119.369
21286651,2011-02-02T00:00:00,Cystine,D12.125.166.230.369
21286651,2011-02-02T00:00:00,DNA,D13.444.308
21286651,2011-02-02T00:00:00,DNA Damage,C21.111
21286651,2011-02-02T00:00:00,DNA Damage,G05.355.180
21286651,2011-02-02T00:00:00,Electrochemical Techniques,E05.301
21286651,2011-02-02T00:00:00,Hydrogen Peroxide,D01.248.497.158.685.750.424
21286651,2011-02-02T00:00:00,Hydrogen Peroxide,D01.339.431.374.424
21286651,2011-02-02T00:00:00,Hydrogen Peroxide,D01.650.550.750.400
21286651,2011-02-02T00:00:00,Iron,D01.268.556.412
21286651,2011-02-02T00:00:00,Iron,D01.268.956.287
21286651,2011-02-02T00:00:00,Iron,D01.552.544.412
21286651,2011-02-02T00:00:00,Mass Spectrometry,E05.196.566
21286651,2011-02-02T00:00:00,Metals,D01.552
21286651,2011-02-02T00:00:00,Molecular Structure,G02.111.570
21286651,2011-02-02T00:00:00,Molecular Structure,G02.575
21286651,2011-02-02T00:00:00,Molecular Structure,G02.842.575
21286651,2011-02-02T00:00:00,Organoselenium Compounds,D02.712
21288233,2011-02-02T00:00:00,Aged,M01.060.116.100
21288233,2011-02-02T00:00:00,Calcium,D01.268.552.100
21288233,2011-02-02T00:00:00,Calcium,D01.552.539.288
21288233,2011-02-02T00:00:00,Calcium,D23.119.100
21288233,2011-02-02T00:00:00,Cholecalciferol,D04.808.247.222.159
21288233,2011-02-02T00:00:00,Cholecalciferol,D04.808.247.808.146
21288233,2011-02-02T00:00:00,Cholecalciferol,D04.808.812.768.196
21288233,2011-02-02T00:00:00,Cholecalciferol,D10.570.938.146
21288233,2011-02-02T00:00:00,Dietary Supplements,J02.500.456
21288233,2011-02-02T00:00:00,Double-Blind Method,E05.318.780.300
21288233,2011-02-02T00:00:00,Double-Blind Method,E05.581.500.300
21288233,2011-02-02T00:00:00,Double-Blind Method,N05.715.360.780.320
21288233,2011-02-02T00:00:00,Double-Blind Method,N06.850.520.445.300
21288233,2011-02-02T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21288233,2011-02-02T00:00:00,Parathyroid Hormone,D06.472.699.590
21288233,2011-02-02T00:00:00,Parathyroid Hormone,D12.644.548.587
21288233,2011-02-02T00:00:00,Pilot Projects,E05.318.760.750
21288233,2011-02-02T00:00:00,Pilot Projects,E05.337.737
21288233,2011-02-02T00:00:00,Pilot Projects,N05.715.360.775.625
21288233,2011-02-02T00:00:00,Pilot Projects,N06.850.520.450.720
21288233,2011-02-02T00:00:00,Treatment Outcome,E01.789.800
21288233,2011-02-02T00:00:00,Treatment Outcome,N04.761.559.590.800
21288233,2011-02-02T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21288233,2011-02-02T00:00:00,Veterans,M01.930
21288233,2011-02-02T00:00:00,Vitamin D,D04.808.812.768
21288233,2011-02-02T00:00:00,Vitamin D Deficiency,C18.654.521.500.133.770
21289298,2011-02-02T00:00:00,Adult,M01.060.116
21289298,2011-02-02T00:00:00,Aged,M01.060.116.100
21289298,2011-02-02T00:00:00,"Diabetes Mellitus, Type 2",C18.452.394.750.149
21289298,2011-02-02T00:00:00,"Diabetes Mellitus, Type 2",C19.246.300
21289298,2011-02-02T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21289298,2011-02-02T00:00:00,Middle Aged,M01.060.116.630
21289298,2011-02-02T00:00:00,"Quality Indicators, Health Care",N04.761.789
21289298,2011-02-02T00:00:00,Quality of Health Care,N04.761
21289298,2011-02-02T00:00:00,Quality of Health Care,N05.715
21289298,2011-02-02T00:00:00,Rural Health Services,N02.421.816
21289298,2011-02-02T00:00:00,Rural Population,N01.600.725
21289298,2011-02-02T00:00:00,Self Care,E02.900
21289298,2011-02-02T00:00:00,Self Care,N02.421.784.680
21289298,2011-02-02T00:00:00,United States,Z01.107.567.875
21289298,2011-02-02T00:00:00,Urban Population,N01.600.900
21290412,2011-02-02T00:00:00,Animals,B01.050
21290412,2011-02-02T00:00:00,Apoptosis,G04.299.139.160
21290412,2011-02-02T00:00:00,Calpain,D08.811.277.656.262.500.120
21290412,2011-02-02T00:00:00,Calpain,D08.811.277.656.300.200.120
21290412,2011-02-02T00:00:00,Cell Line,A11.251.210
21290412,2011-02-02T00:00:00,Cyclooxygenase 2,D08.811.600.720.750
21290412,2011-02-02T00:00:00,Inflammation,C23.550.470
21290412,2011-02-02T00:00:00,Interferon-gamma,D12.644.276.374.440.893
21290412,2011-02-02T00:00:00,Interferon-gamma,D12.644.276.374.480.350
21290412,2011-02-02T00:00:00,Interferon-gamma,D12.644.276.374.480.615.350
21290412,2011-02-02T00:00:00,Interferon-gamma,D12.644.276.718.550
21290412,2011-02-02T00:00:00,Interferon-gamma,D12.776.467.374.440.893
21290412,2011-02-02T00:00:00,Interferon-gamma,D12.776.467.374.480.350
21290412,2011-02-02T00:00:00,Interferon-gamma,D12.776.467.374.480.615.350
21290412,2011-02-02T00:00:00,Interferon-gamma,D12.776.467.718.550
21290412,2011-02-02T00:00:00,Interferon-gamma,D23.529.374.440.893
21290412,2011-02-02T00:00:00,Interferon-gamma,D23.529.374.480.350
21290412,2011-02-02T00:00:00,Interferon-gamma,D23.529.374.480.615.350
21290412,2011-02-02T00:00:00,Interferon-gamma,D23.529.718.550
21290412,2011-02-02T00:00:00,Myositis,C05.651.594
21290412,2011-02-02T00:00:00,Myositis,C10.668.491.562
21290412,2011-02-02T00:00:00,NF-kappa B,D12.776.260.600
21290412,2011-02-02T00:00:00,NF-kappa B,D12.776.660.600
21290412,2011-02-02T00:00:00,NF-kappa B,D12.776.930.600
21290412,2011-02-02T00:00:00,Rats,B01.050.150.900.649.865.635.505.700
21290412,2011-02-02T00:00:00,Signal Transduction,G02.111.087.800
21290412,2011-02-02T00:00:00,Signal Transduction,G02.149.115.800
21290412,2011-02-02T00:00:00,Signal Transduction,G04.299.880
21290412,2011-02-02T00:00:00,"Transcription, Genetic",G02.111.087.847
21290412,2011-02-02T00:00:00,"Transcription, Genetic",G02.149.115.847
21290412,2011-02-02T00:00:00,"Transcription, Genetic",G05.355.310.700
21290412,2011-02-02T00:00:00,Tumor Necrosis Factor-alpha,D12.644.276.374.500.800
21290412,2011-02-02T00:00:00,Tumor Necrosis Factor-alpha,D12.644.276.374.750.626
21290412,2011-02-02T00:00:00,Tumor Necrosis Factor-alpha,D12.644.276.972.626
21290412,2011-02-02T00:00:00,Tumor Necrosis Factor-alpha,D12.776.124.900
21290412,2011-02-02T00:00:00,Tumor Necrosis Factor-alpha,D12.776.395.930
21290412,2011-02-02T00:00:00,Tumor Necrosis Factor-alpha,D12.776.467.374.500.800
21290412,2011-02-02T00:00:00,Tumor Necrosis Factor-alpha,D12.776.467.374.750.626
21290412,2011-02-02T00:00:00,Tumor Necrosis Factor-alpha,D12.776.467.972.626
21290412,2011-02-02T00:00:00,Tumor Necrosis Factor-alpha,D23.529.374.500.800
21290412,2011-02-02T00:00:00,Tumor Necrosis Factor-alpha,D23.529.374.750.626
21290412,2011-02-02T00:00:00,Tumor Necrosis Factor-alpha,D23.529.972.626
21990832,2011-02-02T00:00:00,"Embolization, Therapeutic",E02.520.360
21990832,2011-02-02T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21990832,2011-02-02T00:00:00,Intracranial Aneurysm,C10.228.140.300.510.600
21990832,2011-02-02T00:00:00,Intracranial Aneurysm,C14.907.055.635
21990832,2011-02-02T00:00:00,Intracranial Aneurysm,C14.907.253.560.300
21990832,2011-02-02T00:00:00,Magnetic Resonance Imaging,E01.370.350.500
21990832,2011-02-02T00:00:00,Magnetic Resonance Imaging,E01.370.350.825.500
21990832,2011-02-02T00:00:00,Subarachnoid Hemorrhage,C10.228.140.300.535.800
21990832,2011-02-02T00:00:00,Subarachnoid Hemorrhage,C14.907.253.573.800
21990832,2011-02-02T00:00:00,Subarachnoid Hemorrhage,C23.550.414.913.850
21990832,2011-02-02T00:00:00,"Tomography, X-Ray Computed",E01.370.350.350.810
21990832,2011-02-02T00:00:00,"Tomography, X-Ray Computed",E01.370.350.600.350.700.810
21990832,2011-02-02T00:00:00,"Tomography, X-Ray Computed",E01.370.350.700.700.810
21990832,2011-02-02T00:00:00,"Tomography, X-Ray Computed",E01.370.350.700.810.810
21990832,2011-02-02T00:00:00,"Tomography, X-Ray Computed",E01.370.350.825.810.810
21290386,2011-02-03T00:00:00,Computer Simulation,L01.224.160
21290386,2011-02-03T00:00:00,Electrophoresis,E05.196.401
21290386,2011-02-03T00:00:00,Electrophoresis,E05.301.300
21290386,2011-02-03T00:00:00,Electrophoresis,G02.149.767.570
21290386,2011-02-03T00:00:00,Electrophoresis,G02.842.750.570
21290386,2011-02-03T00:00:00,Fluorescent Dyes,D27.720.233.348
21290386,2011-02-03T00:00:00,Fluorescent Dyes,D27.720.470.330.348
21290386,2011-02-03T00:00:00,Fluorescent Dyes,D27.720.470.410.505.500
21290386,2011-02-03T00:00:00,Microfluidic Analytical Techniques,E05.196.630.465
21290386,2011-02-03T00:00:00,Microfluidic Analytical Techniques,E05.588.465
21290386,2011-02-03T00:00:00,"Models, Chemical",E05.599.495
21293789,2011-02-03T00:00:00,DNA,D13.444.308
21293789,2011-02-03T00:00:00,DNA Damage,C21.111
21293789,2011-02-03T00:00:00,DNA Damage,G05.355.180
21293789,2011-02-03T00:00:00,Light,G01.201.875.770.578
21293789,2011-02-03T00:00:00,Light,G01.590.540
21293789,2011-02-03T00:00:00,Materials Testing,E05.570
21293789,2011-02-03T00:00:00,Nanoparticles,J01.637.512.600
21293789,2011-02-03T00:00:00,Photons,G01.201.875.770.578.782
21293789,2011-02-03T00:00:00,Photons,G01.249.705
21293789,2011-02-03T00:00:00,Photons,G01.590.540.782
21293789,2011-02-03T00:00:00,Photosensitizing Agents,D27.505.696.750.710
21293789,2011-02-03T00:00:00,Photosensitizing Agents,D27.505.954.444.600
21293789,2011-02-03T00:00:00,Polymers,D05.750
21293789,2011-02-03T00:00:00,Polymers,D25.720
21293789,2011-02-03T00:00:00,Polymers,J01.637.051.720
21294249,2011-02-03T00:00:00,Case-Control Studies,E05.318.760.500.500
21294249,2011-02-03T00:00:00,Case-Control Studies,N05.715.360.775.175.200
21294249,2011-02-03T00:00:00,Case-Control Studies,N06.850.520.450.500.500
21294249,2011-02-03T00:00:00,European Continental Ancestry Group,M01.686.508.400
21294249,2011-02-03T00:00:00,Genetic Variation,G05.365
21294249,2011-02-03T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21294249,2011-02-03T00:00:00,Mood Disorders,F03.600
21294249,2011-02-03T00:00:00,Nerve Growth Factor,D12.644.276.860.437
21294249,2011-02-03T00:00:00,Nerve Growth Factor,D12.776.467.860.437
21294249,2011-02-03T00:00:00,Nerve Growth Factor,D12.776.641.600.437
21294249,2011-02-03T00:00:00,Nerve Growth Factor,D23.529.850.437
21294249,2011-02-03T00:00:00,Oligonucleotide Array Sequence Analysis,E05.196.630.570.660
21294249,2011-02-03T00:00:00,Oligonucleotide Array Sequence Analysis,E05.393.525.640
21294249,2011-02-03T00:00:00,Oligonucleotide Array Sequence Analysis,E05.393.661.640
21294249,2011-02-03T00:00:00,Oligonucleotide Array Sequence Analysis,E05.393.760.640
21294249,2011-02-03T00:00:00,Oligonucleotide Array Sequence Analysis,E05.588.570.660
21294249,2011-02-03T00:00:00,Oligonucleotide Array Sequence Analysis,E05.601.640
21294249,2011-02-03T00:00:00,"Polymorphism, Single Nucleotide",G05.365.795.598
21294249,2011-02-03T00:00:00,Sex Factors,N05.715.350.675
21294249,2011-02-03T00:00:00,Sex Factors,N06.850.490.875
21294249,2011-02-03T00:00:00,Substance-Related Disorders,C21.739
21294249,2011-02-03T00:00:00,Substance-Related Disorders,F03.900
21297231,2011-02-04T00:00:00,Computational Biology,H01.158.273.180
21297231,2011-02-04T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21297231,2011-02-04T00:00:00,"Models, Molecular",E05.599.595
21297231,2011-02-04T00:00:00,Protein Folding,G01.154.100.640
21297231,2011-02-04T00:00:00,Protein Folding,G01.595.100.640
21297231,2011-02-04T00:00:00,Protein Folding,G02.111.087.690
21297231,2011-02-04T00:00:00,Protein Folding,G02.149.115.690
21297231,2011-02-04T00:00:00,Protein Stability,G02.111.700
21294664,2011-02-05T00:00:00,Brain Ischemia,C10.228.140.300.150
21294664,2011-02-05T00:00:00,Brain Ischemia,C14.907.253.092
21294664,2011-02-05T00:00:00,Clinical Trials as Topic,E05.318.760.535
21294664,2011-02-05T00:00:00,Clinical Trials as Topic,E05.337.250
21294664,2011-02-05T00:00:00,Clinical Trials as Topic,N05.715.360.775.235
21294664,2011-02-05T00:00:00,Clinical Trials as Topic,N06.850.520.450.535
21294664,2011-02-05T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21294664,2011-02-05T00:00:00,Neurosurgical Procedures,E04.525
21294664,2011-02-05T00:00:00,Stroke,C10.228.140.300.775
21294664,2011-02-05T00:00:00,Stroke,C14.907.253.855
21294664,2011-02-05T00:00:00,"Surgical Procedures, Minimally Invasive",E04.800
21294664,2011-02-05T00:00:00,Thrombectomy,E04.100.814.842
21294664,2011-02-05T00:00:00,Thrombolytic Therapy,E02.319.913
21294664,2011-02-05T00:00:00,Time Factors,G01.910.857
21294664,2011-02-05T00:00:00,Tissue Plasminogen Activator,D08.811.277.656.300.760.875
21294664,2011-02-05T00:00:00,Tissue Plasminogen Activator,D08.811.277.656.959.350.875
21294664,2011-02-05T00:00:00,Tissue Plasminogen Activator,D12.776.124.125.662.768
21294664,2011-02-05T00:00:00,Tissue Plasminogen Activator,D23.119.970
21299402,2011-02-07T00:00:00,Adult,M01.060.116
21299402,2011-02-07T00:00:00,"Diabetes Mellitus, Type 2",C18.452.394.750.149
21299402,2011-02-07T00:00:00,"Diabetes Mellitus, Type 2",C19.246.300
21299402,2011-02-07T00:00:00,Health Behavior,F01.145.488
21299402,2011-02-07T00:00:00,"Health Knowledge, Attitudes, Practice",F01.100.150.500
21299402,2011-02-07T00:00:00,"Health Knowledge, Attitudes, Practice",N05.300.150.410
21299402,2011-02-07T00:00:00,"Hemoglobin A, Glycosylated",D09.408.375
21299402,2011-02-07T00:00:00,"Hemoglobin A, Glycosylated",D12.776.124.400.405.440
21299402,2011-02-07T00:00:00,"Hemoglobin A, Glycosylated",D12.776.422.316.762.380.440
21299402,2011-02-07T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21299402,2011-02-07T00:00:00,Middle Aged,M01.060.116.630
21299402,2011-02-07T00:00:00,Regression Analysis,E05.318.740.750
21299402,2011-02-07T00:00:00,Regression Analysis,N05.715.360.750.695
21299402,2011-02-07T00:00:00,Regression Analysis,N06.850.520.830.750
21299402,2011-02-07T00:00:00,Self Care,E02.900
21299402,2011-02-07T00:00:00,Self Care,N02.421.784.680
21299555,2011-02-07T00:00:00,Environmental Remediation,N06.850.460.375
21299555,2011-02-07T00:00:00,Solubility,G02.842.800
21299555,2011-02-07T00:00:00,Water Movements,G16.500.240.960
21299555,2011-02-07T00:00:00,Water Movements,N06.230.850
21299555,2011-02-07T00:00:00,"Water Pollutants, Chemical",D27.888.284.903.655
21292133,2011-02-08T00:00:00,Adult,M01.060.116
21292133,2011-02-08T00:00:00,Case-Control Studies,E05.318.760.500.500
21292133,2011-02-08T00:00:00,Case-Control Studies,N05.715.360.775.175.200
21292133,2011-02-08T00:00:00,Case-Control Studies,N06.850.520.450.500.500
21292133,2011-02-08T00:00:00,Echocardiography,E01.370.350.850.220
21292133,2011-02-08T00:00:00,Echocardiography,E01.370.370.380.220
21292133,2011-02-08T00:00:00,Gastric Bypass,E02.065.062.249
21292133,2011-02-08T00:00:00,Gastric Bypass,E04.035.398.385
21292133,2011-02-08T00:00:00,Gastric Bypass,E04.062.249
21292133,2011-02-08T00:00:00,Gastric Bypass,E04.210.457.430
21292133,2011-02-08T00:00:00,Heart Atria,A07.541.358
21292133,2011-02-08T00:00:00,Heart Ventricles,A07.541.560
21292133,2011-02-08T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21292133,2011-02-08T00:00:00,Middle Aged,M01.060.116.630
21292133,2011-02-08T00:00:00,Myocardial Contraction,G09.330.190.541
21292133,2011-02-08T00:00:00,Myocardial Contraction,G11.427.590.540.570
21292133,2011-02-08T00:00:00,Obesity,C18.654.726.500
21292133,2011-02-08T00:00:00,Obesity,C23.888.144.699.500
21292133,2011-02-08T00:00:00,Obesity,E01.370.600.115.100.160.120.699.500
21292133,2011-02-08T00:00:00,Obesity,G07.100.100.160.120.699.500
21292133,2011-02-08T00:00:00,Treatment Outcome,E01.789.800
21292133,2011-02-08T00:00:00,Treatment Outcome,N04.761.559.590.800
21292133,2011-02-08T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21292133,2011-02-08T00:00:00,Ventricular Remodeling,C23.300.985
21292133,2011-02-08T00:00:00,Ventricular Remodeling,G09.330.190.962.975
21303920,2011-02-08T00:00:00,Acetylcysteine,D02.886.030.230.259
21303920,2011-02-08T00:00:00,Acetylcysteine,D12.125.166.230.259
21303920,2011-02-08T00:00:00,Animals,B01.050
21303920,2011-02-08T00:00:00,Cocaine,D02.145.074.722.388
21303920,2011-02-08T00:00:00,Cocaine,D03.132.889.354
21303920,2011-02-08T00:00:00,Cocaine,D03.605.869.388
21303920,2011-02-08T00:00:00,Cocaine,D04.075.080.875.099.722.388
21303920,2011-02-08T00:00:00,Cocaine-Related Disorders,C21.739.300
21303920,2011-02-08T00:00:00,Cocaine-Related Disorders,F03.900.300
21303920,2011-02-08T00:00:00,Cues,F02.463.425.234
21303920,2011-02-08T00:00:00,Glutamic Acid,D12.125.067.750
21303920,2011-02-08T00:00:00,Glutamic Acid,D12.125.119.450
21303920,2011-02-08T00:00:00,Glutamic Acid,D12.125.427.300
21303920,2011-02-08T00:00:00,Homeostasis,G07.700.360
21303920,2011-02-08T00:00:00,Rats,B01.050.150.900.649.865.635.505.700
21303920,2011-02-08T00:00:00,"Rats, Sprague-Dawley",B01.050.150.900.649.865.635.505.700.750
21303920,2011-02-08T00:00:00,Self Administration,E02.319.890
21303920,2011-02-08T00:00:00,Self Administration,E02.900.890
21303920,2011-02-08T00:00:00,Substance Withdrawal Syndrome,C21.739.835
21303920,2011-02-08T00:00:00,Substance Withdrawal Syndrome,F03.900.825
21306385,2011-02-08T00:00:00,Alveolar Bone Loss,C05.116.264.150
21306385,2011-02-08T00:00:00,Alveolar Bone Loss,C07.465.714.354.500
21306385,2011-02-08T00:00:00,Animals,B01.050
21306385,2011-02-08T00:00:00,Collagen,D05.750.078.280
21306385,2011-02-08T00:00:00,Collagen,D12.776.860.300.250
21306385,2011-02-08T00:00:00,Cyclooxygenase 2,D08.811.600.720.750
21306385,2011-02-08T00:00:00,Fibroblasts,A11.329.228
21306385,2011-02-08T00:00:00,Fibroblasts,A11.872.228
21306385,2011-02-08T00:00:00,"Image Processing, Computer-Assisted",L01.224.308
21306385,2011-02-08T00:00:00,"Imaging, Three-Dimensional",E01.370.350.400
21306385,2011-02-08T00:00:00,"Imaging, Three-Dimensional",L01.224.308.410
21306385,2011-02-08T00:00:00,Inflammation,C23.550.470
21306385,2011-02-08T00:00:00,Interleukin-6,D12.644.276.374.465.506
21306385,2011-02-08T00:00:00,Interleukin-6,D12.776.467.374.465.506
21306385,2011-02-08T00:00:00,Interleukin-6,D23.529.374.465.506
21306385,2011-02-08T00:00:00,NF-kappa B,D12.776.260.600
21306385,2011-02-08T00:00:00,NF-kappa B,D12.776.660.600
21306385,2011-02-08T00:00:00,NF-kappa B,D12.776.930.600
21306385,2011-02-08T00:00:00,Periodontitis,C07.465.714.533
21306385,2011-02-08T00:00:00,Rats,B01.050.150.900.649.865.635.505.700
21306385,2011-02-08T00:00:00,"Rats, Sprague-Dawley",B01.050.150.900.649.865.635.505.700.750
21306385,2011-02-08T00:00:00,Tumor Necrosis Factor-alpha,D12.644.276.374.500.800
21306385,2011-02-08T00:00:00,Tumor Necrosis Factor-alpha,D12.644.276.374.750.626
21306385,2011-02-08T00:00:00,Tumor Necrosis Factor-alpha,D12.644.276.972.626
21306385,2011-02-08T00:00:00,Tumor Necrosis Factor-alpha,D12.776.124.900
21306385,2011-02-08T00:00:00,Tumor Necrosis Factor-alpha,D12.776.395.930
21306385,2011-02-08T00:00:00,Tumor Necrosis Factor-alpha,D12.776.467.374.500.800
21306385,2011-02-08T00:00:00,Tumor Necrosis Factor-alpha,D12.776.467.374.750.626
21306385,2011-02-08T00:00:00,Tumor Necrosis Factor-alpha,D12.776.467.972.626
21306385,2011-02-08T00:00:00,Tumor Necrosis Factor-alpha,D23.529.374.500.800
21306385,2011-02-08T00:00:00,Tumor Necrosis Factor-alpha,D23.529.374.750.626
21306385,2011-02-08T00:00:00,Tumor Necrosis Factor-alpha,D23.529.972.626
21306385,2011-02-08T00:00:00,X-Ray Microtomography,E01.370.350.700.810.810.900
21306385,2011-02-08T00:00:00,X-Ray Microtomography,E01.370.350.825.810.810.900
21306385,2011-02-08T00:00:00,p38 Mitogen-Activated Protein Kinases,D08.811.913.696.620.682.700.567.878
21306385,2011-02-08T00:00:00,p38 Mitogen-Activated Protein Kinases,D08.811.913.696.620.682.700.646.750.843
21306385,2011-02-08T00:00:00,p38 Mitogen-Activated Protein Kinases,D12.644.360.450.835
21306385,2011-02-08T00:00:00,p38 Mitogen-Activated Protein Kinases,D12.776.476.450.835
21306838,2011-02-08T00:00:00,Adult,M01.060.116
21306838,2011-02-08T00:00:00,Aggression,F01.145.126.125
21306838,2011-02-08T00:00:00,Aggression,F01.145.813.045
21306838,2011-02-08T00:00:00,Central Nervous System Stimulants,D27.505.696.282
21306838,2011-02-08T00:00:00,Central Nervous System Stimulants,D27.505.954.427.220
21306838,2011-02-08T00:00:00,Cocaine,D02.145.074.722.388
21306838,2011-02-08T00:00:00,Cocaine,D03.132.889.354
21306838,2011-02-08T00:00:00,Cocaine,D03.605.869.388
21306838,2011-02-08T00:00:00,Cocaine,D04.075.080.875.099.722.388
21306838,2011-02-08T00:00:00,Cocaine-Related Disorders,C21.739.300
21306838,2011-02-08T00:00:00,Cocaine-Related Disorders,F03.900.300
21306838,2011-02-08T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21306838,2011-02-08T00:00:00,Hydrocortisone,D04.808.745.745.654.600
21306838,2011-02-08T00:00:00,Hydrocortisone,D06.472.040.585.353.476
21306838,2011-02-08T00:00:00,Hydrocortisone,D06.472.040.585.478.392
21306838,2011-02-08T00:00:00,Impulsive Behavior,F01.145.527
21306838,2011-02-08T00:00:00,Middle Aged,M01.060.116.630
21306838,2011-02-08T00:00:00,Personality,F01.752
21306838,2011-02-08T00:00:00,Psychiatric Status Rating Scales,F04.586
21306838,2011-02-08T00:00:00,Psychotic Disorders,F03.700.675
21306838,2011-02-08T00:00:00,"Stress, Psychological",F01.145.126.990
21306838,2011-02-08T00:00:00,"Stress, Psychological",F02.830.900
21306838,2011-02-08T00:00:00,Time Factors,G01.910.857
21307334,2011-02-09T00:00:00,Animals,B01.050
21307334,2011-02-09T00:00:00,Cell Proliferation,G04.299.233.750
21307334,2011-02-09T00:00:00,Cell Proliferation,G07.700.320.249.410.750
21307334,2011-02-09T00:00:00,Flow Cytometry,E05.196.712.516.600.240.350
21307334,2011-02-09T00:00:00,Flow Cytometry,E05.200.500.386.350
21307334,2011-02-09T00:00:00,Lymphocytes,A11.118.637.555.567
21307334,2011-02-09T00:00:00,Lymphocytes,A15.145.229.637.555.567
21307334,2011-02-09T00:00:00,Lymphocytes,A15.382.490.555.567
21307334,2011-02-09T00:00:00,Muromegalovirus,B04.280.382.150.500
21307334,2011-02-09T00:00:00,Muromegalovirus,B04.909.204.382.150.500
21308728,2011-02-09T00:00:00,Alligators and Crocodiles,B01.050.150.900.833.100
21308728,2011-02-09T00:00:00,Animals,B01.050
21308728,2011-02-09T00:00:00,Estrogen Receptor alpha,D12.776.260.698.750.350.174
21308728,2011-02-09T00:00:00,Estrogen Receptor alpha,D12.776.826.750.350.174
21308728,2011-02-09T00:00:00,Estrogen Receptor alpha,D12.776.930.669.750.350.174
21308728,2011-02-09T00:00:00,Polymerase Chain Reaction,E05.393.620.500
21308728,2011-02-09T00:00:00,"Receptors, Androgen",D12.776.260.698.750.150
21308728,2011-02-09T00:00:00,"Receptors, Androgen",D12.776.826.750.150
21308728,2011-02-09T00:00:00,"Receptors, Androgen",D12.776.930.669.750.150
21308728,2011-02-09T00:00:00,"Receptors, Estrogen",D12.776.260.698.750.350
21308728,2011-02-09T00:00:00,"Receptors, Estrogen",D12.776.826.750.350
21308728,2011-02-09T00:00:00,"Receptors, Estrogen",D12.776.930.669.750.350
21315841,2011-02-09T00:00:00,Aged,M01.060.116.100
21315841,2011-02-09T00:00:00,"Defibrillators, Implantable",E07.305.250.159.175
21315841,2011-02-09T00:00:00,"Defibrillators, Implantable",E07.305.250.319.175
21315841,2011-02-09T00:00:00,"Defibrillators, Implantable",E07.695.175
21315841,2011-02-09T00:00:00,Echocardiography,E01.370.350.850.220
21315841,2011-02-09T00:00:00,Echocardiography,E01.370.370.380.220
21315841,2011-02-09T00:00:00,Heart Ventricles,A07.541.560
21315841,2011-02-09T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21315841,2011-02-09T00:00:00,Ventricular Fibrillation,C14.280.067.922
21315841,2011-02-09T00:00:00,Ventricular Fibrillation,C23.550.073.922
21315841,2011-02-09T00:00:00,Ventricular Remodeling,C23.300.985
21315841,2011-02-09T00:00:00,Ventricular Remodeling,G09.330.190.962.975
21310784,2011-02-10T00:00:00,Bacterial Proteins,D12.776.097
21310784,2011-02-10T00:00:00,Carrier State,N06.850.160
21310784,2011-02-10T00:00:00,Iron,D01.268.556.412
21310784,2011-02-10T00:00:00,Iron,D01.268.956.287
21310784,2011-02-10T00:00:00,Iron,D01.552.544.412
21310784,2011-02-10T00:00:00,Meningococcal Infections,C01.252.400.625.549
21310784,2011-02-10T00:00:00,Molecular Sequence Data,L01.453.245.667
21310784,2011-02-10T00:00:00,Neisseria meningitidis,B03.440.400.425.550.550.641
21310784,2011-02-10T00:00:00,Neisseria meningitidis,B03.660.075.525.520.500
21311066,2011-02-10T00:00:00,Aged,M01.060.116.100
21311066,2011-02-10T00:00:00,Balloon Occlusion,E02.148.106
21311066,2011-02-10T00:00:00,Balloon Occlusion,E02.520.179
21311066,2011-02-10T00:00:00,Blood Vessel Prosthesis Implantation,E04.100.814.200
21311066,2011-02-10T00:00:00,Blood Vessel Prosthesis Implantation,E04.650.200
21311066,2011-02-10T00:00:00,Brain Ischemia,C10.228.140.300.150
21311066,2011-02-10T00:00:00,Brain Ischemia,C14.907.253.092
21311066,2011-02-10T00:00:00,Diffusion Magnetic Resonance Imaging,E01.370.350.500.150
21311066,2011-02-10T00:00:00,Diffusion Magnetic Resonance Imaging,E01.370.350.825.500.150
21311066,2011-02-10T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21311066,2011-02-10T00:00:00,Intracranial Aneurysm,C10.228.140.300.510.600
21311066,2011-02-10T00:00:00,Intracranial Aneurysm,C14.907.055.635
21311066,2011-02-10T00:00:00,Intracranial Aneurysm,C14.907.253.560.300
21311066,2011-02-10T00:00:00,Middle Aged,M01.060.116.630
21311066,2011-02-10T00:00:00,Postoperative Complications,C23.550.767
21311066,2011-02-10T00:00:00,Risk Factors,E05.318.740.600.800.725
21311066,2011-02-10T00:00:00,Risk Factors,N05.715.350.200.700
21311066,2011-02-10T00:00:00,Risk Factors,N05.715.360.750.625.700.700
21311066,2011-02-10T00:00:00,Risk Factors,N06.850.490.625.750
21311066,2011-02-10T00:00:00,Risk Factors,N06.850.520.830.600.800.725
21311066,2011-02-10T00:00:00,Time Factors,G01.910.857
21337470,2011-02-10T00:00:00,Actins,D05.750.078.730.250
21337470,2011-02-10T00:00:00,Actins,D12.776.210.500.100
21337470,2011-02-10T00:00:00,Actins,D12.776.220.525.255
21337470,2011-02-10T00:00:00,Animals,B01.050
21337470,2011-02-10T00:00:00,Golgi Apparatus,A11.284.430.214.190.875.336
21337470,2011-02-10T00:00:00,Nuclear Proteins,D12.776.660
21337470,2011-02-10T00:00:00,Rats,B01.050.150.900.649.865.635.505.700
21337470,2011-02-10T00:00:00,Tumor Suppressor Proteins,D12.776.624.776
21439910,2011-02-10T00:00:00,Antigen-Antibody Complex,D12.776.124.486.485.114.257
21439910,2011-02-10T00:00:00,Antigen-Antibody Complex,D12.776.124.790.651.114.257
21439910,2011-02-10T00:00:00,Antigen-Antibody Complex,D12.776.377.715.548.114.257
21439910,2011-02-10T00:00:00,Antigen-Antibody Complex,D23.050.101
21439910,2011-02-10T00:00:00,Collagen Type IV,D12.776.860.300.250.400.100
21439910,2011-02-10T00:00:00,Diabetic Nephropathies,C12.777.419.192
21439910,2011-02-10T00:00:00,Diabetic Nephropathies,C13.351.968.419.192
21439910,2011-02-10T00:00:00,Diabetic Nephropathies,C19.246.099.875
21439910,2011-02-10T00:00:00,Flow Cytometry,E05.196.712.516.600.240.350
21439910,2011-02-10T00:00:00,Flow Cytometry,E05.200.500.386.350
21439910,2011-02-10T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21439910,2011-02-10T00:00:00,"Lipoproteins, LDL",D10.532.515
21439910,2011-02-10T00:00:00,"Lipoproteins, LDL",D12.776.521.550
21439910,2011-02-10T00:00:00,Mesangial Cells,A05.810.453.324.359.620
21439910,2011-02-10T00:00:00,Mesangial Cells,A05.810.453.736.520.620
21439910,2011-02-10T00:00:00,Mesangial Cells,A11.329.228.950
21439910,2011-02-10T00:00:00,Mitogen-Activated Protein Kinases,D08.811.913.696.620.682.700.567
21439910,2011-02-10T00:00:00,Mitogen-Activated Protein Kinases,D08.811.913.696.620.682.700.646.750
21439910,2011-02-10T00:00:00,Mitogen-Activated Protein Kinases,D12.644.360.450
21439910,2011-02-10T00:00:00,Mitogen-Activated Protein Kinases,D12.776.476.450
21439910,2011-02-10T00:00:00,Protein Kinase Inhibitors,D27.505.519.389.755
21439910,2011-02-10T00:00:00,RNA,D13.444.735
21439910,2011-02-10T00:00:00,"Receptors, IgG",D12.776.543.750.705.871.300
21439910,2011-02-10T00:00:00,"Receptors, IgG",D23.050.301.264.035.695
21439910,2011-02-10T00:00:00,"Receptors, IgG",D23.101.100.110.695
21451763,2011-02-10T00:00:00,"Education, Pharmacy",I02.358.525
21451763,2011-02-10T00:00:00,"History, 20th Century",K01.400.504.968
21451763,2011-02-10T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21451763,2011-02-10T00:00:00,Periodicals as Topic,L01.178.682.829.678
21451763,2011-02-10T00:00:00,United States,Z01.107.567.875
21311920,2011-02-11T00:00:00,Cytomegalovirus,B04.280.382.150.150
21311920,2011-02-11T00:00:00,Cytomegalovirus,B04.909.204.382.150.150
21311920,2011-02-11T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21311920,2011-02-11T00:00:00,Immunoglobulin G,D12.776.124.486.485.114.619.393
21311920,2011-02-11T00:00:00,Immunoglobulin G,D12.776.124.790.651.114.619.393
21311920,2011-02-11T00:00:00,Immunoglobulin G,D12.776.377.715.548.114.619.393
21311920,2011-02-11T00:00:00,Membrane Glycoproteins,D12.776.395.550
21311920,2011-02-11T00:00:00,Membrane Glycoproteins,D12.776.543.550
21311920,2011-02-11T00:00:00,"Receptors, IgG",D12.776.543.750.705.871.300
21311920,2011-02-11T00:00:00,"Receptors, IgG",D23.050.301.264.035.695
21311920,2011-02-11T00:00:00,"Receptors, IgG",D23.101.100.110.695
21311920,2011-02-11T00:00:00,Viral Proteins,D12.776.964
21314100,2011-02-11T00:00:00,Animals,B01.050
21314100,2011-02-11T00:00:00,Cattle,B01.050.150.900.649.077.380.271
21314100,2011-02-11T00:00:00,Cone Opsins,D12.776.306.466.249
21314100,2011-02-11T00:00:00,Cone Opsins,D23.767.930.750.249
21314100,2011-02-11T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21314100,2011-02-11T00:00:00,Molecular Structure,G02.111.570
21314100,2011-02-11T00:00:00,Molecular Structure,G02.575
21314100,2011-02-11T00:00:00,Molecular Structure,G02.842.575
21314100,2011-02-11T00:00:00,Retina,A09.371.729
21314100,2011-02-11T00:00:00,Retinaldehyde,D02.047.850
21314100,2011-02-11T00:00:00,Retinaldehyde,D02.455.326.271.665.202.495.690
21314100,2011-02-11T00:00:00,Retinaldehyde,D02.455.426.392.368.367.379.249.700.690
21314100,2011-02-11T00:00:00,Retinaldehyde,D02.455.849.131.495.690
21314100,2011-02-11T00:00:00,Retinaldehyde,D23.767.261.700.690
21314100,2011-02-11T00:00:00,Rhodopsin,D12.776.543.750.100.955
21314100,2011-02-11T00:00:00,Rhodopsin,D23.767.930.750.500.500
21314100,2011-02-11T00:00:00,Transducin,D08.811.277.040.330.300.200.800
21314100,2011-02-11T00:00:00,Transducin,D12.644.360.375.940
21314100,2011-02-11T00:00:00,Transducin,D12.776.157.325.332.940
21314100,2011-02-11T00:00:00,Transducin,D12.776.476.375.940
21314100,2011-02-11T00:00:00,Transducin,D12.776.543.325.800
21314693,2011-02-11T00:00:00,Alcohol Drinking,F01.145.317.269
21314693,2011-02-11T00:00:00,Alcoholism,C21.739.100.250
21314693,2011-02-11T00:00:00,Alcoholism,F03.900.100.350
21314693,2011-02-11T00:00:00,Animals,B01.050
21314693,2011-02-11T00:00:00,Ethanol,D02.033.375
21314693,2011-02-11T00:00:00,Substance Withdrawal Syndrome,C21.739.835
21314693,2011-02-11T00:00:00,Substance Withdrawal Syndrome,F03.900.825
21316240,2011-02-11T00:00:00,"Adaptation, Physiological",G07.700.062
21316240,2011-02-11T00:00:00,"Adaptation, Physiological",G16.100.057.500
21316240,2011-02-11T00:00:00,Aged,M01.060.116.100
21316240,2011-02-11T00:00:00,Gait,E01.370.600.250
21316240,2011-02-11T00:00:00,Gait,G11.427.590.530.389
21316240,2011-02-11T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21316240,2011-02-11T00:00:00,Leg,A01.378.610.500
21316240,2011-02-11T00:00:00,Middle Aged,M01.060.116.630
21316240,2011-02-11T00:00:00,Paresis,C10.597.636
21316240,2011-02-11T00:00:00,Paresis,C23.888.592.643
21316240,2011-02-11T00:00:00,Stroke,C10.228.140.300.775
21316240,2011-02-11T00:00:00,Stroke,C14.907.253.855
21316240,2011-02-11T00:00:00,Walking,G11.427.590.530.568.900
21316240,2011-02-11T00:00:00,Walking,G11.427.590.530.698.940
21316240,2011-02-11T00:00:00,Walking,I03.450.642.845.940
21317395,2011-02-11T00:00:00,Animals,B01.050
21317395,2011-02-11T00:00:00,Cell Differentiation,G04.299.151
21317395,2011-02-11T00:00:00,"Diabetes Mellitus, Type 1",C18.452.394.750.124
21317395,2011-02-11T00:00:00,"Diabetes Mellitus, Type 1",C19.246.267
21317395,2011-02-11T00:00:00,"Diabetes Mellitus, Type 1",C20.111.327
21317395,2011-02-11T00:00:00,Gastrointestinal Tract,A03.556
21317395,2011-02-11T00:00:00,Lymph Nodes,A10.549.400
21317395,2011-02-11T00:00:00,Lymph Nodes,A15.382.520.604.412
21317395,2011-02-11T00:00:00,Rats,B01.050.150.900.649.865.635.505.700
21316670,2011-02-12T00:00:00,"Cholangiopancreatography, Endoscopic Retrograde",E01.370.350.700.715.200.200
21316670,2011-02-12T00:00:00,"Cholangiopancreatography, Endoscopic Retrograde",E01.370.372.200.200
21316670,2011-02-12T00:00:00,"Cholangiopancreatography, Endoscopic Retrograde",E01.370.372.250.200
21316670,2011-02-12T00:00:00,"Cholangiopancreatography, Endoscopic Retrograde",E01.370.388.250.250.160
21316670,2011-02-12T00:00:00,"Cholangiopancreatography, Endoscopic Retrograde",E04.210.240.160
21316670,2011-02-12T00:00:00,"Cholangiopancreatography, Endoscopic Retrograde",E04.800.250.250.160
21316670,2011-02-12T00:00:00,Cholestasis,C06.130.120.135
21316670,2011-02-12T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21316670,2011-02-12T00:00:00,Liver Transplantation,E04.210.650
21316670,2011-02-12T00:00:00,Liver Transplantation,E04.936.450.490
21316670,2011-02-12T00:00:00,Liver Transplantation,E04.936.580.490
21316670,2011-02-12T00:00:00,Postoperative Complications,C23.550.767
21320109,2011-02-14T00:00:00,Adult,M01.060.116
21320109,2011-02-14T00:00:00,Anticonvulsants,D27.505.954.427.080
21320109,2011-02-14T00:00:00,Carbamates,D02.241.081.251
21320109,2011-02-14T00:00:00,Double-Blind Method,E05.318.780.300
21320109,2011-02-14T00:00:00,Double-Blind Method,E05.581.500.300
21320109,2011-02-14T00:00:00,Double-Blind Method,N05.715.360.780.320
21320109,2011-02-14T00:00:00,Double-Blind Method,N06.850.520.445.300
21320109,2011-02-14T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21320109,2011-02-14T00:00:00,Middle Aged,M01.060.116.630
21320109,2011-02-14T00:00:00,Outcome Assessment (Health Care),N04.761.559.590
21320109,2011-02-14T00:00:00,Outcome Assessment (Health Care),N05.715.360.575.575
21325123,2011-02-14T00:00:00,Aged,M01.060.116.100
21325123,2011-02-14T00:00:00,Alzheimer Disease,C10.228.140.380.100
21325123,2011-02-14T00:00:00,Alzheimer Disease,C10.574.945.249
21325123,2011-02-14T00:00:00,Alzheimer Disease,F03.087.400.100
21325123,2011-02-14T00:00:00,Cognition Disorders,F03.087.250
21325123,2011-02-14T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21325123,2011-02-14T00:00:00,Risk Factors,E05.318.740.600.800.725
21325123,2011-02-14T00:00:00,Risk Factors,N05.715.350.200.700
21325123,2011-02-14T00:00:00,Risk Factors,N05.715.360.750.625.700.700
21325123,2011-02-14T00:00:00,Risk Factors,N06.850.490.625.750
21325123,2011-02-14T00:00:00,Risk Factors,N06.850.520.830.600.800.725
21325123,2011-02-14T00:00:00,Treatment Outcome,E01.789.800
21325123,2011-02-14T00:00:00,Treatment Outcome,N04.761.559.590.800
21325123,2011-02-14T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21325123,2011-02-14T00:00:00,Vitamin D,D04.808.812.768
21325123,2011-02-14T00:00:00,Vitamin D Deficiency,C18.654.521.500.133.770
22170024,2011-02-14T00:00:00,Adult,M01.060.116
22170024,2011-02-14T00:00:00,Bulimia,C23.888.821.645.500
22170024,2011-02-14T00:00:00,Health Surveys,E05.318.308.250
22170024,2011-02-14T00:00:00,Health Surveys,N05.715.360.300.375
22170024,2011-02-14T00:00:00,Health Surveys,N06.850.520.308.250
22170024,2011-02-14T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22170024,2011-02-14T00:00:00,Vomiting,C23.888.821.937
21990441,2011-02-15T00:00:00,Aged,M01.060.116.100
21990441,2011-02-15T00:00:00,"Databases, Factual",L01.470.750.750
21990441,2011-02-15T00:00:00,"Databases, Factual",L01.700.508.300.188.400
21990441,2011-02-15T00:00:00,"Embolization, Therapeutic",E02.520.360
21990441,2011-02-15T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21990441,2011-02-15T00:00:00,Intracranial Aneurysm,C10.228.140.300.510.600
21990441,2011-02-15T00:00:00,Intracranial Aneurysm,C14.907.055.635
21990441,2011-02-15T00:00:00,Intracranial Aneurysm,C14.907.253.560.300
21990441,2011-02-15T00:00:00,Middle Aged,M01.060.116.630
21990441,2011-02-15T00:00:00,Postoperative Complications,C23.550.767
21990441,2011-02-15T00:00:00,Treatment Outcome,E01.789.800
21990441,2011-02-15T00:00:00,Treatment Outcome,N04.761.559.590.800
21990441,2011-02-15T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21323413,2011-02-16T00:00:00,Brain Injuries,C10.228.140.199
21323413,2011-02-16T00:00:00,Brain Injuries,C10.900.300.087
21323413,2011-02-16T00:00:00,Brain Injuries,C21.866.260.118
21323413,2011-02-16T00:00:00,Brain Injuries,C21.866.915.300.200
21323413,2011-02-16T00:00:00,Cognition,F02.463.188
21323413,2011-02-16T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21323413,2011-02-16T00:00:00,Neuropsychological Tests,F04.711.513
21323413,2011-02-16T00:00:00,Psychometrics,F04.711.780
21323413,2011-02-16T00:00:00,Quality of Life,I01.800
21323413,2011-02-16T00:00:00,Quality of Life,K01.752.400.750
21323413,2011-02-16T00:00:00,Recovery of Function,G16.757
21324647,2011-02-16T00:00:00,Aged,M01.060.116.100
21324647,2011-02-16T00:00:00,Brain Injuries,C10.228.140.199
21324647,2011-02-16T00:00:00,Brain Injuries,C10.900.300.087
21324647,2011-02-16T00:00:00,Brain Injuries,C21.866.260.118
21324647,2011-02-16T00:00:00,Brain Injuries,C21.866.915.300.200
21324647,2011-02-16T00:00:00,Health Surveys,E05.318.308.250
21324647,2011-02-16T00:00:00,Health Surveys,N05.715.360.300.375
21324647,2011-02-16T00:00:00,Health Surveys,N06.850.520.308.250
21324647,2011-02-16T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21324647,2011-02-16T00:00:00,Outcome Assessment (Health Care),N04.761.559.590
21324647,2011-02-16T00:00:00,Outcome Assessment (Health Care),N05.715.360.575.575
21324647,2011-02-16T00:00:00,United States,Z01.107.567.875
21327491,2011-02-16T00:00:00,Case-Control Studies,E05.318.760.500.500
21327491,2011-02-16T00:00:00,Case-Control Studies,N05.715.360.775.175.200
21327491,2011-02-16T00:00:00,Case-Control Studies,N06.850.520.450.500.500
21327491,2011-02-16T00:00:00,"Death, Sudden, Cardiac",C14.280.383.220
21327491,2011-02-16T00:00:00,"Death, Sudden, Cardiac",C23.550.260.322.250
21327491,2011-02-16T00:00:00,"Defibrillators, Implantable",E07.305.250.159.175
21327491,2011-02-16T00:00:00,"Defibrillators, Implantable",E07.305.250.319.175
21327491,2011-02-16T00:00:00,"Defibrillators, Implantable",E07.695.175
21327491,2011-02-16T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21327491,2011-02-16T00:00:00,Risk Assessment,E05.318.740.600.800.715
21327491,2011-02-16T00:00:00,Risk Assessment,N04.452.871.715
21327491,2011-02-16T00:00:00,Risk Assessment,N05.715.360.750.625.700.690
21327491,2011-02-16T00:00:00,Risk Assessment,N06.850.505.715
21327491,2011-02-16T00:00:00,Risk Assessment,N06.850.520.830.600.800.715
21327491,2011-02-16T00:00:00,"Tachycardia, Ventricular",C14.280.067.845.940
21327491,2011-02-16T00:00:00,"Tachycardia, Ventricular",C23.550.073.845.940
21327491,2011-02-16T00:00:00,"Ventricular Dysfunction, Left",C14.280.945.900
21327491,2011-02-16T00:00:00,Ventricular Fibrillation,C14.280.067.922
21327491,2011-02-16T00:00:00,Ventricular Fibrillation,C23.550.073.922
21328636,2011-02-16T00:00:00,Adult,M01.060.116
21328636,2011-02-16T00:00:00,Corticotropin-Releasing Hormone,D06.472.699.327.740.140
21328636,2011-02-16T00:00:00,Corticotropin-Releasing Hormone,D12.644.400.400.740.140
21328636,2011-02-16T00:00:00,Corticotropin-Releasing Hormone,D12.644.548.365.740.140
21328636,2011-02-16T00:00:00,Corticotropin-Releasing Hormone,D12.776.641.650.405.740.140
21328636,2011-02-16T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21328636,2011-02-16T00:00:00,Hydrocortisone,D04.808.745.745.654.600
21328636,2011-02-16T00:00:00,Hydrocortisone,D06.472.040.585.353.476
21328636,2011-02-16T00:00:00,Hydrocortisone,D06.472.040.585.478.392
21328636,2011-02-16T00:00:00,Hypothalamo-Hypophyseal System,A06.688.357
21328636,2011-02-16T00:00:00,Hypothalamo-Hypophyseal System,A08.186.211.730.317.357.352.435
21328636,2011-02-16T00:00:00,Hypothalamo-Hypophyseal System,A08.713.357
21328636,2011-02-16T00:00:00,Life Change Events,F01.829.458.410
21328636,2011-02-16T00:00:00,Middle Aged,M01.060.116.630
21328636,2011-02-16T00:00:00,Pituitary-Adrenal System,A06.407.691
21328636,2011-02-16T00:00:00,Sex Factors,N05.715.350.675
21328636,2011-02-16T00:00:00,Sex Factors,N06.850.490.875
21330592,2011-02-17T00:00:00,Adult,M01.060.116
21330592,2011-02-17T00:00:00,African Americans,M01.686.508.100.100
21330592,2011-02-17T00:00:00,African Americans,M01.686.754.100
21330592,2011-02-17T00:00:00,Aged,M01.060.116.100
21330592,2011-02-17T00:00:00,Cardiovascular Diseases,C14
21330592,2011-02-17T00:00:00,Community-Based Participatory Research,N05.425.104
21330592,2011-02-17T00:00:00,Health Behavior,F01.145.488
21330592,2011-02-17T00:00:00,Health Services,N02.421
21330592,2011-02-17T00:00:00,Health Services Accessibility,N04.590.374.350
21330592,2011-02-17T00:00:00,Health Services Accessibility,N05.300.430
21330592,2011-02-17T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21330592,2011-02-17T00:00:00,Middle Aged,M01.060.116.630
21330592,2011-02-17T00:00:00,Neoplasms,C04
21330592,2011-02-17T00:00:00,Obesity,C18.654.726.500
21330592,2011-02-17T00:00:00,Obesity,C23.888.144.699.500
21330592,2011-02-17T00:00:00,Obesity,E01.370.600.115.100.160.120.699.500
21330592,2011-02-17T00:00:00,Obesity,G07.100.100.160.120.699.500
21330592,2011-02-17T00:00:00,Risk Factors,E05.318.740.600.800.725
21330592,2011-02-17T00:00:00,Risk Factors,N05.715.350.200.700
21330592,2011-02-17T00:00:00,Risk Factors,N05.715.360.750.625.700.700
21330592,2011-02-17T00:00:00,Risk Factors,N06.850.490.625.750
21330592,2011-02-17T00:00:00,Risk Factors,N06.850.520.830.600.800.725
21330592,2011-02-17T00:00:00,Sexually Transmitted Diseases,C01.539.778
21330592,2011-02-17T00:00:00,Sexually Transmitted Diseases,C02.800
21330592,2011-02-17T00:00:00,Sexually Transmitted Diseases,C12.294.668
21330592,2011-02-17T00:00:00,Sexually Transmitted Diseases,C13.351.500.711
21330592,2011-02-17T00:00:00,Substance-Related Disorders,C21.739
21330592,2011-02-17T00:00:00,Substance-Related Disorders,F03.900
21330592,2011-02-17T00:00:00,Urban Population,N01.600.900
21330592,2011-02-17T00:00:00,Violence,I01.198.240.856
21330592,2011-02-17T00:00:00,Violence,I01.880.735.900
21316465,2011-02-18T00:00:00,Adult,M01.060.116
21316465,2011-02-18T00:00:00,Alcoholism,C21.739.100.250
21316465,2011-02-18T00:00:00,Alcoholism,F03.900.100.350
21316465,2011-02-18T00:00:00,Brain Mapping,E01.370.350.086
21316465,2011-02-18T00:00:00,Brain Mapping,E01.370.376.149
21316465,2011-02-18T00:00:00,Brain Mapping,E05.132
21316465,2011-02-18T00:00:00,Corpus Striatum,A08.186.211.730.885.287.249.487
21316465,2011-02-18T00:00:00,Cues,F02.463.425.234
21316465,2011-02-18T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21316465,2011-02-18T00:00:00,"Image Interpretation, Computer-Assisted",E01.158.600
21316465,2011-02-18T00:00:00,"Image Interpretation, Computer-Assisted",E01.370.350.350
21316465,2011-02-18T00:00:00,"Image Interpretation, Computer-Assisted",L01.700.508.100.158.600
21316465,2011-02-18T00:00:00,Magnetic Resonance Imaging,E01.370.350.500
21316465,2011-02-18T00:00:00,Magnetic Resonance Imaging,E01.370.350.825.500
21329880,2011-02-18T00:00:00,Animals,B01.050
21329880,2011-02-18T00:00:00,Neoplasms,C04
21329880,2011-02-18T00:00:00,Ribonucleoproteins,D12.776.157.725.500
21329880,2011-02-18T00:00:00,Ribonucleoproteins,D12.776.664.962.500
21329880,2011-02-18T00:00:00,Signal Transduction,G02.111.087.800
21329880,2011-02-18T00:00:00,Signal Transduction,G02.149.115.800
21329880,2011-02-18T00:00:00,Signal Transduction,G04.299.880
21329880,2011-02-18T00:00:00,Transforming Growth Factor beta,D12.644.276.374.687
21329880,2011-02-18T00:00:00,Transforming Growth Factor beta,D12.644.276.954.800.720
21329880,2011-02-18T00:00:00,Transforming Growth Factor beta,D12.644.276.963.720
21329880,2011-02-18T00:00:00,Transforming Growth Factor beta,D12.776.467.374.687
21329880,2011-02-18T00:00:00,Transforming Growth Factor beta,D12.776.467.942.800.720
21329880,2011-02-18T00:00:00,Transforming Growth Factor beta,D12.776.467.960.720
21329880,2011-02-18T00:00:00,Transforming Growth Factor beta,D23.529.374.687
21329880,2011-02-18T00:00:00,Transforming Growth Factor beta,D23.529.942.800.720
21329880,2011-02-18T00:00:00,Transforming Growth Factor beta,D23.529.960.720
21335370,2011-02-18T00:00:00,African Continental Ancestry Group,M01.686.508.100
21335370,2011-02-18T00:00:00,Blood Glucose,D09.546.359.448.500
21335370,2011-02-18T00:00:00,"Diabetes Mellitus, Type 2",C18.452.394.750.149
21335370,2011-02-18T00:00:00,"Diabetes Mellitus, Type 2",C19.246.300
21335370,2011-02-18T00:00:00,European Continental Ancestry Group,M01.686.508.400
21335370,2011-02-18T00:00:00,"Hemoglobin A, Glycosylated",D09.408.375
21335370,2011-02-18T00:00:00,"Hemoglobin A, Glycosylated",D12.776.124.400.405.440
21335370,2011-02-18T00:00:00,"Hemoglobin A, Glycosylated",D12.776.422.316.762.380.440
21335370,2011-02-18T00:00:00,Hispanic Americans,M01.686.754.441
21335370,2011-02-18T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21335370,2011-02-18T00:00:00,Hypoglycemic Agents,D27.505.696.422
21335370,2011-02-18T00:00:00,Insulin,D06.472.699.587.740.625
21335370,2011-02-18T00:00:00,Insulin,D12.644.548.586.740.625
21335370,2011-02-18T00:00:00,Veterans,M01.930
21332380,2011-02-19T00:00:00,Breast Neoplasms,C04.588.180
21332380,2011-02-19T00:00:00,Breast Neoplasms,C17.800.090.500
21332380,2011-02-19T00:00:00,Genetic Testing,E01.370.427
21332380,2011-02-19T00:00:00,Genetic Testing,E05.393.435
21332380,2011-02-19T00:00:00,Genetic Testing,N02.421.143.827.233.221
21332380,2011-02-19T00:00:00,Genetic Testing,N02.421.308.430
21332380,2011-02-19T00:00:00,Glycoproteins,D09.400.430
21332380,2011-02-19T00:00:00,Glycoproteins,D12.776.395
21332380,2011-02-19T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21332380,2011-02-19T00:00:00,Proteomics,H01.158.201.843
21332380,2011-02-19T00:00:00,Proteomics,H01.158.273.180.350.700
21332380,2011-02-19T00:00:00,Proteomics,H01.158.273.343.350.700
21332380,2011-02-19T00:00:00,Proteomics,H01.181.122.738
21332380,2011-02-19T00:00:00,"Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization",E05.196.566.755
21332380,2011-02-19T00:00:00,"Tumor Markers, Biological",D23.101.840
21336553,2011-02-19T00:00:00,Animals,B01.050
21336553,2011-02-19T00:00:00,Contrast Media,D27.720.259
21336553,2011-02-19T00:00:00,"Diagnosis, Differential",E01.171
21336553,2011-02-19T00:00:00,"Disease Models, Animal",C22.232
21336553,2011-02-19T00:00:00,"Disease Models, Animal",E05.598.500
21336553,2011-02-19T00:00:00,"Disease Models, Animal",E05.599.395.080
21336553,2011-02-19T00:00:00,Dogs,B01.050.150.900.649.147.153.200
21336553,2011-02-19T00:00:00,Gadolinium DTPA,D01.632.400
21336553,2011-02-19T00:00:00,Gadolinium DTPA,D02.092.782.590.401
21336553,2011-02-19T00:00:00,Gadolinium DTPA,D02.241.081.038.694.400
21336553,2011-02-19T00:00:00,Gadolinium DTPA,D02.691.400
21336553,2011-02-19T00:00:00,Magnetic Resonance Imaging,E01.370.350.500
21336553,2011-02-19T00:00:00,Magnetic Resonance Imaging,E01.370.350.825.500
21336553,2011-02-19T00:00:00,Myocardial Infarction,C14.280.647.500
21336553,2011-02-19T00:00:00,Myocardial Infarction,C14.907.585.500
21336553,2011-02-19T00:00:00,Myocardium,A02.633.580
21336553,2011-02-19T00:00:00,Myocardium,A07.541.704
21336553,2011-02-19T00:00:00,Myocardium,A10.690.552.750
21336553,2011-02-19T00:00:00,Organometallic Compounds,D01.632
21336553,2011-02-19T00:00:00,Organometallic Compounds,D02.691
21336553,2011-02-19T00:00:00,Time Factors,G01.910.857
21336642,2011-02-19T00:00:00,Adolescent,M01.060.057
21336642,2011-02-19T00:00:00,"Diagnosis, Differential",E01.171
21336642,2011-02-19T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21336642,2011-02-19T00:00:00,"Pyelonephritis, Xanthogranulomatous",C12.777.419.570.643.790.810
21336642,2011-02-19T00:00:00,"Pyelonephritis, Xanthogranulomatous",C12.777.419.570.821.717.810
21336642,2011-02-19T00:00:00,"Pyelonephritis, Xanthogranulomatous",C13.351.968.419.570.643.790.810
21336642,2011-02-19T00:00:00,"Pyelonephritis, Xanthogranulomatous",C13.351.968.419.570.821.717.810
21336642,2011-02-19T00:00:00,"Tomography, X-Ray Computed",E01.370.350.350.810
21336642,2011-02-19T00:00:00,"Tomography, X-Ray Computed",E01.370.350.600.350.700.810
21336642,2011-02-19T00:00:00,"Tomography, X-Ray Computed",E01.370.350.700.700.810
21336642,2011-02-19T00:00:00,"Tomography, X-Ray Computed",E01.370.350.700.810.810
21336642,2011-02-19T00:00:00,"Tomography, X-Ray Computed",E01.370.350.825.810.810
21336280,2011-02-20T00:00:00,DNA-Binding Proteins,D12.776.260
21336280,2011-02-20T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21336280,2011-02-20T00:00:00,Intracellular Signaling Peptides and Proteins,D12.644.360
21336280,2011-02-20T00:00:00,Intracellular Signaling Peptides and Proteins,D12.776.476
21336280,2011-02-20T00:00:00,Linkage Disequilibrium,G05.540.500
21336280,2011-02-20T00:00:00,"Lupus Erythematosus, Systemic",C17.300.480
21336280,2011-02-20T00:00:00,"Lupus Erythematosus, Systemic",C20.111.590
21336280,2011-02-20T00:00:00,Molecular Sequence Data,L01.453.245.667
21336280,2011-02-20T00:00:00,Nuclear Proteins,D12.776.660
21336280,2011-02-20T00:00:00,"Polymorphism, Single Nucleotide",G05.365.795.598
21338244,2011-02-21T00:00:00,Animals,B01.050
21338244,2011-02-21T00:00:00,Biological Markers,D23.101
21338244,2011-02-21T00:00:00,Magnetic Resonance Spectroscopy,E05.196.867.519
21338244,2011-02-21T00:00:00,Mass Spectrometry,E05.196.566
21338244,2011-02-21T00:00:00,X-Rays,G01.201.875.750.918
21339413,2011-02-21T00:00:00,Adolescent,M01.060.057
21339413,2011-02-21T00:00:00,Appendectomy,E04.210.078
21339413,2011-02-21T00:00:00,Appendicitis,C06.405.205.099
21339413,2011-02-21T00:00:00,Appendicitis,C06.405.469.110.207
21339413,2011-02-21T00:00:00,Child,M01.060.406
21339413,2011-02-21T00:00:00,"Child, Preschool",M01.060.406.448
21339413,2011-02-21T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21339413,2011-02-21T00:00:00,Infant,M01.060.703
21339413,2011-02-21T00:00:00,Laparoscopy,E01.370.388.250.520
21339413,2011-02-21T00:00:00,Laparoscopy,E04.800.250.520
21339413,2011-02-21T00:00:00,Length of Stay,E02.760.400.480
21339413,2011-02-21T00:00:00,Length of Stay,N02.421.585.400.480
21339413,2011-02-21T00:00:00,Recovery of Function,G16.757
21339413,2011-02-21T00:00:00,Time Factors,G01.910.857
21334643,2011-02-22T00:00:00,Angiography,E01.370.350.700.060
21334643,2011-02-22T00:00:00,Angiography,E01.370.370.050
21334643,2011-02-22T00:00:00,"Embolization, Therapeutic",E02.520.360
21334643,2011-02-22T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21334643,2011-02-22T00:00:00,Kidney,A05.810.453
21334643,2011-02-22T00:00:00,"Wounds, Nonpenetrating",C21.866.974
21334643,2011-02-22T00:00:00,"Wounds, Penetrating",C21.866.986
21343176,2011-02-22T00:00:00,Animals,B01.050
21343176,2011-02-22T00:00:00,Carrier Proteins,D12.776.157
21343176,2011-02-22T00:00:00,Gene Expression Regulation,G05.355.315
21343176,2011-02-22T00:00:00,Kidney Tubules,A05.810.453.736.560
21343176,2011-02-22T00:00:00,Rats,B01.050.150.900.649.865.635.505.700
21343176,2011-02-22T00:00:00,"Rats, Sprague-Dawley",B01.050.150.900.649.865.635.505.700.750
21343176,2011-02-22T00:00:00,Regeneration,G16.100.856
21343176,2011-02-22T00:00:00,Reperfusion Injury,C14.907.725
21343176,2011-02-22T00:00:00,Reperfusion Injury,C23.550.767.877
21343176,2011-02-22T00:00:00,Time Factors,G01.910.857
21343634,2011-02-22T00:00:00,Cell Adhesion,G04.299.117
21343634,2011-02-22T00:00:00,Cell Proliferation,G04.299.233.750
21343634,2011-02-22T00:00:00,Cell Proliferation,G07.700.320.249.410.750
21343634,2011-02-22T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21343634,2011-02-22T00:00:00,Tissue Engineering,E05.200.249.750
21343634,2011-02-22T00:00:00,Tissue Scaffolds,E07.206.627
21343634,2011-02-22T00:00:00,Tissue Scaffolds,E07.695.825
21421176,2011-02-22T00:00:00,Activities of Daily Living,E02.831.067
21421176,2011-02-22T00:00:00,Activities of Daily Living,I03.050
21421176,2011-02-22T00:00:00,Activities of Daily Living,N02.421.784.110
21421176,2011-02-22T00:00:00,Adolescent,M01.060.057
21421176,2011-02-22T00:00:00,Child,M01.060.406
21421176,2011-02-22T00:00:00,Disability Evaluation,E01.370.400
21421176,2011-02-22T00:00:00,Health Surveys,E05.318.308.250
21421176,2011-02-22T00:00:00,Health Surveys,N05.715.360.300.375
21421176,2011-02-22T00:00:00,Health Surveys,N06.850.520.308.250
21421176,2011-02-22T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21421176,2011-02-22T00:00:00,Interviews as Topic,E05.318.308.420
21421176,2011-02-22T00:00:00,Interviews as Topic,L01.280.520
21421176,2011-02-22T00:00:00,Interviews as Topic,N05.715.360.300.400
21421176,2011-02-22T00:00:00,Interviews as Topic,N06.850.520.308.420
21421176,2011-02-22T00:00:00,Life Change Events,F01.829.458.410
21421176,2011-02-22T00:00:00,"Resilience, Psychological",F02.940
21421176,2011-02-22T00:00:00,"Stress Disorders, Post-Traumatic",F03.080.931.500
21421176,2011-02-22T00:00:00,United States,Z01.107.567.875
21344472,2011-02-23T00:00:00,"Clinical Trials, Phase I as Topic",E05.318.760.535.200
21344472,2011-02-23T00:00:00,"Clinical Trials, Phase I as Topic",E05.337.250.200
21344472,2011-02-23T00:00:00,"Clinical Trials, Phase I as Topic",N05.715.360.775.235.200
21344472,2011-02-23T00:00:00,"Clinical Trials, Phase I as Topic",N06.850.520.450.535.200
21344472,2011-02-23T00:00:00,Computer Simulation,L01.224.160
21344472,2011-02-23T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21344472,2011-02-23T00:00:00,"Models, Statistical",E05.318.740.500
21344472,2011-02-23T00:00:00,"Models, Statistical",E05.599.835
21344472,2011-02-23T00:00:00,"Models, Statistical",N05.715.360.750.530
21344472,2011-02-23T00:00:00,"Models, Statistical",N06.850.520.830.500
21344472,2011-02-23T00:00:00,Research Design,E05.581.500
21344472,2011-02-23T00:00:00,Research Design,H01.770.644.728
21345450,2011-02-23T00:00:00,Diabetes Mellitus,C18.452.394.750
21345450,2011-02-23T00:00:00,Diabetes Mellitus,C19.246
21345450,2011-02-23T00:00:00,"Diabetes, Gestational",C13.703.170
21345450,2011-02-23T00:00:00,"Diabetes, Gestational",C18.452.394.750.448
21345450,2011-02-23T00:00:00,"Diabetes, Gestational",C19.246.200
21345450,2011-02-23T00:00:00,Dietary Supplements,J02.500.456
21345450,2011-02-23T00:00:00,Folic Acid,D03.438.733.631.400
21345450,2011-02-23T00:00:00,"Health Knowledge, Attitudes, Practice",F01.100.150.500
21345450,2011-02-23T00:00:00,"Health Knowledge, Attitudes, Practice",N05.300.150.410
21345450,2011-02-23T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21345450,2011-02-23T00:00:00,"Infant, Newborn",M01.060.703.520
21345450,2011-02-23T00:00:00,Neural Tube Defects,C10.500.680
21345450,2011-02-23T00:00:00,Neural Tube Defects,C16.131.666.680
21345450,2011-02-23T00:00:00,Pregnancy,G08.686.785.760.769
21345450,2011-02-23T00:00:00,Program Evaluation,E05.337.820
21345450,2011-02-23T00:00:00,Program Evaluation,N04.761.685
21345450,2011-02-23T00:00:00,Program Evaluation,N05.715.360.650
21345450,2011-02-23T00:00:00,South Carolina,Z01.107.567.875.075.662
21345450,2011-02-23T00:00:00,South Carolina,Z01.107.567.875.750.700
21345450,2011-02-23T00:00:00,"Ultrasonography, Prenatal",E01.370.350.850.865
21345450,2011-02-23T00:00:00,"Ultrasonography, Prenatal",E01.370.378.630.865
21345450,2011-02-23T00:00:00,Vitamin B Complex,D27.505.696.377.605.600.708
21345975,2011-02-23T00:00:00,Animals,B01.050
21345975,2011-02-23T00:00:00,Cell Differentiation,G04.299.151
21345975,2011-02-23T00:00:00,Cell Line,A11.251.210
21345975,2011-02-23T00:00:00,Cell Proliferation,G04.299.233.750
21345975,2011-02-23T00:00:00,Cell Proliferation,G07.700.320.249.410.750
21345975,2011-02-23T00:00:00,Cilia,A11.284.180.165
21345975,2011-02-23T00:00:00,Epithelial Cells,A11.436
21345975,2011-02-23T00:00:00,Extracellular Signal-Regulated MAP Kinases,D08.811.913.696.620.682.700.567.342
21345975,2011-02-23T00:00:00,Extracellular Signal-Regulated MAP Kinases,D08.811.913.696.620.682.700.646.750.249
21345975,2011-02-23T00:00:00,Extracellular Signal-Regulated MAP Kinases,D12.644.360.450.169
21345975,2011-02-23T00:00:00,Extracellular Signal-Regulated MAP Kinases,D12.776.476.450.169
21345975,2011-02-23T00:00:00,"Kidney Tubules, Collecting",A05.810.453.736.560.510
21345975,2011-02-23T00:00:00,"Mechanotransduction, Cellular",G01.154.100.440
21345975,2011-02-23T00:00:00,"Mechanotransduction, Cellular",G01.595.100.440
21345975,2011-02-23T00:00:00,"Mechanotransduction, Cellular",G02.111.087.800.580
21345975,2011-02-23T00:00:00,"Mechanotransduction, Cellular",G02.149.115.800.580
21345975,2011-02-23T00:00:00,"Mechanotransduction, Cellular",G04.299.880.580
21345975,2011-02-23T00:00:00,Phosphorylation,G02.111.087.677
21345975,2011-02-23T00:00:00,Phosphorylation,G02.149.115.677
21345975,2011-02-23T00:00:00,Phosphorylation,G02.149.465.700
21345975,2011-02-23T00:00:00,Phosphorylation,G02.607.750.700
21345975,2011-02-23T00:00:00,Phosphorylation,G03.495.790
21345975,2011-02-23T00:00:00,Protein Kinase C,D08.811.913.696.620.682.700.725
21345975,2011-02-23T00:00:00,Protein Kinase Inhibitors,D27.505.519.389.755
21345975,2011-02-23T00:00:00,Proteomics,H01.158.201.843
21345975,2011-02-23T00:00:00,Proteomics,H01.158.273.180.350.700
21345975,2011-02-23T00:00:00,Proteomics,H01.158.273.343.350.700
21345975,2011-02-23T00:00:00,Proteomics,H01.181.122.738
21345975,2011-02-23T00:00:00,Time Factors,G01.910.857
21345975,2011-02-23T00:00:00,Tumor Suppressor Proteins,D12.776.624.776
21349579,2011-02-23T00:00:00,Animals,B01.050
21349579,2011-02-23T00:00:00,Calcium,D01.268.552.100
21349579,2011-02-23T00:00:00,Calcium,D01.552.539.288
21349579,2011-02-23T00:00:00,Calcium,D23.119.100
21349579,2011-02-23T00:00:00,"Calcium Channels, L-Type",D12.776.157.530.400.150.400
21349579,2011-02-23T00:00:00,"Calcium Channels, L-Type",D12.776.543.550.425.150.400
21349579,2011-02-23T00:00:00,"Calcium Channels, L-Type",D12.776.543.585.400.150.400
21349579,2011-02-23T00:00:00,Cyclic AMP-Dependent Protein Kinases,D08.811.913.696.620.682.700.150.125
21349579,2011-02-23T00:00:00,Cyclic AMP-Dependent Protein Kinases,D12.644.360.200.125
21349579,2011-02-23T00:00:00,Cyclic AMP-Dependent Protein Kinases,D12.776.476.200.125
21349579,2011-02-23T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21349579,2011-02-23T00:00:00,"Myocytes, Cardiac",A07.541.704.570
21349579,2011-02-23T00:00:00,"Myocytes, Cardiac",A10.690.552.750.570
21349579,2011-02-23T00:00:00,"Myocytes, Cardiac",A11.620.500
21349579,2011-02-23T00:00:00,Phosphorylation,G02.111.087.677
21349579,2011-02-23T00:00:00,Phosphorylation,G02.149.115.677
21349579,2011-02-23T00:00:00,Phosphorylation,G02.149.465.700
21349579,2011-02-23T00:00:00,Phosphorylation,G02.607.750.700
21349579,2011-02-23T00:00:00,Phosphorylation,G03.495.790
21349579,2011-02-23T00:00:00,Rats,B01.050.150.900.649.865.635.505.700
21349579,2011-02-23T00:00:00,Recombinant Proteins,D12.776.828
21349579,2011-02-23T00:00:00,Sodium,D01.268.549.750
21349579,2011-02-23T00:00:00,Sodium,D01.552.528.850
21349579,2011-02-23T00:00:00,Sodium-Calcium Exchanger,D12.776.157.530.450.162.442
21349579,2011-02-23T00:00:00,Sodium-Calcium Exchanger,D12.776.543.585.450.162.442
21351127,2011-02-23T00:00:00,Adolescent,M01.060.057
21351127,2011-02-23T00:00:00,Adult,M01.060.116
21351127,2011-02-23T00:00:00,Aged,M01.060.116.100
21351127,2011-02-23T00:00:00,Double-Blind Method,E05.318.780.300
21351127,2011-02-23T00:00:00,Double-Blind Method,E05.581.500.300
21351127,2011-02-23T00:00:00,Double-Blind Method,N05.715.360.780.320
21351127,2011-02-23T00:00:00,Double-Blind Method,N06.850.520.445.300
21351127,2011-02-23T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21351127,2011-02-23T00:00:00,Middle Aged,M01.060.116.630
21351127,2011-02-23T00:00:00,Patient Selection,E05.581.500.653
21351127,2011-02-23T00:00:00,Patient Selection,N04.590.731
21351127,2011-02-23T00:00:00,Treatment Outcome,E01.789.800
21351127,2011-02-23T00:00:00,Treatment Outcome,N04.761.559.590.800
21351127,2011-02-23T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21351127,2011-02-23T00:00:00,"Urinary Bladder, Overactive",C12.777.829.866
21351127,2011-02-23T00:00:00,"Urinary Bladder, Overactive",C13.351.968.829.813
21351127,2011-02-23T00:00:00,"Urinary Bladder, Overactive",C23.888.942.775
21351127,2011-02-23T00:00:00,Urinary Incontinence,C12.777.934.852
21351127,2011-02-23T00:00:00,Urinary Incontinence,C13.351.968.934.814
21351127,2011-02-23T00:00:00,Urinary Incontinence,C23.888.942.800
21351127,2011-02-23T00:00:00,Urodynamics,G08.852.898
21352881,2011-02-23T00:00:00,Adult,M01.060.116
21352881,2011-02-23T00:00:00,Aged,M01.060.116.100
21352881,2011-02-23T00:00:00,Feeding Behavior,F01.145.113.547
21352881,2011-02-23T00:00:00,Feeding Behavior,F01.145.407
21352881,2011-02-23T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21352881,2011-02-23T00:00:00,Middle Aged,M01.060.116.630
21352881,2011-02-23T00:00:00,Photic Stimulation,E05.723.729
21352881,2011-02-23T00:00:00,Prefrontal Cortex,A08.186.211.730.885.287.500.270.700
21352881,2011-02-23T00:00:00,South Carolina,Z01.107.567.875.075.662
21352881,2011-02-23T00:00:00,South Carolina,Z01.107.567.875.750.700
21352881,2011-02-23T00:00:00,Transcranial Magnetic Stimulation,E01.370.376.850
21352881,2011-02-23T00:00:00,Transcranial Magnetic Stimulation,E02.621.820
21352881,2011-02-23T00:00:00,Young Adult,M01.060.116.815
21347871,2011-02-24T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21347871,2011-02-24T00:00:00,Length of Stay,E02.760.400.480
21347871,2011-02-24T00:00:00,Length of Stay,N02.421.585.400.480
21347871,2011-02-24T00:00:00,Middle Aged,M01.060.116.630
21347871,2011-02-24T00:00:00,Postoperative Complications,C23.550.767
21347871,2011-02-24T00:00:00,Time Factors,G01.910.857
21347871,2011-02-24T00:00:00,Treatment Outcome,E01.789.800
21347871,2011-02-24T00:00:00,Treatment Outcome,N04.761.559.590.800
21347871,2011-02-24T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21350053,2011-02-24T00:00:00,Aged,M01.060.116.100
21350053,2011-02-24T00:00:00,Biphenyl Compounds,D02.455.426.559.389.185
21350053,2011-02-24T00:00:00,Body Mass Index,E01.370.600.115.100.125
21350053,2011-02-24T00:00:00,Body Mass Index,E05.041.124.125
21350053,2011-02-24T00:00:00,Body Mass Index,G07.100.100.125
21350053,2011-02-24T00:00:00,Body Mass Index,N06.850.505.200.100.175
21350053,2011-02-24T00:00:00,Cardiovascular Diseases,C14
21350053,2011-02-24T00:00:00,Heart Failure,C14.280.434
21350053,2011-02-24T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21350053,2011-02-24T00:00:00,Middle Aged,M01.060.116.630
21350053,2011-02-24T00:00:00,Obesity,C18.654.726.500
21350053,2011-02-24T00:00:00,Obesity,C23.888.144.699.500
21350053,2011-02-24T00:00:00,Obesity,E01.370.600.115.100.160.120.699.500
21350053,2011-02-24T00:00:00,Obesity,G07.100.100.160.120.699.500
21350053,2011-02-24T00:00:00,Stroke Volume,E01.370.370.380.150.700
21350053,2011-02-24T00:00:00,Stroke Volume,G09.330.380.124.882
21350055,2011-02-24T00:00:00,Aged,M01.060.116.100
21350055,2011-02-24T00:00:00,Biological Markers,D23.101
21350055,2011-02-24T00:00:00,Collagen,D05.750.078.280
21350055,2011-02-24T00:00:00,Collagen,D12.776.860.300.250
21350055,2011-02-24T00:00:00,Extracellular Matrix,A11.284.295.310
21350055,2011-02-24T00:00:00,Homeostasis,G07.700.360
21350055,2011-02-24T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21350055,2011-02-24T00:00:00,"Hypertrophy, Left Ventricular",C14.280.195.400
21350055,2011-02-24T00:00:00,"Hypertrophy, Left Ventricular",C23.300.775.250.400
21350055,2011-02-24T00:00:00,Middle Aged,M01.060.116.630
21350751,2011-02-24T00:00:00,Materials Testing,E05.570
21350751,2011-02-24T00:00:00,"Nanotubes, Carbon",D01.268.150.250.500
21350751,2011-02-24T00:00:00,"Nanotubes, Carbon",J01.637.512.850.500
21350751,2011-02-24T00:00:00,Quantum Dots,E07.595.650
21350751,2011-02-24T00:00:00,Quantum Dots,J01.637.512.600.650
21350751,2011-02-24T00:00:00,"Spectrometry, Fluorescence",E05.196.712.516.600.676
21350751,2011-02-24T00:00:00,"Spectrometry, Fluorescence",E05.196.867.726
21350751,2011-02-24T00:00:00,Surface Properties,G02.842.850
21695720,2011-02-24T00:00:00,Biological Markers,D23.101
21695720,2011-02-24T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21350820,2011-02-25T00:00:00,Adult,M01.060.116
21350820,2011-02-25T00:00:00,Aged,M01.060.116.100
21350820,2011-02-25T00:00:00,Antineoplastic Agents,D27.505.954.248
21350820,2011-02-25T00:00:00,Breast Neoplasms,C04.588.180
21350820,2011-02-25T00:00:00,Breast Neoplasms,C17.800.090.500
21350820,2011-02-25T00:00:00,Drug Interactions,G07.690.812.240
21350820,2011-02-25T00:00:00,Drug Interactions,G07.700.680.240
21350820,2011-02-25T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21350820,2011-02-25T00:00:00,Middle Aged,M01.060.116.630
21350820,2011-02-25T00:00:00,Piperazines,D03.383.606
21350820,2011-02-25T00:00:00,Pyrimidines,D03.383.742
21350820,2011-02-25T00:00:00,Treatment Outcome,E01.789.800
21350820,2011-02-25T00:00:00,Treatment Outcome,N04.761.559.590.800
21350820,2011-02-25T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21351850,2011-02-25T00:00:00,Antineoplastic Agents,D27.505.954.248
21351850,2011-02-25T00:00:00,Drug Resistance,G07.690.320
21351850,2011-02-25T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21351850,2011-02-25T00:00:00,"Models, Molecular",E05.599.595
21351850,2011-02-25T00:00:00,Molecular Structure,G02.111.570
21351850,2011-02-25T00:00:00,Molecular Structure,G02.575
21351850,2011-02-25T00:00:00,Molecular Structure,G02.842.575
21351850,2011-02-25T00:00:00,Neoplasms,C04
21351850,2011-02-25T00:00:00,Oxidative Stress,G03.495.710
21351850,2011-02-25T00:00:00,Oxidative Stress,G07.700.830.750
21354438,2011-02-25T00:00:00,Adult,M01.060.116
21354438,2011-02-25T00:00:00,Aged,M01.060.116.100
21354438,2011-02-25T00:00:00,Breast Neoplasms,C04.588.180
21354438,2011-02-25T00:00:00,Breast Neoplasms,C17.800.090.500
21354438,2011-02-25T00:00:00,Genetic Predisposition to Disease,C23.550.291.687.500
21354438,2011-02-25T00:00:00,Genetic Predisposition to Disease,G05.380.355
21354438,2011-02-25T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21354438,2011-02-25T00:00:00,Middle Aged,M01.060.116.630
21357504,2011-02-25T00:00:00,Animals,B01.050
21357504,2011-02-25T00:00:00,Calpain,D08.811.277.656.262.500.120
21357504,2011-02-25T00:00:00,Calpain,D08.811.277.656.300.200.120
21357504,2011-02-25T00:00:00,Immunosuppressive Agents,D27.505.696.477.656
21357504,2011-02-25T00:00:00,"Models, Animal",E05.598
21357504,2011-02-25T00:00:00,Myocardium,A02.633.580
21357504,2011-02-25T00:00:00,Myocardium,A07.541.704
21357504,2011-02-25T00:00:00,Myocardium,A10.690.552.750
21357504,2011-02-25T00:00:00,Proteins,D12.776
21357504,2011-02-25T00:00:00,Proto-Oncogene Proteins c-akt,D08.811.913.696.620.682.700.755
21357504,2011-02-25T00:00:00,Proto-Oncogene Proteins c-akt,D12.776.476.565
21357504,2011-02-25T00:00:00,Proto-Oncogene Proteins c-akt,D12.776.624.664.700.168
21357504,2011-02-25T00:00:00,Rats,B01.050.150.900.649.865.635.505.700
21357504,2011-02-25T00:00:00,Signal Transduction,G02.111.087.800
21357504,2011-02-25T00:00:00,Signal Transduction,G02.149.115.800
21357504,2011-02-25T00:00:00,Signal Transduction,G04.299.880
21402502,2011-02-25T00:00:00,Ethanol,D02.033.375
21402502,2011-02-25T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21402502,2011-02-25T00:00:00,Methylphenidate,D02.241.223.601.600
21402502,2011-02-25T00:00:00,Methylphenidate,D03.383.621.460
21402502,2011-02-25T00:00:00,Tandem Mass Spectrometry,E05.196.566.880
21406316,2011-02-25T00:00:00,Adult,M01.060.116
21406316,2011-02-25T00:00:00,African Continental Ancestry Group,M01.686.508.100
21406316,2011-02-25T00:00:00,Aged,M01.060.116.100
21406316,2011-02-25T00:00:00,Attitude to Health,F01.100.150
21406316,2011-02-25T00:00:00,Attitude to Health,N05.300.150
21406316,2011-02-25T00:00:00,"Behavior, Addictive",F01.145.527.100.120
21406316,2011-02-25T00:00:00,European Continental Ancestry Group,M01.686.508.400
21406316,2011-02-25T00:00:00,Genetic Predisposition to Disease,C23.550.291.687.500
21406316,2011-02-25T00:00:00,Genetic Predisposition to Disease,G05.380.355
21406316,2011-02-25T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21406316,2011-02-25T00:00:00,Middle Aged,M01.060.116.630
21406316,2011-02-25T00:00:00,Qualitative Research,H01.770.644.241.850
21406316,2011-02-25T00:00:00,Smoking,F01.145.466.753
21406316,2011-02-25T00:00:00,Smoking Cessation,F01.145.940.700
21406316,2011-02-25T00:00:00,Tobacco Use Disorder,C21.739.912
21406316,2011-02-25T00:00:00,Tobacco Use Disorder,F03.900.912
21406316,2011-02-25T00:00:00,Young Adult,M01.060.116.815
21471106,2011-02-25T00:00:00,Adult,M01.060.116
21471106,2011-02-25T00:00:00,Anti-Bacterial Agents,D27.505.954.122.085
21471106,2011-02-25T00:00:00,Cystic Fibrosis,C06.689.202
21471106,2011-02-25T00:00:00,Cystic Fibrosis,C08.381.187
21471106,2011-02-25T00:00:00,Cystic Fibrosis,C16.320.190
21471106,2011-02-25T00:00:00,Cystic Fibrosis,C16.614.213
21471106,2011-02-25T00:00:00,Double-Blind Method,E05.318.780.300
21471106,2011-02-25T00:00:00,Double-Blind Method,E05.581.500.300
21471106,2011-02-25T00:00:00,Double-Blind Method,N05.715.360.780.320
21471106,2011-02-25T00:00:00,Double-Blind Method,N06.850.520.445.300
21471106,2011-02-25T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21471106,2011-02-25T00:00:00,Ofloxacin,D03.438.810.835.322.500
21471106,2011-02-25T00:00:00,Pseudomonas Infections,C01.252.400.739
21471106,2011-02-25T00:00:00,Pseudomonas aeruginosa,B03.440.400.425.625.625.100
21471106,2011-02-25T00:00:00,Pseudomonas aeruginosa,B03.660.250.580.590.050
21471106,2011-02-25T00:00:00,Treatment Outcome,E01.789.800
21471106,2011-02-25T00:00:00,Treatment Outcome,N04.761.559.590.800
21471106,2011-02-25T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21356343,2011-02-26T00:00:00,Animals,B01.050
21356343,2011-02-26T00:00:00,Cytokines,D12.644.276.374
21356343,2011-02-26T00:00:00,Cytokines,D12.776.467.374
21356343,2011-02-26T00:00:00,Cytokines,D23.529.374
21356343,2011-02-26T00:00:00,Down-Regulation,G02.111.087.225
21356343,2011-02-26T00:00:00,Down-Regulation,G02.149.115.225
21356343,2011-02-26T00:00:00,Down-Regulation,G05.355.315.200
21356343,2011-02-26T00:00:00,Down-Regulation,G07.690.812.230
21356343,2011-02-26T00:00:00,Down-Regulation,G07.700.680.230
21356343,2011-02-26T00:00:00,Inflammation,C23.550.470
21356343,2011-02-26T00:00:00,Interleukin-10,D12.644.276.374.465.510
21356343,2011-02-26T00:00:00,Interleukin-10,D12.776.467.374.465.510
21356343,2011-02-26T00:00:00,Interleukin-10,D23.529.374.465.510
21356343,2011-02-26T00:00:00,Lipopolysaccharides,D09.400.500
21356343,2011-02-26T00:00:00,Lipopolysaccharides,D09.698.718.450
21356343,2011-02-26T00:00:00,Lipopolysaccharides,D10.494
21356343,2011-02-26T00:00:00,Lipopolysaccharides,D23.050.161.616.525
21356343,2011-02-26T00:00:00,Lipopolysaccharides,D23.946.123.329.500
21356343,2011-02-26T00:00:00,Macrophages,A11.329.372
21356343,2011-02-26T00:00:00,Macrophages,A11.627.482
21356343,2011-02-26T00:00:00,Macrophages,A11.733.397
21356343,2011-02-26T00:00:00,Macrophages,A15.382.680.397
21356343,2011-02-26T00:00:00,Macrophages,A15.382.812.522
21356343,2011-02-26T00:00:00,NF-kappa B,D12.776.260.600
21356343,2011-02-26T00:00:00,NF-kappa B,D12.776.660.600
21356343,2011-02-26T00:00:00,NF-kappa B,D12.776.930.600
21356343,2011-02-26T00:00:00,"Protein Tyrosine Phosphatase, Non-Receptor Type 6",D08.811.277.352.650.775.300.600
21356343,2011-02-26T00:00:00,"Protein Tyrosine Phosphatase, Non-Receptor Type 6",D08.811.277.352.650.775.700.200
21356343,2011-02-26T00:00:00,"Protein Tyrosine Phosphatase, Non-Receptor Type 6",D12.644.360.585.600
21356343,2011-02-26T00:00:00,"Protein Tyrosine Phosphatase, Non-Receptor Type 6",D12.644.360.800.200
21356343,2011-02-26T00:00:00,"Protein Tyrosine Phosphatase, Non-Receptor Type 6",D12.776.476.564.600
21356343,2011-02-26T00:00:00,"Protein Tyrosine Phosphatase, Non-Receptor Type 6",D12.776.476.800.200
21356343,2011-02-26T00:00:00,STAT1 Transcription Factor,D12.644.360.024.303.500.500
21356343,2011-02-26T00:00:00,STAT1 Transcription Factor,D12.644.360.024.342.100
21356343,2011-02-26T00:00:00,STAT1 Transcription Factor,D12.776.157.057.061.500.500
21356343,2011-02-26T00:00:00,STAT1 Transcription Factor,D12.776.157.057.186.100
21356343,2011-02-26T00:00:00,STAT1 Transcription Factor,D12.776.260.513.249.500
21356343,2011-02-26T00:00:00,STAT1 Transcription Factor,D12.776.476.024.387.500.500
21356343,2011-02-26T00:00:00,STAT1 Transcription Factor,D12.776.476.024.421.100
21356343,2011-02-26T00:00:00,STAT1 Transcription Factor,D12.776.930.354.249.500
21356343,2011-02-26T00:00:00,STAT1 Transcription Factor,D12.776.930.840.100
21356343,2011-02-26T00:00:00,Signal Transduction,G02.111.087.800
21356343,2011-02-26T00:00:00,Signal Transduction,G02.149.115.800
21356343,2011-02-26T00:00:00,Signal Transduction,G04.299.880
21356343,2011-02-26T00:00:00,Sitosterols,D04.808.247.222.857
21356343,2011-02-26T00:00:00,Sitosterols,D04.808.247.808.756.669
21356590,2011-02-26T00:00:00,Adult,M01.060.116
21356590,2011-02-26T00:00:00,Ankle Joint,A02.835.583.378.062
21356590,2011-02-26T00:00:00,Deceleration,G01.595.560.107.373
21356590,2011-02-26T00:00:00,Hip Joint,A02.835.583.411
21356590,2011-02-26T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21356590,2011-02-26T00:00:00,Knee Joint,A02.835.583.475
21356590,2011-02-26T00:00:00,Walking,G11.427.590.530.568.900
21356590,2011-02-26T00:00:00,Walking,G11.427.590.530.698.940
21356590,2011-02-26T00:00:00,Walking,I03.450.642.845.940
21440865,2011-02-26T00:00:00,Aged,M01.060.116.100
21440865,2011-02-26T00:00:00,Blood Pressure,E01.370.600.875.249
21440865,2011-02-26T00:00:00,Blood Pressure,G09.330.380.076
21440865,2011-02-26T00:00:00,Disease Progression,C23.550.291.656
21440865,2011-02-26T00:00:00,Heart Failure,C14.280.434
21440865,2011-02-26T00:00:00,Hemodynamics,G09.330.190.400
21440865,2011-02-26T00:00:00,Hemodynamics,G09.330.380
21440865,2011-02-26T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21440865,2011-02-26T00:00:00,Middle Aged,M01.060.116.630
21481816,2011-02-26T00:00:00,Antioxidants,D27.505.519.217
21481816,2011-02-26T00:00:00,Antioxidants,D27.505.696.706.125
21481816,2011-02-26T00:00:00,Antioxidants,D27.720.799.047
21481816,2011-02-26T00:00:00,Copper,D01.268.556.195
21481816,2011-02-26T00:00:00,Copper,D01.268.956.170
21481816,2011-02-26T00:00:00,Copper,D01.552.544.195
21481816,2011-02-26T00:00:00,DNA Damage,C21.111
21481816,2011-02-26T00:00:00,DNA Damage,G05.355.180
21481816,2011-02-26T00:00:00,Hydrogen Peroxide,D01.248.497.158.685.750.424
21481816,2011-02-26T00:00:00,Hydrogen Peroxide,D01.339.431.374.424
21481816,2011-02-26T00:00:00,Hydrogen Peroxide,D01.650.550.750.400
21481816,2011-02-26T00:00:00,Iron,D01.268.556.412
21481816,2011-02-26T00:00:00,Iron,D01.268.956.287
21481816,2011-02-26T00:00:00,Iron,D01.552.544.412
21131897,2011-02-27T00:00:00,Adenosine Triphosphate,D03.438.759.646.138.236
21131897,2011-02-27T00:00:00,Adenosine Triphosphate,D13.695.667.138.236
21131897,2011-02-27T00:00:00,Adenosine Triphosphate,D13.695.827.068.236
21131897,2011-02-27T00:00:00,Animals,B01.050
21131897,2011-02-27T00:00:00,Cell Death,G04.299.139
21131897,2011-02-27T00:00:00,Cyclosporine,D04.345.566.235.300
21131897,2011-02-27T00:00:00,Cyclosporine,D12.644.641.235.300
21131897,2011-02-27T00:00:00,Hepatectomy,E04.210.556
21131897,2011-02-27T00:00:00,Liver,A03.620
21131897,2011-02-27T00:00:00,Liver Regeneration,G10.261.326.520
21131897,2011-02-27T00:00:00,Liver Regeneration,G16.100.856.468
21131897,2011-02-27T00:00:00,Mitochondrial Diseases,C18.452.660
21359880,2011-02-27T00:00:00,Cadaver,C23.550.260.224
21359880,2011-02-27T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21355721,2011-02-28T00:00:00,Blood Glucose,D09.546.359.448.500
21355721,2011-02-28T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21355721,2011-02-28T00:00:00,Hypoglycemic Agents,D27.505.696.422
21355721,2011-02-28T00:00:00,Insulin,D06.472.699.587.740.625
21355721,2011-02-28T00:00:00,Insulin,D12.644.548.586.740.625
21355721,2011-02-28T00:00:00,Intensive Care,E02.760.190.400
21355721,2011-02-28T00:00:00,Intensive Care,N02.421.585.190.400
21355721,2011-02-28T00:00:00,Middle Aged,M01.060.116.630
21355721,2011-02-28T00:00:00,Workload,N04.452.677.950
21357706,2011-02-28T00:00:00,Gene Silencing,G05.355.315.203.374
21357706,2011-02-28T00:00:00,Homeodomain Proteins,D12.776.260.400
21357706,2011-02-28T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21357706,2011-02-28T00:00:00,"Leukemia, Myeloid, Acute",C04.557.337.539.550
21357706,2011-02-28T00:00:00,Phosphorylation,G02.111.087.677
21357706,2011-02-28T00:00:00,Phosphorylation,G02.149.115.677
21357706,2011-02-28T00:00:00,Phosphorylation,G02.149.465.700
21357706,2011-02-28T00:00:00,Phosphorylation,G02.607.750.700
21357706,2011-02-28T00:00:00,Phosphorylation,G03.495.790
21357706,2011-02-28T00:00:00,Protein Kinase Inhibitors,D27.505.519.389.755
21357706,2011-02-28T00:00:00,Signal Transduction,G02.111.087.800
21357706,2011-02-28T00:00:00,Signal Transduction,G02.149.115.800
21357706,2011-02-28T00:00:00,Signal Transduction,G04.299.880
21357706,2011-02-28T00:00:00,Transcription Factors,D12.776.930
21357706,2011-02-28T00:00:00,Transforming Growth Factor beta,D12.644.276.374.687
21357706,2011-02-28T00:00:00,Transforming Growth Factor beta,D12.644.276.954.800.720
21357706,2011-02-28T00:00:00,Transforming Growth Factor beta,D12.644.276.963.720
21357706,2011-02-28T00:00:00,Transforming Growth Factor beta,D12.776.467.374.687
21357706,2011-02-28T00:00:00,Transforming Growth Factor beta,D12.776.467.942.800.720
21357706,2011-02-28T00:00:00,Transforming Growth Factor beta,D12.776.467.960.720
21357706,2011-02-28T00:00:00,Transforming Growth Factor beta,D23.529.374.687
21357706,2011-02-28T00:00:00,Transforming Growth Factor beta,D23.529.942.800.720
21357706,2011-02-28T00:00:00,Transforming Growth Factor beta,D23.529.960.720
21357807,2011-02-28T00:00:00,Adult,M01.060.116
21357807,2011-02-28T00:00:00,Attitude of Health Personnel,F01.100.050
21357807,2011-02-28T00:00:00,Attitude of Health Personnel,N05.300.100
21357807,2011-02-28T00:00:00,Body Mass Index,E01.370.600.115.100.125
21357807,2011-02-28T00:00:00,Body Mass Index,E05.041.124.125
21357807,2011-02-28T00:00:00,Body Mass Index,G07.100.100.125
21357807,2011-02-28T00:00:00,Body Mass Index,N06.850.505.200.100.175
21357807,2011-02-28T00:00:00,Body Weight,C23.888.144
21357807,2011-02-28T00:00:00,Body Weight,E01.370.600.115.100.160.120
21357807,2011-02-28T00:00:00,Body Weight,E05.041.124.160.750
21357807,2011-02-28T00:00:00,Body Weight,G07.100.100.160.120
21357807,2011-02-28T00:00:00,Body Weight,G07.700.320.249.314.120
21357807,2011-02-28T00:00:00,Communication,F01.145.209
21357807,2011-02-28T00:00:00,Communication,L01.143
21357807,2011-02-28T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21357807,2011-02-28T00:00:00,Middle Aged,M01.060.116.630
21357807,2011-02-28T00:00:00,Motivation,F01.658
21357807,2011-02-28T00:00:00,Motivation,F01.752.543.500.750
21357807,2011-02-28T00:00:00,Obesity,C18.654.726.500
21357807,2011-02-28T00:00:00,Obesity,C23.888.144.699.500
21357807,2011-02-28T00:00:00,Obesity,E01.370.600.115.100.160.120.699.500
21357807,2011-02-28T00:00:00,Obesity,G07.100.100.160.120.699.500
21357807,2011-02-28T00:00:00,Overweight,C23.888.144.699
21357807,2011-02-28T00:00:00,Overweight,E01.370.600.115.100.160.120.699
21357807,2011-02-28T00:00:00,Overweight,G07.100.100.160.120.699
21357807,2011-02-28T00:00:00,Perception,F02.463.593
21357807,2011-02-28T00:00:00,Physician-Patient Relations,F01.829.401.650.675
21357807,2011-02-28T00:00:00,Physician-Patient Relations,N05.300.660.625
21357807,2011-02-28T00:00:00,Self Concept,F01.752.747.792
21357807,2011-02-28T00:00:00,United States,Z01.107.567.875
21357807,2011-02-28T00:00:00,Weight Loss,C23.888.144.243.963
21357807,2011-02-28T00:00:00,Weight Loss,G07.700.320.249.314.120.200.963
21357807,2011-02-28T00:00:00,Young Adult,M01.060.116.815
21357819,2011-02-28T00:00:00,Aged,M01.060.116.100
21357819,2011-02-28T00:00:00,"Defibrillators, Implantable",E07.305.250.159.175
21357819,2011-02-28T00:00:00,"Defibrillators, Implantable",E07.305.250.319.175
21357819,2011-02-28T00:00:00,"Defibrillators, Implantable",E07.695.175
21357819,2011-02-28T00:00:00,Heart Failure,C14.280.434
21357819,2011-02-28T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21357819,2011-02-28T00:00:00,Middle Aged,M01.060.116.630
21357819,2011-02-28T00:00:00,Stroke Volume,E01.370.370.380.150.700
21357819,2011-02-28T00:00:00,Stroke Volume,G09.330.380.124.882
21357819,2011-02-28T00:00:00,"Tachycardia, Ventricular",C14.280.067.845.940
21357819,2011-02-28T00:00:00,"Tachycardia, Ventricular",C23.550.073.845.940
21357819,2011-02-28T00:00:00,Treatment Outcome,E01.789.800
21357819,2011-02-28T00:00:00,Treatment Outcome,N04.761.559.590.800
21357819,2011-02-28T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21357819,2011-02-28T00:00:00,Ventricular Fibrillation,C14.280.067.922
21357819,2011-02-28T00:00:00,Ventricular Fibrillation,C23.550.073.922
21360737,2011-02-28T00:00:00,Algorithms,G17.035
21360737,2011-02-28T00:00:00,Algorithms,L01.224.050
21360737,2011-02-28T00:00:00,Artifacts,E05.047
21360737,2011-02-28T00:00:00,Cardiovascular Diseases,C14
21360737,2011-02-28T00:00:00,Edema,C23.888.277
21360737,2011-02-28T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21360737,2011-02-28T00:00:00,Image Enhancement,E01.370.350.600.350
21360737,2011-02-28T00:00:00,Image Enhancement,L01.224.308.380
21360737,2011-02-28T00:00:00,"Image Interpretation, Computer-Assisted",E01.158.600
21360737,2011-02-28T00:00:00,"Image Interpretation, Computer-Assisted",E01.370.350.350
21360737,2011-02-28T00:00:00,"Image Interpretation, Computer-Assisted",L01.700.508.100.158.600
21360737,2011-02-28T00:00:00,Magnetic Resonance Imaging,E01.370.350.500
21360737,2011-02-28T00:00:00,Magnetic Resonance Imaging,E01.370.350.825.500
21360737,2011-02-28T00:00:00,"Phantoms, Imaging",E07.671
21446768,2011-02-28T00:00:00,Adsorption,G02.149.047
21446768,2011-02-28T00:00:00,Adsorption,G02.149.767.029
21446768,2011-02-28T00:00:00,Adsorption,G02.842.750.029
21446768,2011-02-28T00:00:00,Colloids,D20.280
21446768,2011-02-28T00:00:00,Colloids,D26.255.165
21446768,2011-02-28T00:00:00,Colloids,D27.720.280.165
21446768,2011-02-28T00:00:00,Iron Compounds,D01.485
21446768,2011-02-28T00:00:00,Metal Nanoparticles,J01.637.512.600.500
21446768,2011-02-28T00:00:00,"Microscopy, Electron, Transmission",E01.370.350.515.402.580
21446768,2011-02-28T00:00:00,"Microscopy, Electron, Transmission",E05.595.402.580
21446768,2011-02-28T00:00:00,Minerals,D01.578
21446768,2011-02-28T00:00:00,Plutonium,D01.268.033.700
21446768,2011-02-28T00:00:00,Plutonium,D01.268.271.100.700
21446768,2011-02-28T00:00:00,Plutonium,D01.268.556.700
21446768,2011-02-28T00:00:00,Plutonium,D01.552.020.734
21446768,2011-02-28T00:00:00,Plutonium,D01.552.544.700
21446768,2011-02-28T00:00:00,Quartz,D01.578.750.600
21446768,2011-02-28T00:00:00,Quartz,D01.650.550.825.600
21446768,2011-02-28T00:00:00,Quartz,D01.837.725.600
21446768,2011-02-28T00:00:00,Surface Properties,G02.842.850
20559144,2011-03-01T00:00:00,Adolescent,M01.060.057
20559144,2011-03-01T00:00:00,Adult,M01.060.116
20559144,2011-03-01T00:00:00,Aged,M01.060.116.100
20559144,2011-03-01T00:00:00,"Depressive Disorder, Major",F03.600.300.375
20559144,2011-03-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
20559144,2011-03-01T00:00:00,Middle Aged,M01.060.116.630
20559144,2011-03-01T00:00:00,Prefrontal Cortex,A08.186.211.730.885.287.500.270.700
20559144,2011-03-01T00:00:00,Transcranial Magnetic Stimulation,E01.370.376.850
20559144,2011-03-01T00:00:00,Transcranial Magnetic Stimulation,E02.621.820
20559893,2011-03-01T00:00:00,Body Mass Index,E01.370.600.115.100.125
20559893,2011-03-01T00:00:00,Body Mass Index,E05.041.124.125
20559893,2011-03-01T00:00:00,Body Mass Index,G07.100.100.125
20559893,2011-03-01T00:00:00,Body Mass Index,N06.850.505.200.100.175
20559893,2011-03-01T00:00:00,Depression,F01.145.126.350
20559893,2011-03-01T00:00:00,Gastroplasty,E02.065.062.750
20559893,2011-03-01T00:00:00,Gastroplasty,E04.062.750
20559893,2011-03-01T00:00:00,Gastroplasty,E04.210.485
20559893,2011-03-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
20559893,2011-03-01T00:00:00,"Obesity, Morbid",C18.654.726.500.700
20559893,2011-03-01T00:00:00,"Obesity, Morbid",C23.888.144.699.500.500
20559893,2011-03-01T00:00:00,"Obesity, Morbid",E01.370.600.115.100.160.120.699.500.500
20559893,2011-03-01T00:00:00,"Obesity, Morbid",G07.100.100.160.120.699.500.500
20559893,2011-03-01T00:00:00,Quality of Life,I01.800
20559893,2011-03-01T00:00:00,Quality of Life,K01.752.400.750
21102316,2011-03-01T00:00:00,Critical Illness,C23.550.291.625
21102316,2011-03-01T00:00:00,Enteral Nutrition,E02.421.360
21102316,2011-03-01T00:00:00,Enteral Nutrition,E02.642.500.360
21102316,2011-03-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21102316,2011-03-01T00:00:00,"Intubation, Gastrointestinal",E05.497.412
21102316,2011-03-01T00:00:00,"Pneumonia, Aspiration",C08.381.677.529
21102316,2011-03-01T00:00:00,"Pneumonia, Aspiration",C08.730.610.529
21164380,2011-03-01T00:00:00,Adolescent,M01.060.057
21164380,2011-03-01T00:00:00,Adult,M01.060.116
21164380,2011-03-01T00:00:00,Aged,M01.060.116.100
21164380,2011-03-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21164380,2011-03-01T00:00:00,Incidence,E05.318.308.985.525.375
21164380,2011-03-01T00:00:00,Incidence,L01.280.975.525.375
21164380,2011-03-01T00:00:00,Incidence,N01.224.935.597.500
21164380,2011-03-01T00:00:00,Incidence,N06.850.505.400.975.525.375
21164380,2011-03-01T00:00:00,Incidence,N06.850.520.308.985.525.375
21164380,2011-03-01T00:00:00,Intracranial Aneurysm,C10.228.140.300.510.600
21164380,2011-03-01T00:00:00,Intracranial Aneurysm,C14.907.055.635
21164380,2011-03-01T00:00:00,Intracranial Aneurysm,C14.907.253.560.300
21164380,2011-03-01T00:00:00,Middle Aged,M01.060.116.630
21164380,2011-03-01T00:00:00,Risk Assessment,E05.318.740.600.800.715
21164380,2011-03-01T00:00:00,Risk Assessment,N04.452.871.715
21164380,2011-03-01T00:00:00,Risk Assessment,N05.715.360.750.625.700.690
21164380,2011-03-01T00:00:00,Risk Assessment,N06.850.505.715
21164380,2011-03-01T00:00:00,Risk Assessment,N06.850.520.830.600.800.715
21164380,2011-03-01T00:00:00,Risk Factors,E05.318.740.600.800.725
21164380,2011-03-01T00:00:00,Risk Factors,N05.715.350.200.700
21164380,2011-03-01T00:00:00,Risk Factors,N05.715.360.750.625.700.700
21164380,2011-03-01T00:00:00,Risk Factors,N06.850.490.625.750
21164380,2011-03-01T00:00:00,Risk Factors,N06.850.520.830.600.800.725
21164380,2011-03-01T00:00:00,Treatment Outcome,E01.789.800
21164380,2011-03-01T00:00:00,Treatment Outcome,N04.761.559.590.800
21164380,2011-03-01T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21164380,2011-03-01T00:00:00,Young Adult,M01.060.116.815
21249360,2011-03-01T00:00:00,"Adaptation, Psychological",F01.058
21249360,2011-03-01T00:00:00,Cost-Benefit Analysis,N03.219.151.125
21249360,2011-03-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21249360,2011-03-01T00:00:00,Pancreatectomy,E04.210.752
21249360,2011-03-01T00:00:00,Pancreatic Neoplasms,C04.588.274.761
21249360,2011-03-01T00:00:00,Pancreatic Neoplasms,C04.588.322.421
21249360,2011-03-01T00:00:00,Pancreatic Neoplasms,C06.301.761
21249360,2011-03-01T00:00:00,Pancreatic Neoplasms,C06.689.667
21249360,2011-03-01T00:00:00,Pancreatic Neoplasms,C19.344.421
21249360,2011-03-01T00:00:00,Quality of Life,I01.800
21249360,2011-03-01T00:00:00,Quality of Life,K01.752.400.750
21249360,2011-03-01T00:00:00,Survivors,M01.643.836
21249360,2011-03-01T00:00:00,Survivors,M01.860
21249360,2011-03-01T00:00:00,United States,Z01.107.567.875
21292654,2011-03-01T00:00:00,Anti-Bacterial Agents,D27.505.954.122.085
21292654,2011-03-01T00:00:00,Bacteria,B03
21292654,2011-03-01T00:00:00,Bacterial Infections,C01.252
21292654,2011-03-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21297541,2011-03-01T00:00:00,"Analgesics, Opioid",D27.505.696.663.850.014.520
21297541,2011-03-01T00:00:00,"Analgesics, Opioid",D27.505.954.427.040.325
21297541,2011-03-01T00:00:00,"Analgesics, Opioid",D27.505.954.427.210.049
21297541,2011-03-01T00:00:00,Bradycardia,C14.280.067.319
21297541,2011-03-01T00:00:00,Bradycardia,C23.550.073.300
21297541,2011-03-01T00:00:00,"Diverticulitis, Colonic",C06.405.469.158.587.500
21297541,2011-03-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21297541,2011-03-01T00:00:00,Hydromorphone,D03.132.577.249.547.547.450
21297541,2011-03-01T00:00:00,Hydromorphone,D03.549.686.575.547.500
21297541,2011-03-01T00:00:00,Hydromorphone,D03.605.497.575.547.500
21297541,2011-03-01T00:00:00,Hydromorphone,D04.615.723.795.547.547.450
21297541,2011-03-01T00:00:00,Middle Aged,M01.060.116.630
21297541,2011-03-01T00:00:00,"Pain, Postoperative",C23.550.767.700
21297541,2011-03-01T00:00:00,"Pain, Postoperative",C23.888.646.530
21297541,2011-03-01T00:00:00,Sinoatrial Node,A07.541.409.819
21317742,2011-03-01T00:00:00,Adenocarcinoma,C04.557.470.200.025
21317742,2011-03-01T00:00:00,African Americans,M01.686.508.100.100
21317742,2011-03-01T00:00:00,African Americans,M01.686.754.100
21317742,2011-03-01T00:00:00,Antineoplastic Agents,D27.505.954.248
21317742,2011-03-01T00:00:00,"Carcinoma, Non-Small-Cell Lung",C04.588.894.797.520.109.220.249
21317742,2011-03-01T00:00:00,"Carcinoma, Non-Small-Cell Lung",C08.381.540.140.500
21317742,2011-03-01T00:00:00,"Carcinoma, Non-Small-Cell Lung",C08.785.520.100.220.500
21317742,2011-03-01T00:00:00,"Carcinoma, Squamous Cell",C04.557.470.200.400
21317742,2011-03-01T00:00:00,"Carcinoma, Squamous Cell",C04.557.470.700.400
21317742,2011-03-01T00:00:00,Case-Control Studies,E05.318.760.500.500
21317742,2011-03-01T00:00:00,Case-Control Studies,N05.715.360.775.175.200
21317742,2011-03-01T00:00:00,Case-Control Studies,N06.850.520.450.500.500
21317742,2011-03-01T00:00:00,European Continental Ancestry Group,M01.686.508.400
21317742,2011-03-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21317742,2011-03-01T00:00:00,Lung Neoplasms,C04.588.894.797.520
21317742,2011-03-01T00:00:00,Lung Neoplasms,C08.381.540
21317742,2011-03-01T00:00:00,Lung Neoplasms,C08.785.520
21317742,2011-03-01T00:00:00,Middle Aged,M01.060.116.630
21317742,2011-03-01T00:00:00,Mutation,G05.365.590
21317742,2011-03-01T00:00:00,Polymerase Chain Reaction,E05.393.620.500
21317742,2011-03-01T00:00:00,"Receptor, Epidermal Growth Factor",D08.811.913.696.620.682.725.400.100
21317742,2011-03-01T00:00:00,"Receptor, Epidermal Growth Factor",D12.776.543.750.060.249
21317742,2011-03-01T00:00:00,"Receptor, Epidermal Growth Factor",D12.776.543.750.750.360.300
21317742,2011-03-01T00:00:00,"Receptor, Epidermal Growth Factor",D12.776.543.750.750.400.340
21317742,2011-03-01T00:00:00,Treatment Outcome,E01.789.800
21317742,2011-03-01T00:00:00,Treatment Outcome,N04.761.559.590.800
21317742,2011-03-01T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21324944,2011-03-01T00:00:00,Behavior Therapy,F04.754.137
21324944,2011-03-01T00:00:00,Depression,F01.145.126.350
21324944,2011-03-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21326055,2011-03-01T00:00:00,Hot Temperature,G01.906.595.543
21326055,2011-03-01T00:00:00,Hot Temperature,G16.500.275.063.725.710.380
21326055,2011-03-01T00:00:00,Hot Temperature,G16.500.750.775.710.380
21326055,2011-03-01T00:00:00,Hot Temperature,N06.230.300.100.725.232
21326055,2011-03-01T00:00:00,Hot Temperature,N06.230.300.100.725.710.380
21326055,2011-03-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21333874,2011-03-01T00:00:00,Adolescent,M01.060.057
21333874,2011-03-01T00:00:00,Biometry,E05.318.740.225
21333874,2011-03-01T00:00:00,Biometry,N06.850.505.200
21333874,2011-03-01T00:00:00,Child,M01.060.406
21333874,2011-03-01T00:00:00,"Child, Preschool",M01.060.406.448
21333874,2011-03-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21333874,2011-03-01T00:00:00,Infant,M01.060.703
21333874,2011-03-01T00:00:00,"Lens Implantation, Intraocular",E04.540.825.600
21333874,2011-03-01T00:00:00,"Lenses, Intraocular",E07.632.500.460
21333874,2011-03-01T00:00:00,"Lenses, Intraocular",E07.695.460
21333874,2011-03-01T00:00:00,"Refraction, Ocular",E01.370.380.850.700
21333874,2011-03-01T00:00:00,"Refraction, Ocular",G01.590.770.760
21333874,2011-03-01T00:00:00,"Refraction, Ocular",G01.595.640.760
21333874,2011-03-01T00:00:00,"Refraction, Ocular",G14.760
21333874,2011-03-01T00:00:00,Visual Acuity,E01.370.380.850.950
21333874,2011-03-01T00:00:00,Visual Acuity,F02.463.593.932.901
21333874,2011-03-01T00:00:00,Visual Acuity,G14.940
21335118,2011-03-01T00:00:00,Anti-Bacterial Agents,D27.505.954.122.085
21335118,2011-03-01T00:00:00,Esophagus,A03.556.875.500
21335118,2011-03-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21335118,2011-03-01T00:00:00,Laparoscopy,E01.370.388.250.520
21335118,2011-03-01T00:00:00,Laparoscopy,E04.800.250.520
21335118,2011-03-01T00:00:00,Middle Aged,M01.060.116.630
21335118,2011-03-01T00:00:00,Proton Pump Inhibitors,D27.505.519.389.848
21335118,2011-03-01T00:00:00,Syndrome,C23.550.288.500
21335118,2011-03-01T00:00:00,Treatment Outcome,E01.789.800
21335118,2011-03-01T00:00:00,Treatment Outcome,N04.761.559.590.800
21335118,2011-03-01T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21335118,2011-03-01T00:00:00,Wound Healing,G16.100.856.891
21343473,2011-03-01T00:00:00,Cardiovascular Diseases,C14
21343473,2011-03-01T00:00:00,Contrast Media,D27.720.259
21343473,2011-03-01T00:00:00,Coronary Angiography,E01.370.350.700.060.200
21343473,2011-03-01T00:00:00,Coronary Angiography,E01.370.370.050.200
21343473,2011-03-01T00:00:00,Coronary Angiography,E01.370.370.380.200
21343473,2011-03-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21343473,2011-03-01T00:00:00,Radiographic Image Enhancement,E01.370.350.600.350.700
21343473,2011-03-01T00:00:00,Radiographic Image Enhancement,E01.370.350.700.700
21343473,2011-03-01T00:00:00,Radiographic Image Enhancement,L01.224.308.380.600
21343473,2011-03-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.350.810
21343473,2011-03-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.600.350.700.810
21343473,2011-03-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.700.700.810
21343473,2011-03-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.700.810.810
21343473,2011-03-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.825.810.810
21343710,2011-03-01T00:00:00,Adolescent,M01.060.057
21343710,2011-03-01T00:00:00,Adult,M01.060.116
21343710,2011-03-01T00:00:00,Aged,M01.060.116.100
21343710,2011-03-01T00:00:00,"Depressive Disorder, Major",F03.600.300.375
21343710,2011-03-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21343710,2011-03-01T00:00:00,Middle Aged,M01.060.116.630
21343710,2011-03-01T00:00:00,Prefrontal Cortex,A08.186.211.730.885.287.500.270.700
21343710,2011-03-01T00:00:00,Transcranial Magnetic Stimulation,E01.370.376.850
21343710,2011-03-01T00:00:00,Transcranial Magnetic Stimulation,E02.621.820
21343710,2011-03-01T00:00:00,Treatment Outcome,E01.789.800
21343710,2011-03-01T00:00:00,Treatment Outcome,N04.761.559.590.800
21343710,2011-03-01T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21353818,2011-03-01T00:00:00,Age Factors,N05.715.350.075
21353818,2011-03-01T00:00:00,Age Factors,N06.850.490.250
21353818,2011-03-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21353818,2011-03-01T00:00:00,Income,N01.824.417
21353818,2011-03-01T00:00:00,Sex Factors,N05.715.350.675
21353818,2011-03-01T00:00:00,Sex Factors,N06.850.490.875
21353818,2011-03-01T00:00:00,Spinal Cord Injuries,C10.228.854.770
21353818,2011-03-01T00:00:00,Spinal Cord Injuries,C10.900.850
21353818,2011-03-01T00:00:00,Spinal Cord Injuries,C21.866.819
21353818,2011-03-01T00:00:00,United States,Z01.107.567.875
21353823,2011-03-01T00:00:00,Adult,M01.060.116
21353823,2011-03-01T00:00:00,Age Factors,N05.715.350.075
21353823,2011-03-01T00:00:00,Age Factors,N06.850.490.250
21353823,2011-03-01T00:00:00,"Depressive Disorder, Major",F03.600.300.375
21353823,2011-03-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21353823,2011-03-01T00:00:00,Middle Aged,M01.060.116.630
21353823,2011-03-01T00:00:00,Risk Factors,E05.318.740.600.800.725
21353823,2011-03-01T00:00:00,Risk Factors,N05.715.350.200.700
21353823,2011-03-01T00:00:00,Risk Factors,N05.715.360.750.625.700.700
21353823,2011-03-01T00:00:00,Risk Factors,N06.850.490.625.750
21353823,2011-03-01T00:00:00,Risk Factors,N06.850.520.830.600.800.725
21353823,2011-03-01T00:00:00,Sex Factors,N05.715.350.675
21353823,2011-03-01T00:00:00,Sex Factors,N06.850.490.875
21353823,2011-03-01T00:00:00,Spinal Cord Injuries,C10.228.854.770
21353823,2011-03-01T00:00:00,Spinal Cord Injuries,C10.900.850
21353823,2011-03-01T00:00:00,Spinal Cord Injuries,C21.866.819
21353825,2011-03-01T00:00:00,Adolescent,M01.060.057
21353825,2011-03-01T00:00:00,Adult,M01.060.116
21353825,2011-03-01T00:00:00,Employment,N01.824.245
21353825,2011-03-01T00:00:00,Health Status,I01.240.425
21353825,2011-03-01T00:00:00,Health Status,N01.224.425
21353825,2011-03-01T00:00:00,Health Status,N06.850.505.400.425
21353825,2011-03-01T00:00:00,Hospitalization,E02.760.400
21353825,2011-03-01T00:00:00,Hospitalization,N02.421.585.400
21353825,2011-03-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21353825,2011-03-01T00:00:00,Length of Stay,E02.760.400.480
21353825,2011-03-01T00:00:00,Length of Stay,N02.421.585.400.480
21353825,2011-03-01T00:00:00,Middle Aged,M01.060.116.630
21353825,2011-03-01T00:00:00,Nursing Homes,N02.278.825.610
21353825,2011-03-01T00:00:00,Pain,C10.597.617
21353825,2011-03-01T00:00:00,Pain,C23.888.592.612
21353825,2011-03-01T00:00:00,Pain,C23.888.646
21353825,2011-03-01T00:00:00,Pain,F02.830.816.444
21353825,2011-03-01T00:00:00,Pain,G11.561.600.810.444
21353825,2011-03-01T00:00:00,Spinal Cord Injuries,C10.228.854.770
21353825,2011-03-01T00:00:00,Spinal Cord Injuries,C10.900.850
21353825,2011-03-01T00:00:00,Spinal Cord Injuries,C21.866.819
21353825,2011-03-01T00:00:00,Time Factors,G01.910.857
21353825,2011-03-01T00:00:00,Young Adult,M01.060.116.815
21353857,2011-03-01T00:00:00,Cardiovascular Diseases,C14
21353857,2011-03-01T00:00:00,Endoscopy,E01.370.388.250
21353857,2011-03-01T00:00:00,Endoscopy,E04.800.250
21353857,2011-03-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21353857,2011-03-01T00:00:00,Lung Diseases,C08.381
21353857,2011-03-01T00:00:00,Risk Assessment,E05.318.740.600.800.715
21353857,2011-03-01T00:00:00,Risk Assessment,N04.452.871.715
21353857,2011-03-01T00:00:00,Risk Assessment,N05.715.360.750.625.700.690
21353857,2011-03-01T00:00:00,Risk Assessment,N06.850.505.715
21353857,2011-03-01T00:00:00,Risk Assessment,N06.850.520.830.600.800.715
21353857,2011-03-01T00:00:00,Risk Factors,E05.318.740.600.800.725
21353857,2011-03-01T00:00:00,Risk Factors,N05.715.350.200.700
21353857,2011-03-01T00:00:00,Risk Factors,N05.715.360.750.625.700.700
21353857,2011-03-01T00:00:00,Risk Factors,N06.850.490.625.750
21353857,2011-03-01T00:00:00,Risk Factors,N06.850.520.830.600.800.725
21353858,2011-03-01T00:00:00,Endoscopy,E01.370.388.250
21353858,2011-03-01T00:00:00,Endoscopy,E04.800.250
21353858,2011-03-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21353858,2011-03-01T00:00:00,Risk Assessment,E05.318.740.600.800.715
21353858,2011-03-01T00:00:00,Risk Assessment,N04.452.871.715
21353858,2011-03-01T00:00:00,Risk Assessment,N05.715.360.750.625.700.690
21353858,2011-03-01T00:00:00,Risk Assessment,N06.850.505.715
21353858,2011-03-01T00:00:00,Risk Assessment,N06.850.520.830.600.800.715
21353858,2011-03-01T00:00:00,Risk Factors,E05.318.740.600.800.725
21353858,2011-03-01T00:00:00,Risk Factors,N05.715.350.200.700
21353858,2011-03-01T00:00:00,Risk Factors,N05.715.360.750.625.700.700
21353858,2011-03-01T00:00:00,Risk Factors,N06.850.490.625.750
21353858,2011-03-01T00:00:00,Risk Factors,N06.850.520.830.600.800.725
21356423,2011-03-01T00:00:00,Adolescent,M01.060.057
21356423,2011-03-01T00:00:00,Adult,M01.060.116
21356423,2011-03-01T00:00:00,Age Factors,N05.715.350.075
21356423,2011-03-01T00:00:00,Age Factors,N06.850.490.250
21356423,2011-03-01T00:00:00,Alcoholism,C21.739.100.250
21356423,2011-03-01T00:00:00,Alcoholism,F03.900.100.350
21356423,2011-03-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21356423,2011-03-01T00:00:00,Mass Screening,E01.370.500
21356423,2011-03-01T00:00:00,Mass Screening,E05.318.308.250.580
21356423,2011-03-01T00:00:00,Mass Screening,N02.421.143.827.233.443
21356423,2011-03-01T00:00:00,Mass Screening,N02.421.726.233.443
21356423,2011-03-01T00:00:00,Mass Screening,N05.715.360.300.375.500
21356423,2011-03-01T00:00:00,Mass Screening,N06.850.520.308.250.580
21356423,2011-03-01T00:00:00,Mass Screening,N06.850.780.500
21356423,2011-03-01T00:00:00,"Medical Records Systems, Computerized",E05.318.308.940.968.625
21356423,2011-03-01T00:00:00,"Medical Records Systems, Computerized",L01.280.900.968.775
21356423,2011-03-01T00:00:00,"Medical Records Systems, Computerized",L01.700.508.300.695
21356423,2011-03-01T00:00:00,"Medical Records Systems, Computerized",N04.452.859.564.650
21356423,2011-03-01T00:00:00,"Medical Records Systems, Computerized",N05.715.360.300.715.500.530
21356423,2011-03-01T00:00:00,"Medical Records Systems, Computerized",N06.850.520.308.940.968.625
21356423,2011-03-01T00:00:00,Primary Health Care,N04.590.233.727
21356423,2011-03-01T00:00:00,Risk Assessment,E05.318.740.600.800.715
21356423,2011-03-01T00:00:00,Risk Assessment,N04.452.871.715
21356423,2011-03-01T00:00:00,Risk Assessment,N05.715.360.750.625.700.690
21356423,2011-03-01T00:00:00,Risk Assessment,N06.850.505.715
21356423,2011-03-01T00:00:00,Risk Assessment,N06.850.520.830.600.800.715
21356423,2011-03-01T00:00:00,United States,Z01.107.567.875
21356423,2011-03-01T00:00:00,Young Adult,M01.060.116.815
21375862,2011-03-01T00:00:00,Hepatectomy,E04.210.556
21375862,2011-03-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21375862,2011-03-01T00:00:00,Liver Neoplasms,C04.588.274.623
21375862,2011-03-01T00:00:00,Liver Neoplasms,C06.301.623
21375862,2011-03-01T00:00:00,Liver Neoplasms,C06.552.697
21375862,2011-03-01T00:00:00,Young Adult,M01.060.116.815
21376162,2011-03-01T00:00:00,Adolescent,M01.060.057
21376162,2011-03-01T00:00:00,Adult,M01.060.116
21376162,2011-03-01T00:00:00,Biological Markers,D23.101
21376162,2011-03-01T00:00:00,Case-Control Studies,E05.318.760.500.500
21376162,2011-03-01T00:00:00,Case-Control Studies,N05.715.360.775.175.200
21376162,2011-03-01T00:00:00,Case-Control Studies,N06.850.520.450.500.500
21376162,2011-03-01T00:00:00,Cytokines,D12.644.276.374
21376162,2011-03-01T00:00:00,Cytokines,D12.776.467.374
21376162,2011-03-01T00:00:00,Cytokines,D23.529.374
21376162,2011-03-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21376162,2011-03-01T00:00:00,Inflammation,C23.550.470
21376162,2011-03-01T00:00:00,Interleukin-1,D12.644.276.374.465.501
21376162,2011-03-01T00:00:00,Interleukin-1,D12.644.276.374.500.400
21376162,2011-03-01T00:00:00,Interleukin-1,D12.776.467.374.465.501
21376162,2011-03-01T00:00:00,Interleukin-1,D12.776.467.374.500.400
21376162,2011-03-01T00:00:00,Interleukin-1,D23.529.374.465.501
21376162,2011-03-01T00:00:00,Interleukin-1,D23.529.374.500.400
21376162,2011-03-01T00:00:00,Interleukin-6,D12.644.276.374.465.506
21376162,2011-03-01T00:00:00,Interleukin-6,D12.776.467.374.465.506
21376162,2011-03-01T00:00:00,Interleukin-6,D23.529.374.465.506
21376162,2011-03-01T00:00:00,Pregnancy,G08.686.785.760.769
21376162,2011-03-01T00:00:00,Tumor Necrosis Factor-alpha,D12.644.276.374.500.800
21376162,2011-03-01T00:00:00,Tumor Necrosis Factor-alpha,D12.644.276.374.750.626
21376162,2011-03-01T00:00:00,Tumor Necrosis Factor-alpha,D12.644.276.972.626
21376162,2011-03-01T00:00:00,Tumor Necrosis Factor-alpha,D12.776.124.900
21376162,2011-03-01T00:00:00,Tumor Necrosis Factor-alpha,D12.776.395.930
21376162,2011-03-01T00:00:00,Tumor Necrosis Factor-alpha,D12.776.467.374.500.800
21376162,2011-03-01T00:00:00,Tumor Necrosis Factor-alpha,D12.776.467.374.750.626
21376162,2011-03-01T00:00:00,Tumor Necrosis Factor-alpha,D12.776.467.972.626
21376162,2011-03-01T00:00:00,Tumor Necrosis Factor-alpha,D23.529.374.500.800
21376162,2011-03-01T00:00:00,Tumor Necrosis Factor-alpha,D23.529.374.750.626
21376162,2011-03-01T00:00:00,Tumor Necrosis Factor-alpha,D23.529.972.626
21376162,2011-03-01T00:00:00,Young Adult,M01.060.116.815
21398450,2011-03-01T00:00:00,Animals,B01.050
21398450,2011-03-01T00:00:00,Immunoglobulin G,D12.776.124.486.485.114.619.393
21398450,2011-03-01T00:00:00,Immunoglobulin G,D12.776.124.790.651.114.619.393
21398450,2011-03-01T00:00:00,Immunoglobulin G,D12.776.377.715.548.114.619.393
21399706,2011-03-01T00:00:00,Adult,M01.060.116
21399706,2011-03-01T00:00:00,Brain,A08.186.211
21399706,2011-03-01T00:00:00,Brain Mapping,E01.370.350.086
21399706,2011-03-01T00:00:00,Brain Mapping,E01.370.376.149
21399706,2011-03-01T00:00:00,Brain Mapping,E05.132
21399706,2011-03-01T00:00:00,Child,M01.060.406
21399706,2011-03-01T00:00:00,"Child, Preschool",M01.060.406.448
21399706,2011-03-01T00:00:00,Cognition,F02.463.188
21399706,2011-03-01T00:00:00,Face,A01.456.505
21399706,2011-03-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21399706,2011-03-01T00:00:00,Magnetic Resonance Imaging,E01.370.350.500
21399706,2011-03-01T00:00:00,Magnetic Resonance Imaging,E01.370.350.825.500
21399706,2011-03-01T00:00:00,"Pattern Recognition, Visual",F02.463.593.524.500
21399706,2011-03-01T00:00:00,"Pattern Recognition, Visual",F02.463.593.932.622
21399706,2011-03-01T00:00:00,"Pattern Recognition, Visual",F02.463.593.932.869.435.673
21419328,2011-03-01T00:00:00,Appendicitis,C06.405.205.099
21419328,2011-03-01T00:00:00,Appendicitis,C06.405.469.110.207
21419328,2011-03-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21419328,2011-03-01T00:00:00,Pelvic Pain,C23.888.646.587
21419328,2011-03-01T00:00:00,Pregnancy,G08.686.785.760.769
21419328,2011-03-01T00:00:00,Pregnancy Complications,C13.703
21422312,2011-03-01T00:00:00,Adolescent,M01.060.057
21422312,2011-03-01T00:00:00,Child,M01.060.406
21422312,2011-03-01T00:00:00,"Child, Preschool",M01.060.406.448
21422312,2011-03-01T00:00:00,Cleft Palate,C05.500.460.185
21422312,2011-03-01T00:00:00,Cleft Palate,C05.660.207.540.460.185
21422312,2011-03-01T00:00:00,Cleft Palate,C07.320.440.185
21422312,2011-03-01T00:00:00,Cleft Palate,C07.465.525.185
21422312,2011-03-01T00:00:00,Cleft Palate,C07.650.500.460.185
21422312,2011-03-01T00:00:00,Cleft Palate,C07.650.525.185
21422312,2011-03-01T00:00:00,Cleft Palate,C16.131.621.207.540.460.185
21422312,2011-03-01T00:00:00,Cleft Palate,C16.131.850.500.460.185
21422312,2011-03-01T00:00:00,Cleft Palate,C16.131.850.525.185
21422312,2011-03-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21422312,2011-03-01T00:00:00,Infant,M01.060.703
21422312,2011-03-01T00:00:00,Polysomnography,E01.370.520.625
21422312,2011-03-01T00:00:00,Postoperative Complications,C23.550.767
21422312,2011-03-01T00:00:00,"Sleep Apnea, Obstructive",C08.618.085.852.850
21422312,2011-03-01T00:00:00,"Sleep Apnea, Obstructive",C10.886.425.800.750.850
21425439,2011-03-01T00:00:00,Animals,B01.050
21425439,2011-03-01T00:00:00,Environmental Exposure,N06.850.460.350
21425439,2011-03-01T00:00:00,Environmental Pollutants,D27.888.284
21425439,2011-03-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21425439,2011-03-01T00:00:00,Progestins,D27.505.696.399.472.858
21425439,2011-03-01T00:00:00,Reproduction,G08.686.785.760
21425439,2011-03-01T00:00:00,Water Pollutants,D27.888.284.903
21451793,2011-03-01T00:00:00,Gene Silencing,G05.355.315.203.374
21451793,2011-03-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21451793,2011-03-01T00:00:00,Matrix Metalloproteinase 3,D08.811.277.656.300.480.525.700.200
21451793,2011-03-01T00:00:00,Matrix Metalloproteinase 3,D08.811.277.656.675.374.525.700.200
21451793,2011-03-01T00:00:00,Neoplasm Invasiveness,C04.697.645
21451793,2011-03-01T00:00:00,Neoplasm Invasiveness,C23.550.727.645
21451793,2011-03-01T00:00:00,Oxidative Stress,G03.495.710
21451793,2011-03-01T00:00:00,Oxidative Stress,G07.700.830.750
21451793,2011-03-01T00:00:00,Stomach Neoplasms,C04.588.274.476.767
21451793,2011-03-01T00:00:00,Stomach Neoplasms,C06.301.371.767
21451793,2011-03-01T00:00:00,Stomach Neoplasms,C06.405.249.767
21451793,2011-03-01T00:00:00,Stomach Neoplasms,C06.405.748.789
21476364,2011-03-01T00:00:00,Adult,M01.060.116
21476364,2011-03-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21476364,2011-03-01T00:00:00,Middle Aged,M01.060.116.630
21476364,2011-03-01T00:00:00,Outcome Assessment (Health Care),N04.761.559.590
21476364,2011-03-01T00:00:00,Outcome Assessment (Health Care),N05.715.360.575.575
21476364,2011-03-01T00:00:00,Questionnaires,E05.318.308.750
21476364,2011-03-01T00:00:00,Questionnaires,L01.280.800
21476364,2011-03-01T00:00:00,Questionnaires,N05.715.360.300.695
21476364,2011-03-01T00:00:00,Questionnaires,N06.850.520.308.750
21487136,2011-03-01T00:00:00,Activities of Daily Living,E02.831.067
21487136,2011-03-01T00:00:00,Activities of Daily Living,I03.050
21487136,2011-03-01T00:00:00,Activities of Daily Living,N02.421.784.110
21487136,2011-03-01T00:00:00,Age Factors,N05.715.350.075
21487136,2011-03-01T00:00:00,Age Factors,N06.850.490.250
21487136,2011-03-01T00:00:00,Exercise,G11.427.590.237
21487136,2011-03-01T00:00:00,Exercise,I03.350
21487136,2011-03-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21487136,2011-03-01T00:00:00,Middle Aged,M01.060.116.630
21487136,2011-03-01T00:00:00,Sex Factors,N05.715.350.675
21487136,2011-03-01T00:00:00,Sex Factors,N06.850.490.875
21499528,2011-03-01T00:00:00,Computer Simulation,L01.224.160
21499528,2011-03-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21499528,2011-03-01T00:00:00,"Models, Statistical",E05.318.740.500
21499528,2011-03-01T00:00:00,"Models, Statistical",E05.599.835
21499528,2011-03-01T00:00:00,"Models, Statistical",N05.715.360.750.530
21499528,2011-03-01T00:00:00,"Models, Statistical",N06.850.520.830.500
21499528,2011-03-01T00:00:00,Monte Carlo Method,E05.318.740.525
21499528,2011-03-01T00:00:00,Monte Carlo Method,L01.906.575.422
21499528,2011-03-01T00:00:00,Monte Carlo Method,N05.715.360.750.540
21499528,2011-03-01T00:00:00,Monte Carlo Method,N06.850.520.830.525
21499528,2011-03-01T00:00:00,South Carolina,Z01.107.567.875.075.662
21499528,2011-03-01T00:00:00,South Carolina,Z01.107.567.875.750.700
21505641,2011-03-01T00:00:00,Adolescent,M01.060.057
21505641,2011-03-01T00:00:00,Bayes Theorem,E05.318.740.600.200
21505641,2011-03-01T00:00:00,Bayes Theorem,N05.715.360.750.625.150
21505641,2011-03-01T00:00:00,Bayes Theorem,N06.850.520.830.600.200
21505641,2011-03-01T00:00:00,Biometry,E05.318.740.225
21505641,2011-03-01T00:00:00,Biometry,N06.850.505.200
21505641,2011-03-01T00:00:00,Child,M01.060.406
21505641,2011-03-01T00:00:00,Computer Simulation,L01.224.160
21505641,2011-03-01T00:00:00,"Data Interpretation, Statistical",E05.245.380
21505641,2011-03-01T00:00:00,"Data Interpretation, Statistical",E05.318.740.300
21505641,2011-03-01T00:00:00,"Data Interpretation, Statistical",L01.700.508.190.380
21505641,2011-03-01T00:00:00,"Data Interpretation, Statistical",N05.715.360.750.300
21505641,2011-03-01T00:00:00,"Data Interpretation, Statistical",N06.850.520.830.300
21505641,2011-03-01T00:00:00,"Diabetes Mellitus, Type 1",C18.452.394.750.124
21505641,2011-03-01T00:00:00,"Diabetes Mellitus, Type 1",C19.246.267
21505641,2011-03-01T00:00:00,"Diabetes Mellitus, Type 1",C20.111.327
21505641,2011-03-01T00:00:00,"Diabetes Mellitus, Type 2",C18.452.394.750.149
21505641,2011-03-01T00:00:00,"Diabetes Mellitus, Type 2",C19.246.300
21505641,2011-03-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21505641,2011-03-01T00:00:00,Incidence,E05.318.308.985.525.375
21505641,2011-03-01T00:00:00,Incidence,L01.280.975.525.375
21505641,2011-03-01T00:00:00,Incidence,N01.224.935.597.500
21505641,2011-03-01T00:00:00,Incidence,N06.850.505.400.975.525.375
21505641,2011-03-01T00:00:00,Incidence,N06.850.520.308.985.525.375
21505641,2011-03-01T00:00:00,"Models, Statistical",E05.318.740.500
21505641,2011-03-01T00:00:00,"Models, Statistical",E05.599.835
21505641,2011-03-01T00:00:00,"Models, Statistical",N05.715.360.750.530
21505641,2011-03-01T00:00:00,"Models, Statistical",N06.850.520.830.500
21505641,2011-03-01T00:00:00,Poisson Distribution,E05.318.740.994.750
21505641,2011-03-01T00:00:00,Poisson Distribution,G17.820.750
21505641,2011-03-01T00:00:00,Poisson Distribution,N05.715.360.750.750.620
21505641,2011-03-01T00:00:00,Poisson Distribution,N06.850.520.830.994.750
21505641,2011-03-01T00:00:00,South Carolina,Z01.107.567.875.075.662
21505641,2011-03-01T00:00:00,South Carolina,Z01.107.567.875.750.700
21505641,2011-03-01T00:00:00,Young Adult,M01.060.116.815
21520881,2011-03-01T00:00:00,"Phantoms, Imaging",E07.671
21520881,2011-03-01T00:00:00,Radiometry,E05.799
21520881,2011-03-01T00:00:00,Radiosurgery,E02.815.530
21520881,2011-03-01T00:00:00,Radiosurgery,E04.525.800.650
21520881,2011-03-01T00:00:00,Radiosurgery,E05.873.500
21520881,2011-03-01T00:00:00,Radiotherapy Dosage,E02.815.639
21520881,2011-03-01T00:00:00,Water,D01.455.900
21520881,2011-03-01T00:00:00,Water,D01.650.550.925
21537648,2011-03-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21537648,2011-03-01T00:00:00,"Lung Diseases, Interstitial",C08.381.483
21537648,2011-03-01T00:00:00,"Scleroderma, Systemic",C17.300.799
21537648,2011-03-01T00:00:00,"Scleroderma, Systemic",C17.800.784
21608480,2011-03-01T00:00:00,Carbon,D01.268.150
21608480,2011-03-01T00:00:00,Nitrogen,D01.268.604
21608480,2011-03-01T00:00:00,Nitrogen,D01.362.625
21608480,2011-03-01T00:00:00,Rivers,G01.311.750
21608480,2011-03-01T00:00:00,Rivers,G16.500.275.280.500
21608480,2011-03-01T00:00:00,Rivers,N06.230.232.500
21990472,2011-03-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21990472,2011-03-01T00:00:00,Intracranial Aneurysm,C10.228.140.300.510.600
21990472,2011-03-01T00:00:00,Intracranial Aneurysm,C14.907.055.635
21990472,2011-03-01T00:00:00,Intracranial Aneurysm,C14.907.253.560.300
21990472,2011-03-01T00:00:00,Middle Aged,M01.060.116.630
22287329,2011-03-01T00:00:00,Cadaver,C23.550.260.224
22287329,2011-03-01T00:00:00,Endoscopy,E01.370.388.250
22287329,2011-03-01T00:00:00,Endoscopy,E04.800.250
22287329,2011-03-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22287329,2011-03-01T00:00:00,Turbinates,A02.835.232.781.324.948
22287329,2011-03-01T00:00:00,Turbinates,A04.531.898
21367857,2011-03-02T00:00:00,Animals,B01.050
21367857,2011-03-02T00:00:00,Biological Transport,G03.495.166
21367857,2011-03-02T00:00:00,Endocytosis,G04.299.482
21367857,2011-03-02T00:00:00,Gastric Acid,A12.200.307.603
21367857,2011-03-02T00:00:00,Gastric Mucosa,A03.556.875.875.440
21367857,2011-03-02T00:00:00,Gastric Mucosa,A10.615.550.291
21367857,2011-03-02T00:00:00,Gene Expression Regulation,G05.355.315
21367857,2011-03-02T00:00:00,H(+)-K(+)-Exchanging ATPase,D08.811.277.040.025.325.625
21367857,2011-03-02T00:00:00,H(+)-K(+)-Exchanging ATPase,D12.776.157.530.450.250.875.500.625
21367857,2011-03-02T00:00:00,H(+)-K(+)-Exchanging ATPase,D12.776.543.585.450.250.875.500.625
21367857,2011-03-02T00:00:00,"Microscopy, Electron, Transmission",E01.370.350.515.402.580
21367857,2011-03-02T00:00:00,"Microscopy, Electron, Transmission",E05.595.402.580
21367857,2011-03-02T00:00:00,"Microscopy, Fluorescence",E01.370.350.515.458
21367857,2011-03-02T00:00:00,"Microscopy, Fluorescence",E05.595.458
21367857,2011-03-02T00:00:00,"Parietal Cells, Gastric",A03.556.875.875.440.708
21367857,2011-03-02T00:00:00,"Parietal Cells, Gastric",A10.615.550.291.650
21367857,2011-03-02T00:00:00,"Parietal Cells, Gastric",A11.436.708
21376058,2011-03-02T00:00:00,Capsid,A21.249.500.250
21376058,2011-03-02T00:00:00,Capsid,B04.950.500.250
21376058,2011-03-02T00:00:00,Computer Simulation,L01.224.160
21376058,2011-03-02T00:00:00,"Evolution, Molecular",G05.355.265.250
21376058,2011-03-02T00:00:00,"Evolution, Molecular",G16.100.275.250
21376058,2011-03-02T00:00:00,HIV Protease,D08.811.277.656.074.500.340
21376058,2011-03-02T00:00:00,HIV Protease,D08.811.277.656.300.048.340
21376058,2011-03-02T00:00:00,HIV Protease,D12.776.964.775.375.545.750
21376058,2011-03-02T00:00:00,HIV-1,B04.820.650.589.650.350.400
21376058,2011-03-02T00:00:00,HIV-1,B04.909.777.731.589.650.350.400
21376058,2011-03-02T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21376058,2011-03-02T00:00:00,"Models, Molecular",E05.599.595
21376058,2011-03-02T00:00:00,Point Mutation,G05.365.590.675
21376058,2011-03-02T00:00:00,Poisson Distribution,E05.318.740.994.750
21376058,2011-03-02T00:00:00,Poisson Distribution,G17.820.750
21376058,2011-03-02T00:00:00,Poisson Distribution,N05.715.360.750.750.620
21376058,2011-03-02T00:00:00,Poisson Distribution,N06.850.520.830.994.750
21369731,2011-03-03T00:00:00,3' Untranslated Regions,D13.444.735.544.875.880
21369731,2011-03-03T00:00:00,3' Untranslated Regions,D13.444.735.790.878.880
21369731,2011-03-03T00:00:00,3' Untranslated Regions,G05.360.340.024.220.880.880
21369731,2011-03-03T00:00:00,3' Untranslated Regions,G05.360.340.024.340.137.910.880
21369731,2011-03-03T00:00:00,Animals,B01.050
21369731,2011-03-03T00:00:00,CHO Cells,A11.251.210.200
21369731,2011-03-03T00:00:00,CHO Cells,A11.436.155
21369731,2011-03-03T00:00:00,Cricetinae,B01.050.150.900.649.865.635.150
21369731,2011-03-03T00:00:00,Protein Biosynthesis,G02.111.087.675.871
21369731,2011-03-03T00:00:00,Protein Biosynthesis,G02.149.115.675.871
21369731,2011-03-03T00:00:00,Protein Biosynthesis,G03.495.770.871
21369731,2011-03-03T00:00:00,Protein Biosynthesis,G05.355.310.670
21369731,2011-03-03T00:00:00,Proteins,D12.776
21369731,2011-03-03T00:00:00,"RNA, Messenger",D13.444.735.544
21369731,2011-03-03T00:00:00,"Receptors, Adrenergic, beta-2",D12.776.543.750.070.300.300.340.725
21369731,2011-03-03T00:00:00,"Receptors, Adrenergic, beta-2",D12.776.543.750.100.150.300.340.725
21369731,2011-03-03T00:00:00,"Receptors, Adrenergic, beta-2",D12.776.543.750.720.300.300.300.340.200
21371989,2011-03-03T00:00:00,Adult,M01.060.116
21371989,2011-03-03T00:00:00,African Americans,M01.686.508.100.100
21371989,2011-03-03T00:00:00,African Americans,M01.686.754.100
21371989,2011-03-03T00:00:00,Health Services Accessibility,N04.590.374.350
21371989,2011-03-03T00:00:00,Health Services Accessibility,N05.300.430
21371989,2011-03-03T00:00:00,Hispanic Americans,M01.686.754.441
21371989,2011-03-03T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21371989,2011-03-03T00:00:00,Internet,L01.224.230.110.500
21371989,2011-03-03T00:00:00,Middle Aged,M01.060.116.630
21371989,2011-03-03T00:00:00,Rural Population,N01.600.725
21371989,2011-03-03T00:00:00,Travel,I03.883
21371989,2011-03-03T00:00:00,Urban Population,N01.600.900
21371041,2011-03-04T00:00:00,"Nuclear Magnetic Resonance, Biomolecular",E05.196.867.519.550
21371041,2011-03-04T00:00:00,Plant Leaves,A18.024.812
21371041,2011-03-04T00:00:00,"Spectroscopy, Fourier Transform Infrared",E05.196.712.726.676.700
21371041,2011-03-04T00:00:00,"Spectroscopy, Fourier Transform Infrared",E05.196.867.826.676.700
21371041,2011-03-04T00:00:00,"Stress, Physiological",G07.700.830
21371041,2011-03-04T00:00:00,Temperature,G01.906.595
21371041,2011-03-04T00:00:00,Temperature,G16.500.275.063.725.710
21371041,2011-03-04T00:00:00,Temperature,G16.500.750.775.710
21371041,2011-03-04T00:00:00,Temperature,N06.230.150.450
21371041,2011-03-04T00:00:00,Temperature,N06.230.300.100.725.710
21376315,2011-03-04T00:00:00,Developing Countries,I01.615.500.300
21376315,2011-03-04T00:00:00,"Fracture Fixation, Internal",E04.555.300.300
21376315,2011-03-04T00:00:00,Guidelines as Topic,N04.761.700.350
21376315,2011-03-04T00:00:00,Guidelines as Topic,N05.700.350
21376315,2011-03-04T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21378126,2011-03-04T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21378126,2011-03-04T00:00:00,Incidence,E05.318.308.985.525.375
21378126,2011-03-04T00:00:00,Incidence,L01.280.975.525.375
21378126,2011-03-04T00:00:00,Incidence,N01.224.935.597.500
21378126,2011-03-04T00:00:00,Incidence,N06.850.505.400.975.525.375
21378126,2011-03-04T00:00:00,Incidence,N06.850.520.308.985.525.375
21378126,2011-03-04T00:00:00,Melanoma,C04.557.465.625.650.510
21378126,2011-03-04T00:00:00,Melanoma,C04.557.580.625.650.510
21378126,2011-03-04T00:00:00,Melanoma,C04.557.665.510
21378126,2011-03-04T00:00:00,"Neoplasms, Radiation-Induced",C04.682
21378126,2011-03-04T00:00:00,"Neoplasms, Radiation-Induced",C21.866.733.476
21378126,2011-03-04T00:00:00,Risk Factors,E05.318.740.600.800.725
21378126,2011-03-04T00:00:00,Risk Factors,N05.715.350.200.700
21378126,2011-03-04T00:00:00,Risk Factors,N05.715.360.750.625.700.700
21378126,2011-03-04T00:00:00,Risk Factors,N06.850.490.625.750
21378126,2011-03-04T00:00:00,Risk Factors,N06.850.520.830.600.800.725
21378126,2011-03-04T00:00:00,Skin Neoplasms,C04.588.805
21378126,2011-03-04T00:00:00,Skin Neoplasms,C17.800.882
21381164,2011-03-04T00:00:00,Animals,B01.050
21381164,2011-03-04T00:00:00,Drug Delivery Systems,E02.319.300
21381164,2011-03-04T00:00:00,Fluorenes,D02.455.426.559.847.389
21381164,2011-03-04T00:00:00,Fluorenes,D04.615.389
21381164,2011-03-04T00:00:00,Neoplasms,C04
21381164,2011-03-04T00:00:00,Polymers,D05.750
21381164,2011-03-04T00:00:00,Polymers,D25.720
21381164,2011-03-04T00:00:00,Polymers,J01.637.051.720
21381164,2011-03-04T00:00:00,Quantum Dots,E07.595.650
21381164,2011-03-04T00:00:00,Quantum Dots,J01.637.512.600.650
21381164,2011-03-04T00:00:00,"Tumor Markers, Biological",D23.101.840
21377673,2011-03-05T00:00:00,"Endoscopy, Gastrointestinal",E01.370.372.250.250
21377673,2011-03-05T00:00:00,"Endoscopy, Gastrointestinal",E01.370.388.250.250.250
21377673,2011-03-05T00:00:00,"Endoscopy, Gastrointestinal",E04.210.240.250
21377673,2011-03-05T00:00:00,"Endoscopy, Gastrointestinal",E04.800.250.250.250
21377673,2011-03-05T00:00:00,Gastroenterology,H02.403.429.405
21377673,2011-03-05T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21377673,2011-03-05T00:00:00,Risk Assessment,E05.318.740.600.800.715
21377673,2011-03-05T00:00:00,Risk Assessment,N04.452.871.715
21377673,2011-03-05T00:00:00,Risk Assessment,N05.715.360.750.625.700.690
21377673,2011-03-05T00:00:00,Risk Assessment,N06.850.505.715
21377673,2011-03-05T00:00:00,Risk Assessment,N06.850.520.830.600.800.715
21377673,2011-03-05T00:00:00,Risk Factors,E05.318.740.600.800.725
21377673,2011-03-05T00:00:00,Risk Factors,N05.715.350.200.700
21377673,2011-03-05T00:00:00,Risk Factors,N05.715.360.750.625.700.700
21377673,2011-03-05T00:00:00,Risk Factors,N06.850.490.625.750
21377673,2011-03-05T00:00:00,Risk Factors,N06.850.520.830.600.800.725
21377673,2011-03-05T00:00:00,United States,Z01.107.567.875
21377892,2011-03-05T00:00:00,Age Factors,N05.715.350.075
21377892,2011-03-05T00:00:00,Age Factors,N06.850.490.250
21377892,2011-03-05T00:00:00,Fontan Procedure,E04.035.410.295
21377892,2011-03-05T00:00:00,Fontan Procedure,E04.100.376.410.295
21377892,2011-03-05T00:00:00,Fontan Procedure,E04.928.220.370.295
21377892,2011-03-05T00:00:00,Heart Transplantation,E04.100.376.475
21377892,2011-03-05T00:00:00,Heart Transplantation,E04.928.220.390
21377892,2011-03-05T00:00:00,Heart Transplantation,E04.936.450.475
21377892,2011-03-05T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21377892,2011-03-05T00:00:00,Hypoplastic Left Heart Syndrome,C14.240.400.625
21377892,2011-03-05T00:00:00,Hypoplastic Left Heart Syndrome,C14.280.400.625
21377892,2011-03-05T00:00:00,Hypoplastic Left Heart Syndrome,C16.131.240.400.625
21377892,2011-03-05T00:00:00,Infant,M01.060.703
21377892,2011-03-05T00:00:00,Length of Stay,E02.760.400.480
21377892,2011-03-05T00:00:00,Length of Stay,N02.421.585.400.480
21377892,2011-03-05T00:00:00,Palliative Care,E02.760.666
21377892,2011-03-05T00:00:00,Palliative Care,N02.421.585.666
21377892,2011-03-05T00:00:00,Risk Factors,E05.318.740.600.800.725
21377892,2011-03-05T00:00:00,Risk Factors,N05.715.350.200.700
21377892,2011-03-05T00:00:00,Risk Factors,N05.715.360.750.625.700.700
21377892,2011-03-05T00:00:00,Risk Factors,N06.850.490.625.750
21377892,2011-03-05T00:00:00,Risk Factors,N06.850.520.830.600.800.725
21377892,2011-03-05T00:00:00,Treatment Outcome,E01.789.800
21377892,2011-03-05T00:00:00,Treatment Outcome,N04.761.559.590.800
21377892,2011-03-05T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21126216,2011-03-06T00:00:00,Animals,B01.050
21126216,2011-03-06T00:00:00,Green Fluorescent Proteins,D12.776.532.265
21126216,2011-03-06T00:00:00,Hepatocytes,A11.436.348
21126216,2011-03-06T00:00:00,"Microscopy, Confocal",E01.370.350.515.395
21126216,2011-03-06T00:00:00,"Microscopy, Confocal",E05.595.395
21126216,2011-03-06T00:00:00,"Mitochondria, Liver",A11.284.430.214.190.875.564.461
21126216,2011-03-06T00:00:00,"Mitochondria, Liver",A11.284.835.626.461
21384035,2011-03-07T00:00:00,Copper,D01.268.556.195
21384035,2011-03-07T00:00:00,Copper,D01.268.956.170
21384035,2011-03-07T00:00:00,Copper,D01.552.544.195
21384035,2011-03-07T00:00:00,Halogens,D01.268.380
21384035,2011-03-07T00:00:00,Organometallic Compounds,D01.632
21384035,2011-03-07T00:00:00,Organometallic Compounds,D02.691
21384035,2011-03-07T00:00:00,X-Ray Diffraction,E05.196.309.742
21384035,2011-03-07T00:00:00,X-Ray Diffraction,E05.196.822.950
21384035,2011-03-07T00:00:00,X-Ray Diffraction,G01.595.861.950
21384035,2011-03-07T00:00:00,X-Ray Diffraction,G02.149.767.915
21384035,2011-03-07T00:00:00,X-Ray Diffraction,G02.842.750.915
20853355,2011-03-08T00:00:00,Aged,M01.060.116.100
20853355,2011-03-08T00:00:00,Ambulatory Care,E02.760.106
20853355,2011-03-08T00:00:00,Ambulatory Care,N02.421.585.106
20853355,2011-03-08T00:00:00,Arterial Occlusive Diseases,C14.907.137
20853355,2011-03-08T00:00:00,"Constriction, Pathologic",C23.300.287
20853355,2011-03-08T00:00:00,Femoral Artery,A07.231.114.351
20853355,2011-03-08T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
20853355,2011-03-08T00:00:00,Intermittent Claudication,C14.907.137.126.669
20853355,2011-03-08T00:00:00,Intermittent Claudication,C23.888.531
20853355,2011-03-08T00:00:00,Middle Aged,M01.060.116.630
20853355,2011-03-08T00:00:00,Risk Assessment,E05.318.740.600.800.715
20853355,2011-03-08T00:00:00,Risk Assessment,N04.452.871.715
20853355,2011-03-08T00:00:00,Risk Assessment,N05.715.360.750.625.700.690
20853355,2011-03-08T00:00:00,Risk Assessment,N06.850.505.715
20853355,2011-03-08T00:00:00,Risk Assessment,N06.850.520.830.600.800.715
20853355,2011-03-08T00:00:00,Risk Factors,E05.318.740.600.800.725
20853355,2011-03-08T00:00:00,Risk Factors,N05.715.350.200.700
20853355,2011-03-08T00:00:00,Risk Factors,N05.715.360.750.625.700.700
20853355,2011-03-08T00:00:00,Risk Factors,N06.850.490.625.750
20853355,2011-03-08T00:00:00,Risk Factors,N06.850.520.830.600.800.725
20853355,2011-03-08T00:00:00,Stents,E07.695.750
20853355,2011-03-08T00:00:00,Time Factors,G01.910.857
20853355,2011-03-08T00:00:00,Treatment Outcome,E01.789.800
20853355,2011-03-08T00:00:00,Treatment Outcome,N04.761.559.590.800
20853355,2011-03-08T00:00:00,Treatment Outcome,N05.715.360.575.575.800
20853355,2011-03-08T00:00:00,Vascular Patency,G09.330.920
20853355,2011-03-08T00:00:00,Vascular Surgical Procedures,E04.100.814
21385909,2011-03-08T00:00:00,Adolescent,M01.060.057
21385909,2011-03-08T00:00:00,Adult,M01.060.116
21385909,2011-03-08T00:00:00,Health Surveys,E05.318.308.250
21385909,2011-03-08T00:00:00,Health Surveys,N05.715.360.300.375
21385909,2011-03-08T00:00:00,Health Surveys,N06.850.520.308.250
21385909,2011-03-08T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21385909,2011-03-08T00:00:00,Middle Aged,M01.060.116.630
21385909,2011-03-08T00:00:00,Sex Factors,N05.715.350.675
21385909,2011-03-08T00:00:00,Sex Factors,N06.850.490.875
21385909,2011-03-08T00:00:00,Smoking,F01.145.466.753
21385909,2011-03-08T00:00:00,Smoking Cessation,F01.145.940.700
21385909,2011-03-08T00:00:00,United States,Z01.107.567.875
21385909,2011-03-08T00:00:00,Young Adult,M01.060.116.815
21387566,2011-03-08T00:00:00,Anatomy,H01.158.100
21387566,2011-03-08T00:00:00,Computer-Assisted Instruction,I02.903.573.208
21387566,2011-03-08T00:00:00,"Education, Professional",I02.358
21387566,2011-03-08T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21387566,2011-03-08T00:00:00,Occupational Therapy,E02.831.489
21387566,2011-03-08T00:00:00,Occupational Therapy,H02.010.500
21387566,2011-03-08T00:00:00,Pilot Projects,E05.318.760.750
21387566,2011-03-08T00:00:00,Pilot Projects,E05.337.737
21387566,2011-03-08T00:00:00,Pilot Projects,N05.715.360.775.625
21387566,2011-03-08T00:00:00,Pilot Projects,N06.850.520.450.720
21387566,2011-03-08T00:00:00,"Students, Health Occupations",I02.851.686
21387566,2011-03-08T00:00:00,"Students, Health Occupations",M01.848.769
21397860,2011-03-08T00:00:00,"Adaptor Proteins, Vesicular Transport",D12.776.543.990.150
21397860,2011-03-08T00:00:00,Animals,B01.050
21397860,2011-03-08T00:00:00,Breast Neoplasms,C04.588.180
21397860,2011-03-08T00:00:00,Breast Neoplasms,C17.800.090.500
21397860,2011-03-08T00:00:00,Cell Line,A11.251.210
21397860,2011-03-08T00:00:00,Cell Movement,G04.299.283
21397860,2011-03-08T00:00:00,Cell Movement,G07.700.560.500.180
21397860,2011-03-08T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21397860,2011-03-08T00:00:00,Neoplasms,C04
21397860,2011-03-08T00:00:00,Nuclear Proteins,D12.776.660
21397860,2011-03-08T00:00:00,RNA Interference,G05.355.315.203.374.790
21397860,2011-03-08T00:00:00,"Receptor, Platelet-Derived Growth Factor alpha",D08.811.913.696.620.682.725.400.900.500
21397860,2011-03-08T00:00:00,"Receptor, Platelet-Derived Growth Factor alpha",D12.776.543.750.060.625.300
21397860,2011-03-08T00:00:00,"Receptor, Platelet-Derived Growth Factor alpha",D12.776.543.750.750.400.630.300
21397860,2011-03-08T00:00:00,Signal Transduction,G02.111.087.800
21397860,2011-03-08T00:00:00,Signal Transduction,G02.149.115.800
21397860,2011-03-08T00:00:00,Signal Transduction,G04.299.880
21408136,2011-03-08T00:00:00,"Antigens, CD",D23.050.301.264.035
21408136,2011-03-08T00:00:00,"Antigens, CD",D23.101.100.110
21408136,2011-03-08T00:00:00,Cell Movement,G04.299.283
21408136,2011-03-08T00:00:00,Cell Movement,G07.700.560.500.180
21408136,2011-03-08T00:00:00,Glioblastoma,C04.557.465.625.600.380.080.335
21408136,2011-03-08T00:00:00,Glioblastoma,C04.557.470.670.380.080.335
21408136,2011-03-08T00:00:00,Glioblastoma,C04.557.580.625.600.380.080.335
21408136,2011-03-08T00:00:00,HSP90 Heat-Shock Proteins,D12.776.580.216.380
21408136,2011-03-08T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21408136,2011-03-08T00:00:00,Neoplasm Invasiveness,C04.697.645
21408136,2011-03-08T00:00:00,Neoplasm Invasiveness,C23.550.727.645
21408136,2011-03-08T00:00:00,Phosphorylation,G02.111.087.677
21408136,2011-03-08T00:00:00,Phosphorylation,G02.149.115.677
21408136,2011-03-08T00:00:00,Phosphorylation,G02.149.465.700
21408136,2011-03-08T00:00:00,Phosphorylation,G02.607.750.700
21408136,2011-03-08T00:00:00,Phosphorylation,G03.495.790
21408136,2011-03-08T00:00:00,Protein Transport,G03.495.166.700
21408136,2011-03-08T00:00:00,Proto-Oncogene Proteins c-akt,D08.811.913.696.620.682.700.755
21408136,2011-03-08T00:00:00,Proto-Oncogene Proteins c-akt,D12.776.476.565
21408136,2011-03-08T00:00:00,Proto-Oncogene Proteins c-akt,D12.776.624.664.700.168
21408136,2011-03-08T00:00:00,"Receptor, EphA2",D08.811.913.696.620.682.725.400.850.100
21408136,2011-03-08T00:00:00,"Receptor, EphA2",D12.776.543.750.060.500.100
21408136,2011-03-08T00:00:00,Signal Transduction,G02.111.087.800
21408136,2011-03-08T00:00:00,Signal Transduction,G02.149.115.800
21408136,2011-03-08T00:00:00,Signal Transduction,G04.299.880
21385466,2011-03-09T00:00:00,Aged,M01.060.116.100
21385466,2011-03-09T00:00:00,Atrial Fibrillation,C14.280.067.198
21385466,2011-03-09T00:00:00,Atrial Fibrillation,C23.550.073.198
21385466,2011-03-09T00:00:00,Cardiac Surgical Procedures,E04.100.376
21385466,2011-03-09T00:00:00,Cardiac Surgical Procedures,E04.928.220
21385466,2011-03-09T00:00:00,Evaluation Studies as Topic,E05.337
21385466,2011-03-09T00:00:00,Evaluation Studies as Topic,N05.715.360.335
21385466,2011-03-09T00:00:00,Exercise Therapy,E02.779.483
21385466,2011-03-09T00:00:00,Exercise Therapy,E02.831.387
21385466,2011-03-09T00:00:00,Heart Diseases,C14.280
21385466,2011-03-09T00:00:00,Heart Valves,A07.541.510
21385466,2011-03-09T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21385466,2011-03-09T00:00:00,Length of Stay,E02.760.400.480
21385466,2011-03-09T00:00:00,Length of Stay,N02.421.585.400.480
21385466,2011-03-09T00:00:00,Middle Aged,M01.060.116.630
21385466,2011-03-09T00:00:00,Outcome Assessment (Health Care),N04.761.559.590
21385466,2011-03-09T00:00:00,Outcome Assessment (Health Care),N05.715.360.575.575
21385466,2011-03-09T00:00:00,Physical Fitness,I03.621
21385466,2011-03-09T00:00:00,Physical Fitness,N01.400.545
21385466,2011-03-09T00:00:00,Postoperative Complications,C23.550.767
21385466,2011-03-09T00:00:00,Preoperative Care,E02.760.795
21385466,2011-03-09T00:00:00,Preoperative Care,E04.641
21385466,2011-03-09T00:00:00,Preoperative Care,N02.421.585.795
21385466,2011-03-09T00:00:00,Quality of Life,I01.800
21385466,2011-03-09T00:00:00,Quality of Life,K01.752.400.750
21385466,2011-03-09T00:00:00,Questionnaires,E05.318.308.750
21385466,2011-03-09T00:00:00,Questionnaires,L01.280.800
21385466,2011-03-09T00:00:00,Questionnaires,N05.715.360.300.695
21385466,2011-03-09T00:00:00,Questionnaires,N06.850.520.308.750
21385466,2011-03-09T00:00:00,"Stress, Psychological",F01.145.126.990
21385466,2011-03-09T00:00:00,"Stress, Psychological",F02.830.900
21388949,2011-03-09T00:00:00,Apoptosis,G04.299.139.160
21388949,2011-03-09T00:00:00,Ceramides,D02.065.313
21388949,2011-03-09T00:00:00,Ceramides,D09.400.410.420.525.200
21388949,2011-03-09T00:00:00,Ceramides,D10.390.470.675.200
21388949,2011-03-09T00:00:00,Ceramides,D10.570.877.360.612.200
21388949,2011-03-09T00:00:00,Enzyme Inhibitors,D27.505.519.389
21388949,2011-03-09T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21388949,2011-03-09T00:00:00,Oxidoreductases,D08.811.682
21388949,2011-03-09T00:00:00,Sphingosine,D02.033.100.700
21388949,2011-03-09T00:00:00,Sphingosine,D02.033.455.843
21388949,2011-03-09T00:00:00,Sphingosine,D02.092.063.700
21389259,2011-03-09T00:00:00,Carbon Dioxide,D01.200.200
21389259,2011-03-09T00:00:00,Carbon Dioxide,D01.362.150
21389259,2011-03-09T00:00:00,Carbon Dioxide,D01.650.550.200
21389259,2011-03-09T00:00:00,Case-Control Studies,E05.318.760.500.500
21389259,2011-03-09T00:00:00,Case-Control Studies,N05.715.360.775.175.200
21389259,2011-03-09T00:00:00,Case-Control Studies,N06.850.520.450.500.500
21389259,2011-03-09T00:00:00,Gene Expression Regulation,G05.355.315
21389259,2011-03-09T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21389259,2011-03-09T00:00:00,Mutation,G05.365.590
21389259,2011-03-09T00:00:00,Oxygen,D01.268.185.550
21389259,2011-03-09T00:00:00,Oxygen,D01.362.670
21389274,2011-03-09T00:00:00,Animals,B01.050
21389274,2011-03-09T00:00:00,Cyclic AMP-Dependent Protein Kinases,D08.811.913.696.620.682.700.150.125
21389274,2011-03-09T00:00:00,Cyclic AMP-Dependent Protein Kinases,D12.644.360.200.125
21389274,2011-03-09T00:00:00,Cyclic AMP-Dependent Protein Kinases,D12.776.476.200.125
21389274,2011-03-09T00:00:00,Heart,A07.541
21389274,2011-03-09T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21389274,2011-03-09T00:00:00,Phosphorylation,G02.111.087.677
21389274,2011-03-09T00:00:00,Phosphorylation,G02.149.115.677
21389274,2011-03-09T00:00:00,Phosphorylation,G02.149.465.700
21389274,2011-03-09T00:00:00,Phosphorylation,G02.607.750.700
21389274,2011-03-09T00:00:00,Phosphorylation,G03.495.790
21389274,2011-03-09T00:00:00,Sodium-Calcium Exchanger,D12.776.157.530.450.162.442
21389274,2011-03-09T00:00:00,Sodium-Calcium Exchanger,D12.776.543.585.450.162.442
21392017,2011-03-10T00:00:00,Granulocyte Colony-Stimulating Factor,D12.644.276.374.410.240.350
21392017,2011-03-10T00:00:00,Granulocyte Colony-Stimulating Factor,D12.776.395.240.200
21392017,2011-03-10T00:00:00,Granulocyte Colony-Stimulating Factor,D12.776.467.374.410.240.350
21392017,2011-03-10T00:00:00,Granulocyte Colony-Stimulating Factor,D23.529.374.410.240.350
21392017,2011-03-10T00:00:00,Granulocyte-Macrophage Colony-Stimulating Factor,D12.644.276.374.410.240.375
21392017,2011-03-10T00:00:00,Granulocyte-Macrophage Colony-Stimulating Factor,D12.776.395.240.300
21392017,2011-03-10T00:00:00,Granulocyte-Macrophage Colony-Stimulating Factor,D12.776.467.374.410.240.375
21392017,2011-03-10T00:00:00,Granulocyte-Macrophage Colony-Stimulating Factor,D23.529.374.410.240.375
21392017,2011-03-10T00:00:00,Hematopoietic Stem Cell Mobilization,E02.095.410
21392017,2011-03-10T00:00:00,Hematopoietic Stem Cell Transplantation,E04.936.225.687.500
21392017,2011-03-10T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21392017,2011-03-10T00:00:00,Middle Aged,M01.060.116.630
21392017,2011-03-10T00:00:00,Multiple Myeloma,C04.557.595.500
21392017,2011-03-10T00:00:00,Multiple Myeloma,C14.907.454.460
21392017,2011-03-10T00:00:00,Multiple Myeloma,C15.378.147.780.650
21392017,2011-03-10T00:00:00,Multiple Myeloma,C15.378.463.835.460
21392017,2011-03-10T00:00:00,Multiple Myeloma,C20.683.515.845
21392017,2011-03-10T00:00:00,Multiple Myeloma,C20.683.780.650
21393591,2011-03-10T00:00:00,Aged,M01.060.116.100
21393591,2011-03-10T00:00:00,Artifacts,E05.047
21393591,2011-03-10T00:00:00,Blood Platelets,A11.118.188
21393591,2011-03-10T00:00:00,Blood Platelets,A15.145.229.188
21393591,2011-03-10T00:00:00,Fibrin,D12.776.124.270
21393591,2011-03-10T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21393591,2011-03-10T00:00:00,"Infarction, Middle Cerebral Artery",C10.228.140.300.150.477.200.450
21393591,2011-03-10T00:00:00,"Infarction, Middle Cerebral Artery",C10.228.140.300.510.200.387
21393591,2011-03-10T00:00:00,"Infarction, Middle Cerebral Artery",C10.228.140.300.775.200.200.450
21393591,2011-03-10T00:00:00,"Infarction, Middle Cerebral Artery",C14.907.253.092.477.200.450
21393591,2011-03-10T00:00:00,"Infarction, Middle Cerebral Artery",C14.907.253.560.200.387
21393591,2011-03-10T00:00:00,"Infarction, Middle Cerebral Artery",C14.907.253.855.200.200.450
21393591,2011-03-10T00:00:00,Magnetic Resonance Imaging,E01.370.350.500
21393591,2011-03-10T00:00:00,Magnetic Resonance Imaging,E01.370.350.825.500
21393591,2011-03-10T00:00:00,Middle Aged,M01.060.116.630
21393591,2011-03-10T00:00:00,Stroke,C10.228.140.300.775
21393591,2011-03-10T00:00:00,Stroke,C14.907.253.855
21393591,2011-03-10T00:00:00,Thrombectomy,E04.100.814.842
21393591,2011-03-10T00:00:00,Thrombosis,C14.907.355.830
21393591,2011-03-10T00:00:00,"Tomography, X-Ray Computed",E01.370.350.350.810
21393591,2011-03-10T00:00:00,"Tomography, X-Ray Computed",E01.370.350.600.350.700.810
21393591,2011-03-10T00:00:00,"Tomography, X-Ray Computed",E01.370.350.700.700.810
21393591,2011-03-10T00:00:00,"Tomography, X-Ray Computed",E01.370.350.700.810.810
21393591,2011-03-10T00:00:00,"Tomography, X-Ray Computed",E01.370.350.825.810.810
21396853,2011-03-10T00:00:00,Aged,M01.060.116.100
21396853,2011-03-10T00:00:00,Apoptosis,G04.299.139.160
21396853,2011-03-10T00:00:00,Case-Control Studies,E05.318.760.500.500
21396853,2011-03-10T00:00:00,Case-Control Studies,N05.715.360.775.175.200
21396853,2011-03-10T00:00:00,Case-Control Studies,N06.850.520.450.500.500
21396853,2011-03-10T00:00:00,Genetic Predisposition to Disease,C23.550.291.687.500
21396853,2011-03-10T00:00:00,Genetic Predisposition to Disease,G05.380.355
21396853,2011-03-10T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21396853,2011-03-10T00:00:00,Polymerase Chain Reaction,E05.393.620.500
21396853,2011-03-10T00:00:00,"Polymorphism, Single Nucleotide",G05.365.795.598
21396853,2011-03-10T00:00:00,Prostatic Neoplasms,C04.588.945.440.770
21396853,2011-03-10T00:00:00,Prostatic Neoplasms,C12.294.260.750
21396853,2011-03-10T00:00:00,Prostatic Neoplasms,C12.294.565.625
21396853,2011-03-10T00:00:00,Prostatic Neoplasms,C12.758.409.750
21396853,2011-03-10T00:00:00,Risk Factors,E05.318.740.600.800.725
21396853,2011-03-10T00:00:00,Risk Factors,N05.715.350.200.700
21396853,2011-03-10T00:00:00,Risk Factors,N05.715.360.750.625.700.700
21396853,2011-03-10T00:00:00,Risk Factors,N06.850.490.625.750
21396853,2011-03-10T00:00:00,Risk Factors,N06.850.520.830.600.800.725
21396853,2011-03-10T00:00:00,"Tumor Markers, Biological",D23.101.840
21398620,2011-03-11T00:00:00,Animals,B01.050
21398620,2011-03-11T00:00:00,Bronchoalveolar Lavage Fluid,E05.510.100.500
21398620,2011-03-11T00:00:00,Cell Adhesion Molecules,D12.776.395.550.200
21398620,2011-03-11T00:00:00,Cell Adhesion Molecules,D12.776.543.550.200
21398620,2011-03-11T00:00:00,Cell Adhesion Molecules,D23.050.301.350
21398620,2011-03-11T00:00:00,Cytokines,D12.644.276.374
21398620,2011-03-11T00:00:00,Cytokines,D12.776.467.374
21398620,2011-03-11T00:00:00,Cytokines,D23.529.374
21398620,2011-03-11T00:00:00,"Disease Models, Animal",C22.232
21398620,2011-03-11T00:00:00,"Disease Models, Animal",E05.598.500
21398620,2011-03-11T00:00:00,"Disease Models, Animal",E05.599.395.080
21398620,2011-03-11T00:00:00,Gene Expression Regulation,G05.355.315
21398620,2011-03-11T00:00:00,Integrins,D12.776.543.750.705.408
21398620,2011-03-11T00:00:00,Lung,A04.411
21398620,2011-03-11T00:00:00,"Macrophages, Alveolar",A11.329.372.600
21398620,2011-03-11T00:00:00,"Macrophages, Alveolar",A11.627.482.600
21398620,2011-03-11T00:00:00,"Macrophages, Alveolar",A11.733.397.600
21398620,2011-03-11T00:00:00,"Macrophages, Alveolar",A15.382.680.397.600
21398620,2011-03-11T00:00:00,"Macrophages, Alveolar",A15.382.812.522.600
21398620,2011-03-11T00:00:00,"Nanotubes, Carbon",D01.268.150.250.500
21398620,2011-03-11T00:00:00,"Nanotubes, Carbon",J01.637.512.850.500
21398620,2011-03-11T00:00:00,"RNA, Messenger",D13.444.735.544
21398620,2011-03-11T00:00:00,T-Lymphocytes,A11.118.637.555.567.569
21398620,2011-03-11T00:00:00,T-Lymphocytes,A15.145.229.637.555.567.569
21398620,2011-03-11T00:00:00,T-Lymphocytes,A15.382.490.555.567.569
21398620,2011-03-11T00:00:00,Time Factors,G01.910.857
21411963,2011-03-11T00:00:00,Cooperative Behavior,F01.145.813.115
21411963,2011-03-11T00:00:00,Physicians,M01.526.485.810
21411963,2011-03-11T00:00:00,Physicians,N02.360.810
21477048,2011-03-11T00:00:00,Adult,M01.060.116
21477048,2011-03-11T00:00:00,Eating Disorders,F03.375
21477048,2011-03-11T00:00:00,Health Facility Administrators,M01.526.070.490
21477048,2011-03-11T00:00:00,Health Facility Administrators,M01.526.485.430
21477048,2011-03-11T00:00:00,Health Facility Administrators,N02.360.430
21477048,2011-03-11T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21477048,2011-03-11T00:00:00,Interviews as Topic,E05.318.308.420
21477048,2011-03-11T00:00:00,Interviews as Topic,L01.280.520
21477048,2011-03-11T00:00:00,Interviews as Topic,N05.715.360.300.400
21477048,2011-03-11T00:00:00,Interviews as Topic,N06.850.520.308.420
21477048,2011-03-11T00:00:00,Process Assessment (Health Care),N04.761.559.650
21477048,2011-03-11T00:00:00,Process Assessment (Health Care),N05.715.360.575.625
21477048,2011-03-11T00:00:00,Substance Abuse Treatment Centers,N02.278.035.128.800
21477048,2011-03-11T00:00:00,Substance Abuse Treatment Centers,N02.278.808.930
21477048,2011-03-11T00:00:00,Substance-Related Disorders,C21.739
21477048,2011-03-11T00:00:00,Substance-Related Disorders,F03.900
22236316,2011-03-11T00:00:00,Adolescent,M01.060.057
22236316,2011-03-11T00:00:00,Adult,M01.060.116
22236316,2011-03-11T00:00:00,African Americans,M01.686.508.100.100
22236316,2011-03-11T00:00:00,African Americans,M01.686.754.100
22236316,2011-03-11T00:00:00,Aged,M01.060.116.100
22236316,2011-03-11T00:00:00,Breast Neoplasms,C04.588.180
22236316,2011-03-11T00:00:00,Breast Neoplasms,C17.800.090.500
22236316,2011-03-11T00:00:00,Colorectal Neoplasms,C04.588.274.476.411.307
22236316,2011-03-11T00:00:00,Colorectal Neoplasms,C06.301.371.411.307
22236316,2011-03-11T00:00:00,Colorectal Neoplasms,C06.405.249.411.307
22236316,2011-03-11T00:00:00,Colorectal Neoplasms,C06.405.469.158.356
22236316,2011-03-11T00:00:00,Colorectal Neoplasms,C06.405.469.491.307
22236316,2011-03-11T00:00:00,Colorectal Neoplasms,C06.405.469.860.180
22236316,2011-03-11T00:00:00,Early Detection of Cancer,E01.390.500
22236316,2011-03-11T00:00:00,European Continental Ancestry Group,M01.686.508.400
22236316,2011-03-11T00:00:00,Healthcare Disparities,N04.590.374.380
22236316,2011-03-11T00:00:00,Healthcare Disparities,N05.300.493
22236316,2011-03-11T00:00:00,Hispanic Americans,M01.686.754.441
22236316,2011-03-11T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22236316,2011-03-11T00:00:00,Middle Aged,M01.060.116.630
22236316,2011-03-11T00:00:00,Minority Groups,I01.880.371
22236316,2011-03-11T00:00:00,Neoplasms,C04
22236316,2011-03-11T00:00:00,Rural Population,N01.600.725
22236316,2011-03-11T00:00:00,United States,Z01.107.567.875
22236316,2011-03-11T00:00:00,Uterine Cervical Neoplasms,C04.588.945.418.948.850
22236316,2011-03-11T00:00:00,Uterine Cervical Neoplasms,C13.351.500.852.593.131
22236316,2011-03-11T00:00:00,Uterine Cervical Neoplasms,C13.351.500.852.762.850
22236316,2011-03-11T00:00:00,Uterine Cervical Neoplasms,C13.351.937.418.875.850
22236316,2011-03-11T00:00:00,Young Adult,M01.060.116.815
21397269,2011-03-12T00:00:00,Animals,B01.050
21397269,2011-03-12T00:00:00,Blood Pressure,E01.370.600.875.249
21397269,2011-03-12T00:00:00,Blood Pressure,G09.330.380.076
21397269,2011-03-12T00:00:00,"Cardiac Pacing, Artificial",E02.145
21397269,2011-03-12T00:00:00,"Cardiomyopathy, Dilated",C14.280.195.160
21397269,2011-03-12T00:00:00,"Cardiomyopathy, Dilated",C14.280.238.070
21397269,2011-03-12T00:00:00,Coronary Circulation,G09.330.190.163.324
21397269,2011-03-12T00:00:00,"Disease Models, Animal",C22.232
21397269,2011-03-12T00:00:00,"Disease Models, Animal",E05.598.500
21397269,2011-03-12T00:00:00,"Disease Models, Animal",E05.599.395.080
21397269,2011-03-12T00:00:00,Hemodynamics,G09.330.190.400
21397269,2011-03-12T00:00:00,Hemodynamics,G09.330.380
21397269,2011-03-12T00:00:00,Prosthesis Design,E05.320.550
21397269,2011-03-12T00:00:00,Prosthesis Design,E07.695.680
21397269,2011-03-12T00:00:00,Prosthesis Implantation,E04.650
21397269,2011-03-12T00:00:00,Pulmonary Artery,A07.231.114.715
21397269,2011-03-12T00:00:00,Swine,B01.050.150.900.649.077.880
21397269,2011-03-12T00:00:00,Time Factors,G01.910.857
21397269,2011-03-12T00:00:00,"Ventricular Function, Left",G09.330.190.962.800
21397269,2011-03-12T00:00:00,Ventricular Pressure,G09.330.190.962.950
21397269,2011-03-12T00:00:00,Ventricular Pressure,G09.330.380.937
21399896,2011-03-12T00:00:00,Animals,B01.050
21399896,2011-03-12T00:00:00,Extracellular Matrix,A11.284.295.310
21399896,2011-03-12T00:00:00,Fibroblasts,A11.329.228
21399896,2011-03-12T00:00:00,Fibroblasts,A11.872.228
21399896,2011-03-12T00:00:00,"Models, Cardiovascular",E05.599.395.161
21399896,2011-03-12T00:00:00,Myocardium,A02.633.580
21399896,2011-03-12T00:00:00,Myocardium,A07.541.704
21399896,2011-03-12T00:00:00,Myocardium,A10.690.552.750
21399896,2011-03-12T00:00:00,Signal Transduction,G02.111.087.800
21399896,2011-03-12T00:00:00,Signal Transduction,G02.149.115.800
21399896,2011-03-12T00:00:00,Signal Transduction,G04.299.880
21399896,2011-03-12T00:00:00,Stem Cells,A11.872
21401091,2011-03-14T00:00:00,Carbon,D01.268.150
21401091,2011-03-14T00:00:00,Carbon Dioxide,D01.200.200
21401091,2011-03-14T00:00:00,Carbon Dioxide,D01.362.150
21401091,2011-03-14T00:00:00,Carbon Dioxide,D01.650.550.200
21401091,2011-03-14T00:00:00,Light,G01.201.875.770.578
21401091,2011-03-14T00:00:00,Light,G01.590.540
21401091,2011-03-14T00:00:00,Nanoparticles,J01.637.512.600
21401091,2011-03-14T00:00:00,Photochemistry,H01.181.529.711
21401091,2011-03-14T00:00:00,Surface Properties,G02.842.850
21401332,2011-03-14T00:00:00,Activities of Daily Living,E02.831.067
21401332,2011-03-14T00:00:00,Activities of Daily Living,I03.050
21401332,2011-03-14T00:00:00,Activities of Daily Living,N02.421.784.110
21401332,2011-03-14T00:00:00,"Adaptation, Physiological",G07.700.062
21401332,2011-03-14T00:00:00,"Adaptation, Physiological",G16.100.057.500
21401332,2011-03-14T00:00:00,Adult,M01.060.116
21401332,2011-03-14T00:00:00,Aged,M01.060.116.100
21401332,2011-03-14T00:00:00,Disability Evaluation,E01.370.400
21401332,2011-03-14T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21401332,2011-03-14T00:00:00,Middle Aged,M01.060.116.630
21401332,2011-03-14T00:00:00,Psychometrics,F04.711.780
21401332,2011-03-14T00:00:00,Questionnaires,E05.318.308.750
21401332,2011-03-14T00:00:00,Questionnaires,L01.280.800
21401332,2011-03-14T00:00:00,Questionnaires,N05.715.360.300.695
21401332,2011-03-14T00:00:00,Questionnaires,N06.850.520.308.750
21401332,2011-03-14T00:00:00,Recovery of Function,G16.757
21401332,2011-03-14T00:00:00,Upper Extremity,A01.378.800
21401575,2011-03-14T00:00:00,Cholecalciferol,D04.808.247.222.159
21401575,2011-03-14T00:00:00,Cholecalciferol,D04.808.247.808.146
21401575,2011-03-14T00:00:00,Cholecalciferol,D04.808.812.768.196
21401575,2011-03-14T00:00:00,Cholecalciferol,D10.570.938.146
21401575,2011-03-14T00:00:00,Chronic Disease,C23.550.291.500
21401575,2011-03-14T00:00:00,Dendritic Cells,A11.066.270
21401575,2011-03-14T00:00:00,Dendritic Cells,A11.436.270
21401575,2011-03-14T00:00:00,Dendritic Cells,A15.382.066.270
21401575,2011-03-14T00:00:00,Dendritic Cells,A15.382.812.260
21401575,2011-03-14T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21401575,2011-03-14T00:00:00,Macrophages,A11.329.372
21401575,2011-03-14T00:00:00,Macrophages,A11.627.482
21401575,2011-03-14T00:00:00,Macrophages,A11.733.397
21401575,2011-03-14T00:00:00,Macrophages,A15.382.680.397
21401575,2011-03-14T00:00:00,Macrophages,A15.382.812.522
21401575,2011-03-14T00:00:00,Nasal Polyps,C08.460.572
21401575,2011-03-14T00:00:00,Nasal Polyps,C09.603.557
21401575,2011-03-14T00:00:00,Nasal Polyps,C23.300.825.557
21401575,2011-03-14T00:00:00,Rhinitis,C08.460.799
21401575,2011-03-14T00:00:00,Rhinitis,C08.730.674
21401575,2011-03-14T00:00:00,Rhinitis,C09.603.799
21401575,2011-03-14T00:00:00,Sinusitis,C08.460.692.752
21401575,2011-03-14T00:00:00,Sinusitis,C08.730.749
21401575,2011-03-14T00:00:00,Sinusitis,C09.603.692.752
21403051,2011-03-14T00:00:00,Communication,F01.145.209
21403051,2011-03-14T00:00:00,Communication,L01.143
21403051,2011-03-14T00:00:00,Health Literacy,I02.233.332.186.500
21403051,2011-03-14T00:00:00,Health Literacy,N02.421.143.827.407.228.500
21403051,2011-03-14T00:00:00,Health Literacy,N02.421.726.407.228.500
21403051,2011-03-14T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21403051,2011-03-14T00:00:00,Patient-Centered Care,N04.590.233.675
21403051,2011-03-14T00:00:00,Patient-Centered Care,N04.590.233.727.407
21403051,2011-03-14T00:00:00,Patient-Centered Care,N04.590.720
21403051,2011-03-14T00:00:00,Physician-Patient Relations,F01.829.401.650.675
21403051,2011-03-14T00:00:00,Physician-Patient Relations,N05.300.660.625
21320126,2011-03-15T00:00:00,Alzheimer Disease,C10.228.140.380.100
21320126,2011-03-15T00:00:00,Alzheimer Disease,C10.574.945.249
21320126,2011-03-15T00:00:00,Alzheimer Disease,F03.087.400.100
21320126,2011-03-15T00:00:00,Amyloid Precursor Protein Secretases,D08.811.277.656.300.032
21320126,2011-03-15T00:00:00,Animals,B01.050
21320126,2011-03-15T00:00:00,Enzyme Inhibitors,D27.505.519.389
21320126,2011-03-15T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21411243,2011-03-15T00:00:00,Adolescent,M01.060.057
21411243,2011-03-15T00:00:00,Attention Deficit Disorder with Hyperactivity,F03.550.150.150
21411243,2011-03-15T00:00:00,Central Nervous System Stimulants,D27.505.696.282
21411243,2011-03-15T00:00:00,Central Nervous System Stimulants,D27.505.954.427.220
21411243,2011-03-15T00:00:00,Cognitive Therapy,F04.754.137.428
21411243,2011-03-15T00:00:00,Disease Progression,C23.550.291.656
21411243,2011-03-15T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21411243,2011-03-15T00:00:00,Methylphenidate,D02.241.223.601.600
21411243,2011-03-15T00:00:00,Methylphenidate,D03.383.621.460
21411243,2011-03-15T00:00:00,Psychiatric Status Rating Scales,F04.586
21411243,2011-03-15T00:00:00,Smoking,F01.145.466.753
21411243,2011-03-15T00:00:00,Substance-Related Disorders,C21.739
21411243,2011-03-15T00:00:00,Substance-Related Disorders,F03.900
21412852,2011-03-15T00:00:00,Adolescent,M01.060.057
21412852,2011-03-15T00:00:00,Anxiety,F01.470.132
21412852,2011-03-15T00:00:00,Child,M01.060.406
21412852,2011-03-15T00:00:00,Health Surveys,E05.318.308.250
21412852,2011-03-15T00:00:00,Health Surveys,N05.715.360.300.375
21412852,2011-03-15T00:00:00,Health Surveys,N06.850.520.308.250
21412852,2011-03-15T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21412852,2011-03-15T00:00:00,Interviews as Topic,E05.318.308.420
21412852,2011-03-15T00:00:00,Interviews as Topic,L01.280.520
21412852,2011-03-15T00:00:00,Interviews as Topic,N05.715.360.300.400
21412852,2011-03-15T00:00:00,Interviews as Topic,N06.850.520.308.420
21412852,2011-03-15T00:00:00,"Stress Disorders, Post-Traumatic",F03.080.931.500
21412852,2011-03-15T00:00:00,Truth Disclosure,F01.145.209.259.800
21412852,2011-03-15T00:00:00,United States,Z01.107.567.875
21454530,2011-03-15T00:00:00,Animals,B01.050
21454530,2011-03-15T00:00:00,Ceramides,D02.065.313
21454530,2011-03-15T00:00:00,Ceramides,D09.400.410.420.525.200
21454530,2011-03-15T00:00:00,Ceramides,D10.390.470.675.200
21454530,2011-03-15T00:00:00,Ceramides,D10.570.877.360.612.200
21454530,2011-03-15T00:00:00,"Fatty Acids, Monounsaturated",D10.251.355.325
21454530,2011-03-15T00:00:00,Insulin Resistance,C18.452.394.968.500
21454530,2011-03-15T00:00:00,Insulin Resistance,G07.690.320.617
21454530,2011-03-15T00:00:00,Lipids,D10
21454530,2011-03-15T00:00:00,Mass Spectrometry,E05.196.566
21454530,2011-03-15T00:00:00,Obesity,C18.654.726.500
21454530,2011-03-15T00:00:00,Obesity,C23.888.144.699.500
21454530,2011-03-15T00:00:00,Obesity,E01.370.600.115.100.160.120.699.500
21454530,2011-03-15T00:00:00,Obesity,G07.100.100.160.120.699.500
21454530,2011-03-15T00:00:00,Oxidoreductases,D08.811.682
21454530,2011-03-15T00:00:00,Sphingolipids,D10.570.877
21454530,2011-03-15T00:00:00,Sphingolipids,D10.808
21466885,2011-03-15T00:00:00,"Adaptor Proteins, Vesicular Transport",D12.776.543.990.150
21466885,2011-03-15T00:00:00,Adult,M01.060.116
21466885,2011-03-15T00:00:00,Age Factors,N05.715.350.075
21466885,2011-03-15T00:00:00,Age Factors,N06.850.490.250
21466885,2011-03-15T00:00:00,Cardiovascular Diseases,C14
21466885,2011-03-15T00:00:00,"Cholesterol, HDL",D10.532.432.400
21466885,2011-03-15T00:00:00,"Cholesterol, HDL",D10.570.938.208.270
21466885,2011-03-15T00:00:00,"Cholesterol, HDL",D12.776.521.479.470
21466885,2011-03-15T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21466885,2011-03-15T00:00:00,Middle Aged,M01.060.116.630
21466885,2011-03-15T00:00:00,"Polymorphism, Genetic",G05.365.795
21411628,2011-03-16T00:00:00,Cell Cycle,G04.299.134
21411628,2011-03-16T00:00:00,Cell Membrane,A11.284.149
21411628,2011-03-16T00:00:00,Connexin 43,D12.776.543.585.250.200
21411628,2011-03-16T00:00:00,Gap Junctions,A11.284.149.165.420.471
21411628,2011-03-16T00:00:00,Green Fluorescent Proteins,D12.776.532.265
21411628,2011-03-16T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21411628,2011-03-16T00:00:00,Membrane Proteins,D12.776.543
21411628,2011-03-16T00:00:00,Phosphoproteins,D12.776.744
21411628,2011-03-16T00:00:00,Protein Transport,G03.495.166.700
21411628,2011-03-16T00:00:00,RNA Interference,G05.355.315.203.374.790
21414811,2011-03-16T00:00:00,"Adaptation, Psychological",F01.058
21414811,2011-03-16T00:00:00,Adolescent,M01.060.057
21414811,2011-03-16T00:00:00,Adult,M01.060.116
21414811,2011-03-16T00:00:00,Caregivers,M01.085
21414811,2011-03-16T00:00:00,Caregivers,M01.526.485.200
21414811,2011-03-16T00:00:00,Caregivers,N02.360.200
21414811,2011-03-16T00:00:00,Child,M01.060.406
21414811,2011-03-16T00:00:00,Cognitive Therapy,F04.754.137.428
21414811,2011-03-16T00:00:00,Communication,F01.145.209
21414811,2011-03-16T00:00:00,Communication,L01.143
21414811,2011-03-16T00:00:00,Epilepsy,C10.228.140.490
21414811,2011-03-16T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21414811,2011-03-16T00:00:00,Patient Education as Topic,I02.233.332.500
21414811,2011-03-16T00:00:00,Patient Education as Topic,N02.421.143.827.407.680
21414811,2011-03-16T00:00:00,Patient Education as Topic,N02.421.726.407.680
21414811,2011-03-16T00:00:00,Patient Satisfaction,N04.452.822.360.600
21414811,2011-03-16T00:00:00,Patient Satisfaction,N05.300.150.600.630
21414811,2011-03-16T00:00:00,Patient Satisfaction,N05.715.360.600
21414811,2011-03-16T00:00:00,Pilot Projects,E05.318.760.750
21414811,2011-03-16T00:00:00,Pilot Projects,E05.337.737
21414811,2011-03-16T00:00:00,Pilot Projects,N05.715.360.775.625
21414811,2011-03-16T00:00:00,Pilot Projects,N06.850.520.450.720
21414811,2011-03-16T00:00:00,Questionnaires,E05.318.308.750
21414811,2011-03-16T00:00:00,Questionnaires,L01.280.800
21414811,2011-03-16T00:00:00,Questionnaires,N05.715.360.300.695
21414811,2011-03-16T00:00:00,Questionnaires,N06.850.520.308.750
21414811,2011-03-16T00:00:00,Self Care,E02.900
21414811,2011-03-16T00:00:00,Self Care,N02.421.784.680
21414811,2011-03-16T00:00:00,Self Efficacy,F01.752.747.792.700
21419621,2011-03-16T00:00:00,Bioreactors,E07.115
21419621,2011-03-16T00:00:00,Bioreactors,J01.897.120.115
21419621,2011-03-16T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21419621,2011-03-16T00:00:00,Robotics,H01.671.293.643
21419621,2011-03-16T00:00:00,Robotics,J01.897.104.834
21419621,2011-03-16T00:00:00,Robotics,L01.224.065.630
21419621,2011-03-16T00:00:00,Tissue Engineering,E05.200.249.750
21507371,2011-03-16T00:00:00,Adult,M01.060.116
21507371,2011-03-16T00:00:00,Case-Control Studies,E05.318.760.500.500
21507371,2011-03-16T00:00:00,Case-Control Studies,N05.715.360.775.175.200
21507371,2011-03-16T00:00:00,Case-Control Studies,N06.850.520.450.500.500
21507371,2011-03-16T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21507371,2011-03-16T00:00:00,"Infant, Newborn",M01.060.703.520
21507371,2011-03-16T00:00:00,Pre-Eclampsia,C13.703.395.249
21507371,2011-03-16T00:00:00,Pregnancy,G08.686.785.760.769
21507371,2011-03-16T00:00:00,Vitamin D,D04.808.812.768
21507371,2011-03-16T00:00:00,Young Adult,M01.060.116.815
21437235,2011-03-17T00:00:00,Breast Neoplasms,C04.588.180
21437235,2011-03-17T00:00:00,Breast Neoplasms,C17.800.090.500
21437235,2011-03-17T00:00:00,Cell Proliferation,G04.299.233.750
21437235,2011-03-17T00:00:00,Cell Proliferation,G07.700.320.249.410.750
21437235,2011-03-17T00:00:00,"Cell Transformation, Neoplastic",C04.697.152
21437235,2011-03-17T00:00:00,"Cell Transformation, Neoplastic",C23.550.727.152
21437235,2011-03-17T00:00:00,"Gene Expression Regulation, Neoplastic",G05.355.315.370
21437235,2011-03-17T00:00:00,Glucose,D09.546.359.448
21437235,2011-03-17T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21437235,2011-03-17T00:00:00,Insulin,D06.472.699.587.740.625
21437235,2011-03-17T00:00:00,Insulin,D12.644.548.586.740.625
21437235,2011-03-17T00:00:00,Phenotype,G05.695
21437235,2011-03-17T00:00:00,Protein Transport,G03.495.166.700
21437235,2011-03-17T00:00:00,"Receptor, erbB-2",D08.811.913.696.620.682.725.400.150
21437235,2011-03-17T00:00:00,"Receptor, erbB-2",D12.776.543.750.060.374
21437235,2011-03-17T00:00:00,"Receptor, erbB-2",D12.776.543.750.750.400.350
21437235,2011-03-17T00:00:00,"Receptor, erbB-2",D12.776.624.664.700.642
21437235,2011-03-17T00:00:00,"Receptor, erbB-2",D23.101.840.642
21437235,2011-03-17T00:00:00,Signal Transduction,G02.111.087.800
21437235,2011-03-17T00:00:00,Signal Transduction,G02.149.115.800
21437235,2011-03-17T00:00:00,Signal Transduction,G04.299.880
21437932,2011-03-17T00:00:00,Aged,M01.060.116.100
21437932,2011-03-17T00:00:00,"Constriction, Pathologic",C23.300.287
21437932,2011-03-17T00:00:00,Coronary Angiography,E01.370.350.700.060.200
21437932,2011-03-17T00:00:00,Coronary Angiography,E01.370.370.050.200
21437932,2011-03-17T00:00:00,Coronary Angiography,E01.370.370.380.200
21437932,2011-03-17T00:00:00,Double-Blind Method,E05.318.780.300
21437932,2011-03-17T00:00:00,Double-Blind Method,E05.581.500.300
21437932,2011-03-17T00:00:00,Double-Blind Method,N05.715.360.780.320
21437932,2011-03-17T00:00:00,Double-Blind Method,N06.850.520.445.300
21437932,2011-03-17T00:00:00,Fibrinolytic Agents,D27.505.519.421.750
21437932,2011-03-17T00:00:00,Fibrinolytic Agents,D27.505.954.411.320
21437932,2011-03-17T00:00:00,Fibrinolytic Agents,D27.505.954.502.427
21437932,2011-03-17T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21437932,2011-03-17T00:00:00,Intracranial Arteriosclerosis,C10.228.140.300.510.800
21437932,2011-03-17T00:00:00,Intracranial Arteriosclerosis,C14.907.137.126.372
21437932,2011-03-17T00:00:00,Intracranial Arteriosclerosis,C14.907.253.560.350
21437932,2011-03-17T00:00:00,"Ischemic Attack, Transient",C10.228.140.300.150.836
21437932,2011-03-17T00:00:00,"Ischemic Attack, Transient",C14.907.253.092.836
21437932,2011-03-17T00:00:00,Magnetic Resonance Imaging,E01.370.350.500
21437932,2011-03-17T00:00:00,Magnetic Resonance Imaging,E01.370.350.825.500
21437932,2011-03-17T00:00:00,Middle Aged,M01.060.116.630
21437932,2011-03-17T00:00:00,Regression Analysis,E05.318.740.750
21437932,2011-03-17T00:00:00,Regression Analysis,N05.715.360.750.695
21437932,2011-03-17T00:00:00,Regression Analysis,N06.850.520.830.750
21437932,2011-03-17T00:00:00,Risk Factors,E05.318.740.600.800.725
21437932,2011-03-17T00:00:00,Risk Factors,N05.715.350.200.700
21437932,2011-03-17T00:00:00,Risk Factors,N05.715.360.750.625.700.700
21437932,2011-03-17T00:00:00,Risk Factors,N06.850.490.625.750
21437932,2011-03-17T00:00:00,Risk Factors,N06.850.520.830.600.800.725
21437932,2011-03-17T00:00:00,Stroke,C10.228.140.300.775
21437932,2011-03-17T00:00:00,Stroke,C14.907.253.855
21437932,2011-03-17T00:00:00,"Tomography, X-Ray Computed",E01.370.350.350.810
21437932,2011-03-17T00:00:00,"Tomography, X-Ray Computed",E01.370.350.600.350.700.810
21437932,2011-03-17T00:00:00,"Tomography, X-Ray Computed",E01.370.350.700.700.810
21437932,2011-03-17T00:00:00,"Tomography, X-Ray Computed",E01.370.350.700.810.810
21437932,2011-03-17T00:00:00,"Tomography, X-Ray Computed",E01.370.350.825.810.810
21459638,2011-03-17T00:00:00,Brain Mapping,E01.370.350.086
21459638,2011-03-17T00:00:00,Brain Mapping,E01.370.376.149
21459638,2011-03-17T00:00:00,Brain Mapping,E05.132
21459638,2011-03-17T00:00:00,Diffusion Magnetic Resonance Imaging,E01.370.350.500.150
21459638,2011-03-17T00:00:00,Diffusion Magnetic Resonance Imaging,E01.370.350.825.500.150
21459638,2011-03-17T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21459638,2011-03-17T00:00:00,"Image Interpretation, Computer-Assisted",E01.158.600
21459638,2011-03-17T00:00:00,"Image Interpretation, Computer-Assisted",E01.370.350.350
21459638,2011-03-17T00:00:00,"Image Interpretation, Computer-Assisted",L01.700.508.100.158.600
21459638,2011-03-17T00:00:00,"Models, Theoretical",E05.599
21498281,2011-03-17T00:00:00,Contrast Media,D27.720.259
21498281,2011-03-17T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21498281,2011-03-17T00:00:00,Liver Diseases,C06.552
21498281,2011-03-17T00:00:00,Radiation Dosage,E05.799.513
21498281,2011-03-17T00:00:00,Radiation Dosage,G01.201.875.740
21498281,2011-03-17T00:00:00,Radiation Dosage,N06.850.810.250
21498281,2011-03-17T00:00:00,Radiographic Image Enhancement,E01.370.350.600.350.700
21498281,2011-03-17T00:00:00,Radiographic Image Enhancement,E01.370.350.700.700
21498281,2011-03-17T00:00:00,Radiographic Image Enhancement,L01.224.308.380.600
21498281,2011-03-17T00:00:00,"Radiographic Image Interpretation, Computer-Assisted",E01.158.600.680
21498281,2011-03-17T00:00:00,"Radiographic Image Interpretation, Computer-Assisted",E01.370.350.350.700
21498281,2011-03-17T00:00:00,"Radiographic Image Interpretation, Computer-Assisted",E01.370.350.700.705
21498281,2011-03-17T00:00:00,"Radiographic Image Interpretation, Computer-Assisted",L01.700.508.100.158.600.680
21498281,2011-03-17T00:00:00,"Radiography, Abdominal",E01.370.350.700.715
21498281,2011-03-17T00:00:00,Time Factors,G01.910.857
21498281,2011-03-17T00:00:00,"Tomography, X-Ray Computed",E01.370.350.350.810
21498281,2011-03-17T00:00:00,"Tomography, X-Ray Computed",E01.370.350.600.350.700.810
21498281,2011-03-17T00:00:00,"Tomography, X-Ray Computed",E01.370.350.700.700.810
21498281,2011-03-17T00:00:00,"Tomography, X-Ray Computed",E01.370.350.700.810.810
21498281,2011-03-17T00:00:00,"Tomography, X-Ray Computed",E01.370.350.825.810.810
21417702,2011-03-18T00:00:00,Animals,B01.050
21417702,2011-03-18T00:00:00,Central Nervous System,A08.186
21417702,2011-03-18T00:00:00,Craniocerebral Trauma,C10.900.300
21417702,2011-03-18T00:00:00,Craniocerebral Trauma,C21.866.260
21417702,2011-03-18T00:00:00,Craniocerebral Trauma,C21.866.915.300
21417702,2011-03-18T00:00:00,Electroencephalography,E01.370.376.300
21417702,2011-03-18T00:00:00,Electroencephalography,E01.370.405.245
21417702,2011-03-18T00:00:00,"Evoked Potentials, Auditory",G07.265.500.370
21417702,2011-03-18T00:00:00,"Evoked Potentials, Auditory",G11.561.270.370
21417702,2011-03-18T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21417702,2011-03-18T00:00:00,Magnetic Resonance Imaging,E01.370.350.500
21417702,2011-03-18T00:00:00,Magnetic Resonance Imaging,E01.370.350.825.500
21417702,2011-03-18T00:00:00,Middle Aged,M01.060.116.630
21417702,2011-03-18T00:00:00,Multiple Trauma,C21.866.640
21417702,2011-03-18T00:00:00,Peripheral Nerves,A08.800.800
21421909,2011-03-18T00:00:00,Animals,B01.050
21421909,2011-03-18T00:00:00,"Antibodies, Monoclonal",D12.776.124.486.485.114.224
21421909,2011-03-18T00:00:00,"Antibodies, Monoclonal",D12.776.124.790.651.114.224
21421909,2011-03-18T00:00:00,"Antibodies, Monoclonal",D12.776.377.715.548.114.224
21421909,2011-03-18T00:00:00,Complement Activation,G12.425.255
21421909,2011-03-18T00:00:00,Complement C3,D12.776.124.050.140
21421909,2011-03-18T00:00:00,Complement C3,D12.776.124.486.274.250
21421909,2011-03-18T00:00:00,"Disease Models, Animal",C22.232
21421909,2011-03-18T00:00:00,"Disease Models, Animal",E05.598.500
21421909,2011-03-18T00:00:00,"Disease Models, Animal",E05.599.395.080
21421909,2011-03-18T00:00:00,Lung,A04.411
21421909,2011-03-18T00:00:00,Paraquat,D03.383.725.762.621
21421909,2011-03-18T00:00:00,Recombinant Fusion Proteins,D12.776.828.300
21421909,2011-03-18T00:00:00,Signal Transduction,G02.111.087.800
21421909,2011-03-18T00:00:00,Signal Transduction,G02.149.115.800
21421909,2011-03-18T00:00:00,Signal Transduction,G04.299.880
21421909,2011-03-18T00:00:00,Time Factors,G01.910.857
21425193,2011-03-18T00:00:00,Adolescent,M01.060.057
21425193,2011-03-18T00:00:00,Child,M01.060.406
21425193,2011-03-18T00:00:00,Crime Victims,M01.135
21425193,2011-03-18T00:00:00,Forecasting,I01.320
21425193,2011-03-18T00:00:00,Health Surveys,E05.318.308.250
21425193,2011-03-18T00:00:00,Health Surveys,N05.715.360.300.375
21425193,2011-03-18T00:00:00,Health Surveys,N06.850.520.308.250
21425193,2011-03-18T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21425193,2011-03-18T00:00:00,Interviews as Topic,E05.318.308.420
21425193,2011-03-18T00:00:00,Interviews as Topic,L01.280.520
21425193,2011-03-18T00:00:00,Interviews as Topic,N05.715.360.300.400
21425193,2011-03-18T00:00:00,Interviews as Topic,N06.850.520.308.420
21425193,2011-03-18T00:00:00,Rape,I01.198.240.748.640
21425193,2011-03-18T00:00:00,Regression Analysis,E05.318.740.750
21425193,2011-03-18T00:00:00,Regression Analysis,N05.715.360.750.695
21425193,2011-03-18T00:00:00,Regression Analysis,N06.850.520.830.750
21425193,2011-03-18T00:00:00,"Stress Disorders, Post-Traumatic",F03.080.931.500
21425193,2011-03-18T00:00:00,United States,Z01.107.567.875
21425193,2011-03-18T00:00:00,Violence,I01.198.240.856
21425193,2011-03-18T00:00:00,Violence,I01.880.735.900
22236310,2011-03-18T00:00:00,Data Collection,E05.318.308
22236310,2011-03-18T00:00:00,Data Collection,L01.280
22236310,2011-03-18T00:00:00,Data Collection,N05.715.360.300
22236310,2011-03-18T00:00:00,Data Collection,N06.850.520.308
22236310,2011-03-18T00:00:00,Health Services Accessibility,N04.590.374.350
22236310,2011-03-18T00:00:00,Health Services Accessibility,N05.300.430
22236310,2011-03-18T00:00:00,Health Surveys,E05.318.308.250
22236310,2011-03-18T00:00:00,Health Surveys,N05.715.360.300.375
22236310,2011-03-18T00:00:00,Health Surveys,N06.850.520.308.250
22236310,2011-03-18T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22236310,2011-03-18T00:00:00,Primary Health Care,N04.590.233.727
22236310,2011-03-18T00:00:00,South Carolina,Z01.107.567.875.075.662
22236310,2011-03-18T00:00:00,South Carolina,Z01.107.567.875.750.700
22236310,2011-03-18T00:00:00,Telemedicine,H02.403.840
22236310,2011-03-18T00:00:00,Telemedicine,L01.178.847.652
22236310,2011-03-18T00:00:00,Telemedicine,N04.590.374.800
21418194,2011-03-21T00:00:00,Adolescent,M01.060.057
21418194,2011-03-21T00:00:00,Autistic Disorder,F03.550.325.125
21418194,2011-03-21T00:00:00,"Child, Preschool",M01.060.406.448
21418194,2011-03-21T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21421048,2011-03-21T00:00:00,Endothelin-1,D12.644.276.400.225
21421048,2011-03-21T00:00:00,Endothelin-1,D12.776.467.400.225
21421048,2011-03-21T00:00:00,Endothelin-1,D23.529.400.225
21421048,2011-03-21T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21421048,2011-03-21T00:00:00,Liver,A03.620
21421048,2011-03-21T00:00:00,Liver Diseases,C06.552
21421048,2011-03-21T00:00:00,Signal Transduction,G02.111.087.800
21421048,2011-03-21T00:00:00,Signal Transduction,G02.149.115.800
21421048,2011-03-21T00:00:00,Signal Transduction,G04.299.880
21421048,2011-03-21T00:00:00,Wound Healing,G16.100.856.891
21422438,2011-03-21T00:00:00,Adenocarcinoma,C04.557.470.200.025
21422438,2011-03-21T00:00:00,Adult,M01.060.116
21422438,2011-03-21T00:00:00,Aged,M01.060.116.100
21422438,2011-03-21T00:00:00,Antineoplastic Combined Chemotherapy Protocols,E02.183.750.500
21422438,2011-03-21T00:00:00,Antineoplastic Combined Chemotherapy Protocols,E02.319.077.500
21422438,2011-03-21T00:00:00,Antineoplastic Combined Chemotherapy Protocols,E02.319.310.037
21422438,2011-03-21T00:00:00,Biological Markers,D23.101
21422438,2011-03-21T00:00:00,Colorectal Neoplasms,C04.588.274.476.411.307
21422438,2011-03-21T00:00:00,Colorectal Neoplasms,C06.301.371.411.307
21422438,2011-03-21T00:00:00,Colorectal Neoplasms,C06.405.249.411.307
21422438,2011-03-21T00:00:00,Colorectal Neoplasms,C06.405.469.158.356
21422438,2011-03-21T00:00:00,Colorectal Neoplasms,C06.405.469.491.307
21422438,2011-03-21T00:00:00,Colorectal Neoplasms,C06.405.469.860.180
21422438,2011-03-21T00:00:00,Disease Progression,C23.550.291.656
21422438,2011-03-21T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21422438,2011-03-21T00:00:00,Middle Aged,M01.060.116.630
21422438,2011-03-21T00:00:00,Neoplasm Staging,E01.370.550
21422438,2011-03-21T00:00:00,Risk Assessment,E05.318.740.600.800.715
21422438,2011-03-21T00:00:00,Risk Assessment,N04.452.871.715
21422438,2011-03-21T00:00:00,Risk Assessment,N05.715.360.750.625.700.690
21422438,2011-03-21T00:00:00,Risk Assessment,N06.850.505.715
21422438,2011-03-21T00:00:00,Risk Assessment,N06.850.520.830.600.800.715
21422438,2011-03-21T00:00:00,Risk Factors,E05.318.740.600.800.725
21422438,2011-03-21T00:00:00,Risk Factors,N05.715.350.200.700
21422438,2011-03-21T00:00:00,Risk Factors,N05.715.360.750.625.700.700
21422438,2011-03-21T00:00:00,Risk Factors,N06.850.490.625.750
21422438,2011-03-21T00:00:00,Risk Factors,N06.850.520.830.600.800.725
21422438,2011-03-21T00:00:00,Time Factors,G01.910.857
21422438,2011-03-21T00:00:00,Treatment Outcome,E01.789.800
21422438,2011-03-21T00:00:00,Treatment Outcome,N04.761.559.590.800
21422438,2011-03-21T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21422438,2011-03-21T00:00:00,United States,Z01.107.567.875
21422438,2011-03-21T00:00:00,Vitamin D,D04.808.812.768
21422438,2011-03-21T00:00:00,Vitamin D Deficiency,C18.654.521.500.133.770
21426904,2011-03-21T00:00:00,Bradykinin,D12.644.276.812.169
21426904,2011-03-21T00:00:00,Bradykinin,D12.644.400.090
21426904,2011-03-21T00:00:00,Bradykinin,D12.644.456.193
21426904,2011-03-21T00:00:00,Bradykinin,D12.776.467.812.169
21426904,2011-03-21T00:00:00,Bradykinin,D12.776.641.650.090
21426904,2011-03-21T00:00:00,Bradykinin,D23.469.050.375.110
21426904,2011-03-21T00:00:00,Bradykinin,D23.529.812.169
21426904,2011-03-21T00:00:00,Enzyme Inhibitors,D27.505.519.389
21426904,2011-03-21T00:00:00,Extracellular Signal-Regulated MAP Kinases,D08.811.913.696.620.682.700.567.342
21426904,2011-03-21T00:00:00,Extracellular Signal-Regulated MAP Kinases,D08.811.913.696.620.682.700.646.750.249
21426904,2011-03-21T00:00:00,Extracellular Signal-Regulated MAP Kinases,D12.644.360.450.169
21426904,2011-03-21T00:00:00,Extracellular Signal-Regulated MAP Kinases,D12.776.476.450.169
21426904,2011-03-21T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21426904,2011-03-21T00:00:00,Matrix Metalloproteinase 9,D08.811.277.656.300.480.205.360
21426904,2011-03-21T00:00:00,Matrix Metalloproteinase 9,D08.811.277.656.300.480.252.445
21426904,2011-03-21T00:00:00,Matrix Metalloproteinase 9,D08.811.277.656.300.480.525.700.350
21426904,2011-03-21T00:00:00,Matrix Metalloproteinase 9,D08.811.277.656.675.374.205.360
21426904,2011-03-21T00:00:00,Matrix Metalloproteinase 9,D08.811.277.656.675.374.252.445
21426904,2011-03-21T00:00:00,Matrix Metalloproteinase 9,D08.811.277.656.675.374.525.700.350
21426904,2011-03-21T00:00:00,Middle Aged,M01.060.116.630
21426904,2011-03-21T00:00:00,Mitogen-Activated Protein Kinase 1,D08.811.913.696.620.682.700.567.342.500
21426904,2011-03-21T00:00:00,Mitogen-Activated Protein Kinase 1,D08.811.913.696.620.682.700.646.750.249.500
21426904,2011-03-21T00:00:00,Mitogen-Activated Protein Kinase 1,D12.644.360.450.169.500
21426904,2011-03-21T00:00:00,Mitogen-Activated Protein Kinase 1,D12.776.476.450.169.500
21426904,2011-03-21T00:00:00,Mitogen-Activated Protein Kinase 3,D08.811.913.696.620.682.700.567.342.750
21426904,2011-03-21T00:00:00,Mitogen-Activated Protein Kinase 3,D08.811.913.696.620.682.700.646.750.249.750
21426904,2011-03-21T00:00:00,Mitogen-Activated Protein Kinase 3,D12.644.360.450.169.750
21426904,2011-03-21T00:00:00,Mitogen-Activated Protein Kinase 3,D12.776.476.450.169.750
21426904,2011-03-21T00:00:00,Phosphorylation,G02.111.087.677
21426904,2011-03-21T00:00:00,Phosphorylation,G02.149.115.677
21426904,2011-03-21T00:00:00,Phosphorylation,G02.149.465.700
21426904,2011-03-21T00:00:00,Phosphorylation,G02.607.750.700
21426904,2011-03-21T00:00:00,Phosphorylation,G03.495.790
21426904,2011-03-21T00:00:00,Protein Kinase C,D08.811.913.696.620.682.700.725
21426904,2011-03-21T00:00:00,"Receptor, Bradykinin B2",D12.776.543.750.100.080.500
21426904,2011-03-21T00:00:00,"Receptor, Bradykinin B2",D12.776.543.750.720.600.220.500
21426904,2011-03-21T00:00:00,"Receptor, Bradykinin B2",D12.776.543.750.750.555.220.500
21426904,2011-03-21T00:00:00,Trabecular Meshwork,A09.371.060.932
21429515,2011-03-22T00:00:00,Adolescent,M01.060.057
21429515,2011-03-22T00:00:00,Child,M01.060.406
21429515,2011-03-22T00:00:00,Disease Progression,C23.550.291.656
21429515,2011-03-22T00:00:00,Funnel Chest,C05.116.099.386
21429515,2011-03-22T00:00:00,Funnel Chest,C05.660.386
21429515,2011-03-22T00:00:00,Funnel Chest,C16.131.621.386
21429515,2011-03-22T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21429515,2011-03-22T00:00:00,"Radiography, Thoracic",E01.370.350.700.730
21429515,2011-03-22T00:00:00,Respiratory Insufficiency,C08.618.846
21429515,2011-03-22T00:00:00,"Tomography, X-Ray Computed",E01.370.350.350.810
21429515,2011-03-22T00:00:00,"Tomography, X-Ray Computed",E01.370.350.600.350.700.810
21429515,2011-03-22T00:00:00,"Tomography, X-Ray Computed",E01.370.350.700.700.810
21429515,2011-03-22T00:00:00,"Tomography, X-Ray Computed",E01.370.350.700.810.810
21429515,2011-03-22T00:00:00,"Tomography, X-Ray Computed",E01.370.350.825.810.810
21429515,2011-03-22T00:00:00,Young Adult,M01.060.116.815
21430073,2011-03-23T00:00:00,Adult,M01.060.116
21430073,2011-03-23T00:00:00,Aged,M01.060.116.100
21430073,2011-03-23T00:00:00,Case-Control Studies,E05.318.760.500.500
21430073,2011-03-23T00:00:00,Case-Control Studies,N05.715.360.775.175.200
21430073,2011-03-23T00:00:00,Case-Control Studies,N06.850.520.450.500.500
21430073,2011-03-23T00:00:00,Colon,A03.556.124.526.356
21430073,2011-03-23T00:00:00,Colon,A03.556.249.249.356
21430073,2011-03-23T00:00:00,Colonic Neoplasms,C04.588.274.476.411.307.180
21430073,2011-03-23T00:00:00,Colonic Neoplasms,C06.301.371.411.307.180
21430073,2011-03-23T00:00:00,Colonic Neoplasms,C06.405.249.411.307.180
21430073,2011-03-23T00:00:00,Colonic Neoplasms,C06.405.469.158.356.180
21430073,2011-03-23T00:00:00,Colonic Neoplasms,C06.405.469.491.307.180
21430073,2011-03-23T00:00:00,Double-Blind Method,E05.318.780.300
21430073,2011-03-23T00:00:00,Double-Blind Method,E05.581.500.300
21430073,2011-03-23T00:00:00,Double-Blind Method,N05.715.360.780.320
21430073,2011-03-23T00:00:00,Double-Blind Method,N06.850.520.445.300
21430073,2011-03-23T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21430073,2011-03-23T00:00:00,Middle Aged,M01.060.116.630
21430073,2011-03-23T00:00:00,Physicians,M01.526.485.810
21430073,2011-03-23T00:00:00,Physicians,N02.360.810
21430073,2011-03-23T00:00:00,Randomized Controlled Trials as Topic,E05.318.760.535.365.500
21430073,2011-03-23T00:00:00,Randomized Controlled Trials as Topic,E05.337.250.365.500
21430073,2011-03-23T00:00:00,Randomized Controlled Trials as Topic,N05.715.360.775.235.387.500
21430073,2011-03-23T00:00:00,Randomized Controlled Trials as Topic,N06.850.520.450.535.365.500
21430073,2011-03-23T00:00:00,Vitamin D,D04.808.812.768
21430170,2011-03-23T00:00:00,Animals,B01.050
21430170,2011-03-23T00:00:00,Carrier Proteins,D12.776.157
21430170,2011-03-23T00:00:00,"Chromatography, High Pressure Liquid",E05.196.181.400.300
21430170,2011-03-23T00:00:00,Eye Proteins,D12.776.306
21430170,2011-03-23T00:00:00,Light,G01.201.875.770.578
21430170,2011-03-23T00:00:00,Light,G01.590.540
21430170,2011-03-23T00:00:00,Retinal Cone Photoreceptor Cells,A08.663.650.850.625.670.100
21430170,2011-03-23T00:00:00,Retinal Cone Photoreceptor Cells,A08.663.650.915.937.670.100
21430170,2011-03-23T00:00:00,Retinal Cone Photoreceptor Cells,A08.800.950.937.670.100
21430170,2011-03-23T00:00:00,Retinal Cone Photoreceptor Cells,A09.371.729.831.625.670.100
21430170,2011-03-23T00:00:00,Retinal Cone Photoreceptor Cells,A11.671.650.850.625.670.100
21430170,2011-03-23T00:00:00,Retinal Cone Photoreceptor Cells,A11.671.650.915.937.670.100
21430170,2011-03-23T00:00:00,Retinoids,D02.455.326.271.665.202.495
21430170,2011-03-23T00:00:00,Retinoids,D02.455.426.392.368.367.379.249.700
21430170,2011-03-23T00:00:00,Retinoids,D02.455.849.131.495
21430170,2011-03-23T00:00:00,Retinoids,D23.767.261.700
21430170,2011-03-23T00:00:00,"Vision, Ocular",F02.830.816.964
21430170,2011-03-23T00:00:00,"Vision, Ocular",G02.111.087.800.480.900
21430170,2011-03-23T00:00:00,"Vision, Ocular",G02.149.115.800.480.900
21430170,2011-03-23T00:00:00,"Vision, Ocular",G04.299.880.480.900
21430170,2011-03-23T00:00:00,"Vision, Ocular",G11.561.600.810.964
21430170,2011-03-23T00:00:00,"Vision, Ocular",G14.640.816
21430649,2011-03-23T00:00:00,Action Potentials,G04.580.100
21430649,2011-03-23T00:00:00,Action Potentials,G07.265.750.100
21430649,2011-03-23T00:00:00,Action Potentials,G11.561.570.100
21430649,2011-03-23T00:00:00,Animals,B01.050
21430649,2011-03-23T00:00:00,"Animals, Newborn",B01.050.050.282
21430649,2011-03-23T00:00:00,Drug Interactions,G07.690.812.240
21430649,2011-03-23T00:00:00,Drug Interactions,G07.700.680.240
21430649,2011-03-23T00:00:00,Electric Stimulation,E05.723.402
21430649,2011-03-23T00:00:00,Neural Inhibition,G07.265.337.615
21430649,2011-03-23T00:00:00,Neural Inhibition,G07.700.240.615
21430649,2011-03-23T00:00:00,Neural Inhibition,G11.561.600.625
21430649,2011-03-23T00:00:00,Neurons,A08.663
21430649,2011-03-23T00:00:00,Neurons,A11.671
21430649,2011-03-23T00:00:00,Prefrontal Cortex,A08.186.211.730.885.287.500.270.700
21430649,2011-03-23T00:00:00,Probability,E05.318.740.600
21430649,2011-03-23T00:00:00,Probability,G17.680
21430649,2011-03-23T00:00:00,Probability,N05.715.360.750.625
21430649,2011-03-23T00:00:00,Probability,N06.850.520.830.600
21430649,2011-03-23T00:00:00,Pyrazoles,D03.383.129.539
21430649,2011-03-23T00:00:00,Rats,B01.050.150.900.649.865.635.505.700
21430649,2011-03-23T00:00:00,"Rats, Sprague-Dawley",B01.050.150.900.649.865.635.505.700.750
21430649,2011-03-23T00:00:00,Solvents,D27.720.844
21430649,2011-03-23T00:00:00,Synaptic Transmission,G02.111.087.800.850
21430649,2011-03-23T00:00:00,Synaptic Transmission,G02.149.115.800.850
21430649,2011-03-23T00:00:00,Synaptic Transmission,G04.299.880.850
21430649,2011-03-23T00:00:00,Synaptic Transmission,G07.265.337.900
21430649,2011-03-23T00:00:00,Synaptic Transmission,G07.700.240.900
21430649,2011-03-23T00:00:00,Synaptic Transmission,G11.561.600.835
21430649,2011-03-23T00:00:00,Toluene,D02.455.426.559.389.832
21430649,2011-03-23T00:00:00,gamma-Aminobutyric Acid,D02.241.081.160.050.350
21430649,2011-03-23T00:00:00,gamma-Aminobutyric Acid,D12.125.190.350
21431391,2011-03-23T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21431391,2011-03-23T00:00:00,Middle Aged,M01.060.116.630
21431391,2011-03-23T00:00:00,Pelvic Organ Prolapse,C23.300.842.500
21432927,2011-03-23T00:00:00,Animals,B01.050
21432927,2011-03-23T00:00:00,Bone Marrow Transplantation,E04.936.580.040
21432927,2011-03-23T00:00:00,Brain Injuries,C10.228.140.199
21432927,2011-03-23T00:00:00,Brain Injuries,C10.900.300.087
21432927,2011-03-23T00:00:00,Brain Injuries,C21.866.260.118
21432927,2011-03-23T00:00:00,Brain Injuries,C21.866.915.300.200
21432927,2011-03-23T00:00:00,Cell Movement,G04.299.283
21432927,2011-03-23T00:00:00,Cell Movement,G07.700.560.500.180
21432927,2011-03-23T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21432927,2011-03-23T00:00:00,Magnetic Resonance Imaging,E01.370.350.500
21432927,2011-03-23T00:00:00,Magnetic Resonance Imaging,E01.370.350.825.500
21432927,2011-03-23T00:00:00,Rats,B01.050.150.900.649.865.635.505.700
21432927,2011-03-23T00:00:00,Recovery of Function,G16.757
21432927,2011-03-23T00:00:00,Stromal Cells,A11.329.830
21470622,2011-03-23T00:00:00,Animals,B01.050
21470622,2011-03-23T00:00:00,Cell Movement,G04.299.283
21470622,2011-03-23T00:00:00,Cell Movement,G07.700.560.500.180
21470622,2011-03-23T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21470622,2011-03-23T00:00:00,Transcription Factors,D12.776.930
21362138,2011-03-25T00:00:00,"Antigens, CD44",D12.776.395.550.200.625.144
21362138,2011-03-25T00:00:00,"Antigens, CD44",D12.776.543.550.200.625.144
21362138,2011-03-25T00:00:00,"Antigens, CD44",D12.776.543.750.705.877.144
21362138,2011-03-25T00:00:00,"Antigens, CD44",D23.050.301.264.035.850.144
21362138,2011-03-25T00:00:00,"Antigens, CD44",D23.050.301.350.625.144
21362138,2011-03-25T00:00:00,"Antigens, CD44",D23.101.100.110.850.144
21362138,2011-03-25T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21362138,2011-03-25T00:00:00,Hyaluronic Acid,D09.698.373.475
21362138,2011-03-25T00:00:00,Neoplasms,C04
21362138,2011-03-25T00:00:00,Signal Transduction,G02.111.087.800
21362138,2011-03-25T00:00:00,Signal Transduction,G02.149.115.800
21362138,2011-03-25T00:00:00,Signal Transduction,G04.299.880
21435188,2011-03-25T00:00:00,Adolescent,M01.060.057
21435188,2011-03-25T00:00:00,Biological Markers,D23.101
21435188,2011-03-25T00:00:00,Child,M01.060.406
21435188,2011-03-25T00:00:00,Fontan Procedure,E04.035.410.295
21435188,2011-03-25T00:00:00,Fontan Procedure,E04.100.376.410.295
21435188,2011-03-25T00:00:00,Fontan Procedure,E04.928.220.370.295
21435188,2011-03-25T00:00:00,Health Status,I01.240.425
21435188,2011-03-25T00:00:00,Health Status,N01.224.425
21435188,2011-03-25T00:00:00,Health Status,N06.850.505.400.425
21435188,2011-03-25T00:00:00,"Heart Defects, Congenital",C14.240.400
21435188,2011-03-25T00:00:00,"Heart Defects, Congenital",C14.280.400
21435188,2011-03-25T00:00:00,"Heart Defects, Congenital",C16.131.240.400
21435188,2011-03-25T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21435188,2011-03-25T00:00:00,Time Factors,G01.910.857
21435188,2011-03-25T00:00:00,Treatment Outcome,E01.789.800
21435188,2011-03-25T00:00:00,Treatment Outcome,N04.761.559.590.800
21435188,2011-03-25T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21435188,2011-03-25T00:00:00,United States,Z01.107.567.875
21514060,2011-03-25T00:00:00,Adolescent,M01.060.057
21514060,2011-03-25T00:00:00,Adult,M01.060.116
21514060,2011-03-25T00:00:00,Child,M01.060.406
21514060,2011-03-25T00:00:00,Child Abuse,I01.198.240.856.350.250
21514060,2011-03-25T00:00:00,Child Abuse,I01.880.735.900.350.250
21514060,2011-03-25T00:00:00,Child Abuse,I01.880.787.293.292
21514060,2011-03-25T00:00:00,Crime Victims,M01.135
21514060,2011-03-25T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21514060,2011-03-25T00:00:00,Risk Factors,E05.318.740.600.800.725
21514060,2011-03-25T00:00:00,Risk Factors,N05.715.350.200.700
21514060,2011-03-25T00:00:00,Risk Factors,N05.715.360.750.625.700.700
21514060,2011-03-25T00:00:00,Risk Factors,N06.850.490.625.750
21514060,2011-03-25T00:00:00,Risk Factors,N06.850.520.830.600.800.725
21514060,2011-03-25T00:00:00,"Stress Disorders, Post-Traumatic",F03.080.931.500
21514060,2011-03-25T00:00:00,Substance-Related Disorders,C21.739
21514060,2011-03-25T00:00:00,Substance-Related Disorders,F03.900
21514060,2011-03-25T00:00:00,United States,Z01.107.567.875
21514060,2011-03-25T00:00:00,Violence,I01.198.240.856
21514060,2011-03-25T00:00:00,Violence,I01.880.735.900
21514060,2011-03-25T00:00:00,Young Adult,M01.060.116.815
21514061,2011-03-25T00:00:00,Adult,M01.060.116
21514061,2011-03-25T00:00:00,Age of Onset,N05.715.350.075.100
21514061,2011-03-25T00:00:00,Age of Onset,N06.850.490.250.100
21514061,2011-03-25T00:00:00,"Analgesics, Opioid",D27.505.696.663.850.014.520
21514061,2011-03-25T00:00:00,"Analgesics, Opioid",D27.505.954.427.040.325
21514061,2011-03-25T00:00:00,"Analgesics, Opioid",D27.505.954.427.210.049
21514061,2011-03-25T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21514061,2011-03-25T00:00:00,Opioid-Related Disorders,C21.739.675
21514061,2011-03-25T00:00:00,Opioid-Related Disorders,F03.900.675
21514061,2011-03-25T00:00:00,Prescription Drugs,D26.670
21514061,2011-03-25T00:00:00,Qualitative Research,H01.770.644.241.850
21514061,2011-03-25T00:00:00,Sex Factors,N05.715.350.675
21514061,2011-03-25T00:00:00,Sex Factors,N06.850.490.875
21514061,2011-03-25T00:00:00,Substance-Related Disorders,C21.739
21514061,2011-03-25T00:00:00,Substance-Related Disorders,F03.900
21514061,2011-03-25T00:00:00,Time Factors,G01.910.857
21514061,2011-03-25T00:00:00,Young Adult,M01.060.116.815
21442689,2011-03-27T00:00:00,Cooperative Behavior,F01.145.813.115
21442689,2011-03-27T00:00:00,Depressive Disorder,F03.600.300
21442689,2011-03-27T00:00:00,Forecasting,I01.320
21442689,2011-03-27T00:00:00,Health Services Accessibility,N04.590.374.350
21442689,2011-03-27T00:00:00,Health Services Accessibility,N05.300.430
21442689,2011-03-27T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21442689,2011-03-27T00:00:00,Interdisciplinary Communication,F01.145.209.381
21442689,2011-03-27T00:00:00,Interdisciplinary Communication,F01.829.401.205.249
21442689,2011-03-27T00:00:00,Interdisciplinary Communication,L01.143.474
21442689,2011-03-27T00:00:00,Mass Screening,E01.370.500
21442689,2011-03-27T00:00:00,Mass Screening,E05.318.308.250.580
21442689,2011-03-27T00:00:00,Mass Screening,N02.421.143.827.233.443
21442689,2011-03-27T00:00:00,Mass Screening,N02.421.726.233.443
21442689,2011-03-27T00:00:00,Mass Screening,N05.715.360.300.375.500
21442689,2011-03-27T00:00:00,Mass Screening,N06.850.520.308.250.580
21442689,2011-03-27T00:00:00,Mass Screening,N06.850.780.500
21442689,2011-03-27T00:00:00,Neoplasms,C04
21442689,2011-03-27T00:00:00,Primary Health Care,N04.590.233.727
21442689,2011-03-27T00:00:00,Referral and Consultation,N04.452.758.849
21442689,2011-03-27T00:00:00,Research,H01.770.644
21444699,2011-03-28T00:00:00,Adolescent,M01.060.057
21444699,2011-03-28T00:00:00,Adult,M01.060.116
21444699,2011-03-28T00:00:00,Anti-Bacterial Agents,D27.505.954.122.085
21444699,2011-03-28T00:00:00,Cystic Fibrosis,C06.689.202
21444699,2011-03-28T00:00:00,Cystic Fibrosis,C08.381.187
21444699,2011-03-28T00:00:00,Cystic Fibrosis,C16.320.190
21444699,2011-03-28T00:00:00,Cystic Fibrosis,C16.614.213
21444699,2011-03-28T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21444699,2011-03-28T00:00:00,Middle Aged,M01.060.116.630
21444699,2011-03-28T00:00:00,Ofloxacin,D03.438.810.835.322.500
21445957,2011-03-28T00:00:00,Adult,M01.060.116
21445957,2011-03-28T00:00:00,African Americans,M01.686.508.100.100
21445957,2011-03-28T00:00:00,African Americans,M01.686.754.100
21445957,2011-03-28T00:00:00,European Continental Ancestry Group,M01.686.508.400
21445957,2011-03-28T00:00:00,Genome-Wide Association Study,E05.318.416.249
21445957,2011-03-28T00:00:00,Genome-Wide Association Study,E05.318.780.392
21445957,2011-03-28T00:00:00,Genome-Wide Association Study,E05.393.385.500
21445957,2011-03-28T00:00:00,Genome-Wide Association Study,E05.393.522.500
21445957,2011-03-28T00:00:00,Genome-Wide Association Study,E05.393.760.640.500
21445957,2011-03-28T00:00:00,Genome-Wide Association Study,N06.850.520.445.392
21445957,2011-03-28T00:00:00,Genome-Wide Association Study,N06.850.520.470.500
21445957,2011-03-28T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21445957,2011-03-28T00:00:00,Linkage Disequilibrium,G05.540.500
21445957,2011-03-28T00:00:00,Middle Aged,M01.060.116.630
21445957,2011-03-28T00:00:00,"Polymorphism, Single Nucleotide",G05.365.795.598
21445957,2011-03-28T00:00:00,"Receptors, Nicotinic",D12.776.543.750.720.360.550
21445957,2011-03-28T00:00:00,Smoking,F01.145.466.753
21445957,2011-03-28T00:00:00,Tobacco Use Disorder,C21.739.912
21445957,2011-03-28T00:00:00,Tobacco Use Disorder,F03.900.912
21446014,2011-03-28T00:00:00,Cell Cycle,G04.299.134
21446014,2011-03-28T00:00:00,Cell Movement,G04.299.283
21446014,2011-03-28T00:00:00,Cell Movement,G07.700.560.500.180
21446014,2011-03-28T00:00:00,Cell Proliferation,G04.299.233.750
21446014,2011-03-28T00:00:00,Cell Proliferation,G07.700.320.249.410.750
21446014,2011-03-28T00:00:00,Disease Progression,C23.550.291.656
21446014,2011-03-28T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21446014,2011-03-28T00:00:00,MicroRNAs,D13.150.650.319
21446014,2011-03-28T00:00:00,MicroRNAs,D13.444.735.150.319
21446014,2011-03-28T00:00:00,MicroRNAs,D13.444.735.790.099
21446014,2011-03-28T00:00:00,Neoplasm Invasiveness,C04.697.645
21446014,2011-03-28T00:00:00,Neoplasm Invasiveness,C23.550.727.645
21446014,2011-03-28T00:00:00,Prostatic Neoplasms,C04.588.945.440.770
21446014,2011-03-28T00:00:00,Prostatic Neoplasms,C12.294.260.750
21446014,2011-03-28T00:00:00,Prostatic Neoplasms,C12.294.565.625
21446014,2011-03-28T00:00:00,Prostatic Neoplasms,C12.758.409.750
21446014,2011-03-28T00:00:00,Proto-Oncogene Proteins c-ets,D12.776.260.665
21446014,2011-03-28T00:00:00,Proto-Oncogene Proteins c-ets,D12.776.624.664.700.175
21446014,2011-03-28T00:00:00,Proto-Oncogene Proteins c-ets,D12.776.930.635
21454620,2011-03-28T00:00:00,Glioblastoma,C04.557.465.625.600.380.080.335
21454620,2011-03-28T00:00:00,Glioblastoma,C04.557.470.670.380.080.335
21454620,2011-03-28T00:00:00,Glioblastoma,C04.557.580.625.600.380.080.335
21454620,2011-03-28T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21454620,2011-03-28T00:00:00,Nuclear Proteins,D12.776.660
21454620,2011-03-28T00:00:00,Phosphoprotein Phosphatases,D08.811.277.352.650.625
21454620,2011-03-28T00:00:00,Proto-Oncogene Proteins c-akt,D08.811.913.696.620.682.700.755
21454620,2011-03-28T00:00:00,Proto-Oncogene Proteins c-akt,D12.776.476.565
21454620,2011-03-28T00:00:00,Proto-Oncogene Proteins c-akt,D12.776.624.664.700.168
21454620,2011-03-28T00:00:00,Ubiquitin-Protein Ligases,D08.811.464.938.750
21454620,2011-03-28T00:00:00,beta Catenin,D12.776.091.249
21454620,2011-03-28T00:00:00,beta Catenin,D12.776.220.145.500
21454620,2011-03-28T00:00:00,beta Catenin,D12.776.930.130
21498280,2011-03-28T00:00:00,Contrast Media,D27.720.259
21498280,2011-03-28T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21498280,2011-03-28T00:00:00,Liver Diseases,C06.552
21498280,2011-03-28T00:00:00,Radiation Dosage,E05.799.513
21498280,2011-03-28T00:00:00,Radiation Dosage,G01.201.875.740
21498280,2011-03-28T00:00:00,Radiation Dosage,N06.850.810.250
21498280,2011-03-28T00:00:00,Radiographic Image Enhancement,E01.370.350.600.350.700
21498280,2011-03-28T00:00:00,Radiographic Image Enhancement,E01.370.350.700.700
21498280,2011-03-28T00:00:00,Radiographic Image Enhancement,L01.224.308.380.600
21498280,2011-03-28T00:00:00,"Radiography, Abdominal",E01.370.350.700.715
21498280,2011-03-28T00:00:00,"Tomography, X-Ray Computed",E01.370.350.350.810
21498280,2011-03-28T00:00:00,"Tomography, X-Ray Computed",E01.370.350.600.350.700.810
21498280,2011-03-28T00:00:00,"Tomography, X-Ray Computed",E01.370.350.700.700.810
21498280,2011-03-28T00:00:00,"Tomography, X-Ray Computed",E01.370.350.700.810.810
21498280,2011-03-28T00:00:00,"Tomography, X-Ray Computed",E01.370.350.825.810.810
21990466,2011-03-28T00:00:00,Animals,B01.050
21990466,2011-03-28T00:00:00,Balloon Occlusion,E02.148.106
21990466,2011-03-28T00:00:00,Balloon Occlusion,E02.520.179
21990466,2011-03-28T00:00:00,Swine,B01.050.150.900.649.077.880
21447706,2011-03-29T00:00:00,"Antigens, CD",D23.050.301.264.035
21447706,2011-03-29T00:00:00,"Antigens, CD",D23.101.100.110
21447706,2011-03-29T00:00:00,"Antigens, CD29",D12.776.543.750.705.408.200.500
21447706,2011-03-29T00:00:00,"Antigens, CD29",D23.050.301.264.035.129
21447706,2011-03-29T00:00:00,"Antigens, CD29",D23.050.301.264.129
21447706,2011-03-29T00:00:00,"Antigens, CD29",D23.101.100.110.129
21447706,2011-03-29T00:00:00,"Antigens, CD29",D23.101.100.129
21447706,2011-03-29T00:00:00,Cell Adhesion Molecules,D12.776.395.550.200
21447706,2011-03-29T00:00:00,Cell Adhesion Molecules,D12.776.543.550.200
21447706,2011-03-29T00:00:00,Cell Adhesion Molecules,D23.050.301.350
21447706,2011-03-29T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21447706,2011-03-29T00:00:00,Neoplasm Proteins,D12.776.624
21447706,2011-03-29T00:00:00,Prostatic Neoplasms,C04.588.945.440.770
21447706,2011-03-29T00:00:00,Prostatic Neoplasms,C12.294.260.750
21447706,2011-03-29T00:00:00,Prostatic Neoplasms,C12.294.565.625
21447706,2011-03-29T00:00:00,Prostatic Neoplasms,C12.758.409.750
21447706,2011-03-29T00:00:00,Tandem Mass Spectrometry,E05.196.566.880
21447706,2011-03-29T00:00:00,"Tumor Markers, Biological",D23.101.840
21447728,2011-03-29T00:00:00,Adult,M01.060.116
21447728,2011-03-29T00:00:00,Aged,M01.060.116.100
21447728,2011-03-29T00:00:00,Antineoplastic Combined Chemotherapy Protocols,E02.183.750.500
21447728,2011-03-29T00:00:00,Antineoplastic Combined Chemotherapy Protocols,E02.319.077.500
21447728,2011-03-29T00:00:00,Antineoplastic Combined Chemotherapy Protocols,E02.319.310.037
21447728,2011-03-29T00:00:00,"Drug Resistance, Neoplasm",G07.690.320.395
21447728,2011-03-29T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21447728,2011-03-29T00:00:00,Middle Aged,M01.060.116.630
21447728,2011-03-29T00:00:00,Piperidines,D03.383.621
21450328,2011-03-29T00:00:00,Adolescent,M01.060.057
21450328,2011-03-29T00:00:00,Adult,M01.060.116
21450328,2011-03-29T00:00:00,Birth Weight,C23.888.144.186
21450328,2011-03-29T00:00:00,Birth Weight,E01.370.600.115.100.160.120.186
21450328,2011-03-29T00:00:00,Birth Weight,E05.041.124.160.750.149
21450328,2011-03-29T00:00:00,Birth Weight,G07.100.100.160.120.186
21450328,2011-03-29T00:00:00,Birth Weight,G07.700.320.249.314.120.186
21450328,2011-03-29T00:00:00,Environmental Monitoring,N06.850.460.350.080
21450328,2011-03-29T00:00:00,Environmental Monitoring,N06.850.780.375
21450328,2011-03-29T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21450328,2011-03-29T00:00:00,Pregnancy,G08.686.785.760.769
21450328,2011-03-29T00:00:00,Young Adult,M01.060.116.815
21454132,2011-03-30T00:00:00,Amnesia,C10.597.606.525.100
21454132,2011-03-30T00:00:00,Amnesia,C23.888.592.604.529.100
21454132,2011-03-30T00:00:00,Amnesia,F01.700.625.100
21454132,2011-03-30T00:00:00,Amnesia,F03.087.200
21454132,2011-03-30T00:00:00,Epilepsy,C10.228.140.490
21454132,2011-03-30T00:00:00,Hippocampus,A08.186.211.464.405
21454132,2011-03-30T00:00:00,Hippocampus,A08.186.211.730.885.287.500.345
21454132,2011-03-30T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21454132,2011-03-30T00:00:00,Magnetic Resonance Imaging,E01.370.350.500
21454132,2011-03-30T00:00:00,Magnetic Resonance Imaging,E01.370.350.825.500
21454132,2011-03-30T00:00:00,Middle Aged,M01.060.116.630
21454132,2011-03-30T00:00:00,Neurosurgery,H02.403.810.425
21549292,2011-03-30T00:00:00,Adult,M01.060.116
21549292,2011-03-30T00:00:00,Aged,M01.060.116.100
21549292,2011-03-30T00:00:00,Blood Pressure,E01.370.600.875.249
21549292,2011-03-30T00:00:00,Blood Pressure,G09.330.380.076
21549292,2011-03-30T00:00:00,"Blood Pressure Monitoring, Ambulatory",E01.370.370.140.100
21549292,2011-03-30T00:00:00,"Blood Pressure Monitoring, Ambulatory",E01.370.520.500.100
21549292,2011-03-30T00:00:00,Heart Failure,C14.280.434
21549292,2011-03-30T00:00:00,Hemodynamics,G09.330.190.400
21549292,2011-03-30T00:00:00,Hemodynamics,G09.330.380
21549292,2011-03-30T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21549292,2011-03-30T00:00:00,Middle Aged,M01.060.116.630
21549292,2011-03-30T00:00:00,"Monitoring, Physiologic",E01.370.520
21453914,2011-03-31T00:00:00,Adolescent,M01.060.057
21453914,2011-03-31T00:00:00,Adult,M01.060.116
21453914,2011-03-31T00:00:00,Aged,M01.060.116.100
21453914,2011-03-31T00:00:00,Air Pollutants,D27.888.284.101
21453914,2011-03-31T00:00:00,Air Pollution,N06.850.460.100
21453914,2011-03-31T00:00:00,Environmental Exposure,N06.850.460.350
21453914,2011-03-31T00:00:00,Gasoline,D20.345.630.540
21453914,2011-03-31T00:00:00,Gasoline,N06.230.132.258.630.540
21453914,2011-03-31T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21453914,2011-03-31T00:00:00,Leukemia,C04.557.337
21453914,2011-03-31T00:00:00,Middle Aged,M01.060.116.630
21453914,2011-03-31T00:00:00,Risk Assessment,E05.318.740.600.800.715
21453914,2011-03-31T00:00:00,Risk Assessment,N04.452.871.715
21453914,2011-03-31T00:00:00,Risk Assessment,N05.715.360.750.625.700.690
21453914,2011-03-31T00:00:00,Risk Assessment,N06.850.505.715
21453914,2011-03-31T00:00:00,Risk Assessment,N06.850.520.830.600.800.715
21453914,2011-03-31T00:00:00,Young Adult,M01.060.116.815
21454917,2011-03-31T00:00:00,Adult,M01.060.116
21454917,2011-03-31T00:00:00,Alcohol Drinking,F01.145.317.269
21454917,2011-03-31T00:00:00,Alcoholism,C21.739.100.250
21454917,2011-03-31T00:00:00,Alcoholism,F03.900.100.350
21454917,2011-03-31T00:00:00,Amines,D02.092
21454917,2011-03-31T00:00:00,Cyclohexanecarboxylic Acids,D02.241.223.268
21454917,2011-03-31T00:00:00,Cyclohexanecarboxylic Acids,D02.455.426.392.368.367.218
21454917,2011-03-31T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21454917,2011-03-31T00:00:00,Middle Aged,M01.060.116.630
21454917,2011-03-31T00:00:00,Naltrexone,D03.132.577.249.706.550
21454917,2011-03-31T00:00:00,Naltrexone,D03.549.686.750.550
21454917,2011-03-31T00:00:00,Naltrexone,D03.605.497.750.550
21454917,2011-03-31T00:00:00,Naltrexone,D04.615.723.795.706.550
21454917,2011-03-31T00:00:00,Narcotic Antagonists,D27.505.696.543
21454917,2011-03-31T00:00:00,Narcotic Antagonists,D27.505.696.663.850.512
21454917,2011-03-31T00:00:00,Narcotic Antagonists,D27.505.954.427.550
21454917,2011-03-31T00:00:00,Substance Withdrawal Syndrome,C21.739.835
21454917,2011-03-31T00:00:00,Substance Withdrawal Syndrome,F03.900.825
21454917,2011-03-31T00:00:00,Treatment Outcome,E01.789.800
21454917,2011-03-31T00:00:00,Treatment Outcome,N04.761.559.590.800
21454917,2011-03-31T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21454917,2011-03-31T00:00:00,gamma-Aminobutyric Acid,D02.241.081.160.050.350
21454917,2011-03-31T00:00:00,gamma-Aminobutyric Acid,D12.125.190.350
21457998,2011-03-31T00:00:00,Adolescent,M01.060.057
21457998,2011-03-31T00:00:00,Adult,M01.060.116
21457998,2011-03-31T00:00:00,Aged,M01.060.116.100
21457998,2011-03-31T00:00:00,Cardiac Surgical Procedures,E04.100.376
21457998,2011-03-31T00:00:00,Cardiac Surgical Procedures,E04.928.220
21457998,2011-03-31T00:00:00,Cost-Benefit Analysis,N03.219.151.125
21457998,2011-03-31T00:00:00,Factor VIIa,D08.811.277.656.300.760.300
21457998,2011-03-31T00:00:00,Factor VIIa,D08.811.277.656.959.350.300
21457998,2011-03-31T00:00:00,Factor VIIa,D12.776.124.125.325.300
21457998,2011-03-31T00:00:00,Factor VIIa,D23.119.325.300
21457998,2011-03-31T00:00:00,Hemostatic Techniques,E02.520
21457998,2011-03-31T00:00:00,Hospital Costs,N03.219.151.400.687
21457998,2011-03-31T00:00:00,Hospital Costs,N03.219.262.500
21457998,2011-03-31T00:00:00,Hospital Costs,N05.300.375.500
21457998,2011-03-31T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21457998,2011-03-31T00:00:00,Intensive Care,E02.760.190.400
21457998,2011-03-31T00:00:00,Intensive Care,N02.421.585.190.400
21457998,2011-03-31T00:00:00,Middle Aged,M01.060.116.630
21457998,2011-03-31T00:00:00,Patient Selection,E05.581.500.653
21457998,2011-03-31T00:00:00,Patient Selection,N04.590.731
21457998,2011-03-31T00:00:00,Postoperative Care,E02.760.722.700
21457998,2011-03-31T00:00:00,Postoperative Care,E04.624
21457998,2011-03-31T00:00:00,Postoperative Care,N02.421.585.722.700
21457998,2011-03-31T00:00:00,Recombinant Proteins,D12.776.828
21457998,2011-03-31T00:00:00,Reoperation,E04.690
21457998,2011-03-31T00:00:00,Risk Assessment,E05.318.740.600.800.715
21457998,2011-03-31T00:00:00,Risk Assessment,N04.452.871.715
21457998,2011-03-31T00:00:00,Risk Assessment,N05.715.360.750.625.700.690
21457998,2011-03-31T00:00:00,Risk Assessment,N06.850.505.715
21457998,2011-03-31T00:00:00,Risk Assessment,N06.850.520.830.600.800.715
21457998,2011-03-31T00:00:00,Risk Factors,E05.318.740.600.800.725
21457998,2011-03-31T00:00:00,Risk Factors,N05.715.350.200.700
21457998,2011-03-31T00:00:00,Risk Factors,N05.715.360.750.625.700.700
21457998,2011-03-31T00:00:00,Risk Factors,N06.850.490.625.750
21457998,2011-03-31T00:00:00,Risk Factors,N06.850.520.830.600.800.725
21457998,2011-03-31T00:00:00,South Carolina,Z01.107.567.875.075.662
21457998,2011-03-31T00:00:00,South Carolina,Z01.107.567.875.750.700
21457998,2011-03-31T00:00:00,Treatment Outcome,E01.789.800
21457998,2011-03-31T00:00:00,Treatment Outcome,N04.761.559.590.800
21457998,2011-03-31T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21457998,2011-03-31T00:00:00,Young Adult,M01.060.116.815
19909397,2011-04-01T00:00:00,Hemorrhage,C23.550.414
19909397,2011-04-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
19909397,2011-04-01T00:00:00,"Imaging, Three-Dimensional",E01.370.350.400
19909397,2011-04-01T00:00:00,"Imaging, Three-Dimensional",L01.224.308.410
19909397,2011-04-01T00:00:00,Intracranial Arteriosclerosis,C10.228.140.300.510.800
19909397,2011-04-01T00:00:00,Intracranial Arteriosclerosis,C14.907.137.126.372
19909397,2011-04-01T00:00:00,Intracranial Arteriosclerosis,C14.907.253.560.350
19909397,2011-04-01T00:00:00,Magnetic Resonance Angiography,E01.370.350.500.500
19909397,2011-04-01T00:00:00,Magnetic Resonance Angiography,E01.370.350.825.500.500
19909397,2011-04-01T00:00:00,Magnetic Resonance Angiography,E01.370.370.050.500
19909397,2011-04-01T00:00:00,Middle Aged,M01.060.116.630
19909397,2011-04-01T00:00:00,Risk Assessment,E05.318.740.600.800.715
19909397,2011-04-01T00:00:00,Risk Assessment,N04.452.871.715
19909397,2011-04-01T00:00:00,Risk Assessment,N05.715.360.750.625.700.690
19909397,2011-04-01T00:00:00,Risk Assessment,N06.850.505.715
19909397,2011-04-01T00:00:00,Risk Assessment,N06.850.520.830.600.800.715
20637010,2011-04-01T00:00:00,Brain Injuries,C10.228.140.199
20637010,2011-04-01T00:00:00,Brain Injuries,C10.900.300.087
20637010,2011-04-01T00:00:00,Brain Injuries,C21.866.260.118
20637010,2011-04-01T00:00:00,Brain Injuries,C21.866.915.300.200
20637010,2011-04-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
20820940,2011-04-01T00:00:00,Adult,M01.060.116
20820940,2011-04-01T00:00:00,Gastric Bypass,E02.065.062.249
20820940,2011-04-01T00:00:00,Gastric Bypass,E04.035.398.385
20820940,2011-04-01T00:00:00,Gastric Bypass,E04.062.249
20820940,2011-04-01T00:00:00,Gastric Bypass,E04.210.457.430
20820940,2011-04-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
20820940,2011-04-01T00:00:00,Middle Aged,M01.060.116.630
20820940,2011-04-01T00:00:00,"Obesity, Morbid",C18.654.726.500.700
20820940,2011-04-01T00:00:00,"Obesity, Morbid",C23.888.144.699.500.500
20820940,2011-04-01T00:00:00,"Obesity, Morbid",E01.370.600.115.100.160.120.699.500.500
20820940,2011-04-01T00:00:00,"Obesity, Morbid",G07.100.100.160.120.699.500.500
20820940,2011-04-01T00:00:00,Physical Fitness,I03.621
20820940,2011-04-01T00:00:00,Physical Fitness,N01.400.545
20820940,2011-04-01T00:00:00,Quality of Life,I01.800
20820940,2011-04-01T00:00:00,Quality of Life,K01.752.400.750
20820940,2011-04-01T00:00:00,Questionnaires,E05.318.308.750
20820940,2011-04-01T00:00:00,Questionnaires,L01.280.800
20820940,2011-04-01T00:00:00,Questionnaires,N05.715.360.300.695
20820940,2011-04-01T00:00:00,Questionnaires,N06.850.520.308.750
21061038,2011-04-01T00:00:00,Animals,B01.050
21061038,2011-04-01T00:00:00,Cell Proliferation,G04.299.233.750
21061038,2011-04-01T00:00:00,Cell Proliferation,G07.700.320.249.410.750
21061038,2011-04-01T00:00:00,Cochlear Nerve,A08.800.800.120.910.120
21061038,2011-04-01T00:00:00,"Disease Models, Animal",C22.232
21061038,2011-04-01T00:00:00,"Disease Models, Animal",E05.598.500
21061038,2011-04-01T00:00:00,"Disease Models, Animal",E05.599.395.080
21061038,2011-04-01T00:00:00,"Ear, Inner",A09.246.631
21061038,2011-04-01T00:00:00,Enzyme Inhibitors,D27.505.519.389
21061038,2011-04-01T00:00:00,"Mice, Inbred CBA",B01.050.050.157.520.440
21061038,2011-04-01T00:00:00,"Mice, Inbred CBA",B01.050.050.199.520.520.440
21061038,2011-04-01T00:00:00,"Mice, Inbred CBA",B01.050.150.900.649.865.635.505.500.400.440
21061038,2011-04-01T00:00:00,Neuroglia,A08.637
21061038,2011-04-01T00:00:00,Neuroglia,A11.650
21061038,2011-04-01T00:00:00,SOXB1 Transcription Factors,D12.776.260.719.100
21061038,2011-04-01T00:00:00,SOXB1 Transcription Factors,D12.776.660.235.400.750.100
21061038,2011-04-01T00:00:00,SOXB1 Transcription Factors,D12.776.664.235.400.750.100
21061038,2011-04-01T00:00:00,SOXB1 Transcription Factors,D12.776.930.823.100
21061038,2011-04-01T00:00:00,Spiral Ganglion,A08.340.390.800
21061038,2011-04-01T00:00:00,Spiral Ganglion,A08.800.350.800
21061038,2011-04-01T00:00:00,Spiral Ganglion,A08.800.800.120.910.120.800
21061038,2011-04-01T00:00:00,Spiral Ganglion,A09.246.631.246.900
21061074,2011-04-01T00:00:00,Aged,M01.060.116.100
21061074,2011-04-01T00:00:00,Breast Neoplasms,C04.588.180
21061074,2011-04-01T00:00:00,Breast Neoplasms,C17.800.090.500
21061074,2011-04-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21061074,2011-04-01T00:00:00,Middle Aged,M01.060.116.630
21061074,2011-04-01T00:00:00,"Neoplasm Recurrence, Local",C04.697.655
21061074,2011-04-01T00:00:00,"Neoplasm Recurrence, Local",C23.550.727.655
21061074,2011-04-01T00:00:00,Neoplasm Staging,E01.370.550
21061074,2011-04-01T00:00:00,Radiotherapy Dosage,E02.815.639
21061074,2011-04-01T00:00:00,"Radiotherapy, Adjuvant",E02.186.775
21061074,2011-04-01T00:00:00,"Radiotherapy, Adjuvant",E02.815.600
21061074,2011-04-01T00:00:00,Treatment Outcome,E01.789.800
21061074,2011-04-01T00:00:00,Treatment Outcome,N04.761.559.590.800
21061074,2011-04-01T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21153930,2011-04-01T00:00:00,Brain Injuries,C10.228.140.199
21153930,2011-04-01T00:00:00,Brain Injuries,C10.900.300.087
21153930,2011-04-01T00:00:00,Brain Injuries,C21.866.260.118
21153930,2011-04-01T00:00:00,Brain Injuries,C21.866.915.300.200
21153930,2011-04-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21153930,2011-04-01T00:00:00,Intensive Care,E02.760.190.400
21153930,2011-04-01T00:00:00,Intensive Care,N02.421.585.190.400
21153930,2011-04-01T00:00:00,Intracranial Hypertension,C10.228.140.631
21153930,2011-04-01T00:00:00,Intracranial Pressure,G11.561.170.505
21153930,2011-04-01T00:00:00,"Medical Staff, Hospital",M01.526.485.630.490
21153930,2011-04-01T00:00:00,"Medical Staff, Hospital",M01.526.485.740.422
21153930,2011-04-01T00:00:00,"Medical Staff, Hospital",N02.360.630.490
21153930,2011-04-01T00:00:00,"Medical Staff, Hospital",N02.360.740.422
21153930,2011-04-01T00:00:00,"Saline Solution, Hypertonic",D26.776.314.890
21301325,2011-04-01T00:00:00,Animals,B01.050
21301325,2011-04-01T00:00:00,Attention,F02.830.104.214
21301325,2011-04-01T00:00:00,Columbidae,B01.050.150.900.248.165.150
21301325,2011-04-01T00:00:00,Dextroamphetamine,D02.092.471.683.152.110.200
21301325,2011-04-01T00:00:00,Discrimination Learning,F02.463.425.280
21301325,2011-04-01T00:00:00,Dopamine Uptake Inhibitors,D27.505.519.625.150.800
21301325,2011-04-01T00:00:00,Dopamine Uptake Inhibitors,D27.505.519.625.600.220
21301325,2011-04-01T00:00:00,Dopamine Uptake Inhibitors,D27.505.696.577.150.800
21301325,2011-04-01T00:00:00,Dopamine Uptake Inhibitors,D27.505.696.577.600.220
21301325,2011-04-01T00:00:00,Nicotine,D03.132.760.570
21301325,2011-04-01T00:00:00,Nicotine,D03.383.725.518
21301325,2011-04-01T00:00:00,Nicotinic Agonists,D27.505.519.625.120.140.700
21301325,2011-04-01T00:00:00,Nicotinic Agonists,D27.505.696.577.120.140.700
21301325,2011-04-01T00:00:00,Time Factors,G01.910.857
21366630,2011-04-01T00:00:00,Adult,M01.060.116
21366630,2011-04-01T00:00:00,Asthma,C08.127.108
21366630,2011-04-01T00:00:00,Asthma,C08.381.495.108
21366630,2011-04-01T00:00:00,Asthma,C08.674.095
21366630,2011-04-01T00:00:00,Asthma,C20.543.480.680.095
21366630,2011-04-01T00:00:00,Child,M01.060.406
21366630,2011-04-01T00:00:00,Cough,C08.618.248
21366630,2011-04-01T00:00:00,Cough,C23.888.852.293
21366630,2011-04-01T00:00:00,Gastroesophageal Reflux,C06.405.117.119.500.484
21366630,2011-04-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21366630,2011-04-01T00:00:00,Laryngeal Diseases,C08.360
21366630,2011-04-01T00:00:00,Laryngeal Diseases,C09.400
21373949,2011-04-01T00:00:00,Animals,B01.050
21373949,2011-04-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21373949,2011-04-01T00:00:00,Neuroprotective Agents,D27.505.696.706.548
21373949,2011-04-01T00:00:00,Neuroprotective Agents,D27.505.954.427.575
21373949,2011-04-01T00:00:00,Spinal Cord Injuries,C10.228.854.770
21373949,2011-04-01T00:00:00,Spinal Cord Injuries,C10.900.850
21373949,2011-04-01T00:00:00,Spinal Cord Injuries,C21.866.819
21399515,2011-04-01T00:00:00,Algorithms,G17.035
21399515,2011-04-01T00:00:00,Algorithms,L01.224.050
21399515,2011-04-01T00:00:00,Artifacts,E05.047
21399515,2011-04-01T00:00:00,Brain,A08.186.211
21399515,2011-04-01T00:00:00,"Diagnosis, Computer-Assisted",E01.158
21399515,2011-04-01T00:00:00,"Diagnosis, Computer-Assisted",L01.700.508.100.158
21399515,2011-04-01T00:00:00,Electroencephalography,E01.370.376.300
21399515,2011-04-01T00:00:00,Electroencephalography,E01.370.405.245
21399515,2011-04-01T00:00:00,Epilepsy,C10.228.140.490
21399515,2011-04-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21399515,2011-04-01T00:00:00,Internet,L01.224.230.110.500
21399515,2011-04-01T00:00:00,"Signal Processing, Computer-Assisted",L01.224.800
21399515,2011-04-01T00:00:00,Software,L01.224.900
21399515,2011-04-01T00:00:00,Time Factors,G01.910.857
21399515,2011-04-01T00:00:00,User-Computer Interface,L01.224.900.910
21406365,2011-04-01T00:00:00,Animals,B01.050
21406365,2011-04-01T00:00:00,Body Weight,C23.888.144
21406365,2011-04-01T00:00:00,Body Weight,E01.370.600.115.100.160.120
21406365,2011-04-01T00:00:00,Body Weight,E05.041.124.160.750
21406365,2011-04-01T00:00:00,Body Weight,G07.100.100.160.120
21406365,2011-04-01T00:00:00,Body Weight,G07.700.320.249.314.120
21406365,2011-04-01T00:00:00,Chickens,B01.050.150.900.248.350.150
21406365,2011-04-01T00:00:00,Chickens,B01.050.150.900.248.617.192
21406365,2011-04-01T00:00:00,Dietary Fats,D10.212.302
21406365,2011-04-01T00:00:00,Dietary Fats,J02.500.375
21406365,2011-04-01T00:00:00,Mycoplasma Infections,C01.252.400.610.610
21406365,2011-04-01T00:00:00,Mycoplasma gallisepticum,B03.440.560.580.553.553.345
21411800,2011-04-01T00:00:00,Adult,M01.060.116
21411800,2011-04-01T00:00:00,Aged,M01.060.116.100
21411800,2011-04-01T00:00:00,Benzazepines,D03.438.079
21411800,2011-04-01T00:00:00,"Chemistry, Pharmaceutical",H01.158.703.007
21411800,2011-04-01T00:00:00,"Chemistry, Pharmaceutical",H01.181.466
21411800,2011-04-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21411800,2011-04-01T00:00:00,Hyponatremia,C18.452.950.620
21411800,2011-04-01T00:00:00,"Infusions, Intravenous",E02.319.267.510.590
21411800,2011-04-01T00:00:00,Middle Aged,M01.060.116.630
21411800,2011-04-01T00:00:00,Treatment Outcome,E01.789.800
21411800,2011-04-01T00:00:00,Treatment Outcome,N04.761.559.590.800
21411800,2011-04-01T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21411800,2011-04-01T00:00:00,Young Adult,M01.060.116.815
21415828,2011-04-01T00:00:00,African Americans,M01.686.508.100.100
21415828,2011-04-01T00:00:00,African Americans,M01.686.754.100
21415828,2011-04-01T00:00:00,Awareness,F02.463.188.150
21415828,2011-04-01T00:00:00,Cultural Characteristics,I01.076.201.450.324
21415828,2011-04-01T00:00:00,Cultural Characteristics,I01.880.143.329
21415828,2011-04-01T00:00:00,Fear,F01.470.361
21415828,2011-04-01T00:00:00,"Health Knowledge, Attitudes, Practice",F01.100.150.500
21415828,2011-04-01T00:00:00,"Health Knowledge, Attitudes, Practice",N05.300.150.410
21415828,2011-04-01T00:00:00,Health Services Accessibility,N04.590.374.350
21415828,2011-04-01T00:00:00,Health Services Accessibility,N05.300.430
21415828,2011-04-01T00:00:00,Healthcare Disparities,N04.590.374.380
21415828,2011-04-01T00:00:00,Healthcare Disparities,N05.300.493
21415828,2011-04-01T00:00:00,Hispanic Americans,M01.686.754.441
21415828,2011-04-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21415828,2011-04-01T00:00:00,Minority Groups,I01.880.371
21415828,2011-04-01T00:00:00,Patient Education as Topic,I02.233.332.500
21415828,2011-04-01T00:00:00,Patient Education as Topic,N02.421.143.827.407.680
21415828,2011-04-01T00:00:00,Patient Education as Topic,N02.421.726.407.680
21415828,2011-04-01T00:00:00,Tissue Donors,M01.898
21415828,2011-04-01T00:00:00,Tissue and Organ Procurement,N02.421.911
21435288,2011-04-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21435288,2011-04-01T00:00:00,Infant,M01.060.703
21435288,2011-04-01T00:00:00,Infant Nutritional Physiological Phenomena,G07.610.220.500
21435288,2011-04-01T00:00:00,"Infant, Newborn",M01.060.703.520
21435288,2011-04-01T00:00:00,Lactation,G08.686.702.500
21435288,2011-04-01T00:00:00,Lactation,G08.686.785.420
21435288,2011-04-01T00:00:00,"Milk, Human",A12.200.467
21435288,2011-04-01T00:00:00,"Milk, Human",J02.200.700.500
21435288,2011-04-01T00:00:00,"Milk, Human",J02.500.350.525.500
21435288,2011-04-01T00:00:00,Vitamin D,D04.808.812.768
21435428,2011-04-01T00:00:00,Aged,M01.060.116.100
21435428,2011-04-01T00:00:00,Breast Neoplasms,C04.588.180
21435428,2011-04-01T00:00:00,Breast Neoplasms,C17.800.090.500
21435428,2011-04-01T00:00:00,Health Status,I01.240.425
21435428,2011-04-01T00:00:00,Health Status,N01.224.425
21435428,2011-04-01T00:00:00,Health Status,N06.850.505.400.425
21435428,2011-04-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21435428,2011-04-01T00:00:00,Mammography,E01.370.350.700.500
21435428,2011-04-01T00:00:00,Medicare,N03.219.521.346.506.564.663
21435428,2011-04-01T00:00:00,Medicare,N03.219.521.576.343.840
21435428,2011-04-01T00:00:00,Medicare,N03.706.615.696
21435428,2011-04-01T00:00:00,Risk Factors,E05.318.740.600.800.725
21435428,2011-04-01T00:00:00,Risk Factors,N05.715.350.200.700
21435428,2011-04-01T00:00:00,Risk Factors,N05.715.360.750.625.700.700
21435428,2011-04-01T00:00:00,Risk Factors,N06.850.490.625.750
21435428,2011-04-01T00:00:00,Risk Factors,N06.850.520.830.600.800.725
21435428,2011-04-01T00:00:00,United States,Z01.107.567.875
21439502,2011-04-01T00:00:00,"Cardiac Pacing, Artificial",E02.145
21439502,2011-04-01T00:00:00,Cost-Benefit Analysis,N03.219.151.125
21439502,2011-04-01T00:00:00,"Death, Sudden, Cardiac",C14.280.383.220
21439502,2011-04-01T00:00:00,"Death, Sudden, Cardiac",C23.550.260.322.250
21439502,2011-04-01T00:00:00,"Defibrillators, Implantable",E07.305.250.159.175
21439502,2011-04-01T00:00:00,"Defibrillators, Implantable",E07.305.250.319.175
21439502,2011-04-01T00:00:00,"Defibrillators, Implantable",E07.695.175
21439502,2011-04-01T00:00:00,Disease Progression,C23.550.291.656
21439502,2011-04-01T00:00:00,Heart Failure,C14.280.434
21439502,2011-04-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21439502,2011-04-01T00:00:00,Primary Prevention,N02.421.726.758
21439502,2011-04-01T00:00:00,Primary Prevention,N06.850.780.680
21439502,2011-04-01T00:00:00,Secondary Prevention,N02.421.726.825
21439502,2011-04-01T00:00:00,Secondary Prevention,N06.850.780.750
21439502,2011-04-01T00:00:00,United States,Z01.107.567.875
21440212,2011-04-01T00:00:00,Cardiology,H02.403.429.163
21440212,2011-04-01T00:00:00,Certification,N03.706.110.120
21440212,2011-04-01T00:00:00,Certification,N05.700.200.190
21440212,2011-04-01T00:00:00,"Echocardiography, Transesophageal",E01.370.350.850.220.235
21440212,2011-04-01T00:00:00,"Echocardiography, Transesophageal",E01.370.370.380.220.235
21440212,2011-04-01T00:00:00,"Education, Medical, Continuing",I02.358.212.350
21440212,2011-04-01T00:00:00,"Education, Medical, Continuing",I02.358.399.250
21440212,2011-04-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21440212,2011-04-01T00:00:00,Perioperative Care,E02.760.722
21440212,2011-04-01T00:00:00,Perioperative Care,E04.604
21440212,2011-04-01T00:00:00,Perioperative Care,N02.421.585.722
21440212,2011-04-01T00:00:00,United States,Z01.107.567.875
21440709,2011-04-01T00:00:00,Adult,M01.060.116
21440709,2011-04-01T00:00:00,African Continental Ancestry Group,M01.686.508.100
21440709,2011-04-01T00:00:00,European Continental Ancestry Group,M01.686.508.400
21440709,2011-04-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21440709,2011-04-01T00:00:00,Middle Aged,M01.060.116.630
21440709,2011-04-01T00:00:00,Sex Factors,N05.715.350.675
21440709,2011-04-01T00:00:00,Sex Factors,N06.850.490.875
21440709,2011-04-01T00:00:00,Spinal Cord Injuries,C10.228.854.770
21440709,2011-04-01T00:00:00,Spinal Cord Injuries,C10.900.850
21440709,2011-04-01T00:00:00,Spinal Cord Injuries,C21.866.819
21452327,2011-04-01T00:00:00,Animals,B01.050
21452327,2011-04-01T00:00:00,Antigen-Antibody Complex,D12.776.124.486.485.114.257
21452327,2011-04-01T00:00:00,Antigen-Antibody Complex,D12.776.124.790.651.114.257
21452327,2011-04-01T00:00:00,Antigen-Antibody Complex,D12.776.377.715.548.114.257
21452327,2011-04-01T00:00:00,Antigen-Antibody Complex,D23.050.101
21452327,2011-04-01T00:00:00,Autoimmunity,G12.450.192
21452327,2011-04-01T00:00:00,Complement C3,D12.776.124.050.140
21452327,2011-04-01T00:00:00,Complement C3,D12.776.124.486.274.250
21452327,2011-04-01T00:00:00,"Complement Pathway, Alternative",G12.425.255.695
21452327,2011-04-01T00:00:00,DNA,D13.444.308
21452327,2011-04-01T00:00:00,"Disease Models, Animal",C22.232
21452327,2011-04-01T00:00:00,"Disease Models, Animal",E05.598.500
21452327,2011-04-01T00:00:00,"Disease Models, Animal",E05.599.395.080
21452327,2011-04-01T00:00:00,Immunoglobulin G,D12.776.124.486.485.114.619.393
21452327,2011-04-01T00:00:00,Immunoglobulin G,D12.776.124.790.651.114.619.393
21452327,2011-04-01T00:00:00,Immunoglobulin G,D12.776.377.715.548.114.619.393
21452327,2011-04-01T00:00:00,Kidney,A05.810.453
21452327,2011-04-01T00:00:00,Kidney Diseases,C12.777.419
21452327,2011-04-01T00:00:00,Kidney Diseases,C13.351.968.419
21452327,2011-04-01T00:00:00,"Lupus Erythematosus, Systemic",C17.300.480
21452327,2011-04-01T00:00:00,"Lupus Erythematosus, Systemic",C20.111.590
21452327,2011-04-01T00:00:00,Recombinant Fusion Proteins,D12.776.828.300
21459225,2011-04-01T00:00:00,Biomedical Research,H01.770.644.145
21459225,2011-04-01T00:00:00,Blood Pressure,E01.370.600.875.249
21459225,2011-04-01T00:00:00,Blood Pressure,G09.330.380.076
21459225,2011-04-01T00:00:00,"Ethics, Medical",K01.316.333.132.750
21459225,2011-04-01T00:00:00,"Ethics, Medical",N05.350.340.162.500
21459225,2011-04-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21459225,2011-04-01T00:00:00,Intraocular Pressure,G14.440
21459225,2011-04-01T00:00:00,Optic Nerve Diseases,C10.292.700
21459225,2011-04-01T00:00:00,Optic Nerve Diseases,C11.640
21459225,2011-04-01T00:00:00,Spinal Puncture,E01.370.376.700
21459225,2011-04-01T00:00:00,Spinal Puncture,E01.450.230.700
21459225,2011-04-01T00:00:00,Spinal Puncture,E01.450.865.632.700
21459225,2011-04-01T00:00:00,Visual Fields,E01.370.380.850.975
21459225,2011-04-01T00:00:00,Visual Fields,F02.463.593.932.934
21459225,2011-04-01T00:00:00,Visual Fields,G14.950
21460495,2011-04-01T00:00:00,Anti-Bacterial Agents,D27.505.954.122.085
21460495,2011-04-01T00:00:00,Anti-Infective Agents,D27.505.954.122
21460495,2011-04-01T00:00:00,Cephalosporins,D02.065.589.099.249
21460495,2011-04-01T00:00:00,Cephalosporins,D02.886.665.074
21460495,2011-04-01T00:00:00,Cephalosporins,D04.075.080.875.099.221.249
21460495,2011-04-01T00:00:00,Fluoroquinolones,D03.438.810.835.322
21460495,2011-04-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21460495,2011-04-01T00:00:00,Pseudomonas Infections,C01.252.400.739
21460495,2011-04-01T00:00:00,Pseudomonas aeruginosa,B03.440.400.425.625.625.100
21460495,2011-04-01T00:00:00,Pseudomonas aeruginosa,B03.660.250.580.590.050
21467896,2011-04-01T00:00:00,Health Expenditures,N03.219.151.450
21467896,2011-04-01T00:00:00,Health Expenditures,N05.300.385
21467896,2011-04-01T00:00:00,Health Services,N02.421
21467896,2011-04-01T00:00:00,Hospitalization,E02.760.400
21467896,2011-04-01T00:00:00,Hospitalization,N02.421.585.400
21467896,2011-04-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21467896,2011-04-01T00:00:00,Length of Stay,E02.760.400.480
21467896,2011-04-01T00:00:00,Length of Stay,N02.421.585.400.480
21467896,2011-04-01T00:00:00,Mental Disorders,F03
21467896,2011-04-01T00:00:00,Pilot Projects,E05.318.760.750
21467896,2011-04-01T00:00:00,Pilot Projects,E05.337.737
21467896,2011-04-01T00:00:00,Pilot Projects,N05.715.360.775.625
21467896,2011-04-01T00:00:00,Pilot Projects,N06.850.520.450.720
21474597,2011-04-01T00:00:00,Depressive Disorder,F03.600.300
21474597,2011-04-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21474597,2011-04-01T00:00:00,Middle Aged,M01.060.116.630
21474597,2011-04-01T00:00:00,Prefrontal Cortex,A08.186.211.730.885.287.500.270.700
21474597,2011-04-01T00:00:00,Psychiatric Status Rating Scales,F04.586
21474597,2011-04-01T00:00:00,Transcranial Magnetic Stimulation,E01.370.376.850
21474597,2011-04-01T00:00:00,Transcranial Magnetic Stimulation,E02.621.820
21476674,2011-04-01T00:00:00,Adolescent,M01.060.057
21476674,2011-04-01T00:00:00,Adult,M01.060.116
21476674,2011-04-01T00:00:00,Aged,M01.060.116.100
21476674,2011-04-01T00:00:00,Cues,F02.463.425.234
21476674,2011-04-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21476674,2011-04-01T00:00:00,Middle Aged,M01.060.116.630
21476674,2011-04-01T00:00:00,"Models, Neurological",E05.599.395.642
21476674,2011-04-01T00:00:00,Speech Perception,F02.463.593.071.875
21476674,2011-04-01T00:00:00,Young Adult,M01.060.116.815
21483776,2011-04-01T00:00:00,Animals,B01.050
21483776,2011-04-01T00:00:00,Cytokines,D12.644.276.374
21483776,2011-04-01T00:00:00,Cytokines,D12.776.467.374
21483776,2011-04-01T00:00:00,Cytokines,D23.529.374
21483776,2011-04-01T00:00:00,Drug Discovery,E05.295
21483776,2011-04-01T00:00:00,Drug Discovery,H01.158.703.007.675
21483776,2011-04-01T00:00:00,Drug Discovery,H01.181.466.675
21483776,2011-04-01T00:00:00,Drug-Induced Liver Injury,C06.552.195
21483776,2011-04-01T00:00:00,Drug-Induced Liver Injury,C21.613.260
21483776,2011-04-01T00:00:00,"Hepatitis, Autoimmune",C06.552.380.350.050
21483776,2011-04-01T00:00:00,"Hepatitis, Autoimmune",C20.111.567
21483776,2011-04-01T00:00:00,Immune Tolerance,G12.425.746.425
21483776,2011-04-01T00:00:00,Liver,A03.620
21483776,2011-04-01T00:00:00,Myeloid Cells,A11.627
21483776,2011-04-01T00:00:00,T-Lymphocyte Subsets,A11.118.637.555.567.550.500
21483776,2011-04-01T00:00:00,T-Lymphocyte Subsets,A11.118.637.555.567.569.500
21483776,2011-04-01T00:00:00,T-Lymphocyte Subsets,A15.145.229.637.555.567.550.500
21483776,2011-04-01T00:00:00,T-Lymphocyte Subsets,A15.145.229.637.555.567.569.500
21483776,2011-04-01T00:00:00,T-Lymphocyte Subsets,A15.382.490.555.567.550.500
21483776,2011-04-01T00:00:00,T-Lymphocyte Subsets,A15.382.490.555.567.569.500
21483776,2011-04-01T00:00:00,"T-Lymphocytes, Regulatory",A11.118.637.555.567.569.200.700
21483776,2011-04-01T00:00:00,"T-Lymphocytes, Regulatory",A15.145.229.637.555.567.569.200.700
21483776,2011-04-01T00:00:00,"T-Lymphocytes, Regulatory",A15.382.490.555.567.569.200.700
21486262,2011-04-01T00:00:00,"Adaptation, Psychological",F01.058
21486262,2011-04-01T00:00:00,Adolescent,M01.060.057
21486262,2011-04-01T00:00:00,Adult,M01.060.116
21486262,2011-04-01T00:00:00,Aged,M01.060.116.100
21486262,2011-04-01T00:00:00,Health Status,I01.240.425
21486262,2011-04-01T00:00:00,Health Status,N01.224.425
21486262,2011-04-01T00:00:00,Health Status,N06.850.505.400.425
21486262,2011-04-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21486262,2011-04-01T00:00:00,Interviews as Topic,E05.318.308.420
21486262,2011-04-01T00:00:00,Interviews as Topic,L01.280.520
21486262,2011-04-01T00:00:00,Interviews as Topic,N05.715.360.300.400
21486262,2011-04-01T00:00:00,Interviews as Topic,N06.850.520.308.420
21486262,2011-04-01T00:00:00,Mental Disorders,F03
21486262,2011-04-01T00:00:00,Middle Aged,M01.060.116.630
21486262,2011-04-01T00:00:00,Questionnaires,E05.318.308.750
21486262,2011-04-01T00:00:00,Questionnaires,L01.280.800
21486262,2011-04-01T00:00:00,Questionnaires,N05.715.360.300.695
21486262,2011-04-01T00:00:00,Questionnaires,N06.850.520.308.750
21486262,2011-04-01T00:00:00,Rape,I01.198.240.748.640
21499995,2011-04-01T00:00:00,Clinical Clerkship,I02.358.399.450.110
21499995,2011-04-01T00:00:00,Cooperative Behavior,F01.145.813.115
21499995,2011-04-01T00:00:00,Educational Measurement,I02.399
21499995,2011-04-01T00:00:00,"Faculty, Medical",I02.463.373
21499995,2011-04-01T00:00:00,"Faculty, Medical",M01.526.339.373
21499995,2011-04-01T00:00:00,"Faculty, Medical",M01.526.485.375
21499995,2011-04-01T00:00:00,"Faculty, Medical",N02.360.375
21499995,2011-04-01T00:00:00,Family Practice,H02.403.280
21499995,2011-04-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21499995,2011-04-01T00:00:00,Questionnaires,E05.318.308.750
21499995,2011-04-01T00:00:00,Questionnaires,L01.280.800
21499995,2011-04-01T00:00:00,Questionnaires,N05.715.360.300.695
21499995,2011-04-01T00:00:00,Questionnaires,N06.850.520.308.750
21499995,2011-04-01T00:00:00,"Students, Medical",I02.851.686.602
21499995,2011-04-01T00:00:00,"Students, Medical",M01.848.769.602
21502925,2011-04-01T00:00:00,Animals,B01.050
21502925,2011-04-01T00:00:00,Aprotinin,D12.776.083
21502925,2011-04-01T00:00:00,Fluorescent Dyes,D27.720.233.348
21502925,2011-04-01T00:00:00,Fluorescent Dyes,D27.720.470.330.348
21502925,2011-04-01T00:00:00,Fluorescent Dyes,D27.720.470.410.505.500
21502925,2011-04-01T00:00:00,Kidney,A05.810.453
21502925,2011-04-01T00:00:00,"Muscle, Skeletal",A02.633.567
21502925,2011-04-01T00:00:00,"Muscle, Skeletal",A10.690.552.500
21502925,2011-04-01T00:00:00,Myocardium,A02.633.580
21502925,2011-04-01T00:00:00,Myocardium,A07.541.704
21502925,2011-04-01T00:00:00,Myocardium,A10.690.552.750
21502925,2011-04-01T00:00:00,Serine Proteinase Inhibitors,D27.505.519.389.745.800
21502925,2011-04-01T00:00:00,Swine,B01.050.150.900.649.077.880
21524046,2011-04-01T00:00:00,Anti-Bacterial Agents,D27.505.954.122.085
21524046,2011-04-01T00:00:00,Anti-Infective Agents,D27.505.954.122
21524046,2011-04-01T00:00:00,Antifungal Agents,D27.505.954.122.136
21524046,2011-04-01T00:00:00,"Candidiasis, Vulvovaginal",C01.703.160.190
21524046,2011-04-01T00:00:00,"Candidiasis, Vulvovaginal",C13.351.500.894.906.820.500
21524046,2011-04-01T00:00:00,"Candidiasis, Vulvovaginal",C13.351.500.944.902.737.500
21524046,2011-04-01T00:00:00,Estrogens,D27.505.696.399.472.277
21524046,2011-04-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21524046,2011-04-01T00:00:00,Treatment Outcome,E01.789.800
21524046,2011-04-01T00:00:00,Treatment Outcome,N04.761.559.590.800
21524046,2011-04-01T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21539006,2011-04-01T00:00:00,Aged,M01.060.116.100
21539006,2011-04-01T00:00:00,Blood Glucose,D09.546.359.448.500
21539006,2011-04-01T00:00:00,"Diabetes Mellitus, Type 2",C18.452.394.750.149
21539006,2011-04-01T00:00:00,"Diabetes Mellitus, Type 2",C19.246.300
21539006,2011-04-01T00:00:00,"Hemoglobin A, Glycosylated",D09.408.375
21539006,2011-04-01T00:00:00,"Hemoglobin A, Glycosylated",D12.776.124.400.405.440
21539006,2011-04-01T00:00:00,"Hemoglobin A, Glycosylated",D12.776.422.316.762.380.440
21539006,2011-04-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21539006,2011-04-01T00:00:00,Insulin,D06.472.699.587.740.625
21539006,2011-04-01T00:00:00,Insulin,D12.644.548.586.740.625
21539006,2011-04-01T00:00:00,Practice Guidelines as Topic,N04.761.700.350.650
21539006,2011-04-01T00:00:00,Practice Guidelines as Topic,N05.700.350.650
21540254,2011-04-01T00:00:00,Biostatistics,E05.318.740.237
21540254,2011-04-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21543911,2011-04-01T00:00:00,"Emergency Service, Hospital",N02.278.354.422.336
21543911,2011-04-01T00:00:00,"Emergency Service, Hospital",N02.421.297.195
21543911,2011-04-01T00:00:00,"Emergency Service, Hospital",N04.452.442.422.336
21543911,2011-04-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21543911,2011-04-01T00:00:00,Nurse's Role,F01.829.316.616.625.450
21543911,2011-04-01T00:00:00,Nurse's Role,N05.300.100.337
21543911,2011-04-01T00:00:00,Pressure Ulcer,C17.800.893.665
21543911,2011-04-01T00:00:00,Risk Assessment,E05.318.740.600.800.715
21543911,2011-04-01T00:00:00,Risk Assessment,N04.452.871.715
21543911,2011-04-01T00:00:00,Risk Assessment,N05.715.360.750.625.700.690
21543911,2011-04-01T00:00:00,Risk Assessment,N06.850.505.715
21543911,2011-04-01T00:00:00,Risk Assessment,N06.850.520.830.600.800.715
21560911,2011-04-01T00:00:00,Adolescent,M01.060.057
21560911,2011-04-01T00:00:00,Adult,M01.060.116
21560911,2011-04-01T00:00:00,Aged,M01.060.116.100
21560911,2011-04-01T00:00:00,Automobile Driving,I03.125
21560911,2011-04-01T00:00:00,Behavior,F01.145
21560911,2011-04-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21560911,2011-04-01T00:00:00,Middle Aged,M01.060.116.630
21560911,2011-04-01T00:00:00,Questionnaires,E05.318.308.750
21560911,2011-04-01T00:00:00,Questionnaires,L01.280.800
21560911,2011-04-01T00:00:00,Questionnaires,N05.715.360.300.695
21560911,2011-04-01T00:00:00,Questionnaires,N06.850.520.308.750
21560911,2011-04-01T00:00:00,Young Adult,M01.060.116.815
21854246,2011-04-01T00:00:00,"Education, Nursing, Graduate",I02.358.337.450
21854246,2011-04-01T00:00:00,"Education, Nursing, Graduate",I02.358.462.565
21854246,2011-04-01T00:00:00,Educational Measurement,I02.399
21854246,2011-04-01T00:00:00,"History, 20th Century",K01.400.504.968
21854246,2011-04-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21854246,2011-04-01T00:00:00,United States,Z01.107.567.875
21902985,2011-04-01T00:00:00,Adolescent,M01.060.057
21902985,2011-04-01T00:00:00,Child,M01.060.406
21902985,2011-04-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21902985,2011-04-01T00:00:00,Robotics,H01.671.293.643
21902985,2011-04-01T00:00:00,Robotics,J01.897.104.834
21902985,2011-04-01T00:00:00,Robotics,L01.224.065.630
21902985,2011-04-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.350.810
21902985,2011-04-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.600.350.700.810
21902985,2011-04-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.700.700.810
21902985,2011-04-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.700.810.810
21902985,2011-04-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.825.810.810
21461698,2011-04-02T00:00:00,Equipment Failure Analysis,E05.325.192
21461698,2011-04-02T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21461698,2011-04-02T00:00:00,Knee Prosthesis,E07.695.400.410
21461698,2011-04-02T00:00:00,Materials Testing,E05.570
21461698,2011-04-02T00:00:00,Photography,E01.370.350.600
21461698,2011-04-02T00:00:00,Photography,E05.712
21461698,2011-04-02T00:00:00,Polyethylene,D02.455.326.271.665.550.500
21461698,2011-04-02T00:00:00,Polyethylene,D05.750.716.507.500
21461698,2011-04-02T00:00:00,Polyethylene,D25.720.716.507.500
21461698,2011-04-02T00:00:00,Polyethylene,J01.637.051.720.716.507.500
21461698,2011-04-02T00:00:00,Prosthesis Design,E05.320.550
21461698,2011-04-02T00:00:00,Prosthesis Design,E07.695.680
21443943,2011-04-03T00:00:00,Animals,B01.050
21443943,2011-04-03T00:00:00,Calcium,D01.268.552.100
21443943,2011-04-03T00:00:00,Calcium,D01.552.539.288
21443943,2011-04-03T00:00:00,Calcium,D23.119.100
21443943,2011-04-03T00:00:00,Fatty Acids,D10.251
21443943,2011-04-03T00:00:00,Homeostasis,G07.700.360
21443943,2011-04-03T00:00:00,Mitochondria,A11.284.430.214.190.875.564
21443943,2011-04-03T00:00:00,Mitochondria,A11.284.835.626
21443943,2011-04-03T00:00:00,"Models, Animal",E05.598
21443943,2011-04-03T00:00:00,Rabbits,B01.050.150.900.649.521.700
21457063,2011-04-03T00:00:00,3' Untranslated Regions,D13.444.735.544.875.880
21457063,2011-04-03T00:00:00,3' Untranslated Regions,D13.444.735.790.878.880
21457063,2011-04-03T00:00:00,3' Untranslated Regions,G05.360.340.024.220.880.880
21457063,2011-04-03T00:00:00,3' Untranslated Regions,G05.360.340.024.340.137.910.880
21457063,2011-04-03T00:00:00,Animals,B01.050
21457063,2011-04-03T00:00:00,Fibroblasts,A11.329.228
21457063,2011-04-03T00:00:00,Fibroblasts,A11.872.228
21457063,2011-04-03T00:00:00,Interleukin-6,D12.644.276.374.465.506
21457063,2011-04-03T00:00:00,Interleukin-6,D12.776.467.374.465.506
21457063,2011-04-03T00:00:00,Interleukin-6,D23.529.374.465.506
21457063,2011-04-03T00:00:00,"Mutagenesis, Site-Directed",E05.393.420.601.575
21457063,2011-04-03T00:00:00,Mutation,G05.365.590
21457063,2011-04-03T00:00:00,"RNA Processing, Post-Transcriptional",G02.111.087.750
21457063,2011-04-03T00:00:00,"RNA Processing, Post-Transcriptional",G02.149.115.750
21457063,2011-04-03T00:00:00,"RNA Processing, Post-Transcriptional",G03.495.839
21457063,2011-04-03T00:00:00,"RNA Processing, Post-Transcriptional",G05.355.315.700
21457063,2011-04-03T00:00:00,p38 Mitogen-Activated Protein Kinases,D08.811.913.696.620.682.700.567.878
21457063,2011-04-03T00:00:00,p38 Mitogen-Activated Protein Kinases,D08.811.913.696.620.682.700.646.750.843
21457063,2011-04-03T00:00:00,p38 Mitogen-Activated Protein Kinases,D12.644.360.450.835
21457063,2011-04-03T00:00:00,p38 Mitogen-Activated Protein Kinases,D12.776.476.450.835
21459647,2011-04-03T00:00:00,Adult,M01.060.116
21459647,2011-04-03T00:00:00,African Continental Ancestry Group,M01.686.508.100
21459647,2011-04-03T00:00:00,Aged,M01.060.116.100
21459647,2011-04-03T00:00:00,Albuminuria,C12.777.934.734.269
21459647,2011-04-03T00:00:00,Albuminuria,C13.351.968.934.734.269
21459647,2011-04-03T00:00:00,Albuminuria,C23.888.942.750.269
21459647,2011-04-03T00:00:00,Carotid Stenosis,C10.228.140.300.200.360
21459647,2011-04-03T00:00:00,Carotid Stenosis,C14.907.137.230
21459647,2011-04-03T00:00:00,Carotid Stenosis,C14.907.253.123.360
21459647,2011-04-03T00:00:00,Coronary Artery Disease,C14.280.647.250.260
21459647,2011-04-03T00:00:00,Coronary Artery Disease,C14.907.137.126.339
21459647,2011-04-03T00:00:00,Coronary Artery Disease,C14.907.585.250.260
21459647,2011-04-03T00:00:00,Ethnic Groups,M01.686.754
21459647,2011-04-03T00:00:00,Ethnic Groups,N01.224.317
21459647,2011-04-03T00:00:00,European Continental Ancestry Group,M01.686.508.400
21459647,2011-04-03T00:00:00,Hispanic Americans,M01.686.754.441
21459647,2011-04-03T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21459647,2011-04-03T00:00:00,Middle Aged,M01.060.116.630
21459647,2011-04-03T00:00:00,Risk Factors,E05.318.740.600.800.725
21459647,2011-04-03T00:00:00,Risk Factors,N05.715.350.200.700
21459647,2011-04-03T00:00:00,Risk Factors,N05.715.360.750.625.700.700
21459647,2011-04-03T00:00:00,Risk Factors,N06.850.490.625.750
21459647,2011-04-03T00:00:00,Risk Factors,N06.850.520.830.600.800.725
21459647,2011-04-03T00:00:00,United States,Z01.107.567.875
21463960,2011-04-03T00:00:00,Adolescent,M01.060.057
21463960,2011-04-03T00:00:00,Cataract,C11.510.245
21463960,2011-04-03T00:00:00,Cataract Extraction,E04.540.825.249
21463960,2011-04-03T00:00:00,Child,M01.060.406
21463960,2011-04-03T00:00:00,"Child, Preschool",M01.060.406.448
21463960,2011-04-03T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21463960,2011-04-03T00:00:00,Infant,M01.060.703
21463960,2011-04-03T00:00:00,"Lens Implantation, Intraocular",E04.540.825.600
21463960,2011-04-03T00:00:00,Postoperative Complications,C23.550.767
21463960,2011-04-03T00:00:00,Visual Acuity,E01.370.380.850.950
21463960,2011-04-03T00:00:00,Visual Acuity,F02.463.593.932.901
21463960,2011-04-03T00:00:00,Visual Acuity,G14.940
21464200,2011-04-04T00:00:00,Adult,M01.060.116
21464200,2011-04-04T00:00:00,African Continental Ancestry Group,M01.686.508.100
21464200,2011-04-04T00:00:00,Aged,M01.060.116.100
21464200,2011-04-04T00:00:00,Attitude to Health,F01.100.150
21464200,2011-04-04T00:00:00,Attitude to Health,N05.300.150
21464200,2011-04-04T00:00:00,Demography,I01.240
21464200,2011-04-04T00:00:00,Demography,N01.224
21464200,2011-04-04T00:00:00,Demography,N06.850.505.400
21464200,2011-04-04T00:00:00,European Continental Ancestry Group,M01.686.508.400
21464200,2011-04-04T00:00:00,Health Surveys,E05.318.308.250
21464200,2011-04-04T00:00:00,Health Surveys,N05.715.360.300.375
21464200,2011-04-04T00:00:00,Health Surveys,N06.850.520.308.250
21464200,2011-04-04T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21464200,2011-04-04T00:00:00,Interviews as Topic,E05.318.308.420
21464200,2011-04-04T00:00:00,Interviews as Topic,L01.280.520
21464200,2011-04-04T00:00:00,Interviews as Topic,N05.715.360.300.400
21464200,2011-04-04T00:00:00,Interviews as Topic,N06.850.520.308.420
21464200,2011-04-04T00:00:00,Middle Aged,M01.060.116.630
21464200,2011-04-04T00:00:00,Smoking,F01.145.466.753
21464200,2011-04-04T00:00:00,Smoking Cessation,F01.145.940.700
21464200,2011-04-04T00:00:00,South Carolina,Z01.107.567.875.075.662
21464200,2011-04-04T00:00:00,South Carolina,Z01.107.567.875.750.700
21844852,2011-04-04T00:00:00,Computer Simulation,L01.224.160
21844852,2011-04-04T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21844852,2011-04-04T00:00:00,Middle Aged,M01.060.116.630
21844852,2011-04-04T00:00:00,Posture,G11.427.695
21844852,2011-04-04T00:00:00,Prostatic Neoplasms,C04.588.945.440.770
21844852,2011-04-04T00:00:00,Prostatic Neoplasms,C12.294.260.750
21844852,2011-04-04T00:00:00,Prostatic Neoplasms,C12.294.565.625
21844852,2011-04-04T00:00:00,Prostatic Neoplasms,C12.758.409.750
21844852,2011-04-04T00:00:00,Radiometry,E05.799
21844852,2011-04-04T00:00:00,Radiotherapy Dosage,E02.815.639
21844852,2011-04-04T00:00:00,"Radiotherapy Planning, Computer-Assisted",E02.950.825
21844852,2011-04-04T00:00:00,"Radiotherapy Planning, Computer-Assisted",L01.700.508.100.710.600.608
21447400,2011-04-05T00:00:00,3T3 Cells,A11.251.210.700
21447400,2011-04-05T00:00:00,3T3 Cells,A11.329.228.900
21447400,2011-04-05T00:00:00,Adenosine Triphosphate,D03.438.759.646.138.236
21447400,2011-04-05T00:00:00,Adenosine Triphosphate,D13.695.667.138.236
21447400,2011-04-05T00:00:00,Adenosine Triphosphate,D13.695.827.068.236
21447400,2011-04-05T00:00:00,Animals,B01.050
21447400,2011-04-05T00:00:00,Calcium,D01.268.552.100
21447400,2011-04-05T00:00:00,Calcium,D01.552.539.288
21447400,2011-04-05T00:00:00,Calcium,D23.119.100
21447400,2011-04-05T00:00:00,Calcium Signaling,G02.111.087.800.800.100
21447400,2011-04-05T00:00:00,Calcium Signaling,G02.149.115.800.800.100
21447400,2011-04-05T00:00:00,Calcium Signaling,G03.495.166.500.100
21447400,2011-04-05T00:00:00,Calcium Signaling,G04.299.880.800.100
21447400,2011-04-05T00:00:00,Cell Movement,G04.299.283
21447400,2011-04-05T00:00:00,Cell Movement,G07.700.560.500.180
21447400,2011-04-05T00:00:00,Fibroblasts,A11.329.228
21447400,2011-04-05T00:00:00,Fibroblasts,A11.872.228
21447400,2011-04-05T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21447400,2011-04-05T00:00:00,Transforming Growth Factor beta,D12.644.276.374.687
21447400,2011-04-05T00:00:00,Transforming Growth Factor beta,D12.644.276.954.800.720
21447400,2011-04-05T00:00:00,Transforming Growth Factor beta,D12.644.276.963.720
21447400,2011-04-05T00:00:00,Transforming Growth Factor beta,D12.776.467.374.687
21447400,2011-04-05T00:00:00,Transforming Growth Factor beta,D12.776.467.942.800.720
21447400,2011-04-05T00:00:00,Transforming Growth Factor beta,D12.776.467.960.720
21447400,2011-04-05T00:00:00,Transforming Growth Factor beta,D23.529.374.687
21447400,2011-04-05T00:00:00,Transforming Growth Factor beta,D23.529.942.800.720
21447400,2011-04-05T00:00:00,Transforming Growth Factor beta,D23.529.960.720
21453840,2011-04-05T00:00:00,Cardiovascular Diseases,C14
21453840,2011-04-05T00:00:00,Depression,F01.145.126.350
21453840,2011-04-05T00:00:00,Depressive Disorder,F03.600.300
21453840,2011-04-05T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21453840,2011-04-05T00:00:00,Risk Factors,E05.318.740.600.800.725
21453840,2011-04-05T00:00:00,Risk Factors,N05.715.350.200.700
21453840,2011-04-05T00:00:00,Risk Factors,N05.715.360.750.625.700.700
21453840,2011-04-05T00:00:00,Risk Factors,N06.850.490.625.750
21453840,2011-04-05T00:00:00,Risk Factors,N06.850.520.830.600.800.725
21467239,2011-04-05T00:00:00,African Americans,M01.686.508.100.100
21467239,2011-04-05T00:00:00,African Americans,M01.686.754.100
21467239,2011-04-05T00:00:00,Body Mass Index,E01.370.600.115.100.125
21467239,2011-04-05T00:00:00,Body Mass Index,E05.041.124.125
21467239,2011-04-05T00:00:00,Body Mass Index,G07.100.100.125
21467239,2011-04-05T00:00:00,Body Mass Index,N06.850.505.200.100.175
21467239,2011-04-05T00:00:00,European Continental Ancestry Group,M01.686.508.400
21467239,2011-04-05T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21467239,2011-04-05T00:00:00,Incidence,E05.318.308.985.525.375
21467239,2011-04-05T00:00:00,Incidence,L01.280.975.525.375
21467239,2011-04-05T00:00:00,Incidence,N01.224.935.597.500
21467239,2011-04-05T00:00:00,Incidence,N06.850.505.400.975.525.375
21467239,2011-04-05T00:00:00,Incidence,N06.850.520.308.985.525.375
21467239,2011-04-05T00:00:00,Middle Aged,M01.060.116.630
21467239,2011-04-05T00:00:00,Obesity,C18.654.726.500
21467239,2011-04-05T00:00:00,Obesity,C23.888.144.699.500
21467239,2011-04-05T00:00:00,Obesity,E01.370.600.115.100.160.120.699.500
21467239,2011-04-05T00:00:00,Obesity,G07.100.100.160.120.699.500
21467239,2011-04-05T00:00:00,Prostate-Specific Antigen,D08.811.277.656.300.760.442.750
21467239,2011-04-05T00:00:00,Prostate-Specific Antigen,D08.811.277.656.959.350.442.750
21467239,2011-04-05T00:00:00,Prostate-Specific Antigen,D12.776.866.249.500
21467239,2011-04-05T00:00:00,Prostate-Specific Antigen,D23.050.285.625
21467239,2011-04-05T00:00:00,Prostate-Specific Antigen,D23.101.840.625
21467239,2011-04-05T00:00:00,Prostatic Neoplasms,C04.588.945.440.770
21467239,2011-04-05T00:00:00,Prostatic Neoplasms,C12.294.260.750
21467239,2011-04-05T00:00:00,Prostatic Neoplasms,C12.294.565.625
21467239,2011-04-05T00:00:00,Prostatic Neoplasms,C12.758.409.750
21467239,2011-04-05T00:00:00,Risk Factors,E05.318.740.600.800.725
21467239,2011-04-05T00:00:00,Risk Factors,N05.715.350.200.700
21467239,2011-04-05T00:00:00,Risk Factors,N05.715.360.750.625.700.700
21467239,2011-04-05T00:00:00,Risk Factors,N06.850.490.625.750
21467239,2011-04-05T00:00:00,Risk Factors,N06.850.520.830.600.800.725
21468014,2011-04-05T00:00:00,Critical Illness,C23.550.291.625
21468014,2011-04-05T00:00:00,"Education, Medical, Continuing",I02.358.212.350
21468014,2011-04-05T00:00:00,"Education, Medical, Continuing",I02.358.399.250
21468014,2011-04-05T00:00:00,Enteral Nutrition,E02.421.360
21468014,2011-04-05T00:00:00,Enteral Nutrition,E02.642.500.360
21468014,2011-04-05T00:00:00,Gastroenterology,H02.403.429.405
21468014,2011-04-05T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21468014,2011-04-05T00:00:00,Intensive Care,E02.760.190.400
21468014,2011-04-05T00:00:00,Intensive Care,N02.421.585.190.400
21468014,2011-04-05T00:00:00,Intensive Care Units,N02.278.388.493
21468014,2011-04-05T00:00:00,"Intubation, Gastrointestinal",E05.497.412
21468014,2011-04-05T00:00:00,Patient Selection,E05.581.500.653
21468014,2011-04-05T00:00:00,Patient Selection,N04.590.731
21468014,2011-04-05T00:00:00,Time Factors,G01.910.857
21468014,2011-04-05T00:00:00,Treatment Outcome,E01.789.800
21468014,2011-04-05T00:00:00,Treatment Outcome,N04.761.559.590.800
21468014,2011-04-05T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21468014,2011-04-05T00:00:00,United States,Z01.107.567.875
21470608,2011-04-05T00:00:00,Abdominal Pain,C23.888.646.100
21470608,2011-04-05T00:00:00,Abdominal Pain,C23.888.821.030
21470608,2011-04-05T00:00:00,Adult,M01.060.116
21470608,2011-04-05T00:00:00,"Analgesics, Opioid",D27.505.696.663.850.014.520
21470608,2011-04-05T00:00:00,"Analgesics, Opioid",D27.505.954.427.040.325
21470608,2011-04-05T00:00:00,"Analgesics, Opioid",D27.505.954.427.210.049
21470608,2011-04-05T00:00:00,"Cholangiopancreatography, Endoscopic Retrograde",E01.370.350.700.715.200.200
21470608,2011-04-05T00:00:00,"Cholangiopancreatography, Endoscopic Retrograde",E01.370.372.200.200
21470608,2011-04-05T00:00:00,"Cholangiopancreatography, Endoscopic Retrograde",E01.370.372.250.200
21470608,2011-04-05T00:00:00,"Cholangiopancreatography, Endoscopic Retrograde",E01.370.388.250.250.160
21470608,2011-04-05T00:00:00,"Cholangiopancreatography, Endoscopic Retrograde",E04.210.240.160
21470608,2011-04-05T00:00:00,"Cholangiopancreatography, Endoscopic Retrograde",E04.800.250.250.160
21470608,2011-04-05T00:00:00,Electric Stimulation Therapy,E02.342
21470608,2011-04-05T00:00:00,Electric Stimulation Therapy,E02.779.468
21470608,2011-04-05T00:00:00,Electrodes,E07.305.250
21470608,2011-04-05T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21470608,2011-04-05T00:00:00,Hydromorphone,D03.132.577.249.547.547.450
21470608,2011-04-05T00:00:00,Hydromorphone,D03.549.686.575.547.500
21470608,2011-04-05T00:00:00,Hydromorphone,D03.605.497.575.547.500
21470608,2011-04-05T00:00:00,Hydromorphone,D04.615.723.795.547.547.450
21470608,2011-04-05T00:00:00,Middle Aged,M01.060.116.630
21470608,2011-04-05T00:00:00,Pain Measurement,E01.370.376.550.600
21470608,2011-04-05T00:00:00,Pilot Projects,E05.318.760.750
21470608,2011-04-05T00:00:00,Pilot Projects,E05.337.737
21470608,2011-04-05T00:00:00,Pilot Projects,N05.715.360.775.625
21470608,2011-04-05T00:00:00,Pilot Projects,N06.850.520.450.720
21470608,2011-04-05T00:00:00,Young Adult,M01.060.116.815
21468441,2011-04-06T00:00:00,Luminescent Measurements,E05.196.712.516
21470191,2011-04-06T00:00:00,Adult,M01.060.116
21470191,2011-04-06T00:00:00,"Epilepsy, Temporal Lobe",C10.228.140.490.360.290
21470191,2011-04-06T00:00:00,Hippocampus,A08.186.211.464.405
21470191,2011-04-06T00:00:00,Hippocampus,A08.186.211.730.885.287.500.345
21470191,2011-04-06T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21470191,2011-04-06T00:00:00,"Image Processing, Computer-Assisted",L01.224.308
21470191,2011-04-06T00:00:00,Magnetic Resonance Imaging,E01.370.350.500
21470191,2011-04-06T00:00:00,Magnetic Resonance Imaging,E01.370.350.825.500
21470191,2011-04-06T00:00:00,Middle Aged,M01.060.116.630
21470993,2011-04-06T00:00:00,Aged,M01.060.116.100
21470993,2011-04-06T00:00:00,Fetal Blood,A12.207.152.200
21470993,2011-04-06T00:00:00,Fetal Blood,A15.145.300
21470993,2011-04-06T00:00:00,Fetal Blood,A16.378.200
21470993,2011-04-06T00:00:00,Gene Expression,G05.355.310
21470993,2011-04-06T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21470993,2011-04-06T00:00:00,"Immunity, Innate",G12.450.575
21470993,2011-04-06T00:00:00,"Infant, Newborn",M01.060.703.520
21470993,2011-04-06T00:00:00,Middle Aged,M01.060.116.630
21470993,2011-04-06T00:00:00,Monocytes,A11.118.637.555.652
21470993,2011-04-06T00:00:00,Monocytes,A11.148.580
21470993,2011-04-06T00:00:00,Monocytes,A11.627.624
21470993,2011-04-06T00:00:00,Monocytes,A11.733.547
21470993,2011-04-06T00:00:00,Monocytes,A15.145.229.637.555.652
21470993,2011-04-06T00:00:00,Monocytes,A15.378.316.580
21470993,2011-04-06T00:00:00,Monocytes,A15.382.490.555.652
21470993,2011-04-06T00:00:00,Monocytes,A15.382.680.547
21470993,2011-04-06T00:00:00,Monocytes,A15.382.812.547
21470993,2011-04-06T00:00:00,Toll-Like Receptor 4,D12.776.543.750.705.910.500.400
21470993,2011-04-06T00:00:00,Vitamin D,D04.808.812.768
21470993,2011-04-06T00:00:00,Vitamin D Deficiency,C18.654.521.500.133.770
21474950,2011-04-06T00:00:00,Genetic Predisposition to Disease,C23.550.291.687.500
21474950,2011-04-06T00:00:00,Genetic Predisposition to Disease,G05.380.355
21474950,2011-04-06T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21474950,2011-04-06T00:00:00,Hypertension,C14.907.489
21474950,2011-04-06T00:00:00,Phenotype,G05.695
21494639,2011-04-06T00:00:00,Adult,M01.060.116
21494639,2011-04-06T00:00:00,Aged,M01.060.116.100
21494639,2011-04-06T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21494639,2011-04-06T00:00:00,Middle Aged,M01.060.116.630
21494639,2011-04-06T00:00:00,Prostatic Neoplasms,C04.588.945.440.770
21494639,2011-04-06T00:00:00,Prostatic Neoplasms,C12.294.260.750
21494639,2011-04-06T00:00:00,Prostatic Neoplasms,C12.294.565.625
21494639,2011-04-06T00:00:00,Prostatic Neoplasms,C12.758.409.750
21494639,2011-04-06T00:00:00,Vitamin D,D04.808.812.768
21990846,2011-04-06T00:00:00,Combined Modality Therapy,E02.186
21990846,2011-04-06T00:00:00,"Embolization, Therapeutic",E02.520.360
21990846,2011-04-06T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21990846,2011-04-06T00:00:00,Lumbosacral Region,A01.176.519
21990846,2011-04-06T00:00:00,Skin Neoplasms,C04.588.805
21990846,2011-04-06T00:00:00,Skin Neoplasms,C17.800.882
21990846,2011-04-06T00:00:00,Syndrome,C23.550.288.500
21472456,2011-04-07T00:00:00,Angiogenesis Inhibitors,D27.505.696.377.077.099
21472456,2011-04-07T00:00:00,Angiogenesis Inhibitors,D27.505.696.377.450.100
21472456,2011-04-07T00:00:00,Angiogenesis Inhibitors,D27.505.954.248.025
21472456,2011-04-07T00:00:00,Anticarcinogenic Agents,D27.505.696.706.018
21472456,2011-04-07T00:00:00,Anticarcinogenic Agents,D27.505.954.248.125
21472456,2011-04-07T00:00:00,Anticarcinogenic Agents,D27.720.799.018
21472456,2011-04-07T00:00:00,Apoptosis,G04.299.139.160
21472456,2011-04-07T00:00:00,Cell Cycle,G04.299.134
21472456,2011-04-07T00:00:00,Cell Movement,G04.299.283
21472456,2011-04-07T00:00:00,Cell Movement,G07.700.560.500.180
21472456,2011-04-07T00:00:00,Cell Survival,G04.299.316
21472456,2011-04-07T00:00:00,Cyclin-Dependent Kinase Inhibitor p21,D12.644.360.225.500
21472456,2011-04-07T00:00:00,Cyclin-Dependent Kinase Inhibitor p21,D12.776.167.187.500
21472456,2011-04-07T00:00:00,Cyclin-Dependent Kinase Inhibitor p21,D12.776.476.225.500
21472456,2011-04-07T00:00:00,Cyclin-Dependent Kinase Inhibitor p21,D12.776.624.776.355.500
21472456,2011-04-07T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21472456,2011-04-07T00:00:00,"Neovascularization, Pathologic",C23.550.589.500
21472456,2011-04-07T00:00:00,Neuroblastoma,C04.557.465.625.600.590.650.550
21472456,2011-04-07T00:00:00,Neuroblastoma,C04.557.470.670.590.650.550
21472456,2011-04-07T00:00:00,Neuroblastoma,C04.557.580.625.600.590.650.550
21472456,2011-04-07T00:00:00,Proto-Oncogene Proteins c-bcl-2,D12.644.360.075.718
21472456,2011-04-07T00:00:00,Proto-Oncogene Proteins c-bcl-2,D12.776.476.075.718
21472456,2011-04-07T00:00:00,Proto-Oncogene Proteins c-bcl-2,D12.776.624.664.700.169
21472456,2011-04-07T00:00:00,Pyrroles,D03.383.129.578
21472456,2011-04-07T00:00:00,Vascular Endothelial Growth Factor A,D12.644.276.100.800.200
21472456,2011-04-07T00:00:00,Vascular Endothelial Growth Factor A,D12.776.467.100.800.200
21472456,2011-04-07T00:00:00,Vascular Endothelial Growth Factor A,D23.529.100.800.200
21473808,2011-04-08T00:00:00,Animals,B01.050
21473808,2011-04-08T00:00:00,Bone Marrow Transplantation,E04.936.580.040
21473808,2011-04-08T00:00:00,Green Fluorescent Proteins,D12.776.532.265
21473808,2011-04-08T00:00:00,"Microscopy, Fluorescence",E01.370.350.515.458
21473808,2011-04-08T00:00:00,"Microscopy, Fluorescence",E05.595.458
21476810,2011-04-08T00:00:00,Adult,M01.060.116
21476810,2011-04-08T00:00:00,Brain Neoplasms,C04.588.614.250.195
21476810,2011-04-08T00:00:00,Brain Neoplasms,C10.228.140.211
21476810,2011-04-08T00:00:00,Brain Neoplasms,C10.551.240.250
21476810,2011-04-08T00:00:00,Combined Modality Therapy,E02.186
21476810,2011-04-08T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21476810,2011-04-08T00:00:00,Melanoma,C04.557.465.625.650.510
21476810,2011-04-08T00:00:00,Melanoma,C04.557.580.625.650.510
21476810,2011-04-08T00:00:00,Melanoma,C04.557.665.510
21476810,2011-04-08T00:00:00,Middle Aged,M01.060.116.630
21476810,2011-04-08T00:00:00,Treatment Outcome,E01.789.800
21476810,2011-04-08T00:00:00,Treatment Outcome,N04.761.559.590.800
21476810,2011-04-08T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21478228,2011-04-08T00:00:00,Animals,B01.050
21478228,2011-04-08T00:00:00,"Antigens, CD",D23.050.301.264.035
21478228,2011-04-08T00:00:00,"Antigens, CD",D23.101.100.110
21478228,2011-04-08T00:00:00,Apolipoproteins E,D10.532.091.500
21478228,2011-04-08T00:00:00,Apolipoproteins E,D12.776.070.400.500
21478228,2011-04-08T00:00:00,Apolipoproteins E,D12.776.521.120.500
21478228,2011-04-08T00:00:00,Diabetic Angiopathies,C14.907.320
21478228,2011-04-08T00:00:00,Diabetic Angiopathies,C19.246.099.500
21478228,2011-04-08T00:00:00,Gene Expression Regulation,G05.355.315
21478228,2011-04-08T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21478228,2011-04-08T00:00:00,Hyperglycemia,C18.452.394.952
21478228,2011-04-08T00:00:00,Insulin,D06.472.699.587.740.625
21478228,2011-04-08T00:00:00,Insulin,D12.644.548.586.740.625
21478228,2011-04-08T00:00:00,Interleukin-6,D12.644.276.374.465.506
21478228,2011-04-08T00:00:00,Interleukin-6,D12.776.467.374.465.506
21478228,2011-04-08T00:00:00,Interleukin-6,D23.529.374.465.506
21478228,2011-04-08T00:00:00,"Leukocytes, Mononuclear",A11.118.637.555
21478228,2011-04-08T00:00:00,"Leukocytes, Mononuclear",A15.145.229.637.555
21478228,2011-04-08T00:00:00,"Leukocytes, Mononuclear",A15.382.490.555
21478228,2011-04-08T00:00:00,Macrophages,A11.329.372
21478228,2011-04-08T00:00:00,Macrophages,A11.627.482
21478228,2011-04-08T00:00:00,Macrophages,A11.733.397
21478228,2011-04-08T00:00:00,Macrophages,A15.382.680.397
21478228,2011-04-08T00:00:00,Macrophages,A15.382.812.522
21478228,2011-04-08T00:00:00,Matrix Metalloproteinase 9,D08.811.277.656.300.480.205.360
21478228,2011-04-08T00:00:00,Matrix Metalloproteinase 9,D08.811.277.656.300.480.252.445
21478228,2011-04-08T00:00:00,Matrix Metalloproteinase 9,D08.811.277.656.300.480.525.700.350
21478228,2011-04-08T00:00:00,Matrix Metalloproteinase 9,D08.811.277.656.675.374.205.360
21478228,2011-04-08T00:00:00,Matrix Metalloproteinase 9,D08.811.277.656.675.374.252.445
21478228,2011-04-08T00:00:00,Matrix Metalloproteinase 9,D08.811.277.656.675.374.525.700.350
21478228,2011-04-08T00:00:00,"RNA, Messenger",D13.444.735.544
21478228,2011-04-08T00:00:00,Tissue Inhibitor of Metalloproteinase-1,D12.776.926.450
21480531,2011-04-08T00:00:00,Azides,D01.625.100
21480531,2011-04-08T00:00:00,Azides,D02.159
21480531,2011-04-08T00:00:00,Cell Death,G04.299.139
21480531,2011-04-08T00:00:00,Fluorescent Dyes,D27.720.233.348
21480531,2011-04-08T00:00:00,Fluorescent Dyes,D27.720.470.330.348
21480531,2011-04-08T00:00:00,Fluorescent Dyes,D27.720.470.410.505.500
21480531,2011-04-08T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21480531,2011-04-08T00:00:00,Nanoparticles,J01.637.512.600
21480531,2011-04-08T00:00:00,Neoplasms,C04
21480531,2011-04-08T00:00:00,Photosensitizing Agents,D27.505.696.750.710
21480531,2011-04-08T00:00:00,Photosensitizing Agents,D27.505.954.444.600
21501697,2011-04-09T00:00:00,Animals,B01.050
21501697,2011-04-09T00:00:00,Endothelial Cells,A11.436.275
21501697,2011-04-09T00:00:00,Fibroblasts,A11.329.228
21501697,2011-04-09T00:00:00,Fibroblasts,A11.872.228
21501697,2011-04-09T00:00:00,Lung,A04.411
21501697,2011-04-09T00:00:00,Procollagen,D12.776.811.690
21501697,2011-04-09T00:00:00,Procollagen,D12.776.860.300.250.600
21482550,2011-04-10T00:00:00,Aging,G07.700.320.124
21482550,2011-04-10T00:00:00,Animals,B01.050
21482550,2011-04-10T00:00:00,Biomedical Research,H01.770.644.145
21482550,2011-04-10T00:00:00,Cognition Disorders,F03.087.250
21482550,2011-04-10T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21482550,2011-04-10T00:00:00,Neuronal Plasticity,G11.561.600.635
21482550,2011-04-10T00:00:00,Recovery of Function,G16.757
21482550,2011-04-10T00:00:00,Stroke,C10.228.140.300.775
21482550,2011-04-10T00:00:00,Stroke,C14.907.253.855
21494591,2011-04-11T00:00:00,Animals,B01.050
21494591,2011-04-11T00:00:00,Cell Proliferation,G04.299.233.750
21494591,2011-04-11T00:00:00,Cell Proliferation,G07.700.320.249.410.750
21494591,2011-04-11T00:00:00,"Disease Models, Animal",C22.232
21494591,2011-04-11T00:00:00,"Disease Models, Animal",E05.598.500
21494591,2011-04-11T00:00:00,"Disease Models, Animal",E05.599.395.080
21494591,2011-04-11T00:00:00,"Lymphocytes, Tumor-Infiltrating",A11.118.637.555.567.650
21494591,2011-04-11T00:00:00,"Lymphocytes, Tumor-Infiltrating",A15.145.229.637.555.567.650
21494591,2011-04-11T00:00:00,"Lymphocytes, Tumor-Infiltrating",A15.382.490.555.567.650
21494591,2011-04-11T00:00:00,"Models, Biological",E05.599.395
21494591,2011-04-11T00:00:00,Neoplasm Staging,E01.370.550
21494591,2011-04-11T00:00:00,Time Factors,G01.910.857
22287435,2011-04-11T00:00:00,Adult,M01.060.116
22287435,2011-04-11T00:00:00,Aged,M01.060.116.100
22287435,2011-04-11T00:00:00,Biological Markers,D23.101
22287435,2011-04-11T00:00:00,Case-Control Studies,E05.318.760.500.500
22287435,2011-04-11T00:00:00,Case-Control Studies,N05.715.360.775.175.200
22287435,2011-04-11T00:00:00,Case-Control Studies,N06.850.520.450.500.500
22287435,2011-04-11T00:00:00,Chronic Disease,C23.550.291.500
22287435,2011-04-11T00:00:00,Dendritic Cells,A11.066.270
22287435,2011-04-11T00:00:00,Dendritic Cells,A11.436.270
22287435,2011-04-11T00:00:00,Dendritic Cells,A15.382.066.270
22287435,2011-04-11T00:00:00,Dendritic Cells,A15.382.812.260
22287435,2011-04-11T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22287435,2011-04-11T00:00:00,Middle Aged,M01.060.116.630
22287435,2011-04-11T00:00:00,Nasal Polyps,C08.460.572
22287435,2011-04-11T00:00:00,Nasal Polyps,C09.603.557
22287435,2011-04-11T00:00:00,Nasal Polyps,C23.300.825.557
22287435,2011-04-11T00:00:00,Paranasal Sinuses,A04.531.621
22287435,2011-04-11T00:00:00,Sinusitis,C08.460.692.752
22287435,2011-04-11T00:00:00,Sinusitis,C08.730.749
22287435,2011-04-11T00:00:00,Sinusitis,C09.603.692.752
21487040,2011-04-12T00:00:00,Acid Ceramidase,D08.811.277.087.250.100
21487040,2011-04-12T00:00:00,Animals,B01.050
21487040,2011-04-12T00:00:00,Apoptosis,G04.299.139.160
21487040,2011-04-12T00:00:00,Ceramides,D02.065.313
21487040,2011-04-12T00:00:00,Ceramides,D09.400.410.420.525.200
21487040,2011-04-12T00:00:00,Ceramides,D10.390.470.675.200
21487040,2011-04-12T00:00:00,Ceramides,D10.570.877.360.612.200
21487040,2011-04-12T00:00:00,DNA Methylation,G02.111.087.029.538.161
21487040,2011-04-12T00:00:00,DNA Methylation,G02.111.087.218
21487040,2011-04-12T00:00:00,DNA Methylation,G02.149.115.029.538.161
21487040,2011-04-12T00:00:00,DNA Methylation,G02.149.115.218
21487040,2011-04-12T00:00:00,DNA Methylation,G03.495.130.538.161
21487040,2011-04-12T00:00:00,DNA Methylation,G05.355.190
21487040,2011-04-12T00:00:00,Fas Ligand Protein,D12.644.276.374.750.249
21487040,2011-04-12T00:00:00,Fas Ligand Protein,D12.644.276.972.249
21487040,2011-04-12T00:00:00,Fas Ligand Protein,D12.776.395.550.312
21487040,2011-04-12T00:00:00,Fas Ligand Protein,D12.776.467.374.750.249
21487040,2011-04-12T00:00:00,Fas Ligand Protein,D12.776.467.972.249
21487040,2011-04-12T00:00:00,Fas Ligand Protein,D12.776.543.550.312
21487040,2011-04-12T00:00:00,Fas Ligand Protein,D23.050.301.264.035.283
21487040,2011-04-12T00:00:00,Fas Ligand Protein,D23.101.100.110.282
21487040,2011-04-12T00:00:00,Fas Ligand Protein,D23.529.374.750.249
21487040,2011-04-12T00:00:00,Fas Ligand Protein,D23.529.972.249
21487040,2011-04-12T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21487040,2011-04-12T00:00:00,Interferon Regulatory Factors,D12.644.360.024.302
21487040,2011-04-12T00:00:00,Interferon Regulatory Factors,D12.776.157.057.050
21487040,2011-04-12T00:00:00,Interferon Regulatory Factors,D12.776.260.504
21487040,2011-04-12T00:00:00,Interferon Regulatory Factors,D12.776.476.024.385
21487040,2011-04-12T00:00:00,Interferon Regulatory Factors,D12.776.930.332
21487040,2011-04-12T00:00:00,"Leukemia, Myelogenous, Chronic, BCR-ABL Positive",C04.557.337.539.250
21487040,2011-04-12T00:00:00,"Leukemia, Myelogenous, Chronic, BCR-ABL Positive",C15.378.190.636.370
21487040,2011-04-12T00:00:00,Myeloid Cells,A11.627
21487040,2011-04-12T00:00:00,"Promoter Regions, Genetic",G02.111.570.080.689.675
21487040,2011-04-12T00:00:00,"Promoter Regions, Genetic",G05.360.080.689.675
21487040,2011-04-12T00:00:00,"Promoter Regions, Genetic",G05.360.340.024.340.137.750.680
21487040,2011-04-12T00:00:00,"Transcription, Genetic",G02.111.087.847
21487040,2011-04-12T00:00:00,"Transcription, Genetic",G02.149.115.847
21487040,2011-04-12T00:00:00,"Transcription, Genetic",G05.355.310.700
21487224,2011-04-12T00:00:00,Anticoagulants,D27.505.954.502.119
21487224,2011-04-12T00:00:00,Fibrinolytic Agents,D27.505.519.421.750
21487224,2011-04-12T00:00:00,Fibrinolytic Agents,D27.505.954.411.320
21487224,2011-04-12T00:00:00,Fibrinolytic Agents,D27.505.954.502.427
21487224,2011-04-12T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21487224,2011-04-12T00:00:00,Intracranial Arteriosclerosis,C10.228.140.300.510.800
21487224,2011-04-12T00:00:00,Intracranial Arteriosclerosis,C14.907.137.126.372
21487224,2011-04-12T00:00:00,Intracranial Arteriosclerosis,C14.907.253.560.350
21487224,2011-04-12T00:00:00,Randomized Controlled Trials as Topic,E05.318.760.535.365.500
21487224,2011-04-12T00:00:00,Randomized Controlled Trials as Topic,E05.337.250.365.500
21487224,2011-04-12T00:00:00,Randomized Controlled Trials as Topic,N05.715.360.775.235.387.500
21487224,2011-04-12T00:00:00,Randomized Controlled Trials as Topic,N06.850.520.450.535.365.500
21487224,2011-04-12T00:00:00,Risk Factors,E05.318.740.600.800.725
21487224,2011-04-12T00:00:00,Risk Factors,N05.715.350.200.700
21487224,2011-04-12T00:00:00,Risk Factors,N05.715.360.750.625.700.700
21487224,2011-04-12T00:00:00,Risk Factors,N06.850.490.625.750
21487224,2011-04-12T00:00:00,Risk Factors,N06.850.520.830.600.800.725
21487224,2011-04-12T00:00:00,Warfarin,D03.438.150.446.520.914
21487224,2011-04-12T00:00:00,Warfarin,D03.830.219.446.520.914
21489719,2011-04-12T00:00:00,Bone Screws,E07.695.130
21489719,2011-04-12T00:00:00,Bone Screws,E07.858.442.660.115
21489719,2011-04-12T00:00:00,Bone Screws,E07.858.690.650.115
21489719,2011-04-12T00:00:00,Cadaver,C23.550.260.224
21489719,2011-04-12T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21489719,2011-04-12T00:00:00,Suture Techniques,E04.901
21490129,2011-04-13T00:00:00,Animals,B01.050
21490129,2011-04-13T00:00:00,"Behavior, Addictive",F01.145.527.100.120
21490129,2011-04-13T00:00:00,"Behavior, Animal",F01.145.113
21490129,2011-04-13T00:00:00,Conditioning (Psychology),F02.463.425.179
21490129,2011-04-13T00:00:00,"Disease Models, Animal",C22.232
21490129,2011-04-13T00:00:00,"Disease Models, Animal",E05.598.500
21490129,2011-04-13T00:00:00,"Disease Models, Animal",E05.599.395.080
21490129,2011-04-13T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21490129,2011-04-13T00:00:00,Self Administration,E02.319.890
21490129,2011-04-13T00:00:00,Self Administration,E02.900.890
21490129,2011-04-13T00:00:00,Substance-Related Disorders,C21.739
21490129,2011-04-13T00:00:00,Substance-Related Disorders,F03.900
21490206,2011-04-13T00:00:00,Amino Acid Sequence,G02.111.570.060
21490206,2011-04-13T00:00:00,Amino Acid Sequence,L01.453.245.667.060
21490206,2011-04-13T00:00:00,Animals,B01.050
21490206,2011-04-13T00:00:00,"Behavior, Animal",F01.145.113
21490206,2011-04-13T00:00:00,"Chromatography, High Pressure Liquid",E05.196.181.400.300
21490206,2011-04-13T00:00:00,"Chromatography, Ion Exchange",E05.196.181.400.383
21490206,2011-04-13T00:00:00,Cocaine-Related Disorders,C21.739.300
21490206,2011-04-13T00:00:00,Cocaine-Related Disorders,F03.900.300
21490206,2011-04-13T00:00:00,Cyclic AMP-Dependent Protein Kinases,D08.811.913.696.620.682.700.150.125
21490206,2011-04-13T00:00:00,Cyclic AMP-Dependent Protein Kinases,D12.644.360.200.125
21490206,2011-04-13T00:00:00,Cyclic AMP-Dependent Protein Kinases,D12.776.476.200.125
21490206,2011-04-13T00:00:00,Molecular Sequence Data,L01.453.245.667
21490206,2011-04-13T00:00:00,Nerve Tissue Proteins,D12.776.641
21490206,2011-04-13T00:00:00,Neural Networks (Computer),G17.485
21490206,2011-04-13T00:00:00,Neural Networks (Computer),L01.224.065.605
21490206,2011-04-13T00:00:00,Neural Networks (Computer),L01.725.500
21490206,2011-04-13T00:00:00,Nucleus Accumbens,A08.186.211.730.885.287.249.683
21490206,2011-04-13T00:00:00,Proteomics,H01.158.201.843
21490206,2011-04-13T00:00:00,Proteomics,H01.158.273.180.350.700
21490206,2011-04-13T00:00:00,Proteomics,H01.158.273.343.350.700
21490206,2011-04-13T00:00:00,Proteomics,H01.181.122.738
21490206,2011-04-13T00:00:00,Rats,B01.050.150.900.649.865.635.505.700
21490206,2011-04-13T00:00:00,"Rats, Sprague-Dawley",B01.050.150.900.649.865.635.505.700.750
21490206,2011-04-13T00:00:00,"Receptors, AMPA",D12.776.543.750.720.200.450.200
21490206,2011-04-13T00:00:00,Self Administration,E02.319.890
21490206,2011-04-13T00:00:00,Self Administration,E02.900.890
21490206,2011-04-13T00:00:00,Signal Transduction,G02.111.087.800
21490206,2011-04-13T00:00:00,Signal Transduction,G02.149.115.800
21490206,2011-04-13T00:00:00,Signal Transduction,G04.299.880
21490206,2011-04-13T00:00:00,"Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization",E05.196.566.755
21490206,2011-04-13T00:00:00,Synapses,A08.850
21490206,2011-04-13T00:00:00,Synapses,A11.284.149.165.420.780
21491498,2011-04-13T00:00:00,Amidohydrolases,D08.811.277.087
21491498,2011-04-13T00:00:00,Animals,B01.050
21491498,2011-04-13T00:00:00,Brain,A08.186.211
21491498,2011-04-13T00:00:00,Central Nervous System Diseases,C10.228
21491498,2011-04-13T00:00:00,Demyelinating Diseases,C10.314
21491498,2011-04-13T00:00:00,"Disease Models, Animal",C22.232
21491498,2011-04-13T00:00:00,"Disease Models, Animal",E05.598.500
21491498,2011-04-13T00:00:00,"Disease Models, Animal",E05.599.395.080
21491498,2011-04-13T00:00:00,Electromyography,E01.370.405.255
21491498,2011-04-13T00:00:00,Electromyography,E01.370.530.255
21491498,2011-04-13T00:00:00,Lipids,D10
21491498,2011-04-13T00:00:00,Maze Learning,F02.463.425.507
21491498,2011-04-13T00:00:00,"Microscopy, Electron, Transmission",E01.370.350.515.402.580
21491498,2011-04-13T00:00:00,"Microscopy, Electron, Transmission",E05.595.402.580
21491498,2011-04-13T00:00:00,Motor Activity,F01.145.632
21491498,2011-04-13T00:00:00,Motor Activity,G11.427.590.530.698
21491498,2011-04-13T00:00:00,Spinal Cord,A08.186.854
21491498,2011-04-13T00:00:00,Tandem Mass Spectrometry,E05.196.566.880
21228385,2011-04-14T00:00:00,Animals,B01.050
21228385,2011-04-14T00:00:00,Carrier Proteins,D12.776.157
21228385,2011-04-14T00:00:00,Cell Survival,G04.299.316
21228385,2011-04-14T00:00:00,"Disease Models, Animal",C22.232
21228385,2011-04-14T00:00:00,"Disease Models, Animal",E05.598.500
21228385,2011-04-14T00:00:00,"Disease Models, Animal",E05.599.395.080
21228385,2011-04-14T00:00:00,Eye Proteins,D12.776.306
21228385,2011-04-14T00:00:00,Light,G01.201.875.770.578
21228385,2011-04-14T00:00:00,Light,G01.590.540
21228385,2011-04-14T00:00:00,"Microscopy, Fluorescence",E01.370.350.515.458
21228385,2011-04-14T00:00:00,"Microscopy, Fluorescence",E05.595.458
21228385,2011-04-14T00:00:00,Retinal Cone Photoreceptor Cells,A08.663.650.850.625.670.100
21228385,2011-04-14T00:00:00,Retinal Cone Photoreceptor Cells,A08.663.650.915.937.670.100
21228385,2011-04-14T00:00:00,Retinal Cone Photoreceptor Cells,A08.800.950.937.670.100
21228385,2011-04-14T00:00:00,Retinal Cone Photoreceptor Cells,A09.371.729.831.625.670.100
21228385,2011-04-14T00:00:00,Retinal Cone Photoreceptor Cells,A11.671.650.850.625.670.100
21228385,2011-04-14T00:00:00,Retinal Cone Photoreceptor Cells,A11.671.650.915.937.670.100
21228385,2011-04-14T00:00:00,Retinaldehyde,D02.047.850
21228385,2011-04-14T00:00:00,Retinaldehyde,D02.455.326.271.665.202.495.690
21228385,2011-04-14T00:00:00,Retinaldehyde,D02.455.426.392.368.367.379.249.700.690
21228385,2011-04-14T00:00:00,Retinaldehyde,D02.455.849.131.495.690
21228385,2011-04-14T00:00:00,Retinaldehyde,D23.767.261.700.690
21228385,2011-04-14T00:00:00,Rhodopsin,D12.776.543.750.100.955
21228385,2011-04-14T00:00:00,Rhodopsin,D23.767.930.750.500.500
21493775,2011-04-14T00:00:00,Animals,B01.050
21493775,2011-04-14T00:00:00,Cell Proliferation,G04.299.233.750
21493775,2011-04-14T00:00:00,Cell Proliferation,G07.700.320.249.410.750
21493775,2011-04-14T00:00:00,Cilia,A11.284.180.165
21493775,2011-04-14T00:00:00,Kidney,A05.810.453
21493775,2011-04-14T00:00:00,"Kidney Diseases, Cystic",C12.777.419.403
21493775,2011-04-14T00:00:00,"Kidney Diseases, Cystic",C13.351.968.419.403
21493775,2011-04-14T00:00:00,Signal Transduction,G02.111.087.800
21493775,2011-04-14T00:00:00,Signal Transduction,G02.149.115.800
21493775,2011-04-14T00:00:00,Signal Transduction,G04.299.880
21493775,2011-04-14T00:00:00,Tumor Suppressor Proteins,D12.776.624.776
21477510,2011-04-15T00:00:00,Community-Based Participatory Research,N05.425.104
21477510,2011-04-15T00:00:00,Governing Board,N04.452.394
21477510,2011-04-15T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21498743,2011-04-15T00:00:00,Carbon,D01.268.150
21498743,2011-04-15T00:00:00,"Colony Count, Microbial",E05.200.875.220
21498743,2011-04-15T00:00:00,Hot Temperature,G01.906.595.543
21498743,2011-04-15T00:00:00,Hot Temperature,G16.500.275.063.725.710.380
21498743,2011-04-15T00:00:00,Hot Temperature,G16.500.750.775.710.380
21498743,2011-04-15T00:00:00,Hot Temperature,N06.230.300.100.725.232
21498743,2011-04-15T00:00:00,Hot Temperature,N06.230.300.100.725.710.380
21498743,2011-04-15T00:00:00,Nitrogen,D01.268.604
21498743,2011-04-15T00:00:00,Nitrogen,D01.362.625
21498785,2011-04-15T00:00:00,"Diabetes Mellitus, Type 1",C18.452.394.750.124
21498785,2011-04-15T00:00:00,"Diabetes Mellitus, Type 1",C19.246.267
21498785,2011-04-15T00:00:00,"Diabetes Mellitus, Type 1",C20.111.327
21498785,2011-04-15T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21498785,2011-04-15T00:00:00,Pre-Eclampsia,C13.703.395.249
21498785,2011-04-15T00:00:00,Pregnancy,G08.686.785.760.769
21498785,2011-04-15T00:00:00,Vitamin D,D04.808.812.768
21536089,2011-04-15T00:00:00,Adult,M01.060.116
21536089,2011-04-15T00:00:00,African Americans,M01.686.508.100.100
21536089,2011-04-15T00:00:00,African Americans,M01.686.754.100
21536089,2011-04-15T00:00:00,Alleles,G05.360.340.024.340.030
21536089,2011-04-15T00:00:00,Antiviral Agents,D27.505.954.122.388
21536089,2011-04-15T00:00:00,European Continental Ancestry Group,M01.686.508.400
21536089,2011-04-15T00:00:00,Genetic Loci,G05.360.340.024.380
21536089,2011-04-15T00:00:00,Genetic Variation,G05.365
21536089,2011-04-15T00:00:00,Hepacivirus,B04.450.410
21536089,2011-04-15T00:00:00,Hepacivirus,B04.820.250.475
21536089,2011-04-15T00:00:00,Hepacivirus,B04.909.777.310.475
21536089,2011-04-15T00:00:00,Hepatitis C,C02.440.440
21536089,2011-04-15T00:00:00,Hepatitis C,C02.782.350.350
21536089,2011-04-15T00:00:00,Hepatitis C,C06.552.380.705.440
21536089,2011-04-15T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21536089,2011-04-15T00:00:00,Interferon-alpha,D12.644.276.374.440.890.250
21536089,2011-04-15T00:00:00,Interferon-alpha,D12.644.276.718.500.250
21536089,2011-04-15T00:00:00,Interferon-alpha,D12.776.467.374.440.890.250
21536089,2011-04-15T00:00:00,Interferon-alpha,D12.776.467.718.500.250
21536089,2011-04-15T00:00:00,Interferon-alpha,D23.529.374.440.890.250
21536089,2011-04-15T00:00:00,Interferon-alpha,D23.529.718.500.250
21536089,2011-04-15T00:00:00,Middle Aged,M01.060.116.630
21536089,2011-04-15T00:00:00,Polyethylene Glycols,D02.033.455.250.700
21536089,2011-04-15T00:00:00,Polyethylene Glycols,D05.750.741
21536089,2011-04-15T00:00:00,Polyethylene Glycols,D25.720.741
21536089,2011-04-15T00:00:00,Polyethylene Glycols,J01.637.051.720.741
21536089,2011-04-15T00:00:00,"RNA, Viral",D13.444.735.828
21536089,2011-04-15T00:00:00,Recombinant Proteins,D12.776.828
21536089,2011-04-15T00:00:00,Treatment Outcome,E01.789.800
21536089,2011-04-15T00:00:00,Treatment Outcome,N04.761.559.590.800
21536089,2011-04-15T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21536089,2011-04-15T00:00:00,United States,Z01.107.567.875
21502318,2011-04-18T00:00:00,Angiotensin II,D06.472.699.094.078
21502318,2011-04-18T00:00:00,Angiotensin II,D12.644.400.070.078
21502318,2011-04-18T00:00:00,Angiotensin II,D12.644.456.073.041
21502318,2011-04-18T00:00:00,Angiotensin II,D12.644.548.058.078
21502318,2011-04-18T00:00:00,Angiotensin II,D12.776.641.650.070.078
21502318,2011-04-18T00:00:00,Angiotensin II,D23.469.050.050.050
21502318,2011-04-18T00:00:00,Arrestins,D12.776.306.090
21502318,2011-04-18T00:00:00,Arrestins,D12.776.543.090
21502318,2011-04-18T00:00:00,Dinoprostone,D10.251.355.255.100.637.250.200
21502318,2011-04-18T00:00:00,Dinoprostone,D10.251.355.255.550.250.200
21502318,2011-04-18T00:00:00,Dinoprostone,D23.469.050.175.725.780.200
21502318,2011-04-18T00:00:00,GTP-Binding Proteins,D08.811.277.040.330.300
21502318,2011-04-18T00:00:00,GTP-Binding Proteins,D12.776.157.325
21502318,2011-04-18T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21502318,2011-04-18T00:00:00,Mitogen-Activated Protein Kinase 1,D08.811.913.696.620.682.700.567.342.500
21502318,2011-04-18T00:00:00,Mitogen-Activated Protein Kinase 1,D08.811.913.696.620.682.700.646.750.249.500
21502318,2011-04-18T00:00:00,Mitogen-Activated Protein Kinase 1,D12.644.360.450.169.500
21502318,2011-04-18T00:00:00,Mitogen-Activated Protein Kinase 1,D12.776.476.450.169.500
21502318,2011-04-18T00:00:00,Mitogen-Activated Protein Kinase 3,D08.811.913.696.620.682.700.567.342.750
21502318,2011-04-18T00:00:00,Mitogen-Activated Protein Kinase 3,D08.811.913.696.620.682.700.646.750.249.750
21502318,2011-04-18T00:00:00,Mitogen-Activated Protein Kinase 3,D12.644.360.450.169.750
21502318,2011-04-18T00:00:00,Mitogen-Activated Protein Kinase 3,D12.776.476.450.169.750
21502318,2011-04-18T00:00:00,Phosphorylation,G02.111.087.677
21502318,2011-04-18T00:00:00,Phosphorylation,G02.149.115.677
21502318,2011-04-18T00:00:00,Phosphorylation,G02.149.465.700
21502318,2011-04-18T00:00:00,Phosphorylation,G02.607.750.700
21502318,2011-04-18T00:00:00,Phosphorylation,G03.495.790
21502318,2011-04-18T00:00:00,Protein Phosphatase 2,D08.811.277.352.650.625.706
21502318,2011-04-18T00:00:00,Protein Phosphatase 2,D12.644.360.583
21502318,2011-04-18T00:00:00,Protein Phosphatase 2,D12.776.476.561
21502318,2011-04-18T00:00:00,"Receptor, Angiotensin, Type 1",D12.776.543.750.100.047.625
21502318,2011-04-18T00:00:00,"Receptor, Angiotensin, Type 1",D12.776.543.750.720.600.150.625
21502318,2011-04-18T00:00:00,"Receptor, Angiotensin, Type 1",D12.776.543.750.750.130.750
21502318,2011-04-18T00:00:00,"Receptor, Angiotensin, Type 1",D12.776.543.750.750.555.150.750
21502318,2011-04-18T00:00:00,Signal Transduction,G02.111.087.800
21502318,2011-04-18T00:00:00,Signal Transduction,G02.149.115.800
21502318,2011-04-18T00:00:00,Signal Transduction,G04.299.880
21502318,2011-04-18T00:00:00,Transcription Factors,D12.776.930
21502318,2011-04-18T00:00:00,Vasoconstrictor Agents,D27.505.954.411.793
21502382,2011-04-18T00:00:00,Adult,M01.060.116
21502382,2011-04-18T00:00:00,Aged,M01.060.116.100
21502382,2011-04-18T00:00:00,Breast Neoplasms,C04.588.180
21502382,2011-04-18T00:00:00,Breast Neoplasms,C17.800.090.500
21502382,2011-04-18T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21502382,2011-04-18T00:00:00,Mammography,E01.370.350.700.500
21502382,2011-04-18T00:00:00,Mass Screening,E01.370.500
21502382,2011-04-18T00:00:00,Mass Screening,E05.318.308.250.580
21502382,2011-04-18T00:00:00,Mass Screening,N02.421.143.827.233.443
21502382,2011-04-18T00:00:00,Mass Screening,N02.421.726.233.443
21502382,2011-04-18T00:00:00,Mass Screening,N05.715.360.300.375.500
21502382,2011-04-18T00:00:00,Mass Screening,N06.850.520.308.250.580
21502382,2011-04-18T00:00:00,Mass Screening,N06.850.780.500
21502382,2011-04-18T00:00:00,Middle Aged,M01.060.116.630
21502382,2011-04-18T00:00:00,Radiographic Image Enhancement,E01.370.350.600.350.700
21502382,2011-04-18T00:00:00,Radiographic Image Enhancement,E01.370.350.700.700
21502382,2011-04-18T00:00:00,Radiographic Image Enhancement,L01.224.308.380.600
21502382,2011-04-18T00:00:00,United States,Z01.107.567.875
21609416,2011-04-18T00:00:00,Adult,M01.060.116
21609416,2011-04-18T00:00:00,Aged,M01.060.116.100
21609416,2011-04-18T00:00:00,Ethnic Groups,M01.686.754
21609416,2011-04-18T00:00:00,Ethnic Groups,N01.224.317
21609416,2011-04-18T00:00:00,Hospital Mortality,E05.318.308.985.550.400
21609416,2011-04-18T00:00:00,Hospital Mortality,L01.280.975.550.400
21609416,2011-04-18T00:00:00,Hospital Mortality,N01.224.935.698.400
21609416,2011-04-18T00:00:00,Hospital Mortality,N06.850.505.400.975.550.400
21609416,2011-04-18T00:00:00,Hospital Mortality,N06.850.520.308.985.550.400
21609416,2011-04-18T00:00:00,Hospitalization,E02.760.400
21609416,2011-04-18T00:00:00,Hospitalization,N02.421.585.400
21609416,2011-04-18T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21609416,2011-04-18T00:00:00,Inpatients,M01.643.470
21609416,2011-04-18T00:00:00,Middle Aged,M01.060.116.630
21609416,2011-04-18T00:00:00,Stroke,C10.228.140.300.775
21609416,2011-04-18T00:00:00,Stroke,C14.907.253.855
21609416,2011-04-18T00:00:00,United States,Z01.107.567.875
21502997,2011-04-19T00:00:00,Career Choice,F02.463.785.373.346.400
21502997,2011-04-19T00:00:00,Gastroenterology,H02.403.429.405
21502997,2011-04-19T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21502997,2011-04-19T00:00:00,Teaching,I02.903
21503742,2011-04-19T00:00:00,Adolescent,M01.060.057
21503742,2011-04-19T00:00:00,Child,M01.060.406
21503742,2011-04-19T00:00:00,"Child, Preschool",M01.060.406.448
21503742,2011-04-19T00:00:00,"Hospitals, Pediatric",N02.278.421.556.437
21503742,2011-04-19T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21503742,2011-04-19T00:00:00,Infant,M01.060.703
21503742,2011-04-19T00:00:00,"Infant, Newborn",M01.060.703.520
21503742,2011-04-19T00:00:00,Medical Order Entry Systems,L01.700.508.300.408.600
21503742,2011-04-19T00:00:00,Medical Order Entry Systems,L01.700.508.300.680.360.450
21503742,2011-04-19T00:00:00,Medical Order Entry Systems,L01.700.508.300.695.600
21503742,2011-04-19T00:00:00,Medical Order Entry Systems,N04.452.442.452.500
21503742,2011-04-19T00:00:00,Medical Order Entry Systems,N04.452.515.360.500
21503742,2011-04-19T00:00:00,Medical Order Entry Systems,N04.452.859.564.650.500
21503742,2011-04-19T00:00:00,United States,Z01.107.567.875
21505092,2011-04-19T00:00:00,Animals,B01.050
21505092,2011-04-19T00:00:00,"Image Processing, Computer-Assisted",L01.224.308
21505092,2011-04-19T00:00:00,Matrix Metalloproteinases,D08.811.277.656.300.480.525
21505092,2011-04-19T00:00:00,Matrix Metalloproteinases,D08.811.277.656.675.374.525
21505092,2011-04-19T00:00:00,Myocardial Infarction,C14.280.647.500
21505092,2011-04-19T00:00:00,Myocardial Infarction,C14.907.585.500
21505092,2011-04-19T00:00:00,Swine,B01.050.150.900.649.077.880
21505092,2011-04-19T00:00:00,"Tomography, Emission-Computed, Single-Photon",E01.370.350.350.800.800
21505092,2011-04-19T00:00:00,"Tomography, Emission-Computed, Single-Photon",E01.370.350.600.350.800.800
21505092,2011-04-19T00:00:00,"Tomography, Emission-Computed, Single-Photon",E01.370.350.710.800.800
21505092,2011-04-19T00:00:00,"Tomography, Emission-Computed, Single-Photon",E01.370.350.825.800.800
21505092,2011-04-19T00:00:00,"Tomography, Emission-Computed, Single-Photon",E01.370.384.730.800.800
21505092,2011-04-19T00:00:00,"Tomography, X-Ray Computed",E01.370.350.350.810
21505092,2011-04-19T00:00:00,"Tomography, X-Ray Computed",E01.370.350.600.350.700.810
21505092,2011-04-19T00:00:00,"Tomography, X-Ray Computed",E01.370.350.700.700.810
21505092,2011-04-19T00:00:00,"Tomography, X-Ray Computed",E01.370.350.700.810.810
21505092,2011-04-19T00:00:00,"Tomography, X-Ray Computed",E01.370.350.825.810.810
21505092,2011-04-19T00:00:00,Ventricular Remodeling,C23.300.985
21505092,2011-04-19T00:00:00,Ventricular Remodeling,G09.330.190.962.975
21505149,2011-04-19T00:00:00,Animals,B01.050
21505149,2011-04-19T00:00:00,Cytokines,D12.644.276.374
21505149,2011-04-19T00:00:00,Cytokines,D12.776.467.374
21505149,2011-04-19T00:00:00,Cytokines,D23.529.374
21505149,2011-04-19T00:00:00,Gene Expression Regulation,G05.355.315
21505149,2011-04-19T00:00:00,Glucose,D09.546.359.448
21505149,2011-04-19T00:00:00,Inflammation,C23.550.470
21505149,2011-04-19T00:00:00,Lipid Metabolism,G03.495.520
21505149,2011-04-19T00:00:00,Lipids,D10
21505149,2011-04-19T00:00:00,Lipoproteins,D10.532
21505149,2011-04-19T00:00:00,Lipoproteins,D12.776.521
21505149,2011-04-19T00:00:00,Liver,A03.620
21282567,2011-04-20T00:00:00,Animals,B01.050
21282567,2011-04-20T00:00:00,Astrocytes,A08.637.200
21282567,2011-04-20T00:00:00,Astrocytes,A11.650.200
21282567,2011-04-20T00:00:00,Lipopolysaccharides,D09.400.500
21282567,2011-04-20T00:00:00,Lipopolysaccharides,D09.698.718.450
21282567,2011-04-20T00:00:00,Lipopolysaccharides,D10.494
21282567,2011-04-20T00:00:00,Lipopolysaccharides,D23.050.161.616.525
21282567,2011-04-20T00:00:00,Lipopolysaccharides,D23.946.123.329.500
21282567,2011-04-20T00:00:00,Microglia,A08.637.400
21282567,2011-04-20T00:00:00,Microglia,A11.650.400
21282567,2011-04-20T00:00:00,Morphine,D03.132.577.249.547
21282567,2011-04-20T00:00:00,Morphine,D03.549.686.575
21282567,2011-04-20T00:00:00,Morphine,D03.605.497.575
21282567,2011-04-20T00:00:00,Morphine,D04.615.723.795.547
21282567,2011-04-20T00:00:00,Rats,B01.050.150.900.649.865.635.505.700
21282567,2011-04-20T00:00:00,"Receptors, Opioid",D12.776.543.750.100.620
21282567,2011-04-20T00:00:00,"Receptors, Opioid",D12.776.543.750.720.600.610
21282567,2011-04-20T00:00:00,"Receptors, Opioid",D12.776.543.750.750.555.610
21282567,2011-04-20T00:00:00,Reperfusion Injury,C14.907.725
21282567,2011-04-20T00:00:00,Reperfusion Injury,C23.550.767.877
21282567,2011-04-20T00:00:00,Retina,A09.371.729
21282567,2011-04-20T00:00:00,Time Factors,G01.910.857
21282567,2011-04-20T00:00:00,Tumor Necrosis Factor-alpha,D12.644.276.374.500.800
21282567,2011-04-20T00:00:00,Tumor Necrosis Factor-alpha,D12.644.276.374.750.626
21282567,2011-04-20T00:00:00,Tumor Necrosis Factor-alpha,D12.644.276.972.626
21282567,2011-04-20T00:00:00,Tumor Necrosis Factor-alpha,D12.776.124.900
21282567,2011-04-20T00:00:00,Tumor Necrosis Factor-alpha,D12.776.395.930
21282567,2011-04-20T00:00:00,Tumor Necrosis Factor-alpha,D12.776.467.374.500.800
21282567,2011-04-20T00:00:00,Tumor Necrosis Factor-alpha,D12.776.467.374.750.626
21282567,2011-04-20T00:00:00,Tumor Necrosis Factor-alpha,D12.776.467.972.626
21282567,2011-04-20T00:00:00,Tumor Necrosis Factor-alpha,D23.529.374.500.800
21282567,2011-04-20T00:00:00,Tumor Necrosis Factor-alpha,D23.529.374.750.626
21282567,2011-04-20T00:00:00,Tumor Necrosis Factor-alpha,D23.529.972.626
21351097,2011-04-20T00:00:00,Animals,B01.050
21351097,2011-04-20T00:00:00,Endoplasmic Reticulum,A11.284.430.214.190.875.248
21351097,2011-04-20T00:00:00,"Gene Expression Regulation, Neoplastic",G05.355.315.370
21351097,2011-04-20T00:00:00,Gene Silencing,G05.355.315.203.374
21351097,2011-04-20T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21351097,2011-04-20T00:00:00,Mitochondria,A11.284.430.214.190.875.564
21351097,2011-04-20T00:00:00,Mitochondria,A11.284.835.626
21351097,2011-04-20T00:00:00,"Neovascularization, Pathologic",C23.550.589.500
21351097,2011-04-20T00:00:00,Ovarian Neoplasms,C04.588.322.455
21351097,2011-04-20T00:00:00,Ovarian Neoplasms,C13.351.500.056.630.705
21351097,2011-04-20T00:00:00,Ovarian Neoplasms,C13.351.937.418.685
21351097,2011-04-20T00:00:00,Ovarian Neoplasms,C19.344.410
21351097,2011-04-20T00:00:00,Ovarian Neoplasms,C19.391.630.705
21351097,2011-04-20T00:00:00,PTEN Phosphohydrolase,D08.811.277.352.650.850
21351097,2011-04-20T00:00:00,PTEN Phosphohydrolase,D12.776.476.590
21351097,2011-04-20T00:00:00,PTEN Phosphohydrolase,D12.776.624.776.695
21351097,2011-04-20T00:00:00,Proto-Oncogene Proteins c-akt,D08.811.913.696.620.682.700.755
21351097,2011-04-20T00:00:00,Proto-Oncogene Proteins c-akt,D12.776.476.565
21351097,2011-04-20T00:00:00,Proto-Oncogene Proteins c-akt,D12.776.624.664.700.168
21351097,2011-04-20T00:00:00,Signal Transduction,G02.111.087.800
21351097,2011-04-20T00:00:00,Signal Transduction,G02.149.115.800
21351097,2011-04-20T00:00:00,Signal Transduction,G04.299.880
21351097,2011-04-20T00:00:00,"Tumor Markers, Biological",D23.101.840
21351097,2011-04-20T00:00:00,Vascular Endothelial Growth Factor A,D12.644.276.100.800.200
21351097,2011-04-20T00:00:00,Vascular Endothelial Growth Factor A,D12.776.467.100.800.200
21351097,2011-04-20T00:00:00,Vascular Endothelial Growth Factor A,D23.529.100.800.200
21507937,2011-04-20T00:00:00,Animals,B01.050
21507937,2011-04-20T00:00:00,Binding Sites,G02.111.570.120
21507937,2011-04-20T00:00:00,CHO Cells,A11.251.210.200
21507937,2011-04-20T00:00:00,CHO Cells,A11.436.155
21507937,2011-04-20T00:00:00,Cricetinae,B01.050.150.900.649.865.635.150
21507937,2011-04-20T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21507937,2011-04-20T00:00:00,Mutation,G05.365.590
21508228,2011-04-20T00:00:00,Animals,B01.050
21508228,2011-04-20T00:00:00,Cataplexy,C10.886.425.800.200.750.500
21508228,2011-04-20T00:00:00,Cataplexy,F03.870.400.800.200.750.500
21508228,2011-04-20T00:00:00,"Disease Models, Animal",C22.232
21508228,2011-04-20T00:00:00,"Disease Models, Animal",E05.598.500
21508228,2011-04-20T00:00:00,"Disease Models, Animal",E05.599.395.080
21508228,2011-04-20T00:00:00,Electroencephalography,E01.370.376.300
21508228,2011-04-20T00:00:00,Electroencephalography,E01.370.405.245
21508228,2011-04-20T00:00:00,Electromyography,E01.370.405.255
21508228,2011-04-20T00:00:00,Electromyography,E01.370.530.255
21508228,2011-04-20T00:00:00,Gene Transfer Techniques,E05.393.350
21508228,2011-04-20T00:00:00,Intracellular Signaling Peptides and Proteins,D12.644.360
21508228,2011-04-20T00:00:00,Intracellular Signaling Peptides and Proteins,D12.776.476
21508228,2011-04-20T00:00:00,Narcolepsy,C10.886.425.800.200.750
21508228,2011-04-20T00:00:00,Narcolepsy,F03.870.400.800.200.750
21508228,2011-04-20T00:00:00,Neurons,A08.663
21508228,2011-04-20T00:00:00,Neurons,A11.671
21508228,2011-04-20T00:00:00,Neuropeptides,D12.644.400
21508228,2011-04-20T00:00:00,Neuropeptides,D12.776.641.650
21508228,2011-04-20T00:00:00,Sleep,F02.830.855
21508228,2011-04-20T00:00:00,Sleep,G11.561.600.815
21508919,2011-04-20T00:00:00,Adolescent,M01.060.057
21508919,2011-04-20T00:00:00,Adult,M01.060.116
21508919,2011-04-20T00:00:00,Age Factors,N05.715.350.075
21508919,2011-04-20T00:00:00,Age Factors,N06.850.490.250
21508919,2011-04-20T00:00:00,Child,M01.060.406
21508919,2011-04-20T00:00:00,"Child, Preschool",M01.060.406.448
21508919,2011-04-20T00:00:00,Exercise Therapy,E02.779.483
21508919,2011-04-20T00:00:00,Exercise Therapy,E02.831.387
21508919,2011-04-20T00:00:00,Gait,E01.370.600.250
21508919,2011-04-20T00:00:00,Gait,G11.427.590.530.389
21508919,2011-04-20T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21508919,2011-04-20T00:00:00,Infant,M01.060.703
21508919,2011-04-20T00:00:00,Neuronal Plasticity,G11.561.600.635
21508919,2011-04-20T00:00:00,Postural Balance,G11.427.690
21508919,2011-04-20T00:00:00,Postural Balance,G11.561.600.810.541.595
21508919,2011-04-20T00:00:00,Recovery of Function,G16.757
21508919,2011-04-20T00:00:00,Walking,G11.427.590.530.568.900
21508919,2011-04-20T00:00:00,Walking,G11.427.590.530.698.940
21508919,2011-04-20T00:00:00,Walking,I03.450.642.845.940
21508919,2011-04-20T00:00:00,Young Adult,M01.060.116.815
21509848,2011-04-20T00:00:00,Polymers,D05.750
21509848,2011-04-20T00:00:00,Polymers,D25.720
21509848,2011-04-20T00:00:00,Polymers,J01.637.051.720
21509848,2011-04-20T00:00:00,Surface Properties,G02.842.850
21533102,2011-04-20T00:00:00,Animals,B01.050
21533102,2011-04-20T00:00:00,"Disease Models, Animal",C22.232
21533102,2011-04-20T00:00:00,"Disease Models, Animal",E05.598.500
21533102,2011-04-20T00:00:00,"Disease Models, Animal",E05.599.395.080
21533102,2011-04-20T00:00:00,Inflammation,C23.550.470
21533102,2011-04-20T00:00:00,Phosphorylation,G02.111.087.677
21533102,2011-04-20T00:00:00,Phosphorylation,G02.149.115.677
21533102,2011-04-20T00:00:00,Phosphorylation,G02.149.465.700
21533102,2011-04-20T00:00:00,Phosphorylation,G02.607.750.700
21533102,2011-04-20T00:00:00,Phosphorylation,G03.495.790
21533102,2011-04-20T00:00:00,Tumor Necrosis Factor-alpha,D12.644.276.374.500.800
21533102,2011-04-20T00:00:00,Tumor Necrosis Factor-alpha,D12.644.276.374.750.626
21533102,2011-04-20T00:00:00,Tumor Necrosis Factor-alpha,D12.644.276.972.626
21533102,2011-04-20T00:00:00,Tumor Necrosis Factor-alpha,D12.776.124.900
21533102,2011-04-20T00:00:00,Tumor Necrosis Factor-alpha,D12.776.395.930
21533102,2011-04-20T00:00:00,Tumor Necrosis Factor-alpha,D12.776.467.374.500.800
21533102,2011-04-20T00:00:00,Tumor Necrosis Factor-alpha,D12.776.467.374.750.626
21533102,2011-04-20T00:00:00,Tumor Necrosis Factor-alpha,D12.776.467.972.626
21533102,2011-04-20T00:00:00,Tumor Necrosis Factor-alpha,D23.529.374.500.800
21533102,2011-04-20T00:00:00,Tumor Necrosis Factor-alpha,D23.529.374.750.626
21533102,2011-04-20T00:00:00,Tumor Necrosis Factor-alpha,D23.529.972.626
21533102,2011-04-20T00:00:00,p38 Mitogen-Activated Protein Kinases,D08.811.913.696.620.682.700.567.878
21533102,2011-04-20T00:00:00,p38 Mitogen-Activated Protein Kinases,D08.811.913.696.620.682.700.646.750.843
21533102,2011-04-20T00:00:00,p38 Mitogen-Activated Protein Kinases,D12.644.360.450.835
21533102,2011-04-20T00:00:00,p38 Mitogen-Activated Protein Kinases,D12.776.476.450.835
21550594,2011-04-20T00:00:00,"Analgesics, Opioid",D27.505.696.663.850.014.520
21550594,2011-04-20T00:00:00,"Analgesics, Opioid",D27.505.954.427.040.325
21550594,2011-04-20T00:00:00,"Analgesics, Opioid",D27.505.954.427.210.049
21550594,2011-04-20T00:00:00,Animals,B01.050
21550594,2011-04-20T00:00:00,"Disease Models, Animal",C22.232
21550594,2011-04-20T00:00:00,"Disease Models, Animal",E05.598.500
21550594,2011-04-20T00:00:00,"Disease Models, Animal",E05.599.395.080
21550594,2011-04-20T00:00:00,Neuropeptides,D12.644.400
21550594,2011-04-20T00:00:00,Neuropeptides,D12.776.641.650
21550594,2011-04-20T00:00:00,Oligopeptides,D12.644.456
21550594,2011-04-20T00:00:00,Peripheral Nervous System Diseases,C10.668.829
21550594,2011-04-20T00:00:00,Rats,B01.050.150.900.649.865.635.505.700
21550594,2011-04-20T00:00:00,"Rats, Sprague-Dawley",B01.050.150.900.649.865.635.505.700.750
21550594,2011-04-20T00:00:00,"Receptors, Neuropeptide",D12.776.543.750.720.600
21550594,2011-04-20T00:00:00,"Receptors, Neuropeptide",D12.776.543.750.750.555
21550594,2011-04-20T00:00:00,"Receptors, Opioid, delta",D12.776.543.750.100.620.200
21550594,2011-04-20T00:00:00,"Receptors, Opioid, delta",D12.776.543.750.720.600.610.200
21550594,2011-04-20T00:00:00,"Receptors, Opioid, delta",D12.776.543.750.750.555.610.200
21515541,2011-04-21T00:00:00,Adult,M01.060.116
21515541,2011-04-21T00:00:00,African Americans,M01.686.508.100.100
21515541,2011-04-21T00:00:00,African Americans,M01.686.754.100
21515541,2011-04-21T00:00:00,Aged,M01.060.116.100
21515541,2011-04-21T00:00:00,"Diabetes Mellitus, Type 2",C18.452.394.750.149
21515541,2011-04-21T00:00:00,"Diabetes Mellitus, Type 2",C19.246.300
21515541,2011-04-21T00:00:00,"Emergency Service, Hospital",N02.278.354.422.336
21515541,2011-04-21T00:00:00,"Emergency Service, Hospital",N02.421.297.195
21515541,2011-04-21T00:00:00,"Emergency Service, Hospital",N04.452.442.422.336
21515541,2011-04-21T00:00:00,Emotions,F01.470
21515541,2011-04-21T00:00:00,"Health Knowledge, Attitudes, Practice",F01.100.150.500
21515541,2011-04-21T00:00:00,"Health Knowledge, Attitudes, Practice",N05.300.150.410
21515541,2011-04-21T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21515541,2011-04-21T00:00:00,Middle Aged,M01.060.116.630
21515541,2011-04-21T00:00:00,Patient Education as Topic,I02.233.332.500
21515541,2011-04-21T00:00:00,Patient Education as Topic,N02.421.143.827.407.680
21515541,2011-04-21T00:00:00,Patient Education as Topic,N02.421.726.407.680
21515541,2011-04-21T00:00:00,Self Care,E02.900
21515541,2011-04-21T00:00:00,Self Care,N02.421.784.680
21515541,2011-04-21T00:00:00,South Carolina,Z01.107.567.875.075.662
21515541,2011-04-21T00:00:00,South Carolina,Z01.107.567.875.750.700
21515823,2011-04-22T00:00:00,Adolescent,M01.060.057
21515823,2011-04-22T00:00:00,"Anemia, Sickle Cell",C15.378.071.141.150.150
21515823,2011-04-22T00:00:00,"Anemia, Sickle Cell",C15.378.420.155
21515823,2011-04-22T00:00:00,"Anemia, Sickle Cell",C16.320.070.150
21515823,2011-04-22T00:00:00,"Anemia, Sickle Cell",C16.320.365.155
21515823,2011-04-22T00:00:00,Child,M01.060.406
21515823,2011-04-22T00:00:00,"Child, Preschool",M01.060.406.448
21515823,2011-04-22T00:00:00,Genetic Predisposition to Disease,C23.550.291.687.500
21515823,2011-04-22T00:00:00,Genetic Predisposition to Disease,G05.380.355
21515823,2011-04-22T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21515823,2011-04-22T00:00:00,"Polymorphism, Single Nucleotide",G05.365.795.598
21515823,2011-04-22T00:00:00,Risk Factors,E05.318.740.600.800.725
21515823,2011-04-22T00:00:00,Risk Factors,N05.715.350.200.700
21515823,2011-04-22T00:00:00,Risk Factors,N05.715.360.750.625.700.700
21515823,2011-04-22T00:00:00,Risk Factors,N06.850.490.625.750
21515823,2011-04-22T00:00:00,Risk Factors,N06.850.520.830.600.800.725
21515823,2011-04-22T00:00:00,Stroke,C10.228.140.300.775
21515823,2011-04-22T00:00:00,Stroke,C14.907.253.855
21536062,2011-04-22T00:00:00,Animals,B01.050
21536062,2011-04-22T00:00:00,Glutamic Acid,D12.125.067.750
21536062,2011-04-22T00:00:00,Glutamic Acid,D12.125.119.450
21536062,2011-04-22T00:00:00,Glutamic Acid,D12.125.427.300
21536062,2011-04-22T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21536062,2011-04-22T00:00:00,Mental Disorders,F03
21536062,2011-04-22T00:00:00,Substance-Related Disorders,C21.739
21536062,2011-04-22T00:00:00,Substance-Related Disorders,F03.900
21558000,2011-04-22T00:00:00,Glutathione,D12.644.456.448
21558000,2011-04-22T00:00:00,Glutathione Transferase,D08.811.913.225.500
21558000,2011-04-22T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21558000,2011-04-22T00:00:00,Neoplasms,C04
21558000,2011-04-22T00:00:00,Signal Transduction,G02.111.087.800
21558000,2011-04-22T00:00:00,Signal Transduction,G02.149.115.800
21558000,2011-04-22T00:00:00,Signal Transduction,G04.299.880
21762365,2011-04-22T00:00:00,Antihypertensive Agents,D27.505.954.411.162
21762365,2011-04-22T00:00:00,"Blood Pressure Monitoring, Ambulatory",E01.370.370.140.100
21762365,2011-04-22T00:00:00,"Blood Pressure Monitoring, Ambulatory",E01.370.520.500.100
21762365,2011-04-22T00:00:00,Disease Progression,C23.550.291.656
21762365,2011-04-22T00:00:00,"Education, Medical, Continuing",I02.358.212.350
21762365,2011-04-22T00:00:00,"Education, Medical, Continuing",I02.358.399.250
21762365,2011-04-22T00:00:00,Health Personnel,M01.526.485
21762365,2011-04-22T00:00:00,Health Personnel,N02.360
21762365,2011-04-22T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21762365,2011-04-22T00:00:00,Hypertension,C14.907.489
21762365,2011-04-22T00:00:00,Middle Aged,M01.060.116.630
21762365,2011-04-22T00:00:00,Needs Assessment,I02.594
21762365,2011-04-22T00:00:00,Needs Assessment,N03.349.380.565
21762365,2011-04-22T00:00:00,Needs Assessment,N05.300.537
21762365,2011-04-22T00:00:00,Program Evaluation,E05.337.820
21762365,2011-04-22T00:00:00,Program Evaluation,N04.761.685
21762365,2011-04-22T00:00:00,Program Evaluation,N05.715.360.650
21762365,2011-04-22T00:00:00,Staff Development,I02.574.700
21762365,2011-04-22T00:00:00,Staff Development,N04.452.677.822
21545791,2011-04-24T00:00:00,Animals,B01.050
21545791,2011-04-24T00:00:00,Antineoplastic Agents,D27.505.954.248
21545791,2011-04-24T00:00:00,"Carcinoma, Squamous Cell",C04.557.470.200.400
21545791,2011-04-24T00:00:00,"Carcinoma, Squamous Cell",C04.557.470.700.400
21545791,2011-04-24T00:00:00,Ceramides,D02.065.313
21545791,2011-04-24T00:00:00,Ceramides,D09.400.410.420.525.200
21545791,2011-04-24T00:00:00,Ceramides,D10.390.470.675.200
21545791,2011-04-24T00:00:00,Ceramides,D10.570.877.360.612.200
21545791,2011-04-24T00:00:00,Head and Neck Neoplasms,C04.588.443
21545791,2011-04-24T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21545791,2011-04-24T00:00:00,Lysophospholipids,D10.570.755.375.760.550
21545791,2011-04-24T00:00:00,Photochemotherapy,E02.186.500
21545791,2011-04-24T00:00:00,Photochemotherapy,E02.319.685
21545791,2011-04-24T00:00:00,Photochemotherapy,E02.774.722
21545791,2011-04-24T00:00:00,Photosensitizing Agents,D27.505.696.750.710
21545791,2011-04-24T00:00:00,Photosensitizing Agents,D27.505.954.444.600
21545791,2011-04-24T00:00:00,Propanolamines,D02.033.100.624
21545791,2011-04-24T00:00:00,Propanolamines,D02.033.755.624
21545791,2011-04-24T00:00:00,Propanolamines,D02.092.063.624
21545791,2011-04-24T00:00:00,Pyridinium Compounds,D03.383.725.762
21545791,2011-04-24T00:00:00,Sphingolipids,D10.570.877
21545791,2011-04-24T00:00:00,Sphingolipids,D10.808
21545791,2011-04-24T00:00:00,Sphingosine,D02.033.100.700
21545791,2011-04-24T00:00:00,Sphingosine,D02.033.455.843
21545791,2011-04-24T00:00:00,Sphingosine,D02.092.063.700
21518449,2011-04-25T00:00:00,Adult,M01.060.116
21518449,2011-04-25T00:00:00,Aged,M01.060.116.100
21518449,2011-04-25T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21518449,2011-04-25T00:00:00,Middle Aged,M01.060.116.630
21518449,2011-04-25T00:00:00,Nasal Cavity,A04.531.449
21518449,2011-04-25T00:00:00,Regression Analysis,E05.318.740.750
21518449,2011-04-25T00:00:00,Regression Analysis,N05.715.360.750.695
21518449,2011-04-25T00:00:00,Regression Analysis,N06.850.520.830.750
21518449,2011-04-25T00:00:00,SEER Program,E05.318.308.970.725
21518449,2011-04-25T00:00:00,SEER Program,L01.280.950.725
21518449,2011-04-25T00:00:00,SEER Program,N04.452.859.819.725
21518449,2011-04-25T00:00:00,SEER Program,N05.715.360.300.715.700.725
21518449,2011-04-25T00:00:00,SEER Program,N06.850.520.308.970.725
21518449,2011-04-25T00:00:00,Treatment Outcome,E01.789.800
21518449,2011-04-25T00:00:00,Treatment Outcome,N04.761.559.590.800
21518449,2011-04-25T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21519339,2011-04-26T00:00:00,"Adaptation, Physiological",G07.700.062
21519339,2011-04-26T00:00:00,"Adaptation, Physiological",G16.100.057.500
21519339,2011-04-26T00:00:00,"Behavior, Addictive",F01.145.527.100.120
21519339,2011-04-26T00:00:00,Glutamic Acid,D12.125.067.750
21519339,2011-04-26T00:00:00,Glutamic Acid,D12.125.119.450
21519339,2011-04-26T00:00:00,Glutamic Acid,D12.125.427.300
21519339,2011-04-26T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21519339,2011-04-26T00:00:00,Neural Pathways,A08.612
21519339,2011-04-26T00:00:00,Neuronal Plasticity,G11.561.600.635
21519339,2011-04-26T00:00:00,Nucleus Accumbens,A08.186.211.730.885.287.249.683
21519339,2011-04-26T00:00:00,Prefrontal Cortex,A08.186.211.730.885.287.500.270.700
21519339,2011-04-26T00:00:00,Substance-Related Disorders,C21.739
21519339,2011-04-26T00:00:00,Substance-Related Disorders,F03.900
21520490,2011-04-26T00:00:00,Animals,B01.050
21520490,2011-04-26T00:00:00,Anticarcinogenic Agents,D27.505.696.706.018
21520490,2011-04-26T00:00:00,Anticarcinogenic Agents,D27.505.954.248.125
21520490,2011-04-26T00:00:00,Anticarcinogenic Agents,D27.720.799.018
21520490,2011-04-26T00:00:00,Apoptosis,G04.299.139.160
21520490,2011-04-26T00:00:00,Fas Ligand Protein,D12.644.276.374.750.249
21520490,2011-04-26T00:00:00,Fas Ligand Protein,D12.644.276.972.249
21520490,2011-04-26T00:00:00,Fas Ligand Protein,D12.776.395.550.312
21520490,2011-04-26T00:00:00,Fas Ligand Protein,D12.776.467.374.750.249
21520490,2011-04-26T00:00:00,Fas Ligand Protein,D12.776.467.972.249
21520490,2011-04-26T00:00:00,Fas Ligand Protein,D12.776.543.550.312
21520490,2011-04-26T00:00:00,Fas Ligand Protein,D23.050.301.264.035.283
21520490,2011-04-26T00:00:00,Fas Ligand Protein,D23.101.100.110.282
21520490,2011-04-26T00:00:00,Fas Ligand Protein,D23.529.374.750.249
21520490,2011-04-26T00:00:00,Fas Ligand Protein,D23.529.972.249
21520490,2011-04-26T00:00:00,"Gene Expression Regulation, Neoplastic",G05.355.315.370
21520490,2011-04-26T00:00:00,NF-kappa B,D12.776.260.600
21520490,2011-04-26T00:00:00,NF-kappa B,D12.776.660.600
21520490,2011-04-26T00:00:00,NF-kappa B,D12.776.930.600
21520490,2011-04-26T00:00:00,"Receptors, Aryl Hydrocarbon",D12.776.260.698.209.715
21520490,2011-04-26T00:00:00,"Receptors, Aryl Hydrocarbon",D12.776.826.209.715
21520490,2011-04-26T00:00:00,"Receptors, Aryl Hydrocarbon",D12.776.930.662
21520490,2011-04-26T00:00:00,"Receptors, Aryl Hydrocarbon",D12.776.930.669.209.715
21520490,2011-04-26T00:00:00,Stilbenes,D02.455.426.559.389.150.700
21524201,2011-04-27T00:00:00,Adult,M01.060.116
21524201,2011-04-27T00:00:00,Health Surveys,E05.318.308.250
21524201,2011-04-27T00:00:00,Health Surveys,N05.715.360.300.375
21524201,2011-04-27T00:00:00,Health Surveys,N06.850.520.308.250
21524201,2011-04-27T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21524201,2011-04-27T00:00:00,Internet,L01.224.230.110.500
21524201,2011-04-27T00:00:00,Middle Aged,M01.060.116.630
21524201,2011-04-27T00:00:00,Patient Acceptance of Health Care,N05.300.150.600
21524201,2011-04-27T00:00:00,Patient Education as Topic,I02.233.332.500
21524201,2011-04-27T00:00:00,Patient Education as Topic,N02.421.143.827.407.680
21524201,2011-04-27T00:00:00,Patient Education as Topic,N02.421.726.407.680
21524201,2011-04-27T00:00:00,Rural Population,N01.600.725
21524201,2011-04-27T00:00:00,United States,Z01.107.567.875
21524201,2011-04-27T00:00:00,Young Adult,M01.060.116.815
21525430,2011-04-27T00:00:00,Animals,B01.050
21525430,2011-04-27T00:00:00,Epithelial Cells,A11.436
21525430,2011-04-27T00:00:00,"Microscopy, Confocal",E01.370.350.515.395
21525430,2011-04-27T00:00:00,"Microscopy, Confocal",E05.595.395
21525430,2011-04-27T00:00:00,"Microscopy, Electron, Transmission",E01.370.350.515.402.580
21525430,2011-04-27T00:00:00,"Microscopy, Electron, Transmission",E05.595.402.580
21525430,2011-04-27T00:00:00,Protein Transport,G03.495.166.700
21525430,2011-04-27T00:00:00,Rabbits,B01.050.150.900.649.521.700
21525430,2011-04-27T00:00:00,Recombinant Fusion Proteins,D12.776.828.300
21525430,2011-04-27T00:00:00,Time Factors,G01.910.857
21525430,2011-04-27T00:00:00,rab GTP-Binding Proteins,D08.811.277.040.330.300.400.400
21525430,2011-04-27T00:00:00,rab GTP-Binding Proteins,D12.644.360.525.400
21525430,2011-04-27T00:00:00,rab GTP-Binding Proteins,D12.776.157.325.515.400
21525430,2011-04-27T00:00:00,rab GTP-Binding Proteins,D12.776.476.525.400
21592479,2011-04-27T00:00:00,Biological Markers,D23.101
21592479,2011-04-27T00:00:00,Cardiovascular Diseases,C14
21592479,2011-04-27T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21592479,2011-04-27T00:00:00,Lipids,D10
21592479,2011-04-27T00:00:00,Primary Prevention,N02.421.726.758
21592479,2011-04-27T00:00:00,Primary Prevention,N06.850.780.680
21592479,2011-04-27T00:00:00,Randomized Controlled Trials as Topic,E05.318.760.535.365.500
21592479,2011-04-27T00:00:00,Randomized Controlled Trials as Topic,E05.337.250.365.500
21592479,2011-04-27T00:00:00,Randomized Controlled Trials as Topic,N05.715.360.775.235.387.500
21592479,2011-04-27T00:00:00,Randomized Controlled Trials as Topic,N06.850.520.450.535.365.500
21592479,2011-04-27T00:00:00,Risk Assessment,E05.318.740.600.800.715
21592479,2011-04-27T00:00:00,Risk Assessment,N04.452.871.715
21592479,2011-04-27T00:00:00,Risk Assessment,N05.715.360.750.625.700.690
21592479,2011-04-27T00:00:00,Risk Assessment,N06.850.505.715
21592479,2011-04-27T00:00:00,Risk Assessment,N06.850.520.830.600.800.715
21592479,2011-04-27T00:00:00,Risk Factors,E05.318.740.600.800.725
21592479,2011-04-27T00:00:00,Risk Factors,N05.715.350.200.700
21592479,2011-04-27T00:00:00,Risk Factors,N05.715.360.750.625.700.700
21592479,2011-04-27T00:00:00,Risk Factors,N06.850.490.625.750
21592479,2011-04-27T00:00:00,Risk Factors,N06.850.520.830.600.800.725
21592479,2011-04-27T00:00:00,Treatment Outcome,E01.789.800
21592479,2011-04-27T00:00:00,Treatment Outcome,N04.761.559.590.800
21592479,2011-04-27T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21596012,2011-04-27T00:00:00,Adult,M01.060.116
21596012,2011-04-27T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21596012,2011-04-27T00:00:00,Life Change Events,F01.829.458.410
21596012,2011-04-27T00:00:00,Mood Disorders,F03.600
21596012,2011-04-27T00:00:00,Schizophrenia,F03.700.750
21596012,2011-04-27T00:00:00,"Stress Disorders, Post-Traumatic",F03.080.931.500
21649770,2011-04-27T00:00:00,Adolescent,M01.060.057
21649770,2011-04-27T00:00:00,Anti-Obesity Agents,D27.505.954.427.140
21649770,2011-04-27T00:00:00,Bariatric Surgery,E02.065.062
21649770,2011-04-27T00:00:00,Bariatric Surgery,E04.062
21649770,2011-04-27T00:00:00,Body Mass Index,E01.370.600.115.100.125
21649770,2011-04-27T00:00:00,Body Mass Index,E05.041.124.125
21649770,2011-04-27T00:00:00,Body Mass Index,G07.100.100.125
21649770,2011-04-27T00:00:00,Body Mass Index,N06.850.505.200.100.175
21649770,2011-04-27T00:00:00,Child,M01.060.406
21649770,2011-04-27T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21649770,2011-04-27T00:00:00,Hypoglycemic Agents,D27.505.696.422
21649770,2011-04-27T00:00:00,Lactones,D02.540
21649770,2011-04-27T00:00:00,Life Style,F01.829.458
21649770,2011-04-27T00:00:00,Obesity,C18.654.726.500
21649770,2011-04-27T00:00:00,Obesity,C23.888.144.699.500
21649770,2011-04-27T00:00:00,Obesity,E01.370.600.115.100.160.120.699.500
21649770,2011-04-27T00:00:00,Obesity,G07.100.100.160.120.699.500
21649770,2011-04-27T00:00:00,Pediatrics,H02.403.670
21649770,2011-04-27T00:00:00,Primary Health Care,N04.590.233.727
21649770,2011-04-27T00:00:00,Risk Factors,E05.318.740.600.800.725
21649770,2011-04-27T00:00:00,Risk Factors,N05.715.350.200.700
21649770,2011-04-27T00:00:00,Risk Factors,N05.715.360.750.625.700.700
21649770,2011-04-27T00:00:00,Risk Factors,N06.850.490.625.750
21649770,2011-04-27T00:00:00,Risk Factors,N06.850.520.830.600.800.725
21527515,2011-04-28T00:00:00,Animals,B01.050
21527515,2011-04-28T00:00:00,Antineoplastic Combined Chemotherapy Protocols,E02.183.750.500
21527515,2011-04-28T00:00:00,Antineoplastic Combined Chemotherapy Protocols,E02.319.077.500
21527515,2011-04-28T00:00:00,Antineoplastic Combined Chemotherapy Protocols,E02.319.310.037
21527515,2011-04-28T00:00:00,"Drug Resistance, Neoplasm",G07.690.320.395
21527515,2011-04-28T00:00:00,"Fusion Proteins, bcr-abl",D08.811.913.696.620.682.725.500.500
21527515,2011-04-28T00:00:00,"Fusion Proteins, bcr-abl",D12.776.602.500.500.100
21527515,2011-04-28T00:00:00,"Fusion Proteins, bcr-abl",D12.776.624.100
21527515,2011-04-28T00:00:00,"Fusion Proteins, bcr-abl",D12.776.624.664.500.100
21527515,2011-04-28T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21527515,2011-04-28T00:00:00,"Leukemia, Myelogenous, Chronic, BCR-ABL Positive",C04.557.337.539.250
21527515,2011-04-28T00:00:00,"Leukemia, Myelogenous, Chronic, BCR-ABL Positive",C15.378.190.636.370
21527515,2011-04-28T00:00:00,Lysophospholipids,D10.570.755.375.760.550
21527515,2011-04-28T00:00:00,Phosphorylation,G02.111.087.677
21527515,2011-04-28T00:00:00,Phosphorylation,G02.149.115.677
21527515,2011-04-28T00:00:00,Phosphorylation,G02.149.465.700
21527515,2011-04-28T00:00:00,Phosphorylation,G02.607.750.700
21527515,2011-04-28T00:00:00,Phosphorylation,G03.495.790
21527515,2011-04-28T00:00:00,Phosphotransferases (Alcohol Group Acceptor),D08.811.913.696.620
21527515,2011-04-28T00:00:00,Piperazines,D03.383.606
21527515,2011-04-28T00:00:00,Protein Phosphatase 2,D08.811.277.352.650.625.706
21527515,2011-04-28T00:00:00,Protein Phosphatase 2,D12.644.360.583
21527515,2011-04-28T00:00:00,Protein Phosphatase 2,D12.776.476.561
21527515,2011-04-28T00:00:00,Pyrimidines,D03.383.742
21527515,2011-04-28T00:00:00,"Receptors, Lysosphingolipid",D12.776.543.750.100.420.500
21527515,2011-04-28T00:00:00,Signal Transduction,G02.111.087.800
21527515,2011-04-28T00:00:00,Signal Transduction,G02.149.115.800
21527515,2011-04-28T00:00:00,Signal Transduction,G04.299.880
21527515,2011-04-28T00:00:00,Sphingosine,D02.033.100.700
21527515,2011-04-28T00:00:00,Sphingosine,D02.033.455.843
21527515,2011-04-28T00:00:00,Sphingosine,D02.092.063.700
21530935,2011-04-29T00:00:00,African Continental Ancestry Group,M01.686.508.100
21530935,2011-04-29T00:00:00,Atrial Fibrillation,C14.280.067.198
21530935,2011-04-29T00:00:00,Atrial Fibrillation,C23.550.073.198
21530935,2011-04-29T00:00:00,Blood Glucose,D09.546.359.448.500
21530935,2011-04-29T00:00:00,"Cholesterol, HDL",D10.532.432.400
21530935,2011-04-29T00:00:00,"Cholesterol, HDL",D10.570.938.208.270
21530935,2011-04-29T00:00:00,"Cholesterol, HDL",D12.776.521.479.470
21530935,2011-04-29T00:00:00,European Continental Ancestry Group,M01.686.508.400
21530935,2011-04-29T00:00:00,Health Surveys,E05.318.308.250
21530935,2011-04-29T00:00:00,Health Surveys,N05.715.360.300.375
21530935,2011-04-29T00:00:00,Health Surveys,N06.850.520.308.250
21530935,2011-04-29T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21530935,2011-04-29T00:00:00,Hypertension,C14.907.489
21530935,2011-04-29T00:00:00,Metabolic Syndrome X,C18.452.394.968.500.570
21530935,2011-04-29T00:00:00,Metabolic Syndrome X,C18.452.625
21530935,2011-04-29T00:00:00,Middle Aged,M01.060.116.630
21530935,2011-04-29T00:00:00,United States,Z01.107.567.875
21557964,2011-04-29T00:00:00,Central Nervous System Stimulants,D27.505.696.282
21557964,2011-04-29T00:00:00,Central Nervous System Stimulants,D27.505.954.427.220
21557964,2011-04-29T00:00:00,Cholinesterase Inhibitors,D27.505.519.389.275
21557964,2011-04-29T00:00:00,Cholinesterase Inhibitors,D27.505.519.625.120.300
21557964,2011-04-29T00:00:00,Cholinesterase Inhibitors,D27.505.696.577.120.300
21557964,2011-04-29T00:00:00,Cognition,F02.463.188
21557964,2011-04-29T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21557964,2011-04-29T00:00:00,Nicotinic Agonists,D27.505.519.625.120.140.700
21557964,2011-04-29T00:00:00,Nicotinic Agonists,D27.505.696.577.120.140.700
21557964,2011-04-29T00:00:00,Substance-Related Disorders,C21.739
21557964,2011-04-29T00:00:00,Substance-Related Disorders,F03.900
21559496,2011-04-29T00:00:00,Acetylglucosamine,D09.067.342.531.050
21559496,2011-04-29T00:00:00,Animals,B01.050
21559496,2011-04-29T00:00:00,Anti-Infective Agents,D27.505.954.122
21559496,2011-04-29T00:00:00,Cytokines,D12.644.276.374
21559496,2011-04-29T00:00:00,Cytokines,D12.776.467.374
21559496,2011-04-29T00:00:00,Cytokines,D23.529.374
21559496,2011-04-29T00:00:00,Endothelial Cells,A11.436.275
21559496,2011-04-29T00:00:00,Keratinocytes,A11.436.397
21559496,2011-04-29T00:00:00,"Microscopy, Fluorescence",E01.370.350.515.458
21559496,2011-04-29T00:00:00,"Microscopy, Fluorescence",E05.595.458
21559496,2011-04-29T00:00:00,Proto-Oncogene Proteins c-akt,D08.811.913.696.620.682.700.755
21559496,2011-04-29T00:00:00,Proto-Oncogene Proteins c-akt,D12.776.476.565
21559496,2011-04-29T00:00:00,Proto-Oncogene Proteins c-akt,D12.776.624.664.700.168
21559496,2011-04-29T00:00:00,Wound Healing,G16.100.856.891
21559496,2011-04-29T00:00:00,beta-Defensins,D12.644.050.200.075
21559496,2011-04-29T00:00:00,beta-Defensins,D12.776.543.695.054.200.075
21531408,2011-04-30T00:00:00,Aged,M01.060.116.100
21531408,2011-04-30T00:00:00,"Cholangiopancreatography, Endoscopic Retrograde",E01.370.350.700.715.200.200
21531408,2011-04-30T00:00:00,"Cholangiopancreatography, Endoscopic Retrograde",E01.370.372.200.200
21531408,2011-04-30T00:00:00,"Cholangiopancreatography, Endoscopic Retrograde",E01.370.372.250.200
21531408,2011-04-30T00:00:00,"Cholangiopancreatography, Endoscopic Retrograde",E01.370.388.250.250.160
21531408,2011-04-30T00:00:00,"Cholangiopancreatography, Endoscopic Retrograde",E04.210.240.160
21531408,2011-04-30T00:00:00,"Cholangiopancreatography, Endoscopic Retrograde",E04.800.250.250.160
21531408,2011-04-30T00:00:00,Debridement,E04.176
21531408,2011-04-30T00:00:00,"Decompression, Surgical",E04.188
21531408,2011-04-30T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21531408,2011-04-30T00:00:00,Stents,E07.695.750
21531408,2011-04-30T00:00:00,"Tomography, X-Ray Computed",E01.370.350.350.810
21531408,2011-04-30T00:00:00,"Tomography, X-Ray Computed",E01.370.350.600.350.700.810
21531408,2011-04-30T00:00:00,"Tomography, X-Ray Computed",E01.370.350.700.700.810
21531408,2011-04-30T00:00:00,"Tomography, X-Ray Computed",E01.370.350.700.810.810
21531408,2011-04-30T00:00:00,"Tomography, X-Ray Computed",E01.370.350.825.810.810
21531438,2011-04-30T00:00:00,Ethylene Dichlorides,D02.455.326.146.379.350
21531438,2011-04-30T00:00:00,Ethylene Dichlorides,D02.455.526.439.458
21531438,2011-04-30T00:00:00,Trichloroethylene,D02.455.526.439.939
21076283,2011-05-01T00:00:00,Delphi Technique,L01.280.800.310
21076283,2011-05-01T00:00:00,Mass Casualty Incidents,I01.198.240.856.800.537
21076283,2011-05-01T00:00:00,Mass Casualty Incidents,I01.880.735.900.800.575
21076283,2011-05-01T00:00:00,Mass Casualty Incidents,N06.230.100.160
21076283,2011-05-01T00:00:00,"Models, Theoretical",E05.599
21301357,2011-05-01T00:00:00,Antineoplastic Agents,D27.505.954.248
21301357,2011-05-01T00:00:00,Clinical Trials as Topic,E05.318.760.535
21301357,2011-05-01T00:00:00,Clinical Trials as Topic,E05.337.250
21301357,2011-05-01T00:00:00,Clinical Trials as Topic,N05.715.360.775.235
21301357,2011-05-01T00:00:00,Clinical Trials as Topic,N06.850.520.450.535
21301357,2011-05-01T00:00:00,Combined Modality Therapy,E02.186
21301357,2011-05-01T00:00:00,Esophageal Neoplasms,C04.588.274.476.205
21301357,2011-05-01T00:00:00,Esophageal Neoplasms,C04.588.443.353
21301357,2011-05-01T00:00:00,Esophageal Neoplasms,C06.301.371.205
21301357,2011-05-01T00:00:00,Esophageal Neoplasms,C06.405.117.430
21301357,2011-05-01T00:00:00,Esophageal Neoplasms,C06.405.249.205
21301357,2011-05-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21301357,2011-05-01T00:00:00,Treatment Outcome,E01.789.800
21301357,2011-05-01T00:00:00,Treatment Outcome,N04.761.559.590.800
21301357,2011-05-01T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21311374,2011-05-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21311374,2011-05-01T00:00:00,Intracranial Aneurysm,C10.228.140.300.510.600
21311374,2011-05-01T00:00:00,Intracranial Aneurysm,C14.907.055.635
21311374,2011-05-01T00:00:00,Intracranial Aneurysm,C14.907.253.560.300
21311374,2011-05-01T00:00:00,Middle Aged,M01.060.116.630
21311374,2011-05-01T00:00:00,Reconstructive Surgical Procedures,E04.680
21311374,2011-05-01T00:00:00,Stents,E07.695.750
21312187,2011-05-01T00:00:00,Animals,B01.050
21312187,2011-05-01T00:00:00,"Disease Models, Animal",C22.232
21312187,2011-05-01T00:00:00,"Disease Models, Animal",E05.598.500
21312187,2011-05-01T00:00:00,"Disease Models, Animal",E05.599.395.080
21312187,2011-05-01T00:00:00,"Lung Diseases, Interstitial",C08.381.483
21312187,2011-05-01T00:00:00,Pulmonary Fibrosis,C08.381.765
21312187,2011-05-01T00:00:00,Thrombin,D08.811.277.656.300.760.855
21312187,2011-05-01T00:00:00,Thrombin,D08.811.277.656.959.350.855
21312187,2011-05-01T00:00:00,Thrombin,D12.776.124.125.890
21312187,2011-05-01T00:00:00,Thrombin,D23.119.960
21370280,2011-05-01T00:00:00,Animals,B01.050
21370280,2011-05-01T00:00:00,Central Nervous System Stimulants,D27.505.696.282
21370280,2011-05-01T00:00:00,Central Nervous System Stimulants,D27.505.954.427.220
21370280,2011-05-01T00:00:00,Corpus Striatum,A08.186.211.730.885.287.249.487
21370280,2011-05-01T00:00:00,Dopamine,D02.092.211.215.311.342
21370280,2011-05-01T00:00:00,Dopamine,D02.092.311.342
21370280,2011-05-01T00:00:00,Methamphetamine,D02.092.471.683.152.619
21370280,2011-05-01T00:00:00,Rats,B01.050.150.900.649.865.635.505.700
21370280,2011-05-01T00:00:00,"Rats, Sprague-Dawley",B01.050.150.900.649.865.635.505.700.750
21370280,2011-05-01T00:00:00,Time Factors,G01.910.857
21370280,2011-05-01T00:00:00,Vesicular Monoamine Transport Proteins,D12.776.157.530.450.162.887.500.500
21370280,2011-05-01T00:00:00,Vesicular Monoamine Transport Proteins,D12.776.157.530.562.750.500.500
21370280,2011-05-01T00:00:00,Vesicular Monoamine Transport Proteins,D12.776.543.585.450.162.887.500.500
21370280,2011-05-01T00:00:00,Vesicular Monoamine Transport Proteins,D12.776.543.585.562.750.500.500
21451409,2011-05-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21451409,2011-05-01T00:00:00,Liver Diseases,C06.552
21451410,2011-05-01T00:00:00,Chronic Disease,C23.550.291.500
21451410,2011-05-01T00:00:00,Gastrointestinal Hemorrhage,C06.405.227
21451410,2011-05-01T00:00:00,Gastrointestinal Hemorrhage,C23.550.414.788
21451410,2011-05-01T00:00:00,Hepatic Encephalopathy,C06.552.308.500.356
21451410,2011-05-01T00:00:00,Hepatic Encephalopathy,C10.228.140.163.360
21451410,2011-05-01T00:00:00,Hepatic Encephalopathy,C18.452.132.360
21451410,2011-05-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21451410,2011-05-01T00:00:00,Liver Diseases,C06.552
21451410,2011-05-01T00:00:00,Treatment Outcome,E01.789.800
21451410,2011-05-01T00:00:00,Treatment Outcome,N04.761.559.590.800
21451410,2011-05-01T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21453848,2011-05-01T00:00:00,Bladder Exstrophy,C12.706.132
21453848,2011-05-01T00:00:00,Bladder Exstrophy,C12.777.829.132
21453848,2011-05-01T00:00:00,Bladder Exstrophy,C13.351.875.132
21453848,2011-05-01T00:00:00,Bladder Exstrophy,C13.351.968.829.132
21453848,2011-05-01T00:00:00,Bladder Exstrophy,C16.131.939.132
21453848,2011-05-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21453848,2011-05-01T00:00:00,Pelvic Bones,A02.835.232.043.825
21453848,2011-05-01T00:00:00,Pelvic Floor,A01.673.600
21453848,2011-05-01T00:00:00,Pelvic Floor,A02.633.567.050.750
21453849,2011-05-01T00:00:00,Bladder Exstrophy,C12.706.132
21453849,2011-05-01T00:00:00,Bladder Exstrophy,C12.777.829.132
21453849,2011-05-01T00:00:00,Bladder Exstrophy,C13.351.875.132
21453849,2011-05-01T00:00:00,Bladder Exstrophy,C13.351.968.829.132
21453849,2011-05-01T00:00:00,Bladder Exstrophy,C16.131.939.132
21453849,2011-05-01T00:00:00,Child,M01.060.406
21453849,2011-05-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21453849,2011-05-01T00:00:00,Infant,M01.060.703
21453849,2011-05-01T00:00:00,Pelvic Bones,A02.835.232.043.825
21453849,2011-05-01T00:00:00,Pelvic Floor,A01.673.600
21453849,2011-05-01T00:00:00,Pelvic Floor,A02.633.567.050.750
21453850,2011-05-01T00:00:00,Bladder Exstrophy,C12.706.132
21453850,2011-05-01T00:00:00,Bladder Exstrophy,C12.777.829.132
21453850,2011-05-01T00:00:00,Bladder Exstrophy,C13.351.875.132
21453850,2011-05-01T00:00:00,Bladder Exstrophy,C13.351.968.829.132
21453850,2011-05-01T00:00:00,Bladder Exstrophy,C16.131.939.132
21453850,2011-05-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21453850,2011-05-01T00:00:00,Infant,M01.060.703
21453850,2011-05-01T00:00:00,Reconstructive Surgical Procedures,E04.680
21453850,2011-05-01T00:00:00,Treatment Outcome,E01.789.800
21453850,2011-05-01T00:00:00,Treatment Outcome,N04.761.559.590.800
21453850,2011-05-01T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21453850,2011-05-01T00:00:00,Urologic Surgical Procedures,E04.950.774
21464678,2011-05-01T00:00:00,Data Collection,E05.318.308
21464678,2011-05-01T00:00:00,Data Collection,L01.280
21464678,2011-05-01T00:00:00,Data Collection,N05.715.360.300
21464678,2011-05-01T00:00:00,Data Collection,N06.850.520.308
21464678,2011-05-01T00:00:00,Health Policy,I01.880.604.825.608.400
21464678,2011-05-01T00:00:00,Health Policy,N03.706.825.608.428
21464678,2011-05-01T00:00:00,Health Promotion,N02.370
21464678,2011-05-01T00:00:00,Health Promotion,N02.421.726.507
21464678,2011-05-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21464678,2011-05-01T00:00:00,New York,Z01.107.567.875.075.437
21464678,2011-05-01T00:00:00,New York,Z01.107.567.875.350.530
21464678,2011-05-01T00:00:00,New York,Z01.107.567.875.500.530
21464678,2011-05-01T00:00:00,Tobacco Smoke Pollution,D20.633.937.680
21464678,2011-05-01T00:00:00,Tobacco Smoke Pollution,N06.850.460.100.555
21464679,2011-05-01T00:00:00,Adolescent,M01.060.057
21464679,2011-05-01T00:00:00,Adult,M01.060.116
21464679,2011-05-01T00:00:00,Aged,M01.060.116.100
21464679,2011-05-01T00:00:00,Cost-Benefit Analysis,N03.219.151.125
21464679,2011-05-01T00:00:00,Counseling,F02.784.176
21464679,2011-05-01T00:00:00,Counseling,F04.408.413
21464679,2011-05-01T00:00:00,Counseling,N02.421.143.303
21464679,2011-05-01T00:00:00,Counseling,N02.421.461.363
21464679,2011-05-01T00:00:00,Health Promotion,N02.370
21464679,2011-05-01T00:00:00,Health Promotion,N02.421.726.507
21464679,2011-05-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21464679,2011-05-01T00:00:00,Middle Aged,M01.060.116.630
21464679,2011-05-01T00:00:00,Nicotine,D03.132.760.570
21464679,2011-05-01T00:00:00,Nicotine,D03.383.725.518
21464679,2011-05-01T00:00:00,Smoking Cessation,F01.145.940.700
21464679,2011-05-01T00:00:00,Tobacco Use Disorder,C21.739.912
21464679,2011-05-01T00:00:00,Tobacco Use Disorder,F03.900.912
21464679,2011-05-01T00:00:00,Treatment Outcome,E01.789.800
21464679,2011-05-01T00:00:00,Treatment Outcome,N04.761.559.590.800
21464679,2011-05-01T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21464679,2011-05-01T00:00:00,Young Adult,M01.060.116.815
21464680,2011-05-01T00:00:00,Adult,M01.060.116
21464680,2011-05-01T00:00:00,Counseling,F02.784.176
21464680,2011-05-01T00:00:00,Counseling,F04.408.413
21464680,2011-05-01T00:00:00,Counseling,N02.421.143.303
21464680,2011-05-01T00:00:00,Counseling,N02.421.461.363
21464680,2011-05-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21464680,2011-05-01T00:00:00,New York,Z01.107.567.875.075.437
21464680,2011-05-01T00:00:00,New York,Z01.107.567.875.350.530
21464680,2011-05-01T00:00:00,New York,Z01.107.567.875.500.530
21464680,2011-05-01T00:00:00,Nicotine,D03.132.760.570
21464680,2011-05-01T00:00:00,Nicotine,D03.383.725.518
21464680,2011-05-01T00:00:00,Smoking,F01.145.466.753
21464680,2011-05-01T00:00:00,Smoking Cessation,F01.145.940.700
21464680,2011-05-01T00:00:00,United States,Z01.107.567.875
21486329,2011-05-01T00:00:00,Clinical Clerkship,I02.358.399.450.110
21486329,2011-05-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21486329,2011-05-01T00:00:00,Internal Medicine,H02.403.429
21486329,2011-05-01T00:00:00,Internet,L01.224.230.110.500
21486329,2011-05-01T00:00:00,Problem-Based Learning,F02.463.425.720
21486329,2011-05-01T00:00:00,Problem-Based Learning,I02.158.660
21486329,2011-05-01T00:00:00,Problem-Based Learning,I02.903.565
21486329,2011-05-01T00:00:00,South Carolina,Z01.107.567.875.075.662
21486329,2011-05-01T00:00:00,South Carolina,Z01.107.567.875.750.700
21486329,2011-05-01T00:00:00,Time Factors,G01.910.857
21489955,2011-05-01T00:00:00,Aging,G07.700.320.124
21489955,2011-05-01T00:00:00,Animals,B01.050
21489955,2011-05-01T00:00:00,Chick Embryo,A13.350.150
21489955,2011-05-01T00:00:00,Chick Embryo,A16.331.200
21489955,2011-05-01T00:00:00,Chickens,B01.050.150.900.248.350.150
21489955,2011-05-01T00:00:00,Chickens,B01.050.150.900.248.617.192
21489955,2011-05-01T00:00:00,Electrolytes,D01.248
21493327,2011-05-01T00:00:00,"Antibodies, Monoclonal",D12.776.124.486.485.114.224
21493327,2011-05-01T00:00:00,"Antibodies, Monoclonal",D12.776.124.790.651.114.224
21493327,2011-05-01T00:00:00,"Antibodies, Monoclonal",D12.776.377.715.548.114.224
21493327,2011-05-01T00:00:00,Antineoplastic Agents,D27.505.954.248
21493327,2011-05-01T00:00:00,"Carcinoma, Squamous Cell",C04.557.470.200.400
21493327,2011-05-01T00:00:00,"Carcinoma, Squamous Cell",C04.557.470.700.400
21493327,2011-05-01T00:00:00,Head and Neck Neoplasms,C04.588.443
21493327,2011-05-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21493366,2011-05-01T00:00:00,Chronic Disease,C23.550.291.500
21493366,2011-05-01T00:00:00,Gene Expression Profiling,E05.393.332
21493366,2011-05-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21493366,2011-05-01T00:00:00,Nasal Polyps,C08.460.572
21493366,2011-05-01T00:00:00,Nasal Polyps,C09.603.557
21493366,2011-05-01T00:00:00,Nasal Polyps,C23.300.825.557
21493366,2011-05-01T00:00:00,Sinusitis,C08.460.692.752
21493366,2011-05-01T00:00:00,Sinusitis,C08.730.749
21493366,2011-05-01T00:00:00,Sinusitis,C09.603.692.752
21496696,2011-05-01T00:00:00,Adult,M01.060.116
21496696,2011-05-01T00:00:00,Animals,B01.050
21496696,2011-05-01T00:00:00,Back,A01.176
21496696,2011-05-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21496696,2011-05-01T00:00:00,Lower Extremity,A01.378.610
21497232,2011-05-01T00:00:00,Curriculum,I02.158
21497232,2011-05-01T00:00:00,"Education, Medical, Graduate",I02.358.337.350
21497232,2011-05-01T00:00:00,"Education, Medical, Graduate",I02.358.399.350
21497232,2011-05-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21497232,2011-05-01T00:00:00,Leadership,F01.752.609
21497232,2011-05-01T00:00:00,Program Development,N04.452.760
21497232,2011-05-01T00:00:00,Thoracic Surgical Procedures,E04.928
21497232,2011-05-01T00:00:00,United States,Z01.107.567.875
21499211,2011-05-01T00:00:00,Aged,M01.060.116.100
21499211,2011-05-01T00:00:00,"Biopsy, Needle",E01.370.388.100.100
21499211,2011-05-01T00:00:00,"Biopsy, Needle",E01.450.230.100.100
21499211,2011-05-01T00:00:00,"Biopsy, Needle",E01.450.865.100.100
21499211,2011-05-01T00:00:00,"Biopsy, Needle",E01.450.865.632.100
21499211,2011-05-01T00:00:00,"Biopsy, Needle",E04.074.119
21499211,2011-05-01T00:00:00,Endosonography,E01.370.350.850.280
21499211,2011-05-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21499211,2011-05-01T00:00:00,Magnetic Resonance Imaging,E01.370.350.500
21499211,2011-05-01T00:00:00,Magnetic Resonance Imaging,E01.370.350.825.500
21499211,2011-05-01T00:00:00,Middle Aged,M01.060.116.630
21499211,2011-05-01T00:00:00,Neoplasm Staging,E01.370.550
21499211,2011-05-01T00:00:00,Pancreatic Neoplasms,C04.588.274.761
21499211,2011-05-01T00:00:00,Pancreatic Neoplasms,C04.588.322.421
21499211,2011-05-01T00:00:00,Pancreatic Neoplasms,C06.301.761
21499211,2011-05-01T00:00:00,Pancreatic Neoplasms,C06.689.667
21499211,2011-05-01T00:00:00,Pancreatic Neoplasms,C19.344.421
21504916,2011-05-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21504916,2011-05-01T00:00:00,Smoking,F01.145.466.753
21508726,2011-05-01T00:00:00,Evidence-Based Medicine,H02.249.750
21508726,2011-05-01T00:00:00,Evidence-Based Medicine,H02.403.200.400
21508726,2011-05-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21508726,2011-05-01T00:00:00,Patient Selection,E05.581.500.653
21508726,2011-05-01T00:00:00,Patient Selection,N04.590.731
21508726,2011-05-01T00:00:00,Practice Guidelines as Topic,N04.761.700.350.650
21508726,2011-05-01T00:00:00,Practice Guidelines as Topic,N05.700.350.650
21508726,2011-05-01T00:00:00,"Radiography, Thoracic",E01.370.350.700.730
21508726,2011-05-01T00:00:00,Respiratory Tract Diseases,C08
21508726,2011-05-01T00:00:00,Risk Factors,E05.318.740.600.800.725
21508726,2011-05-01T00:00:00,Risk Factors,N05.715.350.200.700
21508726,2011-05-01T00:00:00,Risk Factors,N05.715.360.750.625.700.700
21508726,2011-05-01T00:00:00,Risk Factors,N06.850.490.625.750
21508726,2011-05-01T00:00:00,Risk Factors,N06.850.520.830.600.800.725
21508726,2011-05-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.350.810
21508726,2011-05-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.600.350.700.810
21508726,2011-05-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.700.700.810
21508726,2011-05-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.700.810.810
21508726,2011-05-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.825.810.810
21508726,2011-05-01T00:00:00,United States,Z01.107.567.875
21508729,2011-05-01T00:00:00,Diagnostic Imaging,E01.370.350
21508729,2011-05-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21508729,2011-05-01T00:00:00,Lung Neoplasms,C04.588.894.797.520
21508729,2011-05-01T00:00:00,Lung Neoplasms,C08.381.540
21508729,2011-05-01T00:00:00,Lung Neoplasms,C08.785.520
21508729,2011-05-01T00:00:00,Neoplasm Staging,E01.370.550
21515182,2011-05-01T00:00:00,Abdominal Pain,C23.888.646.100
21515182,2011-05-01T00:00:00,Abdominal Pain,C23.888.821.030
21515182,2011-05-01T00:00:00,"Diagnosis, Differential",E01.171
21515182,2011-05-01T00:00:00,"Hernia, Abdominal",C23.300.707.374
21515182,2011-05-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21521157,2011-05-01T00:00:00,Animals,B01.050
21521157,2011-05-01T00:00:00,Anticarcinogenic Agents,D27.505.696.706.018
21521157,2011-05-01T00:00:00,Anticarcinogenic Agents,D27.505.954.248.125
21521157,2011-05-01T00:00:00,Anticarcinogenic Agents,D27.720.799.018
21521157,2011-05-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21521157,2011-05-01T00:00:00,Neuroblastoma,C04.557.465.625.600.590.650.550
21521157,2011-05-01T00:00:00,Neuroblastoma,C04.557.470.670.590.650.550
21521157,2011-05-01T00:00:00,Neuroblastoma,C04.557.580.625.600.590.650.550
21521157,2011-05-01T00:00:00,Plant Extracts,D20.215.784.500
21521157,2011-05-01T00:00:00,Plant Extracts,D26.667
21532072,2011-05-01T00:00:00,"Hospitals, Psychiatric",N02.278.421.556.508
21532072,2011-05-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21532072,2011-05-01T00:00:00,"Models, Theoretical",E05.599
21532072,2011-05-01T00:00:00,Patient Isolation,E02.770
21532072,2011-05-01T00:00:00,Patient Isolation,N06.850.780.200.450.650
21532072,2011-05-01T00:00:00,"Restraint, Physical",E02.085.700
21532072,2011-05-01T00:00:00,"Restraint, Physical",E05.472.760
21532072,2011-05-01T00:00:00,United States,Z01.107.567.875
21532342,2011-05-01T00:00:00,Animals,B01.050
21532342,2011-05-01T00:00:00,Biomimetic Materials,J01.637.087
21532342,2011-05-01T00:00:00,Connexin 43,D12.776.543.585.250.200
21532342,2011-05-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21532342,2011-05-01T00:00:00,Myocardial Ischemia,C14.280.647
21532342,2011-05-01T00:00:00,Myocardial Ischemia,C14.907.585
21532342,2011-05-01T00:00:00,Myocardium,A02.633.580
21532342,2011-05-01T00:00:00,Myocardium,A07.541.704
21532342,2011-05-01T00:00:00,Myocardium,A10.690.552.750
21532342,2011-05-01T00:00:00,Peptides,D12.644
21532342,2011-05-01T00:00:00,Phosphorylation,G02.111.087.677
21532342,2011-05-01T00:00:00,Phosphorylation,G02.149.115.677
21532342,2011-05-01T00:00:00,Phosphorylation,G02.149.465.700
21532342,2011-05-01T00:00:00,Phosphorylation,G02.607.750.700
21532342,2011-05-01T00:00:00,Phosphorylation,G03.495.790
21533864,2011-05-01T00:00:00,Adult,M01.060.116
21533864,2011-05-01T00:00:00,Aged,M01.060.116.100
21533864,2011-05-01T00:00:00,Contrast Media,D27.720.259
21533864,2011-05-01T00:00:00,Coronary Angiography,E01.370.350.700.060.200
21533864,2011-05-01T00:00:00,Coronary Angiography,E01.370.370.050.200
21533864,2011-05-01T00:00:00,Coronary Angiography,E01.370.370.380.200
21533864,2011-05-01T00:00:00,Coronary Stenosis,C14.280.647.250.285
21533864,2011-05-01T00:00:00,Coronary Stenosis,C14.907.585.250.285
21533864,2011-05-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21533864,2011-05-01T00:00:00,Middle Aged,M01.060.116.630
21533864,2011-05-01T00:00:00,Radiographic Image Enhancement,E01.370.350.600.350.700
21533864,2011-05-01T00:00:00,Radiographic Image Enhancement,E01.370.350.700.700
21533864,2011-05-01T00:00:00,Radiographic Image Enhancement,L01.224.308.380.600
21533864,2011-05-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.350.810
21533864,2011-05-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.600.350.700.810
21533864,2011-05-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.700.700.810
21533864,2011-05-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.700.810.810
21533864,2011-05-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.825.810.810
21551933,2011-05-01T00:00:00,Adolescent,M01.060.057
21551933,2011-05-01T00:00:00,African Americans,M01.686.508.100.100
21551933,2011-05-01T00:00:00,African Americans,M01.686.754.100
21551933,2011-05-01T00:00:00,Age Factors,N05.715.350.075
21551933,2011-05-01T00:00:00,Age Factors,N06.850.490.250
21551933,2011-05-01T00:00:00,"Health Knowledge, Attitudes, Practice",F01.100.150.500
21551933,2011-05-01T00:00:00,"Health Knowledge, Attitudes, Practice",N05.300.150.410
21551933,2011-05-01T00:00:00,Health Services Accessibility,N04.590.374.350
21551933,2011-05-01T00:00:00,Health Services Accessibility,N05.300.430
21551933,2011-05-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21551933,2011-05-01T00:00:00,Papillomavirus Vaccines,D20.215.894.899.498
21551933,2011-05-01T00:00:00,Patient Acceptance of Health Care,N05.300.150.600
21551933,2011-05-01T00:00:00,Questionnaires,E05.318.308.750
21551933,2011-05-01T00:00:00,Questionnaires,L01.280.800
21551933,2011-05-01T00:00:00,Questionnaires,N05.715.360.300.695
21551933,2011-05-01T00:00:00,Questionnaires,N06.850.520.308.750
21551933,2011-05-01T00:00:00,Uterine Cervical Neoplasms,C04.588.945.418.948.850
21551933,2011-05-01T00:00:00,Uterine Cervical Neoplasms,C13.351.500.852.593.131
21551933,2011-05-01T00:00:00,Uterine Cervical Neoplasms,C13.351.500.852.762.850
21551933,2011-05-01T00:00:00,Uterine Cervical Neoplasms,C13.351.937.418.875.850
21551933,2011-05-01T00:00:00,Vaccination,E02.095.465.425.400.530.890
21551933,2011-05-01T00:00:00,Vaccination,E05.478.550.600.890
21551933,2011-05-01T00:00:00,Vaccination,N02.421.726.758.310.890
21551933,2011-05-01T00:00:00,Vaccination,N06.850.780.200.425.900
21551933,2011-05-01T00:00:00,Vaccination,N06.850.780.680.310.890
21551933,2011-05-01T00:00:00,Young Adult,M01.060.116.815
21553664,2011-05-01T00:00:00,Anti-Bacterial Agents,D27.505.954.122.085
21553664,2011-05-01T00:00:00,Bacterial Infections,C01.252
21553664,2011-05-01T00:00:00,Hospitalization,E02.760.400
21553664,2011-05-01T00:00:00,Hospitalization,N02.421.585.400
21553664,2011-05-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21553664,2011-05-01T00:00:00,Length of Stay,E02.760.400.480
21553664,2011-05-01T00:00:00,Length of Stay,N02.421.585.400.480
21553664,2011-05-01T00:00:00,Risk Factors,E05.318.740.600.800.725
21553664,2011-05-01T00:00:00,Risk Factors,N05.715.350.200.700
21553664,2011-05-01T00:00:00,Risk Factors,N05.715.360.750.625.700.700
21553664,2011-05-01T00:00:00,Risk Factors,N06.850.490.625.750
21553664,2011-05-01T00:00:00,Risk Factors,N06.850.520.830.600.800.725
21553664,2011-05-01T00:00:00,United States,Z01.107.567.875
21555747,2011-05-01T00:00:00,"Fractures, Bone",C21.866.404
21555747,2011-05-01T00:00:00,Gastroesophageal Reflux,C06.405.117.119.500.484
21555747,2011-05-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21555747,2011-05-01T00:00:00,Osteoporosis,C05.116.198.579
21555747,2011-05-01T00:00:00,Peptic Ulcer,C06.405.469.275.800
21555747,2011-05-01T00:00:00,Peptic Ulcer,C06.405.608
21555747,2011-05-01T00:00:00,Peptic Ulcer,C06.405.748.586
21555747,2011-05-01T00:00:00,Proton Pump Inhibitors,D27.505.519.389.848
21555747,2011-05-01T00:00:00,United States,Z01.107.567.875
21586930,2011-05-01T00:00:00,Adult,M01.060.116
21586930,2011-05-01T00:00:00,Aged,M01.060.116.100
21586930,2011-05-01T00:00:00,Artifacts,E05.047
21586930,2011-05-01T00:00:00,Contrast Media,D27.720.259
21586930,2011-05-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21586930,2011-05-01T00:00:00,Middle Aged,M01.060.116.630
21586930,2011-05-01T00:00:00,"Radiography, Abdominal",E01.370.350.700.715
21586930,2011-05-01T00:00:00,Time Factors,G01.910.857
21586930,2011-05-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.350.810
21586930,2011-05-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.600.350.700.810
21586930,2011-05-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.700.700.810
21586930,2011-05-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.700.810.810
21586930,2011-05-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.825.810.810
21647460,2011-05-01T00:00:00,Algorithms,G17.035
21647460,2011-05-01T00:00:00,Algorithms,L01.224.050
21647460,2011-05-01T00:00:00,Endosonography,E01.370.350.850.280
21647460,2011-05-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21647460,2011-05-01T00:00:00,"Pancreatitis, Chronic",C06.689.750.830
21653491,2011-05-01T00:00:00,Antidepressive Agents,D27.505.954.427.700.122
21653491,2011-05-01T00:00:00,Cerebral Cortex,A08.186.211.730.885.287.500
21653491,2011-05-01T00:00:00,Deep Brain Stimulation,E02.342.250
21653491,2011-05-01T00:00:00,Deep Brain Stimulation,E04.190
21653491,2011-05-01T00:00:00,"Depressive Disorder, Major",F03.600.300.375
21653491,2011-05-01T00:00:00,Electroconvulsive Therapy,F04.570.200.583
21653491,2011-05-01T00:00:00,Electroconvulsive Therapy,F04.669.224.300
21653491,2011-05-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21653491,2011-05-01T00:00:00,Limbic System,A08.186.211.464
21653491,2011-05-01T00:00:00,Mood Disorders,F03.600
21653491,2011-05-01T00:00:00,Treatment Outcome,E01.789.800
21653491,2011-05-01T00:00:00,Treatment Outcome,N04.761.559.590.800
21653491,2011-05-01T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21663717,2011-05-01T00:00:00,Adult,M01.060.116
21663717,2011-05-01T00:00:00,Amides,D02.065
21663717,2011-05-01T00:00:00,Analgesics,D27.505.696.663.850.014
21663717,2011-05-01T00:00:00,Analgesics,D27.505.954.427.040
21663717,2011-05-01T00:00:00,Arthroscopy,E01.370.388.250.070
21663717,2011-05-01T00:00:00,Arthroscopy,E04.555.113
21663717,2011-05-01T00:00:00,Arthroscopy,E04.800.250.070
21663717,2011-05-01T00:00:00,Double-Blind Method,E05.318.780.300
21663717,2011-05-01T00:00:00,Double-Blind Method,E05.581.500.300
21663717,2011-05-01T00:00:00,Double-Blind Method,N05.715.360.780.320
21663717,2011-05-01T00:00:00,Double-Blind Method,N06.850.520.445.300
21663717,2011-05-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21663717,2011-05-01T00:00:00,Nerve Block,E03.155.086.711
21663717,2011-05-01T00:00:00,Nerve Block,E04.525.210.550
21663717,2011-05-01T00:00:00,Pain Measurement,E01.370.376.550.600
21663717,2011-05-01T00:00:00,"Pain, Postoperative",C23.550.767.700
21663717,2011-05-01T00:00:00,"Pain, Postoperative",C23.888.646.530
21663717,2011-05-01T00:00:00,Postoperative Care,E02.760.722.700
21663717,2011-05-01T00:00:00,Postoperative Care,E04.624
21663717,2011-05-01T00:00:00,Postoperative Care,N02.421.585.722.700
21663717,2011-05-01T00:00:00,Preoperative Care,E02.760.795
21663717,2011-05-01T00:00:00,Preoperative Care,E04.641
21663717,2011-05-01T00:00:00,Preoperative Care,N02.421.585.795
21663717,2011-05-01T00:00:00,Time Factors,G01.910.857
21679531,2011-05-01T00:00:00,Adult,M01.060.116
21679531,2011-05-01T00:00:00,Aged,M01.060.116.100
21679531,2011-05-01T00:00:00,Cerebrospinal Fluid Rhinorrhea,C10.597.267
21679531,2011-05-01T00:00:00,Cerebrospinal Fluid Rhinorrhea,C10.900.300.153
21679531,2011-05-01T00:00:00,Cerebrospinal Fluid Rhinorrhea,C21.866.260.207
21679531,2011-05-01T00:00:00,Cerebrospinal Fluid Rhinorrhea,C21.866.915.300.300
21679531,2011-05-01T00:00:00,Cerebrospinal Fluid Rhinorrhea,C23.888.592.264
21679531,2011-05-01T00:00:00,Diagnostic Imaging,E01.370.350
21679531,2011-05-01T00:00:00,Endoscopy,E01.370.388.250
21679531,2011-05-01T00:00:00,Endoscopy,E04.800.250
21679531,2011-05-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21679531,2011-05-01T00:00:00,Incidence,E05.318.308.985.525.375
21679531,2011-05-01T00:00:00,Incidence,L01.280.975.525.375
21679531,2011-05-01T00:00:00,Incidence,N01.224.935.597.500
21679531,2011-05-01T00:00:00,Incidence,N06.850.505.400.975.525.375
21679531,2011-05-01T00:00:00,Incidence,N06.850.520.308.985.525.375
21679531,2011-05-01T00:00:00,Middle Aged,M01.060.116.630
21679531,2011-05-01T00:00:00,Mucocele,C04.182.511
21679531,2011-05-01T00:00:00,Postoperative Complications,C23.550.767
21679531,2011-05-01T00:00:00,Reconstructive Surgical Procedures,E04.680
21679531,2011-05-01T00:00:00,Skull Base,A01.456.830
21679531,2011-05-01T00:00:00,Skull Base,A02.835.232.781.750
21679531,2011-05-01T00:00:00,Surgical Flaps,A10.850.710
21679531,2011-05-01T00:00:00,Surgical Flaps,E07.862.710
21679597,2011-05-01T00:00:00,Adolescent,M01.060.057
21679597,2011-05-01T00:00:00,Age Factors,N05.715.350.075
21679597,2011-05-01T00:00:00,Age Factors,N06.850.490.250
21679597,2011-05-01T00:00:00,"Anastomosis, Surgical",E04.035
21679597,2011-05-01T00:00:00,Child,M01.060.406
21679597,2011-05-01T00:00:00,"Child, Preschool",M01.060.406.448
21679597,2011-05-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21679597,2011-05-01T00:00:00,Infant,M01.060.703
21679597,2011-05-01T00:00:00,Pancreatectomy,E04.210.752
21679597,2011-05-01T00:00:00,Postoperative Care,E02.760.722.700
21679597,2011-05-01T00:00:00,Postoperative Care,E04.624
21679597,2011-05-01T00:00:00,Postoperative Care,N02.421.585.722.700
21679597,2011-05-01T00:00:00,Postoperative Complications,C23.550.767
21679597,2011-05-01T00:00:00,Risk Assessment,E05.318.740.600.800.715
21679597,2011-05-01T00:00:00,Risk Assessment,N04.452.871.715
21679597,2011-05-01T00:00:00,Risk Assessment,N05.715.360.750.625.700.690
21679597,2011-05-01T00:00:00,Risk Assessment,N06.850.505.715
21679597,2011-05-01T00:00:00,Risk Assessment,N06.850.520.830.600.800.715
21679597,2011-05-01T00:00:00,Salvage Therapy,E02.186.800
21679597,2011-05-01T00:00:00,Salvage Therapy,E02.895
21679597,2011-05-01T00:00:00,"Surgical Procedures, Minimally Invasive",E04.800
21679597,2011-05-01T00:00:00,Treatment Outcome,E01.789.800
21679597,2011-05-01T00:00:00,Treatment Outcome,N04.761.559.590.800
21679597,2011-05-01T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21679597,2011-05-01T00:00:00,"Wounds, Nonpenetrating",C21.866.974
21679604,2011-05-01T00:00:00,"History, 19th Century",K01.400.504.937
21679604,2011-05-01T00:00:00,"History, 20th Century",K01.400.504.968
21679604,2011-05-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21679604,2011-05-01T00:00:00,Neurosurgery,H02.403.810.425
21679604,2011-05-01T00:00:00,United States,Z01.107.567.875
21679609,2011-05-01T00:00:00,"History, 19th Century",K01.400.504.937
21679609,2011-05-01T00:00:00,"History, 20th Century",K01.400.504.968
21679609,2011-05-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21679609,2011-05-01T00:00:00,Medical Oncology,H02.403.429.515
21679611,2011-05-01T00:00:00,"History, 19th Century",K01.400.504.937
21679611,2011-05-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21689617,2011-05-01T00:00:00,"Carcinoma, Hepatocellular",C04.557.470.200.025.255
21689617,2011-05-01T00:00:00,"Carcinoma, Hepatocellular",C04.588.274.623.160
21689617,2011-05-01T00:00:00,"Carcinoma, Hepatocellular",C06.301.623.160
21689617,2011-05-01T00:00:00,"Carcinoma, Hepatocellular",C06.552.697.160
21689617,2011-05-01T00:00:00,"Diagnosis, Differential",E01.171
21689617,2011-05-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21689617,2011-05-01T00:00:00,Liver Cirrhosis,C06.552.630
21689617,2011-05-01T00:00:00,Liver Neoplasms,C04.588.274.623
21689617,2011-05-01T00:00:00,Liver Neoplasms,C06.301.623
21689617,2011-05-01T00:00:00,Liver Neoplasms,C06.552.697
21689617,2011-05-01T00:00:00,Magnetic Resonance Imaging,E01.370.350.500
21689617,2011-05-01T00:00:00,Magnetic Resonance Imaging,E01.370.350.825.500
21689617,2011-05-01T00:00:00,Positron-Emission Tomography,E01.370.350.350.800.700
21689617,2011-05-01T00:00:00,Positron-Emission Tomography,E01.370.350.600.350.800.399
21689617,2011-05-01T00:00:00,Positron-Emission Tomography,E01.370.350.710.800.399
21689617,2011-05-01T00:00:00,Positron-Emission Tomography,E01.370.350.825.800.399
21689617,2011-05-01T00:00:00,Positron-Emission Tomography,E01.370.384.730.800.399
21689617,2011-05-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.350.810
21689617,2011-05-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.600.350.700.810
21689617,2011-05-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.700.700.810
21689617,2011-05-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.700.810.810
21689617,2011-05-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.825.810.810
21689619,2011-05-01T00:00:00,"Carcinoma, Hepatocellular",C04.557.470.200.025.255
21689619,2011-05-01T00:00:00,"Carcinoma, Hepatocellular",C04.588.274.623.160
21689619,2011-05-01T00:00:00,"Carcinoma, Hepatocellular",C06.301.623.160
21689619,2011-05-01T00:00:00,"Carcinoma, Hepatocellular",C06.552.697.160
21689619,2011-05-01T00:00:00,Hepatectomy,E04.210.556
21689619,2011-05-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21689619,2011-05-01T00:00:00,Laparoscopy,E01.370.388.250.520
21689619,2011-05-01T00:00:00,Laparoscopy,E04.800.250.520
21689619,2011-05-01T00:00:00,Liver Neoplasms,C04.588.274.623
21689619,2011-05-01T00:00:00,Liver Neoplasms,C06.301.623
21689619,2011-05-01T00:00:00,Liver Neoplasms,C06.552.697
21689621,2011-05-01T00:00:00,"Carcinoma, Hepatocellular",C04.557.470.200.025.255
21689621,2011-05-01T00:00:00,"Carcinoma, Hepatocellular",C04.588.274.623.160
21689621,2011-05-01T00:00:00,"Carcinoma, Hepatocellular",C06.301.623.160
21689621,2011-05-01T00:00:00,"Carcinoma, Hepatocellular",C06.552.697.160
21689621,2011-05-01T00:00:00,Combined Modality Therapy,E02.186
21689621,2011-05-01T00:00:00,"Embolization, Therapeutic",E02.520.360
21689621,2011-05-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21689621,2011-05-01T00:00:00,"Hyperthermia, Induced",E02.565
21689621,2011-05-01T00:00:00,"Hyperthermia, Induced",E02.779.496
21689621,2011-05-01T00:00:00,Liver Neoplasms,C04.588.274.623
21689621,2011-05-01T00:00:00,Liver Neoplasms,C06.301.623
21689621,2011-05-01T00:00:00,Liver Neoplasms,C06.552.697
21721860,2011-05-01T00:00:00,Adult,M01.060.116
21721860,2011-05-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21721860,2011-05-01T00:00:00,Hydrocortisone,D04.808.745.745.654.600
21721860,2011-05-01T00:00:00,Hydrocortisone,D06.472.040.585.353.476
21721860,2011-05-01T00:00:00,Hydrocortisone,D06.472.040.585.478.392
21721860,2011-05-01T00:00:00,Middle Aged,M01.060.116.630
21721860,2011-05-01T00:00:00,Saliva,A12.200.666
21721860,2011-05-01T00:00:00,Work Schedule Tolerance,I03.946.900
21533981,2011-05-02T00:00:00,Animals,B01.050
21533981,2011-05-02T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21533981,2011-05-02T00:00:00,Macrophages,A11.329.372
21533981,2011-05-02T00:00:00,Macrophages,A11.627.482
21533981,2011-05-02T00:00:00,Macrophages,A11.733.397
21533981,2011-05-02T00:00:00,Macrophages,A15.382.680.397
21533981,2011-05-02T00:00:00,Macrophages,A15.382.812.522
21533981,2011-05-02T00:00:00,Sphingomyelin Phosphodiesterase,D08.811.277.352.640.750
21536668,2011-05-02T00:00:00,Cell Cycle,G04.299.134
21536668,2011-05-02T00:00:00,Cell Proliferation,G04.299.233.750
21536668,2011-05-02T00:00:00,Cell Proliferation,G07.700.320.249.410.750
21536668,2011-05-02T00:00:00,Ceramides,D02.065.313
21536668,2011-05-02T00:00:00,Ceramides,D09.400.410.420.525.200
21536668,2011-05-02T00:00:00,Ceramides,D10.390.470.675.200
21536668,2011-05-02T00:00:00,Ceramides,D10.570.877.360.612.200
21536668,2011-05-02T00:00:00,"Gene Expression Regulation, Neoplastic",G05.355.315.370
21536668,2011-05-02T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21536668,2011-05-02T00:00:00,Phosphorylation,G02.111.087.677
21536668,2011-05-02T00:00:00,Phosphorylation,G02.149.115.677
21536668,2011-05-02T00:00:00,Phosphorylation,G02.149.465.700
21536668,2011-05-02T00:00:00,Phosphorylation,G02.607.750.700
21536668,2011-05-02T00:00:00,Phosphorylation,G03.495.790
21536668,2011-05-02T00:00:00,Signal Transduction,G02.111.087.800
21536668,2011-05-02T00:00:00,Signal Transduction,G02.149.115.800
21536668,2011-05-02T00:00:00,Signal Transduction,G04.299.880
21536668,2011-05-02T00:00:00,Sphingolipids,D10.570.877
21536668,2011-05-02T00:00:00,Sphingolipids,D10.808
21536668,2011-05-02T00:00:00,Sphingomyelin Phosphodiesterase,D08.811.277.352.640.750
21538358,2011-05-02T00:00:00,Adult,M01.060.116
21538358,2011-05-02T00:00:00,Aged,M01.060.116.100
21538358,2011-05-02T00:00:00,Antineoplastic Combined Chemotherapy Protocols,E02.183.750.500
21538358,2011-05-02T00:00:00,Antineoplastic Combined Chemotherapy Protocols,E02.319.077.500
21538358,2011-05-02T00:00:00,Antineoplastic Combined Chemotherapy Protocols,E02.319.310.037
21538358,2011-05-02T00:00:00,Brachytherapy,E02.815.150
21538358,2011-05-02T00:00:00,"Carcinoma, Squamous Cell",C04.557.470.200.400
21538358,2011-05-02T00:00:00,"Carcinoma, Squamous Cell",C04.557.470.700.400
21538358,2011-05-02T00:00:00,"Chemotherapy, Adjuvant",E02.186.170
21538358,2011-05-02T00:00:00,"Chemotherapy, Adjuvant",E02.319.170
21538358,2011-05-02T00:00:00,Cisplatin,D01.210.375
21538358,2011-05-02T00:00:00,Cisplatin,D01.625.125
21538358,2011-05-02T00:00:00,Cisplatin,D01.710.100
21538358,2011-05-02T00:00:00,Combined Modality Therapy,E02.186
21538358,2011-05-02T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21538358,2011-05-02T00:00:00,Hysterectomy,E04.950.300.399
21538358,2011-05-02T00:00:00,Middle Aged,M01.060.116.630
21538358,2011-05-02T00:00:00,"Neoplasm Recurrence, Local",C04.697.655
21538358,2011-05-02T00:00:00,"Neoplasm Recurrence, Local",C23.550.727.655
21538358,2011-05-02T00:00:00,Neoplasm Staging,E01.370.550
21538358,2011-05-02T00:00:00,"Radiotherapy, Adjuvant",E02.186.775
21538358,2011-05-02T00:00:00,"Radiotherapy, Adjuvant",E02.815.600
21538358,2011-05-02T00:00:00,Risk Factors,E05.318.740.600.800.725
21538358,2011-05-02T00:00:00,Risk Factors,N05.715.350.200.700
21538358,2011-05-02T00:00:00,Risk Factors,N05.715.360.750.625.700.700
21538358,2011-05-02T00:00:00,Risk Factors,N06.850.490.625.750
21538358,2011-05-02T00:00:00,Risk Factors,N06.850.520.830.600.800.725
21538358,2011-05-02T00:00:00,Treatment Outcome,E01.789.800
21538358,2011-05-02T00:00:00,Treatment Outcome,N04.761.559.590.800
21538358,2011-05-02T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21538358,2011-05-02T00:00:00,Uterine Cervical Neoplasms,C04.588.945.418.948.850
21538358,2011-05-02T00:00:00,Uterine Cervical Neoplasms,C13.351.500.852.593.131
21538358,2011-05-02T00:00:00,Uterine Cervical Neoplasms,C13.351.500.852.762.850
21538358,2011-05-02T00:00:00,Uterine Cervical Neoplasms,C13.351.937.418.875.850
21538358,2011-05-02T00:00:00,Young Adult,M01.060.116.815
21536631,2011-05-03T00:00:00,Brachial Artery,A07.231.114.139
21536631,2011-05-03T00:00:00,"Diagnosis, Differential",E01.171
21536631,2011-05-03T00:00:00,Embolism,C14.907.355.350
21536631,2011-05-03T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21536631,2011-05-03T00:00:00,Stroke,C10.228.140.300.775
21536631,2011-05-03T00:00:00,Stroke,C14.907.253.855
21540278,2011-05-03T00:00:00,Algorithms,G17.035
21540278,2011-05-03T00:00:00,Algorithms,L01.224.050
21540278,2011-05-03T00:00:00,Child Behavior Disorders,F03.550.300
21540278,2011-05-03T00:00:00,"Child, Preschool",M01.060.406.448
21540278,2011-05-03T00:00:00,Developmental Disabilities,F03.550.362
21540278,2011-05-03T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21540278,2011-05-03T00:00:00,Infant,M01.060.703
21540278,2011-05-03T00:00:00,"Infant, Newborn",M01.060.703.520
21540278,2011-05-03T00:00:00,Mass Screening,E01.370.500
21540278,2011-05-03T00:00:00,Mass Screening,E05.318.308.250.580
21540278,2011-05-03T00:00:00,Mass Screening,N02.421.143.827.233.443
21540278,2011-05-03T00:00:00,Mass Screening,N02.421.726.233.443
21540278,2011-05-03T00:00:00,Mass Screening,N05.715.360.300.375.500
21540278,2011-05-03T00:00:00,Mass Screening,N06.850.520.308.250.580
21540278,2011-05-03T00:00:00,Mass Screening,N06.850.780.500
21540278,2011-05-03T00:00:00,Pediatrics,H02.403.670
21540278,2011-05-03T00:00:00,Practice Guidelines as Topic,N04.761.700.350.650
21540278,2011-05-03T00:00:00,Practice Guidelines as Topic,N05.700.350.650
21540278,2011-05-03T00:00:00,United States,Z01.107.567.875
21536249,2011-05-04T00:00:00,Cardiac Surgical Procedures,E04.100.376
21536249,2011-05-04T00:00:00,Cardiac Surgical Procedures,E04.928.220
21536249,2011-05-04T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21536249,2011-05-04T00:00:00,Interprofessional Relations,F01.829.401.205
21536249,2011-05-04T00:00:00,Thoracic Surgical Procedures,E04.928
21536249,2011-05-04T00:00:00,United States,Z01.107.567.875
21541816,2011-05-04T00:00:00,Animals,B01.050
21541816,2011-05-04T00:00:00,Diagnostic Imaging,E01.370.350
21541816,2011-05-04T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21541816,2011-05-04T00:00:00,Prostatic Neoplasms,C04.588.945.440.770
21541816,2011-05-04T00:00:00,Prostatic Neoplasms,C12.294.260.750
21541816,2011-05-04T00:00:00,Prostatic Neoplasms,C12.294.565.625
21541816,2011-05-04T00:00:00,Prostatic Neoplasms,C12.758.409.750
21541816,2011-05-04T00:00:00,"Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization",E05.196.566.755
21541816,2011-05-04T00:00:00,"Tumor Markers, Biological",D23.101.840
21543267,2011-05-04T00:00:00,"Chromosomal Proteins, Non-Histone",D12.776.660.235
21543267,2011-05-04T00:00:00,"Chromosomal Proteins, Non-Histone",D12.776.664.235
21543267,2011-05-04T00:00:00,"DNA, Single-Stranded",D13.444.308.497
21543267,2011-05-04T00:00:00,Rad51 Recombinase,D08.811.739.650.500
21543267,2011-05-04T00:00:00,Rad51 Recombinase,D12.776.260.695
21543267,2011-05-04T00:00:00,Saccharomyces cerevisiae,B01.300.107.795.785.800
21543267,2011-05-04T00:00:00,Saccharomyces cerevisiae,B01.300.930.705.655
21543267,2011-05-04T00:00:00,Saccharomyces cerevisiae Proteins,D12.776.354.750
21543327,2011-05-04T00:00:00,Animals,B01.050
21543327,2011-05-04T00:00:00,Antineoplastic Agents,D27.505.954.248
21543327,2011-05-04T00:00:00,Fenretinide,D02.455.326.271.665.202.495.270
21543327,2011-05-04T00:00:00,Fenretinide,D02.455.426.392.368.367.379.249.700.270
21543327,2011-05-04T00:00:00,Fenretinide,D02.455.849.131.495.270
21543327,2011-05-04T00:00:00,Fenretinide,D23.767.261.700.270
21543327,2011-05-04T00:00:00,"Microsomes, Liver",A11.284.835.540.541
21543327,2011-05-04T00:00:00,Oxidoreductases,D08.811.682
21543327,2011-05-04T00:00:00,Rats,B01.050.150.900.649.865.635.505.700
21543327,2011-05-04T00:00:00,"Rats, Sprague-Dawley",B01.050.150.900.649.865.635.505.700.750
21543327,2011-05-04T00:00:00,Time Factors,G01.910.857
21543458,2011-05-04T00:00:00,Counseling,F02.784.176
21543458,2011-05-04T00:00:00,Counseling,F04.408.413
21543458,2011-05-04T00:00:00,Counseling,N02.421.143.303
21543458,2011-05-04T00:00:00,Counseling,N02.421.461.363
21543458,2011-05-04T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21543458,2011-05-04T00:00:00,Motivation,F01.658
21543458,2011-05-04T00:00:00,Motivation,F01.752.543.500.750
21543458,2011-05-04T00:00:00,Smoking,F01.145.466.753
21543458,2011-05-04T00:00:00,Smoking Cessation,F01.145.940.700
21544060,2011-05-04T00:00:00,Animals,B01.050
21544060,2011-05-04T00:00:00,Complement Activation,G12.425.255
21544060,2011-05-04T00:00:00,"Complement Pathway, Alternative",G12.425.255.695
21544060,2011-05-04T00:00:00,Epithelial Cells,A11.436
21544060,2011-05-04T00:00:00,Kidney Tubules,A05.810.453.736.560
21544060,2011-05-04T00:00:00,Reperfusion Injury,C14.907.725
21544060,2011-05-04T00:00:00,Reperfusion Injury,C23.550.767.877
21601905,2011-05-04T00:00:00,Bacteria,B03
21601905,2011-05-04T00:00:00,"Biodegradation, Environmental",N06.850.460.375.500
21601905,2011-05-04T00:00:00,"Biodegradation, Environmental",N06.850.860.510.900.299
21601905,2011-05-04T00:00:00,Geologic Sediments,G01.311.500
21601905,2011-05-04T00:00:00,Geologic Sediments,G16.500.320
21601905,2011-05-04T00:00:00,Polychlorinated Biphenyls,D02.455.426.559.389.185.698
21601905,2011-05-04T00:00:00,Polychlorinated Biphenyls,D02.455.526.439.773
21601905,2011-05-04T00:00:00,"Sequence Analysis, DNA",E05.393.760.700
22417452,2011-05-04T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22417452,2011-05-04T00:00:00,Research Design,E05.581.500
22417452,2011-05-04T00:00:00,Research Design,H01.770.644.728
22417452,2011-05-04T00:00:00,Volatile Organic Compounds,D02.974
21273550,2011-05-05T00:00:00,Animals,B01.050
21273550,2011-05-05T00:00:00,Apoptosis,G04.299.139.160
21273550,2011-05-05T00:00:00,Cell Survival,G04.299.316
21273550,2011-05-05T00:00:00,Immunosuppressive Agents,D27.505.696.477.656
21273550,2011-05-05T00:00:00,Light,G01.201.875.770.578
21273550,2011-05-05T00:00:00,Light,G01.590.540
21273550,2011-05-05T00:00:00,Retinal Cone Photoreceptor Cells,A08.663.650.850.625.670.100
21273550,2011-05-05T00:00:00,Retinal Cone Photoreceptor Cells,A08.663.650.915.937.670.100
21273550,2011-05-05T00:00:00,Retinal Cone Photoreceptor Cells,A08.800.950.937.670.100
21273550,2011-05-05T00:00:00,Retinal Cone Photoreceptor Cells,A09.371.729.831.625.670.100
21273550,2011-05-05T00:00:00,Retinal Cone Photoreceptor Cells,A11.671.650.850.625.670.100
21273550,2011-05-05T00:00:00,Retinal Cone Photoreceptor Cells,A11.671.650.915.937.670.100
21273550,2011-05-05T00:00:00,Retinal Degeneration,C11.768.585
21273550,2011-05-05T00:00:00,Retinal Rod Photoreceptor Cells,A08.663.650.850.625.670.650
21273550,2011-05-05T00:00:00,Retinal Rod Photoreceptor Cells,A08.663.650.915.937.670.650
21273550,2011-05-05T00:00:00,Retinal Rod Photoreceptor Cells,A08.800.950.937.670.650
21273550,2011-05-05T00:00:00,Retinal Rod Photoreceptor Cells,A09.371.729.831.625.670.650
21273550,2011-05-05T00:00:00,Retinal Rod Photoreceptor Cells,A11.671.650.850.625.670.650
21273550,2011-05-05T00:00:00,Retinal Rod Photoreceptor Cells,A11.671.650.915.937.670.650
21544599,2011-05-05T00:00:00,Adolescent,M01.060.057
21544599,2011-05-05T00:00:00,Adult,M01.060.116
21544599,2011-05-05T00:00:00,African Americans,M01.686.508.100.100
21544599,2011-05-05T00:00:00,African Americans,M01.686.754.100
21544599,2011-05-05T00:00:00,Body Mass Index,E01.370.600.115.100.125
21544599,2011-05-05T00:00:00,Body Mass Index,E05.041.124.125
21544599,2011-05-05T00:00:00,Body Mass Index,G07.100.100.125
21544599,2011-05-05T00:00:00,Body Mass Index,N06.850.505.200.100.175
21544599,2011-05-05T00:00:00,Body Weight,C23.888.144
21544599,2011-05-05T00:00:00,Body Weight,E01.370.600.115.100.160.120
21544599,2011-05-05T00:00:00,Body Weight,E05.041.124.160.750
21544599,2011-05-05T00:00:00,Body Weight,G07.100.100.160.120
21544599,2011-05-05T00:00:00,Body Weight,G07.700.320.249.314.120
21544599,2011-05-05T00:00:00,Child,M01.060.406
21544599,2011-05-05T00:00:00,"Child, Preschool",M01.060.406.448
21544599,2011-05-05T00:00:00,European Continental Ancestry Group,M01.686.508.400
21544599,2011-05-05T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21544599,2011-05-05T00:00:00,Intracellular Signaling Peptides and Proteins,D12.644.360
21544599,2011-05-05T00:00:00,Intracellular Signaling Peptides and Proteins,D12.776.476
21544599,2011-05-05T00:00:00,Membrane Proteins,D12.776.543
21544599,2011-05-05T00:00:00,"Polymorphism, Single Nucleotide",G05.365.795.598
21544599,2011-05-05T00:00:00,Proteins,D12.776
21544599,2011-05-05T00:00:00,Sex Factors,N05.715.350.675
21544599,2011-05-05T00:00:00,Sex Factors,N06.850.490.875
21544599,2011-05-05T00:00:00,United States,Z01.107.567.875
21544599,2011-05-05T00:00:00,Young Adult,M01.060.116.815
21544929,2011-05-05T00:00:00,Algorithms,G17.035
21544929,2011-05-05T00:00:00,Algorithms,L01.224.050
21544929,2011-05-05T00:00:00,Computer Simulation,L01.224.160
21544929,2011-05-05T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21544929,2011-05-05T00:00:00,Probability,E05.318.740.600
21544929,2011-05-05T00:00:00,Probability,G17.680
21544929,2011-05-05T00:00:00,Probability,N05.715.360.750.625
21544929,2011-05-05T00:00:00,Probability,N06.850.520.830.600
21544929,2011-05-05T00:00:00,Randomized Controlled Trials as Topic,E05.318.760.535.365.500
21544929,2011-05-05T00:00:00,Randomized Controlled Trials as Topic,E05.337.250.365.500
21544929,2011-05-05T00:00:00,Randomized Controlled Trials as Topic,N05.715.360.775.235.387.500
21544929,2011-05-05T00:00:00,Randomized Controlled Trials as Topic,N06.850.520.450.535.365.500
21544929,2011-05-05T00:00:00,Research Design,E05.581.500
21544929,2011-05-05T00:00:00,Research Design,H01.770.644.728
21546491,2011-05-05T00:00:00,Aged,M01.060.116.100
21546491,2011-05-05T00:00:00,Albumins,D12.776.034
21546491,2011-05-05T00:00:00,Double-Blind Method,E05.318.780.300
21546491,2011-05-05T00:00:00,Double-Blind Method,E05.581.500.300
21546491,2011-05-05T00:00:00,Double-Blind Method,N05.715.360.780.320
21546491,2011-05-05T00:00:00,Double-Blind Method,N06.850.520.445.300
21546491,2011-05-05T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21546491,2011-05-05T00:00:00,Stroke,C10.228.140.300.775
21546491,2011-05-05T00:00:00,Stroke,C14.907.253.855
21546491,2011-05-05T00:00:00,Thrombolytic Therapy,E02.319.913
21546491,2011-05-05T00:00:00,Treatment Outcome,E01.789.800
21546491,2011-05-05T00:00:00,Treatment Outcome,N04.761.559.590.800
21546491,2011-05-05T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21549558,2011-05-05T00:00:00,Biometry,E05.318.740.225
21549558,2011-05-05T00:00:00,Biometry,N06.850.505.200
21549558,2011-05-05T00:00:00,Cataract Extraction,E04.540.825.249
21549558,2011-05-05T00:00:00,Child,M01.060.406
21549558,2011-05-05T00:00:00,"Child, Preschool",M01.060.406.448
21549558,2011-05-05T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21549558,2011-05-05T00:00:00,Infant,M01.060.703
21549558,2011-05-05T00:00:00,"Lens Implantation, Intraocular",E04.540.825.600
21549558,2011-05-05T00:00:00,"Lenses, Intraocular",E07.632.500.460
21549558,2011-05-05T00:00:00,"Lenses, Intraocular",E07.695.460
21549558,2011-05-05T00:00:00,"Refraction, Ocular",E01.370.380.850.700
21549558,2011-05-05T00:00:00,"Refraction, Ocular",G01.590.770.760
21549558,2011-05-05T00:00:00,"Refraction, Ocular",G01.595.640.760
21549558,2011-05-05T00:00:00,"Refraction, Ocular",G14.760
21549558,2011-05-05T00:00:00,Visual Acuity,E01.370.380.850.950
21549558,2011-05-05T00:00:00,Visual Acuity,F02.463.593.932.901
21549558,2011-05-05T00:00:00,Visual Acuity,G14.940
21550314,2011-05-05T00:00:00,Aged,M01.060.116.100
21550314,2011-05-05T00:00:00,Brain Ischemia,C10.228.140.300.150
21550314,2011-05-05T00:00:00,Brain Ischemia,C14.907.253.092
21550314,2011-05-05T00:00:00,Carotid Stenosis,C10.228.140.300.200.360
21550314,2011-05-05T00:00:00,Carotid Stenosis,C14.907.137.230
21550314,2011-05-05T00:00:00,Carotid Stenosis,C14.907.253.123.360
21550314,2011-05-05T00:00:00,Clinical Trials as Topic,E05.318.760.535
21550314,2011-05-05T00:00:00,Clinical Trials as Topic,E05.337.250
21550314,2011-05-05T00:00:00,Clinical Trials as Topic,N05.715.360.775.235
21550314,2011-05-05T00:00:00,Clinical Trials as Topic,N06.850.520.450.535
21550314,2011-05-05T00:00:00,"Endarterectomy, Carotid",E04.100.814.456.250
21550314,2011-05-05T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21550314,2011-05-05T00:00:00,Middle Aged,M01.060.116.630
21550314,2011-05-05T00:00:00,Myocardial Infarction,C14.280.647.500
21550314,2011-05-05T00:00:00,Myocardial Infarction,C14.907.585.500
21550314,2011-05-05T00:00:00,Risk Factors,E05.318.740.600.800.725
21550314,2011-05-05T00:00:00,Risk Factors,N05.715.350.200.700
21550314,2011-05-05T00:00:00,Risk Factors,N05.715.360.750.625.700.700
21550314,2011-05-05T00:00:00,Risk Factors,N06.850.490.625.750
21550314,2011-05-05T00:00:00,Risk Factors,N06.850.520.830.600.800.725
21550314,2011-05-05T00:00:00,Sex Factors,N05.715.350.675
21550314,2011-05-05T00:00:00,Sex Factors,N06.850.490.875
21550314,2011-05-05T00:00:00,Stents,E07.695.750
21550314,2011-05-05T00:00:00,Stroke,C10.228.140.300.775
21550314,2011-05-05T00:00:00,Stroke,C14.907.253.855
21550314,2011-05-05T00:00:00,Treatment Outcome,E01.789.800
21550314,2011-05-05T00:00:00,Treatment Outcome,N04.761.559.590.800
21550314,2011-05-05T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21551019,2011-05-05T00:00:00,Adult,M01.060.116
21551019,2011-05-05T00:00:00,African Americans,M01.686.508.100.100
21551019,2011-05-05T00:00:00,African Americans,M01.686.754.100
21551019,2011-05-05T00:00:00,Age Factors,N05.715.350.075
21551019,2011-05-05T00:00:00,Age Factors,N06.850.490.250
21551019,2011-05-05T00:00:00,Albuminuria,C12.777.934.734.269
21551019,2011-05-05T00:00:00,Albuminuria,C13.351.968.934.734.269
21551019,2011-05-05T00:00:00,Albuminuria,C23.888.942.750.269
21551019,2011-05-05T00:00:00,Blood Pressure,E01.370.600.875.249
21551019,2011-05-05T00:00:00,Blood Pressure,G09.330.380.076
21551019,2011-05-05T00:00:00,European Continental Ancestry Group,M01.686.508.400
21551019,2011-05-05T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21551019,2011-05-05T00:00:00,Hypertension,C14.907.489
21551019,2011-05-05T00:00:00,Kidney,A05.810.453
21551019,2011-05-05T00:00:00,Kidney Diseases,C12.777.419
21551019,2011-05-05T00:00:00,Kidney Diseases,C13.351.968.419
21551019,2011-05-05T00:00:00,Kidney Transplantation,E02.870.500
21551019,2011-05-05T00:00:00,Kidney Transplantation,E04.936.450.485
21551019,2011-05-05T00:00:00,Kidney Transplantation,E04.950.774.400
21551019,2011-05-05T00:00:00,Middle Aged,M01.060.116.630
21551019,2011-05-05T00:00:00,Nephrectomy,E04.950.774.435
21551019,2011-05-05T00:00:00,Regression Analysis,E05.318.740.750
21551019,2011-05-05T00:00:00,Regression Analysis,N05.715.360.750.695
21551019,2011-05-05T00:00:00,Regression Analysis,N06.850.520.830.750
21551019,2011-05-05T00:00:00,Risk Assessment,E05.318.740.600.800.715
21551019,2011-05-05T00:00:00,Risk Assessment,N04.452.871.715
21551019,2011-05-05T00:00:00,Risk Assessment,N05.715.360.750.625.700.690
21551019,2011-05-05T00:00:00,Risk Assessment,N06.850.505.715
21551019,2011-05-05T00:00:00,Risk Assessment,N06.850.520.830.600.800.715
21551019,2011-05-05T00:00:00,Risk Factors,E05.318.740.600.800.725
21551019,2011-05-05T00:00:00,Risk Factors,N05.715.350.200.700
21551019,2011-05-05T00:00:00,Risk Factors,N05.715.360.750.625.700.700
21551019,2011-05-05T00:00:00,Risk Factors,N06.850.490.625.750
21551019,2011-05-05T00:00:00,Risk Factors,N06.850.520.830.600.800.725
21551019,2011-05-05T00:00:00,South Carolina,Z01.107.567.875.075.662
21551019,2011-05-05T00:00:00,South Carolina,Z01.107.567.875.750.700
21551019,2011-05-05T00:00:00,Time Factors,G01.910.857
21551019,2011-05-05T00:00:00,Tissue Donors,M01.898
21696759,2011-05-05T00:00:00,Animals,B01.050
21696759,2011-05-05T00:00:00,Biocompatible Materials,D25.130
21696759,2011-05-05T00:00:00,Biocompatible Materials,D27.720.102.130
21696759,2011-05-05T00:00:00,Biocompatible Materials,J01.637.051.130
21696759,2011-05-05T00:00:00,"Hernia, Abdominal",C23.300.707.374
21696759,2011-05-05T00:00:00,Lysostaphin,D08.811.277.656.300.480.452
21696759,2011-05-05T00:00:00,Lysostaphin,D08.811.277.656.675.374.452
21696759,2011-05-05T00:00:00,Rats,B01.050.150.900.649.865.635.505.700
21696759,2011-05-05T00:00:00,Risk Factors,E05.318.740.600.800.725
21696759,2011-05-05T00:00:00,Risk Factors,N05.715.350.200.700
21696759,2011-05-05T00:00:00,Risk Factors,N05.715.360.750.625.700.700
21696759,2011-05-05T00:00:00,Risk Factors,N06.850.490.625.750
21696759,2011-05-05T00:00:00,Risk Factors,N06.850.520.830.600.800.725
21696759,2011-05-05T00:00:00,Staphylococcal Infections,C01.252.410.868
21696759,2011-05-05T00:00:00,Staphylococcus aureus,B03.300.390.400.800.750.100
21696759,2011-05-05T00:00:00,Staphylococcus aureus,B03.510.100.750.750.100
21696759,2011-05-05T00:00:00,Staphylococcus aureus,B03.510.400.790.750.100
21696759,2011-05-05T00:00:00,Surgical Mesh,E07.858.708
21696759,2011-05-05T00:00:00,Surgical Wound Infection,C01.539.947.692
21696759,2011-05-05T00:00:00,Surgical Wound Infection,C23.550.767.925
21696759,2011-05-05T00:00:00,Swine,B01.050.150.900.649.077.880
22287430,2011-05-05T00:00:00,Cell Differentiation,G04.299.151
22287430,2011-05-05T00:00:00,Chronic Disease,C23.550.291.500
22287430,2011-05-05T00:00:00,Dendritic Cells,A11.066.270
22287430,2011-05-05T00:00:00,Dendritic Cells,A11.436.270
22287430,2011-05-05T00:00:00,Dendritic Cells,A15.382.066.270
22287430,2011-05-05T00:00:00,Dendritic Cells,A15.382.812.260
22287430,2011-05-05T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22287430,2011-05-05T00:00:00,Interferon-gamma,D12.644.276.374.440.893
22287430,2011-05-05T00:00:00,Interferon-gamma,D12.644.276.374.480.350
22287430,2011-05-05T00:00:00,Interferon-gamma,D12.644.276.374.480.615.350
22287430,2011-05-05T00:00:00,Interferon-gamma,D12.644.276.718.550
22287430,2011-05-05T00:00:00,Interferon-gamma,D12.776.467.374.440.893
22287430,2011-05-05T00:00:00,Interferon-gamma,D12.776.467.374.480.350
22287430,2011-05-05T00:00:00,Interferon-gamma,D12.776.467.374.480.615.350
22287430,2011-05-05T00:00:00,Interferon-gamma,D12.776.467.718.550
22287430,2011-05-05T00:00:00,Interferon-gamma,D23.529.374.440.893
22287430,2011-05-05T00:00:00,Interferon-gamma,D23.529.374.480.350
22287430,2011-05-05T00:00:00,Interferon-gamma,D23.529.374.480.615.350
22287430,2011-05-05T00:00:00,Interferon-gamma,D23.529.718.550
22287430,2011-05-05T00:00:00,Nasal Polyps,C08.460.572
22287430,2011-05-05T00:00:00,Nasal Polyps,C09.603.557
22287430,2011-05-05T00:00:00,Nasal Polyps,C23.300.825.557
22287430,2011-05-05T00:00:00,Phenotype,G05.695
22287430,2011-05-05T00:00:00,Sinusitis,C08.460.692.752
22287430,2011-05-05T00:00:00,Sinusitis,C08.730.749
22287430,2011-05-05T00:00:00,Sinusitis,C09.603.692.752
21529934,2011-05-06T00:00:00,Adsorption,G02.149.047
21529934,2011-05-06T00:00:00,Adsorption,G02.149.767.029
21529934,2011-05-06T00:00:00,Adsorption,G02.842.750.029
21529934,2011-05-06T00:00:00,"Antibodies, Monoclonal",D12.776.124.486.485.114.224
21529934,2011-05-06T00:00:00,"Antibodies, Monoclonal",D12.776.124.790.651.114.224
21529934,2011-05-06T00:00:00,"Antibodies, Monoclonal",D12.776.377.715.548.114.224
21529934,2011-05-06T00:00:00,Fibrinogen,D12.776.124.050.250
21529934,2011-05-06T00:00:00,Fibrinogen,D12.776.124.125.500
21529934,2011-05-06T00:00:00,Fibrinogen,D12.776.811.300
21529934,2011-05-06T00:00:00,Fibrinogen,D23.119.490
21529934,2011-05-06T00:00:00,Gold,D01.268.556.322
21529934,2011-05-06T00:00:00,Gold,D01.268.956.186
21529934,2011-05-06T00:00:00,Gold,D01.552.544.322
21529934,2011-05-06T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21529934,2011-05-06T00:00:00,Platelet Membrane Glycoproteins,D12.776.395.550.625
21529934,2011-05-06T00:00:00,Platelet Membrane Glycoproteins,D12.776.543.550.625
21529934,2011-05-06T00:00:00,Platelet Membrane Glycoproteins,D12.776.543.750.705.675
21529934,2011-05-06T00:00:00,Protein Conformation,G02.111.570.790.709
21529934,2011-05-06T00:00:00,"Protein Structure, Secondary",G02.111.570.790.709.600
21529934,2011-05-06T00:00:00,Serum Albumin,D12.776.034.841
21529934,2011-05-06T00:00:00,Serum Albumin,D12.776.124.050.700
21529934,2011-05-06T00:00:00,Serum Albumin,D12.776.124.727
21529934,2011-05-06T00:00:00,Tyrosine,D12.125.072.050.875
21548953,2011-05-06T00:00:00,Algorithms,G17.035
21548953,2011-05-06T00:00:00,Algorithms,L01.224.050
21548953,2011-05-06T00:00:00,Animals,B01.050
21548953,2011-05-06T00:00:00,Cell Cycle,G04.299.134
21548953,2011-05-06T00:00:00,Cell Survival,G04.299.316
21548953,2011-05-06T00:00:00,Computational Biology,H01.158.273.180
21548953,2011-05-06T00:00:00,DNA,D13.444.308
21548953,2011-05-06T00:00:00,Drosophila melanogaster,B01.050.500.131.617.289.310.250.500
21548953,2011-05-06T00:00:00,Phenotype,G05.695
21548953,2011-05-06T00:00:00,Protein Interaction Mapping,E05.601.690
21548953,2011-05-06T00:00:00,Proteins,D12.776
21548953,2011-05-06T00:00:00,RNA Interference,G05.355.315.203.374.790
21549529,2011-05-06T00:00:00,Adult,M01.060.116
21549529,2011-05-06T00:00:00,Alcoholism,C21.739.100.250
21549529,2011-05-06T00:00:00,Alcoholism,F03.900.100.350
21549529,2011-05-06T00:00:00,Bipolar Disorder,F03.600.150.150
21549529,2011-05-06T00:00:00,Clinical Trials as Topic,E05.318.760.535
21549529,2011-05-06T00:00:00,Clinical Trials as Topic,E05.337.250
21549529,2011-05-06T00:00:00,Clinical Trials as Topic,N05.715.360.775.235
21549529,2011-05-06T00:00:00,Clinical Trials as Topic,N06.850.520.450.535
21549529,2011-05-06T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21549529,2011-05-06T00:00:00,Middle Aged,M01.060.116.630
21549529,2011-05-06T00:00:00,"Models, Psychological",E05.599.695
21549529,2011-05-06T00:00:00,Patient Dropouts,M01.643.673
21549529,2011-05-06T00:00:00,Risk-Taking,F01.145.722
21600285,2011-05-06T00:00:00,Amyotrophic Lateral Sclerosis,C10.228.854.139
21600285,2011-05-06T00:00:00,Amyotrophic Lateral Sclerosis,C10.574.562.250
21600285,2011-05-06T00:00:00,Amyotrophic Lateral Sclerosis,C10.574.950.050
21600285,2011-05-06T00:00:00,Amyotrophic Lateral Sclerosis,C10.668.460.250
21600285,2011-05-06T00:00:00,Amyotrophic Lateral Sclerosis,C18.452.845.800.050
21600285,2011-05-06T00:00:00,Animals,B01.050
21600285,2011-05-06T00:00:00,"Disease Models, Animal",C22.232
21600285,2011-05-06T00:00:00,"Disease Models, Animal",E05.598.500
21600285,2011-05-06T00:00:00,"Disease Models, Animal",E05.599.395.080
21600285,2011-05-06T00:00:00,Glutathione,D12.644.456.448
21600285,2011-05-06T00:00:00,Glycine,D12.125.481
21600285,2011-05-06T00:00:00,Mitochondria,A11.284.430.214.190.875.564
21600285,2011-05-06T00:00:00,Mitochondria,A11.284.835.626
21600285,2011-05-06T00:00:00,Motor Neurons,A08.663.655.500
21600285,2011-05-06T00:00:00,Motor Neurons,A11.671.655.500
21600285,2011-05-06T00:00:00,Superoxide Dismutase,D08.811.682.881
21679712,2011-05-06T00:00:00,Adenocarcinoma,C04.557.470.200.025
21679712,2011-05-06T00:00:00,Aged,M01.060.116.100
21679712,2011-05-06T00:00:00,Catheter Ablation,E01.370.370.380.410.200
21679712,2011-05-06T00:00:00,Catheter Ablation,E02.148.110
21679712,2011-05-06T00:00:00,Catheter Ablation,E02.148.442.110
21679712,2011-05-06T00:00:00,Catheter Ablation,E02.154.402.110
21679712,2011-05-06T00:00:00,Catheter Ablation,E04.014.170.402.110
21679712,2011-05-06T00:00:00,Disease Progression,C23.550.291.656
21679712,2011-05-06T00:00:00,Esophageal Neoplasms,C04.588.274.476.205
21679712,2011-05-06T00:00:00,Esophageal Neoplasms,C04.588.443.353
21679712,2011-05-06T00:00:00,Esophageal Neoplasms,C06.301.371.205
21679712,2011-05-06T00:00:00,Esophageal Neoplasms,C06.405.117.430
21679712,2011-05-06T00:00:00,Esophageal Neoplasms,C06.405.249.205
21679712,2011-05-06T00:00:00,Esophagus,A03.556.875.500
21679712,2011-05-06T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21679712,2011-05-06T00:00:00,Middle Aged,M01.060.116.630
21679712,2011-05-06T00:00:00,Treatment Outcome,E01.789.800
21679712,2011-05-06T00:00:00,Treatment Outcome,N04.761.559.590.800
21679712,2011-05-06T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21762826,2011-05-06T00:00:00,Adult,M01.060.116
21762826,2011-05-06T00:00:00,Health Expenditures,N03.219.151.450
21762826,2011-05-06T00:00:00,Health Expenditures,N05.300.385
21762826,2011-05-06T00:00:00,Health Services,N02.421
21762826,2011-05-06T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21762826,2011-05-06T00:00:00,Middle Aged,M01.060.116.630
21762826,2011-05-06T00:00:00,"Stress, Psychological",F01.145.126.990
21762826,2011-05-06T00:00:00,"Stress, Psychological",F02.830.900
21762826,2011-05-06T00:00:00,United States,Z01.107.567.875
21555138,2011-05-08T00:00:00,Conflict of Interest,K01.316.130
21555138,2011-05-08T00:00:00,Conflict of Interest,N05.350.225
21555138,2011-05-08T00:00:00,Health Care Sector,J01.576.489
21555138,2011-05-08T00:00:00,Health Care Sector,N03.219.650
21555138,2011-05-08T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21555138,2011-05-08T00:00:00,Terminology as Topic,L01.143.506.598.400
21555138,2011-05-08T00:00:00,Thoracic Surgery,H02.403.810.803
21341992,2011-05-09T00:00:00,Animals,B01.050
21341992,2011-05-09T00:00:00,"Aortic Aneurysm, Abdominal",C14.907.055.239.075
21341992,2011-05-09T00:00:00,"Aortic Aneurysm, Abdominal",C14.907.109.139.075
21341992,2011-05-09T00:00:00,Cell Proliferation,G04.299.233.750
21341992,2011-05-09T00:00:00,Cell Proliferation,G07.700.320.249.410.750
21341992,2011-05-09T00:00:00,"Disease Models, Animal",C22.232
21341992,2011-05-09T00:00:00,"Disease Models, Animal",E05.598.500
21341992,2011-05-09T00:00:00,"Disease Models, Animal",E05.599.395.080
21341992,2011-05-09T00:00:00,Disease Progression,C23.550.291.656
21341992,2011-05-09T00:00:00,Elastin,D05.750.078.421
21341992,2011-05-09T00:00:00,Elastin,D12.776.860.300.350
21341992,2011-05-09T00:00:00,Extracellular Matrix,A11.284.295.310
21341992,2011-05-09T00:00:00,Gene Expression Profiling,E05.393.332
21341992,2011-05-09T00:00:00,Gene Expression Regulation,G05.355.315
21341992,2011-05-09T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21341992,2011-05-09T00:00:00,"Myocytes, Smooth Muscle",A11.620.520
21341992,2011-05-09T00:00:00,Oligonucleotide Array Sequence Analysis,E05.196.630.570.660
21341992,2011-05-09T00:00:00,Oligonucleotide Array Sequence Analysis,E05.393.525.640
21341992,2011-05-09T00:00:00,Oligonucleotide Array Sequence Analysis,E05.393.661.640
21341992,2011-05-09T00:00:00,Oligonucleotide Array Sequence Analysis,E05.393.760.640
21341992,2011-05-09T00:00:00,Oligonucleotide Array Sequence Analysis,E05.588.570.660
21341992,2011-05-09T00:00:00,Oligonucleotide Array Sequence Analysis,E05.601.640
21341992,2011-05-09T00:00:00,Perfusion,E05.680
21341992,2011-05-09T00:00:00,Phenotype,G05.695
21341992,2011-05-09T00:00:00,"Protein Processing, Post-Translational",G02.111.087.675.871.790.600
21341992,2011-05-09T00:00:00,"Protein Processing, Post-Translational",G02.111.087.693.600
21341992,2011-05-09T00:00:00,"Protein Processing, Post-Translational",G02.149.115.675.871.790.600
21341992,2011-05-09T00:00:00,"Protein Processing, Post-Translational",G02.149.115.693.600
21341992,2011-05-09T00:00:00,"Protein Processing, Post-Translational",G03.495.770.871.790.600
21341992,2011-05-09T00:00:00,"Protein Processing, Post-Translational",G05.355.315.670.600
21341992,2011-05-09T00:00:00,Rats,B01.050.150.900.649.865.635.505.700
21341992,2011-05-09T00:00:00,"Rats, Sprague-Dawley",B01.050.150.900.649.865.635.505.700.750
21341992,2011-05-09T00:00:00,Transforming Growth Factor beta,D12.644.276.374.687
21341992,2011-05-09T00:00:00,Transforming Growth Factor beta,D12.644.276.954.800.720
21341992,2011-05-09T00:00:00,Transforming Growth Factor beta,D12.644.276.963.720
21341992,2011-05-09T00:00:00,Transforming Growth Factor beta,D12.776.467.374.687
21341992,2011-05-09T00:00:00,Transforming Growth Factor beta,D12.776.467.942.800.720
21341992,2011-05-09T00:00:00,Transforming Growth Factor beta,D12.776.467.960.720
21341992,2011-05-09T00:00:00,Transforming Growth Factor beta,D23.529.374.687
21341992,2011-05-09T00:00:00,Transforming Growth Factor beta,D23.529.942.800.720
21341992,2011-05-09T00:00:00,Transforming Growth Factor beta,D23.529.960.720
21554699,2011-05-09T00:00:00,Cell Movement,G04.299.283
21554699,2011-05-09T00:00:00,Cell Movement,G07.700.560.500.180
21554699,2011-05-09T00:00:00,Ceramides,D02.065.313
21554699,2011-05-09T00:00:00,Ceramides,D09.400.410.420.525.200
21554699,2011-05-09T00:00:00,Ceramides,D10.390.470.675.200
21554699,2011-05-09T00:00:00,Ceramides,D10.570.877.360.612.200
21554699,2011-05-09T00:00:00,Chemical Fractionation,E05.196.155
21554699,2011-05-09T00:00:00,Endothelial Cells,A11.436.275
21554699,2011-05-09T00:00:00,"Endothelium, Vascular",A07.231.330
21554699,2011-05-09T00:00:00,"Endothelium, Vascular",A10.272.491.355
21554699,2011-05-09T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21554699,2011-05-09T00:00:00,"Lipoproteins, HDL",D10.532.432
21554699,2011-05-09T00:00:00,"Lipoproteins, HDL",D12.776.521.479
21554699,2011-05-09T00:00:00,Lysophospholipids,D10.570.755.375.760.550
21554699,2011-05-09T00:00:00,Mass Spectrometry,E05.196.566
21554699,2011-05-09T00:00:00,Middle Aged,M01.060.116.630
21554699,2011-05-09T00:00:00,Myocardial Ischemia,C14.280.647
21554699,2011-05-09T00:00:00,Myocardial Ischemia,C14.907.585
21554699,2011-05-09T00:00:00,Sphingolipids,D10.570.877
21554699,2011-05-09T00:00:00,Sphingolipids,D10.808
21554699,2011-05-09T00:00:00,Sphingosine,D02.033.100.700
21554699,2011-05-09T00:00:00,Sphingosine,D02.033.455.843
21554699,2011-05-09T00:00:00,Sphingosine,D02.092.063.700
21561743,2011-05-10T00:00:00,Adult,M01.060.116
21561743,2011-05-10T00:00:00,Bipolar Disorder,F03.600.150.150
21561743,2011-05-10T00:00:00,Brain,A08.186.211
21561743,2011-05-10T00:00:00,Brain Mapping,E01.370.350.086
21561743,2011-05-10T00:00:00,Brain Mapping,E01.370.376.149
21561743,2011-05-10T00:00:00,Brain Mapping,E05.132
21561743,2011-05-10T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21561743,2011-05-10T00:00:00,"Imaging, Three-Dimensional",E01.370.350.400
21561743,2011-05-10T00:00:00,"Imaging, Three-Dimensional",L01.224.308.410
21561743,2011-05-10T00:00:00,Magnetic Resonance Imaging,E01.370.350.500
21561743,2011-05-10T00:00:00,Magnetic Resonance Imaging,E01.370.350.825.500
21561743,2011-05-10T00:00:00,Middle Aged,M01.060.116.630
21561743,2011-05-10T00:00:00,Psychiatric Status Rating Scales,F04.586
21769137,2011-05-10T00:00:00,Cooperative Behavior,F01.145.813.115
21769137,2011-05-10T00:00:00,"Education, Pharmacy",I02.358.525
21769137,2011-05-10T00:00:00,Educational Measurement,I02.399
21769137,2011-05-10T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21769137,2011-05-10T00:00:00,Interprofessional Relations,F01.829.401.205
21769137,2011-05-10T00:00:00,Patient Care Team,N04.590.715
21769137,2011-05-10T00:00:00,Patient Simulation,I02.903.525
21769137,2011-05-10T00:00:00,"Students, Pharmacy",I02.851.686.768
21769137,2011-05-10T00:00:00,"Students, Pharmacy",M01.848.769.768
21561946,2011-05-11T00:00:00,Computer Simulation,L01.224.160
21561946,2011-05-11T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21561946,2011-05-11T00:00:00,Monte Carlo Method,E05.318.740.525
21561946,2011-05-11T00:00:00,Monte Carlo Method,L01.906.575.422
21561946,2011-05-11T00:00:00,Monte Carlo Method,N05.715.360.750.540
21561946,2011-05-11T00:00:00,Monte Carlo Method,N06.850.520.830.525
21561946,2011-05-11T00:00:00,"Phantoms, Imaging",E07.671
21561946,2011-05-11T00:00:00,Radiometry,E05.799
21561946,2011-05-11T00:00:00,Software,L01.224.900
21561946,2011-05-11T00:00:00,"Tomography, X-Ray Computed",E01.370.350.350.810
21561946,2011-05-11T00:00:00,"Tomography, X-Ray Computed",E01.370.350.600.350.700.810
21561946,2011-05-11T00:00:00,"Tomography, X-Ray Computed",E01.370.350.700.700.810
21561946,2011-05-11T00:00:00,"Tomography, X-Ray Computed",E01.370.350.700.810.810
21561946,2011-05-11T00:00:00,"Tomography, X-Ray Computed",E01.370.350.825.810.810
21561946,2011-05-11T00:00:00,X-Rays,G01.201.875.750.918
21562046,2011-05-11T00:00:00,Aging,G07.700.320.124
21562046,2011-05-11T00:00:00,Animals,B01.050
21562046,2011-05-11T00:00:00,Cell Proliferation,G04.299.233.750
21562046,2011-05-11T00:00:00,Cell Proliferation,G07.700.320.249.410.750
21562046,2011-05-11T00:00:00,"Immunity, Innate",G12.450.575
21562046,2011-05-11T00:00:00,Lymphocyte Activation,E01.450.495.482
21562046,2011-05-11T00:00:00,Lymphocyte Activation,E05.478.594.530
21562046,2011-05-11T00:00:00,Lymphocyte Activation,G12.425.747
21562046,2011-05-11T00:00:00,Lymphocyte Activation,G12.450.050.400.545
21562046,2011-05-11T00:00:00,"Mice, Inbred DBA",B01.050.050.157.520.460
21562046,2011-05-11T00:00:00,"Mice, Inbred DBA",B01.050.050.199.520.520.460
21562046,2011-05-11T00:00:00,"Mice, Inbred DBA",B01.050.150.900.649.865.635.505.500.400.460
21569367,2011-05-11T00:00:00,Adult,M01.060.116
21569367,2011-05-11T00:00:00,Body Mass Index,E01.370.600.115.100.125
21569367,2011-05-11T00:00:00,Body Mass Index,E05.041.124.125
21569367,2011-05-11T00:00:00,Body Mass Index,G07.100.100.125
21569367,2011-05-11T00:00:00,Body Mass Index,N06.850.505.200.100.175
21569367,2011-05-11T00:00:00,Breast Neoplasms,C04.588.180
21569367,2011-05-11T00:00:00,Breast Neoplasms,C17.800.090.500
21569367,2011-05-11T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21569367,2011-05-11T00:00:00,Middle Aged,M01.060.116.630
21569367,2011-05-11T00:00:00,Questionnaires,E05.318.308.750
21569367,2011-05-11T00:00:00,Questionnaires,L01.280.800
21569367,2011-05-11T00:00:00,Questionnaires,N05.715.360.300.695
21569367,2011-05-11T00:00:00,Questionnaires,N06.850.520.308.750
21569367,2011-05-11T00:00:00,"Receptors, Estrogen",D12.776.260.698.750.350
21569367,2011-05-11T00:00:00,"Receptors, Estrogen",D12.776.826.750.350
21569367,2011-05-11T00:00:00,"Receptors, Estrogen",D12.776.930.669.750.350
21569367,2011-05-11T00:00:00,"Receptors, Progesterone",D12.776.260.698.750.765
21569367,2011-05-11T00:00:00,"Receptors, Progesterone",D12.776.826.750.765
21569367,2011-05-11T00:00:00,"Receptors, Progesterone",D12.776.930.669.750.765
21569367,2011-05-11T00:00:00,Risk Factors,E05.318.740.600.800.725
21569367,2011-05-11T00:00:00,Risk Factors,N05.715.350.200.700
21569367,2011-05-11T00:00:00,Risk Factors,N05.715.360.750.625.700.700
21569367,2011-05-11T00:00:00,Risk Factors,N06.850.490.625.750
21569367,2011-05-11T00:00:00,Risk Factors,N06.850.520.830.600.800.725
21569367,2011-05-11T00:00:00,Vitamin D,D04.808.812.768
21990440,2011-05-11T00:00:00,Critical Care,E02.760.190
21990440,2011-05-11T00:00:00,Critical Care,N02.421.585.190
21990440,2011-05-11T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21990440,2011-05-11T00:00:00,Neurosurgery,H02.403.810.425
21990440,2011-05-11T00:00:00,Program Development,N04.452.760
21562365,2011-05-12T00:00:00,Cell Size,G04.190
21562365,2011-05-12T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21562365,2011-05-12T00:00:00,"Spheroids, Cellular",A11.251.800
21562365,2011-05-12T00:00:00,Tissue Engineering,E05.200.249.750
21564525,2011-05-12T00:00:00,"Antibodies, Monoclonal",D12.776.124.486.485.114.224
21564525,2011-05-12T00:00:00,"Antibodies, Monoclonal",D12.776.124.790.651.114.224
21564525,2011-05-12T00:00:00,"Antibodies, Monoclonal",D12.776.377.715.548.114.224
21564525,2011-05-12T00:00:00,Antilymphocyte Serum,A12.207.152.846.500.203
21564525,2011-05-12T00:00:00,Antilymphocyte Serum,D12.776.124.486.485.114.573.203
21564525,2011-05-12T00:00:00,Antilymphocyte Serum,D12.776.124.790.651.114.573.203
21564525,2011-05-12T00:00:00,Antilymphocyte Serum,D12.776.377.715.548.114.573.203
21564525,2011-05-12T00:00:00,Antilymphocyte Serum,D20.215.401.203
21564525,2011-05-12T00:00:00,CD4-Positive T-Lymphocytes,A11.118.637.555.567.569.200
21564525,2011-05-12T00:00:00,CD4-Positive T-Lymphocytes,A15.145.229.637.555.567.569.200
21564525,2011-05-12T00:00:00,CD4-Positive T-Lymphocytes,A15.382.490.555.567.569.200
21564525,2011-05-12T00:00:00,CD8-Positive T-Lymphocytes,A11.118.637.555.567.569.220
21564525,2011-05-12T00:00:00,CD8-Positive T-Lymphocytes,A15.145.229.637.555.567.569.220
21564525,2011-05-12T00:00:00,CD8-Positive T-Lymphocytes,A15.382.490.555.567.569.220
21564525,2011-05-12T00:00:00,Graft Rejection,G12.425.901.545.328
21564525,2011-05-12T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21564525,2011-05-12T00:00:00,Kidney Transplantation,E02.870.500
21564525,2011-05-12T00:00:00,Kidney Transplantation,E04.936.450.485
21564525,2011-05-12T00:00:00,Kidney Transplantation,E04.950.774.400
21564525,2011-05-12T00:00:00,Recombinant Fusion Proteins,D12.776.828.300
21564525,2011-05-12T00:00:00,T-Lymphocytes,A11.118.637.555.567.569
21564525,2011-05-12T00:00:00,T-Lymphocytes,A15.145.229.637.555.567.569
21564525,2011-05-12T00:00:00,T-Lymphocytes,A15.382.490.555.567.569
21566015,2011-05-12T00:00:00,Amides,D02.065
21566015,2011-05-12T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21566015,2011-05-12T00:00:00,Muscle Contraction,G11.427.590.540
21566015,2011-05-12T00:00:00,"Myocytes, Smooth Muscle",A11.620.520
21566015,2011-05-12T00:00:00,Pyridines,D03.383.725
21566015,2011-05-12T00:00:00,Signal Transduction,G02.111.087.800
21566015,2011-05-12T00:00:00,Signal Transduction,G02.149.115.800
21566015,2011-05-12T00:00:00,Signal Transduction,G04.299.880
21569442,2011-05-12T00:00:00,Adenoviridae,B04.280.030
21569442,2011-05-12T00:00:00,Adenoviridae,B04.909.204.097
21569442,2011-05-12T00:00:00,"Gene Expression Regulation, Neoplastic",G05.355.315.370
21569442,2011-05-12T00:00:00,Genetic Vectors,G05.360.337
21569442,2011-05-12T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21569442,2011-05-12T00:00:00,"Promoter Regions, Genetic",G02.111.570.080.689.675
21569442,2011-05-12T00:00:00,"Promoter Regions, Genetic",G05.360.080.689.675
21569442,2011-05-12T00:00:00,"Promoter Regions, Genetic",G05.360.340.024.340.137.750.680
21569442,2011-05-12T00:00:00,"Transduction, Genetic",E05.393.350.800
21569442,2011-05-12T00:00:00,"Transduction, Genetic",G05.355.760.850
21569442,2011-05-12T00:00:00,Urinary Bladder Neoplasms,C04.588.945.947.960
21569442,2011-05-12T00:00:00,Urinary Bladder Neoplasms,C12.758.820.968
21569442,2011-05-12T00:00:00,Urinary Bladder Neoplasms,C12.777.829.813
21569442,2011-05-12T00:00:00,Urinary Bladder Neoplasms,C13.351.937.820.945
21569442,2011-05-12T00:00:00,Urinary Bladder Neoplasms,C13.351.968.829.707
21586215,2011-05-12T00:00:00,Adult,M01.060.116
21586215,2011-05-12T00:00:00,Aged,M01.060.116.100
21586215,2011-05-12T00:00:00,Exercise Therapy,E02.779.483
21586215,2011-05-12T00:00:00,Exercise Therapy,E02.831.387
21586215,2011-05-12T00:00:00,Gingivitis,C07.465.714.258.480
21586215,2011-05-12T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21586215,2011-05-12T00:00:00,Middle Aged,M01.060.116.630
21586215,2011-05-12T00:00:00,Oral Health,N01.400.535
21586215,2011-05-12T00:00:00,Patient Education as Topic,I02.233.332.500
21586215,2011-05-12T00:00:00,Patient Education as Topic,N02.421.143.827.407.680
21586215,2011-05-12T00:00:00,Patient Education as Topic,N02.421.726.407.680
21586215,2011-05-12T00:00:00,"Scleroderma, Systemic",C17.300.799
21586215,2011-05-12T00:00:00,"Scleroderma, Systemic",C17.800.784
21586215,2011-05-12T00:00:00,Treatment Outcome,E01.789.800
21586215,2011-05-12T00:00:00,Treatment Outcome,N04.761.559.590.800
21586215,2011-05-12T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21570797,2011-05-13T00:00:00,Aging,G07.700.320.124
21570797,2011-05-13T00:00:00,Animals,B01.050
21570797,2011-05-13T00:00:00,"Behavior, Animal",F01.145.113
21570797,2011-05-13T00:00:00,Ethanol,D02.033.375
21570797,2011-05-13T00:00:00,Glutamic Acid,D12.125.067.750
21570797,2011-05-13T00:00:00,Glutamic Acid,D12.125.119.450
21570797,2011-05-13T00:00:00,Glutamic Acid,D12.125.427.300
21570797,2011-05-13T00:00:00,Motor Activity,F01.145.632
21570797,2011-05-13T00:00:00,Motor Activity,G11.427.590.530.698
21570797,2011-05-13T00:00:00,Nucleus Accumbens,A08.186.211.730.885.287.249.683
21572097,2011-05-13T00:00:00,Animals,B01.050
21572097,2011-05-13T00:00:00,Apoptosis Inducing Factor,D08.811.682.608.047
21572097,2011-05-13T00:00:00,Apoptosis Inducing Factor,D12.644.360.075.311
21572097,2011-05-13T00:00:00,Apoptosis Inducing Factor,D12.776.331.161
21572097,2011-05-13T00:00:00,Apoptosis Inducing Factor,D12.776.476.075.311
21572097,2011-05-13T00:00:00,Drug-Induced Liver Injury,C06.552.195
21572097,2011-05-13T00:00:00,Drug-Induced Liver Injury,C21.613.260
21572097,2011-05-13T00:00:00,Glutathione Disulfide,D12.644.456.448.500
21572097,2011-05-13T00:00:00,Hepatocytes,A11.436.348
21572097,2011-05-13T00:00:00,Liver,A03.620
21572097,2011-05-13T00:00:00,"Mitochondria, Liver",A11.284.430.214.190.875.564.461
21572097,2011-05-13T00:00:00,"Mitochondria, Liver",A11.284.835.626.461
21572097,2011-05-13T00:00:00,Oxidative Stress,G03.495.710
21572097,2011-05-13T00:00:00,Oxidative Stress,G07.700.830.750
21572097,2011-05-13T00:00:00,Peroxynitrous Acid,D01.625.600.800
21572097,2011-05-13T00:00:00,Peroxynitrous Acid,D01.625.700.750
21572097,2011-05-13T00:00:00,Reactive Oxygen Species,D01.339.431
21572097,2011-05-13T00:00:00,Reactive Oxygen Species,D01.650.775
21572182,2011-05-13T00:00:00,Computational Biology,H01.158.273.180
21572182,2011-05-13T00:00:00,Computer Simulation,L01.224.160
21572182,2011-05-13T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21572182,2011-05-13T00:00:00,"Models, Chemical",E05.599.495
21572182,2011-05-13T00:00:00,Proteins,D12.776
21572182,2011-05-13T00:00:00,Static Electricity,G01.201.249.820
21990446,2011-05-13T00:00:00,Carotid Stenosis,C10.228.140.300.200.360
21990446,2011-05-13T00:00:00,Carotid Stenosis,C14.907.137.230
21990446,2011-05-13T00:00:00,Carotid Stenosis,C14.907.253.123.360
21990446,2011-05-13T00:00:00,"Embolization, Therapeutic",E02.520.360
21990446,2011-05-13T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21990446,2011-05-13T00:00:00,Treatment Outcome,E01.789.800
21990446,2011-05-13T00:00:00,Treatment Outcome,N04.761.559.590.800
21990446,2011-05-13T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21572159,2011-05-15T00:00:00,Adult,M01.060.116
21572159,2011-05-15T00:00:00,African Americans,M01.686.508.100.100
21572159,2011-05-15T00:00:00,African Americans,M01.686.754.100
21572159,2011-05-15T00:00:00,"Antibodies, Antinuclear",D12.776.124.486.485.114.323.204
21572159,2011-05-15T00:00:00,"Antibodies, Antinuclear",D12.776.124.790.651.114.323.204
21572159,2011-05-15T00:00:00,"Antibodies, Antinuclear",D12.776.377.715.548.114.323.204
21572159,2011-05-15T00:00:00,Autoantibodies,D12.776.124.486.485.114.323
21572159,2011-05-15T00:00:00,Autoantibodies,D12.776.124.790.651.114.323
21572159,2011-05-15T00:00:00,Autoantibodies,D12.776.377.715.548.114.323
21572159,2011-05-15T00:00:00,"Chromosomal Proteins, Non-Histone",D12.776.660.235
21572159,2011-05-15T00:00:00,"Chromosomal Proteins, Non-Histone",D12.776.664.235
21572159,2011-05-15T00:00:00,Histocompatibility Antigens Class II,D23.050.301.500.410
21572159,2011-05-15T00:00:00,Histocompatibility Antigens Class II,D23.050.705.552.410
21572159,2011-05-15T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21572159,2011-05-15T00:00:00,Middle Aged,M01.060.116.630
21572159,2011-05-15T00:00:00,"Scleroderma, Systemic",C17.300.799
21572159,2011-05-15T00:00:00,"Scleroderma, Systemic",C17.800.784
21576655,2011-05-16T00:00:00,Double-Blind Method,E05.318.780.300
21576655,2011-05-16T00:00:00,Double-Blind Method,E05.581.500.300
21576655,2011-05-16T00:00:00,Double-Blind Method,N05.715.360.780.320
21576655,2011-05-16T00:00:00,Double-Blind Method,N06.850.520.445.300
21576655,2011-05-16T00:00:00,Growth Disorders,C23.550.393
21576655,2011-05-16T00:00:00,Heart Ventricles,A07.541.560
21576655,2011-05-16T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21576655,2011-05-16T00:00:00,Infant,M01.060.703
21576655,2011-05-16T00:00:00,"Infant, Newborn",M01.060.703.520
21576655,2011-05-16T00:00:00,"Polymorphism, Genetic",G05.365.795
21576655,2011-05-16T00:00:00,Renin,D08.811.277.656.074.500.780
21576655,2011-05-16T00:00:00,Renin,D08.811.277.656.300.048.780
21576655,2011-05-16T00:00:00,Renin,D08.811.277.656.837.750
21576655,2011-05-16T00:00:00,Renin-Angiotensin System,G03.495.805
21576655,2011-05-16T00:00:00,Renin-Angiotensin System,G09.330.190.400.750
21576655,2011-05-16T00:00:00,Ventricular Remodeling,C23.300.985
21576655,2011-05-16T00:00:00,Ventricular Remodeling,G09.330.190.962.975
21586150,2011-05-17T00:00:00,Algorithms,G17.035
21586150,2011-05-17T00:00:00,Algorithms,L01.224.050
21586150,2011-05-17T00:00:00,Computational Biology,H01.158.273.180
21586150,2011-05-17T00:00:00,"Models, Biological",E05.599.395
21586150,2011-05-17T00:00:00,"Models, Genetic",E05.599.395.397
21586150,2011-05-17T00:00:00,"Models, Statistical",E05.318.740.500
21586150,2011-05-17T00:00:00,"Models, Statistical",E05.599.835
21586150,2011-05-17T00:00:00,"Models, Statistical",N05.715.360.750.530
21586150,2011-05-17T00:00:00,"Models, Statistical",N06.850.520.830.500
21586150,2011-05-17T00:00:00,Probability,E05.318.740.600
21586150,2011-05-17T00:00:00,Probability,G17.680
21586150,2011-05-17T00:00:00,Probability,N05.715.360.750.625
21586150,2011-05-17T00:00:00,Probability,N06.850.520.830.600
21586150,2011-05-17T00:00:00,Saccharomyces cerevisiae,B01.300.107.795.785.800
21586150,2011-05-17T00:00:00,Saccharomyces cerevisiae,B01.300.930.705.655
21586150,2011-05-17T00:00:00,Saccharomyces cerevisiae Proteins,D12.776.354.750
21586442,2011-05-17T00:00:00,"Antibodies, Antinuclear",D12.776.124.486.485.114.323.204
21586442,2011-05-17T00:00:00,"Antibodies, Antinuclear",D12.776.124.790.651.114.323.204
21586442,2011-05-17T00:00:00,"Antibodies, Antinuclear",D12.776.377.715.548.114.323.204
21586442,2011-05-17T00:00:00,Autoimmunity,G12.450.192
21586442,2011-05-17T00:00:00,B-Lymphocytes,A11.063.438
21586442,2011-05-17T00:00:00,B-Lymphocytes,A11.118.637.555.567.562
21586442,2011-05-17T00:00:00,B-Lymphocytes,A15.145.229.637.555.567.562
21586442,2011-05-17T00:00:00,B-Lymphocytes,A15.382.032.438
21586442,2011-05-17T00:00:00,B-Lymphocytes,A15.382.490.555.567.562
21586442,2011-05-17T00:00:00,Case-Control Studies,E05.318.760.500.500
21586442,2011-05-17T00:00:00,Case-Control Studies,N05.715.360.775.175.200
21586442,2011-05-17T00:00:00,Case-Control Studies,N06.850.520.450.500.500
21586442,2011-05-17T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21586442,2011-05-17T00:00:00,Interferon-alpha,D12.644.276.374.440.890.250
21586442,2011-05-17T00:00:00,Interferon-alpha,D12.644.276.718.500.250
21586442,2011-05-17T00:00:00,Interferon-alpha,D12.776.467.374.440.890.250
21586442,2011-05-17T00:00:00,Interferon-alpha,D12.776.467.718.500.250
21586442,2011-05-17T00:00:00,Interferon-alpha,D23.529.374.440.890.250
21586442,2011-05-17T00:00:00,Interferon-alpha,D23.529.718.500.250
21586442,2011-05-17T00:00:00,"Lupus Erythematosus, Systemic",C17.300.480
21586442,2011-05-17T00:00:00,"Lupus Erythematosus, Systemic",C20.111.590
21586442,2011-05-17T00:00:00,Lymphocyte Activation,E01.450.495.482
21586442,2011-05-17T00:00:00,Lymphocyte Activation,E05.478.594.530
21586442,2011-05-17T00:00:00,Lymphocyte Activation,G12.425.747
21586442,2011-05-17T00:00:00,Lymphocyte Activation,G12.450.050.400.545
21586442,2011-05-17T00:00:00,Vitamin D,D04.808.812.768
21586442,2011-05-17T00:00:00,Vitamin D Deficiency,C18.654.521.500.133.770
21586624,2011-05-17T00:00:00,Cytomegalovirus,B04.280.382.150.150
21586624,2011-05-17T00:00:00,Cytomegalovirus,B04.909.204.382.150.150
21586624,2011-05-17T00:00:00,Glioblastoma,C04.557.465.625.600.380.080.335
21586624,2011-05-17T00:00:00,Glioblastoma,C04.557.470.670.380.080.335
21586624,2011-05-17T00:00:00,Glioblastoma,C04.557.580.625.600.380.080.335
21586624,2011-05-17T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21586624,2011-05-17T00:00:00,Membrane Glycoproteins,D12.776.395.550
21586624,2011-05-17T00:00:00,Membrane Glycoproteins,D12.776.543.550
21586624,2011-05-17T00:00:00,Viral Proteins,D12.776.964
21655140,2011-05-17T00:00:00,African Continental Ancestry Group,M01.686.508.100
21655140,2011-05-17T00:00:00,Aged,M01.060.116.100
21655140,2011-05-17T00:00:00,Alcohol Drinking,F01.145.317.269
21655140,2011-05-17T00:00:00,Blood Pressure,E01.370.600.875.249
21655140,2011-05-17T00:00:00,Blood Pressure,G09.330.380.076
21655140,2011-05-17T00:00:00,Diabetes Mellitus,C18.452.394.750
21655140,2011-05-17T00:00:00,Diabetes Mellitus,C19.246
21655140,2011-05-17T00:00:00,European Continental Ancestry Group,M01.686.508.400
21655140,2011-05-17T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21655140,2011-05-17T00:00:00,Hypertension,C14.907.489
21655140,2011-05-17T00:00:00,Middle Aged,M01.060.116.630
21736838,2011-05-17T00:00:00,Aged,M01.060.116.100
21736838,2011-05-17T00:00:00,Chronic Disease,C23.550.291.500
21736838,2011-05-17T00:00:00,Diabetes Complications,C19.246.099
21736838,2011-05-17T00:00:00,Diabetes Mellitus,C18.452.394.750
21736838,2011-05-17T00:00:00,Diabetes Mellitus,C19.246
21736838,2011-05-17T00:00:00,European Continental Ancestry Group,M01.686.508.400
21736838,2011-05-17T00:00:00,Heart Diseases,C14.280
21736838,2011-05-17T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21736838,2011-05-17T00:00:00,Hypertension,C14.907.489
21736838,2011-05-17T00:00:00,Middle Aged,M01.060.116.630
21736838,2011-05-17T00:00:00,Questionnaires,E05.318.308.750
21736838,2011-05-17T00:00:00,Questionnaires,L01.280.800
21736838,2011-05-17T00:00:00,Questionnaires,N05.715.360.300.695
21736838,2011-05-17T00:00:00,Questionnaires,N06.850.520.308.750
21736838,2011-05-17T00:00:00,Risk Factors,E05.318.740.600.800.725
21736838,2011-05-17T00:00:00,Risk Factors,N05.715.350.200.700
21736838,2011-05-17T00:00:00,Risk Factors,N05.715.360.750.625.700.700
21736838,2011-05-17T00:00:00,Risk Factors,N06.850.490.625.750
21736838,2011-05-17T00:00:00,Risk Factors,N06.850.520.830.600.800.725
21736838,2011-05-17T00:00:00,United States,Z01.107.567.875
21736838,2011-05-17T00:00:00,Vitamin D,D04.808.812.768
21736838,2011-05-17T00:00:00,Vitamin D Deficiency,C18.654.521.500.133.770
21593052,2011-05-18T00:00:00,"Anemia, Sickle Cell",C15.378.071.141.150.150
21593052,2011-05-18T00:00:00,"Anemia, Sickle Cell",C15.378.420.155
21593052,2011-05-18T00:00:00,"Anemia, Sickle Cell",C16.320.070.150
21593052,2011-05-18T00:00:00,"Anemia, Sickle Cell",C16.320.365.155
21593052,2011-05-18T00:00:00,"Child, Preschool",M01.060.406.448
21593052,2011-05-18T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21593052,2011-05-18T00:00:00,Osteomyelitis,C01.539.160.495
21593052,2011-05-18T00:00:00,Osteomyelitis,C05.116.165.495
21598864,2011-05-18T00:00:00,Accidental Falls,N06.850.135.122
21598864,2011-05-18T00:00:00,Aged,M01.060.116.100
21598864,2011-05-18T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21598864,2011-05-18T00:00:00,Nursing Homes,N02.278.825.610
21598864,2011-05-18T00:00:00,Risk Factors,E05.318.740.600.800.725
21598864,2011-05-18T00:00:00,Risk Factors,N05.715.350.200.700
21598864,2011-05-18T00:00:00,Risk Factors,N05.715.360.750.625.700.700
21598864,2011-05-18T00:00:00,Risk Factors,N06.850.490.625.750
21598864,2011-05-18T00:00:00,Risk Factors,N06.850.520.830.600.800.725
21592186,2011-05-19T00:00:00,Adult,M01.060.116
21592186,2011-05-19T00:00:00,African Americans,M01.686.508.100.100
21592186,2011-05-19T00:00:00,African Americans,M01.686.754.100
21592186,2011-05-19T00:00:00,Aged,M01.060.116.100
21592186,2011-05-19T00:00:00,Body Mass Index,E01.370.600.115.100.125
21592186,2011-05-19T00:00:00,Body Mass Index,E05.041.124.125
21592186,2011-05-19T00:00:00,Body Mass Index,G07.100.100.125
21592186,2011-05-19T00:00:00,Body Mass Index,N06.850.505.200.100.175
21592186,2011-05-19T00:00:00,Chronic Disease,C23.550.291.500
21592186,2011-05-19T00:00:00,Cryotherapy,E02.258
21592186,2011-05-19T00:00:00,European Continental Ancestry Group,M01.686.508.400
21592186,2011-05-19T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21592186,2011-05-19T00:00:00,Leg,A01.378.610.500
21592186,2011-05-19T00:00:00,Microcirculation,G09.330.190.163.645
21592186,2011-05-19T00:00:00,Middle Aged,M01.060.116.630
21592186,2011-05-19T00:00:00,Obesity,C18.654.726.500
21592186,2011-05-19T00:00:00,Obesity,C23.888.144.699.500
21592186,2011-05-19T00:00:00,Obesity,E01.370.600.115.100.160.120.699.500
21592186,2011-05-19T00:00:00,Obesity,G07.100.100.160.120.699.500
21592186,2011-05-19T00:00:00,Skin,A17.815
21592186,2011-05-19T00:00:00,Skin Temperature,G07.110.753
21592186,2011-05-19T00:00:00,Skin Temperature,G13.750.844
21592186,2011-05-19T00:00:00,Time Factors,G01.910.857
21592186,2011-05-19T00:00:00,Varicose Ulcer,C14.907.927.730
21592186,2011-05-19T00:00:00,Varicose Ulcer,C17.800.893.592.730
21592186,2011-05-19T00:00:00,Venous Insufficiency,C14.907.952
21598242,2011-05-19T00:00:00,Antineoplastic Agents,D27.505.954.248
21598242,2011-05-19T00:00:00,Antineoplastic Combined Chemotherapy Protocols,E02.183.750.500
21598242,2011-05-19T00:00:00,Antineoplastic Combined Chemotherapy Protocols,E02.319.077.500
21598242,2011-05-19T00:00:00,Antineoplastic Combined Chemotherapy Protocols,E02.319.310.037
21598242,2011-05-19T00:00:00,Cost-Benefit Analysis,N03.219.151.125
21598242,2011-05-19T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21598242,2011-05-19T00:00:00,Ovarian Neoplasms,C04.588.322.455
21598242,2011-05-19T00:00:00,Ovarian Neoplasms,C13.351.500.056.630.705
21598242,2011-05-19T00:00:00,Ovarian Neoplasms,C13.351.937.418.685
21598242,2011-05-19T00:00:00,Ovarian Neoplasms,C19.344.410
21598242,2011-05-19T00:00:00,Ovarian Neoplasms,C19.391.630.705
21598242,2011-05-19T00:00:00,Quality of Life,I01.800
21598242,2011-05-19T00:00:00,Quality of Life,K01.752.400.750
21633156,2011-05-19T00:00:00,Cations,D01.248.497.300
21633156,2011-05-19T00:00:00,Copper,D01.268.556.195
21633156,2011-05-19T00:00:00,Copper,D01.268.956.170
21633156,2011-05-19T00:00:00,Copper,D01.552.544.195
21633156,2011-05-19T00:00:00,"Crystallography, X-Ray",E05.196.309.742.225
21633156,2011-05-19T00:00:00,Molecular Structure,G02.111.570
21633156,2011-05-19T00:00:00,Molecular Structure,G02.575
21633156,2011-05-19T00:00:00,Molecular Structure,G02.842.575
21633156,2011-05-19T00:00:00,Organoselenium Compounds,D02.712
21633156,2011-05-19T00:00:00,Polymers,D05.750
21633156,2011-05-19T00:00:00,Polymers,D25.720
21633156,2011-05-19T00:00:00,Polymers,J01.637.051.720
21599921,2011-05-20T00:00:00,Case-Control Studies,E05.318.760.500.500
21599921,2011-05-20T00:00:00,Case-Control Studies,N05.715.360.775.175.200
21599921,2011-05-20T00:00:00,Case-Control Studies,N06.850.520.450.500.500
21599921,2011-05-20T00:00:00,"Chromatography, High Pressure Liquid",E05.196.181.400.300
21599921,2011-05-20T00:00:00,Fatty Acids,D10.251
21599921,2011-05-20T00:00:00,Fibroblasts,A11.329.228
21599921,2011-05-20T00:00:00,Fibroblasts,A11.872.228
21599921,2011-05-20T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21599921,2011-05-20T00:00:00,Lymphocytes,A11.118.637.555.567
21599921,2011-05-20T00:00:00,Lymphocytes,A15.145.229.637.555.567
21599921,2011-05-20T00:00:00,Lymphocytes,A15.382.490.555.567
21599921,2011-05-20T00:00:00,Mass Spectrometry,E05.196.566
21599921,2011-05-20T00:00:00,Mutation,G05.365.590
21599921,2011-05-20T00:00:00,"RNA, Messenger",D13.444.735.544
21600592,2011-05-20T00:00:00,"Cardiac Output, Low",C14.280.148
21600592,2011-05-20T00:00:00,"Cardiac Output, Low",C23.888.192
21600592,2011-05-20T00:00:00,Cardiac Surgical Procedures,E04.100.376
21600592,2011-05-20T00:00:00,Cardiac Surgical Procedures,E04.928.220
21600592,2011-05-20T00:00:00,Cardiopulmonary Bypass,E04.292.413
21600592,2011-05-20T00:00:00,Double-Blind Method,E05.318.780.300
21600592,2011-05-20T00:00:00,Double-Blind Method,E05.581.500.300
21600592,2011-05-20T00:00:00,Double-Blind Method,N05.715.360.780.320
21600592,2011-05-20T00:00:00,Double-Blind Method,N06.850.520.445.300
21600592,2011-05-20T00:00:00,Glucocorticoids,D06.472.040.543
21600592,2011-05-20T00:00:00,Glucocorticoids,D27.505.696.399.472.488
21600592,2011-05-20T00:00:00,"Heart Defects, Congenital",C14.240.400
21600592,2011-05-20T00:00:00,"Heart Defects, Congenital",C14.280.400
21600592,2011-05-20T00:00:00,"Heart Defects, Congenital",C16.131.240.400
21600592,2011-05-20T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21600592,2011-05-20T00:00:00,"Infant, Newborn",M01.060.703.520
21600592,2011-05-20T00:00:00,Interleukin-6,D12.644.276.374.465.506
21600592,2011-05-20T00:00:00,Interleukin-6,D12.776.467.374.465.506
21600592,2011-05-20T00:00:00,Interleukin-6,D23.529.374.465.506
21600592,2011-05-20T00:00:00,Postoperative Care,E02.760.722.700
21600592,2011-05-20T00:00:00,Postoperative Care,E04.624
21600592,2011-05-20T00:00:00,Postoperative Care,N02.421.585.722.700
21600592,2011-05-20T00:00:00,Postoperative Complications,C23.550.767
21600592,2011-05-20T00:00:00,Preoperative Care,E02.760.795
21600592,2011-05-20T00:00:00,Preoperative Care,E04.641
21600592,2011-05-20T00:00:00,Preoperative Care,N02.421.585.795
21600592,2011-05-20T00:00:00,Treatment Outcome,E01.789.800
21600592,2011-05-20T00:00:00,Treatment Outcome,N04.761.559.590.800
21600592,2011-05-20T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21602200,2011-05-20T00:00:00,Aged,M01.060.116.100
21602200,2011-05-20T00:00:00,Aggression,F01.145.126.125
21602200,2011-05-20T00:00:00,Aggression,F01.145.813.045
21602200,2011-05-20T00:00:00,Crime Victims,M01.135
21602200,2011-05-20T00:00:00,Elder Abuse,I01.198.240.856.350.390
21602200,2011-05-20T00:00:00,Elder Abuse,I01.880.735.900.350.390
21602200,2011-05-20T00:00:00,Geriatric Assessment,E05.318.308.225
21602200,2011-05-20T00:00:00,Geriatric Assessment,I01.240.425.350
21602200,2011-05-20T00:00:00,Geriatric Assessment,L01.280.360
21602200,2011-05-20T00:00:00,Geriatric Assessment,N01.224.425.350
21602200,2011-05-20T00:00:00,Geriatric Assessment,N05.715.360.300.360
21602200,2011-05-20T00:00:00,Geriatric Assessment,N06.850.505.400.425.350
21602200,2011-05-20T00:00:00,Geriatric Assessment,N06.850.520.308.225
21602200,2011-05-20T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21602200,2011-05-20T00:00:00,Middle Aged,M01.060.116.630
21602200,2011-05-20T00:00:00,Questionnaires,E05.318.308.750
21602200,2011-05-20T00:00:00,Questionnaires,L01.280.800
21602200,2011-05-20T00:00:00,Questionnaires,N05.715.360.300.695
21602200,2011-05-20T00:00:00,Questionnaires,N06.850.520.308.750
21602200,2011-05-20T00:00:00,Risk Assessment,E05.318.740.600.800.715
21602200,2011-05-20T00:00:00,Risk Assessment,N04.452.871.715
21602200,2011-05-20T00:00:00,Risk Assessment,N05.715.360.750.625.700.690
21602200,2011-05-20T00:00:00,Risk Assessment,N06.850.505.715
21602200,2011-05-20T00:00:00,Risk Assessment,N06.850.520.830.600.800.715
21602200,2011-05-20T00:00:00,Social Support,I01.880.656.600
21602200,2011-05-20T00:00:00,South Carolina,Z01.107.567.875.075.662
21602200,2011-05-20T00:00:00,South Carolina,Z01.107.567.875.750.700
21602472,2011-05-20T00:00:00,Animals,B01.050
21602472,2011-05-20T00:00:00,"Disease Models, Animal",C22.232
21602472,2011-05-20T00:00:00,"Disease Models, Animal",E05.598.500
21602472,2011-05-20T00:00:00,"Disease Models, Animal",E05.599.395.080
21602472,2011-05-20T00:00:00,Extracellular Matrix Proteins,D12.776.860.300
21602472,2011-05-20T00:00:00,Fibroblasts,A11.329.228
21602472,2011-05-20T00:00:00,Fibroblasts,A11.872.228
21602472,2011-05-20T00:00:00,Gene Expression Profiling,E05.393.332
21602472,2011-05-20T00:00:00,Gene Expression Regulation,G05.355.315
21602472,2011-05-20T00:00:00,Myocardial Contraction,G09.330.190.541
21602472,2011-05-20T00:00:00,Myocardial Contraction,G11.427.590.540.570
21602472,2011-05-20T00:00:00,Myocardial Infarction,C14.280.647.500
21602472,2011-05-20T00:00:00,Myocardial Infarction,C14.907.585.500
21602472,2011-05-20T00:00:00,Myocardium,A02.633.580
21602472,2011-05-20T00:00:00,Myocardium,A07.541.704
21602472,2011-05-20T00:00:00,Myocardium,A10.690.552.750
21602472,2011-05-20T00:00:00,Oligonucleotide Array Sequence Analysis,E05.196.630.570.660
21602472,2011-05-20T00:00:00,Oligonucleotide Array Sequence Analysis,E05.393.525.640
21602472,2011-05-20T00:00:00,Oligonucleotide Array Sequence Analysis,E05.393.661.640
21602472,2011-05-20T00:00:00,Oligonucleotide Array Sequence Analysis,E05.393.760.640
21602472,2011-05-20T00:00:00,Oligonucleotide Array Sequence Analysis,E05.588.570.660
21602472,2011-05-20T00:00:00,Oligonucleotide Array Sequence Analysis,E05.601.640
21602472,2011-05-20T00:00:00,Osteonectin,D12.776.157.125.715
21602472,2011-05-20T00:00:00,Osteonectin,D12.776.395.600
21602472,2011-05-20T00:00:00,Stroke Volume,E01.370.370.380.150.700
21602472,2011-05-20T00:00:00,Stroke Volume,G09.330.380.124.882
21602472,2011-05-20T00:00:00,Time Factors,G01.910.857
21602472,2011-05-20T00:00:00,"Ventricular Function, Left",G09.330.190.962.800
21602472,2011-05-20T00:00:00,Ventricular Remodeling,C23.300.985
21602472,2011-05-20T00:00:00,Ventricular Remodeling,G09.330.190.962.975
21655144,2011-05-20T00:00:00,Adolescent,M01.060.057
21655144,2011-05-20T00:00:00,Adult,M01.060.116
21655144,2011-05-20T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21655144,2011-05-20T00:00:00,Middle Aged,M01.060.116.630
21655144,2011-05-20T00:00:00,Smoking,F01.145.466.753
21655144,2011-05-20T00:00:00,Smoking Cessation,F01.145.940.700
21655144,2011-05-20T00:00:00,Tobacco Use Disorder,C21.739.912
21655144,2011-05-20T00:00:00,Tobacco Use Disorder,F03.900.912
21655144,2011-05-20T00:00:00,Young Adult,M01.060.116.815
21603967,2011-05-21T00:00:00,Adolescent,M01.060.057
21603967,2011-05-21T00:00:00,Adult,M01.060.116
21603967,2011-05-21T00:00:00,Aged,M01.060.116.100
21603967,2011-05-21T00:00:00,"Depressive Disorder, Major",F03.600.300.375
21603967,2011-05-21T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21603967,2011-05-21T00:00:00,Interviews as Topic,E05.318.308.420
21603967,2011-05-21T00:00:00,Interviews as Topic,L01.280.520
21603967,2011-05-21T00:00:00,Interviews as Topic,N05.715.360.300.400
21603967,2011-05-21T00:00:00,Interviews as Topic,N06.850.520.308.420
21603967,2011-05-21T00:00:00,Middle Aged,M01.060.116.630
21603967,2011-05-21T00:00:00,Rape,I01.198.240.748.640
21603967,2011-05-21T00:00:00,Risk Factors,E05.318.740.600.800.725
21603967,2011-05-21T00:00:00,Risk Factors,N05.715.350.200.700
21603967,2011-05-21T00:00:00,Risk Factors,N05.715.360.750.625.700.700
21603967,2011-05-21T00:00:00,Risk Factors,N06.850.490.625.750
21603967,2011-05-21T00:00:00,Risk Factors,N06.850.520.830.600.800.725
21603967,2011-05-21T00:00:00,"Stress Disorders, Post-Traumatic",F03.080.931.500
21603967,2011-05-21T00:00:00,Substance-Related Disorders,C21.739
21603967,2011-05-21T00:00:00,Substance-Related Disorders,F03.900
21603967,2011-05-21T00:00:00,United States,Z01.107.567.875
21602054,2011-05-23T00:00:00,Antioxidants,D27.505.519.217
21602054,2011-05-23T00:00:00,Antioxidants,D27.505.696.706.125
21602054,2011-05-23T00:00:00,Antioxidants,D27.720.799.047
21602054,2011-05-23T00:00:00,Apoptosis,G04.299.139.160
21602054,2011-05-23T00:00:00,Cell Proliferation,G04.299.233.750
21602054,2011-05-23T00:00:00,Cell Proliferation,G07.700.320.249.410.750
21602054,2011-05-23T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21602054,2011-05-23T00:00:00,Hydrogen Peroxide,D01.248.497.158.685.750.424
21602054,2011-05-23T00:00:00,Hydrogen Peroxide,D01.339.431.374.424
21602054,2011-05-23T00:00:00,Hydrogen Peroxide,D01.650.550.750.400
21602054,2011-05-23T00:00:00,"Immunity, Innate",G12.450.575
21602054,2011-05-23T00:00:00,Interleukin-15,D12.644.276.374.465.515
21602054,2011-05-23T00:00:00,Interleukin-15,D12.776.467.374.465.515
21602054,2011-05-23T00:00:00,Interleukin-15,D23.529.374.465.515
21602054,2011-05-23T00:00:00,Interleukin-2,D12.644.276.374.465.502
21602054,2011-05-23T00:00:00,Interleukin-2,D12.644.276.374.480.372
21602054,2011-05-23T00:00:00,Interleukin-2,D12.776.467.374.465.502
21602054,2011-05-23T00:00:00,Interleukin-2,D12.776.467.374.480.372
21602054,2011-05-23T00:00:00,Interleukin-2,D23.529.374.465.502
21602054,2011-05-23T00:00:00,Interleukin-2,D23.529.374.480.372
21602054,2011-05-23T00:00:00,Nitric Oxide,D01.339.387
21602054,2011-05-23T00:00:00,Nitric Oxide,D01.625.550.500
21602054,2011-05-23T00:00:00,Nitric Oxide,D01.625.700.500
21602054,2011-05-23T00:00:00,Nitric Oxide,D01.650.550.587.600
21602054,2011-05-23T00:00:00,Oxidative Stress,G03.495.710
21602054,2011-05-23T00:00:00,Oxidative Stress,G07.700.830.750
21602054,2011-05-23T00:00:00,Reactive Nitrogen Species,D01.625.700
21602054,2011-05-23T00:00:00,Reactive Nitrogen Species,D02.654.846
21602054,2011-05-23T00:00:00,Reactive Oxygen Species,D01.339.431
21602054,2011-05-23T00:00:00,Reactive Oxygen Species,D01.650.775
21602054,2011-05-23T00:00:00,T-Lymphocytes,A11.118.637.555.567.569
21602054,2011-05-23T00:00:00,T-Lymphocytes,A15.145.229.637.555.567.569
21602054,2011-05-23T00:00:00,T-Lymphocytes,A15.382.490.555.567.569
21606054,2011-05-23T00:00:00,Aged,M01.060.116.100
21606054,2011-05-23T00:00:00,Collagen,D05.750.078.280
21606054,2011-05-23T00:00:00,Collagen,D12.776.860.300.250
21606054,2011-05-23T00:00:00,Esophageal Neoplasms,C04.588.274.476.205
21606054,2011-05-23T00:00:00,Esophageal Neoplasms,C04.588.443.353
21606054,2011-05-23T00:00:00,Esophageal Neoplasms,C06.301.371.205
21606054,2011-05-23T00:00:00,Esophageal Neoplasms,C06.405.117.430
21606054,2011-05-23T00:00:00,Esophageal Neoplasms,C06.405.249.205
21606054,2011-05-23T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21606054,2011-05-23T00:00:00,Laparoscopy,E01.370.388.250.520
21606054,2011-05-23T00:00:00,Laparoscopy,E04.800.250.520
21606054,2011-05-23T00:00:00,Prosthesis Design,E05.320.550
21606054,2011-05-23T00:00:00,Prosthesis Design,E07.695.680
21606054,2011-05-23T00:00:00,"Skin, Artificial",E07.858.082.800
21606054,2011-05-23T00:00:00,Surgical Mesh,E07.858.708
21606054,2011-05-23T00:00:00,Wound Healing,G16.100.856.891
21606394,2011-05-23T00:00:00,Aged,M01.060.116.100
21606394,2011-05-23T00:00:00,Biological Markers,D23.101
21606394,2011-05-23T00:00:00,Carotid Arteries,A07.231.114.186
21606394,2011-05-23T00:00:00,"Endarterectomy, Carotid",E04.100.814.456.250
21606394,2011-05-23T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21606394,2011-05-23T00:00:00,Middle Aged,M01.060.116.630
21606394,2011-05-23T00:00:00,Myocardial Infarction,C14.280.647.500
21606394,2011-05-23T00:00:00,Myocardial Infarction,C14.907.585.500
21606394,2011-05-23T00:00:00,Risk Factors,E05.318.740.600.800.725
21606394,2011-05-23T00:00:00,Risk Factors,N05.715.350.200.700
21606394,2011-05-23T00:00:00,Risk Factors,N05.715.360.750.625.700.700
21606394,2011-05-23T00:00:00,Risk Factors,N06.850.490.625.750
21606394,2011-05-23T00:00:00,Risk Factors,N06.850.520.830.600.800.725
21606394,2011-05-23T00:00:00,Stents,E07.695.750
21606394,2011-05-23T00:00:00,Time Factors,G01.910.857
21606394,2011-05-23T00:00:00,Treatment Outcome,E01.789.800
21606394,2011-05-23T00:00:00,Treatment Outcome,N04.761.559.590.800
21606394,2011-05-23T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21605927,2011-05-24T00:00:00,Aged,M01.060.116.100
21605927,2011-05-24T00:00:00,Case-Control Studies,E05.318.760.500.500
21605927,2011-05-24T00:00:00,Case-Control Studies,N05.715.360.775.175.200
21605927,2011-05-24T00:00:00,Case-Control Studies,N06.850.520.450.500.500
21605927,2011-05-24T00:00:00,Computer Simulation,L01.224.160
21605927,2011-05-24T00:00:00,Gait,E01.370.600.250
21605927,2011-05-24T00:00:00,Gait,G11.427.590.530.389
21605927,2011-05-24T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21605927,2011-05-24T00:00:00,"Imaging, Three-Dimensional",E01.370.350.400
21605927,2011-05-24T00:00:00,"Imaging, Three-Dimensional",L01.224.308.410
21605927,2011-05-24T00:00:00,Middle Aged,M01.060.116.630
21605927,2011-05-24T00:00:00,"Muscle, Skeletal",A02.633.567
21605927,2011-05-24T00:00:00,"Muscle, Skeletal",A10.690.552.500
21605927,2011-05-24T00:00:00,Muscles,A02.633
21605927,2011-05-24T00:00:00,Muscles,A10.690
21605927,2011-05-24T00:00:00,Paresis,C10.597.636
21605927,2011-05-24T00:00:00,Paresis,C23.888.592.643
21605927,2011-05-24T00:00:00,"Stress, Mechanical",G01.374.676.830
21605927,2011-05-24T00:00:00,"Stress, Mechanical",G01.595.540.830
21605927,2011-05-24T00:00:00,Stroke,C10.228.140.300.775
21605927,2011-05-24T00:00:00,Stroke,C14.907.253.855
21605927,2011-05-24T00:00:00,Walking,G11.427.590.530.568.900
21605927,2011-05-24T00:00:00,Walking,G11.427.590.530.698.940
21605927,2011-05-24T00:00:00,Walking,I03.450.642.845.940
21606929,2011-05-24T00:00:00,Adult,M01.060.116
21606929,2011-05-24T00:00:00,Health Surveys,E05.318.308.250
21606929,2011-05-24T00:00:00,Health Surveys,N05.715.360.300.375
21606929,2011-05-24T00:00:00,Health Surveys,N06.850.520.308.250
21606929,2011-05-24T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21606929,2011-05-24T00:00:00,Middle Aged,M01.060.116.630
21606929,2011-05-24T00:00:00,Patient Satisfaction,N04.452.822.360.600
21606929,2011-05-24T00:00:00,Patient Satisfaction,N05.300.150.600.630
21606929,2011-05-24T00:00:00,Patient Satisfaction,N05.715.360.600
21606929,2011-05-24T00:00:00,Quality of Life,I01.800
21606929,2011-05-24T00:00:00,Quality of Life,K01.752.400.750
21606929,2011-05-24T00:00:00,Spinal Cord Injuries,C10.228.854.770
21606929,2011-05-24T00:00:00,Spinal Cord Injuries,C10.900.850
21606929,2011-05-24T00:00:00,Spinal Cord Injuries,C21.866.819
21729517,2011-05-24T00:00:00,Aged,M01.060.116.100
21729517,2011-05-24T00:00:00,Child,M01.060.406
21729517,2011-05-24T00:00:00,"Child, Preschool",M01.060.406.448
21729517,2011-05-24T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21729517,2011-05-24T00:00:00,Infant,M01.060.703
21729517,2011-05-24T00:00:00,Pulmonary Veins,A07.231.908.713
21729517,2011-05-24T00:00:00,"Tomography, X-Ray Computed",E01.370.350.350.810
21729517,2011-05-24T00:00:00,"Tomography, X-Ray Computed",E01.370.350.600.350.700.810
21729517,2011-05-24T00:00:00,"Tomography, X-Ray Computed",E01.370.350.700.700.810
21729517,2011-05-24T00:00:00,"Tomography, X-Ray Computed",E01.370.350.700.810.810
21729517,2011-05-24T00:00:00,"Tomography, X-Ray Computed",E01.370.350.825.810.810
21729517,2011-05-24T00:00:00,"Vena Cava, Superior",A07.231.908.949.815
22697444,2011-05-24T00:00:00,Adult,M01.060.116
22697444,2011-05-24T00:00:00,"Depressive Disorder, Major",F03.600.300.375
22697444,2011-05-24T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22697444,2011-05-24T00:00:00,Implosive Therapy,F04.754.137.506.325
22697444,2011-05-24T00:00:00,Psychiatric Status Rating Scales,F04.586
22697444,2011-05-24T00:00:00,"Stress Disorders, Post-Traumatic",F03.080.931.500
22697444,2011-05-24T00:00:00,Telemedicine,H02.403.840
22697444,2011-05-24T00:00:00,Telemedicine,L01.178.847.652
22697444,2011-05-24T00:00:00,Telemedicine,N04.590.374.800
22697444,2011-05-24T00:00:00,Veterans,M01.930
21235352,2011-05-25T00:00:00,Animals,B01.050
21235352,2011-05-25T00:00:00,Glutathione,D12.644.456.448
21235352,2011-05-25T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21235352,2011-05-25T00:00:00,"Protein Processing, Post-Translational",G02.111.087.675.871.790.600
21235352,2011-05-25T00:00:00,"Protein Processing, Post-Translational",G02.111.087.693.600
21235352,2011-05-25T00:00:00,"Protein Processing, Post-Translational",G02.149.115.675.871.790.600
21235352,2011-05-25T00:00:00,"Protein Processing, Post-Translational",G02.149.115.693.600
21235352,2011-05-25T00:00:00,"Protein Processing, Post-Translational",G03.495.770.871.790.600
21235352,2011-05-25T00:00:00,"Protein Processing, Post-Translational",G05.355.315.670.600
21235352,2011-05-25T00:00:00,Reactive Oxygen Species,D01.339.431
21235352,2011-05-25T00:00:00,Reactive Oxygen Species,D01.650.775
21235352,2011-05-25T00:00:00,Signal Transduction,G02.111.087.800
21235352,2011-05-25T00:00:00,Signal Transduction,G02.149.115.800
21235352,2011-05-25T00:00:00,Signal Transduction,G04.299.880
21611758,2011-05-25T00:00:00,Adult,M01.060.116
21611758,2011-05-25T00:00:00,Aged,M01.060.116.100
21611758,2011-05-25T00:00:00,Algorithms,G17.035
21611758,2011-05-25T00:00:00,Algorithms,L01.224.050
21611758,2011-05-25T00:00:00,Catheterization,E02.148
21611758,2011-05-25T00:00:00,Catheterization,E05.157
21611758,2011-05-25T00:00:00,"Constriction, Pathologic",C23.300.287
21611758,2011-05-25T00:00:00,Coronary Angiography,E01.370.350.700.060.200
21611758,2011-05-25T00:00:00,Coronary Angiography,E01.370.370.050.200
21611758,2011-05-25T00:00:00,Coronary Angiography,E01.370.370.380.200
21611758,2011-05-25T00:00:00,Diagnostic Imaging,E01.370.350
21611758,2011-05-25T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21611758,2011-05-25T00:00:00,"Image Processing, Computer-Assisted",L01.224.308
21611758,2011-05-25T00:00:00,Middle Aged,M01.060.116.630
21611758,2011-05-25T00:00:00,"Tomography, X-Ray Computed",E01.370.350.350.810
21611758,2011-05-25T00:00:00,"Tomography, X-Ray Computed",E01.370.350.600.350.700.810
21611758,2011-05-25T00:00:00,"Tomography, X-Ray Computed",E01.370.350.700.700.810
21611758,2011-05-25T00:00:00,"Tomography, X-Ray Computed",E01.370.350.700.810.810
21611758,2011-05-25T00:00:00,"Tomography, X-Ray Computed",E01.370.350.825.810.810
21611834,2011-05-25T00:00:00,Animals,B01.050
21611834,2011-05-25T00:00:00,Cell Death,G04.299.139
21611834,2011-05-25T00:00:00,Estradiol,D04.808.365.415.248
21611834,2011-05-25T00:00:00,Estradiol,D06.472.334.851.437.500
21611834,2011-05-25T00:00:00,Estrogens,D27.505.696.399.472.277
21611834,2011-05-25T00:00:00,Inflammation,C23.550.470
21611834,2011-05-25T00:00:00,Microglia,A08.637.400
21611834,2011-05-25T00:00:00,Microglia,A11.650.400
21611834,2011-05-25T00:00:00,Neuroprotective Agents,D27.505.696.706.548
21611834,2011-05-25T00:00:00,Neuroprotective Agents,D27.505.954.427.575
21611834,2011-05-25T00:00:00,Proto-Oncogene Proteins c-bcl-2,D12.644.360.075.718
21611834,2011-05-25T00:00:00,Proto-Oncogene Proteins c-bcl-2,D12.776.476.075.718
21611834,2011-05-25T00:00:00,Proto-Oncogene Proteins c-bcl-2,D12.776.624.664.700.169
21611834,2011-05-25T00:00:00,Rats,B01.050.150.900.649.865.635.505.700
21611834,2011-05-25T00:00:00,"Rats, Sprague-Dawley",B01.050.150.900.649.865.635.505.700.750
21611834,2011-05-25T00:00:00,Recovery of Function,G16.757
21611834,2011-05-25T00:00:00,Spinal Cord Injuries,C10.228.854.770
21611834,2011-05-25T00:00:00,Spinal Cord Injuries,C10.900.850
21611834,2011-05-25T00:00:00,Spinal Cord Injuries,C21.866.819
21611834,2011-05-25T00:00:00,bcl-2-Associated X Protein,D12.644.360.075.718.400
21611834,2011-05-25T00:00:00,bcl-2-Associated X Protein,D12.776.476.075.718.400
21613224,2011-05-25T00:00:00,Animals,B01.050
21613224,2011-05-25T00:00:00,Ceramides,D02.065.313
21613224,2011-05-25T00:00:00,Ceramides,D09.400.410.420.525.200
21613224,2011-05-25T00:00:00,Ceramides,D10.390.470.675.200
21613224,2011-05-25T00:00:00,Ceramides,D10.570.877.360.612.200
21613224,2011-05-25T00:00:00,Lipid Metabolism,G03.495.520
21613224,2011-05-25T00:00:00,"Mitochondria, Liver",A11.284.430.214.190.875.564.461
21613224,2011-05-25T00:00:00,"Mitochondria, Liver",A11.284.835.626.461
21613224,2011-05-25T00:00:00,Mitochondrial Proteins,D12.776.575
21613224,2011-05-25T00:00:00,Rats,B01.050.150.900.649.865.635.505.700
21613224,2011-05-25T00:00:00,"Rats, Sprague-Dawley",B01.050.150.900.649.865.635.505.700.750
21613224,2011-05-25T00:00:00,Sphingosine,D02.033.100.700
21613224,2011-05-25T00:00:00,Sphingosine,D02.033.455.843
21613224,2011-05-25T00:00:00,Sphingosine,D02.092.063.700
21613331,2011-05-25T00:00:00,Academic Medical Centers,N02.278.020
21613331,2011-05-25T00:00:00,Animals,B01.050
21613331,2011-05-25T00:00:00,Cardiopulmonary Bypass,E04.292.413
21613331,2011-05-25T00:00:00,"Education, Medical, Graduate",I02.358.337.350
21613331,2011-05-25T00:00:00,"Education, Medical, Graduate",I02.358.399.350
21613331,2011-05-25T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21613331,2011-05-25T00:00:00,South Carolina,Z01.107.567.875.075.662
21613331,2011-05-25T00:00:00,South Carolina,Z01.107.567.875.750.700
21613331,2011-05-25T00:00:00,Teaching,I02.903
21613504,2011-05-25T00:00:00,Animals,B01.050
21613504,2011-05-25T00:00:00,Cone Opsins,D12.776.306.466.249
21613504,2011-05-25T00:00:00,Cone Opsins,D23.767.930.750.249
21613504,2011-05-25T00:00:00,Eye Proteins,D12.776.306
21613504,2011-05-25T00:00:00,Photic Stimulation,E05.723.729
21613504,2011-05-25T00:00:00,Retina,A09.371.729
21613504,2011-05-25T00:00:00,Retinal Cone Photoreceptor Cells,A08.663.650.850.625.670.100
21613504,2011-05-25T00:00:00,Retinal Cone Photoreceptor Cells,A08.663.650.915.937.670.100
21613504,2011-05-25T00:00:00,Retinal Cone Photoreceptor Cells,A08.800.950.937.670.100
21613504,2011-05-25T00:00:00,Retinal Cone Photoreceptor Cells,A09.371.729.831.625.670.100
21613504,2011-05-25T00:00:00,Retinal Cone Photoreceptor Cells,A11.671.650.850.625.670.100
21613504,2011-05-25T00:00:00,Retinal Cone Photoreceptor Cells,A11.671.650.915.937.670.100
21613504,2011-05-25T00:00:00,Retinal Pigment Epithelium,A09.371.670.500
21613504,2011-05-25T00:00:00,Retinal Pigment Epithelium,A09.371.729.887
21613504,2011-05-25T00:00:00,Time Factors,G01.910.857
21613504,2011-05-25T00:00:00,Visual Perception,F02.463.593.932
21616526,2011-05-25T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21616526,2011-05-25T00:00:00,Platelet Aggregation Inhibitors,D27.505.954.502.780
21616526,2011-05-25T00:00:00,Propionates,D02.241.081.751
21616526,2011-05-25T00:00:00,Propionates,D10.251.400.706
21616526,2011-05-25T00:00:00,"Receptors, Thromboxane",D12.776.543.750.075.800
21616526,2011-05-25T00:00:00,"Receptors, Thromboxane",D12.776.543.750.100.200.800
21616526,2011-05-25T00:00:00,Secondary Prevention,N02.421.726.825
21616526,2011-05-25T00:00:00,Secondary Prevention,N06.850.780.750
21616526,2011-05-25T00:00:00,Stroke,C10.228.140.300.775
21616526,2011-05-25T00:00:00,Stroke,C14.907.253.855
21612487,2011-05-26T00:00:00,Alleles,G05.360.340.024.340.030
21612487,2011-05-26T00:00:00,Genome-Wide Association Study,E05.318.416.249
21612487,2011-05-26T00:00:00,Genome-Wide Association Study,E05.318.780.392
21612487,2011-05-26T00:00:00,Genome-Wide Association Study,E05.393.385.500
21612487,2011-05-26T00:00:00,Genome-Wide Association Study,E05.393.522.500
21612487,2011-05-26T00:00:00,Genome-Wide Association Study,E05.393.760.640.500
21612487,2011-05-26T00:00:00,Genome-Wide Association Study,N06.850.520.445.392
21612487,2011-05-26T00:00:00,Genome-Wide Association Study,N06.850.520.470.500
21612487,2011-05-26T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21612487,2011-05-26T00:00:00,Immunoglobulin G,D12.776.124.486.485.114.619.393
21612487,2011-05-26T00:00:00,Immunoglobulin G,D12.776.124.790.651.114.619.393
21612487,2011-05-26T00:00:00,Immunoglobulin G,D12.776.377.715.548.114.619.393
21612487,2011-05-26T00:00:00,"Polymorphism, Single Nucleotide",G05.365.795.598
21614535,2011-05-26T00:00:00,"Databases, Factual",L01.470.750.750
21614535,2011-05-26T00:00:00,"Databases, Factual",L01.700.508.300.188.400
21614535,2011-05-26T00:00:00,Electronic Health Records,E05.318.308.940.968.625.500
21614535,2011-05-26T00:00:00,Health Services Research,N03.349.380
21614535,2011-05-26T00:00:00,Health Services Research,N05.425
21614535,2011-05-26T00:00:00,Hospital Information Systems,L01.700.508.300.408
21614535,2011-05-26T00:00:00,Hospital Information Systems,L01.700.508.300.680.360
21614535,2011-05-26T00:00:00,Hospital Information Systems,N04.452.442.452
21614535,2011-05-26T00:00:00,Hospital Information Systems,N04.452.515.360
21614535,2011-05-26T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21614535,2011-05-26T00:00:00,United States,Z01.107.567.875
21614592,2011-05-26T00:00:00,Adult,M01.060.116
21614592,2011-05-26T00:00:00,Ambulatory Care,E02.760.106
21614592,2011-05-26T00:00:00,Ambulatory Care,N02.421.585.106
21614592,2011-05-26T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21614592,2011-05-26T00:00:00,Liver Cirrhosis,C06.552.630
21614592,2011-05-26T00:00:00,Middle Aged,M01.060.116.630
21614592,2011-05-26T00:00:00,Practice Guidelines as Topic,N04.761.700.350.650
21614592,2011-05-26T00:00:00,Practice Guidelines as Topic,N05.700.350.650
21614592,2011-05-26T00:00:00,Primary Prevention,N02.421.726.758
21614592,2011-05-26T00:00:00,Primary Prevention,N06.850.780.680
21614592,2011-05-26T00:00:00,Secondary Prevention,N02.421.726.825
21614592,2011-05-26T00:00:00,Secondary Prevention,N06.850.780.750
21617147,2011-05-26T00:00:00,Adult,M01.060.116
21617147,2011-05-26T00:00:00,African Americans,M01.686.508.100.100
21617147,2011-05-26T00:00:00,African Americans,M01.686.754.100
21617147,2011-05-26T00:00:00,African Continental Ancestry Group,M01.686.508.100
21617147,2011-05-26T00:00:00,Aged,M01.060.116.100
21617147,2011-05-26T00:00:00,Delivery of Health Care,N04.590.374
21617147,2011-05-26T00:00:00,Delivery of Health Care,N05.300
21617147,2011-05-26T00:00:00,Ethnic Groups,M01.686.754
21617147,2011-05-26T00:00:00,Ethnic Groups,N01.224.317
21617147,2011-05-26T00:00:00,Health Services Accessibility,N04.590.374.350
21617147,2011-05-26T00:00:00,Health Services Accessibility,N05.300.430
21617147,2011-05-26T00:00:00,Healthcare Disparities,N04.590.374.380
21617147,2011-05-26T00:00:00,Healthcare Disparities,N05.300.493
21617147,2011-05-26T00:00:00,Hispanic Americans,M01.686.754.441
21617147,2011-05-26T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21617147,2011-05-26T00:00:00,Middle Aged,M01.060.116.630
21617147,2011-05-26T00:00:00,Patient Selection,E05.581.500.653
21617147,2011-05-26T00:00:00,Patient Selection,N04.590.731
21617147,2011-05-26T00:00:00,Quality of Health Care,N04.761
21617147,2011-05-26T00:00:00,Quality of Health Care,N05.715
21617147,2011-05-26T00:00:00,Stroke,C10.228.140.300.775
21617147,2011-05-26T00:00:00,Stroke,C14.907.253.855
21617147,2011-05-26T00:00:00,United States,Z01.107.567.875
21620515,2011-05-26T00:00:00,Acetylglucosamine,D09.067.342.531.050
21620515,2011-05-26T00:00:00,Aged,M01.060.116.100
21620515,2011-05-26T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21620515,2011-05-26T00:00:00,Middle Aged,M01.060.116.630
21620515,2011-05-26T00:00:00,Varicose Ulcer,C14.907.927.730
21620515,2011-05-26T00:00:00,Varicose Ulcer,C17.800.893.592.730
21620515,2011-05-26T00:00:00,Wound Healing,G16.100.856.891
21637784,2011-05-26T00:00:00,African Americans,M01.686.508.100.100
21637784,2011-05-26T00:00:00,African Americans,M01.686.754.100
21637784,2011-05-26T00:00:00,Alleles,G05.360.340.024.340.030
21637784,2011-05-26T00:00:00,Case-Control Studies,E05.318.760.500.500
21637784,2011-05-26T00:00:00,Case-Control Studies,N05.715.360.775.175.200
21637784,2011-05-26T00:00:00,Case-Control Studies,N06.850.520.450.500.500
21637784,2011-05-26T00:00:00,European Continental Ancestry Group,M01.686.508.400
21637784,2011-05-26T00:00:00,Gene Deletion,G05.355.600.800.320
21637784,2011-05-26T00:00:00,Gene Deletion,G05.365.590.762.320
21637784,2011-05-26T00:00:00,Genetic Predisposition to Disease,C23.550.291.687.500
21637784,2011-05-26T00:00:00,Genetic Predisposition to Disease,G05.380.355
21637784,2011-05-26T00:00:00,Hispanic Americans,M01.686.754.441
21637784,2011-05-26T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21637784,2011-05-26T00:00:00,"Lupus Erythematosus, Systemic",C17.300.480
21637784,2011-05-26T00:00:00,"Lupus Erythematosus, Systemic",C20.111.590
21637784,2011-05-26T00:00:00,"Polymorphism, Single Nucleotide",G05.365.795.598
21637784,2011-05-26T00:00:00,"Tumor Markers, Biological",D23.101.840
21623564,2011-05-27T00:00:00,Adult,M01.060.116
21623564,2011-05-27T00:00:00,Ankle Injuries,C21.866.558.100
21623564,2011-05-27T00:00:00,Bone Plates,E07.695.125
21623564,2011-05-27T00:00:00,Bone Plates,E07.858.442.660.110
21623564,2011-05-27T00:00:00,Bone Plates,E07.858.690.650.110
21623564,2011-05-27T00:00:00,Bone Screws,E07.695.130
21623564,2011-05-27T00:00:00,Bone Screws,E07.858.442.660.115
21623564,2011-05-27T00:00:00,Bone Screws,E07.858.690.650.115
21623564,2011-05-27T00:00:00,Bone Transplantation,E04.555.130
21623564,2011-05-27T00:00:00,Bone Transplantation,E04.936.450.050
21623564,2011-05-27T00:00:00,Device Removal,E04.199
21623564,2011-05-27T00:00:00,Dislocations,C21.866.289
21623564,2011-05-27T00:00:00,"Fracture Fixation, Internal",E04.555.300.300
21623564,2011-05-27T00:00:00,Fracture Healing,G16.100.856.891.500
21623564,2011-05-27T00:00:00,"Fractures, Bone",C21.866.404
21623564,2011-05-27T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21623564,2011-05-27T00:00:00,Multiple Trauma,C21.866.640
21623564,2011-05-27T00:00:00,Reconstructive Surgical Procedures,E04.680
21623564,2011-05-27T00:00:00,Reoperation,E04.690
21623564,2011-05-27T00:00:00,Risk Assessment,E05.318.740.600.800.715
21623564,2011-05-27T00:00:00,Risk Assessment,N04.452.871.715
21623564,2011-05-27T00:00:00,Risk Assessment,N05.715.360.750.625.700.690
21623564,2011-05-27T00:00:00,Risk Assessment,N06.850.505.715
21623564,2011-05-27T00:00:00,Risk Assessment,N06.850.520.830.600.800.715
21623564,2011-05-27T00:00:00,Subtalar Joint,A02.835.583.378.831.780
21623564,2011-05-27T00:00:00,Wound Healing,G16.100.856.891
21647366,2011-05-27T00:00:00,Computational Biology,H01.158.273.180
21647366,2011-05-27T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21647366,2011-05-27T00:00:00,Hydrogen Bonding,G02.149.767.620
21647366,2011-05-27T00:00:00,Hydrogen Bonding,G02.842.750.620
21647366,2011-05-27T00:00:00,"Models, Molecular",E05.599.595
21647366,2011-05-27T00:00:00,"Mutagenesis, Site-Directed",E05.393.420.601.575
21647366,2011-05-27T00:00:00,"Mutation, Missense",G05.365.590.650
21622988,2011-05-28T00:00:00,Genetic Predisposition to Disease,C23.550.291.687.500
21622988,2011-05-28T00:00:00,Genetic Predisposition to Disease,G05.380.355
21622988,2011-05-28T00:00:00,Genome-Wide Association Study,E05.318.416.249
21622988,2011-05-28T00:00:00,Genome-Wide Association Study,E05.318.780.392
21622988,2011-05-28T00:00:00,Genome-Wide Association Study,E05.393.385.500
21622988,2011-05-28T00:00:00,Genome-Wide Association Study,E05.393.522.500
21622988,2011-05-28T00:00:00,Genome-Wide Association Study,E05.393.760.640.500
21622988,2011-05-28T00:00:00,Genome-Wide Association Study,N06.850.520.445.392
21622988,2011-05-28T00:00:00,Genome-Wide Association Study,N06.850.520.470.500
21622988,2011-05-28T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21622988,2011-05-28T00:00:00,"Kidney Failure, Chronic",C12.777.419.780.500.602
21622988,2011-05-28T00:00:00,"Kidney Failure, Chronic",C12.777.419.780.750.500
21622988,2011-05-28T00:00:00,"Kidney Failure, Chronic",C13.351.968.419.780.500.602
21622988,2011-05-28T00:00:00,"Kidney Failure, Chronic",C13.351.968.419.780.750.500
21628322,2011-05-31T00:00:00,Aged,M01.060.116.100
21628322,2011-05-31T00:00:00,Cardiac Surgical Procedures,E04.100.376
21628322,2011-05-31T00:00:00,Cardiac Surgical Procedures,E04.928.220
21628322,2011-05-31T00:00:00,Echocardiography,E01.370.350.850.220
21628322,2011-05-31T00:00:00,Echocardiography,E01.370.370.380.220
21628322,2011-05-31T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21628322,2011-05-31T00:00:00,Middle Aged,M01.060.116.630
21630309,2011-05-31T00:00:00,Adult,M01.060.116
21630309,2011-05-31T00:00:00,Aged,M01.060.116.100
21630309,2011-05-31T00:00:00,Antineoplastic Agents,D27.505.954.248
21630309,2011-05-31T00:00:00,Cyclophosphamide,D02.455.526.728.650.730.243
21630309,2011-05-31T00:00:00,Cyclophosphamide,D02.705.670.243
21630309,2011-05-31T00:00:00,"Drug Resistance, Neoplasm",G07.690.320.395
21630309,2011-05-31T00:00:00,"Hospitals, University",N02.278.020.300.310
21630309,2011-05-31T00:00:00,"Hospitals, University",N02.278.421.639.725
21630309,2011-05-31T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21630309,2011-05-31T00:00:00,Immunologic Factors,D27.505.696.477
21630309,2011-05-31T00:00:00,Middle Aged,M01.060.116.630
21630309,2011-05-31T00:00:00,Multiple Myeloma,C04.557.595.500
21630309,2011-05-31T00:00:00,Multiple Myeloma,C14.907.454.460
21630309,2011-05-31T00:00:00,Multiple Myeloma,C15.378.147.780.650
21630309,2011-05-31T00:00:00,Multiple Myeloma,C15.378.463.835.460
21630309,2011-05-31T00:00:00,Multiple Myeloma,C20.683.515.845
21630309,2011-05-31T00:00:00,Multiple Myeloma,C20.683.780.650
21630309,2011-05-31T00:00:00,Salvage Therapy,E02.186.800
21630309,2011-05-31T00:00:00,Salvage Therapy,E02.895
21630357,2011-05-31T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21630357,2011-05-31T00:00:00,Middle Aged,M01.060.116.630
21630357,2011-05-31T00:00:00,Molecular Dynamics Simulation,E05.599.595.500
21630357,2011-05-31T00:00:00,Molecular Dynamics Simulation,G02.575.750
21630357,2011-05-31T00:00:00,Molecular Dynamics Simulation,L01.224.160.500
21630357,2011-05-31T00:00:00,"Mutation, Missense",G05.365.590.650
21630357,2011-05-31T00:00:00,"Polymorphism, Single Nucleotide",G05.365.795.598
21630357,2011-05-31T00:00:00,"Protein Structure, Secondary",G02.111.570.790.709.600
21637915,2011-05-31T00:00:00,Amino Acid Sequence,G02.111.570.060
21637915,2011-05-31T00:00:00,Amino Acid Sequence,L01.453.245.667.060
21637915,2011-05-31T00:00:00,"Antigens, CD147",D12.776.395.550.045
21637915,2011-05-31T00:00:00,"Antigens, CD147",D12.776.543.550.188
21637915,2011-05-31T00:00:00,"Antigens, CD147",D23.050.285.040
21637915,2011-05-31T00:00:00,"Antigens, CD147",D23.050.301.264.035.247
21637915,2011-05-31T00:00:00,"Antigens, CD147",D23.101.100.110.247
21637915,2011-05-31T00:00:00,Fibroblasts,A11.329.228
21637915,2011-05-31T00:00:00,Fibroblasts,A11.872.228
21637915,2011-05-31T00:00:00,Glioblastoma,C04.557.465.625.600.380.080.335
21637915,2011-05-31T00:00:00,Glioblastoma,C04.557.470.670.380.080.335
21637915,2011-05-31T00:00:00,Glioblastoma,C04.557.580.625.600.380.080.335
21637915,2011-05-31T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21637915,2011-05-31T00:00:00,Matrix Metalloproteinase 2,D08.811.277.656.300.480.205.352
21637915,2011-05-31T00:00:00,Matrix Metalloproteinase 2,D08.811.277.656.300.480.252.420
21637915,2011-05-31T00:00:00,Matrix Metalloproteinase 2,D08.811.277.656.300.480.525.700.150
21637915,2011-05-31T00:00:00,Matrix Metalloproteinase 2,D08.811.277.656.675.374.205.352
21637915,2011-05-31T00:00:00,Matrix Metalloproteinase 2,D08.811.277.656.675.374.252.420
21637915,2011-05-31T00:00:00,Matrix Metalloproteinase 2,D08.811.277.656.675.374.525.700.150
21637915,2011-05-31T00:00:00,Molecular Sequence Data,L01.453.245.667
21637915,2011-05-31T00:00:00,Neoplasm Invasiveness,C04.697.645
21637915,2011-05-31T00:00:00,Neoplasm Invasiveness,C23.550.727.645
21637915,2011-05-31T00:00:00,Neoplasms,C04
21637915,2011-05-31T00:00:00,Peptide Fragments,D12.644.541
20672243,2011-06-01T00:00:00,Aged,M01.060.116.100
20672243,2011-06-01T00:00:00,Alzheimer Disease,C10.228.140.380.100
20672243,2011-06-01T00:00:00,Alzheimer Disease,C10.574.945.249
20672243,2011-06-01T00:00:00,Alzheimer Disease,F03.087.400.100
20672243,2011-06-01T00:00:00,Antidepressive Agents,D27.505.954.427.700.122
20672243,2011-06-01T00:00:00,Depressive Disorder,F03.600.300
20672243,2011-06-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
20672243,2011-06-01T00:00:00,Outcome Assessment (Health Care),N04.761.559.590
20672243,2011-06-01T00:00:00,Outcome Assessment (Health Care),N05.715.360.575.575
20672243,2011-06-01T00:00:00,Psychiatric Status Rating Scales,F04.586
20672243,2011-06-01T00:00:00,Serotonin Uptake Inhibitors,D27.505.519.625.600.850
20672243,2011-06-01T00:00:00,Serotonin Uptake Inhibitors,D27.505.519.625.850.900
20672243,2011-06-01T00:00:00,Serotonin Uptake Inhibitors,D27.505.696.577.600.850
20672243,2011-06-01T00:00:00,Serotonin Uptake Inhibitors,D27.505.696.577.850.900
20672243,2011-06-01T00:00:00,Sertraline,D02.092.705.800
20672243,2011-06-01T00:00:00,Sertraline,D02.455.426.559.847.638.845.800
20672243,2011-06-01T00:00:00,Sertraline,D04.615.638.845.800
21129028,2011-06-01T00:00:00,Adult,M01.060.116
21129028,2011-06-01T00:00:00,Blood Transfusion,E02.095.135
21129028,2011-06-01T00:00:00,Gastrointestinal Hemorrhage,C06.405.227
21129028,2011-06-01T00:00:00,Gastrointestinal Hemorrhage,C23.550.414.788
21129028,2011-06-01T00:00:00,Hepatic Encephalopathy,C06.552.308.500.356
21129028,2011-06-01T00:00:00,Hepatic Encephalopathy,C10.228.140.163.360
21129028,2011-06-01T00:00:00,Hepatic Encephalopathy,C18.452.132.360
21129028,2011-06-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21129028,2011-06-01T00:00:00,Liver Cirrhosis,C06.552.630
21129028,2011-06-01T00:00:00,Middle Aged,M01.060.116.630
21129028,2011-06-01T00:00:00,Risk Assessment,E05.318.740.600.800.715
21129028,2011-06-01T00:00:00,Risk Assessment,N04.452.871.715
21129028,2011-06-01T00:00:00,Risk Assessment,N05.715.360.750.625.700.690
21129028,2011-06-01T00:00:00,Risk Assessment,N06.850.505.715
21129028,2011-06-01T00:00:00,Risk Assessment,N06.850.520.830.600.800.715
21129028,2011-06-01T00:00:00,Risk Factors,E05.318.740.600.800.725
21129028,2011-06-01T00:00:00,Risk Factors,N05.715.350.200.700
21129028,2011-06-01T00:00:00,Risk Factors,N05.715.360.750.625.700.700
21129028,2011-06-01T00:00:00,Risk Factors,N06.850.490.625.750
21129028,2011-06-01T00:00:00,Risk Factors,N06.850.520.830.600.800.725
21129028,2011-06-01T00:00:00,Time Factors,G01.910.857
21129028,2011-06-01T00:00:00,Treatment Outcome,E01.789.800
21129028,2011-06-01T00:00:00,Treatment Outcome,N04.761.559.590.800
21129028,2011-06-01T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21129028,2011-06-01T00:00:00,Young Adult,M01.060.116.815
21174173,2011-06-01T00:00:00,Brain,A08.186.211
21174173,2011-06-01T00:00:00,Critical Care,E02.760.190
21174173,2011-06-01T00:00:00,Critical Care,N02.421.585.190
21174173,2011-06-01T00:00:00,Diffusion Magnetic Resonance Imaging,E01.370.350.500.150
21174173,2011-06-01T00:00:00,Diffusion Magnetic Resonance Imaging,E01.370.350.825.500.150
21174173,2011-06-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21174173,2011-06-01T00:00:00,"Image Processing, Computer-Assisted",L01.224.308
21174173,2011-06-01T00:00:00,Intensive Care Units,N02.278.388.493
21174173,2011-06-01T00:00:00,Magnetic Resonance Imaging,E01.370.350.500
21174173,2011-06-01T00:00:00,Magnetic Resonance Imaging,E01.370.350.825.500
21174173,2011-06-01T00:00:00,Pregnancy,G08.686.785.760.769
21174173,2011-06-01T00:00:00,Young Adult,M01.060.116.815
21311375,2011-06-01T00:00:00,Adult,M01.060.116
21311375,2011-06-01T00:00:00,Aged,M01.060.116.100
21311375,2011-06-01T00:00:00,"Embolization, Therapeutic",E02.520.360
21311375,2011-06-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21311375,2011-06-01T00:00:00,Neurosurgical Procedures,E04.525
21398289,2011-06-01T00:00:00,ATP-Binding Cassette Transporters,D12.776.157.530.100
21398289,2011-06-01T00:00:00,ATP-Binding Cassette Transporters,D12.776.395.550.020
21398289,2011-06-01T00:00:00,ATP-Binding Cassette Transporters,D12.776.543.550.192
21398289,2011-06-01T00:00:00,ATP-Binding Cassette Transporters,D12.776.543.585.100
21398289,2011-06-01T00:00:00,Animals,B01.050
21398289,2011-06-01T00:00:00,"Chromatography, High Pressure Liquid",E05.196.181.400.300
21398289,2011-06-01T00:00:00,Rhodopsin,D12.776.543.750.100.955
21398289,2011-06-01T00:00:00,Rhodopsin,D23.767.930.750.500.500
21398289,2011-06-01T00:00:00,"Spectrometry, Fluorescence",E05.196.712.516.600.676
21398289,2011-06-01T00:00:00,"Spectrometry, Fluorescence",E05.196.867.726
21425124,2011-06-01T00:00:00,African Continental Ancestry Group,M01.686.508.100
21425124,2011-06-01T00:00:00,European Continental Ancestry Group,M01.686.508.400
21425124,2011-06-01T00:00:00,Genetic Predisposition to Disease,C23.550.291.687.500
21425124,2011-06-01T00:00:00,Genetic Predisposition to Disease,G05.380.355
21425124,2011-06-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21425124,2011-06-01T00:00:00,Interleukin-2,D12.644.276.374.465.502
21425124,2011-06-01T00:00:00,Interleukin-2,D12.644.276.374.480.372
21425124,2011-06-01T00:00:00,Interleukin-2,D12.776.467.374.465.502
21425124,2011-06-01T00:00:00,Interleukin-2,D12.776.467.374.480.372
21425124,2011-06-01T00:00:00,Interleukin-2,D23.529.374.465.502
21425124,2011-06-01T00:00:00,Interleukin-2,D23.529.374.480.372
21425124,2011-06-01T00:00:00,"Lupus Erythematosus, Systemic",C17.300.480
21425124,2011-06-01T00:00:00,"Lupus Erythematosus, Systemic",C20.111.590
21425124,2011-06-01T00:00:00,"Polymorphism, Single Nucleotide",G05.365.795.598
21443365,2011-06-01T00:00:00,Attention,F02.830.104.214
21443365,2011-06-01T00:00:00,Attention Deficit Disorder with Hyperactivity,F03.550.150.150
21443365,2011-06-01T00:00:00,Eye Movements,G11.427.590.530.140
21443365,2011-06-01T00:00:00,Eye Movements,G14.640.260
21443365,2011-06-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21443365,2011-06-01T00:00:00,Neuropsychological Tests,F04.711.513
21443365,2011-06-01T00:00:00,Psychiatric Status Rating Scales,F04.586
21443365,2011-06-01T00:00:00,Reaction Time,F02.830.650
21443365,2011-06-01T00:00:00,Reaction Time,F04.669.817
21443365,2011-06-01T00:00:00,Reaction Time,G11.561.677
21443365,2011-06-01T00:00:00,Young Adult,M01.060.116.815
21516073,2011-06-01T00:00:00,Algorithms,G17.035
21516073,2011-06-01T00:00:00,Algorithms,L01.224.050
21516073,2011-06-01T00:00:00,Cardiopulmonary Resuscitation,E02.365.647.110
21516073,2011-06-01T00:00:00,Electric Countershock,E02.342.287
21516073,2011-06-01T00:00:00,Guidelines as Topic,N04.761.700.350
21516073,2011-06-01T00:00:00,Guidelines as Topic,N05.700.350
21516073,2011-06-01T00:00:00,Heart Arrest,C14.280.383
21516073,2011-06-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21516073,2011-06-01T00:00:00,"Hypothermia, Induced",E02.258.750
21516073,2011-06-01T00:00:00,Treatment Outcome,E01.789.800
21516073,2011-06-01T00:00:00,Treatment Outcome,N04.761.559.590.800
21516073,2011-06-01T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21516073,2011-06-01T00:00:00,United States,Z01.107.567.875
21558764,2011-06-01T00:00:00,Cross Infection,C01.539.248
21558764,2011-06-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21565661,2011-06-01T00:00:00,Adolescent,M01.060.057
21565661,2011-06-01T00:00:00,Adult,M01.060.116
21565661,2011-06-01T00:00:00,Aged,M01.060.116.100
21565661,2011-06-01T00:00:00,Attitude to Health,F01.100.150
21565661,2011-06-01T00:00:00,Attitude to Health,N05.300.150
21565661,2011-06-01T00:00:00,Health Education,I02.233.332
21565661,2011-06-01T00:00:00,Health Education,N02.421.143.827.407
21565661,2011-06-01T00:00:00,Health Education,N02.421.726.407
21565661,2011-06-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21565661,2011-06-01T00:00:00,Middle Aged,M01.060.116.630
21565661,2011-06-01T00:00:00,New York,Z01.107.567.875.075.437
21565661,2011-06-01T00:00:00,New York,Z01.107.567.875.350.530
21565661,2011-06-01T00:00:00,New York,Z01.107.567.875.500.530
21565661,2011-06-01T00:00:00,Smoking,F01.145.466.753
21565661,2011-06-01T00:00:00,Smoking Cessation,F01.145.940.700
21565661,2011-06-01T00:00:00,Young Adult,M01.060.116.815
21565662,2011-06-01T00:00:00,Adolescent,M01.060.057
21565662,2011-06-01T00:00:00,Adult,M01.060.116
21565662,2011-06-01T00:00:00,Attitude to Health,F01.100.150
21565662,2011-06-01T00:00:00,Attitude to Health,N05.300.150
21565662,2011-06-01T00:00:00,Color,G01.201.875.770.578.199
21565662,2011-06-01T00:00:00,Color,G01.590.540.199
21565662,2011-06-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21565662,2011-06-01T00:00:00,Smoking,F01.145.466.753
21565662,2011-06-01T00:00:00,United States,Z01.107.567.875
21565662,2011-06-01T00:00:00,Young Adult,M01.060.116.815
21565663,2011-06-01T00:00:00,Adolescent,M01.060.057
21565663,2011-06-01T00:00:00,Adult,M01.060.116
21565663,2011-06-01T00:00:00,Aged,M01.060.116.100
21565663,2011-06-01T00:00:00,"Health Knowledge, Attitudes, Practice",F01.100.150.500
21565663,2011-06-01T00:00:00,"Health Knowledge, Attitudes, Practice",N05.300.150.410
21565663,2011-06-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21565663,2011-06-01T00:00:00,Middle Aged,M01.060.116.630
21565663,2011-06-01T00:00:00,Perception,F02.463.593
21565663,2011-06-01T00:00:00,Smoking,F01.145.466.753
21565663,2011-06-01T00:00:00,Tobacco Industry,J01.576.919
21565663,2011-06-01T00:00:00,Young Adult,M01.060.116.815
21590998,2011-06-01T00:00:00,Animals,B01.050
21590998,2011-06-01T00:00:00,Drug Monitoring,E01.370.520.200
21590998,2011-06-01T00:00:00,Edema,C23.888.277
21590998,2011-06-01T00:00:00,Magnetic Resonance Imaging,E01.370.350.500
21590998,2011-06-01T00:00:00,Magnetic Resonance Imaging,E01.370.350.825.500
21590998,2011-06-01T00:00:00,Neuroprotective Agents,D27.505.696.706.548
21590998,2011-06-01T00:00:00,Neuroprotective Agents,D27.505.954.427.575
21590998,2011-06-01T00:00:00,Rats,B01.050.150.900.649.865.635.505.700
21590998,2011-06-01T00:00:00,"Rats, Sprague-Dawley",B01.050.150.900.649.865.635.505.700.750
21590998,2011-06-01T00:00:00,S-Nitrosoglutathione,D02.654.846.500.249
21590998,2011-06-01T00:00:00,S-Nitrosoglutathione,D02.886.489.650.750
21590998,2011-06-01T00:00:00,S-Nitrosoglutathione,D12.644.456.448.750
21590998,2011-06-01T00:00:00,Spinal Cord Injuries,C10.228.854.770
21590998,2011-06-01T00:00:00,Spinal Cord Injuries,C10.900.850
21590998,2011-06-01T00:00:00,Spinal Cord Injuries,C21.866.819
21590998,2011-06-01T00:00:00,Time Factors,G01.910.857
21590998,2011-06-01T00:00:00,Treatment Outcome,E01.789.800
21590998,2011-06-01T00:00:00,Treatment Outcome,N04.761.559.590.800
21590998,2011-06-01T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21591022,2011-06-01T00:00:00,Adult,M01.060.116
21591022,2011-06-01T00:00:00,Blood Transfusion,E02.095.135
21591022,2011-06-01T00:00:00,Ferritins,D12.776.157.427.249
21591022,2011-06-01T00:00:00,Ferritins,D12.776.556.579.249
21591022,2011-06-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21591022,2011-06-01T00:00:00,Iron,D01.268.556.412
21591022,2011-06-01T00:00:00,Iron,D01.268.956.287
21591022,2011-06-01T00:00:00,Iron,D01.552.544.412
21591022,2011-06-01T00:00:00,Magnetic Resonance Imaging,E01.370.350.500
21591022,2011-06-01T00:00:00,Magnetic Resonance Imaging,E01.370.350.825.500
21591022,2011-06-01T00:00:00,Myocardium,A02.633.580
21591022,2011-06-01T00:00:00,Myocardium,A07.541.704
21591022,2011-06-01T00:00:00,Myocardium,A10.690.552.750
21591022,2011-06-01T00:00:00,Time Factors,G01.910.857
21593755,2011-06-01T00:00:00,Animals,B01.050
21593755,2011-06-01T00:00:00,Fetus,A16.378
21593755,2011-06-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21593755,2011-06-01T00:00:00,Pregnancy,G08.686.785.760.769
21593755,2011-06-01T00:00:00,Prenatal Exposure Delayed Effects,C13.703.824.500
21597058,2011-06-01T00:00:00,Animals,B01.050
21597058,2011-06-01T00:00:00,Chick Embryo,A13.350.150
21597058,2011-06-01T00:00:00,Chick Embryo,A16.331.200
21597058,2011-06-01T00:00:00,Temperature,G01.906.595
21597058,2011-06-01T00:00:00,Temperature,G16.500.275.063.725.710
21597058,2011-06-01T00:00:00,Temperature,G16.500.750.775.710
21597058,2011-06-01T00:00:00,Temperature,N06.230.150.450
21597058,2011-06-01T00:00:00,Temperature,N06.230.300.100.725.710
21597058,2011-06-01T00:00:00,Water,D01.455.900
21597058,2011-06-01T00:00:00,Water,D01.650.550.925
21599621,2011-06-01T00:00:00,Arrestins,D12.776.306.090
21599621,2011-06-01T00:00:00,Arrestins,D12.776.543.090
21599621,2011-06-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21599621,2011-06-01T00:00:00,"Receptors, G-Protein-Coupled",D12.776.543.750.100
21599621,2011-06-01T00:00:00,Research,H01.770.644
21599621,2011-06-01T00:00:00,Signal Transduction,G02.111.087.800
21599621,2011-06-01T00:00:00,Signal Transduction,G02.149.115.800
21599621,2011-06-01T00:00:00,Signal Transduction,G04.299.880
21605735,2011-06-01T00:00:00,Budgets,N03.219.463.060
21605735,2011-06-01T00:00:00,Efficiency,F02.784.692.351
21605735,2011-06-01T00:00:00,"Faculty, Medical",I02.463.373
21605735,2011-06-01T00:00:00,"Faculty, Medical",M01.526.339.373
21605735,2011-06-01T00:00:00,"Faculty, Medical",M01.526.485.375
21605735,2011-06-01T00:00:00,"Faculty, Medical",N02.360.375
21605735,2011-06-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21605735,2011-06-01T00:00:00,Research,H01.770.644
21605735,2011-06-01T00:00:00,Salaries and Fringe Benefits,N01.824.417.700
21605735,2011-06-01T00:00:00,Salaries and Fringe Benefits,N04.452.677.800
21605735,2011-06-01T00:00:00,Teaching,I02.903
21605735,2011-06-01T00:00:00,United States,Z01.107.567.875
21617553,2011-06-01T00:00:00,Antirheumatic Agents,D27.505.954.329
21617553,2011-06-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21617553,2011-06-01T00:00:00,Methotrexate,D03.438.733.631.192.500
21617553,2011-06-01T00:00:00,Middle Aged,M01.060.116.630
21617553,2011-06-01T00:00:00,"Sarcoidosis, Pulmonary",C08.381.483.725
21617553,2011-06-01T00:00:00,"Sarcoidosis, Pulmonary",C15.604.515.827.725
21617553,2011-06-01T00:00:00,Tenosynovitis,C05.651.869.870
21617553,2011-06-01T00:00:00,Treatment Outcome,E01.789.800
21617553,2011-06-01T00:00:00,Treatment Outcome,N04.761.559.590.800
21617553,2011-06-01T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21628008,2011-06-01T00:00:00,Cross Infection,C01.539.248
21628008,2011-06-01T00:00:00,Disinfection,N06.850.780.200.450.850.375
21628008,2011-06-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21631542,2011-06-01T00:00:00,Adult,M01.060.116
21631542,2011-06-01T00:00:00,Alcohol Drinking,F01.145.317.269
21631542,2011-06-01T00:00:00,Alcoholism,C21.739.100.250
21631542,2011-06-01T00:00:00,Alcoholism,F03.900.100.350
21631542,2011-06-01T00:00:00,Amines,D02.092
21631542,2011-06-01T00:00:00,Cognition,F02.463.188
21631542,2011-06-01T00:00:00,Cyclohexanecarboxylic Acids,D02.241.223.268
21631542,2011-06-01T00:00:00,Cyclohexanecarboxylic Acids,D02.455.426.392.368.367.218
21631542,2011-06-01T00:00:00,Glutamic Acid,D12.125.067.750
21631542,2011-06-01T00:00:00,Glutamic Acid,D12.125.119.450
21631542,2011-06-01T00:00:00,Glutamic Acid,D12.125.427.300
21631542,2011-06-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21631542,2011-06-01T00:00:00,Middle Aged,M01.060.116.630
21631542,2011-06-01T00:00:00,Substance Withdrawal Syndrome,C21.739.835
21631542,2011-06-01T00:00:00,Substance Withdrawal Syndrome,F03.900.825
21631542,2011-06-01T00:00:00,Treatment Outcome,E01.789.800
21631542,2011-06-01T00:00:00,Treatment Outcome,N04.761.559.590.800
21631542,2011-06-01T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21631542,2011-06-01T00:00:00,gamma-Aminobutyric Acid,D02.241.081.160.050.350
21631542,2011-06-01T00:00:00,gamma-Aminobutyric Acid,D12.125.190.350
21632938,2011-06-01T00:00:00,Animals,B01.050
21632938,2011-06-01T00:00:00,Cocaine,D02.145.074.722.388
21632938,2011-06-01T00:00:00,Cocaine,D03.132.889.354
21632938,2011-06-01T00:00:00,Cocaine,D03.605.869.388
21632938,2011-06-01T00:00:00,Cocaine,D04.075.080.875.099.722.388
21632938,2011-06-01T00:00:00,Gene Expression Regulation,G05.355.315
21632938,2011-06-01T00:00:00,Genetic Vectors,G05.360.337
21632938,2011-06-01T00:00:00,Motor Activity,F01.145.632
21632938,2011-06-01T00:00:00,Motor Activity,G11.427.590.530.698
21632938,2011-06-01T00:00:00,Nucleus Accumbens,A08.186.211.730.885.287.249.683
21632938,2011-06-01T00:00:00,Piperidines,D03.383.621
21632938,2011-06-01T00:00:00,Rats,B01.050.150.900.649.865.635.505.700
21632938,2011-06-01T00:00:00,"Rats, Sprague-Dawley",B01.050.150.900.649.865.635.505.700.750
21632938,2011-06-01T00:00:00,"Receptors, N-Methyl-D-Aspartate",D12.776.543.750.720.200.450.580
21632938,2011-06-01T00:00:00,Synapses,A08.850
21632938,2011-06-01T00:00:00,Synapses,A11.284.149.165.420.780
21633086,2011-06-01T00:00:00,"Anemia, Sickle Cell",C15.378.071.141.150.150
21633086,2011-06-01T00:00:00,"Anemia, Sickle Cell",C15.378.420.155
21633086,2011-06-01T00:00:00,"Anemia, Sickle Cell",C16.320.070.150
21633086,2011-06-01T00:00:00,"Anemia, Sickle Cell",C16.320.365.155
21633086,2011-06-01T00:00:00,Blood Transfusion,E02.095.135
21633086,2011-06-01T00:00:00,Brain,A08.186.211
21633086,2011-06-01T00:00:00,Brain Infarction,C10.228.140.300.150.477
21633086,2011-06-01T00:00:00,Brain Infarction,C10.228.140.300.775.200
21633086,2011-06-01T00:00:00,Brain Infarction,C14.907.253.092.477
21633086,2011-06-01T00:00:00,Brain Infarction,C14.907.253.855.200
21633086,2011-06-01T00:00:00,Child,M01.060.406
21633086,2011-06-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21633086,2011-06-01T00:00:00,Magnetic Resonance Imaging,E01.370.350.500
21633086,2011-06-01T00:00:00,Magnetic Resonance Imaging,E01.370.350.825.500
21639660,2011-06-01T00:00:00,Adolescent,M01.060.057
21639660,2011-06-01T00:00:00,Adult,M01.060.116
21639660,2011-06-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21639660,2011-06-01T00:00:00,Middle Aged,M01.060.116.630
21639660,2011-06-01T00:00:00,Outcome and Process Assessment (Health Care),N04.761.559
21639660,2011-06-01T00:00:00,Outcome and Process Assessment (Health Care),N05.715.360.575
21639660,2011-06-01T00:00:00,Patient Dropouts,M01.643.673
21639660,2011-06-01T00:00:00,Patient Education as Topic,I02.233.332.500
21639660,2011-06-01T00:00:00,Patient Education as Topic,N02.421.143.827.407.680
21639660,2011-06-01T00:00:00,Patient Education as Topic,N02.421.726.407.680
21639660,2011-06-01T00:00:00,Professional-Patient Relations,F01.829.401.650
21639660,2011-06-01T00:00:00,Professional-Patient Relations,N05.300.660
21639660,2011-06-01T00:00:00,Psychotherapy,F04.754
21639660,2011-06-01T00:00:00,Young Adult,M01.060.116.815
21641391,2011-06-01T00:00:00,Animals,B01.050
21641391,2011-06-01T00:00:00,Body Weight,C23.888.144
21641391,2011-06-01T00:00:00,Body Weight,E01.370.600.115.100.160.120
21641391,2011-06-01T00:00:00,Body Weight,E05.041.124.160.750
21641391,2011-06-01T00:00:00,Body Weight,G07.100.100.160.120
21641391,2011-06-01T00:00:00,Body Weight,G07.700.320.249.314.120
21641391,2011-06-01T00:00:00,Gene Deletion,G05.355.600.800.320
21641391,2011-06-01T00:00:00,Gene Deletion,G05.365.590.762.320
21641391,2011-06-01T00:00:00,Liver,A03.620
21641391,2011-06-01T00:00:00,Liver Cirrhosis,C06.552.630
21641391,2011-06-01T00:00:00,Phenotype,G05.695
21642525,2011-06-01T00:00:00,Alcohol Drinking,F01.145.317.269
21642525,2011-06-01T00:00:00,Computer-Assisted Instruction,I02.903.573.208
21642525,2011-06-01T00:00:00,Curriculum,I02.158
21642525,2011-06-01T00:00:00,"Education, Dental",I02.358.274
21642525,2011-06-01T00:00:00,"Health Knowledge, Attitudes, Practice",F01.100.150.500
21642525,2011-06-01T00:00:00,"Health Knowledge, Attitudes, Practice",N05.300.150.410
21642525,2011-06-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21642525,2011-06-01T00:00:00,Mass Screening,E01.370.500
21642525,2011-06-01T00:00:00,Mass Screening,E05.318.308.250.580
21642525,2011-06-01T00:00:00,Mass Screening,N02.421.143.827.233.443
21642525,2011-06-01T00:00:00,Mass Screening,N02.421.726.233.443
21642525,2011-06-01T00:00:00,Mass Screening,N05.715.360.300.375.500
21642525,2011-06-01T00:00:00,Mass Screening,N06.850.520.308.250.580
21642525,2011-06-01T00:00:00,Mass Screening,N06.850.780.500
21642525,2011-06-01T00:00:00,Mouth Neoplasms,C04.588.443.591
21642525,2011-06-01T00:00:00,Mouth Neoplasms,C07.465.565
21642525,2011-06-01T00:00:00,Oropharyngeal Neoplasms,C04.588.443.665.710.684
21642525,2011-06-01T00:00:00,Oropharyngeal Neoplasms,C07.550.745.671
21642525,2011-06-01T00:00:00,Oropharyngeal Neoplasms,C09.647.710.685
21642525,2011-06-01T00:00:00,Oropharyngeal Neoplasms,C09.775.549.685
21642525,2011-06-01T00:00:00,Pilot Projects,E05.318.760.750
21642525,2011-06-01T00:00:00,Pilot Projects,E05.337.737
21642525,2011-06-01T00:00:00,Pilot Projects,N05.715.360.775.625
21642525,2011-06-01T00:00:00,Pilot Projects,N06.850.520.450.720
21642525,2011-06-01T00:00:00,Program Development,N04.452.760
21642525,2011-06-01T00:00:00,Program Evaluation,E05.337.820
21642525,2011-06-01T00:00:00,Program Evaluation,N04.761.685
21642525,2011-06-01T00:00:00,Program Evaluation,N05.715.360.650
21642525,2011-06-01T00:00:00,South Carolina,Z01.107.567.875.075.662
21642525,2011-06-01T00:00:00,South Carolina,Z01.107.567.875.750.700
21642525,2011-06-01T00:00:00,Tobacco Use Disorder,C21.739.912
21642525,2011-06-01T00:00:00,Tobacco Use Disorder,F03.900.912
21642525,2011-06-01T00:00:00,User-Computer Interface,L01.224.900.910
21656395,2011-06-01T00:00:00,Adolescent,M01.060.057
21656395,2011-06-01T00:00:00,Adult,M01.060.116
21656395,2011-06-01T00:00:00,Family Practice,H02.403.280
21656395,2011-06-01T00:00:00,"Health Knowledge, Attitudes, Practice",F01.100.150.500
21656395,2011-06-01T00:00:00,"Health Knowledge, Attitudes, Practice",N05.300.150.410
21656395,2011-06-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21656395,2011-06-01T00:00:00,Internship and Residency,I02.358.399.644
21656395,2011-06-01T00:00:00,Sex Factors,N05.715.350.675
21656395,2011-06-01T00:00:00,Sex Factors,N06.850.490.875
21656395,2011-06-01T00:00:00,South Carolina,Z01.107.567.875.075.662
21656395,2011-06-01T00:00:00,South Carolina,Z01.107.567.875.750.700
21665166,2011-06-01T00:00:00,Adult,M01.060.116
21665166,2011-06-01T00:00:00,Depression,F01.145.126.350
21665166,2011-06-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21665166,2011-06-01T00:00:00,Interviews as Topic,E05.318.308.420
21665166,2011-06-01T00:00:00,Interviews as Topic,L01.280.520
21665166,2011-06-01T00:00:00,Interviews as Topic,N05.715.360.300.400
21665166,2011-06-01T00:00:00,Interviews as Topic,N06.850.520.308.420
21665166,2011-06-01T00:00:00,Mass Screening,E01.370.500
21665166,2011-06-01T00:00:00,Mass Screening,E05.318.308.250.580
21665166,2011-06-01T00:00:00,Mass Screening,N02.421.143.827.233.443
21665166,2011-06-01T00:00:00,Mass Screening,N02.421.726.233.443
21665166,2011-06-01T00:00:00,Mass Screening,N05.715.360.300.375.500
21665166,2011-06-01T00:00:00,Mass Screening,N06.850.520.308.250.580
21665166,2011-06-01T00:00:00,Mass Screening,N06.850.780.500
21665166,2011-06-01T00:00:00,Outcome Assessment (Health Care),N04.761.559.590
21665166,2011-06-01T00:00:00,Outcome Assessment (Health Care),N05.715.360.575.575
21665166,2011-06-01T00:00:00,Questionnaires,E05.318.308.750
21665166,2011-06-01T00:00:00,Questionnaires,L01.280.800
21665166,2011-06-01T00:00:00,Questionnaires,N05.715.360.300.695
21665166,2011-06-01T00:00:00,Questionnaires,N06.850.520.308.750
21665166,2011-06-01T00:00:00,Spinal Cord Injuries,C10.228.854.770
21665166,2011-06-01T00:00:00,Spinal Cord Injuries,C10.900.850
21665166,2011-06-01T00:00:00,Spinal Cord Injuries,C21.866.819
21671699,2011-06-01T00:00:00,Anticoagulants,D27.505.954.502.119
21671699,2011-06-01T00:00:00,"Arthroplasty, Replacement, Hip",E04.555.110.110.110
21671699,2011-06-01T00:00:00,"Arthroplasty, Replacement, Hip",E04.650.110.110
21671699,2011-06-01T00:00:00,"Arthroplasty, Replacement, Knee",E04.555.110.110.115
21671699,2011-06-01T00:00:00,"Arthroplasty, Replacement, Knee",E04.650.110.115
21671699,2011-06-01T00:00:00,Cost Savings,N03.219.151.160.200
21671699,2011-06-01T00:00:00,Health Care Costs,N03.219.151.400
21671699,2011-06-01T00:00:00,Health Care Costs,N05.300.375
21671699,2011-06-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21671699,2011-06-01T00:00:00,Practice Guidelines as Topic,N04.761.700.350.650
21671699,2011-06-01T00:00:00,Practice Guidelines as Topic,N05.700.350.650
21671699,2011-06-01T00:00:00,Thiophenes,D02.886.778
21671699,2011-06-01T00:00:00,Thiophenes,D03.383.903
21671699,2011-06-01T00:00:00,Venous Thromboembolism,C14.907.355.590.700
21671699,2011-06-01T00:00:00,Venous Thromboembolism,C14.907.355.830.850.700
21675832,2011-06-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21675832,2011-06-01T00:00:00,Neoplasms,C04
21675832,2011-06-01T00:00:00,Signal Transduction,G02.111.087.800
21675832,2011-06-01T00:00:00,Signal Transduction,G02.149.115.800
21675832,2011-06-01T00:00:00,Signal Transduction,G04.299.880
21679659,2011-06-01T00:00:00,"Education, Medical",I02.358.399
21679659,2011-06-01T00:00:00,General Surgery,H02.403.810.300
21679659,2011-06-01T00:00:00,"History, 19th Century",K01.400.504.937
21679659,2011-06-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21679659,2011-06-01T00:00:00,"Schools, Medical",I02.783.660.552
21679659,2011-06-01T00:00:00,"Schools, Medical",N02.278.020.578
21712470,2011-06-01T00:00:00,African Americans,M01.686.508.100.100
21712470,2011-06-01T00:00:00,African Americans,M01.686.754.100
21712470,2011-06-01T00:00:00,Chest Pain,C23.888.646.215
21712470,2011-06-01T00:00:00,Contrast Media,D27.720.259
21712470,2011-06-01T00:00:00,Coronary Angiography,E01.370.350.700.060.200
21712470,2011-06-01T00:00:00,Coronary Angiography,E01.370.370.050.200
21712470,2011-06-01T00:00:00,Coronary Angiography,E01.370.370.380.200
21712470,2011-06-01T00:00:00,Coronary Artery Disease,C14.280.647.250.260
21712470,2011-06-01T00:00:00,Coronary Artery Disease,C14.907.137.126.339
21712470,2011-06-01T00:00:00,Coronary Artery Disease,C14.907.585.250.260
21712470,2011-06-01T00:00:00,European Continental Ancestry Group,M01.686.508.400
21712470,2011-06-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21712470,2011-06-01T00:00:00,Middle Aged,M01.060.116.630
21712470,2011-06-01T00:00:00,"Radiographic Image Interpretation, Computer-Assisted",E01.158.600.680
21712470,2011-06-01T00:00:00,"Radiographic Image Interpretation, Computer-Assisted",E01.370.350.350.700
21712470,2011-06-01T00:00:00,"Radiographic Image Interpretation, Computer-Assisted",E01.370.350.700.705
21712470,2011-06-01T00:00:00,"Radiographic Image Interpretation, Computer-Assisted",L01.700.508.100.158.600.680
21712470,2011-06-01T00:00:00,Regression Analysis,E05.318.740.750
21712470,2011-06-01T00:00:00,Regression Analysis,N05.715.360.750.695
21712470,2011-06-01T00:00:00,Regression Analysis,N06.850.520.830.750
21712470,2011-06-01T00:00:00,Risk Factors,E05.318.740.600.800.725
21712470,2011-06-01T00:00:00,Risk Factors,N05.715.350.200.700
21712470,2011-06-01T00:00:00,Risk Factors,N05.715.360.750.625.700.700
21712470,2011-06-01T00:00:00,Risk Factors,N06.850.490.625.750
21712470,2011-06-01T00:00:00,Risk Factors,N06.850.520.830.600.800.725
21712470,2011-06-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.350.810
21712470,2011-06-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.600.350.700.810
21712470,2011-06-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.700.700.810
21712470,2011-06-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.700.810.810
21712470,2011-06-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.825.810.810
21721817,2011-06-01T00:00:00,Algorithms,G17.035
21721817,2011-06-01T00:00:00,Algorithms,L01.224.050
21721817,2011-06-01T00:00:00,Animals,B01.050
21721817,2011-06-01T00:00:00,Chick Embryo,A13.350.150
21721817,2011-06-01T00:00:00,Chick Embryo,A16.331.200
21721817,2011-06-01T00:00:00,Heart,A07.541
21721817,2011-06-01T00:00:00,"Tomography, Optical Coherence",E01.370.350.825.805.500
21764001,2011-06-01T00:00:00,"Endoscopy, Gastrointestinal",E01.370.372.250.250
21764001,2011-06-01T00:00:00,"Endoscopy, Gastrointestinal",E01.370.388.250.250.250
21764001,2011-06-01T00:00:00,"Endoscopy, Gastrointestinal",E04.210.240.250
21764001,2011-06-01T00:00:00,"Endoscopy, Gastrointestinal",E04.800.250.250.250
21764001,2011-06-01T00:00:00,Gastroenterology,H02.403.429.405
21764001,2011-06-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21764001,2011-06-01T00:00:00,"Quality Assurance, Health Care",N04.761.700
21764001,2011-06-01T00:00:00,"Quality Assurance, Health Care",N05.700
21815384,2011-06-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21815384,2011-06-01T00:00:00,"Phantoms, Imaging",E07.671
21815384,2011-06-01T00:00:00,Radiation Dosage,E05.799.513
21815384,2011-06-01T00:00:00,Radiation Dosage,G01.201.875.740
21815384,2011-06-01T00:00:00,Radiation Dosage,N06.850.810.250
21815384,2011-06-01T00:00:00,Radiometry,E05.799
21815384,2011-06-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.350.810
21815384,2011-06-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.600.350.700.810
21815384,2011-06-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.700.700.810
21815384,2011-06-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.700.810.810
21815384,2011-06-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.825.810.810
21830340,2011-06-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21830340,2011-06-01T00:00:00,Neoplasm Invasiveness,C04.697.645
21830340,2011-06-01T00:00:00,Neoplasm Invasiveness,C23.550.727.645
21830340,2011-06-01T00:00:00,Pancreatic Neoplasms,C04.588.274.761
21830340,2011-06-01T00:00:00,Pancreatic Neoplasms,C04.588.322.421
21830340,2011-06-01T00:00:00,Pancreatic Neoplasms,C06.301.761
21830340,2011-06-01T00:00:00,Pancreatic Neoplasms,C06.689.667
21830340,2011-06-01T00:00:00,Pancreatic Neoplasms,C19.344.421
21834332,2011-06-01T00:00:00,Animals,B01.050
21844867,2011-06-01T00:00:00,Algorithms,G17.035
21844867,2011-06-01T00:00:00,Algorithms,L01.224.050
21844867,2011-06-01T00:00:00,Film Dosimetry,E05.799.638.420
21844867,2011-06-01T00:00:00,Film Dosimetry,N06.850.810.370.310
21844867,2011-06-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21844867,2011-06-01T00:00:00,Particle Accelerators,E07.710.680
21844867,2011-06-01T00:00:00,"Phantoms, Imaging",E07.671
21844867,2011-06-01T00:00:00,"Quality Assurance, Health Care",N04.761.700
21844867,2011-06-01T00:00:00,"Quality Assurance, Health Care",N05.700
21844867,2011-06-01T00:00:00,Time Factors,G01.910.857
21848180,2011-06-01T00:00:00,Blood Transfusion,E02.095.135
21848180,2011-06-01T00:00:00,Extracorporeal Membrane Oxygenation,E02.880.301
21848180,2011-06-01T00:00:00,Extracorporeal Membrane Oxygenation,E04.292.451
21848180,2011-06-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21848180,2011-06-01T00:00:00,Liver Transplantation,E04.210.650
21848180,2011-06-01T00:00:00,Liver Transplantation,E04.936.450.490
21848180,2011-06-01T00:00:00,Liver Transplantation,E04.936.580.490
22057707,2011-06-01T00:00:00,Delivery of Health Care,N04.590.374
22057707,2011-06-01T00:00:00,Delivery of Health Care,N05.300
22057707,2011-06-01T00:00:00,Disaster Planning,N06.230.100.035
22057707,2011-06-01T00:00:00,Health Personnel,M01.526.485
22057707,2011-06-01T00:00:00,Health Personnel,N02.360
22057707,2011-06-01T00:00:00,Hospitals,N02.278.421
22057707,2011-06-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22057707,2011-06-01T00:00:00,Resource Allocation,I01.261.750
22057707,2011-06-01T00:00:00,South Carolina,Z01.107.567.875.075.662
22057707,2011-06-01T00:00:00,South Carolina,Z01.107.567.875.750.700
22822511,2011-06-01T00:00:00,Biological Availability,G03.787.151
22822511,2011-06-01T00:00:00,Biological Availability,G07.690.725.129
22822511,2011-06-01T00:00:00,Drug Delivery Systems,E02.319.300
22822511,2011-06-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22822511,2011-06-01T00:00:00,"Hyperthermia, Induced",E02.565
22822511,2011-06-01T00:00:00,"Hyperthermia, Induced",E02.779.496
22822511,2011-06-01T00:00:00,Metal Nanoparticles,J01.637.512.600.500
22822511,2011-06-01T00:00:00,Neoplasms,C04
22822511,2011-06-01T00:00:00,Physicochemical Phenomena,G02.842
21636663,2011-06-02T00:00:00,Adult,M01.060.116
21636663,2011-06-02T00:00:00,Aged,M01.060.116.100
21636663,2011-06-02T00:00:00,"Biopsy, Needle",E01.370.388.100.100
21636663,2011-06-02T00:00:00,"Biopsy, Needle",E01.450.230.100.100
21636663,2011-06-02T00:00:00,"Biopsy, Needle",E01.450.865.100.100
21636663,2011-06-02T00:00:00,"Biopsy, Needle",E01.450.865.632.100
21636663,2011-06-02T00:00:00,"Biopsy, Needle",E04.074.119
21636663,2011-06-02T00:00:00,Endosonography,E01.370.350.850.280
21636663,2011-06-02T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21636663,2011-06-02T00:00:00,Lung Neoplasms,C04.588.894.797.520
21636663,2011-06-02T00:00:00,Lung Neoplasms,C08.381.540
21636663,2011-06-02T00:00:00,Lung Neoplasms,C08.785.520
21636663,2011-06-02T00:00:00,Lymph Nodes,A10.549.400
21636663,2011-06-02T00:00:00,Lymph Nodes,A15.382.520.604.412
21636663,2011-06-02T00:00:00,Middle Aged,M01.060.116.630
21636663,2011-06-02T00:00:00,Neoplasm Invasiveness,C04.697.645
21636663,2011-06-02T00:00:00,Neoplasm Invasiveness,C23.550.727.645
21636663,2011-06-02T00:00:00,Neoplasm Staging,E01.370.550
21636663,2011-06-02T00:00:00,Positron-Emission Tomography,E01.370.350.350.800.700
21636663,2011-06-02T00:00:00,Positron-Emission Tomography,E01.370.350.600.350.800.399
21636663,2011-06-02T00:00:00,Positron-Emission Tomography,E01.370.350.710.800.399
21636663,2011-06-02T00:00:00,Positron-Emission Tomography,E01.370.350.825.800.399
21636663,2011-06-02T00:00:00,Positron-Emission Tomography,E01.370.384.730.800.399
21636663,2011-06-02T00:00:00,"Tomography, X-Ray Computed",E01.370.350.350.810
21636663,2011-06-02T00:00:00,"Tomography, X-Ray Computed",E01.370.350.600.350.700.810
21636663,2011-06-02T00:00:00,"Tomography, X-Ray Computed",E01.370.350.700.700.810
21636663,2011-06-02T00:00:00,"Tomography, X-Ray Computed",E01.370.350.700.810.810
21636663,2011-06-02T00:00:00,"Tomography, X-Ray Computed",E01.370.350.825.810.810
21636812,2011-06-02T00:00:00,Adult,M01.060.116
21636812,2011-06-02T00:00:00,Aged,M01.060.116.100
21636812,2011-06-02T00:00:00,Angioplasty,E02.148.050
21636812,2011-06-02T00:00:00,Angioplasty,E04.100.814.050
21636812,2011-06-02T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21636812,2011-06-02T00:00:00,Intracranial Arteriosclerosis,C10.228.140.300.510.800
21636812,2011-06-02T00:00:00,Intracranial Arteriosclerosis,C14.907.137.126.372
21636812,2011-06-02T00:00:00,Intracranial Arteriosclerosis,C14.907.253.560.350
21636812,2011-06-02T00:00:00,Middle Aged,M01.060.116.630
21636812,2011-06-02T00:00:00,Stents,E07.695.750
21636812,2011-06-02T00:00:00,Treatment Outcome,E01.789.800
21636812,2011-06-02T00:00:00,Treatment Outcome,N04.761.559.590.800
21636812,2011-06-02T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21636812,2011-06-02T00:00:00,United States,Z01.107.567.875
21636831,2011-06-02T00:00:00,Aged,M01.060.116.100
21636831,2011-06-02T00:00:00,Electromyography,E01.370.405.255
21636831,2011-06-02T00:00:00,Electromyography,E01.370.530.255
21636831,2011-06-02T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21636831,2011-06-02T00:00:00,Middle Aged,M01.060.116.630
21636831,2011-06-02T00:00:00,Paresis,C10.597.636
21636831,2011-06-02T00:00:00,Paresis,C23.888.592.643
21636831,2011-06-02T00:00:00,Stroke,C10.228.140.300.775
21636831,2011-06-02T00:00:00,Stroke,C14.907.253.855
21636831,2011-06-02T00:00:00,Walking,G11.427.590.530.568.900
21636831,2011-06-02T00:00:00,Walking,G11.427.590.530.698.940
21636831,2011-06-02T00:00:00,Walking,I03.450.642.845.940
21640688,2011-06-02T00:00:00,Communication,F01.145.209
21640688,2011-06-02T00:00:00,Communication,L01.143
21640688,2011-06-02T00:00:00,Electronic Health Records,E05.318.308.940.968.625.500
21640688,2011-06-02T00:00:00,Health Services Accessibility,N04.590.374.350
21640688,2011-06-02T00:00:00,Health Services Accessibility,N05.300.430
21640688,2011-06-02T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21640688,2011-06-02T00:00:00,Hypertension,C14.907.489
21640688,2011-06-02T00:00:00,Outcome Assessment (Health Care),N04.761.559.590
21640688,2011-06-02T00:00:00,Outcome Assessment (Health Care),N05.715.360.575.575
21640688,2011-06-02T00:00:00,Patient Care Team,N04.590.715
21640688,2011-06-02T00:00:00,Practice Guidelines as Topic,N04.761.700.350.650
21640688,2011-06-02T00:00:00,Practice Guidelines as Topic,N05.700.350.650
21639697,2011-06-03T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21639697,2011-06-03T00:00:00,Intracranial Aneurysm,C10.228.140.300.510.600
21639697,2011-06-03T00:00:00,Intracranial Aneurysm,C14.907.055.635
21639697,2011-06-03T00:00:00,Intracranial Aneurysm,C14.907.253.560.300
21639697,2011-06-03T00:00:00,Middle Aged,M01.060.116.630
21639697,2011-06-03T00:00:00,Risk Factors,E05.318.740.600.800.725
21639697,2011-06-03T00:00:00,Risk Factors,N05.715.350.200.700
21639697,2011-06-03T00:00:00,Risk Factors,N05.715.360.750.625.700.700
21639697,2011-06-03T00:00:00,Risk Factors,N06.850.490.625.750
21639697,2011-06-03T00:00:00,Risk Factors,N06.850.520.830.600.800.725
21639697,2011-06-03T00:00:00,Subarachnoid Hemorrhage,C10.228.140.300.535.800
21639697,2011-06-03T00:00:00,Subarachnoid Hemorrhage,C14.907.253.573.800
21639697,2011-06-03T00:00:00,Subarachnoid Hemorrhage,C23.550.414.913.850
21642431,2011-06-03T00:00:00,DNA Repair,G02.111.087.219
21642431,2011-06-03T00:00:00,DNA Repair,G02.149.115.219
21642431,2011-06-03T00:00:00,DNA Repair,G05.355.195
21642431,2011-06-03T00:00:00,"Evolution, Molecular",G05.355.265.250
21642431,2011-06-03T00:00:00,"Evolution, Molecular",G16.100.275.250
21642431,2011-06-03T00:00:00,Phylogeny,G05.697
21642431,2011-06-03T00:00:00,Phylogeny,G16.100.275.605
21642431,2011-06-03T00:00:00,Phylogeny,L01.100.697
21642431,2011-06-03T00:00:00,Uracil-DNA Glycosidase,D08.811.074.249.875
21357388,2011-06-06T00:00:00,ATP-Binding Cassette Transporters,D12.776.157.530.100
21357388,2011-06-06T00:00:00,ATP-Binding Cassette Transporters,D12.776.395.550.020
21357388,2011-06-06T00:00:00,ATP-Binding Cassette Transporters,D12.776.543.550.192
21357388,2011-06-06T00:00:00,ATP-Binding Cassette Transporters,D12.776.543.585.100
21357388,2011-06-06T00:00:00,Animals,B01.050
21357388,2011-06-06T00:00:00,Macular Degeneration,C11.768.585.439
21357388,2011-06-06T00:00:00,"Microscopy, Fluorescence",E01.370.350.515.458
21357388,2011-06-06T00:00:00,"Microscopy, Fluorescence",E05.595.458
21357388,2011-06-06T00:00:00,Oxides,D01.248.497.158.685
21357388,2011-06-06T00:00:00,Oxides,D01.650.550
21357388,2011-06-06T00:00:00,Pyridinium Compounds,D03.383.725.762
21357388,2011-06-06T00:00:00,Retinal Pigment Epithelium,A09.371.670.500
21357388,2011-06-06T00:00:00,Retinal Pigment Epithelium,A09.371.729.887
21357388,2011-06-06T00:00:00,Retinoids,D02.455.326.271.665.202.495
21357388,2011-06-06T00:00:00,Retinoids,D02.455.426.392.368.367.379.249.700
21357388,2011-06-06T00:00:00,Retinoids,D02.455.849.131.495
21357388,2011-06-06T00:00:00,Retinoids,D23.767.261.700
21357388,2011-06-06T00:00:00,"Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization",E05.196.566.755
21619005,2011-06-06T00:00:00,X-Rays,G01.201.875.750.918
21645379,2011-06-06T00:00:00,African Americans,M01.686.508.100.100
21645379,2011-06-06T00:00:00,African Americans,M01.686.754.100
21645379,2011-06-06T00:00:00,Aged,M01.060.116.100
21645379,2011-06-06T00:00:00,"Diabetes Mellitus, Type 2",C18.452.394.750.149
21645379,2011-06-06T00:00:00,"Diabetes Mellitus, Type 2",C19.246.300
21645379,2011-06-06T00:00:00,European Continental Ancestry Group,M01.686.508.400
21645379,2011-06-06T00:00:00,Hispanic Americans,M01.686.754.441
21645379,2011-06-06T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21645379,2011-06-06T00:00:00,Medication Adherence,F01.145.488.500.500
21645379,2011-06-06T00:00:00,Medication Adherence,N05.300.150.600.600.500
21645379,2011-06-06T00:00:00,Middle Aged,M01.060.116.630
21645379,2011-06-06T00:00:00,Prescriptions,N02.421.668.778
21645379,2011-06-06T00:00:00,Regression Analysis,E05.318.740.750
21645379,2011-06-06T00:00:00,Regression Analysis,N05.715.360.750.695
21645379,2011-06-06T00:00:00,Regression Analysis,N06.850.520.830.750
21645379,2011-06-06T00:00:00,Veterans,M01.930
21646472,2011-06-06T00:00:00,Adenocarcinoma,C04.557.470.200.025
21646472,2011-06-06T00:00:00,Angiogenesis Inhibitors,D27.505.696.377.077.099
21646472,2011-06-06T00:00:00,Angiogenesis Inhibitors,D27.505.696.377.450.100
21646472,2011-06-06T00:00:00,Angiogenesis Inhibitors,D27.505.954.248.025
21646472,2011-06-06T00:00:00,Animals,B01.050
21646472,2011-06-06T00:00:00,Antineoplastic Agents,D27.505.954.248
21646472,2011-06-06T00:00:00,Apoptosis,G04.299.139.160
21646472,2011-06-06T00:00:00,Colonic Neoplasms,C04.588.274.476.411.307.180
21646472,2011-06-06T00:00:00,Colonic Neoplasms,C06.301.371.411.307.180
21646472,2011-06-06T00:00:00,Colonic Neoplasms,C06.405.249.411.307.180
21646472,2011-06-06T00:00:00,Colonic Neoplasms,C06.405.469.158.356.180
21646472,2011-06-06T00:00:00,Colonic Neoplasms,C06.405.469.491.307.180
21646472,2011-06-06T00:00:00,"Gene Expression Regulation, Neoplastic",G05.355.315.370
21646472,2011-06-06T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21646472,2011-06-06T00:00:00,Neoplasm Proteins,D12.776.624
21646472,2011-06-06T00:00:00,Protein Kinase Inhibitors,D27.505.519.389.755
21646472,2011-06-06T00:00:00,Pyrimidines,D03.383.742
21646472,2011-06-06T00:00:00,Recombinant Proteins,D12.776.828
21646472,2011-06-06T00:00:00,TNF-Related Apoptosis-Inducing Ligand,D12.644.276.374.750.625
21646472,2011-06-06T00:00:00,TNF-Related Apoptosis-Inducing Ligand,D12.644.276.972.625
21646472,2011-06-06T00:00:00,TNF-Related Apoptosis-Inducing Ligand,D12.776.467.374.750.625
21646472,2011-06-06T00:00:00,TNF-Related Apoptosis-Inducing Ligand,D12.776.467.972.625
21646472,2011-06-06T00:00:00,TNF-Related Apoptosis-Inducing Ligand,D23.529.374.750.625
21646472,2011-06-06T00:00:00,TNF-Related Apoptosis-Inducing Ligand,D23.529.972.625
21646472,2011-06-06T00:00:00,Thiazoles,D02.886.675
21646472,2011-06-06T00:00:00,Thiazoles,D03.383.129.708
21646472,2011-06-06T00:00:00,Tumor Suppressor Protein p53,D12.776.260.820
21646472,2011-06-06T00:00:00,Tumor Suppressor Protein p53,D12.776.624.776.775
21646472,2011-06-06T00:00:00,Tumor Suppressor Protein p53,D12.776.660.825
21646472,2011-06-06T00:00:00,Tumor Suppressor Protein p53,D12.776.744.845
21647914,2011-06-06T00:00:00,Body Weight,C23.888.144
21647914,2011-06-06T00:00:00,Body Weight,E01.370.600.115.100.160.120
21647914,2011-06-06T00:00:00,Body Weight,E05.041.124.160.750
21647914,2011-06-06T00:00:00,Body Weight,G07.100.100.160.120
21647914,2011-06-06T00:00:00,Body Weight,G07.700.320.249.314.120
21647914,2011-06-06T00:00:00,Case-Control Studies,E05.318.760.500.500
21647914,2011-06-06T00:00:00,Case-Control Studies,N05.715.360.775.175.200
21647914,2011-06-06T00:00:00,Case-Control Studies,N06.850.520.450.500.500
21647914,2011-06-06T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21647914,2011-06-06T00:00:00,Infant,M01.060.703
21647914,2011-06-06T00:00:00,Laryngomalacia,C05.182.310
21647914,2011-06-06T00:00:00,Laryngomalacia,C08.360.563
21647914,2011-06-06T00:00:00,Laryngomalacia,C09.400.563
21647914,2011-06-06T00:00:00,Laryngomalacia,C16.131.621.568
21647914,2011-06-06T00:00:00,Laryngomalacia,C17.300.182.310
21647914,2011-06-06T00:00:00,Laryngoscopy,E01.370.386.460
21647914,2011-06-06T00:00:00,Laryngoscopy,E01.370.388.250.525
21647914,2011-06-06T00:00:00,Laryngoscopy,E04.580.373
21647914,2011-06-06T00:00:00,Laryngoscopy,E04.800.250.525
21647914,2011-06-06T00:00:00,Otorhinolaryngologic Surgical Procedures,E04.580
21647914,2011-06-06T00:00:00,Reconstructive Surgical Procedures,E04.680
21647914,2011-06-06T00:00:00,Risk Assessment,E05.318.740.600.800.715
21647914,2011-06-06T00:00:00,Risk Assessment,N04.452.871.715
21647914,2011-06-06T00:00:00,Risk Assessment,N05.715.360.750.625.700.690
21647914,2011-06-06T00:00:00,Risk Assessment,N06.850.505.715
21647914,2011-06-06T00:00:00,Risk Assessment,N06.850.520.830.600.800.715
21647914,2011-06-06T00:00:00,Treatment Outcome,E01.789.800
21647914,2011-06-06T00:00:00,Treatment Outcome,N04.761.559.590.800
21647914,2011-06-06T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21672594,2011-06-06T00:00:00,Animals,B01.050
21672594,2011-06-06T00:00:00,Apoptosis,G04.299.139.160
21672594,2011-06-06T00:00:00,Cytokines,D12.644.276.374
21672594,2011-06-06T00:00:00,Cytokines,D12.776.467.374
21672594,2011-06-06T00:00:00,Cytokines,D23.529.374
21672594,2011-06-06T00:00:00,Interferon-gamma,D12.644.276.374.440.893
21672594,2011-06-06T00:00:00,Interferon-gamma,D12.644.276.374.480.350
21672594,2011-06-06T00:00:00,Interferon-gamma,D12.644.276.374.480.615.350
21672594,2011-06-06T00:00:00,Interferon-gamma,D12.644.276.718.550
21672594,2011-06-06T00:00:00,Interferon-gamma,D12.776.467.374.440.893
21672594,2011-06-06T00:00:00,Interferon-gamma,D12.776.467.374.480.350
21672594,2011-06-06T00:00:00,Interferon-gamma,D12.776.467.374.480.615.350
21672594,2011-06-06T00:00:00,Interferon-gamma,D12.776.467.718.550
21672594,2011-06-06T00:00:00,Interferon-gamma,D23.529.374.440.893
21672594,2011-06-06T00:00:00,Interferon-gamma,D23.529.374.480.350
21672594,2011-06-06T00:00:00,Interferon-gamma,D23.529.374.480.615.350
21672594,2011-06-06T00:00:00,Interferon-gamma,D23.529.718.550
21672594,2011-06-06T00:00:00,Microglia,A08.637.400
21672594,2011-06-06T00:00:00,Microglia,A11.650.400
21672594,2011-06-06T00:00:00,Mitochondria,A11.284.430.214.190.875.564
21672594,2011-06-06T00:00:00,Mitochondria,A11.284.835.626
21672594,2011-06-06T00:00:00,Motor Neurons,A08.663.655.500
21672594,2011-06-06T00:00:00,Motor Neurons,A11.671.655.500
21672594,2011-06-06T00:00:00,Neuroprotective Agents,D27.505.696.706.548
21672594,2011-06-06T00:00:00,Neuroprotective Agents,D27.505.954.427.575
21672594,2011-06-06T00:00:00,Rats,B01.050.150.900.649.865.635.505.700
21672594,2011-06-06T00:00:00,"Rats, Sprague-Dawley",B01.050.150.900.649.865.635.505.700.750
21672594,2011-06-06T00:00:00,Reactive Oxygen Species,D01.339.431
21672594,2011-06-06T00:00:00,Reactive Oxygen Species,D01.650.775
22144061,2011-06-06T00:00:00,Chronic Disease,C23.550.291.500
22144061,2011-06-06T00:00:00,Endoscopy,E01.370.388.250
22144061,2011-06-06T00:00:00,Endoscopy,E04.800.250
22144061,2011-06-06T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22144061,2011-06-06T00:00:00,Maxilla,A02.835.232.781.324.502.645
22144061,2011-06-06T00:00:00,Maxilla,A14.521.645
22144061,2011-06-06T00:00:00,Middle Aged,M01.060.116.630
22144061,2011-06-06T00:00:00,Otorhinolaryngologic Surgical Procedures,E04.580
22144061,2011-06-06T00:00:00,Pseudomonas Infections,C01.252.400.739
22144061,2011-06-06T00:00:00,Pseudomonas aeruginosa,B03.440.400.425.625.625.100
22144061,2011-06-06T00:00:00,Pseudomonas aeruginosa,B03.660.250.580.590.050
22144061,2011-06-06T00:00:00,Staphylococcal Infections,C01.252.410.868
22144061,2011-06-06T00:00:00,Staphylococcus aureus,B03.300.390.400.800.750.100
22144061,2011-06-06T00:00:00,Staphylococcus aureus,B03.510.100.750.750.100
22144061,2011-06-06T00:00:00,Staphylococcus aureus,B03.510.400.790.750.100
22144061,2011-06-06T00:00:00,Treatment Outcome,E01.789.800
22144061,2011-06-06T00:00:00,Treatment Outcome,N04.761.559.590.800
22144061,2011-06-06T00:00:00,Treatment Outcome,N05.715.360.575.575.800
22287426,2011-06-06T00:00:00,Adult,M01.060.116
22287426,2011-06-06T00:00:00,Aged,M01.060.116.100
22287426,2011-06-06T00:00:00,Anti-Bacterial Agents,D27.505.954.122.085
22287426,2011-06-06T00:00:00,Chronic Disease,C23.550.291.500
22287426,2011-06-06T00:00:00,Combined Modality Therapy,E02.186
22287426,2011-06-06T00:00:00,Endoscopy,E01.370.388.250
22287426,2011-06-06T00:00:00,Endoscopy,E04.800.250
22287426,2011-06-06T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22287426,2011-06-06T00:00:00,Middle Aged,M01.060.116.630
22287426,2011-06-06T00:00:00,Quality of Life,I01.800
22287426,2011-06-06T00:00:00,Quality of Life,K01.752.400.750
22287426,2011-06-06T00:00:00,Rhinitis,C08.460.799
22287426,2011-06-06T00:00:00,Rhinitis,C08.730.674
22287426,2011-06-06T00:00:00,Rhinitis,C09.603.799
22287426,2011-06-06T00:00:00,Sinusitis,C08.460.692.752
22287426,2011-06-06T00:00:00,Sinusitis,C08.730.749
22287426,2011-06-06T00:00:00,Sinusitis,C09.603.692.752
22287426,2011-06-06T00:00:00,Steroids,D04.808
22287426,2011-06-06T00:00:00,Treatment Outcome,E01.789.800
22287426,2011-06-06T00:00:00,Treatment Outcome,N04.761.559.590.800
22287426,2011-06-06T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21641663,2011-06-08T00:00:00,Adult,M01.060.116
21641663,2011-06-08T00:00:00,Alcohol Deterrents,D27.505.954.427.020
21641663,2011-06-08T00:00:00,Alcoholism,C21.739.100.250
21641663,2011-06-08T00:00:00,Alcoholism,F03.900.100.350
21641663,2011-06-08T00:00:00,Anxiety Disorders,F03.080
21641663,2011-06-08T00:00:00,Bipolar Disorder,F03.600.150.150
21641663,2011-06-08T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21641663,2011-06-08T00:00:00,Middle Aged,M01.060.116.630
21641663,2011-06-08T00:00:00,Patient Compliance,F01.145.488.500
21641663,2011-06-08T00:00:00,Patient Compliance,N05.300.150.600.600
21641663,2011-06-08T00:00:00,Taurine,D02.455.326.146.100.850
21641663,2011-06-08T00:00:00,Taurine,D02.886.645.600.055.850
21641663,2011-06-08T00:00:00,Treatment Outcome,E01.789.800
21641663,2011-06-08T00:00:00,Treatment Outcome,N04.761.559.590.800
21641663,2011-06-08T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21653830,2011-06-08T00:00:00,Animals,B01.050
21653830,2011-06-08T00:00:00,Antineoplastic Agents,D27.505.954.248
21653830,2011-06-08T00:00:00,Apoptosis,G04.299.139.160
21653830,2011-06-08T00:00:00,Cell Survival,G04.299.316
21653830,2011-06-08T00:00:00,Colonic Neoplasms,C04.588.274.476.411.307.180
21653830,2011-06-08T00:00:00,Colonic Neoplasms,C06.301.371.411.307.180
21653830,2011-06-08T00:00:00,Colonic Neoplasms,C06.405.249.411.307.180
21653830,2011-06-08T00:00:00,Colonic Neoplasms,C06.405.469.158.356.180
21653830,2011-06-08T00:00:00,Colonic Neoplasms,C06.405.469.491.307.180
21653830,2011-06-08T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21653830,2011-06-08T00:00:00,"Microscopy, Fluorescence",E01.370.350.515.458
21653830,2011-06-08T00:00:00,"Microscopy, Fluorescence",E05.595.458
21653830,2011-06-08T00:00:00,Quinazolines,D03.438.786
21653830,2011-06-08T00:00:00,"Receptors, TNF-Related Apoptosis-Inducing Ligand",D12.776.543.750.073.600
21653830,2011-06-08T00:00:00,"Receptors, TNF-Related Apoptosis-Inducing Ligand",D12.776.543.750.705.852.760.396
21656904,2011-06-08T00:00:00,African Americans,M01.686.508.100.100
21656904,2011-06-08T00:00:00,African Americans,M01.686.754.100
21656904,2011-06-08T00:00:00,Case-Control Studies,E05.318.760.500.500
21656904,2011-06-08T00:00:00,Case-Control Studies,N05.715.360.775.175.200
21656904,2011-06-08T00:00:00,Case-Control Studies,N06.850.520.450.500.500
21656904,2011-06-08T00:00:00,Cocaine,D02.145.074.722.388
21656904,2011-06-08T00:00:00,Cocaine,D03.132.889.354
21656904,2011-06-08T00:00:00,Cocaine,D03.605.869.388
21656904,2011-06-08T00:00:00,Cocaine,D04.075.080.875.099.722.388
21656904,2011-06-08T00:00:00,Cocaine-Related Disorders,C21.739.300
21656904,2011-06-08T00:00:00,Cocaine-Related Disorders,F03.900.300
21656904,2011-06-08T00:00:00,Dopamine,D02.092.211.215.311.342
21656904,2011-06-08T00:00:00,Dopamine,D02.092.311.342
21656904,2011-06-08T00:00:00,European Continental Ancestry Group,M01.686.508.400
21656904,2011-06-08T00:00:00,Genetic Predisposition to Disease,C23.550.291.687.500
21656904,2011-06-08T00:00:00,Genetic Predisposition to Disease,G05.380.355
21656904,2011-06-08T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21656904,2011-06-08T00:00:00,Norepinephrine,D02.033.100.291.502
21656904,2011-06-08T00:00:00,Norepinephrine,D02.092.063.480
21656904,2011-06-08T00:00:00,Norepinephrine,D02.092.211.215.311.560
21656904,2011-06-08T00:00:00,Norepinephrine,D02.092.311.461.484
21656904,2011-06-08T00:00:00,"Polymorphism, Single Nucleotide",G05.365.795.598
21731887,2011-06-08T00:00:00,Cardiovascular Agents,D27.505.954.411
21731887,2011-06-08T00:00:00,Chronic Disease,C23.550.291.500
21731887,2011-06-08T00:00:00,Heart Failure,C14.280.434
21731887,2011-06-08T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21731887,2011-06-08T00:00:00,Patient Selection,E05.581.500.653
21731887,2011-06-08T00:00:00,Patient Selection,N04.590.731
21731887,2011-06-08T00:00:00,Risk Assessment,E05.318.740.600.800.715
21731887,2011-06-08T00:00:00,Risk Assessment,N04.452.871.715
21731887,2011-06-08T00:00:00,Risk Assessment,N05.715.360.750.625.700.690
21731887,2011-06-08T00:00:00,Risk Assessment,N06.850.505.715
21731887,2011-06-08T00:00:00,Risk Assessment,N06.850.520.830.600.800.715
21731887,2011-06-08T00:00:00,Treatment Outcome,E01.789.800
21731887,2011-06-08T00:00:00,Treatment Outcome,N04.761.559.590.800
21731887,2011-06-08T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21660043,2011-06-10T00:00:00,"Antigens, CD147",D12.776.395.550.045
21660043,2011-06-10T00:00:00,"Antigens, CD147",D12.776.543.550.188
21660043,2011-06-10T00:00:00,"Antigens, CD147",D23.050.285.040
21660043,2011-06-10T00:00:00,"Antigens, CD147",D23.050.301.264.035.247
21660043,2011-06-10T00:00:00,"Antigens, CD147",D23.101.100.110.247
21660043,2011-06-10T00:00:00,Antineoplastic Agents,D27.505.954.248
21660043,2011-06-10T00:00:00,"Drug Resistance, Neoplasm",G07.690.320.395
21660043,2011-06-10T00:00:00,Flow Cytometry,E05.196.712.516.600.240.350
21660043,2011-06-10T00:00:00,Flow Cytometry,E05.200.500.386.350
21660043,2011-06-10T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21660043,2011-06-10T00:00:00,RNA Interference,G05.355.315.203.374.790
21660043,2011-06-10T00:00:00,Vesicular Transport Proteins,D12.776.543.990
21666116,2011-06-10T00:00:00,Animals,B01.050
21666116,2011-06-10T00:00:00,Cell Membrane,A11.284.149
21666116,2011-06-10T00:00:00,Cell Proliferation,G04.299.233.750
21666116,2011-06-10T00:00:00,Cell Proliferation,G07.700.320.249.410.750
21666116,2011-06-10T00:00:00,Collagen Type I,D05.750.078.280.300.100
21666116,2011-06-10T00:00:00,Collagen Type I,D12.776.860.300.250.300.100
21666116,2011-06-10T00:00:00,Extracellular Matrix,A11.284.295.310
21666116,2011-06-10T00:00:00,Fibroblasts,A11.329.228
21666116,2011-06-10T00:00:00,Fibroblasts,A11.872.228
21666116,2011-06-10T00:00:00,Myocardium,A02.633.580
21666116,2011-06-10T00:00:00,Myocardium,A07.541.704
21666116,2011-06-10T00:00:00,Myocardium,A10.690.552.750
21666116,2011-06-10T00:00:00,Osteonectin,D12.776.157.125.715
21666116,2011-06-10T00:00:00,Osteonectin,D12.776.395.600
21666116,2011-06-10T00:00:00,Procollagen,D12.776.811.690
21666116,2011-06-10T00:00:00,Procollagen,D12.776.860.300.250.600
21666116,2011-06-10T00:00:00,"Protein Processing, Post-Translational",G02.111.087.675.871.790.600
21666116,2011-06-10T00:00:00,"Protein Processing, Post-Translational",G02.111.087.693.600
21666116,2011-06-10T00:00:00,"Protein Processing, Post-Translational",G02.149.115.675.871.790.600
21666116,2011-06-10T00:00:00,"Protein Processing, Post-Translational",G02.149.115.693.600
21666116,2011-06-10T00:00:00,"Protein Processing, Post-Translational",G03.495.770.871.790.600
21666116,2011-06-10T00:00:00,"Protein Processing, Post-Translational",G05.355.315.670.600
21666116,2011-06-10T00:00:00,Recombinant Proteins,D12.776.828
21666120,2011-06-10T00:00:00,Animals,B01.050
21666120,2011-06-10T00:00:00,Collagen,D05.750.078.280
21666120,2011-06-10T00:00:00,Collagen,D12.776.860.300.250
21666120,2011-06-10T00:00:00,Heart,A07.541
21666120,2011-06-10T00:00:00,Matrix Metalloproteinase 14,D08.811.277.656.300.480.525.300.500
21666120,2011-06-10T00:00:00,Matrix Metalloproteinase 14,D08.811.277.656.675.374.525.300.500
21666120,2011-06-10T00:00:00,Myocardial Infarction,C14.280.647.500
21666120,2011-06-10T00:00:00,Myocardial Infarction,C14.907.585.500
21666120,2011-06-10T00:00:00,"RNA, Messenger",D13.444.735.544
21666120,2011-06-10T00:00:00,"Ventricular Function, Left",G09.330.190.962.800
21666120,2011-06-10T00:00:00,Ventricular Remodeling,C23.300.985
21666120,2011-06-10T00:00:00,Ventricular Remodeling,G09.330.190.962.975
21666135,2011-06-10T00:00:00,Animals,B01.050
21666135,2011-06-10T00:00:00,Dextrans,D05.750.078.562.272
21666135,2011-06-10T00:00:00,Dextrans,D09.698.365.272
21666135,2011-06-10T00:00:00,Glutamic Acid,D12.125.067.750
21666135,2011-06-10T00:00:00,Glutamic Acid,D12.125.119.450
21666135,2011-06-10T00:00:00,Glutamic Acid,D12.125.427.300
21666135,2011-06-10T00:00:00,Neural Pathways,A08.612
21666135,2011-06-10T00:00:00,Neurons,A08.663
21666135,2011-06-10T00:00:00,Neurons,A11.671
21666135,2011-06-10T00:00:00,Prefrontal Cortex,A08.186.211.730.885.287.500.270.700
21666135,2011-06-10T00:00:00,Rats,B01.050.150.900.649.865.635.505.700
21666135,2011-06-10T00:00:00,"Rats, Sprague-Dawley",B01.050.150.900.649.865.635.505.700.750
21666135,2011-06-10T00:00:00,Tyrosine 3-Monooxygenase,D08.811.682.690.708.923
21666135,2011-06-10T00:00:00,Tyrosine 3-Monooxygenase,D12.776.556.579.374.925
21666135,2011-06-10T00:00:00,Ventral Tegmental Area,A08.186.211.132.659.822.820
21666135,2011-06-10T00:00:00,Ventral Tegmental Area,A08.186.211.653.822.820
21671235,2011-06-10T00:00:00,Adult,M01.060.116
21671235,2011-06-10T00:00:00,Cadaver,C23.550.260.224
21671235,2011-06-10T00:00:00,Cerebrospinal Fluid Rhinorrhea,C10.597.267
21671235,2011-06-10T00:00:00,Cerebrospinal Fluid Rhinorrhea,C10.900.300.153
21671235,2011-06-10T00:00:00,Cerebrospinal Fluid Rhinorrhea,C21.866.260.207
21671235,2011-06-10T00:00:00,Cerebrospinal Fluid Rhinorrhea,C21.866.915.300.300
21671235,2011-06-10T00:00:00,Cerebrospinal Fluid Rhinorrhea,C23.888.592.264
21671235,2011-06-10T00:00:00,Endoscopy,E01.370.388.250
21671235,2011-06-10T00:00:00,Endoscopy,E04.800.250
21671235,2011-06-10T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21671235,2011-06-10T00:00:00,Reconstructive Surgical Procedures,E04.680
21671235,2011-06-10T00:00:00,Skull Base,A01.456.830
21671235,2011-06-10T00:00:00,Skull Base,A02.835.232.781.750
21671235,2011-06-10T00:00:00,Surgical Flaps,A10.850.710
21671235,2011-06-10T00:00:00,Surgical Flaps,E07.862.710
21671235,2011-06-10T00:00:00,"Tomography, X-Ray Computed",E01.370.350.350.810
21671235,2011-06-10T00:00:00,"Tomography, X-Ray Computed",E01.370.350.600.350.700.810
21671235,2011-06-10T00:00:00,"Tomography, X-Ray Computed",E01.370.350.700.700.810
21671235,2011-06-10T00:00:00,"Tomography, X-Ray Computed",E01.370.350.700.810.810
21671235,2011-06-10T00:00:00,"Tomography, X-Ray Computed",E01.370.350.825.810.810
21829271,2011-06-10T00:00:00,"Education, Pharmacy",I02.358.525
21829271,2011-06-10T00:00:00,Faculty,I02.463
21829271,2011-06-10T00:00:00,Faculty,M01.526.339
21829271,2011-06-10T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21719204,2011-06-12T00:00:00,Adolescent,M01.060.057
21719204,2011-06-12T00:00:00,Child,M01.060.406
21719204,2011-06-12T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21719204,2011-06-12T00:00:00,Risk Factors,E05.318.740.600.800.725
21719204,2011-06-12T00:00:00,Risk Factors,N05.715.350.200.700
21719204,2011-06-12T00:00:00,Risk Factors,N05.715.360.750.625.700.700
21719204,2011-06-12T00:00:00,Risk Factors,N06.850.490.625.750
21719204,2011-06-12T00:00:00,Risk Factors,N06.850.520.830.600.800.725
21719204,2011-06-12T00:00:00,Sex Offenses,I01.198.240.748
21719204,2011-06-12T00:00:00,Smoking,F01.145.466.753
21719204,2011-06-12T00:00:00,"Stress Disorders, Post-Traumatic",F03.080.931.500
21719204,2011-06-12T00:00:00,United States,Z01.107.567.875
21719204,2011-06-12T00:00:00,Violence,I01.198.240.856
21719204,2011-06-12T00:00:00,Violence,I01.880.735.900
21801867,2011-06-12T00:00:00,Acyl-CoA Oxidase,D08.811.682.660.150.200
21801867,2011-06-12T00:00:00,Acyl-CoA Oxidase,D12.776.331.149
21801867,2011-06-12T00:00:00,Animals,B01.050
21801867,2011-06-12T00:00:00,DNA-Binding Proteins,D12.776.260
21801867,2011-06-12T00:00:00,Endoplasmic Reticulum,A11.284.430.214.190.875.248
21801867,2011-06-12T00:00:00,Gene Expression Regulation,G05.355.315
21801867,2011-06-12T00:00:00,Hepatocytes,A11.436.348
21801867,2011-06-12T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21801867,2011-06-12T00:00:00,Liver,A03.620
21801867,2011-06-12T00:00:00,Liver Neoplasms,C04.588.274.623
21801867,2011-06-12T00:00:00,Liver Neoplasms,C06.301.623
21801867,2011-06-12T00:00:00,Liver Neoplasms,C06.552.697
21801867,2011-06-12T00:00:00,"Models, Biological",E05.599.395
21801867,2011-06-12T00:00:00,Neoplasm Proteins,D12.776.624
21666724,2011-06-13T00:00:00,Breast Neoplasms,C04.588.180
21666724,2011-06-13T00:00:00,Breast Neoplasms,C17.800.090.500
21666724,2011-06-13T00:00:00,"Carcinoma, Squamous Cell",C04.557.470.200.400
21666724,2011-06-13T00:00:00,"Carcinoma, Squamous Cell",C04.557.470.700.400
21666724,2011-06-13T00:00:00,Carrier Proteins,D12.776.157
21666724,2011-06-13T00:00:00,Cell Proliferation,G04.299.233.750
21666724,2011-06-13T00:00:00,Cell Proliferation,G07.700.320.249.410.750
21666724,2011-06-13T00:00:00,"Cell Transformation, Neoplastic",C04.697.152
21666724,2011-06-13T00:00:00,"Cell Transformation, Neoplastic",C23.550.727.152
21666724,2011-06-13T00:00:00,Cyclin-Dependent Kinase Inhibitor p16,D12.644.360.225.200
21666724,2011-06-13T00:00:00,Cyclin-Dependent Kinase Inhibitor p16,D12.776.167.187.200
21666724,2011-06-13T00:00:00,Cyclin-Dependent Kinase Inhibitor p16,D12.776.476.225.200
21666724,2011-06-13T00:00:00,Cyclin-Dependent Kinase Inhibitor p16,D12.776.624.776.355.200
21666724,2011-06-13T00:00:00,Cyclin-Dependent Kinase Inhibitor p21,D12.644.360.225.500
21666724,2011-06-13T00:00:00,Cyclin-Dependent Kinase Inhibitor p21,D12.776.167.187.500
21666724,2011-06-13T00:00:00,Cyclin-Dependent Kinase Inhibitor p21,D12.776.476.225.500
21666724,2011-06-13T00:00:00,Cyclin-Dependent Kinase Inhibitor p21,D12.776.624.776.355.500
21666724,2011-06-13T00:00:00,Cyclin-Dependent Kinase Inhibitor p27,D12.644.360.225.600
21666724,2011-06-13T00:00:00,Cyclin-Dependent Kinase Inhibitor p27,D12.776.167.187.600
21666724,2011-06-13T00:00:00,Cyclin-Dependent Kinase Inhibitor p27,D12.776.476.225.600
21666724,2011-06-13T00:00:00,Cyclin-Dependent Kinase Inhibitor p27,D12.776.624.776.355.600
21666724,2011-06-13T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21666724,2011-06-13T00:00:00,Membrane Proteins,D12.776.543
21666724,2011-06-13T00:00:00,Ubiquitin-Protein Ligases,D08.811.464.938.750
21699989,2011-06-13T00:00:00,Adult,M01.060.116
21699989,2011-06-13T00:00:00,Algorithms,G17.035
21699989,2011-06-13T00:00:00,Algorithms,L01.224.050
21699989,2011-06-13T00:00:00,Brain,A08.186.211
21699989,2011-06-13T00:00:00,"Data Interpretation, Statistical",E05.245.380
21699989,2011-06-13T00:00:00,"Data Interpretation, Statistical",E05.318.740.300
21699989,2011-06-13T00:00:00,"Data Interpretation, Statistical",L01.700.508.190.380
21699989,2011-06-13T00:00:00,"Data Interpretation, Statistical",N05.715.360.750.300
21699989,2011-06-13T00:00:00,"Data Interpretation, Statistical",N06.850.520.830.300
21699989,2011-06-13T00:00:00,Diffusion Tensor Imaging,E01.370.350.500.150.500
21699989,2011-06-13T00:00:00,Diffusion Tensor Imaging,E01.370.376.224
21699989,2011-06-13T00:00:00,Diffusion Tensor Imaging,E05.278
21699989,2011-06-13T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21699989,2011-06-13T00:00:00,"Image Processing, Computer-Assisted",L01.224.308
21699989,2011-06-13T00:00:00,"Models, Neurological",E05.599.395.642
21699989,2011-06-13T00:00:00,Normal Distribution,E05.318.740.994.500
21699989,2011-06-13T00:00:00,Normal Distribution,G17.820.500
21699989,2011-06-13T00:00:00,Normal Distribution,N05.715.360.750.750.565
21699989,2011-06-13T00:00:00,Normal Distribution,N06.850.520.830.994.500
21658565,2011-06-14T00:00:00,Adolescent,M01.060.057
21658565,2011-06-14T00:00:00,"Anastomosis, Surgical",E04.035
21658565,2011-06-14T00:00:00,Child,M01.060.406
21658565,2011-06-14T00:00:00,Fontan Procedure,E04.035.410.295
21658565,2011-06-14T00:00:00,Fontan Procedure,E04.100.376.410.295
21658565,2011-06-14T00:00:00,Fontan Procedure,E04.928.220.370.295
21658565,2011-06-14T00:00:00,Heart Atria,A07.541.358
21658565,2011-06-14T00:00:00,"Heart Defects, Congenital",C14.240.400
21658565,2011-06-14T00:00:00,"Heart Defects, Congenital",C14.280.400
21658565,2011-06-14T00:00:00,"Heart Defects, Congenital",C16.131.240.400
21658565,2011-06-14T00:00:00,Hemodynamics,G09.330.190.400
21658565,2011-06-14T00:00:00,Hemodynamics,G09.330.380
21658565,2011-06-14T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21658565,2011-06-14T00:00:00,Length of Stay,E02.760.400.480
21658565,2011-06-14T00:00:00,Length of Stay,N02.421.585.400.480
21658565,2011-06-14T00:00:00,Postoperative Care,E02.760.722.700
21658565,2011-06-14T00:00:00,Postoperative Care,E04.624
21658565,2011-06-14T00:00:00,Postoperative Care,N02.421.585.722.700
21658565,2011-06-14T00:00:00,Pulmonary Veins,A07.231.908.713
21658565,2011-06-14T00:00:00,Risk Assessment,E05.318.740.600.800.715
21658565,2011-06-14T00:00:00,Risk Assessment,N04.452.871.715
21658565,2011-06-14T00:00:00,Risk Assessment,N05.715.360.750.625.700.690
21658565,2011-06-14T00:00:00,Risk Assessment,N06.850.505.715
21658565,2011-06-14T00:00:00,Risk Assessment,N06.850.520.830.600.800.715
21658565,2011-06-14T00:00:00,Treatment Outcome,E01.789.800
21658565,2011-06-14T00:00:00,Treatment Outcome,N04.761.559.590.800
21658565,2011-06-14T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21665515,2011-06-14T00:00:00,Adolescent,M01.060.057
21665515,2011-06-14T00:00:00,Adult,M01.060.116
21665515,2011-06-14T00:00:00,Aged,M01.060.116.100
21665515,2011-06-14T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21665515,2011-06-14T00:00:00,Middle Aged,M01.060.116.630
21665515,2011-06-14T00:00:00,Obesity,C18.654.726.500
21665515,2011-06-14T00:00:00,Obesity,C23.888.144.699.500
21665515,2011-06-14T00:00:00,Obesity,E01.370.600.115.100.160.120.699.500
21665515,2011-06-14T00:00:00,Obesity,G07.100.100.160.120.699.500
21665515,2011-06-14T00:00:00,Rural Population,N01.600.725
21665515,2011-06-14T00:00:00,United States,Z01.107.567.875
21665515,2011-06-14T00:00:00,Young Adult,M01.060.116.815
21670755,2011-06-14T00:00:00,Animals,B01.050
21670755,2011-06-14T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21670755,2011-06-14T00:00:00,Kidney Neoplasms,C04.588.945.947.535
21670755,2011-06-14T00:00:00,Kidney Neoplasms,C12.758.820.750
21670755,2011-06-14T00:00:00,Kidney Neoplasms,C12.777.419.473
21670755,2011-06-14T00:00:00,Kidney Neoplasms,C13.351.937.820.535
21670755,2011-06-14T00:00:00,Kidney Neoplasms,C13.351.968.419.473
21670755,2011-06-14T00:00:00,Prostatic Neoplasms,C04.588.945.440.770
21670755,2011-06-14T00:00:00,Prostatic Neoplasms,C12.294.260.750
21670755,2011-06-14T00:00:00,Prostatic Neoplasms,C12.294.565.625
21670755,2011-06-14T00:00:00,Prostatic Neoplasms,C12.758.409.750
21670755,2011-06-14T00:00:00,"Receptors, TNF-Related Apoptosis-Inducing Ligand",D12.776.543.750.073.600
21670755,2011-06-14T00:00:00,"Receptors, TNF-Related Apoptosis-Inducing Ligand",D12.776.543.750.705.852.760.396
21670755,2011-06-14T00:00:00,Recombinant Proteins,D12.776.828
21670755,2011-06-14T00:00:00,Signal Transduction,G02.111.087.800
21670755,2011-06-14T00:00:00,Signal Transduction,G02.149.115.800
21670755,2011-06-14T00:00:00,Signal Transduction,G04.299.880
21670755,2011-06-14T00:00:00,TNF-Related Apoptosis-Inducing Ligand,D12.644.276.374.750.625
21670755,2011-06-14T00:00:00,TNF-Related Apoptosis-Inducing Ligand,D12.644.276.972.625
21670755,2011-06-14T00:00:00,TNF-Related Apoptosis-Inducing Ligand,D12.776.467.374.750.625
21670755,2011-06-14T00:00:00,TNF-Related Apoptosis-Inducing Ligand,D12.776.467.972.625
21670755,2011-06-14T00:00:00,TNF-Related Apoptosis-Inducing Ligand,D23.529.374.750.625
21670755,2011-06-14T00:00:00,TNF-Related Apoptosis-Inducing Ligand,D23.529.972.625
21670755,2011-06-14T00:00:00,Urinary Bladder Neoplasms,C04.588.945.947.960
21670755,2011-06-14T00:00:00,Urinary Bladder Neoplasms,C12.758.820.968
21670755,2011-06-14T00:00:00,Urinary Bladder Neoplasms,C12.777.829.813
21670755,2011-06-14T00:00:00,Urinary Bladder Neoplasms,C13.351.937.820.945
21670755,2011-06-14T00:00:00,Urinary Bladder Neoplasms,C13.351.968.829.707
21671132,2011-06-14T00:00:00,Aged,M01.060.116.100
21671132,2011-06-14T00:00:00,Blood Pressure,E01.370.600.875.249
21671132,2011-06-14T00:00:00,Blood Pressure,G09.330.380.076
21671132,2011-06-14T00:00:00,"Diabetes Mellitus, Type 2",C18.452.394.750.149
21671132,2011-06-14T00:00:00,"Diabetes Mellitus, Type 2",C19.246.300
21671132,2011-06-14T00:00:00,Ethnic Groups,M01.686.754
21671132,2011-06-14T00:00:00,Ethnic Groups,N01.224.317
21671132,2011-06-14T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21671132,2011-06-14T00:00:00,Hypertension,C14.907.489
21671132,2011-06-14T00:00:00,Risk Factors,E05.318.740.600.800.725
21671132,2011-06-14T00:00:00,Risk Factors,N05.715.350.200.700
21671132,2011-06-14T00:00:00,Risk Factors,N05.715.360.750.625.700.700
21671132,2011-06-14T00:00:00,Risk Factors,N06.850.490.625.750
21671132,2011-06-14T00:00:00,Risk Factors,N06.850.520.830.600.800.725
21671132,2011-06-14T00:00:00,United States,Z01.107.567.875
21671132,2011-06-14T00:00:00,United States Department of Veterans Affairs,I01.409.137.500.700
21671132,2011-06-14T00:00:00,United States Department of Veterans Affairs,N03.540.348.500.500.700
21671132,2011-06-14T00:00:00,Veterans,M01.930
21672161,2011-06-14T00:00:00,Ethnic Groups,M01.686.754
21672161,2011-06-14T00:00:00,Ethnic Groups,N01.224.317
21672161,2011-06-14T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21672161,2011-06-14T00:00:00,"Kidney Failure, Chronic",C12.777.419.780.500.602
21672161,2011-06-14T00:00:00,"Kidney Failure, Chronic",C12.777.419.780.750.500
21672161,2011-06-14T00:00:00,"Kidney Failure, Chronic",C13.351.968.419.780.500.602
21672161,2011-06-14T00:00:00,"Kidney Failure, Chronic",C13.351.968.419.780.750.500
21672161,2011-06-14T00:00:00,Kidney Transplantation,E02.870.500
21672161,2011-06-14T00:00:00,Kidney Transplantation,E04.936.450.485
21672161,2011-06-14T00:00:00,Kidney Transplantation,E04.950.774.400
21672161,2011-06-14T00:00:00,Living Donors,M01.898.656
21672161,2011-06-14T00:00:00,Sex Factors,N05.715.350.675
21672161,2011-06-14T00:00:00,Sex Factors,N06.850.490.875
21673072,2011-06-14T00:00:00,Animals,B01.050
21673072,2011-06-14T00:00:00,"Antibodies, Monoclonal",D12.776.124.486.485.114.224
21673072,2011-06-14T00:00:00,"Antibodies, Monoclonal",D12.776.124.790.651.114.224
21673072,2011-06-14T00:00:00,"Antibodies, Monoclonal",D12.776.377.715.548.114.224
21673072,2011-06-14T00:00:00,Cell Proliferation,G04.299.233.750
21673072,2011-06-14T00:00:00,Cell Proliferation,G07.700.320.249.410.750
21673072,2011-06-14T00:00:00,Cytokines,D12.644.276.374
21673072,2011-06-14T00:00:00,Cytokines,D12.776.467.374
21673072,2011-06-14T00:00:00,Cytokines,D23.529.374
21673072,2011-06-14T00:00:00,Flow Cytometry,E05.196.712.516.600.240.350
21673072,2011-06-14T00:00:00,Flow Cytometry,E05.200.500.386.350
21673072,2011-06-14T00:00:00,"Mice, Inbred DBA",B01.050.050.157.520.460
21673072,2011-06-14T00:00:00,"Mice, Inbred DBA",B01.050.050.199.520.520.460
21673072,2011-06-14T00:00:00,"Mice, Inbred DBA",B01.050.150.900.649.865.635.505.500.400.460
21673072,2011-06-14T00:00:00,"Receptor, Cannabinoid, CB1",D12.776.543.750.100.125.100
21673072,2011-06-14T00:00:00,"Receptor, Cannabinoid, CB2",D12.776.543.750.100.125.200
21673072,2011-06-14T00:00:00,Spleen,A10.549.700
21673072,2011-06-14T00:00:00,Spleen,A15.382.520.604.700
21673072,2011-06-14T00:00:00,T-Lymphocytes,A11.118.637.555.567.569
21673072,2011-06-14T00:00:00,T-Lymphocytes,A15.145.229.637.555.567.569
21673072,2011-06-14T00:00:00,T-Lymphocytes,A15.382.490.555.567.569
21673072,2011-06-14T00:00:00,Weight Loss,C23.888.144.243.963
21673072,2011-06-14T00:00:00,Weight Loss,G07.700.320.249.314.120.200.963
21478816,2011-06-15T00:00:00,Adult,M01.060.116
21478816,2011-06-15T00:00:00,Aged,M01.060.116.100
21478816,2011-06-15T00:00:00,Graft Survival,G12.425.901.545.340
21478816,2011-06-15T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21478816,2011-06-15T00:00:00,Immunosuppression,E02.095.465.425.450
21478816,2011-06-15T00:00:00,Immunosuppression,E05.478.610
21478816,2011-06-15T00:00:00,Kidney Transplantation,E02.870.500
21478816,2011-06-15T00:00:00,Kidney Transplantation,E04.936.450.485
21478816,2011-06-15T00:00:00,Kidney Transplantation,E04.950.774.400
21478816,2011-06-15T00:00:00,Liver Transplantation,E04.210.650
21478816,2011-06-15T00:00:00,Liver Transplantation,E04.936.450.490
21478816,2011-06-15T00:00:00,Liver Transplantation,E04.936.580.490
21478816,2011-06-15T00:00:00,Middle Aged,M01.060.116.630
21478816,2011-06-15T00:00:00,Treatment Outcome,E01.789.800
21478816,2011-06-15T00:00:00,Treatment Outcome,N04.761.559.590.800
21478816,2011-06-15T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21618476,2011-06-15T00:00:00,Adsorption,G02.149.047
21618476,2011-06-15T00:00:00,Adsorption,G02.149.767.029
21618476,2011-06-15T00:00:00,Adsorption,G02.842.750.029
21618476,2011-06-15T00:00:00,Animals,B01.050
21618476,2011-06-15T00:00:00,Anion Exchange Resins,D27.720.470.420.050
21618476,2011-06-15T00:00:00,Biotechnology,H01.158.550
21618476,2011-06-15T00:00:00,Biotechnology,J01.897.120
21618476,2011-06-15T00:00:00,"Chromatography, Ion Exchange",E05.196.181.400.383
21618476,2011-06-15T00:00:00,DNA,D13.444.308
21618476,2011-06-15T00:00:00,Membranes,A10.615
21618476,2011-06-15T00:00:00,Nanostructures,J01.637.512
21618476,2011-06-15T00:00:00,Polymers,D05.750
21618476,2011-06-15T00:00:00,Polymers,D25.720
21618476,2011-06-15T00:00:00,Polymers,J01.637.051.720
21667891,2011-06-15T00:00:00,Bone Density Conservation Agents,D27.505.696.242
21667891,2011-06-15T00:00:00,Evidence-Based Medicine,H02.249.750
21667891,2011-06-15T00:00:00,Evidence-Based Medicine,H02.403.200.400
21667891,2011-06-15T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21667891,2011-06-15T00:00:00,Life Style,F01.829.458
21667891,2011-06-15T00:00:00,Osteoporosis,C05.116.198.579
21667891,2011-06-15T00:00:00,Patient Education as Topic,I02.233.332.500
21667891,2011-06-15T00:00:00,Patient Education as Topic,N02.421.143.827.407.680
21667891,2011-06-15T00:00:00,Patient Education as Topic,N02.421.726.407.680
21673747,2011-06-15T00:00:00,African Americans,M01.686.508.100.100
21673747,2011-06-15T00:00:00,African Americans,M01.686.754.100
21673747,2011-06-15T00:00:00,Genome-Wide Association Study,E05.318.416.249
21673747,2011-06-15T00:00:00,Genome-Wide Association Study,E05.318.780.392
21673747,2011-06-15T00:00:00,Genome-Wide Association Study,E05.393.385.500
21673747,2011-06-15T00:00:00,Genome-Wide Association Study,E05.393.522.500
21673747,2011-06-15T00:00:00,Genome-Wide Association Study,E05.393.760.640.500
21673747,2011-06-15T00:00:00,Genome-Wide Association Study,N06.850.520.445.392
21673747,2011-06-15T00:00:00,Genome-Wide Association Study,N06.850.520.470.500
21673747,2011-06-15T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21673747,2011-06-15T00:00:00,"Models, Genetic",E05.599.395.397
21673747,2011-06-15T00:00:00,"Models, Statistical",E05.318.740.500
21673747,2011-06-15T00:00:00,"Models, Statistical",E05.599.835
21673747,2011-06-15T00:00:00,"Models, Statistical",N05.715.360.750.530
21673747,2011-06-15T00:00:00,"Models, Statistical",N06.850.520.830.500
21676451,2011-06-15T00:00:00,"Child, Preschool",M01.060.406.448
21676451,2011-06-15T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21676451,2011-06-15T00:00:00,Magnetic Resonance Imaging,E01.370.350.500
21676451,2011-06-15T00:00:00,Magnetic Resonance Imaging,E01.370.350.825.500
21679990,2011-06-15T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21679990,2011-06-15T00:00:00,Nephrectomy,E04.950.774.435
21679990,2011-06-15T00:00:00,Postoperative Complications,C23.550.767
21679990,2011-06-15T00:00:00,Robotics,H01.671.293.643
21679990,2011-06-15T00:00:00,Robotics,J01.897.104.834
21679990,2011-06-15T00:00:00,Robotics,L01.224.065.630
21693717,2011-06-15T00:00:00,Child,M01.060.406
21693717,2011-06-15T00:00:00,Cystic Fibrosis,C06.689.202
21693717,2011-06-15T00:00:00,Cystic Fibrosis,C08.381.187
21693717,2011-06-15T00:00:00,Cystic Fibrosis,C16.320.190
21693717,2011-06-15T00:00:00,Cystic Fibrosis,C16.614.213
21693717,2011-06-15T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22071054,2011-06-15T00:00:00,Birth Weight,C23.888.144.186
22071054,2011-06-15T00:00:00,Birth Weight,E01.370.600.115.100.160.120.186
22071054,2011-06-15T00:00:00,Birth Weight,E05.041.124.160.750.149
22071054,2011-06-15T00:00:00,Birth Weight,G07.100.100.160.120.186
22071054,2011-06-15T00:00:00,Birth Weight,G07.700.320.249.314.120.186
22071054,2011-06-15T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22071054,2011-06-15T00:00:00,"Infant, Newborn",M01.060.703.520
22071054,2011-06-15T00:00:00,Pregnancy,G08.686.785.760.769
22071054,2011-06-15T00:00:00,"Ultrasonography, Prenatal",E01.370.350.850.865
22071054,2011-06-15T00:00:00,"Ultrasonography, Prenatal",E01.370.378.630.865
21615738,2011-06-17T00:00:00,Animals,B01.050
21615738,2011-06-17T00:00:00,Antiparkinson Agents,D27.505.954.427.090.050
21615738,2011-06-17T00:00:00,Central Nervous System,A08.186
21615738,2011-06-17T00:00:00,"Disease Models, Animal",C22.232
21615738,2011-06-17T00:00:00,"Disease Models, Animal",E05.598.500
21615738,2011-06-17T00:00:00,"Disease Models, Animal",E05.599.395.080
21615738,2011-06-17T00:00:00,Dogs,B01.050.150.900.649.147.153.200
21615738,2011-06-17T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21615738,2011-06-17T00:00:00,Parkinson Disease,C10.228.140.079.862.500
21615738,2011-06-17T00:00:00,Parkinson Disease,C10.228.662.600.400
21615738,2011-06-17T00:00:00,Parkinson Disease,C10.574.812
21615738,2011-06-17T00:00:00,Rats,B01.050.150.900.649.865.635.505.700
21615738,2011-06-17T00:00:00,Spinal Cord,A08.186.854
21615738,2011-06-17T00:00:00,Substantia Nigra,A08.186.211.132.659.822.731
21615738,2011-06-17T00:00:00,Substantia Nigra,A08.186.211.653.822.731
21678080,2011-06-17T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21678080,2011-06-17T00:00:00,Iron,D01.268.556.412
21678080,2011-06-17T00:00:00,Iron,D01.268.956.287
21678080,2011-06-17T00:00:00,Iron,D01.552.544.412
21678080,2011-06-17T00:00:00,"Models, Molecular",E05.599.595
21678080,2011-06-17T00:00:00,Nickel,D01.268.556.607
21678080,2011-06-17T00:00:00,Nickel,D01.268.956.625
21678080,2011-06-17T00:00:00,Nickel,D01.552.544.607
21678080,2011-06-17T00:00:00,Protein Conformation,G02.111.570.790.709
21678080,2011-06-17T00:00:00,Transferrin,D12.776.124.050.800
21678080,2011-06-17T00:00:00,Transferrin,D12.776.124.790.223.839
21678080,2011-06-17T00:00:00,Transferrin,D12.776.157.427.500
21678080,2011-06-17T00:00:00,Transferrin,D12.776.377.715.182.839
21678080,2011-06-17T00:00:00,Transferrin,D12.776.556.579.500
21681615,2011-06-17T00:00:00,Cardiology,H02.403.429.163
21681615,2011-06-17T00:00:00,"Databases, Factual",L01.470.750.750
21681615,2011-06-17T00:00:00,"Databases, Factual",L01.700.508.300.188.400
21681615,2011-06-17T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21683344,2011-06-17T00:00:00,Adult,M01.060.116
21683344,2011-06-17T00:00:00,Brain,A08.186.211
21683344,2011-06-17T00:00:00,Case-Control Studies,E05.318.760.500.500
21683344,2011-06-17T00:00:00,Case-Control Studies,N05.715.360.775.175.200
21683344,2011-06-17T00:00:00,Case-Control Studies,N06.850.520.450.500.500
21683344,2011-06-17T00:00:00,Genetic Predisposition to Disease,C23.550.291.687.500
21683344,2011-06-17T00:00:00,Genetic Predisposition to Disease,G05.380.355
21683344,2011-06-17T00:00:00,Genetic Variation,G05.365
21683344,2011-06-17T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21683344,2011-06-17T00:00:00,Molecular Structure,G02.111.570
21683344,2011-06-17T00:00:00,Molecular Structure,G02.575
21683344,2011-06-17T00:00:00,Molecular Structure,G02.842.575
21683344,2011-06-17T00:00:00,"Polymorphism, Single Nucleotide",G05.365.795.598
21683344,2011-06-17T00:00:00,Pyridines,D03.383.725
21683344,2011-06-17T00:00:00,"Receptors, Nicotinic",D12.776.543.750.720.360.550
21683344,2011-06-17T00:00:00,Tobacco Use Disorder,C21.739.912
21683344,2011-06-17T00:00:00,Tobacco Use Disorder,F03.900.912
21683344,2011-06-17T00:00:00,"Tomography, Emission-Computed, Single-Photon",E01.370.350.350.800.800
21683344,2011-06-17T00:00:00,"Tomography, Emission-Computed, Single-Photon",E01.370.350.600.350.800.800
21683344,2011-06-17T00:00:00,"Tomography, Emission-Computed, Single-Photon",E01.370.350.710.800.800
21683344,2011-06-17T00:00:00,"Tomography, Emission-Computed, Single-Photon",E01.370.350.825.800.800
21683344,2011-06-17T00:00:00,"Tomography, Emission-Computed, Single-Photon",E01.370.384.730.800.800
21685428,2011-06-17T00:00:00,Aged,M01.060.116.100
21685428,2011-06-17T00:00:00,Bereavement,F01.470.142
21685428,2011-06-17T00:00:00,Cognitive Therapy,F04.754.137.428
21685428,2011-06-17T00:00:00,"Depressive Disorder, Major",F03.600.300.375
21685428,2011-06-17T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21685428,2011-06-17T00:00:00,"Interview, Psychological",F04.669.599
21685428,2011-06-17T00:00:00,Middle Aged,M01.060.116.630
21685428,2011-06-17T00:00:00,Outcome Assessment (Health Care),N04.761.559.590
21685428,2011-06-17T00:00:00,Outcome Assessment (Health Care),N05.715.360.575.575
21685428,2011-06-17T00:00:00,"Stress Disorders, Post-Traumatic",F03.080.931.500
21685428,2011-06-17T00:00:00,Time Factors,G01.910.857
21681395,2011-06-18T00:00:00,Adolescent,M01.060.057
21681395,2011-06-18T00:00:00,Adult,M01.060.116
21681395,2011-06-18T00:00:00,Aged,M01.060.116.100
21681395,2011-06-18T00:00:00,Air Pollutants,D27.888.284.101
21681395,2011-06-18T00:00:00,Child,M01.060.406
21681395,2011-06-18T00:00:00,"Child, Preschool",M01.060.406.448
21681395,2011-06-18T00:00:00,Fluorides,D01.248.497.158.380
21681395,2011-06-18T00:00:00,Fluorides,D01.303.350.300
21681395,2011-06-18T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21681395,2011-06-18T00:00:00,Middle Aged,M01.060.116.630
21681395,2011-06-18T00:00:00,Rural Population,N01.600.725
21681395,2011-06-18T00:00:00,"Water Pollutants, Chemical",D27.888.284.903.655
21681395,2011-06-18T00:00:00,Young Adult,M01.060.116.815
21690466,2011-06-20T00:00:00,Colorectal Neoplasms,C04.588.274.476.411.307
21690466,2011-06-20T00:00:00,Colorectal Neoplasms,C06.301.371.411.307
21690466,2011-06-20T00:00:00,Colorectal Neoplasms,C06.405.249.411.307
21690466,2011-06-20T00:00:00,Colorectal Neoplasms,C06.405.469.158.356
21690466,2011-06-20T00:00:00,Colorectal Neoplasms,C06.405.469.491.307
21690466,2011-06-20T00:00:00,Colorectal Neoplasms,C06.405.469.860.180
21690466,2011-06-20T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21690466,2011-06-20T00:00:00,Individualized Medicine,E02.574
21690466,2011-06-20T00:00:00,Individualized Medicine,H02.403.200.700
21690466,2011-06-20T00:00:00,Neoplasm Invasiveness,C04.697.645
21690466,2011-06-20T00:00:00,Neoplasm Invasiveness,C23.550.727.645
21690466,2011-06-20T00:00:00,Neoplasm Staging,E01.370.550
21690466,2011-06-20T00:00:00,Neoplastic Stem Cells,A11.872.650
21690466,2011-06-20T00:00:00,Patient Selection,E05.581.500.653
21690466,2011-06-20T00:00:00,Patient Selection,N04.590.731
21690466,2011-06-20T00:00:00,"Tumor Markers, Biological",D23.101.840
21716499,2011-06-20T00:00:00,Algorithms,G17.035
21716499,2011-06-20T00:00:00,Algorithms,L01.224.050
21716499,2011-06-20T00:00:00,Computer Simulation,L01.224.160
21716499,2011-06-20T00:00:00,Crystallization,E05.196.300
21716499,2011-06-20T00:00:00,Crystallization,G02.149.767.505
21716499,2011-06-20T00:00:00,Crystallization,G02.842.750.505
21716499,2011-06-20T00:00:00,Fiber Optic Technology,H01.671.617.249
21716499,2011-06-20T00:00:00,"Models, Theoretical",E05.599
21716499,2011-06-20T00:00:00,Refractometry,E05.196.808
21716499,2011-06-20T00:00:00,Refractometry,H01.671.617.755
21618475,2011-06-21T00:00:00,Adsorption,G02.149.047
21618475,2011-06-21T00:00:00,Adsorption,G02.149.767.029
21618475,2011-06-21T00:00:00,Adsorption,G02.842.750.029
21618475,2011-06-21T00:00:00,Anion Exchange Resins,D27.720.470.420.050
21618475,2011-06-21T00:00:00,Biotechnology,H01.158.550
21618475,2011-06-21T00:00:00,Biotechnology,J01.897.120
21618475,2011-06-21T00:00:00,"Chromatography, Ion Exchange",E05.196.181.400.383
21618475,2011-06-21T00:00:00,Immunoglobulin G,D12.776.124.486.485.114.619.393
21618475,2011-06-21T00:00:00,Immunoglobulin G,D12.776.124.790.651.114.619.393
21618475,2011-06-21T00:00:00,Immunoglobulin G,D12.776.377.715.548.114.619.393
21618475,2011-06-21T00:00:00,Membranes,A10.615
21618475,2011-06-21T00:00:00,Nanostructures,J01.637.512
21618475,2011-06-21T00:00:00,Polymers,D05.750
21618475,2011-06-21T00:00:00,Polymers,D25.720
21618475,2011-06-21T00:00:00,Polymers,J01.637.051.720
21618475,2011-06-21T00:00:00,Proteins,D12.776
21618475,2011-06-21T00:00:00,"Serum Albumin, Bovine",D12.776.034.841.540
21618475,2011-06-21T00:00:00,"Serum Albumin, Bovine",D12.776.124.727.540
21690592,2011-06-21T00:00:00,Aged,M01.060.116.100
21690592,2011-06-21T00:00:00,Blood Pressure,E01.370.600.875.249
21690592,2011-06-21T00:00:00,Blood Pressure,G09.330.380.076
21690592,2011-06-21T00:00:00,"Blood Pressure Monitoring, Ambulatory",E01.370.370.140.100
21690592,2011-06-21T00:00:00,"Blood Pressure Monitoring, Ambulatory",E01.370.520.500.100
21690592,2011-06-21T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21690592,2011-06-21T00:00:00,Hypertension,C14.907.489
21690592,2011-06-21T00:00:00,Middle Aged,M01.060.116.630
21690592,2011-06-21T00:00:00,Probability,E05.318.740.600
21690592,2011-06-21T00:00:00,Probability,G17.680
21690592,2011-06-21T00:00:00,Probability,N05.715.360.750.625
21690592,2011-06-21T00:00:00,Probability,N06.850.520.830.600
21690592,2011-06-21T00:00:00,"Quality Assurance, Health Care",N04.761.700
21690592,2011-06-21T00:00:00,"Quality Assurance, Health Care",N05.700
21691839,2011-06-21T00:00:00,Chlorella,B01.040.080.469
21691839,2011-06-21T00:00:00,Glucose,D09.546.359.448
21691839,2011-06-21T00:00:00,Lipids,D10
21691839,2011-06-21T00:00:00,Oxygen,D01.268.185.550
21691839,2011-06-21T00:00:00,Oxygen,D01.362.670
21692640,2011-06-21T00:00:00,Adult,M01.060.116
21692640,2011-06-21T00:00:00,Face,A01.456.505
21692640,2011-06-21T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21692640,2011-06-21T00:00:00,Treatment Outcome,E01.789.800
21692640,2011-06-21T00:00:00,Treatment Outcome,N04.761.559.590.800
21692640,2011-06-21T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21692640,2011-06-21T00:00:00,Young Adult,M01.060.116.815
21693660,2011-06-21T00:00:00,Artifacts,E05.047
21693660,2011-06-21T00:00:00,Calcinosis,C18.452.174.130
21693660,2011-06-21T00:00:00,Contrast Media,D27.720.259
21693660,2011-06-21T00:00:00,Coronary Angiography,E01.370.350.700.060.200
21693660,2011-06-21T00:00:00,Coronary Angiography,E01.370.370.050.200
21693660,2011-06-21T00:00:00,Coronary Angiography,E01.370.370.380.200
21693660,2011-06-21T00:00:00,Coronary Stenosis,C14.280.647.250.285
21693660,2011-06-21T00:00:00,Coronary Stenosis,C14.907.585.250.285
21693660,2011-06-21T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21693660,2011-06-21T00:00:00,Middle Aged,M01.060.116.630
21693660,2011-06-21T00:00:00,"Radiographic Image Interpretation, Computer-Assisted",E01.158.600.680
21693660,2011-06-21T00:00:00,"Radiographic Image Interpretation, Computer-Assisted",E01.370.350.350.700
21693660,2011-06-21T00:00:00,"Radiographic Image Interpretation, Computer-Assisted",E01.370.350.700.705
21693660,2011-06-21T00:00:00,"Radiographic Image Interpretation, Computer-Assisted",L01.700.508.100.158.600.680
21693660,2011-06-21T00:00:00,"Tomography, X-Ray Computed",E01.370.350.350.810
21693660,2011-06-21T00:00:00,"Tomography, X-Ray Computed",E01.370.350.600.350.700.810
21693660,2011-06-21T00:00:00,"Tomography, X-Ray Computed",E01.370.350.700.700.810
21693660,2011-06-21T00:00:00,"Tomography, X-Ray Computed",E01.370.350.700.810.810
21693660,2011-06-21T00:00:00,"Tomography, X-Ray Computed",E01.370.350.825.810.810
21695291,2011-06-21T00:00:00,Animals,B01.050
21695291,2011-06-21T00:00:00,Diagnostic Imaging,E01.370.350
21695291,2011-06-21T00:00:00,Hydrogen Peroxide,D01.248.497.158.685.750.424
21695291,2011-06-21T00:00:00,Hydrogen Peroxide,D01.339.431.374.424
21695291,2011-06-21T00:00:00,Hydrogen Peroxide,D01.650.550.750.400
21695291,2011-06-21T00:00:00,Luminescent Measurements,E05.196.712.516
21695291,2011-06-21T00:00:00,Silver,D01.268.556.812
21695291,2011-06-21T00:00:00,Silver,D01.268.956.843
21695291,2011-06-21T00:00:00,Silver,D01.552.544.812
21695291,2011-06-21T00:00:00,Swine,B01.050.150.900.649.077.880
21695291,2011-06-21T00:00:00,X-Rays,G01.201.875.750.918
21691942,2011-06-22T00:00:00,Adult,M01.060.116
21691942,2011-06-22T00:00:00,Brain,A08.186.211
21691942,2011-06-22T00:00:00,Brain Mapping,E01.370.350.086
21691942,2011-06-22T00:00:00,Brain Mapping,E01.370.376.149
21691942,2011-06-22T00:00:00,Brain Mapping,E05.132
21691942,2011-06-22T00:00:00,Case-Control Studies,E05.318.760.500.500
21691942,2011-06-22T00:00:00,Case-Control Studies,N05.715.360.775.175.200
21691942,2011-06-22T00:00:00,Case-Control Studies,N06.850.520.450.500.500
21691942,2011-06-22T00:00:00,Cocaine-Related Disorders,C21.739.300
21691942,2011-06-22T00:00:00,Cocaine-Related Disorders,F03.900.300
21691942,2011-06-22T00:00:00,Cognition Disorders,F03.087.250
21691942,2011-06-22T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21691942,2011-06-22T00:00:00,Magnetic Resonance Imaging,E01.370.350.500
21691942,2011-06-22T00:00:00,Magnetic Resonance Imaging,E01.370.350.825.500
21691942,2011-06-22T00:00:00,Time Factors,G01.910.857
21695658,2011-06-22T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21695658,2011-06-22T00:00:00,Stroke,C10.228.140.300.775
21695658,2011-06-22T00:00:00,Stroke,C14.907.253.855
21697543,2011-06-22T00:00:00,Adult,M01.060.116
21697543,2011-06-22T00:00:00,Aged,M01.060.116.100
21697543,2011-06-22T00:00:00,Gene Expression Regulation,G05.355.315
21697543,2011-06-22T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21697543,2011-06-22T00:00:00,Middle Aged,M01.060.116.630
21697543,2011-06-22T00:00:00,Muscle Contraction,G11.427.590.540
21697543,2011-06-22T00:00:00,"Muscle, Smooth",A02.633.570
21697543,2011-06-22T00:00:00,"Muscle, Smooth",A10.690.467
21697543,2011-06-22T00:00:00,"Myocytes, Smooth Muscle",A11.620.520
21697543,2011-06-22T00:00:00,Peptides,D12.644
21723922,2011-06-22T00:00:00,Animals,B01.050
21723922,2011-06-22T00:00:00,Apoptosis,G04.299.139.160
21723922,2011-06-22T00:00:00,Calpain,D08.811.277.656.262.500.120
21723922,2011-06-22T00:00:00,Calpain,D08.811.277.656.300.200.120
21723922,2011-06-22T00:00:00,Cell Line,A11.251.210
21723922,2011-06-22T00:00:00,Motor Neurons,A08.663.655.500
21723922,2011-06-22T00:00:00,Motor Neurons,A11.671.655.500
21723922,2011-06-22T00:00:00,Spinal Cord,A08.186.854
21700656,2011-06-23T00:00:00,Adult,M01.060.116
21700656,2011-06-23T00:00:00,African Americans,M01.686.508.100.100
21700656,2011-06-23T00:00:00,African Americans,M01.686.754.100
21700656,2011-06-23T00:00:00,Aged,M01.060.116.100
21700656,2011-06-23T00:00:00,Exercise Therapy,E02.779.483
21700656,2011-06-23T00:00:00,Exercise Therapy,E02.831.387
21700656,2011-06-23T00:00:00,Fatigue,C23.888.369
21700656,2011-06-23T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21700656,2011-06-23T00:00:00,"Lupus Erythematosus, Systemic",C17.300.480
21700656,2011-06-23T00:00:00,"Lupus Erythematosus, Systemic",C20.111.590
21700656,2011-06-23T00:00:00,Middle Aged,M01.060.116.630
21700656,2011-06-23T00:00:00,Patient Compliance,F01.145.488.500
21700656,2011-06-23T00:00:00,Patient Compliance,N05.300.150.600.600
21700656,2011-06-23T00:00:00,Pilot Projects,E05.318.760.750
21700656,2011-06-23T00:00:00,Pilot Projects,E05.337.737
21700656,2011-06-23T00:00:00,Pilot Projects,N05.715.360.775.625
21700656,2011-06-23T00:00:00,Pilot Projects,N06.850.520.450.720
21700656,2011-06-23T00:00:00,Video Games,I03.450.642.693.930
21700656,2011-06-23T00:00:00,Video Games,L01.224.900.930
21700944,2011-06-23T00:00:00,Aged,M01.060.116.100
21700944,2011-06-23T00:00:00,Brain Ischemia,C10.228.140.300.150
21700944,2011-06-23T00:00:00,Brain Ischemia,C14.907.253.092
21700944,2011-06-23T00:00:00,Fibrinolytic Agents,D27.505.519.421.750
21700944,2011-06-23T00:00:00,Fibrinolytic Agents,D27.505.954.411.320
21700944,2011-06-23T00:00:00,Fibrinolytic Agents,D27.505.954.502.427
21700944,2011-06-23T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21700944,2011-06-23T00:00:00,Middle Aged,M01.060.116.630
21700944,2011-06-23T00:00:00,Stroke,C10.228.140.300.775
21700944,2011-06-23T00:00:00,Stroke,C14.907.253.855
21700944,2011-06-23T00:00:00,Tissue Plasminogen Activator,D08.811.277.656.300.760.875
21700944,2011-06-23T00:00:00,Tissue Plasminogen Activator,D08.811.277.656.959.350.875
21700944,2011-06-23T00:00:00,Tissue Plasminogen Activator,D12.776.124.125.662.768
21700944,2011-06-23T00:00:00,Tissue Plasminogen Activator,D23.119.970
21700944,2011-06-23T00:00:00,Treatment Outcome,E01.789.800
21700944,2011-06-23T00:00:00,Treatment Outcome,N04.761.559.590.800
21700944,2011-06-23T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21703649,2011-06-23T00:00:00,Advanced Practice Nursing,H02.478.676.074
21703649,2011-06-23T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21703649,2011-06-23T00:00:00,Nurse's Role,F01.829.316.616.625.450
21703649,2011-06-23T00:00:00,Nurse's Role,N05.300.100.337
21703649,2011-06-23T00:00:00,Organizational Objectives,N04.452.615
21703649,2011-06-23T00:00:00,Psychiatric Nursing,H02.478.676.710
21703649,2011-06-23T00:00:00,Psychiatric Nursing,N02.421.533.778
21703649,2011-06-23T00:00:00,Staff Development,I02.574.700
21703649,2011-06-23T00:00:00,Staff Development,N04.452.677.822
21703649,2011-06-23T00:00:00,United States,Z01.107.567.875
21704282,2011-06-23T00:00:00,Aged,M01.060.116.100
21704282,2011-06-23T00:00:00,Diastole,G09.330.190.541.295
21704282,2011-06-23T00:00:00,Diastole,G11.427.590.540.554.250
21704282,2011-06-23T00:00:00,Diastole,G11.427.590.540.570.295
21704282,2011-06-23T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21704282,2011-06-23T00:00:00,Physical Endurance,G11.427.680
21704282,2011-06-23T00:00:00,Physical Endurance,I03.450.642.845.054.600
21704282,2011-06-23T00:00:00,Risk Factors,E05.318.740.600.800.725
21704282,2011-06-23T00:00:00,Risk Factors,N05.715.350.200.700
21704282,2011-06-23T00:00:00,Risk Factors,N05.715.360.750.625.700.700
21704282,2011-06-23T00:00:00,Risk Factors,N06.850.490.625.750
21704282,2011-06-23T00:00:00,Risk Factors,N06.850.520.830.600.800.725
21704282,2011-06-23T00:00:00,"Ventricular Dysfunction, Left",C14.280.945.900
21704282,2011-06-23T00:00:00,Walking,G11.427.590.530.568.900
21704282,2011-06-23T00:00:00,Walking,G11.427.590.530.698.940
21704282,2011-06-23T00:00:00,Walking,I03.450.642.845.940
21783340,2011-06-23T00:00:00,Adolescent,M01.060.057
21783340,2011-06-23T00:00:00,Alcohol Drinking,F01.145.317.269
21783340,2011-06-23T00:00:00,Child,M01.060.406
21783340,2011-06-23T00:00:00,Health Surveys,E05.318.308.250
21783340,2011-06-23T00:00:00,Health Surveys,N05.715.360.300.375
21783340,2011-06-23T00:00:00,Health Surveys,N06.850.520.308.250
21783340,2011-06-23T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21783340,2011-06-23T00:00:00,Life Change Events,F01.829.458.410
21783340,2011-06-23T00:00:00,Questionnaires,E05.318.308.750
21783340,2011-06-23T00:00:00,Questionnaires,L01.280.800
21783340,2011-06-23T00:00:00,Questionnaires,N05.715.360.300.695
21783340,2011-06-23T00:00:00,Questionnaires,N06.850.520.308.750
21783340,2011-06-23T00:00:00,Risk Factors,E05.318.740.600.800.725
21783340,2011-06-23T00:00:00,Risk Factors,N05.715.350.200.700
21783340,2011-06-23T00:00:00,Risk Factors,N05.715.360.750.625.700.700
21783340,2011-06-23T00:00:00,Risk Factors,N06.850.490.625.750
21783340,2011-06-23T00:00:00,Risk Factors,N06.850.520.830.600.800.725
21783340,2011-06-23T00:00:00,"Stress Disorders, Post-Traumatic",F03.080.931.500
21783340,2011-06-23T00:00:00,United States,Z01.107.567.875
21701813,2011-06-24T00:00:00,Animals,B01.050
21701813,2011-06-24T00:00:00,Cannabinoids,D02.455.849.090
21701813,2011-06-24T00:00:00,Drug Tolerance,G07.690.812.260
21701813,2011-06-24T00:00:00,Drug Tolerance,G07.700.680.260
21701813,2011-06-24T00:00:00,Ethanol,D02.033.375
21701813,2011-06-24T00:00:00,Motor Activity,F01.145.632
21701813,2011-06-24T00:00:00,Motor Activity,G11.427.590.530.698
21701813,2011-06-24T00:00:00,"Receptor, Cannabinoid, CB1",D12.776.543.750.100.125.100
21774606,2011-06-24T00:00:00,Adult,M01.060.116
21774606,2011-06-24T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21774606,2011-06-24T00:00:00,Huntington Disease,C10.228.140.079.545
21774606,2011-06-24T00:00:00,Huntington Disease,C10.228.140.380.278
21774606,2011-06-24T00:00:00,Huntington Disease,C10.228.662.262.249.750
21774606,2011-06-24T00:00:00,Huntington Disease,C10.574.500.497
21774606,2011-06-24T00:00:00,Huntington Disease,C16.320.400.430
21774606,2011-06-24T00:00:00,Huntington Disease,F03.087.250.400
21774606,2011-06-24T00:00:00,Huntington Disease,F03.087.400.390
21774606,2011-06-24T00:00:00,Inhibition (Psychology),F01.145.544
21774606,2011-06-24T00:00:00,Inhibition (Psychology),F02.463.425.475
21774606,2011-06-24T00:00:00,Inhibition (Psychology),F02.739.794.405
21774606,2011-06-24T00:00:00,Middle Aged,M01.060.116.630
21774606,2011-06-24T00:00:00,Photic Stimulation,E05.723.729
21774606,2011-06-24T00:00:00,Psychological Tests,F04.711
21774606,2011-06-24T00:00:00,Reaction Time,F02.830.650
21774606,2011-06-24T00:00:00,Reaction Time,F04.669.817
21774606,2011-06-24T00:00:00,Reaction Time,G11.561.677
21774606,2011-06-24T00:00:00,Saccades,G14.640.260.500
21705279,2011-06-25T00:00:00,Adolescent,M01.060.057
21705279,2011-06-25T00:00:00,Child,M01.060.406
21705279,2011-06-25T00:00:00,Continuity of Patient Care,N04.590.233.727.210
21705279,2011-06-25T00:00:00,Epilepsy,C10.228.140.490
21705279,2011-06-25T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21705279,2011-06-25T00:00:00,Parent-Child Relations,F01.829.263.370.290
21705279,2011-06-25T00:00:00,Parenting,F01.829.263.370.310
21705279,2011-06-25T00:00:00,Psychology,F04.096.628
21705279,2011-06-25T00:00:00,Young Adult,M01.060.116.815
21705294,2011-06-25T00:00:00,Academic Medical Centers,N02.278.020
21705294,2011-06-25T00:00:00,Biological Markers,D23.101
21705294,2011-06-25T00:00:00,"Diabetes Mellitus, Type 2",C18.452.394.750.149
21705294,2011-06-25T00:00:00,"Diabetes Mellitus, Type 2",C19.246.300
21705294,2011-06-25T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21705294,2011-06-25T00:00:00,Hypoglycemic Agents,D27.505.696.422
21705294,2011-06-25T00:00:00,Middle Aged,M01.060.116.630
21705294,2011-06-25T00:00:00,Oxidative Stress,G03.495.710
21705294,2011-06-25T00:00:00,Oxidative Stress,G07.700.830.750
21705294,2011-06-25T00:00:00,South Carolina,Z01.107.567.875.075.662
21705294,2011-06-25T00:00:00,South Carolina,Z01.107.567.875.750.700
21705294,2011-06-25T00:00:00,Time Factors,G01.910.857
21705294,2011-06-25T00:00:00,Treatment Outcome,E01.789.800
21705294,2011-06-25T00:00:00,Treatment Outcome,N04.761.559.590.800
21705294,2011-06-25T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21708206,2011-06-25T00:00:00,Adolescent,M01.060.057
21708206,2011-06-25T00:00:00,Adult,M01.060.116
21708206,2011-06-25T00:00:00,Aged,M01.060.116.100
21708206,2011-06-25T00:00:00,Healthcare Disparities,N04.590.374.380
21708206,2011-06-25T00:00:00,Healthcare Disparities,N05.300.493
21708206,2011-06-25T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21708206,2011-06-25T00:00:00,Influenza Vaccines,D20.215.894.899.302
21708206,2011-06-25T00:00:00,"Influenza, Human",C02.782.620.365
21708206,2011-06-25T00:00:00,"Influenza, Human",C08.730.310
21708206,2011-06-25T00:00:00,Middle Aged,M01.060.116.630
21708206,2011-06-25T00:00:00,Rural Health Services,N02.421.816
21708206,2011-06-25T00:00:00,Vaccination,E02.095.465.425.400.530.890
21708206,2011-06-25T00:00:00,Vaccination,E05.478.550.600.890
21708206,2011-06-25T00:00:00,Vaccination,N02.421.726.758.310.890
21708206,2011-06-25T00:00:00,Vaccination,N06.850.780.200.425.900
21708206,2011-06-25T00:00:00,Vaccination,N06.850.780.680.310.890
21708206,2011-06-25T00:00:00,Young Adult,M01.060.116.815
21729768,2011-06-26T00:00:00,C-Reactive Protein,D12.776.034.145
21729768,2011-06-26T00:00:00,C-Reactive Protein,D12.776.124.050.120
21729768,2011-06-26T00:00:00,C-Reactive Protein,D12.776.124.486.157
21729768,2011-06-26T00:00:00,Genetic Predisposition to Disease,C23.550.291.687.500
21729768,2011-06-26T00:00:00,Genetic Predisposition to Disease,G05.380.355
21729768,2011-06-26T00:00:00,Host-Pathogen Interactions,G06.590.470
21729768,2011-06-26T00:00:00,Host-Pathogen Interactions,G16.100.380
21729768,2011-06-26T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21729768,2011-06-26T00:00:00,Immunoglobulin G,D12.776.124.486.485.114.619.393
21729768,2011-06-26T00:00:00,Immunoglobulin G,D12.776.124.790.651.114.619.393
21729768,2011-06-26T00:00:00,Immunoglobulin G,D12.776.377.715.548.114.619.393
21729768,2011-06-26T00:00:00,Immunoglobulin Gm Allotypes,D12.776.124.486.485.114.606.586
21729768,2011-06-26T00:00:00,Immunoglobulin Gm Allotypes,D12.776.124.486.485.114.619.393.522.400
21729768,2011-06-26T00:00:00,Immunoglobulin Gm Allotypes,D12.776.124.486.485.705.500.380.500
21729768,2011-06-26T00:00:00,Immunoglobulin Gm Allotypes,D12.776.124.790.651.114.606.586
21729768,2011-06-26T00:00:00,Immunoglobulin Gm Allotypes,D12.776.124.790.651.114.619.393.522.400
21729768,2011-06-26T00:00:00,Immunoglobulin Gm Allotypes,D12.776.124.790.651.705.500.380.500
21729768,2011-06-26T00:00:00,Immunoglobulin Gm Allotypes,D12.776.377.715.548.114.606.586
21729768,2011-06-26T00:00:00,Immunoglobulin Gm Allotypes,D12.776.377.715.548.114.619.393.522.400
21729768,2011-06-26T00:00:00,Immunoglobulin Gm Allotypes,D12.776.377.715.548.705.500.380.500
21729768,2011-06-26T00:00:00,Immunoglobulin Gm Allotypes,G12.500.400.586
21729768,2011-06-26T00:00:00,"Polymorphism, Genetic",G05.365.795
21729768,2011-06-26T00:00:00,"Receptors, IgG",D12.776.543.750.705.871.300
21729768,2011-06-26T00:00:00,"Receptors, IgG",D23.050.301.264.035.695
21729768,2011-06-26T00:00:00,"Receptors, IgG",D23.101.100.110.695
21516067,2011-06-27T00:00:00,Adolescent,M01.060.057
21516067,2011-06-27T00:00:00,Adult,M01.060.116
21516067,2011-06-27T00:00:00,Aged,M01.060.116.100
21516067,2011-06-27T00:00:00,Biomedical Research,H01.770.644.145
21516067,2011-06-27T00:00:00,Graft Survival,G12.425.901.545.340
21516067,2011-06-27T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21516067,2011-06-27T00:00:00,Immunosuppressive Agents,D27.505.696.477.656
21516067,2011-06-27T00:00:00,Middle Aged,M01.060.116.630
21516067,2011-06-27T00:00:00,Organ Transplantation,E04.936.450
21516067,2011-06-27T00:00:00,Tissue and Organ Procurement,N02.421.911
21516067,2011-06-27T00:00:00,United States,Z01.107.567.875
21709102,2011-06-27T00:00:00,Animals,B01.050
21709102,2011-06-27T00:00:00,Cattle,B01.050.150.900.649.077.380.271
21709102,2011-06-27T00:00:00,Lysostaphin,D08.811.277.656.300.480.452
21709102,2011-06-27T00:00:00,Lysostaphin,D08.811.277.656.675.374.452
21709102,2011-06-27T00:00:00,Rats,B01.050.150.900.649.865.635.505.700
21709102,2011-06-27T00:00:00,Staphylococcal Infections,C01.252.410.868
21709102,2011-06-27T00:00:00,Staphylococcus aureus,B03.300.390.400.800.750.100
21709102,2011-06-27T00:00:00,Staphylococcus aureus,B03.510.100.750.750.100
21709102,2011-06-27T00:00:00,Staphylococcus aureus,B03.510.400.790.750.100
21709102,2011-06-27T00:00:00,Surgical Mesh,E07.858.708
21709162,2011-06-27T00:00:00,Electronic Health Records,E05.318.308.940.968.625.500
21709162,2011-06-27T00:00:00,Emergency Medical Service Communication Systems,N02.421.297.058
21709162,2011-06-27T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21709162,2011-06-27T00:00:00,Mass Casualty Incidents,I01.198.240.856.800.537
21709162,2011-06-27T00:00:00,Mass Casualty Incidents,I01.880.735.900.800.575
21709162,2011-06-27T00:00:00,Mass Casualty Incidents,N06.230.100.160
21709162,2011-06-27T00:00:00,Software,L01.224.900
21709162,2011-06-27T00:00:00,Time Factors,G01.910.857
21707788,2011-06-28T00:00:00,Gene Deletion,G05.355.600.800.320
21707788,2011-06-28T00:00:00,Gene Deletion,G05.365.590.762.320
21707788,2011-06-28T00:00:00,Mitochondria,A11.284.430.214.190.875.564
21707788,2011-06-28T00:00:00,Mitochondria,A11.284.835.626
21707788,2011-06-28T00:00:00,Oxidative Stress,G03.495.710
21707788,2011-06-28T00:00:00,Oxidative Stress,G07.700.830.750
21707788,2011-06-28T00:00:00,Protein Phosphatase 2,D08.811.277.352.650.625.706
21707788,2011-06-28T00:00:00,Protein Phosphatase 2,D12.644.360.583
21707788,2011-06-28T00:00:00,Protein Phosphatase 2,D12.776.476.561
21707788,2011-06-28T00:00:00,Saccharomyces cerevisiae,B01.300.107.795.785.800
21707788,2011-06-28T00:00:00,Saccharomyces cerevisiae,B01.300.930.705.655
21707788,2011-06-28T00:00:00,Saccharomyces cerevisiae Proteins,D12.776.354.750
21707788,2011-06-28T00:00:00,Sphingolipids,D10.570.877
21707788,2011-06-28T00:00:00,Sphingolipids,D10.808
21710170,2011-06-28T00:00:00,Adolescent,M01.060.057
21710170,2011-06-28T00:00:00,Adult,M01.060.116
21710170,2011-06-28T00:00:00,Cues,F02.463.425.234
21710170,2011-06-28T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21710170,2011-06-28T00:00:00,Hydrocortisone,D04.808.745.745.654.600
21710170,2011-06-28T00:00:00,Hydrocortisone,D06.472.040.585.353.476
21710170,2011-06-28T00:00:00,Hydrocortisone,D06.472.040.585.478.392
21710170,2011-06-28T00:00:00,Marijuana Abuse,C21.739.635
21710170,2011-06-28T00:00:00,Marijuana Abuse,F03.900.635
21710170,2011-06-28T00:00:00,Psychological Tests,F04.711
21710170,2011-06-28T00:00:00,"Stress, Psychological",F01.145.126.990
21710170,2011-06-28T00:00:00,"Stress, Psychological",F02.830.900
21710170,2011-06-28T00:00:00,Young Adult,M01.060.116.815
21714085,2011-06-28T00:00:00,Animals,B01.050
21714085,2011-06-28T00:00:00,Anti-Bacterial Agents,D27.505.954.122.085
21714085,2011-06-28T00:00:00,Aortic Valve,A07.541.510.110
21714085,2011-06-28T00:00:00,Bioprosthesis,E07.695.100
21714085,2011-06-28T00:00:00,Collagen,D05.750.078.280
21714085,2011-06-28T00:00:00,Collagen,D12.776.860.300.250
21714085,2011-06-28T00:00:00,Elastin,D05.750.078.421
21714085,2011-06-28T00:00:00,Elastin,D12.776.860.300.350
21714085,2011-06-28T00:00:00,Extracellular Matrix,A11.284.295.310
21714085,2011-06-28T00:00:00,Glycosaminoglycans,D09.698.373
21714085,2011-06-28T00:00:00,Heart Valve Prosthesis,E07.695.310
21714085,2011-06-28T00:00:00,"Microscopy, Electron, Transmission",E01.370.350.515.402.580
21714085,2011-06-28T00:00:00,"Microscopy, Electron, Transmission",E05.595.402.580
21714085,2011-06-28T00:00:00,Neomycin,D09.408.051.623
21714085,2011-06-28T00:00:00,Swine,B01.050.150.900.649.077.880
21714085,2011-06-28T00:00:00,Temperature,G01.906.595
21714085,2011-06-28T00:00:00,Temperature,G16.500.275.063.725.710
21714085,2011-06-28T00:00:00,Temperature,G16.500.750.775.710
21714085,2011-06-28T00:00:00,Temperature,N06.230.150.450
21714085,2011-06-28T00:00:00,Temperature,N06.230.300.100.725.710
21733228,2011-06-28T00:00:00,Animals,B01.050
21733228,2011-06-28T00:00:00,Central Nervous System Stimulants,D27.505.696.282
21733228,2011-06-28T00:00:00,Central Nervous System Stimulants,D27.505.954.427.220
21733228,2011-06-28T00:00:00,"Conditioning, Operant",F02.463.425.179.509
21733228,2011-06-28T00:00:00,Methamphetamine,D02.092.471.683.152.619
21733228,2011-06-28T00:00:00,Rats,B01.050.150.900.649.865.635.505.700
21733228,2011-06-28T00:00:00,Self Administration,E02.319.890
21733228,2011-06-28T00:00:00,Self Administration,E02.900.890
21733228,2011-06-28T00:00:00,Time Factors,G01.910.857
21714919,2011-06-29T00:00:00,Algorithms,G17.035
21714919,2011-06-29T00:00:00,Algorithms,L01.224.050
21714919,2011-06-29T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21714919,2011-06-29T00:00:00,Mutation,G05.365.590
21714919,2011-06-29T00:00:00,Neoplasms,C04
21715583,2011-06-29T00:00:00,Aged,M01.060.116.100
21715583,2011-06-29T00:00:00,Biological Markers,D23.101
21715583,2011-06-29T00:00:00,Biphenyl Compounds,D02.455.426.559.389.185
21715583,2011-06-29T00:00:00,Double-Blind Method,E05.318.780.300
21715583,2011-06-29T00:00:00,Double-Blind Method,E05.581.500.300
21715583,2011-06-29T00:00:00,Double-Blind Method,N05.715.360.780.320
21715583,2011-06-29T00:00:00,Double-Blind Method,N06.850.520.445.300
21715583,2011-06-29T00:00:00,Heart Failure,C14.280.434
21715583,2011-06-29T00:00:00,Hospitalization,E02.760.400
21715583,2011-06-29T00:00:00,Hospitalization,N02.421.585.400
21715583,2011-06-29T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21715583,2011-06-29T00:00:00,Middle Aged,M01.060.116.630
21715583,2011-06-29T00:00:00,Peptide Fragments,D12.644.541
21715583,2011-06-29T00:00:00,Stroke Volume,E01.370.370.380.150.700
21715583,2011-06-29T00:00:00,Stroke Volume,G09.330.380.124.882
21715583,2011-06-29T00:00:00,Treatment Outcome,E01.789.800
21715583,2011-06-29T00:00:00,Treatment Outcome,N04.761.559.590.800
21715583,2011-06-29T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21715693,2011-06-29T00:00:00,Animals,B01.050
21715693,2011-06-29T00:00:00,Antigen Presentation,G12.425.107
21715693,2011-06-29T00:00:00,Antigen Presentation,G12.450.050.400.070
21715693,2011-06-29T00:00:00,B-Lymphocytes,A11.063.438
21715693,2011-06-29T00:00:00,B-Lymphocytes,A11.118.637.555.567.562
21715693,2011-06-29T00:00:00,B-Lymphocytes,A15.145.229.637.555.567.562
21715693,2011-06-29T00:00:00,B-Lymphocytes,A15.382.032.438
21715693,2011-06-29T00:00:00,B-Lymphocytes,A15.382.490.555.567.562
21715693,2011-06-29T00:00:00,Cell Differentiation,G04.299.151
21715693,2011-06-29T00:00:00,Dendritic Cells,A11.066.270
21715693,2011-06-29T00:00:00,Dendritic Cells,A11.436.270
21715693,2011-06-29T00:00:00,Dendritic Cells,A15.382.066.270
21715693,2011-06-29T00:00:00,Dendritic Cells,A15.382.812.260
21715693,2011-06-29T00:00:00,Lymphocyte Activation,E01.450.495.482
21715693,2011-06-29T00:00:00,Lymphocyte Activation,E05.478.594.530
21715693,2011-06-29T00:00:00,Lymphocyte Activation,G12.425.747
21715693,2011-06-29T00:00:00,Lymphocyte Activation,G12.450.050.400.545
21715693,2011-06-29T00:00:00,T-Lymphocyte Subsets,A11.118.637.555.567.550.500
21715693,2011-06-29T00:00:00,T-Lymphocyte Subsets,A11.118.637.555.567.569.500
21715693,2011-06-29T00:00:00,T-Lymphocyte Subsets,A15.145.229.637.555.567.550.500
21715693,2011-06-29T00:00:00,T-Lymphocyte Subsets,A15.145.229.637.555.567.569.500
21715693,2011-06-29T00:00:00,T-Lymphocyte Subsets,A15.382.490.555.567.550.500
21715693,2011-06-29T00:00:00,T-Lymphocyte Subsets,A15.382.490.555.567.569.500
21715693,2011-06-29T00:00:00,"T-Lymphocytes, Helper-Inducer",A11.118.637.555.567.569.200.400
21715693,2011-06-29T00:00:00,"T-Lymphocytes, Helper-Inducer",A15.145.229.637.555.567.569.200.400
21715693,2011-06-29T00:00:00,"T-Lymphocytes, Helper-Inducer",A15.382.490.555.567.569.200.400
21714671,2011-06-30T00:00:00,"Education, Medical, Continuing",I02.358.212.350
21714671,2011-06-30T00:00:00,"Education, Medical, Continuing",I02.358.399.250
21714671,2011-06-30T00:00:00,"Education, Pharmacy",I02.358.525
21714671,2011-06-30T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21714671,2011-06-30T00:00:00,Interprofessional Relations,F01.829.401.205
21714671,2011-06-30T00:00:00,Pharmacists,M01.526.485.780
21714671,2011-06-30T00:00:00,Pharmacists,N02.360.780
21714671,2011-06-30T00:00:00,Prescription Drugs,D26.670
21714671,2011-06-30T00:00:00,Teaching,I02.903
21719445,2011-06-30T00:00:00,Adult,M01.060.116
21719445,2011-06-30T00:00:00,African Americans,M01.686.508.100.100
21719445,2011-06-30T00:00:00,African Americans,M01.686.754.100
21719445,2011-06-30T00:00:00,European Continental Ancestry Group,M01.686.508.400
21719445,2011-06-30T00:00:00,Genetic Loci,G05.360.340.024.380
21719445,2011-06-30T00:00:00,Genetic Predisposition to Disease,C23.550.291.687.500
21719445,2011-06-30T00:00:00,Genetic Predisposition to Disease,G05.380.355
21719445,2011-06-30T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21719445,2011-06-30T00:00:00,"Lupus Erythematosus, Systemic",C17.300.480
21719445,2011-06-30T00:00:00,"Lupus Erythematosus, Systemic",C20.111.590
21719445,2011-06-30T00:00:00,Lupus Nephritis,C12.777.419.570.363.680
21719445,2011-06-30T00:00:00,Lupus Nephritis,C13.351.968.419.570.363.680
21719445,2011-06-30T00:00:00,Lupus Nephritis,C17.300.480.680
21719445,2011-06-30T00:00:00,Lupus Nephritis,C20.111.590.560
21719445,2011-06-30T00:00:00,Middle Aged,M01.060.116.630
21719445,2011-06-30T00:00:00,Phenotype,G05.695
21719445,2011-06-30T00:00:00,"Polymorphism, Single Nucleotide",G05.365.795.598
21719445,2011-06-30T00:00:00,Young Adult,M01.060.116.815
21719547,2011-06-30T00:00:00,"Aneurysm, Dissecting",C14.907.055.050
21719547,2011-06-30T00:00:00,"Aortic Aneurysm, Thoracic",C14.907.055.239.125
21719547,2011-06-30T00:00:00,"Aortic Aneurysm, Thoracic",C14.907.109.139.125
21719547,2011-06-30T00:00:00,Cardiac Tamponade,C14.280.155
21719547,2011-06-30T00:00:00,Cardiac Volume,G09.330.380.249
21719547,2011-06-30T00:00:00,Echocardiography,E01.370.350.850.220
21719547,2011-06-30T00:00:00,Echocardiography,E01.370.370.380.220
21719547,2011-06-30T00:00:00,"Echocardiography, Transesophageal",E01.370.350.850.220.235
21719547,2011-06-30T00:00:00,"Echocardiography, Transesophageal",E01.370.370.380.220.235
21719547,2011-06-30T00:00:00,Endocarditis,C14.280.282
21719547,2011-06-30T00:00:00,"Foramen Ovale, Patent",C14.240.400.560.375.258
21719547,2011-06-30T00:00:00,"Foramen Ovale, Patent",C14.280.400.560.375.258
21719547,2011-06-30T00:00:00,"Foramen Ovale, Patent",C16.131.240.400.560.375.258
21719547,2011-06-30T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21719547,2011-06-30T00:00:00,Intensive Care Units,N02.278.388.493
21719547,2011-06-30T00:00:00,"Ventricular Function, Left",G09.330.190.962.800
20523245,2011-07-01T00:00:00,Adolescent,M01.060.057
20523245,2011-07-01T00:00:00,"Diagnosis, Differential",E01.171
20523245,2011-07-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
20523245,2011-07-01T00:00:00,"Tumor Markers, Biological",D23.101.840
21399557,2011-07-01T00:00:00,Action Potentials,G04.580.100
21399557,2011-07-01T00:00:00,Action Potentials,G07.265.750.100
21399557,2011-07-01T00:00:00,Action Potentials,G11.561.570.100
21399557,2011-07-01T00:00:00,Animals,B01.050
21399557,2011-07-01T00:00:00,Cell Adhesion Molecules,D12.776.395.550.200
21399557,2011-07-01T00:00:00,Cell Adhesion Molecules,D12.776.543.550.200
21399557,2011-07-01T00:00:00,Cell Adhesion Molecules,D23.050.301.350
21399557,2011-07-01T00:00:00,Connexin 43,D12.776.543.585.250.200
21399557,2011-07-01T00:00:00,Homeodomain Proteins,D12.776.260.400
21399557,2011-07-01T00:00:00,Transcription Factors,D12.776.930
21415720,2011-07-01T00:00:00,Adult,M01.060.116
21415720,2011-07-01T00:00:00,Hot Temperature,G01.906.595.543
21415720,2011-07-01T00:00:00,Hot Temperature,G16.500.275.063.725.710.380
21415720,2011-07-01T00:00:00,Hot Temperature,G16.500.750.775.710.380
21415720,2011-07-01T00:00:00,Hot Temperature,N06.230.300.100.725.232
21415720,2011-07-01T00:00:00,Hot Temperature,N06.230.300.100.725.710.380
21415720,2011-07-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21415720,2011-07-01T00:00:00,Motor Cortex,A08.186.211.730.885.287.500.270.548
21415720,2011-07-01T00:00:00,Pain,C10.597.617
21415720,2011-07-01T00:00:00,Pain,C23.888.592.612
21415720,2011-07-01T00:00:00,Pain,C23.888.646
21415720,2011-07-01T00:00:00,Pain,F02.830.816.444
21415720,2011-07-01T00:00:00,Pain,G11.561.600.810.444
21415720,2011-07-01T00:00:00,Pain Measurement,E01.370.376.550.600
21415720,2011-07-01T00:00:00,Pain Threshold,F02.463.593.710.560
21415720,2011-07-01T00:00:00,Pain Threshold,F02.830.816.444.700
21415720,2011-07-01T00:00:00,Pain Threshold,G11.561.600.810.444.700
21415720,2011-07-01T00:00:00,Transcranial Magnetic Stimulation,E01.370.376.850
21415720,2011-07-01T00:00:00,Transcranial Magnetic Stimulation,E02.621.820
21415720,2011-07-01T00:00:00,Young Adult,M01.060.116.815
21460730,2011-07-01T00:00:00,Cystic Fibrosis,C06.689.202
21460730,2011-07-01T00:00:00,Cystic Fibrosis,C08.381.187
21460730,2011-07-01T00:00:00,Cystic Fibrosis,C16.320.190
21460730,2011-07-01T00:00:00,Cystic Fibrosis,C16.614.213
21460730,2011-07-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21460730,2011-07-01T00:00:00,Pneumothorax,C08.528.778
21493287,2011-07-01T00:00:00,Adult,M01.060.116
21493287,2011-07-01T00:00:00,Aged,M01.060.116.100
21493287,2011-07-01T00:00:00,Carrier Proteins,D12.776.157
21493287,2011-07-01T00:00:00,Cell Adhesion Molecules,D12.776.395.550.200
21493287,2011-07-01T00:00:00,Cell Adhesion Molecules,D12.776.543.550.200
21493287,2011-07-01T00:00:00,Cell Adhesion Molecules,D23.050.301.350
21493287,2011-07-01T00:00:00,Chronic Disease,C23.550.291.500
21493287,2011-07-01T00:00:00,Down-Regulation,G02.111.087.225
21493287,2011-07-01T00:00:00,Down-Regulation,G02.149.115.225
21493287,2011-07-01T00:00:00,Down-Regulation,G05.355.315.200
21493287,2011-07-01T00:00:00,Down-Regulation,G07.690.812.230
21493287,2011-07-01T00:00:00,Down-Regulation,G07.700.680.230
21493287,2011-07-01T00:00:00,Gene Expression,G05.355.310
21493287,2011-07-01T00:00:00,Glycoproteins,D09.400.430
21493287,2011-07-01T00:00:00,Glycoproteins,D12.776.395
21493287,2011-07-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21493287,2011-07-01T00:00:00,Middle Aged,M01.060.116.630
21493287,2011-07-01T00:00:00,Nasal Polyps,C08.460.572
21493287,2011-07-01T00:00:00,Nasal Polyps,C09.603.557
21493287,2011-07-01T00:00:00,Nasal Polyps,C23.300.825.557
21493287,2011-07-01T00:00:00,Nerve Tissue Proteins,D12.776.641
21493287,2011-07-01T00:00:00,Paranasal Sinuses,A04.531.621
21493287,2011-07-01T00:00:00,Polymerase Chain Reaction,E05.393.620.500
21493287,2011-07-01T00:00:00,"Transcription, Genetic",G02.111.087.847
21493287,2011-07-01T00:00:00,"Transcription, Genetic",G02.149.115.847
21493287,2011-07-01T00:00:00,"Transcription, Genetic",G05.355.310.700
21519271,2011-07-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21519271,2011-07-01T00:00:00,Postoperative Complications,C23.550.767
21519271,2011-07-01T00:00:00,Suburethral Slings,E07.695.752
21519271,2011-07-01T00:00:00,Treatment Outcome,E01.789.800
21519271,2011-07-01T00:00:00,Treatment Outcome,N04.761.559.590.800
21519271,2011-07-01T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21519271,2011-07-01T00:00:00,"Urinary Incontinence, Stress",C12.777.934.852.249
21519271,2011-07-01T00:00:00,"Urinary Incontinence, Stress",C13.351.968.934.814.500
21519271,2011-07-01T00:00:00,"Urinary Incontinence, Stress",C23.888.942.800.500
21519271,2011-07-01T00:00:00,Urologic Surgical Procedures,E04.950.774
21597369,2011-07-01T00:00:00,Age Factors,N05.715.350.075
21597369,2011-07-01T00:00:00,Age Factors,N06.850.490.250
21597369,2011-07-01T00:00:00,Antihypertensive Agents,D27.505.954.411.162
21597369,2011-07-01T00:00:00,Blood Pressure,E01.370.600.875.249
21597369,2011-07-01T00:00:00,Blood Pressure,G09.330.380.076
21597369,2011-07-01T00:00:00,Drug Resistance,G07.690.320
21597369,2011-07-01T00:00:00,Health Behavior,F01.145.488
21597369,2011-07-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21597369,2011-07-01T00:00:00,Hypertension,C14.907.489
21597369,2011-07-01T00:00:00,Patient Care,E02.760
21597369,2011-07-01T00:00:00,Patient Care,N02.421.585
21597369,2011-07-01T00:00:00,Physician's Practice Patterns,N04.590.748
21597369,2011-07-01T00:00:00,Physician's Practice Patterns,N05.300.625
21597369,2011-07-01T00:00:00,Practice Guidelines as Topic,N04.761.700.350.650
21597369,2011-07-01T00:00:00,Practice Guidelines as Topic,N05.700.350.650
21597369,2011-07-01T00:00:00,Risk Factors,E05.318.740.600.800.725
21597369,2011-07-01T00:00:00,Risk Factors,N05.715.350.200.700
21597369,2011-07-01T00:00:00,Risk Factors,N05.715.360.750.625.700.700
21597369,2011-07-01T00:00:00,Risk Factors,N06.850.490.625.750
21597369,2011-07-01T00:00:00,Risk Factors,N06.850.520.830.600.800.725
21597369,2011-07-01T00:00:00,United States,Z01.107.567.875
21613375,2011-07-01T00:00:00,Animals,B01.050
21613375,2011-07-01T00:00:00,Apoptosis,G04.299.139.160
21613375,2011-07-01T00:00:00,Calpain,D08.811.277.656.262.500.120
21613375,2011-07-01T00:00:00,Calpain,D08.811.277.656.300.200.120
21613375,2011-07-01T00:00:00,"Disease Models, Animal",C22.232
21613375,2011-07-01T00:00:00,"Disease Models, Animal",E05.598.500
21613375,2011-07-01T00:00:00,"Disease Models, Animal",E05.599.395.080
21613375,2011-07-01T00:00:00,Gene Expression Regulation,G05.355.315
21613375,2011-07-01T00:00:00,RNA,D13.444.735
21613375,2011-07-01T00:00:00,Rats,B01.050.150.900.649.865.635.505.700
21613375,2011-07-01T00:00:00,Treatment Outcome,E01.789.800
21613375,2011-07-01T00:00:00,Treatment Outcome,N04.761.559.590.800
21613375,2011-07-01T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21654215,2011-07-01T00:00:00,3' Untranslated Regions,D13.444.735.544.875.880
21654215,2011-07-01T00:00:00,3' Untranslated Regions,D13.444.735.790.878.880
21654215,2011-07-01T00:00:00,3' Untranslated Regions,G05.360.340.024.220.880.880
21654215,2011-07-01T00:00:00,3' Untranslated Regions,G05.360.340.024.340.137.910.880
21654215,2011-07-01T00:00:00,"Gene Expression Regulation, Neoplastic",G05.355.315.370
21654215,2011-07-01T00:00:00,Heterogeneous-Nuclear Ribonucleoproteins,D12.776.157.725.500.500
21654215,2011-07-01T00:00:00,Heterogeneous-Nuclear Ribonucleoproteins,D12.776.664.962.500.500
21654215,2011-07-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21654215,2011-07-01T00:00:00,Neoplasms,C04
21654215,2011-07-01T00:00:00,Proto-Oncogene Proteins c-akt,D08.811.913.696.620.682.700.755
21654215,2011-07-01T00:00:00,Proto-Oncogene Proteins c-akt,D12.776.476.565
21654215,2011-07-01T00:00:00,Proto-Oncogene Proteins c-akt,D12.776.624.664.700.168
21654215,2011-07-01T00:00:00,"RNA, Messenger",D13.444.735.544
21654215,2011-07-01T00:00:00,Signal Transduction,G02.111.087.800
21654215,2011-07-01T00:00:00,Signal Transduction,G02.149.115.800
21654215,2011-07-01T00:00:00,Signal Transduction,G04.299.880
21654215,2011-07-01T00:00:00,Transforming Growth Factor beta,D12.644.276.374.687
21654215,2011-07-01T00:00:00,Transforming Growth Factor beta,D12.644.276.954.800.720
21654215,2011-07-01T00:00:00,Transforming Growth Factor beta,D12.644.276.963.720
21654215,2011-07-01T00:00:00,Transforming Growth Factor beta,D12.776.467.374.687
21654215,2011-07-01T00:00:00,Transforming Growth Factor beta,D12.776.467.942.800.720
21654215,2011-07-01T00:00:00,Transforming Growth Factor beta,D12.776.467.960.720
21654215,2011-07-01T00:00:00,Transforming Growth Factor beta,D23.529.374.687
21654215,2011-07-01T00:00:00,Transforming Growth Factor beta,D23.529.942.800.720
21654215,2011-07-01T00:00:00,Transforming Growth Factor beta,D23.529.960.720
21669351,2011-07-01T00:00:00,Adult,M01.060.116
21669351,2011-07-01T00:00:00,Aged,M01.060.116.100
21669351,2011-07-01T00:00:00,Calcinosis,C18.452.174.130
21669351,2011-07-01T00:00:00,Contrast Media,D27.720.259
21669351,2011-07-01T00:00:00,Coronary Angiography,E01.370.350.700.060.200
21669351,2011-07-01T00:00:00,Coronary Angiography,E01.370.370.050.200
21669351,2011-07-01T00:00:00,Coronary Angiography,E01.370.370.380.200
21669351,2011-07-01T00:00:00,Coronary Artery Disease,C14.280.647.250.260
21669351,2011-07-01T00:00:00,Coronary Artery Disease,C14.907.137.126.339
21669351,2011-07-01T00:00:00,Coronary Artery Disease,C14.907.585.250.260
21669351,2011-07-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21669351,2011-07-01T00:00:00,Middle Aged,M01.060.116.630
21669351,2011-07-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.350.810
21669351,2011-07-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.600.350.700.810
21669351,2011-07-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.700.700.810
21669351,2011-07-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.700.810.810
21669351,2011-07-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.825.810.810
21676120,2011-07-01T00:00:00,Anti-Infective Agents,D27.505.954.122
21676120,2011-07-01T00:00:00,Clinical Trials as Topic,E05.318.760.535
21676120,2011-07-01T00:00:00,Clinical Trials as Topic,E05.337.250
21676120,2011-07-01T00:00:00,Clinical Trials as Topic,N05.715.360.775.235
21676120,2011-07-01T00:00:00,Clinical Trials as Topic,N06.850.520.450.535
21676120,2011-07-01T00:00:00,Critical Pathways,N04.590.233.624.625
21676120,2011-07-01T00:00:00,Critical Pathways,N04.590.275
21676120,2011-07-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21676120,2011-07-01T00:00:00,"Infusions, Intravenous",E02.319.267.510.590
21676120,2011-07-01T00:00:00,Medical Informatics,L01.313.500
21676120,2011-07-01T00:00:00,Medical Informatics,L01.700
21676120,2011-07-01T00:00:00,Pharmaceutical Services,N02.421.668
21676120,2011-07-01T00:00:00,Practice Guidelines as Topic,N04.761.700.350.650
21676120,2011-07-01T00:00:00,Practice Guidelines as Topic,N05.700.350.650
21676120,2011-07-01T00:00:00,Research Design,E05.581.500
21676120,2011-07-01T00:00:00,Research Design,H01.770.644.728
21680987,2011-07-01T00:00:00,Blood Glucose,D09.546.359.448.500
21680987,2011-07-01T00:00:00,"Diabetes Mellitus, Type 2",C18.452.394.750.149
21680987,2011-07-01T00:00:00,"Diabetes Mellitus, Type 2",C19.246.300
21680987,2011-07-01T00:00:00,Homeostasis,G07.700.360
21680987,2011-07-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21680987,2011-07-01T00:00:00,Hypoglycemic Agents,D27.505.696.422
21680987,2011-07-01T00:00:00,Kidney,A05.810.453
21680987,2011-07-01T00:00:00,Thiophenes,D02.886.778
21680987,2011-07-01T00:00:00,Thiophenes,D03.383.903
21681105,2011-07-01T00:00:00,"Abnormalities, Multiple",C16.131.077
21681105,2011-07-01T00:00:00,Child,M01.060.406
21681105,2011-07-01T00:00:00,Developmental Disabilities,F03.550.362
21681105,2011-07-01T00:00:00,Genetic Testing,E01.370.427
21681105,2011-07-01T00:00:00,Genetic Testing,E05.393.435
21681105,2011-07-01T00:00:00,Genetic Testing,N02.421.143.827.233.221
21681105,2011-07-01T00:00:00,Genetic Testing,N02.421.308.430
21681105,2011-07-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21681105,2011-07-01T00:00:00,Oligonucleotide Array Sequence Analysis,E05.196.630.570.660
21681105,2011-07-01T00:00:00,Oligonucleotide Array Sequence Analysis,E05.393.525.640
21681105,2011-07-01T00:00:00,Oligonucleotide Array Sequence Analysis,E05.393.661.640
21681105,2011-07-01T00:00:00,Oligonucleotide Array Sequence Analysis,E05.393.760.640
21681105,2011-07-01T00:00:00,Oligonucleotide Array Sequence Analysis,E05.588.570.660
21681105,2011-07-01T00:00:00,Oligonucleotide Array Sequence Analysis,E05.601.640
21689235,2011-07-01T00:00:00,Adult,M01.060.116
21689235,2011-07-01T00:00:00,Diabetes Mellitus,C18.452.394.750
21689235,2011-07-01T00:00:00,Diabetes Mellitus,C19.246
21689235,2011-07-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21689235,2011-07-01T00:00:00,Islets of Langerhans Transplantation,E04.270.550
21689235,2011-07-01T00:00:00,Islets of Langerhans Transplantation,E04.936.225.375
21689235,2011-07-01T00:00:00,Middle Aged,M01.060.116.630
21689235,2011-07-01T00:00:00,Pancreatectomy,E04.210.752
21689235,2011-07-01T00:00:00,"Pancreatitis, Chronic",C06.689.750.830
21689235,2011-07-01T00:00:00,Treatment Outcome,E01.789.800
21689235,2011-07-01T00:00:00,Treatment Outcome,N04.761.559.590.800
21689235,2011-07-01T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21689235,2011-07-01T00:00:00,Young Adult,M01.060.116.815
21691873,2011-07-01T00:00:00,Age Factors,N05.715.350.075
21691873,2011-07-01T00:00:00,Age Factors,N06.850.490.250
21691873,2011-07-01T00:00:00,Alcohol Drinking,F01.145.317.269
21691873,2011-07-01T00:00:00,Ethnic Groups,M01.686.754
21691873,2011-07-01T00:00:00,Ethnic Groups,N01.224.317
21691873,2011-07-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21691873,2011-07-01T00:00:00,Incidence,E05.318.308.985.525.375
21691873,2011-07-01T00:00:00,Incidence,L01.280.975.525.375
21691873,2011-07-01T00:00:00,Incidence,N01.224.935.597.500
21691873,2011-07-01T00:00:00,Incidence,N06.850.505.400.975.525.375
21691873,2011-07-01T00:00:00,Incidence,N06.850.520.308.985.525.375
21691873,2011-07-01T00:00:00,Life Style,F01.829.458
21691873,2011-07-01T00:00:00,Risk Factors,E05.318.740.600.800.725
21691873,2011-07-01T00:00:00,Risk Factors,N05.715.350.200.700
21691873,2011-07-01T00:00:00,Risk Factors,N05.715.360.750.625.700.700
21691873,2011-07-01T00:00:00,Risk Factors,N06.850.490.625.750
21691873,2011-07-01T00:00:00,Risk Factors,N06.850.520.830.600.800.725
21691873,2011-07-01T00:00:00,Sex Factors,N05.715.350.675
21691873,2011-07-01T00:00:00,Sex Factors,N06.850.490.875
21691873,2011-07-01T00:00:00,Stroke,C10.228.140.300.775
21691873,2011-07-01T00:00:00,Stroke,C14.907.253.855
21703381,2011-07-01T00:00:00,"Child, Preschool",M01.060.406.448
21703381,2011-07-01T00:00:00,Diet,E05.272
21703381,2011-07-01T00:00:00,Diet,G07.610.240
21703381,2011-07-01T00:00:00,Health Education,I02.233.332
21703381,2011-07-01T00:00:00,Health Education,N02.421.143.827.407
21703381,2011-07-01T00:00:00,Health Education,N02.421.726.407
21703381,2011-07-01T00:00:00,"Health Knowledge, Attitudes, Practice",F01.100.150.500
21703381,2011-07-01T00:00:00,"Health Knowledge, Attitudes, Practice",N05.300.150.410
21703381,2011-07-01T00:00:00,Health Promotion,N02.370
21703381,2011-07-01T00:00:00,Health Promotion,N02.421.726.507
21703381,2011-07-01T00:00:00,Hispanic Americans,M01.686.754.441
21703381,2011-07-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21703381,2011-07-01T00:00:00,Language,F01.145.209.399
21703381,2011-07-01T00:00:00,Language,L01.143.506
21703381,2011-07-01T00:00:00,Social Environment,I01.880.656
21704815,2011-07-01T00:00:00,"Cholangiopancreatography, Endoscopic Retrograde",E01.370.350.700.715.200.200
21704815,2011-07-01T00:00:00,"Cholangiopancreatography, Endoscopic Retrograde",E01.370.372.200.200
21704815,2011-07-01T00:00:00,"Cholangiopancreatography, Endoscopic Retrograde",E01.370.372.250.200
21704815,2011-07-01T00:00:00,"Cholangiopancreatography, Endoscopic Retrograde",E01.370.388.250.250.160
21704815,2011-07-01T00:00:00,"Cholangiopancreatography, Endoscopic Retrograde",E04.210.240.160
21704815,2011-07-01T00:00:00,"Cholangiopancreatography, Endoscopic Retrograde",E04.800.250.250.160
21704815,2011-07-01T00:00:00,Gastroenterology,H02.403.429.405
21704815,2011-07-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21712123,2011-07-01T00:00:00,Adult,M01.060.116
21712123,2011-07-01T00:00:00,Aged,M01.060.116.100
21712123,2011-07-01T00:00:00,"Catheters, Indwelling",E07.150
21712123,2011-07-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21712123,2011-07-01T00:00:00,Middle Aged,M01.060.116.630
21712123,2011-07-01T00:00:00,Surgical Flaps,A10.850.710
21712123,2011-07-01T00:00:00,Surgical Flaps,E07.862.710
21712123,2011-07-01T00:00:00,Urethra,A05.360.444.492.726
21712123,2011-07-01T00:00:00,Urethra,A05.810.876
21712123,2011-07-01T00:00:00,Urinary Bladder,A05.810.890
21712123,2011-07-01T00:00:00,Urologic Surgical Procedures,E04.950.774
21715986,2011-07-01T00:00:00,Decision Making,F02.463.785.373
21715986,2011-07-01T00:00:00,Educational Measurement,I02.399
21715986,2011-07-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21715986,2011-07-01T00:00:00,Internship and Residency,I02.358.399.644
21715986,2011-07-01T00:00:00,"Licensure, Medical",N03.706.110.510.410
21715986,2011-07-01T00:00:00,"Licensure, Medical",N05.700.200.450.500
21715986,2011-07-01T00:00:00,School Admission Criteria,I02.399.750
21715986,2011-07-01T00:00:00,"Students, Medical",I02.851.686.602
21715986,2011-07-01T00:00:00,"Students, Medical",M01.848.769.602
21722852,2011-07-01T00:00:00,Anesthesiology,H02.403.066
21722852,2011-07-01T00:00:00,"Arrhythmias, Cardiac",C14.280.067
21722852,2011-07-01T00:00:00,"Arrhythmias, Cardiac",C23.550.073
21722852,2011-07-01T00:00:00,Cardiology,H02.403.429.163
21722852,2011-07-01T00:00:00,"Defibrillators, Implantable",E07.305.250.159.175
21722852,2011-07-01T00:00:00,"Defibrillators, Implantable",E07.305.250.319.175
21722852,2011-07-01T00:00:00,"Defibrillators, Implantable",E07.695.175
21722852,2011-07-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21722852,2011-07-01T00:00:00,"Monitoring, Physiologic",E01.370.520
21722852,2011-07-01T00:00:00,"Pacemaker, Artificial",E07.858.082.748
21722852,2011-07-01T00:00:00,Perioperative Care,E02.760.722
21722852,2011-07-01T00:00:00,Perioperative Care,E04.604
21722852,2011-07-01T00:00:00,Perioperative Care,N02.421.585.722
21722852,2011-07-01T00:00:00,Practice Guidelines as Topic,N04.761.700.350.650
21722852,2011-07-01T00:00:00,Practice Guidelines as Topic,N05.700.350.650
21722852,2011-07-01T00:00:00,"Surgical Procedures, Operative",E04
21722852,2011-07-01T00:00:00,United States,Z01.107.567.875
21722856,2011-07-01T00:00:00,"Arrhythmias, Cardiac",C14.280.067
21722856,2011-07-01T00:00:00,"Arrhythmias, Cardiac",C23.550.073
21722856,2011-07-01T00:00:00,"Defibrillators, Implantable",E07.305.250.159.175
21722856,2011-07-01T00:00:00,"Defibrillators, Implantable",E07.305.250.319.175
21722856,2011-07-01T00:00:00,"Defibrillators, Implantable",E07.695.175
21722856,2011-07-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21722856,2011-07-01T00:00:00,Practice Guidelines as Topic,N04.761.700.350.650
21722856,2011-07-01T00:00:00,Practice Guidelines as Topic,N05.700.350.650
21722856,2011-07-01T00:00:00,United States,Z01.107.567.875
21724105,2011-07-01T00:00:00,Actins,D05.750.078.730.250
21724105,2011-07-01T00:00:00,Actins,D12.776.210.500.100
21724105,2011-07-01T00:00:00,Actins,D12.776.220.525.255
21724105,2011-07-01T00:00:00,Animals,B01.050
21724105,2011-07-01T00:00:00,Biological Markers,D23.101
21724105,2011-07-01T00:00:00,Cell Proliferation,G04.299.233.750
21724105,2011-07-01T00:00:00,Cell Proliferation,G07.700.320.249.410.750
21724105,2011-07-01T00:00:00,"Microscopy, Confocal",E01.370.350.515.395
21724105,2011-07-01T00:00:00,"Microscopy, Confocal",E05.595.395
21724105,2011-07-01T00:00:00,"Muscle, Smooth, Vascular",A02.633.570.491
21724105,2011-07-01T00:00:00,"Muscle, Smooth, Vascular",A07.231.491
21724105,2011-07-01T00:00:00,"Muscle, Smooth, Vascular",A10.690.467.491
21724105,2011-07-01T00:00:00,"Myocytes, Smooth Muscle",A11.620.520
21724105,2011-07-01T00:00:00,Phenotype,G05.695
21724105,2011-07-01T00:00:00,Prosthesis Design,E05.320.550
21724105,2011-07-01T00:00:00,Prosthesis Design,E07.695.680
21724105,2011-07-01T00:00:00,Rats,B01.050.150.900.649.865.635.505.700
21724105,2011-07-01T00:00:00,"Rats, Sprague-Dawley",B01.050.150.900.649.865.635.505.700.750
21724105,2011-07-01T00:00:00,Stents,E07.695.750
21724105,2011-07-01T00:00:00,Surface Properties,G02.842.850
21724105,2011-07-01T00:00:00,Time Factors,G01.910.857
21725138,2011-07-01T00:00:00,Actins,D05.750.078.730.250
21725138,2011-07-01T00:00:00,Actins,D12.776.210.500.100
21725138,2011-07-01T00:00:00,Actins,D12.776.220.525.255
21725138,2011-07-01T00:00:00,Animals,B01.050
21725138,2011-07-01T00:00:00,Breast Neoplasms,C04.588.180
21725138,2011-07-01T00:00:00,Breast Neoplasms,C17.800.090.500
21725138,2011-07-01T00:00:00,Extracellular Matrix,A11.284.295.310
21725138,2011-07-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21725138,2011-07-01T00:00:00,Neoplasm Invasiveness,C04.697.645
21725138,2011-07-01T00:00:00,Neoplasm Invasiveness,C23.550.727.645
21725138,2011-07-01T00:00:00,Nuclear Proteins,D12.776.660
21725138,2011-07-01T00:00:00,Signal Transduction,G02.111.087.800
21725138,2011-07-01T00:00:00,Signal Transduction,G02.149.115.800
21725138,2011-07-01T00:00:00,Signal Transduction,G04.299.880
21725138,2011-07-01T00:00:00,src-Family Kinases,D08.811.913.696.620.682.725.800
21725149,2011-07-01T00:00:00,Animals,B01.050
21725149,2011-07-01T00:00:00,Biocompatible Materials,D25.130
21725149,2011-07-01T00:00:00,Biocompatible Materials,D27.720.102.130
21725149,2011-07-01T00:00:00,Biocompatible Materials,J01.637.051.130
21725149,2011-07-01T00:00:00,Electrodes,E07.305.250
21725149,2011-07-01T00:00:00,"Microscopy, Confocal",E01.370.350.515.395
21725149,2011-07-01T00:00:00,"Microscopy, Confocal",E05.595.395
21725149,2011-07-01T00:00:00,"Myocytes, Cardiac",A07.541.704.570
21725149,2011-07-01T00:00:00,"Myocytes, Cardiac",A10.690.552.750.570
21725149,2011-07-01T00:00:00,"Myocytes, Cardiac",A11.620.500
21725149,2011-07-01T00:00:00,Rats,B01.050.150.900.649.865.635.505.700
21729789,2011-07-01T00:00:00,Angioplasty,E02.148.050
21729789,2011-07-01T00:00:00,Angioplasty,E04.100.814.050
21729789,2011-07-01T00:00:00,Antihypertensive Agents,D27.505.954.411.162
21729789,2011-07-01T00:00:00,Arterial Occlusive Diseases,C14.907.137
21729789,2011-07-01T00:00:00,Cerebral Arterial Diseases,C10.228.140.300.510.200
21729789,2011-07-01T00:00:00,Cerebral Arterial Diseases,C14.907.253.560.200
21729789,2011-07-01T00:00:00,"Constriction, Pathologic",C23.300.287
21729789,2011-07-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21729789,2011-07-01T00:00:00,"Ischemic Attack, Transient",C10.228.140.300.150.836
21729789,2011-07-01T00:00:00,"Ischemic Attack, Transient",C14.907.253.092.836
21729789,2011-07-01T00:00:00,Platelet Aggregation Inhibitors,D27.505.954.502.780
21729789,2011-07-01T00:00:00,Research Design,E05.581.500
21729789,2011-07-01T00:00:00,Research Design,H01.770.644.728
21729789,2011-07-01T00:00:00,Risk Assessment,E05.318.740.600.800.715
21729789,2011-07-01T00:00:00,Risk Assessment,N04.452.871.715
21729789,2011-07-01T00:00:00,Risk Assessment,N05.715.360.750.625.700.690
21729789,2011-07-01T00:00:00,Risk Assessment,N06.850.505.715
21729789,2011-07-01T00:00:00,Risk Assessment,N06.850.520.830.600.800.715
21729789,2011-07-01T00:00:00,Risk Factors,E05.318.740.600.800.725
21729789,2011-07-01T00:00:00,Risk Factors,N05.715.350.200.700
21729789,2011-07-01T00:00:00,Risk Factors,N05.715.360.750.625.700.700
21729789,2011-07-01T00:00:00,Risk Factors,N06.850.490.625.750
21729789,2011-07-01T00:00:00,Risk Factors,N06.850.520.830.600.800.725
21729789,2011-07-01T00:00:00,Risk Reduction Behavior,F01.145.699
21729789,2011-07-01T00:00:00,Secondary Prevention,N02.421.726.825
21729789,2011-07-01T00:00:00,Secondary Prevention,N06.850.780.750
21729789,2011-07-01T00:00:00,Stents,E07.695.750
21729789,2011-07-01T00:00:00,Stroke,C10.228.140.300.775
21729789,2011-07-01T00:00:00,Stroke,C14.907.253.855
21729789,2011-07-01T00:00:00,Ticlopidine,D02.886.778.834
21729789,2011-07-01T00:00:00,Ticlopidine,D03.383.903.834
21729789,2011-07-01T00:00:00,Time Factors,G01.910.857
21729789,2011-07-01T00:00:00,Treatment Outcome,E01.789.800
21729789,2011-07-01T00:00:00,Treatment Outcome,N04.761.559.590.800
21729789,2011-07-01T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21729789,2011-07-01T00:00:00,United States,Z01.107.567.875
21730810,2011-07-01T00:00:00,Animals,B01.050
21730810,2011-07-01T00:00:00,Antivenins,D12.776.124.486.485.114.301.138
21730810,2011-07-01T00:00:00,Antivenins,D12.776.124.486.485.114.573.601.138
21730810,2011-07-01T00:00:00,Antivenins,D12.776.124.790.651.114.301.138
21730810,2011-07-01T00:00:00,Antivenins,D12.776.377.715.548.114.301.138
21730810,2011-07-01T00:00:00,Antivenins,D20.215.121.163
21730810,2011-07-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21730810,2011-07-01T00:00:00,Immunologic Factors,D27.505.696.477
21732785,2011-07-01T00:00:00,"DNA, Mitochondrial",D13.444.308.283.225
21732785,2011-07-01T00:00:00,DNA-Directed DNA Polymerase,D08.811.913.696.445.308.300
21732785,2011-07-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21732785,2011-07-01T00:00:00,Mitochondria,A11.284.430.214.190.875.564
21732785,2011-07-01T00:00:00,Mitochondria,A11.284.835.626
21732785,2011-07-01T00:00:00,Mitochondrial Diseases,C18.452.660
21732785,2011-07-01T00:00:00,Molecular Diagnostic Techniques,E05.200.880
21732785,2011-07-01T00:00:00,Molecular Diagnostic Techniques,E05.393.520
21737766,2011-07-01T00:00:00,Adult,M01.060.116
21737766,2011-07-01T00:00:00,Aged,M01.060.116.100
21737766,2011-07-01T00:00:00,Biological Markers,D23.101
21737766,2011-07-01T00:00:00,Ferritins,D12.776.157.427.249
21737766,2011-07-01T00:00:00,Ferritins,D12.776.556.579.249
21737766,2011-07-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21737766,2011-07-01T00:00:00,Liver,A03.620
21737766,2011-07-01T00:00:00,Middle Aged,M01.060.116.630
21737766,2011-07-01T00:00:00,Nutrition Surveys,E05.318.308.250.600
21737766,2011-07-01T00:00:00,Nutrition Surveys,E05.318.308.585.550
21737766,2011-07-01T00:00:00,Nutrition Surveys,N05.715.360.300.375.560
21737766,2011-07-01T00:00:00,Nutrition Surveys,N05.715.360.300.560.565
21737766,2011-07-01T00:00:00,Nutrition Surveys,N06.850.520.308.250.600
21737766,2011-07-01T00:00:00,Nutrition Surveys,N06.850.520.308.585.550
21737766,2011-07-01T00:00:00,Proteinuria,C12.777.934.734
21737766,2011-07-01T00:00:00,Proteinuria,C13.351.968.934.734
21737766,2011-07-01T00:00:00,Proteinuria,C23.888.942.750
21737766,2011-07-01T00:00:00,Risk Assessment,E05.318.740.600.800.715
21737766,2011-07-01T00:00:00,Risk Assessment,N04.452.871.715
21737766,2011-07-01T00:00:00,Risk Assessment,N05.715.360.750.625.700.690
21737766,2011-07-01T00:00:00,Risk Assessment,N06.850.505.715
21737766,2011-07-01T00:00:00,Risk Assessment,N06.850.520.830.600.800.715
21737766,2011-07-01T00:00:00,United States,Z01.107.567.875
21742098,2011-07-01T00:00:00,Adolescent,M01.060.057
21742098,2011-07-01T00:00:00,Child,M01.060.406
21742098,2011-07-01T00:00:00,"Child, Preschool",M01.060.406.448
21742098,2011-07-01T00:00:00,Echocardiography,E01.370.350.850.220
21742098,2011-07-01T00:00:00,Echocardiography,E01.370.370.380.220
21742098,2011-07-01T00:00:00,"Embolization, Therapeutic",E02.520.360
21742098,2011-07-01T00:00:00,Fontan Procedure,E04.035.410.295
21742098,2011-07-01T00:00:00,Fontan Procedure,E04.100.376.410.295
21742098,2011-07-01T00:00:00,Fontan Procedure,E04.928.220.370.295
21742098,2011-07-01T00:00:00,"Heart Defects, Congenital",C14.240.400
21742098,2011-07-01T00:00:00,"Heart Defects, Congenital",C14.280.400
21742098,2011-07-01T00:00:00,"Heart Defects, Congenital",C16.131.240.400
21742098,2011-07-01T00:00:00,Heart Ventricles,A07.541.560
21742098,2011-07-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21742098,2011-07-01T00:00:00,Length of Stay,E02.760.400.480
21742098,2011-07-01T00:00:00,Length of Stay,N02.421.585.400.480
21742098,2011-07-01T00:00:00,Preoperative Care,E02.760.795
21742098,2011-07-01T00:00:00,Preoperative Care,E04.641
21742098,2011-07-01T00:00:00,Preoperative Care,N02.421.585.795
21742098,2011-07-01T00:00:00,Pulmonary Artery,A07.231.114.715
21742098,2011-07-01T00:00:00,Treatment Outcome,E01.789.800
21742098,2011-07-01T00:00:00,Treatment Outcome,N04.761.559.590.800
21742098,2011-07-01T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21742098,2011-07-01T00:00:00,"Ventricular Function, Left",G09.330.190.962.800
21745066,2011-07-01T00:00:00,Academic Medical Centers,N02.278.020
21745066,2011-07-01T00:00:00,"Models, Organizational",E05.599.670
21745066,2011-07-01T00:00:00,"Models, Organizational",N04.452.534
21745066,2011-07-01T00:00:00,Professional Competence,I02.399.630
21745066,2011-07-01T00:00:00,"Schools, Medical",I02.783.660.552
21745066,2011-07-01T00:00:00,"Schools, Medical",N02.278.020.578
21745066,2011-07-01T00:00:00,South Carolina,Z01.107.567.875.075.662
21745066,2011-07-01T00:00:00,South Carolina,Z01.107.567.875.750.700
21745066,2011-07-01T00:00:00,Teaching,I02.903
21745066,2011-07-01T00:00:00,Writing,L01.143.506.423.906
21747100,2011-07-01T00:00:00,Adolescent,M01.060.057
21747100,2011-07-01T00:00:00,Adult,M01.060.116
21747100,2011-07-01T00:00:00,Aged,M01.060.116.100
21747100,2011-07-01T00:00:00,Carrier State,N06.850.160
21747100,2011-07-01T00:00:00,Child,M01.060.406
21747100,2011-07-01T00:00:00,"Child, Preschool",M01.060.406.448
21747100,2011-07-01T00:00:00,Hot Temperature,G01.906.595.543
21747100,2011-07-01T00:00:00,Hot Temperature,G16.500.275.063.725.710.380
21747100,2011-07-01T00:00:00,Hot Temperature,G16.500.750.775.710.380
21747100,2011-07-01T00:00:00,Hot Temperature,N06.230.300.100.725.232
21747100,2011-07-01T00:00:00,Hot Temperature,N06.230.300.100.725.710.380
21747100,2011-07-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21747100,2011-07-01T00:00:00,Methicillin-Resistant Staphylococcus aureus,B03.300.390.400.800.750.100.500
21747100,2011-07-01T00:00:00,Methicillin-Resistant Staphylococcus aureus,B03.510.100.750.750.100.500
21747100,2011-07-01T00:00:00,Methicillin-Resistant Staphylococcus aureus,B03.510.400.790.750.100.500
21747100,2011-07-01T00:00:00,Middle Aged,M01.060.116.630
21747100,2011-07-01T00:00:00,Nasal Cavity,A04.531.449
21747100,2011-07-01T00:00:00,Staphylococcal Infections,C01.252.410.868
21747100,2011-07-01T00:00:00,United States,Z01.107.567.875
21747100,2011-07-01T00:00:00,Young Adult,M01.060.116.815
21749862,2011-07-01T00:00:00,ADAM Proteins,D08.811.277.656.675.374.102
21749862,2011-07-01T00:00:00,ADAM Proteins,D09.400.430.500
21749862,2011-07-01T00:00:00,ADAM Proteins,D12.776.395.033
21749862,2011-07-01T00:00:00,Animals,B01.050
21749862,2011-07-01T00:00:00,Bone Morphogenetic Protein 2,D12.644.276.954.200.200
21749862,2011-07-01T00:00:00,Bone Morphogenetic Protein 2,D12.776.467.942.200.200
21749862,2011-07-01T00:00:00,Bone Morphogenetic Protein 2,D23.529.942.200.200
21749862,2011-07-01T00:00:00,Cell Proliferation,G04.299.233.750
21749862,2011-07-01T00:00:00,Cell Proliferation,G07.700.320.249.410.750
21749862,2011-07-01T00:00:00,Endocardium,A07.541.207
21749862,2011-07-01T00:00:00,"Gene Expression Regulation, Developmental",G05.355.315.310
21749862,2011-07-01T00:00:00,Heart,A07.541
21749862,2011-07-01T00:00:00,Heart Valve Diseases,C14.280.484
21749862,2011-07-01T00:00:00,Heart Valves,A07.541.510
21749862,2011-07-01T00:00:00,Mesoderm,A16.504.660
21749862,2011-07-01T00:00:00,Versicans,D09.698.735.830.750
21749862,2011-07-01T00:00:00,Versicans,D12.776.395.650.750.750
21749862,2011-07-01T00:00:00,Versicans,D12.776.503.280.625
21757077,2011-07-01T00:00:00,Aged,M01.060.116.100
21757077,2011-07-01T00:00:00,Dementia,C10.228.140.380
21757077,2011-07-01T00:00:00,Dementia,F03.087.400
21757077,2011-07-01T00:00:00,Health Policy,I01.880.604.825.608.400
21757077,2011-07-01T00:00:00,Health Policy,N03.706.825.608.428
21757077,2011-07-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21757077,2011-07-01T00:00:00,Nursing Homes,N02.278.825.610
21768417,2011-07-01T00:00:00,Endoscopy,E01.370.388.250
21768417,2011-07-01T00:00:00,Endoscopy,E04.800.250
21768417,2011-07-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21768417,2011-07-01T00:00:00,Otorhinolaryngologic Surgical Procedures,E04.580
21768417,2011-07-01T00:00:00,Paranasal Sinuses,A04.531.621
21768417,2011-07-01T00:00:00,Rhinitis,C08.460.799
21768417,2011-07-01T00:00:00,Rhinitis,C08.730.674
21768417,2011-07-01T00:00:00,Rhinitis,C09.603.799
21768417,2011-07-01T00:00:00,Sinusitis,C08.460.692.752
21768417,2011-07-01T00:00:00,Sinusitis,C08.730.749
21768417,2011-07-01T00:00:00,Sinusitis,C09.603.692.752
21790339,2011-07-01T00:00:00,Anticoagulants,D27.505.954.502.119
21790339,2011-07-01T00:00:00,Brain Ischemia,C10.228.140.300.150
21790339,2011-07-01T00:00:00,Brain Ischemia,C14.907.253.092
21790339,2011-07-01T00:00:00,Cerebrovascular Disorders,C10.228.140.300
21790339,2011-07-01T00:00:00,Cerebrovascular Disorders,C14.907.253
21790339,2011-07-01T00:00:00,Evidence-Based Medicine,H02.249.750
21790339,2011-07-01T00:00:00,Evidence-Based Medicine,H02.403.200.400
21790339,2011-07-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21790339,2011-07-01T00:00:00,Myocardial Infarction,C14.280.647.500
21790339,2011-07-01T00:00:00,Myocardial Infarction,C14.907.585.500
21790339,2011-07-01T00:00:00,Platelet Aggregation Inhibitors,D27.505.954.502.780
21790339,2011-07-01T00:00:00,Risk Factors,E05.318.740.600.800.725
21790339,2011-07-01T00:00:00,Risk Factors,N05.715.350.200.700
21790339,2011-07-01T00:00:00,Risk Factors,N05.715.360.750.625.700.700
21790339,2011-07-01T00:00:00,Risk Factors,N06.850.490.625.750
21790339,2011-07-01T00:00:00,Risk Factors,N06.850.520.830.600.800.725
21790339,2011-07-01T00:00:00,Sex Factors,N05.715.350.675
21790339,2011-07-01T00:00:00,Sex Factors,N06.850.490.875
21790339,2011-07-01T00:00:00,United States,Z01.107.567.875
21793929,2011-07-01T00:00:00,Adult,M01.060.116
21793929,2011-07-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21793929,2011-07-01T00:00:00,Hypertension,C14.907.489
21793929,2011-07-01T00:00:00,Intermittent Claudication,C14.907.137.126.669
21793929,2011-07-01T00:00:00,Intermittent Claudication,C23.888.531
21800747,2011-07-01T00:00:00,Adult,M01.060.116
21800747,2011-07-01T00:00:00,Aged,M01.060.116.100
21800747,2011-07-01T00:00:00,Health Behavior,F01.145.488
21800747,2011-07-01T00:00:00,"Health Knowledge, Attitudes, Practice",F01.100.150.500
21800747,2011-07-01T00:00:00,"Health Knowledge, Attitudes, Practice",N05.300.150.410
21800747,2011-07-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21800747,2011-07-01T00:00:00,Middle Aged,M01.060.116.630
21800747,2011-07-01T00:00:00,Skin,A17.815
21800747,2011-07-01T00:00:00,Skin Neoplasms,C04.588.805
21800747,2011-07-01T00:00:00,Skin Neoplasms,C17.800.882
21800747,2011-07-01T00:00:00,Vitamin D,D04.808.812.768
21800752,2011-07-01T00:00:00,Adolescent,M01.060.057
21800752,2011-07-01T00:00:00,Age Factors,N05.715.350.075
21800752,2011-07-01T00:00:00,Age Factors,N06.850.490.250
21800752,2011-07-01T00:00:00,Automobiles,J01.937.500.100
21800752,2011-07-01T00:00:00,Child,M01.060.406
21800752,2011-07-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21800752,2011-07-01T00:00:00,Sex Factors,N05.715.350.675
21800752,2011-07-01T00:00:00,Sex Factors,N06.850.490.875
21800752,2011-07-01T00:00:00,Tobacco Smoke Pollution,D20.633.937.680
21800752,2011-07-01T00:00:00,Tobacco Smoke Pollution,N06.850.460.100.555
21812167,2011-07-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21812167,2011-07-01T00:00:00,Immunization Programs,N02.421.143.827.608
21812167,2011-07-01T00:00:00,Immunization Programs,N02.421.726.608
21812167,2011-07-01T00:00:00,Immunization Schedule,E02.095.465.425.400.470
21812167,2011-07-01T00:00:00,Immunization Schedule,E05.478.550.545
21812167,2011-07-01T00:00:00,Infant,M01.060.703
21812167,2011-07-01T00:00:00,Physician's Practice Patterns,N04.590.748
21812167,2011-07-01T00:00:00,Physician's Practice Patterns,N05.300.625
21812167,2011-07-01T00:00:00,Time Factors,G01.910.857
21812167,2011-07-01T00:00:00,Vaccination,E02.095.465.425.400.530.890
21812167,2011-07-01T00:00:00,Vaccination,E05.478.550.600.890
21812167,2011-07-01T00:00:00,Vaccination,N02.421.726.758.310.890
21812167,2011-07-01T00:00:00,Vaccination,N06.850.780.200.425.900
21812167,2011-07-01T00:00:00,Vaccination,N06.850.780.680.310.890
21812169,2011-07-01T00:00:00,"Child, Preschool",M01.060.406.448
21812169,2011-07-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21812169,2011-07-01T00:00:00,Infant,M01.060.703
21812169,2011-07-01T00:00:00,Patient-Centered Care,N04.590.233.675
21812169,2011-07-01T00:00:00,Patient-Centered Care,N04.590.233.727.407
21812169,2011-07-01T00:00:00,Patient-Centered Care,N04.590.720
21812169,2011-07-01T00:00:00,"Quality Indicators, Health Care",N04.761.789
21812169,2011-07-01T00:00:00,Vaccines,D20.215.894
21818014,2011-07-01T00:00:00,Double-Blind Method,E05.318.780.300
21818014,2011-07-01T00:00:00,Double-Blind Method,E05.581.500.300
21818014,2011-07-01T00:00:00,Double-Blind Method,N05.715.360.780.320
21818014,2011-07-01T00:00:00,Double-Blind Method,N06.850.520.445.300
21818014,2011-07-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21818014,2011-07-01T00:00:00,Outcome Assessment (Health Care),N04.761.559.590
21818014,2011-07-01T00:00:00,Outcome Assessment (Health Care),N05.715.360.575.575
21818014,2011-07-01T00:00:00,Patient Simulation,I02.903.525
21818014,2011-07-01T00:00:00,Telemedicine,H02.403.840
21818014,2011-07-01T00:00:00,Telemedicine,L01.178.847.652
21818014,2011-07-01T00:00:00,Telemedicine,N04.590.374.800
21818014,2011-07-01T00:00:00,United States,Z01.107.567.875
21818014,2011-07-01T00:00:00,Wounds and Injuries,C21.866
21937903,2011-07-01T00:00:00,Accidental Falls,N06.850.135.122
21937903,2011-07-01T00:00:00,Aged,M01.060.116.100
21937903,2011-07-01T00:00:00,Gait,E01.370.600.250
21937903,2011-07-01T00:00:00,Gait,G11.427.590.530.389
21937903,2011-07-01T00:00:00,Geriatric Assessment,E05.318.308.225
21937903,2011-07-01T00:00:00,Geriatric Assessment,I01.240.425.350
21937903,2011-07-01T00:00:00,Geriatric Assessment,L01.280.360
21937903,2011-07-01T00:00:00,Geriatric Assessment,N01.224.425.350
21937903,2011-07-01T00:00:00,Geriatric Assessment,N05.715.360.300.360
21937903,2011-07-01T00:00:00,Geriatric Assessment,N06.850.505.400.425.350
21937903,2011-07-01T00:00:00,Geriatric Assessment,N06.850.520.308.225
21937903,2011-07-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21937903,2011-07-01T00:00:00,Physical Therapy Modalities,E02.779
21937903,2011-07-01T00:00:00,Postural Balance,G11.427.690
21937903,2011-07-01T00:00:00,Postural Balance,G11.561.600.810.541.595
21937903,2011-07-01T00:00:00,Risk Assessment,E05.318.740.600.800.715
21937903,2011-07-01T00:00:00,Risk Assessment,N04.452.871.715
21937903,2011-07-01T00:00:00,Risk Assessment,N05.715.360.750.625.700.690
21937903,2011-07-01T00:00:00,Risk Assessment,N06.850.505.715
21937903,2011-07-01T00:00:00,Risk Assessment,N06.850.520.830.600.800.715
21944329,2011-07-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21944329,2011-07-01T00:00:00,Intraoperative Complications,C23.550.505
21944329,2011-07-01T00:00:00,Middle Aged,M01.060.116.630
21944331,2011-07-01T00:00:00,Adult,M01.060.116
21944331,2011-07-01T00:00:00,"Aneurysm, Dissecting",C14.907.055.050
21944331,2011-07-01T00:00:00,"Aortic Aneurysm, Thoracic",C14.907.055.239.125
21944331,2011-07-01T00:00:00,"Aortic Aneurysm, Thoracic",C14.907.109.139.125
21944331,2011-07-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21944331,2011-07-01T00:00:00,alpha 1-Antitrypsin Deficiency,C17.300.050
21944335,2011-07-01T00:00:00,Aged,M01.060.116.100
21944335,2011-07-01T00:00:00,Breast Neoplasms,C04.588.180
21944335,2011-07-01T00:00:00,Breast Neoplasms,C17.800.090.500
21944335,2011-07-01T00:00:00,"Carcinoma, Intraductal, Noninfiltrating",C04.557.470.200.025.275
21944335,2011-07-01T00:00:00,"Carcinoma, Intraductal, Noninfiltrating",C04.557.470.615.275
21944335,2011-07-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21944363,2011-07-01T00:00:00,Colon,A03.556.124.526.356
21944363,2011-07-01T00:00:00,Colon,A03.556.249.249.356
21944363,2011-07-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21944363,2011-07-01T00:00:00,Infant,M01.060.703
21944363,2011-07-01T00:00:00,Laparoscopy,E01.370.388.250.520
21944363,2011-07-01T00:00:00,Laparoscopy,E04.800.250.520
21944363,2011-07-01T00:00:00,Robotics,H01.671.293.643
21944363,2011-07-01T00:00:00,Robotics,J01.897.104.834
21944363,2011-07-01T00:00:00,Robotics,L01.224.065.630
21999033,2011-07-01T00:00:00,Adolescent,M01.060.057
21999033,2011-07-01T00:00:00,Adult,M01.060.116
21999033,2011-07-01T00:00:00,African Continental Ancestry Group,M01.686.508.100
21999033,2011-07-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21999033,2011-07-01T00:00:00,Mental Health Services,F04.408
21999033,2011-07-01T00:00:00,Mental Health Services,N02.421.461
21999033,2011-07-01T00:00:00,Middle Aged,M01.060.116.630
21999033,2011-07-01T00:00:00,Practice Guidelines as Topic,N04.761.700.350.650
21999033,2011-07-01T00:00:00,Practice Guidelines as Topic,N05.700.350.650
21999033,2011-07-01T00:00:00,Primary Health Care,N04.590.233.727
21999033,2011-07-01T00:00:00,Psychotherapy,F04.754
21999033,2011-07-01T00:00:00,"Stress Disorders, Post-Traumatic",F03.080.931.500
21724428,2011-07-02T00:00:00,Adolescent,M01.060.057
21724428,2011-07-02T00:00:00,"Anemia, Sickle Cell",C15.378.071.141.150.150
21724428,2011-07-02T00:00:00,"Anemia, Sickle Cell",C15.378.420.155
21724428,2011-07-02T00:00:00,"Anemia, Sickle Cell",C16.320.070.150
21724428,2011-07-02T00:00:00,"Anemia, Sickle Cell",C16.320.365.155
21724428,2011-07-02T00:00:00,Blood Transfusion,E02.095.135
21724428,2011-07-02T00:00:00,Brain,A08.186.211
21724428,2011-07-02T00:00:00,Child,M01.060.406
21724428,2011-07-02T00:00:00,"Child, Preschool",M01.060.406.448
21724428,2011-07-02T00:00:00,Disease Progression,C23.550.291.656
21724428,2011-07-02T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21724428,2011-07-02T00:00:00,Magnetic Resonance Angiography,E01.370.350.500.500
21724428,2011-07-02T00:00:00,Magnetic Resonance Angiography,E01.370.350.825.500.500
21724428,2011-07-02T00:00:00,Magnetic Resonance Angiography,E01.370.370.050.500
21724428,2011-07-02T00:00:00,Magnetic Resonance Imaging,E01.370.350.500
21724428,2011-07-02T00:00:00,Magnetic Resonance Imaging,E01.370.350.825.500
21724428,2011-07-02T00:00:00,Pediatrics,H02.403.670
21724428,2011-07-02T00:00:00,Stroke,C10.228.140.300.775
21724428,2011-07-02T00:00:00,Stroke,C14.907.253.855
21724428,2011-07-02T00:00:00,"Ultrasonography, Doppler, Transcranial",E01.370.350.700.560.260.850
21724428,2011-07-02T00:00:00,"Ultrasonography, Doppler, Transcranial",E01.370.350.850.260.850
21724428,2011-07-02T00:00:00,"Ultrasonography, Doppler, Transcranial",E01.370.350.850.850.870
21724428,2011-07-02T00:00:00,"Ultrasonography, Doppler, Transcranial",E01.370.376.560.260.850
21721997,2011-07-03T00:00:00,Adult,M01.060.116
21721997,2011-07-03T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21721997,2011-07-03T00:00:00,Immunoglobulin G,D12.776.124.486.485.114.619.393
21721997,2011-07-03T00:00:00,Immunoglobulin G,D12.776.124.790.651.114.619.393
21721997,2011-07-03T00:00:00,Immunoglobulin G,D12.776.377.715.548.114.619.393
21721997,2011-07-03T00:00:00,Low Back Pain,C10.597.617.152.400
21721997,2011-07-03T00:00:00,Low Back Pain,C23.888.592.612.107.400
21721997,2011-07-03T00:00:00,Low Back Pain,C23.888.646.172.500
21721997,2011-07-03T00:00:00,Magnetic Resonance Imaging,E01.370.350.500
21721997,2011-07-03T00:00:00,Magnetic Resonance Imaging,E01.370.350.825.500
21721997,2011-07-03T00:00:00,Pain Measurement,E01.370.376.550.600
21721997,2011-07-03T00:00:00,Physical Therapy Modalities,E02.779
21721997,2011-07-03T00:00:00,Referral and Consultation,N04.452.758.849
21721997,2011-07-03T00:00:00,"Spondylitis, Ankylosing",C05.116.900.853.625.800.850
21721997,2011-07-03T00:00:00,"Spondylitis, Ankylosing",C05.550.069.680
21721997,2011-07-03T00:00:00,"Spondylitis, Ankylosing",C05.550.114.865.800.850
21721997,2011-07-03T00:00:00,Treatment Outcome,E01.789.800
21721997,2011-07-03T00:00:00,Treatment Outcome,N04.761.559.590.800
21721997,2011-07-03T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21615707,2011-07-05T00:00:00,Animals,B01.050
21615707,2011-07-05T00:00:00,Carrier Proteins,D12.776.157
21615707,2011-07-05T00:00:00,GTP-Binding Protein Regulators,D12.644.360.325
21615707,2011-07-05T00:00:00,GTP-Binding Protein Regulators,D12.776.402
21615707,2011-07-05T00:00:00,GTP-Binding Protein Regulators,D12.776.476.325
21615707,2011-07-05T00:00:00,Heterotrimeric GTP-Binding Proteins,D08.811.277.040.330.300.200
21615707,2011-07-05T00:00:00,Heterotrimeric GTP-Binding Proteins,D12.644.360.375
21615707,2011-07-05T00:00:00,Heterotrimeric GTP-Binding Proteins,D12.776.157.325.332
21615707,2011-07-05T00:00:00,Heterotrimeric GTP-Binding Proteins,D12.776.476.375
21615707,2011-07-05T00:00:00,Heterotrimeric GTP-Binding Proteins,D12.776.543.325
21615707,2011-07-05T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21615707,2011-07-05T00:00:00,"Receptors, G-Protein-Coupled",D12.776.543.750.100
21615707,2011-07-05T00:00:00,Signal Transduction,G02.111.087.800
21615707,2011-07-05T00:00:00,Signal Transduction,G02.149.115.800
21615707,2011-07-05T00:00:00,Signal Transduction,G04.299.880
21718912,2011-07-05T00:00:00,Calcium,D01.268.552.100
21718912,2011-07-05T00:00:00,Calcium,D01.552.539.288
21718912,2011-07-05T00:00:00,Calcium,D23.119.100
21718912,2011-07-05T00:00:00,Echocardiography,E01.370.350.850.220
21718912,2011-07-05T00:00:00,Echocardiography,E01.370.370.380.220
21718912,2011-07-05T00:00:00,Heart Ventricles,A07.541.560
21718912,2011-07-05T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21718912,2011-07-05T00:00:00,Myocardial Contraction,G09.330.190.541
21718912,2011-07-05T00:00:00,Myocardial Contraction,G11.427.590.540.570
21718912,2011-07-05T00:00:00,Myocardium,A02.633.580
21718912,2011-07-05T00:00:00,Myocardium,A07.541.704
21718912,2011-07-05T00:00:00,Myocardium,A10.690.552.750
21718912,2011-07-05T00:00:00,Randomized Controlled Trials as Topic,E05.318.760.535.365.500
21718912,2011-07-05T00:00:00,Randomized Controlled Trials as Topic,E05.337.250.365.500
21718912,2011-07-05T00:00:00,Randomized Controlled Trials as Topic,N05.715.360.775.235.387.500
21718912,2011-07-05T00:00:00,Randomized Controlled Trials as Topic,N06.850.520.450.535.365.500
21733716,2011-07-05T00:00:00,Animals,B01.050
21733716,2011-07-05T00:00:00,Cell Line,A11.251.210
21733716,2011-07-05T00:00:00,Cytokines,D12.644.276.374
21733716,2011-07-05T00:00:00,Cytokines,D12.776.467.374
21733716,2011-07-05T00:00:00,Cytokines,D23.529.374
21733716,2011-07-05T00:00:00,Dual Specificity Phosphatase 1,D08.811.277.352.650.587.200
21733716,2011-07-05T00:00:00,Dual Specificity Phosphatase 1,D08.811.277.352.650.625.225.200
21733716,2011-07-05T00:00:00,Dual Specificity Phosphatase 1,D08.811.277.352.650.775.250.200
21733716,2011-07-05T00:00:00,Dual Specificity Phosphatase 1,D12.644.360.268.200
21733716,2011-07-05T00:00:00,Dual Specificity Phosphatase 1,D12.644.360.445.100
21733716,2011-07-05T00:00:00,Dual Specificity Phosphatase 1,D12.776.476.268.200
21733716,2011-07-05T00:00:00,Dual Specificity Phosphatase 1,D12.776.476.445.200
21733716,2011-07-05T00:00:00,GTP-Binding Proteins,D08.811.277.040.330.300
21733716,2011-07-05T00:00:00,GTP-Binding Proteins,D12.776.157.325
21733716,2011-07-05T00:00:00,Protein Transport,G03.495.166.700
21733716,2011-07-05T00:00:00,"RNA, Messenger",D13.444.735.544
21733716,2011-07-05T00:00:00,Rats,B01.050.150.900.649.865.635.505.700
21732197,2011-07-06T00:00:00,Aged,M01.060.116.100
21732197,2011-07-06T00:00:00,Colonoscopy,E01.370.372.250.250.200
21732197,2011-07-06T00:00:00,Colonoscopy,E01.370.388.250.250.250.160
21732197,2011-07-06T00:00:00,Colonoscopy,E04.210.240.250.160
21732197,2011-07-06T00:00:00,Colonoscopy,E04.800.250.250.250.160
21732197,2011-07-06T00:00:00,Colorectal Neoplasms,C04.588.274.476.411.307
21732197,2011-07-06T00:00:00,Colorectal Neoplasms,C06.301.371.411.307
21732197,2011-07-06T00:00:00,Colorectal Neoplasms,C06.405.249.411.307
21732197,2011-07-06T00:00:00,Colorectal Neoplasms,C06.405.469.158.356
21732197,2011-07-06T00:00:00,Colorectal Neoplasms,C06.405.469.491.307
21732197,2011-07-06T00:00:00,Colorectal Neoplasms,C06.405.469.860.180
21732197,2011-07-06T00:00:00,"Health Knowledge, Attitudes, Practice",F01.100.150.500
21732197,2011-07-06T00:00:00,"Health Knowledge, Attitudes, Practice",N05.300.150.410
21732197,2011-07-06T00:00:00,Health Surveys,E05.318.308.250
21732197,2011-07-06T00:00:00,Health Surveys,N05.715.360.300.375
21732197,2011-07-06T00:00:00,Health Surveys,N06.850.520.308.250
21732197,2011-07-06T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21732197,2011-07-06T00:00:00,Middle Aged,M01.060.116.630
21732197,2011-07-06T00:00:00,Patient Satisfaction,N04.452.822.360.600
21732197,2011-07-06T00:00:00,Patient Satisfaction,N05.300.150.600.630
21732197,2011-07-06T00:00:00,Patient Satisfaction,N05.715.360.600
21732197,2011-07-06T00:00:00,Risk Factors,E05.318.740.600.800.725
21732197,2011-07-06T00:00:00,Risk Factors,N05.715.350.200.700
21732197,2011-07-06T00:00:00,Risk Factors,N05.715.360.750.625.700.700
21732197,2011-07-06T00:00:00,Risk Factors,N06.850.490.625.750
21732197,2011-07-06T00:00:00,Risk Factors,N06.850.520.830.600.800.725
21732197,2011-07-06T00:00:00,Self Efficacy,F01.752.747.792.700
21732197,2011-07-06T00:00:00,United States,Z01.107.567.875
21733162,2011-07-06T00:00:00,Animals,B01.050
21733162,2011-07-06T00:00:00,Blood-Brain Barrier,A07.035
21733162,2011-07-06T00:00:00,Blood-Brain Barrier,A08.186.211.035
21733162,2011-07-06T00:00:00,Brain,A08.186.211
21733162,2011-07-06T00:00:00,Brain Injuries,C10.228.140.199
21733162,2011-07-06T00:00:00,Brain Injuries,C10.900.300.087
21733162,2011-07-06T00:00:00,Brain Injuries,C21.866.260.118
21733162,2011-07-06T00:00:00,Brain Injuries,C21.866.915.300.200
21733162,2011-07-06T00:00:00,Glutathione,D12.644.456.448
21733162,2011-07-06T00:00:00,Intercellular Adhesion Molecule-1,D12.776.395.550.200.450
21733162,2011-07-06T00:00:00,Intercellular Adhesion Molecule-1,D12.776.543.550.200.450
21733162,2011-07-06T00:00:00,Intercellular Adhesion Molecule-1,D23.050.301.264.035.400
21733162,2011-07-06T00:00:00,Intercellular Adhesion Molecule-1,D23.050.301.350.450
21733162,2011-07-06T00:00:00,Intercellular Adhesion Molecule-1,D23.101.100.110.400
21733162,2011-07-06T00:00:00,Nerve Regeneration,G11.561.600.615
21733162,2011-07-06T00:00:00,Nerve Regeneration,G16.100.856.611
21733162,2011-07-06T00:00:00,Neuroprotective Agents,D27.505.696.706.548
21733162,2011-07-06T00:00:00,Neuroprotective Agents,D27.505.954.427.575
21733162,2011-07-06T00:00:00,Nitric Oxide,D01.339.387
21733162,2011-07-06T00:00:00,Nitric Oxide,D01.625.550.500
21733162,2011-07-06T00:00:00,Nitric Oxide,D01.625.700.500
21733162,2011-07-06T00:00:00,Nitric Oxide,D01.650.550.587.600
21733162,2011-07-06T00:00:00,Oxidative Stress,G03.495.710
21733162,2011-07-06T00:00:00,Oxidative Stress,G07.700.830.750
21733162,2011-07-06T00:00:00,Peroxynitrous Acid,D01.625.600.800
21733162,2011-07-06T00:00:00,Peroxynitrous Acid,D01.625.700.750
21733162,2011-07-06T00:00:00,Rats,B01.050.150.900.649.865.635.505.700
21733162,2011-07-06T00:00:00,"Rats, Sprague-Dawley",B01.050.150.900.649.865.635.505.700.750
21733162,2011-07-06T00:00:00,S-Nitrosoglutathione,D02.654.846.500.249
21733162,2011-07-06T00:00:00,S-Nitrosoglutathione,D02.886.489.650.750
21733162,2011-07-06T00:00:00,S-Nitrosoglutathione,D12.644.456.448.750
21735178,2011-07-07T00:00:00,Calcinosis,C18.452.174.130
21735178,2011-07-07T00:00:00,Child,M01.060.406
21735178,2011-07-07T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21735178,2011-07-07T00:00:00,Myositis,C05.651.594
21735178,2011-07-07T00:00:00,Myositis,C10.668.491.562
21735178,2011-07-07T00:00:00,"Scleroderma, Systemic",C17.300.799
21735178,2011-07-07T00:00:00,"Scleroderma, Systemic",C17.800.784
21735178,2011-07-07T00:00:00,"Tomography, X-Ray Computed",E01.370.350.350.810
21735178,2011-07-07T00:00:00,"Tomography, X-Ray Computed",E01.370.350.600.350.700.810
21735178,2011-07-07T00:00:00,"Tomography, X-Ray Computed",E01.370.350.700.700.810
21735178,2011-07-07T00:00:00,"Tomography, X-Ray Computed",E01.370.350.700.810.810
21735178,2011-07-07T00:00:00,"Tomography, X-Ray Computed",E01.370.350.825.810.810
21737798,2011-07-07T00:00:00,Aged,M01.060.116.100
21737798,2011-07-07T00:00:00,Brain Ischemia,C10.228.140.300.150
21737798,2011-07-07T00:00:00,Brain Ischemia,C14.907.253.092
21737798,2011-07-07T00:00:00,Fibrinolytic Agents,D27.505.519.421.750
21737798,2011-07-07T00:00:00,Fibrinolytic Agents,D27.505.954.411.320
21737798,2011-07-07T00:00:00,Fibrinolytic Agents,D27.505.954.502.427
21737798,2011-07-07T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21737798,2011-07-07T00:00:00,Intracranial Hemorrhages,C10.228.140.300.535
21737798,2011-07-07T00:00:00,Intracranial Hemorrhages,C14.907.253.573
21737798,2011-07-07T00:00:00,Intracranial Hemorrhages,C23.550.414.913
21737798,2011-07-07T00:00:00,Middle Aged,M01.060.116.630
21737798,2011-07-07T00:00:00,Stroke,C10.228.140.300.775
21737798,2011-07-07T00:00:00,Stroke,C14.907.253.855
21737798,2011-07-07T00:00:00,Thrombectomy,E04.100.814.842
21737798,2011-07-07T00:00:00,Thrombolytic Therapy,E02.319.913
21737798,2011-07-07T00:00:00,Tissue Plasminogen Activator,D08.811.277.656.300.760.875
21737798,2011-07-07T00:00:00,Tissue Plasminogen Activator,D08.811.277.656.959.350.875
21737798,2011-07-07T00:00:00,Tissue Plasminogen Activator,D12.776.124.125.662.768
21737798,2011-07-07T00:00:00,Tissue Plasminogen Activator,D23.119.970
21737798,2011-07-07T00:00:00,Treatment Outcome,E01.789.800
21737798,2011-07-07T00:00:00,Treatment Outcome,N04.761.559.590.800
21737798,2011-07-07T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21742659,2011-07-07T00:00:00,Adsorption,G02.149.047
21742659,2011-07-07T00:00:00,Adsorption,G02.149.767.029
21742659,2011-07-07T00:00:00,Adsorption,G02.842.750.029
21742659,2011-07-07T00:00:00,Animals,B01.050
21742659,2011-07-07T00:00:00,Anti-Infective Agents,D27.505.954.122
21742659,2011-07-07T00:00:00,Antimicrobial Cationic Peptides,D12.644.050
21742659,2011-07-07T00:00:00,Antimicrobial Cationic Peptides,D12.776.543.695.054
21742659,2011-07-07T00:00:00,"Colony Count, Microbial",E05.200.875.220
21742659,2011-07-07T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21742659,2011-07-07T00:00:00,Lysostaphin,D08.811.277.656.300.480.452
21742659,2011-07-07T00:00:00,Lysostaphin,D08.811.277.656.675.374.452
21742659,2011-07-07T00:00:00,Muramidase,D08.811.277.450.642
21742659,2011-07-07T00:00:00,Polypropylenes,D02.455.326.271.665.590
21742659,2011-07-07T00:00:00,Polypropylenes,D05.750.716.550
21742659,2011-07-07T00:00:00,Polypropylenes,D25.720.716.550
21742659,2011-07-07T00:00:00,Polypropylenes,J01.637.051.720.716.550
21742659,2011-07-07T00:00:00,Staphylococcal Infections,C01.252.410.868
21742659,2011-07-07T00:00:00,Staphylococcus aureus,B03.300.390.400.800.750.100
21742659,2011-07-07T00:00:00,Staphylococcus aureus,B03.510.100.750.750.100
21742659,2011-07-07T00:00:00,Staphylococcus aureus,B03.510.400.790.750.100
21742659,2011-07-07T00:00:00,Surgical Mesh,E07.858.708
21742659,2011-07-07T00:00:00,Surgical Wound Infection,C01.539.947.692
21742659,2011-07-07T00:00:00,Surgical Wound Infection,C23.550.767.925
21742659,2011-07-07T00:00:00,beta-Defensins,D12.644.050.200.075
21742659,2011-07-07T00:00:00,beta-Defensins,D12.776.543.695.054.200.075
21742724,2011-07-08T00:00:00,Adolescent,M01.060.057
21742724,2011-07-08T00:00:00,African Americans,M01.686.508.100.100
21742724,2011-07-08T00:00:00,African Americans,M01.686.754.100
21742724,2011-07-08T00:00:00,Delivery of Health Care,N04.590.374
21742724,2011-07-08T00:00:00,Delivery of Health Care,N05.300
21742724,2011-07-08T00:00:00,"Health Knowledge, Attitudes, Practice",F01.100.150.500
21742724,2011-07-08T00:00:00,"Health Knowledge, Attitudes, Practice",N05.300.150.410
21742724,2011-07-08T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21742724,2011-07-08T00:00:00,Papillomavirus Infections,C02.256.650
21742724,2011-07-08T00:00:00,Papillomavirus Infections,C02.928.725
21742724,2011-07-08T00:00:00,Papillomavirus Vaccines,D20.215.894.899.498
21742724,2011-07-08T00:00:00,Patient Acceptance of Health Care,N05.300.150.600
21742724,2011-07-08T00:00:00,Social Identification,F01.145.813.708
21742724,2011-07-08T00:00:00,United States,Z01.107.567.875
21742724,2011-07-08T00:00:00,Young Adult,M01.060.116.815
21744395,2011-07-08T00:00:00,Amino Acids,D12.125
21744395,2011-07-08T00:00:00,Bacterial Proteins,D12.776.097
21744395,2011-07-08T00:00:00,Computer Simulation,L01.224.160
21744395,2011-07-08T00:00:00,Micrococcal Nuclease,D08.811.277.352.335.350.500
21744395,2011-07-08T00:00:00,Micrococcal Nuclease,D08.811.277.352.355.325.500
21744395,2011-07-08T00:00:00,Micrococcal Nuclease,D08.811.277.352.355.350.500
21744395,2011-07-08T00:00:00,Micrococcal Nuclease,D08.811.277.352.700.350.500
21744395,2011-07-08T00:00:00,"Models, Chemical",E05.599.495
21744395,2011-07-08T00:00:00,"Models, Molecular",E05.599.595
21744395,2011-07-08T00:00:00,Molecular Dynamics Simulation,E05.599.595.500
21744395,2011-07-08T00:00:00,Molecular Dynamics Simulation,G02.575.750
21744395,2011-07-08T00:00:00,Molecular Dynamics Simulation,L01.224.160.500
21744395,2011-07-08T00:00:00,Mutation,G05.365.590
21744395,2011-07-08T00:00:00,Protein Conformation,G02.111.570.790.709
21744395,2011-07-08T00:00:00,Protons,D01.248.497.300.459.700
21744395,2011-07-08T00:00:00,Protons,D01.435.550
21744395,2011-07-08T00:00:00,Protons,G01.249.765
21744395,2011-07-08T00:00:00,Static Electricity,G01.201.249.820
21775956,2011-07-08T00:00:00,Bacterial Proteins,D12.776.097
21775956,2011-07-08T00:00:00,Bacteriophages,B04.123
21775956,2011-07-08T00:00:00,Luminescent Measurements,E05.196.712.516
21775956,2011-07-08T00:00:00,Yersinia pestis,B03.440.450.425.900.600
21775956,2011-07-08T00:00:00,Yersinia pestis,B03.660.250.150.950.580
21745099,2011-07-11T00:00:00,Adolescent,M01.060.057
21745099,2011-07-11T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21745099,2011-07-11T00:00:00,Lung Diseases,C08.381
21745099,2011-07-11T00:00:00,Thoracic Injuries,C21.866.891
21745099,2011-07-11T00:00:00,"Thoracic Surgery, Video-Assisted",E01.370.388.250.840.830
21745099,2011-07-11T00:00:00,"Thoracic Surgery, Video-Assisted",E01.370.388.250.950.830
21745099,2011-07-11T00:00:00,"Thoracic Surgery, Video-Assisted",E04.800.250.840.830
21745099,2011-07-11T00:00:00,"Thoracic Surgery, Video-Assisted",E04.800.250.950.830
21745099,2011-07-11T00:00:00,"Thoracic Surgery, Video-Assisted",E04.928.752.830
21745099,2011-07-11T00:00:00,"Wounds, Nonpenetrating",C21.866.974
21806763,2011-07-11T00:00:00,Adult,M01.060.116
21806763,2011-07-11T00:00:00,Aged,M01.060.116.100
21806763,2011-07-11T00:00:00,Cardiovascular Diseases,C14
21806763,2011-07-11T00:00:00,Community Health Services,N02.421.143
21806763,2011-07-11T00:00:00,Community Networks,I01.880.656.300
21806763,2011-07-11T00:00:00,Community Networks,L01.700.508.300.184
21806763,2011-07-11T00:00:00,Community Networks,N02.421.143.202
21806763,2011-07-11T00:00:00,"Education, Medical, Continuing",I02.358.212.350
21806763,2011-07-11T00:00:00,"Education, Medical, Continuing",I02.358.399.250
21806763,2011-07-11T00:00:00,Electronic Health Records,E05.318.308.940.968.625.500
21806763,2011-07-11T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21806763,2011-07-11T00:00:00,Hypertension,C14.907.489
21806763,2011-07-11T00:00:00,Middle Aged,M01.060.116.630
21806763,2011-07-11T00:00:00,South Carolina,Z01.107.567.875.075.662
21806763,2011-07-11T00:00:00,South Carolina,Z01.107.567.875.750.700
21749226,2011-07-12T00:00:00,Animals,B01.050
21749226,2011-07-12T00:00:00,Carotid Arteries,A07.231.114.186
21749226,2011-07-12T00:00:00,Compressive Strength,G01.374.180
21749226,2011-07-12T00:00:00,Computer Simulation,L01.224.160
21749226,2011-07-12T00:00:00,Finite Element Analysis,E05.355
21749226,2011-07-12T00:00:00,"Imaging, Three-Dimensional",E01.370.350.400
21749226,2011-07-12T00:00:00,"Imaging, Three-Dimensional",L01.224.308.410
21749226,2011-07-12T00:00:00,Materials Testing,E05.570
21749226,2011-07-12T00:00:00,"Models, Biological",E05.599.395
21750125,2011-07-12T00:00:00,Aged,M01.060.116.100
21750125,2011-07-12T00:00:00,Biological Markers,D23.101
21750125,2011-07-12T00:00:00,Biphenyl Compounds,D02.455.426.559.389.185
21750125,2011-07-12T00:00:00,Collagen,D05.750.078.280
21750125,2011-07-12T00:00:00,Collagen,D12.776.860.300.250
21750125,2011-07-12T00:00:00,Double-Blind Method,E05.318.780.300
21750125,2011-07-12T00:00:00,Double-Blind Method,E05.581.500.300
21750125,2011-07-12T00:00:00,Double-Blind Method,N05.715.360.780.320
21750125,2011-07-12T00:00:00,Double-Blind Method,N06.850.520.445.300
21750125,2011-07-12T00:00:00,Fibrosis,C23.550.355
21750125,2011-07-12T00:00:00,Heart Failure,C14.280.434
21750125,2011-07-12T00:00:00,Hospitalization,E02.760.400
21750125,2011-07-12T00:00:00,Hospitalization,N02.421.585.400
21750125,2011-07-12T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21750125,2011-07-12T00:00:00,Myocardium,A02.633.580
21750125,2011-07-12T00:00:00,Myocardium,A07.541.704
21750125,2011-07-12T00:00:00,Myocardium,A10.690.552.750
21750125,2011-07-12T00:00:00,Peptide Fragments,D12.644.541
21750125,2011-07-12T00:00:00,Procollagen,D12.776.811.690
21750125,2011-07-12T00:00:00,Procollagen,D12.776.860.300.250.600
21750125,2011-07-12T00:00:00,Stroke Volume,E01.370.370.380.150.700
21750125,2011-07-12T00:00:00,Stroke Volume,G09.330.380.124.882
21756852,2011-07-12T00:00:00,Animals,B01.050
21756852,2011-07-12T00:00:00,Cell Death,G04.299.139
21756852,2011-07-12T00:00:00,Enzyme Inhibitors,D27.505.519.389
21756852,2011-07-12T00:00:00,Hepatocytes,A11.436.348
21756852,2011-07-12T00:00:00,Inflammation,C23.550.470
21756852,2011-07-12T00:00:00,Liver,A03.620
21756852,2011-07-12T00:00:00,Lysophospholipids,D10.570.755.375.760.550
21756852,2011-07-12T00:00:00,"Mitochondria, Liver",A11.284.430.214.190.875.564.461
21756852,2011-07-12T00:00:00,"Mitochondria, Liver",A11.284.835.626.461
21756852,2011-07-12T00:00:00,Nitric Oxide Synthase Type II,D08.811.682.664.500.772.500
21756852,2011-07-12T00:00:00,Phosphotransferases (Alcohol Group Acceptor),D08.811.913.696.620
21756852,2011-07-12T00:00:00,Pyridines,D03.383.725
21756852,2011-07-12T00:00:00,"RNA, Messenger",D13.444.735.544
21756852,2011-07-12T00:00:00,Reperfusion Injury,C14.907.725
21756852,2011-07-12T00:00:00,Reperfusion Injury,C23.550.767.877
21756852,2011-07-12T00:00:00,Sphingosine,D02.033.100.700
21756852,2011-07-12T00:00:00,Sphingosine,D02.033.455.843
21756852,2011-07-12T00:00:00,Sphingosine,D02.092.063.700
21990528,2011-07-12T00:00:00,Fellowships and Scholarships,N03.219.483.838.276
21990528,2011-07-12T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21990528,2011-07-12T00:00:00,Internship and Residency,I02.358.399.644
21990528,2011-07-12T00:00:00,Neurosurgery,H02.403.810.425
22287467,2011-07-12T00:00:00,Endoscopy,E01.370.388.250
22287467,2011-07-12T00:00:00,Endoscopy,E04.800.250
22287467,2011-07-12T00:00:00,Fluorescent Dyes,D27.720.233.348
22287467,2011-07-12T00:00:00,Fluorescent Dyes,D27.720.470.330.348
22287467,2011-07-12T00:00:00,Fluorescent Dyes,D27.720.470.410.505.500
22287467,2011-07-12T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22287467,2011-07-12T00:00:00,"Image Interpretation, Computer-Assisted",E01.158.600
22287467,2011-07-12T00:00:00,"Image Interpretation, Computer-Assisted",E01.370.350.350
22287467,2011-07-12T00:00:00,"Image Interpretation, Computer-Assisted",L01.700.508.100.158.600
22287467,2011-07-12T00:00:00,Turbinates,A02.835.232.781.324.948
22287467,2011-07-12T00:00:00,Turbinates,A04.531.898
21753017,2011-07-13T00:00:00,Animals,B01.050
21753017,2011-07-13T00:00:00,Carrier Proteins,D12.776.157
21753017,2011-07-13T00:00:00,Eye Proteins,D12.776.306
21753017,2011-07-13T00:00:00,Photic Stimulation,E05.723.729
21753017,2011-07-13T00:00:00,Regeneration,G16.100.856
21753017,2011-07-13T00:00:00,Retinal Cone Photoreceptor Cells,A08.663.650.850.625.670.100
21753017,2011-07-13T00:00:00,Retinal Cone Photoreceptor Cells,A08.663.650.915.937.670.100
21753017,2011-07-13T00:00:00,Retinal Cone Photoreceptor Cells,A08.800.950.937.670.100
21753017,2011-07-13T00:00:00,Retinal Cone Photoreceptor Cells,A09.371.729.831.625.670.100
21753017,2011-07-13T00:00:00,Retinal Cone Photoreceptor Cells,A11.671.650.850.625.670.100
21753017,2011-07-13T00:00:00,Retinal Cone Photoreceptor Cells,A11.671.650.915.937.670.100
21753017,2011-07-13T00:00:00,Retinal Pigment Epithelium,A09.371.670.500
21753017,2011-07-13T00:00:00,Retinal Pigment Epithelium,A09.371.729.887
21753017,2011-07-13T00:00:00,Retinal Rod Photoreceptor Cells,A08.663.650.850.625.670.650
21753017,2011-07-13T00:00:00,Retinal Rod Photoreceptor Cells,A08.663.650.915.937.670.650
21753017,2011-07-13T00:00:00,Retinal Rod Photoreceptor Cells,A08.800.950.937.670.650
21753017,2011-07-13T00:00:00,Retinal Rod Photoreceptor Cells,A09.371.729.831.625.670.650
21753017,2011-07-13T00:00:00,Retinal Rod Photoreceptor Cells,A11.671.650.850.625.670.650
21753017,2011-07-13T00:00:00,Retinal Rod Photoreceptor Cells,A11.671.650.915.937.670.650
21757197,2011-07-14T00:00:00,Animals,B01.050
21757197,2011-07-14T00:00:00,Apolipoproteins E,D10.532.091.500
21757197,2011-07-14T00:00:00,Apolipoproteins E,D12.776.070.400.500
21757197,2011-07-14T00:00:00,Apolipoproteins E,D12.776.521.120.500
21757197,2011-07-14T00:00:00,Cell Adhesion,G04.299.117
21990525,2011-07-14T00:00:00,Brain Ischemia,C10.228.140.300.150
21990525,2011-07-14T00:00:00,Brain Ischemia,C14.907.253.092
21990525,2011-07-14T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21990525,2011-07-14T00:00:00,Stroke,C10.228.140.300.775
21990525,2011-07-14T00:00:00,Stroke,C14.907.253.855
21990525,2011-07-14T00:00:00,Treatment Outcome,E01.789.800
21990525,2011-07-14T00:00:00,Treatment Outcome,N04.761.559.590.800
21990525,2011-07-14T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21532336,2011-07-15T00:00:00,Aged,M01.060.116.100
21532336,2011-07-15T00:00:00,Antineoplastic Combined Chemotherapy Protocols,E02.183.750.500
21532336,2011-07-15T00:00:00,Antineoplastic Combined Chemotherapy Protocols,E02.319.077.500
21532336,2011-07-15T00:00:00,Antineoplastic Combined Chemotherapy Protocols,E02.319.310.037
21532336,2011-07-15T00:00:00,Gonadotropin-Releasing Hormone,D06.472.699.327.740.320
21532336,2011-07-15T00:00:00,Gonadotropin-Releasing Hormone,D12.644.400.400.740.320
21532336,2011-07-15T00:00:00,Gonadotropin-Releasing Hormone,D12.644.456.460
21532336,2011-07-15T00:00:00,Gonadotropin-Releasing Hormone,D12.644.548.365.740.320
21532336,2011-07-15T00:00:00,Gonadotropin-Releasing Hormone,D12.776.641.650.405.740.320
21532336,2011-07-15T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21532336,2011-07-15T00:00:00,Middle Aged,M01.060.116.630
21532336,2011-07-15T00:00:00,"Neoplasm Recurrence, Local",C04.697.655
21532336,2011-07-15T00:00:00,"Neoplasm Recurrence, Local",C23.550.727.655
21532336,2011-07-15T00:00:00,Neoplasm Staging,E01.370.550
21532336,2011-07-15T00:00:00,Prostate-Specific Antigen,D08.811.277.656.300.760.442.750
21532336,2011-07-15T00:00:00,Prostate-Specific Antigen,D08.811.277.656.959.350.442.750
21532336,2011-07-15T00:00:00,Prostate-Specific Antigen,D12.776.866.249.500
21532336,2011-07-15T00:00:00,Prostate-Specific Antigen,D23.050.285.625
21532336,2011-07-15T00:00:00,Prostate-Specific Antigen,D23.101.840.625
21532336,2011-07-15T00:00:00,Prostatic Neoplasms,C04.588.945.440.770
21532336,2011-07-15T00:00:00,Prostatic Neoplasms,C12.294.260.750
21532336,2011-07-15T00:00:00,Prostatic Neoplasms,C12.294.565.625
21532336,2011-07-15T00:00:00,Prostatic Neoplasms,C12.758.409.750
21720213,2011-07-15T00:00:00,Animals,B01.050
21720213,2011-07-15T00:00:00,"Antibodies, Monoclonal",D12.776.124.486.485.114.224
21720213,2011-07-15T00:00:00,"Antibodies, Monoclonal",D12.776.124.790.651.114.224
21720213,2011-07-15T00:00:00,"Antibodies, Monoclonal",D12.776.377.715.548.114.224
21720213,2011-07-15T00:00:00,Antineoplastic Agents,D27.505.954.248
21720213,2011-07-15T00:00:00,Colonic Neoplasms,C04.588.274.476.411.307.180
21720213,2011-07-15T00:00:00,Colonic Neoplasms,C06.301.371.411.307.180
21720213,2011-07-15T00:00:00,Colonic Neoplasms,C06.405.249.411.307.180
21720213,2011-07-15T00:00:00,Colonic Neoplasms,C06.405.469.158.356.180
21720213,2011-07-15T00:00:00,Colonic Neoplasms,C06.405.469.491.307.180
21720213,2011-07-15T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21720213,2011-07-15T00:00:00,"Immunoglobulins, Intravenous",D12.776.124.486.485.114.619.393.536
21720213,2011-07-15T00:00:00,"Immunoglobulins, Intravenous",D12.776.124.486.485.114.632
21720213,2011-07-15T00:00:00,"Immunoglobulins, Intravenous",D12.776.124.790.651.114.632
21720213,2011-07-15T00:00:00,"Immunoglobulins, Intravenous",D12.776.377.715.548.114.632
21720213,2011-07-15T00:00:00,Insulin-Like Growth Factor I,D12.644.276.937.400
21720213,2011-07-15T00:00:00,Insulin-Like Growth Factor I,D12.776.124.862.400
21720213,2011-07-15T00:00:00,Insulin-Like Growth Factor I,D12.776.467.937.400
21720213,2011-07-15T00:00:00,Insulin-Like Growth Factor I,D23.529.937.400
21720213,2011-07-15T00:00:00,Neoplastic Stem Cells,A11.872.650
21720213,2011-07-15T00:00:00,Proto-Oncogene Proteins c-akt,D08.811.913.696.620.682.700.755
21720213,2011-07-15T00:00:00,Proto-Oncogene Proteins c-akt,D12.776.476.565
21720213,2011-07-15T00:00:00,Proto-Oncogene Proteins c-akt,D12.776.624.664.700.168
21720213,2011-07-15T00:00:00,RNA Interference,G05.355.315.203.374.790
21720213,2011-07-15T00:00:00,"Receptor, IGF Type 1",D08.811.913.696.620.682.725.400.185
21720213,2011-07-15T00:00:00,"Receptor, IGF Type 1",D12.776.543.750.060.468
21720213,2011-07-15T00:00:00,"Receptor, IGF Type 1",D12.776.543.750.750.400.780.400
21720213,2011-07-15T00:00:00,beta Catenin,D12.776.091.249
21720213,2011-07-15T00:00:00,beta Catenin,D12.776.220.145.500
21720213,2011-07-15T00:00:00,beta Catenin,D12.776.930.130
21765024,2011-07-15T00:00:00,Adult,M01.060.116
21765024,2011-07-15T00:00:00,Cell Proliferation,G04.299.233.750
21765024,2011-07-15T00:00:00,Cell Proliferation,G07.700.320.249.410.750
21765024,2011-07-15T00:00:00,DNA Methylation,G02.111.087.029.538.161
21765024,2011-07-15T00:00:00,DNA Methylation,G02.111.087.218
21765024,2011-07-15T00:00:00,DNA Methylation,G02.149.115.029.538.161
21765024,2011-07-15T00:00:00,DNA Methylation,G02.149.115.218
21765024,2011-07-15T00:00:00,DNA Methylation,G03.495.130.538.161
21765024,2011-07-15T00:00:00,DNA Methylation,G05.355.190
21765024,2011-07-15T00:00:00,"Gene Expression Regulation, Neoplastic",G05.355.315.370
21765024,2011-07-15T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21765024,2011-07-15T00:00:00,"Models, Biological",E05.599.395
21765024,2011-07-15T00:00:00,Protein Kinase Inhibitors,D27.505.519.389.755
21765024,2011-07-15T00:00:00,Protein-Tyrosine Kinases,D08.811.913.696.620.682.725
21762938,2011-07-16T00:00:00,Animals,B01.050
21762938,2011-07-16T00:00:00,Aortic Valve Stenosis,C14.280.484.150
21762938,2011-07-16T00:00:00,Aortic Valve Stenosis,C14.280.955.249
21762938,2011-07-16T00:00:00,Disease Progression,C23.550.291.656
21762938,2011-07-16T00:00:00,Extracellular Matrix Proteins,D12.776.860.300
21762938,2011-07-16T00:00:00,Fibrosis,C23.550.355
21762938,2011-07-16T00:00:00,Heart Failure,C14.280.434
21762938,2011-07-16T00:00:00,Heart Valve Prosthesis Implantation,E04.100.376.485
21762938,2011-07-16T00:00:00,Heart Valve Prosthesis Implantation,E04.650.410
21762938,2011-07-16T00:00:00,Heart Valve Prosthesis Implantation,E04.928.220.410
21762938,2011-07-16T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21762938,2011-07-16T00:00:00,"Hypertrophy, Left Ventricular",C14.280.195.400
21762938,2011-07-16T00:00:00,"Hypertrophy, Left Ventricular",C23.300.775.250.400
21762938,2011-07-16T00:00:00,Myocardium,A02.633.580
21762938,2011-07-16T00:00:00,Myocardium,A07.541.704
21762938,2011-07-16T00:00:00,Myocardium,A10.690.552.750
21762938,2011-07-16T00:00:00,Risk Assessment,E05.318.740.600.800.715
21762938,2011-07-16T00:00:00,Risk Assessment,N04.452.871.715
21762938,2011-07-16T00:00:00,Risk Assessment,N05.715.360.750.625.700.690
21762938,2011-07-16T00:00:00,Risk Assessment,N06.850.505.715
21762938,2011-07-16T00:00:00,Risk Assessment,N06.850.520.830.600.800.715
21762938,2011-07-16T00:00:00,Risk Factors,E05.318.740.600.800.725
21762938,2011-07-16T00:00:00,Risk Factors,N05.715.350.200.700
21762938,2011-07-16T00:00:00,Risk Factors,N05.715.360.750.625.700.700
21762938,2011-07-16T00:00:00,Risk Factors,N06.850.490.625.750
21762938,2011-07-16T00:00:00,Risk Factors,N06.850.520.830.600.800.725
21762938,2011-07-16T00:00:00,Treatment Outcome,E01.789.800
21762938,2011-07-16T00:00:00,Treatment Outcome,N04.761.559.590.800
21762938,2011-07-16T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21762938,2011-07-16T00:00:00,"Ventricular Dysfunction, Left",C14.280.945.900
21762938,2011-07-16T00:00:00,"Ventricular Function, Left",G09.330.190.962.800
21762938,2011-07-16T00:00:00,Ventricular Pressure,G09.330.190.962.950
21762938,2011-07-16T00:00:00,Ventricular Pressure,G09.330.380.937
21762938,2011-07-16T00:00:00,Ventricular Remodeling,C23.300.985
21762938,2011-07-16T00:00:00,Ventricular Remodeling,G09.330.190.962.975
21766161,2011-07-16T00:00:00,Adenocarcinoma,C04.557.470.200.025
21766161,2011-07-16T00:00:00,Antineoplastic Combined Chemotherapy Protocols,E02.183.750.500
21766161,2011-07-16T00:00:00,Antineoplastic Combined Chemotherapy Protocols,E02.319.077.500
21766161,2011-07-16T00:00:00,Antineoplastic Combined Chemotherapy Protocols,E02.319.310.037
21766161,2011-07-16T00:00:00,Cisplatin,D01.210.375
21766161,2011-07-16T00:00:00,Cisplatin,D01.625.125
21766161,2011-07-16T00:00:00,Cisplatin,D01.710.100
21766161,2011-07-16T00:00:00,Esophageal Neoplasms,C04.588.274.476.205
21766161,2011-07-16T00:00:00,Esophageal Neoplasms,C04.588.443.353
21766161,2011-07-16T00:00:00,Esophageal Neoplasms,C06.301.371.205
21766161,2011-07-16T00:00:00,Esophageal Neoplasms,C06.405.117.430
21766161,2011-07-16T00:00:00,Esophageal Neoplasms,C06.405.249.205
21766161,2011-07-16T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21766161,2011-07-16T00:00:00,Middle Aged,M01.060.116.630
21766161,2011-07-16T00:00:00,Peripheral Nervous System Diseases,C10.668.829
21766161,2011-07-16T00:00:00,Quality of Life,I01.800
21766161,2011-07-16T00:00:00,Quality of Life,K01.752.400.750
21779822,2011-07-16T00:00:00,Animals,B01.050
21779822,2011-07-16T00:00:00,Environmental Exposure,N06.850.460.350
21779822,2011-07-16T00:00:00,Environmental Monitoring,N06.850.460.350.080
21779822,2011-07-16T00:00:00,Environmental Monitoring,N06.850.780.375
21779822,2011-07-16T00:00:00,Environmental Pollutants,D27.888.284
21779822,2011-07-16T00:00:00,Mercury,D01.268.556.504
21779822,2011-07-16T00:00:00,Mercury,D01.268.956.437
21779822,2011-07-16T00:00:00,Mercury,D01.552.544.504
21779822,2011-07-16T00:00:00,Reproduction,G08.686.785.760
21762534,2011-07-17T00:00:00,Acetylglucosamine,D09.067.342.531.050
21762534,2011-07-17T00:00:00,Adenocarcinoma,C04.557.470.200.025
21762534,2011-07-17T00:00:00,Adult,M01.060.116
21762534,2011-07-17T00:00:00,"Antigens, CD147",D12.776.395.550.045
21762534,2011-07-17T00:00:00,"Antigens, CD147",D12.776.543.550.188
21762534,2011-07-17T00:00:00,"Antigens, CD147",D23.050.285.040
21762534,2011-07-17T00:00:00,"Antigens, CD147",D23.050.301.264.035.247
21762534,2011-07-17T00:00:00,"Antigens, CD147",D23.101.100.110.247
21762534,2011-07-17T00:00:00,Fibroblasts,A11.329.228
21762534,2011-07-17T00:00:00,Fibroblasts,A11.872.228
21762534,2011-07-17T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21762534,2011-07-17T00:00:00,Lung Neoplasms,C04.588.894.797.520
21762534,2011-07-17T00:00:00,Lung Neoplasms,C08.381.540
21762534,2011-07-17T00:00:00,Lung Neoplasms,C08.785.520
21762534,2011-07-17T00:00:00,Matrix Metalloproteinase 2,D08.811.277.656.300.480.205.352
21762534,2011-07-17T00:00:00,Matrix Metalloproteinase 2,D08.811.277.656.300.480.252.420
21762534,2011-07-17T00:00:00,Matrix Metalloproteinase 2,D08.811.277.656.300.480.525.700.150
21762534,2011-07-17T00:00:00,Matrix Metalloproteinase 2,D08.811.277.656.675.374.205.352
21762534,2011-07-17T00:00:00,Matrix Metalloproteinase 2,D08.811.277.656.675.374.252.420
21762534,2011-07-17T00:00:00,Matrix Metalloproteinase 2,D08.811.277.656.675.374.525.700.150
21762534,2011-07-17T00:00:00,Molecular Sequence Data,L01.453.245.667
21762534,2011-07-17T00:00:00,Peptide Fragments,D12.644.541
21762534,2011-07-17T00:00:00,"Protein Processing, Post-Translational",G02.111.087.675.871.790.600
21762534,2011-07-17T00:00:00,"Protein Processing, Post-Translational",G02.111.087.693.600
21762534,2011-07-17T00:00:00,"Protein Processing, Post-Translational",G02.149.115.675.871.790.600
21762534,2011-07-17T00:00:00,"Protein Processing, Post-Translational",G02.149.115.693.600
21762534,2011-07-17T00:00:00,"Protein Processing, Post-Translational",G03.495.770.871.790.600
21762534,2011-07-17T00:00:00,"Protein Processing, Post-Translational",G05.355.315.670.600
21762534,2011-07-17T00:00:00,Sarcoma,C04.557.450.795
21765468,2011-07-18T00:00:00,Animals,B01.050
21765468,2011-07-18T00:00:00,Cell Aging,G04.299.119
21765468,2011-07-18T00:00:00,Cell Line,A11.251.210
21765468,2011-07-18T00:00:00,"Cell Transformation, Neoplastic",C04.697.152
21765468,2011-07-18T00:00:00,"Cell Transformation, Neoplastic",C23.550.727.152
21765468,2011-07-18T00:00:00,Neoplasms,C04
21765468,2011-07-18T00:00:00,Phosphotransferases (Alcohol Group Acceptor),D08.811.913.696.620
21765468,2011-07-18T00:00:00,Tumor Suppressor Protein p53,D12.776.260.820
21765468,2011-07-18T00:00:00,Tumor Suppressor Protein p53,D12.776.624.776.775
21765468,2011-07-18T00:00:00,Tumor Suppressor Protein p53,D12.776.660.825
21765468,2011-07-18T00:00:00,Tumor Suppressor Protein p53,D12.776.744.845
21766118,2011-07-18T00:00:00,Actins,D05.750.078.730.250
21766118,2011-07-18T00:00:00,Actins,D12.776.210.500.100
21766118,2011-07-18T00:00:00,Actins,D12.776.220.525.255
21766118,2011-07-18T00:00:00,Alloys,D01.552.033
21766118,2011-07-18T00:00:00,Alloys,D25.058
21766118,2011-07-18T00:00:00,Alloys,J01.637.051.058
21766118,2011-07-18T00:00:00,Animals,B01.050
21766118,2011-07-18T00:00:00,Cell Proliferation,G04.299.233.750
21766118,2011-07-18T00:00:00,Cell Proliferation,G07.700.320.249.410.750
21766118,2011-07-18T00:00:00,"Myocytes, Smooth Muscle",A11.620.520
21766118,2011-07-18T00:00:00,Nickel,D01.268.556.607
21766118,2011-07-18T00:00:00,Nickel,D01.268.956.625
21766118,2011-07-18T00:00:00,Nickel,D01.552.544.607
21766118,2011-07-18T00:00:00,Rats,B01.050.150.900.649.865.635.505.700
21766118,2011-07-18T00:00:00,"Rats, Sprague-Dawley",B01.050.150.900.649.865.635.505.700.750
21766118,2011-07-18T00:00:00,Titanium,D01.268.557.800
21766118,2011-07-18T00:00:00,Titanium,D01.268.956.878
21766118,2011-07-18T00:00:00,Titanium,D01.552.547.800
21767030,2011-07-18T00:00:00,Animals,B01.050
21767030,2011-07-18T00:00:00,Central Nervous System Stimulants,D27.505.696.282
21767030,2011-07-18T00:00:00,Central Nervous System Stimulants,D27.505.954.427.220
21767030,2011-07-18T00:00:00,"Conditioning, Operant",F02.463.425.179.509
21767030,2011-07-18T00:00:00,Dextroamphetamine,D02.092.471.683.152.110.200
21767030,2011-07-18T00:00:00,Rats,B01.050.150.900.649.865.635.505.700
21767030,2011-07-18T00:00:00,"Rats, Sprague-Dawley",B01.050.150.900.649.865.635.505.700.750
21767030,2011-07-18T00:00:00,Self Administration,E02.319.890
21767030,2011-07-18T00:00:00,Self Administration,E02.900.890
21770001,2011-07-18T00:00:00,Adult,M01.060.116
21770001,2011-07-18T00:00:00,Anxiety,F01.470.132
21770001,2011-07-18T00:00:00,Cognitive Therapy,F04.754.137.428
21770001,2011-07-18T00:00:00,Depression,F01.145.126.350
21770001,2011-07-18T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21770001,2011-07-18T00:00:00,Panic Disorder,F03.080.700
21770001,2011-07-18T00:00:00,Pilot Projects,E05.318.760.750
21770001,2011-07-18T00:00:00,Pilot Projects,E05.337.737
21770001,2011-07-18T00:00:00,Pilot Projects,N05.715.360.775.625
21770001,2011-07-18T00:00:00,Pilot Projects,N06.850.520.450.720
21770001,2011-07-18T00:00:00,Psychiatric Status Rating Scales,F04.586
21770001,2011-07-18T00:00:00,Treatment Outcome,E01.789.800
21770001,2011-07-18T00:00:00,Treatment Outcome,N04.761.559.590.800
21770001,2011-07-18T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21838844,2011-07-18T00:00:00,Adolescent,M01.060.057
21838844,2011-07-18T00:00:00,Adult,M01.060.116
21838844,2011-07-18T00:00:00,Amphetamine-Related Disorders,C21.739.225
21838844,2011-07-18T00:00:00,Amphetamine-Related Disorders,F03.900.225
21838844,2011-07-18T00:00:00,Cognition,F02.463.188
21838844,2011-07-18T00:00:00,Cognition Disorders,F03.087.250
21838844,2011-07-18T00:00:00,Demography,I01.240
21838844,2011-07-18T00:00:00,Demography,N01.224
21838844,2011-07-18T00:00:00,Demography,N06.850.505.400
21838844,2011-07-18T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21838844,2011-07-18T00:00:00,Middle Aged,M01.060.116.630
21838844,2011-07-18T00:00:00,Neuropsychological Tests,F04.711.513
21838844,2011-07-18T00:00:00,Rural Population,N01.600.725
21838844,2011-07-18T00:00:00,Sex Characteristics,G08.686.815
21838844,2011-07-18T00:00:00,South Carolina,Z01.107.567.875.075.662
21838844,2011-07-18T00:00:00,South Carolina,Z01.107.567.875.750.700
21924688,2011-07-18T00:00:00,Adult,M01.060.116
21924688,2011-07-18T00:00:00,Bariatric Surgery,E02.065.062
21924688,2011-07-18T00:00:00,Bariatric Surgery,E04.062
21924688,2011-07-18T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21924688,2011-07-18T00:00:00,"Interview, Psychological",F04.669.599
21924688,2011-07-18T00:00:00,Patient Selection,E05.581.500.653
21924688,2011-07-18T00:00:00,Patient Selection,N04.590.731
21924688,2011-07-18T00:00:00,Preoperative Care,E02.760.795
21924688,2011-07-18T00:00:00,Preoperative Care,E04.641
21924688,2011-07-18T00:00:00,Preoperative Care,N02.421.585.795
21924688,2011-07-18T00:00:00,Psychiatric Status Rating Scales,F04.586
21924688,2011-07-18T00:00:00,Psychometrics,F04.711.780
21772329,2011-07-19T00:00:00,Adult,M01.060.116
21772329,2011-07-19T00:00:00,Aged,M01.060.116.100
21772329,2011-07-19T00:00:00,Breast Neoplasms,C04.588.180
21772329,2011-07-19T00:00:00,Breast Neoplasms,C17.800.090.500
21772329,2011-07-19T00:00:00,Carcinoma,C04.557.470.200
21772329,2011-07-19T00:00:00,Gonadal Steroid Hormones,D06.472.334.851
21772329,2011-07-19T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21772329,2011-07-19T00:00:00,Middle Aged,M01.060.116.630
21772329,2011-07-19T00:00:00,Pregnancy,G08.686.785.760.769
21772329,2011-07-19T00:00:00,Risk Factors,E05.318.740.600.800.725
21772329,2011-07-19T00:00:00,Risk Factors,N05.715.350.200.700
21772329,2011-07-19T00:00:00,Risk Factors,N05.715.360.750.625.700.700
21772329,2011-07-19T00:00:00,Risk Factors,N06.850.490.625.750
21772329,2011-07-19T00:00:00,Risk Factors,N06.850.520.830.600.800.725
22188834,2011-07-19T00:00:00,Adolescent,M01.060.057
22188834,2011-07-19T00:00:00,Central Nervous System Depressants,D27.505.696.277
22188834,2011-07-19T00:00:00,Central Nervous System Depressants,D27.505.954.427.210
22188834,2011-07-19T00:00:00,Child,M01.060.406
22188834,2011-07-19T00:00:00,Crime Victims,M01.135
22188834,2011-07-19T00:00:00,Ethanol,D02.033.375
22188834,2011-07-19T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22188834,2011-07-19T00:00:00,Interviews as Topic,E05.318.308.420
22188834,2011-07-19T00:00:00,Interviews as Topic,L01.280.520
22188834,2011-07-19T00:00:00,Interviews as Topic,N05.715.360.300.400
22188834,2011-07-19T00:00:00,Interviews as Topic,N06.850.520.308.420
22188834,2011-07-19T00:00:00,Sex Offenses,I01.198.240.748
22188834,2011-07-19T00:00:00,"Stress Disorders, Post-Traumatic",F03.080.931.500
22188834,2011-07-19T00:00:00,United States,Z01.107.567.875
22748177,2011-07-19T00:00:00,Animals,B01.050
22748177,2011-07-19T00:00:00,Bayes Theorem,E05.318.740.600.200
22748177,2011-07-19T00:00:00,Bayes Theorem,N05.715.360.750.625.150
22748177,2011-07-19T00:00:00,Bayes Theorem,N06.850.520.830.600.200
22748177,2011-07-19T00:00:00,Disease Outbreaks,N06.850.290
22748177,2011-07-19T00:00:00,Foot-and-Mouth Disease,C02.782.687.484
22748177,2011-07-19T00:00:00,Foot-and-Mouth Disease,C22.380
22748177,2011-07-19T00:00:00,Incidence,E05.318.308.985.525.375
22748177,2011-07-19T00:00:00,Incidence,L01.280.975.525.375
22748177,2011-07-19T00:00:00,Incidence,N01.224.935.597.500
22748177,2011-07-19T00:00:00,Incidence,N06.850.505.400.975.525.375
22748177,2011-07-19T00:00:00,Incidence,N06.850.520.308.985.525.375
22748177,2011-07-19T00:00:00,"Models, Biological",E05.599.395
22748177,2011-07-19T00:00:00,"Models, Statistical",E05.318.740.500
22748177,2011-07-19T00:00:00,"Models, Statistical",E05.599.835
22748177,2011-07-19T00:00:00,"Models, Statistical",N05.715.360.750.530
22748177,2011-07-19T00:00:00,"Models, Statistical",N06.850.520.830.500
21764215,2011-07-20T00:00:00,Adult,M01.060.116
21764215,2011-07-20T00:00:00,Aged,M01.060.116.100
21764215,2011-07-20T00:00:00,Depression,F01.145.126.350
21764215,2011-07-20T00:00:00,Fibromyalgia,C05.651.324
21764215,2011-07-20T00:00:00,Fibromyalgia,C05.799.321
21764215,2011-07-20T00:00:00,Fibromyalgia,C10.668.491.425
21764215,2011-07-20T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21764215,2011-07-20T00:00:00,Medical Records,E05.318.308.940.968
21764215,2011-07-20T00:00:00,Medical Records,L01.280.900.968
21764215,2011-07-20T00:00:00,Medical Records,N04.452.859.564
21764215,2011-07-20T00:00:00,Medical Records,N05.715.360.300.715.500
21764215,2011-07-20T00:00:00,Medical Records,N06.850.520.308.940.968
21764215,2011-07-20T00:00:00,Middle Aged,M01.060.116.630
21764215,2011-07-20T00:00:00,Pilot Projects,E05.318.760.750
21764215,2011-07-20T00:00:00,Pilot Projects,E05.337.737
21764215,2011-07-20T00:00:00,Pilot Projects,N05.715.360.775.625
21764215,2011-07-20T00:00:00,Pilot Projects,N06.850.520.450.720
21764215,2011-07-20T00:00:00,Prefrontal Cortex,A08.186.211.730.885.287.500.270.700
21764215,2011-07-20T00:00:00,Transcranial Magnetic Stimulation,E01.370.376.850
21764215,2011-07-20T00:00:00,Transcranial Magnetic Stimulation,E02.621.820
21778148,2011-07-20T00:00:00,Adult,M01.060.116
21778148,2011-07-20T00:00:00,Health Care Costs,N03.219.151.400
21778148,2011-07-20T00:00:00,Health Care Costs,N05.300.375
21778148,2011-07-20T00:00:00,Hispanic Americans,M01.686.754.441
21778148,2011-07-20T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21778148,2011-07-20T00:00:00,"Infant, Newborn",M01.060.703.520
21778148,2011-07-20T00:00:00,"Intensive Care Units, Neonatal",N02.278.388.493.390.380
21778148,2011-07-20T00:00:00,Length of Stay,E02.760.400.480
21778148,2011-07-20T00:00:00,Length of Stay,N02.421.585.400.480
21778148,2011-07-20T00:00:00,Maternal-Fetal Exchange,G08.686.785.760.769.455
21778148,2011-07-20T00:00:00,Pregnancy,G08.686.785.760.769
21778148,2011-07-20T00:00:00,Pregnancy Complications,C13.703
21778148,2011-07-20T00:00:00,Risk Assessment,E05.318.740.600.800.715
21778148,2011-07-20T00:00:00,Risk Assessment,N04.452.871.715
21778148,2011-07-20T00:00:00,Risk Assessment,N05.715.360.750.625.700.690
21778148,2011-07-20T00:00:00,Risk Assessment,N06.850.505.715
21778148,2011-07-20T00:00:00,Risk Assessment,N06.850.520.830.600.800.715
21778148,2011-07-20T00:00:00,Smoking,F01.145.466.753
21778148,2011-07-20T00:00:00,United States,Z01.107.567.875
21778148,2011-07-20T00:00:00,Young Adult,M01.060.116.815
21778151,2011-07-20T00:00:00,Adolescent,M01.060.057
21778151,2011-07-20T00:00:00,Benzazepines,D03.438.079
21778151,2011-07-20T00:00:00,Double-Blind Method,E05.318.780.300
21778151,2011-07-20T00:00:00,Double-Blind Method,E05.581.500.300
21778151,2011-07-20T00:00:00,Double-Blind Method,N05.715.360.780.320
21778151,2011-07-20T00:00:00,Double-Blind Method,N06.850.520.445.300
21778151,2011-07-20T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21778151,2011-07-20T00:00:00,Pilot Projects,E05.318.760.750
21778151,2011-07-20T00:00:00,Pilot Projects,E05.337.737
21778151,2011-07-20T00:00:00,Pilot Projects,N05.715.360.775.625
21778151,2011-07-20T00:00:00,Pilot Projects,N06.850.520.450.720
21778151,2011-07-20T00:00:00,Sleep Initiation and Maintenance Disorders,C10.886.425.800.800
21778151,2011-07-20T00:00:00,Sleep Initiation and Maintenance Disorders,F03.870.400.800.800
21778151,2011-07-20T00:00:00,Smoking,F01.145.466.753
21778151,2011-07-20T00:00:00,Smoking Cessation,F01.145.940.700
21778151,2011-07-20T00:00:00,Treatment Outcome,E01.789.800
21778151,2011-07-20T00:00:00,Treatment Outcome,N04.761.559.590.800
21778151,2011-07-20T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21778151,2011-07-20T00:00:00,Young Adult,M01.060.116.815
21801811,2011-07-20T00:00:00,Apoptosis,G04.299.139.160
21801811,2011-07-20T00:00:00,Apoptosis Regulatory Proteins,D12.644.360.075
21801811,2011-07-20T00:00:00,Apoptosis Regulatory Proteins,D12.776.476.075
21801811,2011-07-20T00:00:00,Cell Survival,G04.299.316
21801811,2011-07-20T00:00:00,Down-Regulation,G02.111.087.225
21801811,2011-07-20T00:00:00,Down-Regulation,G02.149.115.225
21801811,2011-07-20T00:00:00,Down-Regulation,G05.355.315.200
21801811,2011-07-20T00:00:00,Down-Regulation,G07.690.812.230
21801811,2011-07-20T00:00:00,Down-Regulation,G07.700.680.230
21801811,2011-07-20T00:00:00,Fenretinide,D02.455.326.271.665.202.495.270
21801811,2011-07-20T00:00:00,Fenretinide,D02.455.426.392.368.367.379.249.700.270
21801811,2011-07-20T00:00:00,Fenretinide,D02.455.849.131.495.270
21801811,2011-07-20T00:00:00,Fenretinide,D23.767.261.700.270
21801811,2011-07-20T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21801811,2011-07-20T00:00:00,Signal Transduction,G02.111.087.800
21801811,2011-07-20T00:00:00,Signal Transduction,G02.149.115.800
21801811,2011-07-20T00:00:00,Signal Transduction,G04.299.880
21778330,2011-07-21T00:00:00,Adult,M01.060.116
21778330,2011-07-21T00:00:00,Aged,M01.060.116.100
21778330,2011-07-21T00:00:00,Apoptosis,G04.299.139.160
21778330,2011-07-21T00:00:00,"Biopsy, Fine-Needle",E01.370.388.100.100.500
21778330,2011-07-21T00:00:00,"Biopsy, Fine-Needle",E01.450.230.100.100.500
21778330,2011-07-21T00:00:00,"Biopsy, Fine-Needle",E01.450.865.100.100.500
21778330,2011-07-21T00:00:00,"Biopsy, Fine-Needle",E04.074.119.500
21778330,2011-07-21T00:00:00,Breast Neoplasms,C04.588.180
21778330,2011-07-21T00:00:00,Breast Neoplasms,C17.800.090.500
21778330,2011-07-21T00:00:00,"Carcinoma, Lobular",C04.557.470.200.025.305
21778330,2011-07-21T00:00:00,"Carcinoma, Lobular",C04.557.470.615.305
21778330,2011-07-21T00:00:00,Cell Proliferation,G04.299.233.750
21778330,2011-07-21T00:00:00,Cell Proliferation,G07.700.320.249.410.750
21778330,2011-07-21T00:00:00,DNA Methylation,G02.111.087.029.538.161
21778330,2011-07-21T00:00:00,DNA Methylation,G02.111.087.218
21778330,2011-07-21T00:00:00,DNA Methylation,G02.149.115.029.538.161
21778330,2011-07-21T00:00:00,DNA Methylation,G02.149.115.218
21778330,2011-07-21T00:00:00,DNA Methylation,G03.495.130.538.161
21778330,2011-07-21T00:00:00,DNA Methylation,G05.355.190
21778330,2011-07-21T00:00:00,DNA-Binding Proteins,D12.776.260
21778330,2011-07-21T00:00:00,Double-Blind Method,E05.318.780.300
21778330,2011-07-21T00:00:00,Double-Blind Method,E05.581.500.300
21778330,2011-07-21T00:00:00,Double-Blind Method,N05.715.360.780.320
21778330,2011-07-21T00:00:00,Double-Blind Method,N06.850.520.445.300
21778330,2011-07-21T00:00:00,Down-Regulation,G02.111.087.225
21778330,2011-07-21T00:00:00,Down-Regulation,G02.149.115.225
21778330,2011-07-21T00:00:00,Down-Regulation,G05.355.315.200
21778330,2011-07-21T00:00:00,Down-Regulation,G07.690.812.230
21778330,2011-07-21T00:00:00,Down-Regulation,G07.700.680.230
21778330,2011-07-21T00:00:00,Gene Expression Profiling,E05.393.332
21778330,2011-07-21T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21778330,2011-07-21T00:00:00,Middle Aged,M01.060.116.630
21778330,2011-07-21T00:00:00,Neoplasm Staging,E01.370.550
21778330,2011-07-21T00:00:00,Oligonucleotide Array Sequence Analysis,E05.196.630.570.660
21778330,2011-07-21T00:00:00,Oligonucleotide Array Sequence Analysis,E05.393.525.640
21778330,2011-07-21T00:00:00,Oligonucleotide Array Sequence Analysis,E05.393.661.640
21778330,2011-07-21T00:00:00,Oligonucleotide Array Sequence Analysis,E05.393.760.640
21778330,2011-07-21T00:00:00,Oligonucleotide Array Sequence Analysis,E05.588.570.660
21778330,2011-07-21T00:00:00,Oligonucleotide Array Sequence Analysis,E05.601.640
21778330,2011-07-21T00:00:00,Proto-Oncogene Proteins,D12.776.624.664.700
21778330,2011-07-21T00:00:00,Risk Reduction Behavior,F01.145.699
21778330,2011-07-21T00:00:00,Transcription Factors,D12.776.930
21778330,2011-07-21T00:00:00,Treatment Outcome,E01.789.800
21778330,2011-07-21T00:00:00,Treatment Outcome,N04.761.559.590.800
21778330,2011-07-21T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21778330,2011-07-21T00:00:00,"Tumor Markers, Biological",D23.101.840
21779880,2011-07-21T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21779880,2011-07-21T00:00:00,Mouth Mucosa,A10.615.550.599
21779880,2011-07-21T00:00:00,Mouth Mucosa,A14.549.512
21779880,2011-07-21T00:00:00,Neoplasms,C04
21779880,2011-07-21T00:00:00,Vascular Neoplasms,C04.588.839.750
21779880,2011-07-21T00:00:00,Vascular Neoplasms,C14.907.936
21779880,2011-07-21T00:00:00,Young Adult,M01.060.116.815
21782465,2011-07-22T00:00:00,"Decompression, Surgical",E04.188
21782465,2011-07-22T00:00:00,Enteral Nutrition,E02.421.360
21782465,2011-07-22T00:00:00,Enteral Nutrition,E02.642.500.360
21782465,2011-07-22T00:00:00,Gastrostomy,E04.210.496
21782465,2011-07-22T00:00:00,Gastrostomy,E04.579.408
21782465,2011-07-22T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21782465,2011-07-22T00:00:00,"Intubation, Gastrointestinal",E05.497.412
21782465,2011-07-22T00:00:00,Jejunostomy,E04.210.338.523
21782465,2011-07-22T00:00:00,Jejunostomy,E04.579.338.523
21782465,2011-07-22T00:00:00,Postoperative Complications,C23.550.767
21782528,2011-07-22T00:00:00,Aged,M01.060.116.100
21782528,2011-07-22T00:00:00,Alzheimer Disease,C10.228.140.380.100
21782528,2011-07-22T00:00:00,Alzheimer Disease,C10.574.945.249
21782528,2011-07-22T00:00:00,Alzheimer Disease,F03.087.400.100
21782528,2011-07-22T00:00:00,Cholinesterase Inhibitors,D27.505.519.389.275
21782528,2011-07-22T00:00:00,Cholinesterase Inhibitors,D27.505.519.625.120.300
21782528,2011-07-22T00:00:00,Cholinesterase Inhibitors,D27.505.696.577.120.300
21782528,2011-07-22T00:00:00,Cognition Disorders,F03.087.250
21782528,2011-07-22T00:00:00,Disease Progression,C23.550.291.656
21782528,2011-07-22T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21782528,2011-07-22T00:00:00,Middle Aged,M01.060.116.630
21782528,2011-07-22T00:00:00,"Models, Theoretical",E05.599
21782528,2011-07-22T00:00:00,Neuropsychological Tests,F04.711.513
21782528,2011-07-22T00:00:00,Randomized Controlled Trials as Topic,E05.318.760.535.365.500
21782528,2011-07-22T00:00:00,Randomized Controlled Trials as Topic,E05.337.250.365.500
21782528,2011-07-22T00:00:00,Randomized Controlled Trials as Topic,N05.715.360.775.235.387.500
21782528,2011-07-22T00:00:00,Randomized Controlled Trials as Topic,N06.850.520.450.535.365.500
21782528,2011-07-22T00:00:00,Time Factors,G01.910.857
21783176,2011-07-23T00:00:00,Animals,B01.050
21783176,2011-07-23T00:00:00,Cocaine,D02.145.074.722.388
21783176,2011-07-23T00:00:00,Cocaine,D03.132.889.354
21783176,2011-07-23T00:00:00,Cocaine,D03.605.869.388
21783176,2011-07-23T00:00:00,Cocaine,D04.075.080.875.099.722.388
21783176,2011-07-23T00:00:00,Cues,F02.463.425.234
21783176,2011-07-23T00:00:00,Drug Interactions,G07.690.812.240
21783176,2011-07-23T00:00:00,Drug Interactions,G07.700.680.240
21783176,2011-07-23T00:00:00,Motor Activity,F01.145.632
21783176,2011-07-23T00:00:00,Motor Activity,G11.427.590.530.698
21783176,2011-07-23T00:00:00,Pyrimidines,D03.383.742
21783176,2011-07-23T00:00:00,Pyrroles,D03.383.129.578
21783176,2011-07-23T00:00:00,Rats,B01.050.150.900.649.865.635.505.700
21783176,2011-07-23T00:00:00,"Rats, Sprague-Dawley",B01.050.150.900.649.865.635.505.700.750
21783176,2011-07-23T00:00:00,Self Administration,E02.319.890
21783176,2011-07-23T00:00:00,Self Administration,E02.900.890
21784436,2011-07-23T00:00:00,Angiotensin-Converting Enzyme Inhibitors,D27.505.519.389.745.085
21784436,2011-07-23T00:00:00,Enalapril,D12.644.456.345.360
21784436,2011-07-23T00:00:00,Growth Disorders,C23.550.393
21784436,2011-07-23T00:00:00,"Heart Defects, Congenital",C14.240.400
21784436,2011-07-23T00:00:00,"Heart Defects, Congenital",C14.280.400
21784436,2011-07-23T00:00:00,"Heart Defects, Congenital",C16.131.240.400
21784436,2011-07-23T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21784436,2011-07-23T00:00:00,Infant,M01.060.703
21784436,2011-07-23T00:00:00,"Infant, Newborn",M01.060.703.520
21784464,2011-07-23T00:00:00,Bladder Exstrophy,C12.706.132
21784464,2011-07-23T00:00:00,Bladder Exstrophy,C12.777.829.132
21784464,2011-07-23T00:00:00,Bladder Exstrophy,C13.351.875.132
21784464,2011-07-23T00:00:00,Bladder Exstrophy,C13.351.968.829.132
21784464,2011-07-23T00:00:00,Bladder Exstrophy,C16.131.939.132
21784464,2011-07-23T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21784464,2011-07-23T00:00:00,Infant,M01.060.703
21784464,2011-07-23T00:00:00,"Infant, Newborn",M01.060.703.520
21784464,2011-07-23T00:00:00,Postoperative Complications,C23.550.767
21784464,2011-07-23T00:00:00,Referral and Consultation,N04.452.758.849
21784537,2011-07-23T00:00:00,Adolescent,M01.060.057
21784537,2011-07-23T00:00:00,Adrenal Cortex Hormones,D06.472.040
21784537,2011-07-23T00:00:00,Bronchoscopy,E01.370.386.105
21784537,2011-07-23T00:00:00,Bronchoscopy,E01.370.388.250.100
21784537,2011-07-23T00:00:00,Bronchoscopy,E04.800.250.100
21784537,2011-07-23T00:00:00,Bronchoscopy,E04.928.600.080
21784537,2011-07-23T00:00:00,"Child, Preschool",M01.060.406.448
21784537,2011-07-23T00:00:00,Combined Modality Therapy,E02.186
21784537,2011-07-23T00:00:00,Craniofacial Abnormalities,C05.660.207
21784537,2011-07-23T00:00:00,Craniofacial Abnormalities,C16.131.621.207
21784537,2011-07-23T00:00:00,Craniosynostoses,C05.116.099.370.894.232
21784537,2011-07-23T00:00:00,Craniosynostoses,C05.660.207.240
21784537,2011-07-23T00:00:00,Craniosynostoses,C05.660.906.364
21784537,2011-07-23T00:00:00,Craniosynostoses,C16.131.621.207.240
21784537,2011-07-23T00:00:00,Craniosynostoses,C16.131.621.906.364
21784537,2011-07-23T00:00:00,Edema,C23.888.277
21784537,2011-07-23T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21784537,2011-07-23T00:00:00,"Intubation, Intratracheal",E05.497.578
21784537,2011-07-23T00:00:00,Reconstructive Surgical Procedures,E04.680
21784537,2011-07-23T00:00:00,Risk Assessment,E05.318.740.600.800.715
21784537,2011-07-23T00:00:00,Risk Assessment,N04.452.871.715
21784537,2011-07-23T00:00:00,Risk Assessment,N05.715.360.750.625.700.690
21784537,2011-07-23T00:00:00,Risk Assessment,N06.850.505.715
21784537,2011-07-23T00:00:00,Risk Assessment,N06.850.520.830.600.800.715
21784537,2011-07-23T00:00:00,Tongue Diseases,C07.465.910
21784537,2011-07-23T00:00:00,Tracheotomy,E04.580.907
21784537,2011-07-23T00:00:00,Tracheotomy,E04.928.790
21784537,2011-07-23T00:00:00,Treatment Outcome,E01.789.800
21784537,2011-07-23T00:00:00,Treatment Outcome,N04.761.559.590.800
21784537,2011-07-23T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21807020,2011-07-23T00:00:00,Amphetamine-Related Disorders,C21.739.225
21807020,2011-07-23T00:00:00,Amphetamine-Related Disorders,F03.900.225
21807020,2011-07-23T00:00:00,Animals,B01.050
21807020,2011-07-23T00:00:00,Attention Deficit Disorder with Hyperactivity,F03.550.150.150
21807020,2011-07-23T00:00:00,"Behavior, Animal",F01.145.113
21807020,2011-07-23T00:00:00,Central Nervous System Stimulants,D27.505.696.282
21807020,2011-07-23T00:00:00,Central Nervous System Stimulants,D27.505.954.427.220
21807020,2011-07-23T00:00:00,"Conditioning, Operant",F02.463.425.179.509
21807020,2011-07-23T00:00:00,Dextroamphetamine,D02.092.471.683.152.110.200
21807020,2011-07-23T00:00:00,Dopamine Uptake Inhibitors,D27.505.519.625.150.800
21807020,2011-07-23T00:00:00,Dopamine Uptake Inhibitors,D27.505.519.625.600.220
21807020,2011-07-23T00:00:00,Dopamine Uptake Inhibitors,D27.505.696.577.150.800
21807020,2011-07-23T00:00:00,Dopamine Uptake Inhibitors,D27.505.696.577.600.220
21807020,2011-07-23T00:00:00,Drug Resistance,G07.690.320
21807020,2011-07-23T00:00:00,Impulsive Behavior,F01.145.527
21807020,2011-07-23T00:00:00,Motor Activity,F01.145.632
21807020,2011-07-23T00:00:00,Motor Activity,G11.427.590.530.698
21807020,2011-07-23T00:00:00,Rats,B01.050.150.900.649.865.635.505.700
21807020,2011-07-23T00:00:00,"Rats, Sprague-Dawley",B01.050.150.900.649.865.635.505.700.750
21807089,2011-07-23T00:00:00,Animals,B01.050
21807089,2011-07-23T00:00:00,Cell Proliferation,G04.299.233.750
21807089,2011-07-23T00:00:00,Cell Proliferation,G07.700.320.249.410.750
21807089,2011-07-23T00:00:00,Cell Separation,E05.200.500.363
21807089,2011-07-23T00:00:00,Chronic Disease,C23.550.291.500
21807089,2011-07-23T00:00:00,Cytokines,D12.644.276.374
21807089,2011-07-23T00:00:00,Cytokines,D12.776.467.374
21807089,2011-07-23T00:00:00,Cytokines,D23.529.374
21807089,2011-07-23T00:00:00,Disease Progression,C23.550.291.656
21807089,2011-07-23T00:00:00,Flow Cytometry,E05.196.712.516.600.240.350
21807089,2011-07-23T00:00:00,Flow Cytometry,E05.200.500.386.350
21807089,2011-07-23T00:00:00,Immunoglobulin G,D12.776.124.486.485.114.619.393
21807089,2011-07-23T00:00:00,Immunoglobulin G,D12.776.124.790.651.114.619.393
21807089,2011-07-23T00:00:00,Immunoglobulin G,D12.776.377.715.548.114.619.393
21807089,2011-07-23T00:00:00,Interleukin-10,D12.644.276.374.465.510
21807089,2011-07-23T00:00:00,Interleukin-10,D12.776.467.374.465.510
21807089,2011-07-23T00:00:00,Interleukin-10,D23.529.374.465.510
21807089,2011-07-23T00:00:00,Myeloid Cells,A11.627
21807089,2011-07-23T00:00:00,Serum Amyloid A Protein,D12.776.049.790
21807089,2011-07-23T00:00:00,Serum Amyloid A Protein,D12.776.124.050.725
21807089,2011-07-23T00:00:00,Spleen,A10.549.700
21807089,2011-07-23T00:00:00,Spleen,A15.382.520.604.700
21807089,2011-07-23T00:00:00,Stilbenes,D02.455.426.559.389.150.700
21807089,2011-07-23T00:00:00,T-Lymphocytes,A11.118.637.555.567.569
21807089,2011-07-23T00:00:00,T-Lymphocytes,A15.145.229.637.555.567.569
21807089,2011-07-23T00:00:00,T-Lymphocytes,A15.382.490.555.567.569
21807089,2011-07-23T00:00:00,Weight Loss,C23.888.144.243.963
21807089,2011-07-23T00:00:00,Weight Loss,G07.700.320.249.314.120.200.963
21786169,2011-07-24T00:00:00,Albumins,D12.776.034
21786169,2011-07-24T00:00:00,Apoptosis,G04.299.139.160
21786169,2011-07-24T00:00:00,Apoptosis Inducing Factor,D08.811.682.608.047
21786169,2011-07-24T00:00:00,Apoptosis Inducing Factor,D12.644.360.075.311
21786169,2011-07-24T00:00:00,Apoptosis Inducing Factor,D12.776.331.161
21786169,2011-07-24T00:00:00,Apoptosis Inducing Factor,D12.776.476.075.311
21786169,2011-07-24T00:00:00,Cell Differentiation,G04.299.151
21786169,2011-07-24T00:00:00,Cell Survival,G04.299.316
21786169,2011-07-24T00:00:00,Down-Regulation,G02.111.087.225
21786169,2011-07-24T00:00:00,Down-Regulation,G02.149.115.225
21786169,2011-07-24T00:00:00,Down-Regulation,G05.355.315.200
21786169,2011-07-24T00:00:00,Down-Regulation,G07.690.812.230
21786169,2011-07-24T00:00:00,Down-Regulation,G07.700.680.230
21786169,2011-07-24T00:00:00,Glioblastoma,C04.557.465.625.600.380.080.335
21786169,2011-07-24T00:00:00,Glioblastoma,C04.557.470.670.380.080.335
21786169,2011-07-24T00:00:00,Glioblastoma,C04.557.580.625.600.380.080.335
21786169,2011-07-24T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21786169,2011-07-24T00:00:00,P-Glycoprotein,D12.776.157.530.100.652.500
21786169,2011-07-24T00:00:00,P-Glycoprotein,D12.776.157.530.450.074.500.500.750
21786169,2011-07-24T00:00:00,P-Glycoprotein,D12.776.395.550.020.610.610
21786169,2011-07-24T00:00:00,P-Glycoprotein,D12.776.543.550.192.610.610
21786169,2011-07-24T00:00:00,P-Glycoprotein,D12.776.543.585.100.610.500
21786169,2011-07-24T00:00:00,P-Glycoprotein,D12.776.543.585.450.074.500.500.750
21786169,2011-07-24T00:00:00,Proto-Oncogene Proteins c-bcl-2,D12.644.360.075.718
21786169,2011-07-24T00:00:00,Proto-Oncogene Proteins c-bcl-2,D12.776.476.075.718
21786169,2011-07-24T00:00:00,Proto-Oncogene Proteins c-bcl-2,D12.776.624.664.700.169
21786169,2011-07-24T00:00:00,Valproic Acid,D02.241.081.944.509.900
21786169,2011-07-24T00:00:00,Valproic Acid,D10.251.400.895.593.900
21786169,2011-07-24T00:00:00,bcl-2-Associated X Protein,D12.644.360.075.718.400
21786169,2011-07-24T00:00:00,bcl-2-Associated X Protein,D12.776.476.075.718.400
21787182,2011-07-25T00:00:00,Adolescent,M01.060.057
21787182,2011-07-25T00:00:00,Adult,M01.060.116
21787182,2011-07-25T00:00:00,Aged,M01.060.116.100
21787182,2011-07-25T00:00:00,Cardiovascular Diseases,C14
21787182,2011-07-25T00:00:00,Child,M01.060.406
21787182,2011-07-25T00:00:00,"Child, Preschool",M01.060.406.448
21787182,2011-07-25T00:00:00,Environmental Exposure,N06.850.460.350
21787182,2011-07-25T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21787182,2011-07-25T00:00:00,Infant,M01.060.703
21787182,2011-07-25T00:00:00,"Infant, Newborn",M01.060.703.520
21787182,2011-07-25T00:00:00,Middle Aged,M01.060.116.630
21787182,2011-07-25T00:00:00,Radiation Injuries,C21.866.733
21787182,2011-07-25T00:00:00,Radiation Injuries,N06.850.810.300.360
21787182,2011-07-25T00:00:00,Risk Assessment,E05.318.740.600.800.715
21787182,2011-07-25T00:00:00,Risk Assessment,N04.452.871.715
21787182,2011-07-25T00:00:00,Risk Assessment,N05.715.360.750.625.700.690
21787182,2011-07-25T00:00:00,Risk Assessment,N06.850.505.715
21787182,2011-07-25T00:00:00,Risk Assessment,N06.850.520.830.600.800.715
21787182,2011-07-25T00:00:00,Young Adult,M01.060.116.815
21788442,2011-07-25T00:00:00,Animals,B01.050
21788442,2011-07-25T00:00:00,Autoimmune Diseases,C20.111
21788442,2011-07-25T00:00:00,Cell Separation,E05.200.500.363
21788442,2011-07-25T00:00:00,Flow Cytometry,E05.196.712.516.600.240.350
21788442,2011-07-25T00:00:00,Flow Cytometry,E05.200.500.386.350
21788442,2011-07-25T00:00:00,Homeostasis,G07.700.360
21788442,2011-07-25T00:00:00,Inflammation,C23.550.470
21788442,2011-07-25T00:00:00,Suppressor of Cytokine Signaling Proteins,D12.644.360.024.374
21788442,2011-07-25T00:00:00,Suppressor of Cytokine Signaling Proteins,D12.776.157.057.249
21788442,2011-07-25T00:00:00,Suppressor of Cytokine Signaling Proteins,D12.776.476.024.437
21788442,2011-07-25T00:00:00,T-Lymphocyte Subsets,A11.118.637.555.567.550.500
21788442,2011-07-25T00:00:00,T-Lymphocyte Subsets,A11.118.637.555.567.569.500
21788442,2011-07-25T00:00:00,T-Lymphocyte Subsets,A15.145.229.637.555.567.550.500
21788442,2011-07-25T00:00:00,T-Lymphocyte Subsets,A15.145.229.637.555.567.569.500
21788442,2011-07-25T00:00:00,T-Lymphocyte Subsets,A15.382.490.555.567.550.500
21788442,2011-07-25T00:00:00,T-Lymphocyte Subsets,A15.382.490.555.567.569.500
21788442,2011-07-25T00:00:00,"T-Lymphocytes, Regulatory",A11.118.637.555.567.569.200.700
21788442,2011-07-25T00:00:00,"T-Lymphocytes, Regulatory",A15.145.229.637.555.567.569.200.700
21788442,2011-07-25T00:00:00,"T-Lymphocytes, Regulatory",A15.382.490.555.567.569.200.700
21790899,2011-07-25T00:00:00,Adult,M01.060.116
21790899,2011-07-25T00:00:00,Brain,A08.186.211
21790899,2011-07-25T00:00:00,Brain Mapping,E01.370.350.086
21790899,2011-07-25T00:00:00,Brain Mapping,E01.370.376.149
21790899,2011-07-25T00:00:00,Brain Mapping,E05.132
21790899,2011-07-25T00:00:00,Cues,F02.463.425.234
21790899,2011-07-25T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21790899,2011-07-25T00:00:00,"Image Processing, Computer-Assisted",L01.224.308
21790899,2011-07-25T00:00:00,Magnetic Resonance Imaging,E01.370.350.500
21790899,2011-07-25T00:00:00,Magnetic Resonance Imaging,E01.370.350.825.500
21790899,2011-07-25T00:00:00,Middle Aged,M01.060.116.630
21790899,2011-07-25T00:00:00,Motivation,F01.658
21790899,2011-07-25T00:00:00,Motivation,F01.752.543.500.750
21790899,2011-07-25T00:00:00,Smoking Cessation,F01.145.940.700
21790899,2011-07-25T00:00:00,Substance Withdrawal Syndrome,C21.739.835
21790899,2011-07-25T00:00:00,Substance Withdrawal Syndrome,F03.900.825
21790899,2011-07-25T00:00:00,Tobacco Use Disorder,C21.739.912
21790899,2011-07-25T00:00:00,Tobacco Use Disorder,F03.900.912
21790899,2011-07-25T00:00:00,Young Adult,M01.060.116.815
21789664,2011-07-26T00:00:00,Bone Diseases,C05.116
21789664,2011-07-26T00:00:00,"Diagnosis, Differential",E01.171
21789664,2011-07-26T00:00:00,Hereditary Autoinflammatory Diseases,C16.320.382
21789664,2011-07-26T00:00:00,Hereditary Autoinflammatory Diseases,C17.800.827.368
21789664,2011-07-26T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21789664,2011-07-26T00:00:00,"Infant, Newborn",M01.060.703.520
21791630,2011-07-26T00:00:00,Aged,M01.060.116.100
21791630,2011-07-26T00:00:00,Antineoplastic Combined Chemotherapy Protocols,E02.183.750.500
21791630,2011-07-26T00:00:00,Antineoplastic Combined Chemotherapy Protocols,E02.319.077.500
21791630,2011-07-26T00:00:00,Antineoplastic Combined Chemotherapy Protocols,E02.319.310.037
21791630,2011-07-26T00:00:00,Biological Markers,D23.101
21791630,2011-07-26T00:00:00,"Carcinoma, Squamous Cell",C04.557.470.200.400
21791630,2011-07-26T00:00:00,"Carcinoma, Squamous Cell",C04.557.470.700.400
21791630,2011-07-26T00:00:00,Ceramides,D02.065.313
21791630,2011-07-26T00:00:00,Ceramides,D09.400.410.420.525.200
21791630,2011-07-26T00:00:00,Ceramides,D10.390.470.675.200
21791630,2011-07-26T00:00:00,Ceramides,D10.570.877.360.612.200
21791630,2011-07-26T00:00:00,Deoxycytidine,D03.383.742.680.245.500
21791630,2011-07-26T00:00:00,Deoxycytidine,D13.570.230.329
21791630,2011-07-26T00:00:00,Deoxycytidine,D13.570.685.245.500
21791630,2011-07-26T00:00:00,Doxorubicin,D02.455.426.559.847.562.050.200.175
21791630,2011-07-26T00:00:00,Doxorubicin,D04.615.562.050.200.175
21791630,2011-07-26T00:00:00,Doxorubicin,D09.408.051.059.200.175
21791630,2011-07-26T00:00:00,Head and Neck Neoplasms,C04.588.443
21791630,2011-07-26T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21791630,2011-07-26T00:00:00,Middle Aged,M01.060.116.630
21791630,2011-07-26T00:00:00,Treatment Outcome,E01.789.800
21791630,2011-07-26T00:00:00,Treatment Outcome,N04.761.559.590.800
21791630,2011-07-26T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21816177,2011-07-26T00:00:00,Animals,B01.050
21816177,2011-07-26T00:00:00,Brain,A08.186.211
21816177,2011-07-26T00:00:00,Brain Mapping,E01.370.350.086
21816177,2011-07-26T00:00:00,Brain Mapping,E01.370.376.149
21816177,2011-07-26T00:00:00,Brain Mapping,E05.132
21816177,2011-07-26T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21816177,2011-07-26T00:00:00,Motivation,F01.658
21816177,2011-07-26T00:00:00,Motivation,F01.752.543.500.750
21822367,2011-07-26T00:00:00,Anti-Bacterial Agents,D27.505.954.122.085
21822367,2011-07-26T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21822367,2011-07-26T00:00:00,Pelvic Inflammatory Disease,C01.539.635.500
21822367,2011-07-26T00:00:00,Pelvic Inflammatory Disease,C13.351.500.056.750
21822367,2011-07-26T00:00:00,Sexually Transmitted Diseases,C01.539.778
21822367,2011-07-26T00:00:00,Sexually Transmitted Diseases,C02.800
21822367,2011-07-26T00:00:00,Sexually Transmitted Diseases,C12.294.668
21822367,2011-07-26T00:00:00,Sexually Transmitted Diseases,C13.351.500.711
21674560,2011-07-27T00:00:00,Animals,B01.050
21674560,2011-07-27T00:00:00,Cell Proliferation,G04.299.233.750
21674560,2011-07-27T00:00:00,Cell Proliferation,G07.700.320.249.410.750
21674560,2011-07-27T00:00:00,Cytokines,D12.644.276.374
21674560,2011-07-27T00:00:00,Cytokines,D12.776.467.374
21674560,2011-07-27T00:00:00,Cytokines,D23.529.374
21674560,2011-07-27T00:00:00,Endothelial Cells,A11.436.275
21674560,2011-07-27T00:00:00,Lipopolysaccharides,D09.400.500
21674560,2011-07-27T00:00:00,Lipopolysaccharides,D09.698.718.450
21674560,2011-07-27T00:00:00,Lipopolysaccharides,D10.494
21674560,2011-07-27T00:00:00,Lipopolysaccharides,D23.050.161.616.525
21674560,2011-07-27T00:00:00,Lipopolysaccharides,D23.946.123.329.500
21674560,2011-07-27T00:00:00,Nitric Oxide Synthase,D08.811.682.664.500.772
21674560,2011-07-27T00:00:00,Toll-Like Receptor 4,D12.776.543.750.705.910.500.400
21792988,2011-07-27T00:00:00,Computer Simulation,L01.224.160
21792988,2011-07-27T00:00:00,Electromagnetic Fields,G01.201.260
21792988,2011-07-27T00:00:00,Electromagnetic Fields,G01.201.875.240
21792988,2011-07-27T00:00:00,Electroosmosis,E05.196.385
21792988,2011-07-27T00:00:00,Electroosmosis,E05.301.270
21792988,2011-07-27T00:00:00,Electroosmosis,G02.149.535.250
21792988,2011-07-27T00:00:00,Electroosmosis,G02.149.767.645.250
21792988,2011-07-27T00:00:00,Electroosmosis,G02.685.495.250
21792988,2011-07-27T00:00:00,Electroosmosis,G02.842.700.495.250
21792988,2011-07-27T00:00:00,Electroosmosis,G02.842.750.645.250
21792988,2011-07-27T00:00:00,Electrophoresis,E05.196.401
21792988,2011-07-27T00:00:00,Electrophoresis,E05.301.300
21792988,2011-07-27T00:00:00,Electrophoresis,G02.149.767.570
21792988,2011-07-27T00:00:00,Electrophoresis,G02.842.750.570
21792988,2011-07-27T00:00:00,Microfluidic Analytical Techniques,E05.196.630.465
21792988,2011-07-27T00:00:00,Microfluidic Analytical Techniques,E05.588.465
21792988,2011-07-27T00:00:00,"Models, Theoretical",E05.599
21795698,2011-07-27T00:00:00,3' Untranslated Regions,D13.444.735.544.875.880
21795698,2011-07-27T00:00:00,3' Untranslated Regions,D13.444.735.790.878.880
21795698,2011-07-27T00:00:00,3' Untranslated Regions,G05.360.340.024.220.880.880
21795698,2011-07-27T00:00:00,3' Untranslated Regions,G05.360.340.024.340.137.910.880
21795698,2011-07-27T00:00:00,"Carcinoma, Squamous Cell",C04.557.470.200.400
21795698,2011-07-27T00:00:00,"Carcinoma, Squamous Cell",C04.557.470.700.400
21795698,2011-07-27T00:00:00,Cobalt,D01.268.556.185
21795698,2011-07-27T00:00:00,Cobalt,D01.268.956.155
21795698,2011-07-27T00:00:00,Cobalt,D01.552.544.185
21795698,2011-07-27T00:00:00,"Gene Expression Regulation, Neoplastic",G05.355.315.370
21795698,2011-07-27T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21795698,2011-07-27T00:00:00,Mouth Neoplasms,C04.588.443.591
21795698,2011-07-27T00:00:00,Mouth Neoplasms,C07.465.565
21795698,2011-07-27T00:00:00,Proto-Oncogene Proteins c-myc,D12.776.260.676
21795698,2011-07-27T00:00:00,Proto-Oncogene Proteins c-myc,D12.776.624.664.700.189
21795698,2011-07-27T00:00:00,Proto-Oncogene Proteins c-myc,D12.776.660.765
21795698,2011-07-27T00:00:00,"Stress, Physiological",G07.700.830
21796101,2011-07-27T00:00:00,"Adaptation, Physiological",G07.700.062
21796101,2011-07-27T00:00:00,"Adaptation, Physiological",G16.100.057.500
21796101,2011-07-27T00:00:00,Animals,B01.050
21796101,2011-07-27T00:00:00,Cocaine,D02.145.074.722.388
21796101,2011-07-27T00:00:00,Cocaine,D03.132.889.354
21796101,2011-07-27T00:00:00,Cocaine,D03.605.869.388
21796101,2011-07-27T00:00:00,Cocaine,D04.075.080.875.099.722.388
21796101,2011-07-27T00:00:00,Motor Activity,F01.145.632
21796101,2011-07-27T00:00:00,Motor Activity,G11.427.590.530.698
21796101,2011-07-27T00:00:00,Neuronal Plasticity,G11.561.600.635
21796101,2011-07-27T00:00:00,Oxidative Stress,G03.495.710
21796101,2011-07-27T00:00:00,Oxidative Stress,G07.700.830.750
21796101,2011-07-27T00:00:00,Rats,B01.050.150.900.649.865.635.505.700
21796663,2011-07-27T00:00:00,Antihypertensive Agents,D27.505.954.411.162
21796663,2011-07-27T00:00:00,Blood Pressure,E01.370.600.875.249
21796663,2011-07-27T00:00:00,Blood Pressure,G09.330.380.076
21796663,2011-07-27T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21796663,2011-07-27T00:00:00,Hypertension,C14.907.489
21796663,2011-07-27T00:00:00,Randomized Controlled Trials as Topic,E05.318.760.535.365.500
21796663,2011-07-27T00:00:00,Randomized Controlled Trials as Topic,E05.337.250.365.500
21796663,2011-07-27T00:00:00,Randomized Controlled Trials as Topic,N05.715.360.775.235.387.500
21796663,2011-07-27T00:00:00,Randomized Controlled Trials as Topic,N06.850.520.450.535.365.500
21796663,2011-07-27T00:00:00,Stroke,C10.228.140.300.775
21796663,2011-07-27T00:00:00,Stroke,C14.907.253.855
21799152,2011-07-28T00:00:00,Aging,G07.700.320.124
21799152,2011-07-28T00:00:00,Animals,B01.050
21799152,2011-07-28T00:00:00,Blood Pressure,E01.370.600.875.249
21799152,2011-07-28T00:00:00,Blood Pressure,G09.330.380.076
21799152,2011-07-28T00:00:00,"Disease Models, Animal",C22.232
21799152,2011-07-28T00:00:00,"Disease Models, Animal",E05.598.500
21799152,2011-07-28T00:00:00,"Disease Models, Animal",E05.599.395.080
21799152,2011-07-28T00:00:00,Disease Progression,C23.550.291.656
21799152,2011-07-28T00:00:00,Energy Metabolism,G03.495.335
21799152,2011-07-28T00:00:00,Fatty Acids,D10.251
21799152,2011-07-28T00:00:00,Gene Expression Regulation,G05.355.315
21799152,2011-07-28T00:00:00,Glucose,D09.546.359.448
21799152,2011-07-28T00:00:00,Heart Failure,C14.280.434
21799152,2011-07-28T00:00:00,"Hypertrophy, Left Ventricular",C14.280.195.400
21799152,2011-07-28T00:00:00,"Hypertrophy, Left Ventricular",C23.300.775.250.400
21799152,2011-07-28T00:00:00,"Mitochondria, Heart",A11.284.430.214.190.875.564.627.603
21799152,2011-07-28T00:00:00,"Mitochondria, Heart",A11.284.835.626.627.603
21799152,2011-07-28T00:00:00,Myocardial Contraction,G09.330.190.541
21799152,2011-07-28T00:00:00,Myocardial Contraction,G11.427.590.540.570
21799152,2011-07-28T00:00:00,Myocardium,A02.633.580
21799152,2011-07-28T00:00:00,Myocardium,A07.541.704
21799152,2011-07-28T00:00:00,Myocardium,A10.690.552.750
21799152,2011-07-28T00:00:00,Oxidative Stress,G03.495.710
21799152,2011-07-28T00:00:00,Oxidative Stress,G07.700.830.750
21799152,2011-07-28T00:00:00,Trans-Activators,D12.776.260.755
21799152,2011-07-28T00:00:00,Trans-Activators,D12.776.930.900
21799152,2011-07-28T00:00:00,Trans-Activators,D12.776.964.925.984
21799152,2011-07-28T00:00:00,Transcription Factors,D12.776.930
21799152,2011-07-28T00:00:00,"Ventricular Dysfunction, Left",C14.280.945.900
21799152,2011-07-28T00:00:00,"Ventricular Function, Left",G09.330.190.962.800
21799158,2011-07-28T00:00:00,Adult,M01.060.116
21799158,2011-07-28T00:00:00,Hospital Mortality,E05.318.308.985.550.400
21799158,2011-07-28T00:00:00,Hospital Mortality,L01.280.975.550.400
21799158,2011-07-28T00:00:00,Hospital Mortality,N01.224.935.698.400
21799158,2011-07-28T00:00:00,Hospital Mortality,N06.850.505.400.975.550.400
21799158,2011-07-28T00:00:00,Hospital Mortality,N06.850.520.308.985.550.400
21799158,2011-07-28T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21799158,2011-07-28T00:00:00,Middle Aged,M01.060.116.630
21799158,2011-07-28T00:00:00,Sex Factors,N05.715.350.675
21799158,2011-07-28T00:00:00,Sex Factors,N06.850.490.875
21799158,2011-07-28T00:00:00,Stroke,C10.228.140.300.775
21799158,2011-07-28T00:00:00,Stroke,C14.907.253.855
21799158,2011-07-28T00:00:00,United States,Z01.107.567.875
21800355,2011-07-28T00:00:00,Adult,M01.060.116
21800355,2011-07-28T00:00:00,Aged,M01.060.116.100
21800355,2011-07-28T00:00:00,Ferritins,D12.776.157.427.249
21800355,2011-07-28T00:00:00,Ferritins,D12.776.556.579.249
21800355,2011-07-28T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21800355,2011-07-28T00:00:00,Iron,D01.268.556.412
21800355,2011-07-28T00:00:00,Iron,D01.268.956.287
21800355,2011-07-28T00:00:00,Iron,D01.552.544.412
21800355,2011-07-28T00:00:00,Mass Screening,E01.370.500
21800355,2011-07-28T00:00:00,Mass Screening,E05.318.308.250.580
21800355,2011-07-28T00:00:00,Mass Screening,N02.421.143.827.233.443
21800355,2011-07-28T00:00:00,Mass Screening,N02.421.726.233.443
21800355,2011-07-28T00:00:00,Mass Screening,N05.715.360.300.375.500
21800355,2011-07-28T00:00:00,Mass Screening,N06.850.520.308.250.580
21800355,2011-07-28T00:00:00,Mass Screening,N06.850.780.500
21800355,2011-07-28T00:00:00,Middle Aged,M01.060.116.630
21800355,2011-07-28T00:00:00,"Models, Biological",E05.599.395
21800355,2011-07-28T00:00:00,Nutrition Surveys,E05.318.308.250.600
21800355,2011-07-28T00:00:00,Nutrition Surveys,E05.318.308.585.550
21800355,2011-07-28T00:00:00,Nutrition Surveys,N05.715.360.300.375.560
21800355,2011-07-28T00:00:00,Nutrition Surveys,N05.715.360.300.560.565
21800355,2011-07-28T00:00:00,Nutrition Surveys,N06.850.520.308.250.600
21800355,2011-07-28T00:00:00,Nutrition Surveys,N06.850.520.308.585.550
21800355,2011-07-28T00:00:00,Primary Health Care,N04.590.233.727
21800355,2011-07-28T00:00:00,Risk Factors,E05.318.740.600.800.725
21800355,2011-07-28T00:00:00,Risk Factors,N05.715.350.200.700
21800355,2011-07-28T00:00:00,Risk Factors,N05.715.360.750.625.700.700
21800355,2011-07-28T00:00:00,Risk Factors,N06.850.490.625.750
21800355,2011-07-28T00:00:00,Risk Factors,N06.850.520.830.600.800.725
21800355,2011-07-28T00:00:00,Transferrin,D12.776.124.050.800
21800355,2011-07-28T00:00:00,Transferrin,D12.776.124.790.223.839
21800355,2011-07-28T00:00:00,Transferrin,D12.776.157.427.500
21800355,2011-07-28T00:00:00,Transferrin,D12.776.377.715.182.839
21800355,2011-07-28T00:00:00,Transferrin,D12.776.556.579.500
21800355,2011-07-28T00:00:00,United States,Z01.107.567.875
21800355,2011-07-28T00:00:00,Young Adult,M01.060.116.815
21864809,2011-07-28T00:00:00,Antioxidants,D27.505.519.217
21864809,2011-07-28T00:00:00,Antioxidants,D27.505.696.706.125
21864809,2011-07-28T00:00:00,Antioxidants,D27.720.799.047
21864809,2011-07-28T00:00:00,Binding Sites,G02.111.570.120
21864809,2011-07-28T00:00:00,DNA Damage,C21.111
21864809,2011-07-28T00:00:00,DNA Damage,G05.355.180
21864809,2011-07-28T00:00:00,Iron,D01.268.556.412
21864809,2011-07-28T00:00:00,Iron,D01.268.956.287
21864809,2011-07-28T00:00:00,Iron,D01.552.544.412
21864809,2011-07-28T00:00:00,Metals,D01.552
21802222,2011-07-29T00:00:00,Adolescent,M01.060.057
21802222,2011-07-29T00:00:00,Adult,M01.060.116
21802222,2011-07-29T00:00:00,Counseling,F02.784.176
21802222,2011-07-29T00:00:00,Counseling,F04.408.413
21802222,2011-07-29T00:00:00,Counseling,N02.421.143.303
21802222,2011-07-29T00:00:00,Counseling,N02.421.461.363
21802222,2011-07-29T00:00:00,Education,I02
21802222,2011-07-29T00:00:00,Employment,N01.824.245
21802222,2011-07-29T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21802222,2011-07-29T00:00:00,Middle Aged,M01.060.116.630
21802222,2011-07-29T00:00:00,"Rehabilitation, Vocational",E02.831.782
21802222,2011-07-29T00:00:00,"Rehabilitation, Vocational",N02.421.784.644
21802222,2011-07-29T00:00:00,Substance-Related Disorders,C21.739
21802222,2011-07-29T00:00:00,Substance-Related Disorders,F03.900
21802222,2011-07-29T00:00:00,Time Factors,G01.910.857
21802222,2011-07-29T00:00:00,Young Adult,M01.060.116.815
21849231,2011-07-29T00:00:00,Adolescent,M01.060.057
21849231,2011-07-29T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21849231,2011-07-29T00:00:00,Qualitative Research,H01.770.644.241.850
21849231,2011-07-29T00:00:00,Self Concept,F01.752.747.792
21849231,2011-07-29T00:00:00,Smoking,F01.145.466.753
21849231,2011-07-29T00:00:00,Smoking Cessation,F01.145.940.700
21849231,2011-07-29T00:00:00,Students,I02.233.748
21849231,2011-07-29T00:00:00,Students,I02.851
21849231,2011-07-29T00:00:00,Students,M01.848
21849231,2011-07-29T00:00:00,Young Adult,M01.060.116.815
21862227,2011-07-29T00:00:00,Adolescent,M01.060.057
21862227,2011-07-29T00:00:00,Adult,M01.060.116
21862227,2011-07-29T00:00:00,Aged,M01.060.116.100
21862227,2011-07-29T00:00:00,Cocaine-Related Disorders,C21.739.300
21862227,2011-07-29T00:00:00,Cocaine-Related Disorders,F03.900.300
21862227,2011-07-29T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21862227,2011-07-29T00:00:00,Middle Aged,M01.060.116.630
21862227,2011-07-29T00:00:00,Obsessive-Compulsive Disorder,F03.080.600
21862227,2011-07-29T00:00:00,Psychiatric Status Rating Scales,F04.586
21862227,2011-07-29T00:00:00,Psychometrics,F04.711.780
21862227,2011-07-29T00:00:00,Questionnaires,E05.318.308.750
21862227,2011-07-29T00:00:00,Questionnaires,L01.280.800
21862227,2011-07-29T00:00:00,Questionnaires,N05.715.360.300.695
21862227,2011-07-29T00:00:00,Questionnaires,N06.850.520.308.750
21862227,2011-07-29T00:00:00,Young Adult,M01.060.116.815
21805138,2011-07-30T00:00:00,Breast Neoplasms,C04.588.180
21805138,2011-07-30T00:00:00,Breast Neoplasms,C17.800.090.500
21805138,2011-07-30T00:00:00,Gene Expression Profiling,E05.393.332
21805138,2011-07-30T00:00:00,"Gene Expression Regulation, Neoplastic",G05.355.315.370
21805138,2011-07-30T00:00:00,Histone Demethylases,D08.811.682.662.582.475
21805138,2011-07-30T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21805138,2011-07-30T00:00:00,Polyamines,D02.092.782
20938743,2011-08-01T00:00:00,Adolescent,M01.060.057
20938743,2011-08-01T00:00:00,Adult,M01.060.116
20938743,2011-08-01T00:00:00,Aggression,F01.145.126.125
20938743,2011-08-01T00:00:00,Aggression,F01.145.813.045
20938743,2011-08-01T00:00:00,Child,M01.060.406
20938743,2011-08-01T00:00:00,Child Welfare,I01.880.787.293
20938743,2011-08-01T00:00:00,"Child, Preschool",M01.060.406.448
20938743,2011-08-01T00:00:00,Cultural Characteristics,I01.076.201.450.324
20938743,2011-08-01T00:00:00,Cultural Characteristics,I01.880.143.329
20938743,2011-08-01T00:00:00,"Databases, Factual",L01.470.750.750
20938743,2011-08-01T00:00:00,"Databases, Factual",L01.700.508.300.188.400
20938743,2011-08-01T00:00:00,European Continental Ancestry Group,M01.686.508.400
20938743,2011-08-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
20938743,2011-08-01T00:00:00,Incidence,E05.318.308.985.525.375
20938743,2011-08-01T00:00:00,Incidence,L01.280.975.525.375
20938743,2011-08-01T00:00:00,Incidence,N01.224.935.597.500
20938743,2011-08-01T00:00:00,Incidence,N06.850.505.400.975.525.375
20938743,2011-08-01T00:00:00,Incidence,N06.850.520.308.985.525.375
20938743,2011-08-01T00:00:00,Middle Aged,M01.060.116.630
20938743,2011-08-01T00:00:00,Parent-Child Relations,F01.829.263.370.290
20938743,2011-08-01T00:00:00,Parenting,F01.829.263.370.310
20938743,2011-08-01T00:00:00,Risk Assessment,E05.318.740.600.800.715
20938743,2011-08-01T00:00:00,Risk Assessment,N04.452.871.715
20938743,2011-08-01T00:00:00,Risk Assessment,N05.715.360.750.625.700.690
20938743,2011-08-01T00:00:00,Risk Assessment,N06.850.505.715
20938743,2011-08-01T00:00:00,Risk Assessment,N06.850.520.830.600.800.715
20938743,2011-08-01T00:00:00,United States,Z01.107.567.875
20938743,2011-08-01T00:00:00,Young Adult,M01.060.116.815
21389887,2011-08-01T00:00:00,Adult,M01.060.116
21389887,2011-08-01T00:00:00,Aged,M01.060.116.100
21389887,2011-08-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21389887,2011-08-01T00:00:00,Intracranial Aneurysm,C10.228.140.300.510.600
21389887,2011-08-01T00:00:00,Intracranial Aneurysm,C14.907.055.635
21389887,2011-08-01T00:00:00,Intracranial Aneurysm,C14.907.253.560.300
21389887,2011-08-01T00:00:00,Middle Aged,M01.060.116.630
21389887,2011-08-01T00:00:00,Postoperative Complications,C23.550.767
21389887,2011-08-01T00:00:00,Reoperation,E04.690
21389887,2011-08-01T00:00:00,Stents,E07.695.750
21547403,2011-08-01T00:00:00,Device Removal,E04.199
21547403,2011-08-01T00:00:00,Foreign-Body Migration,C21.866.392.500
21547403,2011-08-01T00:00:00,Gastroplasty,E02.065.062.750
21547403,2011-08-01T00:00:00,Gastroplasty,E04.062.750
21547403,2011-08-01T00:00:00,Gastroplasty,E04.210.485
21547403,2011-08-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21547403,2011-08-01T00:00:00,Laparoscopy,E01.370.388.250.520
21547403,2011-08-01T00:00:00,Laparoscopy,E04.800.250.520
21547403,2011-08-01T00:00:00,"Obesity, Morbid",C18.654.726.500.700
21547403,2011-08-01T00:00:00,"Obesity, Morbid",C23.888.144.699.500.500
21547403,2011-08-01T00:00:00,"Obesity, Morbid",E01.370.600.115.100.160.120.699.500.500
21547403,2011-08-01T00:00:00,"Obesity, Morbid",G07.100.100.160.120.699.500.500
21547403,2011-08-01T00:00:00,Postoperative Complications,C23.550.767
21547403,2011-08-01T00:00:00,Prostheses and Implants,E07.695
21547403,2011-08-01T00:00:00,Regression Analysis,E05.318.740.750
21547403,2011-08-01T00:00:00,Regression Analysis,N05.715.360.750.695
21547403,2011-08-01T00:00:00,Regression Analysis,N06.850.520.830.750
21547403,2011-08-01T00:00:00,Reoperation,E04.690
21558879,2011-08-01T00:00:00,Animals,B01.050
21558879,2011-08-01T00:00:00,Apolipoproteins E,D10.532.091.500
21558879,2011-08-01T00:00:00,Apolipoproteins E,D12.776.070.400.500
21558879,2011-08-01T00:00:00,Apolipoproteins E,D12.776.521.120.500
21558879,2011-08-01T00:00:00,Blood Glucose,D09.546.359.448.500
21558879,2011-08-01T00:00:00,Cholesterol,D04.808.247.222.284
21558879,2011-08-01T00:00:00,Cholesterol,D04.808.247.808.197
21558879,2011-08-01T00:00:00,Cholesterol,D10.570.938.208
21558879,2011-08-01T00:00:00,Cholesterol,D10.851.208
21558879,2011-08-01T00:00:00,"Diabetes Mellitus, Experimental",C18.452.394.750.074
21558879,2011-08-01T00:00:00,"Diabetes Mellitus, Experimental",C19.246.240
21558879,2011-08-01T00:00:00,"Diabetes Mellitus, Experimental",E05.598.500.374
21558879,2011-08-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21558879,2011-08-01T00:00:00,Interleukin-1beta,D12.644.276.374.465.501.600
21558879,2011-08-01T00:00:00,Interleukin-1beta,D12.644.276.374.500.400.600
21558879,2011-08-01T00:00:00,Interleukin-1beta,D12.776.467.374.465.501.600
21558879,2011-08-01T00:00:00,Interleukin-1beta,D12.776.467.374.500.400.600
21558879,2011-08-01T00:00:00,Interleukin-1beta,D23.529.374.465.501.600
21558879,2011-08-01T00:00:00,Interleukin-1beta,D23.529.374.500.400.600
21558879,2011-08-01T00:00:00,Interleukin-6,D12.644.276.374.465.506
21558879,2011-08-01T00:00:00,Interleukin-6,D12.776.467.374.465.506
21558879,2011-08-01T00:00:00,Interleukin-6,D23.529.374.465.506
21558879,2011-08-01T00:00:00,Piperidines,D03.383.621
21558879,2011-08-01T00:00:00,Uracil,D03.383.742.698.875
21563016,2011-08-01T00:00:00,Adolescent,M01.060.057
21563016,2011-08-01T00:00:00,"Anemia, Sickle Cell",C15.378.071.141.150.150
21563016,2011-08-01T00:00:00,"Anemia, Sickle Cell",C15.378.420.155
21563016,2011-08-01T00:00:00,"Anemia, Sickle Cell",C16.320.070.150
21563016,2011-08-01T00:00:00,"Anemia, Sickle Cell",C16.320.365.155
21563016,2011-08-01T00:00:00,Child,M01.060.406
21563016,2011-08-01T00:00:00,Cognition Disorders,F03.087.250
21563016,2011-08-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21563016,2011-08-01T00:00:00,Neuropsychological Tests,F04.711.513
21563016,2011-08-01T00:00:00,Pediatrics,H02.403.670
21672085,2011-08-01T00:00:00,"Carcinoma, Non-Small-Cell Lung",C04.588.894.797.520.109.220.249
21672085,2011-08-01T00:00:00,"Carcinoma, Non-Small-Cell Lung",C08.381.540.140.500
21672085,2011-08-01T00:00:00,"Carcinoma, Non-Small-Cell Lung",C08.785.520.100.220.500
21672085,2011-08-01T00:00:00,"Catheters, Indwelling",E07.150
21672085,2011-08-01T00:00:00,Fibrinolytic Agents,D27.505.519.421.750
21672085,2011-08-01T00:00:00,Fibrinolytic Agents,D27.505.954.411.320
21672085,2011-08-01T00:00:00,Fibrinolytic Agents,D27.505.954.502.427
21672085,2011-08-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21672085,2011-08-01T00:00:00,Lung Neoplasms,C04.588.894.797.520
21672085,2011-08-01T00:00:00,Lung Neoplasms,C08.381.540
21672085,2011-08-01T00:00:00,Lung Neoplasms,C08.785.520
21672085,2011-08-01T00:00:00,Pleural Diseases,C08.528
21672085,2011-08-01T00:00:00,Streptokinase,D08.811.277.656.300.775
21672085,2011-08-01T00:00:00,Streptokinase,D12.776.124.125.662.537
21672085,2011-08-01T00:00:00,Superantigens,D23.050.820
21725212,2011-08-01T00:00:00,Animals,B01.050
21725212,2011-08-01T00:00:00,Antineoplastic Agents,D27.505.954.248
21725212,2011-08-01T00:00:00,"Carcinoma, Hepatocellular",C04.557.470.200.025.255
21725212,2011-08-01T00:00:00,"Carcinoma, Hepatocellular",C04.588.274.623.160
21725212,2011-08-01T00:00:00,"Carcinoma, Hepatocellular",C06.301.623.160
21725212,2011-08-01T00:00:00,"Carcinoma, Hepatocellular",C06.552.697.160
21725212,2011-08-01T00:00:00,Cell Death,G04.299.139
21725212,2011-08-01T00:00:00,Deoxycytidine,D03.383.742.680.245.500
21725212,2011-08-01T00:00:00,Deoxycytidine,D13.570.230.329
21725212,2011-08-01T00:00:00,Deoxycytidine,D13.570.685.245.500
21725212,2011-08-01T00:00:00,Doxorubicin,D02.455.426.559.847.562.050.200.175
21725212,2011-08-01T00:00:00,Doxorubicin,D04.615.562.050.200.175
21725212,2011-08-01T00:00:00,Doxorubicin,D09.408.051.059.200.175
21725212,2011-08-01T00:00:00,"Genes, p53",G05.360.340.024.340.375.249.385
21725212,2011-08-01T00:00:00,"Genes, p53",G05.360.340.024.340.415.400.385
21725212,2011-08-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21725212,2011-08-01T00:00:00,Liver Neoplasms,C04.588.274.623
21725212,2011-08-01T00:00:00,Liver Neoplasms,C06.301.623
21725212,2011-08-01T00:00:00,Liver Neoplasms,C06.552.697
21725212,2011-08-01T00:00:00,Proto-Oncogene Proteins c-bcl-2,D12.644.360.075.718
21725212,2011-08-01T00:00:00,Proto-Oncogene Proteins c-bcl-2,D12.776.476.075.718
21725212,2011-08-01T00:00:00,Proto-Oncogene Proteins c-bcl-2,D12.776.624.664.700.169
21725212,2011-08-01T00:00:00,Pyridines,D03.383.725
21725212,2011-08-01T00:00:00,"Receptors, TNF-Related Apoptosis-Inducing Ligand",D12.776.543.750.073.600
21725212,2011-08-01T00:00:00,"Receptors, TNF-Related Apoptosis-Inducing Ligand",D12.776.543.750.705.852.760.396
21725212,2011-08-01T00:00:00,TNF-Related Apoptosis-Inducing Ligand,D12.644.276.374.750.625
21725212,2011-08-01T00:00:00,TNF-Related Apoptosis-Inducing Ligand,D12.644.276.972.625
21725212,2011-08-01T00:00:00,TNF-Related Apoptosis-Inducing Ligand,D12.776.467.374.750.625
21725212,2011-08-01T00:00:00,TNF-Related Apoptosis-Inducing Ligand,D12.776.467.972.625
21725212,2011-08-01T00:00:00,TNF-Related Apoptosis-Inducing Ligand,D23.529.374.750.625
21725212,2011-08-01T00:00:00,TNF-Related Apoptosis-Inducing Ligand,D23.529.972.625
21725213,2011-08-01T00:00:00,Animals,B01.050
21725213,2011-08-01T00:00:00,Antineoplastic Agents,D27.505.954.248
21725213,2011-08-01T00:00:00,Antineoplastic Combined Chemotherapy Protocols,E02.183.750.500
21725213,2011-08-01T00:00:00,Antineoplastic Combined Chemotherapy Protocols,E02.319.077.500
21725213,2011-08-01T00:00:00,Antineoplastic Combined Chemotherapy Protocols,E02.319.310.037
21725213,2011-08-01T00:00:00,Cell Proliferation,G04.299.233.750
21725213,2011-08-01T00:00:00,Cell Proliferation,G07.700.320.249.410.750
21725213,2011-08-01T00:00:00,Colorectal Neoplasms,C04.588.274.476.411.307
21725213,2011-08-01T00:00:00,Colorectal Neoplasms,C06.301.371.411.307
21725213,2011-08-01T00:00:00,Colorectal Neoplasms,C06.405.249.411.307
21725213,2011-08-01T00:00:00,Colorectal Neoplasms,C06.405.469.158.356
21725213,2011-08-01T00:00:00,Colorectal Neoplasms,C06.405.469.491.307
21725213,2011-08-01T00:00:00,Colorectal Neoplasms,C06.405.469.860.180
21725213,2011-08-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21725213,2011-08-01T00:00:00,Mutation,G05.365.590
21725213,2011-08-01T00:00:00,NF-kappa B,D12.776.260.600
21725213,2011-08-01T00:00:00,NF-kappa B,D12.776.660.600
21725213,2011-08-01T00:00:00,NF-kappa B,D12.776.930.600
21725213,2011-08-01T00:00:00,Proto-Oncogene Proteins,D12.776.624.664.700
21725213,2011-08-01T00:00:00,Proto-Oncogene Proteins c-bcl-2,D12.644.360.075.718
21725213,2011-08-01T00:00:00,Proto-Oncogene Proteins c-bcl-2,D12.776.476.075.718
21725213,2011-08-01T00:00:00,Proto-Oncogene Proteins c-bcl-2,D12.776.624.664.700.169
21725213,2011-08-01T00:00:00,Pyridines,D03.383.725
21725213,2011-08-01T00:00:00,Tumor Suppressor Protein p53,D12.776.260.820
21725213,2011-08-01T00:00:00,Tumor Suppressor Protein p53,D12.776.624.776.775
21725213,2011-08-01T00:00:00,Tumor Suppressor Protein p53,D12.776.660.825
21725213,2011-08-01T00:00:00,Tumor Suppressor Protein p53,D12.776.744.845
21738069,2011-08-01T00:00:00,"Amputation, Traumatic",C21.866.062
21738069,2011-08-01T00:00:00,Animals,B01.050
21738069,2011-08-01T00:00:00,"Disease Models, Animal",C22.232
21738069,2011-08-01T00:00:00,"Disease Models, Animal",E05.598.500
21738069,2011-08-01T00:00:00,"Disease Models, Animal",E05.599.395.080
21738069,2011-08-01T00:00:00,Extremities,A01.378
21738069,2011-08-01T00:00:00,Rats,B01.050.150.900.649.865.635.505.700
21738069,2011-08-01T00:00:00,"Rats, Sprague-Dawley",B01.050.150.900.649.865.635.505.700.750
21772298,2011-08-01T00:00:00,Biomedical Research,H01.770.644.145
21772298,2011-08-01T00:00:00,Ethnic Groups,M01.686.754
21772298,2011-08-01T00:00:00,Ethnic Groups,N01.224.317
21772298,2011-08-01T00:00:00,Health Services Accessibility,N04.590.374.350
21772298,2011-08-01T00:00:00,Health Services Accessibility,N05.300.430
21772298,2011-08-01T00:00:00,Healthcare Disparities,N04.590.374.380
21772298,2011-08-01T00:00:00,Healthcare Disparities,N05.300.493
21772298,2011-08-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21772298,2011-08-01T00:00:00,"Kidney Failure, Chronic",C12.777.419.780.500.602
21772298,2011-08-01T00:00:00,"Kidney Failure, Chronic",C12.777.419.780.750.500
21772298,2011-08-01T00:00:00,"Kidney Failure, Chronic",C13.351.968.419.780.500.602
21772298,2011-08-01T00:00:00,"Kidney Failure, Chronic",C13.351.968.419.780.750.500
21772298,2011-08-01T00:00:00,Kidney Transplantation,E02.870.500
21772298,2011-08-01T00:00:00,Kidney Transplantation,E04.936.450.485
21772298,2011-08-01T00:00:00,Kidney Transplantation,E04.950.774.400
21772298,2011-08-01T00:00:00,Patient Education as Topic,I02.233.332.500
21772298,2011-08-01T00:00:00,Patient Education as Topic,N02.421.143.827.407.680
21772298,2011-08-01T00:00:00,Patient Education as Topic,N02.421.726.407.680
21772298,2011-08-01T00:00:00,Referral and Consultation,N04.452.758.849
21772298,2011-08-01T00:00:00,United States,Z01.107.567.875
21785102,2011-08-01T00:00:00,Adult,M01.060.116
21785102,2011-08-01T00:00:00,Aged,M01.060.116.100
21785102,2011-08-01T00:00:00,Catheter Ablation,E01.370.370.380.410.200
21785102,2011-08-01T00:00:00,Catheter Ablation,E02.148.110
21785102,2011-08-01T00:00:00,Catheter Ablation,E02.148.442.110
21785102,2011-08-01T00:00:00,Catheter Ablation,E02.154.402.110
21785102,2011-08-01T00:00:00,Catheter Ablation,E04.014.170.402.110
21785102,2011-08-01T00:00:00,Cryosurgery,E04.014.180
21785102,2011-08-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21785102,2011-08-01T00:00:00,Length of Stay,E02.760.400.480
21785102,2011-08-01T00:00:00,Length of Stay,N02.421.585.400.480
21785102,2011-08-01T00:00:00,Middle Aged,M01.060.116.630
21785102,2011-08-01T00:00:00,Pain Measurement,E01.370.376.550.600
21785102,2011-08-01T00:00:00,Palliative Care,E02.760.666
21785102,2011-08-01T00:00:00,Palliative Care,N02.421.585.666
21785102,2011-08-01T00:00:00,"Radiography, Interventional",E01.370.350.700.725
21785102,2011-08-01T00:00:00,"Radiography, Interventional",E02.148.694
21785102,2011-08-01T00:00:00,"Radiography, Interventional",E04.800.780
21785102,2011-08-01T00:00:00,Treatment Outcome,E01.789.800
21785102,2011-08-01T00:00:00,Treatment Outcome,N04.761.559.590.800
21785102,2011-08-01T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21785288,2011-08-01T00:00:00,Adolescent,M01.060.057
21785288,2011-08-01T00:00:00,Adult,M01.060.116
21785288,2011-08-01T00:00:00,Aged,M01.060.116.100
21785288,2011-08-01T00:00:00,Child,M01.060.406
21785288,2011-08-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21785288,2011-08-01T00:00:00,Middle Aged,M01.060.116.630
21785288,2011-08-01T00:00:00,Nocardia Infections,C01.252.410.040.692
21785288,2011-08-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.350.810
21785288,2011-08-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.600.350.700.810
21785288,2011-08-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.700.700.810
21785288,2011-08-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.700.810.810
21785288,2011-08-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.825.810.810
21787049,2011-08-01T00:00:00,Adolescent,M01.060.057
21787049,2011-08-01T00:00:00,Adolescent Behavior,F01.145.022
21787049,2011-08-01T00:00:00,Child,M01.060.406
21787049,2011-08-01T00:00:00,Depression,F01.145.126.350
21787049,2011-08-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21787049,2011-08-01T00:00:00,Interviews as Topic,E05.318.308.420
21787049,2011-08-01T00:00:00,Interviews as Topic,L01.280.520
21787049,2011-08-01T00:00:00,Interviews as Topic,N05.715.360.300.400
21787049,2011-08-01T00:00:00,Interviews as Topic,N06.850.520.308.420
21787049,2011-08-01T00:00:00,Juvenile Delinquency,I01.880.735.479
21787049,2011-08-01T00:00:00,Risk Factors,E05.318.740.600.800.725
21787049,2011-08-01T00:00:00,Risk Factors,N05.715.350.200.700
21787049,2011-08-01T00:00:00,Risk Factors,N05.715.360.750.625.700.700
21787049,2011-08-01T00:00:00,Risk Factors,N06.850.490.625.750
21787049,2011-08-01T00:00:00,Risk Factors,N06.850.520.830.600.800.725
21792140,2011-08-01T00:00:00,Animals,B01.050
21792140,2011-08-01T00:00:00,Cattle,B01.050.150.900.649.077.380.271
21792140,2011-08-01T00:00:00,Craniocerebral Trauma,C10.900.300
21792140,2011-08-01T00:00:00,Craniocerebral Trauma,C21.866.260
21792140,2011-08-01T00:00:00,Craniocerebral Trauma,C21.866.915.300
21792140,2011-08-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21792140,2011-08-01T00:00:00,Neck Injuries,C21.866.700
21792140,2011-08-01T00:00:00,Neurosurgical Procedures,E04.525
21792140,2011-08-01T00:00:00,"Wounds, Penetrating",C21.866.986
21801901,2011-08-01T00:00:00,Conflict of Interest,K01.316.130
21801901,2011-08-01T00:00:00,Conflict of Interest,N05.350.225
21801901,2011-08-01T00:00:00,Data Collection,E05.318.308
21801901,2011-08-01T00:00:00,Data Collection,L01.280
21801901,2011-08-01T00:00:00,Data Collection,N05.715.360.300
21801901,2011-08-01T00:00:00,Data Collection,N06.850.520.308
21801901,2011-08-01T00:00:00,Employment,N01.824.245
21801901,2011-08-01T00:00:00,"Ethics, Medical",K01.316.333.132.750
21801901,2011-08-01T00:00:00,"Ethics, Medical",N05.350.340.162.500
21801901,2011-08-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21801901,2011-08-01T00:00:00,Publishing,L01.737
21801901,2011-08-01T00:00:00,Referral and Consultation,N04.452.758.849
21801901,2011-08-01T00:00:00,Research Design,E05.581.500
21801901,2011-08-01T00:00:00,Research Design,H01.770.644.728
21801901,2011-08-01T00:00:00,Thoracic Surgery,H02.403.810.803
21801901,2011-08-01T00:00:00,United States,Z01.107.567.875
21807143,2011-08-01T00:00:00,Adolescent,M01.060.057
21807143,2011-08-01T00:00:00,Adult,M01.060.116
21807143,2011-08-01T00:00:00,Age Factors,N05.715.350.075
21807143,2011-08-01T00:00:00,Age Factors,N06.850.490.250
21807143,2011-08-01T00:00:00,Aged,M01.060.116.100
21807143,2011-08-01T00:00:00,Drug Prescriptions,E02.319.307
21807143,2011-08-01T00:00:00,Drug Prescriptions,N02.421.668.778.500
21807143,2011-08-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21807143,2011-08-01T00:00:00,Middle Aged,M01.060.116.630
21807143,2011-08-01T00:00:00,Pain Measurement,E01.370.376.550.600
21807143,2011-08-01T00:00:00,Questionnaires,E05.318.308.750
21807143,2011-08-01T00:00:00,Questionnaires,L01.280.800
21807143,2011-08-01T00:00:00,Questionnaires,N05.715.360.300.695
21807143,2011-08-01T00:00:00,Questionnaires,N06.850.520.308.750
21807143,2011-08-01T00:00:00,Sex Factors,N05.715.350.675
21807143,2011-08-01T00:00:00,Sex Factors,N06.850.490.875
21807143,2011-08-01T00:00:00,Spinal Cord Injuries,C10.228.854.770
21807143,2011-08-01T00:00:00,Spinal Cord Injuries,C10.900.850
21807143,2011-08-01T00:00:00,Spinal Cord Injuries,C21.866.819
21807143,2011-08-01T00:00:00,Walking,G11.427.590.530.568.900
21807143,2011-08-01T00:00:00,Walking,G11.427.590.530.698.940
21807143,2011-08-01T00:00:00,Walking,I03.450.642.845.940
21807929,2011-08-01T00:00:00,Energy Metabolism,G03.495.335
21807929,2011-08-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21807929,2011-08-01T00:00:00,Intensive Care Units,N02.278.388.493
21807929,2011-08-01T00:00:00,"Muscle, Skeletal",A02.633.567
21807929,2011-08-01T00:00:00,"Muscle, Skeletal",A10.690.552.500
21807929,2011-08-01T00:00:00,Obesity,C18.654.726.500
21807929,2011-08-01T00:00:00,Obesity,C23.888.144.699.500
21807929,2011-08-01T00:00:00,Obesity,E01.370.600.115.100.160.120.699.500
21807929,2011-08-01T00:00:00,Obesity,G07.100.100.160.120.699.500
21807929,2011-08-01T00:00:00,Phenotype,G05.695
21810777,2011-08-01T00:00:00,Adult,M01.060.116
21810777,2011-08-01T00:00:00,Aged,M01.060.116.100
21810777,2011-08-01T00:00:00,"Carcinoma, Squamous Cell",C04.557.470.200.400
21810777,2011-08-01T00:00:00,"Carcinoma, Squamous Cell",C04.557.470.700.400
21810777,2011-08-01T00:00:00,Endoscopy,E01.370.388.250
21810777,2011-08-01T00:00:00,Endoscopy,E04.800.250
21810777,2011-08-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21810777,2011-08-01T00:00:00,Middle Aged,M01.060.116.630
21810777,2011-08-01T00:00:00,Neoplasm Staging,E01.370.550
21810777,2011-08-01T00:00:00,Oropharyngeal Neoplasms,C04.588.443.665.710.684
21810777,2011-08-01T00:00:00,Oropharyngeal Neoplasms,C07.550.745.671
21810777,2011-08-01T00:00:00,Oropharyngeal Neoplasms,C09.647.710.685
21810777,2011-08-01T00:00:00,Oropharyngeal Neoplasms,C09.775.549.685
21810777,2011-08-01T00:00:00,Otorhinolaryngologic Surgical Procedures,E04.580
21810777,2011-08-01T00:00:00,Pilot Projects,E05.318.760.750
21810777,2011-08-01T00:00:00,Pilot Projects,E05.337.737
21810777,2011-08-01T00:00:00,Pilot Projects,N05.715.360.775.625
21810777,2011-08-01T00:00:00,Pilot Projects,N06.850.520.450.720
21810777,2011-08-01T00:00:00,Robotics,H01.671.293.643
21810777,2011-08-01T00:00:00,Robotics,J01.897.104.834
21810777,2011-08-01T00:00:00,Robotics,L01.224.065.630
21810777,2011-08-01T00:00:00,Treatment Outcome,E01.789.800
21810777,2011-08-01T00:00:00,Treatment Outcome,N04.761.559.590.800
21810777,2011-08-01T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21814118,2011-08-01T00:00:00,Acetylglucosamine,D09.067.342.531.050
21814118,2011-08-01T00:00:00,Animals,B01.050
21814118,2011-08-01T00:00:00,"Disease Models, Animal",C22.232
21814118,2011-08-01T00:00:00,"Disease Models, Animal",E05.598.500
21814118,2011-08-01T00:00:00,"Disease Models, Animal",E05.599.395.080
21814118,2011-08-01T00:00:00,Osteoblasts,A11.329.629
21814118,2011-08-01T00:00:00,Rabbits,B01.050.150.900.649.521.700
21817861,2011-08-01T00:00:00,Behavior,F01.145
21817861,2011-08-01T00:00:00,Clinical Competence,I02.399.630.210
21817861,2011-08-01T00:00:00,Clinical Competence,N04.761.210
21817861,2011-08-01T00:00:00,Computer Simulation,L01.224.160
21817861,2011-08-01T00:00:00,"Education, Medical",I02.358.399
21817861,2011-08-01T00:00:00,"Education, Nursing",I02.358.462
21817861,2011-08-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21819875,2011-08-01T00:00:00,Cerebrospinal Fluid Rhinorrhea,C10.597.267
21819875,2011-08-01T00:00:00,Cerebrospinal Fluid Rhinorrhea,C10.900.300.153
21819875,2011-08-01T00:00:00,Cerebrospinal Fluid Rhinorrhea,C21.866.260.207
21819875,2011-08-01T00:00:00,Cerebrospinal Fluid Rhinorrhea,C21.866.915.300.300
21819875,2011-08-01T00:00:00,Cerebrospinal Fluid Rhinorrhea,C23.888.592.264
21819875,2011-08-01T00:00:00,Clinical Trials as Topic,E05.318.760.535
21819875,2011-08-01T00:00:00,Clinical Trials as Topic,E05.337.250
21819875,2011-08-01T00:00:00,Clinical Trials as Topic,N05.715.360.775.235
21819875,2011-08-01T00:00:00,Clinical Trials as Topic,N06.850.520.450.535
21819875,2011-08-01T00:00:00,"Diagnosis, Differential",E01.171
21819875,2011-08-01T00:00:00,Endoscopy,E01.370.388.250
21819875,2011-08-01T00:00:00,Endoscopy,E04.800.250
21819875,2011-08-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21819875,2011-08-01T00:00:00,Magnetic Resonance Imaging,E01.370.350.500
21819875,2011-08-01T00:00:00,Magnetic Resonance Imaging,E01.370.350.825.500
21819875,2011-08-01T00:00:00,Meningocele,C10.500.680.598
21819875,2011-08-01T00:00:00,Meningocele,C16.131.666.680.598
21819875,2011-08-01T00:00:00,Middle Aged,M01.060.116.630
21819875,2011-08-01T00:00:00,Skull Base,A01.456.830
21819875,2011-08-01T00:00:00,Skull Base,A02.835.232.781.750
21819875,2011-08-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.350.810
21819875,2011-08-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.600.350.700.810
21819875,2011-08-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.700.700.810
21819875,2011-08-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.700.810.810
21819875,2011-08-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.825.810.810
21819875,2011-08-01T00:00:00,Treatment Outcome,E01.789.800
21819875,2011-08-01T00:00:00,Treatment Outcome,N04.761.559.590.800
21819875,2011-08-01T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21820533,2011-08-01T00:00:00,"Decompression, Surgical",E04.188
21820533,2011-08-01T00:00:00,Enteral Nutrition,E02.421.360
21820533,2011-08-01T00:00:00,Enteral Nutrition,E02.642.500.360
21820533,2011-08-01T00:00:00,Gastrostomy,E04.210.496
21820533,2011-08-01T00:00:00,Gastrostomy,E04.579.408
21820533,2011-08-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21820533,2011-08-01T00:00:00,"Intubation, Gastrointestinal",E05.497.412
21820533,2011-08-01T00:00:00,Jejunostomy,E04.210.338.523
21820533,2011-08-01T00:00:00,Jejunostomy,E04.579.338.523
21825932,2011-08-01T00:00:00,"Accidents, Traffic",N06.850.135.392
21825932,2011-08-01T00:00:00,Adult,M01.060.116
21825932,2011-08-01T00:00:00,Aged,M01.060.116.100
21825932,2011-08-01T00:00:00,Cardiopulmonary Resuscitation,E02.365.647.110
21825932,2011-08-01T00:00:00,"Fractures, Bone",C21.866.404
21825932,2011-08-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21825932,2011-08-01T00:00:00,Incidence,E05.318.308.985.525.375
21825932,2011-08-01T00:00:00,Incidence,L01.280.975.525.375
21825932,2011-08-01T00:00:00,Incidence,N01.224.935.597.500
21825932,2011-08-01T00:00:00,Incidence,N06.850.505.400.975.525.375
21825932,2011-08-01T00:00:00,Incidence,N06.850.520.308.985.525.375
21825932,2011-08-01T00:00:00,Intracranial Embolism,C10.228.140.300.525.400
21825932,2011-08-01T00:00:00,Intracranial Embolism,C14.907.253.566.300
21825932,2011-08-01T00:00:00,Intracranial Embolism,C14.907.355.590.213.300
21825932,2011-08-01T00:00:00,Intracranial Embolism,C14.907.355.830.850.213.300
21825932,2011-08-01T00:00:00,Middle Aged,M01.060.116.630
21825932,2011-08-01T00:00:00,Pulmonary Embolism,C08.381.746
21825932,2011-08-01T00:00:00,Pulmonary Embolism,C14.907.355.350.700
21825932,2011-08-01T00:00:00,Wounds and Injuries,C21.866
21825932,2011-08-01T00:00:00,Young Adult,M01.060.116.815
21825943,2011-08-01T00:00:00,Anticoagulants,D27.505.954.502.119
21825943,2011-08-01T00:00:00,Brain Injuries,C10.228.140.199
21825943,2011-08-01T00:00:00,Brain Injuries,C10.900.300.087
21825943,2011-08-01T00:00:00,Brain Injuries,C21.866.260.118
21825943,2011-08-01T00:00:00,Brain Injuries,C21.866.915.300.200
21825943,2011-08-01T00:00:00,Disease Progression,C23.550.291.656
21825943,2011-08-01T00:00:00,Enoxaparin,D09.698.373.400.300.200
21825943,2011-08-01T00:00:00,Heparin,D09.698.373.400
21825943,2011-08-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21825943,2011-08-01T00:00:00,Length of Stay,E02.760.400.480
21825943,2011-08-01T00:00:00,Length of Stay,N02.421.585.400.480
21825943,2011-08-01T00:00:00,Pulmonary Embolism,C08.381.746
21825943,2011-08-01T00:00:00,Pulmonary Embolism,C14.907.355.350.700
21825943,2011-08-01T00:00:00,Venous Thrombosis,C14.907.355.830.925
21825943,2011-08-01T00:00:00,"Wounds, Nonpenetrating",C21.866.974
21835376,2011-08-01T00:00:00,Adult,M01.060.116
21835376,2011-08-01T00:00:00,Aged,M01.060.116.100
21835376,2011-08-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21835376,2011-08-01T00:00:00,"Imaging, Three-Dimensional",E01.370.350.400
21835376,2011-08-01T00:00:00,"Imaging, Three-Dimensional",L01.224.308.410
21835376,2011-08-01T00:00:00,Middle Aged,M01.060.116.630
21835376,2011-08-01T00:00:00,Pulmonary Embolism,C08.381.746
21835376,2011-08-01T00:00:00,Pulmonary Embolism,C14.907.355.350.700
21835376,2011-08-01T00:00:00,"Radiographic Image Interpretation, Computer-Assisted",E01.158.600.680
21835376,2011-08-01T00:00:00,"Radiographic Image Interpretation, Computer-Assisted",E01.370.350.350.700
21835376,2011-08-01T00:00:00,"Radiographic Image Interpretation, Computer-Assisted",E01.370.350.700.705
21835376,2011-08-01T00:00:00,"Radiographic Image Interpretation, Computer-Assisted",L01.700.508.100.158.600.680
21835376,2011-08-01T00:00:00,Risk Assessment,E05.318.740.600.800.715
21835376,2011-08-01T00:00:00,Risk Assessment,N04.452.871.715
21835376,2011-08-01T00:00:00,Risk Assessment,N05.715.360.750.625.700.690
21835376,2011-08-01T00:00:00,Risk Assessment,N06.850.505.715
21835376,2011-08-01T00:00:00,Risk Assessment,N06.850.520.830.600.800.715
21835376,2011-08-01T00:00:00,Risk Factors,E05.318.740.600.800.725
21835376,2011-08-01T00:00:00,Risk Factors,N05.715.350.200.700
21835376,2011-08-01T00:00:00,Risk Factors,N05.715.360.750.625.700.700
21835376,2011-08-01T00:00:00,Risk Factors,N06.850.490.625.750
21835376,2011-08-01T00:00:00,Risk Factors,N06.850.520.830.600.800.725
21835376,2011-08-01T00:00:00,Time Factors,G01.910.857
21835376,2011-08-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.350.810
21835376,2011-08-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.600.350.700.810
21835376,2011-08-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.700.700.810
21835376,2011-08-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.700.810.810
21835376,2011-08-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.825.810.810
21835376,2011-08-01T00:00:00,"Ventricular Dysfunction, Right",C14.280.945.910
21843170,2011-08-01T00:00:00,Adolescent,M01.060.057
21843170,2011-08-01T00:00:00,Adult,M01.060.116
21843170,2011-08-01T00:00:00,Aged,M01.060.116.100
21843170,2011-08-01T00:00:00,"Carcinoma, Hepatocellular",C04.557.470.200.025.255
21843170,2011-08-01T00:00:00,"Carcinoma, Hepatocellular",C04.588.274.623.160
21843170,2011-08-01T00:00:00,"Carcinoma, Hepatocellular",C06.301.623.160
21843170,2011-08-01T00:00:00,"Carcinoma, Hepatocellular",C06.552.697.160
21843170,2011-08-01T00:00:00,Diffusion Magnetic Resonance Imaging,E01.370.350.500.150
21843170,2011-08-01T00:00:00,Diffusion Magnetic Resonance Imaging,E01.370.350.825.500.150
21843170,2011-08-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21843170,2011-08-01T00:00:00,"Image Interpretation, Computer-Assisted",E01.158.600
21843170,2011-08-01T00:00:00,"Image Interpretation, Computer-Assisted",E01.370.350.350
21843170,2011-08-01T00:00:00,"Image Interpretation, Computer-Assisted",L01.700.508.100.158.600
21843170,2011-08-01T00:00:00,Liver Neoplasms,C04.588.274.623
21843170,2011-08-01T00:00:00,Liver Neoplasms,C06.301.623
21843170,2011-08-01T00:00:00,Liver Neoplasms,C06.552.697
21843170,2011-08-01T00:00:00,Middle Aged,M01.060.116.630
21844423,2011-08-01T00:00:00,Adult,M01.060.116
21844423,2011-08-01T00:00:00,Gastric Mucosa,A03.556.875.875.440
21844423,2011-08-01T00:00:00,Gastric Mucosa,A10.615.550.291
21844423,2011-08-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21900218,2011-08-01T00:00:00,Adenocarcinoma,C04.557.470.200.025
21900218,2011-08-01T00:00:00,Antineoplastic Combined Chemotherapy Protocols,E02.183.750.500
21900218,2011-08-01T00:00:00,Antineoplastic Combined Chemotherapy Protocols,E02.319.077.500
21900218,2011-08-01T00:00:00,Antineoplastic Combined Chemotherapy Protocols,E02.319.310.037
21900218,2011-08-01T00:00:00,"Carcinoma, Squamous Cell",C04.557.470.200.400
21900218,2011-08-01T00:00:00,"Carcinoma, Squamous Cell",C04.557.470.700.400
21900218,2011-08-01T00:00:00,Combined Modality Therapy,E02.186
21900218,2011-08-01T00:00:00,Esophageal Neoplasms,C04.588.274.476.205
21900218,2011-08-01T00:00:00,Esophageal Neoplasms,C04.588.443.353
21900218,2011-08-01T00:00:00,Esophageal Neoplasms,C06.301.371.205
21900218,2011-08-01T00:00:00,Esophageal Neoplasms,C06.405.117.430
21900218,2011-08-01T00:00:00,Esophageal Neoplasms,C06.405.249.205
21900218,2011-08-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21900218,2011-08-01T00:00:00,Neoplasm Staging,E01.370.550
21900218,2011-08-01T00:00:00,Palliative Care,E02.760.666
21900218,2011-08-01T00:00:00,Palliative Care,N02.421.585.666
21900218,2011-08-01T00:00:00,Randomized Controlled Trials as Topic,E05.318.760.535.365.500
21900218,2011-08-01T00:00:00,Randomized Controlled Trials as Topic,E05.337.250.365.500
21900218,2011-08-01T00:00:00,Randomized Controlled Trials as Topic,N05.715.360.775.235.387.500
21900218,2011-08-01T00:00:00,Randomized Controlled Trials as Topic,N06.850.520.450.535.365.500
21917707,2011-08-01T00:00:00,Antineoplastic Agents,D27.505.954.248
21917707,2011-08-01T00:00:00,Apoptosis,G04.299.139.160
21917707,2011-08-01T00:00:00,"Fatty Acids, Unsaturated",D10.251.355
21917707,2011-08-01T00:00:00,Gene Expression Regulation,G05.355.315
21917707,2011-08-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21917707,2011-08-01T00:00:00,P-Glycoprotein,D12.776.157.530.100.652.500
21917707,2011-08-01T00:00:00,P-Glycoprotein,D12.776.157.530.450.074.500.500.750
21917707,2011-08-01T00:00:00,P-Glycoprotein,D12.776.395.550.020.610.610
21917707,2011-08-01T00:00:00,P-Glycoprotein,D12.776.543.550.192.610.610
21917707,2011-08-01T00:00:00,P-Glycoprotein,D12.776.543.585.100.610.500
21917707,2011-08-01T00:00:00,P-Glycoprotein,D12.776.543.585.450.074.500.500.750
21917707,2011-08-01T00:00:00,RNA,D13.444.735
21917707,2011-08-01T00:00:00,"RNA, Messenger",D13.444.735.544
21922953,2011-08-01T00:00:00,"Arthroplasty, Replacement, Knee",E04.555.110.110.115
21922953,2011-08-01T00:00:00,"Arthroplasty, Replacement, Knee",E04.650.110.115
21922953,2011-08-01T00:00:00,Computer Simulation,L01.224.160
21922953,2011-08-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21922953,2011-08-01T00:00:00,Knee Prosthesis,E07.695.400.410
21922953,2011-08-01T00:00:00,Movement,G07.700.560
21922953,2011-08-01T00:00:00,Movement,G11.427.590.530
21922953,2011-08-01T00:00:00,Prosthesis Design,E05.320.550
21922953,2011-08-01T00:00:00,Prosthesis Design,E07.695.680
21944500,2011-08-01T00:00:00,"Biopsy, Needle",E01.370.388.100.100
21944500,2011-08-01T00:00:00,"Biopsy, Needle",E01.450.230.100.100
21944500,2011-08-01T00:00:00,"Biopsy, Needle",E01.450.865.100.100
21944500,2011-08-01T00:00:00,"Biopsy, Needle",E01.450.865.632.100
21944500,2011-08-01T00:00:00,"Biopsy, Needle",E04.074.119
21944500,2011-08-01T00:00:00,Cysts,C04.182
21944500,2011-08-01T00:00:00,Cysts,C23.300.306
21944500,2011-08-01T00:00:00,"Diagnosis, Differential",E01.171
21944500,2011-08-01T00:00:00,Hamartoma,C04.445
21944500,2011-08-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21944500,2011-08-01T00:00:00,Magnetic Resonance Imaging,E01.370.350.500
21944500,2011-08-01T00:00:00,Magnetic Resonance Imaging,E01.370.350.825.500
21944500,2011-08-01T00:00:00,Middle Aged,M01.060.116.630
21944500,2011-08-01T00:00:00,Risk Assessment,E05.318.740.600.800.715
21944500,2011-08-01T00:00:00,Risk Assessment,N04.452.871.715
21944500,2011-08-01T00:00:00,Risk Assessment,N05.715.360.750.625.700.690
21944500,2011-08-01T00:00:00,Risk Assessment,N06.850.505.715
21944500,2011-08-01T00:00:00,Risk Assessment,N06.850.520.830.600.800.715
21944500,2011-08-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.350.810
21944500,2011-08-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.600.350.700.810
21944500,2011-08-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.700.700.810
21944500,2011-08-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.700.810.810
21944500,2011-08-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.825.810.810
21944500,2011-08-01T00:00:00,Treatment Outcome,E01.789.800
21944500,2011-08-01T00:00:00,Treatment Outcome,N04.761.559.590.800
21944500,2011-08-01T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21944518,2011-08-01T00:00:00,Animals,B01.050
21944518,2011-08-01T00:00:00,"Coated Materials, Biocompatible",D25.130.420
21944518,2011-08-01T00:00:00,"Coated Materials, Biocompatible",J01.637.051.130.420
21944518,2011-08-01T00:00:00,Dermis,A17.815.180
21944518,2011-08-01T00:00:00,"Disease Models, Animal",C22.232
21944518,2011-08-01T00:00:00,"Disease Models, Animal",E05.598.500
21944518,2011-08-01T00:00:00,"Disease Models, Animal",E05.599.395.080
21944518,2011-08-01T00:00:00,Lysostaphin,D08.811.277.656.300.480.452
21944518,2011-08-01T00:00:00,Lysostaphin,D08.811.277.656.675.374.452
21944518,2011-08-01T00:00:00,Rats,B01.050.150.900.649.865.635.505.700
21944518,2011-08-01T00:00:00,Risk Assessment,E05.318.740.600.800.715
21944518,2011-08-01T00:00:00,Risk Assessment,N04.452.871.715
21944518,2011-08-01T00:00:00,Risk Assessment,N05.715.360.750.625.700.690
21944518,2011-08-01T00:00:00,Risk Assessment,N06.850.505.715
21944518,2011-08-01T00:00:00,Risk Assessment,N06.850.520.830.600.800.715
21944518,2011-08-01T00:00:00,Staphylococcal Infections,C01.252.410.868
21944518,2011-08-01T00:00:00,Surgical Mesh,E07.858.708
21944518,2011-08-01T00:00:00,Surgical Wound Infection,C01.539.947.692
21944518,2011-08-01T00:00:00,Surgical Wound Infection,C23.550.767.925
21944518,2011-08-01T00:00:00,Wound Healing,G16.100.856.891
22057740,2011-08-01T00:00:00,Cardiac Surgical Procedures,E04.100.376
22057740,2011-08-01T00:00:00,Cardiac Surgical Procedures,E04.928.220
22057740,2011-08-01T00:00:00,Cardiology,H02.403.429.163
22057740,2011-08-01T00:00:00,"Education, Medical, Continuing",I02.358.212.350
22057740,2011-08-01T00:00:00,"Education, Medical, Continuing",I02.358.399.250
22057740,2011-08-01T00:00:00,"Heart Defects, Congenital",C14.240.400
22057740,2011-08-01T00:00:00,"Heart Defects, Congenital",C14.280.400
22057740,2011-08-01T00:00:00,"Heart Defects, Congenital",C16.131.240.400
22057740,2011-08-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22057740,2011-08-01T00:00:00,United States,Z01.107.567.875
22057741,2011-08-01T00:00:00,Clinical Competence,I02.399.630.210
22057741,2011-08-01T00:00:00,Clinical Competence,N04.761.210
22057741,2011-08-01T00:00:00,"Education, Medical, Continuing",I02.358.212.350
22057741,2011-08-01T00:00:00,"Education, Medical, Continuing",I02.358.399.250
22057741,2011-08-01T00:00:00,Educational Measurement,I02.399
22057741,2011-08-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22057741,2011-08-01T00:00:00,"Specialties, Surgical",H02.403.810
22057741,2011-08-01T00:00:00,Thoracic Surgery,H02.403.810.803
22057741,2011-08-01T00:00:00,United States,Z01.107.567.875
22057742,2011-08-01T00:00:00,Adolescent,M01.060.057
22057742,2011-08-01T00:00:00,Adult,M01.060.116
22057742,2011-08-01T00:00:00,Aged,M01.060.116.100
22057742,2011-08-01T00:00:00,Child,M01.060.406
22057742,2011-08-01T00:00:00,"Child, Preschool",M01.060.406.448
22057742,2011-08-01T00:00:00,Heart Diseases,C14.280
22057742,2011-08-01T00:00:00,Heart Transplantation,E04.100.376.475
22057742,2011-08-01T00:00:00,Heart Transplantation,E04.928.220.390
22057742,2011-08-01T00:00:00,Heart Transplantation,E04.936.450.475
22057742,2011-08-01T00:00:00,Hospital Mortality,E05.318.308.985.550.400
22057742,2011-08-01T00:00:00,Hospital Mortality,L01.280.975.550.400
22057742,2011-08-01T00:00:00,Hospital Mortality,N01.224.935.698.400
22057742,2011-08-01T00:00:00,Hospital Mortality,N06.850.505.400.975.550.400
22057742,2011-08-01T00:00:00,Hospital Mortality,N06.850.520.308.985.550.400
22057742,2011-08-01T00:00:00,"Hospitals, University",N02.278.020.300.310
22057742,2011-08-01T00:00:00,"Hospitals, University",N02.278.421.639.725
22057742,2011-08-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22057742,2011-08-01T00:00:00,Infant,M01.060.703
22057742,2011-08-01T00:00:00,"Infant, Newborn",M01.060.703.520
22057742,2011-08-01T00:00:00,Middle Aged,M01.060.116.630
22057742,2011-08-01T00:00:00,South Carolina,Z01.107.567.875.075.662
22057742,2011-08-01T00:00:00,South Carolina,Z01.107.567.875.750.700
22057742,2011-08-01T00:00:00,Time Factors,G01.910.857
22057742,2011-08-01T00:00:00,Treatment Outcome,E01.789.800
22057742,2011-08-01T00:00:00,Treatment Outcome,N04.761.559.590.800
22057742,2011-08-01T00:00:00,Treatment Outcome,N05.715.360.575.575.800
22057742,2011-08-01T00:00:00,Young Adult,M01.060.116.815
22057744,2011-08-01T00:00:00,Adolescent,M01.060.057
22057744,2011-08-01T00:00:00,Adult,M01.060.116
22057744,2011-08-01T00:00:00,Child,M01.060.406
22057744,2011-08-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22057744,2011-08-01T00:00:00,Lung Diseases,C08.381
22057744,2011-08-01T00:00:00,Lung Transplantation,E04.928.600.495
22057744,2011-08-01T00:00:00,Lung Transplantation,E04.936.450.495
22057744,2011-08-01T00:00:00,Middle Aged,M01.060.116.630
22057744,2011-08-01T00:00:00,Risk Factors,E05.318.740.600.800.725
22057744,2011-08-01T00:00:00,Risk Factors,N05.715.350.200.700
22057744,2011-08-01T00:00:00,Risk Factors,N05.715.360.750.625.700.700
22057744,2011-08-01T00:00:00,Risk Factors,N06.850.490.625.750
22057744,2011-08-01T00:00:00,Risk Factors,N06.850.520.830.600.800.725
22057744,2011-08-01T00:00:00,United States,Z01.107.567.875
22057744,2011-08-01T00:00:00,Young Adult,M01.060.116.815
22057745,2011-08-01T00:00:00,Adolescent,M01.060.057
22057745,2011-08-01T00:00:00,Adult,M01.060.116
22057745,2011-08-01T00:00:00,Aged,M01.060.116.100
22057745,2011-08-01T00:00:00,"Aortic Aneurysm, Thoracic",C14.907.055.239.125
22057745,2011-08-01T00:00:00,"Aortic Aneurysm, Thoracic",C14.907.109.139.125
22057745,2011-08-01T00:00:00,Blood Vessel Prosthesis Implantation,E04.100.814.200
22057745,2011-08-01T00:00:00,Blood Vessel Prosthesis Implantation,E04.650.200
22057745,2011-08-01T00:00:00,"Echocardiography, Transesophageal",E01.370.350.850.220.235
22057745,2011-08-01T00:00:00,"Echocardiography, Transesophageal",E01.370.370.380.220.235
22057745,2011-08-01T00:00:00,Heart Valve Prosthesis Implantation,E04.100.376.485
22057745,2011-08-01T00:00:00,Heart Valve Prosthesis Implantation,E04.650.410
22057745,2011-08-01T00:00:00,Heart Valve Prosthesis Implantation,E04.928.220.410
22057745,2011-08-01T00:00:00,"Hospitals, University",N02.278.020.300.310
22057745,2011-08-01T00:00:00,"Hospitals, University",N02.278.421.639.725
22057745,2011-08-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22057745,2011-08-01T00:00:00,Middle Aged,M01.060.116.630
22057745,2011-08-01T00:00:00,South Carolina,Z01.107.567.875.075.662
22057745,2011-08-01T00:00:00,South Carolina,Z01.107.567.875.750.700
22057745,2011-08-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.350.810
22057745,2011-08-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.600.350.700.810
22057745,2011-08-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.700.700.810
22057745,2011-08-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.700.810.810
22057745,2011-08-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.825.810.810
22057745,2011-08-01T00:00:00,Treatment Outcome,E01.789.800
22057745,2011-08-01T00:00:00,Treatment Outcome,N04.761.559.590.800
22057745,2011-08-01T00:00:00,Treatment Outcome,N05.715.360.575.575.800
22057745,2011-08-01T00:00:00,Young Adult,M01.060.116.815
22057747,2011-08-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22057747,2011-08-01T00:00:00,Tissue Donors,M01.898
22057747,2011-08-01T00:00:00,Tissue and Organ Harvesting,E01.450.865.820
22057747,2011-08-01T00:00:00,Tissue and Organ Harvesting,E04.932
22057748,2011-08-01T00:00:00,Animals,B01.050
22057748,2011-08-01T00:00:00,Cardiac Surgical Procedures,E04.100.376
22057748,2011-08-01T00:00:00,Cardiac Surgical Procedures,E04.928.220
22057748,2011-08-01T00:00:00,Heart Diseases,C14.280
22057748,2011-08-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22057748,2011-08-01T00:00:00,Stem Cells,A11.872
22057748,2011-08-01T00:00:00,Treatment Outcome,E01.789.800
22057748,2011-08-01T00:00:00,Treatment Outcome,N04.761.559.590.800
22057748,2011-08-01T00:00:00,Treatment Outcome,N05.715.360.575.575.800
22057748,2011-08-01T00:00:00,Ventricular Remodeling,C23.300.985
22057748,2011-08-01T00:00:00,Ventricular Remodeling,G09.330.190.962.975
22057750,2011-08-01T00:00:00,Heart Failure,C14.280.434
22057750,2011-08-01T00:00:00,Heart-Assist Devices,E04.050.430
22057750,2011-08-01T00:00:00,Heart-Assist Devices,E07.695.300.300
22057750,2011-08-01T00:00:00,Heart-Assist Devices,E07.858.082.374.300
22057750,2011-08-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22057750,2011-08-01T00:00:00,United States,Z01.107.567.875
22057751,2011-08-01T00:00:00,Adolescent,M01.060.057
22057751,2011-08-01T00:00:00,Adult,M01.060.116
22057751,2011-08-01T00:00:00,Aged,M01.060.116.100
22057751,2011-08-01T00:00:00,Angiography,E01.370.350.700.060
22057751,2011-08-01T00:00:00,Angiography,E01.370.370.050
22057751,2011-08-01T00:00:00,"Aorta, Thoracic",A07.231.114.056.372
22057751,2011-08-01T00:00:00,Aortic Valve Stenosis,C14.280.484.150
22057751,2011-08-01T00:00:00,Aortic Valve Stenosis,C14.280.955.249
22057751,2011-08-01T00:00:00,Blood Vessel Prosthesis Implantation,E04.100.814.200
22057751,2011-08-01T00:00:00,Blood Vessel Prosthesis Implantation,E04.650.200
22057751,2011-08-01T00:00:00,Child,M01.060.406
22057751,2011-08-01T00:00:00,"Child, Preschool",M01.060.406.448
22057751,2011-08-01T00:00:00,Echocardiography,E01.370.350.850.220
22057751,2011-08-01T00:00:00,Echocardiography,E01.370.370.380.220
22057751,2011-08-01T00:00:00,Heart Valve Prosthesis Implantation,E04.100.376.485
22057751,2011-08-01T00:00:00,Heart Valve Prosthesis Implantation,E04.650.410
22057751,2011-08-01T00:00:00,Heart Valve Prosthesis Implantation,E04.928.220.410
22057751,2011-08-01T00:00:00,"Hospitals, University",N02.278.020.300.310
22057751,2011-08-01T00:00:00,"Hospitals, University",N02.278.421.639.725
22057751,2011-08-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22057751,2011-08-01T00:00:00,Infant,M01.060.703
22057751,2011-08-01T00:00:00,Middle Aged,M01.060.116.630
22057751,2011-08-01T00:00:00,South Carolina,Z01.107.567.875.075.662
22057751,2011-08-01T00:00:00,South Carolina,Z01.107.567.875.750.700
22057751,2011-08-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.350.810
22057751,2011-08-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.600.350.700.810
22057751,2011-08-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.700.700.810
22057751,2011-08-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.700.810.810
22057751,2011-08-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.825.810.810
22057751,2011-08-01T00:00:00,Treatment Outcome,E01.789.800
22057751,2011-08-01T00:00:00,Treatment Outcome,N04.761.559.590.800
22057751,2011-08-01T00:00:00,Treatment Outcome,N05.715.360.575.575.800
22057751,2011-08-01T00:00:00,Young Adult,M01.060.116.815
22123346,2011-08-01T00:00:00,"Catheters, Indwelling",E07.150
22123346,2011-08-01T00:00:00,"Hematoma, Subdural",C10.228.140.300.535.450.400
22123346,2011-08-01T00:00:00,"Hematoma, Subdural",C10.900.300.837.600
22123346,2011-08-01T00:00:00,"Hematoma, Subdural",C14.907.253.573.400.450
22123346,2011-08-01T00:00:00,"Hematoma, Subdural",C21.866.260.616.600
22123346,2011-08-01T00:00:00,"Hematoma, Subdural",C21.866.915.300.490.450
22123346,2011-08-01T00:00:00,"Hematoma, Subdural",C23.550.414.838.700
22123346,2011-08-01T00:00:00,"Hematoma, Subdural",C23.550.414.913.700
22123346,2011-08-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22123346,2011-08-01T00:00:00,"Infant, Newborn",M01.060.703.520
22123346,2011-08-01T00:00:00,"Infant, Premature",M01.060.703.520.520
22123346,2011-08-01T00:00:00,"Infusions, Intravenous",E02.319.267.510.590
22123346,2011-08-01T00:00:00,Treatment Outcome,E01.789.800
22123346,2011-08-01T00:00:00,Treatment Outcome,N04.761.559.590.800
22123346,2011-08-01T00:00:00,Treatment Outcome,N05.715.360.575.575.800
22319906,2011-08-01T00:00:00,General Surgery,H02.403.810.300
22319906,2011-08-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22319906,2011-08-01T00:00:00,Physicians,M01.526.485.810
22319906,2011-08-01T00:00:00,Physicians,N02.360.810
22319906,2011-08-01T00:00:00,United States,Z01.107.567.875
21800782,2011-08-02T00:00:00,Adolescent,M01.060.057
21800782,2011-08-02T00:00:00,Adult,M01.060.116
21800782,2011-08-02T00:00:00,Child,M01.060.406
21800782,2011-08-02T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21800782,2011-08-02T00:00:00,Intraoperative Complications,C23.550.505
21800782,2011-08-02T00:00:00,"Lens Implantation, Intraocular",E04.540.825.600
21800782,2011-08-02T00:00:00,"Lenses, Intraocular",E07.632.500.460
21800782,2011-08-02T00:00:00,"Lenses, Intraocular",E07.695.460
21800782,2011-08-02T00:00:00,Treatment Outcome,E01.789.800
21800782,2011-08-02T00:00:00,Treatment Outcome,N04.761.559.590.800
21800782,2011-08-02T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21800782,2011-08-02T00:00:00,Visual Acuity,E01.370.380.850.950
21800782,2011-08-02T00:00:00,Visual Acuity,F02.463.593.932.901
21800782,2011-08-02T00:00:00,Visual Acuity,G14.940
21800782,2011-08-02T00:00:00,Young Adult,M01.060.116.815
21808257,2011-08-02T00:00:00,Activities of Daily Living,E02.831.067
21808257,2011-08-02T00:00:00,Activities of Daily Living,I03.050
21808257,2011-08-02T00:00:00,Activities of Daily Living,N02.421.784.110
21808257,2011-08-02T00:00:00,Adult,M01.060.116
21808257,2011-08-02T00:00:00,Depressive Disorder,F03.600.300
21808257,2011-08-02T00:00:00,Health Status,I01.240.425
21808257,2011-08-02T00:00:00,Health Status,N01.224.425
21808257,2011-08-02T00:00:00,Health Status,N06.850.505.400.425
21808257,2011-08-02T00:00:00,Health Surveys,E05.318.308.250
21808257,2011-08-02T00:00:00,Health Surveys,N05.715.360.300.375
21808257,2011-08-02T00:00:00,Health Surveys,N06.850.520.308.250
21808257,2011-08-02T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21808257,2011-08-02T00:00:00,Middle Aged,M01.060.116.630
21808257,2011-08-02T00:00:00,Questionnaires,E05.318.308.750
21808257,2011-08-02T00:00:00,Questionnaires,L01.280.800
21808257,2011-08-02T00:00:00,Questionnaires,N05.715.360.300.695
21808257,2011-08-02T00:00:00,Questionnaires,N06.850.520.308.750
21808257,2011-08-02T00:00:00,Spinal Cord Injuries,C10.228.854.770
21808257,2011-08-02T00:00:00,Spinal Cord Injuries,C10.900.850
21808257,2011-08-02T00:00:00,Spinal Cord Injuries,C21.866.819
21809106,2011-08-02T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21809106,2011-08-02T00:00:00,"Hypertension, Pulmonary",C08.381.423
21809106,2011-08-02T00:00:00,"Infusions, Intravenous",E02.319.267.510.590
21809106,2011-08-02T00:00:00,Intensive Care,E02.760.190.400
21809106,2011-08-02T00:00:00,Intensive Care,N02.421.585.190.400
21809106,2011-08-02T00:00:00,Iron,D01.268.556.412
21809106,2011-08-02T00:00:00,Iron,D01.268.956.287
21809106,2011-08-02T00:00:00,Iron,D01.552.544.412
21816380,2011-08-02T00:00:00,Adult,M01.060.116
21816380,2011-08-02T00:00:00,Hospitalization,E02.760.400
21816380,2011-08-02T00:00:00,Hospitalization,N02.421.585.400
21816380,2011-08-02T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21816380,2011-08-02T00:00:00,Middle Aged,M01.060.116.630
21816380,2011-08-02T00:00:00,Myocardial Infarction,C14.280.647.500
21816380,2011-08-02T00:00:00,Myocardial Infarction,C14.907.585.500
21816380,2011-08-02T00:00:00,Risk Factors,E05.318.740.600.800.725
21816380,2011-08-02T00:00:00,Risk Factors,N05.715.350.200.700
21816380,2011-08-02T00:00:00,Risk Factors,N05.715.360.750.625.700.700
21816380,2011-08-02T00:00:00,Risk Factors,N06.850.490.625.750
21816380,2011-08-02T00:00:00,Risk Factors,N06.850.520.830.600.800.725
21816380,2011-08-02T00:00:00,United States,Z01.107.567.875
21868171,2011-08-02T00:00:00,Adolescent,M01.060.057
21868171,2011-08-02T00:00:00,Adult,M01.060.116
21868171,2011-08-02T00:00:00,Aged,M01.060.116.100
21868171,2011-08-02T00:00:00,Alcohol Drinking,F01.145.317.269
21868171,2011-08-02T00:00:00,Ethanol,D02.033.375
21868171,2011-08-02T00:00:00,Health Behavior,F01.145.488
21868171,2011-08-02T00:00:00,"Health Knowledge, Attitudes, Practice",F01.100.150.500
21868171,2011-08-02T00:00:00,"Health Knowledge, Attitudes, Practice",N05.300.150.410
21868171,2011-08-02T00:00:00,Health Status,I01.240.425
21868171,2011-08-02T00:00:00,Health Status,N01.224.425
21868171,2011-08-02T00:00:00,Health Status,N06.850.505.400.425
21868171,2011-08-02T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21868171,2011-08-02T00:00:00,Life Style,F01.829.458
21868171,2011-08-02T00:00:00,Middle Aged,M01.060.116.630
21868171,2011-08-02T00:00:00,Quality of Life,I01.800
21868171,2011-08-02T00:00:00,Quality of Life,K01.752.400.750
21868171,2011-08-02T00:00:00,Risk Factors,E05.318.740.600.800.725
21868171,2011-08-02T00:00:00,Risk Factors,N05.715.350.200.700
21868171,2011-08-02T00:00:00,Risk Factors,N05.715.360.750.625.700.700
21868171,2011-08-02T00:00:00,Risk Factors,N06.850.490.625.750
21868171,2011-08-02T00:00:00,Risk Factors,N06.850.520.830.600.800.725
21868171,2011-08-02T00:00:00,United States,Z01.107.567.875
21868171,2011-08-02T00:00:00,Young Adult,M01.060.116.815
21816481,2011-08-03T00:00:00,Adult,M01.060.116
21816481,2011-08-03T00:00:00,Aged,M01.060.116.100
21816481,2011-08-03T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21816481,2011-08-03T00:00:00,"Interview, Psychological",F04.669.599
21816481,2011-08-03T00:00:00,Middle Aged,M01.060.116.630
21816481,2011-08-03T00:00:00,Panic Disorder,F03.080.700
21816481,2011-08-03T00:00:00,Primary Health Care,N04.590.233.727
21816481,2011-08-03T00:00:00,"Stress Disorders, Post-Traumatic",F03.080.931.500
21816481,2011-08-03T00:00:00,United States,Z01.107.567.875
21816481,2011-08-03T00:00:00,United States Department of Veterans Affairs,I01.409.137.500.700
21816481,2011-08-03T00:00:00,United States Department of Veterans Affairs,N03.540.348.500.500.700
21816481,2011-08-03T00:00:00,Veterans,M01.930
21816848,2011-08-03T00:00:00,Alligators and Crocodiles,B01.050.150.900.833.100
21816848,2011-08-03T00:00:00,Animals,B01.050
21816848,2011-08-03T00:00:00,Biometry,E05.318.740.225
21816848,2011-08-03T00:00:00,Biometry,N06.850.505.200
21816848,2011-08-03T00:00:00,Testosterone,D04.808.054.079.429.824
21816848,2011-08-03T00:00:00,Testosterone,D06.472.334.851.968.984
21812870,2011-08-04T00:00:00,Actins,D05.750.078.730.250
21812870,2011-08-04T00:00:00,Actins,D12.776.210.500.100
21812870,2011-08-04T00:00:00,Actins,D12.776.220.525.255
21812870,2011-08-04T00:00:00,Alcoholism,C21.739.100.250
21812870,2011-08-04T00:00:00,Alcoholism,F03.900.100.350
21812870,2011-08-04T00:00:00,Animals,B01.050
21812870,2011-08-04T00:00:00,Brain,A08.186.211
21812870,2011-08-04T00:00:00,Central Nervous System Depressants,D27.505.696.277
21812870,2011-08-04T00:00:00,Central Nervous System Depressants,D27.505.954.427.210
21812870,2011-08-04T00:00:00,Circadian Rhythm,G07.180.562.190
21812870,2011-08-04T00:00:00,Down-Regulation,G02.111.087.225
21812870,2011-08-04T00:00:00,Down-Regulation,G02.149.115.225
21812870,2011-08-04T00:00:00,Down-Regulation,G05.355.315.200
21812870,2011-08-04T00:00:00,Down-Regulation,G07.690.812.230
21812870,2011-08-04T00:00:00,Down-Regulation,G07.700.680.230
21812870,2011-08-04T00:00:00,Ethanol,D02.033.375
21812870,2011-08-04T00:00:00,Gene Expression,G05.355.310
21812870,2011-08-04T00:00:00,MAP Kinase Signaling System,G02.111.087.800.560
21812870,2011-08-04T00:00:00,MAP Kinase Signaling System,G02.149.115.800.560
21812870,2011-08-04T00:00:00,MAP Kinase Signaling System,G03.495.553.560
21812870,2011-08-04T00:00:00,MAP Kinase Signaling System,G04.299.880.560
21812870,2011-08-04T00:00:00,"RNA Processing, Post-Transcriptional",G02.111.087.750
21812870,2011-08-04T00:00:00,"RNA Processing, Post-Transcriptional",G02.149.115.750
21812870,2011-08-04T00:00:00,"RNA Processing, Post-Transcriptional",G03.495.839
21812870,2011-08-04T00:00:00,"RNA Processing, Post-Transcriptional",G05.355.315.700
21812870,2011-08-04T00:00:00,Substance Withdrawal Syndrome,C21.739.835
21812870,2011-08-04T00:00:00,Substance Withdrawal Syndrome,F03.900.825
21814790,2011-08-04T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21814790,2011-08-04T00:00:00,Lung Neoplasms,C04.588.894.797.520
21814790,2011-08-04T00:00:00,Lung Neoplasms,C08.381.540
21814790,2011-08-04T00:00:00,Lung Neoplasms,C08.785.520
21814790,2011-08-04T00:00:00,Molecular Sequence Data,L01.453.245.667
21814790,2011-08-04T00:00:00,Polyamines,D02.092.782
21814790,2011-08-04T00:00:00,Proteins,D12.776
21814790,2011-08-04T00:00:00,Spermine,D02.092.211.415.701.801.821
21814790,2011-08-04T00:00:00,Spermine,D02.092.782.802
21816525,2011-08-04T00:00:00,African Americans,M01.686.508.100.100
21816525,2011-08-04T00:00:00,African Americans,M01.686.754.100
21816525,2011-08-04T00:00:00,Aged,M01.060.116.100
21816525,2011-08-04T00:00:00,Body Mass Index,E01.370.600.115.100.125
21816525,2011-08-04T00:00:00,Body Mass Index,E05.041.124.125
21816525,2011-08-04T00:00:00,Body Mass Index,G07.100.100.125
21816525,2011-08-04T00:00:00,Body Mass Index,N06.850.505.200.100.175
21816525,2011-08-04T00:00:00,Cause of Death,E05.318.308.985.550.250
21816525,2011-08-04T00:00:00,Cause of Death,L01.280.975.550.250
21816525,2011-08-04T00:00:00,Cause of Death,N01.224.935.698.100
21816525,2011-08-04T00:00:00,Cause of Death,N06.850.505.400.975.550.250
21816525,2011-08-04T00:00:00,Cause of Death,N06.850.520.308.985.550.250
21816525,2011-08-04T00:00:00,Chronic Disease,C23.550.291.500
21816525,2011-08-04T00:00:00,Diabetic Nephropathies,C12.777.419.192
21816525,2011-08-04T00:00:00,Diabetic Nephropathies,C13.351.968.419.192
21816525,2011-08-04T00:00:00,Diabetic Nephropathies,C19.246.099.875
21816525,2011-08-04T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21816525,2011-08-04T00:00:00,Kidney Diseases,C12.777.419
21816525,2011-08-04T00:00:00,Kidney Diseases,C13.351.968.419
21816525,2011-08-04T00:00:00,Middle Aged,M01.060.116.630
21816525,2011-08-04T00:00:00,United States,Z01.107.567.875
21816525,2011-08-04T00:00:00,Vitamin D,D04.808.812.768
21816525,2011-08-04T00:00:00,Vitamin D Deficiency,C18.654.521.500.133.770
21818152,2011-08-04T00:00:00,Adolescent,M01.060.057
21818152,2011-08-04T00:00:00,Adult,M01.060.116
21818152,2011-08-04T00:00:00,Aged,M01.060.116.100
21818152,2011-08-04T00:00:00,Alleles,G05.360.340.024.340.030
21818152,2011-08-04T00:00:00,Body Mass Index,E01.370.600.115.100.125
21818152,2011-08-04T00:00:00,Body Mass Index,E05.041.124.125
21818152,2011-08-04T00:00:00,Body Mass Index,G07.100.100.125
21818152,2011-08-04T00:00:00,Body Mass Index,N06.850.505.200.100.175
21818152,2011-08-04T00:00:00,European Continental Ancestry Group,M01.686.508.400
21818152,2011-08-04T00:00:00,Genetic Loci,G05.360.340.024.380
21818152,2011-08-04T00:00:00,Genetic Predisposition to Disease,C23.550.291.687.500
21818152,2011-08-04T00:00:00,Genetic Predisposition to Disease,G05.380.355
21818152,2011-08-04T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21818152,2011-08-04T00:00:00,Middle Aged,M01.060.116.630
21818152,2011-08-04T00:00:00,Obesity,C18.654.726.500
21818152,2011-08-04T00:00:00,Obesity,C23.888.144.699.500
21818152,2011-08-04T00:00:00,Obesity,E01.370.600.115.100.160.120.699.500
21818152,2011-08-04T00:00:00,Obesity,G07.100.100.160.120.699.500
21818152,2011-08-04T00:00:00,"Polymorphism, Single Nucleotide",G05.365.795.598
21818152,2011-08-04T00:00:00,Proteins,D12.776
21818152,2011-08-04T00:00:00,"Receptors, Neuropeptide",D12.776.543.750.720.600
21818152,2011-08-04T00:00:00,"Receptors, Neuropeptide",D12.776.543.750.750.555
21818152,2011-08-04T00:00:00,Young Adult,M01.060.116.815
21818827,2011-08-04T00:00:00,Adult,M01.060.116
21818827,2011-08-04T00:00:00,Alleles,G05.360.340.024.340.030
21818827,2011-08-04T00:00:00,Combat Disorders,F03.080.931.249
21818827,2011-08-04T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21818827,2011-08-04T00:00:00,Middle Aged,M01.060.116.630
21818827,2011-08-04T00:00:00,"Polymorphism, Genetic",G05.365.795
21818827,2011-08-04T00:00:00,Psychiatric Status Rating Scales,F04.586
21818827,2011-08-04T00:00:00,Risk Factors,E05.318.740.600.800.725
21818827,2011-08-04T00:00:00,Risk Factors,N05.715.350.200.700
21818827,2011-08-04T00:00:00,Risk Factors,N05.715.360.750.625.700.700
21818827,2011-08-04T00:00:00,Risk Factors,N06.850.490.625.750
21818827,2011-08-04T00:00:00,Risk Factors,N06.850.520.830.600.800.725
21818827,2011-08-04T00:00:00,Serotonin Plasma Membrane Transport Proteins,D12.776.157.530.450.625.311
21818827,2011-08-04T00:00:00,Serotonin Plasma Membrane Transport Proteins,D12.776.157.530.562.374.875
21818827,2011-08-04T00:00:00,Serotonin Plasma Membrane Transport Proteins,D12.776.543.585.450.625.374
21818827,2011-08-04T00:00:00,Serotonin Plasma Membrane Transport Proteins,D12.776.543.585.562.374.875
21818827,2011-08-04T00:00:00,"Stress Disorders, Post-Traumatic",F03.080.931.500
21818827,2011-08-04T00:00:00,Veterans,M01.930
21820109,2011-08-05T00:00:00,Aged,M01.060.116.100
21820109,2011-08-05T00:00:00,Esophageal Neoplasms,C04.588.274.476.205
21820109,2011-08-05T00:00:00,Esophageal Neoplasms,C04.588.443.353
21820109,2011-08-05T00:00:00,Esophageal Neoplasms,C06.301.371.205
21820109,2011-08-05T00:00:00,Esophageal Neoplasms,C06.405.117.430
21820109,2011-08-05T00:00:00,Esophageal Neoplasms,C06.405.249.205
21820109,2011-08-05T00:00:00,Esophageal Stenosis,C06.405.117.544
21820109,2011-08-05T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21820109,2011-08-05T00:00:00,Middle Aged,M01.060.116.630
21823112,2011-08-05T00:00:00,Age of Onset,N05.715.350.075.100
21823112,2011-08-05T00:00:00,Age of Onset,N06.850.490.250.100
21823112,2011-08-05T00:00:00,Aged,M01.060.116.100
21823112,2011-08-05T00:00:00,Carcinoma,C04.557.470.200
21823112,2011-08-05T00:00:00,Diagnostic Imaging,E01.370.350
21823112,2011-08-05T00:00:00,Health Care Costs,N03.219.151.400
21823112,2011-08-05T00:00:00,Health Care Costs,N05.300.375
21823112,2011-08-05T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21823112,2011-08-05T00:00:00,Prostatic Neoplasms,C04.588.945.440.770
21823112,2011-08-05T00:00:00,Prostatic Neoplasms,C12.294.260.750
21823112,2011-08-05T00:00:00,Prostatic Neoplasms,C12.294.565.625
21823112,2011-08-05T00:00:00,Prostatic Neoplasms,C12.758.409.750
21823112,2011-08-05T00:00:00,Risk Factors,E05.318.740.600.800.725
21823112,2011-08-05T00:00:00,Risk Factors,N05.715.350.200.700
21823112,2011-08-05T00:00:00,Risk Factors,N05.715.360.750.625.700.700
21823112,2011-08-05T00:00:00,Risk Factors,N06.850.490.625.750
21823112,2011-08-05T00:00:00,Risk Factors,N06.850.520.830.600.800.725
21823112,2011-08-05T00:00:00,SEER Program,E05.318.308.970.725
21823112,2011-08-05T00:00:00,SEER Program,L01.280.950.725
21823112,2011-08-05T00:00:00,SEER Program,N04.452.859.819.725
21823112,2011-08-05T00:00:00,SEER Program,N05.715.360.300.715.700.725
21823112,2011-08-05T00:00:00,SEER Program,N06.850.520.308.970.725
21823112,2011-08-05T00:00:00,United States,Z01.107.567.875
22145654,2011-08-05T00:00:00,Brain Injuries,C10.228.140.199
22145654,2011-08-05T00:00:00,Brain Injuries,C10.900.300.087
22145654,2011-08-05T00:00:00,Brain Injuries,C21.866.260.118
22145654,2011-08-05T00:00:00,Brain Injuries,C21.866.915.300.200
22145654,2011-08-05T00:00:00,Clinical Competence,I02.399.630.210
22145654,2011-08-05T00:00:00,Clinical Competence,N04.761.210
22145654,2011-08-05T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22145654,2011-08-05T00:00:00,Primary Health Care,N04.590.233.727
21822645,2011-08-06T00:00:00,Animals,B01.050
21822645,2011-08-06T00:00:00,Extracellular Matrix Proteins,D12.776.860.300
21822645,2011-08-06T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21822645,2011-08-06T00:00:00,"Neovascularization, Physiologic",G09.330.190.751
21822645,2011-08-06T00:00:00,Osteonectin,D12.776.157.125.715
21822645,2011-08-06T00:00:00,Osteonectin,D12.776.395.600
21822645,2011-08-06T00:00:00,Signal Transduction,G02.111.087.800
21822645,2011-08-06T00:00:00,Signal Transduction,G02.149.115.800
21822645,2011-08-06T00:00:00,Signal Transduction,G04.299.880
21822645,2011-08-06T00:00:00,Transforming Growth Factor beta1,D12.644.276.374.687.100
21822645,2011-08-06T00:00:00,Transforming Growth Factor beta1,D12.644.276.954.800.720.100
21822645,2011-08-06T00:00:00,Transforming Growth Factor beta1,D12.644.276.963.720.100
21822645,2011-08-06T00:00:00,Transforming Growth Factor beta1,D12.776.467.374.687.100
21822645,2011-08-06T00:00:00,Transforming Growth Factor beta1,D12.776.467.942.800.720.100
21822645,2011-08-06T00:00:00,Transforming Growth Factor beta1,D12.776.467.960.720.100
21822645,2011-08-06T00:00:00,Transforming Growth Factor beta1,D23.529.374.687.100
21822645,2011-08-06T00:00:00,Transforming Growth Factor beta1,D23.529.942.800.720.100
21822645,2011-08-06T00:00:00,Transforming Growth Factor beta1,D23.529.960.720.100
21822645,2011-08-06T00:00:00,Vascular Endothelial Growth Factor A,D12.644.276.100.800.200
21822645,2011-08-06T00:00:00,Vascular Endothelial Growth Factor A,D12.776.467.100.800.200
21822645,2011-08-06T00:00:00,Vascular Endothelial Growth Factor A,D23.529.100.800.200
21875825,2011-08-06T00:00:00,Cardiology,H02.403.429.163
21875825,2011-08-06T00:00:00,Certification,N03.706.110.120
21875825,2011-08-06T00:00:00,Certification,N05.700.200.190
21875825,2011-08-06T00:00:00,Clinical Competence,I02.399.630.210
21875825,2011-08-06T00:00:00,Clinical Competence,N04.761.210
21875825,2011-08-06T00:00:00,Coronary Angiography,E01.370.350.700.060.200
21875825,2011-08-06T00:00:00,Coronary Angiography,E01.370.370.050.200
21875825,2011-08-06T00:00:00,Coronary Angiography,E01.370.370.380.200
21875825,2011-08-06T00:00:00,Curriculum,I02.158
21875825,2011-08-06T00:00:00,"Education, Medical, Graduate",I02.358.337.350
21875825,2011-08-06T00:00:00,"Education, Medical, Graduate",I02.358.399.350
21875825,2011-08-06T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21875825,2011-08-06T00:00:00,"Tomography, X-Ray Computed",E01.370.350.350.810
21875825,2011-08-06T00:00:00,"Tomography, X-Ray Computed",E01.370.350.600.350.700.810
21875825,2011-08-06T00:00:00,"Tomography, X-Ray Computed",E01.370.350.700.700.810
21875825,2011-08-06T00:00:00,"Tomography, X-Ray Computed",E01.370.350.700.810.810
21875825,2011-08-06T00:00:00,"Tomography, X-Ray Computed",E01.370.350.825.810.810
21875825,2011-08-06T00:00:00,United States,Z01.107.567.875
21875827,2011-08-07T00:00:00,Adult,M01.060.116
21875827,2011-08-07T00:00:00,Aged,M01.060.116.100
21875827,2011-08-07T00:00:00,Algorithms,G17.035
21875827,2011-08-07T00:00:00,Algorithms,L01.224.050
21875827,2011-08-07T00:00:00,Cardiac Output,E01.370.370.380.150
21875827,2011-08-07T00:00:00,Cardiac Output,G09.330.380.124
21875827,2011-08-07T00:00:00,Heart Ventricles,A07.541.560
21875827,2011-08-07T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21875827,2011-08-07T00:00:00,"Hypertrophy, Left Ventricular",C14.280.195.400
21875827,2011-08-07T00:00:00,"Hypertrophy, Left Ventricular",C23.300.775.250.400
21875827,2011-08-07T00:00:00,Middle Aged,M01.060.116.630
21875827,2011-08-07T00:00:00,"Radiographic Image Interpretation, Computer-Assisted",E01.158.600.680
21875827,2011-08-07T00:00:00,"Radiographic Image Interpretation, Computer-Assisted",E01.370.350.350.700
21875827,2011-08-07T00:00:00,"Radiographic Image Interpretation, Computer-Assisted",E01.370.350.700.705
21875827,2011-08-07T00:00:00,"Radiographic Image Interpretation, Computer-Assisted",L01.700.508.100.158.600.680
21875827,2011-08-07T00:00:00,Software,L01.224.900
21875827,2011-08-07T00:00:00,Stroke Volume,E01.370.370.380.150.700
21875827,2011-08-07T00:00:00,Stroke Volume,G09.330.380.124.882
21875827,2011-08-07T00:00:00,"Tomography, X-Ray Computed",E01.370.350.350.810
21875827,2011-08-07T00:00:00,"Tomography, X-Ray Computed",E01.370.350.600.350.700.810
21875827,2011-08-07T00:00:00,"Tomography, X-Ray Computed",E01.370.350.700.700.810
21875827,2011-08-07T00:00:00,"Tomography, X-Ray Computed",E01.370.350.700.810.810
21875827,2011-08-07T00:00:00,"Tomography, X-Ray Computed",E01.370.350.825.810.810
21875827,2011-08-07T00:00:00,"Ventricular Function, Left",G09.330.190.962.800
21824912,2011-08-08T00:00:00,Adult,M01.060.116
21824912,2011-08-08T00:00:00,Aged,M01.060.116.100
21824912,2011-08-08T00:00:00,DNA,D13.444.308
21824912,2011-08-08T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21824912,2011-08-08T00:00:00,Middle Aged,M01.060.116.630
21824912,2011-08-08T00:00:00,Polymerase Chain Reaction,E05.393.620.500
21824920,2011-08-08T00:00:00,Antihypertensive Agents,D27.505.954.411.162
21824920,2011-08-08T00:00:00,Body Mass Index,E01.370.600.115.100.125
21824920,2011-08-08T00:00:00,Body Mass Index,E05.041.124.125
21824920,2011-08-08T00:00:00,Body Mass Index,G07.100.100.125
21824920,2011-08-08T00:00:00,Body Mass Index,N06.850.505.200.100.175
21824920,2011-08-08T00:00:00,Drug Resistance,G07.690.320
21824920,2011-08-08T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21824920,2011-08-08T00:00:00,Hypertension,C14.907.489
21824920,2011-08-08T00:00:00,Kidney Diseases,C12.777.419
21824920,2011-08-08T00:00:00,Kidney Diseases,C13.351.968.419
21824920,2011-08-08T00:00:00,Middle Aged,M01.060.116.630
21824920,2011-08-08T00:00:00,Nutrition Surveys,E05.318.308.250.600
21824920,2011-08-08T00:00:00,Nutrition Surveys,E05.318.308.585.550
21824920,2011-08-08T00:00:00,Nutrition Surveys,N05.715.360.300.375.560
21824920,2011-08-08T00:00:00,Nutrition Surveys,N05.715.360.300.560.565
21824920,2011-08-08T00:00:00,Nutrition Surveys,N06.850.520.308.250.600
21824920,2011-08-08T00:00:00,Nutrition Surveys,N06.850.520.308.585.550
21824920,2011-08-08T00:00:00,Obesity,C18.654.726.500
21824920,2011-08-08T00:00:00,Obesity,C23.888.144.699.500
21824920,2011-08-08T00:00:00,Obesity,E01.370.600.115.100.160.120.699.500
21824920,2011-08-08T00:00:00,Obesity,G07.100.100.160.120.699.500
21824920,2011-08-08T00:00:00,United States,Z01.107.567.875
21825015,2011-08-08T00:00:00,Breast Neoplasms,C04.588.180
21825015,2011-08-08T00:00:00,Breast Neoplasms,C17.800.090.500
21825015,2011-08-08T00:00:00,DNA Methylation,G02.111.087.029.538.161
21825015,2011-08-08T00:00:00,DNA Methylation,G02.111.087.218
21825015,2011-08-08T00:00:00,DNA Methylation,G02.149.115.029.538.161
21825015,2011-08-08T00:00:00,DNA Methylation,G02.149.115.218
21825015,2011-08-08T00:00:00,DNA Methylation,G03.495.130.538.161
21825015,2011-08-08T00:00:00,DNA Methylation,G05.355.190
21825015,2011-08-08T00:00:00,Disease Progression,C23.550.291.656
21825015,2011-08-08T00:00:00,Genome-Wide Association Study,E05.318.416.249
21825015,2011-08-08T00:00:00,Genome-Wide Association Study,E05.318.780.392
21825015,2011-08-08T00:00:00,Genome-Wide Association Study,E05.393.385.500
21825015,2011-08-08T00:00:00,Genome-Wide Association Study,E05.393.522.500
21825015,2011-08-08T00:00:00,Genome-Wide Association Study,E05.393.760.640.500
21825015,2011-08-08T00:00:00,Genome-Wide Association Study,N06.850.520.445.392
21825015,2011-08-08T00:00:00,Genome-Wide Association Study,N06.850.520.470.500
21825015,2011-08-08T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21825015,2011-08-08T00:00:00,"Receptors, Estrogen",D12.776.260.698.750.350
21825015,2011-08-08T00:00:00,"Receptors, Estrogen",D12.776.826.750.350
21825015,2011-08-08T00:00:00,"Receptors, Estrogen",D12.776.930.669.750.350
21825015,2011-08-08T00:00:00,"Tumor Markers, Biological",D23.101.840
21856279,2011-08-09T00:00:00,Adult,M01.060.116
21856279,2011-08-09T00:00:00,Amino Acid Sequence,G02.111.570.060
21856279,2011-08-09T00:00:00,Amino Acid Sequence,L01.453.245.667.060
21856279,2011-08-09T00:00:00,Animals,B01.050
21856279,2011-08-09T00:00:00,"Arrhythmias, Cardiac",C14.280.067
21856279,2011-08-09T00:00:00,"Arrhythmias, Cardiac",C23.550.073
21856279,2011-08-09T00:00:00,Connexin 43,D12.776.543.585.250.200
21856279,2011-08-09T00:00:00,"Death, Sudden, Cardiac",C14.280.383.220
21856279,2011-08-09T00:00:00,"Death, Sudden, Cardiac",C23.550.260.322.250
21856279,2011-08-09T00:00:00,Gap Junctions,A11.284.149.165.420.471
21856279,2011-08-09T00:00:00,Heart Ventricles,A07.541.560
21856279,2011-08-09T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21856279,2011-08-09T00:00:00,"Models, Molecular",E05.599.595
21856279,2011-08-09T00:00:00,Molecular Sequence Data,L01.453.245.667
21856279,2011-08-09T00:00:00,Myocardium,A02.633.580
21856279,2011-08-09T00:00:00,Myocardium,A07.541.704
21856279,2011-08-09T00:00:00,Myocardium,A10.690.552.750
21856279,2011-08-09T00:00:00,Protein Interaction Mapping,E05.601.690
21831355,2011-08-10T00:00:00,Adult,M01.060.116
21831355,2011-08-10T00:00:00,Chronic Disease,C23.550.291.500
21831355,2011-08-10T00:00:00,Gait,E01.370.600.250
21831355,2011-08-10T00:00:00,Gait,G11.427.590.530.389
21831355,2011-08-10T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21831355,2011-08-10T00:00:00,Middle Aged,M01.060.116.630
21831355,2011-08-10T00:00:00,Motor Activity,F01.145.632
21831355,2011-08-10T00:00:00,Motor Activity,G11.427.590.530.698
21831355,2011-08-10T00:00:00,Physical Therapy Modalities,E02.779
21831355,2011-08-10T00:00:00,Pilot Projects,E05.318.760.750
21831355,2011-08-10T00:00:00,Pilot Projects,E05.337.737
21831355,2011-08-10T00:00:00,Pilot Projects,N05.715.360.775.625
21831355,2011-08-10T00:00:00,Pilot Projects,N06.850.520.450.720
21831355,2011-08-10T00:00:00,Postural Balance,G11.427.690
21831355,2011-08-10T00:00:00,Postural Balance,G11.561.600.810.541.595
21831355,2011-08-10T00:00:00,Spinal Cord Injuries,C10.228.854.770
21831355,2011-08-10T00:00:00,Spinal Cord Injuries,C10.900.850
21831355,2011-08-10T00:00:00,Spinal Cord Injuries,C21.866.819
21831965,2011-08-10T00:00:00,Animals,B01.050
21831965,2011-08-10T00:00:00,Apoptosis,G04.299.139.160
21831965,2011-08-10T00:00:00,Caspases,D08.811.277.656.262.500.126
21831965,2011-08-10T00:00:00,Caspases,D08.811.277.656.300.200.126
21831965,2011-08-10T00:00:00,Caspases,D12.644.360.075.405
21831965,2011-08-10T00:00:00,Caspases,D12.776.476.075.405
21831965,2011-08-10T00:00:00,Fetus,A16.378
21831965,2011-08-10T00:00:00,HIV-1,B04.820.650.589.650.350.400
21831965,2011-08-10T00:00:00,HIV-1,B04.909.777.731.589.650.350.400
21831965,2011-08-10T00:00:00,Lymphocyte Activation,E01.450.495.482
21831965,2011-08-10T00:00:00,Lymphocyte Activation,E05.478.594.530
21831965,2011-08-10T00:00:00,Lymphocyte Activation,G12.425.747
21831965,2011-08-10T00:00:00,Lymphocyte Activation,G12.450.050.400.545
21831965,2011-08-10T00:00:00,Piperidines,D03.383.621
21831965,2011-08-10T00:00:00,Pregnancy,G08.686.785.760.769
21831965,2011-08-10T00:00:00,Prenatal Exposure Delayed Effects,C13.703.824.500
21831965,2011-08-10T00:00:00,Pyrazoles,D03.383.129.539
21831965,2011-08-10T00:00:00,T-Lymphocytes,A11.118.637.555.567.569
21831965,2011-08-10T00:00:00,T-Lymphocytes,A15.145.229.637.555.567.569
21831965,2011-08-10T00:00:00,T-Lymphocytes,A15.382.490.555.567.569
21831965,2011-08-10T00:00:00,Thymus Gland,A10.549.750
21831965,2011-08-10T00:00:00,Thymus Gland,A15.382.520.604.750
21832176,2011-08-10T00:00:00,Animals,B01.050
21832176,2011-08-10T00:00:00,Dopamine,D02.092.211.215.311.342
21832176,2011-08-10T00:00:00,Dopamine,D02.092.311.342
21832176,2011-08-10T00:00:00,Habenula,A08.186.211.464.200.360
21832176,2011-08-10T00:00:00,Habenula,A08.186.211.730.317.200.360
21832176,2011-08-10T00:00:00,Macaca mulatta,B01.050.150.900.649.801.400.112.199.120.510.550
21832176,2011-08-10T00:00:00,Neural Inhibition,G07.265.337.615
21832176,2011-08-10T00:00:00,Neural Inhibition,G07.700.240.615
21832176,2011-08-10T00:00:00,Neural Inhibition,G11.561.600.625
21832176,2011-08-10T00:00:00,Neurons,A08.663
21832176,2011-08-10T00:00:00,Neurons,A11.671
21832176,2011-08-10T00:00:00,Photic Stimulation,E05.723.729
21832176,2011-08-10T00:00:00,Psychomotor Performance,F02.808
21832176,2011-08-10T00:00:00,Psychomotor Performance,G11.427.700
21832176,2011-08-10T00:00:00,Psychomotor Performance,G11.561.623
21832176,2011-08-10T00:00:00,Signal Transduction,G02.111.087.800
21832176,2011-08-10T00:00:00,Signal Transduction,G02.149.115.800
21832176,2011-08-10T00:00:00,Signal Transduction,G04.299.880
21834054,2011-08-10T00:00:00,"Abnormalities, Multiple",C16.131.077
21834054,2011-08-10T00:00:00,Adult,M01.060.116
21834054,2011-08-10T00:00:00,Child,M01.060.406
21834054,2011-08-10T00:00:00,"Child, Preschool",M01.060.406.448
21834054,2011-08-10T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21834054,2011-08-10T00:00:00,"In Situ Hybridization, Fluorescence",E05.200.500.620.670.325.350
21834054,2011-08-10T00:00:00,"In Situ Hybridization, Fluorescence",E05.200.750.600.670.325.350
21834054,2011-08-10T00:00:00,"In Situ Hybridization, Fluorescence",E05.393.285.350
21834054,2011-08-10T00:00:00,"In Situ Hybridization, Fluorescence",E05.393.661.475.350
21834054,2011-08-10T00:00:00,Infant,M01.060.703
21834054,2011-08-10T00:00:00,Oligonucleotide Array Sequence Analysis,E05.196.630.570.660
21834054,2011-08-10T00:00:00,Oligonucleotide Array Sequence Analysis,E05.393.525.640
21834054,2011-08-10T00:00:00,Oligonucleotide Array Sequence Analysis,E05.393.661.640
21834054,2011-08-10T00:00:00,Oligonucleotide Array Sequence Analysis,E05.393.760.640
21834054,2011-08-10T00:00:00,Oligonucleotide Array Sequence Analysis,E05.588.570.660
21834054,2011-08-10T00:00:00,Oligonucleotide Array Sequence Analysis,E05.601.640
21834054,2011-08-10T00:00:00,Phenotype,G05.695
21834054,2011-08-10T00:00:00,Polymerase Chain Reaction,E05.393.620.500
21834054,2011-08-10T00:00:00,"Translocation, Genetic",C23.550.210.870
21834054,2011-08-10T00:00:00,"Translocation, Genetic",G05.355.600.860
21834054,2011-08-10T00:00:00,"Translocation, Genetic",G05.365.590.175.870
21906250,2011-08-10T00:00:00,Adult,M01.060.116
21906250,2011-08-10T00:00:00,Aged,M01.060.116.100
21906250,2011-08-10T00:00:00,"Defibrillators, Implantable",E07.305.250.159.175
21906250,2011-08-10T00:00:00,"Defibrillators, Implantable",E07.305.250.319.175
21906250,2011-08-10T00:00:00,"Defibrillators, Implantable",E07.695.175
21906250,2011-08-10T00:00:00,Heart Failure,C14.280.434
21906250,2011-08-10T00:00:00,Hemodynamics,G09.330.190.400
21906250,2011-08-10T00:00:00,Hemodynamics,G09.330.380
21906250,2011-08-10T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21906250,2011-08-10T00:00:00,Middle Aged,M01.060.116.630
21906250,2011-08-10T00:00:00,"Monitoring, Physiologic",E01.370.520
21906250,2011-08-10T00:00:00,Treatment Outcome,E01.789.800
21906250,2011-08-10T00:00:00,Treatment Outcome,N04.761.559.590.800
21906250,2011-08-10T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21906250,2011-08-10T00:00:00,United States,Z01.107.567.875
21982941,2011-08-10T00:00:00,Adult,M01.060.116
21982941,2011-08-10T00:00:00,Biological Markers,D23.101
21982941,2011-08-10T00:00:00,Blood Glucose,D09.546.359.448.500
21982941,2011-08-10T00:00:00,"Diabetes Mellitus, Type 2",C18.452.394.750.149
21982941,2011-08-10T00:00:00,"Diabetes Mellitus, Type 2",C19.246.300
21982941,2011-08-10T00:00:00,Gastric Bypass,E02.065.062.249
21982941,2011-08-10T00:00:00,Gastric Bypass,E04.035.398.385
21982941,2011-08-10T00:00:00,Gastric Bypass,E04.062.249
21982941,2011-08-10T00:00:00,Gastric Bypass,E04.210.457.430
21982941,2011-08-10T00:00:00,"Hemoglobin A, Glycosylated",D09.408.375
21982941,2011-08-10T00:00:00,"Hemoglobin A, Glycosylated",D12.776.124.400.405.440
21982941,2011-08-10T00:00:00,"Hemoglobin A, Glycosylated",D12.776.422.316.762.380.440
21982941,2011-08-10T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21982941,2011-08-10T00:00:00,Length of Stay,E02.760.400.480
21982941,2011-08-10T00:00:00,Length of Stay,N02.421.585.400.480
21982941,2011-08-10T00:00:00,"Obesity, Morbid",C18.654.726.500.700
21982941,2011-08-10T00:00:00,"Obesity, Morbid",C23.888.144.699.500.500
21982941,2011-08-10T00:00:00,"Obesity, Morbid",E01.370.600.115.100.160.120.699.500.500
21982941,2011-08-10T00:00:00,"Obesity, Morbid",G07.100.100.160.120.699.500.500
21982941,2011-08-10T00:00:00,Postoperative Complications,C23.550.767
21982941,2011-08-10T00:00:00,Preoperative Care,E02.760.795
21982941,2011-08-10T00:00:00,Preoperative Care,E04.641
21982941,2011-08-10T00:00:00,Preoperative Care,N02.421.585.795
21982941,2011-08-10T00:00:00,Treatment Outcome,E01.789.800
21982941,2011-08-10T00:00:00,Treatment Outcome,N04.761.559.590.800
21982941,2011-08-10T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21833718,2011-08-11T00:00:00,Antineoplastic Agents,D27.505.954.248
21833718,2011-08-11T00:00:00,Apoptosis,G04.299.139.160
21833718,2011-08-11T00:00:00,Cell Cycle,G04.299.134
21833718,2011-08-11T00:00:00,Ceramides,D02.065.313
21833718,2011-08-11T00:00:00,Ceramides,D09.400.410.420.525.200
21833718,2011-08-11T00:00:00,Ceramides,D10.390.470.675.200
21833718,2011-08-11T00:00:00,Ceramides,D10.570.877.360.612.200
21833718,2011-08-11T00:00:00,"Drug Resistance, Neoplasm",G07.690.320.395
21833718,2011-08-11T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21833718,2011-08-11T00:00:00,"Leukemia, Myelogenous, Chronic, BCR-ABL Positive",C04.557.337.539.250
21833718,2011-08-11T00:00:00,"Leukemia, Myelogenous, Chronic, BCR-ABL Positive",C15.378.190.636.370
21833718,2011-08-11T00:00:00,Piperazines,D03.383.606
21833718,2011-08-11T00:00:00,Pyrimidines,D03.383.742
21835637,2011-08-11T00:00:00,Adult,M01.060.116
21835637,2011-08-11T00:00:00,Echocardiography,E01.370.350.850.220
21835637,2011-08-11T00:00:00,Echocardiography,E01.370.370.380.220
21835637,2011-08-11T00:00:00,"Echocardiography, Transesophageal",E01.370.350.850.220.235
21835637,2011-08-11T00:00:00,"Echocardiography, Transesophageal",E01.370.370.380.220.235
21835637,2011-08-11T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21835637,2011-08-11T00:00:00,"Ventricular Dysfunction, Left",C14.280.945.900
21840863,2011-08-11T00:00:00,Actins,D05.750.078.730.250
21840863,2011-08-11T00:00:00,Actins,D12.776.210.500.100
21840863,2011-08-11T00:00:00,Actins,D12.776.220.525.255
21840863,2011-08-11T00:00:00,Cell Cycle Proteins,D12.776.167
21840863,2011-08-11T00:00:00,DNA Damage,C21.111
21840863,2011-08-11T00:00:00,DNA Damage,G05.355.180
21840863,2011-08-11T00:00:00,DNA Repair,G02.111.087.219
21840863,2011-08-11T00:00:00,DNA Repair,G02.149.115.219
21840863,2011-08-11T00:00:00,DNA Repair,G05.355.195
21840863,2011-08-11T00:00:00,DNA Replication,G02.111.087.222
21840863,2011-08-11T00:00:00,DNA Replication,G02.149.115.222
21840863,2011-08-11T00:00:00,DNA Replication,G05.355.200
21840863,2011-08-11T00:00:00,DNA-Binding Proteins,D12.776.260
21840863,2011-08-11T00:00:00,"Microscopy, Fluorescence",E01.370.350.515.458
21840863,2011-08-11T00:00:00,"Microscopy, Fluorescence",E05.595.458
21840863,2011-08-11T00:00:00,Mutation,G05.365.590
21840863,2011-08-11T00:00:00,Protein-Tyrosine Kinases,D08.811.913.696.620.682.725
21840863,2011-08-11T00:00:00,Saccharomyces cerevisiae,B01.300.107.795.785.800
21840863,2011-08-11T00:00:00,Saccharomyces cerevisiae,B01.300.930.705.655
21840863,2011-08-11T00:00:00,Saccharomyces cerevisiae Proteins,D12.776.354.750
21840863,2011-08-11T00:00:00,Sphingolipids,D10.570.877
21840863,2011-08-11T00:00:00,Sphingolipids,D10.808
21757995,2011-08-15T00:00:00,Animals,B01.050
21757995,2011-08-15T00:00:00,"Antibodies, Monoclonal",D12.776.124.486.485.114.224
21757995,2011-08-15T00:00:00,"Antibodies, Monoclonal",D12.776.124.790.651.114.224
21757995,2011-08-15T00:00:00,"Antibodies, Monoclonal",D12.776.377.715.548.114.224
21757995,2011-08-15T00:00:00,Apoptosis,G04.299.139.160
21757995,2011-08-15T00:00:00,Colonic Neoplasms,C04.588.274.476.411.307.180
21757995,2011-08-15T00:00:00,Colonic Neoplasms,C06.301.371.411.307.180
21757995,2011-08-15T00:00:00,Colonic Neoplasms,C06.405.249.411.307.180
21757995,2011-08-15T00:00:00,Colonic Neoplasms,C06.405.469.158.356.180
21757995,2011-08-15T00:00:00,Colonic Neoplasms,C06.405.469.491.307.180
21757995,2011-08-15T00:00:00,Diagnostic Imaging,E01.370.350
21757995,2011-08-15T00:00:00,Green Fluorescent Proteins,D12.776.532.265
21757995,2011-08-15T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21757995,2011-08-15T00:00:00,"Microscopy, Fluorescence",E01.370.350.515.458
21757995,2011-08-15T00:00:00,"Microscopy, Fluorescence",E05.595.458
21757995,2011-08-15T00:00:00,"Receptors, TNF-Related Apoptosis-Inducing Ligand",D12.776.543.750.073.600
21757995,2011-08-15T00:00:00,"Receptors, TNF-Related Apoptosis-Inducing Ligand",D12.776.543.750.705.852.760.396
21757995,2011-08-15T00:00:00,Recombinant Fusion Proteins,D12.776.828.300
21762461,2011-08-15T00:00:00,Animals,B01.050
21762461,2011-08-15T00:00:00,"Behavior, Animal",F01.145.113
21762461,2011-08-15T00:00:00,Central Nervous System Depressants,D27.505.696.277
21762461,2011-08-15T00:00:00,Central Nervous System Depressants,D27.505.954.427.210
21762461,2011-08-15T00:00:00,Central Nervous System Stimulants,D27.505.696.282
21762461,2011-08-15T00:00:00,Central Nervous System Stimulants,D27.505.954.427.220
21762461,2011-08-15T00:00:00,Ethanol,D02.033.375
21762461,2011-08-15T00:00:00,Motor Activity,F01.145.632
21762461,2011-08-15T00:00:00,Motor Activity,G11.427.590.530.698
21762461,2011-08-15T00:00:00,"Receptors, N-Methyl-D-Aspartate",D12.776.543.750.720.200.450.580
21840730,2011-08-15T00:00:00,Adult,M01.060.116
21840730,2011-08-15T00:00:00,Age Factors,N05.715.350.075
21840730,2011-08-15T00:00:00,Age Factors,N06.850.490.250
21840730,2011-08-15T00:00:00,Diabetes Mellitus,C18.452.394.750
21840730,2011-08-15T00:00:00,Diabetes Mellitus,C19.246
21840730,2011-08-15T00:00:00,European Continental Ancestry Group,M01.686.508.400
21840730,2011-08-15T00:00:00,Hispanic Americans,M01.686.754.441
21840730,2011-08-15T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21840730,2011-08-15T00:00:00,Middle Aged,M01.060.116.630
21840730,2011-08-15T00:00:00,Risk Factors,E05.318.740.600.800.725
21840730,2011-08-15T00:00:00,Risk Factors,N05.715.350.200.700
21840730,2011-08-15T00:00:00,Risk Factors,N05.715.360.750.625.700.700
21840730,2011-08-15T00:00:00,Risk Factors,N06.850.490.625.750
21840730,2011-08-15T00:00:00,Risk Factors,N06.850.520.830.600.800.725
21840730,2011-08-15T00:00:00,Sex Factors,N05.715.350.675
21840730,2011-08-15T00:00:00,Sex Factors,N06.850.490.875
21840730,2011-08-15T00:00:00,United States,Z01.107.567.875
21844180,2011-08-15T00:00:00,Home Care Services,N02.421.143.524
21844180,2011-08-15T00:00:00,Home Care Services,N02.421.539.089
21844180,2011-08-15T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21844180,2011-08-15T00:00:00,Middle Aged,M01.060.116.630
21844180,2011-08-15T00:00:00,"Stress Disorders, Post-Traumatic",F03.080.931.500
21844180,2011-08-15T00:00:00,Suicide,F01.145.126.980.875
21844180,2011-08-15T00:00:00,Suicide,I01.880.735.856
21844180,2011-08-15T00:00:00,Telemedicine,H02.403.840
21844180,2011-08-15T00:00:00,Telemedicine,L01.178.847.652
21844180,2011-08-15T00:00:00,Telemedicine,N04.590.374.800
21844406,2011-08-15T00:00:00,Adolescent,M01.060.057
21844406,2011-08-15T00:00:00,Adult,M01.060.116
21844406,2011-08-15T00:00:00,Aged,M01.060.116.100
21844406,2011-08-15T00:00:00,"Anesthesia, General",E03.155.197
21844406,2011-08-15T00:00:00,Child,M01.060.406
21844406,2011-08-15T00:00:00,"Child, Preschool",M01.060.406.448
21844406,2011-08-15T00:00:00,Chronic Disease,C23.550.291.500
21844406,2011-08-15T00:00:00,Diagnostic Imaging,E01.370.350
21844406,2011-08-15T00:00:00,Endoscopy,E01.370.388.250
21844406,2011-08-15T00:00:00,Endoscopy,E04.800.250
21844406,2011-08-15T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21844406,2011-08-15T00:00:00,Middle Aged,M01.060.116.630
21844406,2011-08-15T00:00:00,Outcome and Process Assessment (Health Care),N04.761.559
21844406,2011-08-15T00:00:00,Outcome and Process Assessment (Health Care),N05.715.360.575
21844406,2011-08-15T00:00:00,Parotid Gland,A03.556.500.760.464
21844406,2011-08-15T00:00:00,Parotid Gland,A10.336.779.464
21844406,2011-08-15T00:00:00,Parotid Gland,A14.549.760.464
21844406,2011-08-15T00:00:00,Physician's Practice Patterns,N04.590.748
21844406,2011-08-15T00:00:00,Physician's Practice Patterns,N05.300.625
21844406,2011-08-15T00:00:00,Postoperative Complications,C23.550.767
21844406,2011-08-15T00:00:00,Sialadenitis,C07.465.815.793
21844406,2011-08-15T00:00:00,United States,Z01.107.567.875
21844406,2011-08-15T00:00:00,Young Adult,M01.060.116.815
21858153,2011-08-15T00:00:00,Animals,B01.050
21858153,2011-08-15T00:00:00,CD4-Positive T-Lymphocytes,A11.118.637.555.567.569.200
21858153,2011-08-15T00:00:00,CD4-Positive T-Lymphocytes,A15.145.229.637.555.567.569.200
21858153,2011-08-15T00:00:00,CD4-Positive T-Lymphocytes,A15.382.490.555.567.569.200
21858153,2011-08-15T00:00:00,Cell Differentiation,G04.299.151
21858153,2011-08-15T00:00:00,Colon,A03.556.124.526.356
21858153,2011-08-15T00:00:00,Colon,A03.556.249.249.356
21858153,2011-08-15T00:00:00,Cytokines,D12.644.276.374
21858153,2011-08-15T00:00:00,Cytokines,D12.776.467.374
21858153,2011-08-15T00:00:00,Cytokines,D23.529.374
21858153,2011-08-15T00:00:00,DNA Methylation,G02.111.087.029.538.161
21858153,2011-08-15T00:00:00,DNA Methylation,G02.111.087.218
21858153,2011-08-15T00:00:00,DNA Methylation,G02.149.115.029.538.161
21858153,2011-08-15T00:00:00,DNA Methylation,G02.149.115.218
21858153,2011-08-15T00:00:00,DNA Methylation,G03.495.130.538.161
21858153,2011-08-15T00:00:00,DNA Methylation,G05.355.190
21858153,2011-08-15T00:00:00,Flow Cytometry,E05.196.712.516.600.240.350
21858153,2011-08-15T00:00:00,Flow Cytometry,E05.200.500.386.350
21858153,2011-08-15T00:00:00,Gene Expression Regulation,G05.355.315
21858153,2011-08-15T00:00:00,"Receptors, Aryl Hydrocarbon",D12.776.260.698.209.715
21858153,2011-08-15T00:00:00,"Receptors, Aryl Hydrocarbon",D12.776.826.209.715
21858153,2011-08-15T00:00:00,"Receptors, Aryl Hydrocarbon",D12.776.930.662
21858153,2011-08-15T00:00:00,"Receptors, Aryl Hydrocarbon",D12.776.930.669.209.715
21858153,2011-08-15T00:00:00,"T-Lymphocytes, Regulatory",A11.118.637.555.567.569.200.700
21858153,2011-08-15T00:00:00,"T-Lymphocytes, Regulatory",A15.145.229.637.555.567.569.200.700
21858153,2011-08-15T00:00:00,"T-Lymphocytes, Regulatory",A15.382.490.555.567.569.200.700
21858153,2011-08-15T00:00:00,Tetrachlorodibenzodioxin,D03.383.231.900
21871458,2011-08-16T00:00:00,Animals,B01.050
21871458,2011-08-16T00:00:00,"Antigens, CD",D23.050.301.264.035
21871458,2011-08-16T00:00:00,"Antigens, CD",D23.101.100.110
21871458,2011-08-16T00:00:00,Cell Differentiation,G04.299.151
21871458,2011-08-16T00:00:00,Glycoproteins,D09.400.430
21871458,2011-08-16T00:00:00,Glycoproteins,D12.776.395
21871458,2011-08-16T00:00:00,Heart Valves,A07.541.510
21871458,2011-08-16T00:00:00,Hematopoietic Stem Cell Transplantation,E04.936.225.687.500
21871458,2011-08-16T00:00:00,Hematopoietic Stem Cells,A11.148.378
21871458,2011-08-16T00:00:00,Hematopoietic Stem Cells,A11.872.378
21871458,2011-08-16T00:00:00,Hematopoietic Stem Cells,A15.378.316.378
21871458,2011-08-16T00:00:00,Homeostasis,G07.700.360
21871458,2011-08-16T00:00:00,Peptides,D12.644
21871458,2011-08-16T00:00:00,Phenotype,G05.695
21848630,2011-08-17T00:00:00,Catheterization,E02.148
21848630,2011-08-17T00:00:00,Catheterization,E05.157
21848630,2011-08-17T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21848630,2011-08-17T00:00:00,Time Factors,G01.910.857
21848630,2011-08-17T00:00:00,Treatment Outcome,E01.789.800
21848630,2011-08-17T00:00:00,Treatment Outcome,N04.761.559.590.800
21848630,2011-08-17T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21849382,2011-08-17T00:00:00,Animals,B01.050
21849382,2011-08-17T00:00:00,Butterflies,B01.050.500.131.617.561.200
21849382,2011-08-17T00:00:00,Feeding Behavior,F01.145.113.547
21849382,2011-08-17T00:00:00,Feeding Behavior,F01.145.407
21849382,2011-08-17T00:00:00,"Models, Biological",E05.599.395
21849382,2011-08-17T00:00:00,Nanostructures,J01.637.512
21852285,2011-08-17T00:00:00,Aging,G07.700.320.124
21852285,2011-08-17T00:00:00,Fibroblasts,A11.329.228
21852285,2011-08-17T00:00:00,Fibroblasts,A11.872.228
21852285,2011-08-17T00:00:00,Gene Expression Regulation,G05.355.315
21852285,2011-08-17T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21852285,2011-08-17T00:00:00,Matrix Metalloproteinase 3,D08.811.277.656.300.480.525.700.200
21852285,2011-08-17T00:00:00,Matrix Metalloproteinase 3,D08.811.277.656.675.374.525.700.200
21852285,2011-08-17T00:00:00,Skin,A17.815
21850057,2011-08-18T00:00:00,African Continental Ancestry Group,M01.686.508.100
21850057,2011-08-18T00:00:00,Blood Pressure,E01.370.600.875.249
21850057,2011-08-18T00:00:00,Blood Pressure,G09.330.380.076
21850057,2011-08-18T00:00:00,European Continental Ancestry Group,M01.686.508.400
21850057,2011-08-18T00:00:00,Genome-Wide Association Study,E05.318.416.249
21850057,2011-08-18T00:00:00,Genome-Wide Association Study,E05.318.780.392
21850057,2011-08-18T00:00:00,Genome-Wide Association Study,E05.393.385.500
21850057,2011-08-18T00:00:00,Genome-Wide Association Study,E05.393.522.500
21850057,2011-08-18T00:00:00,Genome-Wide Association Study,E05.393.760.640.500
21850057,2011-08-18T00:00:00,Genome-Wide Association Study,N06.850.520.445.392
21850057,2011-08-18T00:00:00,Genome-Wide Association Study,N06.850.520.470.500
21850057,2011-08-18T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21850057,2011-08-18T00:00:00,Hypertension,C14.907.489
21850057,2011-08-18T00:00:00,"Polymorphism, Single Nucleotide",G05.365.795.598
21850057,2011-08-18T00:00:00,Quantitative Trait Loci,G05.360.340.024.380.937
21850057,2011-08-18T00:00:00,United States,Z01.107.567.875
21850445,2011-08-18T00:00:00,Alcohol Drinking,F01.145.317.269
21850445,2011-08-18T00:00:00,Animals,B01.050
21850445,2011-08-18T00:00:00,"Disease Models, Animal",C22.232
21850445,2011-08-18T00:00:00,"Disease Models, Animal",E05.598.500
21850445,2011-08-18T00:00:00,"Disease Models, Animal",E05.599.395.080
21850445,2011-08-18T00:00:00,Ethanol,D02.033.375
21850445,2011-08-18T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21850445,2011-08-18T00:00:00,"Stress, Psychological",F01.145.126.990
21850445,2011-08-18T00:00:00,"Stress, Psychological",F02.830.900
21851604,2011-08-18T00:00:00,Animals,B01.050
21851604,2011-08-18T00:00:00,Bronchoalveolar Lavage Fluid,E05.510.100.500
21851604,2011-08-18T00:00:00,Collagen,D05.750.078.280
21851604,2011-08-18T00:00:00,Collagen,D12.776.860.300.250
21851604,2011-08-18T00:00:00,Cytokines,D12.644.276.374
21851604,2011-08-18T00:00:00,Cytokines,D12.776.467.374
21851604,2011-08-18T00:00:00,Cytokines,D23.529.374
21851604,2011-08-18T00:00:00,Lung,A04.411
21851604,2011-08-18T00:00:00,"Microscopy, Electron, Transmission",E01.370.350.515.402.580
21851604,2011-08-18T00:00:00,"Microscopy, Electron, Transmission",E05.595.402.580
21851604,2011-08-18T00:00:00,"Nanotubes, Carbon",D01.268.150.250.500
21851604,2011-08-18T00:00:00,"Nanotubes, Carbon",J01.637.512.850.500
21851604,2011-08-18T00:00:00,Pulmonary Fibrosis,C08.381.765
21851604,2011-08-18T00:00:00,Surface Properties,G02.842.850
21852324,2011-08-18T00:00:00,Animals,B01.050
21852324,2011-08-18T00:00:00,"Animals, Newborn",B01.050.050.282
21852324,2011-08-18T00:00:00,Bone and Bones,A02.835.232
21852324,2011-08-18T00:00:00,Bone and Bones,A10.165.265
21852324,2011-08-18T00:00:00,Cell Differentiation,G04.299.151
21852324,2011-08-18T00:00:00,Cell Line,A11.251.210
21852324,2011-08-18T00:00:00,Dual Specificity Phosphatase 1,D08.811.277.352.650.587.200
21852324,2011-08-18T00:00:00,Dual Specificity Phosphatase 1,D08.811.277.352.650.625.225.200
21852324,2011-08-18T00:00:00,Dual Specificity Phosphatase 1,D08.811.277.352.650.775.250.200
21852324,2011-08-18T00:00:00,Dual Specificity Phosphatase 1,D12.644.360.268.200
21852324,2011-08-18T00:00:00,Dual Specificity Phosphatase 1,D12.644.360.445.100
21852324,2011-08-18T00:00:00,Dual Specificity Phosphatase 1,D12.776.476.268.200
21852324,2011-08-18T00:00:00,Dual Specificity Phosphatase 1,D12.776.476.445.200
21852324,2011-08-18T00:00:00,Gene Expression,G05.355.310
21852324,2011-08-18T00:00:00,Mitogen-Activated Protein Kinase 1,D08.811.913.696.620.682.700.567.342.500
21852324,2011-08-18T00:00:00,Mitogen-Activated Protein Kinase 1,D08.811.913.696.620.682.700.646.750.249.500
21852324,2011-08-18T00:00:00,Mitogen-Activated Protein Kinase 1,D12.644.360.450.169.500
21852324,2011-08-18T00:00:00,Mitogen-Activated Protein Kinase 1,D12.776.476.450.169.500
21852324,2011-08-18T00:00:00,Mitogen-Activated Protein Kinase 3,D08.811.913.696.620.682.700.567.342.750
21852324,2011-08-18T00:00:00,Mitogen-Activated Protein Kinase 3,D08.811.913.696.620.682.700.646.750.249.750
21852324,2011-08-18T00:00:00,Mitogen-Activated Protein Kinase 3,D12.644.360.450.169.750
21852324,2011-08-18T00:00:00,Mitogen-Activated Protein Kinase 3,D12.776.476.450.169.750
21852324,2011-08-18T00:00:00,Osteoblasts,A11.329.629
21852324,2011-08-18T00:00:00,Parathyroid Hormone,D06.472.699.590
21852324,2011-08-18T00:00:00,Parathyroid Hormone,D12.644.548.587
21852324,2011-08-18T00:00:00,X-Ray Microtomography,E01.370.350.700.810.810.900
21852324,2011-08-18T00:00:00,X-Ray Microtomography,E01.370.350.825.810.810.900
21852664,2011-08-18T00:00:00,Adult,M01.060.116
21852664,2011-08-18T00:00:00,Aged,M01.060.116.100
21852664,2011-08-18T00:00:00,Albuminuria,C12.777.934.734.269
21852664,2011-08-18T00:00:00,Albuminuria,C13.351.968.934.734.269
21852664,2011-08-18T00:00:00,Albuminuria,C23.888.942.750.269
21852664,2011-08-18T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21852664,2011-08-18T00:00:00,Kidney Diseases,C12.777.419
21852664,2011-08-18T00:00:00,Kidney Diseases,C13.351.968.419
21852664,2011-08-18T00:00:00,Metabolic Syndrome X,C18.452.394.968.500.570
21852664,2011-08-18T00:00:00,Metabolic Syndrome X,C18.452.625
21852664,2011-08-18T00:00:00,Middle Aged,M01.060.116.630
21852664,2011-08-18T00:00:00,Proteinuria,C12.777.934.734
21852664,2011-08-18T00:00:00,Proteinuria,C13.351.968.934.734
21852664,2011-08-18T00:00:00,Proteinuria,C23.888.942.750
21852664,2011-08-18T00:00:00,Risk Assessment,E05.318.740.600.800.715
21852664,2011-08-18T00:00:00,Risk Assessment,N04.452.871.715
21852664,2011-08-18T00:00:00,Risk Assessment,N05.715.360.750.625.700.690
21852664,2011-08-18T00:00:00,Risk Assessment,N06.850.505.715
21852664,2011-08-18T00:00:00,Risk Assessment,N06.850.520.830.600.800.715
21852664,2011-08-18T00:00:00,Risk Factors,E05.318.740.600.800.725
21852664,2011-08-18T00:00:00,Risk Factors,N05.715.350.200.700
21852664,2011-08-18T00:00:00,Risk Factors,N05.715.360.750.625.700.700
21852664,2011-08-18T00:00:00,Risk Factors,N06.850.490.625.750
21852664,2011-08-18T00:00:00,Risk Factors,N06.850.520.830.600.800.725
21874230,2011-08-18T00:00:00,Animals,B01.050
21874230,2011-08-18T00:00:00,Antineoplastic Agents,D27.505.954.248
21874230,2011-08-18T00:00:00,Apoptosis,G04.299.139.160
21874230,2011-08-18T00:00:00,Cell Cycle,G04.299.134
21874230,2011-08-18T00:00:00,Macrophages,A11.329.372
21874230,2011-08-18T00:00:00,Macrophages,A11.627.482
21874230,2011-08-18T00:00:00,Macrophages,A11.733.397
21874230,2011-08-18T00:00:00,Macrophages,A15.382.680.397
21874230,2011-08-18T00:00:00,Macrophages,A15.382.812.522
21874230,2011-08-18T00:00:00,NF-kappa B,D12.776.260.600
21874230,2011-08-18T00:00:00,NF-kappa B,D12.776.660.600
21874230,2011-08-18T00:00:00,NF-kappa B,D12.776.930.600
21874230,2011-08-18T00:00:00,Nitric Oxide,D01.339.387
21874230,2011-08-18T00:00:00,Nitric Oxide,D01.625.550.500
21874230,2011-08-18T00:00:00,Nitric Oxide,D01.625.700.500
21874230,2011-08-18T00:00:00,Nitric Oxide,D01.650.550.587.600
21874230,2011-08-18T00:00:00,Nitric Oxide Synthase Type II,D08.811.682.664.500.772.500
21874230,2011-08-18T00:00:00,"Promoter Regions, Genetic",G02.111.570.080.689.675
21874230,2011-08-18T00:00:00,"Promoter Regions, Genetic",G05.360.080.689.675
21874230,2011-08-18T00:00:00,"Promoter Regions, Genetic",G05.360.340.024.340.137.750.680
21874230,2011-08-18T00:00:00,"RNA, Messenger",D13.444.735.544
21874230,2011-08-18T00:00:00,Signal Transduction,G02.111.087.800
21874230,2011-08-18T00:00:00,Signal Transduction,G02.149.115.800
21874230,2011-08-18T00:00:00,Signal Transduction,G04.299.880
21903207,2011-08-18T00:00:00,Antigen Presentation,G12.425.107
21903207,2011-08-18T00:00:00,Antigen Presentation,G12.450.050.400.070
21903207,2011-08-18T00:00:00,Bryostatins,D02.540.505.112
21903207,2011-08-18T00:00:00,CD4-Positive T-Lymphocytes,A11.118.637.555.567.569.200
21903207,2011-08-18T00:00:00,CD4-Positive T-Lymphocytes,A15.145.229.637.555.567.569.200
21903207,2011-08-18T00:00:00,CD4-Positive T-Lymphocytes,A15.382.490.555.567.569.200
21903207,2011-08-18T00:00:00,Cathepsin B,D08.811.277.656.224.125
21903207,2011-08-18T00:00:00,Cathepsin B,D08.811.277.656.262.500.133
21903207,2011-08-18T00:00:00,Cathepsin B,D08.811.277.656.300.200.133
21903207,2011-08-18T00:00:00,Enzyme Inhibitors,D27.505.519.389
21903207,2011-08-18T00:00:00,HLA-D Antigens,D23.050.301.500.410.400
21903207,2011-08-18T00:00:00,HLA-D Antigens,D23.050.301.500.450.400
21903207,2011-08-18T00:00:00,HLA-D Antigens,D23.050.705.552.410.400
21903207,2011-08-18T00:00:00,HLA-D Antigens,D23.050.705.552.450.400
21903207,2011-08-18T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21903207,2011-08-18T00:00:00,Melanoma,C04.557.465.625.650.510
21903207,2011-08-18T00:00:00,Melanoma,C04.557.580.625.650.510
21903207,2011-08-18T00:00:00,Melanoma,C04.557.665.510
21903207,2011-08-18T00:00:00,Nuclear Proteins,D12.776.660
21903207,2011-08-18T00:00:00,Trans-Activators,D12.776.260.755
21903207,2011-08-18T00:00:00,Trans-Activators,D12.776.930.900
21903207,2011-08-18T00:00:00,Trans-Activators,D12.776.964.925.984
21853197,2011-08-19T00:00:00,"Carcinoma, Renal Cell",C04.557.470.200.025.390
21853197,2011-08-19T00:00:00,"Carcinoma, Renal Cell",C04.588.945.947.535.160
21853197,2011-08-19T00:00:00,"Carcinoma, Renal Cell",C12.758.820.750.160
21853197,2011-08-19T00:00:00,"Carcinoma, Renal Cell",C12.777.419.473.160
21853197,2011-08-19T00:00:00,"Carcinoma, Renal Cell",C13.351.937.820.535.160
21853197,2011-08-19T00:00:00,"Carcinoma, Renal Cell",C13.351.968.419.473.160
21853197,2011-08-19T00:00:00,"Gene Expression Regulation, Neoplastic",G05.355.315.370
21853197,2011-08-19T00:00:00,Kidney Neoplasms,C04.588.945.947.535
21853197,2011-08-19T00:00:00,Kidney Neoplasms,C12.758.820.750
21853197,2011-08-19T00:00:00,Kidney Neoplasms,C12.777.419.473
21853197,2011-08-19T00:00:00,Kidney Neoplasms,C13.351.937.820.535
21853197,2011-08-19T00:00:00,Kidney Neoplasms,C13.351.968.419.473
21853197,2011-08-19T00:00:00,"Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization",E05.196.566.755
21855149,2011-08-19T00:00:00,Animals,B01.050
21855149,2011-08-19T00:00:00,Arrestins,D12.776.306.090
21855149,2011-08-19T00:00:00,Arrestins,D12.776.543.090
21855149,2011-08-19T00:00:00,"Arthritis, Experimental",C05.550.114.015
21855149,2011-08-19T00:00:00,"Arthritis, Experimental",E05.598.500.249
21855149,2011-08-19T00:00:00,"Arthritis, Rheumatoid",C05.550.114.154
21855149,2011-08-19T00:00:00,"Arthritis, Rheumatoid",C05.799.114
21855149,2011-08-19T00:00:00,"Arthritis, Rheumatoid",C17.300.775.099
21855149,2011-08-19T00:00:00,"Arthritis, Rheumatoid",C20.111.199
21855149,2011-08-19T00:00:00,"Disease Models, Animal",C22.232
21855149,2011-08-19T00:00:00,"Disease Models, Animal",E05.598.500
21855149,2011-08-19T00:00:00,"Disease Models, Animal",E05.599.395.080
21855149,2011-08-19T00:00:00,Fibroblasts,A11.329.228
21855149,2011-08-19T00:00:00,Fibroblasts,A11.872.228
21855149,2011-08-19T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21855149,2011-08-19T00:00:00,Inflammation,C23.550.470
21855149,2011-08-19T00:00:00,"Mice, Inbred DBA",B01.050.050.157.520.460
21855149,2011-08-19T00:00:00,"Mice, Inbred DBA",B01.050.050.199.520.520.460
21855149,2011-08-19T00:00:00,"Mice, Inbred DBA",B01.050.150.900.649.865.635.505.500.400.460
21855149,2011-08-19T00:00:00,Protein Isoforms,D12.776.800
21855149,2011-08-19T00:00:00,Tumor Necrosis Factor-alpha,D12.644.276.374.500.800
21855149,2011-08-19T00:00:00,Tumor Necrosis Factor-alpha,D12.644.276.374.750.626
21855149,2011-08-19T00:00:00,Tumor Necrosis Factor-alpha,D12.644.276.972.626
21855149,2011-08-19T00:00:00,Tumor Necrosis Factor-alpha,D12.776.124.900
21855149,2011-08-19T00:00:00,Tumor Necrosis Factor-alpha,D12.776.395.930
21855149,2011-08-19T00:00:00,Tumor Necrosis Factor-alpha,D12.776.467.374.500.800
21855149,2011-08-19T00:00:00,Tumor Necrosis Factor-alpha,D12.776.467.374.750.626
21855149,2011-08-19T00:00:00,Tumor Necrosis Factor-alpha,D12.776.467.972.626
21855149,2011-08-19T00:00:00,Tumor Necrosis Factor-alpha,D23.529.374.500.800
21855149,2011-08-19T00:00:00,Tumor Necrosis Factor-alpha,D23.529.374.750.626
21855149,2011-08-19T00:00:00,Tumor Necrosis Factor-alpha,D23.529.972.626
21856749,2011-08-19T00:00:00,Animals,B01.050
21856749,2011-08-19T00:00:00,Cell Proliferation,G04.299.233.750
21856749,2011-08-19T00:00:00,Cell Proliferation,G07.700.320.249.410.750
21856749,2011-08-19T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21856749,2011-08-19T00:00:00,Membrane Proteins,D12.776.543
21856749,2011-08-19T00:00:00,Nerve Tissue Proteins,D12.776.641
21856749,2011-08-19T00:00:00,Protein Transport,G03.495.166.700
21856749,2011-08-19T00:00:00,"Receptors, Transferrin",D12.776.157.905.500
21856749,2011-08-19T00:00:00,"Receptors, Transferrin",D12.776.543.750.850
21856749,2011-08-19T00:00:00,Transferases (Other Substituted Phosphate Groups),D08.811.913.696.900
21856749,2011-08-19T00:00:00,Transferrin,D12.776.124.050.800
21856749,2011-08-19T00:00:00,Transferrin,D12.776.124.790.223.839
21856749,2011-08-19T00:00:00,Transferrin,D12.776.157.427.500
21856749,2011-08-19T00:00:00,Transferrin,D12.776.377.715.182.839
21856749,2011-08-19T00:00:00,Transferrin,D12.776.556.579.500
21856749,2011-08-19T00:00:00,rab GTP-Binding Proteins,D08.811.277.040.330.300.400.400
21856749,2011-08-19T00:00:00,rab GTP-Binding Proteins,D12.644.360.525.400
21856749,2011-08-19T00:00:00,rab GTP-Binding Proteins,D12.776.157.325.515.400
21856749,2011-08-19T00:00:00,rab GTP-Binding Proteins,D12.776.476.525.400
21856760,2011-08-19T00:00:00,Adolescent,M01.060.057
21856760,2011-08-19T00:00:00,Adult,M01.060.116
21856760,2011-08-19T00:00:00,Albuminuria,C12.777.934.734.269
21856760,2011-08-19T00:00:00,Albuminuria,C13.351.968.934.734.269
21856760,2011-08-19T00:00:00,Albuminuria,C23.888.942.750.269
21856760,2011-08-19T00:00:00,Antigen-Antibody Complex,D12.776.124.486.485.114.257
21856760,2011-08-19T00:00:00,Antigen-Antibody Complex,D12.776.124.790.651.114.257
21856760,2011-08-19T00:00:00,Antigen-Antibody Complex,D12.776.377.715.548.114.257
21856760,2011-08-19T00:00:00,Antigen-Antibody Complex,D23.050.101
21856760,2011-08-19T00:00:00,Diabetes Complications,C19.246.099
21856760,2011-08-19T00:00:00,"Diabetes Mellitus, Type 1",C18.452.394.750.124
21856760,2011-08-19T00:00:00,"Diabetes Mellitus, Type 1",C19.246.267
21856760,2011-08-19T00:00:00,"Diabetes Mellitus, Type 1",C20.111.327
21856760,2011-08-19T00:00:00,Diabetic Nephropathies,C12.777.419.192
21856760,2011-08-19T00:00:00,Diabetic Nephropathies,C13.351.968.419.192
21856760,2011-08-19T00:00:00,Diabetic Nephropathies,C19.246.099.875
21856760,2011-08-19T00:00:00,Disease Progression,C23.550.291.656
21856760,2011-08-19T00:00:00,"Glycosylation End Products, Advanced",D02.415
21856760,2011-08-19T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21856760,2011-08-19T00:00:00,"Lipoproteins, LDL",D10.532.515
21856760,2011-08-19T00:00:00,"Lipoproteins, LDL",D12.776.521.550
21856760,2011-08-19T00:00:00,Risk Factors,E05.318.740.600.800.725
21856760,2011-08-19T00:00:00,Risk Factors,N05.715.350.200.700
21856760,2011-08-19T00:00:00,Risk Factors,N05.715.360.750.625.700.700
21856760,2011-08-19T00:00:00,Risk Factors,N06.850.490.625.750
21856760,2011-08-19T00:00:00,Risk Factors,N06.850.520.830.600.800.725
21856760,2011-08-19T00:00:00,Young Adult,M01.060.116.815
21862447,2011-08-22T00:00:00,Acoustic Stimulation,E02.037
21862447,2011-08-22T00:00:00,Acoustic Stimulation,E02.190.888.030
21862447,2011-08-22T00:00:00,Acoustic Stimulation,E05.723.136
21862447,2011-08-22T00:00:00,Adult,M01.060.116
21862447,2011-08-22T00:00:00,Age Factors,N05.715.350.075
21862447,2011-08-22T00:00:00,Age Factors,N06.850.490.250
21862447,2011-08-22T00:00:00,Aged,M01.060.116.100
21862447,2011-08-22T00:00:00,Auditory Cortex,A08.186.211.730.885.287.500.863.297
21862447,2011-08-22T00:00:00,Forecasting,I01.320
21862447,2011-08-22T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21862447,2011-08-22T00:00:00,Middle Aged,M01.060.116.630
21862447,2011-08-22T00:00:00,Speech Perception,F02.463.593.071.875
21862447,2011-08-22T00:00:00,Visual Cortex,A08.186.211.730.885.287.500.571.735
21862447,2011-08-22T00:00:00,Young Adult,M01.060.116.815
21878340,2011-08-22T00:00:00,Acetylglucosamine,D09.067.342.531.050
21878340,2011-08-22T00:00:00,Animals,B01.050
21878340,2011-08-22T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21878340,2011-08-22T00:00:00,"Mitochondria, Heart",A11.284.430.214.190.875.564.627.603
21878340,2011-08-22T00:00:00,"Mitochondria, Heart",A11.284.835.626.627.603
21878340,2011-08-22T00:00:00,"Myocytes, Cardiac",A07.541.704.570
21878340,2011-08-22T00:00:00,"Myocytes, Cardiac",A10.690.552.750.570
21878340,2011-08-22T00:00:00,"Myocytes, Cardiac",A11.620.500
21878340,2011-08-22T00:00:00,"Protein Processing, Post-Translational",G02.111.087.675.871.790.600
21878340,2011-08-22T00:00:00,"Protein Processing, Post-Translational",G02.111.087.693.600
21878340,2011-08-22T00:00:00,"Protein Processing, Post-Translational",G02.149.115.675.871.790.600
21878340,2011-08-22T00:00:00,"Protein Processing, Post-Translational",G02.149.115.693.600
21878340,2011-08-22T00:00:00,"Protein Processing, Post-Translational",G03.495.770.871.790.600
21878340,2011-08-22T00:00:00,"Protein Processing, Post-Translational",G05.355.315.670.600
21878340,2011-08-22T00:00:00,Proteins,D12.776
21878340,2011-08-22T00:00:00,Signal Transduction,G02.111.087.800
21878340,2011-08-22T00:00:00,Signal Transduction,G02.149.115.800
21878340,2011-08-22T00:00:00,Signal Transduction,G04.299.880
21893215,2011-08-22T00:00:00,Algorithms,G17.035
21893215,2011-08-22T00:00:00,Algorithms,L01.224.050
21893215,2011-08-22T00:00:00,Computer Simulation,L01.224.160
21893215,2011-08-22T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21893215,2011-08-22T00:00:00,"Models, Statistical",E05.318.740.500
21893215,2011-08-22T00:00:00,"Models, Statistical",E05.599.835
21893215,2011-08-22T00:00:00,"Models, Statistical",N05.715.360.750.530
21893215,2011-08-22T00:00:00,"Models, Statistical",N06.850.520.830.500
21893215,2011-08-22T00:00:00,Probability,E05.318.740.600
21893215,2011-08-22T00:00:00,Probability,G17.680
21893215,2011-08-22T00:00:00,Probability,N05.715.360.750.625
21893215,2011-08-22T00:00:00,Probability,N06.850.520.830.600
21893215,2011-08-22T00:00:00,Randomized Controlled Trials as Topic,E05.318.760.535.365.500
21893215,2011-08-22T00:00:00,Randomized Controlled Trials as Topic,E05.337.250.365.500
21893215,2011-08-22T00:00:00,Randomized Controlled Trials as Topic,N05.715.360.775.235.387.500
21893215,2011-08-22T00:00:00,Randomized Controlled Trials as Topic,N06.850.520.450.535.365.500
21672072,2011-08-23T00:00:00,Adult,M01.060.116
21672072,2011-08-23T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21672072,2011-08-23T00:00:00,Internet,L01.224.230.110.500
21672072,2011-08-23T00:00:00,Middle Aged,M01.060.116.630
21672072,2011-08-23T00:00:00,Motivation,F01.658
21672072,2011-08-23T00:00:00,Motivation,F01.752.543.500.750
21672072,2011-08-23T00:00:00,Self Efficacy,F01.752.747.792.700
21672072,2011-08-23T00:00:00,Smoking,F01.145.466.753
21672072,2011-08-23T00:00:00,Smoking Cessation,F01.145.940.700
21761563,2011-08-23T00:00:00,Algorithms,G17.035
21761563,2011-08-23T00:00:00,Algorithms,L01.224.050
21761563,2011-08-23T00:00:00,Breast Neoplasms,C04.588.180
21761563,2011-08-23T00:00:00,Breast Neoplasms,C17.800.090.500
21761563,2011-08-23T00:00:00,Computer Simulation,L01.224.160
21761563,2011-08-23T00:00:00,Gene Expression Profiling,E05.393.332
21761563,2011-08-23T00:00:00,"Gene Expression Regulation, Neoplastic",G05.355.315.370
21761563,2011-08-23T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21761563,2011-08-23T00:00:00,"Models, Biological",E05.599.395
21761563,2011-08-23T00:00:00,"Models, Statistical",E05.318.740.500
21761563,2011-08-23T00:00:00,"Models, Statistical",E05.599.835
21761563,2011-08-23T00:00:00,"Models, Statistical",N05.715.360.750.530
21761563,2011-08-23T00:00:00,"Models, Statistical",N06.850.520.830.500
21761563,2011-08-23T00:00:00,Oligonucleotide Array Sequence Analysis,E05.196.630.570.660
21761563,2011-08-23T00:00:00,Oligonucleotide Array Sequence Analysis,E05.393.525.640
21761563,2011-08-23T00:00:00,Oligonucleotide Array Sequence Analysis,E05.393.661.640
21761563,2011-08-23T00:00:00,Oligonucleotide Array Sequence Analysis,E05.393.760.640
21761563,2011-08-23T00:00:00,Oligonucleotide Array Sequence Analysis,E05.588.570.660
21761563,2011-08-23T00:00:00,Oligonucleotide Array Sequence Analysis,E05.601.640
21883104,2011-08-24T00:00:00,Accidental Falls,N06.850.135.122
21883104,2011-08-24T00:00:00,Activities of Daily Living,E02.831.067
21883104,2011-08-24T00:00:00,Activities of Daily Living,I03.050
21883104,2011-08-24T00:00:00,Activities of Daily Living,N02.421.784.110
21883104,2011-08-24T00:00:00,Aged,M01.060.116.100
21883104,2011-08-24T00:00:00,Algorithms,G17.035
21883104,2011-08-24T00:00:00,Algorithms,L01.224.050
21883104,2011-08-24T00:00:00,Clinical Competence,I02.399.630.210
21883104,2011-08-24T00:00:00,Clinical Competence,N04.761.210
21883104,2011-08-24T00:00:00,Cooperative Behavior,F01.145.813.115
21883104,2011-08-24T00:00:00,Curriculum,I02.158
21883104,2011-08-24T00:00:00,Disability Evaluation,E01.370.400
21883104,2011-08-24T00:00:00,Electronic Health Records,E05.318.308.940.968.625.500
21883104,2011-08-24T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21883104,2011-08-24T00:00:00,Interdisciplinary Communication,F01.145.209.381
21883104,2011-08-24T00:00:00,Interdisciplinary Communication,F01.829.401.205.249
21883104,2011-08-24T00:00:00,Interdisciplinary Communication,L01.143.474
21883104,2011-08-24T00:00:00,Internal Medicine,H02.403.429
21883104,2011-08-24T00:00:00,Internship and Residency,I02.358.399.644
21883104,2011-08-24T00:00:00,Mass Screening,E01.370.500
21883104,2011-08-24T00:00:00,Mass Screening,E05.318.308.250.580
21883104,2011-08-24T00:00:00,Mass Screening,N02.421.143.827.233.443
21883104,2011-08-24T00:00:00,Mass Screening,N02.421.726.233.443
21883104,2011-08-24T00:00:00,Mass Screening,N05.715.360.300.375.500
21883104,2011-08-24T00:00:00,Mass Screening,N06.850.520.308.250.580
21883104,2011-08-24T00:00:00,Mass Screening,N06.850.780.500
21883104,2011-08-24T00:00:00,Patient Care Team,N04.590.715
21883104,2011-08-24T00:00:00,Postural Balance,G11.427.690
21883104,2011-08-24T00:00:00,Postural Balance,G11.561.600.810.541.595
21883104,2011-08-24T00:00:00,Risk Assessment,E05.318.740.600.800.715
21883104,2011-08-24T00:00:00,Risk Assessment,N04.452.871.715
21883104,2011-08-24T00:00:00,Risk Assessment,N05.715.360.750.625.700.690
21883104,2011-08-24T00:00:00,Risk Assessment,N06.850.505.715
21883104,2011-08-24T00:00:00,Risk Assessment,N06.850.520.830.600.800.715
21883104,2011-08-24T00:00:00,Wounds and Injuries,C21.866
21883357,2011-08-24T00:00:00,Adolescent,M01.060.057
21883357,2011-08-24T00:00:00,Adult,M01.060.116
21883357,2011-08-24T00:00:00,African Continental Ancestry Group,M01.686.508.100
21883357,2011-08-24T00:00:00,Age Factors,N05.715.350.075
21883357,2011-08-24T00:00:00,Age Factors,N06.850.490.250
21883357,2011-08-24T00:00:00,Aged,M01.060.116.100
21883357,2011-08-24T00:00:00,European Continental Ancestry Group,M01.686.508.400
21883357,2011-08-24T00:00:00,Healthcare Disparities,N04.590.374.380
21883357,2011-08-24T00:00:00,Healthcare Disparities,N05.300.493
21883357,2011-08-24T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21883357,2011-08-24T00:00:00,Middle Aged,M01.060.116.630
21883357,2011-08-24T00:00:00,Mouth Neoplasms,C04.588.443.591
21883357,2011-08-24T00:00:00,Mouth Neoplasms,C07.465.565
21883357,2011-08-24T00:00:00,Oropharyngeal Neoplasms,C04.588.443.665.710.684
21883357,2011-08-24T00:00:00,Oropharyngeal Neoplasms,C07.550.745.671
21883357,2011-08-24T00:00:00,Oropharyngeal Neoplasms,C09.647.710.685
21883357,2011-08-24T00:00:00,Oropharyngeal Neoplasms,C09.775.549.685
21883357,2011-08-24T00:00:00,United States,Z01.107.567.875
21883357,2011-08-24T00:00:00,Young Adult,M01.060.116.815
21868742,2011-08-25T00:00:00,Aged,M01.060.116.100
21868742,2011-08-25T00:00:00,Cerebral Hemorrhage,C10.228.140.300.535.200
21868742,2011-08-25T00:00:00,Cerebral Hemorrhage,C14.907.253.573.200
21868742,2011-08-25T00:00:00,Cerebral Hemorrhage,C23.550.414.913.100
21868742,2011-08-25T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21868742,2011-08-25T00:00:00,"Infusions, Intravenous",E02.319.267.510.590
21868742,2011-08-25T00:00:00,Middle Aged,M01.060.116.630
21871819,2011-08-25T00:00:00,Biomedical Research,H01.770.644.145
21871819,2011-08-25T00:00:00,"History, 20th Century",K01.400.504.968
21871819,2011-08-25T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21871819,2011-08-25T00:00:00,"Radiography, Interventional",E01.370.350.700.725
21871819,2011-08-25T00:00:00,"Radiography, Interventional",E02.148.694
21871819,2011-08-25T00:00:00,"Radiography, Interventional",E04.800.780
21871819,2011-08-25T00:00:00,United States,Z01.107.567.875
21871819,2011-08-25T00:00:00,Vascular Surgical Procedures,E04.100.814
21870119,2011-08-26T00:00:00,Animals,B01.050
21870119,2011-08-26T00:00:00,Electric Stimulation,E05.723.402
21870119,2011-08-26T00:00:00,Electric Stimulation Therapy,E02.342
21870119,2011-08-26T00:00:00,Electric Stimulation Therapy,E02.779.468
21870119,2011-08-26T00:00:00,Electromyography,E01.370.405.255
21870119,2011-08-26T00:00:00,Electromyography,E01.370.530.255
21870119,2011-08-26T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21870119,2011-08-26T00:00:00,Muscle Contraction,G11.427.590.540
21870119,2011-08-26T00:00:00,Muscle Fatigue,G11.427.550
21870119,2011-08-26T00:00:00,"Recruitment, Neurophysiological",G07.265.337.600.760
21870119,2011-08-26T00:00:00,"Recruitment, Neurophysiological",G07.700.240.600.760
21870119,2011-08-26T00:00:00,"Recruitment, Neurophysiological",G11.561.600.620.760
21872212,2011-08-26T00:00:00,Cardiac Surgical Procedures,E04.100.376
21872212,2011-08-26T00:00:00,Cardiac Surgical Procedures,E04.928.220
21872212,2011-08-26T00:00:00,"Child, Preschool",M01.060.406.448
21872212,2011-08-26T00:00:00,"Echocardiography, Doppler, Color",E01.370.350.850.220.220.220
21872212,2011-08-26T00:00:00,"Echocardiography, Doppler, Color",E01.370.350.850.850.220.220
21872212,2011-08-26T00:00:00,"Echocardiography, Doppler, Color",E01.370.350.850.850.850.850.220
21872212,2011-08-26T00:00:00,"Echocardiography, Doppler, Color",E01.370.370.380.220.220.220
21872212,2011-08-26T00:00:00,"Hospitals, Pediatric",N02.278.421.556.437
21872212,2011-08-26T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21872212,2011-08-26T00:00:00,Infant,M01.060.703
21872212,2011-08-26T00:00:00,Stroke Volume,E01.370.370.380.150.700
21872212,2011-08-26T00:00:00,Stroke Volume,G09.330.380.124.882
21872212,2011-08-26T00:00:00,Treatment Outcome,E01.789.800
21872212,2011-08-26T00:00:00,Treatment Outcome,N04.761.559.590.800
21872212,2011-08-26T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21872212,2011-08-26T00:00:00,United States,Z01.107.567.875
21872212,2011-08-26T00:00:00,"Ventricular Function, Left",G09.330.190.962.800
21875862,2011-08-29T00:00:00,Aged,M01.060.116.100
21875862,2011-08-29T00:00:00,"Arrhythmias, Cardiac",C14.280.067
21875862,2011-08-29T00:00:00,"Arrhythmias, Cardiac",C23.550.073
21875862,2011-08-29T00:00:00,"Defibrillators, Implantable",E07.305.250.159.175
21875862,2011-08-29T00:00:00,"Defibrillators, Implantable",E07.305.250.319.175
21875862,2011-08-29T00:00:00,"Defibrillators, Implantable",E07.695.175
21875862,2011-08-29T00:00:00,Heart Conduction System,A07.541.409
21875862,2011-08-29T00:00:00,Heart Failure,C14.280.434
21875862,2011-08-29T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21875862,2011-08-29T00:00:00,Middle Aged,M01.060.116.630
21875862,2011-08-29T00:00:00,Quality of Life,I01.800
21875862,2011-08-29T00:00:00,Quality of Life,K01.752.400.750
21875862,2011-08-29T00:00:00,Treatment Outcome,E01.789.800
21875862,2011-08-29T00:00:00,Treatment Outcome,N04.761.559.590.800
21875862,2011-08-29T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21875862,2011-08-29T00:00:00,"Ventricular Dysfunction, Left",C14.280.945.900
21875862,2011-08-29T00:00:00,Ventricular Remodeling,C23.300.985
21875862,2011-08-29T00:00:00,Ventricular Remodeling,G09.330.190.962.975
21876161,2011-08-29T00:00:00,Animals,B01.050
21876161,2011-08-29T00:00:00,Bacterial Toxins,D23.946.123
21876161,2011-08-29T00:00:00,Cell Line,A11.251.210
21876161,2011-08-29T00:00:00,Cell Proliferation,G04.299.233.750
21876161,2011-08-29T00:00:00,Cell Proliferation,G07.700.320.249.410.750
21876161,2011-08-29T00:00:00,Colonic Neoplasms,C04.588.274.476.411.307.180
21876161,2011-08-29T00:00:00,Colonic Neoplasms,C06.301.371.411.307.180
21876161,2011-08-29T00:00:00,Colonic Neoplasms,C06.405.249.411.307.180
21876161,2011-08-29T00:00:00,Colonic Neoplasms,C06.405.469.158.356.180
21876161,2011-08-29T00:00:00,Colonic Neoplasms,C06.405.469.491.307.180
21876161,2011-08-29T00:00:00,DNA Damage,C21.111
21876161,2011-08-29T00:00:00,DNA Damage,G05.355.180
21876161,2011-08-29T00:00:00,"Disease Models, Animal",C22.232
21876161,2011-08-29T00:00:00,"Disease Models, Animal",E05.598.500
21876161,2011-08-29T00:00:00,"Disease Models, Animal",E05.599.395.080
21876161,2011-08-29T00:00:00,Epithelial Cells,A11.436
21876161,2011-08-29T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21876161,2011-08-29T00:00:00,Inflammation,C23.550.470
21876161,2011-08-29T00:00:00,Oxidoreductases Acting on CH-NH Group Donors,D08.811.682.662
21876161,2011-08-29T00:00:00,Polyamines,D02.092.782
21876161,2011-08-29T00:00:00,Recombinant Proteins,D12.776.828
21826645,2011-08-30T00:00:00,"DNA, Mitochondrial",D13.444.308.283.225
21826645,2011-08-30T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21826645,2011-08-30T00:00:00,Lymphocytes,A11.118.637.555.567
21826645,2011-08-30T00:00:00,Lymphocytes,A15.145.229.637.555.567
21826645,2011-08-30T00:00:00,Lymphocytes,A15.382.490.555.567
21826645,2011-08-30T00:00:00,Mitochondria,A11.284.430.214.190.875.564
21826645,2011-08-30T00:00:00,Mitochondria,A11.284.835.626
21826645,2011-08-30T00:00:00,Mutation,G05.365.590
21826645,2011-08-30T00:00:00,Neoplasm Staging,E01.370.550
21826645,2011-08-30T00:00:00,"Sequence Analysis, DNA",E05.393.760.700
21878516,2011-08-30T00:00:00,"Adaptor Proteins, Signal Transducing",D12.644.360.024
21878516,2011-08-30T00:00:00,"Adaptor Proteins, Signal Transducing",D12.776.157.057
21878516,2011-08-30T00:00:00,"Adaptor Proteins, Signal Transducing",D12.776.476.024
21878516,2011-08-30T00:00:00,Animals,B01.050
21878516,2011-08-30T00:00:00,Bone Resorption,C05.116.264
21878516,2011-08-30T00:00:00,Bone Resorption,G11.427.590.195.150
21878516,2011-08-30T00:00:00,Cell Differentiation,G04.299.151
21878516,2011-08-30T00:00:00,Heat-Shock Proteins,D12.776.580.216
21878516,2011-08-30T00:00:00,Mutation,G05.365.590
21878516,2011-08-30T00:00:00,Osteitis Deformans,C05.116.692
21878516,2011-08-30T00:00:00,Osteoclasts,A11.329.372.700
21878516,2011-08-30T00:00:00,Osteoclasts,A11.627.482.700
21878516,2011-08-30T00:00:00,RANK Ligand,D12.644.276.374.750.562
21878516,2011-08-30T00:00:00,RANK Ligand,D12.644.276.972.562
21878516,2011-08-30T00:00:00,RANK Ligand,D12.776.467.374.750.562
21878516,2011-08-30T00:00:00,RANK Ligand,D12.776.467.972.562
21878516,2011-08-30T00:00:00,RANK Ligand,D23.529.374.750.562
21878516,2011-08-30T00:00:00,RANK Ligand,D23.529.972.562
21878516,2011-08-30T00:00:00,Signal Transduction,G02.111.087.800
21878516,2011-08-30T00:00:00,Signal Transduction,G02.149.115.800
21878516,2011-08-30T00:00:00,Signal Transduction,G04.299.880
21880739,2011-08-31T00:00:00,Animals,B01.050
21880739,2011-08-31T00:00:00,"GTP-Binding Protein alpha Subunits, Gi-Go",D08.811.277.040.330.300.200.100.200
21880739,2011-08-31T00:00:00,"GTP-Binding Protein alpha Subunits, Gi-Go",D12.644.360.375.100.200
21880739,2011-08-31T00:00:00,"GTP-Binding Protein alpha Subunits, Gi-Go",D12.776.157.325.332.100.200
21880739,2011-08-31T00:00:00,"GTP-Binding Protein alpha Subunits, Gi-Go",D12.776.476.375.100.200
21880739,2011-08-31T00:00:00,"GTP-Binding Protein alpha Subunits, Gi-Go",D12.776.543.325.100.200
21880739,2011-08-31T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21880739,2011-08-31T00:00:00,"Microscopy, Fluorescence",E01.370.350.515.458
21880739,2011-08-31T00:00:00,"Microscopy, Fluorescence",E05.595.458
21880739,2011-08-31T00:00:00,"Models, Biological",E05.599.395
21880739,2011-08-31T00:00:00,Nuclear Proteins,D12.776.660
21880739,2011-08-31T00:00:00,RGS Proteins,D12.644.360.325.150.750
21880739,2011-08-31T00:00:00,RGS Proteins,D12.776.402.150.750
21880739,2011-08-31T00:00:00,RGS Proteins,D12.776.476.325.150.750
21880739,2011-08-31T00:00:00,Rats,B01.050.150.900.649.865.635.505.700
21880739,2011-08-31T00:00:00,"Receptors, G-Protein-Coupled",D12.776.543.750.100
21880739,2011-08-31T00:00:00,Signal Transduction,G02.111.087.800
21880739,2011-08-31T00:00:00,Signal Transduction,G02.149.115.800
21880739,2011-08-31T00:00:00,Signal Transduction,G04.299.880
21881053,2011-08-31T00:00:00,Adult,M01.060.116
21881053,2011-08-31T00:00:00,Aged,M01.060.116.100
21881053,2011-08-31T00:00:00,Endoscopy,E01.370.388.250
21881053,2011-08-31T00:00:00,Endoscopy,E04.800.250
21881053,2011-08-31T00:00:00,Head and Neck Neoplasms,C04.588.443
21881053,2011-08-31T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21881053,2011-08-31T00:00:00,Middle Aged,M01.060.116.630
21881053,2011-08-31T00:00:00,Quality of Life,I01.800
21881053,2011-08-31T00:00:00,Quality of Life,K01.752.400.750
21881053,2011-08-31T00:00:00,Questionnaires,E05.318.308.750
21881053,2011-08-31T00:00:00,Questionnaires,L01.280.800
21881053,2011-08-31T00:00:00,Questionnaires,N05.715.360.300.695
21881053,2011-08-31T00:00:00,Questionnaires,N06.850.520.308.750
21881053,2011-08-31T00:00:00,Robotics,H01.671.293.643
21881053,2011-08-31T00:00:00,Robotics,J01.897.104.834
21881053,2011-08-31T00:00:00,Robotics,L01.224.065.630
21881053,2011-08-31T00:00:00,Treatment Outcome,E01.789.800
21881053,2011-08-31T00:00:00,Treatment Outcome,N04.761.559.590.800
21881053,2011-08-31T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21885062,2011-08-31T00:00:00,Adolescent,M01.060.057
21885062,2011-08-31T00:00:00,Adrenal Cortex Hormones,D06.472.040
21885062,2011-08-31T00:00:00,Asthma,C08.127.108
21885062,2011-08-31T00:00:00,Asthma,C08.381.495.108
21885062,2011-08-31T00:00:00,Asthma,C08.674.095
21885062,2011-08-31T00:00:00,Asthma,C20.543.480.680.095
21885062,2011-08-31T00:00:00,Child,M01.060.406
21885062,2011-08-31T00:00:00,"Child, Preschool",M01.060.406.448
21885062,2011-08-31T00:00:00,"Emergency Service, Hospital",N02.278.354.422.336
21885062,2011-08-31T00:00:00,"Emergency Service, Hospital",N02.421.297.195
21885062,2011-08-31T00:00:00,"Emergency Service, Hospital",N04.452.442.422.336
21885062,2011-08-31T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21885062,2011-08-31T00:00:00,Office Visits,N04.452.758.635
21885062,2011-08-31T00:00:00,Outpatients,M01.643.630
21885062,2011-08-31T00:00:00,Patient Compliance,F01.145.488.500
21885062,2011-08-31T00:00:00,Patient Compliance,N05.300.150.600.600
21885062,2011-08-31T00:00:00,Treatment Outcome,E01.789.800
21885062,2011-08-31T00:00:00,Treatment Outcome,N04.761.559.590.800
21885062,2011-08-31T00:00:00,Treatment Outcome,N05.715.360.575.575.800
22000541,2011-08-31T00:00:00,Behavior,F01.145
22000541,2011-08-31T00:00:00,General Surgery,H02.403.810.300
22000541,2011-08-31T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22000541,2011-08-31T00:00:00,Internship and Residency,I02.358.399.644
20680505,2011-09-01T00:00:00,Adolescent,M01.060.057
20680505,2011-09-01T00:00:00,Adult,M01.060.116
20680505,2011-09-01T00:00:00,Case-Control Studies,E05.318.760.500.500
20680505,2011-09-01T00:00:00,Case-Control Studies,N05.715.360.775.175.200
20680505,2011-09-01T00:00:00,Case-Control Studies,N06.850.520.450.500.500
20680505,2011-09-01T00:00:00,Gastroplasty,E02.065.062.750
20680505,2011-09-01T00:00:00,Gastroplasty,E04.062.750
20680505,2011-09-01T00:00:00,Gastroplasty,E04.210.485
20680505,2011-09-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
20680505,2011-09-01T00:00:00,Laparoscopy,E01.370.388.250.520
20680505,2011-09-01T00:00:00,Laparoscopy,E04.800.250.520
20680505,2011-09-01T00:00:00,Middle Aged,M01.060.116.630
20680505,2011-09-01T00:00:00,"Obesity, Morbid",C18.654.726.500.700
20680505,2011-09-01T00:00:00,"Obesity, Morbid",C23.888.144.699.500.500
20680505,2011-09-01T00:00:00,"Obesity, Morbid",E01.370.600.115.100.160.120.699.500.500
20680505,2011-09-01T00:00:00,"Obesity, Morbid",G07.100.100.160.120.699.500.500
20680505,2011-09-01T00:00:00,Pregnancy,G08.686.785.760.769
20680505,2011-09-01T00:00:00,Pregnancy Complications,C13.703
20680505,2011-09-01T00:00:00,Reoperation,E04.690
20680505,2011-09-01T00:00:00,Weight Loss,C23.888.144.243.963
20680505,2011-09-01T00:00:00,Weight Loss,G07.700.320.249.314.120.200.963
20680505,2011-09-01T00:00:00,Young Adult,M01.060.116.815
21368686,2011-09-01T00:00:00,Animals,B01.050
21368686,2011-09-01T00:00:00,Dogs,B01.050.150.900.649.147.153.200
21368686,2011-09-01T00:00:00,"Embolization, Therapeutic",E02.520.360
21368686,2011-09-01T00:00:00,Prostheses and Implants,E07.695
21503842,2011-09-01T00:00:00,Adult,M01.060.116
21503842,2011-09-01T00:00:00,Head and Neck Neoplasms,C04.588.443
21503842,2011-09-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21503842,2011-09-01T00:00:00,Middle Aged,M01.060.116.630
21503842,2011-09-01T00:00:00,Patient Education as Topic,I02.233.332.500
21503842,2011-09-01T00:00:00,Patient Education as Topic,N02.421.143.827.407.680
21503842,2011-09-01T00:00:00,Patient Education as Topic,N02.421.726.407.680
21503842,2011-09-01T00:00:00,Questionnaires,E05.318.308.750
21503842,2011-09-01T00:00:00,Questionnaires,L01.280.800
21503842,2011-09-01T00:00:00,Questionnaires,N05.715.360.300.695
21503842,2011-09-01T00:00:00,Questionnaires,N06.850.520.308.750
21503842,2011-09-01T00:00:00,Smoking,F01.145.466.753
21503842,2011-09-01T00:00:00,Smoking Cessation,F01.145.940.700
21503842,2011-09-01T00:00:00,Young Adult,M01.060.116.815
21506957,2011-09-01T00:00:00,Animals,B01.050
21506957,2011-09-01T00:00:00,Bone and Bones,A02.835.232
21506957,2011-09-01T00:00:00,Bone and Bones,A10.165.265
21506957,2011-09-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21506957,2011-09-01T00:00:00,Osteogenesis,G07.700.320.500.325.377.625.100.729
21506957,2011-09-01T00:00:00,Osteogenesis,G11.427.590.560.100.729
21506957,2011-09-01T00:00:00,Osteoporosis,C05.116.198.579
21506957,2011-09-01T00:00:00,"Receptor, Parathyroid Hormone, Type 1",D12.776.543.750.100.650.100
21506957,2011-09-01T00:00:00,"Receptor, Parathyroid Hormone, Type 1",D12.776.543.750.750.600.100
21544866,2011-09-01T00:00:00,Adult,M01.060.116
21544866,2011-09-01T00:00:00,Biological Markers,D23.101
21544866,2011-09-01T00:00:00,Bone Resorption,C05.116.264
21544866,2011-09-01T00:00:00,Bone Resorption,G11.427.590.195.150
21544866,2011-09-01T00:00:00,Calcium,D01.268.552.100
21544866,2011-09-01T00:00:00,Calcium,D01.552.539.288
21544866,2011-09-01T00:00:00,Calcium,D23.119.100
21544866,2011-09-01T00:00:00,Demography,I01.240
21544866,2011-09-01T00:00:00,Demography,N01.224
21544866,2011-09-01T00:00:00,Demography,N06.850.505.400
21544866,2011-09-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21544866,2011-09-01T00:00:00,"Infusions, Intravenous",E02.319.267.510.590
21544866,2011-09-01T00:00:00,Kidney,A05.810.453
21544866,2011-09-01T00:00:00,Minerals,D01.578
21544866,2011-09-01T00:00:00,Osteogenesis,G07.700.320.500.325.377.625.100.729
21544866,2011-09-01T00:00:00,Osteogenesis,G11.427.590.560.100.729
21544866,2011-09-01T00:00:00,Parathyroid Hormone,D06.472.699.590
21544866,2011-09-01T00:00:00,Parathyroid Hormone,D12.644.548.587
21544866,2011-09-01T00:00:00,Time Factors,G01.910.857
21544866,2011-09-01T00:00:00,Young Adult,M01.060.116.815
21563297,2011-09-01T00:00:00,Animals,B01.050
21563297,2011-09-01T00:00:00,Cell Adhesion,G04.299.117
21563297,2011-09-01T00:00:00,Cytokines,D12.644.276.374
21563297,2011-09-01T00:00:00,Cytokines,D12.776.467.374
21563297,2011-09-01T00:00:00,Cytokines,D23.529.374
21563297,2011-09-01T00:00:00,Dendritic Cells,A11.066.270
21563297,2011-09-01T00:00:00,Dendritic Cells,A11.436.270
21563297,2011-09-01T00:00:00,Dendritic Cells,A15.382.066.270
21563297,2011-09-01T00:00:00,Dendritic Cells,A15.382.812.260
21563297,2011-09-01T00:00:00,Endothelial Cells,A11.436.275
21563297,2011-09-01T00:00:00,Ischemia,C23.550.513
21563297,2011-09-01T00:00:00,Liver,A03.620
21563297,2011-09-01T00:00:00,"Microscopy, Confocal",E01.370.350.515.395
21563297,2011-09-01T00:00:00,"Microscopy, Confocal",E05.595.395
21563297,2011-09-01T00:00:00,Reperfusion Injury,C14.907.725
21563297,2011-09-01T00:00:00,Reperfusion Injury,C23.550.767.877
21563297,2011-09-01T00:00:00,Toll-Like Receptor 4,D12.776.543.750.705.910.500.400
21590681,2011-09-01T00:00:00,Adolescent,M01.060.057
21590681,2011-09-01T00:00:00,Adult,M01.060.116
21590681,2011-09-01T00:00:00,Alleles,G05.360.340.024.340.030
21590681,2011-09-01T00:00:00,European Continental Ancestry Group,M01.686.508.400
21590681,2011-09-01T00:00:00,Genetic Predisposition to Disease,C23.550.291.687.500
21590681,2011-09-01T00:00:00,Genetic Predisposition to Disease,G05.380.355
21590681,2011-09-01T00:00:00,Hispanic Americans,M01.686.754.441
21590681,2011-09-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21590681,2011-09-01T00:00:00,Interleukin-2,D12.644.276.374.465.502
21590681,2011-09-01T00:00:00,Interleukin-2,D12.644.276.374.480.372
21590681,2011-09-01T00:00:00,Interleukin-2,D12.776.467.374.465.502
21590681,2011-09-01T00:00:00,Interleukin-2,D12.776.467.374.480.372
21590681,2011-09-01T00:00:00,Interleukin-2,D23.529.374.465.502
21590681,2011-09-01T00:00:00,Interleukin-2,D23.529.374.480.372
21590681,2011-09-01T00:00:00,"Lupus Erythematosus, Systemic",C17.300.480
21590681,2011-09-01T00:00:00,"Lupus Erythematosus, Systemic",C20.111.590
21590681,2011-09-01T00:00:00,Middle Aged,M01.060.116.630
21590681,2011-09-01T00:00:00,"Polymorphism, Genetic",G05.365.795
21590681,2011-09-01T00:00:00,Protein Phosphatase 2,D08.811.277.352.650.625.706
21590681,2011-09-01T00:00:00,Protein Phosphatase 2,D12.644.360.583
21590681,2011-09-01T00:00:00,Protein Phosphatase 2,D12.776.476.561
21590681,2011-09-01T00:00:00,T-Lymphocytes,A11.118.637.555.567.569
21590681,2011-09-01T00:00:00,T-Lymphocytes,A15.145.229.637.555.567.569
21590681,2011-09-01T00:00:00,T-Lymphocytes,A15.382.490.555.567.569
21633292,2011-09-01T00:00:00,Data Collection,E05.318.308
21633292,2011-09-01T00:00:00,Data Collection,L01.280
21633292,2011-09-01T00:00:00,Data Collection,N05.715.360.300
21633292,2011-09-01T00:00:00,Data Collection,N06.850.520.308
21633292,2011-09-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21633292,2011-09-01T00:00:00,Microarray Analysis,E05.196.630.570
21633292,2011-09-01T00:00:00,Microarray Analysis,E05.588.570
21633292,2011-09-01T00:00:00,United States,Z01.107.567.875
21639998,2011-09-01T00:00:00,Adolescent,M01.060.057
21639998,2011-09-01T00:00:00,Adult,M01.060.116
21639998,2011-09-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21639998,2011-09-01T00:00:00,Middle Aged,M01.060.116.630
21639998,2011-09-01T00:00:00,Patient Compliance,F01.145.488.500
21639998,2011-09-01T00:00:00,Patient Compliance,N05.300.150.600.600
21639998,2011-09-01T00:00:00,Pharmaceutical Preparations,D26
21639998,2011-09-01T00:00:00,Pilot Projects,E05.318.760.750
21639998,2011-09-01T00:00:00,Pilot Projects,E05.337.737
21639998,2011-09-01T00:00:00,Pilot Projects,N05.715.360.775.625
21639998,2011-09-01T00:00:00,Pilot Projects,N06.850.520.450.720
21647745,2011-09-01T00:00:00,Diabetes Mellitus,C18.452.394.750
21647745,2011-09-01T00:00:00,Diabetes Mellitus,C19.246
21647745,2011-09-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21647745,2011-09-01T00:00:00,Patient Education as Topic,I02.233.332.500
21647745,2011-09-01T00:00:00,Patient Education as Topic,N02.421.143.827.407.680
21647745,2011-09-01T00:00:00,Patient Education as Topic,N02.421.726.407.680
21647745,2011-09-01T00:00:00,Self Care,E02.900
21647745,2011-09-01T00:00:00,Self Care,N02.421.784.680
21722152,2011-09-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21722152,2011-09-01T00:00:00,Parathyroid Hormone,D06.472.699.590
21722152,2011-09-01T00:00:00,Parathyroid Hormone,D12.644.548.587
21722152,2011-09-01T00:00:00,Pregnancy,G08.686.785.760.769
21722152,2011-09-01T00:00:00,Vitamin D,D04.808.812.768
21799444,2011-09-01T00:00:00,Aged,M01.060.116.100
21799444,2011-09-01T00:00:00,Echocardiography,E01.370.350.850.220
21799444,2011-09-01T00:00:00,Echocardiography,E01.370.370.380.220
21799444,2011-09-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21799444,2011-09-01T00:00:00,Hypertension,C14.907.489
21799444,2011-09-01T00:00:00,Kidney,A05.810.453
21799444,2011-09-01T00:00:00,Middle Aged,M01.060.116.630
21815920,2011-09-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21815920,2011-09-01T00:00:00,Smoking,F01.145.466.753
21815920,2011-09-01T00:00:00,Smoking Cessation,F01.145.940.700
21828968,2011-09-01T00:00:00,Adult,M01.060.116
21828968,2011-09-01T00:00:00,Aged,M01.060.116.100
21828968,2011-09-01T00:00:00,Ambulatory Care,E02.760.106
21828968,2011-09-01T00:00:00,Ambulatory Care,N02.421.585.106
21828968,2011-09-01T00:00:00,Carrier State,N06.850.160
21828968,2011-09-01T00:00:00,"Catheters, Indwelling",E07.150
21828968,2011-09-01T00:00:00,Cross Infection,C01.539.248
21828968,2011-09-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21828968,2011-09-01T00:00:00,Incidence,E05.318.308.985.525.375
21828968,2011-09-01T00:00:00,Incidence,L01.280.975.525.375
21828968,2011-09-01T00:00:00,Incidence,N01.224.935.597.500
21828968,2011-09-01T00:00:00,Incidence,N06.850.505.400.975.525.375
21828968,2011-09-01T00:00:00,Incidence,N06.850.520.308.985.525.375
21828968,2011-09-01T00:00:00,Methicillin-Resistant Staphylococcus aureus,B03.300.390.400.800.750.100.500
21828968,2011-09-01T00:00:00,Methicillin-Resistant Staphylococcus aureus,B03.510.100.750.750.100.500
21828968,2011-09-01T00:00:00,Methicillin-Resistant Staphylococcus aureus,B03.510.400.790.750.100.500
21828968,2011-09-01T00:00:00,Renal Dialysis,E02.870.300
21828968,2011-09-01T00:00:00,Renal Dialysis,E02.912.800
21828968,2011-09-01T00:00:00,"Renal Insufficiency, Chronic",C12.777.419.780.750
21828968,2011-09-01T00:00:00,"Renal Insufficiency, Chronic",C13.351.968.419.780.750
21828968,2011-09-01T00:00:00,Staphylococcal Infections,C01.252.410.868
21854272,2011-09-01T00:00:00,HIV Infections,C02.782.815.616.400
21854272,2011-09-01T00:00:00,HIV Infections,C02.800.801.400
21854272,2011-09-01T00:00:00,HIV Infections,C20.673.480
21854272,2011-09-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21854272,2011-09-01T00:00:00,Multicenter Studies as Topic,E05.318.760.535.500
21854272,2011-09-01T00:00:00,Multicenter Studies as Topic,E05.337.250.500
21854272,2011-09-01T00:00:00,Multicenter Studies as Topic,N05.715.360.775.235.545
21854272,2011-09-01T00:00:00,Multicenter Studies as Topic,N06.850.520.450.535.500
21854272,2011-09-01T00:00:00,Randomized Controlled Trials as Topic,E05.318.760.535.365.500
21854272,2011-09-01T00:00:00,Randomized Controlled Trials as Topic,E05.337.250.365.500
21854272,2011-09-01T00:00:00,Randomized Controlled Trials as Topic,N05.715.360.775.235.387.500
21854272,2011-09-01T00:00:00,Randomized Controlled Trials as Topic,N06.850.520.450.535.365.500
21854272,2011-09-01T00:00:00,Research Design,E05.581.500
21854272,2011-09-01T00:00:00,Research Design,H01.770.644.728
21854272,2011-09-01T00:00:00,Risk-Taking,F01.145.722
21854272,2011-09-01T00:00:00,Sex Factors,N05.715.350.675
21854272,2011-09-01T00:00:00,Sex Factors,N06.850.490.875
21854272,2011-09-01T00:00:00,Substance-Related Disorders,C21.739
21854272,2011-09-01T00:00:00,Substance-Related Disorders,F03.900
21854272,2011-09-01T00:00:00,United States,Z01.107.567.875
21854273,2011-09-01T00:00:00,Adult,M01.060.116
21854273,2011-09-01T00:00:00,"Analgesics, Opioid",D27.505.696.663.850.014.520
21854273,2011-09-01T00:00:00,"Analgesics, Opioid",D27.505.954.427.040.325
21854273,2011-09-01T00:00:00,"Analgesics, Opioid",D27.505.954.427.210.049
21854273,2011-09-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21854273,2011-09-01T00:00:00,Middle Aged,M01.060.116.630
21854273,2011-09-01T00:00:00,Opioid-Related Disorders,C21.739.675
21854273,2011-09-01T00:00:00,Opioid-Related Disorders,F03.900.675
21854273,2011-09-01T00:00:00,Sex Factors,N05.715.350.675
21854273,2011-09-01T00:00:00,Sex Factors,N06.850.490.875
21854273,2011-09-01T00:00:00,Substance-Related Disorders,C21.739
21854273,2011-09-01T00:00:00,Substance-Related Disorders,F03.900
21854273,2011-09-01T00:00:00,United States,Z01.107.567.875
21854278,2011-09-01T00:00:00,Clinical Trials as Topic,E05.318.760.535
21854278,2011-09-01T00:00:00,Clinical Trials as Topic,E05.337.250
21854278,2011-09-01T00:00:00,Clinical Trials as Topic,N05.715.360.775.235
21854278,2011-09-01T00:00:00,Clinical Trials as Topic,N06.850.520.450.535
21854278,2011-09-01T00:00:00,Ethnic Groups,M01.686.754
21854278,2011-09-01T00:00:00,Ethnic Groups,N01.224.317
21854278,2011-09-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21854278,2011-09-01T00:00:00,Outcome Assessment (Health Care),N04.761.559.590
21854278,2011-09-01T00:00:00,Outcome Assessment (Health Care),N05.715.360.575.575
21854278,2011-09-01T00:00:00,Sex Factors,N05.715.350.675
21854278,2011-09-01T00:00:00,Sex Factors,N06.850.490.875
21854278,2011-09-01T00:00:00,Substance Abuse Detection,E05.885
21854278,2011-09-01T00:00:00,Substance Abuse Detection,N06.850.780.500.765
21854278,2011-09-01T00:00:00,Substance-Related Disorders,C21.739
21854278,2011-09-01T00:00:00,Substance-Related Disorders,F03.900
21854278,2011-09-01T00:00:00,Time Factors,G01.910.857
21854278,2011-09-01T00:00:00,United States,Z01.107.567.875
21854280,2011-09-01T00:00:00,Adult,M01.060.116
21854280,2011-09-01T00:00:00,Age Factors,N05.715.350.075
21854280,2011-09-01T00:00:00,Age Factors,N06.850.490.250
21854280,2011-09-01T00:00:00,Cocaine-Related Disorders,C21.739.300
21854280,2011-09-01T00:00:00,Cocaine-Related Disorders,F03.900.300
21854280,2011-09-01T00:00:00,Decision Making,F02.463.785.373
21854280,2011-09-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21854280,2011-09-01T00:00:00,Middle Aged,M01.060.116.630
21854280,2011-09-01T00:00:00,"Models, Statistical",E05.318.740.500
21854280,2011-09-01T00:00:00,"Models, Statistical",E05.599.835
21854280,2011-09-01T00:00:00,"Models, Statistical",N05.715.360.750.530
21854280,2011-09-01T00:00:00,"Models, Statistical",N06.850.520.830.500
21854280,2011-09-01T00:00:00,Poisson Distribution,E05.318.740.994.750
21854280,2011-09-01T00:00:00,Poisson Distribution,G17.820.750
21854280,2011-09-01T00:00:00,Poisson Distribution,N05.715.360.750.750.620
21854280,2011-09-01T00:00:00,Poisson Distribution,N06.850.520.830.994.750
21854280,2011-09-01T00:00:00,Sex Factors,N05.715.350.675
21854280,2011-09-01T00:00:00,Sex Factors,N06.850.490.875
21854280,2011-09-01T00:00:00,Time Factors,G01.910.857
21854280,2011-09-01T00:00:00,Young Adult,M01.060.116.815
21854292,2011-09-01T00:00:00,Adult,M01.060.116
21854292,2011-09-01T00:00:00,Age Factors,N05.715.350.075
21854292,2011-09-01T00:00:00,Age Factors,N06.850.490.250
21854292,2011-09-01T00:00:00,Alcoholism,C21.739.100.250
21854292,2011-09-01T00:00:00,Alcoholism,F03.900.100.350
21854292,2011-09-01T00:00:00,Community Health Services,N02.421.143
21854292,2011-09-01T00:00:00,Ethnic Groups,M01.686.754
21854292,2011-09-01T00:00:00,Ethnic Groups,N01.224.317
21854292,2011-09-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21854292,2011-09-01T00:00:00,Methadone,D02.522.675
21854292,2011-09-01T00:00:00,Middle Aged,M01.060.116.630
21854292,2011-09-01T00:00:00,Smoking Cessation,F01.145.940.700
21854292,2011-09-01T00:00:00,Substance-Related Disorders,C21.739
21854292,2011-09-01T00:00:00,Substance-Related Disorders,F03.900
21854292,2011-09-01T00:00:00,Treatment Outcome,E01.789.800
21854292,2011-09-01T00:00:00,Treatment Outcome,N04.761.559.590.800
21854292,2011-09-01T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21854292,2011-09-01T00:00:00,United States,Z01.107.567.875
21856509,2011-09-01T00:00:00,Anti-Bacterial Agents,D27.505.954.122.085
21856509,2011-09-01T00:00:00,"Defibrillators, Implantable",E07.305.250.159.175
21856509,2011-09-01T00:00:00,"Defibrillators, Implantable",E07.305.250.319.175
21856509,2011-09-01T00:00:00,"Defibrillators, Implantable",E07.695.175
21856509,2011-09-01T00:00:00,Device Removal,E04.199
21856509,2011-09-01T00:00:00,"Echocardiography, Transesophageal",E01.370.350.850.220.235
21856509,2011-09-01T00:00:00,"Echocardiography, Transesophageal",E01.370.370.380.220.235
21856509,2011-09-01T00:00:00,"Endocarditis, Bacterial",C01.252.300
21856509,2011-09-01T00:00:00,"Endocarditis, Bacterial",C01.539.190.249
21856509,2011-09-01T00:00:00,"Endocarditis, Bacterial",C14.260.249
21856509,2011-09-01T00:00:00,"Endocarditis, Bacterial",C14.280.282.407
21856509,2011-09-01T00:00:00,Heart Atria,A07.541.358
21856509,2011-09-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21856509,2011-09-01T00:00:00,Middle Aged,M01.060.116.630
21856509,2011-09-01T00:00:00,Prosthesis-Related Infections,C01.539.685
21856509,2011-09-01T00:00:00,Prosthesis-Related Infections,C23.550.767.868
21856509,2011-09-01T00:00:00,Suction,E04.237.890
21856509,2011-09-01T00:00:00,Treatment Outcome,E01.789.800
21856509,2011-09-01T00:00:00,Treatment Outcome,N04.761.559.590.800
21856509,2011-09-01T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21860267,2011-09-01T00:00:00,Adult,M01.060.116
21860267,2011-09-01T00:00:00,Age Factors,N05.715.350.075
21860267,2011-09-01T00:00:00,Age Factors,N06.850.490.250
21860267,2011-09-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21860267,2011-09-01T00:00:00,"Kidney Failure, Chronic",C12.777.419.780.500.602
21860267,2011-09-01T00:00:00,"Kidney Failure, Chronic",C12.777.419.780.750.500
21860267,2011-09-01T00:00:00,"Kidney Failure, Chronic",C13.351.968.419.780.500.602
21860267,2011-09-01T00:00:00,"Kidney Failure, Chronic",C13.351.968.419.780.750.500
21860267,2011-09-01T00:00:00,Nephrology,H02.403.429.580
21860267,2011-09-01T00:00:00,Referral and Consultation,N04.452.758.849
21860267,2011-09-01T00:00:00,Sex Factors,N05.715.350.675
21860267,2011-09-01T00:00:00,Sex Factors,N06.850.490.875
21860297,2011-09-01T00:00:00,Adult,M01.060.116
21860297,2011-09-01T00:00:00,Cost Savings,N03.219.151.160.200
21860297,2011-09-01T00:00:00,Cost-Benefit Analysis,N03.219.151.125
21860297,2011-09-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21860297,2011-09-01T00:00:00,"Infant, Newborn",M01.060.703.520
21860297,2011-09-01T00:00:00,Pregnancy,G08.686.785.760.769
21860297,2011-09-01T00:00:00,"Pregnancy Complications, Infectious",C01.539.674
21860297,2011-09-01T00:00:00,"Pregnancy Complications, Infectious",C13.703.700
21860297,2011-09-01T00:00:00,Reverse Transcriptase Inhibitors,D27.505.519.389.675.850
21860297,2011-09-01T00:00:00,Reverse Transcriptase Inhibitors,D27.505.954.122.388.077.750
21865967,2011-09-01T00:00:00,Electroconvulsive Therapy,F04.570.200.583
21865967,2011-09-01T00:00:00,Electroconvulsive Therapy,F04.669.224.300
21865967,2011-09-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21865967,2011-09-01T00:00:00,Seizures,C10.228.140.490.631
21865967,2011-09-01T00:00:00,Seizures,C10.597.742
21865967,2011-09-01T00:00:00,Seizures,C23.888.592.742
21871260,2011-09-01T00:00:00,Conflict of Interest,K01.316.130
21871260,2011-09-01T00:00:00,Conflict of Interest,N05.350.225
21871260,2011-09-01T00:00:00,Health Care Sector,J01.576.489
21871260,2011-09-01T00:00:00,Health Care Sector,N03.219.650
21871260,2011-09-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21871260,2011-09-01T00:00:00,Referral and Consultation,N04.452.758.849
21871260,2011-09-01T00:00:00,United States,Z01.107.567.875
21871283,2011-09-01T00:00:00,Aprotinin,D12.776.083
21871283,2011-09-01T00:00:00,Cardiac Surgical Procedures,E04.100.376
21871283,2011-09-01T00:00:00,Cardiac Surgical Procedures,E04.928.220
21871283,2011-09-01T00:00:00,"Heart Defects, Congenital",C14.240.400
21871283,2011-09-01T00:00:00,"Heart Defects, Congenital",C14.280.400
21871283,2011-09-01T00:00:00,"Heart Defects, Congenital",C16.131.240.400
21871283,2011-09-01T00:00:00,Hospital Mortality,E05.318.308.985.550.400
21871283,2011-09-01T00:00:00,Hospital Mortality,L01.280.975.550.400
21871283,2011-09-01T00:00:00,Hospital Mortality,N01.224.935.698.400
21871283,2011-09-01T00:00:00,Hospital Mortality,N06.850.505.400.975.550.400
21871283,2011-09-01T00:00:00,Hospital Mortality,N06.850.520.308.985.550.400
21871283,2011-09-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21871283,2011-09-01T00:00:00,"Infant, Newborn",M01.060.703.520
21871283,2011-09-01T00:00:00,"Intensive Care Units, Neonatal",N02.278.388.493.390.380
21871283,2011-09-01T00:00:00,Length of Stay,E02.760.400.480
21871283,2011-09-01T00:00:00,Length of Stay,N02.421.585.400.480
21871283,2011-09-01T00:00:00,Treatment Outcome,E01.789.800
21871283,2011-09-01T00:00:00,Treatment Outcome,N04.761.559.590.800
21871283,2011-09-01T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21872107,2011-09-01T00:00:00,Bias (Epidemiology),N05.715.350.150
21872107,2011-09-01T00:00:00,Bias (Epidemiology),N06.850.490.500
21872107,2011-09-01T00:00:00,Conflict of Interest,K01.316.130
21872107,2011-09-01T00:00:00,Conflict of Interest,N05.350.225
21872107,2011-09-01T00:00:00,Cooperative Behavior,F01.145.813.115
21872107,2011-09-01T00:00:00,Diffusion of Innovation,L01.143.320
21872107,2011-09-01T00:00:00,Health Care Sector,J01.576.489
21872107,2011-09-01T00:00:00,Health Care Sector,N03.219.650
21872107,2011-09-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21872107,2011-09-01T00:00:00,Interprofessional Relations,F01.829.401.205
21872107,2011-09-01T00:00:00,Leadership,F01.752.609
21872107,2011-09-01T00:00:00,Scientific Misconduct,K01.316.768.500
21872107,2011-09-01T00:00:00,Vascular Surgical Procedures,E04.100.814
21877965,2011-09-01T00:00:00,Conflict of Interest,K01.316.130
21877965,2011-09-01T00:00:00,Conflict of Interest,N05.350.225
21877965,2011-09-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21877965,2011-09-01T00:00:00,Interprofessional Relations,F01.829.401.205
21877965,2011-09-01T00:00:00,Physician-Patient Relations,F01.829.401.650.675
21877965,2011-09-01T00:00:00,Physician-Patient Relations,N05.300.660.625
21878585,2011-09-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21878585,2011-09-01T00:00:00,Virology,H01.158.273.540.859
21881018,2011-09-01T00:00:00,Amino Acids,D12.125
21881018,2011-09-01T00:00:00,Critical Care,E02.760.190
21881018,2011-09-01T00:00:00,Critical Care,N02.421.585.190
21881018,2011-09-01T00:00:00,Dietary Carbohydrates,D09.301
21881018,2011-09-01T00:00:00,Dietary Carbohydrates,J02.500.362
21881018,2011-09-01T00:00:00,Dietary Fats,D10.212.302
21881018,2011-09-01T00:00:00,Dietary Fats,J02.500.375
21881018,2011-09-01T00:00:00,Dietary Proteins,D12.776.256
21881018,2011-09-01T00:00:00,Dietary Proteins,J02.500.428
21881018,2011-09-01T00:00:00,Energy Intake,G07.610.240.340
21881018,2011-09-01T00:00:00,Guidelines as Topic,N04.761.700.350
21881018,2011-09-01T00:00:00,Guidelines as Topic,N05.700.350
21881018,2011-09-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21881018,2011-09-01T00:00:00,Intensive Care Units,N02.278.388.493
21881018,2011-09-01T00:00:00,Obesity,C18.654.726.500
21881018,2011-09-01T00:00:00,Obesity,C23.888.144.699.500
21881018,2011-09-01T00:00:00,Obesity,E01.370.600.115.100.160.120.699.500
21881018,2011-09-01T00:00:00,Obesity,G07.100.100.160.120.699.500
21881018,2011-09-01T00:00:00,Pharmaceutical Preparations,D26
21881019,2011-09-01T00:00:00,Bariatric Surgery,E02.065.062
21881019,2011-09-01T00:00:00,Bariatric Surgery,E04.062
21881019,2011-09-01T00:00:00,Body Mass Index,E01.370.600.115.100.125
21881019,2011-09-01T00:00:00,Body Mass Index,E05.041.124.125
21881019,2011-09-01T00:00:00,Body Mass Index,G07.100.100.125
21881019,2011-09-01T00:00:00,Body Mass Index,N06.850.505.200.100.175
21881019,2011-09-01T00:00:00,Critical Care,E02.760.190
21881019,2011-09-01T00:00:00,Critical Care,N02.421.585.190
21881019,2011-09-01T00:00:00,Critical Illness,C23.550.291.625
21881019,2011-09-01T00:00:00,Enteral Nutrition,E02.421.360
21881019,2011-09-01T00:00:00,Enteral Nutrition,E02.642.500.360
21881019,2011-09-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21881019,2011-09-01T00:00:00,Intensive Care Units,N02.278.388.493
21881019,2011-09-01T00:00:00,Obesity,C18.654.726.500
21881019,2011-09-01T00:00:00,Obesity,C23.888.144.699.500
21881019,2011-09-01T00:00:00,Obesity,E01.370.600.115.100.160.120.699.500
21881019,2011-09-01T00:00:00,Obesity,G07.100.100.160.120.699.500
21881019,2011-09-01T00:00:00,Practice Guidelines as Topic,N04.761.700.350.650
21881019,2011-09-01T00:00:00,Practice Guidelines as Topic,N05.700.350.650
21881019,2011-09-01T00:00:00,Risk Factors,E05.318.740.600.800.725
21881019,2011-09-01T00:00:00,Risk Factors,N05.715.350.200.700
21881019,2011-09-01T00:00:00,Risk Factors,N05.715.360.750.625.700.700
21881019,2011-09-01T00:00:00,Risk Factors,N06.850.490.625.750
21881019,2011-09-01T00:00:00,Risk Factors,N06.850.520.830.600.800.725
21881019,2011-09-01T00:00:00,Treatment Outcome,E01.789.800
21881019,2011-09-01T00:00:00,Treatment Outcome,N04.761.559.590.800
21881019,2011-09-01T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21881476,2011-09-01T00:00:00,Adult,M01.060.116
21881476,2011-09-01T00:00:00,Central Nervous System Diseases,C10.228
21881476,2011-09-01T00:00:00,Cerebral Hemorrhage,C10.228.140.300.535.200
21881476,2011-09-01T00:00:00,Cerebral Hemorrhage,C14.907.253.573.200
21881476,2011-09-01T00:00:00,Cerebral Hemorrhage,C23.550.414.913.100
21881476,2011-09-01T00:00:00,Diagnostic Imaging,E01.370.350
21881476,2011-09-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21881476,2011-09-01T00:00:00,Sarcoidosis,C15.604.515.827
21882094,2011-09-01T00:00:00,Central Nervous System Neoplasms,C04.588.614.250
21882094,2011-09-01T00:00:00,Central Nervous System Neoplasms,C10.551.240
21882094,2011-09-01T00:00:00,Dexamethasone,D04.808.745.432.769.344
21882094,2011-09-01T00:00:00,Dexamethasone,D04.808.908.238
21882094,2011-09-01T00:00:00,Glucocorticoids,D06.472.040.543
21882094,2011-09-01T00:00:00,Glucocorticoids,D27.505.696.399.472.488
21882094,2011-09-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21882094,2011-09-01T00:00:00,Magnetic Resonance Imaging,E01.370.350.500
21882094,2011-09-01T00:00:00,Magnetic Resonance Imaging,E01.370.350.825.500
21882094,2011-09-01T00:00:00,Middle Aged,M01.060.116.630
21882094,2011-09-01T00:00:00,Multiple Myeloma,C04.557.595.500
21882094,2011-09-01T00:00:00,Multiple Myeloma,C14.907.454.460
21882094,2011-09-01T00:00:00,Multiple Myeloma,C15.378.147.780.650
21882094,2011-09-01T00:00:00,Multiple Myeloma,C15.378.463.835.460
21882094,2011-09-01T00:00:00,Multiple Myeloma,C20.683.515.845
21882094,2011-09-01T00:00:00,Multiple Myeloma,C20.683.780.650
21882094,2011-09-01T00:00:00,Optic Nerve Diseases,C10.292.700
21882094,2011-09-01T00:00:00,Optic Nerve Diseases,C11.640
21882094,2011-09-01T00:00:00,Prednisone,D04.808.745.432.719.702
21882094,2011-09-01T00:00:00,Spinal Cord Compression,C10.228.854.761
21882094,2011-09-01T00:00:00,Spinal Cord Compression,C21.866.819.678
21882094,2011-09-01T00:00:00,Spinal Puncture,E01.370.376.700
21882094,2011-09-01T00:00:00,Spinal Puncture,E01.450.230.700
21882094,2011-09-01T00:00:00,Spinal Puncture,E01.450.865.632.700
21885717,2011-09-01T00:00:00,Adult,M01.060.116
21885717,2011-09-01T00:00:00,Brain,A08.186.211
21885717,2011-09-01T00:00:00,Brain Injuries,C10.228.140.199
21885717,2011-09-01T00:00:00,Brain Injuries,C10.900.300.087
21885717,2011-09-01T00:00:00,Brain Injuries,C21.866.260.118
21885717,2011-09-01T00:00:00,Brain Injuries,C21.866.915.300.200
21885717,2011-09-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21885717,2011-09-01T00:00:00,Iron,D01.268.556.412
21885717,2011-09-01T00:00:00,Iron,D01.268.956.287
21885717,2011-09-01T00:00:00,Iron,D01.552.544.412
21885717,2011-09-01T00:00:00,Magnetic Resonance Imaging,E01.370.350.500
21885717,2011-09-01T00:00:00,Magnetic Resonance Imaging,E01.370.350.825.500
21885717,2011-09-01T00:00:00,Magnetic Resonance Spectroscopy,E05.196.867.519
21885787,2011-09-01T00:00:00,Aged,M01.060.116.100
21885787,2011-09-01T00:00:00,Biological Markers,D23.101
21885787,2011-09-01T00:00:00,Chronic Disease,C23.550.291.500
21885787,2011-09-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21885787,2011-09-01T00:00:00,Kidney Diseases,C12.777.419
21885787,2011-09-01T00:00:00,Kidney Diseases,C13.351.968.419
21885787,2011-09-01T00:00:00,Middle Aged,M01.060.116.630
21885787,2011-09-01T00:00:00,Risk Assessment,E05.318.740.600.800.715
21885787,2011-09-01T00:00:00,Risk Assessment,N04.452.871.715
21885787,2011-09-01T00:00:00,Risk Assessment,N05.715.360.750.625.700.690
21885787,2011-09-01T00:00:00,Risk Assessment,N06.850.505.715
21885787,2011-09-01T00:00:00,Risk Assessment,N06.850.520.830.600.800.715
21885787,2011-09-01T00:00:00,Risk Factors,E05.318.740.600.800.725
21885787,2011-09-01T00:00:00,Risk Factors,N05.715.350.200.700
21885787,2011-09-01T00:00:00,Risk Factors,N05.715.360.750.625.700.700
21885787,2011-09-01T00:00:00,Risk Factors,N06.850.490.625.750
21885787,2011-09-01T00:00:00,Risk Factors,N06.850.520.830.600.800.725
21885787,2011-09-01T00:00:00,Time Factors,G01.910.857
21885839,2011-09-01T00:00:00,Adult,M01.060.116
21885839,2011-09-01T00:00:00,Age Factors,N05.715.350.075
21885839,2011-09-01T00:00:00,Age Factors,N06.850.490.250
21885839,2011-09-01T00:00:00,Hospitalization,E02.760.400
21885839,2011-09-01T00:00:00,Hospitalization,N02.421.585.400
21885839,2011-09-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21885839,2011-09-01T00:00:00,Middle Aged,M01.060.116.630
21885839,2011-09-01T00:00:00,Patient Discharge,E02.760.400.610
21885839,2011-09-01T00:00:00,Patient Discharge,N02.421.585.400.610
21885839,2011-09-01T00:00:00,Sex Factors,N05.715.350.675
21885839,2011-09-01T00:00:00,Sex Factors,N06.850.490.875
21885839,2011-09-01T00:00:00,Stroke,C10.228.140.300.775
21885839,2011-09-01T00:00:00,Stroke,C14.907.253.855
21885839,2011-09-01T00:00:00,United States,Z01.107.567.875
21887713,2011-09-01T00:00:00,Adult,M01.060.116
21887713,2011-09-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21887713,2011-09-01T00:00:00,Military Personnel,M01.526.625
21887713,2011-09-01T00:00:00,Spouses,F01.829.263.500.660
21887713,2011-09-01T00:00:00,Spouses,I01.880.225.500.670
21887713,2011-09-01T00:00:00,Spouses,M01.816
21887713,2011-09-01T00:00:00,Writing,L01.143.506.423.906
21888817,2011-09-01T00:00:00,Adolescent,M01.060.057
21888817,2011-09-01T00:00:00,Carrier State,N06.850.160
21888817,2011-09-01T00:00:00,England,Z01.542.363.300
21888817,2011-09-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21888817,2011-09-01T00:00:00,Meningococcal Infections,C01.252.400.625.549
21888817,2011-09-01T00:00:00,Population Surveillance,E05.318.308.250.700
21888817,2011-09-01T00:00:00,Population Surveillance,N05.715.360.300.375.625
21888817,2011-09-01T00:00:00,Population Surveillance,N06.850.520.308.250.700
21888817,2011-09-01T00:00:00,Population Surveillance,N06.850.780.675
21888817,2011-09-01T00:00:00,Students,I02.233.748
21888817,2011-09-01T00:00:00,Students,I02.851
21888817,2011-09-01T00:00:00,Students,M01.848
21888817,2011-09-01T00:00:00,Young Adult,M01.060.116.815
21894044,2011-09-01T00:00:00,Aged,M01.060.116.100
21894044,2011-09-01T00:00:00,Brain Ischemia,C10.228.140.300.150
21894044,2011-09-01T00:00:00,Brain Ischemia,C14.907.253.092
21894044,2011-09-01T00:00:00,Double-Blind Method,E05.318.780.300
21894044,2011-09-01T00:00:00,Double-Blind Method,E05.581.500.300
21894044,2011-09-01T00:00:00,Double-Blind Method,N05.715.360.780.320
21894044,2011-09-01T00:00:00,Double-Blind Method,N06.850.520.445.300
21894044,2011-09-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21894044,2011-09-01T00:00:00,Middle Aged,M01.060.116.630
21894044,2011-09-01T00:00:00,Regression Analysis,E05.318.740.750
21894044,2011-09-01T00:00:00,Regression Analysis,N05.715.360.750.695
21894044,2011-09-01T00:00:00,Regression Analysis,N06.850.520.830.750
21894044,2011-09-01T00:00:00,Stroke,C10.228.140.300.775
21894044,2011-09-01T00:00:00,Stroke,C14.907.253.855
21894044,2011-09-01T00:00:00,Stroke Volume,E01.370.370.380.150.700
21894044,2011-09-01T00:00:00,Stroke Volume,G09.330.380.124.882
21894044,2011-09-01T00:00:00,Tissue Plasminogen Activator,D08.811.277.656.300.760.875
21894044,2011-09-01T00:00:00,Tissue Plasminogen Activator,D08.811.277.656.959.350.875
21894044,2011-09-01T00:00:00,Tissue Plasminogen Activator,D12.776.124.125.662.768
21894044,2011-09-01T00:00:00,Tissue Plasminogen Activator,D23.119.970
21894044,2011-09-01T00:00:00,United States,Z01.107.567.875
21899536,2011-09-01T00:00:00,Cost of Illness,I01.137
21899536,2011-09-01T00:00:00,Cost of Illness,N03.219.151.165
21899536,2011-09-01T00:00:00,Epilepsy,C10.228.140.490
21899536,2011-09-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21899536,2011-09-01T00:00:00,Population Surveillance,E05.318.308.250.700
21899536,2011-09-01T00:00:00,Population Surveillance,N05.715.360.300.375.625
21899536,2011-09-01T00:00:00,Population Surveillance,N06.850.520.308.250.700
21899536,2011-09-01T00:00:00,Population Surveillance,N06.850.780.675
21899536,2011-09-01T00:00:00,Quality of Life,I01.800
21899536,2011-09-01T00:00:00,Quality of Life,K01.752.400.750
21907058,2011-09-01T00:00:00,Age Factors,N05.715.350.075
21907058,2011-09-01T00:00:00,Age Factors,N06.850.490.250
21907058,2011-09-01T00:00:00,Aged,M01.060.116.100
21907058,2011-09-01T00:00:00,"Analgesics, Opioid",D27.505.696.663.850.014.520
21907058,2011-09-01T00:00:00,"Analgesics, Opioid",D27.505.954.427.040.325
21907058,2011-09-01T00:00:00,"Analgesics, Opioid",D27.505.954.427.210.049
21907058,2011-09-01T00:00:00,Antipsychotic Agents,D27.505.696.277.950.040
21907058,2011-09-01T00:00:00,Antipsychotic Agents,D27.505.954.427.210.950.040
21907058,2011-09-01T00:00:00,Antipsychotic Agents,D27.505.954.427.700.872.331
21907058,2011-09-01T00:00:00,"Arthroplasty, Replacement",E04.555.110.110
21907058,2011-09-01T00:00:00,"Arthroplasty, Replacement",E04.650.110
21907058,2011-09-01T00:00:00,Delirium,C10.597.606.337.500
21907058,2011-09-01T00:00:00,Delirium,C23.888.592.604.339.500
21907058,2011-09-01T00:00:00,Delirium,F01.700.250.500
21907058,2011-09-01T00:00:00,Delirium,F03.087.350
21907058,2011-09-01T00:00:00,Double-Blind Method,E05.318.780.300
21907058,2011-09-01T00:00:00,Double-Blind Method,E05.581.500.300
21907058,2011-09-01T00:00:00,Double-Blind Method,N05.715.360.780.320
21907058,2011-09-01T00:00:00,Double-Blind Method,N06.850.520.445.300
21907058,2011-09-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21907058,2011-09-01T00:00:00,Morphine,D03.132.577.249.547
21907058,2011-09-01T00:00:00,Morphine,D03.549.686.575
21907058,2011-09-01T00:00:00,Morphine,D03.605.497.575
21907058,2011-09-01T00:00:00,Morphine,D04.615.723.795.547
21907058,2011-09-01T00:00:00,Postoperative Complications,C23.550.767
21907058,2011-09-01T00:00:00,Risk Factors,E05.318.740.600.800.725
21907058,2011-09-01T00:00:00,Risk Factors,N05.715.350.200.700
21907058,2011-09-01T00:00:00,Risk Factors,N05.715.360.750.625.700.700
21907058,2011-09-01T00:00:00,Risk Factors,N06.850.490.625.750
21907058,2011-09-01T00:00:00,Risk Factors,N06.850.520.830.600.800.725
21908994,2011-09-01T00:00:00,Adolescent,M01.060.057
21908994,2011-09-01T00:00:00,Adult,M01.060.116
21908994,2011-09-01T00:00:00,Age Factors,N05.715.350.075
21908994,2011-09-01T00:00:00,Age Factors,N06.850.490.250
21908994,2011-09-01T00:00:00,Brain Injuries,C10.228.140.199
21908994,2011-09-01T00:00:00,Brain Injuries,C10.900.300.087
21908994,2011-09-01T00:00:00,Brain Injuries,C21.866.260.118
21908994,2011-09-01T00:00:00,Brain Injuries,C21.866.915.300.200
21908994,2011-09-01T00:00:00,Child,M01.060.406
21908994,2011-09-01T00:00:00,"Child, Preschool",M01.060.406.448
21908994,2011-09-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21908994,2011-09-01T00:00:00,Infant,M01.060.703
21908994,2011-09-01T00:00:00,Risk Factors,E05.318.740.600.800.725
21908994,2011-09-01T00:00:00,Risk Factors,N05.715.350.200.700
21908994,2011-09-01T00:00:00,Risk Factors,N05.715.360.750.625.700.700
21908994,2011-09-01T00:00:00,Risk Factors,N06.850.490.625.750
21908994,2011-09-01T00:00:00,Risk Factors,N06.850.520.830.600.800.725
21908994,2011-09-01T00:00:00,Trauma Centers,N02.278.354.422.336.500
21908994,2011-09-01T00:00:00,Trauma Centers,N02.421.297.195.480
21908994,2011-09-01T00:00:00,Trauma Centers,N04.452.442.422.336.400
21908994,2011-09-01T00:00:00,"Wounds, Nonpenetrating",C21.866.974
21923590,2011-09-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21923590,2011-09-01T00:00:00,Patient Education as Topic,I02.233.332.500
21923590,2011-09-01T00:00:00,Patient Education as Topic,N02.421.143.827.407.680
21923590,2011-09-01T00:00:00,Patient Education as Topic,N02.421.726.407.680
21926891,2011-09-01T00:00:00,Adolescent,M01.060.057
21926891,2011-09-01T00:00:00,Anti-Bacterial Agents,D27.505.954.122.085
21926891,2011-09-01T00:00:00,Anticoagulants,D27.505.954.502.119
21926891,2011-09-01T00:00:00,Child,M01.060.406
21926891,2011-09-01T00:00:00,"Child, Preschool",M01.060.406.448
21926891,2011-09-01T00:00:00,Combined Modality Therapy,E02.186
21926891,2011-09-01T00:00:00,Fluid Therapy,E02.319.360
21926891,2011-09-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21926891,2011-09-01T00:00:00,Incidence,E05.318.308.985.525.375
21926891,2011-09-01T00:00:00,Incidence,L01.280.975.525.375
21926891,2011-09-01T00:00:00,Incidence,N01.224.935.597.500
21926891,2011-09-01T00:00:00,Incidence,N06.850.505.400.975.525.375
21926891,2011-09-01T00:00:00,Incidence,N06.850.520.308.985.525.375
21926891,2011-09-01T00:00:00,Infant,M01.060.703
21926891,2011-09-01T00:00:00,"Infant, Newborn",M01.060.703.520
21926891,2011-09-01T00:00:00,Otitis Media,C09.218.705.663
21926891,2011-09-01T00:00:00,South Carolina,Z01.107.567.875.075.662
21926891,2011-09-01T00:00:00,South Carolina,Z01.107.567.875.750.700
21926891,2011-09-01T00:00:00,Thrombectomy,E04.100.814.842
21929986,2011-09-01T00:00:00,Adolescent,M01.060.057
21929986,2011-09-01T00:00:00,Child,M01.060.406
21929986,2011-09-01T00:00:00,"Child, Preschool",M01.060.406.448
21929986,2011-09-01T00:00:00,"Coated Materials, Biocompatible",D25.130.420
21929986,2011-09-01T00:00:00,"Coated Materials, Biocompatible",J01.637.051.130.420
21929986,2011-09-01T00:00:00,Collagen,D05.750.078.280
21929986,2011-09-01T00:00:00,Collagen,D12.776.860.300.250
21929986,2011-09-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21929986,2011-09-01T00:00:00,Infant,M01.060.703
21929986,2011-09-01T00:00:00,Occlusive Dressings,E07.101.650
21929986,2011-09-01T00:00:00,Wound Healing,G16.100.856.891
21929986,2011-09-01T00:00:00,beta-Glucans,D09.698.365.089
21929991,2011-09-01T00:00:00,"Abnormalities, Multiple",C16.131.077
21929991,2011-09-01T00:00:00,Bladder Exstrophy,C12.706.132
21929991,2011-09-01T00:00:00,Bladder Exstrophy,C12.777.829.132
21929991,2011-09-01T00:00:00,Bladder Exstrophy,C13.351.875.132
21929991,2011-09-01T00:00:00,Bladder Exstrophy,C13.351.968.829.132
21929991,2011-09-01T00:00:00,Bladder Exstrophy,C16.131.939.132
21929991,2011-09-01T00:00:00,Colon,A03.556.124.526.356
21929991,2011-09-01T00:00:00,Colon,A03.556.249.249.356
21929991,2011-09-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21929991,2011-09-01T00:00:00,"Infant, Newborn",M01.060.703.520
21934376,2011-09-01T00:00:00,Adult,M01.060.116
21934376,2011-09-01T00:00:00,Exercise Therapy,E02.779.483
21934376,2011-09-01T00:00:00,Exercise Therapy,E02.831.387
21934376,2011-09-01T00:00:00,Gait,E01.370.600.250
21934376,2011-09-01T00:00:00,Gait,G11.427.590.530.389
21934376,2011-09-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21934376,2011-09-01T00:00:00,Middle Aged,M01.060.116.630
21934376,2011-09-01T00:00:00,Motor Activity,F01.145.632
21934376,2011-09-01T00:00:00,Motor Activity,G11.427.590.530.698
21934376,2011-09-01T00:00:00,Parkinson Disease,C10.228.140.079.862.500
21934376,2011-09-01T00:00:00,Parkinson Disease,C10.228.662.600.400
21934376,2011-09-01T00:00:00,Parkinson Disease,C10.574.812
21934376,2011-09-01T00:00:00,Postural Balance,G11.427.690
21934376,2011-09-01T00:00:00,Postural Balance,G11.561.600.810.541.595
21934376,2011-09-01T00:00:00,Spinal Cord Injuries,C10.228.854.770
21934376,2011-09-01T00:00:00,Spinal Cord Injuries,C10.900.850
21934376,2011-09-01T00:00:00,Spinal Cord Injuries,C21.866.819
21934376,2011-09-01T00:00:00,Stroke,C10.228.140.300.775
21934376,2011-09-01T00:00:00,Stroke,C14.907.253.855
21934376,2011-09-01T00:00:00,Treatment Outcome,E01.789.800
21934376,2011-09-01T00:00:00,Treatment Outcome,N04.761.559.590.800
21934376,2011-09-01T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21934376,2011-09-01T00:00:00,Walking,G11.427.590.530.568.900
21934376,2011-09-01T00:00:00,Walking,G11.427.590.530.698.940
21934376,2011-09-01T00:00:00,Walking,I03.450.642.845.940
21938688,2011-09-01T00:00:00,Adolescent,M01.060.057
21938688,2011-09-01T00:00:00,Adult,M01.060.116
21938688,2011-09-01T00:00:00,Aged,M01.060.116.100
21938688,2011-09-01T00:00:00,Child,M01.060.406
21938688,2011-09-01T00:00:00,"Child, Preschool",M01.060.406.448
21938688,2011-09-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21938688,2011-09-01T00:00:00,Middle Aged,M01.060.116.630
21938688,2011-09-01T00:00:00,Young Adult,M01.060.116.815
21944617,2011-09-01T00:00:00,Biomedical Research,H01.770.644.145
21944617,2011-09-01T00:00:00,"Education, Medical",I02.358.399
21944617,2011-09-01T00:00:00,General Surgery,H02.403.810.300
21944617,2011-09-01T00:00:00,"History, 20th Century",K01.400.504.968
21944617,2011-09-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21944617,2011-09-01T00:00:00,United States,Z01.107.567.875
21970646,2011-09-01T00:00:00,Child,M01.060.406
21970646,2011-09-01T00:00:00,"Child Abuse, Sexual",I01.198.240.748.300
21970646,2011-09-01T00:00:00,"Child Abuse, Sexual",I01.198.240.856.350.250.255
21970646,2011-09-01T00:00:00,"Child Abuse, Sexual",I01.880.735.900.350.250.255
21970646,2011-09-01T00:00:00,"Child Abuse, Sexual",I01.880.787.293.292.325
21970646,2011-09-01T00:00:00,Child Behavior Disorders,F03.550.300
21970646,2011-09-01T00:00:00,Child Development,F01.525.200
21970646,2011-09-01T00:00:00,Child Development,G07.700.320.374.750
21970646,2011-09-01T00:00:00,Child Health Services,N02.421.143.130
21970646,2011-09-01T00:00:00,Child Welfare,I01.880.787.293
21970646,2011-09-01T00:00:00,Crime Victims,M01.135
21970646,2011-09-01T00:00:00,Forensic Medicine,H02.403.330
21970646,2011-09-01T00:00:00,Forensic Medicine,I01.198.780.937
21970646,2011-09-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21970646,2011-09-01T00:00:00,Mental Disorders,F03
21970646,2011-09-01T00:00:00,Pediatrics,H02.403.670
21970646,2011-09-01T00:00:00,Professional-Patient Relations,F01.829.401.650
21970646,2011-09-01T00:00:00,Professional-Patient Relations,N05.300.660
21970646,2011-09-01T00:00:00,"Stress Disorders, Post-Traumatic",F03.080.931.500
21970646,2011-09-01T00:00:00,United States,Z01.107.567.875
21979404,2011-09-01T00:00:00,Aged,M01.060.116.100
21979404,2011-09-01T00:00:00,Emergencies,C23.550.291.781
21979404,2011-09-01T00:00:00,Emergencies,N06.230.100.083
21979404,2011-09-01T00:00:00,Emergencies,N06.850.376
21979404,2011-09-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21979404,2011-09-01T00:00:00,Life Change Events,F01.829.458.410
21979404,2011-09-01T00:00:00,Risk Assessment,E05.318.740.600.800.715
21979404,2011-09-01T00:00:00,Risk Assessment,N04.452.871.715
21979404,2011-09-01T00:00:00,Risk Assessment,N05.715.360.750.625.700.690
21979404,2011-09-01T00:00:00,Risk Assessment,N06.850.505.715
21979404,2011-09-01T00:00:00,Risk Assessment,N06.850.520.830.600.800.715
21979404,2011-09-01T00:00:00,Stroke,C10.228.140.300.775
21979404,2011-09-01T00:00:00,Stroke,C14.907.253.855
21979404,2011-09-01T00:00:00,Travel,I03.883
21996798,2011-09-01T00:00:00,Adult,M01.060.116
21996798,2011-09-01T00:00:00,Electric Stimulation,E05.723.402
21996798,2011-09-01T00:00:00,Electric Stimulation Therapy,E02.342
21996798,2011-09-01T00:00:00,Electric Stimulation Therapy,E02.779.468
21996798,2011-09-01T00:00:00,"Feedback, Physiological",G07.700.360.732
21996798,2011-09-01T00:00:00,"Feedback, Physiological",L01.143.283.425.311
21996798,2011-09-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21996798,2011-09-01T00:00:00,Muscle Contraction,G11.427.590.540
21996798,2011-09-01T00:00:00,Muscle Fatigue,G11.427.550
21996798,2011-09-01T00:00:00,Quadriceps Muscle,A02.633.567.850
21996798,2011-09-01T00:00:00,Task Performance and Analysis,F02.784.412.846
21996798,2011-09-01T00:00:00,Task Performance and Analysis,F02.784.692.746
21996798,2011-09-01T00:00:00,Task Performance and Analysis,F02.808.600
21996798,2011-09-01T00:00:00,Time Factors,G01.910.857
22364057,2011-09-01T00:00:00,Adult,M01.060.116
22364057,2011-09-01T00:00:00,African Americans,M01.686.508.100.100
22364057,2011-09-01T00:00:00,African Americans,M01.686.754.100
22364057,2011-09-01T00:00:00,Attitude to Health,F01.100.150
22364057,2011-09-01T00:00:00,Attitude to Health,N05.300.150
22364057,2011-09-01T00:00:00,European Continental Ancestry Group,M01.686.508.400
22364057,2011-09-01T00:00:00,Hispanic Americans,M01.686.754.441
22364057,2011-09-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22364057,2011-09-01T00:00:00,Middle Aged,M01.060.116.630
22364057,2011-09-01T00:00:00,Smoking,F01.145.466.753
22416511,2011-09-01T00:00:00,Diabetic Retinopathy,C11.768.257
22416511,2011-09-01T00:00:00,Diabetic Retinopathy,C14.907.320.382
22416511,2011-09-01T00:00:00,Diabetic Retinopathy,C19.246.099.500.382
22416511,2011-09-01T00:00:00,Health Promotion,N02.370
22416511,2011-09-01T00:00:00,Health Promotion,N02.421.726.507
22416511,2011-09-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22416511,2011-09-01T00:00:00,Mass Screening,E01.370.500
22416511,2011-09-01T00:00:00,Mass Screening,E05.318.308.250.580
22416511,2011-09-01T00:00:00,Mass Screening,N02.421.143.827.233.443
22416511,2011-09-01T00:00:00,Mass Screening,N02.421.726.233.443
22416511,2011-09-01T00:00:00,Mass Screening,N05.715.360.300.375.500
22416511,2011-09-01T00:00:00,Mass Screening,N06.850.520.308.250.580
22416511,2011-09-01T00:00:00,Mass Screening,N06.850.780.500
22416511,2011-09-01T00:00:00,Middle Aged,M01.060.116.630
22416511,2011-09-01T00:00:00,United States,Z01.107.567.875
21898711,2011-09-02T00:00:00,Adult,M01.060.116
21898711,2011-09-02T00:00:00,Aged,M01.060.116.100
21898711,2011-09-02T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21898711,2011-09-02T00:00:00,Middle Aged,M01.060.116.630
21898711,2011-09-02T00:00:00,Prefrontal Cortex,A08.186.211.730.885.287.500.270.700
21898711,2011-09-02T00:00:00,Psychiatric Status Rating Scales,F04.586
21898711,2011-09-02T00:00:00,Time Factors,G01.910.857
21898711,2011-09-02T00:00:00,Transcranial Magnetic Stimulation,E01.370.376.850
21898711,2011-09-02T00:00:00,Transcranial Magnetic Stimulation,E02.621.820
21898711,2011-09-02T00:00:00,Treatment Outcome,E01.789.800
21898711,2011-09-02T00:00:00,Treatment Outcome,N04.761.559.590.800
21898711,2011-09-02T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21898711,2011-09-02T00:00:00,Young Adult,M01.060.116.815
21890282,2011-09-03T00:00:00,Adult,M01.060.116
21890282,2011-09-03T00:00:00,Cocaine-Related Disorders,C21.739.300
21890282,2011-09-03T00:00:00,Cocaine-Related Disorders,F03.900.300
21890282,2011-09-03T00:00:00,Cognition,F02.463.188
21890282,2011-09-03T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21890282,2011-09-03T00:00:00,Questionnaires,E05.318.308.750
21890282,2011-09-03T00:00:00,Questionnaires,L01.280.800
21890282,2011-09-03T00:00:00,Questionnaires,N05.715.360.300.695
21890282,2011-09-03T00:00:00,Questionnaires,N06.850.520.308.750
21891797,2011-09-04T00:00:00,ATP-Binding Cassette Transporters,D12.776.157.530.100
21891797,2011-09-04T00:00:00,ATP-Binding Cassette Transporters,D12.776.395.550.020
21891797,2011-09-04T00:00:00,ATP-Binding Cassette Transporters,D12.776.543.550.192
21891797,2011-09-04T00:00:00,ATP-Binding Cassette Transporters,D12.776.543.585.100
21891797,2011-09-04T00:00:00,Adrenoleukodystrophy,C10.228.140.163.100.680.100
21891797,2011-09-04T00:00:00,Adrenoleukodystrophy,C10.314.400.250
21891797,2011-09-04T00:00:00,Adrenoleukodystrophy,C10.597.606.643.455.124
21891797,2011-09-04T00:00:00,Adrenoleukodystrophy,C16.320.322.500.124
21891797,2011-09-04T00:00:00,Adrenoleukodystrophy,C16.320.400.525.124
21891797,2011-09-04T00:00:00,Adrenoleukodystrophy,C16.320.565.189.680.100
21891797,2011-09-04T00:00:00,Adrenoleukodystrophy,C16.320.565.663.112
21891797,2011-09-04T00:00:00,Adrenoleukodystrophy,C18.452.132.100.680.100
21891797,2011-09-04T00:00:00,Adrenoleukodystrophy,C18.452.648.189.680.100
21891797,2011-09-04T00:00:00,Adrenoleukodystrophy,C18.452.648.663.112
21891797,2011-09-04T00:00:00,Adrenoleukodystrophy,C19.053.500.270
21891797,2011-09-04T00:00:00,Animals,B01.050
21891797,2011-09-04T00:00:00,Astrocytes,A08.637.200
21891797,2011-09-04T00:00:00,Astrocytes,A11.650.200
21891797,2011-09-04T00:00:00,Blood-Brain Barrier,A07.035
21891797,2011-09-04T00:00:00,Blood-Brain Barrier,A08.186.211.035
21891797,2011-09-04T00:00:00,Cytokines,D12.644.276.374
21891797,2011-09-04T00:00:00,Cytokines,D12.776.467.374
21891797,2011-09-04T00:00:00,Cytokines,D23.529.374
21891797,2011-09-04T00:00:00,Down-Regulation,G02.111.087.225
21891797,2011-09-04T00:00:00,Down-Regulation,G02.149.115.225
21891797,2011-09-04T00:00:00,Down-Regulation,G05.355.315.200
21891797,2011-09-04T00:00:00,Down-Regulation,G07.690.812.230
21891797,2011-09-04T00:00:00,Down-Regulation,G07.700.680.230
21891797,2011-09-04T00:00:00,Fatty Acids,D10.251
21891797,2011-09-04T00:00:00,Fibroblasts,A11.329.228
21891797,2011-09-04T00:00:00,Fibroblasts,A11.872.228
21891797,2011-09-04T00:00:00,Gene Silencing,G05.355.315.203.374
21891797,2011-09-04T00:00:00,Histone Deacetylase Inhibitors,D27.505.519.389.360
21891797,2011-09-04T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21891797,2011-09-04T00:00:00,Inflammation,C23.550.470
21891797,2011-09-04T00:00:00,Nitric Oxide Synthase Type II,D08.811.682.664.500.772.500
21891797,2011-09-04T00:00:00,Oxidative Stress,G03.495.710
21891797,2011-09-04T00:00:00,Oxidative Stress,G07.700.830.750
21891797,2011-09-04T00:00:00,Peroxisomes,A11.284.430.214.190.500.585.600
21891797,2011-09-04T00:00:00,Peroxisomes,A11.284.430.214.190.875.190.190.755.600
21891797,2011-09-04T00:00:00,"RNA, Messenger",D13.444.735.544
21891797,2011-09-04T00:00:00,Skin,A17.815
21893614,2011-09-05T00:00:00,Age Factors,N05.715.350.075
21893614,2011-09-05T00:00:00,Age Factors,N06.850.490.250
21893614,2011-09-05T00:00:00,"Biopsy, Needle",E01.370.388.100.100
21893614,2011-09-05T00:00:00,"Biopsy, Needle",E01.450.230.100.100
21893614,2011-09-05T00:00:00,"Biopsy, Needle",E01.450.865.100.100
21893614,2011-09-05T00:00:00,"Biopsy, Needle",E01.450.865.632.100
21893614,2011-09-05T00:00:00,"Biopsy, Needle",E04.074.119
21893614,2011-09-05T00:00:00,Early Detection of Cancer,E01.390.500
21893614,2011-09-05T00:00:00,Hemorrhage,C23.550.414
21893614,2011-09-05T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21893614,2011-09-05T00:00:00,Lung Neoplasms,C04.588.894.797.520
21893614,2011-09-05T00:00:00,Lung Neoplasms,C08.381.540
21893614,2011-09-05T00:00:00,Lung Neoplasms,C08.785.520
21893614,2011-09-05T00:00:00,Mass Screening,E01.370.500
21893614,2011-09-05T00:00:00,Mass Screening,E05.318.308.250.580
21893614,2011-09-05T00:00:00,Mass Screening,N02.421.143.827.233.443
21893614,2011-09-05T00:00:00,Mass Screening,N02.421.726.233.443
21893614,2011-09-05T00:00:00,Mass Screening,N05.715.360.300.375.500
21893614,2011-09-05T00:00:00,Mass Screening,N06.850.520.308.250.580
21893614,2011-09-05T00:00:00,Mass Screening,N06.850.780.500
21893614,2011-09-05T00:00:00,Middle Aged,M01.060.116.630
21893614,2011-09-05T00:00:00,Pneumothorax,C08.528.778
21893614,2011-09-05T00:00:00,Radiation Dosage,E05.799.513
21893614,2011-09-05T00:00:00,Radiation Dosage,G01.201.875.740
21893614,2011-09-05T00:00:00,Radiation Dosage,N06.850.810.250
21893614,2011-09-05T00:00:00,Risk Factors,E05.318.740.600.800.725
21893614,2011-09-05T00:00:00,Risk Factors,N05.715.350.200.700
21893614,2011-09-05T00:00:00,Risk Factors,N05.715.360.750.625.700.700
21893614,2011-09-05T00:00:00,Risk Factors,N06.850.490.625.750
21893614,2011-09-05T00:00:00,Risk Factors,N06.850.520.830.600.800.725
21893614,2011-09-05T00:00:00,Smoking,F01.145.466.753
21893614,2011-09-05T00:00:00,"Tomography, X-Ray Computed",E01.370.350.350.810
21893614,2011-09-05T00:00:00,"Tomography, X-Ray Computed",E01.370.350.600.350.700.810
21893614,2011-09-05T00:00:00,"Tomography, X-Ray Computed",E01.370.350.700.700.810
21893614,2011-09-05T00:00:00,"Tomography, X-Ray Computed",E01.370.350.700.810.810
21893614,2011-09-05T00:00:00,"Tomography, X-Ray Computed",E01.370.350.825.810.810
21893614,2011-09-05T00:00:00,United States,Z01.107.567.875
21898522,2011-09-05T00:00:00,Bayes Theorem,E05.318.740.600.200
21898522,2011-09-05T00:00:00,Bayes Theorem,N05.715.360.750.625.150
21898522,2011-09-05T00:00:00,Bayes Theorem,N06.850.520.830.600.200
21898522,2011-09-05T00:00:00,Computer Simulation,L01.224.160
21898522,2011-09-05T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21898522,2011-09-05T00:00:00,Incidence,E05.318.308.985.525.375
21898522,2011-09-05T00:00:00,Incidence,L01.280.975.525.375
21898522,2011-09-05T00:00:00,Incidence,N01.224.935.597.500
21898522,2011-09-05T00:00:00,Incidence,N06.850.505.400.975.525.375
21898522,2011-09-05T00:00:00,Incidence,N06.850.520.308.985.525.375
21898522,2011-09-05T00:00:00,Poisson Distribution,E05.318.740.994.750
21898522,2011-09-05T00:00:00,Poisson Distribution,G17.820.750
21898522,2011-09-05T00:00:00,Poisson Distribution,N05.715.360.750.750.620
21898522,2011-09-05T00:00:00,Poisson Distribution,N06.850.520.830.994.750
21898522,2011-09-05T00:00:00,Population Surveillance,E05.318.308.250.700
21898522,2011-09-05T00:00:00,Population Surveillance,N05.715.360.300.375.625
21898522,2011-09-05T00:00:00,Population Surveillance,N06.850.520.308.250.700
21898522,2011-09-05T00:00:00,Population Surveillance,N06.850.780.675
21898522,2011-09-05T00:00:00,South Carolina,Z01.107.567.875.075.662
21898522,2011-09-05T00:00:00,South Carolina,Z01.107.567.875.750.700
21895723,2011-09-06T00:00:00,Alcoholism,C21.739.100.250
21895723,2011-09-06T00:00:00,Alcoholism,F03.900.100.350
21895723,2011-09-06T00:00:00,Animals,B01.050
21895723,2011-09-06T00:00:00,"Behavior, Addictive",F01.145.527.100.120
21895723,2011-09-06T00:00:00,Clinical Trials as Topic,E05.318.760.535
21895723,2011-09-06T00:00:00,Clinical Trials as Topic,E05.337.250
21895723,2011-09-06T00:00:00,Clinical Trials as Topic,N05.715.360.775.235
21895723,2011-09-06T00:00:00,Clinical Trials as Topic,N06.850.520.450.535
21895723,2011-09-06T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21895723,2011-09-06T00:00:00,Narcotic Antagonists,D27.505.696.543
21895723,2011-09-06T00:00:00,Narcotic Antagonists,D27.505.696.663.850.512
21895723,2011-09-06T00:00:00,Narcotic Antagonists,D27.505.954.427.550
21895723,2011-09-06T00:00:00,"Polymorphism, Single Nucleotide",G05.365.795.598
21897968,2011-09-06T00:00:00,Enzymes,D08.811
21897968,2011-09-06T00:00:00,Light,G01.201.875.770.578
21897968,2011-09-06T00:00:00,Light,G01.590.540
21897968,2011-09-06T00:00:00,Nanoparticles,J01.637.512.600
21897968,2011-09-06T00:00:00,Polymethacrylic Acids,D02.241.081.069.800
21897968,2011-09-06T00:00:00,Polymethacrylic Acids,D05.750.716.822.111.650
21897968,2011-09-06T00:00:00,Polymethacrylic Acids,D25.720.716.822.111.650
21897968,2011-09-06T00:00:00,Polymethacrylic Acids,J01.637.051.720.716.822.111.650
21897968,2011-09-06T00:00:00,Protein Denaturation,G02.111.087.685
21897968,2011-09-06T00:00:00,Protein Denaturation,G02.149.115.685
21897968,2011-09-06T00:00:00,"Scattering, Radiation",E05.196.822
21897968,2011-09-06T00:00:00,"Scattering, Radiation",G01.595.861
21897968,2011-09-06T00:00:00,beta-Galactosidase,D08.811.277.450.410.100
21924388,2011-09-06T00:00:00,Amino Acid Sequence,G02.111.570.060
21924388,2011-09-06T00:00:00,Amino Acid Sequence,L01.453.245.667.060
21924388,2011-09-06T00:00:00,Animals,B01.050
21924388,2011-09-06T00:00:00,Phosphorylation,G02.111.087.677
21924388,2011-09-06T00:00:00,Phosphorylation,G02.149.115.677
21924388,2011-09-06T00:00:00,Phosphorylation,G02.149.465.700
21924388,2011-09-06T00:00:00,Phosphorylation,G02.607.750.700
21924388,2011-09-06T00:00:00,Phosphorylation,G03.495.790
21924388,2011-09-06T00:00:00,Tandem Mass Spectrometry,E05.196.566.880
21924388,2011-09-06T00:00:00,Ubiquitin-Protein Ligases,D08.811.464.938.750
21899409,2011-09-07T00:00:00,Aged,M01.060.116.100
21899409,2011-09-07T00:00:00,Antihypertensive Agents,D27.505.954.411.162
21899409,2011-09-07T00:00:00,Combined Modality Therapy,E02.186
21899409,2011-09-07T00:00:00,Health Behavior,F01.145.488
21899409,2011-09-07T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21899409,2011-09-07T00:00:00,Intracranial Arteriosclerosis,C10.228.140.300.510.800
21899409,2011-09-07T00:00:00,Intracranial Arteriosclerosis,C14.907.137.126.372
21899409,2011-09-07T00:00:00,Intracranial Arteriosclerosis,C14.907.253.560.350
21899409,2011-09-07T00:00:00,Intracranial Hemorrhages,C10.228.140.300.535
21899409,2011-09-07T00:00:00,Intracranial Hemorrhages,C14.907.253.573
21899409,2011-09-07T00:00:00,Intracranial Hemorrhages,C23.550.414.913
21899409,2011-09-07T00:00:00,"Ischemic Attack, Transient",C10.228.140.300.150.836
21899409,2011-09-07T00:00:00,"Ischemic Attack, Transient",C14.907.253.092.836
21899409,2011-09-07T00:00:00,Middle Aged,M01.060.116.630
21899409,2011-09-07T00:00:00,Platelet Aggregation Inhibitors,D27.505.954.502.780
21899409,2011-09-07T00:00:00,Stents,E07.695.750
21899409,2011-09-07T00:00:00,Stroke,C10.228.140.300.775
21899409,2011-09-07T00:00:00,Stroke,C14.907.253.855
21899409,2011-09-07T00:00:00,Ticlopidine,D02.886.778.834
21899409,2011-09-07T00:00:00,Ticlopidine,D03.383.903.834
21900638,2011-09-07T00:00:00,Aged,M01.060.116.100
21900638,2011-09-07T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21900638,2011-09-07T00:00:00,Medication Adherence,F01.145.488.500.500
21900638,2011-09-07T00:00:00,Medication Adherence,N05.300.150.600.600.500
21900638,2011-09-07T00:00:00,Middle Aged,M01.060.116.630
21900638,2011-09-07T00:00:00,Secondary Prevention,N02.421.726.825
21900638,2011-09-07T00:00:00,Secondary Prevention,N06.850.780.750
21900638,2011-09-07T00:00:00,Stroke,C10.228.140.300.775
21900638,2011-09-07T00:00:00,Stroke,C14.907.253.855
21900883,2011-09-07T00:00:00,Alcoholism,C21.739.100.250
21900883,2011-09-07T00:00:00,Alcoholism,F03.900.100.350
21900883,2011-09-07T00:00:00,Clinical Trials as Topic,E05.318.760.535
21900883,2011-09-07T00:00:00,Clinical Trials as Topic,E05.337.250
21900883,2011-09-07T00:00:00,Clinical Trials as Topic,N05.715.360.775.235
21900883,2011-09-07T00:00:00,Clinical Trials as Topic,N06.850.520.450.535
21900883,2011-09-07T00:00:00,Drug Discovery,E05.295
21900883,2011-09-07T00:00:00,Drug Discovery,H01.158.703.007.675
21900883,2011-09-07T00:00:00,Drug Discovery,H01.181.466.675
21900883,2011-09-07T00:00:00,Goals,F01.658.500
21900883,2011-09-07T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21901526,2011-09-07T00:00:00,Animals,B01.050
21901526,2011-09-07T00:00:00,Heart Valve Diseases,C14.280.484
21901526,2011-09-07T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21901526,2011-09-07T00:00:00,Mitral Valve,A07.541.510.507
21903291,2011-09-07T00:00:00,Adult,M01.060.116
21903291,2011-09-07T00:00:00,African Americans,M01.686.508.100.100
21903291,2011-09-07T00:00:00,African Americans,M01.686.754.100
21903291,2011-09-07T00:00:00,Aged,M01.060.116.100
21903291,2011-09-07T00:00:00,Cardiovascular Diseases,C14
21903291,2011-09-07T00:00:00,Diabetes Complications,C19.246.099
21903291,2011-09-07T00:00:00,"Diabetes Mellitus, Type 2",C18.452.394.750.149
21903291,2011-09-07T00:00:00,"Diabetes Mellitus, Type 2",C19.246.300
21903291,2011-09-07T00:00:00,Ethnic Groups,M01.686.754
21903291,2011-09-07T00:00:00,Ethnic Groups,N01.224.317
21903291,2011-09-07T00:00:00,European Continental Ancestry Group,M01.686.508.400
21903291,2011-09-07T00:00:00,Hispanic Americans,M01.686.754.441
21903291,2011-09-07T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21903291,2011-09-07T00:00:00,Minority Groups,I01.880.371
21903291,2011-09-07T00:00:00,Psychiatric Status Rating Scales,F04.586
21903291,2011-09-07T00:00:00,Risk Factors,E05.318.740.600.800.725
21903291,2011-09-07T00:00:00,Risk Factors,N05.715.350.200.700
21903291,2011-09-07T00:00:00,Risk Factors,N05.715.360.750.625.700.700
21903291,2011-09-07T00:00:00,Risk Factors,N06.850.490.625.750
21903291,2011-09-07T00:00:00,Risk Factors,N06.850.520.830.600.800.725
21903291,2011-09-07T00:00:00,United States,Z01.107.567.875
21903291,2011-09-07T00:00:00,Veterans,M01.930
21990514,2011-09-07T00:00:00,Balloon Occlusion,E02.148.106
21990514,2011-09-07T00:00:00,Balloon Occlusion,E02.520.179
21990514,2011-09-07T00:00:00,"Databases, Factual",L01.470.750.750
21990514,2011-09-07T00:00:00,"Databases, Factual",L01.700.508.300.188.400
21990514,2011-09-07T00:00:00,"Embolization, Therapeutic",E02.520.360
21990514,2011-09-07T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21990514,2011-09-07T00:00:00,Intracranial Aneurysm,C10.228.140.300.510.600
21990514,2011-09-07T00:00:00,Intracranial Aneurysm,C14.907.055.635
21990514,2011-09-07T00:00:00,Intracranial Aneurysm,C14.907.253.560.300
21990514,2011-09-07T00:00:00,Stents,E07.695.750
21990514,2011-09-07T00:00:00,Stroke,C10.228.140.300.775
21990514,2011-09-07T00:00:00,Stroke,C14.907.253.855
21990514,2011-09-07T00:00:00,Treatment Outcome,E01.789.800
21990514,2011-09-07T00:00:00,Treatment Outcome,N04.761.559.590.800
21990514,2011-09-07T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21904296,2011-09-08T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21904296,2011-09-08T00:00:00,"Infant, Newborn",M01.060.703.520
21904296,2011-09-08T00:00:00,"Infant, Very Low Birth Weight",M01.060.703.520.460.600
21904296,2011-09-08T00:00:00,Lactation,G08.686.702.500
21904296,2011-09-08T00:00:00,Lactation,G08.686.785.420
21904296,2011-09-08T00:00:00,"Milk, Human",A12.200.467
21904296,2011-09-08T00:00:00,"Milk, Human",J02.200.700.500
21904296,2011-09-08T00:00:00,"Milk, Human",J02.500.350.525.500
21904296,2011-09-08T00:00:00,Time Factors,G01.910.857
21925201,2011-09-08T00:00:00,Animals,B01.050
21925201,2011-09-08T00:00:00,Drug Interactions,G07.690.812.240
21925201,2011-09-08T00:00:00,Drug Interactions,G07.700.680.240
21925201,2011-09-08T00:00:00,Ethanol,D02.033.375
21925201,2011-09-08T00:00:00,Methylphenidate,D02.241.223.601.600
21925201,2011-09-08T00:00:00,Methylphenidate,D03.383.621.460
21925292,2011-09-08T00:00:00,Alzheimer Disease,C10.228.140.380.100
21925292,2011-09-08T00:00:00,Alzheimer Disease,C10.574.945.249
21925292,2011-09-08T00:00:00,Alzheimer Disease,F03.087.400.100
21925292,2011-09-08T00:00:00,Amino Acid Sequence,G02.111.570.060
21925292,2011-09-08T00:00:00,Amino Acid Sequence,L01.453.245.667.060
21925292,2011-09-08T00:00:00,Animals,B01.050
21925292,2011-09-08T00:00:00,Cathepsin B,D08.811.277.656.224.125
21925292,2011-09-08T00:00:00,Cathepsin B,D08.811.277.656.262.500.133
21925292,2011-09-08T00:00:00,Cathepsin B,D08.811.277.656.300.200.133
21925292,2011-09-08T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21925292,2011-09-08T00:00:00,"Models, Biological",E05.599.395
21925292,2011-09-08T00:00:00,Molecular Sequence Data,L01.453.245.667
21925292,2011-09-08T00:00:00,Peptides,D12.644
21904748,2011-09-09T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21904748,2011-09-09T00:00:00,Iron,D01.268.556.412
21904748,2011-09-09T00:00:00,Iron,D01.268.956.287
21904748,2011-09-09T00:00:00,Iron,D01.552.544.412
21904748,2011-09-09T00:00:00,Protein Denaturation,G02.111.087.685
21904748,2011-09-09T00:00:00,Protein Denaturation,G02.149.115.685
21904748,2011-09-09T00:00:00,Transferrin,D12.776.124.050.800
21904748,2011-09-09T00:00:00,Transferrin,D12.776.124.790.223.839
21904748,2011-09-09T00:00:00,Transferrin,D12.776.157.427.500
21904748,2011-09-09T00:00:00,Transferrin,D12.776.377.715.182.839
21904748,2011-09-09T00:00:00,Transferrin,D12.776.556.579.500
21906312,2011-09-09T00:00:00,Aged,M01.060.116.100
21906312,2011-09-09T00:00:00,Breast Neoplasms,C04.588.180
21906312,2011-09-09T00:00:00,Breast Neoplasms,C17.800.090.500
21906312,2011-09-09T00:00:00,"Drug Resistance, Neoplasm",G07.690.320.395
21906312,2011-09-09T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21906312,2011-09-09T00:00:00,Middle Aged,M01.060.116.630
21906312,2011-09-09T00:00:00,"Receptors, Estrogen",D12.776.260.698.750.350
21906312,2011-09-09T00:00:00,"Receptors, Estrogen",D12.776.826.750.350
21906312,2011-09-09T00:00:00,"Receptors, Estrogen",D12.776.930.669.750.350
21906312,2011-09-09T00:00:00,Salvage Therapy,E02.186.800
21906312,2011-09-09T00:00:00,Salvage Therapy,E02.895
21906312,2011-09-09T00:00:00,Treatment Outcome,E01.789.800
21906312,2011-09-09T00:00:00,Treatment Outcome,N04.761.559.590.800
21906312,2011-09-09T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21906978,2011-09-09T00:00:00,Attitude of Health Personnel,F01.100.050
21906978,2011-09-09T00:00:00,Attitude of Health Personnel,N05.300.100
21906978,2011-09-09T00:00:00,Directive Counseling,F02.784.176.279
21906978,2011-09-09T00:00:00,Directive Counseling,F04.408.413.349
21906978,2011-09-09T00:00:00,Directive Counseling,N02.421.461.363.349
21906978,2011-09-09T00:00:00,Family Practice,H02.403.280
21906978,2011-09-09T00:00:00,Gynecology,H02.403.810.310
21906978,2011-09-09T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21906978,2011-09-09T00:00:00,"Insurance, Health, Reimbursement",N03.219.521.576.343.480
21906978,2011-09-09T00:00:00,"Insurance, Health, Reimbursement",N03.219.521.710
21906978,2011-09-09T00:00:00,Middle Aged,M01.060.116.630
21906978,2011-09-09T00:00:00,Papillomavirus Infections,C02.256.650
21906978,2011-09-09T00:00:00,Papillomavirus Infections,C02.928.725
21906978,2011-09-09T00:00:00,Papillomavirus Vaccines,D20.215.894.899.498
21906978,2011-09-09T00:00:00,Physician's Practice Patterns,N04.590.748
21906978,2011-09-09T00:00:00,Physician's Practice Patterns,N05.300.625
21906978,2011-09-09T00:00:00,Questionnaires,E05.318.308.750
21906978,2011-09-09T00:00:00,Questionnaires,L01.280.800
21906978,2011-09-09T00:00:00,Questionnaires,N05.715.360.300.695
21906978,2011-09-09T00:00:00,Questionnaires,N06.850.520.308.750
21906978,2011-09-09T00:00:00,Vaccination,E02.095.465.425.400.530.890
21906978,2011-09-09T00:00:00,Vaccination,E05.478.550.600.890
21906978,2011-09-09T00:00:00,Vaccination,N02.421.726.758.310.890
21906978,2011-09-09T00:00:00,Vaccination,N06.850.780.200.425.900
21906978,2011-09-09T00:00:00,Vaccination,N06.850.780.680.310.890
21906978,2011-09-09T00:00:00,Virginia,Z01.107.567.875.075.837
21906978,2011-09-09T00:00:00,Virginia,Z01.107.567.875.750.870
21908613,2011-09-09T00:00:00,"Adaptor Proteins, Signal Transducing",D12.644.360.024
21908613,2011-09-09T00:00:00,"Adaptor Proteins, Signal Transducing",D12.776.157.057
21908613,2011-09-09T00:00:00,"Adaptor Proteins, Signal Transducing",D12.776.476.024
21908613,2011-09-09T00:00:00,Animals,B01.050
21908613,2011-09-09T00:00:00,Carrier Proteins,D12.776.157
21908613,2011-09-09T00:00:00,Cell Line,A11.251.210
21908613,2011-09-09T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21908613,2011-09-09T00:00:00,"Models, Biological",E05.599.395
21908613,2011-09-09T00:00:00,Phosphorylation,G02.111.087.677
21908613,2011-09-09T00:00:00,Phosphorylation,G02.149.115.677
21908613,2011-09-09T00:00:00,Phosphorylation,G02.149.465.700
21908613,2011-09-09T00:00:00,Phosphorylation,G02.607.750.700
21908613,2011-09-09T00:00:00,Phosphorylation,G03.495.790
21908613,2011-09-09T00:00:00,"Protein Structure, Secondary",G02.111.570.790.709.600
21908613,2011-09-09T00:00:00,Proto-Oncogene Proteins c-akt,D08.811.913.696.620.682.700.755
21908613,2011-09-09T00:00:00,Proto-Oncogene Proteins c-akt,D12.776.476.565
21908613,2011-09-09T00:00:00,Proto-Oncogene Proteins c-akt,D12.776.624.664.700.168
21908613,2011-09-09T00:00:00,Trans-Activators,D12.776.260.755
21908613,2011-09-09T00:00:00,Trans-Activators,D12.776.930.900
21908613,2011-09-09T00:00:00,Trans-Activators,D12.776.964.925.984
21908613,2011-09-09T00:00:00,Transcription Factors,D12.776.930
21982674,2011-09-09T00:00:00,Cost-Benefit Analysis,N03.219.151.125
21982674,2011-09-09T00:00:00,"Education, Medical, Continuing",I02.358.212.350
21982674,2011-09-09T00:00:00,"Education, Medical, Continuing",I02.358.399.250
21982674,2011-09-09T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21982674,2011-09-09T00:00:00,Hypertension,C14.907.489
21982674,2011-09-09T00:00:00,Practice Guidelines as Topic,N04.761.700.350.650
21982674,2011-09-09T00:00:00,Practice Guidelines as Topic,N05.700.350.650
21982674,2011-09-09T00:00:00,South Carolina,Z01.107.567.875.075.662
21982674,2011-09-09T00:00:00,South Carolina,Z01.107.567.875.750.700
21906257,2011-09-11T00:00:00,Graft Survival,G12.425.901.545.340
21906257,2011-09-11T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21906257,2011-09-11T00:00:00,Kidney Transplantation,E02.870.500
21906257,2011-09-11T00:00:00,Kidney Transplantation,E04.936.450.485
21906257,2011-09-11T00:00:00,Kidney Transplantation,E04.950.774.400
21906257,2011-09-11T00:00:00,Middle Aged,M01.060.116.630
21906257,2011-09-11T00:00:00,Risk Factors,E05.318.740.600.800.725
21906257,2011-09-11T00:00:00,Risk Factors,N05.715.350.200.700
21906257,2011-09-11T00:00:00,Risk Factors,N05.715.360.750.625.700.700
21906257,2011-09-11T00:00:00,Risk Factors,N06.850.490.625.750
21906257,2011-09-11T00:00:00,Risk Factors,N06.850.520.830.600.800.725
21906257,2011-09-11T00:00:00,Time Factors,G01.910.857
21906257,2011-09-11T00:00:00,Tissue Donors,M01.898
21906257,2011-09-11T00:00:00,Tissue and Organ Harvesting,E01.450.865.820
21906257,2011-09-11T00:00:00,Tissue and Organ Harvesting,E04.932
21909115,2011-09-11T00:00:00,Blood Pressure,E01.370.600.875.249
21909115,2011-09-11T00:00:00,Blood Pressure,G09.330.380.076
21909115,2011-09-11T00:00:00,Cardiovascular Diseases,C14
21909115,2011-09-11T00:00:00,Coronary Artery Disease,C14.280.647.250.260
21909115,2011-09-11T00:00:00,Coronary Artery Disease,C14.907.137.126.339
21909115,2011-09-11T00:00:00,Coronary Artery Disease,C14.907.585.250.260
21909115,2011-09-11T00:00:00,Genetic Predisposition to Disease,C23.550.291.687.500
21909115,2011-09-11T00:00:00,Genetic Predisposition to Disease,G05.380.355
21909115,2011-09-11T00:00:00,Genome-Wide Association Study,E05.318.416.249
21909115,2011-09-11T00:00:00,Genome-Wide Association Study,E05.318.780.392
21909115,2011-09-11T00:00:00,Genome-Wide Association Study,E05.393.385.500
21909115,2011-09-11T00:00:00,Genome-Wide Association Study,E05.393.522.500
21909115,2011-09-11T00:00:00,Genome-Wide Association Study,E05.393.760.640.500
21909115,2011-09-11T00:00:00,Genome-Wide Association Study,N06.850.520.445.392
21909115,2011-09-11T00:00:00,Genome-Wide Association Study,N06.850.520.470.500
21909115,2011-09-11T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21909115,2011-09-11T00:00:00,Hypertension,C14.907.489
21909115,2011-09-11T00:00:00,Kidney Diseases,C12.777.419
21909115,2011-09-11T00:00:00,Kidney Diseases,C13.351.968.419
21909115,2011-09-11T00:00:00,"Polymorphism, Single Nucleotide",G05.365.795.598
21909115,2011-09-11T00:00:00,Stroke,C10.228.140.300.775
21909115,2011-09-11T00:00:00,Stroke,C14.907.253.855
21910583,2011-09-12T00:00:00,Animals,B01.050
21910583,2011-09-12T00:00:00,Dogs,B01.050.150.900.649.147.153.200
21910583,2011-09-12T00:00:00,Inbreeding,E05.820.150.520
21910583,2011-09-12T00:00:00,Inbreeding,G05.355.090.403
21910583,2011-09-12T00:00:00,"Models, Biological",E05.599.395
21910583,2011-09-12T00:00:00,Plutonium,D01.268.033.700
21910583,2011-09-12T00:00:00,Plutonium,D01.268.271.100.700
21910583,2011-09-12T00:00:00,Plutonium,D01.268.556.700
21910583,2011-09-12T00:00:00,Plutonium,D01.552.020.734
21910583,2011-09-12T00:00:00,Plutonium,D01.552.544.700
21910583,2011-09-12T00:00:00,Pulmonary Fibrosis,C08.381.765
21911708,2011-09-12T00:00:00,Adolescent,M01.060.057
21911708,2011-09-12T00:00:00,Adult,M01.060.116
21911708,2011-09-12T00:00:00,African Continental Ancestry Group,M01.686.508.100
21911708,2011-09-12T00:00:00,Age Factors,N05.715.350.075
21911708,2011-09-12T00:00:00,Age Factors,N06.850.490.250
21911708,2011-09-12T00:00:00,Aged,M01.060.116.100
21911708,2011-09-12T00:00:00,Diabetes Complications,C19.246.099
21911708,2011-09-12T00:00:00,Disease Progression,C23.550.291.656
21911708,2011-09-12T00:00:00,European Continental Ancestry Group,M01.686.508.400
21911708,2011-09-12T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21911708,2011-09-12T00:00:00,Hypertension,C14.907.489
21911708,2011-09-12T00:00:00,Middle Aged,M01.060.116.630
21911708,2011-09-12T00:00:00,Obesity,C18.654.726.500
21911708,2011-09-12T00:00:00,Obesity,C23.888.144.699.500
21911708,2011-09-12T00:00:00,Obesity,E01.370.600.115.100.160.120.699.500
21911708,2011-09-12T00:00:00,Obesity,G07.100.100.160.120.699.500
21911708,2011-09-12T00:00:00,Overweight,C23.888.144.699
21911708,2011-09-12T00:00:00,Overweight,E01.370.600.115.100.160.120.699
21911708,2011-09-12T00:00:00,Overweight,G07.100.100.160.120.699
21911708,2011-09-12T00:00:00,Risk Factors,E05.318.740.600.800.725
21911708,2011-09-12T00:00:00,Risk Factors,N05.715.350.200.700
21911708,2011-09-12T00:00:00,Risk Factors,N05.715.360.750.625.700.700
21911708,2011-09-12T00:00:00,Risk Factors,N06.850.490.625.750
21911708,2011-09-12T00:00:00,Risk Factors,N06.850.520.830.600.800.725
21911708,2011-09-12T00:00:00,Young Adult,M01.060.116.815
21925521,2011-09-12T00:00:00,Acoustic Stimulation,E02.037
21925521,2011-09-12T00:00:00,Acoustic Stimulation,E02.190.888.030
21925521,2011-09-12T00:00:00,Acoustic Stimulation,E05.723.136
21925521,2011-09-12T00:00:00,Adolescent,M01.060.057
21925521,2011-09-12T00:00:00,Adult,M01.060.116
21925521,2011-09-12T00:00:00,Aged,M01.060.116.100
21925521,2011-09-12T00:00:00,Brain Mapping,E01.370.350.086
21925521,2011-09-12T00:00:00,Brain Mapping,E01.370.376.149
21925521,2011-09-12T00:00:00,Brain Mapping,E05.132
21925521,2011-09-12T00:00:00,Frontal Lobe,A08.186.211.730.885.287.500.270
21925521,2011-09-12T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21925521,2011-09-12T00:00:00,"Image Processing, Computer-Assisted",L01.224.308
21925521,2011-09-12T00:00:00,Magnetic Resonance Imaging,E01.370.350.500
21925521,2011-09-12T00:00:00,Magnetic Resonance Imaging,E01.370.350.825.500
21925521,2011-09-12T00:00:00,Middle Aged,M01.060.116.630
21925521,2011-09-12T00:00:00,Oxygen,D01.268.185.550
21925521,2011-09-12T00:00:00,Oxygen,D01.362.670
21925521,2011-09-12T00:00:00,Psychomotor Performance,F02.808
21925521,2011-09-12T00:00:00,Psychomotor Performance,G11.427.700
21925521,2011-09-12T00:00:00,Psychomotor Performance,G11.561.623
21925521,2011-09-12T00:00:00,Speech Perception,F02.463.593.071.875
21925521,2011-09-12T00:00:00,Vocabulary,L01.143.506.598.901
21925521,2011-09-12T00:00:00,Young Adult,M01.060.116.815
21903059,2011-09-13T00:00:00,Anemia,C15.378.071
21903059,2011-09-13T00:00:00,Heart Failure,C14.280.434
21903059,2011-09-13T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21903059,2011-09-13T00:00:00,Iron,D01.268.556.412
21903059,2011-09-13T00:00:00,Iron,D01.268.956.287
21903059,2011-09-13T00:00:00,Iron,D01.552.544.412
21903059,2011-09-13T00:00:00,Iron Metabolism Disorders,C18.452.565
21911817,2011-09-13T00:00:00,Animals,B01.050
21911817,2011-09-13T00:00:00,Collagen,D05.750.078.280
21911817,2011-09-13T00:00:00,Collagen,D12.776.860.300.250
21911817,2011-09-13T00:00:00,Durapatite,D01.146.360.050.300.200
21911817,2011-09-13T00:00:00,Durapatite,D01.578.122.477.300
21911817,2011-09-13T00:00:00,Durapatite,D01.695.625.675.650.075.025.300.150
21911817,2011-09-13T00:00:00,Extracellular Matrix,A11.284.295.310
21911817,2011-09-13T00:00:00,Matrix Metalloproteinases,D08.811.277.656.300.480.525
21911817,2011-09-13T00:00:00,Matrix Metalloproteinases,D08.811.277.656.675.374.525
21911817,2011-09-13T00:00:00,"Models, Animal",E05.598
21911817,2011-09-13T00:00:00,Myocardial Infarction,C14.280.647.500
21911817,2011-09-13T00:00:00,Myocardial Infarction,C14.907.585.500
21911817,2011-09-13T00:00:00,Signal Transduction,G02.111.087.800
21911817,2011-09-13T00:00:00,Signal Transduction,G02.149.115.800
21911817,2011-09-13T00:00:00,Signal Transduction,G04.299.880
21911817,2011-09-13T00:00:00,Tissue Inhibitor of Metalloproteinases,D12.776.926
21911817,2011-09-13T00:00:00,Treatment Outcome,E01.789.800
21911817,2011-09-13T00:00:00,Treatment Outcome,N04.761.559.590.800
21911817,2011-09-13T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21911817,2011-09-13T00:00:00,Ventricular Remodeling,C23.300.985
21911817,2011-09-13T00:00:00,Ventricular Remodeling,G09.330.190.962.975
21911820,2011-09-13T00:00:00,Aged,M01.060.116.100
21911820,2011-09-13T00:00:00,Aprotinin,D12.776.083
21911820,2011-09-13T00:00:00,Cardiac Surgical Procedures,E04.100.376
21911820,2011-09-13T00:00:00,Cardiac Surgical Procedures,E04.928.220
21911820,2011-09-13T00:00:00,Heart Valve Prosthesis,E07.695.310
21911820,2011-09-13T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21911820,2011-09-13T00:00:00,Lysine,D12.125.068.555
21911820,2011-09-13T00:00:00,Lysine,D12.125.095.647
21911820,2011-09-13T00:00:00,Lysine,D12.125.142.497
21911820,2011-09-13T00:00:00,Middle Aged,M01.060.116.630
21911820,2011-09-13T00:00:00,Respiratory Insufficiency,C08.618.846
21911820,2011-09-13T00:00:00,Risk Factors,E05.318.740.600.800.725
21911820,2011-09-13T00:00:00,Risk Factors,N05.715.350.200.700
21911820,2011-09-13T00:00:00,Risk Factors,N05.715.360.750.625.700.700
21911820,2011-09-13T00:00:00,Risk Factors,N06.850.490.625.750
21911820,2011-09-13T00:00:00,Risk Factors,N06.850.520.830.600.800.725
21911820,2011-09-13T00:00:00,Treatment Outcome,E01.789.800
21911820,2011-09-13T00:00:00,Treatment Outcome,N04.761.559.590.800
21911820,2011-09-13T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21912390,2011-09-13T00:00:00,Adult,M01.060.116
21912390,2011-09-13T00:00:00,African Continental Ancestry Group,M01.686.508.100
21912390,2011-09-13T00:00:00,Age Factors,N05.715.350.075
21912390,2011-09-13T00:00:00,Age Factors,N06.850.490.250
21912390,2011-09-13T00:00:00,Aged,M01.060.116.100
21912390,2011-09-13T00:00:00,European Continental Ancestry Group,M01.686.508.400
21912390,2011-09-13T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21912390,2011-09-13T00:00:00,Middle Aged,M01.060.116.630
21912390,2011-09-13T00:00:00,"Polymorphism, Single Nucleotide",G05.365.795.598
21912390,2011-09-13T00:00:00,"Stress Disorders, Post-Traumatic",F03.080.931.500
21912390,2011-09-13T00:00:00,Substance-Related Disorders,C21.739
21912390,2011-09-13T00:00:00,Substance-Related Disorders,F03.900
21912390,2011-09-13T00:00:00,United States,Z01.107.567.875
21914808,2011-09-13T00:00:00,Animals,B01.050
21914808,2011-09-13T00:00:00,Anoxia,C23.888.852.079
21914808,2011-09-13T00:00:00,Biosensing Techniques,E05.601.123
21914808,2011-09-13T00:00:00,Cell Proliferation,G04.299.233.750
21914808,2011-09-13T00:00:00,Cell Proliferation,G07.700.320.249.410.750
21914808,2011-09-13T00:00:00,Ceramides,D02.065.313
21914808,2011-09-13T00:00:00,Ceramides,D09.400.410.420.525.200
21914808,2011-09-13T00:00:00,Ceramides,D10.390.470.675.200
21914808,2011-09-13T00:00:00,Ceramides,D10.570.877.360.612.200
21914808,2011-09-13T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21914808,2011-09-13T00:00:00,Mass Spectrometry,E05.196.566
21914808,2011-09-13T00:00:00,Oxidoreductases,D08.811.682
21914808,2011-09-13T00:00:00,Oxygen,D01.268.185.550
21914808,2011-09-13T00:00:00,Oxygen,D01.362.670
21914808,2011-09-13T00:00:00,Rats,B01.050.150.900.649.865.635.505.700
21914808,2011-09-13T00:00:00,"Rats, Sprague-Dawley",B01.050.150.900.649.865.635.505.700.750
21917756,2011-09-13T00:00:00,Adolescent,M01.060.057
21917756,2011-09-13T00:00:00,Adult,M01.060.116
21917756,2011-09-13T00:00:00,Aged,M01.060.116.100
21917756,2011-09-13T00:00:00,Child,M01.060.406
21917756,2011-09-13T00:00:00,"Child, Preschool",M01.060.406.448
21917756,2011-09-13T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21917756,2011-09-13T00:00:00,"Leukemia, Myeloid, Acute",C04.557.337.539.550
21917756,2011-09-13T00:00:00,Middle Aged,M01.060.116.630
21917756,2011-09-13T00:00:00,Nuclear Proteins,D12.776.660
21917756,2011-09-13T00:00:00,Proteomics,H01.158.201.843
21917756,2011-09-13T00:00:00,Proteomics,H01.158.273.180.350.700
21917756,2011-09-13T00:00:00,Proteomics,H01.158.273.343.350.700
21917756,2011-09-13T00:00:00,Proteomics,H01.181.122.738
21917756,2011-09-13T00:00:00,Proto-Oncogene Protein c-fli-1,D12.776.260.665.400
21917756,2011-09-13T00:00:00,Proto-Oncogene Protein c-fli-1,D12.776.624.664.700.175.400
21917756,2011-09-13T00:00:00,Proto-Oncogene Protein c-fli-1,D12.776.930.635.400
21917756,2011-09-13T00:00:00,Risk Factors,E05.318.740.600.800.725
21917756,2011-09-13T00:00:00,Risk Factors,N05.715.350.200.700
21917756,2011-09-13T00:00:00,Risk Factors,N05.715.360.750.625.700.700
21917756,2011-09-13T00:00:00,Risk Factors,N06.850.490.625.750
21917756,2011-09-13T00:00:00,Risk Factors,N06.850.520.830.600.800.725
21917756,2011-09-13T00:00:00,Young Adult,M01.060.116.815
21920873,2011-09-13T00:00:00,Adolescent,M01.060.057
21920873,2011-09-13T00:00:00,Adolescent Behavior,F01.145.022
21920873,2011-09-13T00:00:00,Child,M01.060.406
21920873,2011-09-13T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21920873,2011-09-13T00:00:00,Interviews as Topic,E05.318.308.420
21920873,2011-09-13T00:00:00,Interviews as Topic,L01.280.520
21920873,2011-09-13T00:00:00,Interviews as Topic,N05.715.360.300.400
21920873,2011-09-13T00:00:00,Interviews as Topic,N06.850.520.308.420
21920873,2011-09-13T00:00:00,Juvenile Delinquency,I01.880.735.479
21920873,2011-09-13T00:00:00,United States,Z01.107.567.875
21920873,2011-09-13T00:00:00,Violence,I01.198.240.856
21920873,2011-09-13T00:00:00,Violence,I01.880.735.900
21990538,2011-09-13T00:00:00,"Embolization, Therapeutic",E02.520.360
21990538,2011-09-13T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21990538,2011-09-13T00:00:00,Intracranial Aneurysm,C10.228.140.300.510.600
21990538,2011-09-13T00:00:00,Intracranial Aneurysm,C14.907.055.635
21990538,2011-09-13T00:00:00,Intracranial Aneurysm,C14.907.253.560.300
21990538,2011-09-13T00:00:00,Perioperative Care,E02.760.722
21990538,2011-09-13T00:00:00,Perioperative Care,E04.604
21990538,2011-09-13T00:00:00,Perioperative Care,N02.421.585.722
21990538,2011-09-13T00:00:00,Treatment Outcome,E01.789.800
21990538,2011-09-13T00:00:00,Treatment Outcome,N04.761.559.590.800
21990538,2011-09-13T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21882831,2011-09-14T00:00:00,Antimalarials,D27.505.954.122.250.100.085
21882831,2011-09-14T00:00:00,DNA Replication,G02.111.087.222
21882831,2011-09-14T00:00:00,DNA Replication,G02.149.115.222
21882831,2011-09-14T00:00:00,DNA Replication,G05.355.200
21882831,2011-09-14T00:00:00,Drug Resistance,G07.690.320
21882831,2011-09-14T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21882831,2011-09-14T00:00:00,Polyamines,D02.092.782
21639753,2011-09-15T00:00:00,Adult,M01.060.116
21639753,2011-09-15T00:00:00,Brain Injuries,C10.228.140.199
21639753,2011-09-15T00:00:00,Brain Injuries,C10.900.300.087
21639753,2011-09-15T00:00:00,Brain Injuries,C21.866.260.118
21639753,2011-09-15T00:00:00,Brain Injuries,C21.866.915.300.200
21639753,2011-09-15T00:00:00,Diffusion Tensor Imaging,E01.370.350.500.150.500
21639753,2011-09-15T00:00:00,Diffusion Tensor Imaging,E01.370.376.224
21639753,2011-09-15T00:00:00,Diffusion Tensor Imaging,E05.278
21639753,2011-09-15T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21639753,2011-09-15T00:00:00,"Image Processing, Computer-Assisted",L01.224.308
21639753,2011-09-15T00:00:00,Middle Aged,M01.060.116.630
21639753,2011-09-15T00:00:00,Young Adult,M01.060.116.815
21916997,2011-09-15T00:00:00,Adolescent,M01.060.057
21916997,2011-09-15T00:00:00,Adult,M01.060.116
21916997,2011-09-15T00:00:00,Child,M01.060.406
21916997,2011-09-15T00:00:00,"Child, Preschool",M01.060.406.448
21916997,2011-09-15T00:00:00,Eye Movements,G11.427.590.530.140
21916997,2011-09-15T00:00:00,Eye Movements,G14.640.260
21916997,2011-09-15T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21916997,2011-09-15T00:00:00,"Refraction, Ocular",E01.370.380.850.700
21916997,2011-09-15T00:00:00,"Refraction, Ocular",G01.590.770.760
21916997,2011-09-15T00:00:00,"Refraction, Ocular",G01.595.640.760
21916997,2011-09-15T00:00:00,"Refraction, Ocular",G14.760
21916997,2011-09-15T00:00:00,Risk Factors,E05.318.740.600.800.725
21916997,2011-09-15T00:00:00,Risk Factors,N05.715.350.200.700
21916997,2011-09-15T00:00:00,Risk Factors,N05.715.360.750.625.700.700
21916997,2011-09-15T00:00:00,Risk Factors,N06.850.490.625.750
21916997,2011-09-15T00:00:00,Risk Factors,N06.850.520.830.600.800.725
21916997,2011-09-15T00:00:00,Strabismus,C10.292.562.887
21916997,2011-09-15T00:00:00,Strabismus,C11.590.810
21916997,2011-09-15T00:00:00,Young Adult,M01.060.116.815
21919924,2011-09-15T00:00:00,Adult,M01.060.116
21919924,2011-09-15T00:00:00,African Americans,M01.686.508.100.100
21919924,2011-09-15T00:00:00,African Americans,M01.686.754.100
21919924,2011-09-15T00:00:00,Alcoholism,C21.739.100.250
21919924,2011-09-15T00:00:00,Alcoholism,F03.900.100.350
21919924,2011-09-15T00:00:00,DNA,D13.444.308
21919924,2011-09-15T00:00:00,Genetic Variation,G05.365
21919924,2011-09-15T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21919924,2011-09-15T00:00:00,Linkage Disequilibrium,G05.540.500
21919924,2011-09-15T00:00:00,Middle Aged,M01.060.116.630
21919924,2011-09-15T00:00:00,"Polymorphism, Single Nucleotide",G05.365.795.598
21921062,2011-09-15T00:00:00,Allied Health Personnel,M01.526.485.067
21921062,2011-09-15T00:00:00,Allied Health Personnel,N02.360.067
21921062,2011-09-15T00:00:00,Anticonvulsants,D27.505.954.427.080
21921062,2011-09-15T00:00:00,"Clinical Trials, Phase III as Topic",E05.318.760.535.220
21921062,2011-09-15T00:00:00,"Clinical Trials, Phase III as Topic",E05.337.250.220
21921062,2011-09-15T00:00:00,"Clinical Trials, Phase III as Topic",N05.715.360.775.235.220
21921062,2011-09-15T00:00:00,"Clinical Trials, Phase III as Topic",N06.850.520.450.535.220
21921062,2011-09-15T00:00:00,"Data Interpretation, Statistical",E05.245.380
21921062,2011-09-15T00:00:00,"Data Interpretation, Statistical",E05.318.740.300
21921062,2011-09-15T00:00:00,"Data Interpretation, Statistical",L01.700.508.190.380
21921062,2011-09-15T00:00:00,"Data Interpretation, Statistical",N05.715.360.750.300
21921062,2011-09-15T00:00:00,"Data Interpretation, Statistical",N06.850.520.830.300
21921062,2011-09-15T00:00:00,Emergency Medical Services,N02.421.297
21921062,2011-09-15T00:00:00,Emergency Medicine,H02.403.250
21921062,2011-09-15T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21921062,2011-09-15T00:00:00,Organizational Case Studies,N03.349.380.710
21921062,2011-09-15T00:00:00,Organizational Case Studies,N05.715.360.455
21921062,2011-09-15T00:00:00,Research Design,E05.581.500
21921062,2011-09-15T00:00:00,Research Design,H01.770.644.728
21921062,2011-09-15T00:00:00,Status Epilepticus,C10.228.140.490.690
21921062,2011-09-15T00:00:00,United States,Z01.107.567.875
21924874,2011-09-15T00:00:00,Adolescent,M01.060.057
21924874,2011-09-15T00:00:00,Adult,M01.060.116
21924874,2011-09-15T00:00:00,Anticonvulsants,D27.505.954.427.080
21924874,2011-09-15T00:00:00,Brain Mapping,E01.370.350.086
21924874,2011-09-15T00:00:00,Brain Mapping,E01.370.376.149
21924874,2011-09-15T00:00:00,Brain Mapping,E05.132
21924874,2011-09-15T00:00:00,Cerebral Cortex,A08.186.211.730.885.287.500
21924874,2011-09-15T00:00:00,Double-Blind Method,E05.318.780.300
21924874,2011-09-15T00:00:00,Double-Blind Method,E05.581.500.300
21924874,2011-09-15T00:00:00,Double-Blind Method,N05.715.360.780.320
21924874,2011-09-15T00:00:00,Double-Blind Method,N06.850.520.445.300
21924874,2011-09-15T00:00:00,Functional Laterality,F02.830.297.425
21924874,2011-09-15T00:00:00,Functional Laterality,G11.561.225.425
21924874,2011-09-15T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21924874,2011-09-15T00:00:00,Magnetic Resonance Imaging,E01.370.350.500
21924874,2011-09-15T00:00:00,Magnetic Resonance Imaging,E01.370.350.825.500
21924874,2011-09-15T00:00:00,"Models, Neurological",E05.599.395.642
21924874,2011-09-15T00:00:00,Neural Pathways,A08.612
21924874,2011-09-15T00:00:00,Transcranial Magnetic Stimulation,E01.370.376.850
21924874,2011-09-15T00:00:00,Transcranial Magnetic Stimulation,E02.621.820
21924874,2011-09-15T00:00:00,Triazines,D03.383.931
21924874,2011-09-15T00:00:00,Valproic Acid,D02.241.081.944.509.900
21924874,2011-09-15T00:00:00,Valproic Acid,D10.251.400.895.593.900
21924874,2011-09-15T00:00:00,Young Adult,M01.060.116.815
21919422,2011-09-16T00:00:00,Adult,M01.060.116
21919422,2011-09-16T00:00:00,Anticoagulants,D27.505.954.502.119
21919422,2011-09-16T00:00:00,Atrial Fibrillation,C14.280.067.198
21919422,2011-09-16T00:00:00,Atrial Fibrillation,C23.550.073.198
21919422,2011-09-16T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21922170,2011-09-16T00:00:00,Adolescent,M01.060.057
21922170,2011-09-16T00:00:00,Adult,M01.060.116
21922170,2011-09-16T00:00:00,"Behavior, Addictive",F01.145.527.100.120
21922170,2011-09-16T00:00:00,Cognition,F02.463.188
21922170,2011-09-16T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21922170,2011-09-16T00:00:00,Marijuana Abuse,C21.739.635
21922170,2011-09-16T00:00:00,Marijuana Abuse,F03.900.635
21922170,2011-09-16T00:00:00,Middle Aged,M01.060.116.630
21922170,2011-09-16T00:00:00,Psychiatric Status Rating Scales,F04.586
21922170,2011-09-16T00:00:00,Psychomotor Performance,F02.808
21922170,2011-09-16T00:00:00,Psychomotor Performance,G11.427.700
21922170,2011-09-16T00:00:00,Psychomotor Performance,G11.561.623
21922170,2011-09-16T00:00:00,Sleep,F02.830.855
21922170,2011-09-16T00:00:00,Sleep,G11.561.600.815
21922170,2011-09-16T00:00:00,Substance Withdrawal Syndrome,C21.739.835
21922170,2011-09-16T00:00:00,Substance Withdrawal Syndrome,F03.900.825
21926180,2011-09-16T00:00:00,Aged,M01.060.116.100
21926180,2011-09-16T00:00:00,Biological Markers,D23.101
21926180,2011-09-16T00:00:00,Calcium-Binding Proteins,D12.776.157.125
21926180,2011-09-16T00:00:00,Cardiovascular Diseases,C14
21926180,2011-09-16T00:00:00,Case-Control Studies,E05.318.760.500.500
21926180,2011-09-16T00:00:00,Case-Control Studies,N05.715.360.775.175.200
21926180,2011-09-16T00:00:00,Case-Control Studies,N06.850.520.450.500.500
21926180,2011-09-16T00:00:00,"Diabetes Mellitus, Type 2",C18.452.394.750.149
21926180,2011-09-16T00:00:00,"Diabetes Mellitus, Type 2",C19.246.300
21926180,2011-09-16T00:00:00,Extracellular Matrix,A11.284.295.310
21926180,2011-09-16T00:00:00,Extracellular Matrix Proteins,D12.776.860.300
21926180,2011-09-16T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21926180,2011-09-16T00:00:00,Middle Aged,M01.060.116.630
21926180,2011-09-16T00:00:00,Oligonucleotide Array Sequence Analysis,E05.196.630.570.660
21926180,2011-09-16T00:00:00,Oligonucleotide Array Sequence Analysis,E05.393.525.640
21926180,2011-09-16T00:00:00,Oligonucleotide Array Sequence Analysis,E05.393.661.640
21926180,2011-09-16T00:00:00,Oligonucleotide Array Sequence Analysis,E05.393.760.640
21926180,2011-09-16T00:00:00,Oligonucleotide Array Sequence Analysis,E05.588.570.660
21926180,2011-09-16T00:00:00,Oligonucleotide Array Sequence Analysis,E05.601.640
21926458,2011-09-16T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21926458,2011-09-16T00:00:00,"Models, Molecular",E05.599.595
21926458,2011-09-16T00:00:00,Research,H01.770.644
21926458,2011-09-16T00:00:00,South Carolina,Z01.107.567.875.075.662
21926458,2011-09-16T00:00:00,South Carolina,Z01.107.567.875.750.700
21926458,2011-09-16T00:00:00,Tissue Engineering,E05.200.249.750
21949861,2011-09-16T00:00:00,Animals,B01.050
21949861,2011-09-16T00:00:00,Cell Differentiation,G04.299.151
21949861,2011-09-16T00:00:00,Drosophila melanogaster,B01.050.500.131.617.289.310.250.500
21949861,2011-09-16T00:00:00,Gene Expression Regulation,G05.355.315
21949861,2011-09-16T00:00:00,Germ Cells,A05.360.490
21949861,2011-09-16T00:00:00,Germ Cells,A11.497
21949861,2011-09-16T00:00:00,Mutation,G05.365.590
21949861,2011-09-16T00:00:00,Signal Transduction,G02.111.087.800
21949861,2011-09-16T00:00:00,Signal Transduction,G02.149.115.800
21949861,2011-09-16T00:00:00,Signal Transduction,G04.299.880
21949861,2011-09-16T00:00:00,Stem Cells,A11.872
21926977,2011-09-18T00:00:00,Animals,B01.050
21926977,2011-09-18T00:00:00,Cell Proliferation,G04.299.233.750
21926977,2011-09-18T00:00:00,Cell Proliferation,G07.700.320.249.410.750
21926977,2011-09-18T00:00:00,Flow Cytometry,E05.196.712.516.600.240.350
21926977,2011-09-18T00:00:00,Flow Cytometry,E05.200.500.386.350
21926977,2011-09-18T00:00:00,Gene Expression Profiling,E05.393.332
21926977,2011-09-18T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21926977,2011-09-18T00:00:00,T-Lymphocyte Subsets,A11.118.637.555.567.550.500
21926977,2011-09-18T00:00:00,T-Lymphocyte Subsets,A11.118.637.555.567.569.500
21926977,2011-09-18T00:00:00,T-Lymphocyte Subsets,A15.145.229.637.555.567.550.500
21926977,2011-09-18T00:00:00,T-Lymphocyte Subsets,A15.145.229.637.555.567.569.500
21926977,2011-09-18T00:00:00,T-Lymphocyte Subsets,A15.382.490.555.567.550.500
21926977,2011-09-18T00:00:00,T-Lymphocyte Subsets,A15.382.490.555.567.569.500
21926977,2011-09-18T00:00:00,T-Lymphocytes,A11.118.637.555.567.569
21926977,2011-09-18T00:00:00,T-Lymphocytes,A15.145.229.637.555.567.569
21926977,2011-09-18T00:00:00,T-Lymphocytes,A15.382.490.555.567.569
21990520,2011-09-19T00:00:00,Aged,M01.060.116.100
21990520,2011-09-19T00:00:00,Brain Ischemia,C10.228.140.300.150
21990520,2011-09-19T00:00:00,Brain Ischemia,C14.907.253.092
21990520,2011-09-19T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21990520,2011-09-19T00:00:00,Middle Aged,M01.060.116.630
21990520,2011-09-19T00:00:00,Patient Selection,E05.581.500.653
21990520,2011-09-19T00:00:00,Patient Selection,N04.590.731
21990520,2011-09-19T00:00:00,Perfusion Imaging,E01.370.350.710.600
21990520,2011-09-19T00:00:00,Perfusion Imaging,E01.370.384.730.354
21990520,2011-09-19T00:00:00,Stroke,C10.228.140.300.775
21990520,2011-09-19T00:00:00,Stroke,C14.907.253.855
21990520,2011-09-19T00:00:00,Treatment Outcome,E01.789.800
21990520,2011-09-19T00:00:00,Treatment Outcome,N04.761.559.590.800
21990520,2011-09-19T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21932141,2011-09-20T00:00:00,Exercise Therapy,E02.779.483
21932141,2011-09-20T00:00:00,Exercise Therapy,E02.831.387
21932141,2011-09-20T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21932141,2011-09-20T00:00:00,Middle Aged,M01.060.116.630
21932141,2011-09-20T00:00:00,Neoplasms,C04
21932141,2011-09-20T00:00:00,Quality of Life,I01.800
21932141,2011-09-20T00:00:00,Quality of Life,K01.752.400.750
21932141,2011-09-20T00:00:00,Questionnaires,E05.318.308.750
21932141,2011-09-20T00:00:00,Questionnaires,L01.280.800
21932141,2011-09-20T00:00:00,Questionnaires,N05.715.360.300.695
21932141,2011-09-20T00:00:00,Questionnaires,N06.850.520.308.750
21932141,2011-09-20T00:00:00,Regression Analysis,E05.318.740.750
21932141,2011-09-20T00:00:00,Regression Analysis,N05.715.360.750.695
21932141,2011-09-20T00:00:00,Regression Analysis,N06.850.520.830.750
21932141,2011-09-20T00:00:00,South Carolina,Z01.107.567.875.075.662
21932141,2011-09-20T00:00:00,South Carolina,Z01.107.567.875.750.700
21932141,2011-09-20T00:00:00,Survivors,M01.643.836
21932141,2011-09-20T00:00:00,Survivors,M01.860
21932141,2011-09-20T00:00:00,Walking,G11.427.590.530.568.900
21932141,2011-09-20T00:00:00,Walking,G11.427.590.530.698.940
21932141,2011-09-20T00:00:00,Walking,I03.450.642.845.940
21932266,2011-09-20T00:00:00,Acoustic Stimulation,E02.037
21932266,2011-09-20T00:00:00,Acoustic Stimulation,E02.190.888.030
21932266,2011-09-20T00:00:00,Acoustic Stimulation,E05.723.136
21932266,2011-09-20T00:00:00,Adolescent,M01.060.057
21932266,2011-09-20T00:00:00,Adult,M01.060.116
21932266,2011-09-20T00:00:00,Auditory Perception,F02.463.593.071
21932266,2011-09-20T00:00:00,Brain Mapping,E01.370.350.086
21932266,2011-09-20T00:00:00,Brain Mapping,E01.370.376.149
21932266,2011-09-20T00:00:00,Brain Mapping,E05.132
21932266,2011-09-20T00:00:00,Cerebral Cortex,A08.186.211.730.885.287.500
21932266,2011-09-20T00:00:00,Diffusion Magnetic Resonance Imaging,E01.370.350.500.150
21932266,2011-09-20T00:00:00,Diffusion Magnetic Resonance Imaging,E01.370.350.825.500.150
21932266,2011-09-20T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21932266,2011-09-20T00:00:00,"Image Interpretation, Computer-Assisted",E01.158.600
21932266,2011-09-20T00:00:00,"Image Interpretation, Computer-Assisted",E01.370.350.350
21932266,2011-09-20T00:00:00,"Image Interpretation, Computer-Assisted",L01.700.508.100.158.600
21932266,2011-09-20T00:00:00,Neural Pathways,A08.612
21932266,2011-09-20T00:00:00,Space Perception,F02.463.593.778
21932266,2011-09-20T00:00:00,Space Perception,F02.463.593.932.869
21932266,2011-09-20T00:00:00,Young Adult,M01.060.116.815
21933201,2011-09-20T00:00:00,Adolescent,M01.060.057
21933201,2011-09-20T00:00:00,Adult,M01.060.116
21933201,2011-09-20T00:00:00,Aged,M01.060.116.100
21933201,2011-09-20T00:00:00,Alcohol Deterrents,D27.505.954.427.020
21933201,2011-09-20T00:00:00,Alcohol Drinking,F01.145.317.269
21933201,2011-09-20T00:00:00,Alcoholism,C21.739.100.250
21933201,2011-09-20T00:00:00,Alcoholism,F03.900.100.350
21933201,2011-09-20T00:00:00,"Behavior, Addictive",F01.145.527.100.120
21933201,2011-09-20T00:00:00,Bipolar Disorder,F03.600.150.150
21933201,2011-09-20T00:00:00,Depression,F01.145.126.350
21933201,2011-09-20T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21933201,2011-09-20T00:00:00,Markov Chains,E05.318.740.600.500
21933201,2011-09-20T00:00:00,Markov Chains,E05.318.740.996.500
21933201,2011-09-20T00:00:00,Markov Chains,G17.830.500
21933201,2011-09-20T00:00:00,Markov Chains,N05.715.360.750.625.500
21933201,2011-09-20T00:00:00,Markov Chains,N05.715.360.750.770.500
21933201,2011-09-20T00:00:00,Markov Chains,N06.850.520.830.600.500
21933201,2011-09-20T00:00:00,Markov Chains,N06.850.520.830.996.500
21933201,2011-09-20T00:00:00,Middle Aged,M01.060.116.630
21933201,2011-09-20T00:00:00,Psychiatric Status Rating Scales,F04.586
21933201,2011-09-20T00:00:00,Taurine,D02.455.326.146.100.850
21933201,2011-09-20T00:00:00,Taurine,D02.886.645.600.055.850
21935911,2011-09-20T00:00:00,Adult,M01.060.116
21935911,2011-09-20T00:00:00,Breast Neoplasms,C04.588.180
21935911,2011-09-20T00:00:00,Breast Neoplasms,C17.800.090.500
21935911,2011-09-20T00:00:00,Early Detection of Cancer,E01.390.500
21935911,2011-09-20T00:00:00,"Genes, BRCA1",G05.360.340.024.340.375.249.100
21935911,2011-09-20T00:00:00,"Genes, BRCA1",G05.360.340.024.340.415.400.100
21935911,2011-09-20T00:00:00,"Genes, BRCA2",G05.360.340.024.340.375.249.105
21935911,2011-09-20T00:00:00,"Genes, BRCA2",G05.360.340.024.340.415.400.105
21935911,2011-09-20T00:00:00,Genetic Predisposition to Disease,C23.550.291.687.500
21935911,2011-09-20T00:00:00,Genetic Predisposition to Disease,G05.380.355
21935911,2011-09-20T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21935911,2011-09-20T00:00:00,Magnetic Resonance Imaging,E01.370.350.500
21935911,2011-09-20T00:00:00,Magnetic Resonance Imaging,E01.370.350.825.500
21935911,2011-09-20T00:00:00,Mammography,E01.370.350.700.500
21935911,2011-09-20T00:00:00,Mutation,G05.365.590
21935911,2011-09-20T00:00:00,"Neoplasms, Radiation-Induced",C04.682
21935911,2011-09-20T00:00:00,"Neoplasms, Radiation-Induced",C21.866.733.476
22283380,2011-09-20T00:00:00,Adolescent,M01.060.057
22283380,2011-09-20T00:00:00,Adolescent Behavior,F01.145.022
22283380,2011-09-20T00:00:00,Adolescent Health Services,N02.421.044
22283380,2011-09-20T00:00:00,Combined Modality Therapy,E02.186
22283380,2011-09-20T00:00:00,Communication,F01.145.209
22283380,2011-09-20T00:00:00,Communication,L01.143
22283380,2011-09-20T00:00:00,Conduct Disorder,F03.550.150.300
22283380,2011-09-20T00:00:00,Family Therapy,F04.754.864.581.273
22283380,2011-09-20T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22283380,2011-09-20T00:00:00,Juvenile Delinquency,I01.880.735.479
22283380,2011-09-20T00:00:00,Physician's Practice Patterns,N04.590.748
22283380,2011-09-20T00:00:00,Physician's Practice Patterns,N05.300.625
22283380,2011-09-20T00:00:00,"Quality Assurance, Health Care",N04.761.700
22283380,2011-09-20T00:00:00,"Quality Assurance, Health Care",N05.700
22283380,2011-09-20T00:00:00,United States,Z01.107.567.875
21658140,2011-09-21T00:00:00,Adolescent,M01.060.057
21658140,2011-09-21T00:00:00,Adult,M01.060.116
21658140,2011-09-21T00:00:00,Data Collection,E05.318.308
21658140,2011-09-21T00:00:00,Data Collection,L01.280
21658140,2011-09-21T00:00:00,Data Collection,N05.715.360.300
21658140,2011-09-21T00:00:00,Data Collection,N06.850.520.308
21658140,2011-09-21T00:00:00,"Health Knowledge, Attitudes, Practice",F01.100.150.500
21658140,2011-09-21T00:00:00,"Health Knowledge, Attitudes, Practice",N05.300.150.410
21658140,2011-09-21T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21658140,2011-09-21T00:00:00,Middle Aged,M01.060.116.630
21658140,2011-09-21T00:00:00,Program Evaluation,E05.337.820
21658140,2011-09-21T00:00:00,Program Evaluation,N04.761.685
21658140,2011-09-21T00:00:00,Program Evaluation,N05.715.360.650
21658140,2011-09-21T00:00:00,Smoking,F01.145.466.753
21658140,2011-09-21T00:00:00,Terminology as Topic,L01.143.506.598.400
21658140,2011-09-21T00:00:00,Tobacco Industry,J01.576.919
21658140,2011-09-21T00:00:00,United States,Z01.107.567.875
21658140,2011-09-21T00:00:00,Young Adult,M01.060.116.815
21962456,2011-09-21T00:00:00,Adsorption,G02.149.047
21962456,2011-09-21T00:00:00,Adsorption,G02.149.767.029
21962456,2011-09-21T00:00:00,Adsorption,G02.842.750.029
21962456,2011-09-21T00:00:00,Carbon,D01.268.150
21962456,2011-09-21T00:00:00,Chemical Fractionation,E05.196.155
21962456,2011-09-21T00:00:00,Humic Substances,D02.241.444
21962456,2011-09-21T00:00:00,Humic Substances,D02.755.377
21962456,2011-09-21T00:00:00,Humic Substances,D20.721.500
21962456,2011-09-21T00:00:00,Minerals,D01.578
21962456,2011-09-21T00:00:00,Molecular Weight,G02.842.580
21962456,2011-09-21T00:00:00,Organic Chemicals,D02
21962456,2011-09-21T00:00:00,Plant Leaves,A18.024.812
21962456,2011-09-21T00:00:00,Pyrenes,D02.455.426.559.847.799
21962456,2011-09-21T00:00:00,Pyrenes,D04.615.799
21962456,2011-09-21T00:00:00,Refuse Disposal,N06.850.780.200.800.800.700
21962456,2011-09-21T00:00:00,Refuse Disposal,N06.850.860.510.900.600
21962456,2011-09-21T00:00:00,Solubility,G02.842.800
21962456,2011-09-21T00:00:00,Time Factors,G01.910.857
21938546,2011-09-22T00:00:00,Acoustic Stimulation,E02.037
21938546,2011-09-22T00:00:00,Acoustic Stimulation,E02.190.888.030
21938546,2011-09-22T00:00:00,Acoustic Stimulation,E05.723.136
21938546,2011-09-22T00:00:00,Adult,M01.060.116
21938546,2011-09-22T00:00:00,Aged,M01.060.116.100
21938546,2011-09-22T00:00:00,Aging,G07.700.320.124
21938546,2011-09-22T00:00:00,Auditory Threshold,F02.463.593.071.173
21938546,2011-09-22T00:00:00,Auditory Threshold,F02.463.593.710.190
21938546,2011-09-22T00:00:00,"Hearing Loss, Sensorineural",C09.218.458.341.887
21938546,2011-09-22T00:00:00,"Hearing Loss, Sensorineural",C10.597.751.418.341.887
21938546,2011-09-22T00:00:00,"Hearing Loss, Sensorineural",C23.888.592.763.393.341.887
21938546,2011-09-22T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21938546,2011-09-22T00:00:00,Middle Aged,M01.060.116.630
21938546,2011-09-22T00:00:00,"Models, Neurological",E05.599.395.642
21938546,2011-09-22T00:00:00,Nonlinear Dynamics,E05.599.850
21938546,2011-09-22T00:00:00,Nonlinear Dynamics,H01.548.675
21938546,2011-09-22T00:00:00,Perceptual Masking,F02.463.593.071.594
21938546,2011-09-22T00:00:00,Perceptual Masking,F02.463.593.932.733
21938546,2011-09-22T00:00:00,Presbycusis,C09.218.458.341.887.772
21938546,2011-09-22T00:00:00,Presbycusis,C10.597.751.418.341.887.772
21938546,2011-09-22T00:00:00,Presbycusis,C23.888.592.763.393.341.887.772
21938546,2011-09-22T00:00:00,Young Adult,M01.060.116.815
21940966,2011-09-22T00:00:00,Aged,M01.060.116.100
21940966,2011-09-22T00:00:00,Brain Ischemia,C10.228.140.300.150
21940966,2011-09-22T00:00:00,Brain Ischemia,C14.907.253.092
21940966,2011-09-22T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21940966,2011-09-22T00:00:00,Incidence,E05.318.308.985.525.375
21940966,2011-09-22T00:00:00,Incidence,L01.280.975.525.375
21940966,2011-09-22T00:00:00,Incidence,N01.224.935.597.500
21940966,2011-09-22T00:00:00,Incidence,N06.850.505.400.975.525.375
21940966,2011-09-22T00:00:00,Incidence,N06.850.520.308.985.525.375
21940966,2011-09-22T00:00:00,Risk Factors,E05.318.740.600.800.725
21940966,2011-09-22T00:00:00,Risk Factors,N05.715.350.200.700
21940966,2011-09-22T00:00:00,Risk Factors,N05.715.360.750.625.700.700
21940966,2011-09-22T00:00:00,Risk Factors,N06.850.490.625.750
21940966,2011-09-22T00:00:00,Risk Factors,N06.850.520.830.600.800.725
21940966,2011-09-22T00:00:00,Social Environment,I01.880.656
21940966,2011-09-22T00:00:00,Stroke,C10.228.140.300.775
21940966,2011-09-22T00:00:00,Stroke,C14.907.253.855
21940966,2011-09-22T00:00:00,Urban Population,N01.600.900
21945275,2011-09-22T00:00:00,Adult,M01.060.116
21945275,2011-09-22T00:00:00,Bayes Theorem,E05.318.740.600.200
21945275,2011-09-22T00:00:00,Bayes Theorem,N05.715.360.750.625.150
21945275,2011-09-22T00:00:00,Bayes Theorem,N06.850.520.830.600.200
21945275,2011-09-22T00:00:00,Brain Mapping,E01.370.350.086
21945275,2011-09-22T00:00:00,Brain Mapping,E01.370.376.149
21945275,2011-09-22T00:00:00,Brain Mapping,E05.132
21945275,2011-09-22T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21945275,2011-09-22T00:00:00,"Image Processing, Computer-Assisted",L01.224.308
21945275,2011-09-22T00:00:00,Magnetic Resonance Imaging,E01.370.350.500
21945275,2011-09-22T00:00:00,Magnetic Resonance Imaging,E01.370.350.825.500
21945275,2011-09-22T00:00:00,"Models, Neurological",E05.599.395.642
21945275,2011-09-22T00:00:00,Neurophysiology,H01.158.610.268
21945275,2011-09-22T00:00:00,Neurophysiology,H01.158.782.562
21945275,2011-09-22T00:00:00,Oxygen,D01.268.185.550
21945275,2011-09-22T00:00:00,Oxygen,D01.362.670
21945275,2011-09-22T00:00:00,Photic Stimulation,E05.723.729
21945275,2011-09-22T00:00:00,Regression Analysis,E05.318.740.750
21945275,2011-09-22T00:00:00,Regression Analysis,N05.715.360.750.695
21945275,2011-09-22T00:00:00,Regression Analysis,N06.850.520.830.750
21945275,2011-09-22T00:00:00,Time Factors,G01.910.857
21945275,2011-09-22T00:00:00,Visual Cortex,A08.186.211.730.885.287.500.571.735
21945275,2011-09-22T00:00:00,Young Adult,M01.060.116.815
21939561,2011-09-23T00:00:00,Adult,M01.060.116
21939561,2011-09-23T00:00:00,Aged,M01.060.116.100
21939561,2011-09-23T00:00:00,Alleles,G05.360.340.024.340.030
21939561,2011-09-23T00:00:00,Body Mass Index,E01.370.600.115.100.125
21939561,2011-09-23T00:00:00,Body Mass Index,E05.041.124.125
21939561,2011-09-23T00:00:00,Body Mass Index,G07.100.100.125
21939561,2011-09-23T00:00:00,Body Mass Index,N06.850.505.200.100.175
21939561,2011-09-23T00:00:00,Cardiovascular Diseases,C14
21939561,2011-09-23T00:00:00,"Cholesterol, HDL",D10.532.432.400
21939561,2011-09-23T00:00:00,"Cholesterol, HDL",D10.570.938.208.270
21939561,2011-09-23T00:00:00,"Cholesterol, HDL",D12.776.521.479.470
21939561,2011-09-23T00:00:00,Genetic Predisposition to Disease,C23.550.291.687.500
21939561,2011-09-23T00:00:00,Genetic Predisposition to Disease,G05.380.355
21939561,2011-09-23T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21939561,2011-09-23T00:00:00,Middle Aged,M01.060.116.630
21939561,2011-09-23T00:00:00,Overweight,C23.888.144.699
21939561,2011-09-23T00:00:00,Overweight,E01.370.600.115.100.160.120.699
21939561,2011-09-23T00:00:00,Overweight,G07.100.100.160.120.699
21939561,2011-09-23T00:00:00,"Polymorphism, Genetic",G05.365.795
21939561,2011-09-23T00:00:00,United States,Z01.107.567.875
21945159,2011-09-23T00:00:00,Animals,B01.050
21945159,2011-09-23T00:00:00,"Embolization, Therapeutic",E02.520.360
21945159,2011-09-23T00:00:00,Hydrogels,D20.280.320.375
21945159,2011-09-23T00:00:00,Hydrogels,D26.255.165.320.375
21945159,2011-09-23T00:00:00,"Models, Animal",E05.598
21945159,2011-09-23T00:00:00,Swine,B01.050.150.900.649.077.880
21945159,2011-09-23T00:00:00,Time Factors,G01.910.857
21947792,2011-09-23T00:00:00,Animals,B01.050
21947792,2011-09-23T00:00:00,Cochlear Nerve,A08.800.800.120.910.120
21947792,2011-09-23T00:00:00,"Disease Models, Animal",C22.232
21947792,2011-09-23T00:00:00,"Disease Models, Animal",E05.598.500
21947792,2011-09-23T00:00:00,"Disease Models, Animal",E05.599.395.080
21947792,2011-09-23T00:00:00,"Evoked Potentials, Auditory, Brain Stem",G07.265.500.370.300
21947792,2011-09-23T00:00:00,"Evoked Potentials, Auditory, Brain Stem",G11.561.270.370.300
21947792,2011-09-23T00:00:00,Gene Expression Regulation,G05.355.315
21947792,2011-09-23T00:00:00,"Hearing Loss, Sensorineural",C09.218.458.341.887
21947792,2011-09-23T00:00:00,"Hearing Loss, Sensorineural",C10.597.751.418.341.887
21947792,2011-09-23T00:00:00,"Hearing Loss, Sensorineural",C23.888.592.763.393.341.887
21947792,2011-09-23T00:00:00,"Mice, Inbred CBA",B01.050.050.157.520.440
21947792,2011-09-23T00:00:00,"Mice, Inbred CBA",B01.050.050.199.520.520.440
21947792,2011-09-23T00:00:00,"Mice, Inbred CBA",B01.050.150.900.649.865.635.505.500.400.440
22114938,2011-09-24T00:00:00,Breast Neoplasms,C04.588.180
22114938,2011-09-24T00:00:00,Breast Neoplasms,C17.800.090.500
22114938,2011-09-24T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22114938,2011-09-24T00:00:00,Uterine Neoplasms,C04.588.945.418.948
22114938,2011-09-24T00:00:00,Uterine Neoplasms,C13.351.500.852.762
22114938,2011-09-24T00:00:00,Uterine Neoplasms,C13.351.937.418.875
21902247,2011-09-25T00:00:00,"Biodegradation, Environmental",N06.850.460.375.500
21902247,2011-09-25T00:00:00,"Biodegradation, Environmental",N06.850.860.510.900.299
21902247,2011-09-25T00:00:00,Geologic Sediments,G01.311.500
21902247,2011-09-25T00:00:00,Geologic Sediments,G16.500.320
21902247,2011-09-25T00:00:00,Polychlorinated Biphenyls,D02.455.426.559.389.185.698
21902247,2011-09-25T00:00:00,Polychlorinated Biphenyls,D02.455.526.439.773
21945310,2011-09-25T00:00:00,Aged,M01.060.116.100
21945310,2011-09-25T00:00:00,Antineoplastic Combined Chemotherapy Protocols,E02.183.750.500
21945310,2011-09-25T00:00:00,Antineoplastic Combined Chemotherapy Protocols,E02.319.077.500
21945310,2011-09-25T00:00:00,Antineoplastic Combined Chemotherapy Protocols,E02.319.310.037
21945310,2011-09-25T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21945310,2011-09-25T00:00:00,Middle Aged,M01.060.116.630
21945310,2011-09-25T00:00:00,Ovarian Neoplasms,C04.588.322.455
21945310,2011-09-25T00:00:00,Ovarian Neoplasms,C13.351.500.056.630.705
21945310,2011-09-25T00:00:00,Ovarian Neoplasms,C13.351.937.418.685
21945310,2011-09-25T00:00:00,Ovarian Neoplasms,C19.344.410
21945310,2011-09-25T00:00:00,Ovarian Neoplasms,C19.391.630.705
21945310,2011-09-25T00:00:00,Quality of Life,I01.800
21945310,2011-09-25T00:00:00,Quality of Life,K01.752.400.750
21945462,2011-09-25T00:00:00,Aged,M01.060.116.100
21945462,2011-09-25T00:00:00,Blood-Brain Barrier,A07.035
21945462,2011-09-25T00:00:00,Blood-Brain Barrier,A08.186.211.035
21945462,2011-09-25T00:00:00,Brain Ischemia,C10.228.140.300.150
21945462,2011-09-25T00:00:00,Brain Ischemia,C14.907.253.092
21945462,2011-09-25T00:00:00,Cerebral Hemorrhage,C10.228.140.300.535.200
21945462,2011-09-25T00:00:00,Cerebral Hemorrhage,C14.907.253.573.200
21945462,2011-09-25T00:00:00,Cerebral Hemorrhage,C23.550.414.913.100
21945462,2011-09-25T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21945462,2011-09-25T00:00:00,"Ischemic Attack, Transient",C10.228.140.300.150.836
21945462,2011-09-25T00:00:00,"Ischemic Attack, Transient",C14.907.253.092.836
21945462,2011-09-25T00:00:00,Middle Aged,M01.060.116.630
21945462,2011-09-25T00:00:00,Stroke,C10.228.140.300.775
21945462,2011-09-25T00:00:00,Stroke,C14.907.253.855
21945462,2011-09-25T00:00:00,Vertebrobasilar Insufficiency,C10.228.140.300.150.956
21945462,2011-09-25T00:00:00,Vertebrobasilar Insufficiency,C14.907.253.092.956
21945462,2011-09-25T00:00:00,Vertebrobasilar Insufficiency,C14.907.253.956
21947388,2011-09-26T00:00:00,Adult,M01.060.116
21947388,2011-09-26T00:00:00,Aged,M01.060.116.100
21947388,2011-09-26T00:00:00,Anti-Bacterial Agents,D27.505.954.122.085
21947388,2011-09-26T00:00:00,Creatinine,D03.383.129.308.207
21947388,2011-09-26T00:00:00,Cross Infection,C01.539.248
21947388,2011-09-26T00:00:00,Hospitals,N02.278.421
21947388,2011-09-26T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21947388,2011-09-26T00:00:00,Incidence,E05.318.308.985.525.375
21947388,2011-09-26T00:00:00,Incidence,L01.280.975.525.375
21947388,2011-09-26T00:00:00,Incidence,N01.224.935.597.500
21947388,2011-09-26T00:00:00,Incidence,N06.850.505.400.975.525.375
21947388,2011-09-26T00:00:00,Incidence,N06.850.520.308.985.525.375
21947388,2011-09-26T00:00:00,Kidney Diseases,C12.777.419
21947388,2011-09-26T00:00:00,Kidney Diseases,C13.351.968.419
21947388,2011-09-26T00:00:00,Methicillin-Resistant Staphylococcus aureus,B03.300.390.400.800.750.100.500
21947388,2011-09-26T00:00:00,Methicillin-Resistant Staphylococcus aureus,B03.510.100.750.750.100.500
21947388,2011-09-26T00:00:00,Methicillin-Resistant Staphylococcus aureus,B03.510.400.790.750.100.500
21947388,2011-09-26T00:00:00,Microbial Sensitivity Tests,E05.200.875.595
21947388,2011-09-26T00:00:00,Microbial Sensitivity Tests,E05.337.550.400
21947388,2011-09-26T00:00:00,Middle Aged,M01.060.116.630
21947388,2011-09-26T00:00:00,South Carolina,Z01.107.567.875.075.662
21947388,2011-09-26T00:00:00,South Carolina,Z01.107.567.875.750.700
21947388,2011-09-26T00:00:00,Staphylococcal Infections,C01.252.410.868
21947388,2011-09-26T00:00:00,Treatment Outcome,E01.789.800
21947388,2011-09-26T00:00:00,Treatment Outcome,N04.761.559.590.800
21947388,2011-09-26T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21947388,2011-09-26T00:00:00,Vancomycin,D09.400.420.925
21947388,2011-09-26T00:00:00,Vancomycin,D12.644.233.925
22051420,2011-09-26T00:00:00,Blood Pressure,E01.370.600.875.249
22051420,2011-09-26T00:00:00,Blood Pressure,G09.330.380.076
22051420,2011-09-26T00:00:00,"Blood Pressure Monitoring, Ambulatory",E01.370.370.140.100
22051420,2011-09-26T00:00:00,"Blood Pressure Monitoring, Ambulatory",E01.370.520.500.100
22051420,2011-09-26T00:00:00,Cost-Benefit Analysis,N03.219.151.125
22051420,2011-09-26T00:00:00,Evidence-Based Medicine,H02.249.750
22051420,2011-09-26T00:00:00,Evidence-Based Medicine,H02.403.200.400
22051420,2011-09-26T00:00:00,Health Services Accessibility,N04.590.374.350
22051420,2011-09-26T00:00:00,Health Services Accessibility,N05.300.430
22051420,2011-09-26T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22051420,2011-09-26T00:00:00,Hypertension,C14.907.489
22051420,2011-09-26T00:00:00,Practice Guidelines as Topic,N04.761.700.350.650
22051420,2011-09-26T00:00:00,Practice Guidelines as Topic,N05.700.350.650
22051420,2011-09-26T00:00:00,United States,Z01.107.567.875
21946444,2011-09-27T00:00:00,Adolescent,M01.060.057
21946444,2011-09-27T00:00:00,Adult,M01.060.116
21946444,2011-09-27T00:00:00,Employment,N01.824.245
21946444,2011-09-27T00:00:00,Health Status,I01.240.425
21946444,2011-09-27T00:00:00,Health Status,N01.224.425
21946444,2011-09-27T00:00:00,Health Status,N06.850.505.400.425
21946444,2011-09-27T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21946444,2011-09-27T00:00:00,Middle Aged,M01.060.116.630
21946444,2011-09-27T00:00:00,Quality of Life,I01.800
21946444,2011-09-27T00:00:00,Quality of Life,K01.752.400.750
21946444,2011-09-27T00:00:00,Questionnaires,E05.318.308.750
21946444,2011-09-27T00:00:00,Questionnaires,L01.280.800
21946444,2011-09-27T00:00:00,Questionnaires,N05.715.360.300.695
21946444,2011-09-27T00:00:00,Questionnaires,N06.850.520.308.750
21946444,2011-09-27T00:00:00,Social Adjustment,F01.145.813.621
21946444,2011-09-27T00:00:00,Spinal Cord Injuries,C10.228.854.770
21946444,2011-09-27T00:00:00,Spinal Cord Injuries,C10.900.850
21946444,2011-09-27T00:00:00,Spinal Cord Injuries,C21.866.819
21946444,2011-09-27T00:00:00,Young Adult,M01.060.116.815
21951278,2011-09-27T00:00:00,Adult,M01.060.116
21951278,2011-09-27T00:00:00,Aged,M01.060.116.100
21951278,2011-09-27T00:00:00,Exercise Therapy,E02.779.483
21951278,2011-09-27T00:00:00,Exercise Therapy,E02.831.387
21951278,2011-09-27T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21951278,2011-09-27T00:00:00,Middle Aged,M01.060.116.630
21951278,2011-09-27T00:00:00,Patient Compliance,F01.145.488.500
21951278,2011-09-27T00:00:00,Patient Compliance,N05.300.150.600.600
21951278,2011-09-27T00:00:00,Quality of Life,I01.800
21951278,2011-09-27T00:00:00,Quality of Life,K01.752.400.750
21951278,2011-09-27T00:00:00,"Scleroderma, Systemic",C17.300.799
21951278,2011-09-27T00:00:00,"Scleroderma, Systemic",C17.800.784
21951278,2011-09-27T00:00:00,Treatment Outcome,E01.789.800
21951278,2011-09-27T00:00:00,Treatment Outcome,N04.761.559.590.800
21951278,2011-09-27T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21952248,2011-09-27T00:00:00,Adipocytes,A11.329.114
21952248,2011-09-27T00:00:00,Cell Line,A11.251.210
21952248,2011-09-27T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21952248,2011-09-27T00:00:00,Interleukin-6,D12.644.276.374.465.506
21952248,2011-09-27T00:00:00,Interleukin-6,D12.776.467.374.465.506
21952248,2011-09-27T00:00:00,Interleukin-6,D23.529.374.465.506
21952248,2011-09-27T00:00:00,"Leukocytes, Mononuclear",A11.118.637.555
21952248,2011-09-27T00:00:00,"Leukocytes, Mononuclear",A15.145.229.637.555
21952248,2011-09-27T00:00:00,"Leukocytes, Mononuclear",A15.382.490.555
21952248,2011-09-27T00:00:00,Matrix Metalloproteinase 1,D08.811.277.656.300.480.205.351
21952248,2011-09-27T00:00:00,Matrix Metalloproteinase 1,D08.811.277.656.300.480.525.700.100
21952248,2011-09-27T00:00:00,Matrix Metalloproteinase 1,D08.811.277.656.675.374.205.351
21952248,2011-09-27T00:00:00,Matrix Metalloproteinase 1,D08.811.277.656.675.374.525.700.100
21952248,2011-09-27T00:00:00,Obesity,C18.654.726.500
21952248,2011-09-27T00:00:00,Obesity,C23.888.144.699.500
21952248,2011-09-27T00:00:00,Obesity,E01.370.600.115.100.160.120.699.500
21952248,2011-09-27T00:00:00,Obesity,G07.100.100.160.120.699.500
21952248,2011-09-27T00:00:00,Toll-Like Receptor 4,D12.776.543.750.705.910.500.400
21953736,2011-09-27T00:00:00,Adult,M01.060.116
21953736,2011-09-27T00:00:00,Aged,M01.060.116.100
21953736,2011-09-27T00:00:00,"Arthroplasty, Replacement, Hip",E04.555.110.110.110
21953736,2011-09-27T00:00:00,"Arthroplasty, Replacement, Hip",E04.650.110.110
21953736,2011-09-27T00:00:00,Hip Prosthesis,E07.695.400.400
21953736,2011-09-27T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21953736,2011-09-27T00:00:00,Materials Testing,E05.570
21953736,2011-09-27T00:00:00,Middle Aged,M01.060.116.630
21953736,2011-09-27T00:00:00,Prosthesis Design,E05.320.550
21953736,2011-09-27T00:00:00,Prosthesis Design,E07.695.680
21956146,2011-09-28T00:00:00,Case-Control Studies,E05.318.760.500.500
21956146,2011-09-28T00:00:00,Case-Control Studies,N05.715.360.775.175.200
21956146,2011-09-28T00:00:00,Case-Control Studies,N06.850.520.450.500.500
21956146,2011-09-28T00:00:00,Heart Ventricles,A07.541.560
21956146,2011-09-28T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21956146,2011-09-28T00:00:00,MicroRNAs,D13.150.650.319
21956146,2011-09-28T00:00:00,MicroRNAs,D13.444.735.150.319
21956146,2011-09-28T00:00:00,MicroRNAs,D13.444.735.790.099
21956146,2011-09-28T00:00:00,Middle Aged,M01.060.116.630
21956146,2011-09-28T00:00:00,Myocardial Infarction,C14.280.647.500
21956146,2011-09-28T00:00:00,Myocardial Infarction,C14.907.585.500
21956146,2011-09-28T00:00:00,Pilot Projects,E05.318.760.750
21956146,2011-09-28T00:00:00,Pilot Projects,E05.337.737
21956146,2011-09-28T00:00:00,Pilot Projects,N05.715.360.775.625
21956146,2011-09-28T00:00:00,Pilot Projects,N06.850.520.450.720
21956146,2011-09-28T00:00:00,Ventricular Remodeling,C23.300.985
21956146,2011-09-28T00:00:00,Ventricular Remodeling,G09.330.190.962.975
21956722,2011-09-28T00:00:00,Age Factors,N05.715.350.075
21956722,2011-09-28T00:00:00,Age Factors,N06.850.490.250
21956722,2011-09-28T00:00:00,Blood Pressure,E01.370.600.875.249
21956722,2011-09-28T00:00:00,Blood Pressure,G09.330.380.076
21956722,2011-09-28T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21956722,2011-09-28T00:00:00,Incidence,E05.318.308.985.525.375
21956722,2011-09-28T00:00:00,Incidence,L01.280.975.525.375
21956722,2011-09-28T00:00:00,Incidence,N01.224.935.597.500
21956722,2011-09-28T00:00:00,Incidence,N06.850.505.400.975.525.375
21956722,2011-09-28T00:00:00,Incidence,N06.850.520.308.985.525.375
21956722,2011-09-28T00:00:00,Risk Factors,E05.318.740.600.800.725
21956722,2011-09-28T00:00:00,Risk Factors,N05.715.350.200.700
21956722,2011-09-28T00:00:00,Risk Factors,N05.715.360.750.625.700.700
21956722,2011-09-28T00:00:00,Risk Factors,N06.850.490.625.750
21956722,2011-09-28T00:00:00,Risk Factors,N06.850.520.830.600.800.725
21956722,2011-09-28T00:00:00,Stroke,C10.228.140.300.775
21956722,2011-09-28T00:00:00,Stroke,C14.907.253.855
21957170,2011-09-28T00:00:00,Animals,B01.050
21957170,2011-09-28T00:00:00,Clinical Trials as Topic,E05.318.760.535
21957170,2011-09-28T00:00:00,Clinical Trials as Topic,E05.337.250
21957170,2011-09-28T00:00:00,Clinical Trials as Topic,N05.715.360.775.235
21957170,2011-09-28T00:00:00,Clinical Trials as Topic,N06.850.520.450.535
21957170,2011-09-28T00:00:00,Glutamic Acid,D12.125.067.750
21957170,2011-09-28T00:00:00,Glutamic Acid,D12.125.119.450
21957170,2011-09-28T00:00:00,Glutamic Acid,D12.125.427.300
21957170,2011-09-28T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21957230,2011-09-28T00:00:00,Adult,M01.060.116
21957230,2011-09-28T00:00:00,Aged,M01.060.116.100
21957230,2011-09-28T00:00:00,Animals,B01.050
21957230,2011-09-28T00:00:00,Antineoplastic Combined Chemotherapy Protocols,E02.183.750.500
21957230,2011-09-28T00:00:00,Antineoplastic Combined Chemotherapy Protocols,E02.319.077.500
21957230,2011-09-28T00:00:00,Antineoplastic Combined Chemotherapy Protocols,E02.319.310.037
21957230,2011-09-28T00:00:00,Apoptosis,G04.299.139.160
21957230,2011-09-28T00:00:00,Apoptosis Regulatory Proteins,D12.644.360.075
21957230,2011-09-28T00:00:00,Apoptosis Regulatory Proteins,D12.776.476.075
21957230,2011-09-28T00:00:00,Carcinoma,C04.557.470.200
21957230,2011-09-28T00:00:00,Cell Survival,G04.299.316
21957230,2011-09-28T00:00:00,Down-Regulation,G02.111.087.225
21957230,2011-09-28T00:00:00,Down-Regulation,G02.149.115.225
21957230,2011-09-28T00:00:00,Down-Regulation,G05.355.315.200
21957230,2011-09-28T00:00:00,Down-Regulation,G07.690.812.230
21957230,2011-09-28T00:00:00,Down-Regulation,G07.700.680.230
21957230,2011-09-28T00:00:00,"Gene Expression Regulation, Neoplastic",G05.355.315.370
21957230,2011-09-28T00:00:00,Gene Silencing,G05.355.315.203.374
21957230,2011-09-28T00:00:00,Green Fluorescent Proteins,D12.776.532.265
21957230,2011-09-28T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21957230,2011-09-28T00:00:00,Membrane Proteins,D12.776.543
21957230,2011-09-28T00:00:00,"Microscopy, Electron, Transmission",E01.370.350.515.402.580
21957230,2011-09-28T00:00:00,"Microscopy, Electron, Transmission",E05.595.402.580
21957230,2011-09-28T00:00:00,Middle Aged,M01.060.116.630
21957230,2011-09-28T00:00:00,Ovarian Neoplasms,C04.588.322.455
21957230,2011-09-28T00:00:00,Ovarian Neoplasms,C13.351.500.056.630.705
21957230,2011-09-28T00:00:00,Ovarian Neoplasms,C13.351.937.418.685
21957230,2011-09-28T00:00:00,Ovarian Neoplasms,C19.344.410
21957230,2011-09-28T00:00:00,Ovarian Neoplasms,C19.391.630.705
21957230,2011-09-28T00:00:00,Proto-Oncogene Proteins c-akt,D08.811.913.696.620.682.700.755
21957230,2011-09-28T00:00:00,Proto-Oncogene Proteins c-akt,D12.776.476.565
21957230,2011-09-28T00:00:00,Proto-Oncogene Proteins c-akt,D12.776.624.664.700.168
21957230,2011-09-28T00:00:00,Signal Transduction,G02.111.087.800
21957230,2011-09-28T00:00:00,Signal Transduction,G02.149.115.800
21957230,2011-09-28T00:00:00,Signal Transduction,G04.299.880
21958052,2011-09-29T00:00:00,"Aorta, Thoracic",A07.231.114.056.372
21958052,2011-09-29T00:00:00,"Aortic Aneurysm, Abdominal",C14.907.055.239.075
21958052,2011-09-29T00:00:00,"Aortic Aneurysm, Abdominal",C14.907.109.139.075
21958052,2011-09-29T00:00:00,"Aortic Aneurysm, Thoracic",C14.907.055.239.125
21958052,2011-09-29T00:00:00,"Aortic Aneurysm, Thoracic",C14.907.109.139.125
21958052,2011-09-29T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21958052,2011-09-29T00:00:00,Matrix Metalloproteinases,D08.811.277.656.300.480.525
21958052,2011-09-29T00:00:00,Matrix Metalloproteinases,D08.811.277.656.675.374.525
21958600,2011-09-29T00:00:00,Animals,B01.050
21958600,2011-09-29T00:00:00,"Disease Models, Animal",C22.232
21958600,2011-09-29T00:00:00,"Disease Models, Animal",E05.598.500
21958600,2011-09-29T00:00:00,"Disease Models, Animal",E05.599.395.080
21958600,2011-09-29T00:00:00,Gastric Acid,A12.200.307.603
21958600,2011-09-29T00:00:00,Lung,A04.411
21958600,2011-09-29T00:00:00,"Pneumonia, Aspiration",C08.381.677.529
21958600,2011-09-29T00:00:00,"Pneumonia, Aspiration",C08.730.610.529
21958600,2011-09-29T00:00:00,"Radiography, Thoracic",E01.370.350.700.730
21958600,2011-09-29T00:00:00,Rats,B01.050.150.900.649.865.635.505.700
21958600,2011-09-29T00:00:00,"Rats, Sprague-Dawley",B01.050.150.900.649.865.635.505.700.750
21958600,2011-09-29T00:00:00,X-Ray Diffraction,E05.196.309.742
21958600,2011-09-29T00:00:00,X-Ray Diffraction,E05.196.822.950
21958600,2011-09-29T00:00:00,X-Ray Diffraction,G01.595.861.950
21958600,2011-09-29T00:00:00,X-Ray Diffraction,G02.149.767.915
21958600,2011-09-29T00:00:00,X-Ray Diffraction,G02.842.750.915
21960207,2011-09-29T00:00:00,Combined Modality Therapy,E02.186
21960207,2011-09-29T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21960207,2011-09-29T00:00:00,"Thoracic Surgery, Video-Assisted",E01.370.388.250.840.830
21960207,2011-09-29T00:00:00,"Thoracic Surgery, Video-Assisted",E01.370.388.250.950.830
21960207,2011-09-29T00:00:00,"Thoracic Surgery, Video-Assisted",E04.800.250.840.830
21960207,2011-09-29T00:00:00,"Thoracic Surgery, Video-Assisted",E04.800.250.950.830
21960207,2011-09-29T00:00:00,"Thoracic Surgery, Video-Assisted",E04.928.752.830
21960576,2011-09-29T00:00:00,Aged,M01.060.116.100
21960576,2011-09-29T00:00:00,Brain Ischemia,C10.228.140.300.150
21960576,2011-09-29T00:00:00,Brain Ischemia,C14.907.253.092
21960576,2011-09-29T00:00:00,Cardiovascular Diseases,C14
21960576,2011-09-29T00:00:00,"Databases, Factual",L01.470.750.750
21960576,2011-09-29T00:00:00,"Databases, Factual",L01.700.508.300.188.400
21960576,2011-09-29T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21960576,2011-09-29T00:00:00,Middle Aged,M01.060.116.630
21960576,2011-09-29T00:00:00,Obesity,C18.654.726.500
21960576,2011-09-29T00:00:00,Obesity,C23.888.144.699.500
21960576,2011-09-29T00:00:00,Obesity,E01.370.600.115.100.160.120.699.500
21960576,2011-09-29T00:00:00,Obesity,G07.100.100.160.120.699.500
21960576,2011-09-29T00:00:00,Risk Factors,E05.318.740.600.800.725
21960576,2011-09-29T00:00:00,Risk Factors,N05.715.350.200.700
21960576,2011-09-29T00:00:00,Risk Factors,N05.715.360.750.625.700.700
21960576,2011-09-29T00:00:00,Risk Factors,N06.850.490.625.750
21960576,2011-09-29T00:00:00,Risk Factors,N06.850.520.830.600.800.725
21960576,2011-09-29T00:00:00,Stroke,C10.228.140.300.775
21960576,2011-09-29T00:00:00,Stroke,C14.907.253.855
21962618,2011-09-29T00:00:00,Blood Pressure,E01.370.600.875.249
21962618,2011-09-29T00:00:00,Blood Pressure,G09.330.380.076
21962618,2011-09-29T00:00:00,Creatinine,D03.383.129.308.207
21962618,2011-09-29T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21962618,2011-09-29T00:00:00,Recovery of Function,G16.757
21962618,2011-09-29T00:00:00,Renin,D08.811.277.656.074.500.780
21962618,2011-09-29T00:00:00,Renin,D08.811.277.656.300.048.780
21962618,2011-09-29T00:00:00,Renin,D08.811.277.656.837.750
21962618,2011-09-29T00:00:00,Vasoconstrictor Agents,D27.505.954.411.793
21980518,2011-09-29T00:00:00,Adenosine Triphosphate,D03.438.759.646.138.236
21980518,2011-09-29T00:00:00,Adenosine Triphosphate,D13.695.667.138.236
21980518,2011-09-29T00:00:00,Adenosine Triphosphate,D13.695.827.068.236
21980518,2011-09-29T00:00:00,Animals,B01.050
21980518,2011-09-29T00:00:00,"Embryo, Nonmammalian",A13.350
21980518,2011-09-29T00:00:00,"Embryo, Nonmammalian",A16.331
21980518,2011-09-29T00:00:00,Energy Metabolism,G03.495.335
21980518,2011-09-29T00:00:00,Extracellular Space,A10.082.500
21980518,2011-09-29T00:00:00,Extracellular Space,A11.284.295
21980518,2011-09-29T00:00:00,Microarray Analysis,E05.196.630.570
21980518,2011-09-29T00:00:00,Microarray Analysis,E05.588.570
21980518,2011-09-29T00:00:00,Mitochondria,A11.284.430.214.190.875.564
21980518,2011-09-29T00:00:00,Mitochondria,A11.284.835.626
21980518,2011-09-29T00:00:00,Protons,D01.248.497.300.459.700
21980518,2011-09-29T00:00:00,Protons,D01.435.550
21980518,2011-09-29T00:00:00,Protons,G01.249.765
21980518,2011-09-29T00:00:00,Zebrafish,B01.050.150.900.493.200.244.828
21983168,2011-09-29T00:00:00,"Biodegradation, Environmental",N06.850.460.375.500
21983168,2011-09-29T00:00:00,"Biodegradation, Environmental",N06.850.860.510.900.299
21983220,2011-09-29T00:00:00,Case-Control Studies,E05.318.760.500.500
21983220,2011-09-29T00:00:00,Case-Control Studies,N05.715.360.775.175.200
21983220,2011-09-29T00:00:00,Case-Control Studies,N06.850.520.450.500.500
21983220,2011-09-29T00:00:00,"Gene Expression Regulation, Neoplastic",G05.355.315.370
21983220,2011-09-29T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21983220,2011-09-29T00:00:00,Protein Isoforms,D12.776.800
21983220,2011-09-29T00:00:00,"Receptors, Thromboxane",D12.776.543.750.075.800
21983220,2011-09-29T00:00:00,"Receptors, Thromboxane",D12.776.543.750.100.200.800
21983220,2011-09-29T00:00:00,Signal Transduction,G02.111.087.800
21983220,2011-09-29T00:00:00,Signal Transduction,G02.149.115.800
21983220,2011-09-29T00:00:00,Signal Transduction,G04.299.880
21983220,2011-09-29T00:00:00,Thromboxane B2,D10.251.355.255.100.825.810
21983220,2011-09-29T00:00:00,Thromboxane B2,D23.469.050.175.800.810
21983220,2011-09-29T00:00:00,Thromboxane-A Synthase,D08.811.399.475.900
21983220,2011-09-29T00:00:00,"Tumor Markers, Biological",D23.101.840
21983220,2011-09-29T00:00:00,United States,Z01.107.567.875
21983220,2011-09-29T00:00:00,Urinary Bladder Neoplasms,C04.588.945.947.960
21983220,2011-09-29T00:00:00,Urinary Bladder Neoplasms,C12.758.820.968
21983220,2011-09-29T00:00:00,Urinary Bladder Neoplasms,C12.777.829.813
21983220,2011-09-29T00:00:00,Urinary Bladder Neoplasms,C13.351.937.820.945
21983220,2011-09-29T00:00:00,Urinary Bladder Neoplasms,C13.351.968.829.707
21965516,2011-09-30T00:00:00,Adult,M01.060.116
21965516,2011-09-30T00:00:00,Aged,M01.060.116.100
21965516,2011-09-30T00:00:00,Alcohol Drinking,F01.145.317.269
21965516,2011-09-30T00:00:00,Blood Pressure,E01.370.600.875.249
21965516,2011-09-30T00:00:00,Blood Pressure,G09.330.380.076
21965516,2011-09-30T00:00:00,Body Mass Index,E01.370.600.115.100.125
21965516,2011-09-30T00:00:00,Body Mass Index,E05.041.124.125
21965516,2011-09-30T00:00:00,Body Mass Index,G07.100.100.125
21965516,2011-09-30T00:00:00,Body Mass Index,N06.850.505.200.100.175
21965516,2011-09-30T00:00:00,C-Reactive Protein,D12.776.034.145
21965516,2011-09-30T00:00:00,C-Reactive Protein,D12.776.124.050.120
21965516,2011-09-30T00:00:00,C-Reactive Protein,D12.776.124.486.157
21965516,2011-09-30T00:00:00,Cardiovascular Diseases,C14
21965516,2011-09-30T00:00:00,Diet,E05.272
21965516,2011-09-30T00:00:00,Diet,G07.610.240
21965516,2011-09-30T00:00:00,Exercise,G11.427.590.237
21965516,2011-09-30T00:00:00,Exercise,I03.350
21965516,2011-09-30T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21965516,2011-09-30T00:00:00,Life Style,F01.829.458
21965516,2011-09-30T00:00:00,Middle Aged,M01.060.116.630
21965516,2011-09-30T00:00:00,Nutrition Surveys,E05.318.308.250.600
21965516,2011-09-30T00:00:00,Nutrition Surveys,E05.318.308.585.550
21965516,2011-09-30T00:00:00,Nutrition Surveys,N05.715.360.300.375.560
21965516,2011-09-30T00:00:00,Nutrition Surveys,N05.715.360.300.560.565
21965516,2011-09-30T00:00:00,Nutrition Surveys,N06.850.520.308.250.600
21965516,2011-09-30T00:00:00,Nutrition Surveys,N06.850.520.308.585.550
21965516,2011-09-30T00:00:00,Risk Factors,E05.318.740.600.800.725
21965516,2011-09-30T00:00:00,Risk Factors,N05.715.350.200.700
21965516,2011-09-30T00:00:00,Risk Factors,N05.715.360.750.625.700.700
21965516,2011-09-30T00:00:00,Risk Factors,N06.850.490.625.750
21965516,2011-09-30T00:00:00,Risk Factors,N06.850.520.830.600.800.725
21965516,2011-09-30T00:00:00,Smoking,F01.145.466.753
21965516,2011-09-30T00:00:00,Young Adult,M01.060.116.815
21302279,2011-10-01T00:00:00,"Gene Expression Regulation, Neoplastic",G05.355.315.370
21302279,2011-10-01T00:00:00,Glycoproteins,D09.400.430
21302279,2011-10-01T00:00:00,Glycoproteins,D12.776.395
21302279,2011-10-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21302279,2011-10-01T00:00:00,Intercellular Signaling Peptides and Proteins,D12.644.276
21302279,2011-10-01T00:00:00,Intercellular Signaling Peptides and Proteins,D12.776.467
21302279,2011-10-01T00:00:00,Intercellular Signaling Peptides and Proteins,D23.529
21302279,2011-10-01T00:00:00,Neoplasm Invasiveness,C04.697.645
21302279,2011-10-01T00:00:00,Neoplasm Invasiveness,C23.550.727.645
21302279,2011-10-01T00:00:00,Phenotype,G05.695
21302279,2011-10-01T00:00:00,"Receptor, Epidermal Growth Factor",D08.811.913.696.620.682.725.400.100
21302279,2011-10-01T00:00:00,"Receptor, Epidermal Growth Factor",D12.776.543.750.060.249
21302279,2011-10-01T00:00:00,"Receptor, Epidermal Growth Factor",D12.776.543.750.750.360.300
21302279,2011-10-01T00:00:00,"Receptor, Epidermal Growth Factor",D12.776.543.750.750.400.340
21302279,2011-10-01T00:00:00,Signal Transduction,G02.111.087.800
21302279,2011-10-01T00:00:00,Signal Transduction,G02.149.115.800
21302279,2011-10-01T00:00:00,Signal Transduction,G04.299.880
21318376,2011-10-01T00:00:00,Colorectal Neoplasms,C04.588.274.476.411.307
21318376,2011-10-01T00:00:00,Colorectal Neoplasms,C06.301.371.411.307
21318376,2011-10-01T00:00:00,Colorectal Neoplasms,C06.405.249.411.307
21318376,2011-10-01T00:00:00,Colorectal Neoplasms,C06.405.469.158.356
21318376,2011-10-01T00:00:00,Colorectal Neoplasms,C06.405.469.491.307
21318376,2011-10-01T00:00:00,Colorectal Neoplasms,C06.405.469.860.180
21318376,2011-10-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21318376,2011-10-01T00:00:00,Mass Screening,E01.370.500
21318376,2011-10-01T00:00:00,Mass Screening,E05.318.308.250.580
21318376,2011-10-01T00:00:00,Mass Screening,N02.421.143.827.233.443
21318376,2011-10-01T00:00:00,Mass Screening,N02.421.726.233.443
21318376,2011-10-01T00:00:00,Mass Screening,N05.715.360.300.375.500
21318376,2011-10-01T00:00:00,Mass Screening,N06.850.520.308.250.580
21318376,2011-10-01T00:00:00,Mass Screening,N06.850.780.500
21318376,2011-10-01T00:00:00,Physician's Practice Patterns,N04.590.748
21318376,2011-10-01T00:00:00,Physician's Practice Patterns,N05.300.625
21318376,2011-10-01T00:00:00,Pilot Projects,E05.318.760.750
21318376,2011-10-01T00:00:00,Pilot Projects,E05.337.737
21318376,2011-10-01T00:00:00,Pilot Projects,N05.715.360.775.625
21318376,2011-10-01T00:00:00,Pilot Projects,N06.850.520.450.720
21318376,2011-10-01T00:00:00,Questionnaires,E05.318.308.750
21318376,2011-10-01T00:00:00,Questionnaires,L01.280.800
21318376,2011-10-01T00:00:00,Questionnaires,N05.715.360.300.695
21318376,2011-10-01T00:00:00,Questionnaires,N06.850.520.308.750
21318376,2011-10-01T00:00:00,Regression Analysis,E05.318.740.750
21318376,2011-10-01T00:00:00,Regression Analysis,N05.715.360.750.695
21318376,2011-10-01T00:00:00,Regression Analysis,N06.850.520.830.750
21399568,2011-10-01T00:00:00,Adult,M01.060.116
21399568,2011-10-01T00:00:00,African Americans,M01.686.508.100.100
21399568,2011-10-01T00:00:00,African Americans,M01.686.754.100
21399568,2011-10-01T00:00:00,Antisocial Personality Disorder,F03.675.050
21399568,2011-10-01T00:00:00,Child,M01.060.406
21399568,2011-10-01T00:00:00,Child Abuse,I01.198.240.856.350.250
21399568,2011-10-01T00:00:00,Child Abuse,I01.880.735.900.350.250
21399568,2011-10-01T00:00:00,Child Abuse,I01.880.787.293.292
21399568,2011-10-01T00:00:00,European Continental Ancestry Group,M01.686.508.400
21399568,2011-10-01T00:00:00,Genetic Predisposition to Disease,C23.550.291.687.500
21399568,2011-10-01T00:00:00,Genetic Predisposition to Disease,G05.380.355
21399568,2011-10-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21399568,2011-10-01T00:00:00,Risk Factors,E05.318.740.600.800.725
21399568,2011-10-01T00:00:00,Risk Factors,N05.715.350.200.700
21399568,2011-10-01T00:00:00,Risk Factors,N05.715.360.750.625.700.700
21399568,2011-10-01T00:00:00,Risk Factors,N06.850.490.625.750
21399568,2011-10-01T00:00:00,Risk Factors,N06.850.520.830.600.800.725
21399568,2011-10-01T00:00:00,Serotonin Plasma Membrane Transport Proteins,D12.776.157.530.450.625.311
21399568,2011-10-01T00:00:00,Serotonin Plasma Membrane Transport Proteins,D12.776.157.530.562.374.875
21399568,2011-10-01T00:00:00,Serotonin Plasma Membrane Transport Proteins,D12.776.543.585.450.625.374
21399568,2011-10-01T00:00:00,Serotonin Plasma Membrane Transport Proteins,D12.776.543.585.562.374.875
21508881,2011-10-01T00:00:00,Brain,A08.186.211
21508881,2011-10-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21508881,2011-10-01T00:00:00,"Monitoring, Physiologic",E01.370.520
21508881,2011-10-01T00:00:00,Subarachnoid Hemorrhage,C10.228.140.300.535.800
21508881,2011-10-01T00:00:00,Subarachnoid Hemorrhage,C14.907.253.573.800
21508881,2011-10-01T00:00:00,Subarachnoid Hemorrhage,C23.550.414.913.850
21706518,2011-10-01T00:00:00,Dietary Supplements,J02.500.456
21706518,2011-10-01T00:00:00,Double-Blind Method,E05.318.780.300
21706518,2011-10-01T00:00:00,Double-Blind Method,E05.581.500.300
21706518,2011-10-01T00:00:00,Double-Blind Method,N05.715.360.780.320
21706518,2011-10-01T00:00:00,Double-Blind Method,N06.850.520.445.300
21706518,2011-10-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21706518,2011-10-01T00:00:00,Pregnancy,G08.686.785.760.769
21706518,2011-10-01T00:00:00,Vitamin D,D04.808.812.768
21748433,2011-10-01T00:00:00,African Continental Ancestry Group,M01.686.508.100
21748433,2011-10-01T00:00:00,Blood Pressure,E01.370.600.875.249
21748433,2011-10-01T00:00:00,Blood Pressure,G09.330.380.076
21748433,2011-10-01T00:00:00,European Continental Ancestry Group,M01.686.508.400
21748433,2011-10-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21748433,2011-10-01T00:00:00,Vitamin D,D04.808.812.768
21795855,2011-10-01T00:00:00,Animals,B01.050
21795855,2011-10-01T00:00:00,Antineoplastic Combined Chemotherapy Protocols,E02.183.750.500
21795855,2011-10-01T00:00:00,Antineoplastic Combined Chemotherapy Protocols,E02.319.077.500
21795855,2011-10-01T00:00:00,Antineoplastic Combined Chemotherapy Protocols,E02.319.310.037
21795855,2011-10-01T00:00:00,Ceramides,D02.065.313
21795855,2011-10-01T00:00:00,Ceramides,D09.400.410.420.525.200
21795855,2011-10-01T00:00:00,Ceramides,D10.390.470.675.200
21795855,2011-10-01T00:00:00,Ceramides,D10.570.877.360.612.200
21795855,2011-10-01T00:00:00,Deoxycytidine,D03.383.742.680.245.500
21795855,2011-10-01T00:00:00,Deoxycytidine,D13.570.230.329
21795855,2011-10-01T00:00:00,Deoxycytidine,D13.570.685.245.500
21795855,2011-10-01T00:00:00,Drug Carriers,D26.255.260
21795855,2011-10-01T00:00:00,Drug Carriers,D27.720.280.260
21795855,2011-10-01T00:00:00,Drug Carriers,E02.319.300.380
21795855,2011-10-01T00:00:00,"Drug Resistance, Neoplasm",G07.690.320.395
21795855,2011-10-01T00:00:00,Enzyme Inhibitors,D27.505.519.389
21795855,2011-10-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21795855,2011-10-01T00:00:00,Liposomes,D25.479.517
21795855,2011-10-01T00:00:00,Liposomes,D26.255.260.517
21795855,2011-10-01T00:00:00,Liposomes,D27.720.280.260.517
21795855,2011-10-01T00:00:00,Liposomes,J01.637.051.479.517
21795855,2011-10-01T00:00:00,Liposomes,J01.637.087.500.517
21795855,2011-10-01T00:00:00,MAP Kinase Signaling System,G02.111.087.800.560
21795855,2011-10-01T00:00:00,MAP Kinase Signaling System,G02.149.115.800.560
21795855,2011-10-01T00:00:00,MAP Kinase Signaling System,G03.495.553.560
21795855,2011-10-01T00:00:00,MAP Kinase Signaling System,G04.299.880.560
21795855,2011-10-01T00:00:00,Nanoparticles,J01.637.512.600
21795855,2011-10-01T00:00:00,Pancreatic Neoplasms,C04.588.274.761
21795855,2011-10-01T00:00:00,Pancreatic Neoplasms,C04.588.322.421
21795855,2011-10-01T00:00:00,Pancreatic Neoplasms,C06.301.761
21795855,2011-10-01T00:00:00,Pancreatic Neoplasms,C06.689.667
21795855,2011-10-01T00:00:00,Pancreatic Neoplasms,C19.344.421
21795855,2011-10-01T00:00:00,Proto-Oncogene Proteins c-akt,D08.811.913.696.620.682.700.755
21795855,2011-10-01T00:00:00,Proto-Oncogene Proteins c-akt,D12.776.476.565
21795855,2011-10-01T00:00:00,Proto-Oncogene Proteins c-akt,D12.776.624.664.700.168
21892036,2011-10-01T00:00:00,Adult,M01.060.116
21892036,2011-10-01T00:00:00,Aged,M01.060.116.100
21892036,2011-10-01T00:00:00,"Antibodies, Monoclonal",D12.776.124.486.485.114.224
21892036,2011-10-01T00:00:00,"Antibodies, Monoclonal",D12.776.124.790.651.114.224
21892036,2011-10-01T00:00:00,"Antibodies, Monoclonal",D12.776.377.715.548.114.224
21892036,2011-10-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21892036,2011-10-01T00:00:00,Middle Aged,M01.060.116.630
21892036,2011-10-01T00:00:00,Positron-Emission Tomography,E01.370.350.350.800.700
21892036,2011-10-01T00:00:00,Positron-Emission Tomography,E01.370.350.600.350.800.399
21892036,2011-10-01T00:00:00,Positron-Emission Tomography,E01.370.350.710.800.399
21892036,2011-10-01T00:00:00,Positron-Emission Tomography,E01.370.350.825.800.399
21892036,2011-10-01T00:00:00,Positron-Emission Tomography,E01.370.384.730.800.399
21892036,2011-10-01T00:00:00,Prostatic Neoplasms,C04.588.945.440.770
21892036,2011-10-01T00:00:00,Prostatic Neoplasms,C12.294.260.750
21892036,2011-10-01T00:00:00,Prostatic Neoplasms,C12.294.565.625
21892036,2011-10-01T00:00:00,Prostatic Neoplasms,C12.758.409.750
21892036,2011-10-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.350.810
21892036,2011-10-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.600.350.700.810
21892036,2011-10-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.700.700.810
21892036,2011-10-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.700.810.810
21892036,2011-10-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.825.810.810
21893582,2011-10-01T00:00:00,Adult,M01.060.116
21893582,2011-10-01T00:00:00,Autoantibodies,D12.776.124.486.485.114.323
21893582,2011-10-01T00:00:00,Autoantibodies,D12.776.124.790.651.114.323
21893582,2011-10-01T00:00:00,Autoantibodies,D12.776.377.715.548.114.323
21893582,2011-10-01T00:00:00,Biological Markers,D23.101
21893582,2011-10-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21893582,2011-10-01T00:00:00,"Lupus Erythematosus, Systemic",C17.300.480
21893582,2011-10-01T00:00:00,"Lupus Erythematosus, Systemic",C20.111.590
21893582,2011-10-01T00:00:00,Mental Disorders,F03
21893582,2011-10-01T00:00:00,Middle Aged,M01.060.116.630
21893582,2011-10-01T00:00:00,Psychotic Disorders,F03.700.675
21893582,2011-10-01T00:00:00,Young Adult,M01.060.116.815
21897204,2011-10-01T00:00:00,Animals,B01.050
21897204,2011-10-01T00:00:00,Attention Deficit Disorder with Hyperactivity,F03.550.150.150
21897204,2011-10-01T00:00:00,"Behavior, Animal",F01.145.113
21897204,2011-10-01T00:00:00,Central Nervous System Stimulants,D27.505.696.282
21897204,2011-10-01T00:00:00,Central Nervous System Stimulants,D27.505.954.427.220
21897204,2011-10-01T00:00:00,"Conditioning, Operant",F02.463.425.179.509
21897204,2011-10-01T00:00:00,Cues,F02.463.425.234
21897204,2011-10-01T00:00:00,Methylphenidate,D02.241.223.601.600
21897204,2011-10-01T00:00:00,Methylphenidate,D03.383.621.460
21897204,2011-10-01T00:00:00,Motivation,F01.658
21897204,2011-10-01T00:00:00,Motivation,F01.752.543.500.750
21897204,2011-10-01T00:00:00,Rats,B01.050.150.900.649.865.635.505.700
21897204,2011-10-01T00:00:00,"Rats, Sprague-Dawley",B01.050.150.900.649.865.635.505.700.750
21897204,2011-10-01T00:00:00,Self Administration,E02.319.890
21897204,2011-10-01T00:00:00,Self Administration,E02.900.890
21897204,2011-10-01T00:00:00,Time Factors,G01.910.857
21917913,2011-10-01T00:00:00,African Americans,M01.686.508.100.100
21917913,2011-10-01T00:00:00,African Americans,M01.686.754.100
21917913,2011-10-01T00:00:00,"Antibodies, Antinuclear",D12.776.124.486.485.114.323.204
21917913,2011-10-01T00:00:00,"Antibodies, Antinuclear",D12.776.124.790.651.114.323.204
21917913,2011-10-01T00:00:00,"Antibodies, Antinuclear",D12.776.377.715.548.114.323.204
21917913,2011-10-01T00:00:00,Case-Control Studies,E05.318.760.500.500
21917913,2011-10-01T00:00:00,Case-Control Studies,N05.715.360.775.175.200
21917913,2011-10-01T00:00:00,Case-Control Studies,N06.850.520.450.500.500
21917913,2011-10-01T00:00:00,Disease Progression,C23.550.291.656
21917913,2011-10-01T00:00:00,Genetic Predisposition to Disease,C23.550.291.687.500
21917913,2011-10-01T00:00:00,Genetic Predisposition to Disease,G05.380.355
21917913,2011-10-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21917913,2011-10-01T00:00:00,"Lupus Erythematosus, Systemic",C17.300.480
21917913,2011-10-01T00:00:00,"Lupus Erythematosus, Systemic",C20.111.590
21917913,2011-10-01T00:00:00,South Carolina,Z01.107.567.875.075.662
21917913,2011-10-01T00:00:00,South Carolina,Z01.107.567.875.750.700
21917913,2011-10-01T00:00:00,Vitamin D,D04.808.812.768
21933993,2011-10-01T00:00:00,Animals,B01.050
21933993,2011-10-01T00:00:00,Carbohydrates,D09
21933993,2011-10-01T00:00:00,Chick Embryo,A13.350.150
21933993,2011-10-01T00:00:00,Chick Embryo,A16.331.200
21933993,2011-10-01T00:00:00,Liver,A03.620
21934019,2011-10-01T00:00:00,Animals,B01.050
21934019,2011-10-01T00:00:00,Brain Chemistry,G02.111.100
21934019,2011-10-01T00:00:00,Brain Chemistry,G03.200
21934019,2011-10-01T00:00:00,Chickens,B01.050.150.900.248.350.150
21934019,2011-10-01T00:00:00,Chickens,B01.050.150.900.248.617.192
21934019,2011-10-01T00:00:00,Corticosterone,D04.808.745.745.654.237
21934019,2011-10-01T00:00:00,Corticosterone,D06.472.040.585.353.237
21934019,2011-10-01T00:00:00,"Muscle, Skeletal",A02.633.567
21934019,2011-10-01T00:00:00,"Muscle, Skeletal",A10.690.552.500
21934019,2011-10-01T00:00:00,Poultry Diseases,C22.131.728
21934019,2011-10-01T00:00:00,"Stress, Psychological",F01.145.126.990
21934019,2011-10-01T00:00:00,"Stress, Psychological",F02.830.900
21947636,2011-10-01T00:00:00,Endoscopy,E01.370.388.250
21947636,2011-10-01T00:00:00,Endoscopy,E04.800.250
21947636,2011-10-01T00:00:00,Gastric Bypass,E02.065.062.249
21947636,2011-10-01T00:00:00,Gastric Bypass,E04.035.398.385
21947636,2011-10-01T00:00:00,Gastric Bypass,E04.062.249
21947636,2011-10-01T00:00:00,Gastric Bypass,E04.210.457.430
21947636,2011-10-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21947636,2011-10-01T00:00:00,Obesity,C18.654.726.500
21947636,2011-10-01T00:00:00,Obesity,C23.888.144.699.500
21947636,2011-10-01T00:00:00,Obesity,E01.370.600.115.100.160.120.699.500
21947636,2011-10-01T00:00:00,Obesity,G07.100.100.160.120.699.500
21947636,2011-10-01T00:00:00,Weight Loss,C23.888.144.243.963
21947636,2011-10-01T00:00:00,Weight Loss,G07.700.320.249.314.120.200.963
21951411,2011-10-01T00:00:00,Adult,M01.060.116
21951411,2011-10-01T00:00:00,African Americans,M01.686.508.100.100
21951411,2011-10-01T00:00:00,African Americans,M01.686.754.100
21951411,2011-10-01T00:00:00,Aged,M01.060.116.100
21951411,2011-10-01T00:00:00,Diabetes Complications,C19.246.099
21951411,2011-10-01T00:00:00,"Hemoglobin A, Glycosylated",D09.408.375
21951411,2011-10-01T00:00:00,"Hemoglobin A, Glycosylated",D12.776.124.400.405.440
21951411,2011-10-01T00:00:00,"Hemoglobin A, Glycosylated",D12.776.422.316.762.380.440
21951411,2011-10-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21951411,2011-10-01T00:00:00,Hypertension,C14.907.489
21951411,2011-10-01T00:00:00,"Lipoproteins, LDL",D10.532.515
21951411,2011-10-01T00:00:00,"Lipoproteins, LDL",D12.776.521.550
21951411,2011-10-01T00:00:00,Middle Aged,M01.060.116.630
21951411,2011-10-01T00:00:00,Patient Compliance,F01.145.488.500
21951411,2011-10-01T00:00:00,Patient Compliance,N05.300.150.600.600
21951411,2011-10-01T00:00:00,Patient Education as Topic,I02.233.332.500
21951411,2011-10-01T00:00:00,Patient Education as Topic,N02.421.143.827.407.680
21951411,2011-10-01T00:00:00,Patient Education as Topic,N02.421.726.407.680
21951411,2011-10-01T00:00:00,Platelet Aggregation Inhibitors,D27.505.954.502.780
21951411,2011-10-01T00:00:00,Risk Factors,E05.318.740.600.800.725
21951411,2011-10-01T00:00:00,Risk Factors,N05.715.350.200.700
21951411,2011-10-01T00:00:00,Risk Factors,N05.715.360.750.625.700.700
21951411,2011-10-01T00:00:00,Risk Factors,N06.850.490.625.750
21951411,2011-10-01T00:00:00,Risk Factors,N06.850.520.830.600.800.725
21951411,2011-10-01T00:00:00,Secondary Prevention,N02.421.726.825
21951411,2011-10-01T00:00:00,Secondary Prevention,N06.850.780.750
21951411,2011-10-01T00:00:00,Stroke,C10.228.140.300.775
21951411,2011-10-01T00:00:00,Stroke,C14.907.253.855
21951411,2011-10-01T00:00:00,Urban Population,N01.600.900
21952173,2011-10-01T00:00:00,"History, 19th Century",K01.400.504.937
21952173,2011-10-01T00:00:00,"History, 20th Century",K01.400.504.968
21952173,2011-10-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21952173,2011-10-01T00:00:00,Informed Consent,I01.880.604.473.650.718
21952173,2011-10-01T00:00:00,Informed Consent,I01.880.604.583.427
21952173,2011-10-01T00:00:00,Informed Consent,N03.706.437.650.312
21952173,2011-10-01T00:00:00,Informed Consent,N03.706.535.489
21952173,2011-10-01T00:00:00,Social Environment,I01.880.656
21956181,2011-10-01T00:00:00,Anticoagulants,D27.505.954.502.119
21956181,2011-10-01T00:00:00,"Arthroplasty, Replacement",E04.555.110.110
21956181,2011-10-01T00:00:00,"Arthroplasty, Replacement",E04.650.110
21956181,2011-10-01T00:00:00,"Clinical Trials, Phase III as Topic",E05.318.760.535.220
21956181,2011-10-01T00:00:00,"Clinical Trials, Phase III as Topic",E05.337.250.220
21956181,2011-10-01T00:00:00,"Clinical Trials, Phase III as Topic",N05.715.360.775.235.220
21956181,2011-10-01T00:00:00,"Clinical Trials, Phase III as Topic",N06.850.520.450.535.220
21956181,2011-10-01T00:00:00,Enoxaparin,D09.698.373.400.300.200
21956181,2011-10-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21956181,2011-10-01T00:00:00,Pyrazoles,D03.383.129.539
21956181,2011-10-01T00:00:00,Pyridones,D03.383.725.791
21956181,2011-10-01T00:00:00,Thiophenes,D02.886.778
21956181,2011-10-01T00:00:00,Thiophenes,D03.383.903
21956181,2011-10-01T00:00:00,Treatment Outcome,E01.789.800
21956181,2011-10-01T00:00:00,Treatment Outcome,N04.761.559.590.800
21956181,2011-10-01T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21956181,2011-10-01T00:00:00,Venous Thromboembolism,C14.907.355.590.700
21956181,2011-10-01T00:00:00,Venous Thromboembolism,C14.907.355.830.850.700
21958761,2011-10-01T00:00:00,Cardiac Surgical Procedures,E04.100.376
21958761,2011-10-01T00:00:00,Cardiac Surgical Procedures,E04.928.220
21958761,2011-10-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21958761,2011-10-01T00:00:00,Informed Consent,I01.880.604.473.650.718
21958761,2011-10-01T00:00:00,Informed Consent,I01.880.604.583.427
21958761,2011-10-01T00:00:00,Informed Consent,N03.706.437.650.312
21958761,2011-10-01T00:00:00,Informed Consent,N03.706.535.489
21958761,2011-10-01T00:00:00,Middle Aged,M01.060.116.630
21958761,2011-10-01T00:00:00,Patient Education as Topic,I02.233.332.500
21958761,2011-10-01T00:00:00,Patient Education as Topic,N02.421.143.827.407.680
21958761,2011-10-01T00:00:00,Patient Education as Topic,N02.421.726.407.680
21958761,2011-10-01T00:00:00,Physician-Patient Relations,F01.829.401.650.675
21958761,2011-10-01T00:00:00,Physician-Patient Relations,N05.300.660.625
21962318,2011-10-01T00:00:00,Adolescent,M01.060.057
21962318,2011-10-01T00:00:00,Adult,M01.060.116
21962318,2011-10-01T00:00:00,Aged,M01.060.116.100
21962318,2011-10-01T00:00:00,Gastrointestinal Hemorrhage,C06.405.227
21962318,2011-10-01T00:00:00,Gastrointestinal Hemorrhage,C23.550.414.788
21962318,2011-10-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21962318,2011-10-01T00:00:00,Middle Aged,M01.060.116.630
21962318,2011-10-01T00:00:00,Risk Factors,E05.318.740.600.800.725
21962318,2011-10-01T00:00:00,Risk Factors,N05.715.350.200.700
21962318,2011-10-01T00:00:00,Risk Factors,N05.715.360.750.625.700.700
21962318,2011-10-01T00:00:00,Risk Factors,N06.850.490.625.750
21962318,2011-10-01T00:00:00,Risk Factors,N06.850.520.830.600.800.725
21962318,2011-10-01T00:00:00,Young Adult,M01.060.116.815
21962627,2011-10-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21962627,2011-10-01T00:00:00,"Infant, Newborn",M01.060.703.520
21962627,2011-10-01T00:00:00,Pregnancy,G08.686.785.760.769
21962627,2011-10-01T00:00:00,"Pregnancy, Multiple",G08.686.710
21962627,2011-10-01T00:00:00,"Pregnancy, Multiple",G08.686.785.760.769.525
21962627,2011-10-01T00:00:00,Premature Birth,C13.703.420.491.500
21963121,2011-10-01T00:00:00,Adult,M01.060.116
21963121,2011-10-01T00:00:00,Aged,M01.060.116.100
21963121,2011-10-01T00:00:00,Health Services Accessibility,N04.590.374.350
21963121,2011-10-01T00:00:00,Health Services Accessibility,N05.300.430
21963121,2011-10-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21963121,2011-10-01T00:00:00,Incidence,E05.318.308.985.525.375
21963121,2011-10-01T00:00:00,Incidence,L01.280.975.525.375
21963121,2011-10-01T00:00:00,Incidence,N01.224.935.597.500
21963121,2011-10-01T00:00:00,Incidence,N06.850.505.400.975.525.375
21963121,2011-10-01T00:00:00,Incidence,N06.850.520.308.985.525.375
21963121,2011-10-01T00:00:00,Length of Stay,E02.760.400.480
21963121,2011-10-01T00:00:00,Length of Stay,N02.421.585.400.480
21963121,2011-10-01T00:00:00,Middle Aged,M01.060.116.630
21963121,2011-10-01T00:00:00,South Carolina,Z01.107.567.875.075.662
21963121,2011-10-01T00:00:00,South Carolina,Z01.107.567.875.750.700
21963121,2011-10-01T00:00:00,Spinal Cord Injuries,C10.228.854.770
21963121,2011-10-01T00:00:00,Spinal Cord Injuries,C10.900.850
21963121,2011-10-01T00:00:00,Spinal Cord Injuries,C21.866.819
21963121,2011-10-01T00:00:00,Venous Thromboembolism,C14.907.355.590.700
21963121,2011-10-01T00:00:00,Venous Thromboembolism,C14.907.355.830.850.700
21963202,2011-10-01T00:00:00,Adult,M01.060.116
21963202,2011-10-01T00:00:00,Age Factors,N05.715.350.075
21963202,2011-10-01T00:00:00,Age Factors,N06.850.490.250
21963202,2011-10-01T00:00:00,Blood Glucose,D09.546.359.448.500
21963202,2011-10-01T00:00:00,"Diabetes Mellitus, Type 2",C18.452.394.750.149
21963202,2011-10-01T00:00:00,"Diabetes Mellitus, Type 2",C19.246.300
21963202,2011-10-01T00:00:00,"Diabetes, Gestational",C13.703.170
21963202,2011-10-01T00:00:00,"Diabetes, Gestational",C18.452.394.750.448
21963202,2011-10-01T00:00:00,"Diabetes, Gestational",C19.246.200
21963202,2011-10-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21963202,2011-10-01T00:00:00,Mass Screening,E01.370.500
21963202,2011-10-01T00:00:00,Mass Screening,E05.318.308.250.580
21963202,2011-10-01T00:00:00,Mass Screening,N02.421.143.827.233.443
21963202,2011-10-01T00:00:00,Mass Screening,N02.421.726.233.443
21963202,2011-10-01T00:00:00,Mass Screening,N05.715.360.300.375.500
21963202,2011-10-01T00:00:00,Mass Screening,N06.850.520.308.250.580
21963202,2011-10-01T00:00:00,Mass Screening,N06.850.780.500
21963202,2011-10-01T00:00:00,Postpartum Period,G08.686.702
21963202,2011-10-01T00:00:00,Pregnancy,G08.686.785.760.769
21963202,2011-10-01T00:00:00,South Carolina,Z01.107.567.875.075.662
21963202,2011-10-01T00:00:00,South Carolina,Z01.107.567.875.750.700
21963202,2011-10-01T00:00:00,United States,Z01.107.567.875
21963202,2011-10-01T00:00:00,Young Adult,M01.060.116.815
21964742,2011-10-01T00:00:00,Cell Proliferation,G04.299.233.750
21964742,2011-10-01T00:00:00,Cell Proliferation,G07.700.320.249.410.750
21964742,2011-10-01T00:00:00,Endothelin-1,D12.644.276.400.225
21964742,2011-10-01T00:00:00,Endothelin-1,D12.776.467.400.225
21964742,2011-10-01T00:00:00,Endothelin-1,D23.529.400.225
21964742,2011-10-01T00:00:00,Hepatic Veins,A07.231.908.380
21964742,2011-10-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21964742,2011-10-01T00:00:00,Liver Cirrhosis,C06.552.630
21964742,2011-10-01T00:00:00,Middle Aged,M01.060.116.630
21964742,2011-10-01T00:00:00,Pilot Projects,E05.318.760.750
21964742,2011-10-01T00:00:00,Pilot Projects,E05.337.737
21964742,2011-10-01T00:00:00,Pilot Projects,N05.715.360.775.625
21964742,2011-10-01T00:00:00,Pilot Projects,N06.850.520.450.720
21964742,2011-10-01T00:00:00,Pulmonary Veins,A07.231.908.713
21972399,2011-10-01T00:00:00,Adult,M01.060.116
21972399,2011-10-01T00:00:00,Aged,M01.060.116.100
21972399,2011-10-01T00:00:00,Angioplasty,E02.148.050
21972399,2011-10-01T00:00:00,Angioplasty,E04.100.814.050
21972399,2011-10-01T00:00:00,Biological Markers,D23.101
21972399,2011-10-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21972399,2011-10-01T00:00:00,Middle Aged,M01.060.116.630
21972399,2011-10-01T00:00:00,Myocardial Infarction,C14.280.647.500
21972399,2011-10-01T00:00:00,Myocardial Infarction,C14.907.585.500
21972399,2011-10-01T00:00:00,Postoperative Complications,C23.550.767
21972399,2011-10-01T00:00:00,Risk Factors,E05.318.740.600.800.725
21972399,2011-10-01T00:00:00,Risk Factors,N05.715.350.200.700
21972399,2011-10-01T00:00:00,Risk Factors,N05.715.360.750.625.700.700
21972399,2011-10-01T00:00:00,Risk Factors,N06.850.490.625.750
21972399,2011-10-01T00:00:00,Risk Factors,N06.850.520.830.600.800.725
21972399,2011-10-01T00:00:00,"Spectroscopy, Near-Infrared",E01.370.350.750
21972399,2011-10-01T00:00:00,"Spectroscopy, Near-Infrared",E05.196.867.851
21979199,2011-10-01T00:00:00,Aged,M01.060.116.100
21979199,2011-10-01T00:00:00,Colorectal Neoplasms,C04.588.274.476.411.307
21979199,2011-10-01T00:00:00,Colorectal Neoplasms,C06.301.371.411.307
21979199,2011-10-01T00:00:00,Colorectal Neoplasms,C06.405.249.411.307
21979199,2011-10-01T00:00:00,Colorectal Neoplasms,C06.405.469.158.356
21979199,2011-10-01T00:00:00,Colorectal Neoplasms,C06.405.469.491.307
21979199,2011-10-01T00:00:00,Colorectal Neoplasms,C06.405.469.860.180
21979199,2011-10-01T00:00:00,Early Detection of Cancer,E01.390.500
21979199,2011-10-01T00:00:00,Health Services Accessibility,N04.590.374.350
21979199,2011-10-01T00:00:00,Health Services Accessibility,N05.300.430
21979199,2011-10-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21979199,2011-10-01T00:00:00,Middle Aged,M01.060.116.630
21979199,2011-10-01T00:00:00,Sigmoidoscopy,E01.370.372.250.250.200.700
21979199,2011-10-01T00:00:00,Sigmoidoscopy,E01.370.388.250.250.250.160.800
21979199,2011-10-01T00:00:00,Sigmoidoscopy,E04.210.240.250.160.800
21979199,2011-10-01T00:00:00,Sigmoidoscopy,E04.800.250.250.250.160.800
21979199,2011-10-01T00:00:00,United States,Z01.107.567.875
21985908,2011-10-01T00:00:00,Adolescent,M01.060.057
21985908,2011-10-01T00:00:00,Adult,M01.060.116
21985908,2011-10-01T00:00:00,Brain,A08.186.211
21985908,2011-10-01T00:00:00,"Data Interpretation, Statistical",E05.245.380
21985908,2011-10-01T00:00:00,"Data Interpretation, Statistical",E05.318.740.300
21985908,2011-10-01T00:00:00,"Data Interpretation, Statistical",L01.700.508.190.380
21985908,2011-10-01T00:00:00,"Data Interpretation, Statistical",N05.715.360.750.300
21985908,2011-10-01T00:00:00,"Data Interpretation, Statistical",N06.850.520.830.300
21985908,2011-10-01T00:00:00,Estradiol,D04.808.365.415.248
21985908,2011-10-01T00:00:00,Estradiol,D06.472.334.851.437.500
21985908,2011-10-01T00:00:00,Functional Laterality,F02.830.297.425
21985908,2011-10-01T00:00:00,Functional Laterality,G11.561.225.425
21985908,2011-10-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21985908,2011-10-01T00:00:00,"Image Processing, Computer-Assisted",L01.224.308
21985908,2011-10-01T00:00:00,Magnetic Resonance Imaging,E01.370.350.500
21985908,2011-10-01T00:00:00,Magnetic Resonance Imaging,E01.370.350.825.500
21985908,2011-10-01T00:00:00,"Memory, Short-Term",F02.463.425.540.407
21985908,2011-10-01T00:00:00,Reaction Time,F02.830.650
21985908,2011-10-01T00:00:00,Reaction Time,F04.669.817
21985908,2011-10-01T00:00:00,Reaction Time,G11.561.677
21985908,2011-10-01T00:00:00,Young Adult,M01.060.116.815
21986089,2011-10-01T00:00:00,Alligators and Crocodiles,B01.050.150.900.833.100
21986089,2011-10-01T00:00:00,Animals,B01.050
21986089,2011-10-01T00:00:00,Blood Chemical Analysis,E01.450.150.100
21986089,2011-10-01T00:00:00,Iodine,D01.268.380.400
21986089,2011-10-01T00:00:00,Mass Spectrometry,E05.196.566
21992343,2011-10-01T00:00:00,"Education, Medical, Graduate",I02.358.337.350
21992343,2011-10-01T00:00:00,"Education, Medical, Graduate",I02.358.399.350
21992343,2011-10-01T00:00:00,Health Physics,H01.671.368
21992343,2011-10-01T00:00:00,Health Physics,H02.229.333
21992343,2011-10-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21992343,2011-10-01T00:00:00,Radiology,H02.403.740
21992343,2011-10-01T00:00:00,Societies,N03.540.828
21992343,2011-10-01T00:00:00,United States,Z01.107.567.875
22029804,2011-10-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22029804,2011-10-01T00:00:00,Pilot Projects,E05.318.760.750
22029804,2011-10-01T00:00:00,Pilot Projects,E05.337.737
22029804,2011-10-01T00:00:00,Pilot Projects,N05.715.360.775.625
22029804,2011-10-01T00:00:00,Pilot Projects,N06.850.520.450.720
22029804,2011-10-01T00:00:00,Research Design,E05.581.500
22029804,2011-10-01T00:00:00,Research Design,H01.770.644.728
22036064,2011-10-01T00:00:00,Adult,M01.060.116
22036064,2011-10-01T00:00:00,Aged,M01.060.116.100
22036064,2011-10-01T00:00:00,Anxiety,F01.470.132
22036064,2011-10-01T00:00:00,Combat Disorders,F03.080.931.249
22036064,2011-10-01T00:00:00,"Depressive Disorder, Major",F03.600.300.375
22036064,2011-10-01T00:00:00,Fear,F01.470.361
22036064,2011-10-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22036064,2011-10-01T00:00:00,Middle Aged,M01.060.116.630
22036064,2011-10-01T00:00:00,"Models, Psychological",E05.599.695
22036064,2011-10-01T00:00:00,Primary Health Care,N04.590.233.727
22036064,2011-10-01T00:00:00,Psychiatric Status Rating Scales,F04.586
22036064,2011-10-01T00:00:00,Questionnaires,E05.318.308.750
22036064,2011-10-01T00:00:00,Questionnaires,L01.280.800
22036064,2011-10-01T00:00:00,Questionnaires,N05.715.360.300.695
22036064,2011-10-01T00:00:00,Questionnaires,N06.850.520.308.750
22036064,2011-10-01T00:00:00,"Stress Disorders, Post-Traumatic",F03.080.931.500
22036064,2011-10-01T00:00:00,Veterans,M01.930
22040190,2011-10-01T00:00:00,Adolescent,M01.060.057
22040190,2011-10-01T00:00:00,Adult,M01.060.116
22040190,2011-10-01T00:00:00,Attention Deficit Disorder with Hyperactivity,F03.550.150.150
22040190,2011-10-01T00:00:00,Central Nervous System Stimulants,D27.505.696.282
22040190,2011-10-01T00:00:00,Central Nervous System Stimulants,D27.505.954.427.220
22040190,2011-10-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22040190,2011-10-01T00:00:00,Methylphenidate,D02.241.223.601.600
22040190,2011-10-01T00:00:00,Methylphenidate,D03.383.621.460
22040190,2011-10-01T00:00:00,Middle Aged,M01.060.116.630
22040190,2011-10-01T00:00:00,Smoking,F01.145.466.753
22040190,2011-10-01T00:00:00,Substance-Related Disorders,C21.739
22040190,2011-10-01T00:00:00,Substance-Related Disorders,F03.900
22057806,2011-10-01T00:00:00,"Education, Medical, Undergraduate",I02.358.399.450
22057806,2011-10-01T00:00:00,"Ethics, Medical",K01.316.333.132.750
22057806,2011-10-01T00:00:00,"Ethics, Medical",N05.350.340.162.500
22057806,2011-10-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22057806,2011-10-01T00:00:00,"Schools, Medical",I02.783.660.552
22057806,2011-10-01T00:00:00,"Schools, Medical",N02.278.020.578
22057806,2011-10-01T00:00:00,South Carolina,Z01.107.567.875.075.662
22057806,2011-10-01T00:00:00,South Carolina,Z01.107.567.875.750.700
22057806,2011-10-01T00:00:00,"Students, Medical",I02.851.686.602
22057806,2011-10-01T00:00:00,"Students, Medical",M01.848.769.602
22108352,2011-10-01T00:00:00,Cataract,C11.510.245
22108352,2011-10-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22108352,2011-10-01T00:00:00,Infant,M01.060.703
22108352,2011-10-01T00:00:00,"Infant, Newborn",M01.060.703.520
22108352,2011-10-01T00:00:00,Randomized Controlled Trials as Topic,E05.318.760.535.365.500
22108352,2011-10-01T00:00:00,Randomized Controlled Trials as Topic,E05.337.250.365.500
22108352,2011-10-01T00:00:00,Randomized Controlled Trials as Topic,N05.715.360.775.235.387.500
22108352,2011-10-01T00:00:00,Randomized Controlled Trials as Topic,N06.850.520.450.535.365.500
22108352,2011-10-01T00:00:00,Video Recording,L01.240.960
22108353,2011-10-01T00:00:00,Cataract,C11.510.245
22108353,2011-10-01T00:00:00,Cataract Extraction,E04.540.825.249
22108353,2011-10-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22108353,2011-10-01T00:00:00,Infant,M01.060.703
22108353,2011-10-01T00:00:00,"Lens Implantation, Intraocular",E04.540.825.600
22108353,2011-10-01T00:00:00,Postoperative Complications,C23.550.767
22108353,2011-10-01T00:00:00,Treatment Outcome,E01.789.800
22108353,2011-10-01T00:00:00,Treatment Outcome,N04.761.559.590.800
22108353,2011-10-01T00:00:00,Treatment Outcome,N05.715.360.575.575.800
22108354,2011-10-01T00:00:00,Algorithms,G17.035
22108354,2011-10-01T00:00:00,Algorithms,L01.224.050
22108354,2011-10-01T00:00:00,Biometry,E05.318.740.225
22108354,2011-10-01T00:00:00,Biometry,N06.850.505.200
22108354,2011-10-01T00:00:00,Child,M01.060.406
22108354,2011-10-01T00:00:00,"Child, Preschool",M01.060.406.448
22108354,2011-10-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22108354,2011-10-01T00:00:00,Infant,M01.060.703
22108354,2011-10-01T00:00:00,"Lens Implantation, Intraocular",E04.540.825.600
22108354,2011-10-01T00:00:00,"Lenses, Intraocular",E07.632.500.460
22108354,2011-10-01T00:00:00,"Lenses, Intraocular",E07.695.460
22108354,2011-10-01T00:00:00,"Refraction, Ocular",E01.370.380.850.700
22108354,2011-10-01T00:00:00,"Refraction, Ocular",G01.590.770.760
22108354,2011-10-01T00:00:00,"Refraction, Ocular",G01.595.640.760
22108354,2011-10-01T00:00:00,"Refraction, Ocular",G14.760
22155603,2011-10-01T00:00:00,Adult,M01.060.116
22155603,2011-10-01T00:00:00,Aged,M01.060.116.100
22155603,2011-10-01T00:00:00,Case-Control Studies,E05.318.760.500.500
22155603,2011-10-01T00:00:00,Case-Control Studies,N05.715.360.775.175.200
22155603,2011-10-01T00:00:00,Case-Control Studies,N06.850.520.450.500.500
22155603,2011-10-01T00:00:00,Genetic Predisposition to Disease,C23.550.291.687.500
22155603,2011-10-01T00:00:00,Genetic Predisposition to Disease,G05.380.355
22155603,2011-10-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22155603,2011-10-01T00:00:00,Macular Degeneration,C11.768.585.439
22155603,2011-10-01T00:00:00,Middle Aged,M01.060.116.630
22155603,2011-10-01T00:00:00,"Polymorphism, Genetic",G05.365.795
22155603,2011-10-01T00:00:00,Risk Factors,E05.318.740.600.800.725
22155603,2011-10-01T00:00:00,Risk Factors,N05.715.350.200.700
22155603,2011-10-01T00:00:00,Risk Factors,N05.715.360.750.625.700.700
22155603,2011-10-01T00:00:00,Risk Factors,N06.850.490.625.750
22155603,2011-10-01T00:00:00,Risk Factors,N06.850.520.830.600.800.725
22155603,2011-10-01T00:00:00,Vitamin D,D04.808.812.768
22155603,2011-10-01T00:00:00,Vitamin D Deficiency,C18.654.521.500.133.770
22165450,2011-10-01T00:00:00,Cardiac Surgical Procedures,E04.100.376
22165450,2011-10-01T00:00:00,Cardiac Surgical Procedures,E04.928.220
22165450,2011-10-01T00:00:00,Cardiology,H02.403.429.163
22165450,2011-10-01T00:00:00,"Education, Medical, Continuing",I02.358.212.350
22165450,2011-10-01T00:00:00,"Education, Medical, Continuing",I02.358.399.250
22165450,2011-10-01T00:00:00,"Heart Defects, Congenital",C14.240.400
22165450,2011-10-01T00:00:00,"Heart Defects, Congenital",C14.280.400
22165450,2011-10-01T00:00:00,"Heart Defects, Congenital",C16.131.240.400
22165450,2011-10-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22867698,2011-10-01T00:00:00,Arteriosclerosis,C14.907.137.126
22867698,2011-10-01T00:00:00,Calcinosis,C18.452.174.130
22867698,2011-10-01T00:00:00,Chest Pain,C23.888.646.215
22867698,2011-10-01T00:00:00,Coronary Angiography,E01.370.350.700.060.200
22867698,2011-10-01T00:00:00,Coronary Angiography,E01.370.370.050.200
22867698,2011-10-01T00:00:00,Coronary Angiography,E01.370.370.380.200
22867698,2011-10-01T00:00:00,Coronary Artery Disease,C14.280.647.250.260
22867698,2011-10-01T00:00:00,Coronary Artery Disease,C14.907.137.126.339
22867698,2011-10-01T00:00:00,Coronary Artery Disease,C14.907.585.250.260
22867698,2011-10-01T00:00:00,Coronary Vessels,A07.231.114.269
22867698,2011-10-01T00:00:00,Coronary Vessels,A07.231.908.194
22867698,2011-10-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22867698,2011-10-01T00:00:00,Risk Factors,E05.318.740.600.800.725
22867698,2011-10-01T00:00:00,Risk Factors,N05.715.350.200.700
22867698,2011-10-01T00:00:00,Risk Factors,N05.715.360.750.625.700.700
22867698,2011-10-01T00:00:00,Risk Factors,N06.850.490.625.750
22867698,2011-10-01T00:00:00,Risk Factors,N06.850.520.830.600.800.725
22867698,2011-10-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.350.810
22867698,2011-10-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.600.350.700.810
22867698,2011-10-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.700.700.810
22867698,2011-10-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.700.810.810
22867698,2011-10-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.825.810.810
21968792,2011-10-03T00:00:00,Adult,M01.060.116
21968792,2011-10-03T00:00:00,Algorithms,G17.035
21968792,2011-10-03T00:00:00,Algorithms,L01.224.050
21968792,2011-10-03T00:00:00,Electric Stimulation,E05.723.402
21968792,2011-10-03T00:00:00,Electromyography,E01.370.405.255
21968792,2011-10-03T00:00:00,Electromyography,E01.370.530.255
21968792,2011-10-03T00:00:00,Forecasting,I01.320
21968792,2011-10-03T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21968792,2011-10-03T00:00:00,Knee Joint,A02.835.583.475
21968792,2011-10-03T00:00:00,Lower Extremity,A01.378.610
21968792,2011-10-03T00:00:00,"Muscle, Skeletal",A02.633.567
21968792,2011-10-03T00:00:00,"Muscle, Skeletal",A10.690.552.500
21968792,2011-10-03T00:00:00,Nonlinear Dynamics,E05.599.850
21968792,2011-10-03T00:00:00,Nonlinear Dynamics,H01.548.675
21968792,2011-10-03T00:00:00,Young Adult,M01.060.116.815
21975022,2011-10-03T00:00:00,Animals,B01.050
21975022,2011-10-03T00:00:00,Bone Marrow Transplantation,E04.936.580.040
21975022,2011-10-03T00:00:00,Cell Movement,G04.299.283
21975022,2011-10-03T00:00:00,Cell Movement,G07.700.560.500.180
21975022,2011-10-03T00:00:00,Colonic Neoplasms,C04.588.274.476.411.307.180
21975022,2011-10-03T00:00:00,Colonic Neoplasms,C06.301.371.411.307.180
21975022,2011-10-03T00:00:00,Colonic Neoplasms,C06.405.249.411.307.180
21975022,2011-10-03T00:00:00,Colonic Neoplasms,C06.405.469.158.356.180
21975022,2011-10-03T00:00:00,Colonic Neoplasms,C06.405.469.491.307.180
21975022,2011-10-03T00:00:00,Flow Cytometry,E05.196.712.516.600.240.350
21975022,2011-10-03T00:00:00,Flow Cytometry,E05.200.500.386.350
21975022,2011-10-03T00:00:00,Green Fluorescent Proteins,D12.776.532.265
21967628,2011-10-04T00:00:00,"Alcohol-Induced Disorders, Nervous System",C10.720.112
21967628,2011-10-04T00:00:00,"Alcohol-Induced Disorders, Nervous System",C21.613.705.150
21967628,2011-10-04T00:00:00,"Alcohol-Induced Disorders, Nervous System",C21.739.100.087.193
21967628,2011-10-04T00:00:00,Alcoholism,C21.739.100.250
21967628,2011-10-04T00:00:00,Alcoholism,F03.900.100.350
21967628,2011-10-04T00:00:00,Animals,B01.050
21967628,2011-10-04T00:00:00,Central Nervous System Depressants,D27.505.696.277
21967628,2011-10-04T00:00:00,Central Nervous System Depressants,D27.505.954.427.210
21967628,2011-10-04T00:00:00,Ethanol,D02.033.375
21967628,2011-10-04T00:00:00,Glucocorticoids,D06.472.040.543
21967628,2011-10-04T00:00:00,Glucocorticoids,D27.505.696.399.472.488
21967628,2011-10-04T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21967628,2011-10-04T00:00:00,Hypothalamo-Hypophyseal System,A06.688.357
21967628,2011-10-04T00:00:00,Hypothalamo-Hypophyseal System,A08.186.211.730.317.357.352.435
21967628,2011-10-04T00:00:00,Hypothalamo-Hypophyseal System,A08.713.357
21967628,2011-10-04T00:00:00,Pituitary-Adrenal System,A06.407.691
21967628,2011-10-04T00:00:00,Polyamines,D02.092.782
21967628,2011-10-04T00:00:00,"Receptors, N-Methyl-D-Aspartate",D12.776.543.750.720.200.450.580
21967628,2011-10-04T00:00:00,"Stress, Psychological",F01.145.126.990
21967628,2011-10-04T00:00:00,"Stress, Psychological",F02.830.900
21967628,2011-10-04T00:00:00,Synapses,A08.850
21967628,2011-10-04T00:00:00,Synapses,A11.284.149.165.420.780
21968545,2011-10-04T00:00:00,Adenosine,D03.438.759.590.138
21968545,2011-10-04T00:00:00,Adenosine,D13.570.583.138
21968545,2011-10-04T00:00:00,Adenosine,D13.570.800.096
21968545,2011-10-04T00:00:00,Adult,M01.060.116
21968545,2011-10-04T00:00:00,Body Mass Index,E01.370.600.115.100.125
21968545,2011-10-04T00:00:00,Body Mass Index,E05.041.124.125
21968545,2011-10-04T00:00:00,Body Mass Index,G07.100.100.125
21968545,2011-10-04T00:00:00,Body Mass Index,N06.850.505.200.100.175
21968545,2011-10-04T00:00:00,Contrast Media,D27.720.259
21968545,2011-10-04T00:00:00,Coronary Circulation,G09.330.190.163.324
21968545,2011-10-04T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21968545,2011-10-04T00:00:00,"Infusions, Intravenous",E02.319.267.510.590
21968545,2011-10-04T00:00:00,Middle Aged,M01.060.116.630
21968545,2011-10-04T00:00:00,Myocardial Perfusion Imaging,E01.370.350.710.600.500
21968545,2011-10-04T00:00:00,Myocardial Perfusion Imaging,E01.370.370.380.500
21968545,2011-10-04T00:00:00,Myocardial Perfusion Imaging,E01.370.384.730.354.500
21968545,2011-10-04T00:00:00,Obesity,C18.654.726.500
21968545,2011-10-04T00:00:00,Obesity,C23.888.144.699.500
21968545,2011-10-04T00:00:00,Obesity,E01.370.600.115.100.160.120.699.500
21968545,2011-10-04T00:00:00,Obesity,G07.100.100.160.120.699.500
21968545,2011-10-04T00:00:00,Organometallic Compounds,D01.632
21968545,2011-10-04T00:00:00,Organometallic Compounds,D02.691
21968545,2011-10-04T00:00:00,Pyrazoles,D03.383.129.539
21968545,2011-10-04T00:00:00,Time Factors,G01.910.857
21968545,2011-10-04T00:00:00,Vasodilator Agents,D27.505.954.411.918
21978964,2011-10-04T00:00:00,Action Potentials,G04.580.100
21978964,2011-10-04T00:00:00,Action Potentials,G07.265.750.100
21978964,2011-10-04T00:00:00,Action Potentials,G11.561.570.100
21978964,2011-10-04T00:00:00,"Arrhythmias, Cardiac",C14.280.067
21978964,2011-10-04T00:00:00,"Arrhythmias, Cardiac",C23.550.073
21978964,2011-10-04T00:00:00,Connexin 43,D12.776.543.585.250.200
21978964,2011-10-04T00:00:00,Gap Junctions,A11.284.149.165.420.471
21978964,2011-10-04T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21978964,2011-10-04T00:00:00,"Myocytes, Cardiac",A07.541.704.570
21978964,2011-10-04T00:00:00,"Myocytes, Cardiac",A10.690.552.750.570
21978964,2011-10-04T00:00:00,"Myocytes, Cardiac",A11.620.500
21978966,2011-10-04T00:00:00,Aged,M01.060.116.100
21978966,2011-10-04T00:00:00,Algorithms,G17.035
21978966,2011-10-04T00:00:00,Algorithms,L01.224.050
21978966,2011-10-04T00:00:00,"Cardiac Pacing, Artificial",E02.145
21978966,2011-10-04T00:00:00,"Defibrillators, Implantable",E07.305.250.159.175
21978966,2011-10-04T00:00:00,"Defibrillators, Implantable",E07.305.250.319.175
21978966,2011-10-04T00:00:00,"Defibrillators, Implantable",E07.695.175
21978966,2011-10-04T00:00:00,Electric Countershock,E02.342.287
21978966,2011-10-04T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21978966,2011-10-04T00:00:00,Middle Aged,M01.060.116.630
21978966,2011-10-04T00:00:00,"Tachycardia, Supraventricular",C14.280.067.845.880
21978966,2011-10-04T00:00:00,"Tachycardia, Supraventricular",C23.550.073.845.880
21978966,2011-10-04T00:00:00,"Tachycardia, Ventricular",C14.280.067.845.940
21978966,2011-10-04T00:00:00,"Tachycardia, Ventricular",C23.550.073.845.940
21971701,2011-10-05T00:00:00,Adult,M01.060.116
21971701,2011-10-05T00:00:00,Cryptococcosis,C01.703.248
21971701,2011-10-05T00:00:00,HIV Infections,C02.782.815.616.400
21971701,2011-10-05T00:00:00,HIV Infections,C02.800.801.400
21971701,2011-10-05T00:00:00,HIV Infections,C20.673.480
21971701,2011-10-05T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21971701,2011-10-05T00:00:00,Middle Aged,M01.060.116.630
21971701,2011-10-05T00:00:00,Organ Transplantation,E04.936.450
21971701,2011-10-05T00:00:00,South Carolina,Z01.107.567.875.075.662
21971701,2011-10-05T00:00:00,South Carolina,Z01.107.567.875.750.700
21975194,2011-10-05T00:00:00,Adolescent,M01.060.057
21975194,2011-10-05T00:00:00,Adult,M01.060.116
21975194,2011-10-05T00:00:00,Amphetamine,D02.092.471.683.152.110
21975194,2011-10-05T00:00:00,Animals,B01.050
21975194,2011-10-05T00:00:00,"Behavior, Animal",F01.145.113
21975194,2011-10-05T00:00:00,Central Nervous System Stimulants,D27.505.696.282
21975194,2011-10-05T00:00:00,Central Nervous System Stimulants,D27.505.954.427.220
21975194,2011-10-05T00:00:00,"Conditioning, Operant",F02.463.425.179.509
21975194,2011-10-05T00:00:00,"Disease Models, Animal",C22.232
21975194,2011-10-05T00:00:00,"Disease Models, Animal",E05.598.500
21975194,2011-10-05T00:00:00,"Disease Models, Animal",E05.599.395.080
21975194,2011-10-05T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21975194,2011-10-05T00:00:00,Impulsive Behavior,F01.145.527
21975194,2011-10-05T00:00:00,Questionnaires,E05.318.308.750
21975194,2011-10-05T00:00:00,Questionnaires,L01.280.800
21975194,2011-10-05T00:00:00,Questionnaires,N05.715.360.300.695
21975194,2011-10-05T00:00:00,Questionnaires,N06.850.520.308.750
21975194,2011-10-05T00:00:00,Rats,B01.050.150.900.649.865.635.505.700
21975194,2011-10-05T00:00:00,Self Administration,E02.319.890
21975194,2011-10-05T00:00:00,Self Administration,E02.900.890
21975194,2011-10-05T00:00:00,Substance-Related Disorders,C21.739
21975194,2011-10-05T00:00:00,Substance-Related Disorders,F03.900
21978531,2011-10-05T00:00:00,"Carcinoma, Non-Small-Cell Lung",C04.588.894.797.520.109.220.249
21978531,2011-10-05T00:00:00,"Carcinoma, Non-Small-Cell Lung",C08.381.540.140.500
21978531,2011-10-05T00:00:00,"Carcinoma, Non-Small-Cell Lung",C08.785.520.100.220.500
21978531,2011-10-05T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21978531,2011-10-05T00:00:00,Lung Neoplasms,C04.588.894.797.520
21978531,2011-10-05T00:00:00,Lung Neoplasms,C08.381.540
21978531,2011-10-05T00:00:00,Lung Neoplasms,C08.785.520
21978531,2011-10-05T00:00:00,Lymph Nodes,A10.549.400
21978531,2011-10-05T00:00:00,Lymph Nodes,A15.382.520.604.412
21978531,2011-10-05T00:00:00,Radiosurgery,E02.815.530
21978531,2011-10-05T00:00:00,Radiosurgery,E04.525.800.650
21978531,2011-10-05T00:00:00,Radiosurgery,E05.873.500
21978531,2011-10-05T00:00:00,Radiotherapy Dosage,E02.815.639
21981792,2011-10-05T00:00:00,"Colony Count, Microbial",E05.200.875.220
21981792,2011-10-05T00:00:00,Disinfection,N06.850.780.200.450.850.375
21981792,2011-10-05T00:00:00,Environmental Microbiology,H01.158.273.540.274
21981792,2011-10-05T00:00:00,Environmental Microbiology,N06.850.425
21981792,2011-10-05T00:00:00,Hospitals,N02.278.421
21981792,2011-10-05T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21981792,2011-10-05T00:00:00,Pilot Projects,E05.318.760.750
21981792,2011-10-05T00:00:00,Pilot Projects,E05.337.737
21981792,2011-10-05T00:00:00,Pilot Projects,N05.715.360.775.625
21981792,2011-10-05T00:00:00,Pilot Projects,N06.850.520.450.720
21978998,2011-10-06T00:00:00,"Adaptor Proteins, Signal Transducing",D12.644.360.024
21978998,2011-10-06T00:00:00,"Adaptor Proteins, Signal Transducing",D12.776.157.057
21978998,2011-10-06T00:00:00,"Adaptor Proteins, Signal Transducing",D12.776.476.024
21978998,2011-10-06T00:00:00,B-Lymphocytes,A11.063.438
21978998,2011-10-06T00:00:00,B-Lymphocytes,A11.118.637.555.567.562
21978998,2011-10-06T00:00:00,B-Lymphocytes,A15.145.229.637.555.567.562
21978998,2011-10-06T00:00:00,B-Lymphocytes,A15.382.032.438
21978998,2011-10-06T00:00:00,B-Lymphocytes,A15.382.490.555.567.562
21978998,2011-10-06T00:00:00,Case-Control Studies,E05.318.760.500.500
21978998,2011-10-06T00:00:00,Case-Control Studies,N05.715.360.775.175.200
21978998,2011-10-06T00:00:00,Case-Control Studies,N06.850.520.450.500.500
21978998,2011-10-06T00:00:00,"Epistasis, Genetic",G05.355.315.207
21978998,2011-10-06T00:00:00,Genetic Predisposition to Disease,C23.550.291.687.500
21978998,2011-10-06T00:00:00,Genetic Predisposition to Disease,G05.380.355
21978998,2011-10-06T00:00:00,Genome-Wide Association Study,E05.318.416.249
21978998,2011-10-06T00:00:00,Genome-Wide Association Study,E05.318.780.392
21978998,2011-10-06T00:00:00,Genome-Wide Association Study,E05.393.385.500
21978998,2011-10-06T00:00:00,Genome-Wide Association Study,E05.393.522.500
21978998,2011-10-06T00:00:00,Genome-Wide Association Study,E05.393.760.640.500
21978998,2011-10-06T00:00:00,Genome-Wide Association Study,N06.850.520.445.392
21978998,2011-10-06T00:00:00,Genome-Wide Association Study,N06.850.520.470.500
21978998,2011-10-06T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21978998,2011-10-06T00:00:00,"Lupus Erythematosus, Systemic",C17.300.480
21978998,2011-10-06T00:00:00,"Lupus Erythematosus, Systemic",C20.111.590
21978998,2011-10-06T00:00:00,Membrane Proteins,D12.776.543
21978998,2011-10-06T00:00:00,"Polymorphism, Single Nucleotide",G05.365.795.598
21978998,2011-10-06T00:00:00,Signal Transduction,G02.111.087.800
21978998,2011-10-06T00:00:00,Signal Transduction,G02.149.115.800
21978998,2011-10-06T00:00:00,Signal Transduction,G04.299.880
21978998,2011-10-06T00:00:00,src-Family Kinases,D08.811.913.696.620.682.725.800
21980205,2011-10-06T00:00:00,Age Factors,N05.715.350.075
21980205,2011-10-06T00:00:00,Age Factors,N06.850.490.250
21980205,2011-10-06T00:00:00,Aged,M01.060.116.100
21980205,2011-10-06T00:00:00,Carotid Arteries,A07.231.114.186
21980205,2011-10-06T00:00:00,Carotid Stenosis,C10.228.140.300.200.360
21980205,2011-10-06T00:00:00,Carotid Stenosis,C14.907.137.230
21980205,2011-10-06T00:00:00,Carotid Stenosis,C14.907.253.123.360
21980205,2011-10-06T00:00:00,"Endarterectomy, Carotid",E04.100.814.456.250
21980205,2011-10-06T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21980205,2011-10-06T00:00:00,Middle Aged,M01.060.116.630
21980205,2011-10-06T00:00:00,Myocardial Infarction,C14.280.647.500
21980205,2011-10-06T00:00:00,Myocardial Infarction,C14.907.585.500
21980205,2011-10-06T00:00:00,Prosthesis Implantation,E04.650
21980205,2011-10-06T00:00:00,Stents,E07.695.750
21980205,2011-10-06T00:00:00,Stroke,C10.228.140.300.775
21980205,2011-10-06T00:00:00,Stroke,C14.907.253.855
21980205,2011-10-06T00:00:00,Treatment Outcome,E01.789.800
21980205,2011-10-06T00:00:00,Treatment Outcome,N04.761.559.590.800
21980205,2011-10-06T00:00:00,Treatment Outcome,N05.715.360.575.575.800
22099718,2011-10-06T00:00:00,"Education, Medical",I02.358.399
22099718,2011-10-06T00:00:00,"Education, Medical, Continuing",I02.358.212.350
22099718,2011-10-06T00:00:00,"Education, Medical, Continuing",I02.358.399.250
22099718,2011-10-06T00:00:00,Gastroenterology,H02.403.429.405
22099718,2011-10-06T00:00:00,Guidelines as Topic,N04.761.700.350
22099718,2011-10-06T00:00:00,Guidelines as Topic,N05.700.350
22099718,2011-10-06T00:00:00,Health Care Sector,J01.576.489
22099718,2011-10-06T00:00:00,Health Care Sector,N03.219.650
22099718,2011-10-06T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22099721,2011-10-06T00:00:00,Gastroenterology,H02.403.429.405
22099721,2011-10-06T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21983152,2011-10-07T00:00:00,Adolescent,M01.060.057
21983152,2011-10-07T00:00:00,Adult,M01.060.116
21983152,2011-10-07T00:00:00,Aged,M01.060.116.100
21983152,2011-10-07T00:00:00,"Diabetes Mellitus, Type 2",C18.452.394.750.149
21983152,2011-10-07T00:00:00,"Diabetes Mellitus, Type 2",C19.246.300
21983152,2011-10-07T00:00:00,Healthcare Disparities,N04.590.374.380
21983152,2011-10-07T00:00:00,Healthcare Disparities,N05.300.493
21983152,2011-10-07T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21983152,2011-10-07T00:00:00,Life Style,F01.829.458
21983152,2011-10-07T00:00:00,Middle Aged,M01.060.116.630
21983152,2011-10-07T00:00:00,Quality of Health Care,N04.761
21983152,2011-10-07T00:00:00,Quality of Health Care,N05.715
21983152,2011-10-07T00:00:00,Self Care,E02.900
21983152,2011-10-07T00:00:00,Self Care,N02.421.784.680
21983152,2011-10-07T00:00:00,United States,Z01.107.567.875
21983152,2011-10-07T00:00:00,Young Adult,M01.060.116.815
22041087,2011-10-07T00:00:00,"Adaptation, Psychological",F01.058
22041087,2011-10-07T00:00:00,Adult,M01.060.116
22041087,2011-10-07T00:00:00,African Americans,M01.686.508.100.100
22041087,2011-10-07T00:00:00,African Americans,M01.686.754.100
22041087,2011-10-07T00:00:00,"Child, Preschool",M01.060.406.448
22041087,2011-10-07T00:00:00,Cultural Diversity,I01.076.201.450.350
22041087,2011-10-07T00:00:00,Cultural Diversity,I01.880.143.450
22041087,2011-10-07T00:00:00,European Continental Ancestry Group,M01.686.508.400
22041087,2011-10-07T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22041087,2011-10-07T00:00:00,Parenting,F01.829.263.370.310
22041087,2011-10-07T00:00:00,Parents,F01.829.263.500.320
22041087,2011-10-07T00:00:00,Parents,I01.880.225.500.340
22041087,2011-10-07T00:00:00,Parents,M01.620
22041087,2011-10-07T00:00:00,"Stress, Psychological",F01.145.126.990
22041087,2011-10-07T00:00:00,"Stress, Psychological",F02.830.900
22054886,2011-10-07T00:00:00,Age Factors,N05.715.350.075
22054886,2011-10-07T00:00:00,Age Factors,N06.850.490.250
22054886,2011-10-07T00:00:00,"Carcinoma, Non-Small-Cell Lung",C04.588.894.797.520.109.220.249
22054886,2011-10-07T00:00:00,"Carcinoma, Non-Small-Cell Lung",C08.381.540.140.500
22054886,2011-10-07T00:00:00,"Carcinoma, Non-Small-Cell Lung",C08.785.520.100.220.500
22054886,2011-10-07T00:00:00,Catheter Ablation,E01.370.370.380.410.200
22054886,2011-10-07T00:00:00,Catheter Ablation,E02.148.110
22054886,2011-10-07T00:00:00,Catheter Ablation,E02.148.442.110
22054886,2011-10-07T00:00:00,Catheter Ablation,E02.154.402.110
22054886,2011-10-07T00:00:00,Catheter Ablation,E04.014.170.402.110
22054886,2011-10-07T00:00:00,Decision Making,F02.463.785.373
22054886,2011-10-07T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22054886,2011-10-07T00:00:00,Interdisciplinary Communication,F01.145.209.381
22054886,2011-10-07T00:00:00,Interdisciplinary Communication,F01.829.401.205.249
22054886,2011-10-07T00:00:00,Interdisciplinary Communication,L01.143.474
22054886,2011-10-07T00:00:00,Lung Neoplasms,C04.588.894.797.520
22054886,2011-10-07T00:00:00,Lung Neoplasms,C08.381.540
22054886,2011-10-07T00:00:00,Lung Neoplasms,C08.785.520
22054886,2011-10-07T00:00:00,Neoplasm Staging,E01.370.550
22054886,2011-10-07T00:00:00,Patient Preference,N04.452.822.360.600.500
22054886,2011-10-07T00:00:00,Patient Preference,N05.300.150.600.630.500
22054886,2011-10-07T00:00:00,Pneumonectomy,E04.928.600.600
22054886,2011-10-07T00:00:00,Preoperative Care,E02.760.795
22054886,2011-10-07T00:00:00,Preoperative Care,E04.641
22054886,2011-10-07T00:00:00,Preoperative Care,N02.421.585.795
22054886,2011-10-07T00:00:00,Radiosurgery,E02.815.530
22054886,2011-10-07T00:00:00,Radiosurgery,E04.525.800.650
22054886,2011-10-07T00:00:00,Radiosurgery,E05.873.500
22054889,2011-10-07T00:00:00,Age Factors,N05.715.350.075
22054889,2011-10-07T00:00:00,Age Factors,N06.850.490.250
22054889,2011-10-07T00:00:00,"Carcinoma, Non-Small-Cell Lung",C04.588.894.797.520.109.220.249
22054889,2011-10-07T00:00:00,"Carcinoma, Non-Small-Cell Lung",C08.381.540.140.500
22054889,2011-10-07T00:00:00,"Carcinoma, Non-Small-Cell Lung",C08.785.520.100.220.500
22054889,2011-10-07T00:00:00,"Chemotherapy, Adjuvant",E02.186.170
22054889,2011-10-07T00:00:00,"Chemotherapy, Adjuvant",E02.319.170
22054889,2011-10-07T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22054889,2011-10-07T00:00:00,Lung Neoplasms,C04.588.894.797.520
22054889,2011-10-07T00:00:00,Lung Neoplasms,C08.381.540
22054889,2011-10-07T00:00:00,Lung Neoplasms,C08.785.520
22054889,2011-10-07T00:00:00,Neoplasm Staging,E01.370.550
22054889,2011-10-07T00:00:00,Pneumonectomy,E04.928.600.600
22054889,2011-10-07T00:00:00,"Thoracic Surgery, Video-Assisted",E01.370.388.250.840.830
22054889,2011-10-07T00:00:00,"Thoracic Surgery, Video-Assisted",E01.370.388.250.950.830
22054889,2011-10-07T00:00:00,"Thoracic Surgery, Video-Assisted",E04.800.250.840.830
22054889,2011-10-07T00:00:00,"Thoracic Surgery, Video-Assisted",E04.800.250.950.830
22054889,2011-10-07T00:00:00,"Thoracic Surgery, Video-Assisted",E04.928.752.830
21992814,2011-10-10T00:00:00,Adolescent,M01.060.057
21992814,2011-10-10T00:00:00,"Anemia, Sickle Cell",C15.378.071.141.150.150
21992814,2011-10-10T00:00:00,"Anemia, Sickle Cell",C15.378.420.155
21992814,2011-10-10T00:00:00,"Anemia, Sickle Cell",C16.320.070.150
21992814,2011-10-10T00:00:00,"Anemia, Sickle Cell",C16.320.365.155
21992814,2011-10-10T00:00:00,Child,M01.060.406
21992814,2011-10-10T00:00:00,"Child, Preschool",M01.060.406.448
21992814,2011-10-10T00:00:00,"Databases, Factual",L01.470.750.750
21992814,2011-10-10T00:00:00,"Databases, Factual",L01.700.508.300.188.400
21992814,2011-10-10T00:00:00,Hospitalization,E02.760.400
21992814,2011-10-10T00:00:00,Hospitalization,N02.421.585.400
21992814,2011-10-10T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21992814,2011-10-10T00:00:00,Infant,M01.060.703
21992814,2011-10-10T00:00:00,"Infant, Newborn",M01.060.703.520
21992814,2011-10-10T00:00:00,Patient Discharge,E02.760.400.610
21992814,2011-10-10T00:00:00,Patient Discharge,N02.421.585.400.610
21992814,2011-10-10T00:00:00,Stroke,C10.228.140.300.775
21992814,2011-10-10T00:00:00,Stroke,C14.907.253.855
21993239,2011-10-10T00:00:00,Animals,B01.050
21993239,2011-10-10T00:00:00,Bioprosthesis,E07.695.100
21993239,2011-10-10T00:00:00,Cattle,B01.050.150.900.649.077.380.271
21993239,2011-10-10T00:00:00,Heart Valve Prosthesis,E07.695.310
21993239,2011-10-10T00:00:00,Heart Valves,A07.541.510
21993239,2011-10-10T00:00:00,Pericardium,A07.541.795
21993239,2011-10-10T00:00:00,Pericardium,A10.615.789.470
21993239,2011-10-10T00:00:00,Swine,B01.050.150.900.649.077.880
22016766,2011-10-10T00:00:00,Autoantigens,D23.050.422
22016766,2011-10-10T00:00:00,"Carcinoma, Squamous Cell",C04.557.470.200.400
22016766,2011-10-10T00:00:00,"Carcinoma, Squamous Cell",C04.557.470.700.400
22016766,2011-10-10T00:00:00,Cell Cycle,G04.299.134
22016766,2011-10-10T00:00:00,Cell Movement,G04.299.283
22016766,2011-10-10T00:00:00,Cell Movement,G07.700.560.500.180
22016766,2011-10-10T00:00:00,Cell Proliferation,G04.299.233.750
22016766,2011-10-10T00:00:00,Cell Proliferation,G07.700.320.249.410.750
22016766,2011-10-10T00:00:00,Disease Progression,C23.550.291.656
22016766,2011-10-10T00:00:00,"Gene Expression Regulation, Neoplastic",G05.355.315.370
22016766,2011-10-10T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22016766,2011-10-10T00:00:00,Hypopharyngeal Neoplasms,C04.588.443.665.710.485
22016766,2011-10-10T00:00:00,Hypopharyngeal Neoplasms,C07.550.745.436
22016766,2011-10-10T00:00:00,Hypopharyngeal Neoplasms,C09.647.710.485
22016766,2011-10-10T00:00:00,Hypopharyngeal Neoplasms,C09.775.549.485
22016766,2011-10-10T00:00:00,Matrix Metalloproteinase 2,D08.811.277.656.300.480.205.352
22016766,2011-10-10T00:00:00,Matrix Metalloproteinase 2,D08.811.277.656.300.480.252.420
22016766,2011-10-10T00:00:00,Matrix Metalloproteinase 2,D08.811.277.656.300.480.525.700.150
22016766,2011-10-10T00:00:00,Matrix Metalloproteinase 2,D08.811.277.656.675.374.205.352
22016766,2011-10-10T00:00:00,Matrix Metalloproteinase 2,D08.811.277.656.675.374.252.420
22016766,2011-10-10T00:00:00,Matrix Metalloproteinase 2,D08.811.277.656.675.374.525.700.150
22016766,2011-10-10T00:00:00,Neoplasm Invasiveness,C04.697.645
22016766,2011-10-10T00:00:00,Neoplasm Invasiveness,C23.550.727.645
22016766,2011-10-10T00:00:00,Ribonucleoproteins,D12.776.157.725.500
22016766,2011-10-10T00:00:00,Ribonucleoproteins,D12.776.664.962.500
22016766,2011-10-10T00:00:00,beta Catenin,D12.776.091.249
22016766,2011-10-10T00:00:00,beta Catenin,D12.776.220.145.500
22016766,2011-10-10T00:00:00,beta Catenin,D12.776.930.130
21989305,2011-10-11T00:00:00,Animals,B01.050
21989305,2011-10-11T00:00:00,Antineoplastic Agents,D27.505.954.248
21989305,2011-10-11T00:00:00,Combined Modality Therapy,E02.186
21989305,2011-10-11T00:00:00,Forecasting,I01.320
21989305,2011-10-11T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21989305,2011-10-11T00:00:00,Risk Factors,E05.318.740.600.800.725
21989305,2011-10-11T00:00:00,Risk Factors,N05.715.350.200.700
21989305,2011-10-11T00:00:00,Risk Factors,N05.715.360.750.625.700.700
21989305,2011-10-11T00:00:00,Risk Factors,N06.850.490.625.750
21989305,2011-10-11T00:00:00,Risk Factors,N06.850.520.830.600.800.725
21989305,2011-10-11T00:00:00,Treatment Outcome,E01.789.800
21989305,2011-10-11T00:00:00,Treatment Outcome,N04.761.559.590.800
21989305,2011-10-11T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21989305,2011-10-11T00:00:00,Urinary Bladder Neoplasms,C04.588.945.947.960
21989305,2011-10-11T00:00:00,Urinary Bladder Neoplasms,C12.758.820.968
21989305,2011-10-11T00:00:00,Urinary Bladder Neoplasms,C12.777.829.813
21989305,2011-10-11T00:00:00,Urinary Bladder Neoplasms,C13.351.937.820.945
21989305,2011-10-11T00:00:00,Urinary Bladder Neoplasms,C13.351.968.829.707
21990142,2011-10-11T00:00:00,Algorithms,G17.035
21990142,2011-10-11T00:00:00,Algorithms,L01.224.050
21990142,2011-10-11T00:00:00,Arteries,A07.231.114
21990142,2011-10-11T00:00:00,Brain,A08.186.211
21990142,2011-10-11T00:00:00,Diagnostic Imaging,E01.370.350
21990142,2011-10-11T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21990142,2011-10-11T00:00:00,"Image Processing, Computer-Assisted",L01.224.308
21990142,2011-10-11T00:00:00,Magnetic Resonance Imaging,E01.370.350.500
21990142,2011-10-11T00:00:00,Magnetic Resonance Imaging,E01.370.350.825.500
21990142,2011-10-11T00:00:00,"Models, Statistical",E05.318.740.500
21990142,2011-10-11T00:00:00,"Models, Statistical",E05.599.835
21990142,2011-10-11T00:00:00,"Models, Statistical",N05.715.360.750.530
21990142,2011-10-11T00:00:00,"Models, Statistical",N06.850.520.830.500
21990142,2011-10-11T00:00:00,Perfusion,E05.680
21990142,2011-10-11T00:00:00,"Phantoms, Imaging",E07.671
21990416,2011-10-11T00:00:00,Adult,M01.060.116
21990416,2011-10-11T00:00:00,Aged,M01.060.116.100
21990416,2011-10-11T00:00:00,Breast Neoplasms,C04.588.180
21990416,2011-10-11T00:00:00,Breast Neoplasms,C17.800.090.500
21990416,2011-10-11T00:00:00,"Genes, BRCA1",G05.360.340.024.340.375.249.100
21990416,2011-10-11T00:00:00,"Genes, BRCA1",G05.360.340.024.340.415.400.100
21990416,2011-10-11T00:00:00,"Genes, BRCA2",G05.360.340.024.340.375.249.105
21990416,2011-10-11T00:00:00,"Genes, BRCA2",G05.360.340.024.340.415.400.105
21990416,2011-10-11T00:00:00,Genetic Testing,E01.370.427
21990416,2011-10-11T00:00:00,Genetic Testing,E05.393.435
21990416,2011-10-11T00:00:00,Genetic Testing,N02.421.143.827.233.221
21990416,2011-10-11T00:00:00,Genetic Testing,N02.421.308.430
21990416,2011-10-11T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21990416,2011-10-11T00:00:00,Middle Aged,M01.060.116.630
21990416,2011-10-11T00:00:00,Mutation,G05.365.590
21990416,2011-10-11T00:00:00,Ovarian Neoplasms,C04.588.322.455
21990416,2011-10-11T00:00:00,Ovarian Neoplasms,C13.351.500.056.630.705
21990416,2011-10-11T00:00:00,Ovarian Neoplasms,C13.351.937.418.685
21990416,2011-10-11T00:00:00,Ovarian Neoplasms,C19.344.410
21990416,2011-10-11T00:00:00,Ovarian Neoplasms,C19.391.630.705
21990416,2011-10-11T00:00:00,Regression Analysis,E05.318.740.750
21990416,2011-10-11T00:00:00,Regression Analysis,N05.715.360.750.695
21990416,2011-10-11T00:00:00,Regression Analysis,N06.850.520.830.750
22008248,2011-10-11T00:00:00,Disaster Planning,N06.230.100.035
22008248,2011-10-11T00:00:00,Disasters,N06.230.100
22008248,2011-10-11T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22008248,2011-10-11T00:00:00,Internet,L01.224.230.110.500
22008248,2011-10-11T00:00:00,Patient Selection,E05.581.500.653
22008248,2011-10-11T00:00:00,Patient Selection,N04.590.731
22008248,2011-10-11T00:00:00,Randomized Controlled Trials as Topic,E05.318.760.535.365.500
22008248,2011-10-11T00:00:00,Randomized Controlled Trials as Topic,E05.337.250.365.500
22008248,2011-10-11T00:00:00,Randomized Controlled Trials as Topic,N05.715.360.775.235.387.500
22008248,2011-10-11T00:00:00,Randomized Controlled Trials as Topic,N06.850.520.450.535.365.500
22008248,2011-10-11T00:00:00,"Stress Disorders, Post-Traumatic",F03.080.931.500
22008248,2011-10-11T00:00:00,United States,Z01.107.567.875
21992875,2011-10-12T00:00:00,Animals,B01.050
21992875,2011-10-12T00:00:00,Blood Platelets,A11.118.188
21992875,2011-10-12T00:00:00,Blood Platelets,A15.145.229.188
21992875,2011-10-12T00:00:00,Cell Line,A11.251.210
21992875,2011-10-12T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21992875,2011-10-12T00:00:00,Phosphorylation,G02.111.087.677
21992875,2011-10-12T00:00:00,Phosphorylation,G02.149.115.677
21992875,2011-10-12T00:00:00,Phosphorylation,G02.149.465.700
21992875,2011-10-12T00:00:00,Phosphorylation,G02.607.750.700
21992875,2011-10-12T00:00:00,Phosphorylation,G03.495.790
21992875,2011-10-12T00:00:00,Protein Stability,G02.111.700
21992875,2011-10-12T00:00:00,Rats,B01.050.150.900.649.865.635.505.700
21992875,2011-10-12T00:00:00,Serotonin Plasma Membrane Transport Proteins,D12.776.157.530.450.625.311
21992875,2011-10-12T00:00:00,Serotonin Plasma Membrane Transport Proteins,D12.776.157.530.562.374.875
21992875,2011-10-12T00:00:00,Serotonin Plasma Membrane Transport Proteins,D12.776.543.585.450.625.374
21992875,2011-10-12T00:00:00,Serotonin Plasma Membrane Transport Proteins,D12.776.543.585.562.374.875
21992875,2011-10-12T00:00:00,Tyrosine,D12.125.072.050.875
21998409,2011-10-12T00:00:00,Anti-Infective Agents,D27.505.954.122
21998409,2011-10-12T00:00:00,Antimicrobial Cationic Peptides,D12.644.050
21998409,2011-10-12T00:00:00,Antimicrobial Cationic Peptides,D12.776.543.695.054
21998409,2011-10-12T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21998409,2011-10-12T00:00:00,Interferon-gamma,D12.644.276.374.440.893
21998409,2011-10-12T00:00:00,Interferon-gamma,D12.644.276.374.480.350
21998409,2011-10-12T00:00:00,Interferon-gamma,D12.644.276.374.480.615.350
21998409,2011-10-12T00:00:00,Interferon-gamma,D12.644.276.718.550
21998409,2011-10-12T00:00:00,Interferon-gamma,D12.776.467.374.440.893
21998409,2011-10-12T00:00:00,Interferon-gamma,D12.776.467.374.480.350
21998409,2011-10-12T00:00:00,Interferon-gamma,D12.776.467.374.480.615.350
21998409,2011-10-12T00:00:00,Interferon-gamma,D12.776.467.718.550
21998409,2011-10-12T00:00:00,Interferon-gamma,D23.529.374.440.893
21998409,2011-10-12T00:00:00,Interferon-gamma,D23.529.374.480.350
21998409,2011-10-12T00:00:00,Interferon-gamma,D23.529.374.480.615.350
21998409,2011-10-12T00:00:00,Interferon-gamma,D23.529.718.550
21998409,2011-10-12T00:00:00,Lymphocyte Activation,E01.450.495.482
21998409,2011-10-12T00:00:00,Lymphocyte Activation,E05.478.594.530
21998409,2011-10-12T00:00:00,Lymphocyte Activation,G12.425.747
21998409,2011-10-12T00:00:00,Lymphocyte Activation,G12.450.050.400.545
21998409,2011-10-12T00:00:00,Macrophages,A11.329.372
21998409,2011-10-12T00:00:00,Macrophages,A11.627.482
21998409,2011-10-12T00:00:00,Macrophages,A11.733.397
21998409,2011-10-12T00:00:00,Macrophages,A15.382.680.397
21998409,2011-10-12T00:00:00,Macrophages,A15.382.812.522
21998409,2011-10-12T00:00:00,"Models, Biological",E05.599.395
21998409,2011-10-12T00:00:00,Monocytes,A11.118.637.555.652
21998409,2011-10-12T00:00:00,Monocytes,A11.148.580
21998409,2011-10-12T00:00:00,Monocytes,A11.627.624
21998409,2011-10-12T00:00:00,Monocytes,A11.733.547
21998409,2011-10-12T00:00:00,Monocytes,A15.145.229.637.555.652
21998409,2011-10-12T00:00:00,Monocytes,A15.378.316.580
21998409,2011-10-12T00:00:00,Monocytes,A15.382.490.555.652
21998409,2011-10-12T00:00:00,Monocytes,A15.382.680.547
21998409,2011-10-12T00:00:00,Monocytes,A15.382.812.547
21998409,2011-10-12T00:00:00,Mycobacterium tuberculosis,B03.510.024.049.525.500.702
21998409,2011-10-12T00:00:00,Mycobacterium tuberculosis,B03.510.460.400.410.552.552.702
21998409,2011-10-12T00:00:00,Vitamin D,D04.808.812.768
21994037,2011-10-13T00:00:00,Equipment Failure Analysis,E05.325.192
21994037,2011-10-13T00:00:00,Micromanipulation,E05.591
21994037,2011-10-13T00:00:00,Nanostructures,J01.637.512
21994037,2011-10-13T00:00:00,Nanotechnology,H01.603
21994037,2011-10-13T00:00:00,Nanotechnology,J01.897.520.600
21998007,2011-10-13T00:00:00,Adult,M01.060.116
21998007,2011-10-13T00:00:00,African Americans,M01.686.508.100.100
21998007,2011-10-13T00:00:00,African Americans,M01.686.754.100
21998007,2011-10-13T00:00:00,Aged,M01.060.116.100
21998007,2011-10-13T00:00:00,Alcohol Drinking,F01.145.317.269
21998007,2011-10-13T00:00:00,Child,M01.060.406
21998007,2011-10-13T00:00:00,Child Abuse,I01.198.240.856.350.250
21998007,2011-10-13T00:00:00,Child Abuse,I01.880.735.900.350.250
21998007,2011-10-13T00:00:00,Child Abuse,I01.880.787.293.292
21998007,2011-10-13T00:00:00,Depression,F01.145.126.350
21998007,2011-10-13T00:00:00,"Depressive Disorder, Major",F03.600.300.375
21998007,2011-10-13T00:00:00,Genetic Predisposition to Disease,C23.550.291.687.500
21998007,2011-10-13T00:00:00,Genetic Predisposition to Disease,G05.380.355
21998007,2011-10-13T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21998007,2011-10-13T00:00:00,Middle Aged,M01.060.116.630
21998007,2011-10-13T00:00:00,"Polymorphism, Single Nucleotide",G05.365.795.598
21998007,2011-10-13T00:00:00,"Stress, Psychological",F01.145.126.990
21998007,2011-10-13T00:00:00,"Stress, Psychological",F02.830.900
21998007,2011-10-13T00:00:00,Substance-Related Disorders,C21.739
21998007,2011-10-13T00:00:00,Substance-Related Disorders,F03.900
21998328,2011-10-13T00:00:00,Animals,B01.050
21998328,2011-10-13T00:00:00,CD4-Positive T-Lymphocytes,A11.118.637.555.567.569.200
21998328,2011-10-13T00:00:00,CD4-Positive T-Lymphocytes,A15.145.229.637.555.567.569.200
21998328,2011-10-13T00:00:00,CD4-Positive T-Lymphocytes,A15.382.490.555.567.569.200
21998328,2011-10-13T00:00:00,CD8-Positive T-Lymphocytes,A11.118.637.555.567.569.220
21998328,2011-10-13T00:00:00,CD8-Positive T-Lymphocytes,A15.145.229.637.555.567.569.220
21998328,2011-10-13T00:00:00,CD8-Positive T-Lymphocytes,A15.382.490.555.567.569.220
21998328,2011-10-13T00:00:00,Complement C3,D12.776.124.050.140
21998328,2011-10-13T00:00:00,Complement C3,D12.776.124.486.274.250
21998328,2011-10-13T00:00:00,Complement System Proteins,D12.776.124.486.274
21998328,2011-10-13T00:00:00,Graft Rejection,G12.425.901.545.328
21998328,2011-10-13T00:00:00,Homeodomain Proteins,D12.776.260.400
21998328,2011-10-13T00:00:00,Ischemia,C23.550.513
21998328,2011-10-13T00:00:00,Microcirculation,G09.330.190.163.645
21998328,2011-10-13T00:00:00,"Neovascularization, Physiologic",G09.330.190.751
21998328,2011-10-13T00:00:00,Recombinant Fusion Proteins,D12.776.828.300
21998328,2011-10-13T00:00:00,Trachea,A04.889
22022409,2011-10-13T00:00:00,Animals,B01.050
22022409,2011-10-13T00:00:00,Cyclic AMP-Dependent Protein Kinases,D08.811.913.696.620.682.700.150.125
22022409,2011-10-13T00:00:00,Cyclic AMP-Dependent Protein Kinases,D12.644.360.200.125
22022409,2011-10-13T00:00:00,Cyclic AMP-Dependent Protein Kinases,D12.776.476.200.125
22022409,2011-10-13T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22022409,2011-10-13T00:00:00,"Models, Molecular",E05.599.595
22022409,2011-10-13T00:00:00,Phosphorylation,G02.111.087.677
22022409,2011-10-13T00:00:00,Phosphorylation,G02.149.115.677
22022409,2011-10-13T00:00:00,Phosphorylation,G02.149.465.700
22022409,2011-10-13T00:00:00,Phosphorylation,G02.607.750.700
22022409,2011-10-13T00:00:00,Phosphorylation,G03.495.790
22022409,2011-10-13T00:00:00,Tubulin,D05.750.078.734.800
22022409,2011-10-13T00:00:00,Tubulin,D12.776.220.600.800
22022409,2011-10-13T00:00:00,Tubulin,D12.776.641.920
22022409,2011-10-13T00:00:00,Voltage-Dependent Anion Channels,D12.776.157.530.400.500.520
22022409,2011-10-13T00:00:00,Voltage-Dependent Anion Channels,D12.776.543.550.425.730.520
22022409,2011-10-13T00:00:00,Voltage-Dependent Anion Channels,D12.776.543.585.400.730.520
21999616,2011-10-14T00:00:00,Antioxidants,D27.505.519.217
21999616,2011-10-14T00:00:00,Antioxidants,D27.505.696.706.125
21999616,2011-10-14T00:00:00,Antioxidants,D27.720.799.047
21999616,2011-10-14T00:00:00,Coordination Complexes,D01.234
21999616,2011-10-14T00:00:00,Coordination Complexes,D01.632.214
21999616,2011-10-14T00:00:00,Coordination Complexes,D02.256
21999616,2011-10-14T00:00:00,Coordination Complexes,D02.691.214
21999616,2011-10-14T00:00:00,Copper,D01.268.556.195
21999616,2011-10-14T00:00:00,Copper,D01.268.956.170
21999616,2011-10-14T00:00:00,Copper,D01.552.544.195
21999616,2011-10-14T00:00:00,DNA Damage,C21.111
21999616,2011-10-14T00:00:00,DNA Damage,G05.355.180
21999616,2011-10-14T00:00:00,Magnetic Resonance Spectroscopy,E05.196.867.519
21999616,2011-10-14T00:00:00,Nitrogen,D01.268.604
21999616,2011-10-14T00:00:00,Nitrogen,D01.362.625
21999616,2011-10-14T00:00:00,Organoselenium Compounds,D02.712
21999616,2011-10-14T00:00:00,Oxidative Stress,G03.495.710
21999616,2011-10-14T00:00:00,Oxidative Stress,G07.700.830.750
21999616,2011-10-14T00:00:00,Oxygen,D01.268.185.550
21999616,2011-10-14T00:00:00,Oxygen,D01.362.670
21999616,2011-10-14T00:00:00,Selenium,D01.268.185.850
21999616,2011-10-14T00:00:00,Selenium,D01.578.700
21999616,2011-10-14T00:00:00,Sulfur,D01.268.185.900
21999616,2011-10-14T00:00:00,Water,D01.455.900
21999616,2011-10-14T00:00:00,Water,D01.650.550.925
22000699,2011-10-14T00:00:00,"Adaptation, Physiological",G07.700.062
22000699,2011-10-14T00:00:00,"Adaptation, Physiological",G16.100.057.500
22000699,2011-10-14T00:00:00,Adult,M01.060.116
22000699,2011-10-14T00:00:00,Computer Simulation,L01.224.160
22000699,2011-10-14T00:00:00,Gait,E01.370.600.250
22000699,2011-10-14T00:00:00,Gait,G11.427.590.530.389
22000699,2011-10-14T00:00:00,"Gait Disorders, Neurologic",C10.597.404
22000699,2011-10-14T00:00:00,"Gait Disorders, Neurologic",C23.888.592.413
22000699,2011-10-14T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22000699,2011-10-14T00:00:00,Middle Aged,M01.060.116.630
22000699,2011-10-14T00:00:00,"Models, Biological",E05.599.395
22000699,2011-10-14T00:00:00,Postural Balance,G11.427.690
22000699,2011-10-14T00:00:00,Postural Balance,G11.561.600.810.541.595
22000699,2011-10-14T00:00:00,Recovery of Function,G16.757
22000699,2011-10-14T00:00:00,Spinal Cord Injuries,C10.228.854.770
22000699,2011-10-14T00:00:00,Spinal Cord Injuries,C10.900.850
22000699,2011-10-14T00:00:00,Spinal Cord Injuries,C21.866.819
22000699,2011-10-14T00:00:00,Walking,G11.427.590.530.568.900
22000699,2011-10-14T00:00:00,Walking,G11.427.590.530.698.940
22000699,2011-10-14T00:00:00,Walking,I03.450.642.845.940
22000720,2011-10-14T00:00:00,Albuminuria,C12.777.934.734.269
22000720,2011-10-14T00:00:00,Albuminuria,C13.351.968.934.734.269
22000720,2011-10-14T00:00:00,Albuminuria,C23.888.942.750.269
22000720,2011-10-14T00:00:00,Animals,B01.050
22000720,2011-10-14T00:00:00,"Complement Pathway, Alternative",G12.425.255.695
22000720,2011-10-14T00:00:00,Lupus Nephritis,C12.777.419.570.363.680
22000720,2011-10-14T00:00:00,Lupus Nephritis,C13.351.968.419.570.363.680
22000720,2011-10-14T00:00:00,Lupus Nephritis,C17.300.480.680
22000720,2011-10-14T00:00:00,Lupus Nephritis,C20.111.590.560
21767261,2011-10-15T00:00:00,Animals,B01.050
21767261,2011-10-15T00:00:00,Carrier Proteins,D12.776.157
21767261,2011-10-15T00:00:00,Cell Line,A11.251.210
21767261,2011-10-15T00:00:00,Down-Regulation,G02.111.087.225
21767261,2011-10-15T00:00:00,Down-Regulation,G02.149.115.225
21767261,2011-10-15T00:00:00,Down-Regulation,G05.355.315.200
21767261,2011-10-15T00:00:00,Down-Regulation,G07.690.812.230
21767261,2011-10-15T00:00:00,Down-Regulation,G07.700.680.230
21767261,2011-10-15T00:00:00,Sphingolipids,D10.570.877
21767261,2011-10-15T00:00:00,Sphingolipids,D10.808
21767261,2011-10-15T00:00:00,Tandem Mass Spectrometry,E05.196.566.880
21967984,2011-10-15T00:00:00,Cocaine-Related Disorders,C21.739.300
21967984,2011-10-15T00:00:00,Cocaine-Related Disorders,F03.900.300
21967984,2011-10-15T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22002859,2011-10-15T00:00:00,Computational Biology,H01.158.273.180
22002859,2011-10-15T00:00:00,"Models, Chemical",E05.599.495
22002859,2011-10-15T00:00:00,"Models, Molecular",E05.599.595
22002859,2011-10-15T00:00:00,Molecular Dynamics Simulation,E05.599.595.500
22002859,2011-10-15T00:00:00,Molecular Dynamics Simulation,G02.575.750
22002859,2011-10-15T00:00:00,Molecular Dynamics Simulation,L01.224.160.500
22002859,2011-10-15T00:00:00,Protein Conformation,G02.111.570.790.709
22002859,2011-10-15T00:00:00,Proteins,D12.776
22002859,2011-10-15T00:00:00,Research,H01.770.644
22002859,2011-10-15T00:00:00,Static Electricity,G01.201.249.820
22005043,2011-10-17T00:00:00,Central Nervous System Depressants,D27.505.696.277
22005043,2011-10-17T00:00:00,Central Nervous System Depressants,D27.505.954.427.210
22005043,2011-10-17T00:00:00,Ethanol,D02.033.375
22005043,2011-10-17T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22005043,2011-10-17T00:00:00,"Models, Molecular",E05.599.595
22005043,2011-10-17T00:00:00,Mutation,G05.365.590
22005043,2011-10-17T00:00:00,Protein Conformation,G02.111.570.790.709
22005043,2011-10-17T00:00:00,"Receptors, N-Methyl-D-Aspartate",D12.776.543.750.720.200.450.580
22005627,2011-10-17T00:00:00,Adult,M01.060.116
22005627,2011-10-17T00:00:00,African Americans,M01.686.508.100.100
22005627,2011-10-17T00:00:00,African Americans,M01.686.754.100
22005627,2011-10-17T00:00:00,Attitude to Health,F01.100.150
22005627,2011-10-17T00:00:00,Attitude to Health,N05.300.150
22005627,2011-10-17T00:00:00,Colorectal Neoplasms,C04.588.274.476.411.307
22005627,2011-10-17T00:00:00,Colorectal Neoplasms,C06.301.371.411.307
22005627,2011-10-17T00:00:00,Colorectal Neoplasms,C06.405.249.411.307
22005627,2011-10-17T00:00:00,Colorectal Neoplasms,C06.405.469.158.356
22005627,2011-10-17T00:00:00,Colorectal Neoplasms,C06.405.469.491.307
22005627,2011-10-17T00:00:00,Colorectal Neoplasms,C06.405.469.860.180
22005627,2011-10-17T00:00:00,Health Behavior,F01.145.488
22005627,2011-10-17T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22005627,2011-10-17T00:00:00,Incidence,E05.318.308.985.525.375
22005627,2011-10-17T00:00:00,Incidence,L01.280.975.525.375
22005627,2011-10-17T00:00:00,Incidence,N01.224.935.597.500
22005627,2011-10-17T00:00:00,Incidence,N06.850.505.400.975.525.375
22005627,2011-10-17T00:00:00,Incidence,N06.850.520.308.985.525.375
22005627,2011-10-17T00:00:00,Mass Screening,E01.370.500
22005627,2011-10-17T00:00:00,Mass Screening,E05.318.308.250.580
22005627,2011-10-17T00:00:00,Mass Screening,N02.421.143.827.233.443
22005627,2011-10-17T00:00:00,Mass Screening,N02.421.726.233.443
22005627,2011-10-17T00:00:00,Mass Screening,N05.715.360.300.375.500
22005627,2011-10-17T00:00:00,Mass Screening,N06.850.520.308.250.580
22005627,2011-10-17T00:00:00,Mass Screening,N06.850.780.500
22005627,2011-10-17T00:00:00,Patient Acceptance of Health Care,N05.300.150.600
22005627,2011-10-17T00:00:00,Patient Education as Topic,I02.233.332.500
22005627,2011-10-17T00:00:00,Patient Education as Topic,N02.421.143.827.407.680
22005627,2011-10-17T00:00:00,Patient Education as Topic,N02.421.726.407.680
22006290,2011-10-17T00:00:00,Adolescent,M01.060.057
22006290,2011-10-17T00:00:00,Adult,M01.060.116
22006290,2011-10-17T00:00:00,Blood Pressure,E01.370.600.875.249
22006290,2011-10-17T00:00:00,Blood Pressure,G09.330.380.076
22006290,2011-10-17T00:00:00,European Continental Ancestry Group,M01.686.508.400
22006290,2011-10-17T00:00:00,Gene Expression,G05.355.310
22006290,2011-10-17T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22006290,2011-10-17T00:00:00,Hypertension,C14.907.489
22006290,2011-10-17T00:00:00,Kidney,A05.810.453
22006290,2011-10-17T00:00:00,Middle Aged,M01.060.116.630
22006290,2011-10-17T00:00:00,"Polymorphism, Single Nucleotide",G05.365.795.598
22006290,2011-10-17T00:00:00,Quantitative Trait Loci,G05.360.340.024.380.937
22006290,2011-10-17T00:00:00,"RNA, Messenger",D13.444.735.544
22006290,2011-10-17T00:00:00,Sodium,D01.268.549.750
22006290,2011-10-17T00:00:00,Sodium,D01.552.528.850
22006290,2011-10-17T00:00:00,Young Adult,M01.060.116.815
22027492,2011-10-17T00:00:00,Animals,B01.050
22027492,2011-10-17T00:00:00,Brain,A08.186.211
22027492,2011-10-17T00:00:00,Nerve Tissue Proteins,D12.776.641
22027492,2011-10-17T00:00:00,Proteomics,H01.158.201.843
22027492,2011-10-17T00:00:00,Proteomics,H01.158.273.180.350.700
22027492,2011-10-17T00:00:00,Proteomics,H01.158.273.343.350.700
22027492,2011-10-17T00:00:00,Proteomics,H01.181.122.738
22027492,2011-10-17T00:00:00,"RNA, Messenger",D13.444.735.544
22027492,2011-10-17T00:00:00,Rats,B01.050.150.900.649.865.635.505.700
22027492,2011-10-17T00:00:00,"Rats, Sprague-Dawley",B01.050.150.900.649.865.635.505.700.750
21996383,2011-10-18T00:00:00,Cardiac Volume,G09.330.380.249
21996383,2011-10-18T00:00:00,Heart,A07.541
21996383,2011-10-18T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21996383,2011-10-18T00:00:00,"Hypertrophy, Left Ventricular",C14.280.195.400
21996383,2011-10-18T00:00:00,"Hypertrophy, Left Ventricular",C23.300.775.250.400
21996383,2011-10-18T00:00:00,Ventricular Remodeling,C23.300.985
21996383,2011-10-18T00:00:00,Ventricular Remodeling,G09.330.190.962.975
22009992,2011-10-18T00:00:00,Factor VIIa,D08.811.277.656.300.760.300
22009992,2011-10-18T00:00:00,Factor VIIa,D08.811.277.656.959.350.300
22009992,2011-10-18T00:00:00,Factor VIIa,D12.776.124.125.325.300
22009992,2011-10-18T00:00:00,Factor VIIa,D23.119.325.300
22009992,2011-10-18T00:00:00,Hemorrhage,C23.550.414
22009992,2011-10-18T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22009992,2011-10-18T00:00:00,Recombinant Proteins,D12.776.828
22010139,2011-10-18T00:00:00,Aged,M01.060.116.100
22010139,2011-10-18T00:00:00,"Aorta, Thoracic",A07.231.114.056.372
22010139,2011-10-18T00:00:00,"Aortic Aneurysm, Thoracic",C14.907.055.239.125
22010139,2011-10-18T00:00:00,"Aortic Aneurysm, Thoracic",C14.907.109.139.125
22010139,2011-10-18T00:00:00,Down-Regulation,G02.111.087.225
22010139,2011-10-18T00:00:00,Down-Regulation,G02.149.115.225
22010139,2011-10-18T00:00:00,Down-Regulation,G05.355.315.200
22010139,2011-10-18T00:00:00,Down-Regulation,G07.690.812.230
22010139,2011-10-18T00:00:00,Down-Regulation,G07.700.680.230
22010139,2011-10-18T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22010139,2011-10-18T00:00:00,Matrix Metalloproteinase 2,D08.811.277.656.300.480.205.352
22010139,2011-10-18T00:00:00,Matrix Metalloproteinase 2,D08.811.277.656.300.480.252.420
22010139,2011-10-18T00:00:00,Matrix Metalloproteinase 2,D08.811.277.656.300.480.525.700.150
22010139,2011-10-18T00:00:00,Matrix Metalloproteinase 2,D08.811.277.656.675.374.205.352
22010139,2011-10-18T00:00:00,Matrix Metalloproteinase 2,D08.811.277.656.675.374.252.420
22010139,2011-10-18T00:00:00,Matrix Metalloproteinase 2,D08.811.277.656.675.374.525.700.150
22010139,2011-10-18T00:00:00,Matrix Metalloproteinase 9,D08.811.277.656.300.480.205.360
22010139,2011-10-18T00:00:00,Matrix Metalloproteinase 9,D08.811.277.656.300.480.252.445
22010139,2011-10-18T00:00:00,Matrix Metalloproteinase 9,D08.811.277.656.300.480.525.700.350
22010139,2011-10-18T00:00:00,Matrix Metalloproteinase 9,D08.811.277.656.675.374.205.360
22010139,2011-10-18T00:00:00,Matrix Metalloproteinase 9,D08.811.277.656.675.374.252.445
22010139,2011-10-18T00:00:00,Matrix Metalloproteinase 9,D08.811.277.656.675.374.525.700.350
22010139,2011-10-18T00:00:00,MicroRNAs,D13.150.650.319
22010139,2011-10-18T00:00:00,MicroRNAs,D13.444.735.150.319
22010139,2011-10-18T00:00:00,MicroRNAs,D13.444.735.790.099
22010139,2011-10-18T00:00:00,Middle Aged,M01.060.116.630
22024597,2011-10-18T00:00:00,Animals,B01.050
22024597,2011-10-18T00:00:00,Cytokines,D12.644.276.374
22024597,2011-10-18T00:00:00,Cytokines,D12.776.467.374
22024597,2011-10-18T00:00:00,Cytokines,D23.529.374
22024597,2011-10-18T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22024597,2011-10-18T00:00:00,Inflammation,C23.550.470
22024597,2011-10-18T00:00:00,Microglia,A08.637.400
22024597,2011-10-18T00:00:00,Microglia,A11.650.400
22024597,2011-10-18T00:00:00,Neurodegenerative Diseases,C10.574
22024597,2011-10-18T00:00:00,Signal Transduction,G02.111.087.800
22024597,2011-10-18T00:00:00,Signal Transduction,G02.149.115.800
22024597,2011-10-18T00:00:00,Signal Transduction,G04.299.880
22012129,2011-10-19T00:00:00,Animals,B01.050
22012129,2011-10-19T00:00:00,Apoptosis,G04.299.139.160
22012129,2011-10-19T00:00:00,Calpain,D08.811.277.656.262.500.120
22012129,2011-10-19T00:00:00,Calpain,D08.811.277.656.300.200.120
22012129,2011-10-19T00:00:00,Diabetes Mellitus,C18.452.394.750
22012129,2011-10-19T00:00:00,Diabetes Mellitus,C19.246
22012129,2011-10-19T00:00:00,Diabetic Nephropathies,C12.777.419.192
22012129,2011-10-19T00:00:00,Diabetic Nephropathies,C13.351.968.419.192
22012129,2011-10-19T00:00:00,Diabetic Nephropathies,C19.246.099.875
22012129,2011-10-19T00:00:00,Down-Regulation,G02.111.087.225
22012129,2011-10-19T00:00:00,Down-Regulation,G02.149.115.225
22012129,2011-10-19T00:00:00,Down-Regulation,G05.355.315.200
22012129,2011-10-19T00:00:00,Down-Regulation,G07.690.812.230
22012129,2011-10-19T00:00:00,Down-Regulation,G07.700.680.230
22012129,2011-10-19T00:00:00,Glucose,D09.546.359.448
22012129,2011-10-19T00:00:00,"Kidney Tubules, Proximal",A05.810.453.736.560.570
22012129,2011-10-19T00:00:00,"Mice, Obese",B01.050.150.900.649.865.635.505.500.550.530
22012129,2011-10-19T00:00:00,Mitochondria,A11.284.430.214.190.875.564
22012129,2011-10-19T00:00:00,Mitochondria,A11.284.835.626
22012129,2011-10-19T00:00:00,"RNA, Messenger",D13.444.735.544
22012129,2011-10-19T00:00:00,Rabbits,B01.050.150.900.649.521.700
22012129,2011-10-19T00:00:00,Rats,B01.050.150.900.649.865.635.505.700
22012129,2011-10-19T00:00:00,"Rats, Sprague-Dawley",B01.050.150.900.649.865.635.505.700.750
22012472,2011-10-19T00:00:00,Adult,M01.060.116
22012472,2011-10-19T00:00:00,Genetic Predisposition to Disease,C23.550.291.687.500
22012472,2011-10-19T00:00:00,Genetic Predisposition to Disease,G05.380.355
22012472,2011-10-19T00:00:00,Genome-Wide Association Study,E05.318.416.249
22012472,2011-10-19T00:00:00,Genome-Wide Association Study,E05.318.780.392
22012472,2011-10-19T00:00:00,Genome-Wide Association Study,E05.393.385.500
22012472,2011-10-19T00:00:00,Genome-Wide Association Study,E05.393.522.500
22012472,2011-10-19T00:00:00,Genome-Wide Association Study,E05.393.760.640.500
22012472,2011-10-19T00:00:00,Genome-Wide Association Study,N06.850.520.445.392
22012472,2011-10-19T00:00:00,Genome-Wide Association Study,N06.850.520.470.500
22012472,2011-10-19T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22012472,2011-10-19T00:00:00,Life Change Events,F01.829.458.410
22012472,2011-10-19T00:00:00,Middle Aged,M01.060.116.630
22012472,2011-10-19T00:00:00,Nerve Tissue Proteins,D12.776.641
22012472,2011-10-19T00:00:00,"Receptors, Nicotinic",D12.776.543.750.720.360.550
22012472,2011-10-19T00:00:00,Sex Factors,N05.715.350.675
22012472,2011-10-19T00:00:00,Sex Factors,N06.850.490.875
22012472,2011-10-19T00:00:00,Tobacco Use Disorder,C21.739.912
22012472,2011-10-19T00:00:00,Tobacco Use Disorder,F03.900.912
22012863,2011-10-19T00:00:00,Cell Membrane,A11.284.149
22012863,2011-10-19T00:00:00,Exosomes,A11.284.430.214.190.875.190.880.495
22012863,2011-10-19T00:00:00,RNA,D13.444.735
22012863,2011-10-19T00:00:00,Signal Transduction,G02.111.087.800
22012863,2011-10-19T00:00:00,Signal Transduction,G02.149.115.800
22012863,2011-10-19T00:00:00,Signal Transduction,G04.299.880
22013072,2011-10-19T00:00:00,Animals,B01.050
22013072,2011-10-19T00:00:00,Apoptosis,G04.299.139.160
22013072,2011-10-19T00:00:00,Calcium,D01.268.552.100
22013072,2011-10-19T00:00:00,Calcium,D01.552.539.288
22013072,2011-10-19T00:00:00,Calcium,D23.119.100
22013072,2011-10-19T00:00:00,"Carcinoma, Squamous Cell",C04.557.470.200.400
22013072,2011-10-19T00:00:00,"Carcinoma, Squamous Cell",C04.557.470.700.400
22013072,2011-10-19T00:00:00,Ceramides,D02.065.313
22013072,2011-10-19T00:00:00,Ceramides,D09.400.410.420.525.200
22013072,2011-10-19T00:00:00,Ceramides,D10.390.470.675.200
22013072,2011-10-19T00:00:00,Ceramides,D10.570.877.360.612.200
22013072,2011-10-19T00:00:00,Endoplasmic Reticulum,A11.284.430.214.190.875.248
22013072,2011-10-19T00:00:00,Golgi Apparatus,A11.284.430.214.190.875.336
22013072,2011-10-19T00:00:00,Homeostasis,G07.700.360
22013072,2011-10-19T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22013072,2011-10-19T00:00:00,Membrane Proteins,D12.776.543
22013072,2011-10-19T00:00:00,Oxidoreductases,D08.811.682
22013072,2011-10-19T00:00:00,Sphingolipids,D10.570.877
22013072,2011-10-19T00:00:00,Sphingolipids,D10.808
22013072,2011-10-19T00:00:00,Sphingosine N-Acyltransferase,D08.811.913.050.712
22014657,2011-10-19T00:00:00,Bone Screws,E07.695.130
22014657,2011-10-19T00:00:00,Bone Screws,E07.858.442.660.115
22014657,2011-10-19T00:00:00,Bone Screws,E07.858.690.650.115
22014657,2011-10-19T00:00:00,Cadaver,C23.550.260.224
22014657,2011-10-19T00:00:00,Femoral Fractures,C21.866.404.061
22014657,2011-10-19T00:00:00,Femoral Fractures,C21.866.558.276
22014657,2011-10-19T00:00:00,Fracture Fixation,E04.555.300
22014657,2011-10-19T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22014657,2011-10-19T00:00:00,Osteoporosis,C05.116.198.579
22014657,2011-10-19T00:00:00,Periprosthetic Fractures,C21.866.404.550
22014657,2011-10-19T00:00:00,Weight-Bearing,G01.374.676.965
22014657,2011-10-19T00:00:00,Weight-Bearing,G01.595.540.965
22014964,2011-10-19T00:00:00,Adult,M01.060.116
22014964,2011-10-19T00:00:00,Aged,M01.060.116.100
22014964,2011-10-19T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22014964,2011-10-19T00:00:00,Middle Aged,M01.060.116.630
22014964,2011-10-19T00:00:00,Prosthesis Failure,C23.550.767.865
22014964,2011-10-19T00:00:00,Prosthesis Failure,E05.325.771
22014964,2011-10-19T00:00:00,Reoperation,E04.690
22014964,2011-10-19T00:00:00,Risk Assessment,E05.318.740.600.800.715
22014964,2011-10-19T00:00:00,Risk Assessment,N04.452.871.715
22014964,2011-10-19T00:00:00,Risk Assessment,N05.715.360.750.625.700.690
22014964,2011-10-19T00:00:00,Risk Assessment,N06.850.505.715
22014964,2011-10-19T00:00:00,Risk Assessment,N06.850.520.830.600.800.715
22014964,2011-10-19T00:00:00,Suburethral Slings,E07.695.752
22014964,2011-10-19T00:00:00,Treatment Outcome,E01.789.800
22014964,2011-10-19T00:00:00,Treatment Outcome,N04.761.559.590.800
22014964,2011-10-19T00:00:00,Treatment Outcome,N05.715.360.575.575.800
22014964,2011-10-19T00:00:00,"Urinary Incontinence, Stress",C12.777.934.852.249
22014964,2011-10-19T00:00:00,"Urinary Incontinence, Stress",C13.351.968.934.814.500
22014964,2011-10-19T00:00:00,"Urinary Incontinence, Stress",C23.888.942.800.500
22014964,2011-10-19T00:00:00,Urodynamics,G08.852.898
22014964,2011-10-19T00:00:00,Video Recording,L01.240.960
22012690,2011-10-20T00:00:00,Polypropylenes,D02.455.326.271.665.590
22012690,2011-10-20T00:00:00,Polypropylenes,D05.750.716.550
22012690,2011-10-20T00:00:00,Polypropylenes,D25.720.716.550
22012690,2011-10-20T00:00:00,Polypropylenes,J01.637.051.720.716.550
22012690,2011-10-20T00:00:00,Proteins,D12.776
22012690,2011-10-20T00:00:00,"Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization",E05.196.566.755
22014122,2011-10-20T00:00:00,Adult,M01.060.116
22014122,2011-10-20T00:00:00,Blood Glucose,D09.546.359.448.500
22014122,2011-10-20T00:00:00,Blood Pressure,E01.370.600.875.249
22014122,2011-10-20T00:00:00,Blood Pressure,G09.330.380.076
22014122,2011-10-20T00:00:00,Case Management,N04.590.233.624.250
22014122,2011-10-20T00:00:00,"Diabetes Mellitus, Type 2",C18.452.394.750.149
22014122,2011-10-20T00:00:00,"Diabetes Mellitus, Type 2",C19.246.300
22014122,2011-10-20T00:00:00,"Hemoglobin A, Glycosylated",D09.408.375
22014122,2011-10-20T00:00:00,"Hemoglobin A, Glycosylated",D12.776.124.400.405.440
22014122,2011-10-20T00:00:00,"Hemoglobin A, Glycosylated",D12.776.422.316.762.380.440
22014122,2011-10-20T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22014293,2011-10-20T00:00:00,Animals,B01.050
22014293,2011-10-20T00:00:00,Bone Marrow,A15.382.216
22014293,2011-10-20T00:00:00,Cell Aging,G04.299.119
22014293,2011-10-20T00:00:00,Gene Expression Regulation,G05.355.315
22014293,2011-10-20T00:00:00,Hematopoietic Stem Cells,A11.148.378
22014293,2011-10-20T00:00:00,Hematopoietic Stem Cells,A11.872.378
22014293,2011-10-20T00:00:00,Hematopoietic Stem Cells,A15.378.316.378
22014293,2011-10-20T00:00:00,Protein Kinase Inhibitors,D27.505.519.389.755
22014293,2011-10-20T00:00:00,Time Factors,G01.910.857
22014293,2011-10-20T00:00:00,p38 Mitogen-Activated Protein Kinases,D08.811.913.696.620.682.700.567.878
22014293,2011-10-20T00:00:00,p38 Mitogen-Activated Protein Kinases,D08.811.913.696.620.682.700.646.750.843
22014293,2011-10-20T00:00:00,p38 Mitogen-Activated Protein Kinases,D12.644.360.450.835
22014293,2011-10-20T00:00:00,p38 Mitogen-Activated Protein Kinases,D12.776.476.450.835
22015637,2011-10-20T00:00:00,Clinical Competence,I02.399.630.210
22015637,2011-10-20T00:00:00,Clinical Competence,N04.761.210
22015637,2011-10-20T00:00:00,Curriculum,I02.158
22015637,2011-10-20T00:00:00,Educational Measurement,I02.399
22015637,2011-10-20T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22015637,2011-10-20T00:00:00,Internship and Residency,I02.358.399.644
22015637,2011-10-20T00:00:00,Neurosurgery,H02.403.810.425
22015637,2011-10-20T00:00:00,Neurosurgical Procedures,E04.525
22015637,2011-10-20T00:00:00,Pilot Projects,E05.318.760.750
22015637,2011-10-20T00:00:00,Pilot Projects,E05.337.737
22015637,2011-10-20T00:00:00,Pilot Projects,N05.715.360.775.625
22015637,2011-10-20T00:00:00,Pilot Projects,N06.850.520.450.720
22016563,2011-10-20T00:00:00,Cell Proliferation,G04.299.233.750
22016563,2011-10-20T00:00:00,Cell Proliferation,G07.700.320.249.410.750
22016563,2011-10-20T00:00:00,Green Fluorescent Proteins,D12.776.532.265
22016563,2011-10-20T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22016563,2011-10-20T00:00:00,Insulin-Like Growth Factor II,D12.644.276.937.420
22016563,2011-10-20T00:00:00,Insulin-Like Growth Factor II,D12.776.124.862.425
22016563,2011-10-20T00:00:00,Insulin-Like Growth Factor II,D12.776.467.937.420
22016563,2011-10-20T00:00:00,Insulin-Like Growth Factor II,D23.529.937.420
22016563,2011-10-20T00:00:00,Lysophospholipids,D10.570.755.375.760.550
22016563,2011-10-20T00:00:00,Mesangial Cells,A05.810.453.324.359.620
22016563,2011-10-20T00:00:00,Mesangial Cells,A05.810.453.736.520.620
22016563,2011-10-20T00:00:00,Mesangial Cells,A11.329.228.950
22016563,2011-10-20T00:00:00,Phosphotransferases (Alcohol Group Acceptor),D08.811.913.696.620
22016563,2011-10-20T00:00:00,Protein Kinase C,D08.811.913.696.620.682.700.725
22016563,2011-10-20T00:00:00,Protein Transport,G03.495.166.700
22016563,2011-10-20T00:00:00,RNA Interference,G05.355.315.203.374.790
22016563,2011-10-20T00:00:00,"Receptor, IGF Type 1",D08.811.913.696.620.682.725.400.185
22016563,2011-10-20T00:00:00,"Receptor, IGF Type 1",D12.776.543.750.060.468
22016563,2011-10-20T00:00:00,"Receptor, IGF Type 1",D12.776.543.750.750.400.780.400
22016563,2011-10-20T00:00:00,"Receptor, IGF Type 2",D12.776.543.750.750.400.780.410
22016563,2011-10-20T00:00:00,Recombinant Fusion Proteins,D12.776.828.300
22016563,2011-10-20T00:00:00,Signal Transduction,G02.111.087.800
22016563,2011-10-20T00:00:00,Signal Transduction,G02.149.115.800
22016563,2011-10-20T00:00:00,Signal Transduction,G04.299.880
22016563,2011-10-20T00:00:00,Sphingosine,D02.033.100.700
22016563,2011-10-20T00:00:00,Sphingosine,D02.033.455.843
22016563,2011-10-20T00:00:00,Sphingosine,D02.092.063.700
22018935,2011-10-20T00:00:00,Diet,E05.272
22018935,2011-10-20T00:00:00,Diet,G07.610.240
22018935,2011-10-20T00:00:00,Exercise,G11.427.590.237
22018935,2011-10-20T00:00:00,Exercise,I03.350
22018935,2011-10-20T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22018935,2011-10-20T00:00:00,Meditation,E02.190.525.374
22018935,2011-10-20T00:00:00,Meditation,E02.190.901.455
22018935,2011-10-20T00:00:00,Meditation,F04.754.137.750.500
22018935,2011-10-20T00:00:00,"Neoplasm Recurrence, Local",C04.697.655
22018935,2011-10-20T00:00:00,"Neoplasm Recurrence, Local",C23.550.727.655
22018935,2011-10-20T00:00:00,Prostate-Specific Antigen,D08.811.277.656.300.760.442.750
22018935,2011-10-20T00:00:00,Prostate-Specific Antigen,D08.811.277.656.959.350.442.750
22018935,2011-10-20T00:00:00,Prostate-Specific Antigen,D12.776.866.249.500
22018935,2011-10-20T00:00:00,Prostate-Specific Antigen,D23.050.285.625
22018935,2011-10-20T00:00:00,Prostate-Specific Antigen,D23.101.840.625
22018935,2011-10-20T00:00:00,Prostatic Neoplasms,C04.588.945.440.770
22018935,2011-10-20T00:00:00,Prostatic Neoplasms,C12.294.260.750
22018935,2011-10-20T00:00:00,Prostatic Neoplasms,C12.294.565.625
22018935,2011-10-20T00:00:00,Prostatic Neoplasms,C12.758.409.750
22018935,2011-10-20T00:00:00,"Stress, Psychological",F01.145.126.990
22018935,2011-10-20T00:00:00,"Stress, Psychological",F02.830.900
22078225,2011-10-20T00:00:00,Carbon,D01.268.150
22078225,2011-10-20T00:00:00,Iodine,D01.268.380.400
22078225,2011-10-20T00:00:00,Organic Chemicals,D02
22078225,2011-10-20T00:00:00,South Carolina,Z01.107.567.875.075.662
22078225,2011-10-20T00:00:00,South Carolina,Z01.107.567.875.750.700
22078225,2011-10-20T00:00:00,Water Purification,N06.850.780.200.800.800.900.900
22078225,2011-10-20T00:00:00,Water Purification,N06.850.860.510.900.900
22078225,2011-10-20T00:00:00,Water Purification,N06.850.860.510.915.900
22092744,2011-10-20T00:00:00,Adult,M01.060.116
22092744,2011-10-20T00:00:00,Aged,M01.060.116.100
22092744,2011-10-20T00:00:00,Case-Control Studies,E05.318.760.500.500
22092744,2011-10-20T00:00:00,Case-Control Studies,N05.715.360.775.175.200
22092744,2011-10-20T00:00:00,Case-Control Studies,N06.850.520.450.500.500
22092744,2011-10-20T00:00:00,"Diabetes Mellitus, Type 2",C18.452.394.750.149
22092744,2011-10-20T00:00:00,"Diabetes Mellitus, Type 2",C19.246.300
22092744,2011-10-20T00:00:00,Ethnic Groups,M01.686.754
22092744,2011-10-20T00:00:00,Ethnic Groups,N01.224.317
22092744,2011-10-20T00:00:00,Gingivitis,C07.465.714.258.480
22092744,2011-10-20T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22092744,2011-10-20T00:00:00,Hyperglycemia,C18.452.394.952
22092744,2011-10-20T00:00:00,"Image Processing, Computer-Assisted",L01.224.308
22092744,2011-10-20T00:00:00,Lipopolysaccharides,D09.400.500
22092744,2011-10-20T00:00:00,Lipopolysaccharides,D09.698.718.450
22092744,2011-10-20T00:00:00,Lipopolysaccharides,D10.494
22092744,2011-10-20T00:00:00,Lipopolysaccharides,D23.050.161.616.525
22092744,2011-10-20T00:00:00,Lipopolysaccharides,D23.946.123.329.500
22092744,2011-10-20T00:00:00,Middle Aged,M01.060.116.630
22092744,2011-10-20T00:00:00,Periodontitis,C07.465.714.533
22177188,2011-10-20T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22177188,2011-10-20T00:00:00,Ovary,A05.360.319.114.630
22177188,2011-10-20T00:00:00,Ovary,A05.360.576.497
22177188,2011-10-20T00:00:00,Ovary,A06.407.312.497
22177188,2011-10-20T00:00:00,Pregnancy,G08.686.785.760.769
22177188,2011-10-20T00:00:00,Risk Factors,E05.318.740.600.800.725
22177188,2011-10-20T00:00:00,Risk Factors,N05.715.350.200.700
22177188,2011-10-20T00:00:00,Risk Factors,N05.715.360.750.625.700.700
22177188,2011-10-20T00:00:00,Risk Factors,N06.850.490.625.750
22177188,2011-10-20T00:00:00,Risk Factors,N06.850.520.830.600.800.725
22018910,2011-10-21T00:00:00,"Clinical Trials, Phase II as Topic",E05.318.760.535.210
22018910,2011-10-21T00:00:00,"Clinical Trials, Phase II as Topic",E05.337.250.210
22018910,2011-10-21T00:00:00,"Clinical Trials, Phase II as Topic",N05.715.360.775.235.210
22018910,2011-10-21T00:00:00,"Clinical Trials, Phase II as Topic",N06.850.520.450.535.210
22018910,2011-10-21T00:00:00,Disease Progression,C23.550.291.656
22018910,2011-10-21T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22018910,2011-10-21T00:00:00,Middle Aged,M01.060.116.630
22018910,2011-10-21T00:00:00,Parkinson Disease,C10.228.140.079.862.500
22018910,2011-10-21T00:00:00,Parkinson Disease,C10.228.662.600.400
22018910,2011-10-21T00:00:00,Parkinson Disease,C10.574.812
22018910,2011-10-21T00:00:00,Physicians,M01.526.485.810
22018910,2011-10-21T00:00:00,Physicians,N02.360.810
22019548,2011-10-21T00:00:00,Alcohol Drinking,F01.145.317.269
22019548,2011-10-21T00:00:00,Body Mass Index,E01.370.600.115.100.125
22019548,2011-10-21T00:00:00,Body Mass Index,E05.041.124.125
22019548,2011-10-21T00:00:00,Body Mass Index,G07.100.100.125
22019548,2011-10-21T00:00:00,Body Mass Index,N06.850.505.200.100.175
22019548,2011-10-21T00:00:00,Cardiovascular Diseases,C14
22019548,2011-10-21T00:00:00,Diet,E05.272
22019548,2011-10-21T00:00:00,Diet,G07.610.240
22019548,2011-10-21T00:00:00,Exercise,G11.427.590.237
22019548,2011-10-21T00:00:00,Exercise,I03.350
22019548,2011-10-21T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22019548,2011-10-21T00:00:00,Life Style,F01.829.458
22019548,2011-10-21T00:00:00,Middle Aged,M01.060.116.630
22019548,2011-10-21T00:00:00,"Models, Statistical",E05.318.740.500
22019548,2011-10-21T00:00:00,"Models, Statistical",E05.599.835
22019548,2011-10-21T00:00:00,"Models, Statistical",N05.715.360.750.530
22019548,2011-10-21T00:00:00,"Models, Statistical",N06.850.520.830.500
22019548,2011-10-21T00:00:00,Stroke,C10.228.140.300.775
22019548,2011-10-21T00:00:00,Stroke,C14.907.253.855
22019548,2011-10-21T00:00:00,United States,Z01.107.567.875
22024727,2011-10-21T00:00:00,Age Factors,N05.715.350.075
22024727,2011-10-21T00:00:00,Age Factors,N06.850.490.250
22024727,2011-10-21T00:00:00,"Databases, Factual",L01.470.750.750
22024727,2011-10-21T00:00:00,"Databases, Factual",L01.700.508.300.188.400
22024727,2011-10-21T00:00:00,Hospitalization,E02.760.400
22024727,2011-10-21T00:00:00,Hospitalization,N02.421.585.400
22024727,2011-10-21T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22024727,2011-10-21T00:00:00,Myocardial Infarction,C14.280.647.500
22024727,2011-10-21T00:00:00,Myocardial Infarction,C14.907.585.500
22024727,2011-10-21T00:00:00,Sex Factors,N05.715.350.675
22024727,2011-10-21T00:00:00,Sex Factors,N06.850.490.875
22024727,2011-10-21T00:00:00,Time Factors,G01.910.857
22115768,2011-10-21T00:00:00,Adolescent,M01.060.057
22115768,2011-10-21T00:00:00,Adult,M01.060.116
22115768,2011-10-21T00:00:00,Brain,A08.186.211
22115768,2011-10-21T00:00:00,Child,M01.060.406
22115768,2011-10-21T00:00:00,"Child, Preschool",M01.060.406.448
22115768,2011-10-21T00:00:00,Fibroblasts,A11.329.228
22115768,2011-10-21T00:00:00,Fibroblasts,A11.872.228
22115768,2011-10-21T00:00:00,Gene Expression Regulation,G05.355.315
22115768,2011-10-21T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22115768,2011-10-21T00:00:00,Mitochondrial Diseases,C18.452.660
22115768,2011-10-21T00:00:00,Oxidative Stress,G03.495.710
22115768,2011-10-21T00:00:00,Oxidative Stress,G07.700.830.750
22115768,2011-10-21T00:00:00,"Tomography, Emission-Computed, Single-Photon",E01.370.350.350.800.800
22115768,2011-10-21T00:00:00,"Tomography, Emission-Computed, Single-Photon",E01.370.350.600.350.800.800
22115768,2011-10-21T00:00:00,"Tomography, Emission-Computed, Single-Photon",E01.370.350.710.800.800
22115768,2011-10-21T00:00:00,"Tomography, Emission-Computed, Single-Photon",E01.370.350.825.800.800
22115768,2011-10-21T00:00:00,"Tomography, Emission-Computed, Single-Photon",E01.370.384.730.800.800
22024485,2011-10-22T00:00:00,Adolescent,M01.060.057
22024485,2011-10-22T00:00:00,Child,M01.060.406
22024485,2011-10-22T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22024485,2011-10-22T00:00:00,Mood Disorders,F03.600
22024485,2011-10-22T00:00:00,"Polymorphism, Single Nucleotide",G05.365.795.598
22024485,2011-10-22T00:00:00,Psychiatric Status Rating Scales,F04.586
22024485,2011-10-22T00:00:00,Regression Analysis,E05.318.740.750
22024485,2011-10-22T00:00:00,Regression Analysis,N05.715.360.750.695
22024485,2011-10-22T00:00:00,Regression Analysis,N06.850.520.830.750
22024485,2011-10-22T00:00:00,Risk-Taking,F01.145.722
22024485,2011-10-22T00:00:00,Serotonin Plasma Membrane Transport Proteins,D12.776.157.530.450.625.311
22024485,2011-10-22T00:00:00,Serotonin Plasma Membrane Transport Proteins,D12.776.157.530.562.374.875
22024485,2011-10-22T00:00:00,Serotonin Plasma Membrane Transport Proteins,D12.776.543.585.450.625.374
22024485,2011-10-22T00:00:00,Serotonin Plasma Membrane Transport Proteins,D12.776.543.585.562.374.875
21854084,2011-10-24T00:00:00,Antigen Presentation,G12.425.107
21854084,2011-10-24T00:00:00,Antigen Presentation,G12.450.050.400.070
21854084,2011-10-24T00:00:00,CD4-Positive T-Lymphocytes,A11.118.637.555.567.569.200
21854084,2011-10-24T00:00:00,CD4-Positive T-Lymphocytes,A15.145.229.637.555.567.569.200
21854084,2011-10-24T00:00:00,CD4-Positive T-Lymphocytes,A15.382.490.555.567.569.200
21854084,2011-10-24T00:00:00,Cell Proliferation,G04.299.233.750
21854084,2011-10-24T00:00:00,Cell Proliferation,G07.700.320.249.410.750
21854084,2011-10-24T00:00:00,Endocytosis,G04.299.482
21854084,2011-10-24T00:00:00,Flow Cytometry,E05.196.712.516.600.240.350
21854084,2011-10-24T00:00:00,Flow Cytometry,E05.200.500.386.350
21854084,2011-10-24T00:00:00,HLA-D Antigens,D23.050.301.500.410.400
21854084,2011-10-24T00:00:00,HLA-D Antigens,D23.050.301.500.450.400
21854084,2011-10-24T00:00:00,HLA-D Antigens,D23.050.705.552.410.400
21854084,2011-10-24T00:00:00,HLA-D Antigens,D23.050.705.552.450.400
21854084,2011-10-24T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21854084,2011-10-24T00:00:00,Stilbenes,D02.455.426.559.389.150.700
21918972,2011-10-24T00:00:00,"Antigens, CD147",D12.776.395.550.045
21918972,2011-10-24T00:00:00,"Antigens, CD147",D12.776.543.550.188
21918972,2011-10-24T00:00:00,"Antigens, CD147",D23.050.285.040
21918972,2011-10-24T00:00:00,"Antigens, CD147",D23.050.301.264.035.247
21918972,2011-10-24T00:00:00,"Antigens, CD147",D23.101.100.110.247
21918972,2011-10-24T00:00:00,Cell Line,A11.251.210
21918972,2011-10-24T00:00:00,"Endothelium, Vascular",A07.231.330
21918972,2011-10-24T00:00:00,"Endothelium, Vascular",A10.272.491.355
21918972,2011-10-24T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21918972,2011-10-24T00:00:00,Mitogen-Activated Protein Kinases,D08.811.913.696.620.682.700.567
21918972,2011-10-24T00:00:00,Mitogen-Activated Protein Kinases,D08.811.913.696.620.682.700.646.750
21918972,2011-10-24T00:00:00,Mitogen-Activated Protein Kinases,D12.644.360.450
21918972,2011-10-24T00:00:00,Mitogen-Activated Protein Kinases,D12.776.476.450
21918972,2011-10-24T00:00:00,Proto-Oncogene Proteins c-akt,D08.811.913.696.620.682.700.755
21918972,2011-10-24T00:00:00,Proto-Oncogene Proteins c-akt,D12.776.476.565
21918972,2011-10-24T00:00:00,Proto-Oncogene Proteins c-akt,D12.776.624.664.700.168
21918972,2011-10-24T00:00:00,RNA Interference,G05.355.315.203.374.790
21918972,2011-10-24T00:00:00,Signal Transduction,G02.111.087.800
21918972,2011-10-24T00:00:00,Signal Transduction,G02.149.115.800
21918972,2011-10-24T00:00:00,Signal Transduction,G04.299.880
21918972,2011-10-24T00:00:00,Vascular Endothelial Growth Factor A,D12.644.276.100.800.200
21918972,2011-10-24T00:00:00,Vascular Endothelial Growth Factor A,D12.776.467.100.800.200
21918972,2011-10-24T00:00:00,Vascular Endothelial Growth Factor A,D23.529.100.800.200
22024253,2011-10-24T00:00:00,Animals,B01.050
22024253,2011-10-24T00:00:00,Connexin 43,D12.776.543.585.250.200
22024253,2011-10-24T00:00:00,Estrous Cycle,G08.686.195
22024253,2011-10-24T00:00:00,NF-kappa B,D12.776.260.600
22024253,2011-10-24T00:00:00,NF-kappa B,D12.776.660.600
22024253,2011-10-24T00:00:00,NF-kappa B,D12.776.930.600
22024253,2011-10-24T00:00:00,Ovary,A05.360.319.114.630
22024253,2011-10-24T00:00:00,Ovary,A05.360.576.497
22024253,2011-10-24T00:00:00,Ovary,A06.407.312.497
22024253,2011-10-24T00:00:00,Rats,B01.050.150.900.649.865.635.505.700
22024253,2011-10-24T00:00:00,"Rats, Sprague-Dawley",B01.050.150.900.649.865.635.505.700.750
22024253,2011-10-24T00:00:00,S-Nitrosoglutathione,D02.654.846.500.249
22024253,2011-10-24T00:00:00,S-Nitrosoglutathione,D02.886.489.650.750
22024253,2011-10-24T00:00:00,S-Nitrosoglutathione,D12.644.456.448.750
22024253,2011-10-24T00:00:00,Spinal Cord Injuries,C10.228.854.770
22024253,2011-10-24T00:00:00,Spinal Cord Injuries,C10.900.850
22024253,2011-10-24T00:00:00,Spinal Cord Injuries,C21.866.819
22025614,2011-10-24T00:00:00,"Chromatography, High Pressure Liquid",E05.196.181.400.300
22025614,2011-10-24T00:00:00,Gastrointestinal Tract,A03.556
22025614,2011-10-24T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22025614,2011-10-24T00:00:00,Polyamines,D02.092.782
22025614,2011-10-24T00:00:00,Signal Transduction,G02.111.087.800
22025614,2011-10-24T00:00:00,Signal Transduction,G02.149.115.800
22025614,2011-10-24T00:00:00,Signal Transduction,G04.299.880
22025714,2011-10-24T00:00:00,Animals,B01.050
22025714,2011-10-24T00:00:00,Cell Line,A11.251.210
22025714,2011-10-24T00:00:00,Phosphorylation,G02.111.087.677
22025714,2011-10-24T00:00:00,Phosphorylation,G02.149.115.677
22025714,2011-10-24T00:00:00,Phosphorylation,G02.149.465.700
22025714,2011-10-24T00:00:00,Phosphorylation,G02.607.750.700
22025714,2011-10-24T00:00:00,Phosphorylation,G03.495.790
22025714,2011-10-24T00:00:00,Protein Isoforms,D12.776.800
22025714,2011-10-24T00:00:00,Transforming Growth Factor beta,D12.644.276.374.687
22025714,2011-10-24T00:00:00,Transforming Growth Factor beta,D12.644.276.954.800.720
22025714,2011-10-24T00:00:00,Transforming Growth Factor beta,D12.644.276.963.720
22025714,2011-10-24T00:00:00,Transforming Growth Factor beta,D12.776.467.374.687
22025714,2011-10-24T00:00:00,Transforming Growth Factor beta,D12.776.467.942.800.720
22025714,2011-10-24T00:00:00,Transforming Growth Factor beta,D12.776.467.960.720
22025714,2011-10-24T00:00:00,Transforming Growth Factor beta,D23.529.374.687
22025714,2011-10-24T00:00:00,Transforming Growth Factor beta,D23.529.942.800.720
22025714,2011-10-24T00:00:00,Transforming Growth Factor beta,D23.529.960.720
22028416,2011-10-25T00:00:00,Adult,M01.060.116
22028416,2011-10-25T00:00:00,Blood Coagulation Disorders,C15.378.100
22028416,2011-10-25T00:00:00,Factor VIIa,D08.811.277.656.300.760.300
22028416,2011-10-25T00:00:00,Factor VIIa,D08.811.277.656.959.350.300
22028416,2011-10-25T00:00:00,Factor VIIa,D12.776.124.125.325.300
22028416,2011-10-25T00:00:00,Factor VIIa,D23.119.325.300
22028416,2011-10-25T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22028416,2011-10-25T00:00:00,Intracranial Pressure,G11.561.170.505
22028416,2011-10-25T00:00:00,"Monitoring, Physiologic",E01.370.520
22028416,2011-10-25T00:00:00,Recombinant Proteins,D12.776.828
22028416,2011-10-25T00:00:00,Young Adult,M01.060.116.815
22107622,2011-10-25T00:00:00,"Models, Theoretical",E05.599
22107622,2011-10-25T00:00:00,Uncertainty,E05.318.740.600.900
22107622,2011-10-25T00:00:00,Uncertainty,F02.463.785.373.820
22107622,2011-10-25T00:00:00,Uncertainty,G17.680.875
22107622,2011-10-25T00:00:00,Uncertainty,N05.715.360.750.625.850
22107622,2011-10-25T00:00:00,Uncertainty,N06.850.520.830.600.900
22146501,2011-10-25T00:00:00,Aged,M01.060.116.100
22146501,2011-10-25T00:00:00,Coronary Artery Disease,C14.280.647.250.260
22146501,2011-10-25T00:00:00,Coronary Artery Disease,C14.907.137.126.339
22146501,2011-10-25T00:00:00,Coronary Artery Disease,C14.907.585.250.260
22146501,2011-10-25T00:00:00,Coronary Circulation,G09.330.190.163.324
22146501,2011-10-25T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22146501,2011-10-25T00:00:00,Middle Aged,M01.060.116.630
22146501,2011-10-25T00:00:00,Myocardial Perfusion Imaging,E01.370.350.710.600.500
22146501,2011-10-25T00:00:00,Myocardial Perfusion Imaging,E01.370.370.380.500
22146501,2011-10-25T00:00:00,Myocardial Perfusion Imaging,E01.370.384.730.354.500
22146501,2011-10-25T00:00:00,Radiopharmaceuticals,D27.720.470.410.650
22146501,2011-10-25T00:00:00,"Tomography, Emission-Computed, Single-Photon",E01.370.350.350.800.800
22146501,2011-10-25T00:00:00,"Tomography, Emission-Computed, Single-Photon",E01.370.350.600.350.800.800
22146501,2011-10-25T00:00:00,"Tomography, Emission-Computed, Single-Photon",E01.370.350.710.800.800
22146501,2011-10-25T00:00:00,"Tomography, Emission-Computed, Single-Photon",E01.370.350.825.800.800
22146501,2011-10-25T00:00:00,"Tomography, Emission-Computed, Single-Photon",E01.370.384.730.800.800
22146501,2011-10-25T00:00:00,"Tomography, X-Ray Computed",E01.370.350.350.810
22146501,2011-10-25T00:00:00,"Tomography, X-Ray Computed",E01.370.350.600.350.700.810
22146501,2011-10-25T00:00:00,"Tomography, X-Ray Computed",E01.370.350.700.700.810
22146501,2011-10-25T00:00:00,"Tomography, X-Ray Computed",E01.370.350.700.810.810
22146501,2011-10-25T00:00:00,"Tomography, X-Ray Computed",E01.370.350.825.810.810
22030478,2011-10-26T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22030478,2011-10-26T00:00:00,Interleukin-6,D12.644.276.374.465.506
22030478,2011-10-26T00:00:00,Interleukin-6,D12.776.467.374.465.506
22030478,2011-10-26T00:00:00,Interleukin-6,D23.529.374.465.506
22030478,2011-10-26T00:00:00,MAP Kinase Signaling System,G02.111.087.800.560
22030478,2011-10-26T00:00:00,MAP Kinase Signaling System,G02.149.115.800.560
22030478,2011-10-26T00:00:00,MAP Kinase Signaling System,G03.495.553.560
22030478,2011-10-26T00:00:00,MAP Kinase Signaling System,G04.299.880.560
22030478,2011-10-26T00:00:00,NF-kappa B,D12.776.260.600
22030478,2011-10-26T00:00:00,NF-kappa B,D12.776.660.600
22030478,2011-10-26T00:00:00,NF-kappa B,D12.776.930.600
22030478,2011-10-26T00:00:00,RNA Stability,G02.111.780
22030478,2011-10-26T00:00:00,Toll-Like Receptor 4,D12.776.543.750.705.910.500.400
22030478,2011-10-26T00:00:00,"Transcription, Genetic",G02.111.087.847
22030478,2011-10-26T00:00:00,"Transcription, Genetic",G02.149.115.847
22030478,2011-10-26T00:00:00,"Transcription, Genetic",G05.355.310.700
22031537,2011-10-26T00:00:00,"Adaptation, Psychological",F01.058
22031537,2011-10-26T00:00:00,Adult,M01.060.116
22031537,2011-10-26T00:00:00,African Americans,M01.686.508.100.100
22031537,2011-10-26T00:00:00,African Americans,M01.686.754.100
22031537,2011-10-26T00:00:00,Aged,M01.060.116.100
22031537,2011-10-26T00:00:00,Case-Control Studies,E05.318.760.500.500
22031537,2011-10-26T00:00:00,Case-Control Studies,N05.715.360.775.175.200
22031537,2011-10-26T00:00:00,Case-Control Studies,N06.850.520.450.500.500
22031537,2011-10-26T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22031537,2011-10-26T00:00:00,"Lupus Erythematosus, Systemic",C17.300.480
22031537,2011-10-26T00:00:00,"Lupus Erythematosus, Systemic",C20.111.590
22031537,2011-10-26T00:00:00,Middle Aged,M01.060.116.630
22031537,2011-10-26T00:00:00,Quality of Life,I01.800
22031537,2011-10-26T00:00:00,Quality of Life,K01.752.400.750
22031537,2011-10-26T00:00:00,South Carolina,Z01.107.567.875.075.662
22031537,2011-10-26T00:00:00,South Carolina,Z01.107.567.875.750.700
22003894,2011-10-27T00:00:00,Animals,B01.050
22003894,2011-10-27T00:00:00,Endocytosis,G04.299.482
22003894,2011-10-27T00:00:00,Nanoparticles,J01.637.512.600
22003894,2011-10-27T00:00:00,Neurons,A08.663
22003894,2011-10-27T00:00:00,Neurons,A11.671
22003894,2011-10-27T00:00:00,Rats,B01.050.150.900.649.865.635.505.700
22003894,2011-10-27T00:00:00,"Spectrometry, Fluorescence",E05.196.712.516.600.676
22003894,2011-10-27T00:00:00,"Spectrometry, Fluorescence",E05.196.867.726
22033724,2011-10-27T00:00:00,Adult,M01.060.116
22033724,2011-10-27T00:00:00,Algorithms,G17.035
22033724,2011-10-27T00:00:00,Algorithms,L01.224.050
22033724,2011-10-27T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22033724,2011-10-27T00:00:00,Image Enhancement,E01.370.350.600.350
22033724,2011-10-27T00:00:00,Image Enhancement,L01.224.308.380
22033724,2011-10-27T00:00:00,"Image Interpretation, Computer-Assisted",E01.158.600
22033724,2011-10-27T00:00:00,"Image Interpretation, Computer-Assisted",E01.370.350.350
22033724,2011-10-27T00:00:00,"Image Interpretation, Computer-Assisted",L01.700.508.100.158.600
22033724,2011-10-27T00:00:00,Magnetic Resonance Imaging,E01.370.350.500
22033724,2011-10-27T00:00:00,Magnetic Resonance Imaging,E01.370.350.825.500
22033724,2011-10-27T00:00:00,Temporomandibular Joint,A02.835.583.861
22033724,2011-10-27T00:00:00,Temporomandibular Joint,A14.907
22033724,2011-10-27T00:00:00,Temporomandibular Joint Disorders,C05.500.607.221.897
22033724,2011-10-27T00:00:00,Temporomandibular Joint Disorders,C05.550.905
22033724,2011-10-27T00:00:00,Temporomandibular Joint Disorders,C05.651.243.897
22033724,2011-10-27T00:00:00,Temporomandibular Joint Disorders,C07.320.610.291.897
22033724,2011-10-27T00:00:00,Temporomandibular Joint Disorders,C07.678
22033994,2011-10-27T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22033994,2011-10-27T00:00:00,"Infusions, Intravenous",E02.319.267.510.590
22033994,2011-10-27T00:00:00,Stroke,C10.228.140.300.775
22033994,2011-10-27T00:00:00,Stroke,C14.907.253.855
22033994,2011-10-27T00:00:00,Thrombectomy,E04.100.814.842
22033994,2011-10-27T00:00:00,Tissue Plasminogen Activator,D08.811.277.656.300.760.875
22033994,2011-10-27T00:00:00,Tissue Plasminogen Activator,D08.811.277.656.959.350.875
22033994,2011-10-27T00:00:00,Tissue Plasminogen Activator,D12.776.124.125.662.768
22033994,2011-10-27T00:00:00,Tissue Plasminogen Activator,D23.119.970
22034223,2011-10-27T00:00:00,Adolescent,M01.060.057
22034223,2011-10-27T00:00:00,Adult,M01.060.116
22034223,2011-10-27T00:00:00,Aged,M01.060.116.100
22034223,2011-10-27T00:00:00,Chronic Disease,C23.550.291.500
22034223,2011-10-27T00:00:00,Endoscopy,E01.370.388.250
22034223,2011-10-27T00:00:00,Endoscopy,E04.800.250
22034223,2011-10-27T00:00:00,Health Status,I01.240.425
22034223,2011-10-27T00:00:00,Health Status,N01.224.425
22034223,2011-10-27T00:00:00,Health Status,N06.850.505.400.425
22034223,2011-10-27T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22034223,2011-10-27T00:00:00,Middle Aged,M01.060.116.630
22034223,2011-10-27T00:00:00,Patient Selection,E05.581.500.653
22034223,2011-10-27T00:00:00,Patient Selection,N04.590.731
22034223,2011-10-27T00:00:00,Postoperative Care,E02.760.722.700
22034223,2011-10-27T00:00:00,Postoperative Care,E04.624
22034223,2011-10-27T00:00:00,Postoperative Care,N02.421.585.722.700
22034223,2011-10-27T00:00:00,Preoperative Care,E02.760.795
22034223,2011-10-27T00:00:00,Preoperative Care,E04.641
22034223,2011-10-27T00:00:00,Preoperative Care,N02.421.585.795
22034223,2011-10-27T00:00:00,Rhinitis,C08.460.799
22034223,2011-10-27T00:00:00,Rhinitis,C08.730.674
22034223,2011-10-27T00:00:00,Rhinitis,C09.603.799
22034223,2011-10-27T00:00:00,Risk Assessment,E05.318.740.600.800.715
22034223,2011-10-27T00:00:00,Risk Assessment,N04.452.871.715
22034223,2011-10-27T00:00:00,Risk Assessment,N05.715.360.750.625.700.690
22034223,2011-10-27T00:00:00,Risk Assessment,N06.850.505.715
22034223,2011-10-27T00:00:00,Risk Assessment,N06.850.520.830.600.800.715
22034223,2011-10-27T00:00:00,Sinusitis,C08.460.692.752
22034223,2011-10-27T00:00:00,Sinusitis,C08.730.749
22034223,2011-10-27T00:00:00,Sinusitis,C09.603.692.752
22034223,2011-10-27T00:00:00,Treatment Outcome,E01.789.800
22034223,2011-10-27T00:00:00,Treatment Outcome,N04.761.559.590.800
22034223,2011-10-27T00:00:00,Treatment Outcome,N05.715.360.575.575.800
22034223,2011-10-27T00:00:00,Young Adult,M01.060.116.815
22035977,2011-10-27T00:00:00,Anticoagulants,D27.505.954.502.119
22035977,2011-10-27T00:00:00,"Arthroplasty, Replacement, Hip",E04.555.110.110.110
22035977,2011-10-27T00:00:00,"Arthroplasty, Replacement, Hip",E04.650.110.110
22035977,2011-10-27T00:00:00,"Arthroplasty, Replacement, Knee",E04.555.110.110.115
22035977,2011-10-27T00:00:00,"Arthroplasty, Replacement, Knee",E04.650.110.115
22035977,2011-10-27T00:00:00,Drug Monitoring,E01.370.520.200
22035977,2011-10-27T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22035977,2011-10-27T00:00:00,Orthopedics,H02.403.810.494
22035977,2011-10-27T00:00:00,Physician's Practice Patterns,N04.590.748
22035977,2011-10-27T00:00:00,Physician's Practice Patterns,N05.300.625
22035977,2011-10-27T00:00:00,Population Surveillance,E05.318.308.250.700
22035977,2011-10-27T00:00:00,Population Surveillance,N05.715.360.300.375.625
22035977,2011-10-27T00:00:00,Population Surveillance,N06.850.520.308.250.700
22035977,2011-10-27T00:00:00,Population Surveillance,N06.850.780.675
22035977,2011-10-27T00:00:00,Practice Guidelines as Topic,N04.761.700.350.650
22035977,2011-10-27T00:00:00,Practice Guidelines as Topic,N05.700.350.650
22035977,2011-10-27T00:00:00,United States,Z01.107.567.875
22035977,2011-10-27T00:00:00,Venous Thromboembolism,C14.907.355.590.700
22035977,2011-10-27T00:00:00,Venous Thromboembolism,C14.907.355.830.850.700
22035977,2011-10-27T00:00:00,Warfarin,D03.438.150.446.520.914
22035977,2011-10-27T00:00:00,Warfarin,D03.830.219.446.520.914
22036469,2011-10-27T00:00:00,Animals,B01.050
22036469,2011-10-27T00:00:00,Biofilms,G06.120
22036469,2011-10-27T00:00:00,Complement System Proteins,D12.776.124.486.274
22036469,2011-10-27T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22036469,2011-10-27T00:00:00,Periodontitis,C07.465.714.533
22036469,2011-10-27T00:00:00,Porphyromonas gingivalis,B03.140.094.625.515
22036469,2011-10-27T00:00:00,Porphyromonas gingivalis,B03.440.425.410.194.625.515
22036550,2011-10-27T00:00:00,Amino Acids,D12.125
22036550,2011-10-27T00:00:00,Disinfectants,D27.505.954.122.425
22036550,2011-10-27T00:00:00,Disinfectants,D27.720.274
22036550,2011-10-27T00:00:00,Methane,D02.455.326.146.571
22036550,2011-10-27T00:00:00,"Water Pollutants, Chemical",D27.888.284.903.655
22035049,2011-10-28T00:00:00,Aged,M01.060.116.100
22035049,2011-10-28T00:00:00,Algorithms,G17.035
22035049,2011-10-28T00:00:00,Algorithms,L01.224.050
22035049,2011-10-28T00:00:00,"Arrhythmias, Cardiac",C14.280.067
22035049,2011-10-28T00:00:00,"Arrhythmias, Cardiac",C23.550.073
22035049,2011-10-28T00:00:00,Computer Simulation,L01.224.160
22035049,2011-10-28T00:00:00,"Defibrillators, Implantable",E07.305.250.159.175
22035049,2011-10-28T00:00:00,"Defibrillators, Implantable",E07.305.250.319.175
22035049,2011-10-28T00:00:00,"Defibrillators, Implantable",E07.695.175
22035049,2011-10-28T00:00:00,Electric Countershock,E02.342.287
22035049,2011-10-28T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22035049,2011-10-28T00:00:00,Materials Testing,E05.570
22035049,2011-10-28T00:00:00,Middle Aged,M01.060.116.630
22035049,2011-10-28T00:00:00,"Signal Processing, Computer-Assisted",L01.224.800
22035790,2011-10-28T00:00:00,Biological Transport,G03.495.166
22035790,2011-10-28T00:00:00,Nitric Oxide,D01.339.387
22035790,2011-10-28T00:00:00,Nitric Oxide,D01.625.550.500
22035790,2011-10-28T00:00:00,Nitric Oxide,D01.625.700.500
22035790,2011-10-28T00:00:00,Nitric Oxide,D01.650.550.587.600
22035790,2011-10-28T00:00:00,Nitric Oxide Synthase,D08.811.682.664.500.772
22035790,2011-10-28T00:00:00,Nitrogen Oxides,D01.362.635
22035790,2011-10-28T00:00:00,Nitrogen Oxides,D01.625.550
22035790,2011-10-28T00:00:00,Nitrogen Oxides,D01.650.550.587
22035790,2011-10-28T00:00:00,Protein Conformation,G02.111.570.790.709
22036206,2011-10-28T00:00:00,Adolescent,M01.060.057
22036206,2011-10-28T00:00:00,Adult,M01.060.116
22036206,2011-10-28T00:00:00,Aged,M01.060.116.100
22036206,2011-10-28T00:00:00,Child,M01.060.406
22036206,2011-10-28T00:00:00,Decision Making,F02.463.785.373
22036206,2011-10-28T00:00:00,"Diagnosis, Differential",E01.171
22036206,2011-10-28T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22036206,2011-10-28T00:00:00,Middle Aged,M01.060.116.630
22036206,2011-10-28T00:00:00,"Surgical Procedures, Operative",E04
22036206,2011-10-28T00:00:00,"Tomography, X-Ray Computed",E01.370.350.350.810
22036206,2011-10-28T00:00:00,"Tomography, X-Ray Computed",E01.370.350.600.350.700.810
22036206,2011-10-28T00:00:00,"Tomography, X-Ray Computed",E01.370.350.700.700.810
22036206,2011-10-28T00:00:00,"Tomography, X-Ray Computed",E01.370.350.700.810.810
22036206,2011-10-28T00:00:00,"Tomography, X-Ray Computed",E01.370.350.825.810.810
22036206,2011-10-28T00:00:00,"Wounds, Stab",C21.866.986.950
22036206,2011-10-28T00:00:00,Young Adult,M01.060.116.815
22036734,2011-10-28T00:00:00,Animals,B01.050
22036734,2011-10-28T00:00:00,Carbon,D01.268.150
22036734,2011-10-28T00:00:00,Cell Line,A11.251.210
22036734,2011-10-28T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22036734,2011-10-28T00:00:00,"Microscopy, Fluorescence",E01.370.350.515.458
22036734,2011-10-28T00:00:00,"Microscopy, Fluorescence",E05.595.458
22036734,2011-10-28T00:00:00,Nanostructures,J01.637.512
22036734,2011-10-28T00:00:00,Quantum Dots,E07.595.650
22036734,2011-10-28T00:00:00,Quantum Dots,J01.637.512.600.650
22036734,2011-10-28T00:00:00,Surface Properties,G02.842.850
22036734,2011-10-28T00:00:00,Toxicity Tests,E05.940
22061623,2011-10-28T00:00:00,Alligators and Crocodiles,B01.050.150.900.833.100
22061623,2011-10-28T00:00:00,Animals,B01.050
22061623,2011-10-28T00:00:00,Body Weight,C23.888.144
22061623,2011-10-28T00:00:00,Body Weight,E01.370.600.115.100.160.120
22061623,2011-10-28T00:00:00,Body Weight,E05.041.124.160.750
22061623,2011-10-28T00:00:00,Body Weight,G07.100.100.160.120
22061623,2011-10-28T00:00:00,Body Weight,G07.700.320.249.314.120
22061623,2011-10-28T00:00:00,Environmental Exposure,N06.850.460.350
22061623,2011-10-28T00:00:00,Estradiol,D04.808.365.415.248
22061623,2011-10-28T00:00:00,Estradiol,D06.472.334.851.437.500
22061623,2011-10-28T00:00:00,Gene Expression Regulation,G05.355.315
22061623,2011-10-28T00:00:00,Ovary,A05.360.319.114.630
22061623,2011-10-28T00:00:00,Ovary,A05.360.576.497
22061623,2011-10-28T00:00:00,Ovary,A06.407.312.497
22061623,2011-10-28T00:00:00,Testosterone,D04.808.054.079.429.824
22061623,2011-10-28T00:00:00,Testosterone,D06.472.334.851.968.984
22061623,2011-10-28T00:00:00,"Transcription, Genetic",G02.111.087.847
22061623,2011-10-28T00:00:00,"Transcription, Genetic",G02.149.115.847
22061623,2011-10-28T00:00:00,"Transcription, Genetic",G05.355.310.700
22144050,2011-10-29T00:00:00,Adult,M01.060.116
22144050,2011-10-29T00:00:00,Anti-Bacterial Agents,D27.505.954.122.085
22144050,2011-10-29T00:00:00,Debridement,E04.176
22144050,2011-10-29T00:00:00,Drug-Eluting Stents,E07.695.750.500
22144050,2011-10-29T00:00:00,Endoscopy,E01.370.388.250
22144050,2011-10-29T00:00:00,Endoscopy,E04.800.250
22144050,2011-10-29T00:00:00,Evidence-Based Medicine,H02.249.750
22144050,2011-10-29T00:00:00,Evidence-Based Medicine,H02.403.200.400
22144050,2011-10-29T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22144050,2011-10-29T00:00:00,Paranasal Sinuses,A04.531.621
22144050,2011-10-29T00:00:00,Postoperative Care,E02.760.722.700
22144050,2011-10-29T00:00:00,Postoperative Care,E04.624
22144050,2011-10-29T00:00:00,Postoperative Care,N02.421.585.722.700
22144050,2011-10-29T00:00:00,Sinusitis,C08.460.692.752
22144050,2011-10-29T00:00:00,Sinusitis,C08.730.749
22144050,2011-10-29T00:00:00,Sinusitis,C09.603.692.752
22035412,2011-10-30T00:00:00,Cell Line,A11.251.210
22035412,2011-10-30T00:00:00,Cell Movement,G04.299.283
22035412,2011-10-30T00:00:00,Cell Movement,G07.700.560.500.180
22035412,2011-10-30T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22035412,2011-10-30T00:00:00,Lipopolysaccharides,D09.400.500
22035412,2011-10-30T00:00:00,Lipopolysaccharides,D09.698.718.450
22035412,2011-10-30T00:00:00,Lipopolysaccharides,D10.494
22035412,2011-10-30T00:00:00,Lipopolysaccharides,D23.050.161.616.525
22035412,2011-10-30T00:00:00,Lipopolysaccharides,D23.946.123.329.500
22035412,2011-10-30T00:00:00,Matrix Metalloproteinase 9,D08.811.277.656.300.480.205.360
22035412,2011-10-30T00:00:00,Matrix Metalloproteinase 9,D08.811.277.656.300.480.252.445
22035412,2011-10-30T00:00:00,Matrix Metalloproteinase 9,D08.811.277.656.300.480.525.700.350
22035412,2011-10-30T00:00:00,Matrix Metalloproteinase 9,D08.811.277.656.675.374.205.360
22035412,2011-10-30T00:00:00,Matrix Metalloproteinase 9,D08.811.277.656.675.374.252.445
22035412,2011-10-30T00:00:00,Matrix Metalloproteinase 9,D08.811.277.656.675.374.525.700.350
22035412,2011-10-30T00:00:00,Monocytes,A11.118.637.555.652
22035412,2011-10-30T00:00:00,Monocytes,A11.148.580
22035412,2011-10-30T00:00:00,Monocytes,A11.627.624
22035412,2011-10-30T00:00:00,Monocytes,A11.733.547
22035412,2011-10-30T00:00:00,Monocytes,A15.145.229.637.555.652
22035412,2011-10-30T00:00:00,Monocytes,A15.378.316.580
22035412,2011-10-30T00:00:00,Monocytes,A15.382.490.555.652
22035412,2011-10-30T00:00:00,Monocytes,A15.382.680.547
22035412,2011-10-30T00:00:00,Monocytes,A15.382.812.547
22035412,2011-10-30T00:00:00,Porphyromonas gingivalis,B03.140.094.625.515
22035412,2011-10-30T00:00:00,Porphyromonas gingivalis,B03.440.425.410.194.625.515
22035412,2011-10-30T00:00:00,Tissue Inhibitor of Metalloproteinase-1,D12.776.926.450
22051250,2011-10-31T00:00:00,Blood Transfusion,E02.095.135
22051250,2011-10-31T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22051250,2011-10-31T00:00:00,Jehovah's Witnesses,K01.844.188.573
22051250,2011-10-31T00:00:00,Jehovah's Witnesses,M01.352
22051250,2011-10-31T00:00:00,Middle Aged,M01.060.116.630
21707485,2011-11-01T00:00:00,Animals,B01.050
21707485,2011-11-01T00:00:00,Antineoplastic Agents,D27.505.954.248
21707485,2011-11-01T00:00:00,Ceramides,D02.065.313
21707485,2011-11-01T00:00:00,Ceramides,D09.400.410.420.525.200
21707485,2011-11-01T00:00:00,Ceramides,D10.390.470.675.200
21707485,2011-11-01T00:00:00,Ceramides,D10.570.877.360.612.200
21707485,2011-11-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21707485,2011-11-01T00:00:00,Leukemia,C04.557.337
21707485,2011-11-01T00:00:00,Lysophospholipids,D10.570.755.375.760.550
21707485,2011-11-01T00:00:00,Signal Transduction,G02.111.087.800
21707485,2011-11-01T00:00:00,Signal Transduction,G02.149.115.800
21707485,2011-11-01T00:00:00,Signal Transduction,G04.299.880
21707485,2011-11-01T00:00:00,Sphingolipids,D10.570.877
21707485,2011-11-01T00:00:00,Sphingolipids,D10.808
21707485,2011-11-01T00:00:00,Sphingosine,D02.033.100.700
21707485,2011-11-01T00:00:00,Sphingosine,D02.033.455.843
21707485,2011-11-01T00:00:00,Sphingosine,D02.092.063.700
21755534,2011-11-01T00:00:00,Adult,M01.060.116
21755534,2011-11-01T00:00:00,African Americans,M01.686.508.100.100
21755534,2011-11-01T00:00:00,African Americans,M01.686.754.100
21755534,2011-11-01T00:00:00,Body Mass Index,E01.370.600.115.100.125
21755534,2011-11-01T00:00:00,Body Mass Index,E05.041.124.125
21755534,2011-11-01T00:00:00,Body Mass Index,G07.100.100.125
21755534,2011-11-01T00:00:00,Body Mass Index,N06.850.505.200.100.175
21755534,2011-11-01T00:00:00,Bone and Bones,A02.835.232
21755534,2011-11-01T00:00:00,Bone and Bones,A10.165.265
21755534,2011-11-01T00:00:00,European Continental Ancestry Group,M01.686.508.400
21755534,2011-11-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21755534,2011-11-01T00:00:00,"Lupus Erythematosus, Systemic",C17.300.480
21755534,2011-11-01T00:00:00,"Lupus Erythematosus, Systemic",C20.111.590
21755534,2011-11-01T00:00:00,Middle Aged,M01.060.116.630
21792837,2011-11-01T00:00:00,African Americans,M01.686.508.100.100
21792837,2011-11-01T00:00:00,African Americans,M01.686.754.100
21792837,2011-11-01T00:00:00,Alleles,G05.360.340.024.340.030
21792837,2011-11-01T00:00:00,Genetic Loci,G05.360.340.024.380
21792837,2011-11-01T00:00:00,Genetic Predisposition to Disease,C23.550.291.687.500
21792837,2011-11-01T00:00:00,Genetic Predisposition to Disease,G05.380.355
21792837,2011-11-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21792837,2011-11-01T00:00:00,"Lupus Erythematosus, Systemic",C17.300.480
21792837,2011-11-01T00:00:00,"Lupus Erythematosus, Systemic",C20.111.590
21792837,2011-11-01T00:00:00,"Polymorphism, Single Nucleotide",G05.365.795.598
21857530,2011-11-01T00:00:00,Deglutition,G10.261.326.215
21857530,2011-11-01T00:00:00,Esophageal Motility Disorders,C06.405.117.119.500
21857530,2011-11-01T00:00:00,Gastroesophageal Reflux,C06.405.117.119.500.484
21857530,2011-11-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21857530,2011-11-01T00:00:00,Manometry,E05.559
21857530,2011-11-01T00:00:00,Middle Aged,M01.060.116.630
21876428,2011-11-01T00:00:00,Adolescent,M01.060.057
21876428,2011-11-01T00:00:00,Adult,M01.060.116
21876428,2011-11-01T00:00:00,"Antibodies, Monoclonal",D12.776.124.486.485.114.224
21876428,2011-11-01T00:00:00,"Antibodies, Monoclonal",D12.776.124.790.651.114.224
21876428,2011-11-01T00:00:00,"Antibodies, Monoclonal",D12.776.377.715.548.114.224
21876428,2011-11-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21876428,2011-11-01T00:00:00,Middle Aged,M01.060.116.630
21876428,2011-11-01T00:00:00,Tumor Necrosis Factor-alpha,D12.644.276.374.500.800
21876428,2011-11-01T00:00:00,Tumor Necrosis Factor-alpha,D12.644.276.374.750.626
21876428,2011-11-01T00:00:00,Tumor Necrosis Factor-alpha,D12.644.276.972.626
21876428,2011-11-01T00:00:00,Tumor Necrosis Factor-alpha,D12.776.124.900
21876428,2011-11-01T00:00:00,Tumor Necrosis Factor-alpha,D12.776.395.930
21876428,2011-11-01T00:00:00,Tumor Necrosis Factor-alpha,D12.776.467.374.500.800
21876428,2011-11-01T00:00:00,Tumor Necrosis Factor-alpha,D12.776.467.374.750.626
21876428,2011-11-01T00:00:00,Tumor Necrosis Factor-alpha,D12.776.467.972.626
21876428,2011-11-01T00:00:00,Tumor Necrosis Factor-alpha,D23.529.374.500.800
21876428,2011-11-01T00:00:00,Tumor Necrosis Factor-alpha,D23.529.374.750.626
21876428,2011-11-01T00:00:00,Tumor Necrosis Factor-alpha,D23.529.972.626
21876428,2011-11-01T00:00:00,Young Adult,M01.060.116.815
21878749,2011-11-01T00:00:00,Antineoplastic Combined Chemotherapy Protocols,E02.183.750.500
21878749,2011-11-01T00:00:00,Antineoplastic Combined Chemotherapy Protocols,E02.319.077.500
21878749,2011-11-01T00:00:00,Antineoplastic Combined Chemotherapy Protocols,E02.319.310.037
21878749,2011-11-01T00:00:00,Apoptosis,G04.299.139.160
21878749,2011-11-01T00:00:00,Apoptosis Regulatory Proteins,D12.644.360.075
21878749,2011-11-01T00:00:00,Apoptosis Regulatory Proteins,D12.776.476.075
21878749,2011-11-01T00:00:00,Cell Differentiation,G04.299.151
21878749,2011-11-01T00:00:00,Cell Survival,G04.299.316
21878749,2011-11-01T00:00:00,Fenretinide,D02.455.326.271.665.202.495.270
21878749,2011-11-01T00:00:00,Fenretinide,D02.455.426.392.368.367.379.249.700.270
21878749,2011-11-01T00:00:00,Fenretinide,D02.455.849.131.495.270
21878749,2011-11-01T00:00:00,Fenretinide,D23.767.261.700.270
21878749,2011-11-01T00:00:00,"Gene Expression Regulation, Neoplastic",G05.355.315.370
21878749,2011-11-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21878749,2011-11-01T00:00:00,Neuroblastoma,C04.557.465.625.600.590.650.550
21878749,2011-11-01T00:00:00,Neuroblastoma,C04.557.470.670.590.650.550
21878749,2011-11-01T00:00:00,Neuroblastoma,C04.557.580.625.600.590.650.550
21881509,2011-11-01T00:00:00,Cystic Fibrosis,C06.689.202
21881509,2011-11-01T00:00:00,Cystic Fibrosis,C08.381.187
21881509,2011-11-01T00:00:00,Cystic Fibrosis,C16.320.190
21881509,2011-11-01T00:00:00,Cystic Fibrosis,C16.614.213
21881509,2011-11-01T00:00:00,Disease Progression,C23.550.291.656
21881509,2011-11-01T00:00:00,Hemoptysis,C08.381.348
21881509,2011-11-01T00:00:00,Hemoptysis,C23.550.414.896
21881509,2011-11-01T00:00:00,Hemoptysis,C23.888.852.430
21881509,2011-11-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21881509,2011-11-01T00:00:00,Lung Diseases,C08.381
21881509,2011-11-01T00:00:00,Practice Guidelines as Topic,N04.761.700.350.650
21881509,2011-11-01T00:00:00,Practice Guidelines as Topic,N05.700.350.650
21934498,2011-11-01T00:00:00,Arteriosclerosis,C14.907.137.126
21934498,2011-11-01T00:00:00,Bariatric Surgery,E02.065.062
21934498,2011-11-01T00:00:00,Bariatric Surgery,E04.062
21934498,2011-11-01T00:00:00,Cardiovascular Diseases,C14
21934498,2011-11-01T00:00:00,Disease Progression,C23.550.291.656
21934498,2011-11-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21934498,2011-11-01T00:00:00,Hypertension,C14.907.489
21934498,2011-11-01T00:00:00,Obesity,C18.654.726.500
21934498,2011-11-01T00:00:00,Obesity,C23.888.144.699.500
21934498,2011-11-01T00:00:00,Obesity,E01.370.600.115.100.160.120.699.500
21934498,2011-11-01T00:00:00,Obesity,G07.100.100.160.120.699.500
21934498,2011-11-01T00:00:00,Risk Reduction Behavior,F01.145.699
21934498,2011-11-01T00:00:00,Treatment Outcome,E01.789.800
21934498,2011-11-01T00:00:00,Treatment Outcome,N04.761.559.590.800
21934498,2011-11-01T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21934498,2011-11-01T00:00:00,United States,Z01.107.567.875
21934498,2011-11-01T00:00:00,Weight Loss,C23.888.144.243.963
21934498,2011-11-01T00:00:00,Weight Loss,G07.700.320.249.314.120.200.963
21934610,2011-11-01T00:00:00,Cardiovascular Diseases,C14
21934610,2011-11-01T00:00:00,Chronic Disease,C23.550.291.500
21934610,2011-11-01T00:00:00,Dietary Supplements,J02.500.456
21934610,2011-11-01T00:00:00,Guidelines as Topic,N04.761.700.350
21934610,2011-11-01T00:00:00,Guidelines as Topic,N05.700.350
21934610,2011-11-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21934610,2011-11-01T00:00:00,Multiple Sclerosis,C10.114.375.500
21934610,2011-11-01T00:00:00,Multiple Sclerosis,C10.314.350.500
21934610,2011-11-01T00:00:00,Multiple Sclerosis,C20.111.258.250.500
21934610,2011-11-01T00:00:00,Neoplasms,C04
21934610,2011-11-01T00:00:00,Randomized Controlled Trials as Topic,E05.318.760.535.365.500
21934610,2011-11-01T00:00:00,Randomized Controlled Trials as Topic,E05.337.250.365.500
21934610,2011-11-01T00:00:00,Randomized Controlled Trials as Topic,N05.715.360.775.235.387.500
21934610,2011-11-01T00:00:00,Randomized Controlled Trials as Topic,N06.850.520.450.535.365.500
21934610,2011-11-01T00:00:00,United States,Z01.107.567.875
21934610,2011-11-01T00:00:00,Vitamin D,D04.808.812.768
21934610,2011-11-01T00:00:00,Vitamin D Deficiency,C18.654.521.500.133.770
22000537,2011-11-01T00:00:00,Academic Medical Centers,N02.278.020
22000537,2011-11-01T00:00:00,General Surgery,H02.403.810.300
22000537,2011-11-01T00:00:00,"Hospitals, University",N02.278.020.300.310
22000537,2011-11-01T00:00:00,"Hospitals, University",N02.278.421.639.725
22000537,2011-11-01T00:00:00,Internship and Residency,I02.358.399.644
22000537,2011-11-01T00:00:00,Personnel Staffing and Scheduling,N04.452.677.650
22000537,2011-11-01T00:00:00,Time Factors,G01.910.857
22000537,2011-11-01T00:00:00,Workload,N04.452.677.950
22004254,2011-11-01T00:00:00,Catheterization,E02.148
22004254,2011-11-01T00:00:00,Catheterization,E05.157
22004254,2011-11-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22021502,2011-11-01T00:00:00,Adult,M01.060.116
22021502,2011-11-01T00:00:00,Aged,M01.060.116.100
22021502,2011-11-01T00:00:00,Contrast Media,D27.720.259
22021502,2011-11-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22021502,2011-11-01T00:00:00,"Imaging, Three-Dimensional",E01.370.350.400
22021502,2011-11-01T00:00:00,"Imaging, Three-Dimensional",L01.224.308.410
22021502,2011-11-01T00:00:00,Middle Aged,M01.060.116.630
22021502,2011-11-01T00:00:00,Positron-Emission Tomography,E01.370.350.350.800.700
22021502,2011-11-01T00:00:00,Positron-Emission Tomography,E01.370.350.600.350.800.399
22021502,2011-11-01T00:00:00,Positron-Emission Tomography,E01.370.350.710.800.399
22021502,2011-11-01T00:00:00,Positron-Emission Tomography,E01.370.350.825.800.399
22021502,2011-11-01T00:00:00,Positron-Emission Tomography,E01.370.384.730.800.399
22021553,2011-11-01T00:00:00,"Aorta, Thoracic",A07.231.114.056.372
22021553,2011-11-01T00:00:00,Coronary Angiography,E01.370.350.700.060.200
22021553,2011-11-01T00:00:00,Coronary Angiography,E01.370.370.050.200
22021553,2011-11-01T00:00:00,Coronary Angiography,E01.370.370.380.200
22021553,2011-11-01T00:00:00,Coronary Disease,C14.280.647.250
22021553,2011-11-01T00:00:00,Coronary Disease,C14.907.585.250
22021553,2011-11-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22021553,2011-11-01T00:00:00,Pulmonary Artery,A07.231.114.715
22021553,2011-11-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.350.810
22021553,2011-11-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.600.350.700.810
22021553,2011-11-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.700.700.810
22021553,2011-11-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.700.810.810
22021553,2011-11-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.825.810.810
22023060,2011-11-01T00:00:00,"Carcinoma, Squamous Cell",C04.557.470.200.400
22023060,2011-11-01T00:00:00,"Carcinoma, Squamous Cell",C04.557.470.700.400
22023060,2011-11-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22023060,2011-11-01T00:00:00,Lymph Node Excision,E04.446
22023060,2011-11-01T00:00:00,Neoplasm Invasiveness,C04.697.645
22023060,2011-11-01T00:00:00,Neoplasm Invasiveness,C23.550.727.645
22023060,2011-11-01T00:00:00,Neoplasm Staging,E01.370.550
22023060,2011-11-01T00:00:00,Penile Neoplasms,C04.588.945.440.715
22023060,2011-11-01T00:00:00,Penile Neoplasms,C12.294.260.500
22023060,2011-11-01T00:00:00,Penile Neoplasms,C12.294.494.591
22023060,2011-11-01T00:00:00,Penile Neoplasms,C12.758.409.500
22023060,2011-11-01T00:00:00,Risk Factors,E05.318.740.600.800.725
22023060,2011-11-01T00:00:00,Risk Factors,N05.715.350.200.700
22023060,2011-11-01T00:00:00,Risk Factors,N05.715.360.750.625.700.700
22023060,2011-11-01T00:00:00,Risk Factors,N06.850.490.625.750
22023060,2011-11-01T00:00:00,Risk Factors,N06.850.520.830.600.800.725
22032212,2011-11-01T00:00:00,Adult,M01.060.116
22032212,2011-11-01T00:00:00,Age Factors,N05.715.350.075
22032212,2011-11-01T00:00:00,Age Factors,N06.850.490.250
22032212,2011-11-01T00:00:00,Aged,M01.060.116.100
22032212,2011-11-01T00:00:00,Health Status,I01.240.425
22032212,2011-11-01T00:00:00,Health Status,N01.224.425
22032212,2011-11-01T00:00:00,Health Status,N06.850.505.400.425
22032212,2011-11-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22032212,2011-11-01T00:00:00,Middle Aged,M01.060.116.630
22032212,2011-11-01T00:00:00,Risk Factors,E05.318.740.600.800.725
22032212,2011-11-01T00:00:00,Risk Factors,N05.715.350.200.700
22032212,2011-11-01T00:00:00,Risk Factors,N05.715.360.750.625.700.700
22032212,2011-11-01T00:00:00,Risk Factors,N06.850.490.625.750
22032212,2011-11-01T00:00:00,Risk Factors,N06.850.520.830.600.800.725
22032212,2011-11-01T00:00:00,Spinal Cord Injuries,C10.228.854.770
22032212,2011-11-01T00:00:00,Spinal Cord Injuries,C10.900.850
22032212,2011-11-01T00:00:00,Spinal Cord Injuries,C21.866.819
22032311,2011-11-01T00:00:00,Bariatric Surgery,E02.065.062
22032311,2011-11-01T00:00:00,Bariatric Surgery,E04.062
22032311,2011-11-01T00:00:00,"Endoscopy, Gastrointestinal",E01.370.372.250.250
22032311,2011-11-01T00:00:00,"Endoscopy, Gastrointestinal",E01.370.388.250.250.250
22032311,2011-11-01T00:00:00,"Endoscopy, Gastrointestinal",E04.210.240.250
22032311,2011-11-01T00:00:00,"Endoscopy, Gastrointestinal",E04.800.250.250.250
22032311,2011-11-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22032311,2011-11-01T00:00:00,Obesity,C18.654.726.500
22032311,2011-11-01T00:00:00,Obesity,C23.888.144.699.500
22032311,2011-11-01T00:00:00,Obesity,E01.370.600.115.100.160.120.699.500
22032311,2011-11-01T00:00:00,Obesity,G07.100.100.160.120.699.500
22032311,2011-11-01T00:00:00,Prostheses and Implants,E07.695
22032311,2011-11-01T00:00:00,Weight Loss,C23.888.144.243.963
22032311,2011-11-01T00:00:00,Weight Loss,G07.700.320.249.314.120.200.963
22034112,2011-11-01T00:00:00,Adolescent,M01.060.057
22034112,2011-11-01T00:00:00,Child,M01.060.406
22034112,2011-11-01T00:00:00,"Child, Preschool",M01.060.406.448
22034112,2011-11-01T00:00:00,Dexamethasone,D04.808.745.432.769.344
22034112,2011-11-01T00:00:00,Dexamethasone,D04.808.908.238
22034112,2011-11-01T00:00:00,Glucocorticoids,D06.472.040.543
22034112,2011-11-01T00:00:00,Glucocorticoids,D27.505.696.399.472.488
22034112,2011-11-01T00:00:00,"Hospitals, Pediatric",N02.278.421.556.437
22034112,2011-11-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22034112,2011-11-01T00:00:00,Pain Measurement,E01.370.376.550.600
22034112,2011-11-01T00:00:00,Pilot Projects,E05.318.760.750
22034112,2011-11-01T00:00:00,Pilot Projects,E05.337.737
22034112,2011-11-01T00:00:00,Pilot Projects,N05.715.360.775.625
22034112,2011-11-01T00:00:00,Pilot Projects,N06.850.520.450.720
22034112,2011-11-01T00:00:00,Recovery of Function,G16.757
22034112,2011-11-01T00:00:00,Temporomandibular Joint,A02.835.583.861
22034112,2011-11-01T00:00:00,Temporomandibular Joint,A14.907
22034112,2011-11-01T00:00:00,Temporomandibular Joint Disorders,C05.500.607.221.897
22034112,2011-11-01T00:00:00,Temporomandibular Joint Disorders,C05.550.905
22034112,2011-11-01T00:00:00,Temporomandibular Joint Disorders,C05.651.243.897
22034112,2011-11-01T00:00:00,Temporomandibular Joint Disorders,C07.320.610.291.897
22034112,2011-11-01T00:00:00,Temporomandibular Joint Disorders,C07.678
22034112,2011-11-01T00:00:00,Time Factors,G01.910.857
22034112,2011-11-01T00:00:00,Treatment Outcome,E01.789.800
22034112,2011-11-01T00:00:00,Treatment Outcome,N04.761.559.590.800
22034112,2011-11-01T00:00:00,Treatment Outcome,N05.715.360.575.575.800
22034112,2011-11-01T00:00:00,Young Adult,M01.060.116.815
22042566,2011-11-01T00:00:00,Adult,M01.060.116
22042566,2011-11-01T00:00:00,"Analgesics, Opioid",D27.505.696.663.850.014.520
22042566,2011-11-01T00:00:00,"Analgesics, Opioid",D27.505.954.427.040.325
22042566,2011-11-01T00:00:00,"Analgesics, Opioid",D27.505.954.427.210.049
22042566,2011-11-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22042566,2011-11-01T00:00:00,Islets of Langerhans Transplantation,E04.270.550
22042566,2011-11-01T00:00:00,Islets of Langerhans Transplantation,E04.936.225.375
22042566,2011-11-01T00:00:00,Middle Aged,M01.060.116.630
22042566,2011-11-01T00:00:00,"Pain, Intractable",C10.597.617.788
22042566,2011-11-01T00:00:00,"Pain, Intractable",C23.888.592.612.776
22042566,2011-11-01T00:00:00,"Pain, Intractable",C23.888.646.515
22042566,2011-11-01T00:00:00,Pancreatectomy,E04.210.752
22042566,2011-11-01T00:00:00,"Pancreatitis, Chronic",C06.689.750.830
22042566,2011-11-01T00:00:00,Quality of Life,I01.800
22042566,2011-11-01T00:00:00,Quality of Life,K01.752.400.750
22042566,2011-11-01T00:00:00,Young Adult,M01.060.116.815
22045879,2011-11-01T00:00:00,Adult,M01.060.116
22045879,2011-11-01T00:00:00,Analgesics,D27.505.696.663.850.014
22045879,2011-11-01T00:00:00,Analgesics,D27.505.954.427.040
22045879,2011-11-01T00:00:00,Bronchoscopy,E01.370.386.105
22045879,2011-11-01T00:00:00,Bronchoscopy,E01.370.388.250.100
22045879,2011-11-01T00:00:00,Bronchoscopy,E04.800.250.100
22045879,2011-11-01T00:00:00,Bronchoscopy,E04.928.600.080
22045879,2011-11-01T00:00:00,Conscious Sedation,E03.250
22045879,2011-11-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22068066,2011-11-01T00:00:00,Adolescent,M01.060.057
22068066,2011-11-01T00:00:00,Antidotes,D27.505.696.706.037
22068066,2011-11-01T00:00:00,Antidotes,D27.720.799.037
22068066,2011-11-01T00:00:00,Charcoal,D01.268.150.150
22068066,2011-11-01T00:00:00,Child,M01.060.406
22068066,2011-11-01T00:00:00,"Child, Preschool",M01.060.406.448
22068066,2011-11-01T00:00:00,Communication,F01.145.209
22068066,2011-11-01T00:00:00,Communication,L01.143
22068066,2011-11-01T00:00:00,"Emergency Service, Hospital",N02.278.354.422.336
22068066,2011-11-01T00:00:00,"Emergency Service, Hospital",N02.421.297.195
22068066,2011-11-01T00:00:00,"Emergency Service, Hospital",N04.452.442.422.336
22068066,2011-11-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22068066,2011-11-01T00:00:00,Infant,M01.060.703
22068066,2011-11-01T00:00:00,Poison Control Centers,N02.278.726
22068066,2011-11-01T00:00:00,Poison Control Centers,N02.421.297.695
22068066,2011-11-01T00:00:00,Poisoning,C21.613
22068066,2011-11-01T00:00:00,Referral and Consultation,N04.452.758.849
22068066,2011-11-01T00:00:00,Time Factors,G01.910.857
22068066,2011-11-01T00:00:00,Triage,N02.421.297.900
22069473,2011-11-01T00:00:00,Animals,B01.050
22069473,2011-11-01T00:00:00,Complement C3,D12.776.124.050.140
22069473,2011-11-01T00:00:00,Complement C3,D12.776.124.486.274.250
22069473,2011-11-01T00:00:00,"Disease Models, Animal",C22.232
22069473,2011-11-01T00:00:00,"Disease Models, Animal",E05.598.500
22069473,2011-11-01T00:00:00,"Disease Models, Animal",E05.599.395.080
22069473,2011-11-01T00:00:00,Lipopolysaccharides,D09.400.500
22069473,2011-11-01T00:00:00,Lipopolysaccharides,D09.698.718.450
22069473,2011-11-01T00:00:00,Lipopolysaccharides,D10.494
22069473,2011-11-01T00:00:00,Lipopolysaccharides,D23.050.161.616.525
22069473,2011-11-01T00:00:00,Lipopolysaccharides,D23.946.123.329.500
22069473,2011-11-01T00:00:00,Liver,A03.620
22069473,2011-11-01T00:00:00,Signal Transduction,G02.111.087.800
22069473,2011-11-01T00:00:00,Signal Transduction,G02.149.115.800
22069473,2011-11-01T00:00:00,Signal Transduction,G04.299.880
22071924,2011-11-01T00:00:00,Adult,M01.060.116
22071924,2011-11-01T00:00:00,Aged,M01.060.116.100
22071924,2011-11-01T00:00:00,Brain Injuries,C10.228.140.199
22071924,2011-11-01T00:00:00,Brain Injuries,C10.900.300.087
22071924,2011-11-01T00:00:00,Brain Injuries,C21.866.260.118
22071924,2011-11-01T00:00:00,Brain Injuries,C21.866.915.300.200
22071924,2011-11-01T00:00:00,Cross Infection,C01.539.248
22071924,2011-11-01T00:00:00,Hospital Mortality,E05.318.308.985.550.400
22071924,2011-11-01T00:00:00,Hospital Mortality,L01.280.975.550.400
22071924,2011-11-01T00:00:00,Hospital Mortality,N01.224.935.698.400
22071924,2011-11-01T00:00:00,Hospital Mortality,N06.850.505.400.975.550.400
22071924,2011-11-01T00:00:00,Hospital Mortality,N06.850.520.308.985.550.400
22071924,2011-11-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22071924,2011-11-01T00:00:00,Middle Aged,M01.060.116.630
22071924,2011-11-01T00:00:00,Risk Assessment,E05.318.740.600.800.715
22071924,2011-11-01T00:00:00,Risk Assessment,N04.452.871.715
22071924,2011-11-01T00:00:00,Risk Assessment,N05.715.360.750.625.700.690
22071924,2011-11-01T00:00:00,Risk Assessment,N06.850.505.715
22071924,2011-11-01T00:00:00,Risk Assessment,N06.850.520.830.600.800.715
22071924,2011-11-01T00:00:00,Risk Factors,E05.318.740.600.800.725
22071924,2011-11-01T00:00:00,Risk Factors,N05.715.350.200.700
22071924,2011-11-01T00:00:00,Risk Factors,N05.715.360.750.625.700.700
22071924,2011-11-01T00:00:00,Risk Factors,N06.850.490.625.750
22071924,2011-11-01T00:00:00,Risk Factors,N06.850.520.830.600.800.725
22071924,2011-11-01T00:00:00,Sepsis,C01.539.757
22071924,2011-11-01T00:00:00,Sepsis,C23.550.470.790.500
22071924,2011-11-01T00:00:00,South Carolina,Z01.107.567.875.075.662
22071924,2011-11-01T00:00:00,South Carolina,Z01.107.567.875.750.700
22082541,2011-11-01T00:00:00,Adult,M01.060.116
22082541,2011-11-01T00:00:00,Aged,M01.060.116.100
22082541,2011-11-01T00:00:00,"Carcinoma, Hepatocellular",C04.557.470.200.025.255
22082541,2011-11-01T00:00:00,"Carcinoma, Hepatocellular",C04.588.274.623.160
22082541,2011-11-01T00:00:00,"Carcinoma, Hepatocellular",C06.301.623.160
22082541,2011-11-01T00:00:00,"Carcinoma, Hepatocellular",C06.552.697.160
22082541,2011-11-01T00:00:00,Contrast Media,D27.720.259
22082541,2011-11-01T00:00:00,Diffusion Magnetic Resonance Imaging,E01.370.350.500.150
22082541,2011-11-01T00:00:00,Diffusion Magnetic Resonance Imaging,E01.370.350.825.500.150
22082541,2011-11-01T00:00:00,Gadolinium DTPA,D01.632.400
22082541,2011-11-01T00:00:00,Gadolinium DTPA,D02.092.782.590.401
22082541,2011-11-01T00:00:00,Gadolinium DTPA,D02.241.081.038.694.400
22082541,2011-11-01T00:00:00,Gadolinium DTPA,D02.691.400
22082541,2011-11-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22082541,2011-11-01T00:00:00,Liver Cirrhosis,C06.552.630
22082541,2011-11-01T00:00:00,Liver Neoplasms,C04.588.274.623
22082541,2011-11-01T00:00:00,Liver Neoplasms,C06.301.623
22082541,2011-11-01T00:00:00,Liver Neoplasms,C06.552.697
22082541,2011-11-01T00:00:00,Liver Transplantation,E04.210.650
22082541,2011-11-01T00:00:00,Liver Transplantation,E04.936.450.490
22082541,2011-11-01T00:00:00,Liver Transplantation,E04.936.580.490
22082541,2011-11-01T00:00:00,Magnetic Resonance Imaging,E01.370.350.500
22082541,2011-11-01T00:00:00,Magnetic Resonance Imaging,E01.370.350.825.500
22082541,2011-11-01T00:00:00,Middle Aged,M01.060.116.630
22084259,2011-11-01T00:00:00,Adolescent,M01.060.057
22084259,2011-11-01T00:00:00,Adult,M01.060.116
22084259,2011-11-01T00:00:00,Ambulatory Care,E02.760.106
22084259,2011-11-01T00:00:00,Ambulatory Care,N02.421.585.106
22084259,2011-11-01T00:00:00,Hospital Mortality,E05.318.308.985.550.400
22084259,2011-11-01T00:00:00,Hospital Mortality,L01.280.975.550.400
22084259,2011-11-01T00:00:00,Hospital Mortality,N01.224.935.698.400
22084259,2011-11-01T00:00:00,Hospital Mortality,N06.850.505.400.975.550.400
22084259,2011-11-01T00:00:00,Hospital Mortality,N06.850.520.308.985.550.400
22084259,2011-11-01T00:00:00,"Hospitals, Proprietary",N02.278.215.110
22084259,2011-11-01T00:00:00,"Hospitals, Proprietary",N02.278.421.481.500
22084259,2011-11-01T00:00:00,"Hospitals, Public",N02.278.421.510
22084259,2011-11-01T00:00:00,"Hospitals, Religious",N02.278.421.481.600
22084259,2011-11-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22084259,2011-11-01T00:00:00,Length of Stay,E02.760.400.480
22084259,2011-11-01T00:00:00,Length of Stay,N02.421.585.400.480
22084259,2011-11-01T00:00:00,Middle Aged,M01.060.116.630
22084259,2011-11-01T00:00:00,United States,Z01.107.567.875
22084259,2011-11-01T00:00:00,Young Adult,M01.060.116.815
22086820,2011-11-01T00:00:00,Attention Deficit Disorder with Hyperactivity,F03.550.150.150
22086820,2011-11-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22086820,2011-11-01T00:00:00,"Quality Assurance, Health Care",N04.761.700
22086820,2011-11-01T00:00:00,"Quality Assurance, Health Care",N05.700
22087921,2011-11-01T00:00:00,Acoustic Stimulation,E02.037
22087921,2011-11-01T00:00:00,Acoustic Stimulation,E02.190.888.030
22087921,2011-11-01T00:00:00,Acoustic Stimulation,E05.723.136
22087921,2011-11-01T00:00:00,Adult,M01.060.116
22087921,2011-11-01T00:00:00,Aged,M01.060.116.100
22087921,2011-11-01T00:00:00,Auditory Perception,F02.463.593.071
22087921,2011-11-01T00:00:00,Auditory Threshold,F02.463.593.071.173
22087921,2011-11-01T00:00:00,Auditory Threshold,F02.463.593.710.190
22087921,2011-11-01T00:00:00,Case-Control Studies,E05.318.760.500.500
22087921,2011-11-01T00:00:00,Case-Control Studies,N05.715.360.775.175.200
22087921,2011-11-01T00:00:00,Case-Control Studies,N06.850.520.450.500.500
22087921,2011-11-01T00:00:00,Cochlea,A09.246.631.246
22087921,2011-11-01T00:00:00,Hearing Loss,C09.218.458.341
22087921,2011-11-01T00:00:00,Hearing Loss,C10.597.751.418.341
22087921,2011-11-01T00:00:00,Hearing Loss,C23.888.592.763.393.341
22087921,2011-11-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22087921,2011-11-01T00:00:00,Middle Aged,M01.060.116.630
22087921,2011-11-01T00:00:00,Noise,G01.595.907.567
22087921,2011-11-01T00:00:00,Noise,G16.500.275.600
22087921,2011-11-01T00:00:00,Noise,N06.230.400
22087921,2011-11-01T00:00:00,Noise,N06.850.460.610
22087921,2011-11-01T00:00:00,Perceptual Masking,F02.463.593.071.594
22087921,2011-11-01T00:00:00,Perceptual Masking,F02.463.593.932.733
22087921,2011-11-01T00:00:00,Time Factors,G01.910.857
22110215,2011-11-01T00:00:00,Adolescent,M01.060.057
22110215,2011-11-01T00:00:00,Adult,M01.060.116
22110215,2011-11-01T00:00:00,African Americans,M01.686.508.100.100
22110215,2011-11-01T00:00:00,African Americans,M01.686.754.100
22110215,2011-11-01T00:00:00,Aged,M01.060.116.100
22110215,2011-11-01T00:00:00,European Continental Ancestry Group,M01.686.508.400
22110215,2011-11-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22110215,2011-11-01T00:00:00,Middle Aged,M01.060.116.630
22110215,2011-11-01T00:00:00,Neoplasms,C04
22110215,2011-11-01T00:00:00,Risk Factors,E05.318.740.600.800.725
22110215,2011-11-01T00:00:00,Risk Factors,N05.715.350.200.700
22110215,2011-11-01T00:00:00,Risk Factors,N05.715.360.750.625.700.700
22110215,2011-11-01T00:00:00,Risk Factors,N06.850.490.625.750
22110215,2011-11-01T00:00:00,Risk Factors,N06.850.520.830.600.800.725
22110215,2011-11-01T00:00:00,Smoking,F01.145.466.753
22110215,2011-11-01T00:00:00,South Carolina,Z01.107.567.875.075.662
22110215,2011-11-01T00:00:00,South Carolina,Z01.107.567.875.750.700
22110215,2011-11-01T00:00:00,Young Adult,M01.060.116.815
22196632,2011-11-01T00:00:00,General Surgery,H02.403.810.300
22196632,2011-11-01T00:00:00,"History, 19th Century",K01.400.504.937
22196632,2011-11-01T00:00:00,Hospitals,N02.278.421
22196632,2011-11-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22196632,2011-11-01T00:00:00,United States,Z01.107.567.875
22196646,2011-11-01T00:00:00,Agriculture,J01.040
22196646,2011-11-01T00:00:00,"Education, Medical",I02.358.399
22196646,2011-11-01T00:00:00,General Surgery,H02.403.810.300
22196646,2011-11-01T00:00:00,"History, 20th Century",K01.400.504.968
22196646,2011-11-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22196646,2011-11-01T00:00:00,Military Medicine,H02.403.500
22196646,2011-11-01T00:00:00,Military Personnel,M01.526.625
22196646,2011-11-01T00:00:00,Teaching,I02.903
22196646,2011-11-01T00:00:00,United States,Z01.107.567.875
22196674,2011-11-01T00:00:00,Famous Persons,K01.517.211.506
22196674,2011-11-01T00:00:00,Famous Persons,M01.228
22196674,2011-11-01T00:00:00,General Surgery,H02.403.810.300
22196674,2011-11-01T00:00:00,"History, 16th Century",K01.400.475.750
22196674,2011-11-01T00:00:00,"History, Medieval",K01.400.500
22196674,2011-11-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22251767,2011-11-01T00:00:00,Adolescent,M01.060.057
22251767,2011-11-01T00:00:00,Adult,M01.060.116
22251767,2011-11-01T00:00:00,Age Factors,N05.715.350.075
22251767,2011-11-01T00:00:00,Age Factors,N06.850.490.250
22251767,2011-11-01T00:00:00,"Health Knowledge, Attitudes, Practice",F01.100.150.500
22251767,2011-11-01T00:00:00,"Health Knowledge, Attitudes, Practice",N05.300.150.410
22251767,2011-11-01T00:00:00,Health Surveys,E05.318.308.250
22251767,2011-11-01T00:00:00,Health Surveys,N05.715.360.300.375
22251767,2011-11-01T00:00:00,Health Surveys,N06.850.520.308.250
22251767,2011-11-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22251767,2011-11-01T00:00:00,Perception,F02.463.593
22251767,2011-11-01T00:00:00,Sex Factors,N05.715.350.675
22251767,2011-11-01T00:00:00,Sex Factors,N06.850.490.875
22251767,2011-11-01T00:00:00,Smoking,F01.145.466.753
22251767,2011-11-01T00:00:00,Smoking Cessation,F01.145.940.700
22251767,2011-11-01T00:00:00,United States,Z01.107.567.875
22049403,2011-11-02T00:00:00,Adolescent,M01.060.057
22049403,2011-11-02T00:00:00,Adult,M01.060.116
22049403,2011-11-02T00:00:00,Aged,M01.060.116.100
22049403,2011-11-02T00:00:00,Endoscopy,E01.370.388.250
22049403,2011-11-02T00:00:00,Endoscopy,E04.800.250
22049403,2011-11-02T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22049403,2011-11-02T00:00:00,Middle Aged,M01.060.116.630
22049403,2011-11-02T00:00:00,Stroboscopy,E01.370.350.755
22049403,2011-11-02T00:00:00,Video Recording,L01.240.960
22049403,2011-11-02T00:00:00,Vocal Cord Paralysis,C08.360.931
22049403,2011-11-02T00:00:00,Vocal Cord Paralysis,C09.400.931
22049403,2011-11-02T00:00:00,Vocal Cord Paralysis,C10.292.887.800
22049403,2011-11-02T00:00:00,Vocal Cord Paralysis,C10.597.622.943
22049403,2011-11-02T00:00:00,Vocal Cord Paralysis,C23.888.592.636.943
22049403,2011-11-02T00:00:00,Voice,G09.772.925
22049403,2011-11-02T00:00:00,Voice Disorders,C08.360.940
22049403,2011-11-02T00:00:00,Voice Disorders,C09.400.940
22049403,2011-11-02T00:00:00,Voice Disorders,C10.597.975
22049403,2011-11-02T00:00:00,Voice Disorders,C23.888.592.979
22049403,2011-11-02T00:00:00,Young Adult,M01.060.116.815
22050314,2011-11-02T00:00:00,Electroencephalography,E01.370.376.300
22050314,2011-11-02T00:00:00,Electroencephalography,E01.370.405.245
22050314,2011-11-02T00:00:00,"Epilepsy, Temporal Lobe",C10.228.140.490.360.290
22050314,2011-11-02T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22050314,2011-11-02T00:00:00,Magnetic Resonance Imaging,E01.370.350.500
22050314,2011-11-02T00:00:00,Magnetic Resonance Imaging,E01.370.350.825.500
22050314,2011-11-02T00:00:00,Temporal Lobe,A08.186.211.730.885.287.500.863
22050314,2011-11-02T00:00:00,Treatment Outcome,E01.789.800
22050314,2011-11-02T00:00:00,Treatment Outcome,N04.761.559.590.800
22050314,2011-11-02T00:00:00,Treatment Outcome,N05.715.360.575.575.800
22051325,2011-11-02T00:00:00,Graft Survival,G12.425.901.545.340
22051325,2011-11-02T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22051325,2011-11-02T00:00:00,Kidney Transplantation,E02.870.500
22051325,2011-11-02T00:00:00,Kidney Transplantation,E04.936.450.485
22051325,2011-11-02T00:00:00,Kidney Transplantation,E04.950.774.400
22051325,2011-11-02T00:00:00,Middle Aged,M01.060.116.630
22051325,2011-11-02T00:00:00,Risk Factors,E05.318.740.600.800.725
22051325,2011-11-02T00:00:00,Risk Factors,N05.715.350.200.700
22051325,2011-11-02T00:00:00,Risk Factors,N05.715.360.750.625.700.700
22051325,2011-11-02T00:00:00,Risk Factors,N06.850.490.625.750
22051325,2011-11-02T00:00:00,Risk Factors,N06.850.520.830.600.800.725
22051325,2011-11-02T00:00:00,Time Factors,G01.910.857
22051325,2011-11-02T00:00:00,Tissue Donors,M01.898
22051325,2011-11-02T00:00:00,Tissue and Organ Harvesting,E01.450.865.820
22051325,2011-11-02T00:00:00,Tissue and Organ Harvesting,E04.932
22052520,2011-11-03T00:00:00,Angiotensin-Converting Enzyme Inhibitors,D27.505.519.389.745.085
22052520,2011-11-03T00:00:00,Cardiovascular Diseases,C14
22052520,2011-11-03T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22052520,2011-11-03T00:00:00,Randomized Controlled Trials as Topic,E05.318.760.535.365.500
22052520,2011-11-03T00:00:00,Randomized Controlled Trials as Topic,E05.337.250.365.500
22052520,2011-11-03T00:00:00,Randomized Controlled Trials as Topic,N05.715.360.775.235.387.500
22052520,2011-11-03T00:00:00,Randomized Controlled Trials as Topic,N06.850.520.450.535.365.500
22052520,2011-11-03T00:00:00,Renin-Angiotensin System,G03.495.805
22052520,2011-11-03T00:00:00,Renin-Angiotensin System,G09.330.190.400.750
22052520,2011-11-03T00:00:00,Stroke,C10.228.140.300.775
22052520,2011-11-03T00:00:00,Stroke,C14.907.253.855
22052522,2011-11-03T00:00:00,Adult,M01.060.116
22052522,2011-11-03T00:00:00,Aged,M01.060.116.100
22052522,2011-11-03T00:00:00,Brain Ischemia,C10.228.140.300.150
22052522,2011-11-03T00:00:00,Brain Ischemia,C14.907.253.092
22052522,2011-11-03T00:00:00,Gene Expression,G05.355.310
22052522,2011-11-03T00:00:00,Gene Expression Profiling,E05.393.332
22052522,2011-11-03T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22052522,2011-11-03T00:00:00,Middle Aged,M01.060.116.630
22052522,2011-11-03T00:00:00,Oligonucleotide Array Sequence Analysis,E05.196.630.570.660
22052522,2011-11-03T00:00:00,Oligonucleotide Array Sequence Analysis,E05.393.525.640
22052522,2011-11-03T00:00:00,Oligonucleotide Array Sequence Analysis,E05.393.661.640
22052522,2011-11-03T00:00:00,Oligonucleotide Array Sequence Analysis,E05.393.760.640
22052522,2011-11-03T00:00:00,Oligonucleotide Array Sequence Analysis,E05.588.570.660
22052522,2011-11-03T00:00:00,Oligonucleotide Array Sequence Analysis,E05.601.640
22052522,2011-11-03T00:00:00,"Protein Processing, Post-Translational",G02.111.087.675.871.790.600
22052522,2011-11-03T00:00:00,"Protein Processing, Post-Translational",G02.111.087.693.600
22052522,2011-11-03T00:00:00,"Protein Processing, Post-Translational",G02.149.115.675.871.790.600
22052522,2011-11-03T00:00:00,"Protein Processing, Post-Translational",G02.149.115.693.600
22052522,2011-11-03T00:00:00,"Protein Processing, Post-Translational",G03.495.770.871.790.600
22052522,2011-11-03T00:00:00,"Protein Processing, Post-Translational",G05.355.315.670.600
22052522,2011-11-03T00:00:00,RNA,D13.444.735
22052522,2011-11-03T00:00:00,Risk Assessment,E05.318.740.600.800.715
22052522,2011-11-03T00:00:00,Risk Assessment,N04.452.871.715
22052522,2011-11-03T00:00:00,Risk Assessment,N05.715.360.750.625.700.690
22052522,2011-11-03T00:00:00,Risk Assessment,N06.850.505.715
22052522,2011-11-03T00:00:00,Risk Assessment,N06.850.520.830.600.800.715
22052522,2011-11-03T00:00:00,Sex Characteristics,G08.686.815
22052522,2011-11-03T00:00:00,Stroke,C10.228.140.300.775
22052522,2011-11-03T00:00:00,Stroke,C14.907.253.855
22052980,2011-11-03T00:00:00,Animals,B01.050
22052980,2011-11-03T00:00:00,Aortic Valve,A07.541.510.110
22052980,2011-11-03T00:00:00,Bioprosthesis,E07.695.100
22052980,2011-11-03T00:00:00,Heart Valve Prosthesis,E07.695.310
22052980,2011-11-03T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22052980,2011-11-03T00:00:00,Middle Aged,M01.060.116.630
22052980,2011-11-03T00:00:00,Postoperative Complications,C23.550.767
22052980,2011-11-03T00:00:00,Swine,B01.050.150.900.649.077.880
22075446,2011-11-03T00:00:00,Anti-Bacterial Agents,D27.505.954.122.085
22075446,2011-11-03T00:00:00,Binding Sites,G02.111.570.120
22075446,2011-11-03T00:00:00,"Crystallography, X-Ray",E05.196.309.742.225
22075446,2011-11-03T00:00:00,"Evolution, Molecular",G05.355.265.250
22075446,2011-11-03T00:00:00,"Evolution, Molecular",G16.100.275.250
22075446,2011-11-03T00:00:00,Hydrogen Bonding,G02.149.767.620
22075446,2011-11-03T00:00:00,Hydrogen Bonding,G02.842.750.620
22075446,2011-11-03T00:00:00,"Models, Molecular",E05.599.595
22075446,2011-11-03T00:00:00,Molecular Dynamics Simulation,E05.599.595.500
22075446,2011-11-03T00:00:00,Molecular Dynamics Simulation,G02.575.750
22075446,2011-11-03T00:00:00,Molecular Dynamics Simulation,L01.224.160.500
22075446,2011-11-03T00:00:00,Point Mutation,G05.365.590.675
22075446,2011-11-03T00:00:00,Protein Conformation,G02.111.570.790.709
21960553,2011-11-04T00:00:00,Antineoplastic Agents,D27.505.954.248
21960553,2011-11-04T00:00:00,Biological Assay,E05.091
21960553,2011-11-04T00:00:00,Cell Line,A11.251.210
21960553,2011-11-04T00:00:00,Epithelial Cells,A11.436
21960553,2011-11-04T00:00:00,Eye Proteins,D12.776.306
21960553,2011-11-04T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21960553,2011-11-04T00:00:00,Nerve Growth Factors,D12.644.276.860
21960553,2011-11-04T00:00:00,Nerve Growth Factors,D12.776.467.860
21960553,2011-11-04T00:00:00,Nerve Growth Factors,D12.776.641.600
21960553,2011-11-04T00:00:00,Nerve Growth Factors,D23.529.850
21960553,2011-11-04T00:00:00,Retinal Pigment Epithelium,A09.371.670.500
21960553,2011-11-04T00:00:00,Retinal Pigment Epithelium,A09.371.729.887
21960553,2011-11-04T00:00:00,Retinaldehyde,D02.047.850
21960553,2011-11-04T00:00:00,Retinaldehyde,D02.455.326.271.665.202.495.690
21960553,2011-11-04T00:00:00,Retinaldehyde,D02.455.426.392.368.367.379.249.700.690
21960553,2011-11-04T00:00:00,Retinaldehyde,D02.455.849.131.495.690
21960553,2011-11-04T00:00:00,Retinaldehyde,D23.767.261.700.690
21960553,2011-11-04T00:00:00,Serpins,D12.644.822.750
21960553,2011-11-04T00:00:00,Serpins,D12.644.861
21960553,2011-11-04T00:00:00,Serpins,D12.776.645.750
21960553,2011-11-04T00:00:00,Serpins,D12.776.872
21960553,2011-11-04T00:00:00,Vascular Endothelial Growth Factor A,D12.644.276.100.800.200
21960553,2011-11-04T00:00:00,Vascular Endothelial Growth Factor A,D12.776.467.100.800.200
21960553,2011-11-04T00:00:00,Vascular Endothelial Growth Factor A,D23.529.100.800.200
21960553,2011-11-04T00:00:00,Viral Proteins,D12.776.964
22055685,2011-11-04T00:00:00,"Abnormalities, Multiple",C16.131.077
22055685,2011-11-04T00:00:00,Bladder Exstrophy,C12.706.132
22055685,2011-11-04T00:00:00,Bladder Exstrophy,C12.777.829.132
22055685,2011-11-04T00:00:00,Bladder Exstrophy,C13.351.875.132
22055685,2011-11-04T00:00:00,Bladder Exstrophy,C13.351.968.829.132
22055685,2011-11-04T00:00:00,Bladder Exstrophy,C16.131.939.132
22055685,2011-11-04T00:00:00,"Databases, Factual",L01.470.750.750
22055685,2011-11-04T00:00:00,"Databases, Factual",L01.700.508.300.188.400
22055685,2011-11-04T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22055685,2011-11-04T00:00:00,"Infant, Newborn",M01.060.703.520
22055685,2011-11-04T00:00:00,Kidney,A05.810.453
22055685,2011-11-04T00:00:00,Kidney Diseases,C12.777.419
22055685,2011-11-04T00:00:00,Kidney Diseases,C13.351.968.419
22055685,2011-11-04T00:00:00,Risk Assessment,E05.318.740.600.800.715
22055685,2011-11-04T00:00:00,Risk Assessment,N04.452.871.715
22055685,2011-11-04T00:00:00,Risk Assessment,N05.715.360.750.625.700.690
22055685,2011-11-04T00:00:00,Risk Assessment,N06.850.505.715
22055685,2011-11-04T00:00:00,Risk Assessment,N06.850.520.830.600.800.715
22056354,2011-11-04T00:00:00,Animals,B01.050
22056354,2011-11-04T00:00:00,"Cell Transformation, Neoplastic",C04.697.152
22056354,2011-11-04T00:00:00,"Cell Transformation, Neoplastic",C23.550.727.152
22056354,2011-11-04T00:00:00,Cytokines,D12.644.276.374
22056354,2011-11-04T00:00:00,Cytokines,D12.776.467.374
22056354,2011-11-04T00:00:00,Cytokines,D23.529.374
22056354,2011-11-04T00:00:00,"Gene Expression Regulation, Neoplastic",G05.355.315.370
22056354,2011-11-04T00:00:00,Inflammation,C23.550.470
22056354,2011-11-04T00:00:00,"RNA, Messenger",D13.444.735.544
22056354,2011-11-04T00:00:00,"Tumor Markers, Biological",D23.101.840
22056365,2011-11-04T00:00:00,Animals,B01.050
22056365,2011-11-04T00:00:00,"Disease Models, Animal",C22.232
22056365,2011-11-04T00:00:00,"Disease Models, Animal",E05.598.500
22056365,2011-11-04T00:00:00,"Disease Models, Animal",E05.599.395.080
22056365,2011-11-04T00:00:00,Matrix Metalloproteinases,D08.811.277.656.300.480.525
22056365,2011-11-04T00:00:00,Matrix Metalloproteinases,D08.811.277.656.675.374.525
22056365,2011-11-04T00:00:00,Swine,B01.050.150.900.649.077.880
22056365,2011-11-04T00:00:00,Tissue Inhibitor of Metalloproteinases,D12.776.926
22056365,2011-11-04T00:00:00,Ventricular Pressure,G09.330.190.962.950
22056365,2011-11-04T00:00:00,Ventricular Pressure,G09.330.380.937
22056365,2011-11-04T00:00:00,Ventricular Remodeling,C23.300.985
22056365,2011-11-04T00:00:00,Ventricular Remodeling,G09.330.190.962.975
22058212,2011-11-04T00:00:00,Amino Acid Sequence,G02.111.570.060
22058212,2011-11-04T00:00:00,Amino Acid Sequence,L01.453.245.667.060
22058212,2011-11-04T00:00:00,Animals,B01.050
22058212,2011-11-04T00:00:00,Bone Marrow Transplantation,E04.936.580.040
22058212,2011-11-04T00:00:00,Cell Proliferation,G04.299.233.750
22058212,2011-11-04T00:00:00,Cell Proliferation,G07.700.320.249.410.750
22058212,2011-11-04T00:00:00,Gene Expression,G05.355.310
22058212,2011-11-04T00:00:00,Homeodomain Proteins,D12.776.260.400
22058212,2011-11-04T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22058212,2011-11-04T00:00:00,Molecular Sequence Data,L01.453.245.667
22058212,2011-11-04T00:00:00,Neoplasm Proteins,D12.776.624
22058212,2011-11-04T00:00:00,"Oncogene Proteins, Fusion",D12.776.602.500.500
22058212,2011-11-04T00:00:00,"Oncogene Proteins, Fusion",D12.776.624.664.500
22058212,2011-11-04T00:00:00,Protein Isoforms,D12.776.800
22058212,2011-11-04T00:00:00,Protein Transport,G03.495.166.700
22058212,2011-11-04T00:00:00,Proteins,D12.776
22058212,2011-11-04T00:00:00,"Translocation, Genetic",C23.550.210.870
22058212,2011-11-04T00:00:00,"Translocation, Genetic",G05.355.600.860
22058212,2011-11-04T00:00:00,"Translocation, Genetic",G05.365.590.175.870
22152173,2011-11-06T00:00:00,Anti-HIV Agents,D27.505.954.122.388.077.088
22152173,2011-11-06T00:00:00,CD4-Positive T-Lymphocytes,A11.118.637.555.567.569.200
22152173,2011-11-06T00:00:00,CD4-Positive T-Lymphocytes,A15.145.229.637.555.567.569.200
22152173,2011-11-06T00:00:00,CD4-Positive T-Lymphocytes,A15.382.490.555.567.569.200
22152173,2011-11-06T00:00:00,Cost-Benefit Analysis,N03.219.151.125
22152173,2011-11-06T00:00:00,Decision Support Techniques,E05.245
22152173,2011-11-06T00:00:00,Decision Support Techniques,L01.700.508.190
22152173,2011-11-06T00:00:00,HIV Infections,C02.782.815.616.400
22152173,2011-11-06T00:00:00,HIV Infections,C02.800.801.400
22152173,2011-11-06T00:00:00,HIV Infections,C20.673.480
22152173,2011-11-06T00:00:00,Health Care Costs,N03.219.151.400
22152173,2011-11-06T00:00:00,Health Care Costs,N05.300.375
22152173,2011-11-06T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22152173,2011-11-06T00:00:00,Markov Chains,E05.318.740.600.500
22152173,2011-11-06T00:00:00,Markov Chains,E05.318.740.996.500
22152173,2011-11-06T00:00:00,Markov Chains,G17.830.500
22152173,2011-11-06T00:00:00,Markov Chains,N05.715.360.750.625.500
22152173,2011-11-06T00:00:00,Markov Chains,N05.715.360.750.770.500
22152173,2011-11-06T00:00:00,Markov Chains,N06.850.520.830.600.500
22152173,2011-11-06T00:00:00,Markov Chains,N06.850.520.830.996.500
22152173,2011-11-06T00:00:00,Quality of Life,I01.800
22152173,2011-11-06T00:00:00,Quality of Life,K01.752.400.750
22152173,2011-11-06T00:00:00,Ritonavir,D02.886.675.653
22152173,2011-11-06T00:00:00,Ritonavir,D03.383.129.708.653
22697454,2011-11-06T00:00:00,Algorithms,G17.035
22697454,2011-11-06T00:00:00,Algorithms,L01.224.050
22697454,2011-11-06T00:00:00,"Data Interpretation, Statistical",E05.245.380
22697454,2011-11-06T00:00:00,"Data Interpretation, Statistical",E05.318.740.300
22697454,2011-11-06T00:00:00,"Data Interpretation, Statistical",L01.700.508.190.380
22697454,2011-11-06T00:00:00,"Data Interpretation, Statistical",N05.715.360.750.300
22697454,2011-11-06T00:00:00,"Data Interpretation, Statistical",N06.850.520.830.300
22697454,2011-11-06T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22697454,2011-11-06T00:00:00,"Models, Statistical",E05.318.740.500
22697454,2011-11-06T00:00:00,"Models, Statistical",E05.599.835
22697454,2011-11-06T00:00:00,"Models, Statistical",N05.715.360.750.530
22697454,2011-11-06T00:00:00,"Models, Statistical",N06.850.520.830.500
22697454,2011-11-06T00:00:00,Monte Carlo Method,E05.318.740.525
22697454,2011-11-06T00:00:00,Monte Carlo Method,L01.906.575.422
22697454,2011-11-06T00:00:00,Monte Carlo Method,N05.715.360.750.540
22697454,2011-11-06T00:00:00,Monte Carlo Method,N06.850.520.830.525
22697454,2011-11-06T00:00:00,Research Design,E05.581.500
22697454,2011-11-06T00:00:00,Research Design,H01.770.644.728
22064318,2011-11-07T00:00:00,Animals,B01.050
22064318,2011-11-07T00:00:00,Protein-Serine-Threonine Kinases,D08.811.913.696.620.682.700
22064318,2011-11-07T00:00:00,Rats,B01.050.150.900.649.865.635.505.700
22064318,2011-11-07T00:00:00,"Rats, Sprague-Dawley",B01.050.150.900.649.865.635.505.700.750
22064318,2011-11-07T00:00:00,Wound Healing,G16.100.856.891
22064591,2011-11-07T00:00:00,Aged,M01.060.116.100
22064591,2011-11-07T00:00:00,Biphenyl Compounds,D02.455.426.559.389.185
22064591,2011-11-07T00:00:00,Diastole,G09.330.190.541.295
22064591,2011-11-07T00:00:00,Diastole,G11.427.590.540.554.250
22064591,2011-11-07T00:00:00,Diastole,G11.427.590.540.570.295
22064591,2011-11-07T00:00:00,Echocardiography,E01.370.350.850.220
22064591,2011-11-07T00:00:00,Echocardiography,E01.370.370.380.220
22064591,2011-11-07T00:00:00,Heart Failure,C14.280.434
22064591,2011-11-07T00:00:00,Heart Ventricles,A07.541.560
22064591,2011-11-07T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22064591,2011-11-07T00:00:00,Risk Factors,E05.318.740.600.800.725
22064591,2011-11-07T00:00:00,Risk Factors,N05.715.350.200.700
22064591,2011-11-07T00:00:00,Risk Factors,N05.715.360.750.625.700.700
22064591,2011-11-07T00:00:00,Risk Factors,N06.850.490.625.750
22064591,2011-11-07T00:00:00,Risk Factors,N06.850.520.830.600.800.725
22064591,2011-11-07T00:00:00,Stroke Volume,E01.370.370.380.150.700
22064591,2011-11-07T00:00:00,Stroke Volume,G09.330.380.124.882
22064591,2011-11-07T00:00:00,Ventricular Remodeling,C23.300.985
22064591,2011-11-07T00:00:00,Ventricular Remodeling,G09.330.190.962.975
22065252,2011-11-07T00:00:00,Adolescent,M01.060.057
22065252,2011-11-07T00:00:00,Anxiety,F01.470.132
22065252,2011-11-07T00:00:00,Child,M01.060.406
22065252,2011-11-07T00:00:00,Cognitive Therapy,F04.754.137.428
22065252,2011-11-07T00:00:00,Conduct Disorder,F03.550.150.300
22065252,2011-11-07T00:00:00,Depression,F01.145.126.350
22065252,2011-11-07T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22065252,2011-11-07T00:00:00,"Interview, Psychological",F04.669.599
22065252,2011-11-07T00:00:00,Psychiatric Status Rating Scales,F04.586
22065252,2011-11-07T00:00:00,Psychotherapy,F04.754
22065252,2011-11-07T00:00:00,Treatment Outcome,E01.789.800
22065252,2011-11-07T00:00:00,Treatment Outcome,N04.761.559.590.800
22065252,2011-11-07T00:00:00,Treatment Outcome,N05.715.360.575.575.800
22065255,2011-11-07T00:00:00,Adult,M01.060.116
22065255,2011-11-07T00:00:00,Combined Modality Therapy,E02.186
22065255,2011-11-07T00:00:00,Counseling,F02.784.176
22065255,2011-11-07T00:00:00,Counseling,F04.408.413
22065255,2011-11-07T00:00:00,Counseling,N02.421.143.303
22065255,2011-11-07T00:00:00,Counseling,N02.421.461.363
22065255,2011-11-07T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22065255,2011-11-07T00:00:00,"Interview, Psychological",F04.669.599
22065255,2011-11-07T00:00:00,Narcotic Antagonists,D27.505.696.543
22065255,2011-11-07T00:00:00,Narcotic Antagonists,D27.505.696.663.850.512
22065255,2011-11-07T00:00:00,Narcotic Antagonists,D27.505.954.427.550
22065255,2011-11-07T00:00:00,Opioid-Related Disorders,C21.739.675
22065255,2011-11-07T00:00:00,Opioid-Related Disorders,F03.900.675
22065255,2011-11-07T00:00:00,Psychiatric Status Rating Scales,F04.586
22065255,2011-11-07T00:00:00,Treatment Outcome,E01.789.800
22065255,2011-11-07T00:00:00,Treatment Outcome,N04.761.559.590.800
22065255,2011-11-07T00:00:00,Treatment Outcome,N05.715.360.575.575.800
22068232,2011-11-07T00:00:00,Actins,D05.750.078.730.250
22068232,2011-11-07T00:00:00,Actins,D12.776.210.500.100
22068232,2011-11-07T00:00:00,Actins,D12.776.220.525.255
22068232,2011-11-07T00:00:00,Animals,B01.050
22068232,2011-11-07T00:00:00,Antigen Presentation,G12.425.107
22068232,2011-11-07T00:00:00,Antigen Presentation,G12.450.050.400.070
22068232,2011-11-07T00:00:00,B-Lymphocytes,A11.063.438
22068232,2011-11-07T00:00:00,B-Lymphocytes,A11.118.637.555.567.562
22068232,2011-11-07T00:00:00,B-Lymphocytes,A15.145.229.637.555.567.562
22068232,2011-11-07T00:00:00,B-Lymphocytes,A15.382.032.438
22068232,2011-11-07T00:00:00,B-Lymphocytes,A15.382.490.555.567.562
22068232,2011-11-07T00:00:00,Dendritic Cells,A11.066.270
22068232,2011-11-07T00:00:00,Dendritic Cells,A11.436.270
22068232,2011-11-07T00:00:00,Dendritic Cells,A15.382.066.270
22068232,2011-11-07T00:00:00,Dendritic Cells,A15.382.812.260
22068232,2011-11-07T00:00:00,Lymphocyte Activation,E01.450.495.482
22068232,2011-11-07T00:00:00,Lymphocyte Activation,E05.478.594.530
22068232,2011-11-07T00:00:00,Lymphocyte Activation,G12.425.747
22068232,2011-11-07T00:00:00,Lymphocyte Activation,G12.450.050.400.545
22068232,2011-11-07T00:00:00,T-Lymphocytes,A11.118.637.555.567.569
22068232,2011-11-07T00:00:00,T-Lymphocytes,A15.145.229.637.555.567.569
22068232,2011-11-07T00:00:00,T-Lymphocytes,A15.382.490.555.567.569
22142345,2011-11-07T00:00:00,"Blood Pressure Monitoring, Ambulatory",E01.370.370.140.100
22142345,2011-11-07T00:00:00,"Blood Pressure Monitoring, Ambulatory",E01.370.520.500.100
22142345,2011-11-07T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22142345,2011-11-07T00:00:00,Hypertension,C14.907.489
22142345,2011-11-07T00:00:00,Practice Guidelines as Topic,N04.761.700.350.650
22142345,2011-11-07T00:00:00,Practice Guidelines as Topic,N05.700.350.650
22142345,2011-11-07T00:00:00,United States,Z01.107.567.875
22757946,2011-11-07T00:00:00,Aged,M01.060.116.100
22757946,2011-11-07T00:00:00,Diabetes Mellitus,C18.452.394.750
22757946,2011-11-07T00:00:00,Diabetes Mellitus,C19.246
22757946,2011-11-07T00:00:00,Health Services Accessibility,N04.590.374.350
22757946,2011-11-07T00:00:00,Health Services Accessibility,N05.300.430
22757946,2011-11-07T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22757946,2011-11-07T00:00:00,Medicare,N03.219.521.346.506.564.663
22757946,2011-11-07T00:00:00,Medicare,N03.219.521.576.343.840
22757946,2011-11-07T00:00:00,Medicare,N03.706.615.696
22757946,2011-11-07T00:00:00,Rural Population,N01.600.725
22757946,2011-11-07T00:00:00,United States,Z01.107.567.875
22757946,2011-11-07T00:00:00,Urban Population,N01.600.900
22051336,2011-11-08T00:00:00,Adenylate Cyclase,D08.811.520.650.200
22051336,2011-11-08T00:00:00,Adenylate Cyclase,D12.644.360.050
22051336,2011-11-08T00:00:00,Adenylate Cyclase,D12.776.476.050
22051336,2011-11-08T00:00:00,Animals,B01.050
22051336,2011-11-08T00:00:00,Cell Proliferation,G04.299.233.750
22051336,2011-11-08T00:00:00,Cell Proliferation,G07.700.320.249.410.750
22051336,2011-11-08T00:00:00,Cicatrix,A10.165.450.300
22051336,2011-11-08T00:00:00,Cicatrix,C23.550.355.274
22051336,2011-11-08T00:00:00,Cicatrix,G16.100.856.891.249
22051336,2011-11-08T00:00:00,Collagen,D05.750.078.280
22051336,2011-11-08T00:00:00,Collagen,D12.776.860.300.250
22051336,2011-11-08T00:00:00,Echocardiography,E01.370.350.850.220
22051336,2011-11-08T00:00:00,Echocardiography,E01.370.370.380.220
22051336,2011-11-08T00:00:00,Fibrosis,C23.550.355
22051336,2011-11-08T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22051336,2011-11-08T00:00:00,Luminescent Measurements,E05.196.712.516
22051336,2011-11-08T00:00:00,Muscle Development,G07.700.320.500.325.377.625.590
22051336,2011-11-08T00:00:00,Muscle Development,G11.427.590.560.590
22051336,2011-11-08T00:00:00,Myocardial Infarction,C14.280.647.500
22051336,2011-11-08T00:00:00,Myocardial Infarction,C14.907.585.500
22051336,2011-11-08T00:00:00,Myocardium,A02.633.580
22051336,2011-11-08T00:00:00,Myocardium,A07.541.704
22051336,2011-11-08T00:00:00,Myocardium,A10.690.552.750
22051336,2011-11-08T00:00:00,"Neovascularization, Physiologic",G09.330.190.751
22051336,2011-11-08T00:00:00,Rats,B01.050.150.900.649.865.635.505.700
22051336,2011-11-08T00:00:00,Regeneration,G16.100.856
22051336,2011-11-08T00:00:00,"Ventricular Function, Left",G09.330.190.962.800
22051336,2011-11-08T00:00:00,Ventricular Remodeling,C23.300.985
22051336,2011-11-08T00:00:00,Ventricular Remodeling,G09.330.190.962.975
22064956,2011-11-08T00:00:00,Animals,B01.050
22064956,2011-11-08T00:00:00,Cardiomyopathies,C14.280.238
22064956,2011-11-08T00:00:00,Extracellular Matrix,A11.284.295.310
22064956,2011-11-08T00:00:00,Matrix Metalloproteinase 2,D08.811.277.656.300.480.205.352
22064956,2011-11-08T00:00:00,Matrix Metalloproteinase 2,D08.811.277.656.300.480.252.420
22064956,2011-11-08T00:00:00,Matrix Metalloproteinase 2,D08.811.277.656.300.480.525.700.150
22064956,2011-11-08T00:00:00,Matrix Metalloproteinase 2,D08.811.277.656.675.374.205.352
22064956,2011-11-08T00:00:00,Matrix Metalloproteinase 2,D08.811.277.656.675.374.252.420
22064956,2011-11-08T00:00:00,Matrix Metalloproteinase 2,D08.811.277.656.675.374.525.700.150
22064956,2011-11-08T00:00:00,"Ventricular Dysfunction, Left",C14.280.945.900
22064956,2011-11-08T00:00:00,"Ventricular Function, Left",G09.330.190.962.800
22064956,2011-11-08T00:00:00,Ventricular Remodeling,C23.300.985
22064956,2011-11-08T00:00:00,Ventricular Remodeling,G09.330.190.962.975
22071373,2011-11-08T00:00:00,"Hydrocarbons, Chlorinated",D02.455.526.439
22071373,2011-11-08T00:00:00,"Models, Chemical",E05.599.495
22071373,2011-11-08T00:00:00,Solubility,G02.842.800
22071373,2011-11-08T00:00:00,Temperature,G01.906.595
22071373,2011-11-08T00:00:00,Temperature,G16.500.275.063.725.710
22071373,2011-11-08T00:00:00,Temperature,G16.500.750.775.710
22071373,2011-11-08T00:00:00,Temperature,N06.230.150.450
22071373,2011-11-08T00:00:00,Temperature,N06.230.300.100.725.710
22071373,2011-11-08T00:00:00,Volatile Organic Compounds,D02.974
22017459,2011-11-09T00:00:00,Exosomes,A11.284.430.214.190.875.190.880.495
22017459,2011-11-09T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22017459,2011-11-09T00:00:00,Mouth Neoplasms,C04.588.443.591
22017459,2011-11-09T00:00:00,Mouth Neoplasms,C07.465.565
22017459,2011-11-09T00:00:00,Nanostructures,J01.637.512
22017459,2011-11-09T00:00:00,Saliva,A12.200.666
22017459,2011-11-09T00:00:00,Surface Properties,G02.842.850
22072307,2011-11-09T00:00:00,Adult,M01.060.116
22072307,2011-11-09T00:00:00,Aged,M01.060.116.100
22072307,2011-11-09T00:00:00,Antineoplastic Combined Chemotherapy Protocols,E02.183.750.500
22072307,2011-11-09T00:00:00,Antineoplastic Combined Chemotherapy Protocols,E02.319.077.500
22072307,2011-11-09T00:00:00,Antineoplastic Combined Chemotherapy Protocols,E02.319.310.037
22072307,2011-11-09T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22072307,2011-11-09T00:00:00,Middle Aged,M01.060.116.630
22072307,2011-11-09T00:00:00,Ovarian Neoplasms,C04.588.322.455
22072307,2011-11-09T00:00:00,Ovarian Neoplasms,C13.351.500.056.630.705
22072307,2011-11-09T00:00:00,Ovarian Neoplasms,C13.351.937.418.685
22072307,2011-11-09T00:00:00,Ovarian Neoplasms,C19.344.410
22072307,2011-11-09T00:00:00,Ovarian Neoplasms,C19.391.630.705
22072307,2011-11-09T00:00:00,Quality of Life,I01.800
22072307,2011-11-09T00:00:00,Quality of Life,K01.752.400.750
22072330,2011-11-09T00:00:00,Adult,M01.060.116
22072330,2011-11-09T00:00:00,Aged,M01.060.116.100
22072330,2011-11-09T00:00:00,Head and Neck Neoplasms,C04.588.443
22072330,2011-11-09T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22072330,2011-11-09T00:00:00,Melanoma,C04.557.465.625.650.510
22072330,2011-11-09T00:00:00,Melanoma,C04.557.580.625.650.510
22072330,2011-11-09T00:00:00,Melanoma,C04.557.665.510
22072330,2011-11-09T00:00:00,Middle Aged,M01.060.116.630
22072330,2011-11-09T00:00:00,SEER Program,E05.318.308.970.725
22072330,2011-11-09T00:00:00,SEER Program,L01.280.950.725
22072330,2011-11-09T00:00:00,SEER Program,N04.452.859.819.725
22072330,2011-11-09T00:00:00,SEER Program,N05.715.360.300.715.700.725
22072330,2011-11-09T00:00:00,SEER Program,N06.850.520.308.970.725
22072561,2011-11-09T00:00:00,Adenocarcinoma,C04.557.470.200.025
22072561,2011-11-09T00:00:00,Animals,B01.050
22072561,2011-11-09T00:00:00,Diffusion,G01.595.200
22072561,2011-11-09T00:00:00,Diffusion,G02.149.767.560
22072561,2011-11-09T00:00:00,Diffusion,G02.842.750.560
22072561,2011-11-09T00:00:00,Diffusion Magnetic Resonance Imaging,E01.370.350.500.150
22072561,2011-11-09T00:00:00,Diffusion Magnetic Resonance Imaging,E01.370.350.825.500.150
22072561,2011-11-09T00:00:00,Pressure,G01.374.715
22072669,2011-11-09T00:00:00,Animals,B01.050
22072669,2011-11-09T00:00:00,"Behavior, Animal",F01.145.113
22072669,2011-11-09T00:00:00,Cocaine,D02.145.074.722.388
22072669,2011-11-09T00:00:00,Cocaine,D03.132.889.354
22072669,2011-11-09T00:00:00,Cocaine,D03.605.869.388
22072669,2011-11-09T00:00:00,Cocaine,D04.075.080.875.099.722.388
22072669,2011-11-09T00:00:00,"Conditioning, Operant",F02.463.425.179.509
22072669,2011-11-09T00:00:00,Corpus Striatum,A08.186.211.730.885.287.249.487
22072669,2011-11-09T00:00:00,Dopamine Uptake Inhibitors,D27.505.519.625.150.800
22072669,2011-11-09T00:00:00,Dopamine Uptake Inhibitors,D27.505.519.625.600.220
22072669,2011-11-09T00:00:00,Dopamine Uptake Inhibitors,D27.505.696.577.150.800
22072669,2011-11-09T00:00:00,Dopamine Uptake Inhibitors,D27.505.696.577.600.220
22072669,2011-11-09T00:00:00,Gene Expression Regulation,G05.355.315
22072669,2011-11-09T00:00:00,Integrin beta3,D12.776.543.750.705.408.200.750
22072669,2011-11-09T00:00:00,Integrin beta3,D23.050.301.264.035.302
22072669,2011-11-09T00:00:00,Integrin beta3,D23.101.100.110.299
22072669,2011-11-09T00:00:00,Nucleus Accumbens,A08.186.211.730.885.287.249.683
22072669,2011-11-09T00:00:00,Oligopeptides,D12.644.456
22072669,2011-11-09T00:00:00,Rats,B01.050.150.900.649.865.635.505.700
22072669,2011-11-09T00:00:00,"Rats, Sprague-Dawley",B01.050.150.900.649.865.635.505.700.750
22072669,2011-11-09T00:00:00,"Receptors, AMPA",D12.776.543.750.720.200.450.200
22072669,2011-11-09T00:00:00,Self Administration,E02.319.890
22072669,2011-11-09T00:00:00,Self Administration,E02.900.890
22072669,2011-11-09T00:00:00,Time Factors,G01.910.857
22075060,2011-11-09T00:00:00,Age Factors,N05.715.350.075
22075060,2011-11-09T00:00:00,Age Factors,N06.850.490.250
22075060,2011-11-09T00:00:00,Animals,B01.050
22075060,2011-11-09T00:00:00,Cardiac Surgical Procedures,E04.100.376
22075060,2011-11-09T00:00:00,Cardiac Surgical Procedures,E04.928.220
22075060,2011-11-09T00:00:00,Clinical Competence,I02.399.630.210
22075060,2011-11-09T00:00:00,Clinical Competence,N04.761.210
22075060,2011-11-09T00:00:00,Curriculum,I02.158
22075060,2011-11-09T00:00:00,"Education, Medical, Graduate",I02.358.337.350
22075060,2011-11-09T00:00:00,"Education, Medical, Graduate",I02.358.399.350
22075060,2011-11-09T00:00:00,Feedback,L01.143.283.425
22075060,2011-11-09T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22075060,2011-11-09T00:00:00,Internship and Residency,I02.358.399.644
22075060,2011-11-09T00:00:00,Learning,F02.463.425
22075060,2011-11-09T00:00:00,Learning,F02.784.629.529
22075060,2011-11-09T00:00:00,Manikins,J01.897.280.500.545.129.400
22075060,2011-11-09T00:00:00,Manikins,L01.178.820.090.545.129.400
22075060,2011-11-09T00:00:00,"Models, Animal",E05.598
22075060,2011-11-09T00:00:00,Program Evaluation,E05.337.820
22075060,2011-11-09T00:00:00,Program Evaluation,N04.761.685
22075060,2011-11-09T00:00:00,Program Evaluation,N05.715.360.650
22075060,2011-11-09T00:00:00,Questionnaires,E05.318.308.750
22075060,2011-11-09T00:00:00,Questionnaires,L01.280.800
22075060,2011-11-09T00:00:00,Questionnaires,N05.715.360.300.695
22075060,2011-11-09T00:00:00,Questionnaires,N06.850.520.308.750
22075060,2011-11-09T00:00:00,Task Performance and Analysis,F02.784.412.846
22075060,2011-11-09T00:00:00,Task Performance and Analysis,F02.784.692.746
22075060,2011-11-09T00:00:00,Task Performance and Analysis,F02.808.600
22075060,2011-11-09T00:00:00,Thoracic Surgical Procedures,E04.928
22075061,2011-11-09T00:00:00,Age Factors,N05.715.350.075
22075061,2011-11-09T00:00:00,Age Factors,N06.850.490.250
22075061,2011-11-09T00:00:00,Aprotinin,D12.776.083
22075061,2011-11-09T00:00:00,Cardiac Surgical Procedures,E04.100.376
22075061,2011-11-09T00:00:00,Cardiac Surgical Procedures,E04.928.220
22075061,2011-11-09T00:00:00,Cytokines,D12.644.276.374
22075061,2011-11-09T00:00:00,Cytokines,D12.776.467.374
22075061,2011-11-09T00:00:00,Cytokines,D23.529.374
22075061,2011-11-09T00:00:00,Factor VIIa,D08.811.277.656.300.760.300
22075061,2011-11-09T00:00:00,Factor VIIa,D08.811.277.656.959.350.300
22075061,2011-11-09T00:00:00,Factor VIIa,D12.776.124.125.325.300
22075061,2011-11-09T00:00:00,Factor VIIa,D23.119.325.300
22075061,2011-11-09T00:00:00,"Heart Defects, Congenital",C14.240.400
22075061,2011-11-09T00:00:00,"Heart Defects, Congenital",C14.280.400
22075061,2011-11-09T00:00:00,"Heart Defects, Congenital",C16.131.240.400
22075061,2011-11-09T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22075061,2011-11-09T00:00:00,"Infant, Newborn",M01.060.703.520
22075061,2011-11-09T00:00:00,Interleukin-2,D12.644.276.374.465.502
22075061,2011-11-09T00:00:00,Interleukin-2,D12.644.276.374.480.372
22075061,2011-11-09T00:00:00,Interleukin-2,D12.776.467.374.465.502
22075061,2011-11-09T00:00:00,Interleukin-2,D12.776.467.374.480.372
22075061,2011-11-09T00:00:00,Interleukin-2,D23.529.374.465.502
22075061,2011-11-09T00:00:00,Interleukin-2,D23.529.374.480.372
22075061,2011-11-09T00:00:00,Recombinant Proteins,D12.776.828
22075061,2011-11-09T00:00:00,"Respiration, Artificial",E02.365.647.729
22075061,2011-11-09T00:00:00,"Respiration, Artificial",E02.880.820
22075061,2011-11-09T00:00:00,Risk Assessment,E05.318.740.600.800.715
22075061,2011-11-09T00:00:00,Risk Assessment,N04.452.871.715
22075061,2011-11-09T00:00:00,Risk Assessment,N05.715.360.750.625.700.690
22075061,2011-11-09T00:00:00,Risk Assessment,N06.850.505.715
22075061,2011-11-09T00:00:00,Risk Assessment,N06.850.520.830.600.800.715
22075061,2011-11-09T00:00:00,Risk Factors,E05.318.740.600.800.725
22075061,2011-11-09T00:00:00,Risk Factors,N05.715.350.200.700
22075061,2011-11-09T00:00:00,Risk Factors,N05.715.360.750.625.700.700
22075061,2011-11-09T00:00:00,Risk Factors,N06.850.490.625.750
22075061,2011-11-09T00:00:00,Risk Factors,N06.850.520.830.600.800.725
22075061,2011-11-09T00:00:00,South Carolina,Z01.107.567.875.075.662
22075061,2011-11-09T00:00:00,South Carolina,Z01.107.567.875.750.700
22075061,2011-11-09T00:00:00,Time Factors,G01.910.857
22075061,2011-11-09T00:00:00,Treatment Outcome,E01.789.800
22075061,2011-11-09T00:00:00,Treatment Outcome,N04.761.559.590.800
22075061,2011-11-09T00:00:00,Treatment Outcome,N05.715.360.575.575.800
22075061,2011-11-09T00:00:00,Tumor Necrosis Factor-alpha,D12.644.276.374.500.800
22075061,2011-11-09T00:00:00,Tumor Necrosis Factor-alpha,D12.644.276.374.750.626
22075061,2011-11-09T00:00:00,Tumor Necrosis Factor-alpha,D12.644.276.972.626
22075061,2011-11-09T00:00:00,Tumor Necrosis Factor-alpha,D12.776.124.900
22075061,2011-11-09T00:00:00,Tumor Necrosis Factor-alpha,D12.776.395.930
22075061,2011-11-09T00:00:00,Tumor Necrosis Factor-alpha,D12.776.467.374.500.800
22075061,2011-11-09T00:00:00,Tumor Necrosis Factor-alpha,D12.776.467.374.750.626
22075061,2011-11-09T00:00:00,Tumor Necrosis Factor-alpha,D12.776.467.972.626
22075061,2011-11-09T00:00:00,Tumor Necrosis Factor-alpha,D23.529.374.500.800
22075061,2011-11-09T00:00:00,Tumor Necrosis Factor-alpha,D23.529.374.750.626
22075061,2011-11-09T00:00:00,Tumor Necrosis Factor-alpha,D23.529.972.626
22085803,2011-11-09T00:00:00,Community Health Services,N02.421.143
22085803,2011-11-09T00:00:00,Computer-Assisted Instruction,I02.903.573.208
22085803,2011-11-09T00:00:00,Cost-Benefit Analysis,N03.219.151.125
22085803,2011-11-09T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22085803,2011-11-09T00:00:00,Middle Aged,M01.060.116.630
22085803,2011-11-09T00:00:00,"Quality Assurance, Health Care",N04.761.700
22085803,2011-11-09T00:00:00,"Quality Assurance, Health Care",N05.700
22085803,2011-11-09T00:00:00,Research Design,E05.581.500
22085803,2011-11-09T00:00:00,Research Design,H01.770.644.728
22085803,2011-11-09T00:00:00,Substance-Related Disorders,C21.739
22085803,2011-11-09T00:00:00,Substance-Related Disorders,F03.900
22085803,2011-11-09T00:00:00,United States,Z01.107.567.875
22269546,2011-11-09T00:00:00,Adolescent,M01.060.057
22269546,2011-11-09T00:00:00,Attention,F02.830.104.214
22269546,2011-11-09T00:00:00,Automobile Driving,I03.125
22269546,2011-11-09T00:00:00,Automobiles,J01.937.500.100
22269546,2011-11-09T00:00:00,Computer Simulation,L01.224.160
22269546,2011-11-09T00:00:00,Deceleration,G01.595.560.107.373
22269546,2011-11-09T00:00:00,Discrimination (Psychology),F02.463.593.257
22269546,2011-11-09T00:00:00,Eye Movements,G11.427.590.530.140
22269546,2011-11-09T00:00:00,Eye Movements,G14.640.260
22269546,2011-11-09T00:00:00,Field Dependence-Independence,F02.463.593.343
22269546,2011-11-09T00:00:00,Field Dependence-Independence,F02.463.593.932.345
22269546,2011-11-09T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22269546,2011-11-09T00:00:00,Lighting,N06.230.150.410
22269546,2011-11-09T00:00:00,"Pattern Recognition, Visual",F02.463.593.524.500
22269546,2011-11-09T00:00:00,"Pattern Recognition, Visual",F02.463.593.932.622
22269546,2011-11-09T00:00:00,"Pattern Recognition, Visual",F02.463.593.932.869.435.673
22269546,2011-11-09T00:00:00,Reaction Time,F02.830.650
22269546,2011-11-09T00:00:00,Reaction Time,F04.669.817
22269546,2011-11-09T00:00:00,Reaction Time,G11.561.677
22269546,2011-11-09T00:00:00,Workload,N04.452.677.950
22269546,2011-11-09T00:00:00,Young Adult,M01.060.116.815
22171101,2011-11-10T00:00:00,Career Choice,F02.463.785.373.346.400
22171101,2011-11-10T00:00:00,Curriculum,I02.158
22171101,2011-11-10T00:00:00,"Education, Pharmacy",I02.358.525
22171101,2011-11-10T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22171101,2011-11-10T00:00:00,"Students, Pharmacy",I02.851.686.768
22171101,2011-11-10T00:00:00,"Students, Pharmacy",M01.848.769.768
22221605,2011-11-10T00:00:00,Animals,B01.050
22221605,2011-11-10T00:00:00,"Antimetabolites, Antineoplastic",D27.505.519.186.144
22221605,2011-11-10T00:00:00,"Antimetabolites, Antineoplastic",D27.505.954.248.144
22221605,2011-11-10T00:00:00,"Antimetabolites, Antineoplastic",D27.888.569.042.030
22221605,2011-11-10T00:00:00,Cell Division,G04.299.134.220
22221605,2011-11-10T00:00:00,Cell Division,G04.299.233.750.500
22221605,2011-11-10T00:00:00,Cell Division,G05.355.105
22221605,2011-11-10T00:00:00,Cell Division,G07.700.320.249.410.750.500
22221605,2011-11-10T00:00:00,Deoxycytidine,D03.383.742.680.245.500
22221605,2011-11-10T00:00:00,Deoxycytidine,D13.570.230.329
22221605,2011-11-10T00:00:00,Deoxycytidine,D13.570.685.245.500
22221605,2011-11-10T00:00:00,"Disease Models, Animal",C22.232
22221605,2011-11-10T00:00:00,"Disease Models, Animal",E05.598.500
22221605,2011-11-10T00:00:00,"Disease Models, Animal",E05.599.395.080
22221605,2011-11-10T00:00:00,Pancreatic Neoplasms,C04.588.274.761
22221605,2011-11-10T00:00:00,Pancreatic Neoplasms,C04.588.322.421
22221605,2011-11-10T00:00:00,Pancreatic Neoplasms,C06.301.761
22221605,2011-11-10T00:00:00,Pancreatic Neoplasms,C06.689.667
22221605,2011-11-10T00:00:00,Pancreatic Neoplasms,C19.344.421
22221605,2011-11-10T00:00:00,Spleen,A10.549.700
22221605,2011-11-10T00:00:00,Spleen,A15.382.520.604.700
22047054,2011-11-11T00:00:00,Antineoplastic Agents,D27.505.954.248
22047054,2011-11-11T00:00:00,Histone Deacetylase Inhibitors,D27.505.519.389.360
22047054,2011-11-11T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22047054,2011-11-11T00:00:00,"Leukemia, Myeloid, Acute",C04.557.337.539.550
22047054,2011-11-11T00:00:00,Small Molecule Libraries,D27.720.470.765
22076362,2011-11-11T00:00:00,Curriculum,I02.158
22076362,2011-11-11T00:00:00,School Admission Criteria,I02.399.750
22076362,2011-11-11T00:00:00,"Schools, Medical",I02.783.660.552
22076362,2011-11-11T00:00:00,"Schools, Medical",N02.278.020.578
22080474,2011-11-11T00:00:00,"Arrhythmias, Cardiac",C14.280.067
22080474,2011-11-11T00:00:00,"Arrhythmias, Cardiac",C23.550.073
22080474,2011-11-11T00:00:00,"Defibrillators, Implantable",E07.305.250.159.175
22080474,2011-11-11T00:00:00,"Defibrillators, Implantable",E07.305.250.319.175
22080474,2011-11-11T00:00:00,"Defibrillators, Implantable",E07.695.175
22080474,2011-11-11T00:00:00,Equipment Failure Analysis,E05.325.192
22080474,2011-11-11T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22080474,2011-11-11T00:00:00,Patient Discharge,E02.760.400.610
22080474,2011-11-11T00:00:00,Patient Discharge,N02.421.585.400.610
22080474,2011-11-11T00:00:00,Prosthesis Failure,C23.550.767.865
22080474,2011-11-11T00:00:00,Prosthesis Failure,E05.325.771
22081703,2011-11-11T00:00:00,Animals,B01.050
22081703,2011-11-11T00:00:00,Cardiomegaly,C14.280.195
22081703,2011-11-11T00:00:00,Cardiomegaly,C23.300.775.250
22081703,2011-11-11T00:00:00,"Disease Models, Animal",C22.232
22081703,2011-11-11T00:00:00,"Disease Models, Animal",E05.598.500
22081703,2011-11-11T00:00:00,"Disease Models, Animal",E05.599.395.080
22081703,2011-11-11T00:00:00,Heart Failure,C14.280.434
22081703,2011-11-11T00:00:00,"Myocytes, Cardiac",A07.541.704.570
22081703,2011-11-11T00:00:00,"Myocytes, Cardiac",A10.690.552.750.570
22081703,2011-11-11T00:00:00,"Myocytes, Cardiac",A11.620.500
22081703,2011-11-11T00:00:00,Protein Phosphatase 1,D08.811.277.352.650.625.687
22081703,2011-11-11T00:00:00,Protein Phosphatase 2,D08.811.277.352.650.625.706
22081703,2011-11-11T00:00:00,Protein Phosphatase 2,D12.644.360.583
22081703,2011-11-11T00:00:00,Protein Phosphatase 2,D12.776.476.561
22081703,2011-11-11T00:00:00,Tubulin,D05.750.078.734.800
22081703,2011-11-11T00:00:00,Tubulin,D12.776.220.600.800
22081703,2011-11-11T00:00:00,Tubulin,D12.776.641.920
22101225,2011-11-11T00:00:00,Adult,M01.060.116
22101225,2011-11-11T00:00:00,Aged,M01.060.116.100
22101225,2011-11-11T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22101225,2011-11-11T00:00:00,Mental Health Services,F04.408
22101225,2011-11-11T00:00:00,Mental Health Services,N02.421.461
22101225,2011-11-11T00:00:00,Middle Aged,M01.060.116.630
22101225,2011-11-11T00:00:00,Psychotherapy,F04.754
22101225,2011-11-11T00:00:00,"Stress Disorders, Post-Traumatic",F03.080.931.500
22101225,2011-11-11T00:00:00,Telemedicine,H02.403.840
22101225,2011-11-11T00:00:00,Telemedicine,L01.178.847.652
22101225,2011-11-11T00:00:00,Telemedicine,N04.590.374.800
22101225,2011-11-11T00:00:00,Treatment Outcome,E01.789.800
22101225,2011-11-11T00:00:00,Treatment Outcome,N04.761.559.590.800
22101225,2011-11-11T00:00:00,Treatment Outcome,N05.715.360.575.575.800
22101225,2011-11-11T00:00:00,United States,Z01.107.567.875
22101225,2011-11-11T00:00:00,Veterans,M01.930
22101225,2011-11-11T00:00:00,Young Adult,M01.060.116.815
22080430,2011-11-12T00:00:00,Adult,M01.060.116
22080430,2011-11-12T00:00:00,Aged,M01.060.116.100
22080430,2011-11-12T00:00:00,Antineoplastic Agents,D27.505.954.248
22080430,2011-11-12T00:00:00,Antineoplastic Combined Chemotherapy Protocols,E02.183.750.500
22080430,2011-11-12T00:00:00,Antineoplastic Combined Chemotherapy Protocols,E02.319.077.500
22080430,2011-11-12T00:00:00,Antineoplastic Combined Chemotherapy Protocols,E02.319.310.037
22080430,2011-11-12T00:00:00,Apoptosis,G04.299.139.160
22080430,2011-11-12T00:00:00,Carcinoma,C04.557.470.200
22080430,2011-11-12T00:00:00,"Carcinoma, Non-Small-Cell Lung",C04.588.894.797.520.109.220.249
22080430,2011-11-12T00:00:00,"Carcinoma, Non-Small-Cell Lung",C08.381.540.140.500
22080430,2011-11-12T00:00:00,"Carcinoma, Non-Small-Cell Lung",C08.785.520.100.220.500
22080430,2011-11-12T00:00:00,Cell Proliferation,G04.299.233.750
22080430,2011-11-12T00:00:00,Cell Proliferation,G07.700.320.249.410.750
22080430,2011-11-12T00:00:00,Histone Deacetylase Inhibitors,D27.505.519.389.360
22080430,2011-11-12T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22080430,2011-11-12T00:00:00,Lactones,D02.540
22080430,2011-11-12T00:00:00,Lung Neoplasms,C04.588.894.797.520
22080430,2011-11-12T00:00:00,Lung Neoplasms,C08.381.540
22080430,2011-11-12T00:00:00,Lung Neoplasms,C08.785.520
22080430,2011-11-12T00:00:00,Melanoma,C04.557.465.625.650.510
22080430,2011-11-12T00:00:00,Melanoma,C04.557.580.625.650.510
22080430,2011-11-12T00:00:00,Melanoma,C04.557.665.510
22080430,2011-11-12T00:00:00,Middle Aged,M01.060.116.630
22080430,2011-11-12T00:00:00,Pancreatic Neoplasms,C04.588.274.761
22080430,2011-11-12T00:00:00,Pancreatic Neoplasms,C04.588.322.421
22080430,2011-11-12T00:00:00,Pancreatic Neoplasms,C06.301.761
22080430,2011-11-12T00:00:00,Pancreatic Neoplasms,C06.689.667
22080430,2011-11-12T00:00:00,Pancreatic Neoplasms,C19.344.421
22080430,2011-11-12T00:00:00,Pyrroles,D03.383.129.578
22123032,2011-11-12T00:00:00,Actins,D05.750.078.730.250
22123032,2011-11-12T00:00:00,Actins,D12.776.210.500.100
22123032,2011-11-12T00:00:00,Actins,D12.776.220.525.255
22123032,2011-11-12T00:00:00,Animals,B01.050
22123032,2011-11-12T00:00:00,"Animals, Newborn",B01.050.050.282
22123032,2011-11-12T00:00:00,Apoptosis,G04.299.139.160
22123032,2011-11-12T00:00:00,Body Weight,C23.888.144
22123032,2011-11-12T00:00:00,Body Weight,E01.370.600.115.100.160.120
22123032,2011-11-12T00:00:00,Body Weight,E05.041.124.160.750
22123032,2011-11-12T00:00:00,Body Weight,G07.100.100.160.120
22123032,2011-11-12T00:00:00,Body Weight,G07.700.320.249.314.120
22123032,2011-11-12T00:00:00,Epithelial Cells,A11.436
22123032,2011-11-12T00:00:00,Gene Expression,G05.355.310
22123032,2011-11-12T00:00:00,Lactation,G08.686.702.500
22123032,2011-11-12T00:00:00,Lactation,G08.686.785.420
22123032,2011-11-12T00:00:00,Pregnancy,G08.686.785.760.769
22123032,2011-11-12T00:00:00,Protein Isoforms,D12.776.800
22108388,2011-11-13T00:00:00,Artifacts,E05.047
22108388,2011-11-13T00:00:00,Blood Chemical Analysis,E01.450.150.100
22108388,2011-11-13T00:00:00,Light,G01.201.875.770.578
22108388,2011-11-13T00:00:00,Light,G01.590.540
22108388,2011-11-13T00:00:00,Temperature,G01.906.595
22108388,2011-11-13T00:00:00,Temperature,G16.500.275.063.725.710
22108388,2011-11-13T00:00:00,Temperature,G16.500.750.775.710
22108388,2011-11-13T00:00:00,Temperature,N06.230.150.450
22108388,2011-11-13T00:00:00,Temperature,N06.230.300.100.725.710
22108388,2011-11-13T00:00:00,Time Factors,G01.910.857
22309277,2011-11-13T00:00:00,Case-Control Studies,E05.318.760.500.500
22309277,2011-11-13T00:00:00,Case-Control Studies,N05.715.360.775.175.200
22309277,2011-11-13T00:00:00,Case-Control Studies,N06.850.520.450.500.500
22309277,2011-11-13T00:00:00,Chronic Disease,C23.550.291.500
22309277,2011-11-13T00:00:00,Cilia,A11.284.180.165
22309277,2011-11-13T00:00:00,Dexamethasone,D04.808.745.432.769.344
22309277,2011-11-13T00:00:00,Dexamethasone,D04.808.908.238
22309277,2011-11-13T00:00:00,Epithelial Cells,A11.436
22309277,2011-11-13T00:00:00,Glucocorticoids,D06.472.040.543
22309277,2011-11-13T00:00:00,Glucocorticoids,D27.505.696.399.472.488
22309277,2011-11-13T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22309277,2011-11-13T00:00:00,Interleukin-6,D12.644.276.374.465.506
22309277,2011-11-13T00:00:00,Interleukin-6,D12.776.467.374.465.506
22309277,2011-11-13T00:00:00,Interleukin-6,D23.529.374.465.506
22309277,2011-11-13T00:00:00,"Models, Biological",E05.599.395
22309277,2011-11-13T00:00:00,Nasal Polyps,C08.460.572
22309277,2011-11-13T00:00:00,Nasal Polyps,C09.603.557
22309277,2011-11-13T00:00:00,Nasal Polyps,C23.300.825.557
22309277,2011-11-13T00:00:00,Phenotype,G05.695
22309277,2011-11-13T00:00:00,Rhinitis,C08.460.799
22309277,2011-11-13T00:00:00,Rhinitis,C08.730.674
22309277,2011-11-13T00:00:00,Rhinitis,C09.603.799
22309277,2011-11-13T00:00:00,Sinusitis,C08.460.692.752
22309277,2011-11-13T00:00:00,Sinusitis,C08.730.749
22309277,2011-11-13T00:00:00,Sinusitis,C09.603.692.752
22082023,2011-11-14T00:00:00,Anti-Bacterial Agents,D27.505.954.122.085
22082023,2011-11-14T00:00:00,"Endocarditis, Bacterial",C01.252.300
22082023,2011-11-14T00:00:00,"Endocarditis, Bacterial",C01.539.190.249
22082023,2011-11-14T00:00:00,"Endocarditis, Bacterial",C14.260.249
22082023,2011-11-14T00:00:00,"Endocarditis, Bacterial",C14.280.282.407
22082023,2011-11-14T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22082023,2011-11-14T00:00:00,"Pacemaker, Artificial",E07.858.082.748
22082023,2011-11-14T00:00:00,Staphylococcal Infections,C01.252.410.868
22082023,2011-11-14T00:00:00,Staphylococcus aureus,B03.300.390.400.800.750.100
22082023,2011-11-14T00:00:00,Staphylococcus aureus,B03.510.100.750.750.100
22082023,2011-11-14T00:00:00,Staphylococcus aureus,B03.510.400.790.750.100
22084102,2011-11-14T00:00:00,Animals,B01.050
22084102,2011-11-14T00:00:00,"Microscopy, Confocal",E01.370.350.515.395
22084102,2011-11-14T00:00:00,"Microscopy, Confocal",E05.595.395
22084102,2011-11-14T00:00:00,Piperidines,D03.383.621
22084102,2011-11-14T00:00:00,Prefrontal Cortex,A08.186.211.730.885.287.500.270.700
22084102,2011-11-14T00:00:00,Rats,B01.050.150.900.649.865.635.505.700
22084102,2011-11-14T00:00:00,"Rats, Sprague-Dawley",B01.050.150.900.649.865.635.505.700.750
22084102,2011-11-14T00:00:00,"Receptors, N-Methyl-D-Aspartate",D12.776.543.750.720.200.450.580
22084102,2011-11-14T00:00:00,Self Administration,E02.319.890
22084102,2011-11-14T00:00:00,Self Administration,E02.900.890
22084102,2011-11-14T00:00:00,Synaptic Transmission,G02.111.087.800.850
22084102,2011-11-14T00:00:00,Synaptic Transmission,G02.149.115.800.850
22084102,2011-11-14T00:00:00,Synaptic Transmission,G04.299.880.850
22084102,2011-11-14T00:00:00,Synaptic Transmission,G07.265.337.900
22084102,2011-11-14T00:00:00,Synaptic Transmission,G07.700.240.900
22084102,2011-11-14T00:00:00,Synaptic Transmission,G11.561.600.835
22086926,2011-11-15T00:00:00,ATP-Binding Cassette Transporters,D12.776.157.530.100
22086926,2011-11-15T00:00:00,ATP-Binding Cassette Transporters,D12.776.395.550.020
22086926,2011-11-15T00:00:00,ATP-Binding Cassette Transporters,D12.776.543.550.192
22086926,2011-11-15T00:00:00,ATP-Binding Cassette Transporters,D12.776.543.585.100
22086926,2011-11-15T00:00:00,Alzheimer Disease,C10.228.140.380.100
22086926,2011-11-15T00:00:00,Alzheimer Disease,C10.574.945.249
22086926,2011-11-15T00:00:00,Alzheimer Disease,F03.087.400.100
22086926,2011-11-15T00:00:00,Amyloid Precursor Protein Secretases,D08.811.277.656.300.032
22086926,2011-11-15T00:00:00,Amyloid beta-Protein Precursor,D12.776.049.025.150
22086926,2011-11-15T00:00:00,Amyloid beta-Protein Precursor,D12.776.811.050
22086926,2011-11-15T00:00:00,Animals,B01.050
22086926,2011-11-15T00:00:00,Down-Regulation,G02.111.087.225
22086926,2011-11-15T00:00:00,Down-Regulation,G02.149.115.225
22086926,2011-11-15T00:00:00,Down-Regulation,G05.355.315.200
22086926,2011-11-15T00:00:00,Down-Regulation,G07.690.812.230
22086926,2011-11-15T00:00:00,Down-Regulation,G07.700.680.230
22086926,2011-11-15T00:00:00,Drosophila Proteins,D12.776.466.462
22086926,2011-11-15T00:00:00,Drosophila melanogaster,B01.050.500.131.617.289.310.250.500
22086926,2011-11-15T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22086926,2011-11-15T00:00:00,Membrane Glycoproteins,D12.776.395.550
22086926,2011-11-15T00:00:00,Membrane Glycoproteins,D12.776.543.550
22086926,2011-11-15T00:00:00,Nerve Tissue Proteins,D12.776.641
22086926,2011-11-15T00:00:00,Rats,B01.050.150.900.649.865.635.505.700
22365872,2011-11-15T00:00:00,Academic Medical Centers,N02.278.020
22365872,2011-11-15T00:00:00,Adult,M01.060.116
22365872,2011-11-15T00:00:00,Attitude of Health Personnel,F01.100.050
22365872,2011-11-15T00:00:00,Attitude of Health Personnel,N05.300.100
22365872,2011-11-15T00:00:00,Clinical Competence,I02.399.630.210
22365872,2011-11-15T00:00:00,Clinical Competence,N04.761.210
22365872,2011-11-15T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22365872,2011-11-15T00:00:00,Interprofessional Relations,F01.829.401.205
22365872,2011-11-15T00:00:00,Leadership,F01.752.609
22365872,2011-11-15T00:00:00,Middle Aged,M01.060.116.630
22365872,2011-11-15T00:00:00,Patient Care Team,N04.590.715
22365872,2011-11-15T00:00:00,Quality of Health Care,N04.761
22365872,2011-11-15T00:00:00,Quality of Health Care,N05.715
22365872,2011-11-15T00:00:00,Resuscitation,E02.365.647
22365872,2011-11-15T00:00:00,Risk Factors,E05.318.740.600.800.725
22365872,2011-11-15T00:00:00,Risk Factors,N05.715.350.200.700
22365872,2011-11-15T00:00:00,Risk Factors,N05.715.360.750.625.700.700
22365872,2011-11-15T00:00:00,Risk Factors,N06.850.490.625.750
22365872,2011-11-15T00:00:00,Risk Factors,N06.850.520.830.600.800.725
22365872,2011-11-15T00:00:00,Trauma Centers,N02.278.354.422.336.500
22365872,2011-11-15T00:00:00,Trauma Centers,N02.421.297.195.480
22365872,2011-11-15T00:00:00,Trauma Centers,N04.452.442.422.336.400
22365872,2011-11-15T00:00:00,United States,Z01.107.567.875
22088620,2011-11-16T00:00:00,African Americans,M01.686.508.100.100
22088620,2011-11-16T00:00:00,African Americans,M01.686.754.100
22088620,2011-11-16T00:00:00,"Antibodies, Antinuclear",D12.776.124.486.485.114.323.204
22088620,2011-11-16T00:00:00,"Antibodies, Antinuclear",D12.776.124.790.651.114.323.204
22088620,2011-11-16T00:00:00,"Antibodies, Antinuclear",D12.776.377.715.548.114.323.204
22088620,2011-11-16T00:00:00,Autoantibodies,D12.776.124.486.485.114.323
22088620,2011-11-16T00:00:00,Autoantibodies,D12.776.124.790.651.114.323
22088620,2011-11-16T00:00:00,Autoantibodies,D12.776.377.715.548.114.323
22088620,2011-11-16T00:00:00,Case-Control Studies,E05.318.760.500.500
22088620,2011-11-16T00:00:00,Case-Control Studies,N05.715.360.775.175.200
22088620,2011-11-16T00:00:00,Case-Control Studies,N06.850.520.450.500.500
22088620,2011-11-16T00:00:00,DNA,D13.444.308
22088620,2011-11-16T00:00:00,European Continental Ancestry Group,M01.686.508.400
22088620,2011-11-16T00:00:00,Genetic Predisposition to Disease,C23.550.291.687.500
22088620,2011-11-16T00:00:00,Genetic Predisposition to Disease,G05.380.355
22088620,2011-11-16T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22088620,2011-11-16T00:00:00,Interferon Regulatory Factors,D12.644.360.024.302
22088620,2011-11-16T00:00:00,Interferon Regulatory Factors,D12.776.157.057.050
22088620,2011-11-16T00:00:00,Interferon Regulatory Factors,D12.776.260.504
22088620,2011-11-16T00:00:00,Interferon Regulatory Factors,D12.776.476.024.385
22088620,2011-11-16T00:00:00,Interferon Regulatory Factors,D12.776.930.332
22088620,2011-11-16T00:00:00,Interferon-alpha,D12.644.276.374.440.890.250
22088620,2011-11-16T00:00:00,Interferon-alpha,D12.644.276.718.500.250
22088620,2011-11-16T00:00:00,Interferon-alpha,D12.776.467.374.440.890.250
22088620,2011-11-16T00:00:00,Interferon-alpha,D12.776.467.718.500.250
22088620,2011-11-16T00:00:00,Interferon-alpha,D23.529.374.440.890.250
22088620,2011-11-16T00:00:00,Interferon-alpha,D23.529.718.500.250
22088620,2011-11-16T00:00:00,"Lupus Erythematosus, Systemic",C17.300.480
22088620,2011-11-16T00:00:00,"Lupus Erythematosus, Systemic",C20.111.590
22088620,2011-11-16T00:00:00,"Polymorphism, Single Nucleotide",G05.365.795.598
22089721,2011-11-16T00:00:00,Aged,M01.060.116.100
22089721,2011-11-16T00:00:00,Angiotensin-Converting Enzyme Inhibitors,D27.505.519.389.745.085
22089721,2011-11-16T00:00:00,Blood Pressure,E01.370.600.875.249
22089721,2011-11-16T00:00:00,Blood Pressure,G09.330.380.076
22089721,2011-11-16T00:00:00,Brain Ischemia,C10.228.140.300.150
22089721,2011-11-16T00:00:00,Brain Ischemia,C14.907.253.092
22089721,2011-11-16T00:00:00,Diastole,G09.330.190.541.295
22089721,2011-11-16T00:00:00,Diastole,G11.427.590.540.554.250
22089721,2011-11-16T00:00:00,Diastole,G11.427.590.540.570.295
22089721,2011-11-16T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22089721,2011-11-16T00:00:00,Middle Aged,M01.060.116.630
22089721,2011-11-16T00:00:00,Myocardial Infarction,C14.280.647.500
22089721,2011-11-16T00:00:00,Myocardial Infarction,C14.907.585.500
22089721,2011-11-16T00:00:00,Platelet Aggregation Inhibitors,D27.505.954.502.780
22089721,2011-11-16T00:00:00,Randomized Controlled Trials as Topic,E05.318.760.535.365.500
22089721,2011-11-16T00:00:00,Randomized Controlled Trials as Topic,E05.337.250.365.500
22089721,2011-11-16T00:00:00,Randomized Controlled Trials as Topic,N05.715.360.775.235.387.500
22089721,2011-11-16T00:00:00,Randomized Controlled Trials as Topic,N06.850.520.450.535.365.500
22089721,2011-11-16T00:00:00,Stroke,C10.228.140.300.775
22089721,2011-11-16T00:00:00,Stroke,C14.907.253.855
22089721,2011-11-16T00:00:00,Ticlopidine,D02.886.778.834
22089721,2011-11-16T00:00:00,Ticlopidine,D03.383.903.834
22110762,2011-11-16T00:00:00,Animals,B01.050
22110762,2011-11-16T00:00:00,Blood-Brain Barrier,A07.035
22110762,2011-11-16T00:00:00,Blood-Brain Barrier,A08.186.211.035
22110762,2011-11-16T00:00:00,Brain Ischemia,C10.228.140.300.150
22110762,2011-11-16T00:00:00,Brain Ischemia,C14.907.253.092
22110762,2011-11-16T00:00:00,"Disease Models, Animal",C22.232
22110762,2011-11-16T00:00:00,"Disease Models, Animal",E05.598.500
22110762,2011-11-16T00:00:00,"Disease Models, Animal",E05.599.395.080
22110762,2011-11-16T00:00:00,Endothelial Cells,A11.436.275
22110762,2011-11-16T00:00:00,Gene Expression Regulation,G05.355.315
22110762,2011-11-16T00:00:00,Hypoxia-Inducible Factor 1,D12.776.260.103.625
22110762,2011-11-16T00:00:00,Hypoxia-Inducible Factor 1,D12.776.930.125.625
22110762,2011-11-16T00:00:00,Indazoles,D03.383.129.539.487
22110762,2011-11-16T00:00:00,Indazoles,D03.438.449
22110762,2011-11-16T00:00:00,Neurons,A08.663
22110762,2011-11-16T00:00:00,Neurons,A11.671
22110762,2011-11-16T00:00:00,Rats,B01.050.150.900.649.865.635.505.700
22110762,2011-11-16T00:00:00,"Rats, Sprague-Dawley",B01.050.150.900.649.865.635.505.700.750
22110762,2011-11-16T00:00:00,Stroke,C10.228.140.300.775
22110762,2011-11-16T00:00:00,Stroke,C14.907.253.855
22110762,2011-11-16T00:00:00,Vascular Endothelial Growth Factor A,D12.644.276.100.800.200
22110762,2011-11-16T00:00:00,Vascular Endothelial Growth Factor A,D12.776.467.100.800.200
22110762,2011-11-16T00:00:00,Vascular Endothelial Growth Factor A,D23.529.100.800.200
22087683,2011-11-17T00:00:00,Adult,M01.060.116
22087683,2011-11-17T00:00:00,Anti-Bacterial Agents,D27.505.954.122.085
22087683,2011-11-17T00:00:00,Bacteremia,C01.252.100
22087683,2011-11-17T00:00:00,Bacteremia,C01.539.757.100
22087683,2011-11-17T00:00:00,Bacteremia,C23.550.470.790.500.100
22087683,2011-11-17T00:00:00,Clostridium Infections,C01.252.410.222
22087683,2011-11-17T00:00:00,Clostridium perfringens,B03.300.390.400.200.575
22087683,2011-11-17T00:00:00,Clostridium perfringens,B03.510.415.400.200.575
22087683,2011-11-17T00:00:00,"Diagnosis, Differential",E01.171
22087683,2011-11-17T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22087683,2011-11-17T00:00:00,Pre-Eclampsia,C13.703.395.249
22087683,2011-11-17T00:00:00,Pregnancy,G08.686.785.760.769
22091946,2011-11-17T00:00:00,Adult,M01.060.116
22091946,2011-11-17T00:00:00,Anxiety Disorders,F03.080
22091946,2011-11-17T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22091946,2011-11-17T00:00:00,"Interview, Psychological",F04.669.599
22091946,2011-11-17T00:00:00,Personality Inventory,F04.711.647.513
22091946,2011-11-17T00:00:00,Psychiatric Status Rating Scales,F04.586
22091946,2011-11-17T00:00:00,Psychometrics,F04.711.780
22091946,2011-11-17T00:00:00,Questionnaires,E05.318.308.750
22091946,2011-11-17T00:00:00,Questionnaires,L01.280.800
22091946,2011-11-17T00:00:00,Questionnaires,N05.715.360.300.695
22091946,2011-11-17T00:00:00,Questionnaires,N06.850.520.308.750
22091946,2011-11-17T00:00:00,Young Adult,M01.060.116.815
22094235,2011-11-17T00:00:00,Bladder Exstrophy,C12.706.132
22094235,2011-11-17T00:00:00,Bladder Exstrophy,C12.777.829.132
22094235,2011-11-17T00:00:00,Bladder Exstrophy,C13.351.875.132
22094235,2011-11-17T00:00:00,Bladder Exstrophy,C13.351.968.829.132
22094235,2011-11-17T00:00:00,Bladder Exstrophy,C16.131.939.132
22094235,2011-11-17T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22094235,2011-11-17T00:00:00,"Infant, Newborn",M01.060.703.520
22094235,2011-11-17T00:00:00,Postoperative Care,E02.760.722.700
22094235,2011-11-17T00:00:00,Postoperative Care,E04.624
22094235,2011-11-17T00:00:00,Postoperative Care,N02.421.585.722.700
22094235,2011-11-17T00:00:00,Practice Guidelines as Topic,N04.761.700.350.650
22094235,2011-11-17T00:00:00,Practice Guidelines as Topic,N05.700.350.650
22094235,2011-11-17T00:00:00,Reconstructive Surgical Procedures,E04.680
22094235,2011-11-17T00:00:00,Treatment Outcome,E01.789.800
22094235,2011-11-17T00:00:00,Treatment Outcome,N04.761.559.590.800
22094235,2011-11-17T00:00:00,Treatment Outcome,N05.715.360.575.575.800
22094235,2011-11-17T00:00:00,Urinary Bladder,A05.810.890
22094235,2011-11-17T00:00:00,Urologic Surgical Procedures,E04.950.774
22094601,2011-11-17T00:00:00,Adenosine Triphosphate,D03.438.759.646.138.236
22094601,2011-11-17T00:00:00,Adenosine Triphosphate,D13.695.667.138.236
22094601,2011-11-17T00:00:00,Adenosine Triphosphate,D13.695.827.068.236
22094601,2011-11-17T00:00:00,Animals,B01.050
22094601,2011-11-17T00:00:00,Cell Death,G04.299.139
22094601,2011-11-17T00:00:00,Cell Survival,G04.299.316
22094601,2011-11-17T00:00:00,Fatty Acids,D10.251
22094601,2011-11-17T00:00:00,Fatty Liver,C06.552.241
22094601,2011-11-17T00:00:00,Hepatocytes,A11.436.348
22094601,2011-11-17T00:00:00,"Mice, Inbred Strains",B01.050.050.157.520
22094601,2011-11-17T00:00:00,"Mice, Inbred Strains",B01.050.050.199.520.520
22094601,2011-11-17T00:00:00,"Mice, Inbred Strains",B01.050.150.900.649.865.635.505.500.400
22094601,2011-11-17T00:00:00,"Mice, Obese",B01.050.150.900.649.865.635.505.500.550.530
22094601,2011-11-17T00:00:00,Mitochondrial Proteins,D12.776.575
22094601,2011-11-17T00:00:00,Oxygen,D01.268.185.550
22094601,2011-11-17T00:00:00,Oxygen,D01.362.670
22094601,2011-11-17T00:00:00,Phospholipids,D10.570.755
22094601,2011-11-17T00:00:00,Phospholipids,D10.695
22095309,2011-11-17T00:00:00,Checklist,N05.715.360.300.179
22095309,2011-11-17T00:00:00,Endoscopy,E01.370.388.250
22095309,2011-11-17T00:00:00,Endoscopy,E04.800.250
22095309,2011-11-17T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22095309,2011-11-17T00:00:00,Sinusitis,C08.460.692.752
22095309,2011-11-17T00:00:00,Sinusitis,C08.730.749
22095309,2011-11-17T00:00:00,Sinusitis,C09.603.692.752
22099552,2011-11-17T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22099552,2011-11-17T00:00:00,Neurosurgical Procedures,E04.525
22114670,2011-11-17T00:00:00,Carrier State,N06.850.160
22114670,2011-11-17T00:00:00,China,Z01.252.474.164
22114670,2011-11-17T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22114670,2011-11-17T00:00:00,Methicillin-Resistant Staphylococcus aureus,B03.300.390.400.800.750.100.500
22114670,2011-11-17T00:00:00,Methicillin-Resistant Staphylococcus aureus,B03.510.100.750.750.100.500
22114670,2011-11-17T00:00:00,Methicillin-Resistant Staphylococcus aureus,B03.510.400.790.750.100.500
22114670,2011-11-17T00:00:00,Microbial Sensitivity Tests,E05.200.875.595
22114670,2011-11-17T00:00:00,Microbial Sensitivity Tests,E05.337.550.400
22114670,2011-11-17T00:00:00,Polymerase Chain Reaction,E05.393.620.500
22114670,2011-11-17T00:00:00,Staphylococcal Infections,C01.252.410.868
22026721,2011-11-18T00:00:00,Gold,D01.268.556.322
22026721,2011-11-18T00:00:00,Gold,D01.268.956.186
22026721,2011-11-18T00:00:00,Gold,D01.552.544.322
22026721,2011-11-18T00:00:00,Metal Nanoparticles,J01.637.512.600.500
22026721,2011-11-18T00:00:00,"Microscopy, Electron, Transmission",E01.370.350.515.402.580
22026721,2011-11-18T00:00:00,"Microscopy, Electron, Transmission",E05.595.402.580
22026721,2011-11-18T00:00:00,Nanotechnology,H01.603
22026721,2011-11-18T00:00:00,Nanotechnology,J01.897.520.600
22026721,2011-11-18T00:00:00,Plant Extracts,D20.215.784.500
22026721,2011-11-18T00:00:00,Plant Extracts,D26.667
22026721,2011-11-18T00:00:00,Silver,D01.268.556.812
22026721,2011-11-18T00:00:00,Silver,D01.268.956.843
22026721,2011-11-18T00:00:00,Silver,D01.552.544.812
22026721,2011-11-18T00:00:00,"Spectroscopy, Fourier Transform Infrared",E05.196.712.726.676.700
22026721,2011-11-18T00:00:00,"Spectroscopy, Fourier Transform Infrared",E05.196.867.826.676.700
22026721,2011-11-18T00:00:00,Surface Plasmon Resonance,E05.196.890
22026721,2011-11-18T00:00:00,Surface Plasmon Resonance,E05.601.123.700
22115899,2011-11-18T00:00:00,Animals,B01.050
22115899,2011-11-18T00:00:00,Corpus Striatum,A08.186.211.730.885.287.249.487
22115899,2011-11-18T00:00:00,Dopamine Plasma Membrane Transport Proteins,D12.776.157.530.450.625.124
22115899,2011-11-18T00:00:00,Dopamine Plasma Membrane Transport Proteins,D12.776.157.530.562.374.500.500
22115899,2011-11-18T00:00:00,Dopamine Plasma Membrane Transport Proteins,D12.776.543.585.450.625.124
22115899,2011-11-18T00:00:00,Dopamine Plasma Membrane Transport Proteins,D12.776.543.585.562.374.500.500
22115899,2011-11-18T00:00:00,Dopamine Uptake Inhibitors,D27.505.519.625.150.800
22115899,2011-11-18T00:00:00,Dopamine Uptake Inhibitors,D27.505.519.625.600.220
22115899,2011-11-18T00:00:00,Dopamine Uptake Inhibitors,D27.505.696.577.150.800
22115899,2011-11-18T00:00:00,Dopamine Uptake Inhibitors,D27.505.696.577.600.220
22115899,2011-11-18T00:00:00,Hippocampus,A08.186.211.464.405
22115899,2011-11-18T00:00:00,Hippocampus,A08.186.211.730.885.287.500.345
22115899,2011-11-18T00:00:00,Methamphetamine,D02.092.471.683.152.619
22115899,2011-11-18T00:00:00,Norepinephrine Plasma Membrane Transport Proteins,D12.776.157.530.450.625.186
22115899,2011-11-18T00:00:00,Norepinephrine Plasma Membrane Transport Proteins,D12.776.157.530.562.374.500.750
22115899,2011-11-18T00:00:00,Norepinephrine Plasma Membrane Transport Proteins,D12.776.543.585.450.625.186
22115899,2011-11-18T00:00:00,Norepinephrine Plasma Membrane Transport Proteins,D12.776.543.585.562.374.500.750
22115899,2011-11-18T00:00:00,Prefrontal Cortex,A08.186.211.730.885.287.500.270.700
22115899,2011-11-18T00:00:00,Rats,B01.050.150.900.649.865.635.505.700
22115899,2011-11-18T00:00:00,Self Administration,E02.319.890
22115899,2011-11-18T00:00:00,Self Administration,E02.900.890
22115899,2011-11-18T00:00:00,Serotonin Plasma Membrane Transport Proteins,D12.776.157.530.450.625.311
22115899,2011-11-18T00:00:00,Serotonin Plasma Membrane Transport Proteins,D12.776.157.530.562.374.875
22115899,2011-11-18T00:00:00,Serotonin Plasma Membrane Transport Proteins,D12.776.543.585.450.625.374
22115899,2011-11-18T00:00:00,Serotonin Plasma Membrane Transport Proteins,D12.776.543.585.562.374.875
22119709,2011-11-18T00:00:00,Animals,B01.050
22119709,2011-11-18T00:00:00,Apoptosis,G04.299.139.160
22119709,2011-11-18T00:00:00,Body Weight,C23.888.144
22119709,2011-11-18T00:00:00,Body Weight,E01.370.600.115.100.160.120
22119709,2011-11-18T00:00:00,Body Weight,E05.041.124.160.750
22119709,2011-11-18T00:00:00,Body Weight,G07.100.100.160.120
22119709,2011-11-18T00:00:00,Body Weight,G07.700.320.249.314.120
22119709,2011-11-18T00:00:00,Cannabinoids,D02.455.849.090
22119709,2011-11-18T00:00:00,Chronic Disease,C23.550.291.500
22119709,2011-11-18T00:00:00,"Disease Models, Animal",C22.232
22119709,2011-11-18T00:00:00,"Disease Models, Animal",E05.598.500
22119709,2011-11-18T00:00:00,"Disease Models, Animal",E05.599.395.080
22119709,2011-11-18T00:00:00,Disease Progression,C23.550.291.656
22119709,2011-11-18T00:00:00,Interleukin-10,D12.644.276.374.465.510
22119709,2011-11-18T00:00:00,Interleukin-10,D12.776.467.374.465.510
22119709,2011-11-18T00:00:00,Interleukin-10,D23.529.374.465.510
22119709,2011-11-18T00:00:00,Neutrophils,A11.118.637.415.583
22119709,2011-11-18T00:00:00,Neutrophils,A11.627.340.583
22119709,2011-11-18T00:00:00,Neutrophils,A11.733.689
22119709,2011-11-18T00:00:00,Neutrophils,A15.145.229.637.415.583
22119709,2011-11-18T00:00:00,Neutrophils,A15.382.490.315.583
22119709,2011-11-18T00:00:00,Neutrophils,A15.382.680.689
22119709,2011-11-18T00:00:00,"Receptor, Cannabinoid, CB2",D12.776.543.750.100.125.200
22119709,2011-11-18T00:00:00,T-Lymphocytes,A11.118.637.555.567.569
22119709,2011-11-18T00:00:00,T-Lymphocytes,A15.145.229.637.555.567.569
22119709,2011-11-18T00:00:00,T-Lymphocytes,A15.382.490.555.567.569
22021047,2011-11-21T00:00:00,Adsorption,G02.149.047
22021047,2011-11-21T00:00:00,Adsorption,G02.149.767.029
22021047,2011-11-21T00:00:00,Adsorption,G02.842.750.029
22021047,2011-11-21T00:00:00,Charcoal,D01.268.150.150
22021047,2011-11-21T00:00:00,"Nanotubes, Carbon",D01.268.150.250.500
22021047,2011-11-21T00:00:00,"Nanotubes, Carbon",J01.637.512.850.500
22021047,2011-11-21T00:00:00,"Water Pollutants, Chemical",D27.888.284.903.655
22104190,2011-11-21T00:00:00,Adult,M01.060.116
22104190,2011-11-21T00:00:00,Brain Mapping,E01.370.350.086
22104190,2011-11-21T00:00:00,Brain Mapping,E01.370.376.149
22104190,2011-11-21T00:00:00,Brain Mapping,E05.132
22104190,2011-11-21T00:00:00,Computer Simulation,L01.224.160
22104190,2011-11-21T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22104190,2011-11-21T00:00:00,"Models, Biological",E05.599.395
22104190,2011-11-21T00:00:00,Motor Cortex,A08.186.211.730.885.287.500.270.548
22104190,2011-11-21T00:00:00,Pain Measurement,E01.370.376.550.600
22104190,2011-11-21T00:00:00,Pilot Projects,E05.318.760.750
22104190,2011-11-21T00:00:00,Pilot Projects,E05.337.737
22104190,2011-11-21T00:00:00,Pilot Projects,N05.715.360.775.625
22104190,2011-11-21T00:00:00,Pilot Projects,N06.850.520.450.720
22104190,2011-11-21T00:00:00,Transcranial Magnetic Stimulation,E01.370.376.850
22104190,2011-11-21T00:00:00,Transcranial Magnetic Stimulation,E02.621.820
22104190,2011-11-21T00:00:00,Young Adult,M01.060.116.815
22104471,2011-11-21T00:00:00,Adult,M01.060.116
22104471,2011-11-21T00:00:00,Aged,M01.060.116.100
22104471,2011-11-21T00:00:00,Brain Injuries,C10.228.140.199
22104471,2011-11-21T00:00:00,Brain Injuries,C10.900.300.087
22104471,2011-11-21T00:00:00,Brain Injuries,C21.866.260.118
22104471,2011-11-21T00:00:00,Brain Injuries,C21.866.915.300.200
22104471,2011-11-21T00:00:00,Hemodynamics,G09.330.190.400
22104471,2011-11-21T00:00:00,Hemodynamics,G09.330.380
22104471,2011-11-21T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22104471,2011-11-21T00:00:00,Intracranial Pressure,G11.561.170.505
22104471,2011-11-21T00:00:00,Middle Aged,M01.060.116.630
22104471,2011-11-21T00:00:00,"Monitoring, Physiologic",E01.370.520
22104471,2011-11-21T00:00:00,Oxygen,D01.268.185.550
22104471,2011-11-21T00:00:00,Oxygen,D01.362.670
22110124,2011-11-21T00:00:00,Case-Control Studies,E05.318.760.500.500
22110124,2011-11-21T00:00:00,Case-Control Studies,N05.715.360.775.175.200
22110124,2011-11-21T00:00:00,Case-Control Studies,N06.850.520.450.500.500
22110124,2011-11-21T00:00:00,Genetic Predisposition to Disease,C23.550.291.687.500
22110124,2011-11-21T00:00:00,Genetic Predisposition to Disease,G05.380.355
22110124,2011-11-21T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22110124,2011-11-21T00:00:00,"Lupus Erythematosus, Systemic",C17.300.480
22110124,2011-11-21T00:00:00,"Lupus Erythematosus, Systemic",C20.111.590
22110124,2011-11-21T00:00:00,"Polymorphism, Single Nucleotide",G05.365.795.598
22110124,2011-11-21T00:00:00,Quantitative Trait Loci,G05.360.340.024.380.937
22110124,2011-11-21T00:00:00,Risk Factors,E05.318.740.600.800.725
22110124,2011-11-21T00:00:00,Risk Factors,N05.715.350.200.700
22110124,2011-11-21T00:00:00,Risk Factors,N05.715.360.750.625.700.700
22110124,2011-11-21T00:00:00,Risk Factors,N06.850.490.625.750
22110124,2011-11-21T00:00:00,Risk Factors,N06.850.520.830.600.800.725
22110124,2011-11-21T00:00:00,Sex Factors,N05.715.350.675
22110124,2011-11-21T00:00:00,Sex Factors,N06.850.490.875
22108382,2011-11-22T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22108382,2011-11-22T00:00:00,Risk Factors,E05.318.740.600.800.725
22108382,2011-11-22T00:00:00,Risk Factors,N05.715.350.200.700
22108382,2011-11-22T00:00:00,Risk Factors,N05.715.360.750.625.700.700
22108382,2011-11-22T00:00:00,Risk Factors,N06.850.490.625.750
22108382,2011-11-22T00:00:00,Risk Factors,N06.850.520.830.600.800.725
22108895,2011-11-22T00:00:00,Adolescent,M01.060.057
22108895,2011-11-22T00:00:00,Crime Victims,M01.135
22108895,2011-11-22T00:00:00,Health Surveys,E05.318.308.250
22108895,2011-11-22T00:00:00,Health Surveys,N05.715.360.300.375
22108895,2011-11-22T00:00:00,Health Surveys,N06.850.520.308.250
22108895,2011-11-22T00:00:00,Homicide,I01.198.240.470
22108895,2011-11-22T00:00:00,Homicide,I01.880.735.344
22108895,2011-11-22T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22108895,2011-11-22T00:00:00,Interviews as Topic,E05.318.308.420
22108895,2011-11-22T00:00:00,Interviews as Topic,L01.280.520
22108895,2011-11-22T00:00:00,Interviews as Topic,N05.715.360.300.400
22108895,2011-11-22T00:00:00,Interviews as Topic,N06.850.520.308.420
22108895,2011-11-22T00:00:00,"Stress Disorders, Post-Traumatic",F03.080.931.500
22108895,2011-11-22T00:00:00,Survivors,M01.643.836
22108895,2011-11-22T00:00:00,Survivors,M01.860
22108895,2011-11-22T00:00:00,United States,Z01.107.567.875
22108895,2011-11-22T00:00:00,Young Adult,M01.060.116.815
22107797,2011-11-23T00:00:00,Adsorption,G02.149.047
22107797,2011-11-23T00:00:00,Adsorption,G02.149.767.029
22107797,2011-11-23T00:00:00,Adsorption,G02.842.750.029
22107797,2011-11-23T00:00:00,Anti-Bacterial Agents,D27.505.954.122.085
22107797,2011-11-23T00:00:00,Light,G01.201.875.770.578
22107797,2011-11-23T00:00:00,Light,G01.590.540
22107797,2011-11-23T00:00:00,Lysostaphin,D08.811.277.656.300.480.452
22107797,2011-11-23T00:00:00,Lysostaphin,D08.811.277.656.675.374.452
22107797,2011-11-23T00:00:00,Microbial Sensitivity Tests,E05.200.875.595
22107797,2011-11-23T00:00:00,Microbial Sensitivity Tests,E05.337.550.400
22107797,2011-11-23T00:00:00,Nanoparticles,J01.637.512.600
22107797,2011-11-23T00:00:00,Polyesters,D05.750.728
22107797,2011-11-23T00:00:00,Polyesters,D25.720.728
22107797,2011-11-23T00:00:00,Polyesters,J01.637.051.720.728
22107797,2011-11-23T00:00:00,"Scattering, Radiation",E05.196.822
22107797,2011-11-23T00:00:00,"Scattering, Radiation",G01.595.861
22107797,2011-11-23T00:00:00,Staphylococcus aureus,B03.300.390.400.800.750.100
22107797,2011-11-23T00:00:00,Staphylococcus aureus,B03.510.100.750.750.100
22107797,2011-11-23T00:00:00,Staphylococcus aureus,B03.510.400.790.750.100
22114007,2011-11-23T00:00:00,Equipment Failure Analysis,E05.325.192
22114007,2011-11-23T00:00:00,Magnetic Resonance Angiography,E01.370.350.500.500
22114007,2011-11-23T00:00:00,Magnetic Resonance Angiography,E01.370.350.825.500.500
22114007,2011-11-23T00:00:00,Magnetic Resonance Angiography,E01.370.370.050.500
22114007,2011-11-23T00:00:00,Rheology,E05.830
22114007,2011-11-23T00:00:00,Rheology,H01.671.808
22116009,2011-11-23T00:00:00,Attitude of Health Personnel,F01.100.050
22116009,2011-11-23T00:00:00,Attitude of Health Personnel,N05.300.100
22116009,2011-11-23T00:00:00,Counseling,F02.784.176
22116009,2011-11-23T00:00:00,Counseling,F04.408.413
22116009,2011-11-23T00:00:00,Counseling,N02.421.143.303
22116009,2011-11-23T00:00:00,Counseling,N02.421.461.363
22116009,2011-11-23T00:00:00,Data Collection,E05.318.308
22116009,2011-11-23T00:00:00,Data Collection,L01.280
22116009,2011-11-23T00:00:00,Data Collection,N05.715.360.300
22116009,2011-11-23T00:00:00,Data Collection,N06.850.520.308
22116009,2011-11-23T00:00:00,"Data Interpretation, Statistical",E05.245.380
22116009,2011-11-23T00:00:00,"Data Interpretation, Statistical",E05.318.740.300
22116009,2011-11-23T00:00:00,"Data Interpretation, Statistical",L01.700.508.190.380
22116009,2011-11-23T00:00:00,"Data Interpretation, Statistical",N05.715.360.750.300
22116009,2011-11-23T00:00:00,"Data Interpretation, Statistical",N06.850.520.830.300
22116009,2011-11-23T00:00:00,Health Personnel,M01.526.485
22116009,2011-11-23T00:00:00,Health Personnel,N02.360
22116009,2011-11-23T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22116009,2011-11-23T00:00:00,Motivation,F01.658
22116009,2011-11-23T00:00:00,Motivation,F01.752.543.500.750
22116009,2011-11-23T00:00:00,Questionnaires,E05.318.308.750
22116009,2011-11-23T00:00:00,Questionnaires,L01.280.800
22116009,2011-11-23T00:00:00,Questionnaires,N05.715.360.300.695
22116009,2011-11-23T00:00:00,Questionnaires,N06.850.520.308.750
22116009,2011-11-23T00:00:00,Substance Abuse Treatment Centers,N02.278.035.128.800
22116009,2011-11-23T00:00:00,Substance Abuse Treatment Centers,N02.278.808.930
22116009,2011-11-23T00:00:00,Substance-Related Disorders,C21.739
22116009,2011-11-23T00:00:00,Substance-Related Disorders,F03.900
22177020,2011-11-23T00:00:00,Adsorption,G02.149.047
22177020,2011-11-23T00:00:00,Adsorption,G02.149.767.029
22177020,2011-11-23T00:00:00,Adsorption,G02.842.750.029
22177020,2011-11-23T00:00:00,Filtration,E05.196.454
22177020,2011-11-23T00:00:00,Filtration,G01.595.280
22177020,2011-11-23T00:00:00,Filtration,G02.149.767.600
22177020,2011-11-23T00:00:00,Filtration,G02.842.750.600
22177020,2011-11-23T00:00:00,Gold,D01.268.556.322
22177020,2011-11-23T00:00:00,Gold,D01.268.956.186
22177020,2011-11-23T00:00:00,Gold,D01.552.544.322
22177020,2011-11-23T00:00:00,"Membranes, Artificial",D25.479
22177020,2011-11-23T00:00:00,"Membranes, Artificial",J01.637.051.479
22177020,2011-11-23T00:00:00,"Membranes, Artificial",J01.637.087.500
22177020,2011-11-23T00:00:00,Nanoparticles,J01.637.512.600
22177020,2011-11-23T00:00:00,Polymers,D05.750
22177020,2011-11-23T00:00:00,Polymers,D25.720
22177020,2011-11-23T00:00:00,Polymers,J01.637.051.720
22177020,2011-11-23T00:00:00,Silver,D01.268.556.812
22177020,2011-11-23T00:00:00,Silver,D01.268.956.843
22177020,2011-11-23T00:00:00,Silver,D01.552.544.812
22177020,2011-11-23T00:00:00,Titanium,D01.268.557.800
22177020,2011-11-23T00:00:00,Titanium,D01.268.956.878
22177020,2011-11-23T00:00:00,Titanium,D01.552.547.800
22284583,2011-11-23T00:00:00,Age Factors,N05.715.350.075
22284583,2011-11-23T00:00:00,Age Factors,N06.850.490.250
22284583,2011-11-23T00:00:00,Cocaine-Related Disorders,C21.739.300
22284583,2011-11-23T00:00:00,Cocaine-Related Disorders,F03.900.300
22284583,2011-11-23T00:00:00,Cues,F02.463.425.234
22284583,2011-11-23T00:00:00,Emotions,F01.470
22284583,2011-11-23T00:00:00,Employment,N01.824.245
22284583,2011-11-23T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22284583,2011-11-23T00:00:00,Marijuana Abuse,C21.739.635
22284583,2011-11-23T00:00:00,Marijuana Abuse,F03.900.635
22284583,2011-11-23T00:00:00,Motivation,F01.658
22284583,2011-11-23T00:00:00,Motivation,F01.752.543.500.750
22284583,2011-11-23T00:00:00,Opioid-Related Disorders,C21.739.675
22284583,2011-11-23T00:00:00,Opioid-Related Disorders,F03.900.675
22284583,2011-11-23T00:00:00,Prescription Drugs,D26.670
22284583,2011-11-23T00:00:00,Psychiatric Status Rating Scales,F04.586
22284583,2011-11-23T00:00:00,Sex Factors,N05.715.350.675
22284583,2011-11-23T00:00:00,Sex Factors,N06.850.490.875
22284583,2011-11-23T00:00:00,Smoking,F01.145.466.753
22284583,2011-11-23T00:00:00,"Stress, Psychological",F01.145.126.990
22284583,2011-11-23T00:00:00,"Stress, Psychological",F02.830.900
22111724,2011-11-24T00:00:00,"Anesthesia, General",E03.155.197
22111724,2011-11-24T00:00:00,"Anesthetics, Inhalation",D27.505.696.277.100.035.060
22111724,2011-11-24T00:00:00,"Anesthetics, Inhalation",D27.505.954.427.210.100.035.060
22111724,2011-11-24T00:00:00,Consciousness Monitors,E07.858.195
22111724,2011-11-24T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22111724,2011-11-24T00:00:00,"Monitoring, Intraoperative",E01.370.520.510
22111724,2011-11-24T00:00:00,"Monitoring, Intraoperative",E04.510
22111724,2011-11-24T00:00:00,Pulmonary Alveoli,A04.411.715
22119370,2011-11-25T00:00:00,Adult,M01.060.116
22119370,2011-11-25T00:00:00,Aged,M01.060.116.100
22119370,2011-11-25T00:00:00,Head and Neck Neoplasms,C04.588.443
22119370,2011-11-25T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22119370,2011-11-25T00:00:00,Middle Aged,M01.060.116.630
22119370,2011-11-25T00:00:00,Smoking,F01.145.466.753
22119758,2011-11-27T00:00:00,Aged,M01.060.116.100
22119758,2011-11-27T00:00:00,"Drug Resistance, Neoplasm",G07.690.320.395
22119758,2011-11-27T00:00:00,Gastrointestinal Stromal Tumors,C04.588.274.476.308
22119758,2011-11-27T00:00:00,Gastrointestinal Stromal Tumors,C06.301.371.308
22119758,2011-11-27T00:00:00,Gastrointestinal Stromal Tumors,C06.405.249.308
22119758,2011-11-27T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22119758,2011-11-27T00:00:00,Middle Aged,M01.060.116.630
22119758,2011-11-27T00:00:00,Mutation,G05.365.590
22119758,2011-11-27T00:00:00,Piperazines,D03.383.606
22119758,2011-11-27T00:00:00,Protein Kinase Inhibitors,D27.505.519.389.755
22119758,2011-11-27T00:00:00,Protein-Tyrosine Kinases,D08.811.913.696.620.682.725
22119758,2011-11-27T00:00:00,Pyrimidines,D03.383.742
22119758,2011-11-27T00:00:00,Pyrroles,D03.383.129.578
21852658,2011-11-28T00:00:00,Adult,M01.060.116
21852658,2011-11-28T00:00:00,African Americans,M01.686.508.100.100
21852658,2011-11-28T00:00:00,African Americans,M01.686.754.100
21852658,2011-11-28T00:00:00,Aged,M01.060.116.100
21852658,2011-11-28T00:00:00,Brain Injuries,C10.228.140.199
21852658,2011-11-28T00:00:00,Brain Injuries,C10.900.300.087
21852658,2011-11-28T00:00:00,Brain Injuries,C21.866.260.118
21852658,2011-11-28T00:00:00,Brain Injuries,C21.866.915.300.200
21852658,2011-11-28T00:00:00,European Continental Ancestry Group,M01.686.508.400
21852658,2011-11-28T00:00:00,Hispanic Americans,M01.686.754.441
21852658,2011-11-28T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21852658,2011-11-28T00:00:00,Middle Aged,M01.060.116.630
21852658,2011-11-28T00:00:00,Military Personnel,M01.526.625
21852658,2011-11-28T00:00:00,United States,Z01.107.567.875
21852658,2011-11-28T00:00:00,United States Department of Veterans Affairs,I01.409.137.500.700
21852658,2011-11-28T00:00:00,United States Department of Veterans Affairs,N03.540.348.500.500.700
21852658,2011-11-28T00:00:00,Veterans,M01.930
21852658,2011-11-28T00:00:00,Young Adult,M01.060.116.815
22095340,2011-11-28T00:00:00,Community Networks,I01.880.656.300
22095340,2011-11-28T00:00:00,Community Networks,L01.700.508.300.184
22095340,2011-11-28T00:00:00,Community Networks,N02.421.143.202
22095340,2011-11-28T00:00:00,Community-Based Participatory Research,N05.425.104
22095340,2011-11-28T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22095340,2011-11-28T00:00:00,Questionnaires,E05.318.308.750
22095340,2011-11-28T00:00:00,Questionnaires,L01.280.800
22095340,2011-11-28T00:00:00,Questionnaires,N05.715.360.300.695
22095340,2011-11-28T00:00:00,Questionnaires,N06.850.520.308.750
22095340,2011-11-28T00:00:00,Research Design,E05.581.500
22095340,2011-11-28T00:00:00,Research Design,H01.770.644.728
22095340,2011-11-28T00:00:00,United States,Z01.107.567.875
22123796,2011-11-28T00:00:00,Adult,M01.060.116
22123796,2011-11-28T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22123796,2011-11-28T00:00:00,Middle Aged,M01.060.116.630
22123796,2011-11-28T00:00:00,Motivation,F01.658
22123796,2011-11-28T00:00:00,Motivation,F01.752.543.500.750
22123796,2011-11-28T00:00:00,Nicotine,D03.132.760.570
22123796,2011-11-28T00:00:00,Nicotine,D03.383.725.518
22123796,2011-11-28T00:00:00,Nicotinic Agonists,D27.505.519.625.120.140.700
22123796,2011-11-28T00:00:00,Nicotinic Agonists,D27.505.696.577.120.140.700
22123796,2011-11-28T00:00:00,Smoking Cessation,F01.145.940.700
22162713,2011-11-28T00:00:00,Antigen Presentation,G12.425.107
22162713,2011-11-28T00:00:00,Antigen Presentation,G12.450.050.400.070
22162713,2011-11-28T00:00:00,Antineoplastic Agents,D27.505.954.248
22162713,2011-11-28T00:00:00,Bryostatins,D02.540.505.112
22162713,2011-11-28T00:00:00,Burkitt Lymphoma,C02.256.466.313.165
22162713,2011-11-28T00:00:00,Burkitt Lymphoma,C02.928.313.165
22162713,2011-11-28T00:00:00,Burkitt Lymphoma,C04.557.386.480.100
22162713,2011-11-28T00:00:00,Burkitt Lymphoma,C04.557.386.480.150.165
22162713,2011-11-28T00:00:00,Burkitt Lymphoma,C04.619.935.313.165
22162713,2011-11-28T00:00:00,Burkitt Lymphoma,C04.925.313.165
22162713,2011-11-28T00:00:00,Burkitt Lymphoma,C15.604.515.569.480.100
22162713,2011-11-28T00:00:00,Burkitt Lymphoma,C15.604.515.569.480.150.165
22162713,2011-11-28T00:00:00,Burkitt Lymphoma,C20.683.515.761.480.100
22162713,2011-11-28T00:00:00,Burkitt Lymphoma,C20.683.515.761.480.150.165
22162713,2011-11-28T00:00:00,CD4-Positive T-Lymphocytes,A11.118.637.555.567.569.200
22162713,2011-11-28T00:00:00,CD4-Positive T-Lymphocytes,A15.145.229.637.555.567.569.200
22162713,2011-11-28T00:00:00,CD4-Positive T-Lymphocytes,A15.382.490.555.567.569.200
22162713,2011-11-28T00:00:00,HLA-D Antigens,D23.050.301.500.410.400
22162713,2011-11-28T00:00:00,HLA-D Antigens,D23.050.301.500.450.400
22162713,2011-11-28T00:00:00,HLA-D Antigens,D23.050.705.552.410.400
22162713,2011-11-28T00:00:00,HLA-D Antigens,D23.050.705.552.450.400
22162713,2011-11-28T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22162713,2011-11-28T00:00:00,Interleukin-2,D12.644.276.374.465.502
22162713,2011-11-28T00:00:00,Interleukin-2,D12.644.276.374.480.372
22162713,2011-11-28T00:00:00,Interleukin-2,D12.776.467.374.465.502
22162713,2011-11-28T00:00:00,Interleukin-2,D12.776.467.374.480.372
22162713,2011-11-28T00:00:00,Interleukin-2,D23.529.374.465.502
22162713,2011-11-28T00:00:00,Interleukin-2,D23.529.374.480.372
22162713,2011-11-28T00:00:00,Lymphocyte Activation,E01.450.495.482
22162713,2011-11-28T00:00:00,Lymphocyte Activation,E05.478.594.530
22162713,2011-11-28T00:00:00,Lymphocyte Activation,G12.425.747
22162713,2011-11-28T00:00:00,Lymphocyte Activation,G12.450.050.400.545
22162713,2011-11-28T00:00:00,Signal Transduction,G02.111.087.800
22162713,2011-11-28T00:00:00,Signal Transduction,G02.149.115.800
22162713,2011-11-28T00:00:00,Signal Transduction,G04.299.880
22050596,2011-11-29T00:00:00,Disinfectants,D27.505.954.122.425
22050596,2011-11-29T00:00:00,Disinfectants,D27.720.274
22050596,2011-11-29T00:00:00,Iodine,D01.268.380.400
22050596,2011-11-29T00:00:00,"Water Pollutants, Chemical",D27.888.284.903.655
22050596,2011-11-29T00:00:00,Water Purification,N06.850.780.200.800.800.900.900
22050596,2011-11-29T00:00:00,Water Purification,N06.850.860.510.900.900
22050596,2011-11-29T00:00:00,Water Purification,N06.850.860.510.915.900
22127816,2011-11-29T00:00:00,Anesthesia,E03.155
22127816,2011-11-29T00:00:00,Catheterization,E02.148
22127816,2011-11-29T00:00:00,Catheterization,E05.157
22127816,2011-11-29T00:00:00,Clinical Competence,I02.399.630.210
22127816,2011-11-29T00:00:00,Clinical Competence,N04.761.210
22127816,2011-11-29T00:00:00,"Education, Medical, Graduate",I02.358.337.350
22127816,2011-11-29T00:00:00,"Education, Medical, Graduate",I02.358.399.350
22127816,2011-11-29T00:00:00,Evidence-Based Medicine,H02.249.750
22127816,2011-11-29T00:00:00,Evidence-Based Medicine,H02.403.200.400
22127816,2011-11-29T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22127816,2011-11-29T00:00:00,"Ultrasonography, Interventional",E01.370.350.850.855
22127816,2011-11-29T00:00:00,United States,Z01.107.567.875
22155295,2011-11-29T00:00:00,"Drug Resistance, Neoplasm",G07.690.320.395
22155295,2011-11-29T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22155295,2011-11-29T00:00:00,Neoplasms,C04
22127408,2011-11-30T00:00:00,Aged,M01.060.116.100
22127408,2011-11-30T00:00:00,Anti-Bacterial Agents,D27.505.954.122.085
22127408,2011-11-30T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22127408,2011-11-30T00:00:00,"Kidney Failure, Chronic",C12.777.419.780.500.602
22127408,2011-11-30T00:00:00,"Kidney Failure, Chronic",C12.777.419.780.750.500
22127408,2011-11-30T00:00:00,"Kidney Failure, Chronic",C13.351.968.419.780.500.602
22127408,2011-11-30T00:00:00,"Kidney Failure, Chronic",C13.351.968.419.780.750.500
22127408,2011-11-30T00:00:00,Mycobacterium,B03.510.024.049.525.500
22127408,2011-11-30T00:00:00,Mycobacterium,B03.510.460.400.410.552.552
22127408,2011-11-30T00:00:00,Mycobacterium Infections,C01.252.410.040.552
22127408,2011-11-30T00:00:00,Peritoneal Dialysis,E02.870.300.650
22127408,2011-11-30T00:00:00,Peritoneal Dialysis,E02.912.800.650
22127408,2011-11-30T00:00:00,Peritonitis,C06.844.640
22130801,2011-11-30T00:00:00,Adult,M01.060.116
22130801,2011-11-30T00:00:00,Altitude,G16.500.275.058
22130801,2011-11-30T00:00:00,Altitude,N06.230.058
22130801,2011-11-30T00:00:00,Anoxia,C23.888.852.079
22130801,2011-11-30T00:00:00,Antimicrobial Cationic Peptides,D12.644.050
22130801,2011-11-30T00:00:00,Antimicrobial Cationic Peptides,D12.776.543.695.054
22130801,2011-11-30T00:00:00,Case-Control Studies,E05.318.760.500.500
22130801,2011-11-30T00:00:00,Case-Control Studies,N05.715.360.775.175.200
22130801,2011-11-30T00:00:00,Case-Control Studies,N06.850.520.450.500.500
22130801,2011-11-30T00:00:00,Ferritins,D12.776.157.427.249
22130801,2011-11-30T00:00:00,Ferritins,D12.776.556.579.249
22130801,2011-11-30T00:00:00,Gene Expression Regulation,G05.355.315
22130801,2011-11-30T00:00:00,Homeostasis,G07.700.360
22130801,2011-11-30T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22130801,2011-11-30T00:00:00,Iron,D01.268.556.412
22130801,2011-11-30T00:00:00,Iron,D01.268.956.287
22130801,2011-11-30T00:00:00,Iron,D01.552.544.412
22130801,2011-11-30T00:00:00,Iron Metabolism Disorders,C18.452.565
22130801,2011-11-30T00:00:00,Transferrin,D12.776.124.050.800
22130801,2011-11-30T00:00:00,Transferrin,D12.776.124.790.223.839
22130801,2011-11-30T00:00:00,Transferrin,D12.776.157.427.500
22130801,2011-11-30T00:00:00,Transferrin,D12.776.377.715.182.839
22130801,2011-11-30T00:00:00,Transferrin,D12.776.556.579.500
21344387,2011-12-01T00:00:00,"Antigens, CD",D23.050.301.264.035
21344387,2011-12-01T00:00:00,"Antigens, CD",D23.101.100.110
21344387,2011-12-01T00:00:00,Collagen,D05.750.078.280
21344387,2011-12-01T00:00:00,Collagen,D12.776.860.300.250
21344387,2011-12-01T00:00:00,Connective Tissue Growth Factor,D12.644.276.200.100
21344387,2011-12-01T00:00:00,Connective Tissue Growth Factor,D12.776.467.200.100
21344387,2011-12-01T00:00:00,Connective Tissue Growth Factor,D12.776.860.300.200.100
21344387,2011-12-01T00:00:00,Connective Tissue Growth Factor,D23.529.237.100
21344387,2011-12-01T00:00:00,Endothelin-1,D12.644.276.400.225
21344387,2011-12-01T00:00:00,Endothelin-1,D12.776.467.400.225
21344387,2011-12-01T00:00:00,Endothelin-1,D23.529.400.225
21344387,2011-12-01T00:00:00,Fibroblasts,A11.329.228
21344387,2011-12-01T00:00:00,Fibroblasts,A11.872.228
21344387,2011-12-01T00:00:00,Fibrosis,C23.550.355
21344387,2011-12-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21344387,2011-12-01T00:00:00,Mutation,G05.365.590
21344387,2011-12-01T00:00:00,Phenotype,G05.695
21344387,2011-12-01T00:00:00,Phosphorylation,G02.111.087.677
21344387,2011-12-01T00:00:00,Phosphorylation,G02.149.115.677
21344387,2011-12-01T00:00:00,Phosphorylation,G02.149.465.700
21344387,2011-12-01T00:00:00,Phosphorylation,G02.607.750.700
21344387,2011-12-01T00:00:00,Phosphorylation,G03.495.790
21344387,2011-12-01T00:00:00,RNA Interference,G05.355.315.203.374.790
21344387,2011-12-01T00:00:00,"RNA, Messenger",D13.444.735.544
21344387,2011-12-01T00:00:00,"Scleroderma, Diffuse",C17.300.799.602
21344387,2011-12-01T00:00:00,"Scleroderma, Diffuse",C17.800.784.602
21344387,2011-12-01T00:00:00,Signal Transduction,G02.111.087.800
21344387,2011-12-01T00:00:00,Signal Transduction,G02.149.115.800
21344387,2011-12-01T00:00:00,Signal Transduction,G04.299.880
21344387,2011-12-01T00:00:00,Skin,A17.815
21344387,2011-12-01T00:00:00,Transforming Growth Factor beta,D12.644.276.374.687
21344387,2011-12-01T00:00:00,Transforming Growth Factor beta,D12.644.276.954.800.720
21344387,2011-12-01T00:00:00,Transforming Growth Factor beta,D12.644.276.963.720
21344387,2011-12-01T00:00:00,Transforming Growth Factor beta,D12.776.467.374.687
21344387,2011-12-01T00:00:00,Transforming Growth Factor beta,D12.776.467.942.800.720
21344387,2011-12-01T00:00:00,Transforming Growth Factor beta,D12.776.467.960.720
21344387,2011-12-01T00:00:00,Transforming Growth Factor beta,D23.529.374.687
21344387,2011-12-01T00:00:00,Transforming Growth Factor beta,D23.529.942.800.720
21344387,2011-12-01T00:00:00,Transforming Growth Factor beta,D23.529.960.720
21573860,2011-12-01T00:00:00,Aged,M01.060.116.100
21573860,2011-12-01T00:00:00,Antihypertensive Agents,D27.505.954.411.162
21573860,2011-12-01T00:00:00,Blood Glucose,D09.546.359.448.500
21573860,2011-12-01T00:00:00,Cerebral Hemorrhage,C10.228.140.300.535.200
21573860,2011-12-01T00:00:00,Cerebral Hemorrhage,C14.907.253.573.200
21573860,2011-12-01T00:00:00,Cerebral Hemorrhage,C23.550.414.913.100
21573860,2011-12-01T00:00:00,Disease Progression,C23.550.291.656
21573860,2011-12-01T00:00:00,Hematoma,C23.550.414.838
21573860,2011-12-01T00:00:00,Hospitalization,E02.760.400
21573860,2011-12-01T00:00:00,Hospitalization,N02.421.585.400
21573860,2011-12-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21573860,2011-12-01T00:00:00,Hyperglycemia,C18.452.394.952
21573860,2011-12-01T00:00:00,Hypertension,C14.907.489
21573860,2011-12-01T00:00:00,Hypoglycemic Agents,D27.505.696.422
21573860,2011-12-01T00:00:00,"Infusions, Intravenous",E02.319.267.510.590
21573860,2011-12-01T00:00:00,Insulin,D06.472.699.587.740.625
21573860,2011-12-01T00:00:00,Insulin,D12.644.548.586.740.625
21573860,2011-12-01T00:00:00,Middle Aged,M01.060.116.630
21573860,2011-12-01T00:00:00,Pilot Projects,E05.318.760.750
21573860,2011-12-01T00:00:00,Pilot Projects,E05.337.737
21573860,2011-12-01T00:00:00,Pilot Projects,N05.715.360.775.625
21573860,2011-12-01T00:00:00,Pilot Projects,N06.850.520.450.720
21573860,2011-12-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.350.810
21573860,2011-12-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.600.350.700.810
21573860,2011-12-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.700.700.810
21573860,2011-12-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.700.810.810
21573860,2011-12-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.825.810.810
21626077,2011-12-01T00:00:00,Adult,M01.060.116
21626077,2011-12-01T00:00:00,Aged,M01.060.116.100
21626077,2011-12-01T00:00:00,Antihypertensive Agents,D27.505.954.411.162
21626077,2011-12-01T00:00:00,Blood Pressure,E01.370.600.875.249
21626077,2011-12-01T00:00:00,Blood Pressure,G09.330.380.076
21626077,2011-12-01T00:00:00,Cerebral Hemorrhage,C10.228.140.300.535.200
21626077,2011-12-01T00:00:00,Cerebral Hemorrhage,C14.907.253.573.200
21626077,2011-12-01T00:00:00,Cerebral Hemorrhage,C23.550.414.913.100
21626077,2011-12-01T00:00:00,Disability Evaluation,E01.370.400
21626077,2011-12-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21626077,2011-12-01T00:00:00,"Infusions, Intravenous",E02.319.267.510.590
21626077,2011-12-01T00:00:00,Middle Aged,M01.060.116.630
21626077,2011-12-01T00:00:00,Quality of Life,I01.800
21626077,2011-12-01T00:00:00,Quality of Life,K01.752.400.750
21626077,2011-12-01T00:00:00,Treatment Outcome,E01.789.800
21626077,2011-12-01T00:00:00,Treatment Outcome,N04.761.559.590.800
21626077,2011-12-01T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21626077,2011-12-01T00:00:00,United States,Z01.107.567.875
21626077,2011-12-01T00:00:00,Young Adult,M01.060.116.815
21850690,2011-12-01T00:00:00,Adrenal Cortex Hormones,D06.472.040
21850690,2011-12-01T00:00:00,Antiviral Agents,D27.505.954.122.388
21850690,2011-12-01T00:00:00,Graft Rejection,G12.425.901.545.328
21850690,2011-12-01T00:00:00,Hepacivirus,B04.450.410
21850690,2011-12-01T00:00:00,Hepacivirus,B04.820.250.475
21850690,2011-12-01T00:00:00,Hepacivirus,B04.909.777.310.475
21850690,2011-12-01T00:00:00,"Hepatitis C, Chronic",C02.440.440.120
21850690,2011-12-01T00:00:00,"Hepatitis C, Chronic",C02.782.350.350.120
21850690,2011-12-01T00:00:00,"Hepatitis C, Chronic",C06.552.380.350.120
21850690,2011-12-01T00:00:00,"Hepatitis C, Chronic",C06.552.380.705.440.120
21850690,2011-12-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21850690,2011-12-01T00:00:00,Immunoglobulin G,D12.776.124.486.485.114.619.393
21850690,2011-12-01T00:00:00,Immunoglobulin G,D12.776.124.790.651.114.619.393
21850690,2011-12-01T00:00:00,Immunoglobulin G,D12.776.377.715.548.114.619.393
21850690,2011-12-01T00:00:00,Immunosuppressive Agents,D27.505.696.477.656
21850690,2011-12-01T00:00:00,Liver Transplantation,E04.210.650
21850690,2011-12-01T00:00:00,Liver Transplantation,E04.936.450.490
21850690,2011-12-01T00:00:00,Liver Transplantation,E04.936.580.490
21850690,2011-12-01T00:00:00,Middle Aged,M01.060.116.630
21850690,2011-12-01T00:00:00,"RNA, Viral",D13.444.735.828
21850690,2011-12-01T00:00:00,Risk Assessment,E05.318.740.600.800.715
21850690,2011-12-01T00:00:00,Risk Assessment,N04.452.871.715
21850690,2011-12-01T00:00:00,Risk Assessment,N05.715.360.750.625.700.690
21850690,2011-12-01T00:00:00,Risk Assessment,N06.850.505.715
21850690,2011-12-01T00:00:00,Risk Assessment,N06.850.520.830.600.800.715
21850690,2011-12-01T00:00:00,Risk Factors,E05.318.740.600.800.725
21850690,2011-12-01T00:00:00,Risk Factors,N05.715.350.200.700
21850690,2011-12-01T00:00:00,Risk Factors,N05.715.360.750.625.700.700
21850690,2011-12-01T00:00:00,Risk Factors,N06.850.490.625.750
21850690,2011-12-01T00:00:00,Risk Factors,N06.850.520.830.600.800.725
21850690,2011-12-01T00:00:00,Time Factors,G01.910.857
21850690,2011-12-01T00:00:00,Treatment Outcome,E01.789.800
21850690,2011-12-01T00:00:00,Treatment Outcome,N04.761.559.590.800
21850690,2011-12-01T00:00:00,Treatment Outcome,N05.715.360.575.575.800
21850690,2011-12-01T00:00:00,United States,Z01.107.567.875
21857221,2011-12-01T00:00:00,Dietary Supplements,J02.500.456
21857221,2011-12-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21857221,2011-12-01T00:00:00,Pregnancy,G08.686.785.760.769
21857221,2011-12-01T00:00:00,Pregnancy Complications,C13.703
21857221,2011-12-01T00:00:00,Vitamin D,D04.808.812.768
21857221,2011-12-01T00:00:00,Vitamin D Deficiency,C18.654.521.500.133.770
21864273,2011-12-01T00:00:00,Animals,B01.050
21864273,2011-12-01T00:00:00,Fibroblasts,A11.329.228
21864273,2011-12-01T00:00:00,Fibroblasts,A11.872.228
21864273,2011-12-01T00:00:00,Neural Pathways,A08.612
21864273,2011-12-01T00:00:00,Phosphotransferases (Alcohol Group Acceptor),D08.811.913.696.620
21864273,2011-12-01T00:00:00,Signal Transduction,G02.111.087.800
21864273,2011-12-01T00:00:00,Signal Transduction,G02.149.115.800
21864273,2011-12-01T00:00:00,Signal Transduction,G04.299.880
21864273,2011-12-01T00:00:00,Tumor Necrosis Factor-alpha,D12.644.276.374.500.800
21864273,2011-12-01T00:00:00,Tumor Necrosis Factor-alpha,D12.644.276.374.750.626
21864273,2011-12-01T00:00:00,Tumor Necrosis Factor-alpha,D12.644.276.972.626
21864273,2011-12-01T00:00:00,Tumor Necrosis Factor-alpha,D12.776.124.900
21864273,2011-12-01T00:00:00,Tumor Necrosis Factor-alpha,D12.776.395.930
21864273,2011-12-01T00:00:00,Tumor Necrosis Factor-alpha,D12.776.467.374.500.800
21864273,2011-12-01T00:00:00,Tumor Necrosis Factor-alpha,D12.776.467.374.750.626
21864273,2011-12-01T00:00:00,Tumor Necrosis Factor-alpha,D12.776.467.972.626
21864273,2011-12-01T00:00:00,Tumor Necrosis Factor-alpha,D23.529.374.500.800
21864273,2011-12-01T00:00:00,Tumor Necrosis Factor-alpha,D23.529.374.750.626
21864273,2011-12-01T00:00:00,Tumor Necrosis Factor-alpha,D23.529.972.626
21941210,2011-12-01T00:00:00,Hospital Mortality,E05.318.308.985.550.400
21941210,2011-12-01T00:00:00,Hospital Mortality,L01.280.975.550.400
21941210,2011-12-01T00:00:00,Hospital Mortality,N01.224.935.698.400
21941210,2011-12-01T00:00:00,Hospital Mortality,N06.850.505.400.975.550.400
21941210,2011-12-01T00:00:00,Hospital Mortality,N06.850.520.308.985.550.400
21941210,2011-12-01T00:00:00,Hospitalization,E02.760.400
21941210,2011-12-01T00:00:00,Hospitalization,N02.421.585.400
21941210,2011-12-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21941210,2011-12-01T00:00:00,"Kidney Failure, Chronic",C12.777.419.780.500.602
21941210,2011-12-01T00:00:00,"Kidney Failure, Chronic",C12.777.419.780.750.500
21941210,2011-12-01T00:00:00,"Kidney Failure, Chronic",C13.351.968.419.780.500.602
21941210,2011-12-01T00:00:00,"Kidney Failure, Chronic",C13.351.968.419.780.750.500
21941210,2011-12-01T00:00:00,Liver Cirrhosis,C06.552.630
21941210,2011-12-01T00:00:00,Middle Aged,M01.060.116.630
22015805,2011-12-01T00:00:00,Animals,B01.050
22015805,2011-12-01T00:00:00,Attention Deficit Disorder with Hyperactivity,F03.550.150.150
22015805,2011-12-01T00:00:00,"Behavior, Animal",F01.145.113
22015805,2011-12-01T00:00:00,Central Nervous System Stimulants,D27.505.696.282
22015805,2011-12-01T00:00:00,Central Nervous System Stimulants,D27.505.954.427.220
22015805,2011-12-01T00:00:00,"Disease Models, Animal",C22.232
22015805,2011-12-01T00:00:00,"Disease Models, Animal",E05.598.500
22015805,2011-12-01T00:00:00,"Disease Models, Animal",E05.599.395.080
22015805,2011-12-01T00:00:00,Methylphenidate,D02.241.223.601.600
22015805,2011-12-01T00:00:00,Methylphenidate,D03.383.621.460
22015805,2011-12-01T00:00:00,Rats,B01.050.150.900.649.865.635.505.700
22015805,2011-12-01T00:00:00,"Rats, Inbred WKY",B01.050.050.157.760.390
22015805,2011-12-01T00:00:00,"Rats, Inbred WKY",B01.050.050.199.520.760.390
22015805,2011-12-01T00:00:00,"Rats, Inbred WKY",B01.050.150.900.649.865.635.505.700.400.390
22015805,2011-12-01T00:00:00,"Rats, Sprague-Dawley",B01.050.150.900.649.865.635.505.700.750
22015805,2011-12-01T00:00:00,Self Administration,E02.319.890
22015805,2011-12-01T00:00:00,Self Administration,E02.900.890
22059994,2011-12-01T00:00:00,"Antibodies, Monoclonal",D12.776.124.486.485.114.224
22059994,2011-12-01T00:00:00,"Antibodies, Monoclonal",D12.776.124.790.651.114.224
22059994,2011-12-01T00:00:00,"Antibodies, Monoclonal",D12.776.377.715.548.114.224
22059994,2011-12-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22059994,2011-12-01T00:00:00,Immunoglobulin Allotypes,D12.776.124.486.485.114.606
22059994,2011-12-01T00:00:00,Immunoglobulin Allotypes,D12.776.124.790.651.114.606
22059994,2011-12-01T00:00:00,Immunoglobulin Allotypes,D12.776.377.715.548.114.606
22059994,2011-12-01T00:00:00,Immunoglobulin Allotypes,G12.500.400
22059994,2011-12-01T00:00:00,Immunoglobulin G,D12.776.124.486.485.114.619.393
22059994,2011-12-01T00:00:00,Immunoglobulin G,D12.776.124.790.651.114.619.393
22059994,2011-12-01T00:00:00,Immunoglobulin G,D12.776.377.715.548.114.619.393
22059994,2011-12-01T00:00:00,Immunoglobulin Gm Allotypes,D12.776.124.486.485.114.606.586
22059994,2011-12-01T00:00:00,Immunoglobulin Gm Allotypes,D12.776.124.486.485.114.619.393.522.400
22059994,2011-12-01T00:00:00,Immunoglobulin Gm Allotypes,D12.776.124.486.485.705.500.380.500
22059994,2011-12-01T00:00:00,Immunoglobulin Gm Allotypes,D12.776.124.790.651.114.606.586
22059994,2011-12-01T00:00:00,Immunoglobulin Gm Allotypes,D12.776.124.790.651.114.619.393.522.400
22059994,2011-12-01T00:00:00,Immunoglobulin Gm Allotypes,D12.776.124.790.651.705.500.380.500
22059994,2011-12-01T00:00:00,Immunoglobulin Gm Allotypes,D12.776.377.715.548.114.606.586
22059994,2011-12-01T00:00:00,Immunoglobulin Gm Allotypes,D12.776.377.715.548.114.619.393.522.400
22059994,2011-12-01T00:00:00,Immunoglobulin Gm Allotypes,D12.776.377.715.548.705.500.380.500
22059994,2011-12-01T00:00:00,Immunoglobulin Gm Allotypes,G12.500.400.586
22059994,2011-12-01T00:00:00,Neoplasms,C04
22059994,2011-12-01T00:00:00,"Receptors, IgG",D12.776.543.750.705.871.300
22059994,2011-12-01T00:00:00,"Receptors, IgG",D23.050.301.264.035.695
22059994,2011-12-01T00:00:00,"Receptors, IgG",D23.101.100.110.695
22064089,2011-12-01T00:00:00,Breast Implants,E07.695.140
22064089,2011-12-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22064089,2011-12-01T00:00:00,Middle Aged,M01.060.116.630
22064089,2011-12-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.350.810
22064089,2011-12-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.600.350.700.810
22064089,2011-12-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.700.700.810
22064089,2011-12-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.700.810.810
22064089,2011-12-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.825.810.810
22064089,2011-12-01T00:00:00,Ventriculoperitoneal Shunt,E04.035.188.850
22064089,2011-12-01T00:00:00,Ventriculoperitoneal Shunt,E04.525.170.850
22064118,2011-12-01T00:00:00,Child,M01.060.406
22064118,2011-12-01T00:00:00,"Diagnosis, Differential",E01.171
22064118,2011-12-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22064118,2011-12-01T00:00:00,Kidney,A05.810.453
22064118,2011-12-01T00:00:00,Meckel Diverticulum,A03.556.124.684.249.612
22064118,2011-12-01T00:00:00,Meckel Diverticulum,A03.556.249.124.612
22064118,2011-12-01T00:00:00,Meckel Diverticulum,C06.198.859
22064118,2011-12-01T00:00:00,Meckel Diverticulum,C16.131.314.556
22064118,2011-12-01T00:00:00,Meckel Diverticulum,C23.300.415.750
22064118,2011-12-01T00:00:00,"Radiography, Abdominal",E01.370.350.700.715
22064118,2011-12-01T00:00:00,Sodium Pertechnetate Tc 99m,D01.925.800
22080004,2011-12-01T00:00:00,Animals,B01.050
22080004,2011-12-01T00:00:00,Carbohydrates,D09
22080004,2011-12-01T00:00:00,Chick Embryo,A13.350.150
22080004,2011-12-01T00:00:00,Chick Embryo,A16.331.200
22080004,2011-12-01T00:00:00,Chickens,B01.050.150.900.248.350.150
22080004,2011-12-01T00:00:00,Chickens,B01.050.150.900.248.617.192
22080004,2011-12-01T00:00:00,Liver,A03.620
22115203,2011-12-01T00:00:00,Heart Failure,C14.280.434
22115203,2011-12-01T00:00:00,Heart Transplantation,E04.100.376.475
22115203,2011-12-01T00:00:00,Heart Transplantation,E04.928.220.390
22115203,2011-12-01T00:00:00,Heart Transplantation,E04.936.450.475
22115203,2011-12-01T00:00:00,Heart-Assist Devices,E04.050.430
22115203,2011-12-01T00:00:00,Heart-Assist Devices,E07.695.300.300
22115203,2011-12-01T00:00:00,Heart-Assist Devices,E07.858.082.374.300
22115203,2011-12-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22115203,2011-12-01T00:00:00,Practice Guidelines as Topic,N04.761.700.350.650
22115203,2011-12-01T00:00:00,Practice Guidelines as Topic,N05.700.350.650
22115322,2011-12-01T00:00:00,Catheterization,E02.148
22115322,2011-12-01T00:00:00,Catheterization,E05.157
22115322,2011-12-01T00:00:00,Echocardiography,E01.370.350.850.220
22115322,2011-12-01T00:00:00,Echocardiography,E01.370.370.380.220
22115322,2011-12-01T00:00:00,Practice Guidelines as Topic,N04.761.700.350.650
22115322,2011-12-01T00:00:00,Practice Guidelines as Topic,N05.700.350.650
22115322,2011-12-01T00:00:00,"Ultrasonography, Interventional",E01.370.350.850.855
22115322,2011-12-01T00:00:00,United States,Z01.107.567.875
22122149,2011-12-01T00:00:00,Alcoholism,C21.739.100.250
22122149,2011-12-01T00:00:00,Alcoholism,F03.900.100.350
22122149,2011-12-01T00:00:00,Animals,B01.050
22122149,2011-12-01T00:00:00,Ethanol,D02.033.375
22122149,2011-12-01T00:00:00,Frontal Lobe,A08.186.211.730.885.287.500.270
22122149,2011-12-01T00:00:00,Prefrontal Cortex,A08.186.211.730.885.287.500.270.700
22122149,2011-12-01T00:00:00,Psychomotor Performance,F02.808
22122149,2011-12-01T00:00:00,Psychomotor Performance,G11.427.700
22122149,2011-12-01T00:00:00,Psychomotor Performance,G11.561.623
22125586,2011-12-01T00:00:00,African Americans,M01.686.508.100.100
22125586,2011-12-01T00:00:00,African Americans,M01.686.754.100
22125586,2011-12-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22125586,2011-12-01T00:00:00,Incidence,E05.318.308.985.525.375
22125586,2011-12-01T00:00:00,Incidence,L01.280.975.525.375
22125586,2011-12-01T00:00:00,Incidence,N01.224.935.597.500
22125586,2011-12-01T00:00:00,Incidence,N06.850.505.400.975.525.375
22125586,2011-12-01T00:00:00,Incidence,N06.850.520.308.985.525.375
22125586,2011-12-01T00:00:00,"Infant, Low Birth Weight",M01.060.703.520.460
22125586,2011-12-01T00:00:00,"Infant, Newborn",M01.060.703.520
22125586,2011-12-01T00:00:00,"Infant, Premature",M01.060.703.520.520
22125586,2011-12-01T00:00:00,Poisson Distribution,E05.318.740.994.750
22125586,2011-12-01T00:00:00,Poisson Distribution,G17.820.750
22125586,2011-12-01T00:00:00,Poisson Distribution,N05.715.360.750.750.620
22125586,2011-12-01T00:00:00,Poisson Distribution,N06.850.520.830.994.750
22125586,2011-12-01T00:00:00,Pregnancy,G08.686.785.760.769
22125586,2011-12-01T00:00:00,Premature Birth,C13.703.420.491.500
22125586,2011-12-01T00:00:00,Risk Factors,E05.318.740.600.800.725
22125586,2011-12-01T00:00:00,Risk Factors,N05.715.350.200.700
22125586,2011-12-01T00:00:00,Risk Factors,N05.715.360.750.625.700.700
22125586,2011-12-01T00:00:00,Risk Factors,N06.850.490.625.750
22125586,2011-12-01T00:00:00,Risk Factors,N06.850.520.830.600.800.725
22125586,2011-12-01T00:00:00,South Carolina,Z01.107.567.875.075.662
22125586,2011-12-01T00:00:00,South Carolina,Z01.107.567.875.750.700
22126695,2011-12-01T00:00:00,Animals,B01.050
22126695,2011-12-01T00:00:00,Bone Screws,E07.695.130
22126695,2011-12-01T00:00:00,Bone Screws,E07.858.442.660.115
22126695,2011-12-01T00:00:00,Bone Screws,E07.858.690.650.115
22126695,2011-12-01T00:00:00,Bone Substitutes,D25.130.325
22126695,2011-12-01T00:00:00,Bone Substitutes,J01.637.051.130.325
22126695,2011-12-01T00:00:00,Bone and Bones,A02.835.232
22126695,2011-12-01T00:00:00,Bone and Bones,A10.165.265
22126695,2011-12-01T00:00:00,Dogs,B01.050.150.900.649.147.153.200
22126695,2011-12-01T00:00:00,Equipment Failure Analysis,E05.325.192
22126695,2011-12-01T00:00:00,Fracture Fixation,E04.555.300
22126695,2011-12-01T00:00:00,Materials Testing,E05.570
22126695,2011-12-01T00:00:00,"Stress, Mechanical",G01.374.676.830
22126695,2011-12-01T00:00:00,"Stress, Mechanical",G01.595.540.830
22136773,2011-12-01T00:00:00,Aged,M01.060.116.100
22136773,2011-12-01T00:00:00,Anoxia,C23.888.852.079
22136773,2011-12-01T00:00:00,Body Mass Index,E01.370.600.115.100.125
22136773,2011-12-01T00:00:00,Body Mass Index,E05.041.124.125
22136773,2011-12-01T00:00:00,Body Mass Index,G07.100.100.125
22136773,2011-12-01T00:00:00,Body Mass Index,N06.850.505.200.100.175
22136773,2011-12-01T00:00:00,Conscious Sedation,E03.250
22136773,2011-12-01T00:00:00,"Endoscopy, Gastrointestinal",E01.370.372.250.250
22136773,2011-12-01T00:00:00,"Endoscopy, Gastrointestinal",E01.370.388.250.250.250
22136773,2011-12-01T00:00:00,"Endoscopy, Gastrointestinal",E04.210.240.250
22136773,2011-12-01T00:00:00,"Endoscopy, Gastrointestinal",E04.800.250.250.250
22136773,2011-12-01T00:00:00,Endosonography,E01.370.350.850.280
22136773,2011-12-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22136773,2011-12-01T00:00:00,Incidence,E05.318.308.985.525.375
22136773,2011-12-01T00:00:00,Incidence,L01.280.975.525.375
22136773,2011-12-01T00:00:00,Incidence,N01.224.935.597.500
22136773,2011-12-01T00:00:00,Incidence,N06.850.505.400.975.525.375
22136773,2011-12-01T00:00:00,Incidence,N06.850.520.308.985.525.375
22136773,2011-12-01T00:00:00,Middle Aged,M01.060.116.630
22136773,2011-12-01T00:00:00,Obesity,C18.654.726.500
22136773,2011-12-01T00:00:00,Obesity,C23.888.144.699.500
22136773,2011-12-01T00:00:00,Obesity,E01.370.600.115.100.160.120.699.500
22136773,2011-12-01T00:00:00,Obesity,G07.100.100.160.120.699.500
22136773,2011-12-01T00:00:00,Propofol,D02.755.773
22136773,2011-12-01T00:00:00,Risk Factors,E05.318.740.600.800.725
22136773,2011-12-01T00:00:00,Risk Factors,N05.715.350.200.700
22136773,2011-12-01T00:00:00,Risk Factors,N05.715.360.750.625.700.700
22136773,2011-12-01T00:00:00,Risk Factors,N06.850.490.625.750
22136773,2011-12-01T00:00:00,Risk Factors,N06.850.520.830.600.800.725
22136773,2011-12-01T00:00:00,United States,Z01.107.567.875
22136780,2011-12-01T00:00:00,Anesthesiology,H02.403.066
22136780,2011-12-01T00:00:00,Clinical Competence,I02.399.630.210
22136780,2011-12-01T00:00:00,Clinical Competence,N04.761.210
22136780,2011-12-01T00:00:00,Conscious Sedation,E03.250
22136780,2011-12-01T00:00:00,"Endoscopy, Gastrointestinal",E01.370.372.250.250
22136780,2011-12-01T00:00:00,"Endoscopy, Gastrointestinal",E01.370.388.250.250.250
22136780,2011-12-01T00:00:00,"Endoscopy, Gastrointestinal",E04.210.240.250
22136780,2011-12-01T00:00:00,"Endoscopy, Gastrointestinal",E04.800.250.250.250
22136780,2011-12-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22137135,2011-12-01T00:00:00,Adolescent,M01.060.057
22137135,2011-12-01T00:00:00,Adult,M01.060.116
22137135,2011-12-01T00:00:00,Cervical Vertebrae,A02.835.232.834.151
22137135,2011-12-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22137135,2011-12-01T00:00:00,Incidence,E05.318.308.985.525.375
22137135,2011-12-01T00:00:00,Incidence,L01.280.975.525.375
22137135,2011-12-01T00:00:00,Incidence,N01.224.935.597.500
22137135,2011-12-01T00:00:00,Incidence,N06.850.505.400.975.525.375
22137135,2011-12-01T00:00:00,Incidence,N06.850.520.308.985.525.375
22137135,2011-12-01T00:00:00,Multiple Trauma,C21.866.640
22137135,2011-12-01T00:00:00,Spinal Fractures,C21.866.117.500.500
22137135,2011-12-01T00:00:00,Spinal Fractures,C21.866.404.812
22137135,2011-12-01T00:00:00,Spinal Fractures,C21.866.831.600
22137135,2011-12-01T00:00:00,Time Factors,G01.910.857
22137135,2011-12-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.350.810
22137135,2011-12-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.600.350.700.810
22137135,2011-12-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.700.700.810
22137135,2011-12-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.700.810.810
22137135,2011-12-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.825.810.810
22137135,2011-12-01T00:00:00,United States,Z01.107.567.875
22137135,2011-12-01T00:00:00,Vertebral Artery,A07.231.114.955
22137135,2011-12-01T00:00:00,"Wounds, Nonpenetrating",C21.866.974
22137135,2011-12-01T00:00:00,Young Adult,M01.060.116.815
22137300,2011-12-01T00:00:00,"Aorta, Thoracic",A07.231.114.056.372
22137300,2011-12-01T00:00:00,Blood Vessel Prosthesis Implantation,E04.100.814.200
22137300,2011-12-01T00:00:00,Blood Vessel Prosthesis Implantation,E04.650.200
22137300,2011-12-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22154572,2011-12-01T00:00:00,Alligators and Crocodiles,B01.050.150.900.833.100
22154572,2011-12-01T00:00:00,Animals,B01.050
22154572,2011-12-01T00:00:00,Environmental Exposure,N06.850.460.350
22154572,2011-12-01T00:00:00,Gene Expression,G05.355.310
22154572,2011-12-01T00:00:00,Ovary,A05.360.319.114.630
22154572,2011-12-01T00:00:00,Ovary,A05.360.576.497
22154572,2011-12-01T00:00:00,Ovary,A06.407.312.497
22154572,2011-12-01T00:00:00,"RNA, Messenger",D13.444.735.544
22154572,2011-12-01T00:00:00,"Receptors, Androgen",D12.776.260.698.750.150
22154572,2011-12-01T00:00:00,"Receptors, Androgen",D12.776.826.750.150
22154572,2011-12-01T00:00:00,"Receptors, Androgen",D12.776.930.669.750.150
22154572,2011-12-01T00:00:00,"Receptors, Estrogen",D12.776.260.698.750.350
22154572,2011-12-01T00:00:00,"Receptors, Estrogen",D12.776.826.750.350
22154572,2011-12-01T00:00:00,"Receptors, Estrogen",D12.776.930.669.750.350
22154572,2011-12-01T00:00:00,"Receptors, Progesterone",D12.776.260.698.750.765
22154572,2011-12-01T00:00:00,"Receptors, Progesterone",D12.776.826.750.765
22154572,2011-12-01T00:00:00,"Receptors, Progesterone",D12.776.930.669.750.765
22154572,2011-12-01T00:00:00,Signal Transduction,G02.111.087.800
22154572,2011-12-01T00:00:00,Signal Transduction,G02.149.115.800
22154572,2011-12-01T00:00:00,Signal Transduction,G04.299.880
22158281,2011-12-01T00:00:00,"Abdomen, Acute",C23.888.646.100.200
22158281,2011-12-01T00:00:00,"Abdomen, Acute",C23.888.821.030.249
22158281,2011-12-01T00:00:00,Adolescent,M01.060.057
22158281,2011-12-01T00:00:00,"Diagnosis, Differential",E01.171
22158281,2011-12-01T00:00:00,Emergencies,C23.550.291.781
22158281,2011-12-01T00:00:00,Emergencies,N06.230.100.083
22158281,2011-12-01T00:00:00,Emergencies,N06.850.376
22158281,2011-12-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22158281,2011-12-01T00:00:00,Laparoscopy,E01.370.388.250.520
22158281,2011-12-01T00:00:00,Laparoscopy,E04.800.250.520
22158281,2011-12-01T00:00:00,Pregnancy,G08.686.785.760.769
22158281,2011-12-01T00:00:00,Pregnancy Complications,C13.703
22158281,2011-12-01T00:00:00,"Pregnancy, Ectopic",C13.703.733
22158281,2011-12-01T00:00:00,Risk Factors,E05.318.740.600.800.725
22158281,2011-12-01T00:00:00,Risk Factors,N05.715.350.200.700
22158281,2011-12-01T00:00:00,Risk Factors,N05.715.360.750.625.700.700
22158281,2011-12-01T00:00:00,Risk Factors,N06.850.490.625.750
22158281,2011-12-01T00:00:00,Risk Factors,N06.850.520.830.600.800.725
22158281,2011-12-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.350.810
22158281,2011-12-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.600.350.700.810
22158281,2011-12-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.700.700.810
22158281,2011-12-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.700.810.810
22158281,2011-12-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.825.810.810
22172863,2011-12-01T00:00:00,Diastole,G09.330.190.541.295
22172863,2011-12-01T00:00:00,Diastole,G11.427.590.540.554.250
22172863,2011-12-01T00:00:00,Diastole,G11.427.590.540.570.295
22172863,2011-12-01T00:00:00,Graft Rejection,G12.425.901.545.328
22172863,2011-12-01T00:00:00,Heart Transplantation,E04.100.376.475
22172863,2011-12-01T00:00:00,Heart Transplantation,E04.928.220.390
22172863,2011-12-01T00:00:00,Heart Transplantation,E04.936.450.475
22172863,2011-12-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22172863,2011-12-01T00:00:00,Mitral Valve,A07.541.510.507
22172863,2011-12-01T00:00:00,Myocardium,A02.633.580
22172863,2011-12-01T00:00:00,Myocardium,A07.541.704
22172863,2011-12-01T00:00:00,Myocardium,A10.690.552.750
22172863,2011-12-01T00:00:00,Regression Analysis,E05.318.740.750
22172863,2011-12-01T00:00:00,Regression Analysis,N05.715.360.750.695
22172863,2011-12-01T00:00:00,Regression Analysis,N06.850.520.830.750
22172863,2011-12-01T00:00:00,Treatment Outcome,E01.789.800
22172863,2011-12-01T00:00:00,Treatment Outcome,N04.761.559.590.800
22172863,2011-12-01T00:00:00,Treatment Outcome,N05.715.360.575.575.800
22172863,2011-12-01T00:00:00,"Ventricular Function, Left",G09.330.190.962.800
22172898,2011-12-01T00:00:00,"Diabetes Mellitus, Type 1",C18.452.394.750.124
22172898,2011-12-01T00:00:00,"Diabetes Mellitus, Type 1",C19.246.267
22172898,2011-12-01T00:00:00,"Diabetes Mellitus, Type 1",C20.111.327
22172898,2011-12-01T00:00:00,"Embolization, Therapeutic",E02.520.360
22172898,2011-12-01T00:00:00,Gastrointestinal Hemorrhage,C06.405.227
22172898,2011-12-01T00:00:00,Gastrointestinal Hemorrhage,C23.550.414.788
22172898,2011-12-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22172898,2011-12-01T00:00:00,"Mesenteric Artery, Superior",A07.231.114.565.755
22172898,2011-12-01T00:00:00,Mesenteric Veins,A07.231.908.670.385
22172898,2011-12-01T00:00:00,Middle Aged,M01.060.116.630
22172898,2011-12-01T00:00:00,Pancreas Transplantation,E04.210.725
22172898,2011-12-01T00:00:00,Pancreas Transplantation,E04.936.450.650
22172898,2011-12-01T00:00:00,Time Factors,G01.910.857
22172898,2011-12-01T00:00:00,Treatment Outcome,E01.789.800
22172898,2011-12-01T00:00:00,Treatment Outcome,N04.761.559.590.800
22172898,2011-12-01T00:00:00,Treatment Outcome,N05.715.360.575.575.800
22208178,2011-12-01T00:00:00,Animals,B01.050
22208178,2011-12-01T00:00:00,Cardiopulmonary Resuscitation,E02.365.647.110
22208178,2011-12-01T00:00:00,"Disease Models, Animal",C22.232
22208178,2011-12-01T00:00:00,"Disease Models, Animal",E05.598.500
22208178,2011-12-01T00:00:00,"Disease Models, Animal",E05.599.395.080
22208178,2011-12-01T00:00:00,Heart Arrest,C14.280.383
22208178,2011-12-01T00:00:00,Hyperoxia,C23.888.852.567
22208178,2011-12-01T00:00:00,"Mitochondria, Heart",A11.284.430.214.190.875.564.627.603
22208178,2011-12-01T00:00:00,"Mitochondria, Heart",A11.284.835.626.627.603
22208178,2011-12-01T00:00:00,Oxygen,D01.268.185.550
22208178,2011-12-01T00:00:00,Oxygen,D01.362.670
22208178,2011-12-01T00:00:00,Oxygen Consumption,G03.730
22208178,2011-12-01T00:00:00,Rats,B01.050.150.900.649.865.635.505.700
22208178,2011-12-01T00:00:00,"Rats, Sprague-Dawley",B01.050.150.900.649.865.635.505.700.750
22208544,2011-12-01T00:00:00,Anti-Bacterial Agents,D27.505.954.122.085
22208544,2011-12-01T00:00:00,Chronic Disease,C23.550.291.500
22208544,2011-12-01T00:00:00,Cystic Fibrosis,C06.689.202
22208544,2011-12-01T00:00:00,Cystic Fibrosis,C08.381.187
22208544,2011-12-01T00:00:00,Cystic Fibrosis,C16.320.190
22208544,2011-12-01T00:00:00,Cystic Fibrosis,C16.614.213
22208544,2011-12-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22208544,2011-12-01T00:00:00,Pseudomonas Infections,C01.252.400.739
22208544,2011-12-01T00:00:00,Pseudomonas aeruginosa,B03.440.400.425.625.625.100
22208544,2011-12-01T00:00:00,Pseudomonas aeruginosa,B03.660.250.580.590.050
22208544,2011-12-01T00:00:00,Randomized Controlled Trials as Topic,E05.318.760.535.365.500
22208544,2011-12-01T00:00:00,Randomized Controlled Trials as Topic,E05.337.250.365.500
22208544,2011-12-01T00:00:00,Randomized Controlled Trials as Topic,N05.715.360.775.235.387.500
22208544,2011-12-01T00:00:00,Randomized Controlled Trials as Topic,N06.850.520.450.535.365.500
22208544,2011-12-01T00:00:00,Treatment Outcome,E01.789.800
22208544,2011-12-01T00:00:00,Treatment Outcome,N04.761.559.590.800
22208544,2011-12-01T00:00:00,Treatment Outcome,N05.715.360.575.575.800
22208545,2011-12-01T00:00:00,Anti-Bacterial Agents,D27.505.954.122.085
22208545,2011-12-01T00:00:00,Chronic Disease,C23.550.291.500
22208545,2011-12-01T00:00:00,Cystic Fibrosis,C06.689.202
22208545,2011-12-01T00:00:00,Cystic Fibrosis,C08.381.187
22208545,2011-12-01T00:00:00,Cystic Fibrosis,C16.320.190
22208545,2011-12-01T00:00:00,Cystic Fibrosis,C16.614.213
22208545,2011-12-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22208548,2011-12-01T00:00:00,Anti-Bacterial Agents,D27.505.954.122.085
22208548,2011-12-01T00:00:00,Chronic Disease,C23.550.291.500
22208548,2011-12-01T00:00:00,Cystic Fibrosis,C06.689.202
22208548,2011-12-01T00:00:00,Cystic Fibrosis,C08.381.187
22208548,2011-12-01T00:00:00,Cystic Fibrosis,C16.320.190
22208548,2011-12-01T00:00:00,Cystic Fibrosis,C16.614.213
22208548,2011-12-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22208548,2011-12-01T00:00:00,Medication Adherence,F01.145.488.500.500
22208548,2011-12-01T00:00:00,Medication Adherence,N05.300.150.600.600.500
22208548,2011-12-01T00:00:00,Pseudomonas Infections,C01.252.400.739
22208548,2011-12-01T00:00:00,Pseudomonas aeruginosa,B03.440.400.425.625.625.100
22208548,2011-12-01T00:00:00,Pseudomonas aeruginosa,B03.660.250.580.590.050
22208548,2011-12-01T00:00:00,Randomized Controlled Trials as Topic,E05.318.760.535.365.500
22208548,2011-12-01T00:00:00,Randomized Controlled Trials as Topic,E05.337.250.365.500
22208548,2011-12-01T00:00:00,Randomized Controlled Trials as Topic,N05.715.360.775.235.387.500
22208548,2011-12-01T00:00:00,Randomized Controlled Trials as Topic,N06.850.520.450.535.365.500
22208548,2011-12-01T00:00:00,Treatment Outcome,E01.789.800
22208548,2011-12-01T00:00:00,Treatment Outcome,N04.761.559.590.800
22208548,2011-12-01T00:00:00,Treatment Outcome,N05.715.360.575.575.800
22216435,2011-12-01T00:00:00,Animals,B01.050
22216435,2011-12-01T00:00:00,"Cell Transformation, Neoplastic",C04.697.152
22216435,2011-12-01T00:00:00,"Cell Transformation, Neoplastic",C23.550.727.152
22216435,2011-12-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22216435,2011-12-01T00:00:00,NF-E2-Related Factor 2,D12.776.260.108.737
22216435,2011-12-01T00:00:00,NF-E2-Related Factor 2,D12.776.930.127.737
22216435,2011-12-01T00:00:00,Pancreatic Neoplasms,C04.588.274.761
22216435,2011-12-01T00:00:00,Pancreatic Neoplasms,C04.588.322.421
22216435,2011-12-01T00:00:00,Pancreatic Neoplasms,C06.301.761
22216435,2011-12-01T00:00:00,Pancreatic Neoplasms,C06.689.667
22216435,2011-12-01T00:00:00,Pancreatic Neoplasms,C19.344.421
22216435,2011-12-01T00:00:00,Reactive Oxygen Species,D01.339.431
22216435,2011-12-01T00:00:00,Reactive Oxygen Species,D01.650.775
22223408,2011-12-01T00:00:00,Cations,D01.248.497.300
22223408,2011-12-01T00:00:00,Mass Spectrometry,E05.196.566
22223412,2011-12-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22223412,2011-12-01T00:00:00,Polymerase Chain Reaction,E05.393.620.500
22223412,2011-12-01T00:00:00,"Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization",E05.196.566.755
22223412,2011-12-01T00:00:00,Staphylococcal Infections,C01.252.410.868
22223412,2011-12-01T00:00:00,Staphylococcus aureus,B03.300.390.400.800.750.100
22223412,2011-12-01T00:00:00,Staphylococcus aureus,B03.510.100.750.750.100
22223412,2011-12-01T00:00:00,Staphylococcus aureus,B03.510.400.790.750.100
22228829,2011-12-01T00:00:00,Aged,M01.060.116.100
22228829,2011-12-01T00:00:00,Alzheimer Disease,C10.228.140.380.100
22228829,2011-12-01T00:00:00,Alzheimer Disease,C10.574.945.249
22228829,2011-12-01T00:00:00,Alzheimer Disease,F03.087.400.100
22228829,2011-12-01T00:00:00,Depression,F01.145.126.350
22228829,2011-12-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22228829,2011-12-01T00:00:00,Middle Aged,M01.060.116.630
22228829,2011-12-01T00:00:00,Multicenter Studies as Topic,E05.318.760.535.500
22228829,2011-12-01T00:00:00,Multicenter Studies as Topic,E05.337.250.500
22228829,2011-12-01T00:00:00,Multicenter Studies as Topic,N05.715.360.775.235.545
22228829,2011-12-01T00:00:00,Multicenter Studies as Topic,N06.850.520.450.535.500
22228829,2011-12-01T00:00:00,"Polymorphism, Genetic",G05.365.795
22228829,2011-12-01T00:00:00,Randomized Controlled Trials as Topic,E05.318.760.535.365.500
22228829,2011-12-01T00:00:00,Randomized Controlled Trials as Topic,E05.337.250.365.500
22228829,2011-12-01T00:00:00,Randomized Controlled Trials as Topic,N05.715.360.775.235.387.500
22228829,2011-12-01T00:00:00,Randomized Controlled Trials as Topic,N06.850.520.450.535.365.500
22228829,2011-12-01T00:00:00,Serotonin Uptake Inhibitors,D27.505.519.625.600.850
22228829,2011-12-01T00:00:00,Serotonin Uptake Inhibitors,D27.505.519.625.850.900
22228829,2011-12-01T00:00:00,Serotonin Uptake Inhibitors,D27.505.696.577.600.850
22228829,2011-12-01T00:00:00,Serotonin Uptake Inhibitors,D27.505.696.577.850.900
22228829,2011-12-01T00:00:00,Sertraline,D02.092.705.800
22228829,2011-12-01T00:00:00,Sertraline,D02.455.426.559.847.638.845.800
22228829,2011-12-01T00:00:00,Sertraline,D04.615.638.845.800
22228829,2011-12-01T00:00:00,Treatment Outcome,E01.789.800
22228829,2011-12-01T00:00:00,Treatment Outcome,N04.761.559.590.800
22228829,2011-12-01T00:00:00,Treatment Outcome,N05.715.360.575.575.800
22273207,2011-12-01T00:00:00,Colonoscopy,E01.370.372.250.250.200
22273207,2011-12-01T00:00:00,Colonoscopy,E01.370.388.250.250.250.160
22273207,2011-12-01T00:00:00,Colonoscopy,E04.210.240.250.160
22273207,2011-12-01T00:00:00,Colonoscopy,E04.800.250.250.250.160
22273207,2011-12-01T00:00:00,"Diagnosis, Differential",E01.171
22273207,2011-12-01T00:00:00,Gastrointestinal Stromal Tumors,C04.588.274.476.308
22273207,2011-12-01T00:00:00,Gastrointestinal Stromal Tumors,C06.301.371.308
22273207,2011-12-01T00:00:00,Gastrointestinal Stromal Tumors,C06.405.249.308
22273207,2011-12-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22273207,2011-12-01T00:00:00,Laparoscopy,E01.370.388.250.520
22273207,2011-12-01T00:00:00,Laparoscopy,E04.800.250.520
22273207,2011-12-01T00:00:00,Middle Aged,M01.060.116.630
22273207,2011-12-01T00:00:00,Stomach Neoplasms,C04.588.274.476.767
22273207,2011-12-01T00:00:00,Stomach Neoplasms,C06.301.371.767
22273207,2011-12-01T00:00:00,Stomach Neoplasms,C06.405.249.767
22273207,2011-12-01T00:00:00,Stomach Neoplasms,C06.405.748.789
22273207,2011-12-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.350.810
22273207,2011-12-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.600.350.700.810
22273207,2011-12-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.700.700.810
22273207,2011-12-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.700.810.810
22273207,2011-12-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.825.810.810
22273210,2011-12-01T00:00:00,General Surgery,H02.403.810.300
22273210,2011-12-01T00:00:00,"History, 20th Century",K01.400.504.968
22273210,2011-12-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22273210,2011-12-01T00:00:00,United States,Z01.107.567.875
22285017,2011-12-01T00:00:00,Adult,M01.060.116
22285017,2011-12-01T00:00:00,Aged,M01.060.116.100
22285017,2011-12-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22285017,2011-12-01T00:00:00,"In Situ Hybridization, Fluorescence",E05.200.500.620.670.325.350
22285017,2011-12-01T00:00:00,"In Situ Hybridization, Fluorescence",E05.200.750.600.670.325.350
22285017,2011-12-01T00:00:00,"In Situ Hybridization, Fluorescence",E05.393.285.350
22285017,2011-12-01T00:00:00,"In Situ Hybridization, Fluorescence",E05.393.661.475.350
22285017,2011-12-01T00:00:00,Middle Aged,M01.060.116.630
22285017,2011-12-01T00:00:00,Mosaicism,G05.365.590.175.595
22285017,2011-12-01T00:00:00,Oligonucleotide Array Sequence Analysis,E05.196.630.570.660
22285017,2011-12-01T00:00:00,Oligonucleotide Array Sequence Analysis,E05.393.525.640
22285017,2011-12-01T00:00:00,Oligonucleotide Array Sequence Analysis,E05.393.661.640
22285017,2011-12-01T00:00:00,Oligonucleotide Array Sequence Analysis,E05.393.760.640
22285017,2011-12-01T00:00:00,Oligonucleotide Array Sequence Analysis,E05.588.570.660
22285017,2011-12-01T00:00:00,Oligonucleotide Array Sequence Analysis,E05.601.640
22285017,2011-12-01T00:00:00,"Polymorphism, Single Nucleotide",G05.365.795.598
22409130,2011-12-01T00:00:00,Atrial Fibrillation,C14.280.067.198
22409130,2011-12-01T00:00:00,Atrial Fibrillation,C23.550.073.198
22409130,2011-12-01T00:00:00,Clinical Trials as Topic,E05.318.760.535
22409130,2011-12-01T00:00:00,Clinical Trials as Topic,E05.337.250
22409130,2011-12-01T00:00:00,Clinical Trials as Topic,N05.715.360.775.235
22409130,2011-12-01T00:00:00,Clinical Trials as Topic,N06.850.520.450.535
22409130,2011-12-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22409130,2011-12-01T00:00:00,Life Style,F01.829.458
22409130,2011-12-01T00:00:00,Platelet Aggregation Inhibitors,D27.505.954.502.780
22409130,2011-12-01T00:00:00,Risk Factors,E05.318.740.600.800.725
22409130,2011-12-01T00:00:00,Risk Factors,N05.715.350.200.700
22409130,2011-12-01T00:00:00,Risk Factors,N05.715.360.750.625.700.700
22409130,2011-12-01T00:00:00,Risk Factors,N06.850.490.625.750
22409130,2011-12-01T00:00:00,Risk Factors,N06.850.520.830.600.800.725
22409130,2011-12-01T00:00:00,Secondary Prevention,N02.421.726.825
22409130,2011-12-01T00:00:00,Secondary Prevention,N06.850.780.750
22409130,2011-12-01T00:00:00,Stroke,C10.228.140.300.775
22409130,2011-12-01T00:00:00,Stroke,C14.907.253.855
22416603,2011-12-01T00:00:00,Cardiac Surgical Procedures,E04.100.376
22416603,2011-12-01T00:00:00,Cardiac Surgical Procedures,E04.928.220
22416603,2011-12-01T00:00:00,Ethnic Groups,M01.686.754
22416603,2011-12-01T00:00:00,Ethnic Groups,N01.224.317
22416603,2011-12-01T00:00:00,Healthcare Disparities,N04.590.374.380
22416603,2011-12-01T00:00:00,Healthcare Disparities,N05.300.493
22416603,2011-12-01T00:00:00,"Heart Defects, Congenital",C14.240.400
22416603,2011-12-01T00:00:00,"Heart Defects, Congenital",C14.280.400
22416603,2011-12-01T00:00:00,"Heart Defects, Congenital",C16.131.240.400
22416603,2011-12-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22416603,2011-12-01T00:00:00,"Infant, Newborn",M01.060.703.520
22416603,2011-12-01T00:00:00,United States,Z01.107.567.875
23061177,2011-12-01T00:00:00,Adolescent,M01.060.057
23061177,2011-12-01T00:00:00,Adolescent Psychology,F04.096.628.065
23061177,2011-12-01T00:00:00,African Americans,M01.686.508.100.100
23061177,2011-12-01T00:00:00,African Americans,M01.686.754.100
23061177,2011-12-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
23061177,2011-12-01T00:00:00,Psychological Tests,F04.711
23061177,2011-12-01T00:00:00,Psychometrics,F04.711.780
23061177,2011-12-01T00:00:00,Self Concept,F01.752.747.792
23061182,2011-12-01T00:00:00,African Americans,M01.686.508.100.100
23061182,2011-12-01T00:00:00,African Americans,M01.686.754.100
23061182,2011-12-01T00:00:00,Clinical Trials as Topic,E05.318.760.535
23061182,2011-12-01T00:00:00,Clinical Trials as Topic,E05.337.250
23061182,2011-12-01T00:00:00,Clinical Trials as Topic,N05.715.360.775.235
23061182,2011-12-01T00:00:00,Clinical Trials as Topic,N06.850.520.450.535
23061182,2011-12-01T00:00:00,Curriculum,I02.158
23061182,2011-12-01T00:00:00,Health Services Accessibility,N04.590.374.350
23061182,2011-12-01T00:00:00,Health Services Accessibility,N05.300.430
23061182,2011-12-01T00:00:00,Healthcare Disparities,N04.590.374.380
23061182,2011-12-01T00:00:00,Healthcare Disparities,N05.300.493
23061182,2011-12-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
23061182,2011-12-01T00:00:00,"Models, Educational",E05.599.545
23061182,2011-12-01T00:00:00,"Models, Educational",I02.903.302
23061182,2011-12-01T00:00:00,Neoplasms,C04
23061182,2011-12-01T00:00:00,Patient Acceptance of Health Care,N05.300.150.600
23061182,2011-12-01T00:00:00,Patient Selection,E05.581.500.653
23061182,2011-12-01T00:00:00,Patient Selection,N04.590.731
23061182,2011-12-01T00:00:00,Pilot Projects,E05.318.760.750
23061182,2011-12-01T00:00:00,Pilot Projects,E05.337.737
23061182,2011-12-01T00:00:00,Pilot Projects,N05.715.360.775.625
23061182,2011-12-01T00:00:00,Pilot Projects,N06.850.520.450.720
23061182,2011-12-01T00:00:00,Social Support,I01.880.656.600
22137579,2011-12-02T00:00:00,Adolescent,M01.060.057
22137579,2011-12-02T00:00:00,Child,M01.060.406
22137579,2011-12-02T00:00:00,"Child, Preschool",M01.060.406.448
22137579,2011-12-02T00:00:00,Epilepsy,C10.228.140.490
22137579,2011-12-02T00:00:00,Exercise Therapy,E02.779.483
22137579,2011-12-02T00:00:00,Exercise Therapy,E02.831.387
22137579,2011-12-02T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22137579,2011-12-02T00:00:00,Infant,M01.060.703
22137579,2011-12-02T00:00:00,Neuronal Plasticity,G11.561.600.635
22137579,2011-12-02T00:00:00,Pilot Projects,E05.318.760.750
22137579,2011-12-02T00:00:00,Pilot Projects,E05.337.737
22137579,2011-12-02T00:00:00,Pilot Projects,N05.715.360.775.625
22137579,2011-12-02T00:00:00,Pilot Projects,N06.850.520.450.720
22137360,2011-12-03T00:00:00,Animals,B01.050
22137360,2011-12-03T00:00:00,Anura,B01.050.150.900.090.180
22137360,2011-12-03T00:00:00,Environmental Pollutants,D27.888.284
22137360,2011-12-03T00:00:00,Glycine,D12.125.481
22137360,2011-12-03T00:00:00,Herbicides,D27.720.031.700.366
22137360,2011-12-03T00:00:00,Herbicides,D27.720.723.366
22137360,2011-12-03T00:00:00,Herbicides,D27.888.723.366
22137360,2011-12-03T00:00:00,Larva,B05.500.500
22137360,2011-12-03T00:00:00,Larva,G07.700.320.500.550.500.500
22137360,2011-12-03T00:00:00,Polyethylene Glycols,D02.033.455.250.700
22137360,2011-12-03T00:00:00,Polyethylene Glycols,D05.750.741
22137360,2011-12-03T00:00:00,Polyethylene Glycols,D25.720.741
22137360,2011-12-03T00:00:00,Polyethylene Glycols,J01.637.051.720.741
22137360,2011-12-03T00:00:00,Risk Assessment,E05.318.740.600.800.715
22137360,2011-12-03T00:00:00,Risk Assessment,N04.452.871.715
22137360,2011-12-03T00:00:00,Risk Assessment,N05.715.360.750.625.700.690
22137360,2011-12-03T00:00:00,Risk Assessment,N06.850.505.715
22137360,2011-12-03T00:00:00,Risk Assessment,N06.850.520.830.600.800.715
22137594,2011-12-03T00:00:00,Acetylcysteine,D02.886.030.230.259
22137594,2011-12-03T00:00:00,Acetylcysteine,D12.125.166.230.259
22137594,2011-12-03T00:00:00,Animals,B01.050
22137594,2011-12-03T00:00:00,Cocaine,D02.145.074.722.388
22137594,2011-12-03T00:00:00,Cocaine,D03.132.889.354
22137594,2011-12-03T00:00:00,Cocaine,D03.605.869.388
22137594,2011-12-03T00:00:00,Cocaine,D04.075.080.875.099.722.388
22137594,2011-12-03T00:00:00,Cystine,D01.248.497.158.874.390.369
22137594,2011-12-03T00:00:00,Cystine,D01.875.350.850.150.369
22137594,2011-12-03T00:00:00,Cystine,D02.886.030.230.369
22137594,2011-12-03T00:00:00,Cystine,D02.886.520.150.087
22137594,2011-12-03T00:00:00,Cystine,D12.125.095.369
22137594,2011-12-03T00:00:00,Cystine,D12.125.119.369
22137594,2011-12-03T00:00:00,Cystine,D12.125.166.230.369
22137594,2011-12-03T00:00:00,Glutamic Acid,D12.125.067.750
22137594,2011-12-03T00:00:00,Glutamic Acid,D12.125.119.450
22137594,2011-12-03T00:00:00,Glutamic Acid,D12.125.427.300
22137594,2011-12-03T00:00:00,Nucleus Accumbens,A08.186.211.730.885.287.249.683
22137594,2011-12-03T00:00:00,Prefrontal Cortex,A08.186.211.730.885.287.500.270.700
22137594,2011-12-03T00:00:00,Rats,B01.050.150.900.649.865.635.505.700
22137594,2011-12-03T00:00:00,"Rats, Sprague-Dawley",B01.050.150.900.649.865.635.505.700.750
22137594,2011-12-03T00:00:00,"Receptors, Metabotropic Glutamate",D12.776.543.750.100.450
22137594,2011-12-03T00:00:00,"Receptors, Metabotropic Glutamate",D12.776.543.750.720.200.450.500
22137594,2011-12-03T00:00:00,Synaptic Transmission,G02.111.087.800.850
22137594,2011-12-03T00:00:00,Synaptic Transmission,G02.149.115.800.850
22137594,2011-12-03T00:00:00,Synaptic Transmission,G04.299.880.850
22137594,2011-12-03T00:00:00,Synaptic Transmission,G07.265.337.900
22137594,2011-12-03T00:00:00,Synaptic Transmission,G07.700.240.900
22137594,2011-12-03T00:00:00,Synaptic Transmission,G11.561.600.835
22139748,2011-12-03T00:00:00,Algorithms,G17.035
22139748,2011-12-03T00:00:00,Algorithms,L01.224.050
22139748,2011-12-03T00:00:00,Gene Expression Regulation,G05.355.315
22139748,2011-12-03T00:00:00,Gene Regulatory Networks,G05.360.080.689.360
22139748,2011-12-03T00:00:00,"Models, Genetic",E05.599.395.397
22265832,2011-12-03T00:00:00,Antineoplastic Agents,D27.505.954.248
22265832,2011-12-03T00:00:00,Palladium,D01.268.556.680
22265832,2011-12-03T00:00:00,Palladium,D01.268.956.718
22265832,2011-12-03T00:00:00,Palladium,D01.552.544.680
22265832,2011-12-03T00:00:00,Polyamines,D02.092.782
22265832,2011-12-03T00:00:00,"Spectroscopy, Fourier Transform Infrared",E05.196.712.726.676.700
22265832,2011-12-03T00:00:00,"Spectroscopy, Fourier Transform Infrared",E05.196.867.826.676.700
22265832,2011-12-03T00:00:00,"Spectrum Analysis, Raman",E05.196.822.860
22265832,2011-12-03T00:00:00,"Spectrum Analysis, Raman",E05.196.867.890
22141337,2011-12-05T00:00:00,Animals,B01.050
22141337,2011-12-05T00:00:00,Calcium Signaling,G02.111.087.800.800.100
22141337,2011-12-05T00:00:00,Calcium Signaling,G02.149.115.800.800.100
22141337,2011-12-05T00:00:00,Calcium Signaling,G03.495.166.500.100
22141337,2011-12-05T00:00:00,Calcium Signaling,G04.299.880.800.100
22141337,2011-12-05T00:00:00,Central Nervous System Depressants,D27.505.696.277
22141337,2011-12-05T00:00:00,Central Nervous System Depressants,D27.505.954.427.210
22141337,2011-12-05T00:00:00,Cognition,F02.463.188
22141337,2011-12-05T00:00:00,Cognition Disorders,F03.087.250
22141337,2011-12-05T00:00:00,Ethanol,D02.033.375
22141337,2011-12-05T00:00:00,Neurons,A08.663
22141337,2011-12-05T00:00:00,Neurons,A11.671
22141337,2011-12-05T00:00:00,Prefrontal Cortex,A08.186.211.730.885.287.500.270.700
22144674,2011-12-05T00:00:00,Animals,B01.050
22144674,2011-12-05T00:00:00,Apoptosis,G04.299.139.160
22144674,2011-12-05T00:00:00,Cell Proliferation,G04.299.233.750
22144674,2011-12-05T00:00:00,Cell Proliferation,G07.700.320.249.410.750
22144674,2011-12-05T00:00:00,Diabetes Mellitus,C18.452.394.750
22144674,2011-12-05T00:00:00,Diabetes Mellitus,C19.246
22144674,2011-12-05T00:00:00,Heart Diseases,C14.280
22144674,2011-12-05T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22144674,2011-12-05T00:00:00,Neoplasms,C04
22144674,2011-12-05T00:00:00,Nuclear Proteins,D12.776.660
22144674,2011-12-05T00:00:00,Phosphoprotein Phosphatases,D08.811.277.352.650.625
22144674,2011-12-05T00:00:00,Phosphorylation,G02.111.087.677
22144674,2011-12-05T00:00:00,Phosphorylation,G02.149.115.677
22144674,2011-12-05T00:00:00,Phosphorylation,G02.149.465.700
22144674,2011-12-05T00:00:00,Phosphorylation,G02.607.750.700
22144674,2011-12-05T00:00:00,Phosphorylation,G03.495.790
22144674,2011-12-05T00:00:00,Prostatic Neoplasms,C04.588.945.440.770
22144674,2011-12-05T00:00:00,Prostatic Neoplasms,C12.294.260.750
22144674,2011-12-05T00:00:00,Prostatic Neoplasms,C12.294.565.625
22144674,2011-12-05T00:00:00,Prostatic Neoplasms,C12.758.409.750
22144674,2011-12-05T00:00:00,Protein Kinase C,D08.811.913.696.620.682.700.725
22144674,2011-12-05T00:00:00,Protein-Serine-Threonine Kinases,D08.811.913.696.620.682.700
22144674,2011-12-05T00:00:00,Proto-Oncogene Proteins c-akt,D08.811.913.696.620.682.700.755
22144674,2011-12-05T00:00:00,Proto-Oncogene Proteins c-akt,D12.776.476.565
22144674,2011-12-05T00:00:00,Proto-Oncogene Proteins c-akt,D12.776.624.664.700.168
22144674,2011-12-05T00:00:00,Signal Transduction,G02.111.087.800
22144674,2011-12-05T00:00:00,Signal Transduction,G02.149.115.800
22144674,2011-12-05T00:00:00,Signal Transduction,G04.299.880
22144674,2011-12-05T00:00:00,Tumor Suppressor Proteins,D12.776.624.776
22154039,2011-12-05T00:00:00,Adolescent,M01.060.057
22154039,2011-12-05T00:00:00,Attitude of Health Personnel,F01.100.050
22154039,2011-12-05T00:00:00,Attitude of Health Personnel,N05.300.100
22154039,2011-12-05T00:00:00,Caregivers,M01.085
22154039,2011-12-05T00:00:00,Caregivers,M01.526.485.200
22154039,2011-12-05T00:00:00,Caregivers,N02.360.200
22154039,2011-12-05T00:00:00,Child,M01.060.406
22154039,2011-12-05T00:00:00,Community Health Services,N02.421.143
22154039,2011-12-05T00:00:00,"Data Interpretation, Statistical",E05.245.380
22154039,2011-12-05T00:00:00,"Data Interpretation, Statistical",E05.318.740.300
22154039,2011-12-05T00:00:00,"Data Interpretation, Statistical",L01.700.508.190.380
22154039,2011-12-05T00:00:00,"Data Interpretation, Statistical",N05.715.360.750.300
22154039,2011-12-05T00:00:00,"Data Interpretation, Statistical",N06.850.520.830.300
22154039,2011-12-05T00:00:00,Family Therapy,F04.754.864.581.273
22154039,2011-12-05T00:00:00,Health Personnel,M01.526.485
22154039,2011-12-05T00:00:00,Health Personnel,N02.360
22154039,2011-12-05T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22154039,2011-12-05T00:00:00,"Interview, Psychological",F04.669.599
22154039,2011-12-05T00:00:00,Juvenile Delinquency,I01.880.735.479
22154039,2011-12-05T00:00:00,Motivation,F01.658
22154039,2011-12-05T00:00:00,Motivation,F01.752.543.500.750
22154039,2011-12-05T00:00:00,Outcome Assessment (Health Care),N04.761.559.590
22154039,2011-12-05T00:00:00,Outcome Assessment (Health Care),N05.715.360.575.575
22154039,2011-12-05T00:00:00,"Quality Assurance, Health Care",N04.761.700
22154039,2011-12-05T00:00:00,"Quality Assurance, Health Care",N05.700
22154039,2011-12-05T00:00:00,Substance-Related Disorders,C21.739
22154039,2011-12-05T00:00:00,Substance-Related Disorders,F03.900
22154039,2011-12-05T00:00:00,Treatment Outcome,E01.789.800
22154039,2011-12-05T00:00:00,Treatment Outcome,N04.761.559.590.800
22154039,2011-12-05T00:00:00,Treatment Outcome,N05.715.360.575.575.800
22143678,2011-12-06T00:00:00,Aging,G07.700.320.124
22143678,2011-12-06T00:00:00,Disability Evaluation,E01.370.400
22143678,2011-12-06T00:00:00,Health Status,I01.240.425
22143678,2011-12-06T00:00:00,Health Status,N01.224.425
22143678,2011-12-06T00:00:00,Health Status,N06.850.505.400.425
22143678,2011-12-06T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22143678,2011-12-06T00:00:00,"Models, Biological",E05.599.395
22143678,2011-12-06T00:00:00,Quality of Life,I01.800
22143678,2011-12-06T00:00:00,Quality of Life,K01.752.400.750
22143678,2011-12-06T00:00:00,Spinal Cord Injuries,C10.228.854.770
22143678,2011-12-06T00:00:00,Spinal Cord Injuries,C10.900.850
22143678,2011-12-06T00:00:00,Spinal Cord Injuries,C21.866.819
22143678,2011-12-06T00:00:00,Terminology as Topic,L01.143.506.598.400
22147633,2011-12-06T00:00:00,Adolescent,M01.060.057
22147633,2011-12-06T00:00:00,Adult,M01.060.116
22147633,2011-12-06T00:00:00,Aged,M01.060.116.100
22147633,2011-12-06T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22147633,2011-12-06T00:00:00,Middle Aged,M01.060.116.630
22147633,2011-12-06T00:00:00,Thyroid Diseases,C19.874
22147633,2011-12-06T00:00:00,Young Adult,M01.060.116.815
22147937,2011-12-06T00:00:00,"Carcinoma, Non-Small-Cell Lung",C04.588.894.797.520.109.220.249
22147937,2011-12-06T00:00:00,"Carcinoma, Non-Small-Cell Lung",C08.381.540.140.500
22147937,2011-12-06T00:00:00,"Carcinoma, Non-Small-Cell Lung",C08.785.520.100.220.500
22147937,2011-12-06T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22147937,2011-12-06T00:00:00,Lung Neoplasms,C04.588.894.797.520
22147937,2011-12-06T00:00:00,Lung Neoplasms,C08.381.540
22147937,2011-12-06T00:00:00,Lung Neoplasms,C08.785.520
22147937,2011-12-06T00:00:00,"Tumor Markers, Biological",D23.101.840
22163016,2011-12-06T00:00:00,Alleles,G05.360.340.024.340.030
22163016,2011-12-06T00:00:00,Animals,B01.050
22163016,2011-12-06T00:00:00,Autoimmune Diseases,C20.111
22163016,2011-12-06T00:00:00,Central Nervous System,A08.186
22163016,2011-12-06T00:00:00,"Encephalomyelitis, Autoimmune, Experimental",C10.114.703.300
22163016,2011-12-06T00:00:00,"Encephalomyelitis, Autoimmune, Experimental",C10.314.350.250
22163016,2011-12-06T00:00:00,"Encephalomyelitis, Autoimmune, Experimental",C20.111.258.625.300
22163016,2011-12-06T00:00:00,"Encephalomyelitis, Autoimmune, Experimental",E05.598.500.500.500
22163016,2011-12-06T00:00:00,Flow Cytometry,E05.196.712.516.600.240.350
22163016,2011-12-06T00:00:00,Flow Cytometry,E05.200.500.386.350
22163016,2011-12-06T00:00:00,Gene Expression Regulation,G05.355.315
22163016,2011-12-06T00:00:00,Inflammation,C23.550.470
22163016,2011-12-06T00:00:00,Interferon Type I,D12.644.276.374.440.890
22163016,2011-12-06T00:00:00,Interferon Type I,D12.644.276.718.500
22163016,2011-12-06T00:00:00,Interferon Type I,D12.776.467.374.440.890
22163016,2011-12-06T00:00:00,Interferon Type I,D12.776.467.718.500
22163016,2011-12-06T00:00:00,Interferon Type I,D23.529.374.440.890
22163016,2011-12-06T00:00:00,Interferon Type I,D23.529.718.500
22163016,2011-12-06T00:00:00,Interferon-beta,D12.644.276.374.440.890.275
22163016,2011-12-06T00:00:00,Interferon-beta,D12.644.276.718.500.275
22163016,2011-12-06T00:00:00,Interferon-beta,D12.776.467.374.440.890.275
22163016,2011-12-06T00:00:00,Interferon-beta,D12.776.467.718.500.275
22163016,2011-12-06T00:00:00,Interferon-beta,D23.529.374.440.890.275
22163016,2011-12-06T00:00:00,Interferon-beta,D23.529.718.500.275
22163016,2011-12-06T00:00:00,Interleukin-10,D12.644.276.374.465.510
22163016,2011-12-06T00:00:00,Interleukin-10,D12.776.467.374.465.510
22163016,2011-12-06T00:00:00,Interleukin-10,D23.529.374.465.510
22163016,2011-12-06T00:00:00,T-Lymphocytes,A11.118.637.555.567.569
22163016,2011-12-06T00:00:00,T-Lymphocytes,A15.145.229.637.555.567.569
22163016,2011-12-06T00:00:00,T-Lymphocytes,A15.382.490.555.567.569
22156918,2011-12-07T00:00:00,Algorithms,G17.035
22156918,2011-12-07T00:00:00,Algorithms,L01.224.050
22156918,2011-12-07T00:00:00,"Models, Molecular",E05.599.595
22156918,2011-12-07T00:00:00,Molecular Sequence Data,L01.453.245.667
22156918,2011-12-07T00:00:00,Regression Analysis,E05.318.740.750
22156918,2011-12-07T00:00:00,Regression Analysis,N05.715.360.750.695
22156918,2011-12-07T00:00:00,Regression Analysis,N06.850.520.830.750
22156918,2011-12-07T00:00:00,Software,L01.224.900
22160772,2011-12-07T00:00:00,Animals,B01.050
22160772,2011-12-07T00:00:00,Homeostasis,G07.700.360
22160772,2011-12-07T00:00:00,Ischemia,C23.550.513
22160772,2011-12-07T00:00:00,Kidney,A05.810.453
22160772,2011-12-07T00:00:00,Mitochondria,A11.284.430.214.190.875.564
22160772,2011-12-07T00:00:00,Mitochondria,A11.284.835.626
22160772,2011-12-07T00:00:00,Rats,B01.050.150.900.649.865.635.505.700
22160772,2011-12-07T00:00:00,"Rats, Sprague-Dawley",B01.050.150.900.649.865.635.505.700.750
22160772,2011-12-07T00:00:00,Rhabdomyolysis,C05.651.807
22172804,2011-12-07T00:00:00,Animals,B01.050
22172804,2011-12-07T00:00:00,Ethanol,D02.033.375
22172804,2011-12-07T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22172804,2011-12-07T00:00:00,Mitochondria,A11.284.430.214.190.875.564
22172804,2011-12-07T00:00:00,Mitochondria,A11.284.835.626
22172804,2011-12-07T00:00:00,"Models, Biological",E05.599.395
22172804,2011-12-07T00:00:00,Neoplasms,C04
22172804,2011-12-07T00:00:00,Voltage-Dependent Anion Channels,D12.776.157.530.400.500.520
22172804,2011-12-07T00:00:00,Voltage-Dependent Anion Channels,D12.776.543.550.425.730.520
22172804,2011-12-07T00:00:00,Voltage-Dependent Anion Channels,D12.776.543.585.400.730.520
22150243,2011-12-08T00:00:00,Aged,M01.060.116.100
22150243,2011-12-08T00:00:00,Algorithms,G17.035
22150243,2011-12-08T00:00:00,Algorithms,L01.224.050
22150243,2011-12-08T00:00:00,"Cardiac Pacing, Artificial",E02.145
22150243,2011-12-08T00:00:00,"Defibrillators, Implantable",E07.305.250.159.175
22150243,2011-12-08T00:00:00,"Defibrillators, Implantable",E07.305.250.319.175
22150243,2011-12-08T00:00:00,"Defibrillators, Implantable",E07.695.175
22150243,2011-12-08T00:00:00,Heart Ventricles,A07.541.560
22150243,2011-12-08T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22150243,2011-12-08T00:00:00,Middle Aged,M01.060.116.630
22150299,2011-12-08T00:00:00,Adult,M01.060.116
22150299,2011-12-08T00:00:00,Aged,M01.060.116.100
22150299,2011-12-08T00:00:00,Algorithms,G17.035
22150299,2011-12-08T00:00:00,Algorithms,L01.224.050
22150299,2011-12-08T00:00:00,"Cardiac Pacing, Artificial",E02.145
22150299,2011-12-08T00:00:00,Heart Ventricles,A07.541.560
22150299,2011-12-08T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22150299,2011-12-08T00:00:00,Middle Aged,M01.060.116.630
22151696,2011-12-08T00:00:00,Adolescent,M01.060.057
22151696,2011-12-08T00:00:00,Adult,M01.060.116
22151696,2011-12-08T00:00:00,Age Factors,N05.715.350.075
22151696,2011-12-08T00:00:00,Age Factors,N06.850.490.250
22151696,2011-12-08T00:00:00,Aged,M01.060.116.100
22151696,2011-12-08T00:00:00,"Depressive Disorder, Major",F03.600.300.375
22151696,2011-12-08T00:00:00,Health Behavior,F01.145.488
22151696,2011-12-08T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22151696,2011-12-08T00:00:00,Middle Aged,M01.060.116.630
22151696,2011-12-08T00:00:00,Quality of Life,I01.800
22151696,2011-12-08T00:00:00,Quality of Life,K01.752.400.750
22151696,2011-12-08T00:00:00,Questionnaires,E05.318.308.750
22151696,2011-12-08T00:00:00,Questionnaires,L01.280.800
22151696,2011-12-08T00:00:00,Questionnaires,N05.715.360.300.695
22151696,2011-12-08T00:00:00,Questionnaires,N06.850.520.308.750
22151696,2011-12-08T00:00:00,Stroke,C10.228.140.300.775
22151696,2011-12-08T00:00:00,Stroke,C14.907.253.855
22151696,2011-12-08T00:00:00,Young Adult,M01.060.116.815
22151911,2011-12-08T00:00:00,Aged,M01.060.116.100
22151911,2011-12-08T00:00:00,Brain Ischemia,C10.228.140.300.150
22151911,2011-12-08T00:00:00,Brain Ischemia,C14.907.253.092
22151911,2011-12-08T00:00:00,Functional Laterality,F02.830.297.425
22151911,2011-12-08T00:00:00,Functional Laterality,G11.561.225.425
22151911,2011-12-08T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22151911,2011-12-08T00:00:00,Magnetic Resonance Angiography,E01.370.350.500.500
22151911,2011-12-08T00:00:00,Magnetic Resonance Angiography,E01.370.350.825.500.500
22151911,2011-12-08T00:00:00,Magnetic Resonance Angiography,E01.370.370.050.500
22151911,2011-12-08T00:00:00,Middle Aged,M01.060.116.630
22151911,2011-12-08T00:00:00,Psychomotor Disorders,C10.597.606.881
22151911,2011-12-08T00:00:00,Psychomotor Disorders,C23.888.592.604.882
22151911,2011-12-08T00:00:00,Psychomotor Disorders,F01.700.875
22151911,2011-12-08T00:00:00,Stroke,C10.228.140.300.775
22151911,2011-12-08T00:00:00,Stroke,C14.907.253.855
22156562,2011-12-08T00:00:00,Child,M01.060.406
22156562,2011-12-08T00:00:00,"Constriction, Pathologic",C23.300.287
22156562,2011-12-08T00:00:00,"Diagnosis, Differential",E01.171
22156562,2011-12-08T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22156562,2011-12-08T00:00:00,Magnetic Resonance Imaging,E01.370.350.500
22156562,2011-12-08T00:00:00,Magnetic Resonance Imaging,E01.370.350.825.500
22156562,2011-12-08T00:00:00,Middle Aged,M01.060.116.630
22158694,2011-12-08T00:00:00,Microarray Analysis,E05.196.630.570
22158694,2011-12-08T00:00:00,Microarray Analysis,E05.588.570
22158694,2011-12-08T00:00:00,Nanostructures,J01.637.512
22158694,2011-12-08T00:00:00,Palladium,D01.268.556.680
22158694,2011-12-08T00:00:00,Palladium,D01.268.956.718
22158694,2011-12-08T00:00:00,Palladium,D01.552.544.680
22161496,2011-12-08T00:00:00,Diffusion Magnetic Resonance Imaging,E01.370.350.500.150
22161496,2011-12-08T00:00:00,Diffusion Magnetic Resonance Imaging,E01.370.350.825.500.150
22161496,2011-12-08T00:00:00,Equipment Failure Analysis,E05.325.192
22161496,2011-12-08T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22161496,2011-12-08T00:00:00,"Image Interpretation, Computer-Assisted",E01.158.600
22161496,2011-12-08T00:00:00,"Image Interpretation, Computer-Assisted",E01.370.350.350
22161496,2011-12-08T00:00:00,"Image Interpretation, Computer-Assisted",L01.700.508.100.158.600
22161496,2011-12-08T00:00:00,"Phantoms, Imaging",E07.671
22174787,2011-12-08T00:00:00,Fatty Acids,D10.251
22174787,2011-12-08T00:00:00,Lipids,D10
22174787,2011-12-08T00:00:00,Phylogeny,G05.697
22174787,2011-12-08T00:00:00,Phylogeny,G16.100.275.605
22174787,2011-12-08T00:00:00,Phylogeny,L01.100.697
22169775,2011-12-09T00:00:00,Adult,M01.060.116
22169775,2011-12-09T00:00:00,Case-Control Studies,E05.318.760.500.500
22169775,2011-12-09T00:00:00,Case-Control Studies,N05.715.360.775.175.200
22169775,2011-12-09T00:00:00,Case-Control Studies,N06.850.520.450.500.500
22169775,2011-12-09T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22169775,2011-12-09T00:00:00,Incidence,E05.318.308.985.525.375
22169775,2011-12-09T00:00:00,Incidence,L01.280.975.525.375
22169775,2011-12-09T00:00:00,Incidence,N01.224.935.597.500
22169775,2011-12-09T00:00:00,Incidence,N06.850.505.400.975.525.375
22169775,2011-12-09T00:00:00,Incidence,N06.850.520.308.985.525.375
22169775,2011-12-09T00:00:00,Intraoperative Complications,C23.550.505
22169775,2011-12-09T00:00:00,"Lens Implantation, Intraocular",E04.540.825.600
22169775,2011-12-09T00:00:00,"Lenses, Intraocular",E07.632.500.460
22169775,2011-12-09T00:00:00,"Lenses, Intraocular",E07.695.460
22169775,2011-12-09T00:00:00,Risk Factors,E05.318.740.600.800.725
22169775,2011-12-09T00:00:00,Risk Factors,N05.715.350.200.700
22169775,2011-12-09T00:00:00,Risk Factors,N05.715.360.750.625.700.700
22169775,2011-12-09T00:00:00,Risk Factors,N06.850.490.625.750
22169775,2011-12-09T00:00:00,Risk Factors,N06.850.520.830.600.800.725
22169775,2011-12-09T00:00:00,Visual Acuity,E01.370.380.850.950
22169775,2011-12-09T00:00:00,Visual Acuity,F02.463.593.932.901
22169775,2011-12-09T00:00:00,Visual Acuity,G14.940
22179018,2011-12-09T00:00:00,Adenosine Triphosphate,D03.438.759.646.138.236
22179018,2011-12-09T00:00:00,Adenosine Triphosphate,D13.695.667.138.236
22179018,2011-12-09T00:00:00,Adenosine Triphosphate,D13.695.827.068.236
22179018,2011-12-09T00:00:00,Animals,B01.050
22179018,2011-12-09T00:00:00,Calpain,D08.811.277.656.262.500.120
22179018,2011-12-09T00:00:00,Calpain,D08.811.277.656.300.200.120
22179018,2011-12-09T00:00:00,Cisplatin,D01.210.375
22179018,2011-12-09T00:00:00,Cisplatin,D01.625.125
22179018,2011-12-09T00:00:00,Cisplatin,D01.710.100
22179018,2011-12-09T00:00:00,"Kidney Tubules, Proximal",A05.810.453.736.560.570
22179018,2011-12-09T00:00:00,Mitochondria,A11.284.430.214.190.875.564
22179018,2011-12-09T00:00:00,Mitochondria,A11.284.835.626
22179018,2011-12-09T00:00:00,"RNA, Messenger",D13.444.735.544
22179018,2011-12-09T00:00:00,Rabbits,B01.050.150.900.649.521.700
22235820,2011-12-09T00:00:00,Aged,M01.060.116.100
22235820,2011-12-09T00:00:00,Antihypertensive Agents,D27.505.954.411.162
22235820,2011-12-09T00:00:00,Blood Pressure,E01.370.600.875.249
22235820,2011-12-09T00:00:00,Blood Pressure,G09.330.380.076
22235820,2011-12-09T00:00:00,Double-Blind Method,E05.318.780.300
22235820,2011-12-09T00:00:00,Double-Blind Method,E05.581.500.300
22235820,2011-12-09T00:00:00,Double-Blind Method,N05.715.360.780.320
22235820,2011-12-09T00:00:00,Double-Blind Method,N06.850.520.445.300
22235820,2011-12-09T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22235820,2011-12-09T00:00:00,Hypertension,C14.907.489
22235820,2011-12-09T00:00:00,Lipid Metabolism,G03.495.520
22235820,2011-12-09T00:00:00,Middle Aged,M01.060.116.630
22235820,2011-12-09T00:00:00,Outcome and Process Assessment (Health Care),N04.761.559
22235820,2011-12-09T00:00:00,Outcome and Process Assessment (Health Care),N05.715.360.575
22235820,2011-12-09T00:00:00,Population Surveillance,E05.318.308.250.700
22235820,2011-12-09T00:00:00,Population Surveillance,N05.715.360.300.375.625
22235820,2011-12-09T00:00:00,Population Surveillance,N06.850.520.308.250.700
22235820,2011-12-09T00:00:00,Population Surveillance,N06.850.780.675
22235820,2011-12-09T00:00:00,United States,Z01.107.567.875
22213007,2011-12-11T00:00:00,Adult,M01.060.116
22213007,2011-12-11T00:00:00,Carrier State,N06.850.160
22213007,2011-12-11T00:00:00,"Epistasis, Genetic",G05.355.315.207
22213007,2011-12-11T00:00:00,HIV,B04.820.650.589.650.350
22213007,2011-12-11T00:00:00,HIV,B04.909.777.731.589.650.350
22213007,2011-12-11T00:00:00,HIV Infections,C02.782.815.616.400
22213007,2011-12-11T00:00:00,HIV Infections,C02.800.801.400
22213007,2011-12-11T00:00:00,HIV Infections,C20.673.480
22213007,2011-12-11T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22213007,2011-12-11T00:00:00,Immunoglobulin Gm Allotypes,D12.776.124.486.485.114.606.586
22213007,2011-12-11T00:00:00,Immunoglobulin Gm Allotypes,D12.776.124.486.485.114.619.393.522.400
22213007,2011-12-11T00:00:00,Immunoglobulin Gm Allotypes,D12.776.124.486.485.705.500.380.500
22213007,2011-12-11T00:00:00,Immunoglobulin Gm Allotypes,D12.776.124.790.651.114.606.586
22213007,2011-12-11T00:00:00,Immunoglobulin Gm Allotypes,D12.776.124.790.651.114.619.393.522.400
22213007,2011-12-11T00:00:00,Immunoglobulin Gm Allotypes,D12.776.124.790.651.705.500.380.500
22213007,2011-12-11T00:00:00,Immunoglobulin Gm Allotypes,D12.776.377.715.548.114.606.586
22213007,2011-12-11T00:00:00,Immunoglobulin Gm Allotypes,D12.776.377.715.548.114.619.393.522.400
22213007,2011-12-11T00:00:00,Immunoglobulin Gm Allotypes,D12.776.377.715.548.705.500.380.500
22213007,2011-12-11T00:00:00,Immunoglobulin Gm Allotypes,G12.500.400.586
22213007,2011-12-11T00:00:00,Middle Aged,M01.060.116.630
22213007,2011-12-11T00:00:00,"Receptors, IgG",D12.776.543.750.705.871.300
22213007,2011-12-11T00:00:00,"Receptors, IgG",D23.050.301.264.035.695
22213007,2011-12-11T00:00:00,"Receptors, IgG",D23.101.100.110.695
22213007,2011-12-11T00:00:00,Virus Replication,G06.590.875.780
22213007,2011-12-11T00:00:00,Virus Replication,G06.920.875.780
22152112,2011-12-12T00:00:00,Animals,B01.050
22152112,2011-12-12T00:00:00,Fibroblasts,A11.329.228
22152112,2011-12-12T00:00:00,Fibroblasts,A11.872.228
22152112,2011-12-12T00:00:00,Heart,A07.541
22152112,2011-12-12T00:00:00,Rats,B01.050.150.900.649.865.635.505.700
22166964,2011-12-13T00:00:00,Aged,M01.060.116.100
22166964,2011-12-13T00:00:00,"Carcinoma, Merkel Cell",C04.557.465.625.650.240.325
22166964,2011-12-13T00:00:00,"Carcinoma, Merkel Cell",C04.557.470.200.025.370.325
22166964,2011-12-13T00:00:00,"Carcinoma, Merkel Cell",C04.557.580.625.650.240.325
22166964,2011-12-13T00:00:00,Combined Modality Therapy,E02.186
22166964,2011-12-13T00:00:00,Head and Neck Neoplasms,C04.588.443
22166964,2011-12-13T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22166964,2011-12-13T00:00:00,Lymph Node Excision,E04.446
22166964,2011-12-13T00:00:00,Lymph Nodes,A10.549.400
22166964,2011-12-13T00:00:00,Lymph Nodes,A15.382.520.604.412
22166964,2011-12-13T00:00:00,Middle Aged,M01.060.116.630
22166964,2011-12-13T00:00:00,Neoplasm Invasiveness,C04.697.645
22166964,2011-12-13T00:00:00,Neoplasm Invasiveness,C23.550.727.645
22166964,2011-12-13T00:00:00,Neoplasm Staging,E01.370.550
22166964,2011-12-13T00:00:00,Regression Analysis,E05.318.740.750
22166964,2011-12-13T00:00:00,Regression Analysis,N05.715.360.750.695
22166964,2011-12-13T00:00:00,Regression Analysis,N06.850.520.830.750
22166964,2011-12-13T00:00:00,Risk Assessment,E05.318.740.600.800.715
22166964,2011-12-13T00:00:00,Risk Assessment,N04.452.871.715
22166964,2011-12-13T00:00:00,Risk Assessment,N05.715.360.750.625.700.690
22166964,2011-12-13T00:00:00,Risk Assessment,N06.850.505.715
22166964,2011-12-13T00:00:00,Risk Assessment,N06.850.520.830.600.800.715
22166964,2011-12-13T00:00:00,SEER Program,E05.318.308.970.725
22166964,2011-12-13T00:00:00,SEER Program,L01.280.950.725
22166964,2011-12-13T00:00:00,SEER Program,N04.452.859.819.725
22166964,2011-12-13T00:00:00,SEER Program,N05.715.360.300.715.700.725
22166964,2011-12-13T00:00:00,SEER Program,N06.850.520.308.970.725
22166964,2011-12-13T00:00:00,Skin Neoplasms,C04.588.805
22166964,2011-12-13T00:00:00,Skin Neoplasms,C17.800.882
22166964,2011-12-13T00:00:00,Treatment Outcome,E01.789.800
22166964,2011-12-13T00:00:00,Treatment Outcome,N04.761.559.590.800
22166964,2011-12-13T00:00:00,Treatment Outcome,N05.715.360.575.575.800
22167011,2011-12-14T00:00:00,Cations,D01.248.497.300
22167011,2011-12-14T00:00:00,"Membranes, Artificial",D25.479
22167011,2011-12-14T00:00:00,"Membranes, Artificial",J01.637.051.479
22167011,2011-12-14T00:00:00,"Membranes, Artificial",J01.637.087.500
22167011,2011-12-14T00:00:00,Molecular Structure,G02.111.570
22167011,2011-12-14T00:00:00,Molecular Structure,G02.575
22167011,2011-12-14T00:00:00,Molecular Structure,G02.842.575
22167011,2011-12-14T00:00:00,Surface Properties,G02.842.850
22167011,2011-12-14T00:00:00,Zinc Oxide,D01.650.550.975
22167011,2011-12-14T00:00:00,Zinc Oxide,D01.975.975
22167233,2011-12-14T00:00:00,Adolescent,M01.060.057
22167233,2011-12-14T00:00:00,Adult,M01.060.116
22167233,2011-12-14T00:00:00,Aged,M01.060.116.100
22167233,2011-12-14T00:00:00,Brain Ischemia,C10.228.140.300.150
22167233,2011-12-14T00:00:00,Brain Ischemia,C14.907.253.092
22167233,2011-12-14T00:00:00,Gene Expression Profiling,E05.393.332
22167233,2011-12-14T00:00:00,Gene Expression Regulation,G05.355.315
22167233,2011-12-14T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22167233,2011-12-14T00:00:00,Middle Aged,M01.060.116.630
22167233,2011-12-14T00:00:00,Oligonucleotide Array Sequence Analysis,E05.196.630.570.660
22167233,2011-12-14T00:00:00,Oligonucleotide Array Sequence Analysis,E05.393.525.640
22167233,2011-12-14T00:00:00,Oligonucleotide Array Sequence Analysis,E05.393.661.640
22167233,2011-12-14T00:00:00,Oligonucleotide Array Sequence Analysis,E05.393.760.640
22167233,2011-12-14T00:00:00,Oligonucleotide Array Sequence Analysis,E05.588.570.660
22167233,2011-12-14T00:00:00,Oligonucleotide Array Sequence Analysis,E05.601.640
22167233,2011-12-14T00:00:00,Sex Characteristics,G08.686.815
22167233,2011-12-14T00:00:00,Stroke,C10.228.140.300.775
22167233,2011-12-14T00:00:00,Stroke,C14.907.253.855
22167254,2011-12-14T00:00:00,Amygdala,A08.186.211.464.090
22167254,2011-12-14T00:00:00,Amygdala,A08.186.211.730.885.287.249.152
22167254,2011-12-14T00:00:00,"Analgesics, Opioid",D27.505.696.663.850.014.520
22167254,2011-12-14T00:00:00,"Analgesics, Opioid",D27.505.954.427.040.325
22167254,2011-12-14T00:00:00,"Analgesics, Opioid",D27.505.954.427.210.049
22167254,2011-12-14T00:00:00,Animals,B01.050
22167254,2011-12-14T00:00:00,"Behavior, Animal",F01.145.113
22167254,2011-12-14T00:00:00,Cues,F02.463.425.234
22167254,2011-12-14T00:00:00,Eating,G07.610.593.260
22167254,2011-12-14T00:00:00,Eating,G07.700.620.260
22167254,2011-12-14T00:00:00,Eating,G10.261.326.240
22167254,2011-12-14T00:00:00,Rats,B01.050.150.900.649.865.635.505.700
22167254,2011-12-14T00:00:00,"Rats, Sprague-Dawley",B01.050.150.900.649.865.635.505.700.750
22171060,2011-12-14T00:00:00,Carrier Proteins,D12.776.157
22171060,2011-12-14T00:00:00,Cell Line,A11.251.210
22171060,2011-12-14T00:00:00,Child,M01.060.406
22171060,2011-12-14T00:00:00,Eye Proteins,D12.776.306
22171060,2011-12-14T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22171060,2011-12-14T00:00:00,Pigment Epithelium of Eye,A09.371.670
22171060,2011-12-14T00:00:00,Pigment Epithelium of Eye,A10.272.640
22171060,2011-12-14T00:00:00,Regeneration,G16.100.856
22171060,2011-12-14T00:00:00,Retinal Cone Photoreceptor Cells,A08.663.650.850.625.670.100
22171060,2011-12-14T00:00:00,Retinal Cone Photoreceptor Cells,A08.663.650.915.937.670.100
22171060,2011-12-14T00:00:00,Retinal Cone Photoreceptor Cells,A08.800.950.937.670.100
22171060,2011-12-14T00:00:00,Retinal Cone Photoreceptor Cells,A09.371.729.831.625.670.100
22171060,2011-12-14T00:00:00,Retinal Cone Photoreceptor Cells,A11.671.650.850.625.670.100
22171060,2011-12-14T00:00:00,Retinal Cone Photoreceptor Cells,A11.671.650.915.937.670.100
22171060,2011-12-14T00:00:00,Young Adult,M01.060.116.815
22172964,2011-12-14T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22172964,2011-12-14T00:00:00,"Models, Statistical",E05.318.740.500
22172964,2011-12-14T00:00:00,"Models, Statistical",E05.599.835
22172964,2011-12-14T00:00:00,"Models, Statistical",N05.715.360.750.530
22172964,2011-12-14T00:00:00,"Models, Statistical",N06.850.520.830.500
22172964,2011-12-14T00:00:00,Randomized Controlled Trials as Topic,E05.318.760.535.365.500
22172964,2011-12-14T00:00:00,Randomized Controlled Trials as Topic,E05.337.250.365.500
22172964,2011-12-14T00:00:00,Randomized Controlled Trials as Topic,N05.715.360.775.235.387.500
22172964,2011-12-14T00:00:00,Randomized Controlled Trials as Topic,N06.850.520.450.535.365.500
22172964,2011-12-14T00:00:00,Research Design,E05.581.500
22172964,2011-12-14T00:00:00,Research Design,H01.770.644.728
22172964,2011-12-14T00:00:00,Sleep Disorders,C10.886
22172964,2011-12-14T00:00:00,Sleep Disorders,C23.888.592.796
22172964,2011-12-14T00:00:00,Sleep Disorders,F03.870
22174452,2011-12-14T00:00:00,Animals,B01.050
22174452,2011-12-14T00:00:00,Asthma,C08.127.108
22174452,2011-12-14T00:00:00,Asthma,C08.381.495.108
22174452,2011-12-14T00:00:00,Asthma,C08.674.095
22174452,2011-12-14T00:00:00,Asthma,C20.543.480.680.095
22174452,2011-12-14T00:00:00,"Complement Pathway, Alternative",G12.425.255.695
22174452,2011-12-14T00:00:00,Inflammation,C23.550.470
22178870,2011-12-14T00:00:00,Action Potentials,G04.580.100
22178870,2011-12-14T00:00:00,Action Potentials,G07.265.750.100
22178870,2011-12-14T00:00:00,Action Potentials,G11.561.570.100
22178870,2011-12-14T00:00:00,Calcium,D01.268.552.100
22178870,2011-12-14T00:00:00,Calcium,D01.552.539.288
22178870,2011-12-14T00:00:00,Calcium,D23.119.100
22178870,2011-12-14T00:00:00,Catecholamines,D02.092.211.215.311
22178870,2011-12-14T00:00:00,Catecholamines,D02.092.311
22178870,2011-12-14T00:00:00,Cell Differentiation,G04.299.151
22178870,2011-12-14T00:00:00,Cyclic AMP,D03.438.759.646.138.395
22178870,2011-12-14T00:00:00,Cyclic AMP,D13.695.462.200
22178870,2011-12-14T00:00:00,Cyclic AMP,D13.695.667.138.395
22178870,2011-12-14T00:00:00,Cyclic AMP,D13.695.827.068.395
22178870,2011-12-14T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22178870,2011-12-14T00:00:00,"Models, Biological",E05.599.395
22178870,2011-12-14T00:00:00,Mutation,G05.365.590
22178870,2011-12-14T00:00:00,"Myocytes, Cardiac",A07.541.704.570
22178870,2011-12-14T00:00:00,"Myocytes, Cardiac",A10.690.552.750.570
22178870,2011-12-14T00:00:00,"Myocytes, Cardiac",A11.620.500
22178870,2011-12-14T00:00:00,Phenotype,G05.695
22178870,2011-12-14T00:00:00,Ryanodine Receptor Calcium Release Channel,D12.776.157.530.400.150.800
22178870,2011-12-14T00:00:00,Ryanodine Receptor Calcium Release Channel,D12.776.210.500.800
22178870,2011-12-14T00:00:00,Ryanodine Receptor Calcium Release Channel,D12.776.543.550.425.150.800
22178870,2011-12-14T00:00:00,Ryanodine Receptor Calcium Release Channel,D12.776.543.585.400.150.800
22178870,2011-12-14T00:00:00,"Tachycardia, Ventricular",C14.280.067.845.940
22178870,2011-12-14T00:00:00,"Tachycardia, Ventricular",C23.550.073.845.940
22289400,2011-12-14T00:00:00,Adolescent,M01.060.057
22289400,2011-12-14T00:00:00,Adult,M01.060.116
22289400,2011-12-14T00:00:00,Community-Based Participatory Research,N05.425.104
22289400,2011-12-14T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22289400,2011-12-14T00:00:00,Research Design,E05.581.500
22289400,2011-12-14T00:00:00,Research Design,H01.770.644.728
22289400,2011-12-14T00:00:00,Smoking Cessation,F01.145.940.700
22170399,2011-12-15T00:00:00,Animals,B01.050
22170399,2011-12-15T00:00:00,Electric Conductivity,G01.201.249.277
22170399,2011-12-15T00:00:00,Fibroblasts,A11.329.228
22170399,2011-12-15T00:00:00,Fibroblasts,A11.872.228
22170399,2011-12-15T00:00:00,Gap Junctions,A11.284.149.165.420.471
22170399,2011-12-15T00:00:00,Microfluidic Analytical Techniques,E05.196.630.465
22170399,2011-12-15T00:00:00,Microfluidic Analytical Techniques,E05.588.465
22170399,2011-12-15T00:00:00,"Models, Biological",E05.599.395
22170399,2011-12-15T00:00:00,Myocardial Infarction,C14.280.647.500
22170399,2011-12-15T00:00:00,Myocardial Infarction,C14.907.585.500
22170399,2011-12-15T00:00:00,Myocardium,A02.633.580
22170399,2011-12-15T00:00:00,Myocardium,A07.541.704
22170399,2011-12-15T00:00:00,Myocardium,A10.690.552.750
22170399,2011-12-15T00:00:00,"Myocytes, Cardiac",A07.541.704.570
22170399,2011-12-15T00:00:00,"Myocytes, Cardiac",A10.690.552.750.570
22170399,2011-12-15T00:00:00,"Myocytes, Cardiac",A11.620.500
22170399,2011-12-15T00:00:00,Rats,B01.050.150.900.649.865.635.505.700
22170399,2011-12-15T00:00:00,Stem Cells,A11.872
22172030,2011-12-15T00:00:00,Antineoplastic Agents,D27.505.954.248
22172030,2011-12-15T00:00:00,"Carcinoma, Renal Cell",C04.557.470.200.025.390
22172030,2011-12-15T00:00:00,"Carcinoma, Renal Cell",C04.588.945.947.535.160
22172030,2011-12-15T00:00:00,"Carcinoma, Renal Cell",C12.758.820.750.160
22172030,2011-12-15T00:00:00,"Carcinoma, Renal Cell",C12.777.419.473.160
22172030,2011-12-15T00:00:00,"Carcinoma, Renal Cell",C13.351.937.820.535.160
22172030,2011-12-15T00:00:00,"Carcinoma, Renal Cell",C13.351.968.419.473.160
22172030,2011-12-15T00:00:00,Cell Movement,G04.299.283
22172030,2011-12-15T00:00:00,Cell Movement,G07.700.560.500.180
22172030,2011-12-15T00:00:00,Cell Survival,G04.299.316
22172030,2011-12-15T00:00:00,Disease Progression,C23.550.291.656
22172030,2011-12-15T00:00:00,HSP90 Heat-Shock Proteins,D12.776.580.216.380
22172030,2011-12-15T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22172030,2011-12-15T00:00:00,Hypoxia-Inducible Factor 1,D12.776.260.103.625
22172030,2011-12-15T00:00:00,Hypoxia-Inducible Factor 1,D12.776.930.125.625
22172030,2011-12-15T00:00:00,Kidney Neoplasms,C04.588.945.947.535
22172030,2011-12-15T00:00:00,Kidney Neoplasms,C12.758.820.750
22172030,2011-12-15T00:00:00,Kidney Neoplasms,C12.777.419.473
22172030,2011-12-15T00:00:00,Kidney Neoplasms,C13.351.937.820.535
22172030,2011-12-15T00:00:00,Kidney Neoplasms,C13.351.968.419.473
22172030,2011-12-15T00:00:00,Neoplasm Proteins,D12.776.624
22172030,2011-12-15T00:00:00,"Transcription, Genetic",G02.111.087.847
22172030,2011-12-15T00:00:00,"Transcription, Genetic",G02.149.115.847
22172030,2011-12-15T00:00:00,"Transcription, Genetic",G05.355.310.700
22172030,2011-12-15T00:00:00,Vascular Endothelial Growth Factor A,D12.644.276.100.800.200
22172030,2011-12-15T00:00:00,Vascular Endothelial Growth Factor A,D12.776.467.100.800.200
22172030,2011-12-15T00:00:00,Vascular Endothelial Growth Factor A,D23.529.100.800.200
22176813,2011-12-15T00:00:00,"Carcinoma, Non-Small-Cell Lung",C04.588.894.797.520.109.220.249
22176813,2011-12-15T00:00:00,"Carcinoma, Non-Small-Cell Lung",C08.381.540.140.500
22176813,2011-12-15T00:00:00,"Carcinoma, Non-Small-Cell Lung",C08.785.520.100.220.500
22176813,2011-12-15T00:00:00,Clinical Trials as Topic,E05.318.760.535
22176813,2011-12-15T00:00:00,Clinical Trials as Topic,E05.337.250
22176813,2011-12-15T00:00:00,Clinical Trials as Topic,N05.715.360.775.235
22176813,2011-12-15T00:00:00,Clinical Trials as Topic,N06.850.520.450.535
22176813,2011-12-15T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22176813,2011-12-15T00:00:00,Individualized Medicine,E02.574
22176813,2011-12-15T00:00:00,Individualized Medicine,H02.403.200.700
22176813,2011-12-15T00:00:00,Lung Neoplasms,C04.588.894.797.520
22176813,2011-12-15T00:00:00,Lung Neoplasms,C08.381.540
22176813,2011-12-15T00:00:00,Lung Neoplasms,C08.785.520
22176813,2011-12-15T00:00:00,Randomized Controlled Trials as Topic,E05.318.760.535.365.500
22176813,2011-12-15T00:00:00,Randomized Controlled Trials as Topic,E05.337.250.365.500
22176813,2011-12-15T00:00:00,Randomized Controlled Trials as Topic,N05.715.360.775.235.387.500
22176813,2011-12-15T00:00:00,Randomized Controlled Trials as Topic,N06.850.520.450.535.365.500
22176813,2011-12-15T00:00:00,"Receptor, Epidermal Growth Factor",D08.811.913.696.620.682.725.400.100
22176813,2011-12-15T00:00:00,"Receptor, Epidermal Growth Factor",D12.776.543.750.060.249
22176813,2011-12-15T00:00:00,"Receptor, Epidermal Growth Factor",D12.776.543.750.750.360.300
22176813,2011-12-15T00:00:00,"Receptor, Epidermal Growth Factor",D12.776.543.750.750.400.340
22179539,2011-12-15T00:00:00,Adolescent,M01.060.057
22179539,2011-12-15T00:00:00,Adult,M01.060.116
22179539,2011-12-15T00:00:00,Aged,M01.060.116.100
22179539,2011-12-15T00:00:00,Child,M01.060.406
22179539,2011-12-15T00:00:00,"Child, Preschool",M01.060.406.448
22179539,2011-12-15T00:00:00,Heart Diseases,C14.280
22179539,2011-12-15T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22179539,2011-12-15T00:00:00,Middle Aged,M01.060.116.630
22179539,2011-12-15T00:00:00,Risk Factors,E05.318.740.600.800.725
22179539,2011-12-15T00:00:00,Risk Factors,N05.715.350.200.700
22179539,2011-12-15T00:00:00,Risk Factors,N05.715.360.750.625.700.700
22179539,2011-12-15T00:00:00,Risk Factors,N06.850.490.625.750
22179539,2011-12-15T00:00:00,Risk Factors,N06.850.520.830.600.800.725
22179539,2011-12-15T00:00:00,Stroke,C10.228.140.300.775
22179539,2011-12-15T00:00:00,Stroke,C14.907.253.855
22179539,2011-12-15T00:00:00,United States,Z01.107.567.875
22179539,2011-12-15T00:00:00,Young Adult,M01.060.116.815
22044050,2011-12-16T00:00:00,Fluorescence Resonance Energy Transfer,E05.196.712.516.600.676.500
22044050,2011-12-16T00:00:00,Fluorescence Resonance Energy Transfer,G01.154.100.240.280
22044050,2011-12-16T00:00:00,Fluorescence Resonance Energy Transfer,G01.595.100.240.280
22044050,2011-12-16T00:00:00,Fluorescence Resonance Energy Transfer,G02.111.087.242.280
22044050,2011-12-16T00:00:00,Fluorescence Resonance Energy Transfer,G02.149.115.242.280
22044050,2011-12-16T00:00:00,Fluorescent Dyes,D27.720.233.348
22044050,2011-12-16T00:00:00,Fluorescent Dyes,D27.720.470.330.348
22044050,2011-12-16T00:00:00,Fluorescent Dyes,D27.720.470.410.505.500
22044050,2011-12-16T00:00:00,Pseudomonas,B03.440.400.425.625.625
22044050,2011-12-16T00:00:00,Pseudomonas,B03.660.250.580.590
22182496,2011-12-17T00:00:00,Echocardiography,E01.370.350.850.220
22182496,2011-12-17T00:00:00,Echocardiography,E01.370.370.380.220
22182496,2011-12-17T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22182496,2011-12-17T00:00:00,Questionnaires,E05.318.308.750
22182496,2011-12-17T00:00:00,Questionnaires,L01.280.800
22182496,2011-12-17T00:00:00,Questionnaires,N05.715.360.300.695
22182496,2011-12-17T00:00:00,Questionnaires,N06.850.520.308.750
22182496,2011-12-17T00:00:00,Sex Factors,N05.715.350.675
22182496,2011-12-17T00:00:00,Sex Factors,N06.850.490.875
22182496,2011-12-17T00:00:00,Stroke Volume,E01.370.370.380.150.700
22182496,2011-12-17T00:00:00,Stroke Volume,G09.330.380.124.882
22182496,2011-12-17T00:00:00,Treatment Outcome,E01.789.800
22182496,2011-12-17T00:00:00,Treatment Outcome,N04.761.559.590.800
22182496,2011-12-17T00:00:00,Treatment Outcome,N05.715.360.575.575.800
22182496,2011-12-17T00:00:00,"Ventricular Dysfunction, Left",C14.280.945.900
22182496,2011-12-17T00:00:00,Ventricular Remodeling,C23.300.985
22182496,2011-12-17T00:00:00,Ventricular Remodeling,G09.330.190.962.975
22186301,2011-12-17T00:00:00,"Antigens, CD147",D12.776.395.550.045
22186301,2011-12-17T00:00:00,"Antigens, CD147",D12.776.543.550.188
22186301,2011-12-17T00:00:00,"Antigens, CD147",D23.050.285.040
22186301,2011-12-17T00:00:00,"Antigens, CD147",D23.050.301.264.035.247
22186301,2011-12-17T00:00:00,"Antigens, CD147",D23.101.100.110.247
22186301,2011-12-17T00:00:00,Cell Line,A11.251.210
22186301,2011-12-17T00:00:00,Fibroblasts,A11.329.228
22186301,2011-12-17T00:00:00,Fibroblasts,A11.872.228
22186301,2011-12-17T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22186301,2011-12-17T00:00:00,Mouth Neoplasms,C04.588.443.591
22186301,2011-12-17T00:00:00,Mouth Neoplasms,C07.465.565
22186301,2011-12-17T00:00:00,Phenotype,G05.695
22186301,2011-12-17T00:00:00,Polymerase Chain Reaction,E05.393.620.500
22180294,2011-12-19T00:00:00,3' Untranslated Regions,D13.444.735.544.875.880
22180294,2011-12-19T00:00:00,3' Untranslated Regions,D13.444.735.790.878.880
22180294,2011-12-19T00:00:00,3' Untranslated Regions,G05.360.340.024.220.880.880
22180294,2011-12-19T00:00:00,3' Untranslated Regions,G05.360.340.024.340.137.910.880
22180294,2011-12-19T00:00:00,Alternative Splicing,G02.111.087.750.700.100
22180294,2011-12-19T00:00:00,Alternative Splicing,G02.149.115.750.700.100
22180294,2011-12-19T00:00:00,Alternative Splicing,G03.495.839.700.100
22180294,2011-12-19T00:00:00,Alternative Splicing,G05.355.315.700.700.100
22180294,2011-12-19T00:00:00,Cell Proliferation,G04.299.233.750
22180294,2011-12-19T00:00:00,Cell Proliferation,G07.700.320.249.410.750
22180294,2011-12-19T00:00:00,"Gene Expression Regulation, Neoplastic",G05.355.315.370
22180294,2011-12-19T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22180294,2011-12-19T00:00:00,Membrane Proteins,D12.776.543
22180294,2011-12-19T00:00:00,MicroRNAs,D13.150.650.319
22180294,2011-12-19T00:00:00,MicroRNAs,D13.444.735.150.319
22180294,2011-12-19T00:00:00,MicroRNAs,D13.444.735.790.099
22180294,2011-12-19T00:00:00,Neoplasms,C04
22180294,2011-12-19T00:00:00,Signal Transduction,G02.111.087.800
22180294,2011-12-19T00:00:00,Signal Transduction,G02.149.115.800
22180294,2011-12-19T00:00:00,Signal Transduction,G04.299.880
22180294,2011-12-19T00:00:00,Sphingosine N-Acyltransferase,D08.811.913.050.712
22180294,2011-12-19T00:00:00,Tumor Suppressor Proteins,D12.776.624.776
22181024,2011-12-19T00:00:00,"Adaptation, Psychological",F01.058
22181024,2011-12-19T00:00:00,Adolescent,M01.060.057
22181024,2011-12-19T00:00:00,Adult,M01.060.116
22181024,2011-12-19T00:00:00,Attitude of Health Personnel,F01.100.050
22181024,2011-12-19T00:00:00,Attitude of Health Personnel,N05.300.100
22181024,2011-12-19T00:00:00,Child,M01.060.406
22181024,2011-12-19T00:00:00,Conduct Disorder,F03.550.150.300
22181024,2011-12-19T00:00:00,Home Care Services,N02.421.143.524
22181024,2011-12-19T00:00:00,Home Care Services,N02.421.539.089
22181024,2011-12-19T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22181024,2011-12-19T00:00:00,Psychometrics,F04.711.780
22181024,2011-12-19T00:00:00,Psychotherapy,F04.754
22181024,2011-12-19T00:00:00,Questionnaires,E05.318.308.750
22181024,2011-12-19T00:00:00,Questionnaires,L01.280.800
22181024,2011-12-19T00:00:00,Questionnaires,N05.715.360.300.695
22181024,2011-12-19T00:00:00,Questionnaires,N06.850.520.308.750
22181024,2011-12-19T00:00:00,Social Environment,I01.880.656
22183742,2011-12-19T00:00:00,ADAM Proteins,D08.811.277.656.675.374.102
22183742,2011-12-19T00:00:00,ADAM Proteins,D09.400.430.500
22183742,2011-12-19T00:00:00,ADAM Proteins,D12.776.395.033
22183742,2011-12-19T00:00:00,Animals,B01.050
22183742,2011-12-19T00:00:00,Calcium-Binding Proteins,D12.776.157.125
22183742,2011-12-19T00:00:00,Cell Proliferation,G04.299.233.750
22183742,2011-12-19T00:00:00,Cell Proliferation,G07.700.320.249.410.750
22183742,2011-12-19T00:00:00,Heart Ventricles,A07.541.560
22183742,2011-12-19T00:00:00,Mitogen-Activated Protein Kinase 1,D08.811.913.696.620.682.700.567.342.500
22183742,2011-12-19T00:00:00,Mitogen-Activated Protein Kinase 1,D08.811.913.696.620.682.700.646.750.249.500
22183742,2011-12-19T00:00:00,Mitogen-Activated Protein Kinase 1,D12.644.360.450.169.500
22183742,2011-12-19T00:00:00,Mitogen-Activated Protein Kinase 1,D12.776.476.450.169.500
22183742,2011-12-19T00:00:00,Mitogen-Activated Protein Kinase 3,D08.811.913.696.620.682.700.567.342.750
22183742,2011-12-19T00:00:00,Mitogen-Activated Protein Kinase 3,D08.811.913.696.620.682.700.646.750.249.750
22183742,2011-12-19T00:00:00,Mitogen-Activated Protein Kinase 3,D12.644.360.450.169.750
22183742,2011-12-19T00:00:00,Mitogen-Activated Protein Kinase 3,D12.776.476.450.169.750
22183742,2011-12-19T00:00:00,Morphogenesis,G07.700.320.500
22183742,2011-12-19T00:00:00,"Myocytes, Cardiac",A07.541.704.570
22183742,2011-12-19T00:00:00,"Myocytes, Cardiac",A10.690.552.750.570
22183742,2011-12-19T00:00:00,"Myocytes, Cardiac",A11.620.500
22183742,2011-12-19T00:00:00,"Receptor, erbB-2",D08.811.913.696.620.682.725.400.150
22183742,2011-12-19T00:00:00,"Receptor, erbB-2",D12.776.543.750.060.374
22183742,2011-12-19T00:00:00,"Receptor, erbB-2",D12.776.543.750.750.400.350
22183742,2011-12-19T00:00:00,"Receptor, erbB-2",D12.776.624.664.700.642
22183742,2011-12-19T00:00:00,"Receptor, erbB-2",D23.101.840.642
22188756,2011-12-19T00:00:00,Antibiotic Prophylaxis,E02.319.162.150
22188756,2011-12-19T00:00:00,Antibiotic Prophylaxis,E02.319.703.150
22188756,2011-12-19T00:00:00,Bladder Exstrophy,C12.706.132
22188756,2011-12-19T00:00:00,Bladder Exstrophy,C12.777.829.132
22188756,2011-12-19T00:00:00,Bladder Exstrophy,C13.351.875.132
22188756,2011-12-19T00:00:00,Bladder Exstrophy,C13.351.968.829.132
22188756,2011-12-19T00:00:00,Bladder Exstrophy,C16.131.939.132
22188756,2011-12-19T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22188756,2011-12-19T00:00:00,Infant,M01.060.703
22188756,2011-12-19T00:00:00,Length of Stay,E02.760.400.480
22188756,2011-12-19T00:00:00,Length of Stay,N02.421.585.400.480
22188756,2011-12-19T00:00:00,Pelvic Bones,A02.835.232.043.825
22188756,2011-12-19T00:00:00,Postoperative Care,E02.760.722.700
22188756,2011-12-19T00:00:00,Postoperative Care,E04.624
22188756,2011-12-19T00:00:00,Postoperative Care,N02.421.585.722.700
22188756,2011-12-19T00:00:00,Recovery of Function,G16.757
22188756,2011-12-19T00:00:00,Time Factors,G01.910.857
22188756,2011-12-19T00:00:00,Treatment Outcome,E01.789.800
22188756,2011-12-19T00:00:00,Treatment Outcome,N04.761.559.590.800
22188756,2011-12-19T00:00:00,Treatment Outcome,N05.715.360.575.575.800
22183507,2011-12-20T00:00:00,Animals,B01.050
22183507,2011-12-20T00:00:00,Graft Rejection,G12.425.901.545.328
22183507,2011-12-20T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22183507,2011-12-20T00:00:00,Immunosuppression,E02.095.465.425.450
22183507,2011-12-20T00:00:00,Immunosuppression,E05.478.610
22183507,2011-12-20T00:00:00,Immunosuppressive Agents,D27.505.696.477.656
22183507,2011-12-20T00:00:00,"Kidney Failure, Chronic",C12.777.419.780.500.602
22183507,2011-12-20T00:00:00,"Kidney Failure, Chronic",C12.777.419.780.750.500
22183507,2011-12-20T00:00:00,"Kidney Failure, Chronic",C13.351.968.419.780.500.602
22183507,2011-12-20T00:00:00,"Kidney Failure, Chronic",C13.351.968.419.780.750.500
22183507,2011-12-20T00:00:00,Kidney Transplantation,E02.870.500
22183507,2011-12-20T00:00:00,Kidney Transplantation,E04.936.450.485
22183507,2011-12-20T00:00:00,Kidney Transplantation,E04.950.774.400
22183822,2011-12-20T00:00:00,Esophageal Motility Disorders,C06.405.117.119.500
22183822,2011-12-20T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22183822,2011-12-20T00:00:00,Manometry,E05.559
22183956,2011-12-20T00:00:00,Adult,M01.060.116
22183956,2011-12-20T00:00:00,Cervical Vertebrae,A02.835.232.834.151
22183956,2011-12-20T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22183956,2011-12-20T00:00:00,Image Enhancement,E01.370.350.600.350
22183956,2011-12-20T00:00:00,Image Enhancement,L01.224.308.380
22183956,2011-12-20T00:00:00,Magnetic Resonance Imaging,E01.370.350.500
22183956,2011-12-20T00:00:00,Magnetic Resonance Imaging,E01.370.350.825.500
22183956,2011-12-20T00:00:00,Spinal Cord,A08.186.854
22205969,2011-12-20T00:00:00,Adolescent,M01.060.057
22205969,2011-12-20T00:00:00,Adult,M01.060.116
22205969,2011-12-20T00:00:00,Aged,M01.060.116.100
22205969,2011-12-20T00:00:00,Animals,B01.050
22205969,2011-12-20T00:00:00,Environmental Exposure,N06.850.460.350
22205969,2011-12-20T00:00:00,Gene Expression Regulation,G05.355.315
22205969,2011-12-20T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22205969,2011-12-20T00:00:00,Middle Aged,M01.060.116.630
22205969,2011-12-20T00:00:00,Nicotine,D03.132.760.570
22205969,2011-12-20T00:00:00,Nicotine,D03.383.725.518
22205969,2011-12-20T00:00:00,"Polymorphism, Single Nucleotide",G05.365.795.598
22205969,2011-12-20T00:00:00,"RNA, Messenger",D13.444.735.544
22205969,2011-12-20T00:00:00,Rats,B01.050.150.900.649.865.635.505.700
22205969,2011-12-20T00:00:00,"Receptors, Nicotinic",D12.776.543.750.720.360.550
22205969,2011-12-20T00:00:00,Schizophrenia,F03.700.750
22205969,2011-12-20T00:00:00,Smoking,F01.145.466.753
22205969,2011-12-20T00:00:00,Time Factors,G01.910.857
22205969,2011-12-20T00:00:00,Young Adult,M01.060.116.815
22188487,2011-12-21T00:00:00,Action Potentials,G04.580.100
22188487,2011-12-21T00:00:00,Action Potentials,G07.265.750.100
22188487,2011-12-21T00:00:00,Action Potentials,G11.561.570.100
22188487,2011-12-21T00:00:00,Algorithms,G17.035
22188487,2011-12-21T00:00:00,Algorithms,L01.224.050
22188487,2011-12-21T00:00:00,Heart Conduction System,A07.541.409
22188487,2011-12-21T00:00:00,Heart Failure,C14.280.434
22188487,2011-12-21T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22188487,2011-12-21T00:00:00,"Signal Processing, Computer-Assisted",L01.224.800
22188487,2011-12-21T00:00:00,Time Factors,G01.910.857
22188487,2011-12-21T00:00:00,Treatment Outcome,E01.789.800
22188487,2011-12-21T00:00:00,Treatment Outcome,N04.761.559.590.800
22188487,2011-12-21T00:00:00,Treatment Outcome,N05.715.360.575.575.800
22190479,2011-12-21T00:00:00,Alligators and Crocodiles,B01.050.150.900.833.100
22190479,2011-12-21T00:00:00,Animals,B01.050
22190479,2011-12-21T00:00:00,Biological Markers,D23.101
22190479,2011-12-21T00:00:00,"Imaging, Three-Dimensional",E01.370.350.400
22190479,2011-12-21T00:00:00,"Imaging, Three-Dimensional",L01.224.308.410
22190479,2011-12-21T00:00:00,Immune System,A15.382
22190479,2011-12-21T00:00:00,Reproduction,G08.686.785.760
22190500,2011-12-21T00:00:00,"Child, Preschool",M01.060.406.448
22190500,2011-12-21T00:00:00,Chromosome Aberrations,C23.550.210
22190500,2011-12-21T00:00:00,Chromosome Aberrations,G05.365.590.175
22190500,2011-12-21T00:00:00,Fragile X Syndrome,C10.597.606.643.455.500
22190500,2011-12-21T00:00:00,Fragile X Syndrome,C16.131.260.800.300
22190500,2011-12-21T00:00:00,Fragile X Syndrome,C16.320.180.800.300
22190500,2011-12-21T00:00:00,Fragile X Syndrome,C16.320.322.500.500
22190500,2011-12-21T00:00:00,Fragile X Syndrome,C16.320.400.525.500
22190500,2011-12-21T00:00:00,Glycoproteins,D09.400.430
22190500,2011-12-21T00:00:00,Glycoproteins,D12.776.395
22190500,2011-12-21T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22190500,2011-12-21T00:00:00,Nuclear Proteins,D12.776.660
22190508,2011-12-21T00:00:00,Disease Progression,C23.550.291.656
22190508,2011-12-21T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22190508,2011-12-21T00:00:00,Infant,M01.060.703
22190508,2011-12-21T00:00:00,Magnetic Resonance Imaging,E01.370.350.500
22190508,2011-12-21T00:00:00,Magnetic Resonance Imaging,E01.370.350.825.500
22190508,2011-12-21T00:00:00,Microarray Analysis,E05.196.630.570
22190508,2011-12-21T00:00:00,Microarray Analysis,E05.588.570
22190508,2011-12-21T00:00:00,Phenotype,G05.695
22190508,2011-12-21T00:00:00,"Tomography Scanners, X-Ray Computed",E07.913
22192660,2011-12-21T00:00:00,Animals,B01.050
22192660,2011-12-21T00:00:00,Autoantibodies,D12.776.124.486.485.114.323
22192660,2011-12-21T00:00:00,Autoantibodies,D12.776.124.790.651.114.323
22192660,2011-12-21T00:00:00,Autoantibodies,D12.776.377.715.548.114.323
22192660,2011-12-21T00:00:00,Cytokines,D12.644.276.374
22192660,2011-12-21T00:00:00,Cytokines,D12.776.467.374
22192660,2011-12-21T00:00:00,Cytokines,D23.529.374
22192660,2011-12-21T00:00:00,"Disease Models, Animal",C22.232
22192660,2011-12-21T00:00:00,"Disease Models, Animal",E05.598.500
22192660,2011-12-21T00:00:00,"Disease Models, Animal",E05.599.395.080
22192660,2011-12-21T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22192660,2011-12-21T00:00:00,Kidney,A05.810.453
22192660,2011-12-21T00:00:00,"Lupus Erythematosus, Systemic",C17.300.480
22192660,2011-12-21T00:00:00,"Lupus Erythematosus, Systemic",C20.111.590
22192660,2011-12-21T00:00:00,Lupus Nephritis,C12.777.419.570.363.680
22192660,2011-12-21T00:00:00,Lupus Nephritis,C13.351.968.419.570.363.680
22192660,2011-12-21T00:00:00,Lupus Nephritis,C17.300.480.680
22192660,2011-12-21T00:00:00,Lupus Nephritis,C20.111.590.560
22205958,2011-12-21T00:00:00,Adult,M01.060.116
22205958,2011-12-21T00:00:00,African Americans,M01.686.508.100.100
22205958,2011-12-21T00:00:00,African Americans,M01.686.754.100
22205958,2011-12-21T00:00:00,Aged,M01.060.116.100
22205958,2011-12-21T00:00:00,Complement System Proteins,D12.776.124.486.274
22205958,2011-12-21T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22205958,2011-12-21T00:00:00,Middle Aged,M01.060.116.630
22205958,2011-12-21T00:00:00,"Polymorphism, Single Nucleotide",G05.365.795.598
22205958,2011-12-21T00:00:00,Signal Transduction,G02.111.087.800
22205958,2011-12-21T00:00:00,Signal Transduction,G02.149.115.800
22205958,2011-12-21T00:00:00,Signal Transduction,G04.299.880
22205958,2011-12-21T00:00:00,Vitamin D,D04.808.812.768
22189356,2011-12-22T00:00:00,African Americans,M01.686.508.100.100
22189356,2011-12-22T00:00:00,African Americans,M01.686.754.100
22189356,2011-12-22T00:00:00,European Continental Ancestry Group,M01.686.508.400
22189356,2011-12-22T00:00:00,Genetic Predisposition to Disease,C23.550.291.687.500
22189356,2011-12-22T00:00:00,Genetic Predisposition to Disease,G05.380.355
22189356,2011-12-22T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22189356,2011-12-22T00:00:00,Linkage Disequilibrium,G05.540.500
22189356,2011-12-22T00:00:00,"Lipoproteins, HDL",D10.532.432
22189356,2011-12-22T00:00:00,"Lipoproteins, HDL",D12.776.521.479
22189356,2011-12-22T00:00:00,Lupus Nephritis,C12.777.419.570.363.680
22189356,2011-12-22T00:00:00,Lupus Nephritis,C13.351.968.419.570.363.680
22189356,2011-12-22T00:00:00,Lupus Nephritis,C17.300.480.680
22189356,2011-12-22T00:00:00,Lupus Nephritis,C20.111.590.560
22189356,2011-12-22T00:00:00,"Polymorphism, Single Nucleotide",G05.365.795.598
22193724,2011-12-23T00:00:00,Amphetamine,D02.092.471.683.152.110
22193724,2011-12-23T00:00:00,Animals,B01.050
22193724,2011-12-23T00:00:00,"Behavior, Animal",F01.145.113
22193724,2011-12-23T00:00:00,Central Nervous System Stimulants,D27.505.696.282
22193724,2011-12-23T00:00:00,Central Nervous System Stimulants,D27.505.954.427.220
22193724,2011-12-23T00:00:00,Corpus Striatum,A08.186.211.730.885.287.249.487
22193724,2011-12-23T00:00:00,Glycine,D12.125.481
22193724,2011-12-23T00:00:00,MAP Kinase Signaling System,G02.111.087.800.560
22193724,2011-12-23T00:00:00,MAP Kinase Signaling System,G02.149.115.800.560
22193724,2011-12-23T00:00:00,MAP Kinase Signaling System,G03.495.553.560
22193724,2011-12-23T00:00:00,MAP Kinase Signaling System,G04.299.880.560
22193724,2011-12-23T00:00:00,Proto-Oncogene Proteins c-akt,D08.811.913.696.620.682.700.755
22193724,2011-12-23T00:00:00,Proto-Oncogene Proteins c-akt,D12.776.476.565
22193724,2011-12-23T00:00:00,Proto-Oncogene Proteins c-akt,D12.776.624.664.700.168
22193724,2011-12-23T00:00:00,Pyridines,D03.383.725
22193724,2011-12-23T00:00:00,RGS Proteins,D12.644.360.325.150.750
22193724,2011-12-23T00:00:00,RGS Proteins,D12.776.402.150.750
22193724,2011-12-23T00:00:00,RGS Proteins,D12.776.476.325.150.750
22193724,2011-12-23T00:00:00,Rats,B01.050.150.900.649.865.635.505.700
22193724,2011-12-23T00:00:00,"Rats, Sprague-Dawley",B01.050.150.900.649.865.635.505.700.750
22193724,2011-12-23T00:00:00,"Receptors, Metabotropic Glutamate",D12.776.543.750.100.450
22193724,2011-12-23T00:00:00,"Receptors, Metabotropic Glutamate",D12.776.543.750.720.200.450.500
22193724,2011-12-23T00:00:00,Thiazoles,D02.886.675
22193724,2011-12-23T00:00:00,Thiazoles,D03.383.129.708
22198950,2011-12-23T00:00:00,Animals,B01.050
22198950,2011-12-23T00:00:00,"Antibodies, Monoclonal",D12.776.124.486.485.114.224
22198950,2011-12-23T00:00:00,"Antibodies, Monoclonal",D12.776.124.790.651.114.224
22198950,2011-12-23T00:00:00,"Antibodies, Monoclonal",D12.776.377.715.548.114.224
22198950,2011-12-23T00:00:00,Autoantibodies,D12.776.124.486.485.114.323
22198950,2011-12-23T00:00:00,Autoantibodies,D12.776.124.790.651.114.323
22198950,2011-12-23T00:00:00,Autoantibodies,D12.776.377.715.548.114.323
22198950,2011-12-23T00:00:00,Brain Ischemia,C10.228.140.300.150
22198950,2011-12-23T00:00:00,Brain Ischemia,C14.907.253.092
22198950,2011-12-23T00:00:00,Complement Activation,G12.425.255
22198950,2011-12-23T00:00:00,Complement C3,D12.776.124.050.140
22198950,2011-12-23T00:00:00,Complement C3,D12.776.124.486.274.250
22198950,2011-12-23T00:00:00,Reperfusion Injury,C14.907.725
22198950,2011-12-23T00:00:00,Reperfusion Injury,C23.550.767.877
22198950,2011-12-23T00:00:00,Stroke,C10.228.140.300.775
22198950,2011-12-23T00:00:00,Stroke,C14.907.253.855
22200686,2011-12-23T00:00:00,"Endoscopy, Gastrointestinal",E01.370.372.250.250
22200686,2011-12-23T00:00:00,"Endoscopy, Gastrointestinal",E01.370.388.250.250.250
22200686,2011-12-23T00:00:00,"Endoscopy, Gastrointestinal",E04.210.240.250
22200686,2011-12-23T00:00:00,"Endoscopy, Gastrointestinal",E04.800.250.250.250
22200686,2011-12-23T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22200686,2011-12-23T00:00:00,Middle Aged,M01.060.116.630
22211367,2011-12-23T00:00:00,Adolescent,M01.060.057
22211367,2011-12-23T00:00:00,Alcoholism,C21.739.100.250
22211367,2011-12-23T00:00:00,Alcoholism,F03.900.100.350
22211367,2011-12-23T00:00:00,Child,M01.060.406
22211367,2011-12-23T00:00:00,"Depressive Disorder, Major",F03.600.300.375
22211367,2011-12-23T00:00:00,Homicide,I01.198.240.470
22211367,2011-12-23T00:00:00,Homicide,I01.880.735.344
22211367,2011-12-23T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22211367,2011-12-23T00:00:00,"Stress Disorders, Post-Traumatic",F03.080.931.500
22211367,2011-12-23T00:00:00,Substance-Related Disorders,C21.739
22211367,2011-12-23T00:00:00,Substance-Related Disorders,F03.900
22211367,2011-12-23T00:00:00,Survivors,M01.643.836
22211367,2011-12-23T00:00:00,Survivors,M01.860
22211367,2011-12-23T00:00:00,United States,Z01.107.567.875
22211367,2011-12-23T00:00:00,Urban Population,N01.600.900
22213257,2011-12-23T00:00:00,Fluorescent Dyes,D27.720.233.348
22213257,2011-12-23T00:00:00,Fluorescent Dyes,D27.720.470.330.348
22213257,2011-12-23T00:00:00,Fluorescent Dyes,D27.720.470.410.505.500
22213257,2011-12-23T00:00:00,Nanostructures,J01.637.512
22213257,2011-12-23T00:00:00,Polymethacrylic Acids,D02.241.081.069.800
22213257,2011-12-23T00:00:00,Polymethacrylic Acids,D05.750.716.822.111.650
22213257,2011-12-23T00:00:00,Polymethacrylic Acids,D25.720.716.822.111.650
22213257,2011-12-23T00:00:00,Polymethacrylic Acids,J01.637.051.720.716.822.111.650
22213257,2011-12-23T00:00:00,Surface Properties,G02.842.850
22227013,2011-12-26T00:00:00,"Antibodies, Monoclonal",D12.776.124.486.485.114.224
22227013,2011-12-26T00:00:00,"Antibodies, Monoclonal",D12.776.124.790.651.114.224
22227013,2011-12-26T00:00:00,"Antibodies, Monoclonal",D12.776.377.715.548.114.224
22227013,2011-12-26T00:00:00,Antineoplastic Agents,D27.505.954.248
22227013,2011-12-26T00:00:00,"Drug Resistance, Neoplasm",G07.690.320.395
22227013,2011-12-26T00:00:00,"Fusion Proteins, bcr-abl",D08.811.913.696.620.682.725.500.500
22227013,2011-12-26T00:00:00,"Fusion Proteins, bcr-abl",D12.776.602.500.500.100
22227013,2011-12-26T00:00:00,"Fusion Proteins, bcr-abl",D12.776.624.100
22227013,2011-12-26T00:00:00,"Fusion Proteins, bcr-abl",D12.776.624.664.500.100
22227013,2011-12-26T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22227013,2011-12-26T00:00:00,Neoplasms,C04
22227013,2011-12-26T00:00:00,Protein Kinase Inhibitors,D27.505.519.389.755
22227013,2011-12-26T00:00:00,Protein-Tyrosine Kinases,D08.811.913.696.620.682.725
22227013,2011-12-26T00:00:00,"Receptor, Epidermal Growth Factor",D08.811.913.696.620.682.725.400.100
22227013,2011-12-26T00:00:00,"Receptor, Epidermal Growth Factor",D12.776.543.750.060.249
22227013,2011-12-26T00:00:00,"Receptor, Epidermal Growth Factor",D12.776.543.750.750.360.300
22227013,2011-12-26T00:00:00,"Receptor, Epidermal Growth Factor",D12.776.543.750.750.400.340
22227013,2011-12-26T00:00:00,"Receptor, IGF Type 1",D08.811.913.696.620.682.725.400.185
22227013,2011-12-26T00:00:00,"Receptor, IGF Type 1",D12.776.543.750.060.468
22227013,2011-12-26T00:00:00,"Receptor, IGF Type 1",D12.776.543.750.750.400.780.400
22227013,2011-12-26T00:00:00,Signal Transduction,G02.111.087.800
22227013,2011-12-26T00:00:00,Signal Transduction,G02.149.115.800
22227013,2011-12-26T00:00:00,Signal Transduction,G04.299.880
22227992,2011-12-27T00:00:00,Anti-Infective Agents,D27.505.954.122
22227992,2011-12-27T00:00:00,Bacteria,B03
22227992,2011-12-27T00:00:00,"Colony Count, Microbial",E05.200.875.220
22227992,2011-12-27T00:00:00,Copper,D01.268.556.195
22227992,2011-12-27T00:00:00,Copper,D01.268.956.170
22227992,2011-12-27T00:00:00,Copper,D01.552.544.195
22227992,2011-12-27T00:00:00,Disinfection,N06.850.780.200.450.850.375
22227992,2011-12-27T00:00:00,Phlebotomy,E01.450.865.632.150.625
22227992,2011-12-27T00:00:00,Phlebotomy,E02.800.558
22198974,2011-12-28T00:00:00,Adolescent,M01.060.057
22198974,2011-12-28T00:00:00,Adult,M01.060.116
22198974,2011-12-28T00:00:00,Child,M01.060.406
22198974,2011-12-28T00:00:00,Cystic Fibrosis,C06.689.202
22198974,2011-12-28T00:00:00,Cystic Fibrosis,C08.381.187
22198974,2011-12-28T00:00:00,Cystic Fibrosis,C16.320.190
22198974,2011-12-28T00:00:00,Cystic Fibrosis,C16.614.213
22198974,2011-12-28T00:00:00,Double-Blind Method,E05.318.780.300
22198974,2011-12-28T00:00:00,Double-Blind Method,E05.581.500.300
22198974,2011-12-28T00:00:00,Double-Blind Method,N05.715.360.780.320
22198974,2011-12-28T00:00:00,Double-Blind Method,N06.850.520.445.300
22198974,2011-12-28T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22198974,2011-12-28T00:00:00,Middle Aged,M01.060.116.630
22198974,2011-12-28T00:00:00,Powders,D26.255.779
22198974,2011-12-28T00:00:00,Powders,D27.720.280.779
22198974,2011-12-28T00:00:00,Time Factors,G01.910.857
22198974,2011-12-28T00:00:00,Treatment Outcome,E01.789.800
22198974,2011-12-28T00:00:00,Treatment Outcome,N04.761.559.590.800
22198974,2011-12-28T00:00:00,Treatment Outcome,N05.715.360.575.575.800
22198974,2011-12-28T00:00:00,Young Adult,M01.060.116.815
22204504,2011-12-28T00:00:00,Adult,M01.060.116
22204504,2011-12-28T00:00:00,Aged,M01.060.116.100
22204504,2011-12-28T00:00:00,Breast Neoplasms,C04.588.180
22204504,2011-12-28T00:00:00,Breast Neoplasms,C17.800.090.500
22204504,2011-12-28T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22204504,2011-12-28T00:00:00,Lung,A04.411
22204504,2011-12-28T00:00:00,Lymph Nodes,A10.549.400
22204504,2011-12-28T00:00:00,Lymph Nodes,A15.382.520.604.412
22204504,2011-12-28T00:00:00,Mammaplasty,E02.218.565
22204504,2011-12-28T00:00:00,Mammaplasty,E04.680.500
22204504,2011-12-28T00:00:00,Middle Aged,M01.060.116.630
22204504,2011-12-28T00:00:00,Radiation Dosage,E05.799.513
22204504,2011-12-28T00:00:00,Radiation Dosage,G01.201.875.740
22204504,2011-12-28T00:00:00,Radiation Dosage,N06.850.810.250
22205228,2011-12-28T00:00:00,Animals,B01.050
22205228,2011-12-28T00:00:00,Aquaporin 2,D12.776.157.530.400.500.040.437
22205228,2011-12-28T00:00:00,Aquaporin 2,D12.776.543.550.425.730.040.437
22205228,2011-12-28T00:00:00,Aquaporin 2,D12.776.543.585.400.730.040.530
22205228,2011-12-28T00:00:00,Cell Line,A11.251.210
22205228,2011-12-28T00:00:00,Cilia,A11.284.180.165
22205228,2011-12-28T00:00:00,Cyclic AMP-Dependent Protein Kinases,D08.811.913.696.620.682.700.150.125
22205228,2011-12-28T00:00:00,Cyclic AMP-Dependent Protein Kinases,D12.644.360.200.125
22205228,2011-12-28T00:00:00,Cyclic AMP-Dependent Protein Kinases,D12.776.476.200.125
22205228,2011-12-28T00:00:00,"Kidney Tubules, Collecting",A05.810.453.736.560.510
22205228,2011-12-28T00:00:00,Polycystic Kidney Diseases,C12.777.419.403.875
22205228,2011-12-28T00:00:00,Polycystic Kidney Diseases,C13.351.968.419.403.875
22205228,2011-12-28T00:00:00,"Receptors, Vasopressin",D12.776.543.750.100.910
22205228,2011-12-28T00:00:00,"Receptors, Vasopressin",D12.776.543.750.720.600.925
22205228,2011-12-28T00:00:00,"Receptors, Vasopressin",D12.776.543.750.750.555.925
22205228,2011-12-28T00:00:00,"Receptors, Vasopressin",D12.776.543.750.750.660.900
22206805,2011-12-28T00:00:00,Case-Control Studies,E05.318.760.500.500
22206805,2011-12-28T00:00:00,Case-Control Studies,N05.715.360.775.175.200
22206805,2011-12-28T00:00:00,Case-Control Studies,N06.850.520.450.500.500
22206805,2011-12-28T00:00:00,Cataract Extraction,E04.540.825.249
22206805,2011-12-28T00:00:00,Child,M01.060.406
22206805,2011-12-28T00:00:00,"Child, Preschool",M01.060.406.448
22206805,2011-12-28T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22206805,2011-12-28T00:00:00,"Lens Implantation, Intraocular",E04.540.825.600
22206805,2011-12-28T00:00:00,Myopia,C11.744.636
22206805,2011-12-28T00:00:00,"Refraction, Ocular",E01.370.380.850.700
22206805,2011-12-28T00:00:00,"Refraction, Ocular",G01.590.770.760
22206805,2011-12-28T00:00:00,"Refraction, Ocular",G01.595.640.760
22206805,2011-12-28T00:00:00,"Refraction, Ocular",G14.760
22206805,2011-12-28T00:00:00,Visual Acuity,E01.370.380.850.950
22206805,2011-12-28T00:00:00,Visual Acuity,F02.463.593.932.901
22206805,2011-12-28T00:00:00,Visual Acuity,G14.940
22206960,2011-12-28T00:00:00,Adult,M01.060.116
22206960,2011-12-28T00:00:00,Aged,M01.060.116.100
22206960,2011-12-28T00:00:00,"Aortic Aneurysm, Thoracic",C14.907.055.239.125
22206960,2011-12-28T00:00:00,"Aortic Aneurysm, Thoracic",C14.907.109.139.125
22206960,2011-12-28T00:00:00,Aortic Valve,A07.541.510.110
22206960,2011-12-28T00:00:00,Blood Vessel Prosthesis Implantation,E04.100.814.200
22206960,2011-12-28T00:00:00,Blood Vessel Prosthesis Implantation,E04.650.200
22206960,2011-12-28T00:00:00,Extracellular Matrix Proteins,D12.776.860.300
22206960,2011-12-28T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22206960,2011-12-28T00:00:00,Matrix Metalloproteinases,D08.811.277.656.300.480.525
22206960,2011-12-28T00:00:00,Matrix Metalloproteinases,D08.811.277.656.675.374.525
22206960,2011-12-28T00:00:00,Middle Aged,M01.060.116.630
22206960,2011-12-28T00:00:00,Tissue Inhibitor of Metalloproteinases,D12.776.926
22216097,2011-12-28T00:00:00,Adult,M01.060.116
22216097,2011-12-28T00:00:00,Aged,M01.060.116.100
22216097,2011-12-28T00:00:00,Colorectal Neoplasms,C04.588.274.476.411.307
22216097,2011-12-28T00:00:00,Colorectal Neoplasms,C06.301.371.411.307
22216097,2011-12-28T00:00:00,Colorectal Neoplasms,C06.405.249.411.307
22216097,2011-12-28T00:00:00,Colorectal Neoplasms,C06.405.469.158.356
22216097,2011-12-28T00:00:00,Colorectal Neoplasms,C06.405.469.491.307
22216097,2011-12-28T00:00:00,Colorectal Neoplasms,C06.405.469.860.180
22216097,2011-12-28T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22216097,2011-12-28T00:00:00,Insulin-Like Growth Factor I,D12.644.276.937.400
22216097,2011-12-28T00:00:00,Insulin-Like Growth Factor I,D12.776.124.862.400
22216097,2011-12-28T00:00:00,Insulin-Like Growth Factor I,D12.776.467.937.400
22216097,2011-12-28T00:00:00,Insulin-Like Growth Factor I,D23.529.937.400
22216097,2011-12-28T00:00:00,Middle Aged,M01.060.116.630
22216097,2011-12-28T00:00:00,Questionnaires,E05.318.308.750
22216097,2011-12-28T00:00:00,Questionnaires,L01.280.800
22216097,2011-12-28T00:00:00,Questionnaires,N05.715.360.300.695
22216097,2011-12-28T00:00:00,Questionnaires,N06.850.520.308.750
22216097,2011-12-28T00:00:00,Risk Factors,E05.318.740.600.800.725
22216097,2011-12-28T00:00:00,Risk Factors,N05.715.350.200.700
22216097,2011-12-28T00:00:00,Risk Factors,N05.715.360.750.625.700.700
22216097,2011-12-28T00:00:00,Risk Factors,N06.850.490.625.750
22216097,2011-12-28T00:00:00,Risk Factors,N06.850.520.830.600.800.725
22216097,2011-12-28T00:00:00,Vitamin D,D04.808.812.768
22207605,2011-12-29T00:00:00,Animals,B01.050
22207605,2011-12-29T00:00:00,Aortic Valve,A07.541.510.110
22207605,2011-12-29T00:00:00,Biocompatible Materials,D25.130
22207605,2011-12-29T00:00:00,Biocompatible Materials,D27.720.102.130
22207605,2011-12-29T00:00:00,Biocompatible Materials,J01.637.051.130
22207605,2011-12-29T00:00:00,Bioprosthesis,E07.695.100
22207605,2011-12-29T00:00:00,Calcinosis,C18.452.174.130
22207605,2011-12-29T00:00:00,Collagen,D05.750.078.280
22207605,2011-12-29T00:00:00,Collagen,D12.776.860.300.250
22207605,2011-12-29T00:00:00,Elastin,D05.750.078.421
22207605,2011-12-29T00:00:00,Elastin,D12.776.860.300.350
22207605,2011-12-29T00:00:00,Glycosaminoglycans,D09.698.373
22207605,2011-12-29T00:00:00,Heart Valve Prosthesis,E07.695.310
22207605,2011-12-29T00:00:00,Materials Testing,E05.570
22207605,2011-12-29T00:00:00,Neomycin,D09.408.051.623
22207605,2011-12-29T00:00:00,Protein Stability,G02.111.700
22207605,2011-12-29T00:00:00,Rats,B01.050.150.900.649.865.635.505.700
22207605,2011-12-29T00:00:00,"Rats, Sprague-Dawley",B01.050.150.900.649.865.635.505.700.750
22207675,2011-12-29T00:00:00,Adult,M01.060.116
22207675,2011-12-29T00:00:00,Biological Markers,D23.101
22207675,2011-12-29T00:00:00,Bronchoscopy,E01.370.386.105
22207675,2011-12-29T00:00:00,Bronchoscopy,E01.370.388.250.100
22207675,2011-12-29T00:00:00,Bronchoscopy,E04.800.250.100
22207675,2011-12-29T00:00:00,Bronchoscopy,E04.928.600.080
22207675,2011-12-29T00:00:00,"Diagnosis, Differential",E01.171
22207675,2011-12-29T00:00:00,Disease Progression,C23.550.291.656
22207675,2011-12-29T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22207675,2011-12-29T00:00:00,Lung Diseases,C08.381
22207675,2011-12-29T00:00:00,Occupational Exposure,N06.850.460.350.600
22207675,2011-12-29T00:00:00,Risk Factors,E05.318.740.600.800.725
22207675,2011-12-29T00:00:00,Risk Factors,N05.715.350.200.700
22207675,2011-12-29T00:00:00,Risk Factors,N05.715.360.750.625.700.700
22207675,2011-12-29T00:00:00,Risk Factors,N06.850.490.625.750
22207675,2011-12-29T00:00:00,Risk Factors,N06.850.520.830.600.800.725
22207675,2011-12-29T00:00:00,"Tomography, X-Ray Computed",E01.370.350.350.810
22207675,2011-12-29T00:00:00,"Tomography, X-Ray Computed",E01.370.350.600.350.700.810
22207675,2011-12-29T00:00:00,"Tomography, X-Ray Computed",E01.370.350.700.700.810
22207675,2011-12-29T00:00:00,"Tomography, X-Ray Computed",E01.370.350.700.810.810
22207675,2011-12-29T00:00:00,"Tomography, X-Ray Computed",E01.370.350.825.810.810
22224840,2011-12-29T00:00:00,Aged,M01.060.116.100
22224840,2011-12-29T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22208873,2011-12-30T00:00:00,Adolescent,M01.060.057
22208873,2011-12-30T00:00:00,Adult,M01.060.116
22208873,2011-12-30T00:00:00,Aged,M01.060.116.100
22208873,2011-12-30T00:00:00,Complementary Therapies,E02.190
22208873,2011-12-30T00:00:00,Health Literacy,I02.233.332.186.500
22208873,2011-12-30T00:00:00,Health Literacy,N02.421.143.827.407.228.500
22208873,2011-12-30T00:00:00,Health Literacy,N02.421.726.407.228.500
22208873,2011-12-30T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22208873,2011-12-30T00:00:00,Middle Aged,M01.060.116.630
22208873,2011-12-30T00:00:00,Patient Acceptance of Health Care,N05.300.150.600
22208873,2011-12-30T00:00:00,Primary Health Care,N04.590.233.727
22208873,2011-12-30T00:00:00,Questionnaires,E05.318.308.750
22208873,2011-12-30T00:00:00,Questionnaires,L01.280.800
22208873,2011-12-30T00:00:00,Questionnaires,N05.715.360.300.695
22208873,2011-12-30T00:00:00,Questionnaires,N06.850.520.308.750
22208873,2011-12-30T00:00:00,Young Adult,M01.060.116.815
22209098,2011-12-30T00:00:00,Adult,M01.060.116
22209098,2011-12-30T00:00:00,DNA-Binding Proteins,D12.776.260
22209098,2011-12-30T00:00:00,"Diagnosis, Differential",E01.171
22209098,2011-12-30T00:00:00,Gingival Neoplasms,C04.588.443.591.402
22209098,2011-12-30T00:00:00,Gingival Neoplasms,C07.465.565.402
22209098,2011-12-30T00:00:00,Gingival Neoplasms,C07.465.714.258.409
22209098,2011-12-30T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22209098,2011-12-30T00:00:00,"Lymphoma, Large B-Cell, Diffuse",C04.557.386.480.150.585
22209098,2011-12-30T00:00:00,"Lymphoma, Large B-Cell, Diffuse",C15.604.515.569.480.150.585
22209098,2011-12-30T00:00:00,"Lymphoma, Large B-Cell, Diffuse",C20.683.515.761.480.150.585
22209098,2011-12-30T00:00:00,Neoplasm Invasiveness,C04.697.645
22209098,2011-12-30T00:00:00,Neoplasm Invasiveness,C23.550.727.645
22209098,2011-12-30T00:00:00,Transcription Factors,D12.776.930
21102356,2012-01-01T00:00:00,Aged,M01.060.116.100
21102356,2012-01-01T00:00:00,Clinical Competence,I02.399.630.210
21102356,2012-01-01T00:00:00,Clinical Competence,N04.761.210
21102356,2012-01-01T00:00:00,Contrast Media,D27.720.259
21102356,2012-01-01T00:00:00,Coronary Angiography,E01.370.350.700.060.200
21102356,2012-01-01T00:00:00,Coronary Angiography,E01.370.370.050.200
21102356,2012-01-01T00:00:00,Coronary Angiography,E01.370.370.380.200
21102356,2012-01-01T00:00:00,Coronary Artery Disease,C14.280.647.250.260
21102356,2012-01-01T00:00:00,Coronary Artery Disease,C14.907.137.126.339
21102356,2012-01-01T00:00:00,Coronary Artery Disease,C14.907.585.250.260
21102356,2012-01-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21102356,2012-01-01T00:00:00,Middle Aged,M01.060.116.630
21102356,2012-01-01T00:00:00,"Radiographic Image Interpretation, Computer-Assisted",E01.158.600.680
21102356,2012-01-01T00:00:00,"Radiographic Image Interpretation, Computer-Assisted",E01.370.350.350.700
21102356,2012-01-01T00:00:00,"Radiographic Image Interpretation, Computer-Assisted",E01.370.350.700.705
21102356,2012-01-01T00:00:00,"Radiographic Image Interpretation, Computer-Assisted",L01.700.508.100.158.600.680
21153760,2012-01-01T00:00:00,Child Health Services,N02.421.143.130
21153760,2012-01-01T00:00:00,"Child, Preschool",M01.060.406.448
21153760,2012-01-01T00:00:00,Dental Care for Children,E06.170.152
21153760,2012-01-01T00:00:00,Dental Care for Children,N02.421.240.190.215
21153760,2012-01-01T00:00:00,Health Services Accessibility,N04.590.374.350
21153760,2012-01-01T00:00:00,Health Services Accessibility,N05.300.430
21153760,2012-01-01T00:00:00,Healthcare Disparities,N04.590.374.380
21153760,2012-01-01T00:00:00,Healthcare Disparities,N05.300.493
21153760,2012-01-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21153760,2012-01-01T00:00:00,Infant,M01.060.703
21153760,2012-01-01T00:00:00,"Models, Statistical",E05.318.740.500
21153760,2012-01-01T00:00:00,"Models, Statistical",E05.599.835
21153760,2012-01-01T00:00:00,"Models, Statistical",N05.715.360.750.530
21153760,2012-01-01T00:00:00,"Models, Statistical",N06.850.520.830.500
21153760,2012-01-01T00:00:00,"Models, Theoretical",E05.599
21153760,2012-01-01T00:00:00,Patient Acceptance of Health Care,N05.300.150.600
21153760,2012-01-01T00:00:00,Rural Population,N01.600.725
21153760,2012-01-01T00:00:00,South Carolina,Z01.107.567.875.075.662
21153760,2012-01-01T00:00:00,South Carolina,Z01.107.567.875.750.700
21153760,2012-01-01T00:00:00,United States,Z01.107.567.875
21153760,2012-01-01T00:00:00,Urban Population,N01.600.900
21424864,2012-01-01T00:00:00,Autistic Disorder,F03.550.325.125
21424864,2012-01-01T00:00:00,Child,M01.060.406
21424864,2012-01-01T00:00:00,"Child, Preschool",M01.060.406.448
21424864,2012-01-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21424864,2012-01-01T00:00:00,Hydrocortisone,D04.808.745.745.654.600
21424864,2012-01-01T00:00:00,Hydrocortisone,D06.472.040.585.353.476
21424864,2012-01-01T00:00:00,Hydrocortisone,D06.472.040.585.478.392
21424864,2012-01-01T00:00:00,Hypothalamo-Hypophyseal System,A06.688.357
21424864,2012-01-01T00:00:00,Hypothalamo-Hypophyseal System,A08.186.211.730.317.357.352.435
21424864,2012-01-01T00:00:00,Hypothalamo-Hypophyseal System,A08.713.357
21424864,2012-01-01T00:00:00,Pituitary-Adrenal System,A06.407.691
21424864,2012-01-01T00:00:00,Saliva,A12.200.666
21424864,2012-01-01T00:00:00,"Stress, Physiological",G07.700.830
21424864,2012-01-01T00:00:00,"Stress, Psychological",F01.145.126.990
21424864,2012-01-01T00:00:00,"Stress, Psychological",F02.830.900
21681060,2012-01-01T00:00:00,Adult,M01.060.116
21681060,2012-01-01T00:00:00,Aged,M01.060.116.100
21681060,2012-01-01T00:00:00,Aging,G07.700.320.124
21681060,2012-01-01T00:00:00,Biomedical Research,H01.770.644.145
21681060,2012-01-01T00:00:00,Continuity of Patient Care,N04.590.233.727.210
21681060,2012-01-01T00:00:00,Forecasting,I01.320
21681060,2012-01-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21681060,2012-01-01T00:00:00,Middle Aged,M01.060.116.630
21681060,2012-01-01T00:00:00,Needs Assessment,I02.594
21681060,2012-01-01T00:00:00,Needs Assessment,N03.349.380.565
21681060,2012-01-01T00:00:00,Needs Assessment,N05.300.537
21681060,2012-01-01T00:00:00,Practice Guidelines as Topic,N04.761.700.350.650
21681060,2012-01-01T00:00:00,Practice Guidelines as Topic,N05.700.350.650
21681060,2012-01-01T00:00:00,Quadriplegia,C10.597.622.760
21681060,2012-01-01T00:00:00,Quadriplegia,C23.888.592.636.786
21681060,2012-01-01T00:00:00,Spinal Cord Injuries,C10.228.854.770
21681060,2012-01-01T00:00:00,Spinal Cord Injuries,C10.900.850
21681060,2012-01-01T00:00:00,Spinal Cord Injuries,C21.866.819
21681060,2012-01-01T00:00:00,United States,Z01.107.567.875
21681060,2012-01-01T00:00:00,Young Adult,M01.060.116.815
21804415,2012-01-01T00:00:00,Adolescent,M01.060.057
21804415,2012-01-01T00:00:00,Adult,M01.060.116
21804415,2012-01-01T00:00:00,Athletic Injuries,C21.866.115
21804415,2012-01-01T00:00:00,"Hospitals, Teaching",N02.278.020.300
21804415,2012-01-01T00:00:00,"Hospitals, Teaching",N02.278.421.639
21804415,2012-01-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21804415,2012-01-01T00:00:00,Soccer,I03.450.642.845.800
21804415,2012-01-01T00:00:00,Tibial Fractures,C21.866.404.875
21804415,2012-01-01T00:00:00,Tibial Fractures,C21.866.558.857
21804415,2012-01-01T00:00:00,Trauma Centers,N02.278.354.422.336.500
21804415,2012-01-01T00:00:00,Trauma Centers,N02.421.297.195.480
21804415,2012-01-01T00:00:00,Trauma Centers,N04.452.442.422.336.400
21804415,2012-01-01T00:00:00,Young Adult,M01.060.116.815
21811187,2012-01-01T00:00:00,Craniocerebral Trauma,C10.900.300
21811187,2012-01-01T00:00:00,Craniocerebral Trauma,C21.866.260
21811187,2012-01-01T00:00:00,Craniocerebral Trauma,C21.866.915.300
21811187,2012-01-01T00:00:00,Head,A01.456
21811187,2012-01-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21811187,2012-01-01T00:00:00,Soccer,I03.450.642.845.800
21883605,2012-01-01T00:00:00,Health Services Accessibility,N04.590.374.350
21883605,2012-01-01T00:00:00,Health Services Accessibility,N05.300.430
21883605,2012-01-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21883605,2012-01-01T00:00:00,Income,N01.824.417
21883605,2012-01-01T00:00:00,Internet,L01.224.230.110.500
21883605,2012-01-01T00:00:00,North America,Z01.107.567
21883605,2012-01-01T00:00:00,Patient Acceptance of Health Care,N05.300.150.600
21883605,2012-01-01T00:00:00,Program Evaluation,E05.337.820
21883605,2012-01-01T00:00:00,Program Evaluation,N04.761.685
21883605,2012-01-01T00:00:00,Program Evaluation,N05.715.360.650
21883605,2012-01-01T00:00:00,Smoking,F01.145.466.753
21883605,2012-01-01T00:00:00,Smoking Cessation,F01.145.940.700
21898502,2012-01-01T00:00:00,Adenocarcinoma,C04.557.470.200.025
21898502,2012-01-01T00:00:00,Animals,B01.050
21898502,2012-01-01T00:00:00,Antineoplastic Agents,D27.505.954.248
21898502,2012-01-01T00:00:00,CD8-Positive T-Lymphocytes,A11.118.637.555.567.569.220
21898502,2012-01-01T00:00:00,CD8-Positive T-Lymphocytes,A15.145.229.637.555.567.569.220
21898502,2012-01-01T00:00:00,CD8-Positive T-Lymphocytes,A15.382.490.555.567.569.220
21898502,2012-01-01T00:00:00,"Carcinoma, Hepatocellular",C04.557.470.200.025.255
21898502,2012-01-01T00:00:00,"Carcinoma, Hepatocellular",C04.588.274.623.160
21898502,2012-01-01T00:00:00,"Carcinoma, Hepatocellular",C06.301.623.160
21898502,2012-01-01T00:00:00,"Carcinoma, Hepatocellular",C06.552.697.160
21898502,2012-01-01T00:00:00,Combined Modality Therapy,E02.186
21898502,2012-01-01T00:00:00,"Disease Models, Animal",C22.232
21898502,2012-01-01T00:00:00,"Disease Models, Animal",E05.598.500
21898502,2012-01-01T00:00:00,"Disease Models, Animal",E05.599.395.080
21898502,2012-01-01T00:00:00,Hepatocytes,A11.436.348
21898502,2012-01-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21898502,2012-01-01T00:00:00,Immune Tolerance,G12.425.746.425
21898502,2012-01-01T00:00:00,Liver Neoplasms,C04.588.274.623
21898502,2012-01-01T00:00:00,Liver Neoplasms,C06.301.623
21898502,2012-01-01T00:00:00,Liver Neoplasms,C06.552.697
21898502,2012-01-01T00:00:00,Pyrroles,D03.383.129.578
21918464,2012-01-01T00:00:00,Electronic Health Records,E05.318.308.940.968.625.500
21918464,2012-01-01T00:00:00,Hospitals,N02.278.421
21918464,2012-01-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
21918464,2012-01-01T00:00:00,Patient Satisfaction,N04.452.822.360.600
21918464,2012-01-01T00:00:00,Patient Satisfaction,N05.300.150.600.630
21918464,2012-01-01T00:00:00,Patient Satisfaction,N05.715.360.600
21918464,2012-01-01T00:00:00,Regression Analysis,E05.318.740.750
21918464,2012-01-01T00:00:00,Regression Analysis,N05.715.360.750.695
21918464,2012-01-01T00:00:00,Regression Analysis,N06.850.520.830.750
21918464,2012-01-01T00:00:00,United States,Z01.107.567.875
21994124,2012-01-01T00:00:00,Nanoparticles,J01.637.512.600
21994124,2012-01-01T00:00:00,Solubility,G02.842.800
21994124,2012-01-01T00:00:00,Surface Properties,G02.842.850
21994124,2012-01-01T00:00:00,"Water Pollutants, Chemical",D27.888.284.903.655
21994124,2012-01-01T00:00:00,Zinc Oxide,D01.650.550.975
21994124,2012-01-01T00:00:00,Zinc Oxide,D01.975.975
22002628,2012-01-01T00:00:00,Adsorption,G02.149.047
22002628,2012-01-01T00:00:00,Adsorption,G02.149.767.029
22002628,2012-01-01T00:00:00,Adsorption,G02.842.750.029
22002628,2012-01-01T00:00:00,Environmental Pollutants,D27.888.284
22002628,2012-01-01T00:00:00,"Models, Chemical",E05.599.495
22002628,2012-01-01T00:00:00,"Nanotubes, Carbon",D01.268.150.250.500
22002628,2012-01-01T00:00:00,"Nanotubes, Carbon",J01.637.512.850.500
22031171,2012-01-01T00:00:00,Adolescent,M01.060.057
22031171,2012-01-01T00:00:00,Anticholesteremic Agents,D27.505.519.186.071.202
22031171,2012-01-01T00:00:00,Anticholesteremic Agents,D27.505.954.230.202
22031171,2012-01-01T00:00:00,Child,M01.060.406
22031171,2012-01-01T00:00:00,Disease Progression,C23.550.291.656
22031171,2012-01-01T00:00:00,Double-Blind Method,E05.318.780.300
22031171,2012-01-01T00:00:00,Double-Blind Method,E05.581.500.300
22031171,2012-01-01T00:00:00,Double-Blind Method,N05.715.360.780.320
22031171,2012-01-01T00:00:00,Double-Blind Method,N06.850.520.445.300
22031171,2012-01-01T00:00:00,Heptanoic Acids,D10.251.450
22031171,2012-01-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22031171,2012-01-01T00:00:00,Lipids,D10
22031171,2012-01-01T00:00:00,"Lupus Erythematosus, Systemic",C17.300.480
22031171,2012-01-01T00:00:00,"Lupus Erythematosus, Systemic",C20.111.590
22031171,2012-01-01T00:00:00,Pyrroles,D03.383.129.578
22031171,2012-01-01T00:00:00,Treatment Outcome,E01.789.800
22031171,2012-01-01T00:00:00,Treatment Outcome,N04.761.559.590.800
22031171,2012-01-01T00:00:00,Treatment Outcome,N05.715.360.575.575.800
22031171,2012-01-01T00:00:00,Young Adult,M01.060.116.815
22057572,2012-01-01T00:00:00,Animals,B01.050
22057572,2012-01-01T00:00:00,Cell Separation,E05.200.500.363
22057572,2012-01-01T00:00:00,Fluorescent Dyes,D27.720.233.348
22057572,2012-01-01T00:00:00,Fluorescent Dyes,D27.720.470.330.348
22057572,2012-01-01T00:00:00,Fluorescent Dyes,D27.720.470.410.505.500
22057572,2012-01-01T00:00:00,"Microscopy, Confocal",E01.370.350.515.395
22057572,2012-01-01T00:00:00,"Microscopy, Confocal",E05.595.395
22057572,2012-01-01T00:00:00,"Mitochondria, Heart",A11.284.430.214.190.875.564.627.603
22057572,2012-01-01T00:00:00,"Mitochondria, Heart",A11.284.835.626.627.603
22057572,2012-01-01T00:00:00,"Myocytes, Cardiac",A07.541.704.570
22057572,2012-01-01T00:00:00,"Myocytes, Cardiac",A10.690.552.750.570
22057572,2012-01-01T00:00:00,"Myocytes, Cardiac",A11.620.500
22057572,2012-01-01T00:00:00,Rabbits,B01.050.150.900.649.521.700
22059957,2012-01-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22059957,2012-01-01T00:00:00,Metabolic Syndrome X,C18.452.394.968.500.570
22059957,2012-01-01T00:00:00,Metabolic Syndrome X,C18.452.625
22059957,2012-01-01T00:00:00,Risk Factors,E05.318.740.600.800.725
22059957,2012-01-01T00:00:00,Risk Factors,N05.715.350.200.700
22059957,2012-01-01T00:00:00,Risk Factors,N05.715.360.750.625.700.700
22059957,2012-01-01T00:00:00,Risk Factors,N06.850.490.625.750
22059957,2012-01-01T00:00:00,Risk Factors,N06.850.520.830.600.800.725
22059957,2012-01-01T00:00:00,Vitamin D,D04.808.812.768
22059957,2012-01-01T00:00:00,Vitamin D Deficiency,C18.654.521.500.133.770
22080848,2012-01-01T00:00:00,Anemia,C15.378.071
22080848,2012-01-01T00:00:00,Copper,D01.268.556.195
22080848,2012-01-01T00:00:00,Copper,D01.268.956.170
22080848,2012-01-01T00:00:00,Copper,D01.552.544.195
22080848,2012-01-01T00:00:00,"Diagnosis, Differential",E01.171
22080848,2012-01-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22108723,2012-01-01T00:00:00,Animals,B01.050
22108723,2012-01-01T00:00:00,Disease Progression,C23.550.291.656
22108723,2012-01-01T00:00:00,Extracellular Matrix,A11.284.295.310
22108723,2012-01-01T00:00:00,Heart Failure,C14.280.434
22108723,2012-01-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22108723,2012-01-01T00:00:00,Myocardium,A02.633.580
22108723,2012-01-01T00:00:00,Myocardium,A07.541.704
22108723,2012-01-01T00:00:00,Myocardium,A10.690.552.750
22108723,2012-01-01T00:00:00,Ventricular Remodeling,C23.300.985
22108723,2012-01-01T00:00:00,Ventricular Remodeling,G09.330.190.962.975
22108765,2012-01-01T00:00:00,Adolescent,M01.060.057
22108765,2012-01-01T00:00:00,Child,M01.060.406
22108765,2012-01-01T00:00:00,Cognitive Therapy,F04.754.137.428
22108765,2012-01-01T00:00:00,Depression,F01.145.126.350
22108765,2012-01-01T00:00:00,Disability Evaluation,E01.370.400
22108765,2012-01-01T00:00:00,Fibromyalgia,C05.651.324
22108765,2012-01-01T00:00:00,Fibromyalgia,C05.799.321
22108765,2012-01-01T00:00:00,Fibromyalgia,C10.668.491.425
22108765,2012-01-01T00:00:00,Health Status,I01.240.425
22108765,2012-01-01T00:00:00,Health Status,N01.224.425
22108765,2012-01-01T00:00:00,Health Status,N06.850.505.400.425
22108765,2012-01-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22108765,2012-01-01T00:00:00,Pain Measurement,E01.370.376.550.600
22108765,2012-01-01T00:00:00,Pain Threshold,F02.463.593.710.560
22108765,2012-01-01T00:00:00,Pain Threshold,F02.830.816.444.700
22108765,2012-01-01T00:00:00,Pain Threshold,G11.561.600.810.444.700
22108765,2012-01-01T00:00:00,Quality of Life,I01.800
22108765,2012-01-01T00:00:00,Quality of Life,K01.752.400.750
22108765,2012-01-01T00:00:00,Treatment Outcome,E01.789.800
22108765,2012-01-01T00:00:00,Treatment Outcome,N04.761.559.590.800
22108765,2012-01-01T00:00:00,Treatment Outcome,N05.715.360.575.575.800
22129534,2012-01-01T00:00:00,Adult,M01.060.116
22129534,2012-01-01T00:00:00,Blood Substitutes,D27.505.954.502.140
22129534,2012-01-01T00:00:00,Cesarean Section,E04.520.252.500
22129534,2012-01-01T00:00:00,"Diagnosis, Differential",E01.171
22129534,2012-01-01T00:00:00,"Embolism, Amniotic Fluid",C13.703.634.404
22129534,2012-01-01T00:00:00,"Embolism, Amniotic Fluid",C14.583.404
22129534,2012-01-01T00:00:00,"Embolism, Amniotic Fluid",C14.907.355.350.354
22129534,2012-01-01T00:00:00,Hemodynamics,G09.330.190.400
22129534,2012-01-01T00:00:00,Hemodynamics,G09.330.380
22129534,2012-01-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22129534,2012-01-01T00:00:00,"Infant, Newborn",M01.060.703.520
22129534,2012-01-01T00:00:00,Pregnancy,G08.686.785.760.769
22129534,2012-01-01T00:00:00,Resuscitation,E02.365.647
22129534,2012-01-01T00:00:00,Seizures,C10.228.140.490.631
22129534,2012-01-01T00:00:00,Seizures,C10.597.742
22129534,2012-01-01T00:00:00,Seizures,C23.888.592.742
22153093,2012-01-01T00:00:00,Adolescent,M01.060.057
22153093,2012-01-01T00:00:00,African Americans,M01.686.508.100.100
22153093,2012-01-01T00:00:00,African Americans,M01.686.754.100
22153093,2012-01-01T00:00:00,Aging,G07.700.320.124
22153093,2012-01-01T00:00:00,Child,M01.060.406
22153093,2012-01-01T00:00:00,European Continental Ancestry Group,M01.686.508.400
22153093,2012-01-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22153093,2012-01-01T00:00:00,"Lens Implantation, Intraocular",E04.540.825.600
22153093,2012-01-01T00:00:00,Myopia,C11.744.636
22153093,2012-01-01T00:00:00,"Refraction, Ocular",E01.370.380.850.700
22153093,2012-01-01T00:00:00,"Refraction, Ocular",G01.590.770.760
22153093,2012-01-01T00:00:00,"Refraction, Ocular",G01.595.640.760
22153093,2012-01-01T00:00:00,"Refraction, Ocular",G14.760
22153093,2012-01-01T00:00:00,Young Adult,M01.060.116.815
22153288,2012-01-01T00:00:00,Adolescent,M01.060.057
22153288,2012-01-01T00:00:00,Child,M01.060.406
22153288,2012-01-01T00:00:00,"Child Development Disorders, Pervasive",F03.550.325
22153288,2012-01-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22153288,2012-01-01T00:00:00,Population Surveillance,E05.318.308.250.700
22153288,2012-01-01T00:00:00,Population Surveillance,N05.715.360.300.375.625
22153288,2012-01-01T00:00:00,Population Surveillance,N06.850.520.308.250.700
22153288,2012-01-01T00:00:00,Population Surveillance,N06.850.780.675
22153288,2012-01-01T00:00:00,Prescription Drugs,D26.670
22153288,2012-01-01T00:00:00,South Carolina,Z01.107.567.875.075.662
22153288,2012-01-01T00:00:00,South Carolina,Z01.107.567.875.750.700
22153288,2012-01-01T00:00:00,United States,Z01.107.567.875
22157864,2012-01-01T00:00:00,Animals,B01.050
22157864,2012-01-01T00:00:00,Cocaine,D02.145.074.722.388
22157864,2012-01-01T00:00:00,Cocaine,D03.132.889.354
22157864,2012-01-01T00:00:00,Cocaine,D03.605.869.388
22157864,2012-01-01T00:00:00,Cocaine,D04.075.080.875.099.722.388
22157864,2012-01-01T00:00:00,Cocaine-Related Disorders,C21.739.300
22157864,2012-01-01T00:00:00,Cocaine-Related Disorders,F03.900.300
22157864,2012-01-01T00:00:00,Cystine,D01.248.497.158.874.390.369
22157864,2012-01-01T00:00:00,Cystine,D01.875.350.850.150.369
22157864,2012-01-01T00:00:00,Cystine,D02.886.030.230.369
22157864,2012-01-01T00:00:00,Cystine,D02.886.520.150.087
22157864,2012-01-01T00:00:00,Cystine,D12.125.095.369
22157864,2012-01-01T00:00:00,Cystine,D12.125.119.369
22157864,2012-01-01T00:00:00,Cystine,D12.125.166.230.369
22157864,2012-01-01T00:00:00,Dopamine Uptake Inhibitors,D27.505.519.625.150.800
22157864,2012-01-01T00:00:00,Dopamine Uptake Inhibitors,D27.505.519.625.600.220
22157864,2012-01-01T00:00:00,Dopamine Uptake Inhibitors,D27.505.696.577.150.800
22157864,2012-01-01T00:00:00,Dopamine Uptake Inhibitors,D27.505.696.577.600.220
22157864,2012-01-01T00:00:00,Drug Interactions,G07.690.812.240
22157864,2012-01-01T00:00:00,Drug Interactions,G07.700.680.240
22157864,2012-01-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22157864,2012-01-01T00:00:00,Self Administration,E02.319.890
22157864,2012-01-01T00:00:00,Self Administration,E02.900.890
22157944,2012-01-01T00:00:00,Animals,B01.050
22157944,2012-01-01T00:00:00,Brain,A08.186.211
22157944,2012-01-01T00:00:00,Dopamine,D02.092.211.215.311.342
22157944,2012-01-01T00:00:00,Dopamine,D02.092.311.342
22157944,2012-01-01T00:00:00,Gene Expression Regulation,G05.355.315
22166562,2012-01-01T00:00:00,Adult,M01.060.116
22166562,2012-01-01T00:00:00,Aged,M01.060.116.100
22166562,2012-01-01T00:00:00,"Carcinoma, Hepatocellular",C04.557.470.200.025.255
22166562,2012-01-01T00:00:00,"Carcinoma, Hepatocellular",C04.588.274.623.160
22166562,2012-01-01T00:00:00,"Carcinoma, Hepatocellular",C06.301.623.160
22166562,2012-01-01T00:00:00,"Carcinoma, Hepatocellular",C06.552.697.160
22166562,2012-01-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22166562,2012-01-01T00:00:00,Hyponatremia,C18.452.950.620
22166562,2012-01-01T00:00:00,Liver Cirrhosis,C06.552.630
22166562,2012-01-01T00:00:00,Liver Neoplasms,C04.588.274.623
22166562,2012-01-01T00:00:00,Liver Neoplasms,C06.301.623
22166562,2012-01-01T00:00:00,Liver Neoplasms,C06.552.697
22166562,2012-01-01T00:00:00,Liver Transplantation,E04.210.650
22166562,2012-01-01T00:00:00,Liver Transplantation,E04.936.450.490
22166562,2012-01-01T00:00:00,Liver Transplantation,E04.936.580.490
22166562,2012-01-01T00:00:00,Middle Aged,M01.060.116.630
22166562,2012-01-01T00:00:00,Resource Allocation,I01.261.750
22166562,2012-01-01T00:00:00,Risk Factors,E05.318.740.600.800.725
22166562,2012-01-01T00:00:00,Risk Factors,N05.715.350.200.700
22166562,2012-01-01T00:00:00,Risk Factors,N05.715.360.750.625.700.700
22166562,2012-01-01T00:00:00,Risk Factors,N06.850.490.625.750
22166562,2012-01-01T00:00:00,Risk Factors,N06.850.520.830.600.800.725
22166562,2012-01-01T00:00:00,Sodium,D01.268.549.750
22166562,2012-01-01T00:00:00,Sodium,D01.552.528.850
22166562,2012-01-01T00:00:00,Tissue and Organ Procurement,N02.421.911
22166562,2012-01-01T00:00:00,Treatment Outcome,E01.789.800
22166562,2012-01-01T00:00:00,Treatment Outcome,N04.761.559.590.800
22166562,2012-01-01T00:00:00,Treatment Outcome,N05.715.360.575.575.800
22166562,2012-01-01T00:00:00,United States,Z01.107.567.875
22166562,2012-01-01T00:00:00,Waiting Lists,N04.452.095.738
22172751,2012-01-01T00:00:00,Data Collection,E05.318.308
22172751,2012-01-01T00:00:00,Data Collection,L01.280
22172751,2012-01-01T00:00:00,Data Collection,N05.715.360.300
22172751,2012-01-01T00:00:00,Data Collection,N06.850.520.308
22172751,2012-01-01T00:00:00,Thoracic Surgery,H02.403.810.803
22172751,2012-01-01T00:00:00,United States,Z01.107.567.875
22183318,2012-01-01T00:00:00,ATP-Binding Cassette Transporters,D12.776.157.530.100
22183318,2012-01-01T00:00:00,ATP-Binding Cassette Transporters,D12.776.395.550.020
22183318,2012-01-01T00:00:00,ATP-Binding Cassette Transporters,D12.776.543.550.192
22183318,2012-01-01T00:00:00,ATP-Binding Cassette Transporters,D12.776.543.585.100
22183318,2012-01-01T00:00:00,Animals,B01.050
22183318,2012-01-01T00:00:00,Carrier Proteins,D12.776.157
22183318,2012-01-01T00:00:00,"Disease Models, Animal",C22.232
22183318,2012-01-01T00:00:00,"Disease Models, Animal",E05.598.500
22183318,2012-01-01T00:00:00,"Disease Models, Animal",E05.599.395.080
22183318,2012-01-01T00:00:00,Eye Proteins,D12.776.306
22183318,2012-01-01T00:00:00,Macular Degeneration,C11.768.585.439
22183318,2012-01-01T00:00:00,Pyridinium Compounds,D03.383.725.762
22183318,2012-01-01T00:00:00,Retinal Pigment Epithelium,A09.371.670.500
22183318,2012-01-01T00:00:00,Retinal Pigment Epithelium,A09.371.729.887
22183318,2012-01-01T00:00:00,Retinoids,D02.455.326.271.665.202.495
22183318,2012-01-01T00:00:00,Retinoids,D02.455.426.392.368.367.379.249.700
22183318,2012-01-01T00:00:00,Retinoids,D02.455.849.131.495
22183318,2012-01-01T00:00:00,Retinoids,D23.767.261.700
22183318,2012-01-01T00:00:00,"Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization",E05.196.566.755
22184428,2012-01-01T00:00:00,Animals,B01.050
22184428,2012-01-01T00:00:00,Chick Embryo,A13.350.150
22184428,2012-01-01T00:00:00,Chick Embryo,A16.331.200
22184428,2012-01-01T00:00:00,Chickens,B01.050.150.900.248.350.150
22184428,2012-01-01T00:00:00,Chickens,B01.050.150.900.248.617.192
22184428,2012-01-01T00:00:00,Circadian Rhythm,G07.180.562.190
22184428,2012-01-01T00:00:00,Regression Analysis,E05.318.740.750
22184428,2012-01-01T00:00:00,Regression Analysis,N05.715.360.750.695
22184428,2012-01-01T00:00:00,Regression Analysis,N06.850.520.830.750
22184428,2012-01-01T00:00:00,Temperature,G01.906.595
22184428,2012-01-01T00:00:00,Temperature,G16.500.275.063.725.710
22184428,2012-01-01T00:00:00,Temperature,G16.500.750.775.710
22184428,2012-01-01T00:00:00,Temperature,N06.230.150.450
22184428,2012-01-01T00:00:00,Temperature,N06.230.300.100.725.710
22184428,2012-01-01T00:00:00,Time Factors,G01.910.857
22184428,2012-01-01T00:00:00,Water,D01.455.900
22184428,2012-01-01T00:00:00,Water,D01.650.550.925
22186470,2012-01-01T00:00:00,Adult,M01.060.116
22186470,2012-01-01T00:00:00,Aged,M01.060.116.100
22186470,2012-01-01T00:00:00,Career Choice,F02.463.785.373.346.400
22186470,2012-01-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22186470,2012-01-01T00:00:00,Internship and Residency,I02.358.399.644
22186470,2012-01-01T00:00:00,Middle Aged,M01.060.116.630
22186470,2012-01-01T00:00:00,Physicians,M01.526.485.810
22186470,2012-01-01T00:00:00,Physicians,N02.360.810
22186470,2012-01-01T00:00:00,Questionnaires,E05.318.308.750
22186470,2012-01-01T00:00:00,Questionnaires,L01.280.800
22186470,2012-01-01T00:00:00,Questionnaires,N05.715.360.300.695
22186470,2012-01-01T00:00:00,Questionnaires,N06.850.520.308.750
22186470,2012-01-01T00:00:00,Thoracic Surgery,H02.403.810.803
22186470,2012-01-01T00:00:00,Thoracic Surgical Procedures,E04.928
22186470,2012-01-01T00:00:00,United States,Z01.107.567.875
22189662,2012-01-01T00:00:00,Communication,F01.145.209
22189662,2012-01-01T00:00:00,Communication,L01.143
22189662,2012-01-01T00:00:00,Hospital Information Systems,L01.700.508.300.408
22189662,2012-01-01T00:00:00,Hospital Information Systems,L01.700.508.300.680.360
22189662,2012-01-01T00:00:00,Hospital Information Systems,N04.452.442.452
22189662,2012-01-01T00:00:00,Hospital Information Systems,N04.452.515.360
22189662,2012-01-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22189662,2012-01-01T00:00:00,Patient Discharge,E02.760.400.610
22189662,2012-01-01T00:00:00,Patient Discharge,N02.421.585.400.610
22189662,2012-01-01T00:00:00,Primary Health Care,N04.590.233.727
22190317,2012-01-01T00:00:00,Adult,M01.060.116
22190317,2012-01-01T00:00:00,Electric Stimulation,E05.723.402
22190317,2012-01-01T00:00:00,Electromyography,E01.370.405.255
22190317,2012-01-01T00:00:00,Electromyography,E01.370.530.255
22190317,2012-01-01T00:00:00,H-Reflex,G11.561.600.765.643.474
22190317,2012-01-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22190317,2012-01-01T00:00:00,Middle Aged,M01.060.116.630
22190317,2012-01-01T00:00:00,"Muscle, Skeletal",A02.633.567
22190317,2012-01-01T00:00:00,"Muscle, Skeletal",A10.690.552.500
22190317,2012-01-01T00:00:00,Posture,G11.427.695
22190317,2012-01-01T00:00:00,Walking,G11.427.590.530.568.900
22190317,2012-01-01T00:00:00,Walking,G11.427.590.530.698.940
22190317,2012-01-01T00:00:00,Walking,I03.450.642.845.940
22190317,2012-01-01T00:00:00,Young Adult,M01.060.116.815
22192182,2012-01-01T00:00:00,Color,G01.201.875.770.578.199
22192182,2012-01-01T00:00:00,Color,G01.590.540.199
22192182,2012-01-01T00:00:00,Hot Temperature,G01.906.595.543
22192182,2012-01-01T00:00:00,Hot Temperature,G16.500.275.063.725.710.380
22192182,2012-01-01T00:00:00,Hot Temperature,G16.500.750.775.710.380
22192182,2012-01-01T00:00:00,Hot Temperature,N06.230.300.100.725.232
22192182,2012-01-01T00:00:00,Hot Temperature,N06.230.300.100.725.710.380
22192182,2012-01-01T00:00:00,Lipid Metabolism,G03.495.520
22194501,2012-01-01T00:00:00,Adult,M01.060.116
22194501,2012-01-01T00:00:00,Aged,M01.060.116.100
22194501,2012-01-01T00:00:00,Breast Neoplasms,C04.588.180
22194501,2012-01-01T00:00:00,Breast Neoplasms,C17.800.090.500
22194501,2012-01-01T00:00:00,Contrast Media,D27.720.259
22194501,2012-01-01T00:00:00,Fluorodeoxyglucose F18,D09.254.229.500
22194501,2012-01-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22194501,2012-01-01T00:00:00,Magnetic Resonance Imaging,E01.370.350.500
22194501,2012-01-01T00:00:00,Magnetic Resonance Imaging,E01.370.350.825.500
22194501,2012-01-01T00:00:00,Mammography,E01.370.350.700.500
22194501,2012-01-01T00:00:00,Middle Aged,M01.060.116.630
22194501,2012-01-01T00:00:00,Positron-Emission Tomography,E01.370.350.350.800.700
22194501,2012-01-01T00:00:00,Positron-Emission Tomography,E01.370.350.600.350.800.399
22194501,2012-01-01T00:00:00,Positron-Emission Tomography,E01.370.350.710.800.399
22194501,2012-01-01T00:00:00,Positron-Emission Tomography,E01.370.350.825.800.399
22194501,2012-01-01T00:00:00,Positron-Emission Tomography,E01.370.384.730.800.399
22194501,2012-01-01T00:00:00,Radiopharmaceuticals,D27.720.470.410.650
22208487,2012-01-01T00:00:00,Fluorescent Dyes,D27.720.233.348
22208487,2012-01-01T00:00:00,Fluorescent Dyes,D27.720.470.330.348
22208487,2012-01-01T00:00:00,Fluorescent Dyes,D27.720.470.410.505.500
22208487,2012-01-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22208487,2012-01-01T00:00:00,"In Situ Hybridization, Fluorescence",E05.200.500.620.670.325.350
22208487,2012-01-01T00:00:00,"In Situ Hybridization, Fluorescence",E05.200.750.600.670.325.350
22208487,2012-01-01T00:00:00,"In Situ Hybridization, Fluorescence",E05.393.285.350
22208487,2012-01-01T00:00:00,"In Situ Hybridization, Fluorescence",E05.393.661.475.350
22208487,2012-01-01T00:00:00,Molecular Diagnostic Techniques,E05.200.880
22208487,2012-01-01T00:00:00,Molecular Diagnostic Techniques,E05.393.520
22208487,2012-01-01T00:00:00,United States,Z01.107.567.875
22208827,2012-01-01T00:00:00,Behavior,F01.145
22208827,2012-01-01T00:00:00,Internship and Residency,I02.358.399.644
22208827,2012-01-01T00:00:00,School Admission Criteria,I02.399.750
22212975,2012-01-01T00:00:00,Ambulatory Care,E02.760.106
22212975,2012-01-01T00:00:00,Ambulatory Care,N02.421.585.106
22212975,2012-01-01T00:00:00,Anti-Bacterial Agents,D27.505.954.122.085
22212975,2012-01-01T00:00:00,Bacterial Infections,C01.252
22212975,2012-01-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22212975,2012-01-01T00:00:00,"Infusions, Intravenous",E02.319.267.510.590
22212975,2012-01-01T00:00:00,Musculoskeletal Diseases,C05
22214943,2012-01-01T00:00:00,Adult,M01.060.116
22214943,2012-01-01T00:00:00,Aged,M01.060.116.100
22214943,2012-01-01T00:00:00,Aging,G07.700.320.124
22214943,2012-01-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22214943,2012-01-01T00:00:00,Middle Aged,M01.060.116.630
22214943,2012-01-01T00:00:00,Young Adult,M01.060.116.815
22218619,2012-01-01T00:00:00,Adult,M01.060.116
22218619,2012-01-01T00:00:00,Aged,M01.060.116.100
22218619,2012-01-01T00:00:00,Body Mass Index,E01.370.600.115.100.125
22218619,2012-01-01T00:00:00,Body Mass Index,E05.041.124.125
22218619,2012-01-01T00:00:00,Body Mass Index,G07.100.100.125
22218619,2012-01-01T00:00:00,Body Mass Index,N06.850.505.200.100.175
22218619,2012-01-01T00:00:00,Health Surveys,E05.318.308.250
22218619,2012-01-01T00:00:00,Health Surveys,N05.715.360.300.375
22218619,2012-01-01T00:00:00,Health Surveys,N06.850.520.308.250
22218619,2012-01-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22218619,2012-01-01T00:00:00,Life Style,F01.829.458
22218619,2012-01-01T00:00:00,Middle Aged,M01.060.116.630
22218619,2012-01-01T00:00:00,Obesity,C18.654.726.500
22218619,2012-01-01T00:00:00,Obesity,C23.888.144.699.500
22218619,2012-01-01T00:00:00,Obesity,E01.370.600.115.100.160.120.699.500
22218619,2012-01-01T00:00:00,Obesity,G07.100.100.160.120.699.500
22218619,2012-01-01T00:00:00,Overweight,C23.888.144.699
22218619,2012-01-01T00:00:00,Overweight,E01.370.600.115.100.160.120.699
22218619,2012-01-01T00:00:00,Overweight,G07.100.100.160.120.699
22218619,2012-01-01T00:00:00,Risk Reduction Behavior,F01.145.699
22218619,2012-01-01T00:00:00,United States,Z01.107.567.875
22218619,2012-01-01T00:00:00,Young Adult,M01.060.116.815
22218620,2012-01-01T00:00:00,Aged,M01.060.116.100
22218620,2012-01-01T00:00:00,Blood Glucose,D09.546.359.448.500
22218620,2012-01-01T00:00:00,"Diabetes Mellitus, Type 2",C18.452.394.750.149
22218620,2012-01-01T00:00:00,"Diabetes Mellitus, Type 2",C19.246.300
22218620,2012-01-01T00:00:00,"Hemoglobin A, Glycosylated",D09.408.375
22218620,2012-01-01T00:00:00,"Hemoglobin A, Glycosylated",D12.776.124.400.405.440
22218620,2012-01-01T00:00:00,"Hemoglobin A, Glycosylated",D12.776.422.316.762.380.440
22218620,2012-01-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22218620,2012-01-01T00:00:00,Middle Aged,M01.060.116.630
22218620,2012-01-01T00:00:00,Outcome Assessment (Health Care),N04.761.559.590
22218620,2012-01-01T00:00:00,Outcome Assessment (Health Care),N05.715.360.575.575
22226003,2012-01-01T00:00:00,Clinical Trials as Topic,E05.318.760.535
22226003,2012-01-01T00:00:00,Clinical Trials as Topic,E05.337.250
22226003,2012-01-01T00:00:00,Clinical Trials as Topic,N05.715.360.775.235
22226003,2012-01-01T00:00:00,Clinical Trials as Topic,N06.850.520.450.535
22226003,2012-01-01T00:00:00,Cost of Illness,I01.137
22226003,2012-01-01T00:00:00,Cost of Illness,N03.219.151.165
22226003,2012-01-01T00:00:00,Cost-Benefit Analysis,N03.219.151.125
22226003,2012-01-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22226003,2012-01-01T00:00:00,Markov Chains,E05.318.740.600.500
22226003,2012-01-01T00:00:00,Markov Chains,E05.318.740.996.500
22226003,2012-01-01T00:00:00,Markov Chains,G17.830.500
22226003,2012-01-01T00:00:00,Markov Chains,N05.715.360.750.625.500
22226003,2012-01-01T00:00:00,Markov Chains,N05.715.360.750.770.500
22226003,2012-01-01T00:00:00,Markov Chains,N06.850.520.830.600.500
22226003,2012-01-01T00:00:00,Markov Chains,N06.850.520.830.996.500
22226003,2012-01-01T00:00:00,Myocardial Infarction,C14.280.647.500
22226003,2012-01-01T00:00:00,Myocardial Infarction,C14.907.585.500
22239895,2012-01-01T00:00:00,Animals,B01.050
22239895,2012-01-01T00:00:00,Myocardium,A02.633.580
22239895,2012-01-01T00:00:00,Myocardium,A07.541.704
22239895,2012-01-01T00:00:00,Myocardium,A10.690.552.750
22239895,2012-01-01T00:00:00,Positron-Emission Tomography,E01.370.350.350.800.700
22239895,2012-01-01T00:00:00,Positron-Emission Tomography,E01.370.350.600.350.800.399
22239895,2012-01-01T00:00:00,Positron-Emission Tomography,E01.370.350.710.800.399
22239895,2012-01-01T00:00:00,Positron-Emission Tomography,E01.370.350.825.800.399
22239895,2012-01-01T00:00:00,Positron-Emission Tomography,E01.370.384.730.800.399
22239895,2012-01-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.350.810
22239895,2012-01-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.600.350.700.810
22239895,2012-01-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.700.700.810
22239895,2012-01-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.700.810.810
22239895,2012-01-01T00:00:00,"Tomography, X-Ray Computed",E01.370.350.825.810.810
22246122,2012-01-01T00:00:00,Adult,M01.060.116
22246122,2012-01-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22246122,2012-01-01T00:00:00,Psychiatric Status Rating Scales,F04.586
22246122,2012-01-01T00:00:00,Psychotherapy,F04.754
22246122,2012-01-01T00:00:00,Psychotic Disorders,F03.700.675
22246122,2012-01-01T00:00:00,Risk Factors,E05.318.740.600.800.725
22246122,2012-01-01T00:00:00,Risk Factors,N05.715.350.200.700
22246122,2012-01-01T00:00:00,Risk Factors,N05.715.360.750.625.700.700
22246122,2012-01-01T00:00:00,Risk Factors,N06.850.490.625.750
22246122,2012-01-01T00:00:00,Risk Factors,N06.850.520.830.600.800.725
22246122,2012-01-01T00:00:00,Substance-Related Disorders,C21.739
22246122,2012-01-01T00:00:00,Substance-Related Disorders,F03.900
22261607,2012-01-01T00:00:00,"Education, Nursing, Graduate",I02.358.337.450
22261607,2012-01-01T00:00:00,"Education, Nursing, Graduate",I02.358.462.565
22261607,2012-01-01T00:00:00,Program Evaluation,E05.337.820
22261607,2012-01-01T00:00:00,Program Evaluation,N04.761.685
22261607,2012-01-01T00:00:00,Program Evaluation,N05.715.360.650
22273286,2012-01-01T00:00:00,Gynecology,H02.403.810.310
22273286,2012-01-01T00:00:00,"History, 19th Century",K01.400.504.937
22273286,2012-01-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22273286,2012-01-01T00:00:00,United States,Z01.107.567.875
22308578,2012-01-01T00:00:00,Clinical Competence,I02.399.630.210
22308578,2012-01-01T00:00:00,Clinical Competence,N04.761.210
22308578,2012-01-01T00:00:00,"Endoscopy, Gastrointestinal",E01.370.372.250.250
22308578,2012-01-01T00:00:00,"Endoscopy, Gastrointestinal",E01.370.388.250.250.250
22308578,2012-01-01T00:00:00,"Endoscopy, Gastrointestinal",E04.210.240.250
22308578,2012-01-01T00:00:00,"Endoscopy, Gastrointestinal",E04.800.250.250.250
22308578,2012-01-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22308578,2012-01-01T00:00:00,Informed Consent,I01.880.604.473.650.718
22308578,2012-01-01T00:00:00,Informed Consent,I01.880.604.583.427
22308578,2012-01-01T00:00:00,Informed Consent,N03.706.437.650.312
22308578,2012-01-01T00:00:00,Informed Consent,N03.706.535.489
22308578,2012-01-01T00:00:00,Patient Discharge,E02.760.400.610
22308578,2012-01-01T00:00:00,Patient Discharge,N02.421.585.400.610
22308578,2012-01-01T00:00:00,"Quality Indicators, Health Care",N04.761.789
22328390,2012-01-01T00:00:00,Animals,B01.050
22328390,2012-01-01T00:00:00,Candida albicans,B01.300.381.147.326
22328390,2012-01-01T00:00:00,Candida albicans,B01.300.930.176.326
22328390,2012-01-01T00:00:00,Host-Pathogen Interactions,G06.590.470
22328390,2012-01-01T00:00:00,Host-Pathogen Interactions,G16.100.380
22337825,2012-01-01T00:00:00,Age Factors,N05.715.350.075
22337825,2012-01-01T00:00:00,Age Factors,N06.850.490.250
22337825,2012-01-01T00:00:00,Alzheimer Disease,C10.228.140.380.100
22337825,2012-01-01T00:00:00,Alzheimer Disease,C10.574.945.249
22337825,2012-01-01T00:00:00,Alzheimer Disease,F03.087.400.100
22337825,2012-01-01T00:00:00,Amyloid Precursor Protein Secretases,D08.811.277.656.300.032
22337825,2012-01-01T00:00:00,Amyloid beta-Protein Precursor,D12.776.049.025.150
22337825,2012-01-01T00:00:00,Amyloid beta-Protein Precursor,D12.776.811.050
22337825,2012-01-01T00:00:00,Animals,B01.050
22337825,2012-01-01T00:00:00,Aspartic Acid Endopeptidases,D08.811.277.656.074.500
22337825,2012-01-01T00:00:00,Aspartic Acid Endopeptidases,D08.811.277.656.300.048
22337825,2012-01-01T00:00:00,Brain,A08.186.211
22337825,2012-01-01T00:00:00,Cathepsin B,D08.811.277.656.224.125
22337825,2012-01-01T00:00:00,Cathepsin B,D08.811.277.656.262.500.133
22337825,2012-01-01T00:00:00,Cathepsin B,D08.811.277.656.300.200.133
22337825,2012-01-01T00:00:00,"Disease Models, Animal",C22.232
22337825,2012-01-01T00:00:00,"Disease Models, Animal",E05.598.500
22337825,2012-01-01T00:00:00,"Disease Models, Animal",E05.599.395.080
22337825,2012-01-01T00:00:00,Gene Expression Regulation,G05.355.315
22337825,2012-01-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22337825,2012-01-01T00:00:00,Maze Learning,F02.463.425.507
22337825,2012-01-01T00:00:00,Mutation,G05.365.590
22337825,2012-01-01T00:00:00,Peptide Fragments,D12.644.541
22337825,2012-01-01T00:00:00,Reaction Time,F02.830.650
22337825,2012-01-01T00:00:00,Reaction Time,F04.669.817
22337825,2012-01-01T00:00:00,Reaction Time,G11.561.677
22391071,2012-01-01T00:00:00,Animals,B01.050
22391071,2012-01-01T00:00:00,Clinical Trials as Topic,E05.318.760.535
22391071,2012-01-01T00:00:00,Clinical Trials as Topic,E05.337.250
22391071,2012-01-01T00:00:00,Clinical Trials as Topic,N05.715.360.775.235
22391071,2012-01-01T00:00:00,Clinical Trials as Topic,N06.850.520.450.535
22391071,2012-01-01T00:00:00,Evidence-Based Medicine,H02.249.750
22391071,2012-01-01T00:00:00,Evidence-Based Medicine,H02.403.200.400
22391071,2012-01-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22391071,2012-01-01T00:00:00,United States,Z01.107.567.875
22409204,2012-01-01T00:00:00,Attitude of Health Personnel,F01.100.050
22409204,2012-01-01T00:00:00,Attitude of Health Personnel,N05.300.100
22409204,2012-01-01T00:00:00,Continuity of Patient Care,N04.590.233.727.210
22409204,2012-01-01T00:00:00,Delivery of Health Care,N04.590.374
22409204,2012-01-01T00:00:00,Delivery of Health Care,N05.300
22409204,2012-01-01T00:00:00,Health Services Accessibility,N04.590.374.350
22409204,2012-01-01T00:00:00,Health Services Accessibility,N05.300.430
22409204,2012-01-01T00:00:00,"Hospitals, Psychiatric",N02.278.421.556.508
22409204,2012-01-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22409204,2012-01-01T00:00:00,"Interview, Psychological",F04.669.599
22409204,2012-01-01T00:00:00,Mental Disorders,F03
22409204,2012-01-01T00:00:00,Patient Discharge,E02.760.400.610
22409204,2012-01-01T00:00:00,Patient Discharge,N02.421.585.400.610
22409204,2012-01-01T00:00:00,Referral and Consultation,N04.452.758.849
22409204,2012-01-01T00:00:00,United States,Z01.107.567.875
22416543,2012-01-01T00:00:00,Adult,M01.060.116
22416543,2012-01-01T00:00:00,Communication,F01.145.209
22416543,2012-01-01T00:00:00,Communication,L01.143
22416543,2012-01-01T00:00:00,"Education, Nursing, Graduate",I02.358.337.450
22416543,2012-01-01T00:00:00,"Education, Nursing, Graduate",I02.358.462.565
22416543,2012-01-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22416543,2012-01-01T00:00:00,Patient Care Team,N04.590.715
22416543,2012-01-01T00:00:00,Problem-Based Learning,F02.463.425.720
22416543,2012-01-01T00:00:00,Problem-Based Learning,I02.158.660
22416543,2012-01-01T00:00:00,Problem-Based Learning,I02.903.565
22416543,2012-01-01T00:00:00,Role Playing,E02.190.525.781.653
22416543,2012-01-01T00:00:00,Role Playing,F04.754.864.581.679.653
22416543,2012-01-01T00:00:00,United States,Z01.107.567.875
22416743,2012-01-01T00:00:00,"Ethics, Medical",K01.316.333.132.750
22416743,2012-01-01T00:00:00,"Ethics, Medical",N05.350.340.162.500
22416743,2012-01-01T00:00:00,Fraud,I01.198.240.300
22416743,2012-01-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22416743,2012-01-01T00:00:00,"Insurance, Health, Reimbursement",N03.219.521.576.343.480
22416743,2012-01-01T00:00:00,"Insurance, Health, Reimbursement",N03.219.521.710
22416743,2012-01-01T00:00:00,Medical Records,E05.318.308.940.968
22416743,2012-01-01T00:00:00,Medical Records,L01.280.900.968
22416743,2012-01-01T00:00:00,Medical Records,N04.452.859.564
22416743,2012-01-01T00:00:00,Medical Records,N05.715.360.300.715.500
22416743,2012-01-01T00:00:00,Medical Records,N06.850.520.308.940.968
22416743,2012-01-01T00:00:00,Physician-Patient Relations,F01.829.401.650.675
22416743,2012-01-01T00:00:00,Physician-Patient Relations,N05.300.660.625
22416743,2012-01-01T00:00:00,Physicians,M01.526.485.810
22416743,2012-01-01T00:00:00,Physicians,N02.360.810
22435787,2012-01-01T00:00:00,Hospital Costs,N03.219.151.400.687
22435787,2012-01-01T00:00:00,Hospital Costs,N03.219.262.500
22435787,2012-01-01T00:00:00,Hospital Costs,N05.300.375.500
22435787,2012-01-01T00:00:00,Hospitalists,M01.526.485.630.490.400
22435787,2012-01-01T00:00:00,Hospitalists,M01.526.485.740.422.400
22435787,2012-01-01T00:00:00,Hospitalists,M01.526.485.810.580
22435787,2012-01-01T00:00:00,Hospitalists,N02.360.630.490.400
22435787,2012-01-01T00:00:00,Hospitalists,N02.360.740.422.400
22435787,2012-01-01T00:00:00,Hospitalists,N02.360.810.580
22435787,2012-01-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22435787,2012-01-01T00:00:00,Length of Stay,E02.760.400.480
22435787,2012-01-01T00:00:00,Length of Stay,N02.421.585.400.480
22458456,2012-01-01T00:00:00,Aged,M01.060.116.100
22458456,2012-01-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22458456,2012-01-01T00:00:00,Population Dynamics,I01.240.600
22458456,2012-01-01T00:00:00,Population Dynamics,N01.224.625
22458456,2012-01-01T00:00:00,Population Dynamics,N06.850.505.400.700
22458456,2012-01-01T00:00:00,United States,Z01.107.567.875
22474746,2012-01-01T00:00:00,Bioprosthesis,E07.695.100
22474746,2012-01-01T00:00:00,Heart Valve Prosthesis,E07.695.310
22474746,2012-01-01T00:00:00,Heart Valve Prosthesis Implantation,E04.100.376.485
22474746,2012-01-01T00:00:00,Heart Valve Prosthesis Implantation,E04.650.410
22474746,2012-01-01T00:00:00,Heart Valve Prosthesis Implantation,E04.928.220.410
22474746,2012-01-01T00:00:00,Hemorrhage,C23.550.414
22474746,2012-01-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22474746,2012-01-01T00:00:00,Postoperative Complications,C23.550.767
22474746,2012-01-01T00:00:00,Warfarin,D03.438.150.446.520.914
22474746,2012-01-01T00:00:00,Warfarin,D03.830.219.446.520.914
22479900,2012-01-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22479900,2012-01-01T00:00:00,Physician Assistants,M01.526.485.067.740
22479900,2012-01-01T00:00:00,Physician Assistants,N02.360.067.740
22479900,2012-01-01T00:00:00,School Admission Criteria,I02.399.750
22479900,2012-01-01T00:00:00,United States,Z01.107.567.875
22479900,2012-01-01T00:00:00,Veterans,M01.930
22489584,2012-01-01T00:00:00,Adult,M01.060.116
22489584,2012-01-01T00:00:00,Aged,M01.060.116.100
22489584,2012-01-01T00:00:00,Alcoholism,C21.739.100.250
22489584,2012-01-01T00:00:00,Alcoholism,F03.900.100.350
22489584,2012-01-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22489584,2012-01-01T00:00:00,Mass Screening,E01.370.500
22489584,2012-01-01T00:00:00,Mass Screening,E05.318.308.250.580
22489584,2012-01-01T00:00:00,Mass Screening,N02.421.143.827.233.443
22489584,2012-01-01T00:00:00,Mass Screening,N02.421.726.233.443
22489584,2012-01-01T00:00:00,Mass Screening,N05.715.360.300.375.500
22489584,2012-01-01T00:00:00,Mass Screening,N06.850.520.308.250.580
22489584,2012-01-01T00:00:00,Mass Screening,N06.850.780.500
22489584,2012-01-01T00:00:00,Mental Disorders,F03
22489584,2012-01-01T00:00:00,Middle Aged,M01.060.116.630
22489584,2012-01-01T00:00:00,Psychiatry,F04.096.544
22489584,2012-01-01T00:00:00,Psychiatry,H02.403.690
22489584,2012-01-01T00:00:00,Questionnaires,E05.318.308.750
22489584,2012-01-01T00:00:00,Questionnaires,L01.280.800
22489584,2012-01-01T00:00:00,Questionnaires,N05.715.360.300.695
22489584,2012-01-01T00:00:00,Questionnaires,N06.850.520.308.750
22492344,2012-01-01T00:00:00,Activities of Daily Living,E02.831.067
22492344,2012-01-01T00:00:00,Activities of Daily Living,I03.050
22492344,2012-01-01T00:00:00,Activities of Daily Living,N02.421.784.110
22492344,2012-01-01T00:00:00,Brain Injuries,C10.228.140.199
22492344,2012-01-01T00:00:00,Brain Injuries,C10.900.300.087
22492344,2012-01-01T00:00:00,Brain Injuries,C21.866.260.118
22492344,2012-01-01T00:00:00,Brain Injuries,C21.866.915.300.200
22492344,2012-01-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22492344,2012-01-01T00:00:00,Outcome Assessment (Health Care),N04.761.559.590
22492344,2012-01-01T00:00:00,Outcome Assessment (Health Care),N05.715.360.575.575
22492344,2012-01-01T00:00:00,Psychometrics,F04.711.780
22492344,2012-01-01T00:00:00,Quality of Life,I01.800
22492344,2012-01-01T00:00:00,Quality of Life,K01.752.400.750
22492344,2012-01-01T00:00:00,Questionnaires,E05.318.308.750
22492344,2012-01-01T00:00:00,Questionnaires,L01.280.800
22492344,2012-01-01T00:00:00,Questionnaires,N05.715.360.300.695
22492344,2012-01-01T00:00:00,Questionnaires,N06.850.520.308.750
22492344,2012-01-01T00:00:00,Research,H01.770.644
22492344,2012-01-01T00:00:00,Social Adjustment,F01.145.813.621
22492344,2012-01-01T00:00:00,United States,Z01.107.567.875
22492344,2012-01-01T00:00:00,United States Department of Veterans Affairs,I01.409.137.500.700
22492344,2012-01-01T00:00:00,United States Department of Veterans Affairs,N03.540.348.500.500.700
22492344,2012-01-01T00:00:00,Veterans,M01.930
22506703,2012-01-01T00:00:00,Environmental Exposure,N06.850.460.350
22506703,2012-01-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22506703,2012-01-01T00:00:00,South Carolina,Z01.107.567.875.075.662
22506703,2012-01-01T00:00:00,South Carolina,Z01.107.567.875.750.700
22506703,2012-01-01T00:00:00,Stroke,C10.228.140.300.775
22506703,2012-01-01T00:00:00,Stroke,C14.907.253.855
22571995,2012-01-01T00:00:00,Atrial Fibrillation,C14.280.067.198
22571995,2012-01-01T00:00:00,Atrial Fibrillation,C23.550.073.198
22571995,2012-01-01T00:00:00,Cerebrovascular Disorders,C10.228.140.300
22571995,2012-01-01T00:00:00,Cerebrovascular Disorders,C14.907.253
22571995,2012-01-01T00:00:00,Fibrinolytic Agents,D27.505.519.421.750
22571995,2012-01-01T00:00:00,Fibrinolytic Agents,D27.505.954.411.320
22571995,2012-01-01T00:00:00,Fibrinolytic Agents,D27.505.954.502.427
22571995,2012-01-01T00:00:00,Hypertension,C14.907.489
22571995,2012-01-01T00:00:00,Stroke,C10.228.140.300.775
22571995,2012-01-01T00:00:00,Stroke,C14.907.253.855
22608635,2012-01-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22608635,2012-01-01T00:00:00,Substance-Related Disorders,C21.739
22608635,2012-01-01T00:00:00,Substance-Related Disorders,F03.900
22621734,2012-01-01T00:00:00,Animals,B01.050
22621734,2012-01-01T00:00:00,Doxorubicin,D02.455.426.559.847.562.050.200.175
22621734,2012-01-01T00:00:00,Doxorubicin,D04.615.562.050.200.175
22621734,2012-01-01T00:00:00,Doxorubicin,D09.408.051.059.200.175
22621734,2012-01-01T00:00:00,Drug Delivery Systems,E02.319.300
22621734,2012-01-01T00:00:00,"Hyperthermia, Induced",E02.565
22621734,2012-01-01T00:00:00,"Hyperthermia, Induced",E02.779.496
22621734,2012-01-01T00:00:00,Magnetic Resonance Spectroscopy,E05.196.867.519
22621734,2012-01-01T00:00:00,Neoplasms,C04
22621734,2012-01-01T00:00:00,Rabbits,B01.050.150.900.649.521.700
22621735,2012-01-01T00:00:00,Animals,B01.050
22621735,2012-01-01T00:00:00,Computer Simulation,L01.224.160
22621735,2012-01-01T00:00:00,Doxorubicin,D02.455.426.559.847.562.050.200.175
22621735,2012-01-01T00:00:00,Doxorubicin,D04.615.562.050.200.175
22621735,2012-01-01T00:00:00,Doxorubicin,D09.408.051.059.200.175
22621735,2012-01-01T00:00:00,Drug Delivery Systems,E02.319.300
22621735,2012-01-01T00:00:00,"Hyperthermia, Induced",E02.565
22621735,2012-01-01T00:00:00,"Hyperthermia, Induced",E02.779.496
22621735,2012-01-01T00:00:00,Liposomes,D25.479.517
22621735,2012-01-01T00:00:00,Liposomes,D26.255.260.517
22621735,2012-01-01T00:00:00,Liposomes,D27.720.280.260.517
22621735,2012-01-01T00:00:00,Liposomes,J01.637.051.479.517
22621735,2012-01-01T00:00:00,Liposomes,J01.637.087.500.517
22621735,2012-01-01T00:00:00,Neoplasms,C04
22621735,2012-01-01T00:00:00,Rabbits,B01.050.150.900.649.521.700
22621735,2012-01-01T00:00:00,Temperature,G01.906.595
22621735,2012-01-01T00:00:00,Temperature,G16.500.275.063.725.710
22621735,2012-01-01T00:00:00,Temperature,G16.500.750.775.710
22621735,2012-01-01T00:00:00,Temperature,N06.230.150.450
22621735,2012-01-01T00:00:00,Temperature,N06.230.300.100.725.710
22641931,2012-01-01T00:00:00,Aged,M01.060.116.100
22641931,2012-01-01T00:00:00,Caregivers,M01.085
22641931,2012-01-01T00:00:00,Caregivers,M01.526.485.200
22641931,2012-01-01T00:00:00,Caregivers,N02.360.200
22641931,2012-01-01T00:00:00,Depressive Disorder,F03.600.300
22641931,2012-01-01T00:00:00,Double-Blind Method,E05.318.780.300
22641931,2012-01-01T00:00:00,Double-Blind Method,E05.581.500.300
22641931,2012-01-01T00:00:00,Double-Blind Method,N05.715.360.780.320
22641931,2012-01-01T00:00:00,Double-Blind Method,N06.850.520.445.300
22641931,2012-01-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22641931,2012-01-01T00:00:00,Informed Consent,I01.880.604.473.650.718
22641931,2012-01-01T00:00:00,Informed Consent,I01.880.604.583.427
22641931,2012-01-01T00:00:00,Informed Consent,N03.706.437.650.312
22641931,2012-01-01T00:00:00,Informed Consent,N03.706.535.489
22641931,2012-01-01T00:00:00,Mental Recall,F02.463.425.540.641
22641931,2012-01-01T00:00:00,Middle Aged,M01.060.116.630
22641931,2012-01-01T00:00:00,Parkinson Disease,C10.228.140.079.862.500
22641931,2012-01-01T00:00:00,Parkinson Disease,C10.228.662.600.400
22641931,2012-01-01T00:00:00,Parkinson Disease,C10.574.812
22641931,2012-01-01T00:00:00,Quality of Life,I01.800
22641931,2012-01-01T00:00:00,Quality of Life,K01.752.400.750
22641931,2012-01-01T00:00:00,Questionnaires,E05.318.308.750
22641931,2012-01-01T00:00:00,Questionnaires,L01.280.800
22641931,2012-01-01T00:00:00,Questionnaires,N05.715.360.300.695
22641931,2012-01-01T00:00:00,Questionnaires,N06.850.520.308.750
22641931,2012-01-01T00:00:00,Social Environment,I01.880.656
22641931,2012-01-01T00:00:00,Social Support,I01.880.656.600
22651113,2012-01-01T00:00:00,Algorithms,G17.035
22651113,2012-01-01T00:00:00,Algorithms,L01.224.050
22651113,2012-01-01T00:00:00,"Clinical Trials, Phase III as Topic",E05.318.760.535.220
22651113,2012-01-01T00:00:00,"Clinical Trials, Phase III as Topic",E05.337.250.220
22651113,2012-01-01T00:00:00,"Clinical Trials, Phase III as Topic",N05.715.360.775.235.220
22651113,2012-01-01T00:00:00,"Clinical Trials, Phase III as Topic",N06.850.520.450.535.220
22651113,2012-01-01T00:00:00,Computer Simulation,L01.224.160
22651113,2012-01-01T00:00:00,"Data Interpretation, Statistical",E05.245.380
22651113,2012-01-01T00:00:00,"Data Interpretation, Statistical",E05.318.740.300
22651113,2012-01-01T00:00:00,"Data Interpretation, Statistical",L01.700.508.190.380
22651113,2012-01-01T00:00:00,"Data Interpretation, Statistical",N05.715.360.750.300
22651113,2012-01-01T00:00:00,"Data Interpretation, Statistical",N06.850.520.830.300
22651113,2012-01-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22651113,2012-01-01T00:00:00,Monte Carlo Method,E05.318.740.525
22651113,2012-01-01T00:00:00,Monte Carlo Method,L01.906.575.422
22651113,2012-01-01T00:00:00,Monte Carlo Method,N05.715.360.750.540
22651113,2012-01-01T00:00:00,Monte Carlo Method,N06.850.520.830.525
22651113,2012-01-01T00:00:00,Research Design,E05.581.500
22651113,2012-01-01T00:00:00,Research Design,H01.770.644.728
22651113,2012-01-01T00:00:00,Treatment Outcome,E01.789.800
22651113,2012-01-01T00:00:00,Treatment Outcome,N04.761.559.590.800
22651113,2012-01-01T00:00:00,Treatment Outcome,N05.715.360.575.575.800
22717646,2012-01-01T00:00:00,Animals,B01.050
22717646,2012-01-01T00:00:00,Apoptosis,G04.299.139.160
22717646,2012-01-01T00:00:00,Brain Infarction,C10.228.140.300.150.477
22717646,2012-01-01T00:00:00,Brain Infarction,C10.228.140.300.775.200
22717646,2012-01-01T00:00:00,Brain Infarction,C14.907.253.092.477
22717646,2012-01-01T00:00:00,Brain Infarction,C14.907.253.855.200
22717646,2012-01-01T00:00:00,"Disease Models, Animal",C22.232
22717646,2012-01-01T00:00:00,"Disease Models, Animal",E05.598.500
22717646,2012-01-01T00:00:00,"Disease Models, Animal",E05.599.395.080
22717646,2012-01-01T00:00:00,Enzyme Inhibitors,D27.505.519.389
22717646,2012-01-01T00:00:00,Exercise Therapy,E02.779.483
22717646,2012-01-01T00:00:00,Exercise Therapy,E02.831.387
22717646,2012-01-01T00:00:00,Gene Expression Regulation,G05.355.315
22717646,2012-01-01T00:00:00,"Infarction, Middle Cerebral Artery",C10.228.140.300.150.477.200.450
22717646,2012-01-01T00:00:00,"Infarction, Middle Cerebral Artery",C10.228.140.300.510.200.387
22717646,2012-01-01T00:00:00,"Infarction, Middle Cerebral Artery",C10.228.140.300.775.200.200.450
22717646,2012-01-01T00:00:00,"Infarction, Middle Cerebral Artery",C14.907.253.092.477.200.450
22717646,2012-01-01T00:00:00,"Infarction, Middle Cerebral Artery",C14.907.253.560.200.387
22717646,2012-01-01T00:00:00,"Infarction, Middle Cerebral Artery",C14.907.253.855.200.200.450
22717646,2012-01-01T00:00:00,Neuroprotective Agents,D27.505.696.706.548
22717646,2012-01-01T00:00:00,Neuroprotective Agents,D27.505.954.427.575
22717646,2012-01-01T00:00:00,Rats,B01.050.150.900.649.865.635.505.700
22717646,2012-01-01T00:00:00,"Rats, Sprague-Dawley",B01.050.150.900.649.865.635.505.700.750
22717646,2012-01-01T00:00:00,Recovery of Function,G16.757
22717646,2012-01-01T00:00:00,S-Nitrosoglutathione,D02.654.846.500.249
22717646,2012-01-01T00:00:00,S-Nitrosoglutathione,D02.886.489.650.750
22717646,2012-01-01T00:00:00,S-Nitrosoglutathione,D12.644.456.448.750
22717646,2012-01-01T00:00:00,Time Factors,G01.910.857
22735822,2012-01-01T00:00:00,Allied Health Personnel,M01.526.485.067
22735822,2012-01-01T00:00:00,Allied Health Personnel,N02.360.067
22735822,2012-01-01T00:00:00,Curriculum,I02.158
22735822,2012-01-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22735822,2012-01-01T00:00:00,Professional-Patient Relations,F01.829.401.650
22735822,2012-01-01T00:00:00,Professional-Patient Relations,N05.300.660
22735822,2012-01-01T00:00:00,United States,Z01.107.567.875
22747547,2012-01-01T00:00:00,"Analgesics, Opioid",D27.505.696.663.850.014.520
22747547,2012-01-01T00:00:00,"Analgesics, Opioid",D27.505.954.427.040.325
22747547,2012-01-01T00:00:00,"Analgesics, Opioid",D27.505.954.427.210.049
22747547,2012-01-01T00:00:00,Animals,B01.050
22747547,2012-01-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22747547,2012-01-01T00:00:00,Ischemia,C23.550.513
22747547,2012-01-01T00:00:00,Neuroprotective Agents,D27.505.696.706.548
22747547,2012-01-01T00:00:00,Neuroprotective Agents,D27.505.954.427.575
22747547,2012-01-01T00:00:00,"Receptors, Opioid",D12.776.543.750.100.620
22747547,2012-01-01T00:00:00,"Receptors, Opioid",D12.776.543.750.720.600.610
22747547,2012-01-01T00:00:00,"Receptors, Opioid",D12.776.543.750.750.555.610
22747547,2012-01-01T00:00:00,Retinal Degeneration,C11.768.585
22747547,2012-01-01T00:00:00,Signal Transduction,G02.111.087.800
22747547,2012-01-01T00:00:00,Signal Transduction,G02.149.115.800
22747547,2012-01-01T00:00:00,Signal Transduction,G04.299.880
22747547,2012-01-01T00:00:00,Tumor Necrosis Factor-alpha,D12.644.276.374.500.800
22747547,2012-01-01T00:00:00,Tumor Necrosis Factor-alpha,D12.644.276.374.750.626
22747547,2012-01-01T00:00:00,Tumor Necrosis Factor-alpha,D12.644.276.972.626
22747547,2012-01-01T00:00:00,Tumor Necrosis Factor-alpha,D12.776.124.900
22747547,2012-01-01T00:00:00,Tumor Necrosis Factor-alpha,D12.776.395.930
22747547,2012-01-01T00:00:00,Tumor Necrosis Factor-alpha,D12.776.467.374.500.800
22747547,2012-01-01T00:00:00,Tumor Necrosis Factor-alpha,D12.776.467.374.750.626
22747547,2012-01-01T00:00:00,Tumor Necrosis Factor-alpha,D12.776.467.972.626
22747547,2012-01-01T00:00:00,Tumor Necrosis Factor-alpha,D23.529.374.500.800
22747547,2012-01-01T00:00:00,Tumor Necrosis Factor-alpha,D23.529.374.750.626
22747547,2012-01-01T00:00:00,Tumor Necrosis Factor-alpha,D23.529.972.626
22764646,2012-01-01T00:00:00,Adult,M01.060.116
22764646,2012-01-01T00:00:00,African Americans,M01.686.508.100.100
22764646,2012-01-01T00:00:00,African Americans,M01.686.754.100
22764646,2012-01-01T00:00:00,Disability Evaluation,E01.370.400
22764646,2012-01-01T00:00:00,Disease Progression,C23.550.291.656
22764646,2012-01-01T00:00:00,European Continental Ancestry Group,M01.686.508.400
22764646,2012-01-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22764646,2012-01-01T00:00:00,Immunologic Factors,D27.505.696.477
22764646,2012-01-01T00:00:00,Middle Aged,M01.060.116.630
22764646,2012-01-01T00:00:00,Multiple Sclerosis,C10.114.375.500
22764646,2012-01-01T00:00:00,Multiple Sclerosis,C10.314.350.500
22764646,2012-01-01T00:00:00,Multiple Sclerosis,C20.111.258.250.500
22764646,2012-01-01T00:00:00,South Carolina,Z01.107.567.875.075.662
22764646,2012-01-01T00:00:00,South Carolina,Z01.107.567.875.750.700
22764646,2012-01-01T00:00:00,Treatment Outcome,E01.789.800
22764646,2012-01-01T00:00:00,Treatment Outcome,N04.761.559.590.800
22764646,2012-01-01T00:00:00,Treatment Outcome,N05.715.360.575.575.800
22773532,2012-01-01T00:00:00,Adolescent,M01.060.057
22773532,2012-01-01T00:00:00,Adult,M01.060.116
22773532,2012-01-01T00:00:00,Electric Stimulation Therapy,E02.342
22773532,2012-01-01T00:00:00,Electric Stimulation Therapy,E02.779.468
22773532,2012-01-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22773532,2012-01-01T00:00:00,Isometric Contraction,G11.427.590.540.472
22773532,2012-01-01T00:00:00,Magnetic Resonance Imaging,E01.370.350.500
22773532,2012-01-01T00:00:00,Magnetic Resonance Imaging,E01.370.350.825.500
22773532,2012-01-01T00:00:00,Middle Aged,M01.060.116.630
22773532,2012-01-01T00:00:00,Muscle Fatigue,G11.427.550
22773532,2012-01-01T00:00:00,Pain Measurement,E01.370.376.550.600
22773532,2012-01-01T00:00:00,Quadriceps Muscle,A02.633.567.850
22773532,2012-01-01T00:00:00,Time Factors,G01.910.857
22773532,2012-01-01T00:00:00,Young Adult,M01.060.116.815
22774302,2012-01-01T00:00:00,Adult,M01.060.116
22774302,2012-01-01T00:00:00,Cardiovascular Diseases,C14
22774302,2012-01-01T00:00:00,"Diabetes Mellitus, Type 2",C18.452.394.750.149
22774302,2012-01-01T00:00:00,"Diabetes Mellitus, Type 2",C19.246.300
22774302,2012-01-01T00:00:00,Health Behavior,F01.145.488
22774302,2012-01-01T00:00:00,Health Status,I01.240.425
22774302,2012-01-01T00:00:00,Health Status,N01.224.425
22774302,2012-01-01T00:00:00,Health Status,N06.850.505.400.425
22774302,2012-01-01T00:00:00,Hispanic Americans,M01.686.754.441
22774302,2012-01-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22774302,2012-01-01T00:00:00,Middle Aged,M01.060.116.630
22774302,2012-01-01T00:00:00,Questionnaires,E05.318.308.750
22774302,2012-01-01T00:00:00,Questionnaires,L01.280.800
22774302,2012-01-01T00:00:00,Questionnaires,N05.715.360.300.695
22774302,2012-01-01T00:00:00,Questionnaires,N06.850.520.308.750
22774302,2012-01-01T00:00:00,South Carolina,Z01.107.567.875.075.662
22774302,2012-01-01T00:00:00,South Carolina,Z01.107.567.875.750.700
22809047,2012-01-01T00:00:00,Adult,M01.060.116
22809047,2012-01-01T00:00:00,Caregivers,M01.085
22809047,2012-01-01T00:00:00,Caregivers,M01.526.485.200
22809047,2012-01-01T00:00:00,Caregivers,N02.360.200
22809047,2012-01-01T00:00:00,Child,M01.060.406
22809047,2012-01-01T00:00:00,"Child Abuse, Sexual",I01.198.240.748.300
22809047,2012-01-01T00:00:00,"Child Abuse, Sexual",I01.198.240.856.350.250.255
22809047,2012-01-01T00:00:00,"Child Abuse, Sexual",I01.880.735.900.350.250.255
22809047,2012-01-01T00:00:00,"Child Abuse, Sexual",I01.880.787.293.292.325
22809047,2012-01-01T00:00:00,Child Welfare,I01.880.787.293
22809047,2012-01-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22813971,2012-01-01T00:00:00,Animals,B01.050
22813971,2012-01-01T00:00:00,Brain,A08.186.211
22813971,2012-01-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22813971,2012-01-01T00:00:00,Intracellular Signaling Peptides and Proteins,D12.644.360
22813971,2012-01-01T00:00:00,Intracellular Signaling Peptides and Proteins,D12.776.476
22813971,2012-01-01T00:00:00,Motivation,F01.658
22813971,2012-01-01T00:00:00,Motivation,F01.752.543.500.750
22813971,2012-01-01T00:00:00,Neuropeptides,D12.644.400
22813971,2012-01-01T00:00:00,Neuropeptides,D12.776.641.650
22813971,2012-01-01T00:00:00,Substance-Related Disorders,C21.739
22813971,2012-01-01T00:00:00,Substance-Related Disorders,F03.900
22865147,2012-01-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22865147,2012-01-01T00:00:00,Internship and Residency,I02.358.399.644
22865147,2012-01-01T00:00:00,Military Medicine,H02.403.500
22865147,2012-01-01T00:00:00,Military Personnel,M01.526.625
22865147,2012-01-01T00:00:00,Orthopedic Procedures,E02.718
22865147,2012-01-01T00:00:00,Orthopedic Procedures,E04.555
22865147,2012-01-01T00:00:00,War,I01.880.735.944
22894049,2012-01-01T00:00:00,Diffusion of Innovation,L01.143.320
22894049,2012-01-01T00:00:00,Forecasting,I01.320
22894049,2012-01-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22894049,2012-01-01T00:00:00,Internationality,I01.615
22894049,2012-01-01T00:00:00,"Technology Assessment, Biomedical",N03.880
22894049,2012-01-01T00:00:00,"Technology Assessment, Biomedical",N05.715.360.825
22894049,2012-01-01T00:00:00,Telemedicine,H02.403.840
22894049,2012-01-01T00:00:00,Telemedicine,L01.178.847.652
22894049,2012-01-01T00:00:00,Telemedicine,N04.590.374.800
22894049,2012-01-01T00:00:00,United States,Z01.107.567.875
22913502,2012-01-01T00:00:00,Adult,M01.060.116
22913502,2012-01-01T00:00:00,Cyclonic Storms,G16.500.240.135.500
22913502,2012-01-01T00:00:00,Data Collection,E05.318.308
22913502,2012-01-01T00:00:00,Data Collection,L01.280
22913502,2012-01-01T00:00:00,Data Collection,N05.715.360.300
22913502,2012-01-01T00:00:00,Data Collection,N06.850.520.308
22913502,2012-01-01T00:00:00,Depression,F01.145.126.350
22913502,2012-01-01T00:00:00,Disasters,N06.230.100
22913502,2012-01-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22913502,2012-01-01T00:00:00,Internet,L01.224.230.110.500
22913502,2012-01-01T00:00:00,Mental Health Services,F04.408
22913502,2012-01-01T00:00:00,Mental Health Services,N02.421.461
22913502,2012-01-01T00:00:00,Middle Aged,M01.060.116.630
22913502,2012-01-01T00:00:00,Patient Acceptance of Health Care,N05.300.150.600
22913502,2012-01-01T00:00:00,Patient Dropouts,M01.643.673
22913502,2012-01-01T00:00:00,Randomized Controlled Trials as Topic,E05.318.760.535.365.500
22913502,2012-01-01T00:00:00,Randomized Controlled Trials as Topic,E05.337.250.365.500
22913502,2012-01-01T00:00:00,Randomized Controlled Trials as Topic,N05.715.360.775.235.387.500
22913502,2012-01-01T00:00:00,Randomized Controlled Trials as Topic,N06.850.520.450.535.365.500
22913502,2012-01-01T00:00:00,"Stress Disorders, Post-Traumatic",F03.080.931.500
22913502,2012-01-01T00:00:00,"Therapy, Computer-Assisted",E02.950
22913502,2012-01-01T00:00:00,"Therapy, Computer-Assisted",L01.700.508.100.710
22927584,2012-01-01T00:00:00,Community Health Services,N02.421.143
22927584,2012-01-01T00:00:00,Community-Based Participatory Research,N05.425.104
22927584,2012-01-01T00:00:00,Curriculum,I02.158
22927584,2012-01-01T00:00:00,Health Occupations,H02
22927584,2012-01-01T00:00:00,Human Engineering,F02.784.412
22927584,2012-01-01T00:00:00,Human Engineering,J01.293.556
22927584,2012-01-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22927584,2012-01-01T00:00:00,Occupational Therapy,E02.831.489
22927584,2012-01-01T00:00:00,Occupational Therapy,H02.010.500
22927584,2012-01-01T00:00:00,Organizational Case Studies,N03.349.380.710
22927584,2012-01-01T00:00:00,Organizational Case Studies,N05.715.360.455
22927584,2012-01-01T00:00:00,Pilot Projects,E05.318.760.750
22927584,2012-01-01T00:00:00,Pilot Projects,E05.337.737
22927584,2012-01-01T00:00:00,Pilot Projects,N05.715.360.775.625
22927584,2012-01-01T00:00:00,Pilot Projects,N06.850.520.450.720
22927584,2012-01-01T00:00:00,Problem-Based Learning,F02.463.425.720
22927584,2012-01-01T00:00:00,Problem-Based Learning,I02.158.660
22927584,2012-01-01T00:00:00,Problem-Based Learning,I02.903.565
22927584,2012-01-01T00:00:00,Professional Competence,I02.399.630
22927584,2012-01-01T00:00:00,Program Evaluation,E05.337.820
22927584,2012-01-01T00:00:00,Program Evaluation,N04.761.685
22927584,2012-01-01T00:00:00,Program Evaluation,N05.715.360.650
22927584,2012-01-01T00:00:00,Qualitative Research,H01.770.644.241.850
22927584,2012-01-01T00:00:00,Rural Population,N01.600.725
22927584,2012-01-01T00:00:00,South Carolina,Z01.107.567.875.075.662
22927584,2012-01-01T00:00:00,South Carolina,Z01.107.567.875.750.700
22927584,2012-01-01T00:00:00,Students,I02.233.748
22927584,2012-01-01T00:00:00,Students,I02.851
22927584,2012-01-01T00:00:00,Students,M01.848
22927584,2012-01-01T00:00:00,Task Performance and Analysis,F02.784.412.846
22927584,2012-01-01T00:00:00,Task Performance and Analysis,F02.784.692.746
22927584,2012-01-01T00:00:00,Task Performance and Analysis,F02.808.600
22927584,2012-01-01T00:00:00,Workplace,N01.824.245.925
22927584,2012-01-01T00:00:00,Workplace,N04.452.677.975
22941622,2012-01-01T00:00:00,Animals,B01.050
22941622,2012-01-01T00:00:00,CHO Cells,A11.251.210.200
22941622,2012-01-01T00:00:00,CHO Cells,A11.436.155
22941622,2012-01-01T00:00:00,Cricetinae,B01.050.150.900.649.865.635.150
22941622,2012-01-01T00:00:00,DNA Repair,G02.111.087.219
22941622,2012-01-01T00:00:00,DNA Repair,G02.149.115.219
22941622,2012-01-01T00:00:00,DNA Repair,G05.355.195
22941622,2012-01-01T00:00:00,Genetic Loci,G05.360.340.024.380
22941622,2012-01-01T00:00:00,Genetic Vectors,G05.360.337
22941622,2012-01-01T00:00:00,Mutation,G05.365.590
22941622,2012-01-01T00:00:00,"Recombination, Genetic",G05.355.760
22982839,2012-01-01T00:00:00,African Americans,M01.686.508.100.100
22982839,2012-01-01T00:00:00,African Americans,M01.686.754.100
22982839,2012-01-01T00:00:00,Aged,M01.060.116.100
22982839,2012-01-01T00:00:00,Health Education,I02.233.332
22982839,2012-01-01T00:00:00,Health Education,N02.421.143.827.407
22982839,2012-01-01T00:00:00,Health Education,N02.421.726.407
22982839,2012-01-01T00:00:00,"Health Knowledge, Attitudes, Practice",F01.100.150.500
22982839,2012-01-01T00:00:00,"Health Knowledge, Attitudes, Practice",N05.300.150.410
22982839,2012-01-01T00:00:00,Health Promotion,N02.370
22982839,2012-01-01T00:00:00,Health Promotion,N02.421.726.507
22982839,2012-01-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22982839,2012-01-01T00:00:00,Middle Aged,M01.060.116.630
22982839,2012-01-01T00:00:00,Neoplasms,C04
22982839,2012-01-01T00:00:00,Perception,F02.463.593
22982839,2012-01-01T00:00:00,Questionnaires,E05.318.308.750
22982839,2012-01-01T00:00:00,Questionnaires,L01.280.800
22982839,2012-01-01T00:00:00,Questionnaires,N05.715.360.300.695
22982839,2012-01-01T00:00:00,Questionnaires,N06.850.520.308.750
22982839,2012-01-01T00:00:00,Randomized Controlled Trials as Topic,E05.318.760.535.365.500
22982839,2012-01-01T00:00:00,Randomized Controlled Trials as Topic,E05.337.250.365.500
22982839,2012-01-01T00:00:00,Randomized Controlled Trials as Topic,N05.715.360.775.235.387.500
22982839,2012-01-01T00:00:00,Randomized Controlled Trials as Topic,N06.850.520.450.535.365.500
22982839,2012-01-01T00:00:00,South Carolina,Z01.107.567.875.075.662
22982839,2012-01-01T00:00:00,South Carolina,Z01.107.567.875.750.700
22982847,2012-01-01T00:00:00,Community Networks,I01.880.656.300
22982847,2012-01-01T00:00:00,Community Networks,L01.700.508.300.184
22982847,2012-01-01T00:00:00,Community Networks,N02.421.143.202
22982847,2012-01-01T00:00:00,Community-Based Participatory Research,N05.425.104
22982847,2012-01-01T00:00:00,Health Services Research,N03.349.380
22982847,2012-01-01T00:00:00,Health Services Research,N05.425
22982847,2012-01-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22989240,2012-01-01T00:00:00,Adolescent,M01.060.057
22989240,2012-01-01T00:00:00,Child,M01.060.406
22989240,2012-01-01T00:00:00,Crime Victims,M01.135
22989240,2012-01-01T00:00:00,Emotions,F01.470
22989240,2012-01-01T00:00:00,Hispanic Americans,M01.686.754.441
22989240,2012-01-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
22989240,2012-01-01T00:00:00,Interviews as Topic,E05.318.308.420
22989240,2012-01-01T00:00:00,Interviews as Topic,L01.280.520
22989240,2012-01-01T00:00:00,Interviews as Topic,N05.715.360.300.400
22989240,2012-01-01T00:00:00,Interviews as Topic,N06.850.520.308.420
22989240,2012-01-01T00:00:00,Life Change Events,F01.829.458.410
22989240,2012-01-01T00:00:00,Regression Analysis,E05.318.740.750
22989240,2012-01-01T00:00:00,Regression Analysis,N05.715.360.750.695
22989240,2012-01-01T00:00:00,Regression Analysis,N06.850.520.830.750
22989240,2012-01-01T00:00:00,Risk Factors,E05.318.740.600.800.725
22989240,2012-01-01T00:00:00,Risk Factors,N05.715.350.200.700
22989240,2012-01-01T00:00:00,Risk Factors,N05.715.360.750.625.700.700
22989240,2012-01-01T00:00:00,Risk Factors,N06.850.490.625.750
22989240,2012-01-01T00:00:00,Risk Factors,N06.850.520.830.600.800.725
22989240,2012-01-01T00:00:00,"Stress Disorders, Post-Traumatic",F03.080.931.500
23036004,2012-01-01T00:00:00,Adult,M01.060.116
23036004,2012-01-01T00:00:00,China,Z01.252.474.164
23036004,2012-01-01T00:00:00,Curriculum,I02.158
23036004,2012-01-01T00:00:00,"Faculty, Medical",I02.463.373
23036004,2012-01-01T00:00:00,"Faculty, Medical",M01.526.339.373
23036004,2012-01-01T00:00:00,"Faculty, Medical",M01.526.485.375
23036004,2012-01-01T00:00:00,"Faculty, Medical",N02.360.375
23036004,2012-01-01T00:00:00,"Health Knowledge, Attitudes, Practice",F01.100.150.500
23036004,2012-01-01T00:00:00,"Health Knowledge, Attitudes, Practice",N05.300.150.410
23036004,2012-01-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
23036004,2012-01-01T00:00:00,Learning,F02.463.425
23036004,2012-01-01T00:00:00,Learning,F02.784.629.529
23036004,2012-01-01T00:00:00,Middle Aged,M01.060.116.630
23036004,2012-01-01T00:00:00,Pilot Projects,E05.318.760.750
23036004,2012-01-01T00:00:00,Pilot Projects,E05.337.737
23036004,2012-01-01T00:00:00,Pilot Projects,N05.715.360.775.625
23036004,2012-01-01T00:00:00,Pilot Projects,N06.850.520.450.720
23036004,2012-01-01T00:00:00,Professional Competence,I02.399.630
23036004,2012-01-01T00:00:00,Program Development,N04.452.760
23036004,2012-01-01T00:00:00,Program Evaluation,E05.337.820
23036004,2012-01-01T00:00:00,Program Evaluation,N04.761.685
23036004,2012-01-01T00:00:00,Program Evaluation,N05.715.360.650
23036004,2012-01-01T00:00:00,Questionnaires,E05.318.308.750
23036004,2012-01-01T00:00:00,Questionnaires,L01.280.800
23036004,2012-01-01T00:00:00,Questionnaires,N05.715.360.300.695
23036004,2012-01-01T00:00:00,Questionnaires,N06.850.520.308.750
23036004,2012-01-01T00:00:00,Staff Development,I02.574.700
23036004,2012-01-01T00:00:00,Staff Development,N04.452.677.822
23036004,2012-01-01T00:00:00,Teaching,I02.903
23036004,2012-01-01T00:00:00,Time Factors,G01.910.857
23061579,2012-01-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
23061579,2012-01-01T00:00:00,United States,Z01.107.567.875
23140061,2012-01-01T00:00:00,Clinical Competence,I02.399.630.210
23140061,2012-01-01T00:00:00,Clinical Competence,N04.761.210
23140061,2012-01-01T00:00:00,Disaster Planning,N06.230.100.035
23140061,2012-01-01T00:00:00,Emergency Medical Services,N02.421.297
23140061,2012-01-01T00:00:00,Emergency Medicine,H02.403.250
23140061,2012-01-01T00:00:00,Health Personnel,M01.526.485
23140061,2012-01-01T00:00:00,Health Personnel,N02.360
23140061,2012-01-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
23140061,2012-01-01T00:00:00,Inservice Training,I02.574
23140061,2012-01-01T00:00:00,Interdisciplinary Communication,F01.145.209.381
23140061,2012-01-01T00:00:00,Interdisciplinary Communication,F01.829.401.205.249
23140061,2012-01-01T00:00:00,Interdisciplinary Communication,L01.143.474
23140061,2012-01-01T00:00:00,Patient Simulation,I02.903.525
23140061,2012-01-01T00:00:00,Program Evaluation,E05.337.820
23140061,2012-01-01T00:00:00,Program Evaluation,N04.761.685
23140061,2012-01-01T00:00:00,Program Evaluation,N05.715.360.650
23140061,2012-01-01T00:00:00,"Students, Medical",I02.851.686.602
23140061,2012-01-01T00:00:00,"Students, Medical",M01.848.769.602
23140061,2012-01-01T00:00:00,United States,Z01.107.567.875
23327857,2012-01-01T00:00:00,Bone Diseases,C05.116
23327857,2012-01-01T00:00:00,Bone Plates,E07.695.125
23327857,2012-01-01T00:00:00,Bone Plates,E07.858.442.660.110
23327857,2012-01-01T00:00:00,Bone Plates,E07.858.690.650.110
23327857,2012-01-01T00:00:00,Bone Screws,E07.695.130
23327857,2012-01-01T00:00:00,Bone Screws,E07.858.442.660.115
23327857,2012-01-01T00:00:00,Bone Screws,E07.858.690.650.115
23327857,2012-01-01T00:00:00,Child,M01.060.406
23327857,2012-01-01T00:00:00,External Fixators,E07.858.442.660.430
23327857,2012-01-01T00:00:00,External Fixators,E07.858.690.650.430
23327857,2012-01-01T00:00:00,Hip Joint,A02.835.583.411
23327857,2012-01-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
23327857,2012-01-01T00:00:00,Prostheses and Implants,E07.695
23366388,2012-01-01T00:00:00,Algorithms,G17.035
23366388,2012-01-01T00:00:00,Algorithms,L01.224.050
23366388,2012-01-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
23366388,2012-01-01T00:00:00,Image Enhancement,E01.370.350.600.350
23366388,2012-01-01T00:00:00,Image Enhancement,L01.224.308.380
23366388,2012-01-01T00:00:00,"Image Interpretation, Computer-Assisted",E01.158.600
23366388,2012-01-01T00:00:00,"Image Interpretation, Computer-Assisted",E01.370.350.350
23366388,2012-01-01T00:00:00,"Image Interpretation, Computer-Assisted",L01.700.508.100.158.600
23366388,2012-01-01T00:00:00,Joints,A02.835.583
23366388,2012-01-01T00:00:00,Ultrasonography,E01.370.350.850
23366794,2012-01-01T00:00:00,Algorithms,G17.035
23366794,2012-01-01T00:00:00,Algorithms,L01.224.050
23366794,2012-01-01T00:00:00,Electrodes,E07.305.250
23366794,2012-01-01T00:00:00,Electroencephalography,E01.370.376.300
23366794,2012-01-01T00:00:00,Electroencephalography,E01.370.405.245
23366794,2012-01-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
23366794,2012-01-01T00:00:00,"Signal Processing, Computer-Assisted",L01.224.800
23584107,2012-01-01T00:00:00,"Adaptation, Psychological",F01.058
23584107,2012-01-01T00:00:00,Alcohol Deterrents,D27.505.954.427.020
23584107,2012-01-01T00:00:00,Alcoholism,C21.739.100.250
23584107,2012-01-01T00:00:00,Alcoholism,F03.900.100.350
23584107,2012-01-01T00:00:00,Antidepressive Agents,D27.505.954.427.700.122
23584107,2012-01-01T00:00:00,Brain,A08.186.211
23584107,2012-01-01T00:00:00,Cognitive Therapy,F04.754.137.428
23584107,2012-01-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
23584107,2012-01-01T00:00:00,Hypothalamo-Hypophyseal System,A06.688.357
23584107,2012-01-01T00:00:00,Hypothalamo-Hypophyseal System,A08.186.211.730.317.357.352.435
23584107,2012-01-01T00:00:00,Hypothalamo-Hypophyseal System,A08.713.357
23584107,2012-01-01T00:00:00,Pituitary-Adrenal System,A06.407.691
23584107,2012-01-01T00:00:00,Sertraline,D02.092.705.800
23584107,2012-01-01T00:00:00,Sertraline,D02.455.426.559.847.638.845.800
23584107,2012-01-01T00:00:00,Sertraline,D04.615.638.845.800
23584107,2012-01-01T00:00:00,"Stress Disorders, Post-Traumatic",F03.080.931.500
23584108,2012-01-01T00:00:00,Alcohol Deterrents,D27.505.954.427.020
23584108,2012-01-01T00:00:00,Alcohol-Related Disorders,C21.739.100
23584108,2012-01-01T00:00:00,Alcohol-Related Disorders,F03.900.100
23584108,2012-01-01T00:00:00,Anti-Anxiety Agents,D27.505.696.277.950.015
23584108,2012-01-01T00:00:00,Anti-Anxiety Agents,D27.505.954.427.210.950.015
23584108,2012-01-01T00:00:00,Anti-Anxiety Agents,D27.505.954.427.700.872.015
23584108,2012-01-01T00:00:00,Antidepressive Agents,D27.505.954.427.700.122
23584108,2012-01-01T00:00:00,Anxiety Disorders,F03.080
23584108,2012-01-01T00:00:00,Cognitive Therapy,F04.754.137.428
23584108,2012-01-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
23584108,2012-01-01T00:00:00,"Models, Psychological",E05.599.695
23584108,2012-01-01T00:00:00,Obsessive-Compulsive Disorder,F03.080.600
23584108,2012-01-01T00:00:00,Panic Disorder,F03.080.700
23584108,2012-01-01T00:00:00,Phobic Disorders,F03.080.725
23584108,2012-01-01T00:00:00,Sex Factors,N05.715.350.675
23584108,2012-01-01T00:00:00,Sex Factors,N06.850.490.875
23584108,2012-01-01T00:00:00,United States,Z01.107.567.875
23584111,2012-01-01T00:00:00,Adrenal Cortex Hormones,D06.472.040
23584111,2012-01-01T00:00:00,Alcohol Drinking,F01.145.317.269
23584111,2012-01-01T00:00:00,Alcoholism,C21.739.100.250
23584111,2012-01-01T00:00:00,Alcoholism,F03.900.100.350
23584111,2012-01-01T00:00:00,Animals,B01.050
23584111,2012-01-01T00:00:00,Central Nervous System Depressants,D27.505.696.277
23584111,2012-01-01T00:00:00,Central Nervous System Depressants,D27.505.954.427.210
23584111,2012-01-01T00:00:00,Corticotropin-Releasing Hormone,D06.472.699.327.740.140
23584111,2012-01-01T00:00:00,Corticotropin-Releasing Hormone,D12.644.400.400.740.140
23584111,2012-01-01T00:00:00,Corticotropin-Releasing Hormone,D12.644.548.365.740.140
23584111,2012-01-01T00:00:00,Corticotropin-Releasing Hormone,D12.776.641.650.405.740.140
23584111,2012-01-01T00:00:00,Ethanol,D02.033.375
23584111,2012-01-01T00:00:00,Humans,B01.050.150.900.649.801.400.112.400.400
23584111,2012-01-01T00:00:00,Hypothalamo-Hypophyseal System,A06.688.357
23584111,2012-01-01T00:00:00,Hypothalamo-Hypophyseal System,A08.186.211.730.317.357.352.435
23584111,2012-01-01T00:00:00,Hypothalamo-Hypophyseal System,A08.713.357
23584111,2012-01-01T00:00:00,Norepinephrine,D02.033.100.291.502
23584111,2012-01-01T00:00:00,Norepinephrine,D02.092.063.480
23584111,2012-01-01T00:00:00,Norepinephrine,D02.092.211.215.311.560
23584111,2012-01-01T00:00:00,Norepinephrine,D02.092.311.461.484
23584111,2012-01-01T00:00:00,Pituitary-Adrenal System,A06.407.691
23584111,2012-01-01T00:00:00,"Stress, Psychological",F01.145.126.990
23584111,2012-01-01T00:00:00,"Stress, Psychological",F02.830.900
23584111,2012-01-01T00:00:00,Substance Withdrawal Syndrome,C21.739.835
23584111,2012-01-01T00:00:00,Substance Withdrawal Syndrome,F03.900.825
